Part 1. Basic Tools in Routine Evaluation of Cardiac Patients

Chapter 1. History Taking
  Gestational and Natal History
  Postnatal History
  Family History

2. Physical Examination
  Growth Pattern
  Inspection
  Palpation
  Blood Pressure Measurement
  Auscultation
  Some Special Features of the Cardiac Examination of Neonates

3. Electrocardiography
  What Is the Vectorial Approach?
  Comparison of Pediatric and Adult Electrocardiograms
Basic Measurements and Their Normal and Abnormal Values

Atrial Hypertrophy
Ventricular Hypertrophy
Ventricular Conduction Disturbances
ST-Segment and T-Wave Changes

4. Chest Radiography

Heart Size and Silhouette
Evaluation of Cardiac Chambers and Great Arteries
Pulmonary Vascular Markings
Systematic Approach

Part 2. Special Tools in Evaluation of Cardiac Patients

5. Noninvasive Imaging Tools

Echocardiography
Radiologic Techniques: Magnetic Resonance Imaging and Computed Tomography

6. Other Noninvasive Investigation Tools

Stress Testing
Long-Term Electrocardiography Recording
Ambulatory Blood Pressure Monitoring

7. Invasive Procedures

Cardiac Catheterization and Angiocardiography
Catheter Intervention Procedures

Part 3. Pathophysiology

8. Fetal and Perinatal Circulation

Fetal Circulation
Changes in Circulation after Birth
Premature Newborns
9. Pathophysiology of Left-to-Right Shunt Lesions
   - Atrial Septal Defect
   - Ventricular Septal Defect
   - Patent Ductus Arteriosus
   - Endocardial Cushion Defect

10. Pathophysiology of Obstructive and Valvular Regurgitation Lesions
    - Obstruction to Ventricular Output
    - Stenosis of Atrioventricular Valves
    - Valvular Regurgitant Lesions

11. Pathophysiology of Cyanotic Congenital Heart Defects
    - Clinical Cyanosis
    - Common Cyanotic Heart Defects

**Part 4. Specific Congenital Heart Defects**

12. Left-to-Right Shunt Lesions
    - Atrial Septal Defect
    - Ventricular Septal Defect
    - Patent Ductus Arteriosus
    - Patent Ductus Arteriosus in Preterm Neonates
    - Complete Endocardial Cushion Defect
    - Partial Endocardial Cushion Defect
    - Partial Anomalous Pulmonary Venous Return

13. Obstructive Lesions
    - Pulmonary Stenosis
    - Aortic Stenosis
    - Natural History
    - Coarctation of the Aorta
    - Interrupted Aortic Arch
14. Cyanotic Congenital Heart Defects

Approach to a Cyanotic Neonate
Complete Transposition of the Great Arteries
Congenitally Corrected Transposition of the Great Arteries
Tetralogy of Fallot
Tetralogy of Fallot with Pulmonary Atresia (Pulmonary Atresia and Ventricular Septal Defect)
Tetralogy of Fallot with Absent Pulmonary Valve
Total Anomalous Pulmonary Venous Return
Tricuspid Atresia
Results of Fontan Operation
Postoperative Medical Follow-up
Evolution of the Fontan-Type Operation
Pulmonary Atresia with Intact Ventricular Septum
Hypoplastic Left Heart Syndrome
Ebstein's Anomaly
Persistent Truncus Arteriosus
Single Ventricle
Double-Outlet Right Ventricle
Heterotaxia (Atrial Isomerism, Splenic Syndromes)
Asplenia Syndrome
Polysplenia Syndrome
Persistent Pulmonary Hypertension of the Newborn

15. Miscellaneous Congenital Cardiac Conditions

Aneurysm of the Sinus of Valsalva
Anomalous Origin of the Left Coronary Artery from the Pulmonary Artery (Bland-White-Garland Syndrome, ALCAPA Syndrome)
Aortopulmonary Septal Defect
Arteriovenous Fistula, Coronary
Arteriovenous Fistula, Pulmonary
Arteriovenous Fistula, Systemic
Atrial Septal Aneurysm
Cervical Aortic Arch
Cleft Mitral Valve
Common Atrium (or Single Atrium)
Cor Triatriatum
Double-Chambered Right Ventricle
Ectopia Cordis
Hemitruncus Arteriosus
Idiopathic Dilatation of the Pulmonary Artery
Kartagener’s Syndrome
Parachute Mitral Valve
Patent Foramen Ovale
Pericardial Defect, Congenital
Pseudocoarctation of the Aorta
Pulmonary Artery Stenosis
Pulmonary Vein Stenosis
Scimitar Syndrome
Systemic Venous Anomalies

16. Vascular Ring

17. Chamber Localization and Cardiac Malposition
   Chamber Localization
   Dextrocardia and Mesocardia

Part 5. Acquired Heart Disease

18. Primary Myocardial Disease
   Hypertrophic Cardiomyopathy
   Infants of Mothers with Diabetes
   Other Rare Forms of Hypertrophic Cardiomyopathies
   Dilated Cardiomyopathy
   Endocardial Fibroelastosis
Doxorubicin Cardiomyopathy
Carnitine Deficiency
Other Forms of Dilated Cardiomyopathies
Restrictive Cardiomyopathy
Arrhythmogenic Cardiomyopathy
Noncompaction Cardiomyopathy

19. Cardiovascular Infections
  Infective Endocarditis
  Myocarditis
  Pericarditis
  Constrictive Pericarditis
  Kawasaki's Disease
  Lyme Carditis
  Postpericardiotomy Syndrome
  Postperfusion Syndrome
  Human Immunodeficiency Virus Infection

20. Acute Rheumatic Fever

21. Valvular Heart Disease
  Mitral Stenosis
  Mitral Regurgitation
  Aortic Regurgitation
  Mitral Valve Prolapse

22. Cardiac Tumors
  Prevalence
  Pathology
  Pathology of Individual Cardiac Tumor
  Clinical Manifestations
  Diagnostic Procedures
23. Cardiovascular Involvement in Systemic Diseases

Acute Glomerulonephritis
DiGeorge Syndrome
Friedreich's Ataxia
Hyperthyroidism: Congenital and Acquired
Hypothyroidism: Congenital and Acquired
Marfan's Syndrome
Mucopolysaccharidoses
Muscular Dystrophy
Myotonic Dystrophy
Noonan Syndrome
Rheumatoid Arthritis
Sickle Cell Anemia
Systemic Lupus Erythematosus
Turner Syndrome
Williams Syndrome

Part 6. Arrhythmias and Atrioventricular Conduction Disturbances

24. Cardiac Arrhythmias

Rhythms Originating in the Sinus Node
Rhythms Originating in the Atrium
Rhythms Originating in the Atrioventricular Node
Rhythms Originating in the Ventricle

25. Disturbances of Atrioventricular Conduction

First-Degree Atrioventricular Block
Second-Degree Atrioventricular Block
Third-Degree Atrioventricular Block (Complete Heart Block)
26. Cardiac Pacemakers and Implantable Cardioverter-Defibrillators in Children

   Electrocardiograms of Artificial Cardiac Pacemakers
   Pacemaker Therapy in Children
   Implantable Cardioverter-Defibrillator Therapy

Part 7. Special Problems

27. Congestive Heart Failure

   Definition
   Cause
   Pathophysiology
   Diagnosis
   Management

28. Systemic Hypertension

   Definition
   Normative Blood Pressure Standards
   Cause
   Diagnosis and Workup
   Management of Essential Hypertension
   Management of Secondary Hypertension
   White-Coat Hypertension
   Secondary Hypertension
   Hypertensive Crisis

29. Pulmonary Hypertension

   Definition
   Causes
   Physiology of Pulmonary Circulation
   Pathogenesis of Pulmonary Hypertension
   Pathology of Pulmonary Hypertension
   Pathophysiology
Clinical Manifestations

Diagnosis

Natural History

Management

30. Child with Chest Pain

31. Syncope
   Prevalence
   Definition
   Evaluation of a Child with Syncope
   Treatment
   Differential Diagnosis

32. Palpitation
   Definition
   Causes
   Evaluation
   Management

33. Dyslipidemia and Other Cardiovascular Risk Factors
   Childhood Onset of Coronary Artery Disease
   Cardiovascular Risk Factors and Metabolic Syndrome
   Dyslipidemia
   Lipid Screening
   Management of Hypercholesterolemia
   Hypertriglyceridemia
   Low High-Density Lipoprotein Level
   Elevated Triglyceride and Low High-Density Lipoprotein
   Other Risk Factors
   Practice of Preventive Cardiology
34. Athletes with Cardiac Problems
   - Sudden Unexpected Death in Young Athletes
   - Preparticipation Screening
   - Classification of Sports
   - Eligibility Determination of Athletes with Cardiovascular Diseases
   - Cardiac Arrhythmias and Sports
   - Athletes with Systemic Hypertension

35. Cardiac Transplantation
   - Indications
   - Selection of the Recipient
   - Evaluation and Management of the Cardiac Donor
   - Informed Consent from the Family and Recipient
   - Operative Technique
   - Posttransplant Management
   - Prognosis

Appendix A. Miscellaneous

Appendix B. Blood Pressure Values

Appendix C. Cardiovascular Risk Factors

Appendix D. Normal Echocardiographic Values

Appendix E. Drugs Used in Pediatric Cardiology

Suggested Readings

Index
Notices
Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

With respect to any drug or pharmaceutical products identified, readers are advised to check the most current information provided (i) on procedures featured or (ii) by the manufacturer of each product to be administered, to verify the recommended dose or formula, the method and duration of administration, and contraindications. It is the responsibility of practitioners, relying on their own experience and knowledge of their patients, to make diagnoses, to determine dosages and the best treatment
for each individual patient, and to take all appropriate safety precautions.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.
Dedication

This book is affectionately dedicated to

My wife Issun,

Our sons (Douglas, Christopher, and Warren),

Daughters-in-law (Jin-hee and Soyeon), and

Grandchildren (Natalie and Audrey)
Since the publication of the fifth edition of *Pediatric Cardiology for Practitioners* in 2008, important advances have been made not only in the diagnosis but also in the medical and surgical management of children with congenital and acquired heart diseases. These advances make it necessary to update this book. Extensive updating and revisions have been made throughout the book at the level that is appropriate for cardiology fellows, primary care physicians, residents, and medical students. This comprehensive book will also serve as a quick review for practicing cardiologists. Any health care provider who is interested in learning about pediatric cardiology topics will also find this book very informative. Despite extensive revision, the book maintains its original goal of providing practitioners with fundamental and practical information for the management of children with cardiac problems. Thus, the general layout of the book has been preserved to serve as a small reference book, avoiding excessive theoretical and sometimes controversial discussions or detailed surgical descriptions commonly found in subspecialty textbooks.

Although every topic and chapter has been updated, certain topics were given more extensive revision, including certain congenital heart defects, infective endocarditis, cardiomyopathies, cardiac arrhythmias, and long QT syndrome. A major expansion has been made in “Dyslipidemia and Other Cardiovascular Risk Factors” in order to emphasize the need for practitioners’ attention in preventive cardiology. In that chapter, the diagnosis and management of dyslipidemia, obesity, physical inactivity, and smoking are discussed. Recent recommendations by the Expert Panel convened by the National Heart, Lung, and Blood Institute (NHLBI) on screening and management of dyslipidemia in children has been included in the revision.

In the area of cardiac surgery, new approaches such as hybrid procedures have been updated and the recommended timing of some procedures has been updated. No major attempts were made to summarize surgical mortality rates, complications, or the results of long-term follow-up, since such data are institution-dependent, continually changing, and easily accessible through electronic media.

For the chapter on electrocardiography, new normative data are presented based on the recently revised edition of my book “How to Read Pediatric ECGs, 4th edition.” Pediatric concepts of complete and incomplete right bundle branch blocks have expanded. The number of two-dimensional echocardiographic diagrams has been increased, and detailed normative values of echocardiography have been included in the Appendix. Brief discussion of computed tomographic and magnetic resonance imaging modalities has been added.

Sections dealing with blood pressure and systemic hypertension have been rewritten extensively because the normal blood pressure standards based on the age and height
percentile published by the National High Blood Pressure Education Program are not only scientifically and logically unsound but also impractical for busy practitioners to follow. This is an important issue because the consequences of the diagnosis and management of hypertension based on scientifically unsound BP standards are immense. As such, this important topic is discussed and normative blood pressure data obtained from the San Antonio Children’s Blood Pressure Study are presented: the data by the High Blood Pressure Education Program are presented in the Appendix for the sake of completeness. In addition, often neglected basic knowledge of indirect blood pressure measurement in children has been reviewed.

I wish to acknowledge the contributions of the following individuals in the revision. My colleagues at the Driscoll Children’s Hospital provided constructive suggestions. Paula Scott, Ph.D., MLS, and Cindy Munoz, BA, librarians at the Driscoll Children’s Hospital, have helped me with literature search throughout the project. Linda Lopez, a cardiac sonographer (and the manager of Driscoll’s McAllen Cardiology Clinic) has provided me with helpful suggestions on the echocardiographic illustrations. Dr. Mario Ruiz, MD, DABR, of San Antonio, Texas, a pediatric radiologist, has provided me with helpful suggestions for the section of CT and MRI imaging modalities. Most of all, I thank my wife for her understanding during my long period of preoccupation with this project.

Myung K. Park, MD, San Antonio, Texas
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAPVR</td>
<td>partial anomalous pulmonary venous return</td>
</tr>
<tr>
<td>PBF</td>
<td>pulmonary blood flow</td>
</tr>
<tr>
<td>PDA</td>
<td>patent ductus arteriosus</td>
</tr>
<tr>
<td>PFO</td>
<td>patent foramen ovale</td>
</tr>
<tr>
<td>PPHN</td>
<td>persistent pulmonary hypertension of newborn</td>
</tr>
<tr>
<td>PR</td>
<td>pulmonary regurgitation</td>
</tr>
<tr>
<td>PS</td>
<td>pulmonary stenosis</td>
</tr>
<tr>
<td>PVC</td>
<td>premature ventricular contraction</td>
</tr>
<tr>
<td>PVOD</td>
<td>pulmonary vascular obstructive disease</td>
</tr>
<tr>
<td>PVR</td>
<td>pulmonary vascular resistance</td>
</tr>
<tr>
<td>RA</td>
<td>right atrium</td>
</tr>
<tr>
<td>RAD</td>
<td>right axis deviation</td>
</tr>
<tr>
<td>RAH</td>
<td>right atrial hypertrophy</td>
</tr>
<tr>
<td>RBBB</td>
<td>right bundle branch block</td>
</tr>
<tr>
<td>RPA</td>
<td>right pulmonary artery</td>
</tr>
<tr>
<td>RV</td>
<td>right ventricle or ventricular</td>
</tr>
<tr>
<td>RVH</td>
<td>right ventricular hypertrophy</td>
</tr>
<tr>
<td>RVOT</td>
<td>right ventricular outflow tract</td>
</tr>
<tr>
<td>S1</td>
<td>first heart sound</td>
</tr>
<tr>
<td>S2</td>
<td>second heart sound</td>
</tr>
<tr>
<td>S3</td>
<td>third heart sound</td>
</tr>
<tr>
<td>S4</td>
<td>fourth heart sound</td>
</tr>
<tr>
<td>SBE</td>
<td>subacute bacterial endocarditis</td>
</tr>
<tr>
<td>SEM</td>
<td>systolic ejection murmur</td>
</tr>
<tr>
<td>SVC</td>
<td>superior vena cava</td>
</tr>
<tr>
<td>SVR</td>
<td>systemic vascular resistance</td>
</tr>
<tr>
<td>SVT</td>
<td>supraventricular tachycardia</td>
</tr>
<tr>
<td>TAPVR</td>
<td>total anomalous pulmonary venous return</td>
</tr>
<tr>
<td>TGA</td>
<td>transposition of the great arteries</td>
</tr>
<tr>
<td>TOF</td>
<td>tetralogy of Fallot</td>
</tr>
<tr>
<td>TR</td>
<td>tricuspid regurgitation</td>
</tr>
<tr>
<td>TS</td>
<td>tricuspid stenosis</td>
</tr>
<tr>
<td>VSD</td>
<td>ventricular septal defect</td>
</tr>
<tr>
<td>VT</td>
<td>ventricular tachycardia</td>
</tr>
<tr>
<td>WPW</td>
<td>Wolff-Parkinson-White</td>
</tr>
</tbody>
</table>
PART 1
Basic Tools in Routine Evaluation of Cardiac Patients

OUTLINE

Introduction
Chapter 1. History Taking
2. Physical Examination
3. Electrocardiography
4. Chest Radiography
Basic Tools in Routine Evaluation of Cardiac Patients

The initial office evaluation of a child with possible cardiac abnormalities is usually accomplished by history taking; physical examination that includes inspection, palpation, and auscultation; electrocardiography (ECG); and sometimes chest radiography. The weight of the information gained from these different techniques varies with the type and severity of the disease. For example, if a mother had diabetes during her pregnancy, infants with macrosomia have an increased chance of having cardiac problems. The prevalence of congenital heart disease (CHD) increases three to four times that found in the general population. Ventricular septal defect (VSD), transposition of the great arteries (TGA), and coarctation of the aorta (COA) are more common defects. Congenital malformations of all types are increased in these infants. Hypertrophic cardiomyopathy with or without obstruction of the left ventricular outflow tract occurs in 10% to 20% of these infants, and they also have an increased risk of persistent pulmonary hypertension of the newborn (PPHN). The physician should look for these defects when examining the child.

Auscultation may be the most important source of information in the diagnosis of acyanotic heart disease such as VSD or PDA. However, auscultation is rarely diagnostic in cyanotic CHD such as TGA, in which heart murmur is often absent. Careful palpation of the peripheral pulses is more important than auscultation in the detection of COA. Measurement of blood pressure is the most important diagnostic tool in the detection of hypertension. ECG and chest radiography have strengths and weaknesses in their ability to assess the severity of heart disease. ECG detects hypertrophy well and therefore detects conditions of pressure overload, but it is less reliable at detecting dilatation from volume overload. Chest radiography is most reliable in establishing volume overload, but it poorly demonstrates hypertrophy without dilatation.

The next four chapters discuss these basic tools (history, physical examination, ECG, chest roentgenogram) in depth.
History Taking

As in the evaluation of any other system, history taking is a basic step in cardiac evaluation. Maternal history during pregnancy is often helpful in the diagnosis of congenital heart disease (CHD) because certain prenatal events are known to be teratogenic. Past history, including the immediate postnatal period, provides more direct information relevant to the cardiac evaluation. Family history also helps link a cardiac problem to other medical problems that may be prevalent in the family. Box 1-1 lists important aspects of history taking for children with potential cardiac problems.
Gestational and Natal History

Infections, medications, and excessive alcohol intake may cause CHD, especially if they occur early in pregnancy.

Infections

1. Maternal rubella infection during the first trimester of pregnancy commonly results in multiple anomalies, including cardiac defects.
2. Infections by cytomegalovirus, herpesvirus, and coxsackievirus B are suspected to be teratogenic if they occur in early pregnancy. Infections by these viruses later in pregnancy may cause myocarditis.
3. Human immunodeficiency virus infection (in illicit drug users) has been associated with infantile cardiomyopathy.

Medications, Alcohol, and Smoking

1. Several medications are suspected teratogens.
   a. Amphetamines have been associated with ventricular septal defect (VSD), patent ductus arteriosus (PDA), atrial septal defect (ASD), and transposition of the great arteries (TGA).
   b. Anticonvulsants are suspected of causing CHD. Phenytoin (Dilantin) has been associated with pulmonary stenosis (PS), aortic stenosis (AS), coarctation of the aorta (COA), and PDA. Trimethadione (Tridione) has been associated with TGA, tetralogy of Fallot (TOF), and hypoplastic left heart syndrome (HLHS).
   c. Angiotensin-converting enzyme (ACE) inhibitors (captopril, enalapril, lisinopril) and angiotensin II receptor antagonists (losartan) taken during the first trimester have been reported to cause congenital malformations of multiple systems, including cardiac defects (e.g., ASD, VSD, PDA, and PS).
   d. Lithium has been associated with Ebstein’s anomaly.
   e. Retinoic acid may cause conotruncal anomalies.
   f. Valproic acid may be associated with various heart defects such as ASD, VSD, AS, pulmonary atresia with intact ventricular septum, and COA.
   g. Other medications suspected of causing CHD (VSD, TOF, TGA) include progesterone and estrogen.
2. Excessive alcohol intake during pregnancy has been associated with VSD, PDA, ASD, and TOF (fetal alcohol syndrome).
3. Although cigarette smoking has not been proved to be teratogenic, it does cause intrauterine growth retardation.

BOX 1-1 Selected Aspects of History Taking
Gestational and Natal History
Infections, medications, excessive smoking, or alcohol intake during pregnancy
Birth weight

Postnatal, Past and Present History
Weight gain, development, and feeding pattern
Cyanosis, “cyanotic spells,” and squatting
Tachypnea, dyspnea, puffy eyelids
Frequency of respiratory infection
Exercise intolerance
Heart murmur
Chest pain
Syncope
Palpitation
Joint symptoms
Neurologic symptoms
Medications

Family History
Hereditary disease
Congenital heart defect
Rheumatic fever
Sudden unexpected death
Diabetes mellitus, arteriosclerotic heart disease, hypertension, dyslipidemia, and so on

Maternal Conditions
1. There is a high incidence of cardiomyopathy in infants born to mothers with diabetes. In addition, these babies have a higher incidence of structural heart defects (e.g., TGA, VSD, PDA).
2. Maternal lupus erythematosus and mixed connective tissue disease have been associated with a high incidence of congenital heart block in offspring.
3. The incidence of CHD increases from about 1% in the general population to as much as 15% if the mother has CHD even if it is postoperative (see Table A-2 in Appendix A).

Birth Weight
Birth weight provides important information about the nature of the cardiac problem.
1. If an infant is small for gestational age, it may indicate intrauterine infections or use of
chemicals or drugs by the mother. Rubella syndrome and fetal alcohol syndrome are typical examples.

2. Infants with high birth weight, often seen in offspring of mothers with diabetes, show a higher incidence of cardiac anomalies. Infants with TGA often have birth weights higher than average; these infants have cyanosis.
Postnatal History

Weight Gain, Development, and Feeding Pattern
Weight gain and general development may be delayed in infants and children with congestive heart failure (CHF) or severe cyanosis. Weight is affected more significantly than height. If weight is severely affected, physicians should suspect a more general dysmorphic condition. Poor feeding of recent onset may be an early sign of CHF in infants, especially if the poor feeding is the result of fatigue and dyspnea.

Cyanosis, “Cyanotic Spells,” and Squatting
The presence of cyanosis should be assessed. If the parents think that their child has cyanosis, the physician should ask them about the onset (e.g., at birth, several days after birth), severity of cyanosis, permanent or paroxysmal nature, parts of the body that were cyanotic (e.g., fingers, toes, lips), and whether the cyanosis becomes worse after feeding. Evanescent acrocyanosis is normal in neonates.
A “cyanotic spell” is seen most frequently in infants with TOF and requires immediate attention, although it has become less frequent because most surgical repairs are done in early infancy. Physicians should ask about the time of its appearance (e.g., in the morning on awakening, after feeding), duration of the spells, and frequency of the spells. Most important is whether infants were breathing fast and deep during the spell or were holding their breath. This helps differentiate between a true cyanotic spell and a breath-holding spell.
The physician should ask whether the child squats when tired or has a favorite body position (e.g., knee–chest position) when tired. Squatting strongly suggests cyanotic heart disease, particularly TOF. Fortunately, squatting is extremely rare now with early surgical repair of cyanotic CHDs.

Tachypnea, Dyspnea, and Puffy Eyelids
Tachypnea, dyspnea, and puffy eyelids are signs of CHF. Left-sided heart failure produces tachypnea with or without dyspnea. Tachypnea becomes worse with feeding and eventually results in poor feeding and poor weight gain. A sleeping respiratory rate of more than 40 breaths/min is noteworthy. A rate of more than 60 breaths/min is abnormal even in a newborn.
Wheezing or persistent cough at night may be an early sign of CHF. Puffy eyelids and sacral edema are signs of systemic venous congestion. Ankle edema, which is commonly seen in adults, is not found in infants.

Frequency of Respiratory Infections
Congenital heart diseases with large left-to-right shunt and increased pulmonary blood flow predispose to lower respiratory tract infections. Frequent upper respiratory tract
infections are not related to CHD, although children with vascular rings may sound as if they have a chronic upper respiratory tract infection.

Exercise Intolerance

Decreased exercise tolerance may result from any significant heart disease, including large left-to-right shunt lesions, cyanotic defects, valvular stenosis or regurgitation, and arrhythmias. Obese children may be inactive and have decreased exercise tolerance in the absence of heart disease. A good assessment of exercise tolerance can be obtained by asking the following questions: Does the child keep up with other children? How many blocks can the child walk or run? How many flights of stairs can the child climb without fatigue? Does the weather or the time of day influence the child’s exercise tolerance?

With infants who do not walk or run, an estimate of exercise tolerance can be gained from the infant’s history of feeding pattern. Parents often report that the child takes naps; however, many normal children nap regularly.

Heart Murmur

If a heart murmur is the chief complaint, the physician should obtain information about the time of its first appearance and the circumstances of its discovery. A heart murmur heard within a few hours of birth usually indicates a stenotic lesion (AS, PS), atrioventricular (AV) valve regurgitation, or small left-to-right shunt lesions (VSD, PDA). The murmur of large left-to-right shunt lesions, such as VSD or PDA, may be delayed because of slow regression of pulmonary vascular resistance. In the case of stenotic lesion, the onset of the murmur is not affected by the pulmonary vascular resistance, and the murmur is usually heard shortly after birth. A heart murmur that is first noticed on a routine examination of a healthy-looking child is more likely to be innocent, especially if the same physician has been following the child’s progress. A febrile illness is often associated with the discovery of a heart murmur.

Chest Pain

Chest pain is a common reason for referral and parental anxiety. If chest pain is the primary complaint, the physician asks whether the pain is activity related (e.g., Do you have chest pain only when you are active, or does it come even when you watch television?). The physician also asks about the duration (e.g., seconds, minutes, hours) and nature of the pain (e.g., sharp, stabbing, squeezing) and radiation to other parts of the body (e.g., neck, left shoulder, left arm). Chest pain of cardiac origin is not sharp; it manifests as a deep, heavy pressure or the feeling of choking or a squeezing sensation, and it is usually triggered by exercise. The physician should ask whether deep breathing improves or worsens the pain. Pain of cardiac origin, except for pericarditis, is not affected by respiration.

Cardiac conditions that may cause chest pain include severe AS (usually associated
with activity), pulmonary hypertension or pulmonary vascular obstructive disease, and mitral valve prolapse (MVP). Chest pain in MVP is not necessarily associated with activity, but there may be a history of palpitation. There is increasing doubt about the relationship between chest pain and MVP in children. Less common cardiac conditions that can cause chest pain include severe PS, pericarditis of various causes, and Kawasaki’s disease (in which stenosis or aneurysm of the coronary artery is common).

Most children complaining of chest pain do not have a cardiac condition (see Chapter 30, Child with Chest Pain); cardiac causes of chest pain are rare in children and adolescents. The three most common noncardiac causes of chest pain in children are costochondritis, trauma to the chest wall or muscle strain, and respiratory diseases with cough (e.g., bronchitis, asthma, pneumonia, pleuritis). The physician should ask whether the patient has experienced recent trauma to the chest or has engaged in activity that may have resulted in pectoralis muscle soreness.

Gastroesophageal reflux and exercise-induced asthma are other recognizable causes of noncardiac chest pain in children. Exercise-induced asthma (or bronchospasm) typically occurs 5 to 10 minutes into vigorous physical activities in a child with asthma or with inadequately treated asthma. It can occur in a child previously undiagnosed with asthma. A psychogenic cause of chest pain is also possible; parents should be asked whether there has been a recent cardiac death in the family.

**Syncope**

Syncope is a transient loss of consciousness and muscle tone that results from inadequate cerebral perfusion. Dizziness is the most common prodromal symptom of syncope. These complaints could represent a serious cardiac condition that may result in sudden death. It may also be due to noncardiac causes, such as benign vasovagal syncope, dehydration, metabolic abnormalities, or neuropsychiatric disorders. Dehydration or inadequate hydration is an important contributing factor.

A history of exertional syncope may suggest arrhythmias (particularly ventricular arrhythmias, such as seen in long QT syndrome or severe obstructive lesions, e.g., severe AS or hypertrophic cardiomyopathy). Syncope provoked by exercise, that is accompanied by chest pain, or with a history of unoperated or operated heart disease suggests potential cardiac cause of syncope. Syncope while sitting down suggests arrhythmias or seizure disorders. Syncope while standing for a long time suggests vasovagal syncope (often in association with dehydration) without an underlying cardiac disease; this is the most common syncope in children (see Chapter 31 for further discussion). Hypoglycemia is a very rare cause of syncope occurring in the morning. Syncope duration less than 1 min suggests vasovagal syncope, hyperventilation, or syncope caused by another orthostatic mechanism. A longer duration of syncope suggests convulsive disorders, migraine, or cardiac arrhythmias.

Family history should include coronary heart disease risk factors, including history of myocardial infarction in family members younger than 30 years of age, cardiac arrhythmia, CHD, cardiomyopathies, long QT syndrome, seizures, and metabolic and
psychological disorders. A detailed discussion of this topic is presented in Chapter 31.

**Palpitation**

Palpitation is a subjective feeling of rapid heartbeats. Some parents and children report sinus tachycardia as palpitation. Paroxysms of tachycardia (e.g., supraventricular tachycardia) or single premature beats commonly cause palpitation (see Chapter 32, Palpitation). Children with hyperthyroidism or MVP may first be taken to a physician because of complaints of palpitation.

**Joint Symptoms**

When joint pain is the primary complaint, acute rheumatic arthritis or rheumatoid arthritis is a possibility, although the incidence of the former has dramatically decreased in recent years in the United States. The number of joints involved, duration of the symptom, and migratory or stationary nature of the pain are important. Arthritis of acute rheumatic fever typically involves large joints, either simultaneously or in succession, with a characteristic migratory nature. Pain in rheumatic joints is so severe that children refuse to walk. A history of recent sore throat (and throat culture results) or rashes suggestive of scarlet fever may be helpful. The physician also asks whether the joint was swollen, red, hot, or tender (see Chapter 20 for further discussion).

**Neurologic Symptoms**

A history of stroke suggests thromboembolism secondary to cyanotic CHD with polycythemia or infective endocarditis. In the absence of cyanosis, stroke can rarely be caused by paradoxical embolism of a venous thrombus through an ASD. Although very rare, primary hypercoagulable states should also be considered, which include such conditions as antithrombin III deficiency, protein C deficiency, protein S deficiency, disorders of the fibrinolytic system (e.g., hypoplasmminogenemia, abnormal plasminogen, plasminogen activator deficiency), dysfibrinogenemia, factor XII deficiency, and lupus anticoagulant (Barger, 2000). Hosts of other conditions cause secondary hypercoagulable states. A history of headache may be a manifestation of cerebral hypoxia with cyanotic heart disease, severe polycythemia, or brain abscess in cyanotic children. Although it is claimed to occur in adults, hypertension with or without COA rarely causes headaches in children. Choreic movement strongly suggests rheumatic fever.

**Medications**

Physicians should note the name, dosage, timing, and duration of cardiac and noncardiac medications. Medications may be responsible for the chief complaint of the visit or certain physical findings. Tachycardia and palpitation may be caused by cold medications or antiasthmatic drugs.

A history of tobacco and illicit drug use, which could be the cause of chief complaints,
should be obtained, preferably through a private interview with the child.
**Family History**

**Hereditary Disease**

Some hereditary diseases may be associated with certain forms of CHD. For example, Marfan’s syndrome is frequently associated with aortic aneurysm or with aortic or mitral insufficiency. Holt-Oram syndrome (ASD and limb abnormalities), long-QT syndrome (sudden death caused by ventricular arrhythmias), and idiopathic sudden death in the family should be inquired about. PS secondary to a dysplastic pulmonary valve is common in Noonan’s syndrome. Lentiginous skin lesion (LEOPARD syndrome) is often associated with PS and cardiomyopathy. Selected hereditary diseases in which cardiovascular disease is frequently found are listed in Table 2-1 along with other nonhereditary syndromes.

**Congenital Heart Disease**

The incidence of CHD in the general population is about 1% or, more precisely, 8 to 12 of 1000 live births. This does not include PDA in premature infants. The recurrence risk of CHD associated with inherited diseases or chromosomal abnormalities is related to the recurrent risk of the syndrome.

A history of CHD in close relatives increases the chance of CHD in a child. In general, when one child is affected, the risk of recurrence in siblings is about 3%, which is a threefold increase. Having a child with HLHS increases the risk of CHD in subsequent children (to ≈10%), and most centers perform fetal echocardiography. The risk of recurrence is related to the prevalence of particular defects. Whereas lesions with a higher prevalence (e.g., VSD) tend to have a higher risk of recurrence, lesions with a lower prevalence (e.g., tricuspid atresia, persistent truncus arteriosus) have a lower risk of recurrence. Table A-1 in Appendix A lists the recurrence risk figures for various CHDs, which can be used for counseling. The importance of cytoplasmic inheritance has recently been shown in some families based on the observation that the recurrence risk is substantially higher if the mother is the affected parent (see Table A-2 in Appendix A).

**Rheumatic Fever**

Rheumatic fever frequently occurs in more than one family member. There is a higher incidence of the condition among relatives of children with rheumatic fever. Although the knowledge of genetic factors involved in rheumatic fever is incomplete, it is generally agreed that there is an inherited susceptibility to acquiring rheumatic fever.

**Hypertension and Atherosclerosis**

Essential hypertension and coronary artery disease show a strong familial pattern. Therefore, when a physician suspects hypertension in a young person, it is important to obtain the family history of hypertension. Atherosclerosis results from a complex process...
in which hereditary and environmental factors interact. The most important risk factor for atherosclerosis is a positive family history, with coronary heart disease occurring before age 55 years in one’s father or grandfather and before age 65 years in one’s mother or grandmother. Clustering of cardiovascular risk factors occurs frequently in the same individual (metabolic syndrome), which calls for investigation for other risk factors when one risk factor is found. Detailed discussion of cardiovascular risk factors is presented in Chapter 33.
Physical Examination

As with the examination of any child, the order and extent of the physical examination of infants and children with potential cardiac problems should be individualized. The more innocuous procedures, such as inspection, should be done first, and the more frightening or uncomfortable parts should be delayed until later in the examination.

Supine is the preferred position for examining patients in any age group. However, if older infants and young children between 1 and 3 years of age refuse to lie down, they can be examined initially while sitting on their mothers’ laps.
Growth Pattern

Growth impairment is frequently observed in infants with congenital heart diseases (CHDs). The growth chart should reflect height and weight in terms of absolute values and also in percentiles. Accurate plotting and following of the growth curve are essential parts of the initial and follow-up evaluations of a child with significant heart problems. In overweight children, acanthosis nigricans should be checked in the neck and abdomen.

Different patterns of growth impairment are seen in different types of CHD.
1. Cyanotic patients have disturbances in both height and weight.
2. Acyanotic patients, particularly those with large left-to-right shunts, tend to have more problems with weight gain than with linear growth. The degree of growth impairment is proportional to the size of the shunt.
3. Acyanotic patients with pressure overload lesions without intracardiac shunt grow normally.

Poor growth in a child with mild cardiac anomaly or failure of catch-up weight gain after repair of the defect may be due to failure to recognize certain syndromes, inadequate calorie intake, or the underlying genetic predisposition.
**Inspection**

Much information can be gained by simple inspection without disturbing a sleeping infant or frightening a child with a stethoscope. Inspection should include the following: general appearance and nutritional state; any obvious syndrome or chromosomal abnormalities; color (i.e., cyanosis, pallor, jaundice); clubbing; respiratory rate, dyspnea, and retraction; sweat on the forehead; and chest inspection.

**General Appearance and Nutritional State**

The physician should note whether the child is in distress, well nourished or undernourished, and happy or cranky. Obesity should also be noted; besides being associated with other cardiovascular risk factors such as dyslipidemia, hypertension, and hyperinsulinemia, obesity is also an independent risk factor for coronary artery disease.

**Chromosomal Syndromes**

Obvious chromosomal abnormalities known to be associated with certain congenital heart defects should be noted by the physician. For example, about 40% to 50% of children with Down syndrome have a congenital heart defect; the two most common defects are endocardial cushion defect (ECD) and ventricular septal defect (VSD). A newborn with trisomy 18 syndrome usually has a congenital heart defect. Table 2-1 shows cardiac defects associated with selected chromosomal abnormalities along with other hereditary and nonhereditary syndromes.

**Hereditary and Nonhereditary Syndromes and Other Systems Malformations**

Congenital cardiovascular anomalies are associated with a number of hereditary or nonhereditary syndromes and malformations of other systems. For example, a child with a missing thumb or deformities of a forearm may have an atrial septal defect (ASD) or VSD (e.g., Holt-Oram syndrome [cardio-limb syndrome]). Newborns with CHARGE (coloboma, heart defects, choanal atresia, growth or mental retardation, genitourinary anomalies, ear anomalies) association show a high prevalence of conotruncal abnormalities (e.g., tetralogy of Fallot [TOF], double-outlet right ventricle (RV), persistent truncus arteriosus). A list of cardiac anomalies in selected hereditary and nonhereditary syndromes is given in Table 2-1. Certain congenital malformations of other organ systems are associated with an increased prevalence of congenital heart defects (Table 2-2).

**Color**

The physician should note whether the child is cyanotic, pale, or jaundiced. In cases of cyanosis, the degree and distribution should be noted (e.g., throughout the body, only on the lower or upper half of the body). Mild cyanosis is difficult to detect. The arterial saturation is usually 85% or lower before cyanosis is detectable in patients with normal
hemoglobin levels (see Chapter 11). Cyanosis is more noticeable in natural light than in artificial light. Cyanosis of the lips may be misleading, particularly in children who have deep pigmentation. The physician should also check the tongue, nail beds, and conjunctiva. When in doubt, the use of pulse oximetry is confirmatory. Children with cyanosis do not always have cyanotic congenital heart defects. Cyanosis may result from respiratory diseases or central nervous system disorders. Cyanosis that is associated with arterial desaturation is called central cyanosis. Cyanosis associated with normal arterial saturation is called peripheral cyanosis. Even mild cyanosis in a newborn requires thorough investigation (see Chapter 14).

Peripheral cyanosis may be noticeable in newborns who are exposed to cold and those with congestive heart failure (CHF) because, in both conditions, peripheral blood flow is sluggish, losing more oxygen to peripheral tissues. Cyanosis is also seen in polycythemic patients with normal O\textsubscript{2} saturation (see Chapter 11 for the relationship between cyanosis and hemoglobin levels). Circumoral cyanosis, cyanosis around the mouth, is found in normal children with fair skin. Isolated circumoral cyanosis is not significant. Acrocyanosis is a bluish or red discoloration of the fingers and toes of normal newborns in the presence of normal arterial oxygen saturation.

Pallor may be seen in infants with vasoconstriction from CHF or circulatory shock or in severely anemic infants. Newborns with severe CHF and those with congenital hypothyroidism may have prolonged physiologic jaundice. Patent ductus arteriosus (PDA) and pulmonary stenosis (PS) are common in newborns with congenital hypothyroidism. Hepatic disease with jaundice may cause arterial desaturation because of the development of pulmonary arteriovenous fistula (e.g., arteriohepatic dysplasia).

**Clubbing**

Long-standing arterial desaturation (usually longer than 6 months’ duration), even if too mild to be detected by an inexperienced person, results in clubbing of the fingernails and toenails. When fully developed, clubbing is characterized by a widening and thickening of the ends of the fingers and toes, as well as by convex fingernails and loss of the angle between the nail and nail bed (Fig. 2-1). Reddening and shininess of the terminal phalanges are seen in the early stages of clubbing. Clubbing appears earliest and most noticeably in the thumb. Clubbing may also be associated with lung disease (e.g., abscess), cirrhosis of the liver, and subacute bacterial endocarditis. Occasionally, clubbing occurs in normal people, such as in familial clubbing.
FIGURE 2-1  Diagram of normal and clubbed fingers.

TABLE 2-1
MAJOR SYNDROMES ASSOCIATED WITH CARDIOVASCULAR ABNORMALITIES
<table>
<thead>
<tr>
<th>Disorders</th>
<th>CV Abnormalities: Frequency and Types</th>
<th>Major Features</th>
<th>Etiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alagille syndrome (arteriohepatic dysplasia)</td>
<td>Frequent (85%), peripheral PA stenosis with or without complex CV abnormalities</td>
<td>Peculiar facies (95%) consisting of deep-set eyes; broad forehead; long, straight nose with flatterd tip; prominent chin; and small, low-set, malformed ears. Paucity of intrahepatic interlobular bile duct with chronic cholestasis (91%), hypercholesterolemia, butterfly-like vertebral arch defects (87%)</td>
<td>AD Chromosome 22q11.2</td>
</tr>
<tr>
<td>CHARGE association</td>
<td>Common (65%); TOF truncus arteriosus, aortic arch anomalies (e.g., vascular ring, interrupted aortic arch)</td>
<td>Growth retardation (50%) and mild mental retardation (16%)</td>
<td>8q12 deletion</td>
</tr>
<tr>
<td>Carpenter's syndrome</td>
<td>Frequent (50%); PDA, VSD, PS, TGA</td>
<td>Brachycephaly with variable craniosynostosis, mild facial hypoplasia, polydactyly and severe syndactyly (“mitten hands”)</td>
<td>AR</td>
</tr>
<tr>
<td>Cockayne's syndrome</td>
<td>Accelerated atherosclerosis</td>
<td>Senile-like changes beginning in infancy, dwarving, microcephaly, prominent nose and sunken eyes, visual loss (retinal degeneration) and hearing loss</td>
<td>AR</td>
</tr>
<tr>
<td>Cornelia de Lange's (de Lange's) syndrome</td>
<td>Occasional (30%); VSD</td>
<td>Synophrys and hirsutism, prenatal growth retardation, microcephaly, anteverted nares, downturned mouth, mental retardation</td>
<td>Unknown; AD?</td>
</tr>
<tr>
<td>Cri du chat syndrome (deletion 5p syndrome)</td>
<td>Occasional (25%); variable CHD (VSD, PDA, ASD)</td>
<td>Cat-like cry in infancy, microcephaly, downward slant of palpebral fissures</td>
<td>Partial deletion, short arm of chromosome 5</td>
</tr>
<tr>
<td>Crouzon's disease (craniofacial dysostosis)</td>
<td>Occasional; PDA, COA</td>
<td>Ptosis with shallow orbits, premature craniosynostosis, maxillary hypoplasia</td>
<td>AD</td>
</tr>
<tr>
<td>DiGeorge syndrome (overlap with velocardiofacial syndrome)</td>
<td>Frequent; interrupted aortic arch, truncus arteriosus, VSD, PDA, TOF</td>
<td>Hypertelorism, short philtrum, downslanting of eyes, hypoplasia of orbits, absence of thymus and parathyroid, hypocalcemia, deficient cell-mediated immunity</td>
<td>Microdeletion of 22q11.2</td>
</tr>
<tr>
<td>Down syndrome (trisomy 21)</td>
<td>Frequent (40%–50%); ECD, VSD</td>
<td>Hypotonic, flat facies, slanted palpebral fissure, small eyes, mental deficiency, simian crease</td>
<td>Trisomy 21</td>
</tr>
<tr>
<td>Ehlers-Danlos syndrome</td>
<td>Frequent; ASD, aneurysm of aorta and carotids, intracranial aneurysm, MVP</td>
<td>Hyperextensive joints, hyperelasticity, fragility and bruasibility of skin, poor wound healing with thin scar</td>
<td>AD</td>
</tr>
<tr>
<td>Ellis-van Creveld syndrome (chondroectodermal dysplasia)</td>
<td>Frequent (50%); ASD, single atrium</td>
<td>Short stature of prenatal onset, short distal extremities, narrow thorax with short rib, polydactyly, nail hypoplasia, neonatal teeth</td>
<td>AR</td>
</tr>
<tr>
<td>Fetal alcohol syndrome</td>
<td>Occasional (25%–30%); VSD, PDA, ASD, TOF</td>
<td>Prenatal growth retardation, microcephaly, short palpebral fissure, mental deficiency, irritable infant or hyperactive child</td>
<td>Ethanol or its by-products</td>
</tr>
<tr>
<td>Condition</td>
<td>Clinical Features</td>
<td>Genetic Mode</td>
<td>Notes</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>Fetal trimethadione syndrome</td>
<td>Occasional (15%–30%); TGA, VSD, TOF</td>
<td>Ear malformation, hypoplastic midface, unusual eyebrow configuration, mental deficiency, speech disorder</td>
<td>Exposure to trimethadione</td>
</tr>
<tr>
<td>Fetal warfarin syndrome</td>
<td>Occasional (15%–45%); TOF, VSD</td>
<td>Facial asymmetry and hypoplasia, hypoplasia, or aplasia of the pinna with blind or absent external ear canal (microtia); ear tags; cleft lip or palate; epidermal dermoid; hypoplastic vertebral</td>
<td>Exposure to warfarin</td>
</tr>
<tr>
<td>Friedrich’s ataxia</td>
<td>Frequent; hypertrophic cardiomyopathy progressing to heart failure</td>
<td>Late-onset ataxia, skeletal deformities</td>
<td>AR</td>
</tr>
<tr>
<td>Goldenhar syndrome</td>
<td>Frequent (35%); VSD, TOF</td>
<td>Facial asymmetry and hypoplasia, microtia, ear tag, cleft lip or palate, hypoplastic vertebral</td>
<td>Unknown; usually sporadic</td>
</tr>
<tr>
<td>Glycogen storage disease II (Pompe’s disease)</td>
<td>Very common; cardiomyopathy</td>
<td>Large tongue and flabby muscles, cardiomegaly; IVH and short PR on ECG, severe ventricular hypertrophy on echocardiography; normal FBS and GTT</td>
<td>AR</td>
</tr>
<tr>
<td>Holt-Oram syndrome (cardio-limb syndrome)</td>
<td>Frequent; ASD, VSD</td>
<td>Defects or absence of thumb or radius</td>
<td>AD</td>
</tr>
<tr>
<td>Homocystinuria</td>
<td>Frequent; medial degeneration of aorta and carotids, atrial or venous thrombosis</td>
<td>Subluxation of lens (usually by 10 yr), facial flush, osteoporosis, arachnoidcysts, pectus excavatum or carinatum, mental defect</td>
<td>AR</td>
</tr>
<tr>
<td>Infant of mother with diabetes</td>
<td>CHDs (3%–5%); TGA, VSD, COA; cardiomyopathy (10%–20%); PPHN</td>
<td>Macrosomia, hypoglycemia and hypocalcaemia, polycythemia, hyperbilirubinemia, other congenital anomalies</td>
<td>Fetal exposure to high glucose levels</td>
</tr>
<tr>
<td>Kartagener’s syndrome</td>
<td>Dextrocardia</td>
<td>Situs inversus, chronic sinusitis, and otitis media, bronchiectasis, abnormal respiratory cilia, immotile sperm</td>
<td>AR</td>
</tr>
<tr>
<td>LEOPARD syndrome (multiple lentigines syndrome)</td>
<td>Very common; PS, HOCM, long PR interval</td>
<td>Lentiginous skin lesion, ECG abnormalities, ocular hypertelorism, pulmonary stenosis, abnormal genitalia, retarded growth, deafness</td>
<td>AD</td>
</tr>
<tr>
<td>Long QT syndrome: Jervell and Lange-Nielsen syndrome</td>
<td>Very common; long QT interval on ECG, ventricular tachyarrhythmia</td>
<td>Congenital deafness (not in Romano-Ward syndrome), syncope resulting from ventricular arrhythmias, family history of sudden death (±)</td>
<td>AR</td>
</tr>
<tr>
<td>Romano-Ward syndrome</td>
<td></td>
<td></td>
<td>AD</td>
</tr>
<tr>
<td>Marfan’s syndrome</td>
<td>Frequent; aortic aneurysm, aortic or mitral regurgitation</td>
<td>Arachnodactyly with hyperextensibility, subluxation of lens</td>
<td>AD</td>
</tr>
<tr>
<td>Mucopolysaccharidosis: Hurler’s syndrome (type I)</td>
<td>Frequent; aortic or mitral regurgitation, coronary artery disease</td>
<td>Coarse features, large tongue, depressed nasal bridge, kyphosis, retarded growth, hepatomegaly, corneal opacity (not in Hunter’s syndrome), mental retardation; most patients die by 10 to 20 years of age</td>
<td>AR</td>
</tr>
<tr>
<td>Hunter’s syndrome (type II)</td>
<td>Frequent, cardiomyopathy</td>
<td>Waddling gait, “pseudohypertrophy” of calf muscle</td>
<td>XR</td>
</tr>
<tr>
<td>Morquio’s syndrome (type IV)</td>
<td>Frequent; cardiomyopathy</td>
<td></td>
<td>AR</td>
</tr>
<tr>
<td>Muscular dystrophy (Duchenne’s type)</td>
<td>Frequent; cardiomyopathy</td>
<td></td>
<td>XR</td>
</tr>
<tr>
<td>Condition</td>
<td>Frequency/Findings</td>
<td>Comments</td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Neurofibromatosis (von Recklinghausen's disease)</td>
<td>Occasional; PS, COA, pheochromocytoma</td>
<td>AD</td>
<td></td>
</tr>
<tr>
<td>Noonan's syndrome (Turner-like syndrome)</td>
<td>Frequent; PS (dystrophic pulmonary valve); LVH (or anterior septal hypertrophy)</td>
<td>Similar to Turner's syndrome but may occur both in males and females, without chromosomal abnormality</td>
<td></td>
</tr>
<tr>
<td>Pierre Robin syndrome</td>
<td>Occasional; VSD, PDA, less commonly ASD, COA, TOF</td>
<td>Micrognathia, glossoptosis, cleft soft palate</td>
<td></td>
</tr>
<tr>
<td>Osler-Rendu-Weber syndrome (hereditary hemorrhagic telangiectasia)</td>
<td>Occasional; pulmonary arteriovenous fistula</td>
<td>Hepatic involvement, telangiectasias, hemangioma or fibrosis</td>
<td></td>
</tr>
<tr>
<td>Osteogenesis imperfecta</td>
<td>Occasional; aortic dilatation, aortic regurgitation, MVP</td>
<td>Excessive bone fragility with deformities of skeleton, blue sclera, hyperlaxity of joints</td>
<td>AD or AR</td>
</tr>
<tr>
<td>Progeria (Hutchinson-Gilford syndrome)</td>
<td>Accelerated atherosclerosis</td>
<td>Alopecia, atrophy of subcutaneous fat, skeletal hypoplasia and dysplasia</td>
<td>Unknown; occasional AD or AR</td>
</tr>
<tr>
<td>Rubella syndrome</td>
<td>Frequent (&gt;95%); PDA and PA stenosis</td>
<td>Triad of the syndrome: deafness, cataract, and CHDs; others include intrauterine growth retardation, microcephaly, microphthalmia, hepatitis, neonatal thrombocytopenic purpura</td>
<td>Maternal rubella infection during the first trimester</td>
</tr>
<tr>
<td>Rubinstein-Taybi syndrome</td>
<td>Occasional (25%); PDA, VSD, ASD</td>
<td>Broad thumbs or toes; hypoplastic maxilla with narrow palate; beaked nose; short stature; mental retardation</td>
<td>Sporadic; 16p13.3 deletion</td>
</tr>
<tr>
<td>Smith-Lemli-Opitz syndrome</td>
<td>Occasional; VSD, PDA, others</td>
<td>Broad nasal tip with anteverted nostrils; ptosis of eyelids; Syndactyly of second and third toes; short stature; mental retardation</td>
<td>AR</td>
</tr>
<tr>
<td>Thrombocytopenia-absent radius (TAR) syndrome</td>
<td>Occasional (30%); TOF, ASD, dextrocardia</td>
<td>Thrombocytopenia, absent or hypoplastic radius, normal thumb; “leukemoid” granulocytosis and eosinophilia</td>
<td>AR</td>
</tr>
<tr>
<td>Treacher Collins syndrome</td>
<td>Occasional; VSD, PDA, ASD</td>
<td>Defects of lower eyelids; malar hypoplasia with downsloping palpebral fissure; malformation of auricle or ear canal defect, cleft palate</td>
<td>Fresh mutation; AD</td>
</tr>
<tr>
<td>Trisomy 13 syndrome (Patau's syndrome)</td>
<td>Very common (80%); VSD, PDA, dextrocardia</td>
<td>Low birth weight, central facial anomalies, polydactyly, chronic hemangiomas, low-set ears, visceral and genital anomalies</td>
<td>Trisomy 13</td>
</tr>
<tr>
<td>Trisomy 18 syndrome (Edward's syndrome)</td>
<td>Very common (90%); VSD, PDA, PS</td>
<td>Low birth weight, microcephaly, micrognathia, rocker-bottom feet, closed fist with overlapping fingers</td>
<td>Trisomy 18</td>
</tr>
<tr>
<td>Tuberous sclerosis</td>
<td>Frequent; rhabdomyoma</td>
<td>Triad of adenoma sebaceum (2–5 yr of age), seizures, and mental defect; cyst-like lesions in phalanges and elsewhere; fibrous-angiomatosis lesions (83%) with varying colors in nasolabial fold, cheeks, and elsewhere</td>
<td>AD</td>
</tr>
<tr>
<td>Turner’s syndrome (XO syndrome)</td>
<td>Frequent (35%); COA, bicuspid aortic valve, AS, hypertension, aortic dissection later in life</td>
<td>Short female; broad chest with widely spaced nipples; congenital lymphedema with residual pollihness over the dorsum of fingers and toes (80%)</td>
<td>XO with 45 chromosomes</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>---------------------------------</td>
<td>-------------------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>VATER association (VATER or VACTERL syndrome)</td>
<td>Common (&gt;50%); VSD, other defects</td>
<td>Vertebral anomalies, anal atresia, congenital heart defects, tracheoesophageal (TE) fistula, renal dysplasia, limb anomalies (e.g., radial dysplasia)</td>
<td>Sporadic</td>
</tr>
<tr>
<td>Velocardiofacial syndrome (Splintzer syndrome)</td>
<td>Very common (85%); truncus arteriosus, TOF, pulmonary atresia with VSD, interrupted aortic arch type B, VSD, and D-TGA</td>
<td>Structural or functional palatal abnormalities, unique facial characteristics (“elfin facies” with auricular abnormalities, prominent nose with squared nasal root and narrow alar base, vertical maxillary excess with long face), hypernasal speech, conductive hearing loss, hypotonia, developmental delay and learning disability</td>
<td>Unknown; chromosome 22q11 (probably the same disease as DiGeorge syndrome)</td>
</tr>
<tr>
<td>Williams syndrome</td>
<td>Frequent; supravalvular AS, PA stenosis</td>
<td>Varying degree of mental retardation, so-called elfin facies (consisting of some of the following: upturned nose, flat nasal bridge, long philtrum, flat malar area, wide mouth, full lips, widely spaced teeth, peri-orbital fullness) hypercalcaemia of infancy?</td>
<td>Sporadic; 7q23 deletion; AD?</td>
</tr>
<tr>
<td>Zellweger syndrome (Cerebro-hepato-renal syndrome)</td>
<td>Frequent; PDA, VSD or ASD</td>
<td>Hypotonia, high forehead with flat facies, hepatomegaly, albuminemia</td>
<td>AR</td>
</tr>
</tbody>
</table>

AD, autosomal dominant; AR, autosomal recessive; AS, aortic stenosis; ASD, atrial septal defect; CHD, congenital heart disease; Chrom, chromosome; COA, coarctation of the aorta; CV, cardiovascular; ECD, endocardial cushion defect; ECG, electrocardiogram; FBS, fasting blood sugar; GTT, glucose tolerance test; HOCM, hypertrophic obstructive cardiomyopathy; LVH, left ventricular hypertrophy; MR, mitral regurgitation; MVP mitral valve prolapse; PA, pulmonary artery; PDA, patent ductus arteriosus; PFC, persistent fetal circulation; PPHN, persistent pulmonary hypertension of newborn; PS, pulmonary stenosis; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; VSD, ventricular septal defect; XR, sex-linked recessive; ±, may or may not be present.

**TABLE 2-2**

PREVALENCE OF ASSOCIATED CONGENITAL HEART DEFECTS IN PATIENTS WITH OTHER SYSTEM MALFORMATION
<table>
<thead>
<tr>
<th>Organ System and Malformation</th>
<th>Frequency (Range) (%)</th>
<th>Specific Cardiac Defects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Central Nervous System</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrocephalus</td>
<td>6 (4.5–14.9)</td>
<td>VSD, ECD, TOF</td>
</tr>
<tr>
<td>Dandy-Walker syndrome</td>
<td>3 (2.5–4.3)</td>
<td>VSD</td>
</tr>
<tr>
<td>Agenesis of corpus callosum</td>
<td>15</td>
<td>No specific defects</td>
</tr>
<tr>
<td>Meckel-Gruber syndrome</td>
<td>14</td>
<td>No specific defects</td>
</tr>
<tr>
<td><strong>Thoracic Cavity</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TE fistula or esophageal atresia</td>
<td>21 (15–39)</td>
<td>VSD, ASD, TOF</td>
</tr>
<tr>
<td>Diaphragmatic hernia</td>
<td>11 (9.6–22.9)</td>
<td>No specific defects</td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duodenal atresia</td>
<td>17</td>
<td>No specific defects</td>
</tr>
<tr>
<td>Jejunal atresia</td>
<td>5</td>
<td>No specific defects</td>
</tr>
<tr>
<td>Anorectal anomalies</td>
<td>22</td>
<td>No specific defects</td>
</tr>
<tr>
<td>Imperforate anus</td>
<td>12</td>
<td>TOF, VSD</td>
</tr>
<tr>
<td><strong>Ventral Wall</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Omphalocele</td>
<td>21 (19–32)</td>
<td>No specific defects</td>
</tr>
<tr>
<td>Gastrochisis</td>
<td>3 (0–7.7)</td>
<td>No specific defects</td>
</tr>
<tr>
<td><strong>Genitourinary</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal agenisis</td>
<td></td>
<td>No specific defects</td>
</tr>
<tr>
<td>Bilateral</td>
<td>43</td>
<td></td>
</tr>
<tr>
<td>Unilateral</td>
<td>17</td>
<td>No specific defects</td>
</tr>
<tr>
<td>Horseshoe kidney</td>
<td>39</td>
<td>No specific defects</td>
</tr>
<tr>
<td>Renal dysplasia</td>
<td>5</td>
<td>No specific defects</td>
</tr>
</tbody>
</table>

ASD, atrial septal defect; ECD, endocardial cushion defect; TE, trachea-esophageal; TOF, tetralogy of Fallot; VSD, ventricular septal defect.


**Respiratory Rate, Dyspnea, and Retraction**

The physician should note the respiratory rate of every infant and child. If the infant breathes irregularly, the physician should count for a whole minute. The respiratory rate is faster in children who are crying, upset, eating, or feverish. The most reliable respiratory rate is that taken during sleep. After finishing a bottle of formula, an infant may breathe faster than normal for 5 to 10 minutes. A resting respiratory rate more than 40 breaths/min is unusual, and that more than 60 breaths/min is abnormal at any age. Tachypnea, along with tachycardia, is the earliest sign of left-sided heart failure. If the child has dyspnea or retraction, this may be a sign of a more severe degree of left-sided heart failure or a significant lung pathology.

**Sweat on the Forehead**

Infants with CHF often have a cold sweat on their foreheads. This is an expression of heightened sympathetic activity as a compensatory mechanism for decreased cardiac output.
Acanthosis Nigricans
Acanthosis nigricans is a dark pigmentation of skin creases most commonly seen on the neck in the majority of obese children and those with type 2 diabetes. It is also found in the axillae, groins, and inner thighs and on the belt line of the abdomen. Rarely, acanthosis occurs in patients with Addison disease, Cushing syndrome, polycystic ovary syndrome (Stein-Leventhal syndrome), hypothyroidism, and hyperthyroidism. This condition is associated with insulin resistance and a higher risk of developing type 2 diabetes.

Inspection of the Chest
Precordial bulge, with or without actively visible cardiac activity, suggests chronic cardiac enlargement. Acute dilatation of the heart does not cause precordial bulge. Pigeon chest (pectus carinatum), in which the sternum protrudes on the midline, is usually not a result of cardiomegaly.

Pectus excavatum (undue depression of the sternum) rarely, if ever, causes significant cardiac embarrassment. Rather, it may be a cause of a pulmonary systolic murmur or a large cardiac silhouette on a posteroanterior view of a chest roentgenogram, which compensates for the diminished anteroposterior diameter of the chest. As a group, children with a significant pectus excavatum have a shorter endurance time than normal children.

Harrison’s groove, a line of depression in the bottom of the rib cage along the attachment of the diaphragm, indicates poor lung compliance of long duration, such as that seen in large left-to-right shunt lesions.
Palpation

Palpation should include the peripheral pulses (their presence or absence, the pulse rate, the volume of the pulses) and the precordium (the presence of a thrill, the point of maximal impulse [PMI], precordial hyperactivity). Although ordinarily palpation follows inspection, auscultation may be more fruitful on a sleeping infant who might wake up and become uncooperative.

Peripheral Pulses

1. The physician should count the pulse rate and note any irregularities in the rate and volume. The normal pulse rate varies with the patient’s age and status. The younger the patient, the faster the pulse rate. Increased pulse rate may indicate excitement, fever, CHF, or arrhythmia. Bradycardia may mean heart block, effects of drugs, and so on. Irregularity of the pulse suggests arrhythmias, but sinus arrhythmia (an acceleration with inspiration) is normal.

2. The right and left arm and an arm and a leg should be compared for the volume of the pulse. Every patient should have palpable pedal pulses, of the dorsalis pedis, tibialis posterior, or both. It is often easier to feel pedal pulses than femoral pulses. Attempts at palpating a femoral pulse often wake up a sleeping infant or upset a toddler. If a good pedal pulse is felt, coarctation of the aorta (COA) is effectively ruled out, especially if the blood pressure (BP) in the arm is normal. Weak leg pulses and strong arm pulses suggest COA. If the right brachial pulse is stronger than the left brachial pulse, the cause may be COA occurring near the origin of the left subclavian artery or supravalvular aortic stenosis (AS). A weaker right brachial pulse than the left suggests aberrant right subclavian artery arising distal to the coarctation.

3. Bounding pulses are found in aortic run-off lesions such as PDA, aortic regurgitation (AR), large systemic arteriovenous fistula, or persistent truncus arteriosus (rarely). Pulses are bounding in premature infants because of the lack of subcutaneous tissue and because many have PDA.
4. Weak, thready pulses are found in cardiac failure or circulatory shock or in the leg of a patient with COA. A systemic-to-pulmonary artery (PA) shunt (either classic Blalock-Taussig shunt or modified Gore-Tex shunt) or subclavian flap angioplasty for repair of COA may result in an absent or weak pulse in the arm affected by surgery. Arterial injuries resulting from previous cardiac catheterization may cause a weak pulse in the affected limb.

5. Pulsus paradoxus (paradoxical pulse) is suspected when there is marked variation in the volume of arterial pulses with the respiratory cycle. The term pulsus paradoxus does not indicate a phase reversal; rather, it is an exaggeration of normal reduction of systolic pressure during inspiration. When arterial BP is being monitored through an indwelling arterial catheter, the presence of pulsus paradoxus is easily detected by a wide swing (>10 mm Hg) in arterial pressure. In a child without arterial pressure monitoring, accurate evaluation requires sphygmomanometry (Fig. 2-2). Pulsus paradoxus may be associated with cardiac tamponade secondary to pericardial effusion or constrictive pericarditis or to severe respiratory difficulties seen with asthma or pneumonia. It is also seen in patients who are on ventilators with high pressure settings, but in these cases, the BP increases with inflation.

The presence of pulsus paradoxus is confirmed by the use of a sphygmomanometer as described below.

a. The cuff pressure is raised about 20 mm Hg above the systolic pressure.
b. The pressure is lowered slowly until Korotkoff sound 1 is heard for some but not all cardiac cycles, and the reading is noted (line A on Fig. 2-2).
c. The pressure is lowered further until systolic sounds are heard for all cardiac cycles, and the reading is noted (line B on Fig. 2-2).
d. If the difference between readings A and B is greater than 10 mm Hg, pulsus paradoxus is present.

FIGURE 2-2 Diagram of pulsus paradoxus. Note the reduction in systolic pressure of more than 10 mm Hg during inspiration. EXP, expiration; INSP, inspiration.
One should palpate the following on the chest: apical impulse, point of maximal impulse (PMI), hyperactivity of the precordium, and palpable thrill.

**Apical Impulse**

Palpation of the apical impulse is usually superior to percussion in the detection of cardiomegaly. Its location and diffuseness should be noted. Percussion in infants and children is inaccurate and adds little. The apical impulse is normally at the fifth intercostal space in the midclavicular line after age 7 years. Before this age, the apical impulse is in the fourth intercostal space just to the left of the midclavicular line. An apical impulse displaced laterally or downward suggests cardiac enlargement.

**Point of Maximal Impulse**

The PMI is helpful in determining whether the RV or left ventricle (LV) is dominant. With RV dominance, the impulse is maximal at the lower left sternal border or over the xiphoid process; with LV dominance, the impulse is maximal at the apex. Normal newborns and infants have RV dominance and therefore more RV impulse than older children. If the impulse is more diffuse and slow rising, it is called a *heave*. If it is well localized and sharp rising, it is called a *tap*. Heaves are often associated with volume overload. Taps are associated with pressure overload.

**Hyperactive Precordium**

The presence of a hyperactive precordium characterizes heart disease with volume overload, such as that seen in defects with large left-to-right shunts (e.g., PDA, VSD) or heart disease with severe valvular regurgitation (e.g., AR, mitral regurgitation [MR]).

**Thrills**

Thrills are vibratory sensations that represent palpable manifestations of loud, harsh murmurs. Palpation for thrills is often of diagnostic value. A thrill on the chest is felt better with the palm of the hand than with the tips of the fingers. However, the fingers are used to feel a thrill in the suprasternal notch and over the carotid arteries.

1. Thrills in the upper left sternal border originate from the pulmonary valve or PA and therefore are present in PS, PA stenosis, or PDA (rarely).
2. Thrills in the upper right sternal border are usually of aortic origin and are seen in AS.
3. Thrills in the lower left sternal border are characteristic of a VSD.
4. Thrills in the suprasternal notch suggest AS but may be found in PS, PDA, or COA.
5. The presence of a thrill over the carotid artery or arteries accompanied by a thrill in the suprasternal notch suggests diseases of the aorta or aortic valve (e.g., COA, AS). An isolated thrill in one of the carotid arteries without a thrill in the suprasternal notch may be a carotid bruit.
6. Thrills in the intercostal spaces are found in older children with severe COA and extensive intercostal collaterals.
Blood Pressure Measurement

Whenever possible, every child should have his or her BP measured as part of the physical examination. The status of the child at the time of BP measurement, such as moving, crying, or fighting, should be considered in the interpretation of obtained BP values before making any decision about the normalcy of the measurement. When BP is measured in a reasonably quiet situation, an average value of 2 or more BP values is compared with a set of normative BP standards to see if obtained BP values are normal or abnormal. Unfortunately, there have been problems regarding the proper method of measuring BP as well as the normative BP values for children.

Scientifically unsound methods of BP measurement recommended by two previous National Institutes of Health (NIH) Task Forces (1977 and 1987) have dominated the field, and they have been the source of confusion for nearly half a century. At this time, both the methodology and standards recommended by the NIH Task Forces have been abandoned. However, the most recent BP standards recommended by the Working Group of the National High Blood Pressure Education Program (NHBPEP) are still problematic for several reasons.

In this subsection, the following important issues in children’s BP measurement are discussed for a quick overview:

a. What is the currently recommended BP measurement method?
b. How good are normal BP standards recommended by the Working Group of the NHBPEP?
c. Which normal BP standards should be used and why?
d. How accurate are oscillometric BP measurements?
e. Are BP levels obtained by oscillometric devices interchangeable with those obtained by the auscultatory method?
f. How should arm and leg BP values be interpreted in children?
g. What are normative BP levels in neonates and small children?
h. How important is the concept of peripheral amplification of systolic pressure?
1. What is the currently recommended BP measuring method?
In the recent past, two Task Forces of the NIH, 1977 and 1987, recommended BP cuff selection based on the length of the arm, initially recommending the cuff width to be two thirds of the arm length and later changing it to three fourths of the length of the arm. These Task Forces have provided normal BP standards based on these unscientific methods. The BP cuff selection based on the length of the arm is scientifically unsound and violates the physical principles underlying indirect BP measurement, which have been established a century ago. For adults, the Special Task Force of the American Heart Association (AHA) has recommended the correct cuff selection method based on the thickness (or circumference) of the arm, and it has been in use since 1950. The correct width of the BP cuff is 40% to 50% of the circumference of the limb on which the BP is being measured (Fig. 2-3). In 1988, the AHA’s Special Task Force extended the same cuff selection method to children as well, but the 1987 NIH Task Force did not. In 2004, the NHBPEP has accepted the correct BP cuff selection method of the AHA.

The following summarizes current views on BP measurement techniques recommended by the AHA as well as the NHBPEP:

a. The BP cuff width should be 40% to 50% of the circumference (equivalent to 125% to 155% of the diameter) of the extremity with the cuff long enough to completely or nearly completely encircle the extremities (endorsed by both groups).

b. The NHBPEP recommends Korotkoff phase 5 (K5) as the diastolic pressure, but this recommendation is debatable based on a number of earlier reports. Earlier studies indicate that K4 agrees better with direct intraarterial diastolic pressure for children 12 years of age and younger (endorsed by the AHA, NIH Task Forces, and the Bogalusa Heart Study [Hammond et al, 1995]).

c. Both groups recommend averaging two or more readings (because the averaged values are closer to the basal BP level and are more reproducible).

d. Both the AHA and the NHBPEP recommend the sitting position with the arm at the heart level.

2. How good are BP standards recommended by the NHBPEP?
Normative BP standards recommended by the NHBPEP are not as good as it was made to believe for several reasons. Readers should be aware of a few major flaws in the NHBPEP’s normative values.

a. BP data presented in the NHBPEP standards are not obtained by using the same methodology as the program recommends, nor are they from a nationally representative population. They are obtained through an arm’s-length–based cuff selection method, which is currently abandoned because of its unscientific nature. These values are also
from single measurement rather than the averages of multiple readings, as currently recommended. In other words, the original source of the elaborate BP standards of the NHBEP is one that has been abandoned by the program itself, yet the program’s recommended BP standards are from these abandoned studies.

b. Expressing children’s BP levels by age and height percentiles is statistically unsound and unjustified on highly variable office BP readings. Height has no statistically important role in children’s BP levels. Partial correlation analysis in the San Antonio Children’s Blood Pressure Study (SACBPS) shows that when auscultatory BP levels were adjusted for age and weight, the correlation coefficient of systolic BP with height was very small ($r = 0.068$ for boys; $r = 0.072$ for girls), whereas when adjusted for age and height, the correlation of systolic pressure with weight remained high ($r = 0.343$ for boys; $r = 0.294$ for girls). These findings indicate that the contribution of height to BP levels is negligible. The apparent correlation of height to BP levels may all be secondary to a close correlation that exists between height and weight ($r = 0.86$). A similar conclusion was reached with oscillometric BP levels in the same study. Although weight is very important contributor to BP, weight cannot be used as a second variable because this would interfere with the detection of high BP in obese children. Thus, we found no rationale to use anything other than age and gender to express children’s normative BP standards.

c. Recommending additional computations requiring the use of scientifically unsound complex BP tables on such highly variable office BP readings is unreasonable and unproductive relative to what is to be gained by such efforts. Analyzing unscientifically obtained data by additional computations does not improve their value.

d. The NHBPEP does not point out that the auscultatory and oscillometric BP readings are not interchangeable. SACBPS, in which both auscultatory and oscillometric methods were used, found that oscillometric systolic pressures are significantly higher than auscultatory BP readings (see later discussion for further details). This finding is important in view of the popular use of oscillometric devices in BP measurements in pediatric practice.

e. As a national guideline, the NHBPEP does not emphasize the important contribution of the “white-coat phenomenon” in office BP readings. The white-coat phenomenon refers to the finding that BP readings obtained in a health care facility are often significantly higher than those obtained outside the facility. The white-coat phenomenon may be the most common cause of high BP readings, not true hypertension, in pediatric practice.

3. Which normal BP standards should be used and why?

a. Because the NIH Task Forces’ BP standards (of 1987) were obtained by using the unscientific, arm’s-length–based, cuff selection method, these BP standards are no longer acceptable.

b. The BP standards of the NHBPEP (2004) are riddled with major flaws as discussed earlier; they are not the best standards. Health care providers who choose to use these standards should be aware of the flaws. Although not acceptable as reliable pediatric BP
standards, the NHBPEP’s normative values are presented in Appendix B for the sake of completeness (Tables B-1 and B-2).

c. Normative BP percentile values from SACBPS are recommended as a better alternative to BP standards than the NHBPEP’s standards until nationwide data using the currently recommended methods become available. These are the only available BP standards that have been obtained according to the currently recommended method. In the SACBPS, BP levels were obtained in more than 7000 schoolchildren of three ethnic groups (African American, Mexican American, and non-Hispanic white) enrolled in kindergarten through the 12th grade in the San Antonio, Texas, area. Both the auscultatory and oscillometric (model Dinamap 8100) methods were used in the study, and the data were the averages of three readings. No consistent ethnic difference was found among the three ethnic groups, but there were important gender differences. Auscultatory BP data were expressed according to age and gender (Park, 2001). These BP standards are normally distributed from the mean value, and thus the effect of obesity is not a problem in using the standards (Figs. 2-4 and 2-5). Percentile BP values for these figures are presented in Appendix B (Tables B-3 and B-4).

d. When BP is measured using an oscillometric device, one should use device-specific normative BP standards. SACBPS found that the readings by the auscultatory method and those by Dinamap 8100 are significantly different and thus are not interchangeable (Park et al, 2005) as will be described further. This study does not show superiority of any one of the devices but simply indicates that the indirect BP readings are different according to the sensitivity of the detection device used. It may imply that the detection of oscillation by the machine occurs earlier (at a higher level of systolic pressure) than what human ears can hear. The gold standard remains an intraarterial BP reading. Percentile BP values by an oscillometric method (Dinamap 8100) are presented in Tables B-6 and B-7).

4. How accurate are oscillometric BP measurements?
The accuracy of indirect BP measurement by an oscillometric method (Dinamap Model 1846) has been demonstrated. In fact, oscillometric BP levels correlated better with intraarterial pressures than the auscultatory method (Park et al, 1987). Averaging three BP readings makes the BP readings more reproducible. The arm circumference–based cuff selection method is also appropriate for the Dinamap method. The oscillometric method also provides some advantages over auscultation: it eliminates observer-related variations, and it can be successfully used in infants and small children. Auscultatory BP measurement in small infants is not only difficult to obtain but also has not been shown to be accurate. The percentile values of normative oscillometric BPs in neonates and children up to 5 years of age are presented in Appendix B (Table B-5). Aside from the issue of accuracy, the oscillometric method is widely used in large pediatric and pediatric cardiology practices and in the setting of emergency departments. One caution is that not all oscillometric devices in clinical use have been validated for their accuracy.
FIGURE 2-4  Age-specific percentile curves of auscultatory systolic and diastolic (K5) pressures in boys 5 to 17 years of age. Blood pressure values are the average of three readings. The width of the blood pressure cuff was 40% to 50% of the circumference of the arm. Percentile values for the figure are shown in Table B-3, Appendix B. (From Park MK, Menard SW, Yuan C: Comparison of blood pressure in children from three ethnic groups. Am J Cardiol 87:1305-1308, 2001.)
5. Are BP levels obtained by oscillometric devices interchangeable with those obtained by the auscultatory method?

We found that BP levels obtained by the Dinamap (Model 8100) were on the average 10 mm Hg higher than the auscultatory method for the systolic pressure and 5 mm Hg higher for the diastolic pressure (Park et al, 2001). Therefore, the auscultatory and the Dinamap BPs are not interchangeable. This necessitates oscillometric-specific normative BP standards so that one does not use normal auscultatory BP standards when the oscillometric method is used (Park et al, 2005). Dinamap 8100–specific BP standards as presented in Appendix B (see Tables B-6 and B-7).

6. How should arm and leg BP values be interpreted in children?

Four-extremity BP measurements are often obtained to rule out COA. The same cuff
selection criterion (i.e., 40% to 50% of the circumference) applies for calf or thigh pressure determination, often requiring the use of a larger cuff for the lower extremity. The patient should be in the supine position for BP measurements in the arm and leg. When using the auscultatory method, the thigh pressure is obtained with the stethoscope placed in the popliteal fossa (over the popliteal artery) with the legs bent and in the supine or prone position. Calf BP is difficult to obtain by the auscultatory method.

TABLE 2-3
NORMATIVE BLOOD PRESSURE LEVELS BY DINAMAP MONITOR IN CHILDREN AGE 5 YEARS AND YOUNGER

<table>
<thead>
<tr>
<th>Age</th>
<th>Mean BP Levels (mm Hg)</th>
<th>90th Percentile</th>
<th>95th Percentile</th>
</tr>
</thead>
<tbody>
<tr>
<td>1–3 days</td>
<td>64/41 (50)</td>
<td>75/49 (50)</td>
<td>78/52 (62)</td>
</tr>
<tr>
<td>1 mo–2 yr</td>
<td>95/58 (72)</td>
<td>106/68 (83)</td>
<td>110/71 (86)</td>
</tr>
<tr>
<td>2–5 yr</td>
<td>101/57 (74)</td>
<td>112/66 (82)</td>
<td>115/68 (85)</td>
</tr>
</tbody>
</table>

Dinamap Model 1846SX was used.
Blood pressure (BP) levels are systolic/diastolic, with the mean in parentheses.

How do BP levels in the arm and leg compare in normal children? Even when a considerably wider cuff is selected for the thigh, the Dinamap systolic pressure in the thigh or calf is about 5 to 10 mm Hg higher than that in the arm (Park et al, 1993) except in the newborns in whom the arm and calf pressures are the same (see later discuss). This partly reflects the peripheral amplification of systolic pressure (see later discussion). Thus, the systolic pressure in the thigh (or calf) should be higher than or at least equal to that in the arm except in newborns. If the systolic pressure is lower in the leg, COA may be present. Leg BP determinations are mandatory in children with hypertension in the arm to rule out coarctation of he aorta. The presence of a femoral pulse does not rule out a coarctation.

7. What are normative BP levels in neonates and small children?
Blood pressure measurement is important in newborns and small children to diagnose COA, hypertension, or hypotension. In contrast to the recommendations of the NHBEP, the auscultatory method is difficult to apply in newborns and small children because of weak Korotkoff sounds in these age groups, and thus normative standards are not reliable. Therefore, the oscillometric method is frequently used instead. Abbreviated normative Dinamap BP standards for newborns and small children (≤5 years) are presented in Table 2-3. Full percentile values are presented in Appendix B (Table B-5). The same BP cuff selection method as used in older children applies to this age group (i.e., the cuff width approximately 50% of the circumference of the extremity). In
newborns, the systolic pressures in the arm and the calf are the same (Park et al, 1989). The absence of a higher systolic pressure in the leg in newborns may be related to the presence of a normally narrow aortic isthmus.

8. How important is the concept of peripheral amplification of systolic pressure?

Many physicians incorrectly assume that peripherally measured BP, such as that measured in the arm, reflects central aortic pressure, which is the perfusing pressure for the brain. This assumption is incorrect in many clinical situations. Some physicians also incorrectly think that the systolic pressure in the central aorta is higher than that in the brachial, radial, and pedal arteries. As shown schematically in Figure 2-6, systolic pressure becomes higher and higher as one moves further peripherally, although the diastolic and mean pressures remain the same or decrease slightly (O'Rourke, 1968). This phenomenon is known as peripheral amplification of systolic pressure. If this is correct, how does blood flow distally? There is a change in the arterial pressure waveform at different levels in an arterial tree, as shown in Figure 2-6, but the area under the curve decreases slightly in the peripheral sites, so that the blood flows to peripheral sites.

It is important for physicians to understand that peripheral systolic pressures obtained, either by direct or indirect methods, do not always reflect the central aortic pressure. Peripherally obtained systolic pressures are usually higher than the central aortic pressure. The magnitude of difference in the systolic pressure between a peripheral artery and the central aorta is not always predictable. There are some clinically important situations in which the peripheral amplification becomes more marked. The following are some key points of the peripheral amplification of systolic pressure:

a. The amplification is limited to systolic pressure only (but not in diastolic and mean pressures).

b. The systolic amplification is greater in children (with more reactive arteries) than in older adults who may have degenerative arterial disease.

c. Pedal artery systolic pressures are higher than the radial artery pressures.

d. The amplification is more marked in vasoconstricted states, and many of them are clinically important.

1) In impending circulatory shock, in which a high level of circulating catecholamines is present, systolic amplification may become more marked. Early diagnosis of an impending circulatory shock can be missed if one pays attention only to systolic pressure; the mean arterial and diastolic pressures should be low in this situation.

2) A child in CHF (in which peripheral vasoconstriction exists) may exhibit an exaggerated systolic amplification. Mean arterial pressure (MAP) may be more meaningful.

3) Arm systolic pressure in subjects running on a treadmill can be markedly higher than the central aortic pressure. A dramatic illustration of this phenomenon is shown in Figure 6-1 (section on exercise stress test) in a young adult running on a treadmill with catheters in the ascending aorta and the radial artery.

4) Subjects receiving catecholamine infusion or other vasoconstrictors in the setting of
critical care units may show significant amplification of systolic pressure. MAP may be more meaningful in this situation.

e. A reduced level of peripheral amplification of systolic pressure is noted in vasodilated states.

1) Subjects receiving vasodilators
2) After receiving a contract dye injection (which has vasodilating effects) during cardiac catheterization

FIGURE 2-6 Schematic diagram of pulse wave changes at different levels of the systemic arteries. AO, aorta; FA, femoral artery; PA, pedal artery. (Modified from Geddes LA: Handbook of Blood Pressure Measurement. Clifton, NJ: Humana Press, 1991.)
Auscultation

Although auscultation of the heart requires more skill, it also provides more valuable information than other methods of physical examination. Whereas the bell-type chest piece is better suited for detecting low-frequency events, the diaphragm selectively picks up high-frequency events. When the bell is firmly pressed against the chest wall, it acts like the diaphragm by filtering out low-frequency sounds or murmurs and picking up high-frequency events. Physicians should ordinarily use both the bell and the diaphragm, although using the bell both lightly and firmly pressed against the chest may be equally effective, especially in sleeping infants. Using only the diaphragm may result in missing some important low-frequency murmurs or sounds, such as mid-diastolic rumble, pulmonary regurgitation (PR) murmur, and faint Still’s innocent heart murmurs. One should not limit examination to the four traditional auscultatory areas. The entire precordium, as well as the sides and back of the chest, should be explored with the stethoscope. Systematic attention should be given to the following aspects:

1. **Heart rate and regularity**: Heart rate and regularity should be noted on every child. Extremely fast or slow heart rates or irregularity in the rhythm should be evaluated by an electrocardiogram (ECG) and a long rhythm strip.

2. **Heart sounds**: Intensity and quality of the heart sounds, especially the second heart sound (S2), should be evaluated. Abnormalities of the first heart sound (S1) and the third heart sound (S3) and the presence of a gallop rhythm or the fourth sound (S4) should be noted. Muffled heart sounds should also be noted.

3. **Systolic and diastolic sounds**: An ejection click in early systole provides a clue to aortic or pulmonary valve stenosis. A midsystolic click provides important clues to the diagnosis of mitral valve prolapse (MVP). An opening snap in diastole (present in mitral stenosis [MS]) should be noted but it is extremely rare in children.

4. **Heart murmurs**: Heart murmurs should be evaluated in terms of intensity, timing (systolic or diastolic), location, transmission, and quality.

---

**FIGURE 2-7** Diagram showing the relative intensity of A2 and P2 and the respiratory variation in the degree of splitting of the S2 at the upper left sternal border (pulmonary area). Exp, expiration; Insp, inspiration.
Heart Sounds

The heart sound should be identified and analyzed before the analysis of heart murmurs (Fig. 2-7). Muffled and distant heart sounds are present in pericardial effusion and heart failure.

First Heart Sound

The S1 is associated with closure of the mitral and tricuspid valves. It is best heard at the apex or lower left sternal border. Splitting of the S1 may be found in normal children, but it is infrequent. Abnormally wide splitting of S1 may be found in right bundle branch block (RBBB) or Ebstein’s anomaly. Splitting of S1 should be differentiated from ejection click or S4.

1. Ejection click is more easily audible at the upper left sternal border in PS. In bicuspid aortic valve, the click may be louder at the lower left sternal border or apex than at the upper right sternal border.
2. S4 is rare in children.

Second Heart Sound

The S2 in the upper left sternal border (i.e., pulmonary valve area) is of critical importance in pediatric cardiology. The S2 must be evaluated in terms of the degree of splitting and the intensity of the pulmonary closure component of the second heart sound (P2) in relation to the intensity of the aortic closure component of the second heart sound (A2). Although best heard with the diaphragm of a stethoscope, both components are readily audible with the bell. Abnormalities of splitting of the S2 and the intensity of the P2 are summarized in Box 2-1.

BOX 2-1 Summary of Abnormal S2

Abnormal Splitting

Widely Split and Fixed S2
Volume overload (e.g., ASD, PAPVR)
  Pressure overload (e.g., PS)
  Electrical delay (e.g., RBBB)
  Early aortic closure (e.g., MR)
  Occasional normal child

Narrowly Split S2
Pulmonary hypertension
  AS
  Occasional normal child

Single S2
Pulmonary hypertension
One semilunar valve (e.g., pulmonary atresia, aortic atresia, persistent truncus arteriosus)
  P2 not audible (e.g., TGA, TOF, severe PS)
Severe AS
Occasional normal child

Paradoxically split S2
Severe AS
  LBBB, WPW syndrome (type B)

Abnormal Intensity of P2
Increased P2 (e.g., pulmonary hypertension)
  Decreased P2 (e.g., severe PS, TOF, TS)
AS, aortic stenosis; ASD, atrial septal defect; LBBB, left bundle branch block; MR, mitral regurgitation; PAPVR, partial anomalous pulmonary venous return; PS, pulmonary stenosis; RBBB, right bundle branch block; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; TS, tricuspid stenosis; WPW, Wolff-Parkinson-White.

Splitting of the S2
In every normal child, with the exception of occasional newborns, two components of the S2 should be audible in the upper left sternal border. The first is the A2; the second is the P2. Both components are best heard at the pulmonary valve area (upper left sternal border). The A2 is not the second heart sound at the aortic area; rather, it is the first (or aortic closure) component of the second heart sound at the pulmonary area.

Normal Splitting of the S2
The degree of splitting of the S2 varies with respiration, increasing with inspiration and decreasing or becoming single with expiration (see Fig. 2-7). During inspiration, because of a greater negative pressure in the thoracic cavity, there is an increase in systemic venous return to the right side of the heart. This increased volume of blood in the RV prolongs the duration of RV ejection time, which delays the closure of the pulmonary valve, resulting in a wide splitting of the S2. The absence of splitting (i.e., single S2) or a widely split S2 usually indicates an abnormality.

Abnormal Splitting of the S2
Abnormal splitting may be in the form of wide splitting, narrow splitting, a single S2, or paradoxical splitting of the S2 (rarely).
1. A widely split and fixed S2 is found in conditions that prolong the RV ejection time or
that shorten the LV ejection. Therefore, it is found in:

a. ASD or partial anomalous pulmonary venous return (PAPVR) (conditions in which the amount of blood ejected by the RV is increased; volume overload)
b. PS (the valve stenosis prolongs the RV ejection time; pressure overload)
c. RBBB (a delay in electrical activation of the RV) delays the completion of the RV ejection
d. MR (a decreased forward output seen in this condition shortens the LV ejection time, causing aortic closure to occur earlier than normal)
e. An occasional normal child, including “prolonged hangout time” seen in children with dilated PA (a condition called idiopathic dilatation of the PA). In dilated PA, the increased capacity of the artery produces less recoil to close the pulmonary valve, which delays closure.

2. A narrowly split S2 is found in conditions in which the pulmonary valve closes early (e.g., pulmonary hypertension) or the aortic valve closure is delayed (e.g., AS). This is occasionally found in a normal child.

3. A single S2 is found in the following situations:
   a. When only one semilunar valve is present (e.g., aortic or pulmonary atresia, persistent truncus arteriosus)
   b. When the P2 is not audible (e.g., transposition of the great arteries [TGA], TOF, severe PS)
   c. When aortic closure is delayed (e.g., severe AS)

![FIGURE 2-8 Diagram showing the relative relationship of the heart sounds. The filled bar shows an abnormal sound.]
d. When the P2 occurs early (e.g., severe pulmonary hypertension)
e. In an occasional normal child

4. A paradoxically split S2 is found when the aortic closure (A2) follows the pulmonary closure (P2) and therefore is seen when the LV ejection is greatly delayed (e.g., severe AS, left bundle branch block [LBBB], sometimes Wolff-Parkinson-White [WPW] preexcitation).

**Intensity of the P2**
The relative intensity of the P2 compared with the A2 must be assessed in every child. In the pulmonary area, the A2 is usually louder than the P2 (see Fig. 2-7). Judgment as to normal intensity of the P2 is based on experience. There is no substitute for listening to the hearts of many normal children. Abnormal intensity of the P2 may suggest a pathologic condition. Increased intensity of the P2, compared with that of the A2, is found in pulmonary hypertension. Decreased intensity of the P2 is found in conditions with decreased diastolic pressure of the PA (e.g., severe PS, TOF, tricuspid atresia).

**Third Heart Sound**
The S3 is a somewhat low-frequency sound in early diastole and is related to rapid filling of the ventricle (Fig. 2-8). It is best heard at the apex or lower left sternal border. It is commonly heard in normal children and young adults. A loud S3 is abnormal and is audible in conditions with dilated ventricles and decreased ventricular compliance (e.g., large-shunt VSD or CHF). When tachycardia is present, it forms a “Kentucky” gallop.

**Fourth Heart Sound or Atrial Sound**
The S4 is a relatively low-frequency sound of late diastole (i.e., presystole) and is rare in
infants and children (see Fig. 2-8). When present, it is always pathologic and is seen in conditions with decreased ventricular compliance or CHF. With tachycardia, it forms a “Tennessee” gallop.

Gallop Rhythm

A gallop rhythm is a rapid triple rhythm resulting from the combination of a loud S3, with or without an S4, and tachycardia. It generally implies a pathologic condition and is commonly present in CHF. A summation gallop represents tachycardia and a superimposed S3 and S4.

Systolic and Diastolic Sounds

1. An ejection click (or ejection sound) follows the S1 very closely and occurs at the time of the ventricular ejection’s onset. Therefore, it sounds like a splitting of the S1. However, whereas it is usually audible at the base (either side of the upper sternal border), the split S1 is usually audible at the lower left sternal border (exception with an aortic click, discussed in a later section). If the physician hears what sounds like a split S1 at the upper sternal border, it may be an ejection click (Fig. 2-9).

   The pulmonary click is heard at the second and third left intercostal spaces and changes in intensity with respiration, being louder on expiration. The aortic click is best heard at the second right intercostal space but may be louder at the apex or mid-left sternal border. It usually does not change its intensity with respiration. The ejection click is most often associated with:
   a. Stenosis of semilunar valves (e.g., PS or AS)
   b. Dilated great arteries, which are seen in systemic or pulmonary hypertension, idiopathic dilatation of the PA, TOF (in which the aorta is dilated), and persistent truncus arteriosus

2. Midsystolic click with or without a late systolic murmur is heard at the apex in MVP (see Fig. 2-9 and Chapter 21).
3. Diastolic opening snap is rare in children and is audible at the apex or lower left sternal border. It occurs somewhat earlier than the S3 during diastole and originates from a stenosis of the atrioventricular (AV) valve, such as MS (see Fig. 2-9).

Extracardiac Sounds

1. A pericardial friction rub is a grating, to-and-fro sound produced by friction of the heart against the pericardium. This sounds similar to sandpaper rubbed on wood. Such a sound usually indicates pericarditis. The intensity of the rub varies with the phase of the cardiac cycle rather than the respiratory cycle. It may become louder when the patient leans forward. Large accumulation of fluid (pericardial effusion) may result in disappearance of the rub.
2. A pericardial knock is an adventitious sound associated with chronic (i.e., constrictive) pericarditis. It rarely occurs in children.
Heart Murmurs

Each heart murmur must be analyzed in terms of intensity (grade 1 to 6), timing (systolic or diastolic), location, transmission, and quality (musical, vibratory, blowing, and so on).

**Intensity**

Intensity of the murmur is customarily graded from 1 to 6:

- Grade 1: Barely audible
- Grade 2: Soft but easily audible
- Grade 3: Moderately loud but not accompanied by a thrill
- Grade 4: Louder and associated with a thrill
- Grade 5: Audible with the stethoscope barely on the chest
- Grade 6: Audible with the stethoscope off the chest

The difference between grades 2 and 3 or grades 5 and 6 may be somewhat subjective. The intensity of the murmur may be influenced by the status of cardiac output. Thus, any factor that increases the cardiac output (e.g., fever, anemia, anxiety, exercise) intensifies any existing murmur or may even produce a murmur that is not audible at basal conditions.

**Classification of Heart Murmurs.** Based on the timing of the heart murmur in relation to the S1 and S2, the heart murmur is classified into systolic, diastolic, and continuous murmurs.

**Systolic Murmurs**

Most heart murmurs are systolic in timing in that they occur between the S1 and S2. Systolic murmurs was classified by Aubrey Leatham in 1958 into two subtypes according to the time of onset: (1) ejection type and (2) regurgitant type (Fig. 2-10). Recently, Joseph Perloff classified systolic murmurs according to their time of onset and termination into four subtypes: (1) midsystolic (or ejection), (2) holosystolic, (3) early systolic, or (4) late systolic (Fig. 2-11). The holosystolic and early systolic murmurs of Perloff belong to the regurgitant murmur of Leatham. The types of murmurs (described earlier) and the location of the maximum intensity of the murmur are very important in the assessment of a systolic murmur. Transmission of the murmur to a particular direction and the quality of the murmur also help in deciding the cause of the murmur. These aspects will be discussed in detail below.
The classification is based primarily on the relationship of the S1 to the onset of the murmur. Short ejection-type murmur with the apex of the “diamond” in the early part of systole is found with mild stenosis of semilunar valves (top, left). With increasing severity of stenosis, the murmur becomes louder and longer, and its apex moves toward the S2 (middle, left). In severe pulmonary stenosis, the murmur is louder and may go beyond the A2 (bottom, left). A regurgitant systolic murmur is most often due to ventricular septal defect (VSD) and is usually holosystolic, extending all the way to the S2 (top, right). The regurgitant murmur may end in middle or early systole (not holosystolic) in some children, especially in those with small-shunt VSD and in some neonates with VSD (middle and bottom, right). Regardless of the length or intensity of the murmur, all regurgitant systolic murmurs are pathologic.

Midsystolic Murmur
(Ejection systolic murmur)

Holosystolic Murmur
(Regurgitant holosystolic)

Early Systolic Murmur
(Short regurgitant)

Late Systolic Murmur

Late systolic murmur is typically audible with mitral valve prolapse.
Types of Systolic Murmurs. Midsystolic (or Ejection Systolic) Murmurs

A midsystolic murmur (or ejection-type murmur) begins after S1 and ends before S2. Midsystolic murmurs coincide with turbulent flow through the semilunar valves and they occur in the following settings: (1) the flow of blood through stenotic or deformed semilunar valves (e.g., AS or PS); (2) accelerated systolic flow through normal semilunar valves, such as seen during pregnancy, fever, anemia, or thyrotoxicosis; and (3) innocent (normal) midsystolic murmurs (see Innocent Heart Murmurs later in this section). There is an interval between the S1 and the onset of the murmur that coincides with the isovolumic contraction period. The intensity of the murmur increases toward the middle and then decreases during systole (crescendo–decrescendo or diamond shaped in contour). The murmur usually ends before the S2 (see Fig. 2-10, left). The murmur may be short or long and is audible at the second left or second right intercostal space.

Holosystolic Murmurs

Holosystolic murmurs begin with S1 and occupy all of systole up to the S2. No gap exists between the S1 and the onset of the murmur. Analysis of the presence or absence of a gap between the S1 and the onset of the systolic murmur is of utmost importance in distinguishing between midsystolic murmurs and holosystolic or early systolic murmurs. Holosystolic and early systolic murmurs of Perloff are regurgitant systolic murmurs of Leatham. The intensity of holosystolic murmurs usually plateaus all the way to the S2. Holosystolic murmurs are caused by the flow of blood from a chamber that is at a higher pressure throughout systole than the receiving chamber, and they usually occur while the semilunar valves are still closed. These murmurs are associated with only the following three conditions: VSD, MR, and tricuspid regurgitation (TR). None of these ordinarily occurs at the base (i.e., second left or right intercostal space).

Early Systolic Murmurs

Early systolic murmurs (or short regurgitant murmurs) begin with the S1, diminish in decrescendo, and end well before the S2, generally at or before midsystole (see Fig. 2-11). Only the three conditions that cause holosystolic murmurs (VSD, MR, and TR) are the causes of an early systolic murmur. An early systolic murmur is a feature of TR with normal RV systolic pressure. When the RV systolic pressure is elevated, a holosystolic murmur results. Early systolic murmurs may occur in a neonate with a large VSD, children or adults with a very small VSD, or with a large VSD and pulmonary hypertension.

Late Systolic Murmurs

The term late systolic applies when a murmur begins in mid- to late systole and proceeds up to the S2 (see Fig. 2-11). The late systolic murmur of MVP is prototypical (see Chapter 21).

Location of Systolic Murmurs
In addition to the type of systolic murmur, the location of maximal intensity of the murmur is important when diagnosing the heart murmur’s origin. The following four locations are important: (1) upper left sternal border (pulmonary valve area), (2) upper right sternal border (aortic valve area), (3) lower left sternal border, and (4) the apex. For example, a holosystolic murmur heard maximally at the lower left sternal border is characteristic of a VSD. A midsystolic murmur maximally audible at the second left intercostal space is usually pulmonary in origin. The location of the heart murmur often helps differentiate between a midsystolic murmur and a holosystolic murmur. For example, a long PS murmur may sound like the holosystolic murmur of a VSD; however, because the maximal intensity is at the upper left sternal border, it is unlikely that a VSD caused the murmur. Although rare, a subarterial infundibular VSD murmur may be maximally heard at the upper left sternal border. The differential diagnosis of systolic murmurs according to the location is discussed in detail in this section (see Tables 2-4 to 2-7; Fig. 2-12).

### Transmission of Systolic Murmurs

The transmission of systolic murmurs from the site of maximal intensity may help determine the murmur’s origin. For example, an apical systolic murmur that transmits well to the left axilla and lower back is characteristic of MR, but one that radiates to the upper right sternal border and the neck is more likely to originate in the aortic valve. A systolic ejection murmur at the base that transmits well to the neck is more likely to be aortic in origin; one that transmits well to the back is more likely to be of pulmonary valve or PA origin.

### Quality of Systolic Murmurs

The quality of a murmur may help diagnose heart disease. Systolic murmurs of MR or of a VSD have a uniform, high-pitched quality, often described as blowing. Midsystolic murmurs of AS or PS have a rough, grating quality. A common innocent murmur in children, which is best audible between the lower left sternal border and apex, has a characteristic “vibratory” or humming quality.

### Differential Diagnosis of Systolic Murmurs at Various Locations

Systolic murmurs that are audible at the four locations are presented in Figure 2-12. More common conditions are listed in larger type and less common conditions in smaller type. For quick reference, characteristic physical, ECG, and radiography findings that are helpful in differential diagnoses are listed in Tables 2-4 through 2-7.
FIGURE 2-12  Diagram showing systolic murmurs audible at various locations. Less common conditions are shown in smaller type (see Tables 2-4 to 2-7). AS, aortic stenosis; ECD, endocardial cushion defect; HOCM, hypertrophic obstructive cardiomyopathy; IHSS, idiopathic hypertrophic subaortic stenosis; PAPVR, partial anomalous pulmonary venous return; TAPVR, total anomalous pulmonary venous return.

TABLE 2-4
DIFFERENTIAL DIAGNOSIS OF SYSTOLIC MURMURS AT THE UPPER LEFT STERNAL BORDER (PULMONARY AREA)
<table>
<thead>
<tr>
<th>Condition</th>
<th>Important Physical Findings</th>
<th>Chest Radiography Findings</th>
<th>ECG Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary valve stenosis</td>
<td>SEM, grade 2 to 5/6&lt;br&gt;Thrill (±)<em>&lt;br&gt;S2 may be split widely when mild&lt;br&gt;Ejection click (±) at 2LICS</em>&lt;br&gt;Transmit to the back</td>
<td>Prominent MPA (poststenotic dilatation)*&lt;br&gt;Normal PVM</td>
<td>Normal if mild&lt;br&gt;RAD&lt;br&gt;RVH*&lt;br&gt;RAH if severe</td>
</tr>
<tr>
<td>ASD</td>
<td>SEM, grade 2 to 3/6&lt;br&gt;Widely split and fixed S2*</td>
<td>Increased PVM*&lt;br&gt;RAE, RVE*&lt;br&gt;RVH</td>
<td>RAD&lt;br&gt;RVH&lt;br&gt;RBBB* (rsR')</td>
</tr>
<tr>
<td>Pulmonary flow murmur of newborn</td>
<td>SEM, grade 1 to 2/6&lt;br&gt;No thrill&lt;br&gt;Good transmission to the back and axilla*&lt;br&gt;Newborns</td>
<td>Normal&lt;br&gt;Occasional pectus excavatum or straight back</td>
<td>Normal&lt;br&gt;Normal</td>
</tr>
<tr>
<td>Pulmonary flow murmur of older children</td>
<td>SEM, grade 2 to 3/6&lt;br&gt;No thrill&lt;br&gt;Poor transmission</td>
<td>Prominent hilar vessels (±)</td>
<td>RVH or Normal</td>
</tr>
<tr>
<td>PA stenosis</td>
<td>SEM, grade 2 to 3/6&lt;br&gt;Occasional continuous murmur&lt;br&gt;P2 may be loud&lt;br&gt;Transmits well to the back and both lung fields*</td>
<td>Absence of prominent MPA&lt;br&gt;Dilated aorta</td>
<td>Normal or LVH&lt;br&gt;Dilatation aorta</td>
</tr>
<tr>
<td>AS</td>
<td>SEM, grade 2 to 5/6&lt;br&gt;Also audible in 2RICS*&lt;br&gt;Thrill (±) at 2RICS and SSN*&lt;br&gt;Ejection click at apex, 3LICS, or 2RICS (±)*&lt;br&gt;Paradoxically split S2 if severe</td>
<td>Decreased PVM*&lt;br&gt;Normal heart size*&lt;br&gt;Boot-shaped heart&lt;br&gt;Right aortic arch (25%)</td>
<td>RAD&lt;br&gt;RVH or BVH*&lt;br&gt;RAH (±)</td>
</tr>
<tr>
<td>TOF</td>
<td>Long SEM, grade 2 to 4/6, louder at MLSB*&lt;br&gt;Thrill (±)&lt;br&gt;Loud, single S2 (=A2)&lt;br&gt;Cyanosis, clubbing</td>
<td>Classic “3” sign on plain film or “E” sign on barium esophagogram*&lt;br&gt;Rib notching (±)</td>
<td>LVH in children&lt;br&gt;RBBB (or RVH) in infants</td>
</tr>
<tr>
<td>COA</td>
<td>SEM, grade 1 to 3/6&lt;br&gt;Loudest at left interscapular area (back)<em>&lt;br&gt;Weak or absent femorals</em>&lt;br&gt;Hypertension in arms&lt;br&gt;Frequent associated AS, bicuspid aortic valve, or MR</td>
<td>Absent “snowman” sign</td>
<td>Normal or LVH, LVE*&lt;br&gt;or BVH</td>
</tr>
<tr>
<td>FDA</td>
<td>Continuous murmur at left infracavicular area*&lt;br&gt;Occasional crescendic systolic only&lt;br&gt;Grade 2 to 4/6&lt;br&gt;Thrill (±)&lt;br&gt;Bounding pulses</td>
<td>Increased PVM*&lt;br&gt;LAE, LVE*&lt;br&gt;“Scimitar” sign</td>
<td>Normal, LVH, or BVH</td>
</tr>
<tr>
<td>TAPVR</td>
<td>SEM, grade 2 to 3/6&lt;br&gt;Widely split and fixed S2 (±)&lt;br&gt;Quadruple or quintuple rhythm*&lt;br&gt;Diastolic rumble at LLSB*&lt;br&gt;Mild cyanosis (IPO2) and clubbing (±)*</td>
<td>Increased PVM*&lt;br&gt;RAE and RVE*&lt;br&gt;“Snowman” sign</td>
<td>RAD&lt;br&gt;RAH&lt;br&gt;RVH*&lt;br&gt;Same as in ASD</td>
</tr>
<tr>
<td>PAPVR</td>
<td>Physical findings similar to those of ASD&lt;br&gt;S2 may not be fixed unless associated with ASD*</td>
<td>Increased PVM*&lt;br&gt;RAE and RVE*&lt;br&gt;“Scimitar” sign (±)</td>
<td>Same as in ASD</td>
</tr>
</tbody>
</table>

AS, aortic stenosis; ASD, atrial septal defect; BVH, biventricular hypertrophy; COA, coarctation of the aorta; LAE, left atrial enlargement; 2LICS, second left intercostal space; 3LICS, third left intercostal space; LLSB, lower left sternal border; LVE, left ventricular enlargement; LVH, left ventricular hypertrophy; MLSB, mid-left sternal border; MPA, main pulmonary artery; MR, mitral regurgitation; PA, pulmonary artery; PAPVR, partial anomalous pulmonary venous return; PDA, patent ductus arteriosus; PVM, pulmonary vascular markings; RAD, right axis deviation; RAE, right atrial enlargement; RAH, right atrial hypertrophy; RBBB, right bundle branch block; 2RICS, second right intercostal space; RVE, right ventricular enlargement; RVH, right ventricular hypertrophy; SEM, systolic ejection murmur; SSN, suprasternal notch; TAPVR, total anomalous pulmonary venous return.
pulmonary venous return; TOF, tetralogy of Fallot; ±, may or may not be present.

Findings that are characteristic of the condition.

### TABLE 2-5
DIFFERENTIAL DIAGNOSIS OF SYSTOLIC MURMURS AT THE UPPER RIGHT STERNAL BORDER (AORTIC AREA)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Important Physical Findings</th>
<th>Chest Radiography Findings</th>
<th>ECG Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aortic valve stenosis</td>
<td>SEM, grade 2 to 5/6, at 2RICS, may be loudest at 3LICS</td>
<td>Mild LVE (±)</td>
<td>Normal or LVH with or without “strain”</td>
</tr>
<tr>
<td></td>
<td>Thrill (±), URSB, SSN, and carotid arteries*</td>
<td>Prominent ascending aorta or aortic knob</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ejection click*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Transmits well to neck</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S2 may be single*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subaortic stenosis</td>
<td>SEM, grade 2 to 4/6</td>
<td>Usually normal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AR murmur almost always present in discrete stenosis*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>No ejection click</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supravalvular aortic stenosis</td>
<td>SEM, grade 2 to 3/6</td>
<td>Unremarkable</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thrill (±)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>No ejection click</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pulse and BP may be greater in right than left arm*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Peculiar facies and mental retardation (±)*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Murmur may transmit well to the back (PA stenosis)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AR, aortic regurgitation; BP, blood pressure; BVH, biventricular hypertrophy; 3LICS, third left intercostal space; LVE, left ventricular enlargement; LVH, left ventricular hypertrophy; PA, pulmonary artery; 2RICS, second right intercostal space; SEM, systolic ejection murmur; SSN, suprasternal notch; URSB, upper right sternal border; ±, may or may not be present.

Findings that are characteristic of the condition.

### TABLE 2-6
DIFFERENTIAL DIAGNOSIS OF SYSTOLIC MURMURS AT THE LOWER LEFT STERNAL BORDER
<table>
<thead>
<tr>
<th>Condition</th>
<th>Important Physical Findings</th>
<th>Chest Radiography Findings</th>
<th>ECG Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>VSD</td>
<td>Regurgitant systolic, grade 2 to 5/6*</td>
<td>Increased PVM*</td>
<td>Normal</td>
</tr>
<tr>
<td></td>
<td>May not be holosystolic</td>
<td>LAE and LVE</td>
<td>LVH or BVH</td>
</tr>
<tr>
<td></td>
<td>Well localized at LLSB</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thrill often present*</td>
<td>(cardiomegaly)*</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECD, complete</td>
<td>Similar to findings of VSD</td>
<td>Similar to large VSD</td>
<td>Superior QRS axis, LVH, or BVH</td>
</tr>
<tr>
<td></td>
<td>Diastolic rumble at LLSB*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gallop rhythm common in infants*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vibratory inno-cent murmur</td>
<td>Musical or vibratory with midsystolic accentuation</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>(Scills)</td>
<td>Maximum between LLSB and apex*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HOCM or IHSS</td>
<td>SEM, grade 2 to 4/6</td>
<td>Normal or globular LVE</td>
<td>LVH</td>
</tr>
<tr>
<td></td>
<td>Medium pitched</td>
<td></td>
<td>Abnormally</td>
</tr>
<tr>
<td></td>
<td>Maximum at LLSB or apex</td>
<td></td>
<td>deep Q waves in leads V5 and V6</td>
</tr>
<tr>
<td></td>
<td>Thrill (±)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sharp upstroke of brachial pulses*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>May have MR murmur</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TR</td>
<td>Regurgitant systolic, grade 2 to 3/6*</td>
<td>Normal PVM</td>
<td>RBBB, RAH, and first-degree</td>
</tr>
<tr>
<td></td>
<td>Triple or quadruple rhythm (in Ebstein’s anomaly)*</td>
<td>RAE if severe</td>
<td>AV block in Ebstein’s anomaly</td>
</tr>
<tr>
<td></td>
<td>Mild cyanosis (±)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepatomegaly with pulsatile liver and neck vein distention when severe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOF</td>
<td>Murmurs can be louder at ULSB</td>
<td>(see Table 2-4)</td>
<td>(see Table 2-4)</td>
</tr>
</tbody>
</table>

AV, atrioventricular; BVH, biventricular hypertrophy; ECD, endocardial cushion defect; HOCM, hypertrophic obstructive cardiomyopathy; IHSS, idiopathic hypertrophic subaortic stenosis; LAE, left atrial enlargement; LLSB, lower left sternal border; LVE, left ventricular enlargement; LVH, left ventricular hypertrophy; MR, mitral regurgitation; PVM, pulmonary vascular markings; RAE, right atrial enlargement; RAH, right atrial hypertrophy; RBBB, right bundle branch block; SEM, systolic ejection murmur; TR, tricuspid regurgitation; TOF, tetralogy of Fallot; ULSB, upper left sternal border; VSD, ventricular septal defect; ±, may or may not be present.

* Findings that are characteristic of the condition.

**TABLE 2-7**

**DIFFERENTIAL DIAGNOSIS OF SYSTOLIC MURMURS AT THE APEX**
Upper left sternal border (or pulmonary area)

In many conditions, both pathologic and physiologic (i.e., innocent murmur), a systolic murmur is most audible at the upper left sternal border. Audible systolic murmurs at this location are usually midsystolic murmurs and may be the result of one of the following:

- PS
- ASD
- Innocent (normal) pulmonary flow murmur of newborns
- Innocent pulmonary flow murmur of older children
- PA stenosis
- AS
- TOF
- COA
- PDA with pulmonary hypertension (a continuous murmur of a PDA is usually loudest in the left infraclavicular area)
- Total anomalous pulmonary venous return (TAPVR)
- PAPVR

Conditions a through d are more common than the other listed conditions. Table 2-4 summarizes other clinical findings that are useful in the differential diagnosis of systolic murmurs audible at the upper left sternal border.
2. Upper right sternal border or aortic area
Systolic murmurs at the upper right sternal border are also midsystolic type. They are caused by narrowing of the aortic valve or its neighboring vascular structures. The murmur transmits well to the neck. Often it transmits with a thrill over the carotid arteries. The midsystolic murmur of AS may be heard with equal clarity at the upper left sternal border (i.e., “pulmonary area”), as well as at the apex. However, the PS murmur does not transmit well to the upper right sternal border and the neck; rather, it transmits well to the back and the sides of the chest. Systolic murmurs in the upper right sternal border are caused by the following:

a. AS
b. Subvalvular AS (subaortic stenosis)
c. Supravalvular AS

Characteristic physical, ECG, and radiography findings that help in the differential diagnosis of these conditions are presented in Table 2-5.

3. Lower left sternal border
Systolic murmurs that are maximally audible at this location may be a holosystolic, early systolic, or midsystolic type and may result from one of the following conditions:

a. VSD murmur is either holosystolic or early systolic in timing (a small muscular VSD murmur may be heard best between the lower left sternal border and the apex)
b. Vibratory or musical innocent murmur (e.g., Still’s murmur); this murmur may be equally loud or even louder toward the apex, and the maximal intensity may be in the midprecordium
c. Hypertrophic obstructive cardiomyopathy (HOCM) (formerly known as idiopathic hypertrophic subaortic stenosis)
d. TR
e. TOF

Characteristic physical, ECG, and radiography findings that help in the differential diagnosis of these conditions are presented in Table 2-6.

4. Apical area
Systolic murmurs that are maximally audible at the apex may be a holosystolic, midsystolic, or late systolic murmur and result from one of the following conditions:

a. MR (holosystolic)
b. MVP (late systolic murmur, usually preceded by a midsystolic click)
c. AS (midsystolic)
d. HOCM (midsystolic)
e. Vibratory innocent murmur (midsystolic)

Characteristic physical, ECG, and radiography findings are summarized in Table 2-7.
Diastolic Murmurs

Diastolic murmurs occur between the S2 and S1. Based on timing and relation to the heart sounds, they are classified into three types: early diastolic (or protodiastolic), mid-diastolic, and late diastolic (or presystolic) (Fig. 2-13).

1. **Early diastolic decrescendo murmurs** occur early in diastole, immediately after the S2, and are caused by incompetence of the aortic or pulmonary valve (see Fig. 2-13).

   Because the aorta is a high-pressure vessel, AR murmurs are high pitched and best heard with the diaphragm of a stethoscope at the third left intercostal space. The AR murmur radiates well to the apex because the regurgitation is directed toward the apex. Bounding peripheral pulses may be present if the AR is significant. AR murmurs are associated with congenital bicuspid aortic valve, subaortic stenosis, after an intervention for AS (i.e., postvalvotomy or after balloon dilatation), and rheumatic heart disease with AR. Occasionally, a subarterial infundibular VSD with prolapsing aortic cusps may cause an AR murmur.

   Pulmonary regurgitation murmurs also occur early in diastole. They are usually medium pitched but may be high pitched if pulmonary hypertension is present. They are best heard at the third left intercostal space and radiate along the left sternal border. These murmurs are associated with postoperative TOF (because of surgically induced PR), pulmonary hypertension, postoperative pulmonary valvotomy or after balloon valvuloplasty for PS, and mild deformity of the pulmonary valve.

2. **Mid-diastolic murmurs** start with a loud S3 and are heard in early or mid-diastole but are not temporally midway
through diastole (see Fig. 2-13). These murmurs are always low pitched and best heard with the bell of the stethoscope applied lightly to the chest. These murmurs are caused by turbulence caused by the mitral or tricuspid flow secondary to anatomic stenosis or relative stenosis of these valves.

Mitral mid-diastolic murmurs are best heard at the apex and are often referred to as an apical rumble, although frequently they sound more like a hum than a rumble. These murmurs are associated with MS or a large left-to-right shunt VSD or PDA, which produces relative MS secondary to a large flow across the normal-sized mitral valve.

Tricuspid mid-diastolic murmurs are best heard along the lower left sternal border. These murmurs are associated with ASD, PAPVR, TAPVR, and ECD because they all result in relative tricuspid stenosis (TS). Anatomic stenosis of the tricuspid valve is also associated with these murmurs, but such cases are rare.

3. Presystolic (or late diastolic) murmurs
are also caused by flow through the AV valves during ventricular diastole. They result from active atrial contraction that ejects blood into the ventricle rather than a passive pressure difference between the atrium and ventricle. These low-frequency murmurs occur late in diastole or just before the onset of systole (see Fig. 2-13) and are found with anatomic stenosis of the mitral or tricuspid valve.

Continuous Murmurs
Continuous murmurs begin in systole and continue without interruption through the S2 into all or part of diastole (see Fig. 2-13). Continuous murmurs are caused by the following:
1. Aortopulmonary or arteriovenous connection (e.g., PDA, arteriovenous fistula, after systemic-to-PA shunt surgery, persistent truncus arteriosus [rarely])
2. Disturbances of flow patterns in veins (e.g., venous hum)
3. Disturbance of flow pattern in arteries (e.g., COA, PA stenosis)

The murmur of PDA has a machinery-like quality, becoming louder during systole (crescendo), peaking at the S2, and diminishing in diastole (decrescendo). This murmur is maximally heard in the left infraclavicular area or along the upper left sternal border. With pulmonary hypertension, only the systolic portion can be heard, but it is crescendic during systole.

Venous hum is a common innocent murmur that is audible in the upright position, in the infraclavicular region, unilaterally or bilaterally. It is usually heard better on the right side. The murmur’s intensity also changes with the position of the neck. When the child lies supine, the murmur usually disappears. Less common continuous murmurs of severe COA may be heard over the intercostal collaterals. The continuous murmurs of PA stenosis may be heard over the right and left anterior chest, the sides of the chest, and in the back.

The combination of a mid-systolic murmur (e.g., VSD, AS, or PS) and a diastolic murmur (e.g., AR or PR) is referred to as a to-and-fro murmur to distinguish it from a
Innocent Heart Murmurs

Innocent heart murmurs, also called *functional murmurs*, arise from cardiovascular structures in the absence of anatomic abnormalities. Innocent heart murmurs are common in children. More than 80% of children have innocent murmurs of one type or another sometime during childhood (Table 2-8). All innocent heart murmurs (as well as pathological murmurs) are accentuated or brought out in a high-output state, usually during a febrile illness.

<table>
<thead>
<tr>
<th>COMMON INNOCENT HEART MURMURS IN CHILDREN</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type (Timing)</strong></td>
</tr>
<tr>
<td>-------------------</td>
</tr>
<tr>
<td>Classic vibratory murmur (Still’s murmur) (systolic)</td>
</tr>
<tr>
<td>Pulmonary ejection murmur (systolic)</td>
</tr>
<tr>
<td>Pulmonary flow murmur of newborn (systolic)</td>
</tr>
<tr>
<td>Venous hum (continuous)</td>
</tr>
<tr>
<td>Carotid bruit (systolic)</td>
</tr>
</tbody>
</table>

LLSB, lower left sternal border; MLSB, mid-left sternal border; ULSB, upper left sternal border.

Probably the only way a physician can recognize an innocent heart murmur is to become familiar with the more common forms of these murmurs by auscultating under the supervision of pediatric cardiologists. All innocent heart murmurs are associated with normal ECG and radiography findings. When one or more of the following are present, the murmur is more likely pathologic and requires cardiac consultation:

1. Symptoms
2. Abnormal cardiac size or silhouette or abnormal pulmonary vascularity on chest roentgenograms
3. Abnormal ECG findings
4. Diastolic murmur
5. A systolic murmur that is loud (i.e., grade 3 of 6 or with a thrill), long in duration, and transmits well to other parts of the body
6. Cyanosis
7. Abnormally strong or weak pulses
8. Abnormal heart sounds

Classic Vibratory Murmur
This is the most common innocent murmur in children, first described by Still in 1909. Most vibratory murmurs are detected between 3 and 6 years of age, but the same murmur may be present in neonates, infants, and adolescents. It is maximally audible at the mid-left sternal border or over the midprecordium (between the lower left sternal border and the apex). It is generally of low frequency and best heard with the bell of the stethoscope with the patient in the supine position. The murmur is midsystolic (i.e., not regurgitant) in timing and grade 2 to 3 of 6 in intensity. This murmur is not accompanied by a thrill or ejection click. It has a distinctive quality, described as a “twanging string,” groaning, squeaking, buzzing, or vibratory sound, giving a pleasing musical character to the murmur. The murmur is generally loudest in the supine position and often changes in character, pitch, and intensity with upright positioning. The vibratory quality may disappear, and the murmur may become softer when the bell is pressed harder, thereby proving its low frequency. The intensity of the murmur increases during febrile illness or excitement, after exercise, and in anemic states. The murmur may disappear briefly at a maximum Valsalva maneuver. The ECG and chest radiography findings are normal (see Table 2-8; Fig. 2-14).

An inexperienced examiner may confuse this murmur with the murmur of a VSD. The murmur of a VSD is usually harsh, grade 2 to 3 of 6 in intensity, holosystolic starting with the S1 rather than midsystolic, and often accompanied by a palpable thrill. The ECG and radiography findings are often abnormal.

The origin of the murmur remains obscure. It is believed to be generated by low-frequency vibrations of normal pulmonary leaflets at their attachments during systole or periodic vibrations of a left ventricular false tendon.

**Pulmonary Ejection Murmur (Pulmonary Flow Murmur) of Childhood**

This is common in children between 8 and 14 years of age but is most frequent in adolescents. The murmur is maximally audible at the upper left sternal border. This murmur represents an exaggeration of normal ejection vibrations within the pulmonary trunk. The murmur is exaggerated by the presence of pectus excavatum, straight back, or kyphoscoliosis. The murmur is midsystolic in timing and slightly grating (rather than vibratory) in quality, with relatively little radiation. The intensity of the murmur is usually a grade 1 to 3 of 6. The S2 is normal, and there is no associated thrill or ejection click (see Table 2-8; Fig. 2-14). The ECG and chest radiography findings are normal.
This murmur may be confused with the murmur of pulmonary valve stenosis or an ASD. In pulmonary valve stenosis, there may be an ejection click, systolic thrill, widely split S2, right ventricular hypertrophy (RVH) on ECG, and poststenotic dilatation of the main PA segment on chest radiography. Important differential points of ASD include a widely split and fixed S2, a mid-diastolic murmur of relative TS audible at the lower left sternal border if the shunt is large, RBBB or mild RVH on ECG manifested by rsR' in V1, and chest radiography revealing increased pulmonary vascular markings and enlargement of the right atrium, RV, and main PA.

**Pulmonary Flow Murmur of Newborns**

This murmur is commonly present in newborns, especially those with low birth weight. The murmur usually disappears by 3 to 6 months of age. If it persists beyond this age, a structural narrowing of the pulmonary arterial tree (i.e., PA stenosis) should be suspected. It is best audible at the upper left sternal border. Although the murmur is only a grade 1 to 2 of 6 in intensity, it transmits impressively to the right and left chest, both axillae, and the back. There is no ejection click. The ECG and chest radiography findings are normal (see Table 2-8; Fig. 2-14).

In a fetus, the main PA trunk is large, but the branches of the PA are relatively hypoplastic because they receive a small amount of blood flow during fetal life (only 15% of combined ventricular output goes to these vessels). When the ductus closes after birth, the large dome-shaped main PA trunk gives off two small branch pulmonary arteries. The flow through these small vessels produces turbulence with a faster flow velocity, and the turbulence is transmitted along the smaller branches of the PAs. Therefore, this murmur is heard well around the chest wall. The murmur is louder in small preterm babies than the larger full-term neonates.

The murmur resembles the murmur of organic PA stenosis, which may be seen as a component of rubella syndrome, Williams syndrome, or Alagille syndrome. Characteristic noncardiac findings in children with these syndromes lead physicians to suspect that the PA stenosis murmur has an organic cause. Organic PA stenosis is frequently associated with other cardiac defects (e.g., VSD; pulmonary valve stenosis, or TOF), at the site of a previous Blalock-Taussig shunt, or is seen occasionally as an isolated anomaly. The heart murmur of organic PA stenosis persists beyond infancy, and the ECG may show RVH if the stenosis is severe.

**Venous Hum**

This murmur is commonly audible in children between the ages of 3 and 6 years. It originates from turbulence in the jugular venous system. This is a continuous murmur in which the diastolic component is louder than the systolic component. The murmur is maximally audible at the right or left infraclavicular and supraclavicular areas (see Table 2-8; Fig. 2-14). The venous hum is heard only in the upright position and disappears in the supine position. It can be obliterated by rotating the head or by gently occluding the
neck veins with the fingers.

It is important to differentiate a venous hum from the continuous murmur of a PDA. The murmur of a PDA is loudest at the upper left sternal border or left infraclavicular area and may be associated with bounding peripheral pulses and wide pulse pressure if the shunt is large. The systolic component is louder than the diastolic component. The radiographs show increased pulmonary vascular markings and cardiac enlargement. The ECG may be normal (with a small shunt) or show left ventricular hypertrophy or combined ventricular hypertrophy (with a large shunt).

**Carotid Bruit (or Supraclavicular Systolic Murmur)**

This is an early systolic ejection murmur that is best heard in the supraclavicular fossa or over the carotid arteries (see Table 2-8; Fig. 2-14). It is produced by turbulence in the brachiocephalic or carotid arteries. The murmur is a grade 2 to 3 of 6 in intensity. Although it rarely occurs, a faint thrill is palpable over a carotid artery. This bruit may be found in normal children of any age.

The murmur of AS often transmits well to the carotid arteries with a palpable thrill, requiring differentiation from carotid bruits. In AS, the murmur is louder at the upper right sternal border, and a systolic thrill is often present in the upper right sternal border and suprasternal notch, as well as over the carotid artery. An ejection click is often present in aortic valve stenosis. The ECG and radiography findings may appear abnormal.
Some Special Features of the Cardiac Examination of Neonates

The following section briefly summarizes some unique aspects of normal and abnormal physical findings in newborns, which are different from those of older infants and children. The difference is caused by the normal RV dominance and elevated pulmonary vascular resistance (PVR) seen in the early neonatal period. Premature infants in general have less RV dominance and a lower PVR than do full-term neonates, adding variability to this generalization.

Normal Physical Findings of Neonates

The following are normal cardiovascular findings in newborn infants:
1. The heart rate generally is faster in newborns than in older children and adults (the newborn rate is usually 100 beats/min, with a normal range of 70 to 180 beats/min).
2. A varying degree of acrocyanosis is the rule rather than the exception.
3. Mild arterial desaturation with arterial $Po_2$ as low as 60 mm Hg is not unusual in an otherwise normal neonate. This may be caused by an intrapulmonary shunt through an as-yet unexpanded portion of the lungs or by a right atrium–to–left atrium shunt through a patent foramen ovale.
4. The RV is relatively hyperactive, with the point of maximal impulse at the lower left sternal border rather than at the apex.
5. The S2 may be single in the first days of life.
6. An ejection click (representing pulmonary hypertension) occasionally is heard in the first hours of life.
7. A newborn may have an innocent heart murmur. Four common innocent murmurs in the newborn period are pulmonary flow murmur of the newborn (see Fig. 2-14), transient systolic murmur of PDA, transient systolic murmur of TR, and vibratory innocent systolic murmur.
   a. Pulmonary flow murmur of the newborn is the most common heart murmur in newborn infants (see previous section).
   b. Transient systolic murmur of PDA is caused by a closing ductus arteriosus and is audible on the first day of life. It is a grade 1 to 2 of 6 only systolic, at the upper left sternal border and in the left infraclavicular area.
   c. Transient systolic murmur of TR is indistinguishable from that of VSD. It is believed that a minimal tricuspid valve abnormality produces regurgitation in the presence of high PVR (and high RV pressure), but the regurgitation disappears as the PVR falls. Therefore, this murmur is more common in infants who had fetal distress or neonatal asphyxia because they tend to maintain high PVR for a longer period.
   d. Vibratory innocent murmur is a counterpart of Still’s murmur in older children (see previous section).
8. Peripheral pulses are easily palpable in all extremities, including the feet, in every normal infant. The peripheral pulses normally appear to be bounding in premature
babies because of the lack of subcutaneous tissue.

**Abnormal Physical Findings in Neonates**
The following abnormal physical findings suggest cardiac malformation. Repeated examination is important because physical findings change rapidly in normal infants as well as in infants with cardiac problems.

1. Cyanosis, particularly when it does not improve with the administration of oxygen, suggests a cardiac abnormality.
2. Decreased or absent peripheral pulses in the lower extremities suggest coarctation of the aorta (COA). Weak peripheral pulses throughout suggest hypoplastic left heart syndrome (HLHS) or circulatory shock. Bounding peripheral pulses suggest aortic run-off lesions, such as PDA or persistent truncus arteriosus.
3. Tachypnea of greater than 60 breaths/min with or without retraction suggests a cardiac abnormality.
4. Hepatomegaly may suggest a heart defect. A midline liver suggests asplenia or polysplenia syndrome.
5. A heart murmur may be a presenting sign of a congenital heart defect, although innocent murmurs are much more frequent than pathologic murmurs. Most pathologic murmurs should be audible during the first month of life, with the exception of an ASD. However, the time of appearance of a heart murmur depends on the nature of the defect.
   a. Heart murmurs of stenotic lesions (e.g., aortic stenosis, pulmonary stenosis) and those caused by AV valve regurgitation are audible immediately after birth and persist because these murmurs are not affected by the level of PVR.
   b. Heart murmurs of large VSD may not be audible until 1 to 2 weeks of age when the PVR becomes sufficiently low to allow shunt to occur.
   c. The murmur of an ASD appears after 1 or 2 years when the compliance of the RV improves to allow a significant atrial shunt. A newborn or a small infant with a large ASD may not have a heart murmur.
6. Even in the absence of a heart murmur, a newborn infant may have a serious heart defect that requires immediate attention (e.g., severe cyanotic heart defect such as TGA or pulmonary atresia with a closing PDA). Infants who are in severe CHF may not have a loud murmur until the myocardial function is improved through anticongestive measures.
7. An irregular cardiac rhythm and abnormal heart rate suggest a cardiac abnormality.
Electrocardiography

In the clinical diagnosis and management of congenital or acquired heart disease, the presence or absence of electrocardiographic (ECG) abnormalities is often helpful. Hypertrophies (of ventricles and atria) and ventricular conduction disturbances are the two most common forms of ECG abnormalities. The presence of other ECG abnormalities such as atrioventricular (AV) conduction disturbances, arrhythmias, and ST segment and T-wave changes, is also helpful in the clinical diagnosis of cardiac problems.

Throughout this chapter, the vectorial approach will be used whenever possible. The vectorial approach is preferred to “pattern reading,” which has infinite number of possibilities. The following topics will be discussed in the order listed.

• What is the vectorial approach?
• Comparison of pediatric and adult ECGs
• Basic measurements and their normal values that are necessary for correct interpretation of an ECG. The discussion will include rhythm, heart rate, QRS axis, P and T axes, and so on.
• Atrial and ventricular hypertrophy
• Ventricular conduction disturbances
• ST-segment and T-wave changes, including myocardial infarction (MI)

Cardiac arrhythmias and AV conduction disturbances will be discussed separately in Chapters 24 and 25.
What Is the Vectorial Approach?

The vectorial approach views the standard scalar ECG as three-dimensional vector forces that vary with time. Vector is a quantity that possesses magnitude and direction, but scalar is a quantity that has magnitude only. A scalar ECG, which is routinely obtained in clinical practice, shows only magnitude of the forces against time. However, by combining scalar leads that represent the frontal projection and the horizontal projections of the vectorcardiogram, one can derive the direction of the force from scalar ECGs.

The limb leads (leads I, II, III, aVR, aVL, and aVF) provide information about the frontal projection (reflecting superior-inferior and right-to-left forces), and the precordial leads (leads V1 through V6, V3R, and V4R) provide information about the horizontal plane, which reflects forces that are right-to-left and anterior–posterior (Fig. 3-1). It is important for readers to become familiar with the orientation of each scalar ECG lead. After they have been learned, the vectorial approach helps readers retain the knowledge gained.

Hexaxial Reference System

It is necessary to memorize the orientation of the hexaxial reference system (see Fig. 3-1, A). The hexaxial reference system is made up by the six limb leads (leads I, II, III, aVR, aVL, and aVF) and provides information about the superoinferior and right–left relationships of the electromotive forces. In this system, leads I and aVF cross at a right angle at the electrical center (see Fig. 3-1, A). The bipolar limb leads (I, II, and III) are clockwise with the angle between them of 60 degrees. Note the positive poles of aVR, aVL, and aVF are directed toward the right and left shoulders and the foot, respectively. The positive limb of each lead is shown in a solid line and the negative limb in a broken line. The positive pole of each lead is indicated by the lead labels. The positive pole of lead I is labeled as 0 degree, and the negative pole of the same lead as ±180 degrees. The positive pole of aVF is designated as +90 degrees, and the negative pole of the same lead as −90 degrees. The positive poles of leads II and III are +60 and +120 degrees, respectively, and so on. The hexaxial reference system is used in plotting the QRS axis, T axis, and P axis.

The lead I axis represents the left–right relationship with the positive pole on the left and the negative pole on the right. The aVF lead represents the superior-inferior relationship with the positive pole directed inferiorly and the negative pole directed superiorly. The R wave in each lead represents the depolarization force directed toward the positive pole; the Q and S waves are the depolarization force directed toward the negative pole. Therefore, the R wave of lead I represents the leftward force, and the S wave of the same lead represents the rightward force (see Fig. 3-1, A). The R wave in aVF represents the inferiorly directed force, and the S wave the superiorly directed force. By the same token, the R wave in lead II represents the leftward and inferior force, and the R wave in lead III represents the rightward and inferior force. The R wave in aVR
represents the rightward and superior force, and the R wave in aVL represents the leftward and superior forces.

An easy way to memorize the hexaxial reference system is shown in Figure 3-2 by a superimposition of a body with stretched arms and legs on the X and Y axes. The hands and feet are the positive poles of electrodes. The left and right hands are the positive poles of leads aVR and aVL, respectively. The left and right feet are the positive poles of leads II and III, respectively. The bipolar limb leads I, II, and III are clockwise in sequence for the positive electrode.

FIGURE 3-1  Hexaxial reference system (A) shows the frontal projection of a vector loop, and horizontal reference system (B) shows the horizontal projection. The combination of A and B constitutes the 12- (or 13-) lead electrocardiogram. (From Park MK, Guntheroth WG: How to Read Pediatric ECGs, 4th ed. Philadelphia, Mosby, 2006.)
Horizontal Reference System

The horizontal reference system consists of precordial leads (leads V1 through V6, V3R, and V4R) (see Fig. 3-1, B) and provides information about the anterior–posterior and the left–right relationship. The leads V2 and V6 cross approximately at a right angle at the electrical center of the heart. The V6 axis represents the left–right relationship, and the V2 axis represents the anterior–posterior relationship. The positive limb of each lead is shown in a solid line and the negative limb in a broken line. The positive pole of each lead is indicated by the lead labels (V4R, V1, V2, and so on). The precordial leads V3R and V4R are at the mirror image points of V3 and V4, respectively, in the right chest, and these leads are quite popular in pediatric cardiology because right ventricular (RV) forces are more prominent in infants and children.

Therefore, the R wave of V6 represents the leftward force and the R wave of V2 the anterior force. Conversely, the S wave in V6 represents the rightward force and the S wave of V2 the posterior force. The R wave in V1, V3R, and V4R represents the rightward and anterior force, and the S wave of these leads represents the leftward and posterior force (see Fig. 3-1, B). The R wave of lead V5 in general represents the leftward force, and the R waves of leads V3 and V4 represent a transition between the right and left precordial leads. Ordinarily, the S wave in V2 represents the posterior and thus the left ventricular (LV) force, but in the presence of a marked right axis deviation, the S wave of V2 may represent RV force that is directed rightward and posteriorly.

Information Available on the 12-Lead Scalar Electrocardiogram

There are three major types of information available in the commonly available form of a 12-lead ECG tracing (Fig. 3-3):

1. The lower part of the tracing is a rhythm strip (of lead II).
2. The large upper left portion of the recording gives frontal plane information, and the upper right side of the recording presents horizontal plane information. The frontal plane information is provided by the six limbs leads (leads I, II, III, aVR, aVL, and aVF) and the horizontal plane information by the precordial leads. In Figure 3-3, the QRS vector is predominantly directed inferiorly (judged by predominant R waves in leads II, III, and aVF, so-called inferior leads) and is equally anterior and posterior, judged by equiphasic QRS complex in V2.
3. A calibration marker usually appears at the right (or left) margin, which is used to determine the magnitude of the forces. The calibration marker consists of two vertical deflections 2.5 mm in width. The initial deflection shows the calibration factor for the six limb leads, and the latter part of the deflection shows the calibration factor for the six precordial leads. With the full standardization, one millivolt signal introduced into the circuit causes a deflection of 10 mm on the record. With the $\frac{1}{2}$ standardization, the same signal produces 5 mm of deflection. The amplitude of ECG deflections is read in millimeters rather than in millivolts. When the deflections are too big to be recorded, the sensitivity may be reduced to $\frac{1}{4}$. With $\frac{1}{2}$ standardization, the measured height in millimeters should be multiplied by 2 to obtain the correct amplitude of the deflection. In Figure 3-3, $\frac{1}{2}$ standardization was used for the precordial leads.
Thus, from the scalar ECG tracing, one can gain information of the frontal and horizontal orientations of the QRS (or ventricular) complexes and other electrical activities of the heart as well as the magnitude of such forces.
Comparison of Pediatric and Adult Electrocardiograms

Electrocardiograms of normal infants and children are quite different from those of normal adults. The most remarkable difference is RV dominance in infants. RV dominance is most noticeable in newborns, and it gradually changes to LV dominance of adults. By 3 years of age, the child’s ECG resembles that of young adults. The age-related difference in the ECG reflects an age-related anatomic differences; the RV is thicker than the LV in newborns and infants, and the LV is much thicker than the RV in adults.

Right ventricular dominance of infants is expressed in the ECG by right axis deviation (RAD) and large rightward or anterior QRS forces (i.e., tall R waves in lead aVR and the right precordial leads [V4R, V1, and V2] and deep S waves in lead I and the left precordial leads [V5 and V6]) compared with an adult ECG.

A normal ECG from a 1-week-old neonate (Fig. 3-4) is compared with that of a young adult (Fig. 3-5). The infant’s ECG demonstrates RAD (+140 degrees) and dominant R waves in the right precordial leads. The T wave in V1 is usually negative. Upright T waves in V1 in this age group suggest right ventricular hypertrophy (RVH). Adult-type R/S progression in the precordial leads (deep S waves in V1 and V2 and tall R waves in V5 and V6; as seen in Fig. 3-5) is rarely seen in the first month of life; instead, there may be complete reversal of the adult-type R/S progression, with tall R waves in V1 and V2 and deep S waves in V5 and V6. Partial reversal is usually present, with dominant R waves in V1 and V2 as well as in V5 and V6, in children between the ages of 1 month and 3 years.

![Electrocardiogram from a normal young adult.](image)

The normal adult ECG shown in Figure 3-5 demonstrates the QRS axis near +60 degrees and the QRS forces directed to the left, inferiorly and posteriorly, which is manifested by dominant R waves in the left precordial leads and dominant S waves in the right
precordial leads, the so-called adult R/S progression. The T waves are usually anteriorly oriented, resulting in upright T waves in V2 through V6 and sometimes in V1.
Basic Measurements and Their Normal and Abnormal Values

In this section, basic measurements and their normal values that are necessary for routine interpretation of an ECG are briefly discussed in the order listed. This sequence is one of many approaches that can be used in routine interpretation of an ECG. The methods of their measurements will be followed by their normal and abnormal values and the significance of abnormal values.

1. Rhythm (sinus or nonsinus) by considering the P axis
2. Heart rate (atrial and ventricular rates, if different)
3. The QRS axis, the T axis, and the QRS-T angle
4. Intervals: PR, QRS, and QT
5. The P wave amplitude and duration
6. The QRS amplitude and R/S ratio; also abnormal Q waves
7. ST-segment and T-wave abnormalities

Rhythm

Sinus rhythm is the normal rhythm at any age and is characterized by P waves preceding each QRS complex and a normal P axis (0 to +90 degrees); the latter is an often neglected criterion. The requirement of a normal P axis is important in discriminating sinus from nonsinus rhythm. In sinus rhythm, the PR interval is regular but does not have to be of normal interval. (The PR interval may be prolonged as seen in sinus rhythm with first-degree atrioventricular [AV] block.)

Because the sinoatrial node is located in the right upper part of the atrial mass, the direction of atrial depolarization is from the right upper part toward the left lower part, with the resulting P axis in the lower left quadrant (0 to +90 degrees) (Fig. 3-6, A). Some atrial (nonsinus) rhythms may have P waves preceding each QRS complex, but they have an abnormal P axis (Fig. 3-6, B). For the P axis to be between 0 and +90 degrees, P waves must be upright in leads I and aVF or at least not inverted in these leads; simple inspection of these two leads suffices. A normal P axis also results in upright P waves in lead II and inverted P waves in aVR. A method of plotting axes is presented later for the QRS axis.

Heart Rate

There are many different ways to calculate the heart rate, but they are all based on the known time scale of ECG papers. At the usual paper speed of 25 mm/sec, 1 mm = 0.04 second, and 5 mm = 0.20 second (Fig. 3-7). The following methods are often used to calculate the heart rate.

1. Count the R-R cycle in six large divisions (1/50 minute) and multiply it by 50 (Fig. 3-8). 
2. When the heart rate is slow, count the number of large divisions between two R waves and divide that into 300 (because 1 minute = 300 large divisions) (Fig. 3-9).
3. Measure the R-R interval (in seconds) and divide 60 by the R-R interval. The R-R interval is 0.36 second in Figure 3-8: 60 ÷ 0.36 = 166.

4. Use a convenient ECG ruler.

5. An approximate heart rate can be determined by memorizing heart rates for selected R-R intervals (Fig. 3-10). When R-R intervals are 5, 10, 15, 20, and 25 mm, the respective heart rates are 300, 150, 100, 75, and 60 beats/min.

![Figure 3-6](image)  
**FIGURE 3-6**  
Comparison of P axis in sinus rhythm (A) and low atrial rhythm (B). In sinus rhythm, the P axis is between 0 and +90 degrees, and P waves are upright in leads I and aVF. In low atrial rhythm, the P wave is superiorly oriented, and P waves are inverted in lead aVF.

![Figure 3-7](image)  
**FIGURE 3-7**  
Electrocardiographic paper. Time is measured on the horizontal axis. Each 1 mm equals 0.04 second, and each 5 mm (a large division) equals 0.20 second. Thirty millimeters (or six large divisions) equals 1.2 second or 1/50 minute.

When the ventricular and atrial rates are different, as in complete heart block or atrial flutter, the atrial rate can be calculated using the same methods as described for the
ventricular rate; for the atrial rate, the P-P interval rather than the R-R interval is used.

Because of age-related differences in the heart rate, the definitions of bradycardia (<60 beats/min) and tachycardia (>100 beats/min) used for adults do not help distinguish normal from abnormal heart rates in pediatric patients. Operationally, tachycardia is present when the heart rate is faster than the upper range of normal for that age, and bradycardia is present when the heart rate is slower than the lower range of normal. According to age, normal resting heart rates per minute recorded on the ECG are as follows (Davignon et al, 1979/1980).

<table>
<thead>
<tr>
<th>Age</th>
<th>Heart Rate (beats/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newborn</td>
<td>145 (90–180)</td>
</tr>
<tr>
<td>6 mo</td>
<td>145 (105–185)</td>
</tr>
<tr>
<td>1 yr</td>
<td>132 (105–170)</td>
</tr>
<tr>
<td>2 yr</td>
<td>120 (90–150)</td>
</tr>
<tr>
<td>4 yr</td>
<td>108 (72–135)</td>
</tr>
<tr>
<td>6 yr</td>
<td>100 (65–135)</td>
</tr>
<tr>
<td>10 yr</td>
<td>90 (65–130)</td>
</tr>
<tr>
<td>14 yr</td>
<td>85 (60–120)</td>
</tr>
</tbody>
</table>

QRS Axis, T Axis, and QRS-T Angle

QRS Axis

The most convenient way to determine the QRS axis is the successive approximation method using the hexaxial reference system (see Fig. 3-1, A). The same approach is also used for the determination of the T axis (see later discussion). For the determination of the QRS axis (as well as T axis), one uses only the hexaxial reference system (or the six limbs leads), not the horizontal reference system.

FIGURE 3-8  Heart rate of 165 beats/min. There are about 3.3 cardiac cycles (R-R intervals) in six large divisions. Therefore, the heart rate is $3.3 \times 50 = 165$ (by method 1). By method 2, the RR interval is $0.36 \text{ sec.} \ 60 \div 0.36 = 166$. The rates derived by the two methods are very close.
FIGURE 3-9  Heart rate of 52 beats/minute. There are 5.8 large (5 mm) divisions between the two arrows. Therefore the heart rate is $300 \div 5.8 = 52$.

FIGURE 3-10  Quick estimation of heart rate. When the R-R interval is 5 mm, the heart rate is 300 beats/min. When the R-R interval is 10 mm, the rate is 150 beats/min, and so on.

FIGURE 3-11  Locating quadrants of mean QRS axis from leads I and aVF. (From Park MK, Guntheroth WG: How to Read Pediatric ECGs, 4th ed. Philadelphia, Mosby, 2006.)
Successive Approximation Method

**Step 1:** Locate a quadrant using leads I and aVF (Fig. 3-11). In the top panel of Figure 3-11, the net QRS deflection of lead I is positive. This means that the QRS axis is in the left hemicircle (i.e., from –90 degrees through 0 to +90 degrees) from the lead I point of view. The net positive QRS deflection in aVF means that the QRS axis is in the lower hemicircle (i.e., from 0 through +90 degrees to +180 degrees) from the aVF point of view. To satisfy the polarity of both leads I and aVF, the QRS axis must be in the lower left quadrant (i.e., 0 to +90 degrees). Four quadrants can be easily identified based on the QRS complexes in leads I and aVF (see Fig. 3-11).

**Step 2:** Among the remaining four limb leads, find a lead with an equiphasic QRS complex (in which the height of the R wave and the depth of the S wave are equal). The QRS axis is perpendicular to the lead with an equiphasic QRS complex in the predetermined quadrant.

**Example:** Determine the QRS axis in Figure 3-12.

### Table 3-1

**Mean and Ranges of Normal QRS Axes by Age**

<table>
<thead>
<tr>
<th>Age</th>
<th>Mean (Range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 wk–1 mo</td>
<td>+ 110° (+30 to +180°)</td>
</tr>
<tr>
<td>1–3 mo</td>
<td>+ 70° (+10 to +125°)</td>
</tr>
<tr>
<td>3 mo–3 yr</td>
<td>+ 60° (+10 to +110°)</td>
</tr>
<tr>
<td>Older than 3 yr</td>
<td>+ 60° (+20 to +120°)</td>
</tr>
<tr>
<td>Adult</td>
<td>+ 50° (~30 to +105°)</td>
</tr>
</tbody>
</table>

**Step 1:** The axis is in the lower left quadrant (0 to +90 degrees) because the R waves are upright in leads I and aVF.

**Step 2:** The QRS complex is equiphasic in aVL. Therefore, the QRS axis is +60 degrees, which is perpendicular to aVL.
Normal QRS Axis
Normal ranges of QRS axis vary with age. Newborns normally have RAD compared with the adult standard. By 3 years of age, the QRS axis approaches the adult mean value of +50 degrees. The mean and ranges of a normal QRS axis according to age are shown in Table 3-1.

Abnormal QRS Axis
The QRS axis outside normal ranges signifies abnormalities in the ventricular depolarization process.

1. Left axis deviation (LAD) is present when the QRS axis is less than the lower limit of normal for the patient’s age. LAD occurs with left ventricular hypertrophy (LVH), left bundle branch block (LBBB), and left anterior hemiblock.

2. RAD is present when the QRS axis is greater than the upper limit of normal for the patient’s age. RAD occurs with RVH and right bundle branch block (RBBB).

3. “Superior” QRS axis is present when the S wave is greater than the R wave in aVF. The overlap with LAD and left anterior hemiblock should be noted. Left anterior hemiblock (in the range of –30 to –90 degrees is seen in congenital heart diseases such as endocardial cushion defect and tricuspid atresia) or with RBBB. It is rarely seen in otherwise normal children.

T Axis
The T axis is determined by the same methods used to determine the QRS axis. In normal children, including newborns, the mean T axis is +45 degrees, with a range of 0 to +90 degrees, the same as in normal adults. This means that the T waves must be upright in leads I and aVF. The T waves can be flat but must not be inverted in these leads. The T axis outside of the normal quadrant suggests conditions with myocardial dysfunction similar to those listed for abnormal QRS-T angle (see below).

QRS-T Angle
The QRS-T angle is formed by the QRS axis and the T axis. A QRS-T angle of greater than 60 degrees is unusual, and one greater than 90 degrees is certainly abnormal. An abnormally wide QRS-T angle with the T axis outside the normal quadrant (0 to +90 degrees) is seen in severe ventricular hypertrophy with “strain,” ventricular conduction disturbances, and myocardial dysfunction of a metabolic or ischemic nature.

Intervals
Three important intervals are routinely measured in the interpretation of an ECG: PR interval, QRS duration, and QT interval. The duration of the P wave is also inspected (Fig. 3-13).

PR Interval
The normal PR interval varies with age and heart rate (Table 3-2). Davignon et al’s data are unsuitable for clinical use because they are presented separately according to age and heart rate. The PR interval is longer in older individuals and with a slower heart rate.

FIGURE 3-13  Diagram illustrating important intervals (or durations) and segments of an electrocardiographic cycle.

TABLE 3-2
PR INTERVAL ACCORDING TO AGE AND RATE: MEAN (AND UPPER LIMITS OF NORMAL)

<table>
<thead>
<tr>
<th>Rate</th>
<th>0–1 mo</th>
<th>1–6 mo</th>
<th>6 mo–1 yr</th>
<th>1–3 yr</th>
<th>3–8 yr</th>
<th>8–12 yr</th>
<th>12–16 yr</th>
<th>Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;60</td>
<td>0.10 (0.12)</td>
<td>0.11 (0.14)</td>
<td>0.12 (0.14)</td>
<td>0.12 (0.14)</td>
<td>0.16 (0.18)</td>
<td>0.16 (0.19)</td>
<td>0.17 (0.21)</td>
<td></td>
</tr>
<tr>
<td>60–80</td>
<td>0.10 (0.12)</td>
<td>0.11 (0.14)</td>
<td>0.12 (0.14)</td>
<td>0.12 (0.14)</td>
<td>0.16 (0.18)</td>
<td>0.16 (0.19)</td>
<td>0.17 (0.21)</td>
<td></td>
</tr>
<tr>
<td>80–100</td>
<td>0.10 (0.12)</td>
<td>0.11 (0.14)</td>
<td>0.12 (0.14)</td>
<td>0.12 (0.14)</td>
<td>0.16 (0.18)</td>
<td>0.16 (0.19)</td>
<td>0.17 (0.20)</td>
<td></td>
</tr>
<tr>
<td>100–120</td>
<td>0.10 (0.12)</td>
<td>0.11 (0.14)</td>
<td>0.12 (0.14)</td>
<td>0.12 (0.14)</td>
<td>0.16 (0.18)</td>
<td>0.16 (0.19)</td>
<td>0.17 (0.20)</td>
<td></td>
</tr>
<tr>
<td>120–140</td>
<td>0.10 (0.11)</td>
<td>0.11 (0.14)</td>
<td>0.12 (0.14)</td>
<td>0.12 (0.14)</td>
<td>0.16 (0.18)</td>
<td>0.16 (0.19)</td>
<td>0.17 (0.19)</td>
<td></td>
</tr>
<tr>
<td>140–160</td>
<td>0.09 (0.11)</td>
<td>0.10 (0.13)</td>
<td>0.11 (0.13)</td>
<td>0.11 (0.13)</td>
<td>0.16 (0.18)</td>
<td>0.16 (0.19)</td>
<td>0.17 (0.18)</td>
<td></td>
</tr>
<tr>
<td>160–180</td>
<td>0.10 (0.11)</td>
<td>0.10 (0.12)</td>
<td>0.10 (0.12)</td>
<td>0.10 (0.12)</td>
<td>0.16 (0.18)</td>
<td>0.16 (0.19)</td>
<td>0.17 (0.17)</td>
<td></td>
</tr>
<tr>
<td>&gt;180</td>
<td>0.09</td>
<td>0.09 (0.11)</td>
<td>0.10 (0.11)</td>
<td>0.10 (0.11)</td>
<td>0.16 (0.18)</td>
<td>0.16 (0.19)</td>
<td>0.17 (0.17)</td>
<td></td>
</tr>
</tbody>
</table>

Prolongation of the PR interval (i.e., first-degree AV block) is seen in myocarditis (rheumatic, viral, or diphtheric), digitalis or quinidine toxicity, certain congenital heart defects (endocardial cushion defect, atrial septal defect, Ebstein’s anomaly), some myocardial dysfunctions, hyperkalemia, and otherwise normal heart with vagal stimulation.

A short PR interval is present in Wolff-Parkinson-White (WPW) preexcitation, Lown-Ganong-Levine syndrome, myocardiopathies of glycogenosis, Duchene’s muscular dystrophy (or relatives of these patients), Friedrich’s ataxia, pheochromocytoma, and otherwise normal children. The lower limits of normal PR interval are shown under the topic of WPW preexcitation (see later discussion).

Variable PR intervals are seen in the wandering atrial pacemaker and the Wenckebach phenomena (Mobitz type I second-degree AV block).

**QRS Duration**

The QRS duration varies with age (Table 3-3). It is short in infants and increases with age.

The QRS duration is prolonged in conditions grouped as ventricular conduction disturbances, which include RBBB, LBBB, preexcitation (e.g., WPW preexcitation), and intraventricular block (as seen in hyperkalemia, toxicity from quinidine or procainamide, myocardial fibrosis, and myocardial dysfunction of a metabolic or ischemic nature). Ventricular arrhythmias (e.g., premature ventricular contractions, ventricular tachycardia, implanted ventricular pacemaker) also produce a wide QRS duration. Because the QRS duration varies with age, the definition of bundle branch block (BBB) or other ventricular conduction disturbances should vary with age (see the section on ventricular conduction disturbances).

**QT Interval**

The QT interval varies primarily with heart rate. The heart rate–corrected QT (QTc) interval is calculated by the use of Bazett’s formula:

\[ \text{QTc} = \frac{\text{QT}}{\sqrt{R-R'}} \]

**TABLE 3-3**

**QRS DURATION ACCORDING TO AGE: MEAN (UPPER LIMITS OF NORMAL*) (IN SECONDS)**

<table>
<thead>
<tr>
<th></th>
<th>0–1 mo</th>
<th>1–6 mo</th>
<th>6–12 mo</th>
<th>1–3 yr</th>
<th>3–8 yr</th>
<th>8–12 yr</th>
<th>12–16 yr</th>
<th>Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seconds</td>
<td>0.05</td>
<td>0.055</td>
<td>0.055</td>
<td>0.055</td>
<td>0.06</td>
<td>0.06</td>
<td>0.07</td>
<td>0.08</td>
</tr>
<tr>
<td></td>
<td>(0.07)</td>
<td>(0.075)</td>
<td>(0.075)</td>
<td>(0.075)</td>
<td>(0.075)</td>
<td>(0.085)</td>
<td>(0.085)</td>
<td>(0.10)</td>
</tr>
</tbody>
</table>

* Upper limit of normal refers to the 98th percentile.

According to Bazett’s formula, the normal QTc interval (mean ± standard deviation) is 0.40 (±0.014) second with the upper limit of normal 0.44 second in children 6 month and older. The QTc interval is slightly longer in newborn and small infants with the upper limit of normal QTc 0.47 second in the first week of life and 0.45 second in the first 6 months of life.

Long QT intervals may be seen in long QT syndrome (e.g., Jervell and Lange-Nielsen syndrome, Romano-Ward syndrome), hypocalcemia, myocarditis, diffuse myocardial diseases (including hypertrophic and dilated cardiomyopathies), head injury, severe malnutrition, and so on. A number of drugs are also known to prolong the QT interval. Among these are antiarrhythmic agents (especially class IA, IC, and III), antipsychotic phenothiazines (e.g., thioridazine, chlorpromazine), tricyclic antidepressants (e.g., imipramine, amitriptyline), arsenics, organophosphates, antibiotics (e.g., ampicillin, erythromycin, trimethoprim-sulfa, amantadine), and antihistamines (e.g., terfenadine).

A short QT interval is a sign of a digitalis effect or of hypercalcemia. It is also seen with hyperthermia and in short QT syndrome (a familial cause of sudden death with QTc ≤300 millisecond).

**JT Interval**

The JT interval is measured from the J point (the junction between the S wave and the ST segment) to the end of the T wave. A prolonged JT interval has the same significance as a prolonged QT interval. The JT interval is measured only when the QT interval is prolonged or when the QRS duration is prolonged as seen with ventricular conduction disturbances. The JT interval is also expressed as a rate-corrected interval (called JTc) using Bazett’s formula. Normal JTc (mean ± SD) is 0.32 ± 0.02 second with the upper limit of normal 0.34 second in normal children and adolescents.

**P-Wave Duration and Amplitude**

The P-wave duration and amplitude are important in the diagnosis of atrial hypertrophy. Normally, the P amplitude is less than 3 mm. The duration of P waves is shorter than 0.09 second in children and shorter than 0.07 second in infants (see the section on criteria for atrial hypertrophy).

**QRS Amplitude, R/S Ratio, and Abnormal Q Waves**

A comment about normal ECG data for the QRS complex is in order. Normal data of Davignon et al (1979/1980) are not used in this chapter. Their data are severely handicapped because they provide almost no information on the frontal plane leads. Their data include the R wave and S wave voltages of only the aVR lead among the six limb leads; no data are provided for leads I, II, III, aVL, and aVF. Without the QRS amplitude of the frontal plane information, the interpretation of an ECG for ventricular hypertrophy would suffer greatly. In general, the limb leads (which are lacking in Davignon et al’s data) provides much more useful information than the precordial leads.
In addition, the limb leads are more reproducible than the precordial leads because each
cordial lead electrode must be placed precisely on the correct spot on the chest wall
but the limb lead electrodes do not.

The QRS amplitude and R/S ratio are important in the diagnosis of ventricular
hypertrophy. These values also vary with age (Tables 3-4 and 3-5). Because of normal
dominance of RV forces in infants and small children, R waves are taller than S waves in
the right precordial leads (i.e., V4R, V1, V2), and S waves are deeper than R waves in the
left precordial leads (i.e., V5, V6) in this age group. Accordingly, the R/S ratio (the ratio of
the R-wave and S-wave voltages) is large in the right precordial leads and small in the left
precordial leads in infants and small children.

### TABLE 3-4
R VOLTAGES ACCORDING TO LEAD AND AGE: MEAN (AND UPPER LIMIT*) (IN MM)

<table>
<thead>
<tr>
<th>Lead</th>
<th>0–1 mo</th>
<th>1–6 mo</th>
<th>6–12 mo</th>
<th>1–3 yr</th>
<th>3–8 yr</th>
<th>8–12 yr</th>
<th>12–16 yr</th>
<th>Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>4 (8)</td>
<td>7 (13)</td>
<td>8 (16)</td>
<td>8 (16)</td>
<td>7 (15)</td>
<td>7 (15)</td>
<td>6 (13)</td>
<td>6 (13)</td>
</tr>
<tr>
<td>II</td>
<td>6 (14)</td>
<td>13 (24)</td>
<td>13 (27)</td>
<td>12 (23)</td>
<td>13 (22)</td>
<td>14 (24)</td>
<td>14 (24)</td>
<td>5 (25)</td>
</tr>
<tr>
<td>III</td>
<td>8 (16)</td>
<td>9 (20)</td>
<td>9 (20)</td>
<td>9 (20)</td>
<td>9 (20)</td>
<td>9 (24)</td>
<td>9 (24)</td>
<td>6 (22)</td>
</tr>
<tr>
<td>aVR</td>
<td>3 (8)</td>
<td>2 (6)</td>
<td>2 (6)</td>
<td>2 (5)</td>
<td>2 (4)</td>
<td>1 (4)</td>
<td>1 (4)</td>
<td>1 (4)</td>
</tr>
<tr>
<td>aVL</td>
<td>2 (7)</td>
<td>4 (8)</td>
<td>5 (10)</td>
<td>5 (10)</td>
<td>3 (10)</td>
<td>3 (10)</td>
<td>3 (12)</td>
<td>3 (9)</td>
</tr>
<tr>
<td>aVF</td>
<td>7 (14)</td>
<td>10 (20)</td>
<td>10 (16)</td>
<td>8 (20)</td>
<td>10 (19)</td>
<td>10 (20)</td>
<td>11 (21)</td>
<td>5 (23)</td>
</tr>
<tr>
<td>V3R</td>
<td>10 (19)</td>
<td>6 (13)</td>
<td>6 (11)</td>
<td>6 (11)</td>
<td>5 (10)</td>
<td>3 (9)</td>
<td>3 (7)</td>
<td>3 (7)</td>
</tr>
<tr>
<td>V4R</td>
<td>6 (12)</td>
<td>5 (10)</td>
<td>4 (8)</td>
<td>4 (8)</td>
<td>3 (8)</td>
<td>3 (7)</td>
<td>3 (7)</td>
<td>3 (7)</td>
</tr>
<tr>
<td>V1</td>
<td>13 (24)</td>
<td>10 (19)</td>
<td>10 (20)</td>
<td>9 (18)</td>
<td>8 (16)</td>
<td>5 (12)</td>
<td>4 (10)</td>
<td>3 (14)</td>
</tr>
<tr>
<td>V2</td>
<td>18 (30)</td>
<td>20 (31)</td>
<td>22 (32)</td>
<td>19 (28)</td>
<td>15 (25)</td>
<td>12 (20)</td>
<td>10 (19)</td>
<td>6 (21)</td>
</tr>
<tr>
<td>V5</td>
<td>12 (23)</td>
<td>20 (33)</td>
<td>20 (31)</td>
<td>20 (32)</td>
<td>23 (38)</td>
<td>26 (39)</td>
<td>21 (35)</td>
<td>12 (33)</td>
</tr>
<tr>
<td>V6</td>
<td>5 (15)</td>
<td>13 (22)</td>
<td>13 (23)</td>
<td>13 (23)</td>
<td>15 (26)</td>
<td>17 (26)</td>
<td>14 (23)</td>
<td>10 (21)</td>
</tr>
</tbody>
</table>

S VOLTAGES ACCORDING TO LEAD AND AGE: MEAN (AND UPPER LIMIT*) (IN MM)

<table>
<thead>
<tr>
<th>Lead</th>
<th>0–1 mo</th>
<th>1–6 mo</th>
<th>6–12 mo</th>
<th>1–3 yr</th>
<th>3–8 yr</th>
<th>8–12 yr</th>
<th>12–16 yr</th>
<th>Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>5 (10)</td>
<td>4 (9)</td>
<td>4 (9)</td>
<td>3 (8)</td>
<td>2 (8)</td>
<td>2 (8)</td>
<td>2 (8)</td>
<td>1 (6)</td>
</tr>
<tr>
<td>V3R</td>
<td>3 (12)</td>
<td>3 (10)</td>
<td>4 (10)</td>
<td>5 (12)</td>
<td>7 (15)</td>
<td>8 (18)</td>
<td>7 (16)</td>
<td>6 (16)</td>
</tr>
<tr>
<td>V4R</td>
<td>4 (9)</td>
<td>4 (12)</td>
<td>5 (12)</td>
<td>5 (12)</td>
<td>5 (14)</td>
<td>6 (20)</td>
<td>6 (20)</td>
<td>6 (20)</td>
</tr>
<tr>
<td>V1</td>
<td>7 (18)</td>
<td>5 (15)</td>
<td>7 (18)</td>
<td>8 (21)</td>
<td>11 (23)</td>
<td>12 (25)</td>
<td>11 (22)</td>
<td>10 (23)</td>
</tr>
<tr>
<td>V2</td>
<td>18 (33)</td>
<td>15 (26)</td>
<td>16 (29)</td>
<td>18 (30)</td>
<td>20 (33)</td>
<td>21 (36)</td>
<td>18 (33)</td>
<td>14 (36)</td>
</tr>
<tr>
<td>V5</td>
<td>9 (17)</td>
<td>7 (16)</td>
<td>6 (15)</td>
<td>5 (12)</td>
<td>4 (10)</td>
<td>3 (8)</td>
<td>3 (8)</td>
<td>3 (8)</td>
</tr>
<tr>
<td>V6</td>
<td>3 (10)</td>
<td>3 (9)</td>
<td>2 (7)</td>
<td>2 (7)</td>
<td>2 (5)</td>
<td>1 (4)</td>
<td>1 (4)</td>
<td>1 (13)</td>
</tr>
</tbody>
</table>

Voltages measured in millimeters, when 1 mV = 10 mm paper
* Upper limit of normal refers to the 98th percentile.


### TABLE 3-5
R/S RATIO: MEAN AND UPPER AND LOWER LIMITS OF NORMAL ACCORDING TO AGE
Normal mean Q voltages and upper limits are presented in Table 3-6. The average normal Q-wave duration is 0.02 second and does not exceed 0.03 second. Abnormal Q waves may manifest themselves as deep or wide Q waves or as abnormal leads in which they appear. Deep Q waves may be present in ventricular hypertrophy of the “volume overload” type and in septal hypertrophy. Deep and wide Q waves are seen in MI. The presence of Q waves in the right precordial leads (e.g., severe RVH or ventricular inversion) or the absence of Q waves in the left precordial leads (e.g., LBBB or ventricular inversion) is abnormal.

FIGURE 3-14 Criteria for atrial hypertrophy. BAH, bialtrial hypertrophy; LAH, left atrial hypertrophy; RAH, right atrial hypertrophy. (From Park MK, Guntheroth WG: How to Read Pediatric ECGs, 4th ed. Philadelphia, Mosby, 2006.)
ST Segment and T Waves

The normal ST segment is isoelectric. However, in the limb leads, elevation or depression of the ST segment up to 1 mm is not necessarily abnormal in infants and children. An elevation or a depression of the ST segment is judged in relation to the PR segment as the baseline. Some ST-segment changes are normal (non-pathologic), and others are abnormal (pathologic). (See the later section of nonpathologic and pathologic ST-T changes in this chapter.)

Tall peaked T waves may be seen in hyperkalemia and LVH (of the “volume overload” type). Flat or low T waves may occur in normal newborns or with hypothyroidism, hypokalemia, pericarditis, myocarditis, and myocardial ischemia.
Atrial Hypertrophy

Right Atrial Hypertrophy
Tall P waves (>3 mm) indicate right atrial hypertrophy (RAH) or “P pulmonale” (Fig. 3-14).

Left Atrial Hypertrophy
Widened and often notched P wave is seen in left atrial hypertrophy (LAH) or “P mitrale.” In V1, the P wave is diphasic with a prolonged negative segment (see Fig. 3-14). A notched P wave in V1 is not diagnostic of LAH; the P wave duration has to be abnormally prolonged (with the P duration >0.10 second in children and >0.08 second in infants).

Biatrial Hypertrophy
In biatrial hypertrophy (BAH), a combination of an increased amplitude and duration of the P wave is present (see Fig. 3-14).
Ventricular Hypertrophy

General Changes

Ventricular hypertrophy produces abnormalities in one or more of the following: the QRS axis, the QRS voltages, the R/S ratio, the T axis, and miscellaneous areas.

1. Changes in the QRS axis

The QRS axis is usually directed toward the ventricle that is hypertrophied. Although RAD is present with RVH, LAD is seen with volume-overload type but not with pressure-overload type of LVH. Marked LAD (such as that seen with left anterior hemiblock or “superior” QRS axis) usually indicates ventricular conduction disturbances, not hypertrophy.

2. Changes in QRS voltages

Anatomically, the RV occupies the right and anterior aspect, and the LV occupies the left, inferior, and posterior aspect of the ventricular mass. With ventricular hypertrophy, the voltage of the QRS complex increases in the direction of the respective ventricle.

In the frontal plane (Fig. 3-15, A), LVH shows increased R voltages in leads I, II, aVL, aVF, and sometimes III, especially in small infants. RVH shows increased R voltages in aVR and III and increased S voltages in lead I (see Table 3-4 for normal R and S voltages).

In the horizontal plane (Fig. 3-15, B), tall R waves in V4R, V1, and V2 or deep S waves in V5 and V6 are seen in RVH. With LVH, tall R waves in V5 and V6 or deep S waves in V4R, V1, and V2 are present (see Table 3-4).

3. Changes in R/S ratio

The R/S ratio represents the relative electromotive force of opposing ventricles in a given lead. In ventricular hypertrophy, a change may be seen only in the R/S ratio without an increase in the absolute voltage. An increase in the R/S ratio in the right precordial leads suggests RVH; a decrease in the R/S ratio in these leads suggests LVH. Likewise, an increase in the R/S ratio in the left precordial leads suggests LVH, and a decrease in the ratio suggests RVH (see Table 3-5).
4. Changes in the T axis
Changes in the T axis are seen in severe ventricular hypertrophy with relative ischemia of the hypertrophied myocardium. In the presence of other criteria of ventricular hypertrophy, a wide QRS-T angle (i.e., >90 degrees) with the T axis outside the normal range indicates a “strain” pattern. When the T axis remains in the normal quadrant (0 to +90 degrees), a wide QRS-T angle indicates a possible “strain” pattern.

5. Miscellaneous nonspecific changes
a. RVH
1) A q wave in V1 (qR or qRs pattern) suggests RVH, although it may be present in ventricular inversion.
2) An upright T wave in V1 after 3 days of age is a sign of probable RVH.
b. LVH
Deep Q waves (>5 mm) and tall T waves in V5 and V6 are signs of LVH of the “volume overload” type. These may be seen with a large-shunt ventricular septal defect (VSD).

Criteria for Right Ventricular Hypertrophy
In RVH, some or all of the following criteria are present.
1. RAD for the patient’s age (see Table 3-1).
2. Increased rightward and anterior QRS voltages (in the absence of prolonged QRS duration) (see Table 3-4); a wide QRS complex with increased QRS voltages suggests ventricular conduction disturbances (e.g., RBBB) rather than ventricular hypertrophy.
   a. R waves in V1, V2, or aVR greater than the upper limits of normal for the patient’s age
   b. S waves in I and V6 greater than the upper limits of normal for the patient’s age
In general, the abnormal forces to the right and anteriorly are stronger criteria than abnormal forces to the right or anteriorly only.
3. Abnormal R/S ratio in favor of the RV (in the absence of prolonged QRS duration) (i.e., BBB; see Table 3-5).
   a. R/S ratio in V1 and V2 greater than the upper limits of normal for age
   b. R/S ratio in V6 less than 1 after 1 month of age
4. Upright T waves in V1 in patients more than 3 days of age, provided that the T is upright in the left precordial leads (V5, V6); upright T waves in V1 are not abnormal in patients older than 6 years of age.
5. A q wave in V1 (qR or qRs patterns) suggests RVH. (The physician should ascertain that there is not a small r in an rsR’ configuration.)
6. In the presence of RVH, a wide QRS-T angle with T axis outside the normal range (in the 0 to –90 degree quadrant) indicates a “strain” pattern. A wide QRS-T angle with the T
axis within the normal range suggests a possible “strain” pattern.

Figure 3-16 is an example of RVH. There is RAD for the patient’s age (+150 degrees). The T axis is –10 degrees, and the QRS-T angle is abnormally wide (160 degrees) with the T axis in an abnormal quadrant. The QRS duration is normal. The R-wave voltages in leads III and aVR and the S waves in leads I and V6 are beyond the upper limits of normal, indicating an abnormal rightward force. The R/S ratios in V1 and V2 are larger than the upper limits of normal, and the ratio in V6 is smaller than the lower limits of normal, again indicating RVH. Therefore, this tracing shows RVH with “strain.”

The diagnosis of RVH in newborns is particularly difficult because of the normal dominance of the RV during this period of life. Helpful signs in the diagnosis of RVH in newborns are as follows.

1. S waves in lead I that are 12 mm or greater
2. Pure R waves (with no S waves) in V1 that are greater than 10 mm Hg
3. R waves in V1 that are greater than 25 mm or R waves in aVR that are greater than 8 mm
4. A qR pattern seen in V1 (this is also seen in 10% of normal newborns)
5. Upright T waves seen in V1 after 3 days of age
6. RAD with the QRS axis greater than +180 degrees

Criteria for Left Ventricular Hypertrophy

In LVH, some or all of the following abnormalities are present.

1. LAD for the patient’s age in some cases (see Table 3-1)
2. QRS voltages in favor of the LV (in the absence of a prolonged QRS duration for age) (see Table 3-4)
   a. R waves in leads I, II, III, aVL, aVF, V5, or V6 greater than the upper limits of normal for age
   b. S waves in V1 or V2 greater than the upper limits of normal for age

In general, the presence of abnormal forces to more than one direction (e.g., to the left, inferiorly, and posteriorly) is stronger criterion than the abnormality in only one direction.

3. Abnormal R/S ratio in favor of the LV: R/S ratio in V1 and V2 less than the lower limits
of normal for the patient’s age (see Table 3-5)
4. Q waves in V5 and V6, greater than 5 mm, as well as tall symmetrical T waves in the same leads (“LV diastolic overload”)
5. In the presence of LVH, a wide QRS-T angle with the T axis outside the normal range indicates a “strain” pattern; this is manifested by inverted T waves in lead I or aVF. A wide QRS-T angle with the T axis within the normal range suggests a possible “strain” pattern.

Figure 3-17 is an example of LVH. There is LAD for the patient’s age (0 degrees). The R waves in leads I, aVL, V5, and V6 are beyond the upper limits of normal, indicating abnormal leftward force. The QRS duration is normal. The T axis (+55 degrees) remains in the normal quadrant. This tracing shows LVH (without “strain”).

Criteria for Biventricular Hypertrophy

BVH may be manifested in one of the following ways.
1. Positive voltage criteria for RVH and LVH in the absence of BBB or preexcitation (i.e., with normal QRS duration)
2. Positive voltage criteria for RVH or LVH and relatively large voltages for the other ventricle
3. Large equiphasic QRS complexes in two or more of the limb leads and in the midprecordial leads (i.e., V2 through V5), called the Katz-Wachtel phenomenon (with normal QRS duration)

Figure 3-18 is an example of BVH. It is difficult to plot the QRS axis because of large diphasic QRS complexes in limb leads. The QRS duration is not prolonged. The R and S voltages are large in some limb leads and in the midprecordial leads (Katz-Wachtel phenomenon). The S waves in leads I and V6 are abnormally deep (i.e., abnormal rightward force), and the R wave in V1 (i.e., rightward and anterior force) is also abnormally large, suggesting RVH. The R waves in leads I and aVL (i.e., leftward force) are also abnormally large, suggesting LVH. Therefore, this tracing shows BVH.

FIGURE 3-17 Tracing from a 4-year-old child with a moderate ventricular septal defect. Note that some precordial leads are in ½ normal standardization.
FIGURE 3-18  Tracing from a 2-month-old infant with large-shunt ventricular septal defect, patent ductus arteriosus, and severe pulmonary hypertension.
Ventricular Conduction Disturbances

Conditions that are grouped together as ventricular conduction disturbances have abnormal prolongation of the QRS duration in common. Ventricular conduction disturbances include the following:

1. BBB, right and left
2. Preexcitation (e.g., WPW-type preexcitation)
3. Intraventricular block

In BBBS (and ventricular rhythms), the prolongation is in the terminal portion of the QRS complex (i.e., “terminal slurring”). In preexcitation, the prolongation is in the initial portion of the QRS complex (i.e., “initial slurring”), producing “delta” waves. In intraventricular block, the prolongation is throughout the duration of the QRS complex (Fig. 3-19). Normal QRS duration varies with age; it is shorter in infants than in older children or adults (see Table 3-3). In adults, a QRS duration longer than 0.10 second is considered abnormally prolonged. In infants, a QRS duration of 0.08 second is the upper limit of normal. Depending on the degree of prolongation, complete versus incomplete block may be assigned.

By far the most commonly encountered form of ventricular conduction disturbance is RBBB. WPW preexcitation is uncommon, but it is a well-defined entity that deserves a brief description. LBBB is extremely rare in children, although it is common in adults with ischemic and hypertensive heart disease. Intraventricular block is associated with metabolic disorders and diffuse myocardial diseases.

Right Bundle Branch Block

In RBBB, delayed conduction through the right bundle branch prolongs the time required for a depolarization of the RV. When the LV is completely depolarized, RV depolarization is still in progress. This produces prolongation of the QRS duration, involving the terminal portion of the QRS complex, called “terminal slurring” (see Fig. 3-19, B), and the slurring is directed to the right and anteriorly because the RV is located rightward and anteriorly in relation to the LV.
In a normal heart, synchronous depolarization of the opposing electromotive forces of the RV and LV cancels out the forces to some extent, with the resulting voltages that we call normal. In RBBB (and other ventricular conduction disturbances), asynchronous depolarization of the opposing electromotive forces may produce a lesser degree of cancellation of the opposing forces and thus results in greater manifest potentials for both ventricles. Consequently, abnormally large voltages for both RV and LV may result even in the absence of ventricular hypertrophy. Therefore, the diagnosis of ventricular hypertrophy in the presence of BBB (or WPW preexcitation or intraventricular block) is insecure.

In adults, when the QRS duration is longer than 0.12 second it is called complete RBBB, and when the QRS duration is between 0.10 and 0.12 second, it is called incomplete right bundle branch block (IRBBB). Normal QRS duration is shorter in infants and children. Therefore, dividing RBBB into complete and incomplete is generally arbitrary and is particularly meaningless in children. Furthermore, in most of pediatric cases of RBBB, the right bundle branch is intact.

Criteria for Right Bundle Branch Block

1. RAD, at least for the terminal portion of the QRS complex. (The initial QRS force is normal.)
2. The QRS duration clearly longer than the upper limit of normal for the patient’s age (see Table 3-3). When the prolongation of the QRS duration is only mild, it could be called incomplete RBBB.
3. Terminal slurring of the QRS complex that is directed to the right and usually, but not always, anteriorly:
   a. Wide and slurred S waves in leads I, V5, and V6
   b. Terminal, slurred R’ in aVR and the right precordial leads (V4R, V1, and V2).
4. ST-segment shift and T-wave inversion are common in adults but not in children.

   Figure 3-20 is an example of RBBB. The QRS duration is increased (0.11 second), indicating a ventricular conduction disturbance. There is slurring of the terminal portion of the QRS complex, indicating a BBB, and the slurring is directed to the right (slurred S waves in leads I and V6, and slurried R waves in aVR) and anteriorly (slurred R waves in V4R and V1), satisfying the criteria for RBBB. Although the S waves in leads I, V5, and V6 are abnormally deep and the R/S ratio in V1 is abnormally large, it cannot be interpreted as RVH in the presence of RBBB.

Two pediatric conditions commonly associated with RBBB are ASD and conduction disturbances after open heart surgery involving right ventriculotomy. Other congenital heart defects often associated with RBBB include Ebstein’s anomaly, coarctation of the aorta in infants younger than 6 months of age, endocardial cushion defect, and partial anomalous pulmonary venous return; it is also occasionally seen in normal children. Rarely, RBBB is seen in myocardial diseases (cardiomyopathy, myocarditis), muscle diseases (Duchenne’s muscular dystrophy, myotonic dystrophy), and Brugada syndrome.
The significance of RBBB in children is different from that in adults. In several pediatric examples of RBBB, the right bundle is intact. In ASD, the prolonged QRS duration is the result of a longer pathway through a dilated RV rather than an actual block in the right bundle. Right ventriculotomy for repair of VSD or tetralogy of Fallot disrupts the RV subendocardial Purkinje network and causes prolongation of the QRS duration without necessarily injuring the main right bundle, although the latter may occasionally be disrupted.

**Incomplete Right Bundle Branch Block**

IRBBB is one of the more common ECG abnormalities reported by computer readouts and by physicians alike. Because some physicians are concerned with the rsR' pattern in V1 or the diagnosis of IBBB, the topic deserves a little more attention.

Although the RSR' (or rSr') pattern in V1 is unusual in adults, this pattern is a normal finding in infants, toddlers, and children. From vectorcardiographic points of view, in order for a newborn ECG pattern to change to the adult pattern, it has to go through a stage in which rSr' or RsR' pattern appears. It is almost impossible for a newborn ECG to change to an adult pattern without going through the rSr' (or rsR') stage. (For those who are interested in learning about the reason, Park and Gunderoth, 2006, is recommended.)

The following clarifies some issues related to the rSr' pattern in V1.

1. An rsR' pattern in V1 is normal if it is associated with normal QRS duration and normal QRS voltage.
2. If the rSr' pattern is associated with only slightly prolonged QRS duration (not to satisfy the criterion of RBBB), it is then incomplete RBBB. The QRS voltage may be slightly increased in some cases for the same reason as discussed under RBBB.
3. If the rsR' pattern is associated with slightly prolonged QRS duration and an abnormal QRS voltage, it is still IRBBB, not ventricular hypertrophy.
4. RVH is justified only if an abnormal QRS voltage is present in the presence of normal QRS duration.

The pathophysiology and clinical significance of IRBBB are similar to that of RBBB as discussed earlier. Whether to call it “complete” or “incomplete” is arbitrary in children. When structural and functional cardiac anomalies are ruled out, IRBBB does not have
much clinical significance in the pediatric population. Some cardiologists prefer the term “right ventricular conduction delay” rather than a “block” as in IRBBB. The prevalence of IRBBB in the pediatric population is not known, although a large epidemiologic study from Japan suggests it is around 1% among the normal pediatric population. The prevalence of IRBBB in the adult population is estimated to be 5% to 10%, and it tends to increase with advancing age. A recent report suggests it may be a marker for lone atrial fibrillation in adults (which is defined as atrial fibrillation in the absence of identifiable cardiovascular or pulmonary disease).

**Left Bundle Branch Block**

Left Bundle Branch Block (LBBB) is extremely rare in children. In LBBB, the duration of the QRS complex is prolonged for age, and the slurred terminal portion of the QRS complex is directed leftward and posteriorly. A Q wave is absent in V6. A prominent QS pattern is seen in V1, and a tall R wave is seen in V6.

LBBB in children is associated with cardiac disease or surgery in the LV outflow tract, septal myomectomy, and replacement of the aortic valve. Other conditions rarely associated with LBBB include LVH, myocarditis, cardiomyopathy, MI, aortic valve endocarditis, and premature ventricular contractions (or ventricular tachycardia [VT]) originating in the RV outflow tract.

LBBB alone may rarely progress to complete heart block and sudden death, but the prognosis is more dependent on associated disease than on the LBBB itself.

**Intraventricular Block**

In intraventricular block, the prolongation is throughout the duration of the QRS complex (see Fig. 3-19, D). This usually suggests serious conditions such as metabolic disorders (e.g., hyperkalemia), diffuse myocardial diseases (e.g., myocardial fibrosis, systemic diseases with myocardial involvement), severe hypoxia, myocardial ischemia, or drug toxicity (quinidine or procainamide).

**Wolff-Parkinson-White Preexcitation**

Wolff-Parkinson-White preexcitation results from an anomalous conduction pathway (i.e., bundle of Kent) between the atrium and the ventricle, bypassing the normal delay of conduction in the AV node. The premature depolarization of a ventricle produces a delta wave and results in prolongation of the QRS duration (see Fig. 3-19, C).

**Criteria for Wolff-Parkinson-White Syndrome**

1. Short PR interval, less than the lower limit of normal for the patient’s age. The lower limits of normal of the PR interval according to age are as follows.

<table>
<thead>
<tr>
<th>Age</th>
<th>PR Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Younger than 12 mo</td>
<td>0.075 second</td>
</tr>
<tr>
<td>1–3 yr</td>
<td>0.080 second</td>
</tr>
</tbody>
</table>
2. Delta wave (initial slurring of the QRS complex)
3. Wide QRS duration beyond the upper limit of normal

Patients with WPW preexcitation are prone to attacks of paroxysmal supraventricular tachycardia (SVT) (see Chapter 24). When there is a history of SVT, the diagnosis of WPW syndrome is justified. WPW preexcitation may mimic other ECG abnormalities such as ventricular hypertrophy, RBBB, or myocardial disorders. In the presence of preexcitation, the diagnosis of ventricular hypertrophy cannot be safely made. Large QRS deflections are often seen in this condition because of an asynchronous depolarization of the ventricles rather than ventricular hypertrophy.

Figure 3-21 is an example of WPW preexcitation. The most striking abnormalities are a short PR interval (0.08 second) and a wide QRS duration (0.11 second). There are delta waves in most of the leads. Some delta waves are negative, as seen in leads III, aVR, V4R, and V1. The ST segments and T waves are shifted in the opposite direction of the QRS vector, resulting in a wide QRS-T angle. The leftward voltages are abnormally large, but the diagnosis of LVH cannot safely be made in the presence of WPW preexcitation.

![Figure 3-21](image_url)

**FIGURE 3-21** Tracing from an asymptomatic 2-year-old boy whose ventricular septal defect underwent spontaneous closure. The tracing shows the Wolff-Parkinson-White preexcitation (see text for interpretation).
There are two other forms of preexcitation that can also result in extreme tachycardia (SVT).

1. Lown-Ganong-Levine syndrome is characterized by a short PR interval and normal QRS duration. In this condition, James fibers (which connect the atrium and the bundle of His) bypass the upper AV node and produce a short PR interval, but the ventricles are depolarized normally through the His-Purkinje system. When there is no history of SVT, the tracing cannot be read as Lown-Ganong-Levine syndrome; it should read simply as short PR interval.

2. Mahaim-type preexcitation syndrome is characterized by a normal PR interval and long QRS duration with a delta wave. There is an abnormal Mahaim fiber that connects the AV node and one of the ventricles, bypassing the bundle of His and “short circuiting” into the ventricle.

**Ventricular Hypertrophy Versus Ventricular Conduction Disturbances**

Two common ECG abnormalities in children, ventricular hypertrophy and ventricular conduction disturbances, are not always easy to distinguish; both present with increased QRS amplitudes. An accurate measurement of the QRS duration is essential. The following approach may aid in the correct diagnosis of these conditions (Fig. 3-22).

1. When the QRS duration is normal, normal QRS voltages indicate a normal ECG. Increased QRS voltages indicate ventricular hypertrophy.

2. When the QRS duration is clearly prolonged, a ventricular conduction disturbance is present whether the QRS voltages are normal or increased. An additional diagnosis of ventricular hypertrophy should not be made.

3. When the QRS duration is borderline prolonged, distinguishing between these two conditions is difficult. Normal QRS voltages favor a normal ECG or a mild (RV or LV) conduction disturbance. An increased QRS voltage favors ventricular hypertrophy.
ST-Segment and T-Wave Changes

Electrocardiographic changes involving the ST segment and the T wave are common in adults but relatively rare in children. This is because there is a high incidence of ischemic heart disease, BBB, MI, and other myocardial disorders in adults. Some ST-segment changes are normal (nonpathologic), and others are abnormal (pathologic).

Nonpathologic ST-Segment Shift

Not all ST-segment shifts are abnormal. A slight shift of the ST segment is common in normal children. Elevation or depression of up to 1 mm in the limb leads and up to 2 mm in the precordial leads is within normal limits. Two common types of nonpathologic ST-segment shifts are J-depression and early repolarization. The T vector remains normal in these conditions.

J-Depression

J-depression is a shift of the junction between the QRS complex and the ST segment (J-point) without sustained ST segment depression (Fig. 3-23, A). The J-depression is seen more often in the precordial leads than in the limb leads (Fig. 3-24).

Early Repolarization

In early repolarization, all leads with upright T waves have elevated ST segments, and leads with inverted T waves have depressed ST segments (see Fig. 3-24). The T vector remains normal. This condition, seen in healthy adolescents and young adults, resembles the ST-segment shift seen in acute pericarditis; in the former, the ST segment is stable, and in the latter, the ST segment returns to the isoelectric line.

Pathologic ST-Segment Shift

Abnormal shifts of the ST segment often are accompanied by T-wave inversion. A pathologic ST segment shift assumes one of the following forms:
1. Downward slant followed by a diphasic or inverted T wave (see Fig. 3-23, B)
2. Horizontal elevation or depression sustained for longer than 0.08 second (see Fig. 3-23, C)

Pathologic ST segment shifts are seen in left or RVH with “strain” (discussed under ventricular hypertrophy); digitalis effect; pericarditis, including postoperative state; myocarditis (see under myocarditis, Chapter 19); MI; and some electrolyte disturbances (hypokalemia and hyperkalemia).
T-Wave Changes

T-wave changes usually are associated with the conditions manifesting with pathologic ST-segment shift. T-wave changes with or without ST-segment shift are also seen with BBB and ventricular arrhythmias.

Pericarditis

The ECG changes seen in pericarditis are the result of subepicardial myocardial damage or pericardial effusion and consist of the following:

1. Pericardial effusion may produce low QRS voltages (QRS voltages <5 mm in every one of the limb leads).
2. Subepicardial myocardial damage produces the following time-dependent changes in the ST segment and T wave (Fig. 3-25):
   a. ST-segment elevation occurs in the leads representing the LV.
   b. The ST-segment shift returns to normal within 2 to 3 days.
   c. T-wave inversion (with isoelectric ST segment) occurs 2 to 4 weeks after the onset of pericarditis.
FIGURE 3-24  Tracing from a healthy 16-year-old boy that exhibits early repolarization and J-depression. The ST segment is shifted toward the direction of the T wave and is most marked in II, III, and aVF. J-depression is seen in most of the precordial leads.

FIGURE 3-25  Time-dependent changes of the ST segment and T wave in pericarditis. The initial change is ST-segment elevation (A), followed by return of ST segment elevation toward normal (B), and T wave inversion with isoelectric ST segment (C). (From Park MK, Guntheroth WG: How to Read Pediatric ECGs, 4th ed. Philadelphia, Mosby, 2006.)
Myocardial Infarction

MI is rare in infants and children, but correctly diagnosing the condition is important for proper care. All conditions that have been associated with MI in adults have been described as causing MI in children, such as atherosclerosis, inflammatory disease of the myocardium, lupus erythematosus, polyarteritis nodosa, hypertension, and diabetes mellitus. Uncommon causes of MI in pediatric patients include anomalous origin of the left coronary artery from the pulmonary artery, endocardial fibroelastosis, coronary artery embolization resulting from infective endocarditis or from interventional or diagnostic catheterization procedures performed on the left side of the heart, and inadvertent surgical interruption of the coronary artery during cardiac surgery. In recent years, early and late sequelae of Kawasaki’s disease, surgical complications of the arterial switch operation for transposition of the great arteries, and dilated cardiomyopathy have emerged as important causes of MI in the pediatric population.

The ECG findings of adult MI are time dependent and are illustrated in Figure 3-26. Changes seen during the hyperacute phase are short lived. The more common ECG findings are those of the early evolving phase. These consist of pathologic Q waves (abnormally wide and deep), ST-segment elevation, and T-wave inversion. The duration of the Q wave is 0.04 second or greater in adults, and it should be at least 0.03 second in children. Over the next few weeks, the elevated ST segment gradually returns toward the baseline, but inverted T waves persist (late evolving phase). The pathologic Q waves persist for years after MI (see Fig. 3-26). Leads that show these abnormalities vary with the location of the infarction and are summarized in Table 3-7.

![Figure 3-26](https://example.com/image.png)

**FIGURE 3-26** Sequential changes of the ST segment and T wave in myocardial infarction. (From Park MK, Guntheroth WG: How to Read Pediatric ECGs, 4th ed., Philadelphia, Mosby, 2006)

<table>
<thead>
<tr>
<th>Phase</th>
<th>Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperacute Phase</td>
<td>Elevated ST Segment, Deep and Wide Q Wave</td>
</tr>
<tr>
<td>Early Evolving Phase</td>
<td>Deep and Wide Q Wave, Elevated ST Segment, Diphasic T Wave</td>
</tr>
<tr>
<td>Late Evolving Phase</td>
<td>Deep and Wide Q Wave, Sharply Inverted T Wave</td>
</tr>
<tr>
<td>Resolving Phase</td>
<td>Deep and Wide Q Wave, Almost Normal T Wave</td>
</tr>
</tbody>
</table>

**TABLE 3-7**
LEADS SHOWING ABNORMAL ELECTROCARDIOGRAPHIC FINDINGS IN MYOCARDIAL INFARCTION

<table>
<thead>
<tr>
<th>Lead Type</th>
<th>Limb Leads</th>
<th>Precordial Leads</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lateral</td>
<td>I, aVL</td>
<td>V3, V6</td>
</tr>
<tr>
<td>Anterior</td>
<td>V1, V2, V3</td>
<td></td>
</tr>
<tr>
<td>Anterolateral</td>
<td>I, aVL</td>
<td>V2–V6</td>
</tr>
<tr>
<td>Diaphragmatic</td>
<td>II, III, aVF</td>
<td></td>
</tr>
<tr>
<td>Posterior</td>
<td>V1–V3</td>
<td></td>
</tr>
</tbody>
</table>

None of the leads is oriented toward the posterior surface of the heart. Therefore, in posterior infarction, changes that would have been present in the posterior surface leads will be seen in the anterior leads as a mirror image (e.g., tall and slightly wide R waves in V1 and V2, comparable to abnormal Q waves, and tall and wide, symmetric T waves in V1 and V2).

In most pediatric patients with MI, the time of onset is not clearly known, and the evolution of the different phases is difficult to document. Frequent ECG findings in children with acute MI include the following (Towbin et al, 1992):

1. Wide Q waves (>0.035 second) with or without Q-wave notching
2. ST segment elevation (>2 mm)
3. Prolongation of QTc interval (>0.44 second) with accompanying abnormal Q waves

The width of the Q wave is more important than the depth; the depth of the Q wave varies widely in normal children (see Table 3-6).

Figure 3-27 is an ECG of MI in an infant with anomalous origin of the left coronary artery from the pulmonary artery. The most important abnormality is the presence of a deep and wide Q wave (0.04 second) in leads I, aVL, and V6. A QS pattern appears in V2 through V5, indicating anterolateral MI (see Table 3-7).

Electrolyte Disturbances

Two important serum electrolytes that produce ECG changes are calcium and potassium.

**Calcium.** Calcium ion affects the duration of the ST segment and thus change the relative position of the T wave. Hyper- or hypocalcemia does not produce ST-segment shift or T-wave changes. Hypocalcemia prolongs the ST segment and, as a result, prolongs the QTc interval (Fig. 3-28). Hypercalcemia shortens the ST segment, resulting in shortening of the QTc interval (see Fig. 3-28).

**Potassium.** Hypokalemia produces one of the least specific ECG changes. When the serum potassium level is below 2.5 mEq/L, ECG changes consist of a prominent U wave with apparent prolongation of the QTc, flat or diphasic T waves, and ST-segment depression (Fig. 3-29). With further lowering of serum potassium levels, the PR interval becomes prolonged, and sinoatrial block may occur.

The earliest ECG abnormality seen in hyperkalemia is tall, peaked, symmetrical T waves with a narrow base, so-called tented T wave. In hyperkalemia, sinoatrial block, second-degree AV block (either Mobitz I or II), and accelerated junctional or ventricular escape rhythm may occur. Severe hyperkalemia may result in either ventricular fibrillation or arrest. The following ECG sequence is associated with a progressive increase in the serum potassium level (see Fig. 3-29):

1. Tall, tented T waves
2. Prolongation of the QRS duration (intraventricular block)
3. Prolongation of the PR interval (first-degree AV block)
4. Disappearance of the P wave
5. Wide, bizarre diphasic QRS complex ("sine wave")
6. Eventual asystole

**FIGURE 3-27** Tracing from a 2-month-old infant who has anomalous origin of the left coronary artery from the pulmonary artery. An abnormally deep and wide Q wave (0.04 second) seen in I, aVL, and V6 and a QS pattern seen in V2 through V6 are characteristic of anterolateral myocardial infarction.

**FIGURE 3-28** Electrocardiographic findings of hypercalcemia and hypocalcemia. Hypercalcemia shortens and hypocalcemia lengthens the ST segment. (From Park MK, Guntheroth WG: How to Read Pediatric ECGs, 4th ed. Philadelphia, Mosby, 2006.)

**SERUM K**

- **<2.5 mEq/L**
  - Depressed ST Segment
  - Diphasic T Wave
  - Prominent U Wave

- **Normal**

- **>6.0 mEq/L**
  - Tall T Wave

- **>7.5 mEq/L**
  - Long PR Interval
  - Wide QRS Duration
  - Tall T Wave
These ECG changes are usually seen best in leads I and II and the left precordial leads.
Chest Radiography was an essential part of cardiac evaluation before echocardiography and Doppler studies became widely available to cardiologists. This simple test remains very useful to physicians who do not have access to echocardiography and Doppler studies. Cardiovascular abnormalities may be incidentally suspected by x-ray films that were obtained for other reasons. Chest Radiography also supplements information that is not gained by the echocardiography study, such as information on the lung parenchyma, airways, and vascular structures connected to the heart.

Chest radiographic films can provide the following information: heart size and silhouette; enlargement of specific cardiac chambers; pulmonary blood flow or pulmonary vascular markings; and other information regarding lung parenchyma, spine, bony thorax, abdominal situs, and so on. Posteroanterior and lateral views are routinely obtained.
Heart Size and Silhouette

Heart Size

Measurement of the cardiothoracic (CT) ratio is by far the simplest way to estimate the heart size in older children (Fig. 4-1). The CT ratio is obtained by relating the largest transverse diameter of the heart to the widest internal diameter of the chest:

\[
\text{CT ratio} = \frac{A + B}{C}
\]

where \(A\) and \(B\) are maximal cardiac dimensions to the right and left of the midline, respectively, and \(C\) is the widest internal diameter of the chest. A CT ratio of more than 0.5 indicates cardiomegaly. However, the CT ratio cannot be used with accuracy in newborns and small infants, in whom a good inspiratory chest film is rarely obtained. In this situation, the degree of inadequate inspiration should be taken into consideration. Also, an estimation of the cardiac volume should be made by inspecting the posteroanterior and lateral views instead of the CT ratio.

To determine the presence or absence of cardiomegaly, the lateral view of the heart should also be inspected. For example, isolated right ventricular enlargement may not be obvious on a posteroanterior film but will be obvious on a lateral film. In a patient with a flat chest (or narrow anteroposterior diameter of the chest), a posteroanterior film may erroneously show cardiomegaly.

An enlarged heart on chest radiographs more reliably reflects a volume overload than a pressure overload. Electrocardiograms (ECGs) better represent a pressure overload than chest radiographic films.

Normal Cardiac Silhouette

The structures that form the cardiac borders in the posteroanterior projection of a chest roentgenogram are shown in Figure 4-2. The right cardiac silhouette is formed superiorly by the superior vena cava (SVC) and inferiorly by the right atrium (RA). The left cardiac border is formed from the top to the bottom by the aortic knob, the main pulmonary artery (PA), and the left ventricle (LV). The left atrial appendage (LAA) is located between the main PA and the LV and is not prominent in a normal heart. The right ventricle (RV) does not form the cardiac border in the posteroanterior view. The lateral projection of the cardiac silhouette is formed anteriorly by the RV and posteriorly by the left atrium (LA) above and the LV below. In a normal heart, the lower posterior cardiac border (i.e., LV) crosses the inferior vena cava (IVC) line above the diaphragm (see Fig. 4-2).
FIGURE 4-1  Diagram showing how to measure the cardiothoracic (CT) ratio from the posteroanterior view of a chest radiographic film. The CT ratio is obtained by dividing the largest horizontal diameter of the heart (A + B) by the longest internal diameter of the chest (C).

FIGURE 4-2  Posteroanterior and lateral projections of normal cardiac silhouette. Note that in the lateral projection, the right ventricle (RV) is contiguous with the lower third of the sternum and that the left ventricle (LV) normally crosses the posterior margin of the inferior vena cava (IVC) above the diaphragm. AO, aorta; LA, left atrium; LAA, left atrial appendage; LPA, left pulmonary artery; PA, pulmonary artery; RA, right atrium; RPA, right pulmonary artery; SVC, superior vena cava.
However, in a newborn, a typical normal cardiac silhouette is rarely seen because of the presence of a large thymus and because the films are often exposed during expiration. The thymus is situated in the superoanterior mediastinum. Therefore, the base of the heart may be widened, with resulting alteration in the normal silhouette in the posteroanterior view. In the lateral view, the retrosternal space, which is normally clear in older children, may be obliterated by the large thymus.

**Abnormal Cardiac Silhouette**

Although discerning individual chamber enlargement often helps diagnose an acyanotic heart defect, the overall shape of the heart sometimes provides important clues to the type of defect, particularly in dealing with cyanotic infants and children. A few examples follow, relating it to the status of pulmonary blood flow or pulmonary vascular markings.

1. A “boot-shaped” heart with decreased pulmonary blood flow is typical in infants with cyanotic tetralogy of Fallot (TOF). This is also seen in some infants with tricuspid atresia. Typical of both conditions is the presence of a hypoplastic main PA segment (Fig. 4-3, A). ECGs are helpful in differentiating these two conditions. Whereas the ECG shows right axis deviation (RAD), right ventricular hypertrophy (RVH), and occasional right atrial hypertrophy (RAH) in TOF, it shows a “superior” QRS axis (i.e., left anterior hemiblock), RAH, and left ventricular hypertrophy (LVH) in tricuspid atresia.

2. A narrow-waisted and “egg-shaped” heart with increased pulmonary blood flow in a cyanotic infant strongly suggests transposition of the great arteries (TGA). The narrow waist results from the absence of a large thymus and the abnormal relationship of the great arteries (see Fig. 4-3, B).

3. The “snowman” sign with increased pulmonary blood flow is seen in infants with the supracardiac type of total anomalous pulmonary venous return (TAPVR). The left vertical vein, left innominate vein, and dilated SVC make up the snowman’s head (see Fig. 4-3, C).
Individual Chamber Enlargement

Identification of individual chamber enlargement is important in diagnosing a specific lesion, particularly when dealing with acyanotic heart defects. Although enlargement of a single chamber is discussed here, more than one chamber is usually involved.

**Left Atrial Enlargement.** An enlarged LA causes alterations not only of the cardiac silhouette but also of the various adjacent structures (Fig. 4-4). Mild LA enlargement is best appreciated in the lateral projection by the posterior protrusion of the LA border. Enlargement of the LA may produce “double density” on the posteroanterior view. With further enlargement, the LAA becomes prominent on the left cardiac border. The left mainstem bronchus is elevated. The barium-filled esophagus is indented to the right.

**FIGURE 4-5** Diagrammatic representation of changes seen in ventricular septal defect. Left ventricle (LV) enlargement in addition to enlargement of the left atrium (LA) and a prominent pulmonary artery (PA) segment. Other abbreviations are the same as those in Figure 4-2.
FIGURE 4-6  Schematic diagrams of posteroanterior and lateral chest roentgenograms of atrial septal defect. There is enlargement of the right atrium (RA) and right ventricle (RV) and an increased pulmonary vascularity. Other abbreviations are the same as those in Figure 4-2.

Left Ventricular Enlargement. In the posteroanterior view, the apex of the heart is not only farther to the left but also downward. In the lateral view of LV enlargement, the lower posterior cardiac border is displaced farther posteriorly and meets the IVC line below the diaphragm level (Fig. 4-5).

Right Atrial Enlargement. RA enlargement is most obvious in the posteroanterior projection as an increased prominence of the lower right cardiac silhouette (Fig. 4-6). However, this is not an absolute finding because both false-positive and false-negative results are possible.

Right Ventricular Enlargement. Isolated right ventricular enlargement may not be obvious in the posteroanterior projection, and the normal CT ratio may be maintained because the RV does not make up the cardiac silhouette in the posteroanterior projection. RV enlargement is best recognized in the lateral view, in which it manifests itself by filling of the retrosternal space (see Fig. 4-6, lateral view).

Size of the Great Arteries

As in the enlargement of specific cardiac chambers, the size of the great arteries often helps make a specific diagnosis.

Prominent Main Pulmonary Artery Segment. The prominence of a normally placed PA in the posteroanterior view (Fig. 4-7, A) results from one of the following:

1. Poststenotic dilatation (e.g., pulmonary valve stenosis)
2. Increased blood flow through the PA (e.g., atrial septal defect [ASD], ventricular septal defect [VSD])
3. Increased pressure in the PA (e.g., pulmonary hypertension)
4. Occasional normal finding in adolescents, especially girls

Hypoplasia of the Pulmonary Artery. A concave main PA segment with a resulting “boot-shaped” heart is seen in TOF and tricuspid atresia (see Fig. 4-7, B); obviously,
malposition of the PA must be ruled out.

**Dilatation of the Aorta.** An enlarged ascending aorta may be observed in the frontal projection as a rightward bulge of the right upper mediastinum, but a mild degree of enlargement may easily escape detection. Aortic enlargement is seen in TOF and aortic stenosis (as poststenotic dilatation) and less often in patent ductus arteriosus (PDA), coarctation of the aorta (COA), Marfan’s syndrome, or systemic hypertension. When the ascending aorta and aortic arch are enlarged, the aortic knob may become prominent on the posteroanterior view (see Fig. 4-7, C).
Pulmonary Vascular Markings

One of the major goals of radiologic examination is assessment of the pulmonary vasculature. Although many textbooks explain how to detect increased pulmonary blood flow, this is one of the more difficult aspects of interpreting chest radiographs of cardiac patients. There is no substitute for the experience gained by looking at many chest radiographs with normal and abnormal pulmonary blood flow.

Increased Pulmonary Blood Flow

Increased pulmonary vascularity is present when the right and left PAs appear enlarged and extend into the lateral third of the lung field, where they are not usually present; there is increased vascularity to the lung apices where the vessels are normally collapsed; and the external diameter of the right PA visible in the right hilus is wider than the internal diameter of the trachea.

Increased pulmonary blood flow in an acyanotic child represents ASD, VSD, PDA, endocardial cushion defect, partial anomalous pulmonary venous return (PAPVR), or any combination of these. In a cyanotic infant, increased pulmonary vascular markings may indicate TGA, TAPVR, hypoplastic left heart syndrome, persistent truncus arteriosus, or a single ventricle.

Decreased Pulmonary Blood Flow

Decreased pulmonary blood flow is suspected when the hilum appears small, the remaining lung fields appear black, and the vessels appear small and thin. Ischemic lung fields are seen in cyanotic heart diseases with decreased pulmonary blood flow such as critical stenosis or atresia of the pulmonary or tricuspid valves, including TOF.

Pulmonary Venous Congestion

Pulmonary venous congestion is characterized by a hazy and indistinct margin of the pulmonary vasculature. This is caused by pulmonary venous hypertension secondary to LV failure or obstruction to pulmonary venous drainage (e.g., mitral stenosis, TAPVR, cor triatriatum). Kerley’s B lines are short, transverse strips of increased density best seen in the costophrenic sulci. This is caused by engorged lymphatics and interstitial edema of the interlobular septa secondary to pulmonary venous congestion.

Normal Pulmonary Vasculature

Pulmonary vascularity is normal in patients with obstructive lesions such as pulmonary stenosis or aortic stenosis. Unless the stenosis is extremely severe, pulmonary vascularity remains normal in pulmonary stenosis. Patients with small left-to-right shunt lesions also show normal pulmonary vascular markings.
Systematic Approach
The interpretation of chest radiographs should include a systematic routine to avoid overlooking important anatomic changes relevant to cardiac diagnosis.

Location of the Liver and Stomach Gas Bubble
The cardiac apex should be on the same side as the stomach or opposite the hepatic shadow. When there is heterotaxia, with the apex on the right and the stomach on the left (or vice versa), the likelihood of a serious heart defect is great. An even more ominous situation exists with a “midline” liver, associated with asplenia (Ivemark’s) syndrome or polysplenia syndrome (Fig. 4-8). These infants usually have complex cyanotic heart defects that are difficult to correct.

Skeletal Aspect of Chest Radiographic Film
Pectus excavatum may flatten the heart in the anteroposterior dimension and cause a compensatory increase in its transverse diameter, creating the false impression of cardiomegaly. Thoracic scoliosis and vertebral abnormalities are frequent in cardiac patients. Rib notching is a specific finding of COA in an older child (usually older than 5 years) and is usually found between the fourth and eighth ribs (Fig. 4-9).
Identification of the Aorta

1. Identification of the descending aorta along the left margin of the spine usually indicates a left aortic arch; identification along the right margin of the spine indicates a right aortic arch. The right aortic arch is frequently associated with TOF or persistent truncus arteriosus. Some of the patients with right aortic arch may have vascular ring (see Chapter 16).

2. When the descending aorta is not directly visible, the position of the trachea and esophagus may help locate the descending aorta. If the trachea and esophagus are located slightly to the right of the midline, the aorta usually descends normally on the left (i.e., left aortic arch). In the right aortic arch, the trachea and esophagus are shifted to the left.

3. In a heavily exposed film, the precoarctation and postcoarctation dilatation of the aorta may be seen as a “figure of 3.” This may be confirmed by a barium esophagogram with an E-shaped indentation (Fig. 4-10).
FIGURE 4-9  Rib notching (arrows) in an 11-year-old girl with coarctation of the aorta. (From Caffey J: Pediatric X-ray Diagnosis, 7th ed. Chicago, Mosby, 1978.)

FIGURE 4-10  A, The figure-of-3 configuration indicates the site of coarctation with the large proximal segment of aorta or prominent left subclavian artery above and the poststenotic dilatation of the descending aorta below it. B,
Upper Mediastinum

1. The thymus is prominent in healthy infants and may give a false impression of cardiomegaly. It may give the classic “sail sign” (Fig. 4-11). The thymus often has a wavy border because this structure becomes indented by the ribs. On the lateral view, the thymus occupies the superoanterior mediastinum, obscuring the upper retrosternal space.

2. The thymus shrinks in cyanotic infants and infants under severe stress from congestive heart failure. In TGA, the mediastinal shadow is narrow (“narrow waist”), partly because of the shrinkage of the thymus gland. Infants with DiGeorge syndrome have an absent thymic shadow and a high incidence of aortic arch anomalies.

3. “Snowman figure” (or figure-of-8 configuration) is seen in infants, who are usually older than 4 months, with anomalous pulmonary venous return draining into the SVC via the left SVC (vertical vein) and the left innominate vein (see Fig. 4-3, C).

Pulmonary Parenchyma

1. Pneumonia is a common complication in patients with increased pulmonary blood flow, such as those with a large PDA or VSD.

2. A long-standing density, particularly in the lower left lung field, suggests pulmonary sequestration. In this condition, there is an aberrant, nonfunctioning pulmonary tissue, which does not connect with the bronchial tree and derives its blood supply from the
descending aorta. The venous drainage is usually to the pulmonary venous system.

3. A vertical vascular shadow along the lower right cardiac border may suggest PAPVR from the lower lobe and sometimes the middle lobe of the right lung, called *scimitar syndrome*. Its pulmonary venous drainage is usually to the inferior vena cava either just above or below the diaphragm. This syndrome is often associated with other anomalies, including hypoplasia of the right lung and right pulmonary artery, sequestration of right lung tissue receiving arterial supply from the aorta, and ASD.
PART 2
Special Tools in Evaluation of Cardiac Patients

OUTLINE

Introduction
5. Noninvasive Imaging Tools
6. Other Noninvasive Investigation Tools
7. Invasive Procedures
A number of special tools are available to cardiologists in the evaluation of pediatric cardiac patients. Some tools are readily available and frequently used, but others are more specialized and are available only at tertiary centers. Echocardiography is the mainstay of noninvasive imaging tools and is available to almost every cardiologist. This tool usually provides the final diagnosis for most pediatric cardiac problems and is discussed in depth. Magnetic resonance imaging and computed tomography are other noninvasive imaging tools that have gained a supplemental role in cardiac evaluation. The discussion of these tools will be limited to the pros and cons of the techniques. Other noninvasive tools frequently used by cardiologists include exercise stress test and ambulatory electrocardiography (e.g., Holter monitor). These tests are discussed in depth. Cardiac catheterization and angiocardiography are invasive tests that usually provide conclusive anatomic and physiologic information and the final diagnosis. Although catheter intervention procedures are not diagnostic, Part 2 discusses it briefly because they are usually performed with cardiac catheterization. Electrophysiologic evaluation is not included in the discussion because they are too specialized and are only rarely performed by specially trained electrophysiologists.
An ideal modality used for noninvasive imaging of congenital heart defects should be able to delineate all aspects of the cardiac anatomy, including extracardiac vessels; evaluate physiological parameters such as measurement of blood flow, pressure gradients across cardiac valves or blood vessels, and ventricular function; be cost effective, portable, and noninvasive with least risk and discomfort; and include no exposure to ionizing radiation. No single modality satisfies all of these requirements. Chest radiographic films, the original imaging tool, provide only indirect evidence of intracardiac defects that manifest primarily with volume overload. They do not provide images of the defect itself. They are less informative on pressure overload lesions that do not result in chamber enlargement. Echocardiography has become the main noninvasive imaging modality since the 1980s, providing direct images of intracardiac and some extracardiac anatomy. In recent years, noninvasive radiologic techniques such as magnetic resonance imaging (MRI) and computed tomography (CT) have emerged as supplementary modalities in areas for which echocardiography studies are deficient.

In this chapter, two-dimensional (2D) and M-mode echocardiography are presented in some detail. This will be followed by a brief discussion of the two radiologic techniques with emphasis on how to choose an optimal radiologic technique for a given patient.
Echocardiography

Echocardiography (echo) uses ultrasound beams reflected by cardiovascular structures to produce characteristic lines or shapes caused by normal or abnormal cardiac anatomy in one, two, or three dimensions, which are called M-mode, 2D, and three-dimensional (3D) echocardiography, respectively.

An echocardiographic study currently begins with real-time 2D echo, which produces high-resolution tomographic images of cardiac structure, their movement, and vascular structures leaving and entering the heart. The Doppler and color mapping study has added the ability to easily detect valve regurgitation and cardiac shunts during the echo examination. These tests combined provide reliable quantitative information such as ventricular function, pressure gradients across cardiac valves and blood vessels, and estimation of pressures in the great arteries and ventricles. Echo examination can be applied in calculation of cardiac output and the magnitude of cardiac shunts, although this is rarely used. Reliable noninvasive hemodynamic evaluation and confident delineation of cardiovascular structures by echo have dramatically reduced the necessity for cardiac catheterization. Increasingly, patients undergo valvular or congenital heart surgery on the basis of an echo diagnosis. Transesophageal echocardiography (TEE) has markedly improved resolution of echo images. Real-time 3D echocardiography provides improved accuracy of imaging the global perspective visualization of various cardiac anomalies, but this is not presented here because it is not widely used.

Discussion of instruments and techniques is beyond the scope of this book. Normal 2D echo images and M-mode measurements and their role in the diagnosis of common cardiac problems in pediatric patients are the focus of this presentation.

Two-Dimensional Echocardiography

Two-dimensional echo examinations are performed by directing the plane of the transducer beam along a number of cross-sectional planes through the heart and great vessels. A routine 2D echocardiogram is obtained from four transducer locations: parasternal, apical, subcostal, and suprasternal notch (SSN) positions. From each transducer position, images of the long- and short-axis views are obtained by manually rotating and angulating the transducer. The parasternal and apical views usually are obtained with the patient in the left lateral decubitus position and the subcostal and suprasternal notch views with the patient in the supine position. Figures 5-1 through 5-9 illustrate some standard images of the heart and great vessels. Modified transducer positions and different angulations make many other views possible. Measurement of important cardiac structures can be made on the freeze frame of 2D echo studies. Normal values of the dimension of the cardiac chambers, great arteries, and various valve annulus are shown in several tables in Appendix D (see Tables D-1 through D-5).
FIGURE 5-1  Diagram of important two-dimensional echo views obtained from the parasternal long-axis transducer position. Standard long-axis view (A), right ventricular (RV) inflow view (B), and RV outflow view (C). AO, aorta; CS, coronary sinus; Desc. Ao, descending aorta; LA, left atrium; LV, left ventricle; PA, pulmonary artery; RA, right atrium; RAA, right atrial appendage.

FIGURE 5-2  Diagram of a family of parasternal short-axis views. Semilunar valves and great artery level (A), coronary arteries (B), mitral valve level (C), and papillary muscle level (D). AO, aorta; LA, left atrium; LCA, left coronary artery; LPA, left pulmonary artery; LV, left ventricle; MPA, main pulmonary artery; MV, mitral valve; PM, papillary muscle; RA, right atrium; RCA, right coronary artery; RPA, right pulmonary artery; RV, right ventricle; RVOT, right ventricular outflow tract.
FIGURE 5-3  Diagram of two-dimensional echo views obtained with the transducer at the apical position. A, The posterior plane view showing the coronary sinus. B, The standard apical four-chamber view. C, The apical “five-chamber” view is obtained with further anterior angulation of the transducer. AO, aorta; CS, coronary sinus; LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle.

FIGURE 5-4  Apical long-axis view. A, Apical “three-chamber” view. B, Apical “two-chamber” view. AO, aorta; LA, left atrium; LAA, left atrial appendage; LV, left ventricle; RV, right ventricle.

The Parasternal Views
For parasternal views, the transducer is applied to the left parasternal border in the second, third, or fourth space with the patient in the left lateral decubitus position.
Parasternal Long-Axis Views

The plane of sound is oriented along the major axis of the heart, usually from the patient’s left hip to the right shoulder. Three major views are recorded; standard long axis, long axis of the right ventricular (RV) inflow, and long axis of the RV outflow (see Fig. 5-1).

FIGURE 5-5  Diagram of subcostal long-axis view. A, Coronary sinus view posteriorly. B, Standard subcostal four-chamber view. C, View showing the left ventricular outflow tract and the proximal aorta. D, View showing the right ventricular outflow tract (RVOT) and the proximal main pulmonary artery. AO, aorta; CS, coronary sinus; LA, left atrium; LV, left ventricle; PA, pulmonary artery; RA, right atrium; RV, right ventricle, SVS, superior vena cava.
**FIGURE 5-6** Subcostal short-axis (sagittal) view. A, Entry of venae cavae with drainage of the azygous vein. B, View showing the RV, RVOT, and pulmonary artery. C, Short-axis view of the ventricles. Azg. V, azygous vein; LA, left atrium; LV, left ventricle; MV, mitral valve; PA, pulmonary artery; RA, right atrium; RPA, right pulmonary vein; RV, right ventricle; SVC, superior vena cava; TV, tricuspid valve.

**FIGURE 5-7** Abdominal views. Left, abdominal short-axis view. Right, abdominal long-axis view. A, Inferior vena cava (IVC) view; B, Abdominal descending aorta (AO) view. CA, celiac axis; HV, hepatic vein; RA, right atrium; SMA, superior mesenteric artery.
FIGURE 5-8  Diagram of suprasternal notch two-dimensional echo views. A, Long-axis view. B, Short-axis view. AO, aorta; Asc. Ao, ascending aorta; Desc. Ao, descending aorta; Inn. A, innominate artery; Inn. V, innominate vein; LA, left atrium; LCA, left carotid artery; LSA, left subclavian artery; MPA, main pulmonary artery; PA, pulmonary artery; RPA, right pulmonary artery; SVC, superior vena cava.

1. The Standard Long-Axis View

is the most basic view that shows the left atrium (LA), mitral valve, and left ventricular (LV) inflow and outflow tracts (see Fig. 5-1, A). This view is important in evaluating abnormalities in or near the mitral valve, LA, LV, left ventricular outflow tract (LVOT), aortic valve, aortic root, ascending aorta, and ventricular septum. In the normal heart, the anterior leaflet of the mitral valve is continuous with the posterior wall of the aorta (i.e., aortic–mitral continuity). The trabecular septum (apical ward) and infracristal outlet septum (near the aortic valve) constitute the interventricular septum in this view. Therefore, ventricular septal defects (VSDs) of tetralogy of Fallot (TOF) and persistent truncus arteriosus are best shown in this view. Detailed discussion of localizing other types of VSDs is presented in Chapter 12. Pericardial effusion is readily imaged in this view. This is the view to evaluate mitral valve prolapse (MVP). Frequently, the coronary sinus can be seen as a small circle in the atroventricular (AV) groove (see Fig. 5-1, A). An enlarged coronary sinus may be seen with left superior vena cava (LSVC), TAPVR to coronary sinus, coronary AV fistula, and rarely with elevated right atrial (RA) pressure.
2. In the RV Inflow View

A long-axis view of the RV and RA is obtained. In this view, abnormalities in the tricuspid valve (tricuspid regurgitation [TR], prolapse) and inflow portion of the RV are evaluated (Fig. 5-1, B). The ventricular septum in this view consists of the inlet muscular septum (near the AV valve) and trabecular septum (apical ward). The right atrial appendage (RAA) can also be seen in this view. This view is good for recording the velocity of TR (to estimated RV systolic pressure).

3. In the RV Outflow View

The RV outflow tract (RVOT), pulmonary valve, and proximal main pulmonary artery (PA) are visualized (Fig. 5-1, C). The supracristal infundibular (outlet) septum is seen in this view.

Parasternal Short-Axis Views

By rotating the transducer used for the long-axis views clockwise, one obtains a family of important short-axis views (see Fig. 5-2). This projection provides cross-sectional images of the heart and the great arteries at different levels. The parasternal short-axis views are important in the evaluation of the aortic valve (i.e., bicuspid or tricuspid), pulmonary valve, PA and its branches, RVOT, coronary arteries (e.g., absence, aneurysm, stenosis), LA, LV, ventricular septum, AV valves, LV, and right side of the heart.

1. The Aortic Valve

The aortic valve is seen in the center of the image with the RVOT anterior to the aortic valve and the main PA to the right of the aorta (“circle and sausage” view) (see Fig. 5-2, A).
A). The right, left, and noncoronary cusps of the aortic valve are best seen from this view, having the appearance of the letter “Y” during diastole. Stenosis and regurgitation of the pulmonary valve is best examined in this plane. Stenosis of the PA branches can be evaluated by Doppler interrogation and color-flow mapping and Doppler interrogation of the ductal shunt is obtained in this plane. Color-flow studies show the membranous VSDs just distal to the tricuspid valve (at the 10 o’clock direction) and both the infracristal and supracristal outlet VSDs (at the 12 to 2 o’clock direction) anterior to the aortic valve near the pulmonary valve.

2. Coronary Arteries
With a slight manipulation of the transducer from the above plane, the ostia and the proximal portions of the coronary arteries are visualized. The right coronary artery (RCA) arises from the anterior coronary cusp near the tricuspid valve, which should be confirmed to connect to the aorta; there are some venous structures that run in front of the aorta (cardiac vein) but do not connect to the aorta. The left main coronary artery arises in the left coronary cusp near the main PA. Its bifurcation into the left anterior descending and circumflex coronary artery can usually be seen clearly. The proximal coronary arteries can also be seen in other long-axis views.

3. Mitral Valve
The mitral valve is seen as a “fish mouth” during diastole. This view is good for measuring the mitral valve area in patients with mitral stenosis and it is the best view to identify a cleft mitral valve (see Fig. 5-2, C).

4. Papillary Muscles
Two papillary muscles are normally seen at the 4 o’clock (anterolateral) and 8 o’clock (posteromedial) directions. The trabecular septum is seen at this level. This view is good in the assessment of apical portion of the LV such as hypertrophic cardiomyopathy, noncompaction of the apex and apical mass (see Fig. 5-2, D).

The Apical Views
For apical views, the transducer is positioned over the cardiac apex with the patient in the left lateral decubitus position.

Apical Four-Chamber View
The plane of sound is oriented in a nearly coronal body plane and is tilted from posterior to anterior to obtain a family of apical four-chamber views (see Fig. 5-3). This view displays all four chambers of the heart, the ventricular and atrial septa, and the crux of the heart. This is the best view to image the LV apex, where an apical VSD is commonly seen.

1. Coronary Sinus
In the most posterior plane, the coronary sinus is seen to drain into the right atrium (see Fig. 5-3, A). The ventricular septum seen in this view is the posterior trabecular septum.

2. The Apical Four-Chamber View
(see Fig. 5-3, B) evaluates the atrial and ventricular septa and size and contractility of atrial and ventricular chambers, AV valves, and some pulmonary veins and identifies the anatomic RV and LV and detecting pericardial effusion. Normally, the tricuspid valve insertion to the septum is more apicalward than the mitral valve (5–10 mm in older children and adults), with a small portion of the septum (called the AV septum) separating the two AV valves. A defect in this portion of the septum may result in an LV–RA shunt. In Ebstein’s anomaly, the insertion of the septal tricuspid valve is displaced more apically. The inlet ventricular septum (where an endocardial cushion defect occurs) is well imaged in this view just under the AV valves. VSDs in the entire length of the trabecular septum are well imaged, including apical VSD. The membranous septum is not imaged in this view. The anatomic characteristics of each ventricle are also noted, with the heavily trabeculated RV showing the moderator band. Abnormal chordal attachment of the AV valve (straddling) and overriding of the valve are also noted in this view. The relative size of the ventricles is examined in this view.

3. Apical Five-Chamber View
Further anterior angulation of the transducer demonstrates the so-called apical five-chamber view. This view shows the LVOT, aortic valve, subaortic area, and proximal ascending aorta. In this view, color-flow imaging allows qualitative assessment of aortic regurgitation. The membranous VSD is visualized just under the aortic valve, and the infracristal outlet VSD is also imaged in this plane.

Apical Long-Axis Views
The apical long-axis view (or apical three-chamber view) shows structures similar to those shown in the parasternal long-axis view (see Fig. 5-4, A). In the apical two-chamber view, the LA, mitral valve, and LV are imaged. The left atrial appendage can also be imaged (see Fig. 5-4, B). The view of the LV apex provides diagnostic clues for cardiomyopathy, apical thrombus, and aneurysm.

The Subcostal Views
Subcostal long axis (coronal) and short-axis (sagittal) views are obtained from the subxyphoid transducer position, with the patient in the supine position.

Subcostal Long-Axis (Coronal) Views
are obtained by tilting the coronal plane of sound from posterior to anterior (see Fig. 5-5). The coronary sinus is seen posteriorly draining into the RA, similar to that shown for the apical view (see Fig. 5-5, A). Anterior angulation of the transducer shows the atrial and ventricular septa. This is the best view for evaluating the atrial septum, including atrial
septal defect (see Fig. 5-5, B). Further anterior angulation of the transducer shows the LVOT, aortic valve, and ascending aorta (see Fig. 5-5, C). The parts of the ventricular septum visualized in this view (apical ward) are membranous, subaortic outlet, and trabecular septa. The junction of the superior vena cava (SVC) and the RA is seen to the right of the ascending aorta (see Fig. 5-5, C). Further anterior angulation shows the entire RV including the inlet, trabecular and infundibular portions, pulmonary valve, and main PA (see Fig. 5-5, D). The ventricular septum seen in this view includes the (apical ward) supracristal outlet, infracristal outlet, and anterior trabecular and posterior trabecular septa.

Subcostal Short-Axis (or Sagittal) Views
(see Fig. 5-6) are obtained by rotating the long-axis transducer 90 degrees to the sagittal plane.

To the right of the patient, both the superior and inferior venae cavae are seen to enter the right atrium (see Fig. 5-6, A). A small azygous vein can be seen to enter the SVC, and the right PA can also be seen on end beneath this vein (see Fig. 5-6, A).

A leftward angulation of the transducer shows the RVOT, pulmonary valve, PA, and the tricuspid valve on end (see Fig. 5-6, B). This view is orthogonal to the standard subcostal four-chamber view, and both views combined are good for evaluation of the size of a VSD.

Additional leftward angulation of the transducer will show the mitral valve (not shown) and papillary muscle (see Fig. 5-6, C), similar to those seen in the parasternal short-axis views.

Subcostal Views of the Abdomen
Abdominal short- and long-axis views (Fig. 5-7) are obtained from the subxyphoid transducer position, with the patients in supine position.

1. Abdominal Short-Axis View
is obtained by placing the transducer in a transverse body plane (see Fig. 5-7, left). It demonstrates the descending aorta on the left and the inferior vena cava (IVC) on the right of the spine as two round structures. The aorta should pulsate. Both hemidiaphragms, which move symmetrically with respiration, are imaged. Asymmetric or paradoxical movement of the diaphragm is seen with paralysis of the hemidiaphragm.

2. Abdominal Long-Axis View
is obtained by placing the transducer in a sagittal body plane. The IVC is imaged to the right (see Fig. 5-7, right, A), and the descending aorta is imaged to the left of the spine (Fig. 5-7, right, B). The IVC collects the hepatic vein before draining into the right atrium. The eustachian valve may be seen at the junction of the IVC and the RA. The failure of the IVC to join the RA indicates interruption of the IVC (with azygous continuation, which is frequently seen with polysplenia syndrome). Major branches of the descending
The Suprasternal Views

The transducer is positioned in the suprasternal notch to obtain suprasternal long-axis (see Fig. 5-8, A) and short-axis (see Fig. 5-8, B) views, which are important in the evaluation of anomalies in the ascending and descending aortas (e.g., coarctation of the aorta), aortic arch (e.g., interruption), size of the PAs, and anomalies of systemic veins and pulmonary veins. In infants, the transducer can be sometimes placed in a high right subclavicular position.

The Suprasternal Long-Axis View (see Fig. 5-8, A) is obtained by 45-degree clockwise rotation from the sagittal plane in the suprasternal notch to visualize the entire (left) aortic arch. Failure to visualize the aortic arch in this manner may suggest the presence of a right aortic arch. Three arteries arising from the aortic arch (the innominate, left carotid, and left subclavian arteries in that order) are seen. The innominate vein is seen in cross-section in front of the ascending aorta and the right PA behind the ascending aorta. Manipulation of the transducer farther posteriorly and leftward will image the isthmus and upper descending aorta, a very important segment to study for the coarctation of the aorta.

The Suprasternal Short-Axis View (Fig. 5-8, B) is obtained by rotating the ultrasound plane parallel to the sternum. Superior to the circular transverse aorta, the innominate vein is seen to connect to the (right) superior vena cava, which runs vertically to the right of the aorta. The right PA is visualized in its length under the circular aorta. Beneath the RPA is the LA. With a slight posterior angulation of the transducer, four pulmonary veins are seen to enter the LA.

The Subclavicular Views

The Right Subclavicular View (see Fig. 5-9, A) is obtained in the right second intercostal space in a sagittal projection. This view is useful in the assessment of the SVC and right atrial junction as well as the ascending aorta. The right upper pulmonary vein and the azygous vein can also be examined in this view.

The Left Subclavicular View (see Fig. 5-9, B) is useful for examination of the branch PAs. The transducer is positioned in a transverse plane in the second left intercostal space and a little tilted inferiorly. The main PA is seen left of the ascending aorta (circle), and it bifurcates into the right and
Quantitative Values Derived from Two-Dimensional Echocardiography

1. Dimensions of Cardiovascular Structures
Several tables of normal values of cardiovascular structures that were measured from still frames of 2D echocardiography are shown in Appendix D. These tables are frequently useful in the practice of pediatric cardiology. They include M-mode measurements of the LV (Table D-1); stand-alone M-mode measurements of the RV, aorta, and LA (Table D-2); aortic root and aorta (Table D-3); pulmonary valve and PAs (Table D-4); and AV valves (Table D-5). The normal dimension of the coronary arteries is shown in Table D-6.

2. Left Ventricular Mass
LV mass is an indication of LVH. Although the thickness of LV walls (interventricular septum and LV posterior wall) identifies people with increased LV mass, LV mass has become a valuable marker of end-organ damage in patients with systemic hypertension. LV mass can be estimated from M-mode echocardiography or 2D echocardiography measurements.

a. M-mode echo method. LV mass is usually derived from 2D-guided M-mode echo measurement, with assumptions that the LV is spherical in shape and the thickness of the wall measured at the basal area of the LV is representative of the entire LV. It is assumed that a smaller sphere formed by the endocardium is inside a larger sphere formed by the pericardium, and therefore, the difference in the volume of the two spheres would be the volume of LV muscle. Although less accurate than the 2D echo method, the M-mode method is simpler to obtain and thus more popular than the 2D method. There is controversy as to indexing the LV mass for body size, having been variably indexed by body weight, height, body surface area, or 2.7 power of height. M-mode–derived LV mass indexed to 2.7 power of height is popular and normal data by that method are presented in Appendix D (Table D-7).

b. 2D echo method. In the 2D-measured echo technique for calculating LV mass, the LV is assumed to be a bullet shape rather than a sphere, and this technique has been shown to be more accurate than the M-mode method. The LV volume can be estimated from the short- and long-axis views in systole or diastole. The LV area in the short-axis view is calculated by the biplane Simpson’s method. The formula for such a volume would be $\frac{5}{6}$ the LV area of the short axis multiplied by the length of the ventricle (obtained from the long axis):

$$\text{Volume} = \frac{5}{6} \times \text{Area}_{\text{short}} \times \text{Length}$$

The LV volume so calculated is then converted to mass by multiplying it by the specific
gravity of muscle (usually taken as 1.05). This cumbersome method is less popular and not routinely performed in most laboratories. Normal values of 2D echo-derived LV mass indexed to the body surface area are presented in Appendix D (Table D-8).

### M-Mode Echocardiography

M-mode echocardiography, which graphically displays a one-dimensional slice of cardiac structure varying over time, was one of the earliest tools of the echocardiography. Currently, an M-mode echo is obtained as part of 2D tomographic images. M-mode echo is used primarily for the measurement of the dimension (wall thickness and chamber size) and LV function (fractional shortening, wall thickening). It is also useful for assessing the motion of cardiac valves (mitral valve prolapse, mitral stenosis, pulmonary hypertension) and movement of cardiac wall and septa (in RV volume overload).

Figure 5-10 shows examples of M-mode measurements of the dimension of the RV, LV, LA, and aorta and LV wall thickness during systole and diastole. Line 1 passes through the aorta and LA, where the dimensions of these structures are measured. Line 2 traverses the mitral valve. Line 3 goes through the main body of the RV and LV. Along line 3, the dimensions of the RV and LV and the thickness of the interventricular septum and posterior LV wall are measured during systole and diastole. Pericardial effusion is best detected at this level.
Normal M-Mode Echo Values
Two frequent applications of M-mode echo in clinical practice are measurements of dimension of cardiac structures and LV systolic function.

Cardiac Chamber Dimensions
Most dimensions are measured during diastole, coincident with the onset of the QRS complex; the LA dimension and LV systolic dimension are exceptions (see Fig. 5-10). The dimensions of the cardiac chambers and the aorta increase with increasing age and thus normal values are expressed as function of growth (see Appendix D).

Left Ventricular Systolic Function
LV systolic function is evaluated by the fractional shortening (or shortening fraction) or ejection fraction. The ejection fraction is a derivative of the fractional shortening and offers no advantages over the fractional shortening. Serial determinations of these measurements are important in the management of conditions in which LV function may change (e.g., in patients with chronic or acute myocardial disease).

Fractional Shortening
Fractional shortening (or shortening fraction) is derived by the following:

\[
\text{FS} \{\%\} = \frac{\text{Dd} - \text{Ds}}{\text{Dd}} \times 100\%
\]

where FS is fractional shortening, Dd is end-diastolic dimension of the LV, and Ds is end-systolic dimension of the LV. This is a reliable and reproducible index of LV function, provided there is no regional wall-motion abnormality and there is concentric contractility of the LV. If the interventricular septal motion is flat or paradoxical, the shortening fraction will not accurately reflect ventricular ejection.

Mean normal value of FS is 36%, with 95% prediction limits of 28% to 44%. FS is decreased in a poorly compensated LV regardless of cause (e.g., pressure overload, volume overload, primary myocardial disorders, doxorubicin cardiotoxicity). It is increased in volume-overloaded ventricle (e.g., VSD, patent ductus arteriosus, aortic regurgitation, mitral regurgitation [MR]) and pressure overload lesions (e.g., moderately severe aortic valve stenosis, hypertrophic obstructive cardiomyopathy).

Ejection Fraction
Ejection fraction relates to the change in volume of the LV with cardiac contraction. It is obtained by the following formula:
where $EF$ is ejection fraction and $D_d$ and $D_s$ are the end-diastolic and end-systolic dimensions, respectively, of the LV. The volume of the LV is derived from a single measurement of the dimension of the minor axis of the LV. In the preceding formula, the minor axis is assumed to be half of the major axis of the LV; this assumption is incorrect in children. Normal mean ejection fraction is 66% with ranges of 56% to 78%.

**Doppler Echocardiography**

Doppler echocardiography combines the study of cardiac structure and blood flow profiles. The Doppler effect is a change in the observed frequency of sound that results from motion of the source or target. When the moving object or column of blood moves toward the ultrasonic transducer, the frequency of the reflected sound wave increases (i.e., a positive Doppler shift). Conversely, when blood moves away from the transducer, the frequency decreases (i.e., a negative Doppler shift). Doppler ultrasound equipment detects a frequency shift and determines the direction and velocity of red blood cell flow with respect to the ultrasound beam. By convention, velocities of red blood cells moving toward the transducer are displayed above a zero baseline; those moving away from the transducer are displayed below the baseline.

The two commonly used Doppler techniques are continuous wave and pulsed wave. The pulsed wave emits a short burst of ultrasound, and the Doppler echo receiver “listens” for returning information. The continuous wave emits a constant ultrasound beam with one crystal, and another crystal continuously receives returning information. Both techniques have their advantages and disadvantages. Pulsed-wave Doppler can control the site at which the Doppler signals are sampled, but the maximal detectable velocity is limited, making it unusable for quantification of severe obstruction. In contrast, continuous-wave Doppler can measure extremely high velocities (e.g., for the estimation of severe stenosis), but it cannot localize the site of the sampling; rather, it picks up the signal anywhere along the Doppler beam. When these two techniques are used in combination, clinical application expands.

**TABLE 5-1**

**NORMAL DOPPLER VELOCITIES IN CHILDREN AND ADULTS**

<table>
<thead>
<tr>
<th></th>
<th>Children, Mean (Ranges) (m/sec)</th>
<th>Adults, Mean (Ranges) (m/sec)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitral flow</td>
<td>1.0 (0.8–1.3)</td>
<td>0.9 (0.6–1.3)</td>
</tr>
<tr>
<td>Tricuspid flow</td>
<td>0.6 (0.5–0.8)</td>
<td>0.6 (0.3–0.7)</td>
</tr>
<tr>
<td>Pulmonary artery</td>
<td>0.9 (0.7–1.1)</td>
<td>0.75 (0.6–0.9)</td>
</tr>
<tr>
<td>Left ventricle</td>
<td>1.0 (0.7–1.2)</td>
<td>0.9 (0.7–1.1)</td>
</tr>
<tr>
<td>Aorta</td>
<td>1.5 (1.2–1.8)</td>
<td>1.35 (1.0–1.7)</td>
</tr>
</tbody>
</table>


The Doppler echo technique is useful in the study of the following: (1) detecting the presence and direction of cardiac shunts; (2) studying stenosis or regurgitation of cardiac valves; (3) assessing stenosis of blood vessels; (4) assessing the hemodynamic severity of
a lesion, including pressures in various compartments of the cardiovascular system; (5) estimating the cardiac output or blood flow; and (6) assessing diastolic function of the ventricle (see later discussion). The Doppler echo is usually used with color flow mapping (see below) to enhance the technique’s usefulness.

Normal Doppler velocities in children and adults are shown in Table 5-1. Normal Doppler velocity is less than 1 m/sec for the PA; it may be up to 1.8 m/sec for the ascending and descending aortas. Mitral and tricuspid inflow velocities are usually less than 1 m/sec.

Measurement of Pressure Gradients
The simplified Bernoulli equation can be used to estimate the pressure gradient across a stenotic lesion, regurgitant lesion, or shunt lesion. One may use one of the following equations.

\[
P_1 - P_2 = \frac{1}{2} \rho V_1^2
\]

where \((P_1 - P_2)\) is the pressure difference across an obstruction, \(V_1\) is the velocity (m/sec) proximal to the obstruction, and \(V_2\) is the velocity (m/sec) distal to the obstruction in the first equation. When \(V_1\) is less than 1 m/sec, it can be ignored, as in the second equation. However, when \(V_1\) is more than 1.5 m/sec, it should be incorporated into the equation to obtain a more accurate estimation of pressure gradients. This is important in the study of the ascending and descending aortas, where flow velocities are often more than 1.5 m/sec. Ignoring \(V_1\) may significantly overestimate the pressure gradient in patients with aortic stenosis or coarctation of the aorta.

To obtain the most accurate prediction of the peak pressure gradient, the Doppler beam should be aligned parallel to the jet flow, the peak velocity of the jet should be recorded from several different transducer positions, and the highest velocity should be taken. An example of a Doppler study in a patient with moderate pulmonary stenosis is shown in Figure 5-11. The peak instantaneous pressure gradient calculated from the Bernoulli equation is not the same as the peak-to-peak pressure gradient measured during cardiac catheterization. The peak instantaneous pressure gradient is usually larger than the peak-to-peak pressure gradient. The difference between the two is more noticeable in patients with mild to moderate obstruction and less apparent in patients with severe obstruction.

Prediction of Intracardiac or Intravascular Pressures
The Doppler echo allows estimation of pressures in the RV, PA, and LV using the flow velocity of certain valvular or shunt jets. Estimation of PA pressure is particularly important in pediatric patients.
FIGURE 5-11  Doppler echocardiographic study in a child with a moderate pulmonary valve stenosis. The Doppler cursor is placed in the main pulmonary artery near the pulmonary valve in the parasternal short-axis view. The maximum forward flow velocity (negative flow) is 3.91 m/sec (with an estimated pressure gradient of 61 mm Hg). There is a small regurgitant (positive) flow seen during diastole.

The following are some examples of such applications:

1. RV (or PA) systolic pressure (SP) can be estimated from the velocity of the tricuspid regurgitation (TR) jet, if present, by the following equation:

\[
RVSP = \frac{4V^2}{\text{RA pressure}}
\]

where V is the TR jet velocity.

For example, if the TR velocity is 2.5 m/sec, the instantaneous pressure gradient is \(4 \times (2.5)^2 = 4 \times 6.25 = 25\) mm Hg. Using an assumed RA pressure of 10 mm Hg, the RV systolic pressure (or PA systolic pressure in the absence of PS) is 35 mm Hg. (Assuming that the RA pressure of 10 mm Hg is too high for patients who do not have severe TR or RV failure. An RA mean pressure of 5 mm Hg is more reasonable in most children and adolescents).

2. RV (or PA) systolic pressure can also be estimated from the velocity of the VSD jet by the following equation:

\[
RVSP = \frac{4V^2}{\text{Systemic SP} \times \text{RVSP}}
\]

where V is the VSD jet.

For example, if the VSD jet flow velocity is 3 m/sec, the instantaneous pressure drop between the LV and RV is \(4 \times 3^2 = 36\) mm Hg. That is, the RV systolic pressure is 36 mm Hg lower than the LV systolic pressure. If LV systolic pressure is assumed to be 90 mm Hg, the estimated RV systolic pressure is 54 mm Hg \((90 - 36 = 54)\). In the absence of PS, the PA systolic pressure will be about 54 mm Hg. Note that the systolic pressure
obtained in the arm cannot be assumed to be the same as LV systolic pressure; the arm pressure is usually 5 to 10 mm Hg higher than the LV systolic pressure (see peripheral amplification in Chapter 2).

3. LVSP can be estimated from the velocity of flow through the aortic valve (V) by the following equation:

$$\text{LVSP} = \left(\frac{V}{2}\right)^2 \times \text{Systolic SP} \times \frac{5}{8}$$

where V is the aortic flow velocity. The same precaution applies as above in that the arm systolic pressure is slightly higher than the LV systolic pressure.

**Measurement of Cardiac Output or Blood Flow**

Both systemic blood flow and pulmonary blood flow can be calculated by multiplying the mean velocity of flow and the cross-sectional area as shown in the following equation:

$$\text{Cardiac output} = V \times \text{CSA} \times 60 \text{ ml/min}$$

where V is the mean velocity (cm/sec) obtained either by using a computer program or by manually integrating the area under the curve. CSA is the cross-sectional area of flow (cm$^2$) measured or computed from the two-dimensional echo. Usually, the PA flow velocity and diameter are used to calculate pulmonary blood flow; the mean velocity and diameter of the ascending aorta are used to calculate systemic blood flow, or cardiac output.

**Diastolic Function**

Signs of diastolic dysfunction may precede those of systolic dysfunction. Mitral inflow velocities obtained in the apical four-chamber view can evaluate LV diastolic function. There are two flow waves in the AV valves; the E wave and the A wave (Fig. 5-12). The E wave occurs during the early diastolic filling phase, and the A wave occurs during atrial contraction. The E wave is taller than the A wave in normal children and adults. However, the A wave may be normally taller than the E wave in the first 3 weeks of life.

The following simple measurements are useful in evaluating diastolic function of the ventricle (see Fig. 5-12).

1. The E and A wave peak velocities and the ratio of the two (E/A ratio)
2. Deceleration time (DT): The interval from the early peak velocity to the zero intercept of the extrapolated deceleration slope
3. Atrial filling fraction: The integral of the A velocity divided by the integral of the total mitral inflow velocities
4. Isovolumic relaxation time (IVRT): The interval between the end of the LV outflow velocity and the onset of mitral inflow; this is easily obtained by pulsed-wave Doppler with the cursor placed in the LV outflow near the anterior leaflet of the mitral valve and
is measured from the end of the LV ejection to the onset of the mitral inflow.

In normal children, the mitral Doppler indexes are as follows. The average peak E velocity is 0.6 m/sec, the average peak A velocity is 0.3 m/sec, and the average E:A velocity ratio is 2.0. Detailed normal values for other measurements are shown in Figure 18-6.

Abnormalities in the diastolic function are easy to find, but they are usually nonspecific and do not provide independent diagnostic information. In addition, they can be affected by loading conditions (i.e., increase or decrease in preload), heart rate, and the presence of atrial arrhythmias. Two well-known patterns of abnormal diastolic function are a decreased relaxation pattern and a “restrictive” pattern (see Fig. 18-6). The decreased relaxation pattern is seen with hypertrophic and dilated cardiomyopathies, LVH of various causes, ischemic heart disease, other forms of myocardial disease, reduced preload (e.g., dehydration), and increased afterload (e.g., during infusion of arterial vasoconstrictors). The “restrictive” pattern is usually seen in restrictive cardiomyopathy but is also seen with increased preload (e.g., seen with MR) and a variety of heart diseases with heart failure.

**FIGURE 5-12** Selected parameters of diastolic function. (See text for discussion). A, second peak velocity; DT, deceleration time; E, early peak velocity; IVRT, isovolumic relaxation time; LV, left ventricle.

**Color-Flow Mapping**

A color-coded Doppler study provides images of the direction and disturbances of blood flow superimposed on the echo structural image. Although systematic Doppler interrogation can obtain similar information, this technique is more accurate and time saving. In general, red is used to indicate flow toward the transducer, and blue is used to indicate flow away from the transducer. Color may not appear when the direction of flow is perpendicular to the ultrasound beam. The turbulent flow is color coded as either green or yellow.

**Contrast Echocardiography**
Injection of indocyanine green, dextrose in water, saline, or the patient’s blood into a peripheral or central vein produces microcavitations and creates a cloud of echoes on the echocardiogram. Structures of interest are visualized or recorded by 2D echo at the time of the injection. This technique has successfully detected an intracardiac shunt, validated structures, and identified flow patterns within the heart. For example, an injection of any liquid into an intravenous line may confirm the presence of a right-to-left shunt at the atrial or ventricular level. To a large extent, this technique has been replaced by color-flow mapping and Doppler studies.

Other Echocardiographic Techniques

Fetal Echocardiography

Improvement in image resolution makes visualization of the fetal cardiovascular structure possible, thereby permitting in utero diagnosis of cardiovascular anomalies. To obtain a complete examination, the transducer is placed at various positions on the maternal abdominal wall. Doppler examination and color mapping are performed at the same time. The optimal timing for performance of a comprehensive transabdominal fetal echo is 18 to 22 weeks of gestation. Images can be more difficult to obtain after 30 weeks of gestation because the ratio of fetal body mass to amniotic fluid increases (Rychik et al, 2004).

Accurate diagnosis of congenital heart defect (CHD) via fetal echo provides many benefits, including improved surgical outcome for infants with CHDs. In addition, fetal echo continues to teach physicians more about human fetal cardiac physiology. It also enables physicians to study the effects of cardiovascular abnormalities and abnormal cardiac rhythms in utero and then assess the need for therapeutic intervention.

Indications for fetal echo are expanding, and examples are shown in Box 5-1. Increased nuchal translucency present on obstetric ultrasonography at 10 to 13 weeks of gestation has been associated with an increased risk of CHD even in the absence of a chromosomal anomaly. Infants conceived via intracytoplasmic sperm injection and in vitro fertilization have up to a threefold increased prevalence of CHDs.

**BOX 5-1**

Examples of Indications for Fetal Echocardiography

**Maternal Indications**

- Family history of CHD
- Metabolic disorders (e.g., diabetes, PKU)
- Exposure to teratogens
- Exposure to prostaglandin synthetase inhibitors (e.g., ibuprofen, salicylates, indomethacin)
- Rubella infection
Autoimmune disease (e.g., SLE, Sjögren’s syndrome)
Familial inherited disorders (Ellis van Creveld, Marfan, Noonan’s disease)
In vitro fertilization

**Fetal Indications**

Abnormal obstetric ultrasound screen
Extracardiac abnormality
Chromosomal abnormality
Arrhythmia
Hydrops
Increased first trimester nuchal translucency
Multiple gestation and suspicion of twin–twin transfusion syndrome
CHD, congenital heart disease; PKU, phenylketonuria; SLE, systemic lupus erythematosus


---

**Transesophageal Echocardiography**

By placing a 2D or multiplane transducer at the end of a flexible endoscope, it is possible to obtain high-quality 2D images by way of the esophagus. Color-flow mapping and Doppler examination are usually incorporated in this approach.

If satisfactory images of the heart or blood vessels are not possible from the usual transducer position on the surface of the patient’s chest (e.g., in patients with obesity or chronic obstructive pulmonary disease), physicians may use TEE. This approach is especially helpful in assessing thrombus in native or prosthetic valves, endocarditis vegetations, thrombi in the left atrial chamber and appendage, and aortic dissections. TEE is often used for patients who are undergoing cardiac surgery. TEE can monitor LV function throughout the surgical procedure, as well as assess cardiac morphology and function before and after surgical repair of valvular or congenital heart defects. TEE requires general anesthesia or sedation and the presence of an anesthesiologist because a lack of patient cooperation can result in serious complications. Use of this technique in pediatric patients is somewhat limited to intraoperative use and in some obese adolescents and adolescents with complicated heart defects for whom the risk of general anesthesia or sedation is worth taking for the expected benefit. Schematic drawings of biplane images of TEE are shown in Appendix D (Fig. D-1).

**Intravascular Echocardiography**

To provide an intravascular echo, the ultrasonic transducer is placed in a small catheter so that vessels can be imaged by means of the lumen. These devices can evaluate atherosclerotic arteries in adults and coronary artery stenosis or aneurysm in children
with Kawasaki’s disease.
Although the conventional echo study remains the mainstay of noninvasive evaluation of cardiac patients, it has limitations in complete delineation of cardiac anomalies. In addition to being operator dependent, echocardiography may not provide optimal quality of images of cardiovascular structure because of postoperative scars, chest wall deformities, overlying lung tissue, large body size in adolescents, and obesity. In particular, extracardiac structures such as the PAs, pulmonary veins, and aortic arch cannot always be adequately imaged by echo study because of acoustic window limitations. As to the coronary arteries, only the proximal portion can be adequately imaged by echo studies. Although TEE may improve the quality of images, it is not only a more invasive technique requiring deep sedation or anesthesia but also it does not always provide the needed information for patient care. Cardiac catheterization with a higher complication rate may become necessary to make complete anatomic and physiologic evaluation of the patient with complex cardiac pathology. Fortunately, however, some noninvasive radiologic techniques, such as MRI and cardiac CT, are now available that can obviate the need for cardiac catheterization.

Both MRI and CT can provide images of cardiovascular structures and other intrathoracic structures that are not usually imaged by echo studies. However, one of the radiologic techniques may be better than the other in its capability and its practicality. For example, in young pediatric patients, CT may have a broader appeal because of its short duration of study, but exposure to ionizing radiation and contrast administration requirements are important drawbacks. On the other hand, MRI has capability of offering quantitative ventricular function, myocardial viability, and tissue characterization, which CT lacks. However, MRI requires a longer scanning time and cannot be used in patients with implanted metallic objects, such as pacemakers or intracardiac cardioverter-defibrillators (ICDs).

**BOX 5-2**

Advantages and Disadvantages of Magnetic Resonance Imaging and Computed Tomography
Physicians and cardiologists often face the situation to make a decision as to which noninvasive technique best serves a patient. This section provides some insights into the advantages and disadvantages of noninvasive radiologic imaging techniques in pediatric patient care. The decision as to which test to order depends on the physician’s knowledge, the availability of the technique, and the expertise of cardiovascular radiology consultants in the area. Advantages and disadvantages of MRI and CT are summarized in Box 5-2. Additional discussions on the topic follow.

### Magnetic Resonance Imaging

Selected clinical applications and advantages of cardiac MRI in pediatric cardiology are listed below.

1. MRI offers excellent images of intracardiac morphology that is better than CT images.
2. Ventricular function. Cardiac MRI has become the gold standard for the quantification of ventricular function for both the LV and RV because it does not rely on geometric assumptions as used in echo study (and cardiac catheterization). It provides accurate information on stroke volume, systolic function, ventricular mass, and regurgitation fraction. A frequent application of RV function study relates to older children who had surgical repair of TOF with resulting pulmonary regurgitation of significant magnitude. MRI studies play a major role in determining the timing of pulmonary valve placement in these patients.
3. Equal quality images of extracardiac structures such as the PAs and their distal branches, the aorta, the pulmonary veins, and the systemic veins as CT does
4. Almost equal quality imaging of trachea and mainstem bronchus
5. Almost equal quality imaging of small vessels such as the coronary artery (in patients who had Kawasaki’s disease or the arterial switch operation for TGA)
Computed Tomography

Computed tomography provides excellent quality imaging of extracardiac vasculature and may provide this information much more quickly (5–10 minutes) than MRI. Preferential applications of CT may include the following:

1. Almost equal quality definition of intracardiac anatomy as MRI has.
2. Better quality imaging and faster results of coronary artery anomalies than MRI images, a major application of CT angiography
   a) Anomalous origin of left coronary artery
   b) Possible RV-dependent coronary circulation in patients with pulmonary atresia with intact ventricular septum
   c) Postoperative arterial switch operation for D-TGA
   d) Coronary involvement after Kawasaki’s disease.
3. Comprehensive evaluation of the pulmonary arteries and veins, preoperatively and postoperatively.
4. Evaluation of the patency of vascular shunts and conduits, including patients after such operations as B-T shunt, bidirectional Glenn shunt, or Fontan procedure.
5. Evaluating status after balloon dilatation with or without stent placement; for example, in the aorta (for coarctation) and pulmonary arteries. CT has a clear advantage over MRI in metallic stent evaluation.
6. Imaging vascular rings and pulmonary artery sling (as an alternative to MRI or cardiac catheterization).
7. Evaluating aortic collaterals prevalent in certain cyanotic CHD, such as TOF.
8. Clear imaging of the airways is a unique advantage of CT over other imaging modalities, including vascular or nonvascular narrowing, anomalies, and dynamic obstruction (airway malacia, air trapping).
9. Capability of studying patients with pacemakers and ICD in whom cardiac MRI is prohibited and in patients with metallic implants that create unmanageable artifacts on cardiac MRI (e.g., steel coils).

The following are considered disadvantages of cardiac CT:
1. There is significant radiation exposure associated with CT. Radiation exposure during cardiac CT is estimated to be slightly greater than exposure during a pediatric cardiac catheterization. In children with complex CHDs, the risk may be compounded by their previous or subsequent exposure to ionizing radiation during cardiac catheterization or with serial CT studies.
2. Iodinated contrast materials are more toxic to the kidneys. Adverse reactions with nonionic, iodine-based contrast agents (e.g., hypotension, bradycardia, tachycardia, and even angina) occur at three times the rate of reactions to MRI gadolinium-based compounds.

**Choice of Imaging Modalities**

The age of the patient may be an important factor in choosing an imaging modality in studying pediatric cardiac patients. Prakash and colleagues (2010) have made the following suggestions.

**For Infants and Children Younger than 8 Years**, echo studies will provide accurate diagnosis of even complex CHDs in most cases. Sedation may be required in some infants and children. Therefore, the need for using MRI or CT study arises only rarely. MRI can be used to answer most of the questions regarding ventricular size and function and extracardiac vasculature. However, when the question is primarily the extracardiac vasculature, CT can also be used. Its use should be balanced against the risk of ionizing radiation exposure.

**For Adolescents and Adults**, echo remains the primary diagnostic modality. However, MRI plays an increasing role, especially for the evaluation of the extracardiac thoracic vasculature, ventricular volume and function, and flow measurement. MRI is usually preferred over CT or cardiac catheterization in this age group because it avoids exposure to ionizing radiation and can provide a wealth of functional information. CT is used in patients with contraindications to MRI, such as those with cardiac pacemaker or ICD, and those in whom concomitant evaluation for coronary disease is necessary.
Besides imaging, there are other noninvasive investigative tools that are frequently used in the evaluation of cardiac patients. In this chapter, the following will be discussed.

- Stress testing
- Long-term electrocardiography (ECG) recording
- Ambulatory blood pressure monitoring
Stress Testing

Stress testing plays an important role in the evaluation of cardiac symptoms by quantifying the severity of the cardiac abnormality, providing important indications of the need for new or further intervention, and assessing the effectiveness of management. The cardiovascular system can be stressed either by exercise or by pharmacologic agents.

The maximum oxygen uptake ($V_o^2_{max}$) that can be achieved during exercise is probably the best index of describing fitness or exercise capacity (also called “maximum aerobic power”). $V_o^2_{max}$ is defined by the plateau of oxygen uptake ($V_o^2$) that occurs despite continued work. Beyond this level of $V_o^2_{max}$, the work can be performed using anaerobic mechanism of energy production, but the amount of work that can be performed using anaerobic means is quite limited. There is a linear relationship between the heart rate and progressive workload or $V_o^2_{max}$.

Cardiovascular Response in Normal Subjects

During upright dynamic exercise in normal subjects, the heart rate, cardiac index, and mean arterial pressure increase. In addition, the systemic vascular resistance (SVR) drops, and blood flow to the exercising leg muscles greatly increases. Heart rate increase is the major determinant of increased cardiac output seen during exercise. The heart rate reaches a maximum plateau just before the level of total exhaustion. For subjects between 5 and 20 years of age, the maximal heart rate is about 195 to 215 beats/min. For subjects older than 20 years, the maximal heart rate is 210 to $0.65 \times Age$.

Blood pressure (BP) response varies depending on the type of exercise. During dynamic exercise, systolic BP increases, but diastolic and mean arterial pressures remain nearly identical, varying within a few mm Hg from their levels at rest. BP response to isometric exercise is quite different from the response to dynamic exercise. With isometric exercise, both systolic and diastolic pressures increase.

Although similar changes occur in pulmonary circulation as those seen in the systemic circulation, the increase in the mean pulmonary artery (PA) pressure is more than twice that of systemic mean arterial pressure (e.g., 100% increase), and the drop in pulmonary vascular resistance (PVR) is much less than that in SVR (e.g., 17% decrease in PVR vs. 49% decrease in SVR). Because of this, children with pulmonary hypertension or those with RV dysfunction (after Fontan operation or surgery for tetralogy of Fallot [TOF]) may respond abnormally to exercise and demonstrate a decreased exercise capacity.

Cardiovascular Response in Cardiac Patients

1. Congenital Heart Defects
   a. Patients with minor congenital heart defects (CHDs) (e.g., small left-to-right shunt lesions or mild obstructive lesions) have little or no effect on exercise capacity.
   b. Large left-to-right shunt lesions decrease exercise capacity because a ventricle that has a much increased stroke volume at rest has a limited ability to increase the stroke volume.
c. In patients with severe obstructive lesions, the ventricle may not be able to maintain an adequate cardiac output, so that during exercise, the systemic BP may not increase appropriately, and decreased blood flow to exercising muscles may lead to premature fatigue.

d. In cyanotic lesions, the arterial hypoxemia tends to increased cardiac output and decreased mixed venous oxygen saturation, thereby limiting the usual increment in stroke volume and oxygen extraction that occurs with exercise. Furthermore, these patients have an increased minute ventilation at rest and during exercise. In this way, ventilatory as well as cardiac mechanisms may limit exercise capacity.

2. Postsurgical Patients

a. For many patients with CHDs, normal or near-normal exercise tolerance is expected after surgery unless there are significant residual lesions or myocardial damage.

b. After a successful Fontan operation for functional single ventricle, exercise capacity improves, but it remains significantly less compared with normal. This results from both subnormal heart rate response to exercise and abnormal stroke volume (resulting from reduced systemic ventricular function). Cardiac arrhythmias also are common in patients both before and after the Fontan operation and may contribute to the decreased exercise capacity.

c. After arterial switch operation for D-TGA, more than 95% of the children have normal exercise capacity. However, up to 30% of patients have chronotropic impairment with a peak heart rate of less than 180 beats/min. Up to 10% of the patients develop significant ST-segment depression with exercise.

Exercise Stress Testing

Some exercise laboratories have developed bicycle ergometer protocols, but the equipment is not widely used. The treadmill protocols are well standardized and widely used because most hospitals have treadmills. In this chapter, exercise tests, in particular, that using the Bruce protocol will be presented. In the Bruce protocol, the level of exercise increases by increasing the speed and grade of the treadmill for each 3-minute stage.

During exercise stress testing, the patient is continually monitored for symptoms such as chest pain or faintness, ischemic changes or arrhythmias on the ECG, oxygen saturation, and responses in heart rate and BP. In the Bruce protocol, children are not allowed to hold onto the guardrails except to maintain their balance at change of stage because this can decrease the metabolic cost of work and therefore increase the exercise time.

Monitoring During Exercise Stress Testing

1. Endurance Time
Oxygen uptake is difficult to measure in children. However, there is a high correlation between maximal $\text{V}O_2$ and endurance time, and thus endurance time is the best predictor of exercise capacity in children.

The endurance data reported by Cumming et al in 1978 have served as the reference for several decades. Recently, however, two reports from the United States (Ahmed et al, 2001; Chatrath et al, 2002) indicate that the endurance time has been reduced significantly since the 1970s. It is concerning that endurance times reported from two other countries (Italy in 1994; Turkey in 1998) are similar to those published by Cumming et al and are significantly longer than those reported in the two U.S. reports. This may be an indication that U.S. youth are less physically fit than the youth from other countries, which may lead to increased risk of coronary artery disease and stroke in the U.S. population. A new set of endurance data from a recent U.S. study is presented in Table 6-1. The endurance times for boys and girls are close until early adolescence, at which time the endurance time of girls diminishes and that of boys increases.

### TABLE 6-1
PERCENTILES OF ENDURANCE TIME (MIN) BY BRUCE TREADMILL PROTOCOL

<table>
<thead>
<tr>
<th>Age Group (yr)</th>
<th>10</th>
<th>25</th>
<th>50</th>
<th>75</th>
<th>90</th>
<th>Mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>4–5</td>
<td>6.8</td>
<td>7.0</td>
<td>8.2</td>
<td>10.0</td>
<td>12.7</td>
<td>8.9 ± 2.4</td>
</tr>
<tr>
<td>6–7</td>
<td>6.6</td>
<td>7.7</td>
<td>9.6</td>
<td>10.4</td>
<td>13.1</td>
<td>9.6 ± 2.3</td>
</tr>
<tr>
<td>8–9</td>
<td>7.0</td>
<td>9.1</td>
<td>9.9</td>
<td>11.1</td>
<td>15.0</td>
<td>10.2 ± 2.5</td>
</tr>
<tr>
<td>10–12</td>
<td>8.1</td>
<td>9.2</td>
<td>10.7</td>
<td>12.3</td>
<td>13.2</td>
<td>10.7 ± 2.1</td>
</tr>
<tr>
<td>13–15</td>
<td>9.6</td>
<td>10.3</td>
<td>12.0</td>
<td>13.5</td>
<td>15.0</td>
<td>12.0 ± 2.0</td>
</tr>
<tr>
<td>16–18</td>
<td>9.6</td>
<td>11.1</td>
<td>12.5</td>
<td>13.5</td>
<td>14.6</td>
<td>12.2 ± 2.2</td>
</tr>
</tbody>
</table>

SD, standard deviation.

### 2. Heart Rate

Heart rate is measured from the ECG signal. A heart rate of 180 to 200 beats/min correlates with maximal oxygen consumption in both boys and girls. Therefore, an effort
is made to encourage all children to exercise to attain this heart rate. The mean maximal heart rates for all subjects were virtually identical, 198 ± 11 beats/min for boys and 200 ± 9 beats/min for girls. Heart rate declined abruptly during the first minute of recovery to 146 ± 19 beats/min for boys and 157 ± 19 beats/min for girls.

Inadequate increments in heart rate may be seen with sinus node dysfunction, in congenital heart block, and after cardiac surgery. Sinus node dysfunction is common after surgery involving extensive atrial suture lines, such as the Senning operation or Fontan operation. It is also common after repair of TOF. Marked chronotropic impairment significantly decreases aerobic capacity. Trained athletes tend to have lower heart rates at each exercise level. An extremely high heart rate at low levels of work may indicate physical deconditioning or marginal circulatory compensation.

### 3. Blood Pressure

Blood pressure can be measured with a cuff, a sphygmomanometer, and a stethoscope. Numerous commercially available electronic units are also available to measure BP during exercise. However, one must be concerned with the accuracy of these devices. Accurate measurement of BP, especially diastolic pressure, is probably not possible during exercise.

Systolic BP increases linearly with progressive exercise. Systolic BP usually rises to as high as 180 mm Hg (Table 6-2) with little change in diastolic BP. Maximal systolic pressure in children rarely exceeds 200 mm Hg. During recovery, it returns to baseline in about 10 minutes. The diastolic BP ranges between 51 and 76 mm Hg at maximum systolic BP. Diastolic BP also returns to the resting level by 8 to 10 minutes of recovery.

High systolic BP in the arm, to the level of what is considered hypertensive emergency, probably does not reflect the central aortic pressure, and the usefulness of arm BP in assessing cardiovascular function during upright exercise is questionable except in the case of failure to rise. The major portion of the rise in arm systolic BP during treadmill exercise probably reflects peripheral amplification caused by vasoconstriction in the nonexercising arms (associated with increased blood flow to vasodilated exercising legs); central aortic pressure would probably be much lower than the systolic BP in the arm in most cases. Figure 6-1 is a dramatic illustration of a relationship between the central and peripheral arterial pressures measured directly with arterial cannulas inserted in to the ascending aorta and radial artery during upright exercise in young adults. Note that when the radial artery systolic BP is over 230 mm Hg, the aortic pressure is only 160 mm Hg and that there is a very little increase in diastolic BP.
An excessive rise in the peripheral BP has been reported in patients who have had surgical repair of coarctation of the aorta, patients with hypertension and those with the potential to develop hypertension, hypercholesterolemic patients, and patients with aortic regurgitation, but information on the central aortic pressure is lacking in these
reports.
Failure of BP to rise to the expected level may be much more significant than the level of the rise in arm BP. The failure reflects an inadequate increase in cardiac output. This is commonly seen with cardiomyopathy, left ventricular outflow tract obstruction, coronary artery diseases, or the onset of ventricular or atrial arrhythmias.

4. ECG Monitoring
The major reasons for monitoring ECG during exercise testing are to detect exercise-induced arrhythmias and ischemic changes. A complete ECG should be recorded at rest, at least once during each workload, and for several intervals after exercise.

a. Exercise-induced arrhythmias
Arrhythmias that increase in frequency or begin with exercise are usually significant and require thorough evaluation. The type and frequency before and after the exercise and occurrence of new or more advanced arrhythmias should be noted. The occurrence of serious ventricular arrhythmias may be an indication to terminate the test. Changes in the QTc duration, including the recovery period, should be evaluated.

b. Changes suggestive of myocardial ischemia
ST-segment depression is the most common manifestation of exercise-induced myocardial ischemia. For children, downsloping of the ST segment or sustained horizontal depression of the ST segment of 2 mm or greater when measured at 80 msec after the J point is considered abnormal (see Fig. 3-23). Most guidelines for adult exercise testing, however, recommend the ST-segment depression of 1 mm or greater as an abnormal response. With progressive exercise, the depth of ST-segment depression may increase, involving more ECG leads, and the patient may develop anginal pain. Five to 10 minutes after the termination of the exercise, the ST changes (and T-wave inversion) may return to the baseline. Occasionally, the ischemic ST-segment response may appear only in the recovery phase.

The following lists some points in the evaluation of ST-segment shift in certain situations.

1) Specificity of the exercise ECG is poor in the presence of ST-T abnormalities on a resting ECG or with digoxin use
2) If the ST segment is depressed at rest (which occurs occasionally), the J point and ST segment measured at 60 to 80 msec should be depressed an additional 1 mm or greater to be considered abnormal.
3) When there is an abnormal depolarization, such as bundle branch block, ventricular pacemaker, or Wolff-Parkinson-White preexcitation, interpretation of ST-segment displacement is impossible.
4) In patients with early repolarization and resting ST-segment elevation, return to the PQ junction is normal. In such cases, ST depression should be determined from the PQ point, not from the elevated J point.
5) There is a poor correlation between ST-segment changes and nuclear perfusion imaging in such conditions as anomalous origin of the coronary artery from the PA, Kawasaki’s disease, and postoperative arterial switch operation.
5. Oximetry

Pulse oximetry measurement of blood oxygen saturation is useful during exercise testing of children who have CHD. Normal children maintain oxygen saturation greater than 90% during maximal exercise when monitored by pulse oximetry. Desaturation (less than 90%) during exercise is considered an abnormal response and may reflect pulmonary, cardiac, or circulatory compromise. Children who received lateral tunnel Fontan operation with fenestration may desaturate during exercise because of right-to-left shunt through the fenestration.

Safety of Exercise Testing

A properly supervised exercise study is safe. Exercise testing should be performed under the supervision of a physician who has been trained to conduct the test, with patient safety in mind. The examiner should pay close attention to the subject during the treadmill exercise testing and be alert to stopping the treadmill when the patient can no longer exercise or appears to be in jeopardy. At these times, an observer should be positioned to assist the subject. A well-stocked crash cart should be available in the laboratory. A defibrillator should be present. Additional equipment should include a delivery system for oxygen as well as ventilation and suction apparatus.

Indications

Indications of stress testing vary with institutions and cardiologists. However, some of the more common indications for exercise testing in children are as follows:

1. Evaluate specific signs or symptoms that are induced or aggravated by exercise.
2. Assess or identify abnormal responses to exercise in children with cardiac, pulmonary, or other organ disorders, including the presence of myocardial ischemia and arrhythmias.
3. Assess the efficacy of specific medical or surgical treatments.
4. Assess the functional capacity for recreational, athletic, and vocational activities.
5. Evaluate a prognosis, including both baseline and serial testing measurements.
6. Establish baseline data for institution of cardiac, pulmonary, or musculoskeletal rehabilitation.

Contraindications

Good clinical judgment should be foremost in deciding contraindications for exercise testing. Absolute contraindications include patients with acute myocardial or pericardial inflammatory diseases or patients with severe obstructive lesions in whom surgical intervention is clearly indicated (American Heart Association (AHA), 2006, Clinical Stress Testing in Pediatric Age Group).

The patients with following diagnoses are considered a high-risk group:

1. Acute myocarditis or pericarditis
2. Severe aortic or pulmonary stenosis
3. Pulmonary hypertension
Documented long QT syndrome
Uncontrolled resting hypertension
Unstable arrhythmias
Routine testing on Marfan’s syndrome
Routine testing after heart transplantation

Termination of Exercise Testing
Three general indications to terminate an exercise test are (1) when diagnostic findings have been established and further testing would not yield any additional information, (2) when monitoring equipment fails, and (3) when signs or symptoms indicate that further testing may compromise the patient’s well-being. The following indications for termination of exercise testing have been recommended by AHA 2006 Clinical Stress Testing in Pediatric Age Group.

1. Failure of heart rate to increase or a decrease in ventricular rate with increasing workload associated with symptoms (e.g., extreme fatigue, dizziness)
2. Progressive fall in systolic pressure with increasing workload
3. Severe hypertension, above 250 mm Hg systolic or 125 mm Hg diastolic, or BP higher than can be measured by the laboratory equipment
4. Dyspnea that the patient finds intolerable
5. Symptomatic tachycardia that the patient finds intolerable
6. Progressive fall in oxygen saturation to less than 90% or a 10-point drop from resting saturation in a patient who is symptomatic
7. Presence of 3 mm or greater flat or downward-sloping ST-segment depression
8. Increasing ventricular ectopy with increasing workload
9. Patient requests termination of the study

Alternative Stress Testing Protocols
Besides treadmill exercise, there are other types of stress testing that can be performed, including the 6-minute walk test, pharmacologic stress tests, and exercise-induced bronchospasm (EIB) provocation tests.

Six-Minute Walk Test
This test may be more appropriate for assessing exercise tolerance in children with moderate to severe exercise limitation for traditional exercise testing.

The patient is encouraged to try to cover as much distance or as many laps on a measured course (often 30 m) as possible in 6 minutes. Patients using supplemental oxygen should perform the test with oxygen. Portable oximeters may be used if available to the patient. If monitoring equipment is not available, oxygen saturation and heart rate are monitored before and after the test. The total distance walked is the primary outcome. At least two practice tests performed on a separate day are advisable. At this time, reference values for healthy children and adolescents are not available. However, the test is useful for following disease progression and measuring the response to
Pharmacologic Stress Protocols

This protocol is used when conventional exercise testing is unsuitable or impractical, such as for patients who are too young and those who are unable to perform exercise test. After pharmacologic stimulations, either echocardiography or nuclear imaging is performed. Two types of pharmacologic agents are used:

- Agents that increase myocardial oxygen consumption (dobutamine, isoproterenol), which simulate the effects of exercise.
- Agents that cause coronary dilatation (adenosine, dipyridamole). Adenosine cause dilatation of normal coronary artery segments, resulting in a shunting of myocardial blood flow away from diseased segments. Dipyridamole inhibits adenosine reuptake, resulting in the same physiology.

The following are the dosages of the pharmacologic agents recommended in a statement from the AHA (Paridon et al, 2006). Dobutamine is administered in gradually increasing doses from a starting dose of 10 mcg/kg/min to a maximal dose of 50 mcg/kg/min in 3- to 5-minute stages to achieve the target heart rate. Atropine (0.01 mg/kg up to 0.25 mg aliquots every 1–2 minutes up to a maximum of 1 mg) can be administered to augment the heart rate, usually given at 50 mcg/kg/min of dobutamine. Esmolol (10 mg/mL dilution at a dose of 0.5 mg/kg) should be available to rapidly reverse the effects of dobutamine in the event of adverse reaction or development of ischemia. If echocardiography is used, the imaging should be performed at rest and at each dosing stage. Radioisotope for nuclear myocardial perfusion scan should be injected 1 minute before the infusion of dobutamine at maximal dosage is stopped.

Adenosine is infused at 140 mcg/kg/min for 6 minutes. If echocardiography imaging is used, it should be continuous throughout the infusion. Nuclear isotope is given at 3 minutes into the infusion. Dipyridamole is infused over the same time period at a dose of 0.6 mg/kg/min. Radioisotope delivery and echocardiography imaging should be performed at the peak physiologic effect of the dipyridamole, usually 3 to 4 minute after completion of the infusion. Administration of aminophylline is routinely used in many centers after termination of the dipyridamole infusion.

Exercise-Induced Bronchospasm Provocation

Bronchial reactivity is measured while the subject exercises for 5 to 8 minutes on a treadmill at an intensity of 80% of maximum capacity. The exercise room should be as cool (temperature, 20° to 25°C) and dry as possible.

The exercise protocol should be to quickly increase the intensity to 80% maximum capacity within 2 minutes (using predicted heart rate maximum as a surrogate). If the intensity is not reached quickly, the patient may develop refractoriness to bronchospasm. An incremental work used in many exercise tests, such as the Bruce protocol, is less likely to be effective in evaluating EIB because of too short a duration of high ventilation; therefore, it should not be used in the evaluation of EIB.
Exercise is preceded by baseline spirometry. Spirometry is repeated immediately after exercise and again at minutes 5, 10, and 15 of recovery. Most pulmonary function test nadirs occur within 5 to 10 minutes after exercise. Accepted criteria for a significant decline in forced expiratory volume in 1 second (FEV$_1$) after exercise are variable. Declines of 12% to 15% in FEV$_1$ are typically diagnostic.
Long-term ECG recording is the most useful method to document and quantitate the frequency of arrhythmias, correlate the arrhythmia with the patient’s symptoms, and evaluate the effect of antiarrhythmic therapy. There are several different types of long-term ECG recorders, which detect arrhythmias for varying lengths of time. The Holter monitor is used to record events occurring in 24 (or up to 72) hours, event recorders record arrhythmic episodes for up to 30 days, and implantable loop recorders record rhythm up to 14 months.

Holter Recording
The Holter monitor, invented by Dr. Norman Holter, is a device that records the heart rhythm continuously for 24 (to 72) hours using ECG electrodes attached on the chest. The heart rhythm is recorded onto a cassette tape or flash card technology and then processed at a heart center. Two simultaneous channels are usually recorded. This helps distinguish artifacts from arrhythmias. This recorder is useful when a child has symptoms almost daily. This type of monitoring is not helpful in the detection of episodes that occur infrequently (e.g., once a week or once a month). Patients are given a diary so they can record symptoms and activities. The monitor has a built-in timer that is used with the patient’s diary to allow subsequent correlation of symptoms and activities with arrhythmias. The importance of keeping an accurate and complete diary must be impressed on patients and parents. Events of interest can be picked out and printed for review. A wide variety of information can be obtained from the recording, including heart rates, abnormal heartbeats, and recording of rhythm during any symptoms.

The Holter recordings should reveal the frequency, duration, and types of arrhythmias, as well as their precipitating or terminating events. Significant arrhythmias rarely cause symptoms such as palpitation, chest pain, and syncope (<10% of cases). Marked bradycardia (<50 beats/min in infants, <40 beats/min in older children), supraventricular tachycardia with a rate faster than 200 beats/min, and ventricular tachycardia are potentially life threatening. These arrhythmias do occur and may worsen during sleep.

Indications
Ambulatory ECG monitoring is obtained for the following reasons:
1. To determine whether symptoms such as chest pain, palpitations, and syncope are caused by cardiac arrhythmias
2. To evaluate the adequacy of medical therapy for an arrhythmia
3. To screen high-risk cardiac patients such as those with hypertrophic cardiomyopathy or those who have had operations known to predispose to arrhythmias (e.g., Mustard, Senning, Fontan-type operation)
4. To evaluate possible intermittent pacemaker failure in patients who have an implanted pacemaker
5. To determine the effect of sleep on potentially life-threatening arrhythmias
Interpretations

Interpretation of the results usually includes the following:
1. A description of the basic rhythm and the range of the heart rate
2. If there is bradycardia, description of its rate, rhythm, duration (or number of beats) and the presence of escape beats, and so on
3. For extreme tachycardia, description of the rhythm, mode of initiation and termination, and its duration
4. Description of any abnormalities in AV conduction
5. Description of any arrhythmias, including their characteristics, duration, and frequency
6. Correlation of the arrhythmias with the patient’s activities and symptoms
7. If the patient complained of anginal pain, correlation of ST-segment changes with activities

Holter Findings in Normal Children

Meaningful interpretation of the Holter recordings performed in patients with organic heart disease or significant systemic illness requires knowledge of the range of heart rate and rhythm variations in normal subjects of comparable age. Holter ECG recordings of healthy pediatric populations have demonstrated that variations in rate and rhythm, which were previously thought to be abnormal, occur quite frequently.

Premature or Low-Birth-Weight Infants

The minimum heart rate of premature or low-birth-weight infants can be as low as 73 beats/min; the maximum heart rate can be as high as 211 beats/min. Junctional rhythm may be observed in 18% to 70%, premature atrial contractions (PACs) in 2% to 33%, and premature ventricular contractions (PVCs) in 6% to 17%. First-degree atrioventricular (AV) block or Wenckebach’s second-degree AV block occurs in 4% to 6%. Sudden sinus bradycardia and sinus pause occur especially frequently.

Full-Term Neonates

In full-term neonates, the heart rate can be as low as 75 beats/min and as high as 230 beats/min. Junctional rhythm may be present in 28%, PACs in 10% to 35%, and PVCs in 1% to 13%. First-degree AV block or Wenckebach’s (Mobitz type 1) second-degree AV block may be recorded in 25% of neonates. Sinus pause is quite frequent.

Children

Southall et al (1981) reported the following findings in healthy 7- to 11-year-old children.
- The mean highest heart rate was 164 ± 17 beats/min.
- The mean lowest heart rate was 49 ± 6 over 3 beats’ and 56 ± 6 over 9 beats’ duration.
- At their lowest rate, 45% had junction escape rhythm lasting up to 25 minutes.
- AV conduction:
  - PR interval ≥0.20 sec in 9%
• Mobitz type I second-degree AV block in 3%
• Isolated supraventricular or ventricular premature beats in 19% (less than 1 per hour)
• Sinus pause seen in 65%. The maximum duration of sinus pause on each child was 1.36 ± 0.23 seconds

**Adolescent Boys**

Dickinson and Scott (1984) reported the following in healthy 14- to 16-year-old boys.
• Sinus arrhythmia in all cases with heart rate ranging from 45 to 200 beats/min during the day.
• During sleep, the heart rate can become as low as 23 beats/min.
• At their lowest rate, escape rhythm was present in 26%.
• AV conduction:
  • Sudden variation in PR interval was noted in 41%
  • Sinus arrest or sinoatrial block in 15%
  • First-degree AV block in 12%
  • Wenckebach’s (Mobitz type 1) second-degree AV block in 11%
• PVCs (occurring in 26% to 57%), which include multiform PVCs; PACs (occurring in 13% to 20%) were also observed.
• Short episodes of ventricular tachycardia were present in 3%.

**Event Recorders**

Event monitors are devices that are used by patients over a longer period (weeks to months, typically 1 month). The monitor is used when symptoms suggestive of an arrhythmia occur infrequently. A drawback of this device is that the patient must be able to press the event button to begin recording. The information collected by the event monitor can be sent over the phone to a doctor’s office, clinic, or hospital. Two general types of cardiac event monitors are available.

1. **Looping Memory (Presymptom) Event Monitor**

The term “looping” refers to the memory of the monitor, which means that when activated, the monitor can save the previous 30 to 60 seconds of data stored in the memory loop. Two electrodes are attached on the chest. The monitor is always on but only stores the patient’s rhythm when the patient or caregiver pushes the button. Most monitors will save the rhythm for 30 to 60 seconds before the device is activated. The patient can send the stored ECGs by telephone directly to the event monitoring center. This feature is especially useful for people who pass out when their heart problems occur and can press the button only after they wake up.

2. **Nonlooping Memory (Postsymptom) Event Monitor**

This monitor is capable of real-time recording of the cardiac rhythm without having electrodes attached to the chest. This device is used to record symptoms that last longer...
than 45 to 60 seconds. It is a small device that has small metal discs that function as the electrodes. When symptoms occur, the device is pressed against the chest to start the recording. The device records and stores the events in solid-state memory. It can store up to four to six such events before it is necessary to transmit the information.

**Implantable Loop Recorder**

For patients with very infrequent symptoms, such as once every 6 months, neither Holter recorders nor 30-day event recorders may yield diagnostic information. In such patients, implantable loop recorders, about the size of a pack of chewing gum, are implanted beneath the skin in the upper left chest. The patient uses a hand-held activator to record and permanently store the cardiac rhythm when symptoms occur. The device can be “interrogated” through the skin to determine what the heart was doing when the symptoms occurred. This device was shown to be instrumental in establishing the diagnosis in patients with infrequent syncope on whom other recording devices failed to document the cause of syncope.
Ambulatory Blood Pressure Monitoring

Blood pressure is not a static variable; rather, it changes not only from daytime to nighttime but also from minute to minute. Casual BP measurement provides only a snapshot of the daytime BP pattern, which is higher than nighttime readings. In some patients, there is a transient elevation of systolic, diastolic, or mean BP when BP is measured in a health care facility (i.e., “white-coat hypertension”). This could lead to an overdiagnosis of hypertension and to unnecessarily aggressive and costly diagnostic studies and treatment. Ambulatory BP monitoring (ABPM) has emerged as a technology that addresses some of the limitations of casual BP measurements because it permits the observation of BP throughout day and night in a nonmedical environment. Many antihypertensive organizations recommend BP measurement outside the clinic setting, including self-measurement of BP at home or any other place. Although self-measurement of BP was better than clinic BP measurement, ABPM was even better than self-measured BP in the diagnosis of hypertension. Some researchers advocate the use of ABPM in all patients with casual BP elevation.

Multiple BP measurements are obtained with a preapplied BP cuff, usually using the oscillometric method (with or without the ECG’s R-wave gating) for a 24-hour period while children participate in their normal daily activities. Typically, recording frequency varies from every 15 to 30 minutes for daytime or waking measures and every 20 to 60 minutes for nighttime or sleep measures. Sleep periods can be identified by either diary or actigraphy. The most common complaint is sleep disruption. The use of ABPM is usually limited to children 5 to 6 years of age or older. Successful recording has been reported in more than 70% of children younger than 6 years of age. Activity influences the BP readings. Both ambulatory systolic and diastolic BPs varied by 10 mm Hg from lowest to highest levels of activity. Most hypertension specialists recommend that children continue their normal activities but refrain from contact sports and vigorous exercises.

There are three basic calculations of ABPM.

1. **Mean BP value.** The mean BP value can be determined for the entire 24-hour period or for day and night periods separately. Wühl and colleagues (2002) have published mean normative ambulatory BP levels for gender and height from mid-European white children (see Table B-8 for boys and Table B-9 for girls in Appendix B).

2. **BP load.** BP load is defined as the percentage of valid BP measures above a set threshold such as the 95th percentile of BP for age, gender, and height. This may be a better measure of the hemodynamic stress placed on end organs susceptible to hypertensive injury. BP load in excess of 25% to 30% are typically considered elevated. Loads in excess of 50% may be predictive of left ventricular hypertrophy. Most experts use a combination of mean BP and BP load to categorize ABPM results as normal or abnormal (Table 6-3).

3. **Nocturnal dipping.** The nocturnal dipping is calculated by subtracting the mean sleep BP from the mean awake BP and dividing this value by the mean awake BP. Normal nocturnal dipping is generally defined as a 10% or greater decline in mean systolic and
diastolic ambulatory BP levels from day to night (\[\text{Mean daytime ABPM} - \text{Mean nighttime ABPM}\]/\text{Mean daytime ABPM} \times 100\]). Nondipping (defined as a decline of <10%) has been associated with hypertensive end-organ injury, end-stage renal disease, renal transplantation, or insulin-dependent diabetes mellitus. Black children have higher sleep BP levels and less significant decreases in BP during sleep compared with age-matched white counterparts.

ABPM is useful in evaluation of hypertension in the following ways.

a. White-coat hypertension. ABPM is critical in distinguishing white-coat hypertension from true hypertension. Office measurement of BP often fails to account for the transient, stress-induced elevation of BP.

b. Secondary hypertension in adolescents. ABPM may be useful in differentiating primary from secondary hypertension. Adolescents with secondary hypertension have been shown to have greater nocturnal systolic BP loads and greater daytime and nocturnal diastolic BP loads than children with primary hypertension. Decreased nocturnal dipping may be another sign favoring secondary hypertension.

c. Abnormality in ABPM, such as nighttime systolic BP and BP load, is more strongly associated with the end-organ damage, such as left ventricular mass, than with a casual BP measurement in children and adults.

d. ABPM may help quantify the level of BP elevation as shown in Table 6-3. Different levels of hypertension can be defined by using the mean ambulatory systolic BP and systolic BP load.

e. ABPM also allows evaluation of the need for and the effectiveness of pharmacologic therapy for hypertension.

Contraindications to ABPM may include atrial fibrillation, coagulation disorders, and for some brands of equipment, latex allergy.

Although the advantages of ABPM are clear, there are still some technical difficulties and problems with normative ambulatory BP levels in children. With the auscultatory method, it is difficult to keep a microphone under the BP cuff over the brachial artery, and ambient noise levels interfere with accurate detection of Korotkoff sounds. Thus, oscillometric devices are more popular. When one uses an auscultatory method, one should not use the normative data of Wühl et al (2002) because oscillometric BP readings have been shown to be higher than the auscultatory BP levels (see an earlier section of Blood Pressure Measurement in Chapter 2). Another problem is that this technology is not always available, and the cost of the study may be prohibitive.

### Table 6-3

**SUGGESTED SCHEME FOR STAGING OF AMBULATORY BLOOD PRESSURE LEVELS IN CHILDREN**
<table>
<thead>
<tr>
<th>Classification</th>
<th>Clinic BP (percentile)</th>
<th>Mean Ambulatory Systolic BP (percentile)</th>
<th>Systolic BP Load (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal BP</td>
<td>&lt;95th</td>
<td>&lt;95th</td>
<td>&lt;25</td>
</tr>
<tr>
<td>White-coat hypertension</td>
<td>&gt;95th</td>
<td>&lt;95th</td>
<td>&lt;25</td>
</tr>
<tr>
<td>Masked hypertension</td>
<td>&lt;95th</td>
<td>&gt;95th</td>
<td>&gt;25</td>
</tr>
<tr>
<td>Prehypertension</td>
<td>&gt;95th</td>
<td>&lt;95th</td>
<td>25–50</td>
</tr>
<tr>
<td>Ambulatory hypertension</td>
<td>&gt;95th</td>
<td>&gt;95th</td>
<td>25–50</td>
</tr>
<tr>
<td>Severe ambulatory hypertension (at risk for end-organ damage)</td>
<td>&gt;95th</td>
<td>&gt;95th</td>
<td>&gt;50</td>
</tr>
</tbody>
</table>

BP, blood pressure.

Invasive Procedures

There are two kinds of invasive procedures that are used in the practice of pediatric cardiology. The first is cardiac catheterization and angiocardiography, which together are used for diagnosis (diagnostic catheterization). The second is to treat certain structural heart defects nonsurgically using specially designed catheters and implantable devices that are delivered through cardiac catheters (therapeutic cardiac catheterization).
Cardiac catheterization and angiocardiography usually constitute the final definitive diagnostic tests for most cardiac patients. They are carried out under general sedation using various sedatives (discussed later). For newborns, cyanotic infants, and hemodynamically unstable children, general anesthesia with intubation may be used.

Under local anesthesia and with strict aseptic preparation of the skin, catheters are placed in peripheral (most commonly the femoral) vessels and advanced to the heart and central vessels under fluoroscopy with image intensification to reduce radiation exposure. At each position in the heart and blood vessels, values of pressure and oxygen saturation of blood are obtained. The oxygen saturation data provide information on the site and magnitude of the left-to-right or right-to-left shunt, if any. The pressure data provide information on the site and severity of obstruction. Cardiac output may be obtained from oxygen saturation data (e.g., the Fick principle) or by indicator dilution (e.g., indocyanine green dye) or thermodilution (e.g., cold saline injection) technique. Selective angiocardiography is usually performed as part of the catheterization procedure (described later).

Normal Hemodynamic Values

Normal oxygen saturation on the right side of the heart is usually 70% but it may vary between 65% and 80%, depending on cardiac output. Left-sided saturations are usually 95% to 98% in room air. In newborns and heavily sedated children, the oxygen saturation may be lower. Pressures are lower in the right side than in the left side of the heart, with systolic pressures in the right ventricle (RV) and pulmonary artery (PA) about 20% to 30% of those in the left side of the heart (Fig. 7-1).

Routine Hemodynamic Calculations

The following calculations are routinely obtained: flow and resistance for systemic and pulmonary circuits and left-to-right or right-to-left shunt.

**Flows (Cardiac Output) and Shunts.** Flow is calculated by use of the Fick formula:

\[
\text{Systemic Flow (Q_s)} = \frac{\text{Vo}_2}{\text{C}_\text{Ao} - \text{C}_\text{MV}}
\]

\[
\text{Pulmonary Flow (Q_p)} = \frac{\text{Vo}_2}{\text{C}_\text{PV} - \text{C}_\text{PA}}
\]

where flows are in L/min, \(\text{Vo}_2\) is oxygen consumption (mL/min), \(\text{C}\) is oxygen content (mL/L) at various positions, \(\text{PV}\) is pulmonary vein, \(\text{PA}\) is pulmonary artery, \(\text{AO}\) is aorta, and \(\text{MV}\) is mixed systemic venous blood (superior vena cava or right atrium). Normal
systemic flow or pulmonary flow in the absence of a shunt is $3.1 \pm 0.4 \text{ L/min/m}^2$ (i.e., cardiac index).

![Diagram](image)

**FIGURE 7-1** Average values of pressure and oxygen saturation in normal children. AO, aorta; LA, left atrium; LV, left ventricle; M, mean pressure; PA, pulmonary artery; PV, pulmonary vein; RA, right atrium; RV, right ventricle; VC, vena cava.

Oxygen consumption is either directly measured during the procedure or estimated from a table for children 3 years and older (see Appendix A, Table A-6). Assumed oxygen consumption of 150 to 160 mL/min/m$^2$ is used in older infants and children. In infants under 2 to 3 weeks of age, 120-130 mL/min/m$^2$ may be used. Oxygen capacity is the maximum quantity of oxygen that can be bound to each gram of hemoglobin (i.e., $1.36 \text{ mL} \times \text{Hb level}$; each gram of hemoglobin [Hb] combines maximally with 1.36 mL of oxygen). Oxygen saturation is the amount of oxygen bound to hemoglobin compared with the oxygen capacity, and it is expressed as a percentage.

When there is a pure left-to-right or right-to-left shunt, the magnitude of the shunt is calculated as follows:

The flow data are subject to much error because of difficulties in measuring accurate oxygen consumption or because of the frequent use of assumed oxygen consumption in pediatric patients. Therefore, the ratio of pulmonary-to-systemic flow is frequently used because it does not require an oxygen consumption value. The ratio provides information on the magnitude of the shunt. A ratio of 1:1 would indicate no shunting in either direction or bidirectional shunting of equal magnitude. A ratio of
2:1 implies that there is a left-to-right shunt equal to systemic blood flow. A ratio of 0.8:1 signifies that the pulmonary blood flow is 20% less than the systemic blood flow (e.g., the flow ratio seen in a cyanotic patient). Patients with a flow ratio greater than 2:1 are usually surgical candidates.

**Resistance.** Hydraulic resistance (R) is defined by analogy to Ohm’s law as the ratio of the mean pressure drop (ΔP) to flow (Q) between two points in a liquid flowing in a tube (R = ΔP/Q). Therefore, pulmonary vascular resistance (PVR) and systemic vascular resistance (SVR) are calculated using the following formulas:

\[
\text{PVR} = \frac{\text{Mean PA pressure} - \text{Mean LA pressure}}{Q}
\]

\[
\text{SVR} = \frac{\text{Mean systemic pressure} - \text{Mean LA pressure}}{Q}
\]

The normal SVR is about 20 units/m² in children, but it varies markedly between 15 and 30 units/m². In newborn infants, the SVR is lower (10–15 units/m²) and rises gradually to about 20 units/m² by 12 to 18 months of age. The normal PVR is high at birth but approaches adult values by about 6 to 8 weeks after birth. Normal values in children and adults are 1 to 3 units/m². Accordingly, the ratios of PVR to SVR range from 1:10 to 1:20. High PVR values increase the risk associated with corrective surgery for many congenital cardiac defects.

**Selective Angiocardiography**

Information derived from echocardiography and oxygen saturation and pressure data from catheterization help determine the number and sites of selective angiocardiograms required to delineate cardiovascular structures. A radiopaque dye is rapidly injected into a certain site, and angiograms are recorded, often on biplane views. Depending on the cardiovascular anomaly under study, special views are obtained by moving the fluoroscopic camera (or by positioning the patient at desired angles). Multiple injection sites are often necessary to obtain a complete anatomic diagnosis (Fig. 7-2, A).

Contrast agents used in angiocardiography are water-soluble, complex organic compounds, with three iodine atoms bound to a benzene ring. Old contrast agents (e.g., Renografin 76, Renovist, Hypaque M-75, Vascoray) are ionic agents with high osmolality (i.e., osmolality of 1690–2150 mOsm/kg; much [five to eight times] higher than serum osmolality of 275–300 mOsm). Nonionic contrast agents (e.g., Isovue, Omnipaque) are low-osmolality agents (i.e., osmolality of 200–300 mOsm/kg), and some are hypotonic to the serum. After the injection of a high-osmolality contrast medium, there is a rapid shift of fluid from the interstitial and intracellular spaces into the intravascular space. This causes volume expansion, a slight drop in hematocrit, and a change in electrolyte concentration. These changes adversely affect newborns and infants with congestive
heart failure (CHF). Low-osmolality agents cause less volume shift and are safer. Other toxic effects of high-osmolality agents include decreased red cell pliability, increased viscosity, osmolar diuresis, proteinuria, hematuria, and renal failure (occasionally).

Risk
Cardiac catheterization and angiocardiography can lead to serious complications and occasionally death.
- Complications related to catheter insertion and manipulation include serious arrhythmias; heart block; cardiac perforation; cardiac valve injury; hypoxic spells; vascular injury, perforation, or tears; hemorrhage (that requires transfusion); and infection.
- Complications related to contrast injection include reactions to the contrast material, intramyocardial injection, and renal complications (e.g., hematuria, proteinuria, oliguria, anuria).
- Complications related to exposure, anesthesia, sedation, and medications include hypothermia, acidemia, hypoglycemia, convulsions, hypotension, respiratory depression, diffuse central nervous system injury, stroke, and even death. These complications are more likely to occur in newborns.

FIGURE 7-2  Angiocardiography and balloon valvuloplasty. A, Lateral view of a right ventriculogram showing a thick, dome-shaped pulmonary valve and a marked poststenotic dilatation of the pulmonary artery. B, A maximally inflated sausage-shaped valvuloplasty balloon is seen, which suggests that the stenotic pulmonary valve has been widened. The balloon catheter was introduced over a guidewire, which was positioned in the left pulmonary artery.

- Complications also include exposure to ionized radiation.
- The risk of cardiac catheterization and angiocardiography varies with the patient’s age and illness, the type of lesion, and the experience of the physician doing the procedure. The reported rate of fatal complications varies from lower than 1% to as high as 5% in the newborn period. In one study, the incidence of significant but nonfatal complications requiring treatment (e.g., arrhythmias and arterial complications) was 12% in infants younger than 4 months old. In comparison, the incidence of such complications was 1.5% in older infants. Major complications (e.g., ventricular arrhythmias, hypotension, arterial complications, perforation of the heart, breakage or knotting of catheters, allergic
reactions, hypoxic spells) occurred 1.4% of the time, and minor complications occurred 6.8% of the time. With better preparation and monitoring, as well as the use of prostaglandin infusion in critically ill newborns, the mortality and morbidity rates can be minimized.

**Indications**

Details of anatomy, including situs, venous and arterial connections, septal integrity, severity of valvular stenosis or regurgitation, size of pulmonary arteries, coronary artery origins, and aortic arch anatomy, are easily established with echocardiography to the degree of certainty required for surgical intervention. When additional information is needed for intervention, it can be obtained by other noninvasive techniques, such as cardiac magnetic resonance imaging or cardiac computed tomography. In centers where these noninvasive imaging techniques are not available and when echocardiography does not provide sufficient detail, cardiac catheterization is indicated (Feltes et al, 2011). In most centers, two thirds of cardiac catheterizations are for interventional purposes, and only one third are for diagnostic purposes.

- Most congenital heart defects, such as ventricular septal defect (VSD), atrial septal defect (ASD), atrioventricular (AV) canal, tetralogy of Fallot (TOF), double outlet right ventricle (DORV), coarctation of the aorta (COA), HLHS, and other complex congenital heart disease (CHD) do not need diagnostic catheterization. Most of them can be adequately diagnosed by noninvasive methods. It is indicated when complete diagnosis cannot be made by noninvasive testing or when such testing yields incomplete information.

- The following lists some circumstances that suggest the need for diagnostic catheterization.
  
  a. To determine accurate pressure gradients in combined aortic stenosis and aortic regurgitation (AR) or pulmonary stenosis (PS) and pulmonary regurgitation or multiple levels of obstruction. Doppler assessment of pressure gradient is different from true peak-to-peak gradient measurement

  b. Assessment of pulmonary hypertension and its responsiveness to vasodilator therapy

  c. To calculate PVR in the setting of low-flow lesions, such as seen in patients after cavopulmonary anastomosis or after complete Fontan operation

  d. Patients with pulmonary atresia with intact ventricular septum or pulmonary atresia with complex ventricular anatomy (to determine details of pulmonary vascular supply, the aortopulmonary collateral supply, and the coronary artery anatomy)

  e. To find answers to postoperative problems: Some of these situation may require interventional procedures at the time of catheterization.

    1) Excessive desaturation after a systemic-to-pulmonary shunt (to rule out shunt stenosis or occlusion and branch PA stenosis)

    2) Excessive desaturation after cavopulmonary anastomosis (to rule out venovenous, venoatrial, or pulmonary AV malformation)
3) When excessive aortopulmonary collateral is suspected
4) Suspected RV outlet tract (RVOT) obstruction after TOF surgery
f. Cardiac transplantation (for both CHD and cardiomyopathy), to assess
preoperatively and for surveillance of vasculopathy, and to obtain endomyocardial
biopsy for rejection identification
g. Assessment of cardiomyopathy or myocarditis
h. To assess coronary circulation in some cases of Kawasaki’s disease

Sedation
A number of sedatives have been used by different institutions with equal success rates.
Smaller doses of sedatives are usually used in cyanotic infants. When an interventional
procedure is planned, general anesthesia is usually employed.
1. No sedation is used in newborns.
2. For small infants weighing less than 10 kg, a combination of chloral hydrate (75 mg/kg; 
   maximum of 2 g) and diphenhydramine (2 mg/kg; maximum of 100 mg) by mouth has 
   been used with good results.
3. For older children, demerol compound (i.e., a solution containing 25 mg/mL of
   meperidine [Demerol], 12.5 mg/mL of promethazine [Phenergan], and 12.5 mg/mL of
   chlorpromazine [Thorazine]) is a popular sedative mixture. The dosage of the demerol
   compound is 0.11 mL/kg intramuscularly (IM). Some centers exclude chlorpromazine
   from the sedative mixture. In cyanotic children, the dosage of the demerol compound is
   reduced by one third. For children in severe CHF, the dose is reduced by half.
4. Some cardiologists use a combination of meperidine (1 mg/kg) and hydroxyzine
   (Vistaril) (1 mg/kg) intramuscularly. Others use a combination of fentanyl (1.25 µg/kg, 
   maximum of 50 µg) and droperidol (62.5 µg/kg, maximum of 2500 µg) with equal success.
5. Ketamine (3 mg/kg IM or 1 to 2 mg/kg intravenously [IV]) may be used, but it can
   change the hemodynamic data because it increases the SVR and blood pressure.
6. Morphine (0.1–0.2 mg/kg) administered subcutaneously can be used to prevent or treat
   hypoxic spells.
7. If more sedation is required during the study, IV diazepam (Valium) (0.1 mg/kg) or
   morphine (0.1 mg/kg) is used.

Preparation and Monitoring
Adequate preparation of the patient before the procedure and careful monitoring during
the procedure can minimize complications and fatality from the invasive studies.
Every child undergoing cardiac catheterization should have the following studies:
1. A 12-lead electrocardiogram, chest radiographs (both posteroanterior and lateral), two-
dimensional echocardiography, urinalysis, and a complete blood count within days or
weeks in advance of the study
2. Baseline coagulation studies and a platelet count for deeply cyanotic children
3. Blood type and cross-match for infants less than 5 kg of body weight
The following preparation and monitoring are particularly important for the safety of patients:
1. Increasing the temperature in the cardiac catheterization laboratory when an infant is being studied.
2. Using a warming blanket and a rectal thermistor to monitor rectal temperature to avoid hypothermia.
3. Checking arterial blood gases and pH and correcting acidemia and hypoxemia.
4. Correcting hypoglycemia or hypocalcemia before and during the procedure.
5. Monitoring oxygen saturation and administering oxygen (if indicated) during the procedure.
6. All patients undergoing catheterization should have a reliable IV line (for sedation, resuscitation, or volume replacement).
7. Children with high hemoglobin levels should be given overnight IV fluid to reduce the risk of dehydration, thrombosis, and hypotension.
8. Digitalis should be held beginning the night before catheterization to reduce the risks of catheterization-induced arrhythmias.
9. Having emergency medications (e.g., atropine, epinephrine, bicarbonate) drawn up and ready.
10. Initiating prostaglandin infusion in cyanotic infants who seem to be ductus dependent.
11. Intubating or readiness for intubating infants with respiratory difficulties.
12. Whenever possible, having another physician (preferably an anesthesiologist) available to monitor the noncardiac aspects of the patient so that the operator can concentrate on the procedure.
Catheter Intervention Procedures

Recent advances have allowed for the development of a variety of therapeutic procedures using specially modified catheters and catheter-delivered devices. The lives of critically ill neonates may be saved by these procedures. They may also eliminate or delay the need for elective surgical procedures in children with certain CHDs. These procedures can open things that are closed, widen things that are too small, or close things that are open. More specifically, blood vessels and heart valves that are too small can be enlarged using balloon catheters and/or implantable devices known as stents. Too small an opening in the atrial septum can be enlarged by using balloon or blade catheter. An opening can be created in an intact atrial septum for left-to-right or right-to-left shunt to occur. Abnormal connections within the heart (ASDs and VSDs) can be closed using innovative devices. Abnormal blood vessels (patent ductus arteriosus [PDA] or collaterals) can also be closed using coils or plugging devices. In recent years, percutaneous valve replacement in the aortic or pulmonary position is gaining more experience.

Balloon and Blade Atrial Septostomy

In balloon atrial septostomy (Rashkind’s procedure), a special balloon-tipped catheter is placed in the left atrium (LA) from the right atrium (RA) through a patent foramen ovale or an existing ASD. The balloon is inflated with diluted contrast material, and the catheter is rapidly pulled back to the RA through the interatrial communication, thereby creating a large opening in the atrial septum. This procedure is indicated in patients with an intact or nearly intact atrial septum in whom a better mixing of systemic and pulmonary venous blood would benefit their oxygenation, cardiac output, or both. Infants who have transposition of the great arteries (TGA), with or without associated ASD, are candidates for the procedure unless an arterial switch operation is to be performed immediately. It is also indicated in infants with total anomalous pulmonary venous return with restrictive ASD if surgery is delayed for some reason. The procedure may be appropriate in selected patients with pulmonary atresia, mitral atresia, and tricuspid atresia.

In infants older than 6 to 8 weeks of age, the atrial septum may be too thick to allow an effective balloon septostomy. In such cases, the atrial septum can be opened with a blade catheter (i.e., Park blade). The blade catheter uses a small blade that unfolds from the tip of the catheter to actually incise the atrial septum as the catheter tip is withdrawn from the LA to the RA. The opening can be torn further with a balloon catheter. Conditions for which the procedure is necessary are the same as those listed for balloon atrial septostomy.

Balloon Valvuloplasty

The balloons used in these interventional procedures are made of special plastic polymers and retain their predetermined diameters. A long guidewire is advanced far
beyond the valve of interest, and the balloon catheter is placed over the wire. The middle
of the elongated, sausage-shaped balloon is placed in the valve position. The balloon is
then inflated with diluted contrast material to relieve obstruction at the valve.

**Pulmonary Valve Stenosis.** This technique is the treatment of choice for valvular PS in
children and, to a large extent, has replaced the surgical pulmonary valvotomy (see Fig. 7-
2, B). Balloon valvuloplasty may be indicated in patients with Doppler peak gradient of 40
mm Hg or greater. The results of this technique are excellent, and it does not have
significant complications. This technique can be used in neonates with critical PS,
although the complication rate is higher. The effectiveness of balloon valvuloplasty for a
severe dysplastic pulmonary valve is questionable, but it may be attempted. The
procedure is not useful for the treatment of infundibular PS that is not associated with
valvular PS.

**Aortic Valve Stenosis.** This procedure is more difficult and carries a higher
complication rate than does pulmonary valve balloon dilatation, especially for infants.
The gradient reduction is less effective than for the pulmonary valve. Indications for
balloon valvotomy include peak systolic pressure gradients greater than 50 to 60 mm Hg
without significant AR in children and adolescents. Newborns or small infants with
critical valve obstruction are also candidates for the procedure, regardless of the
measured pressure gradient value. Complications include production or worsening of
AR, iliofemoral artery injury and occlusion, ventricular fibrillation, and even death in
small infants. Although the effectiveness of the procedure has been questioned, it may
be tried in discrete membranous subaortic stenosis but not in fibromuscular subaortic
(or “tunnel”) stenosis.

**Mitral Stenosis.** Balloon dilatation valvuloplasty has been effective for rheumatic
mitral stenosis (MS) but less effective for congenital MS. Passage of the balloon catheter
across the atrial septum is necessary. Complications include perforation of the left
ventricle, transient complete AV block, tearing of the anterior leaflet of the mitral valve,
and severe mitral regurgitation.

**Stenosis of Prosthetic Conduits and Valves within Conduits.** The balloon dilatation
procedure may reduce the transconduit gradient across stenotic areas of prosthetic
conduits and across valves contained within conduits.

**Balloon Angioplasty**

Balloon catheters similar to those used in balloon valvuloplasties are used for the relief of
stenosis of blood vessels. Appropriate guidewires are placed beyond the point of
narrowing, and the balloon catheter is placed over the guidewires. The midportion of the
balloon is positioned at the point of narrowing, and the balloon is inflated with diluted
contrast material to relieve the narrowing of vascular structures. This procedure has been
used for COA, PA branch stenosis, and stenosis of the systemic veins. After the balloon
procedure, some blood vessels recoil and do not maintain the dilated caliber of the
vessel.

Endovascular stents are sometimes used to maintain vessel patency after balloon
angioplasty of any vascular structure. The stent prevents recoil of the vessel, providing better acute results and considerably reduced rate of restenosis than with balloon angioplasty alone. The stent is positioned over an angioplasty balloon, and the balloon is inflated after positioning it at an appropriate site. After stent placement, the vascular endothelium grows over the struts over several months, functionally incorporating the stent into the vessel wall. Occasionally, however, the endothelialization may go awry, resulting in a thick neointimal layer causing a functional stenosis. There is also active work in the development of biodegradable stents, which would eliminate some concerns of repeated dilatation in a growing child.

**Recoarctation of the Aorta.** Balloon angioplasty is an extremely useful tool in the management of postoperative residual obstruction of COA. It has become the procedure of choice for patients with this condition, because reoperation carries a significant risk of morbidity and mortality. The procedure’s success rate is close to 80%, and late development of an aortic aneurysm rarely occurs. Some centers use a stent to prevent restenosis (see Chapter 12 for further discussion).

**Native (or Unoperated) Coarctation of the Aorta.** Balloon angioplasty for native unoperated coarctation is controversial. The rate of recoarctation after the balloon procedure appears higher than that after surgery in infants. The complication rate is 17%, with aortic aneurysm formation (both acute and late) occurring in 6% of patients. The long-term effects of the procedure on aneurysm formation are unknown. Therefore, surgery may be a better choice than the balloon procedure for native coarctation. Some centers use a cutting balloon or low-profile stent in very sick infants, which may reduce aneurysm formation.

**Branch Pulmonary Artery Stenosis.** The most frequent use of stents in pediatric patients is to treat peripheral PA stenosis. Peripheral PA stenosis may be seen as an isolated lesion but more commonly as a component of complex cyanotic heart defects. Hypoplastic and stenotic branch PAs are seen with postoperative TOF, pulmonary atresia, and hypoplastic left heart syndrome. Because operative treatment of peripheral PA stenosis is often not possible, attempting the balloon procedure with stent for this condition is well accepted.

The immediate success rate of the balloon procedure is about 60%, but restenosis occurs in a significant number of patients, and aneurysm formation occurs in approximately 3% of patients. High-pressure balloons appears to improve the effectiveness. Vessels resistant to high-pressure balloons respond to either cutting balloon angioplasty alone or that followed by high-pressure ballooning. Cutting balloons have three or four microsurgical blades with a cutting depth of 0.15 mm, which are activated when the balloons are inflated. Use of an intravascular stent has also improved immediate results and may improve the long-term success rate.

**Systemic Venous Stenosis.** For obstructed venous baffles after the Mustard or Senning operation for TGA, the balloon procedure is an attractive alternative. The procedure is inappropriate for stenosis of the pulmonary vein because stenosis recurs in each case.

### Closure Techniques
Various devices have been used for nonsurgical closure of ASD, PDA, and muscular VSD in cardiac catheterization laboratories. All closure devices are delivered through a catheter that goes through long, large sheaths. The sheaths are inserted into the femoral vein, the femoral artery, or both. These nonsurgical devices have the advantages of a short hospital stay, rapid recovery, and no residual thoracic scar. In many centers, these devices and techniques are considered the procedures of choice for ASD, PDA, and collateral arteries.

Atrial Septal Defect. In the past, a double-umbrella device was used to close secundum ASD, but because of fractures of its arms, it has been taken off the market in the United States. Several devices are available, some are approved by the U.S. Food and Drug Administration, and others are in clinical trial stages. In the United States, currently only the Amplatzer septal occluder (AGA Medical) and Helex septal occluder (W. L. Gore and Associates) are approved for closure of secundum ASD.

The use of the closure device may be indicated to close a secundum ASD, measuring 5 mm or more in diameter (but less than 32 mm for the Amplatzer device and less than 18 mm for the Helex device), and there must be at least a 4-mm rim of atrial septal tissue around the defect. The appropriate size of the device allows the connecting stalk to fill the ASD, self-centering the device for a better result. The procedure is performed under general anesthesia under the guide of transesophageal echocardiography. The patient is observed overnight and discharged the next morning. Patients take a baby aspirin daily for 6 months until endothelialization of the device is complete. Follow-up consists of echocardiography and a chest radiograph at 6 months and 1 year. Rare possible complications include infection, arrhythmia, stroke, cardiac perforation, device embolization, and incomplete closure.

Ventricular Septal Defect. Nonsurgical device closure of selected muscular VSDs is possible by using the double-umbrella clamshell (or other devices) when the defect is not too close to cardiac valves. Device closure is not popular for the perimembranous VSD because of the unacceptable rate of postprocedure heart block.

Patent Ductus Arteriosus. A double-umbrella plug has been used outside the United States to close PDA in infants and young children, with a closure rate better than 85%. Recently, less costly coils have become popular in the United States. Most transcatheter PDA closures are now performed using Gianturco vascular occlusion coils. They are small, coiled wires coated with thrombogenic Dacron strands that open like a small “pigtail” when placed in the vessel. When delivered to the aortic ampulla, a blood clot is formed around the coil, obstructing blood flow with ultimate endothelialization. Good candidates for the coil occlusion are children weighing 6 kg and larger with the ductus 4 mm and smaller. The incidence of minor complications is low (less than 5%); complications include coil embolization, incomplete closure, mild left pulmonary artery (LPA) stenosis, and very rarely hemolysis.

For larger PDAs but smaller than 12 mm in diameter, specialized devices, such as the Amplatzer duct occluder, are available for catheter-based closure. The devices are implanted antegrade from the femoral vein. There is a 98% or greater closure rate at 6 months with minimal complications and no mortality. Very large ducti in small infants
are still probably best treated surgically.

**Occlusion of Collaterals and Other Vessels.** This technique is used for closing aortopulmonary collaterals (often seen with TOF), systemic arteriovenous fistulas, pulmonary arteriovenous fistulas, and surgically placed shunts that are no longer needed. The Gianturco coil and the White balloon are examples. When delivered, the coil occludes the vessel by creating a thrombus around the coil. Alternatively, a balloon is placed in a selected spot with an elaborate harpoon-like hydraulic delivery system on a thin catheter. Both devices need a discrete area of stenosis within a tubular vessel for fixation. The vessel should not be larger than 6 to 7 mm in diameter. Peripheral embolization of the coil or balloon into the PAs or the aorta is a major risk.

**Percutaneous Valve Replacement**

Since Bonhoeffer and his colleagues first replaced a pulmonary valve percutaneously in 2000 (Bonhoeffer et al, 2000), this technique is gaining increasing experience. Candidates for this technique are typically patients who received surgery for TOF and late development of severe pulmonary regurgitation. This technique is expected to reduce the need for repeated cardiac surgeries by replacing surgically placed conduits. Most of the reported cases used the Melody transcatheter pulmonary valve (Medtronic, Minneapolis). The Edwards SAPIEN valve (Edwards Lifescience, Irvine, CA) is a new valve with which experience is very limited. This technique has sparked the development of other valve replacement procedures such as transcatheter aortic valve replacement in selected adult patients.
# PART 3
Pathophysiology

## OUTLINE

<table>
<thead>
<tr>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
</tr>
<tr>
<td>8. Fetal and Perinatal Circulation</td>
</tr>
<tr>
<td>9. Pathophysiology of Left-to-Right Shunt Lesions</td>
</tr>
<tr>
<td>10. Pathophysiology of Obstructive and Valvular Regurgitation Lesions</td>
</tr>
<tr>
<td>11. Pathophysiology of Cyanotic Congenital Heart Defects</td>
</tr>
</tbody>
</table>
In this section, discussion of fetal and perinatal circulation and the circulatory changes that take place after birth will be followed by discussion of the pathophysiology of some representative congenital and acquired heart diseases. Knowledge of fetal and perinatal circulation is extremely helpful in understanding the clinical manifestations and natural history of congenital heart diseases (CHDs). A few examples of clinical importance in relation to fetal and perinatal circulation will be examined.

In discussing the pathophysiology of congenital and acquired heart diseases, attempts are made to explain why particular electrocardiographic (ECG) changes, abnormalities in chest radiographs (or echocardiographic study), and physical findings are associated with each defect based on hemodynamic abnormalities. Chamber enlargements are well reflected in chest radiographic films, but pressure overload is not. Although echocardiography and Doppler studies have the capability of demonstrating both pressure and volume overload lesions, an old imaging modality, chest radiographic findings, is used, rather than the new techniques because these new techniques are not available to noncardiologists.

Even when the diagnosis of a heart problem is known, correct understanding of pathophysiology plays an essential role in the appropriate management of cardiac patients, including recognition of important complications, use of medications, timing and types of surgical interventions, and following up with postoperative patients.

As an introduction to pathophysiology, a simplistic approach was chosen and controversies avoided. Careful study of the pathophysiology section will enable readers not only to explain but also recall and predict the physical findings and abnormalities of the ECG and chest radiographic films (or of echocardiography findings) of many cardiac anomalies.
Knowledge of fetal and perinatal circulation is an integral part of understanding the pathophysiology, clinical manifestations, and natural history of CHD, especially anomalies seen in the newborn period. Only a brief discussion of clinically important aspects of fetal and perinatal circulation is presented.
Fetal Circulation

Fetal circulation differs from adult circulation in several ways. Almost all differences are attributable to the fundamental difference in the site of gas exchange. In adults, gas exchange occurs in the lungs. In fetuses, the placenta provides the exchange of gases and nutrients.

Course of Fetal Circulation

There are four shunts in fetal circulation: placenta, ductus venosus, foramen ovale, and ductus arteriosus (Fig. 8-1). The following summarizes some important aspects of fetal circulation:

1. The placenta receives the largest amount of combined (i.e., right and left) ventricular output (55%) and has the lowest vascular resistance in the fetus.
2. The superior vena cava (SVC) drains the upper part of the body, including the brain (15% of combined ventricular output), and the inferior vena cava (IVC) drains the lower part of the body and the placenta (70% of combined ventricular output). Because the blood is oxygenated in the placenta, the oxygen saturation in the IVC (70%) is higher than that in the SVC (40%). The highest $P_o_2$ is found in the umbilical vein (32 mm Hg) (see Fig. 8-1).
3. Most of the SVC blood goes to the right ventricle (RV). About one third of the IVC blood with higher oxygen saturation is directed by the crista dividens to the left atrium (LA) through the foramen ovale, and the remaining two thirds enters the RV and pulmonary artery (PA). The result is that the brain and coronary circulation receive blood with higher oxygen saturation ($P_o_2$ of 28 mm Hg) than the lower half of the body ($P_o_2$ of 24 mm Hg) (see Fig. 8-1).
4. Less oxygenated blood in the PA flows through the widely open ductus arteriosus to the descending aorta and then to the placenta for oxygenation.

Dimensions of Cardiac Chambers

The proportions of the combined ventricular output traversing the heart chambers and the major blood vessels are reflected in the relative dimensions of these chambers and vessels (see Fig. 8-1).

Because the lungs receive only 15% of combined ventricular output, the branches of the PA are small. This is important in the genesis of the pulmonary flow murmur of newborns (see Chapter 2).
The RV is larger and more dominant than the left ventricle (LV). The RV handles 55% of the combined ventricular output, and the LV handles 45% of the combined ventricular output. In addition, the pressure in the RV is identical to that in the LV (unlike in adults). This fact is reflected in electrocardiograms (ECGs) of newborns, which show more RV force than adult ECGs.

**Fetal Cardiac Output**

Unlike the adult heart, which increases its stroke volume when the heart rate decreases, the fetal heart is unable to increase stroke volume when the heart rate falls because it has a low compliance. Therefore, the fetal cardiac output depends on the heart rate; when the
heart rate drops, as in fetal distress, a serious fall in cardiac output results.
Changes in Circulation after Birth

The primary change in circulation after birth is a shift of blood flow for gas exchange from the placenta to the lungs. The placental circulation disappears, and the pulmonary circulation is established.

1. The removal of the placenta results in the following:
   a. An increase in systemic vascular resistance (SVR) results (because the placenta has the lowest vascular resistance in the fetus)
   b. Cessation of blood flow in the umbilical vein results in closure of the ductus venosus

2. Lung expansion results in the following:
   a. A reduction of the pulmonary vascular resistance (PVR), an increase in pulmonary blood flow, and a fall in PA pressure (Fig. 8-2)
   b. Functional closure of the foramen ovale as a result of increased pressure in the LA in excess of the pressure in the right atrium (RA). The RA pressure falls as a result of closure of the ductus venosus
   c. Closure of patent ductus arteriosus (PDA) as a result of increased arterial oxygen

---

**FIGURE 8-2** Changes in pulmonary artery pressure, pulmonary blood flow, and pulmonary vascular resistance during the 7 weeks preceding birth, at birth, and in the 7 weeks after birth. The prenatal data were derived from lambs and the postnatal data from other species. *(From Rudolph AM: Congenital Diseases of the Heart. Chicago, Mosby, 1974.)*
Changes in the PVR and closure of the PDA are so important in understanding many CHDs that further discussion is necessary.

**Pulmonary Vascular Resistance**

The PVR is as high as the SVR near or at term. The high PVR is maintained by an increased amount of smooth muscle in the walls of the pulmonary arterioles and alveolar hypoxia resulting from collapsed lungs. (The role of alveolar hypoxia in increasing pulmonary vascular resistance is further discussed in Chapter 29.)

With expansion of the lungs and the resulting increase in the alveolar oxygen tension, there is an initial, rapid fall in the PVR (Fig. 8-3). This rapid fall is secondary to the vasodilating effect of oxygen on the pulmonary vasculature. Between 6 and 8 weeks after birth, there is a slower fall in the PVR and the PA pressure. This fall is associated with thinning of the medial layer of the pulmonary arterioles. A further decline in the PVR occurs after the first 2 years. This may be related to the increase in the number of alveolar units and their associated vessels.

Many neonatal conditions causing inadequate oxygenation may interfere with the normal maturation (i.e., thinning) of the pulmonary arterioles, resulting in persistent pulmonary hypertension or delay in the fall of PVR (Box 8-1). A few examples of clinical importance follow:

1. Infants with a large ventricular septal defect (VSD) may not develop congestive heart failure (CHF) while living at a high altitude, but they may develop CHF if they move to sea level. This is because of the delayed fall in the PVR associated with high altitudes.
2. Premature infants with severe hyaline membrane disease usually do not develop CHF because of their high PVR, which restricts the left-to-right shunt. Acidosis, which is often present in these infants, may contribute to maintaining a high PVR. CHF may develop as their hyaline membrane disease improves because the resulting increase in arterial $P_{O_2}$ dilates pulmonary vasculature.
In infants with large VSDs, a high PA pressure, resulting from a direct transmission of the LV pressure to the PA through the defect, delays the fall in the PVR. As a result, CHF does not develop until 6 to 8 weeks of age or older. In contrast, the PVR falls normally in infants with a small VSD because direct transmission of the LV pressure to the PA does not occur in this situation.

**Closure of the Ductus Arteriosus**

Functional closure of the ductus arteriosus occurs within 10 to 15 hours after birth by constriction of the medial smooth muscle in the ductus. Anatomic closure is completed by 2 to 3 weeks of age by permanent changes in the endothelium and subintimal layers of the ductus. Oxygen, prostaglandin E₂ (PGE₂) levels, and maturity of the newborn are important factors in closure of the ductus. Acetylcholine and bradykinin also constrict the ductus.

**Oxygen and the Ductus.** A postnatal increase in oxygen saturation of the systemic circulation (from Po₂ of 25 mm Hg in utero to 50 mm Hg after lung expansion) is the strongest stimulus for constriction of the ductal smooth muscle, which leads to closure of the ductus. The responsiveness of the ductal smooth muscle to oxygen is related to the gestational age of the newborn; the ductal tissue of a premature infant responds less intensely to oxygen than that of a full-term infant. This decreased responsiveness of the immature ductus to oxygen is due to its decreased sensitivity to oxygen-induced contraction; it is not the result of a lack of smooth muscle development because the immature ductus constricts well in response to acetylcholine. It may also be due to persistently high levels of PGE₂ in preterm infants (see later section).
Prostaglandin E and the Ductus. A few clinical situations are worth mentioning to show the importance of the PG series in maintaining the patency of the ductus arteriosus in fetuses.

1. A decrease in PGE$_2$ levels after birth results in constriction of the ductus. This decrease results from removal of the placental source of PGE$_2$ production at birth and from the marked increase in pulmonary blood flow, which allows effective removal of circulating PGE$_2$ by the lungs.

2. Constricting effects of indomethacin or ibuprofen and the dilator effects of PGE$_2$ and PGI$_2$ are greater in the ductal tissues of an immature fetus than of a near-term fetus.

3. Prolonged patency of the ductus can be maintained by intravenous infusion of a synthetic PGE$_1$, in newborn infants such as those with pulmonary atresia, whose survival depends on patency of the ductus.

4. Indomethacin or ibuprofen, a cyclooxygenase inhibitor (or “PG synthetase inhibitor”), can be used to close a significant PDA in premature infants (see Chapter 12).

5. Maternal ingestion of a large amount of aspirin, an inhibitor of PG synthetase, may harm fetuses, because the aspirin may constrict the ductus during fetal life and may result in persistent pulmonary hypertension in the newborn (PPHN). It has been suggested that some cases of PPHN (or persistent fetal circulation syndrome) may be caused by a premature constriction of the ductus arteriosus.

Reopening of a Constricted Ductus. Before true anatomic closure occurs, the functionally closed ductus may be dilated by a reduced arterial Po$_2$ or an increased PGE$_2$ concentration. The reopening of the constricted ductus may occur in asphyxia and various pulmonary diseases (as hypoxia and acidosis relax ductal tissues). Ductal closure is delayed at high altitude. There is a much higher incidence of PDA at high altitudes than at sea level. In some newborn infants (e.g., those with coarctation of the aorta) intravenous infusion of PGE$_1$, can open a partially or completely constricted ductus.

Responses of Pulmonary Artery and Ductus Arteriosus to Various Stimuli. The PA responds to oxygen and acidosis in the opposite manner from the ductus arteriosus. Hypoxia and acidosis relax the ductus arteriosus but constrict the pulmonary arterioles. Oxygen constricts the ductus but relaxes the pulmonary arterioles. The PAs are also constricted by sympathetic stimulation and α-adrenergic stimulation (e.g., epinephrine, norepinephrine). Vagal stimulation, β-adrenergic stimulation (e.g., isoproterenol), and bradykinin dilate the PAs.
Two important problems that premature infants may face are related to the rate at which PVR falls and the responsiveness of the ductus arteriosus to oxygen.

The ductus arteriosus is more likely to remain open in preterm infants after birth because premature infants’ ductal smooth muscle does not have a fully developed constrictor response to oxygen. In addition, premature infants have persistently high circulating levels of PGE\(_2\) (caused by decreased degradation in the lungs), and the premature ductal tissue exhibits an increased dilatory response to PGE\(_2\).

In premature infants, the pulmonary vascular smooth muscle is not as well developed as in full-term infants. Therefore, the fall in PVR occurs more rapidly than in mature infants. This accounts for the early onset of a large left-to-right shunt and CHF.
Pathophysiology of Left-to-Right Shunt Lesions

Before discussing the hemodynamic abnormalities of left-to-right shunt lesions, knowledge of the model that will be used throughout this section is helpful. Figure 9-1 is a block diagram of a normal heart in which one arrow represents a “unit” of normal cardiac output. It is assumed that the cardiac chambers and great arteries and veins indicated by one arrow are normal in size. If a cardiac chamber or great artery has more than one arrow in it, that chamber or blood vessel is going to be dilated. A diagram of a normal cardiac roentgenogram is presented in Chapter 4 (see Fig. 4-2). Modifications in appearance of chest roentgenogram secondary to enlargement or reduction of cardiac chambers or great vessels are presented in diagrammatic drawings to aid in the interpretation of chest radiograph films.
Atrial Septal Defect

In acyanotic patients with atrial septal defects (ASDs), the direction of the shunt is from left to right and the magnitude of the left-to-right shunt is determined by the size of the defect and the relative compliance of the right ventricle (RV) and left ventricle (LV). Because the compliance of the RV is greater than that of the LV, a left-to-right shunt is present. The magnitude of the shunt is reflected in the degree of cardiac enlargement. Let it be assumed that there is a left-to-right shunt of one arrow at the atrial level. As seen in Figure 9-2, the right atrium (RA), RV, and main pulmonary artery (PA) and its branches have two arrows and are therefore dilated. These findings are translated into the chest radiographs (Fig. 9-3), which reveal enlargement of the RA, RV, and PA, as well as an increase in pulmonary vascular markings. Note that the left atrium (LA) is not enlarged (see Figs. 9-2 and 9-3). This is because the increased pulmonary venous return to the LA does not stay in that chamber; rather, it is shunted immediately to the RA. The absence of LA enlargement is one of the helpful radiographic signs for differentiating an ASD from a ventricular septal defect (VSD) in patients with increased pulmonary vascularity.

The dilated RV cavity prolongs the time required for depolarization of the RV because of its longer pathway, producing either complete or incomplete right bundle branch block (RBBB) pattern (with rsR' in V1) in the electrocardiogram (ECG). The RBBB pattern in children with ASDs is not the result of actual block in the right bundle. If the duration of the QRS complex is not abnormally prolonged, the ECG may be read as mild right ventricular hypertrophy (RVH). Therefore, either (complete or incomplete) RBBB pattern or mild RVH is seen on the ECG of children with ASD.

The heart murmur in ASD is not caused by the shunt at the atrial level. Because the pressure gradient between the atria is so small and the shunt occurs throughout the cardiac cycle, both in systole and diastole, the left-to-right shunt is silent. The heart murmur in ASD originates from the pulmonary valve because of the increased blood flow (denoted by two arrows) passing through this normal-sized valve, producing a relative stenosis of the pulmonary valve. Therefore, the murmur is systolic in timing and is maximal at the pulmonary valve area (i.e., at the upper left sternal border). When the shunt is large, increased blood flow through the tricuspid valve (denoted by two arrows) results in a relative stenosis of this valve, producing a mid-diastolic murmur at the tricuspid valve area (i.e., lower left sternal border). The widely split S2 that is a characteristic finding in ASD results partly from RBBB. The RBBB delays both the electrical depolarization of the RV and the ventricular contraction, resulting in delayed closure of the pulmonary valve. In addition, the large atrial shunt tends to abolish respiration-related variations in systemic venous return to the right side of the heart, resulting in a fixed S2.

It should be noted that infants and small children rarely manifest with clinical findings described above even in the presence of a moderately large ASD (proved by echocardiographic studies) until they are 3 to 4 years of age. It is because the compliance of the RV improves slowly so that any significant shunt does not occur until that age.
Children with ASD rarely experience congestive heart failure (CHF) even in the presence of a large left-to-right shunt. The PAs can handle an increased amount of blood flow for a long time without developing pulmonary hypertension or CHF because there is no direct transmission of the systemic pressure to the PA, and PA pressure remains normal. However, CHF and pulmonary hypertension eventually develop in the third and fourth decades of life if the shunt is large.

FIGURE 9-1  Block diagram of a normal heart. One arrow represents a unit of normal cardiac output. AO, aorta; LA, left atrium; LV, left ventricle; PA, pulmonary artery; PV, pulmonary vein; RA, right atrium; RV, right ventricle; VC, vena cava.
FIGURE 9-2  Block diagram of an atrial septal defect. The number of arrows in each chamber represents the amount of blood to be handled by that particular chamber. When one redraws the chambers with two arrows larger than normal, one can predict which chambers will be enlarged.

FIGURE 9-3  Diagram of posteroanterior and lateral views of chest roentgenograms. Enlargement of the right atrium (RA) and pulmonary artery (PA) segment and increased pulmonary vascular markings are present in the posteroanterior view. The right ventricular enlargement is best seen in the lateral view. AO, aorta; IVC, inferior vena cava; LA, left atrium; LAA, left atrial appendage; LPA, left pulmonary artery; LV, left ventricle; RPA, right pulmonary artery; RV, right ventricle; SVC, superior vena cava.
Ventricular Septal Defect

The direction of the shunt in acyanotic VSD is left to right. The magnitude of the shunt is determined by the size, not the location, of the defect and the level of pulmonary vascular resistance (PVR). With a small defect, a large resistance to the left-to-right shunt occurs at the defect, and the shunt does not depend on the level of PVR. A decrease in the PVR occurs normally in this situation. With a large VSD, the resistance offered by the defect is minimal, and the left-to-right shunt depends largely on the level of PVR. The lower the PVR, the greater the magnitude of the left-to-right shunt. This type of left-to-right shunt is called a dependent shunt (in contrast to obligatory shunt, to be discussed later in this chapter). Even in the presence of a large VSD in a newborn, the PVR remains elevated, and therefore a large shunt does not occur until the infant reaches 6 to 8 weeks of age, when the shunt increases and CHF may develop.

In a VSD of moderate size, the cardiac chambers or vessels with two arrows enlarge, resulting in enlargement of the main PA, LA, and LV, as well as an increase in pulmonary vascular markings (Fig. 9-4). In VSD, it is the LV that does volume overwork, not the RV. This results in LV enlargement; the RV does not enlarge. Because the shunt of VSD occurs mainly during systole when the RV also contracts, the shunted blood goes directly to the PA rather than remaining in the RV cavity. Therefore, there is no significant volume overload to the RV, and the RV remains relatively normal in size in a VSD with moderate shunt (Figs. 9-4 and 9-5). It should be noted that LA enlargement is present only with VSD but not with ASD. It should also be noted that both VSD and PDA produce an enlargement of the LA and LV.

Figure 9-6 summarizes the hemodynamics of VSDs of varying sizes and helps in the understanding of clinical manifestations. The size of a cardiac chamber directly relates to the amount of blood (or the number of arrows) handled by the chamber. The total number of arrows in the heart diagram also determines the overall size of the heart. Let us examine Figure 9-6 for varying sizes of VSDs.

![Figure 9-4](image)

**Figure 9-4** Block diagram of ventricular septal defect that shows the chambers and vessels that will be enlarged. There is an enlargement of the left atrium and left ventricle. The pulmonary artery is prominent, and the
pulmonary vascularity is increased. Note the absence of right ventricular enlargement (see text for explanation).

With a small VSD, there is only half an arrow coming from the LV to the main PA. In addition, the degree of pulmonary vascular congestion and chamber enlargement is either minimal or too small to result in a significant change in the chest x-ray films (see Fig. 9-6). The degree of volume work imposed on the LV is also too small to produce left ventricular hypertrophy (LVH) on the ECG. The shunt itself produces a heart murmur (regurgitant systolic), and the intensity of the P2 is normal because the PA pressure remains normal.

With a VSD of moderate size, one arrow shunts from the LV to the RV, and all the chambers that are enlarged handle two arrows. Therefore, the degree of cardiomegaly on the radiographic film is significant. The volume overwork done by the LV is significant, so the ECG shows LVH of the “volume overload” type. Although the shunt is large, the RV is not significantly dilated, and the pressure in this chamber is elevated only slightly (see Fig. 9-6). In other words, in a moderate VSD, the RV is not under significant volume or pressure overload; therefore, ECG signs of RVH are absent. As in a small VSD, a heart murmur (regurgitant systolic type) is produced by the left-to-right shunt. The normal-sized mitral valve handles two arrows. This relative mitral stenosis produces a mid-diastolic rumble at the apex. The PA pressure is mildly elevated; therefore, the intensity of the P2 may increase slightly.

With a large VSD, the overall heart size is larger than that seen with a moderate VSD because there is a much greater shunt. Because there is direct transmission of the LV pressure through the large defect to the RV, in addition to a much greater shunt, the RV becomes enlarged and hypertrophied. Therefore, the chest radiograph shows biventricular enlargement, left atrial enlargement, and greatly increased pulmonary
vascularity (see Fig. 9-6). The ECG shows biventricular hypertrophy (BVH) and sometimes left atrial hypertrophy (LAH). A large VSD usually results in CHF in early infancy.

When a large VSD is left untreated, irreversible changes take place in the pulmonary arterioles, producing pulmonary vascular obstructive disease (or Eisenmenger’s syndrome). It may take years to develop this condition. When Eisenmenger’s syndrome occurs, striking changes take place in the heart size, ECG, and clinical findings. Because the PVR is notably elevated at this stage, approaching the systemic level, the magnitude of the left-to-right shunt decreases. This results in removal of the volume overload placed on the LV as well as the LA. Therefore, the size of the LV and the overall heart size decrease, and the ECG evidence of LVH disappears, leaving only RVH because of the persistence of pulmonary hypertension. Although the heart size becomes small, the PA segment remains enlarged because of persistent pulmonary hypertension. In other words, with the development of pulmonary vascular obstructive disease, the heart size returns to normal except for a prominent PA segment, and a pure RVH on the ECG results. A bidirectional shunt causes cyanosis. Because the shunt is small, the loudness of the murmur decreases, or it may even disappear. The S2 is loud and single owing to pulmonary hypertension.

**FIGURE 9-6** Diagrammatic summary of the pathophysiology of ventricular septal defect. Most of the radiographic and electrocardiographic findings can be deduced from this diagram (see text for full description). LAH, left atrial hypertrophy; LVH, left ventricular hypertrophy; LVP, left ventricular pressure; PVR, pulmonary vascular resistance; RVH, right ventricular hypertrophy; RVP, right ventricular pressure.
FIGURE 9-7  Block diagram of the heart in patent ductus arteriosus (PDA). Note the similarities between PDA and ventricular septal defect as to chamber enlargement. There is enlargement of the aorta to the level of the ductus arteriosus.

FIGURE 9-8  Diagrams of the posteroanterior and lateral chest radiographs of patent ductus arteriosus (PDA). Note the similarities between PDA and ventricular septal defect. Abbreviations are the same as those in Figure 9-3.
Patent Ductus Arteriosus

The hemodynamics of PDA are similar to those of VSD. The magnitude of the left-to-right shunt is determined by the resistance offered by the ductus (i.e., diameter, length, and tortuosity) when the ductus is small and by the level of PVR when the ductus is large (i.e., dependent shunt). Therefore, the onset of CHF with PDA is similar to that with VSD.

The chambers and vessels that enlarge are the same as those in VSD except for an enlarged aorta to the level of the PDA (i.e., enlarged ascending aorta and transverse arch), which also handles an increased amount of blood flow (Fig. 9-7). Therefore, in PDA, chest radiographic films show enlargement of the LA and LV, a large ascending aorta and PA, and an increase in pulmonary vascular markings (Fig. 9-8). Although the aorta is enlarged, it usually does not produce an abnormal cardiac silhouette because the ascending aorta does not normally form the cardiac silhouette. Therefore, chest radiographic films of PDA are indistinguishable from those of VSD.

Hemodynamic consequences of PDA are similar to those of VSD. In PDA with a small shunt, the LV enlargement is minimal; therefore, the ECG and chest radiographic findings are close to normal. Because there is a significant pressure gradient between the aorta and the PA in both systole and diastole, the left-to-right shunt occurs in both phases of the cardiac cycle, thereby producing the characteristic continuous murmur of this condition. With a small shunt, the intensity of the P2 is normal because the PA pressure is normal.

In PDA with a moderately large shunt, the heart size is moderately enlarged with increased pulmonary blood flow. The chambers enlarged are the LA, LV, and PA segments. The ECG shows LVH as in moderate VSD. In addition to the characteristic continuous murmur, there may be an apical diastolic flow rumble as a result of relative stenosis of the mitral valve. The P2 slightly increases in intensity if it can be separated from the loud heart murmur.

In a large PDA, marked cardiomegaly and increased pulmonary vascular markings are present. The volume overload is on the LV and LA, which produces LVH and occasional LAH on the ECG. The free transmission of the aortic pressure to the PA produces pulmonary hypertension and RV hypertension, with resulting RVH on the ECG. Therefore, the ECG shows BVH and LAH, as in a large VSD. The continuous murmur is present, with an apical diastolic rumble owing to relative mitral stenosis. The P2 is accentuated in intensity due to pulmonary hypertension.

An untreated large PDA can also produce pulmonary vascular obstructive disease, with a resulting bidirectional (i.e., right-to-left and left-to-right) shunt at the ductus level. The bidirectional shunt may produce cyanosis only in the lower half of the body (i.e., differential cyanosis). As in VSD with Eisenmenger’s syndrome, the heart size returns to normal because of the reduced magnitude of the shunt. The peripheral pulmonary vascularity decreases, but the central hilar vessels and the main PA segment are greatly dilated owing to severe pulmonary hypertension. The ECG shows pure RVH because the LV is no longer under volume overload. Auscultation no longer reveals the continuous
murmur or the apical rumble as a result of the shunt reduction. The S2 is single and loud due to pulmonary hypertension.
During fetal life, the endocardial cushion tissue contributes to the closure of both the lower part of the atrial septum (i.e., ostium primum) and the upper part of the ventricular septum in addition to the formation of the mitral and tricuspid valves. The failure of normal development of this tissue may be either complete or partial. A simple way of understanding the complete form of endocardial cushion defect (ECD) is that the tissue in the center of the heart is missing, with resulting VSD, the primum type of ASD, and clefts in the mitral and tricuspid valves. In the partial form of the defect, only an ASD is present in the ostium primum septum (primum type of ASD), often associated with a cleft in the mitral valve.

Hemodynamic abnormalities of primum-type ASD are similar to those of secundum-type ASD, in which the RA and RV are dilated with increased pulmonary blood flow (Fig. 9-9). These changes are expressed in the chest radiographs (see Fig. 9-3). The cleft mitral valve is usually insignificant from a hemodynamic point of view because blood regurgitated into the LA is immediately shunted to the RA, thereby decompressing the LA. The physical findings are also similar to those of secundum ASD: a widely split and fixed S2, a systolic ejection murmur at the upper left sternal border, and a mid-diastolic rumble of relative tricuspid stenosis at the lower left sternal border. In addition, a systolic murmur of mitral regurgitation (MR) is occasionally present. The ECG findings are also similar: RBBB (with rsR′ in V1) or mild RVH. One exception, which is important in differentiating between the two types of ASDs, is the presence of a “superior” QRS axis or left anterior hemiblock (with the QRS axis in the range of −20 to −150 degrees) in primum-type ASD. The abnormal QRS axis seen in ECD (both partial and complete forms) is not the result of axis deviation or any of the hemodynamic abnormalities mentioned; rather, the abnormal QRS axis occurs as a result of the primary abnormality in the development of the bundle of His and the bundle branches.

Hemodynamic changes seen with complete ECD are the sum of the changes seen in ASD and VSD. There is volume overload of the LA and LV as in VSD and partially due to MR. In addition, it has volume overload of the RA and RV as in ASD (see Fig. 9-9). The result is biventricular enlargement (Fig. 9-10). The magnitude of the left-to-right shunt in complete ECD is determined by the level of PVR (i.e., dependent shunt). The ECG also reflects these changes as BVH and occasional biventricular hypertrophy (BAH). “Superior” QRS axis is also characteristic of ECD as discussed earlier. Physical examination is characterized by a hyperactive precordium and regurgitant systolic murmurs of VSD and MR, loud and narrowly split S2 (because of pulmonary hypertension), apical or tricuspid diastolic rumble (or both), and signs of CHF. Those who survive infancy may develop pulmonary vascular obstructive disease, as already discussed for large VSD and large PDA.
FIGURE 9-9  Hemodynamic changes in different types of endocardial cushion defects (ECD). Hemodynamics of the ostium primum type of atrial septal defect (ASD) are identical to those of the secundum type of ASD. The cleft mitral valve is usually not significant from a hemodynamic point of view, and its effect is not shown here. In complete ECD, the hemodynamic changes are the sum of those of ventricular septal defect (VSD) and ASD, resulting in enlargement of all four cardiac chambers and increased pulmonary blood flow. The shunt depends on the level of the pulmonary vascular resistance (PVR) (e.g., dependent shunt). In the left ventricle–to–right atrial (LV-RA) shunt, the shunt depends not on the level of PVR but on the size of the defect (obligatory shunt). Therefore, congestive heart failure may occur within the first weeks of life. BAH, biatrial hypertrophy; LAHB, left anterior hemiblock; LVH, left ventricular hypertrophy; ↑ PR, prolongation of the PR interval on electrocardiography; RBBB, right bundle branch block; RVH, right ventricular hypertrophy.

<table>
<thead>
<tr>
<th>Cardiomegaly on X-rays</th>
<th>Mild to moderate</th>
<th>Marked</th>
<th>Moderate to marked</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congestive heart failure</td>
<td>Late childhood or adulthood</td>
<td>Within 1–2 months</td>
<td>Within a few weeks</td>
</tr>
<tr>
<td>ECG</td>
<td>↑ PR (±)</td>
<td>↑ PR</td>
<td>↑ PR</td>
</tr>
<tr>
<td></td>
<td>RBBB or RVH</td>
<td>LVH</td>
<td>RVH or RBBB</td>
</tr>
<tr>
<td></td>
<td>BAH (±)</td>
<td>BAH</td>
<td></td>
</tr>
</tbody>
</table>

FIGURE 9-10  Diagrams of chest roentgenograms in the complete form of endocardial cushion defect. All four cardiac chambers are enlarged, with increased pulmonary vascular markings. Abbreviations are the same as those in Figure 9-3.

A direct communication between the LV and RA may occur as part of ECD (or as an isolated defect unrelated to ECD). The direction of the shunt is from the high-pressure LV to the low-pressure RA. The magnitude of the shunt is determined by the size of the defect, regardless of the state of PVR; blood shunted to the RA must go forward through
the lungs even if the PVR is high. This type of shunt, which is independent of the status of PVR, is called an **obligatory shunt** (see Fig. 9-9). When an LV-RA shunt is present as part of complete ECD, CHF may occur within a few weeks, which is earlier than in the usual VSD. The enlarged chambers are identical to those of the complete form of ECD. Therefore, the chest radiographs and ECG findings are similar to those seen in complete ECD. Physical findings also resemble those of complete ECD, although the holosystolic murmur (resulting from the LV-RA shunt) may be more prominent at the mid-right sternal border.
Pathophysiology of Obstructive and Valvular Regurgitation Lesions

This chapter discusses hemodynamic abnormalities of obstructive and valvular regurgitant lesions of congenital and acquired causes. For convenience, they are divided into the following three groups based on their hemodynamic similarities:
1. Ventricular outflow obstructive lesions (e.g., aortic stenosis [AS], pulmonary stenosis [PS], coarctation of the aorta [COA])
2. Stenosis of atrioventricular (AV) valves (e.g., mitral stenosis [MS], tricuspid stenosis [TS])
3. Valvular regurgitant lesions (e.g., mitral regurgitation [MR], tricuspid regurgitation [TR], aortic regurgitation [AR], pulmonary regurgitation [PR])
Obstruction to Ventricular Output

Common congenital obstructive lesions to ventricular output are AS, PS, and COA. All of these obstructive lesions produce the following three pathophysiologic changes (Fig. 10-1):

1. An ejection systolic murmur (as heard on auscultation)
2. Hypertrophy of the respective ventricle (as seen in the electrocardiographic [ECG] or echocardiography study)
3. Poststenotic dilatation (as seen in chest radiographs or echocardiography images) (this is not seen with subvalvular stenosis)

Aortic and Pulmonary Valve Stenoses

An ejection type of systolic murmur can best be heard when the stethoscope is placed over the area distal to the obstruction. Therefore, the murmur of AS is usually loudest over the ascending aorta (i.e., aortic valve area or upper right sternal border), and the murmur of PS is loudest over the pulmonary artery (i.e., pulmonary valve area or upper left sternal border). However, the actual location of the aortic valve is under the sternum at the level of the third left intercostal space; therefore, the murmur of AS may be quite loud at the third left intercostal space.

In isolated stenosis of the pulmonary or aortic valve, the intensity and duration of the ejection systolic murmur are directly proportional to the severity of the stenosis. In mild stenosis of a semilunar valve, the murmur is of low intensity (grade 1 to 2/6) and occurs early in systole, with the apex of the “diamond” in the first half of systole. With increasing severity of the stenosis, the murmur becomes longer and louder (often with a thrill) with the apex of the murmur moving toward the S2.

With mild pulmonary valve stenosis, the S2 is normal or split widely because of prolonged “hangout time” (see Chapter 2). With severe PS, the murmur is long and may continue beyond the A2 and the S2 splits widely, but the intensity of the P2 decreases (Fig. 10-2, A). With severe AS, the S2 becomes single or splits paradoxically because of the delayed closure of the aortic valve (A2) in relation to the P2 (Fig. 10-2, B). In semilunar valve stenosis, an ejection click may be audible. The click is produced by a sudden checking of the valve motion or possibly by the sudden distention of the dilated great arteries.

If the obstruction is severe, the ventricle that has to pump blood against the obstruction will hypertrophy. The left ventricle (LV) hypertrophies in AS and the right ventricle (RV) in PS, which results in left ventricular hypertrophy (LVH) and right ventricular hypertrophy (RVH), respectively, on the ECG. Cardiac output is maintained unless myocardial failure occurs in severe cases; therefore, the heart size remains normal (on chest radiographic films or echo study).

Poststenotic dilatation is the hallmark of a stenosis at the semilunar valve level. The artery distal to the stenotic semilunar valve dilates circumferentially. Poststenotic dilatation is not seen with subvalvular stenosis; it is only mild or not seen at all with
supravalvular stenosis. It was once believed that the jet of blood resulting from the stenosis strikes a localized area of the great artery with weakening of that area causing the dilatation. However, there is a circumferential dilatation of the great artery where the jet does not strike. The current understanding is that sustained vibration of the vessel distal to the narrowing causes generalized fatigue of collagen fibers with resulting dilatation, which may add circumferential dilatation. In pulmonary valve stenosis, a prominent PA segment is visible on chest radiographic film (see Fig. 4-7, A). In aortic valve stenosis, the dilated aorta may look like a bulge on the right upper mediastinum or a prominence of the aortic knob on the left upper mediastinum on chest films (see Fig. 4-7, C). Mild dilatation of the ascending aorta secondary to aortic valve stenosis is usually not visible on plain chest radiographic films because the ascending aorta does not form the cardiac border.

**Coarctation of the Aorta**

In older children with COA, an ejection-type systolic murmur is present over the descending aorta distal to the site of coarctation (i.e., in the left interscapular area). Because many of these patients also have abnormal aortic valves (most commonly bicuspid aortic valves), a soft AS murmur, ejection click, and occasional AR murmur may be heard. Depending on the severity of the obstruction, the femoral pulses are either weak and delayed or absent. The weak pulse results primarily from a slow upstroke of the arterial pulse in the lower extremity sites. On chest radiographs, poststenotic dilatation of the descending aorta (distal to the coarctation) often produces the figure-of-3 sign on the plain film or an E-shaped indentation on the barium esophagogram (see Fig. 4-10). The poststenotic dilatation of the descending aorta distal to the coarctation can be easily imaged by echocardiographic study. The ECG shows LVH because of a pressure overload on the LV. In newborns and small infants, RVH or right bundle branch block (RBBB) is commonly seen, but LVH is not (see later section for the reasons).
Three secondary changes are seen in aortic valve and pulmonary valve stenosis: an ejection systolic murmur, hypertrophy of the responsible ventricle, and poststenotic dilatation of a great artery. A normal-sized ventricle and a great artery are shown by broken lines. The end results of a semilunar valve stenosis are illustrated by solid lines. A similar change occurs with coarctation of the aorta.

Systolic murmurs of pulmonary valve stenosis (PS) (A) and aortic valve stenosis (AS) (B). The duration and intensity of the murmur increase with increasing severity of the stenosis. Note the changes in the splitting of S2 (see text). An ejection click (EC) is present in both conditions. Abnormal heart sounds are shown as black bars.

The coarctation is almost always juxtaductal (i.e., located opposite the entry of the ductus arteriosus). What are the differences in pathology and pathophysiology between symptomatic infants and asymptomatic children with coarctation of the aorta?

1. **Symptomatic newborns with COA**
   Many patients who become symptomatic early in life have an associated defect such as ventricular septal defect (VSD) or left-sided obstructive lesions. The obstructive lesions may be in the left ventricular outflow tract, the aortic valve, or the proximal aorta (see Fig. 10-3, A). These associated defects tend to decrease blood flow to the ascending aorta and to the aortic isthmus (i.e., the segment between the left subclavian artery and the ductus arteriosus) during fetal life. As a result, these structures become relatively hypoplastic.

   These associated anomalies result in more volume work delegated to the RV, which supplies blood to the descending aorta through a large ductus arteriosus. The RV, which is normally dominant, becomes more dilated and hypertrophied, and the LV becomes smaller than normal. This may explain why infants with COA show RVH, rather than LVH, on the ECG. RVH on the ECG is usually replaced with LVH by 2 years of age.

   Decreased flow in the proximal aorta does not produce a pressure gradient between the aortic segments proximal and distal to the coarctation (which is supplied by large PDA). The absence of pressure gradient does not stimulate the development of collateral circulation between the ascending and descending aortas. When the ductus closes after birth, the pressure work imposed on the relatively small LV suddenly increases. This results in a noticeable decrease in the perfusion of the descending aorta (with resulting circulatory shock), renal failure, and signs of left heart failure (i.e., dyspnea and pulmonary venous congestion).

2. **Asymptomatic coarctation of the aorta**
   On the contrary, in the absence of the associated defects, the normal amount of blood
reaching the isthmus area produces a pressure gradient between the aortic segments above and below the coarctation, and it stimulates the development of collateral circulation between them. Most of these infants, who do not have associated defects, tolerate the postnatal closure of the ductus well and remain asymptomatic (see Fig. 10-3, B), although some infants develop LV failure. The ECG will show LVH as expected.

FIGURE 10-3  Diagrammatic comparison of the heart and aorta in symptomatic infants and asymptomatic children with coarctation of the aorta. A, In symptomatic infants, associated defects are frequently found, which include ventricular septal defect, aortic and mitral valve abnormalities, and hypoplasia of the ascending and transverse aortas. These abnormalities are shown in heavy lines. B, In asymptomatic children, the coarctation is usually an isolated lesion except for bicuspid aortic valve (not shown). AO, aorta; LA, left atrium; LV, left ventricle; PA, pulmonary artery; RA, right atrium; RV, right ventricle.
Stenosis of Atrioventricular Valves

Stenosis of the AV valves produces obstruction to pulmonary or systemic venous return. Passive congestion in the pulmonary or systemic venous system cause the clinical manifestations associated with these conditions.

Mitral Stenosis

Stenosis of the mitral valve is more often rheumatic than congenital in origin. It produces a pressure gradient in diastole between the left atrium (LA) and the LV, which in turn produce a series of changes in the structures proximal to the mitral valve (e.g., the LA, pulmonary veins, PAs, and RV). When a significant MS is present, the LA becomes dilated and hypertrophied. The pressure in the LA is raised, which in turn raises pressures in the pulmonary veins and capillaries (Fig. 10-4). Pulmonary edema may result if the hydrostatic pressure in the capillaries exceeds the osmotic pressure of the blood. Therefore, chest radiographs may reveal pulmonary venous congestion or pulmonary edema and enlargement of the LA. Dyspnea with or without exertion and orthopnea may manifest. The high pulmonary capillary pressure results in reflex arteriolar constriction, which in turn causes pulmonary arterial hypertension and eventually hypertrophy of the RV. These changes will be seen as RVH on the ECG and as prominence of the PA segment on chest radiographs. Right heart failure may eventually develop.

The pressure gradient during diastole produces a mid-diastolic rumble that is best heard at the apex on auscultation. When the mitral valve is mobile (not severely stenotic), an opening snap precedes the murmur (see Fig. 21-1). During the last part of diastole, if the pressure gradient still exists between the LA and LV, the LA will contract to push blood forward, producing a presystolic murmur. At the time of the onset of ventricular contraction, the mitral valve leaflets are relatively wide apart due to the prolonged atrial contraction, thereby producing a loud S1. If the cardiac output reduces significantly, thready pulses result. The dilated LA contributes to the frequent occurrence of atrial fibrillation, which may result in the loss of the presystolic murmur.

The following conditions all have in common an elevated pulmonary venous pressure, with similar pathophysiology and must be differentiated from mitral stenosis:
1. Total anomalous pulmonary venous return with obstruction (see Chapter 14)
2. Cor triatriatum (see Chapter 15)
3. Pulmonary vein stenosis (see Chapter 15)
4. Hypoplastic left heart syndrome (see Chapter 14)
5. Left atrial myxoma (see Chapter 22)
Tricuspid Stenosis

Stenosis of the tricuspid valve is rare and usually congenital. It produces dilatation and hypertrophy of the right atrium (RA) for obvious reasons. Therefore, chest radiographs reveal right atrial enlargement, and the ECG may show right atrial hypertrophy (RAH).

Increased pressure in the systemic veins produces hepatomegaly and distended neck veins. A pressure gradient across this valve during diastole produces a mid-diastolic murmur. A prolonged contraction of the RA to push blood through the narrow valve may produce a presystolic murmur.
Valvular Regurgitant Lesions

Important valvular regurgitant lesions are AR and MR. Severe pulmonary valve regurgitation is relatively rare, except in a postoperative state, such as those seen following surgery for tetralogy of Fallot and other conditions that require conduit placement between the RV and the PA. Significant tricuspid valve regurgitation is also rare.

In general, when regurgitation is severe, the chambers both proximal and distal to a regurgitant valve become dilated, with volume overload of these chambers. Whereas with MR both the LV and LA dilate, with AR the LV enlarges and the aorta enlarges or increases its pulsation. If the regurgitation is minimal, only auscultatory abnormalities indicate its presence.

Mitral Regurgitation

The major problem in MR is volume overload of both the LA and LV, with resulting enlargement of these chambers (Fig. 10-5). Therefore, chest radiographs reveal enlargement of the LA and LV, and the ECG may show LVH and left atrial hypertrophy (LAH).

Regurgitation of blood from the LV to the LA produces a regurgitant systolic murmur that is best heard near the apex. Because of an increased amount of blood flows across the mitral orifice during the rapid filling phase of diastole, the S3 is usually loud. When the regurgitation is severe, a mid-diastolic rumble may be present because of “relative” MS that results from handling an excessive amount of left atrial blood through the normal-sized mitral orifice. The dilated LA chamber tends to dampen the transmission of the pressure from the LV, and the pressure in the LA is usually not notably elevated. Therefore, unlike with mitral stenosis, marked pulmonary hypertension occurs only occasionally with mitral regurgitation.

Tricuspid Regurgitation

In tricuspid regurgitation, hemodynamic changes similar to those described for MR result. The RA and RV enlarge for obvious reasons. The ECG may show RAH and RVH (or RBBB).

A systolic regurgitant murmur, a loud S3, and a diastolic rumble develop, as in MR, but they are audible at the tricuspid area (both sides of the lower sternal border) rather than at the apex. With severe regurgitation, pulsation of the liver and neck veins may occur, reflecting a phasic increase in right atrial pressure by the regurgitation.
FIGURE 10-5  Diagrammatic representation of hemodynamic changes in mitral regurgitation. Note that the chambers with two arrows (left atrium [LA] and left ventricle [LV]) are enlarged.
Aortic Regurgitation

There is volume overload of the LV because this chamber must handle normal cardiac output in addition to the amount that leaks back to the LV (Fig. 10-6). This is represented as left ventricular enlargement on radiographs and LVH on the ECG. Because of the increase in stroke volume received by the aorta, the aorta pulsates more than normal and becomes somewhat dilated, although the aorta does not retain all the increased stroke volume.

An increase in systolic pressure results from an increase in stroke volume. The diastolic pressure is lower because of a continuous leak back to the LV during diastole. This results in a wide pulse pressure and bounding peripheral pulse. The regurgitation during diastole produces a high-pitched, decrescendo diastolic murmur immediately after the S2 (see Fig. 21-4). The regurgitant flow is directed toward the apex; therefore, the diastolic decrescendo murmur is well audible at the apex as well as in the third left intercostal space. The AR flow, which coincides with the forward flow of left atrial blood, produces a flutter motion of the mitral valve, producing an Austin-Flint murmur in
diastole. With severe AR, a high left ventricular end-diastolic pressure approximates the mitral valve leaflets at the onset of ventricular systole, resulting in reduced intensity of the S1.

Pulmonary Regurgitation

The pathophysiology of PR is similar to that of AR. The RV dilates, and the PA may enlarge. This is represented in radiographs as right ventricular enlargement and prominence of the PA segment. The ECG may show RVH or RBBB. Because of the low diastolic pressure of the PA, the murmur of PR is low pitched, and the gap between the S2 and the onset of the decrescendo diastolic murmur is wider than that seen in AR. In the presence of pulmonary hypertension, however, the murmur of PR resembles that of AR. The direction of the regurgitation is to the body of the RV; therefore, the PR murmur is audible along the left sternal border rather than at the apex (where the AR murmur is loud). The different direction of the radiation of the diastolic murmur is helpful in differentiating PR from AR.
Pathophysiology of Cyanotic Congenital Heart Defects
Clinical Cyanosis

Detection of Cyanosis

Cyanosis is a bluish discoloration of the skin and mucous membranes resulting from an increased concentration of reduced hemoglobin to about 5 g/100 mL in the cutaneous veins. This level of reduced hemoglobin in the cutaneous vein may result from either desaturation of arterial blood or increased extraction of oxygen by peripheral tissue in the presence of normal arterial saturation (e.g., circulatory shock, hypovolemia, vasoconstriction from cold). Cyanosis associated with desaturation of arterial blood is called central cyanosis; cyanosis with normal arterial oxygen saturation is called peripheral cyanosis.

Cyanosis is more difficult to detect in children with dark pigmentation. Although cyanosis may be detected on many parts of the body, including the lips, fingernails, oral mucous membranes, and conjunctivae, the tip of the tongue is a good place to look for cyanosis; the color of the tongue is not affected by race or ethnic background, and the circulation is not sluggish in the tongue. In a newborn, acrocyanosis may cause confusion. In addition, some newborns are polycythemic, which may contribute to the appearance of cyanosis without arterial desaturation (see later discussion). In older infants and children, chronic subclinical cyanosis produces clubbing.

When in doubt, arterial oxygen saturation should be obtained by a pulse oximeter or arterial \( \text{Po}_2 \) by blood gas determination. Normal \( \text{Po}_2 \) in a 1-day-old infant may be as low as 60 mm Hg. An arterial oxygen saturation of 90% or above does not completely rule out a cyanotic heart defect in a newborn infant. An arterial oxygen saturation of 90% can be seen with a \( \text{Po}_2 \) of 45 to 50 mm Hg in newborns because of the normally leftward oxygen hemoglobin dissociation curve (see later section). In older children and adults, a \( \text{Po}_2 \) of 60 to 65 mm Hg is needed to have 90% oxygen saturation.

Influence of Hemoglobin Level on Cyanosis

The level of hemoglobin greatly influences the occurrence of cyanosis. This effect is graphically illustrated in Figure 11-1. As stated earlier, about 5 g/100 mL of reduced hemoglobin in cutaneous veins is required for the appearance of cyanosis. Normally, about 2 g/100 mL of reduced hemoglobin is present in the venules so that an additional 3 g/100 mL of reduced hemoglobin in arterial blood produces clinical cyanosis. For a normal person with hemoglobin of 15 g/100 mL, 3 g of reduced hemoglobin results from 20% desaturation (because 3 is 20% of 15). Thus, cyanosis appears when the oxygen saturation is reduced to about 80%. Cyanosis is recognized at a higher level of oxygen saturation in patients with polycythemia and at a lower level of oxygen saturation in patients with anemia (see Fig. 11-1). For example, in a person with polycythemia with hemoglobin of 20 g/100 mL, 3 g of reduced hemoglobin results from only 15% desaturation (or at 85% arterial saturation). On the other hand, in a patient with a marked anemia (e.g., hemoglobin of 6 g/100 mL), cyanosis does not appear until arterial
Oxygen saturation is reduced to 50% (3 g of reduced hemoglobin results from 50% desaturation).

**Figure 11-1** Influence of hemoglobin (Hgb) levels on clinical recognition of cyanosis. Cyanosis is recognizable at a higher arterial oxygen saturation in patients with polycythemia and at a lower arterial oxygen saturation in patients with anemia. See text for explanation.

**Box 11-1 Causes of Cyanosis**

**Reduced arterial oxygen saturation (i.e., central cyanosis)**

**Inadequate Alveolar Ventilation**
- Central nervous system depression
- Inadequate ventilatory drive (e.g., obesity, Pickwickian syndrome)
- Obstruction of the airway, congenital or acquired
- Structural changes in the lungs or ventilation–perfusion mismatch (e.g., pneumonia, cystic fibrosis, hyaline membrane disease, pulmonary edema, congestive heart failure)
- Weakness of the respiratory muscles

**Desaturated Blood Bypassing Effective Alveolar Units**
- Intracardiac right-to-left shunt (i.e., cyanotic congenital heart defect)
- Intrapulmonary shunt (e.g., pulmonary arteriovenous fistula, chronic hepatic disease resulting in multiple microvascular fistulas in the lungs)
- Pulmonary hypertension with the resulting right-to-left shunt at the atrial, ventricular, or ductal levels (e.g., Eisenmenger’s syndrome, persistent pulmonary hypertension of the newborn)

**Increased deoxygenation in the capillaries (i.e., peripheral cyanosis)**
Circulatory shock
Congestive heart failure
Acrocyanosis of newborns
Methemoglobinemia
Ingestion of toxic substances (well water, aniline dye)
Congenital methemoglobinemia

Causes of Cyanosis
Cyanosis may result from a number of causes (Box 11-1). Central cyanosis (with reduced arterial oxygen saturation) may be caused by cyanotic congenital heart defects, lung disease, or central nervous system (CNS) depression. Cyanosis of cardiac origin must be diagnosed early for proper management, but the detection of mild cyanosis is not always easy.

Rarely, cyanosis is caused by methemoglobinemia. Methemoglobinemia may occur as a hereditary disorder or be caused by toxic substances. Toxic methemoglobinemia (such as that seen with ingestion of water high in nitrate or exposure to aniline teething gels) is more common than hereditary methemoglobinemia (absence of reductive pathways, or NADH-cytochrome b5 reductase deficiency). When methemoglobin (MHg) levels are greater than 15% of normal hemoglobin, cyanosis is visible, and a level of 70% MHg is lethal. Compensatory polycythemia may occur in this condition. In methemoglobinemia, color of the blood may remain brown even after a full oxygenation or a long exposure to room air.

Acrocyanosis, a bluish color of the fingers seen in neonates and infants, is a form of peripheral cyanosis and reflects sluggish blood flow in the fingers. It has no clinical significance unless associated with circulatory shock. Circumoral cyanosis refers to a bluish skin color around the mouth. This is a form of peripheral cyanosis seen in a healthy child with fair skin because of a sluggish capillary blood flow in association with vasoconstriction. Isolated circumoral cyanosis is of no concern unless it occurs as a result of a low cardiac output.

Cyanosis of Cardiac Versus Pulmonary Origin
Differentiation of cardiac cyanosis from cyanosis caused by pulmonary diseases is crucially important for proper management of cyanotic infants. The hyperoxitest helps differentiate cyanosis caused by cardiac disease from that caused by pulmonary disease. In the hyperoxitest, one tests the response of arterial Po$_2$ to 100% oxygen inhalation. With pulmonary disease, arterial Po$_2$ usually rises to a level greater than 100 mm Hg. When there is a significant intracardiac right-to-left shunt, the arterial Po$_2$ does not exceed 100
mm Hg, and the rise is usually not more than 10 to 30 mm Hg, although some exceptions exist. See Chapter 14 for exceptions and further discussion.

**FIGURE 11-2** Result of hyperoxitest in cyanotic heart defects. **A**, Effect of a right-to-left shunt on the arterial PO$_2$ in room air. The mixing of 1 L blood coming from normal ventilated alveoli (PO$_2$ of 100 mm Hg) with 1 L of venous blood flowing through the cardiac defect (PO$_2$ of 30 mm Hg) results in a significant decrease in arterial PO$_2$ (41 mm Hg). **B**, Effect of a right-to-left shunt on the arterial PO$_2$ in 100% oxygen. The mixing of 1 L of blood coming from normal ventilated alveoli (PO$_2$ of 600 mm Hg) with 1 L of venous blood flowing through the shunt (PO$_2$ of 30 mm Hg) results in arterial PO$_2$ of 46 mm Hg. Breathing 100% oxygen does not significantly influence the hypoxemia because the arterial PO$_2$ increases only from 41 to 46 mm Hg. Note that the oxygen content was calculated using an old number of 1.34 mL (rather than 1.36 mL), which can be bound to 1 g of hemoglobin. See text for a detailed description. (From Duc G: Assessment of hypoxia in the newborn: Suggestions for a practical approach. Pediatrics 48:469-481, 1971.)

**Figure 11-2** explains why breathing 100% oxygen does not significantly increase PO$_2$ in the presence of a right-to-left intracardiac shunt. Figure 11-2, **A**, is a schematic illustration of the effect of a right-to-left shunt on the PO$_2$ while breathing in room air. Assuming a cardiac output of 2 L/min, 1 L of venous blood is distributed to ventilated alveoli, and 1 L is shunted right to left through a cardiac defect. Mixing 1 L of venous blood with an oxygen content of 19.4 mL/100 mL (PO$_2$ of 30 mm Hg) with 1 L of pulmonary venous blood containing 26.3 mL/100 mL (PO$_2$ of 100 mm Hg) results in an oxygen content of 22.8 mL/100 mL. The corresponding PO$_2$ from the dissociation curve is 41 mm Hg. Therefore, mixing 1 L of blood with a PO$_2$ of 100 mm Hg with 1 L of blood with a PO$_2$ of 30 mm Hg results in a PO$_2$ of 41 mm Hg (see Fig. 11-2, **A**), not an arithmetic average of 65 mm Hg. With the patient breathing 100% oxygen (see Fig. 11-2, **B**), the alveolar PO$_2$ becomes 600 mm Hg (with a corresponding oxygen content of 28.6 mL/100 mL, assuming a hemoglobin level of 20 g/100 mL; this figure is derived from 26.8 mg/100 mL of oxygen bound to hemoglobin plus 1.8 mL of oxygen dissolved in plasma [0.003 × 600]). When 1 L of blood with a PO$_2$ of 600 mm Hg (oxygen content 28.6 mg/100 mL) is mixed with 1 L of venous blood with a PO$_2$ of 30 mm Hg (oxygen content of 19.4 mL/100 mL), the resulting oxygen content is 24 mg/100 mL ([28.6 + 19.4]/2), with a corresponding PO$_2$ of 46 mm Hg.
Thus, breathing 100% oxygen does not significantly alter the Po$_2$ (an increase from 41 to 46 mm Hg) even though the alveolar Po$_2$ increases from 100 to 600 mm Hg.

**Hemoglobin Dissociation Curve**

A full understanding of the hyperoxic test and the unique behavior of fetal hemoglobin requires the knowledge of the hemoglobin dissociation curve. The relationship between the Po$_2$ and the amount of oxygen bound to hemoglobin and the relationship between the Po$_2$ and the oxygen dissolved in plasma are different. The relationship is S shaped (sigmoid) for hemoglobin; the relationship is linear for plasma. For dissolved oxygen in plasma, the solubility coefficient is 0.003 mL/100 mL at a Po$_2$ of 1 mm Hg at 37°C (or 0.3 mL of oxygen/100 mL plasma at 100 mm Hg of Po$_2$).

![Hemoglobin Dissociation Curve Diagram](image)

**FIGURE 11-3** Factors that influence the position of the oxygen-hemoglobin dissociation curve. Curve B is from a normal adult at 38°C, pH 7.40, and PCO$_2$ 35.0 mm Hg. Curves A and C illustrate the effect on the affinity for oxygen ($P_{50}$) of variations in temperature (°C), pH, PCO$_2$, 2,3-diphosphoglycerate (DPG), adenosine triphosphate (ATP), methemoglobin (MHg), and carboxyhemoglobin (CO Hb). Curve A is of the newborn. (From Duc G: Assessment of hypoxia in the newborn: Suggestions for a practical approach. Pediatrics 48:469-481, 1971.)

The sigmoid relationship between the Po$_2$ and the amount of oxygen bound to
hemoglobin is expressed by the oxygen-hemoglobin dissociation curve (Fig. 11-3). The \( P_{O_2} \) at which 50% of hemoglobin is saturated has been chosen as the reference point, called \( P_{50} \). The \( P_{50} \) averages 27 mm Hg in adults and 22 mm Hg in fetuses and newborns. The position of the dissociation curve is an expression of the affinity of hemoglobin for oxygen. A newborn’s curve (curve A), with high oxygen affinity, favors the extraction of oxygen from the maternal circulation and suits the conditions of the intrauterine environment, but fetal hemoglobin is “stingy” hemoglobin; it does not allow easy release of oxygen to tissues as in adults. The adult curve (curve B), with a decreased affinity for oxygen, allows the release of more oxygen to tissues. The adult curve is reached by 3 months of age.

The pH, \( P_{CO_2} \), and erythrocyte concentrations of 2,3-diphosphoglycerate (2,3-DPG), adenosine triphosphate (ATP), MHg, and carboxyhemoglobin influence the position of the dissociation curve (see Fig. 11-3).

1. A decrease in hydrogen ion concentration (or increased pH), \( P_{CO_2} \), temperature, 2,3-DPG, and ATP concentrations shifts the curve to the left (curve A).
2. An increase in the above parameters shifts the curve to the right (curve C).
3. Fetal hemoglobin has considerably less affinity for 2,3-DPG (40%) than does the adult hemoglobin. This makes fetal hemoglobin behave as if 2,3-DPG levels are low, thus shifting the curve to the left.
4. The curve shifts to the right in compensation for high altitude, cyanosis, or anemia as a result of an increase in the red cell concentration of 2,3-DPG.

**Consequences and Complications**

1. **Polycythemia.** Low arterial oxygen content stimulates bone marrow through erythropoietin release from the kidneys and produces increased number of red blood cells (RBCs). Polycythemia, with a resulting increase in oxygen-carrying capacity, benefits cyanotic children. However, when the hematocrit reaches 65% or higher, a sharp increase in the viscosity of blood occurs, and the polycythemic response becomes disadvantageous, particularly if the patient has congestive heart failure (CHF). Some cyanotic infants have a relative iron deficiency state, with normal or lower than normal hemoglobin and hypochromia on blood smear. A normal hemoglobin in a cyanotic patient represents a relative iron deficiency state. Although less cyanotic, these infants are usually more symptomatic and improve when iron therapy raises the hemoglobin.

2. **Clubbing.** Clubbing is caused by soft tissue growth under the nail bed as a consequence of central cyanosis. The mechanism for soft tissue growth is unclear. One hypothesis is that megakaryocytes present in the systemic venous blood may be responsible for the change. In normal persons, platelets are formed from the cytoplasm of the megakaryocytes by fragmentation during their passage through the pulmonary circulation. The cytoplasm of megakaryocytes contains growth factors (e.g., platelet-derived growth factor and transforming growth factor B). In patients with right-to-left shunts, megakaryocytes with their cytoplasm may enter the systemic circulation, become trapped in the capillaries of the digits, and release growth factors, which in turn cause
Clubbing usually does not occur until a child is 6 months or older, and it is seen first and is most pronounced in the thumb. In the early stage, it appears as shininess and redness of the fingertips. When fully developed, the fingers and toes become thick and wide and have convex nail beds (see Fig. 2-1). Clubbing is also seen in patients with liver disease or subacute bacterial endocarditis and on a hereditary basis without cyanosis.

3. CNS complications. Either very high hematocrit levels or iron-deficient RBCs place individuals with cyanotic congenital heart defects at risk for disorders of the CNS, such as brain abscess and vascular stroke. In the past, cyanotic congenital heart diseases accounted for 5% to 10% of all cases of brain abscesses. The predisposition for brain abscesses may partially result from the fact that right-to-left intracardiac shunts may bypass the normally effective phagocytic filtering actions of the pulmonary capillary bed. This predisposition may also result from the fact that polycythemia and the consequent high viscosity of blood lead to tissue hypoxia and microinfarction of the brain, which are later complicated by bacterial colonization. The triad of symptoms of brain abscesses are fever, headache, and focal neurologic deficit.

Vascular stroke caused by embolization arising from thrombus in the cardiac chamber or in the systemic veins may be associated with surgery or cardiac catheterization. Cerebral venous thrombosis may occur, often in infants younger than 2 years of age who have cyanosis and relative iron-deficiency anemia. A possible explanation for these findings is that microcytosis further aggravates hyperviscosity resulting from polycythemia.

4. Bleeding disorders. Disturbances of hemostasis are frequently present in children with severe cyanosis and polycythemia. Most frequently noted are thrombocytopenia and defective platelet aggregation. Other abnormalities include prolonged prothrombin time and partial thromboplastin time and lower levels of fibrinogen and factors V and VIII. Clinical manifestations may include easy bruising, petechiae of the skin and mucous membranes, epistaxis, and gingival bleeding. RBC withdrawal from polycythemic patients and replacement with an equal volume of plasma tend to correct the hemorrhagic tendency and lower blood viscosity.

5. Hypoxic spells and squatting. Although most frequently seen in infants with tetralogy of Fallot (TOF), hypoxic spells may occur in infants with other congenital heart defects (see a later section of TOF for further discussion).

6. Scoliosis. Children with chronic cyanosis, particularly girls and patients with TOF, often have scoliosis.

7. Hyperuricemia and gout. Hyperuricemia and gout tend to occur in older patients with uncorrected or inadequately repaired cyanotic heart defects.

The pathophysiology of individual cyanotic heart defects is discussed in the section to follow.
FIGURE 11-4  Circulation pathways of normal “in series” circulation (A) and the “in parallel” circulation of transposition of the great arteries (B). Open arrows indicate oxygenated blood; closed arrows indicate desaturated blood. AO, aorta; LA, left atrium; LV, left ventricle; PA, pulmonary artery; RA, right atrium; RV, right ventricle.

FIGURE 11-5  Diagrammatic presentation of the hemodynamics of transposition of the great arteries with inadequate mixing (A) and with good mixing at the atrial level (B) Numbers within the diagram denote oxygen saturation values, and those outside the diagram denote pressure values. AO, aorta; LA, left atrium; LV, left ventricle; PA, pulmonary artery; PV, pulmonary vein; RA, right atrium; RV, right ventricle; VC, vena cava.
Complete transposition of the great arteries (D-TGA) is the most common cyanotic congenital heart defect in newborns, at least in Western countries. In this condition, the aorta arises from the right ventricle (RV), and the pulmonary artery (PA) arises from the left ventricle (LV). As the result, the normal anteroposterior relationship of the great arteries is reversed, so that the aorta is anterior to the PA (transposition) but the aorta remains to the right of the PA; thus, the prefix D is used for dextroposition. In levotransposition of the great arteries (L-TGA, or congenitally corrected TGA), the aorta is anterior to and to the left of the PA; therefore, the prefix L is used (see Chapter 14). The atria and ventricles are in normal relationship. The coronary arteries arise from the aorta, as in a normal heart. Desaturated blood returning from the body to the right atrium (RA) flows out of the aorta without being oxygenated in the lungs and then returns to the RA. Therefore, tissues, including vital organs such as the brain and heart, are perfused by blood with a low oxygen saturation. Conversely, well-oxygenated blood returning to the left atrium (LA) flows out of the PA and returns to the LA. This results in a complete separation of the two circuits. The two circuits are said to be in parallel rather than in series, as in normal circulation (Fig. 11-4). This defect is incompatible with life unless communication between the two circuits occurs to provide the necessary oxygen to the body. This communication can occur at the atrial, ventricular, or ductal level or at any combination of these levels.

In the most frequently encountered form of D-TGA, only a small communication exists between the atria, usually a patent foramen ovale (PFO) (Fig. 11-5, A). The newborn is notably cyanotic from birth and has an arterial oxygen saturation of 30% to 50%. The low arterial Po$_2$, which ranges from 20 to 30 mm Hg, causes an anaerobic glycolysis, with resulting metabolic acidosis. Hypoxia and acidosis are detrimental to myocardial function. The normal postnatal decrease in pulmonary vascular resistance (PVR) results in increased pulmonary blood flow (PBF) and volume overload to the LA and LV. Severe hypoxia and acidosis (with a resulting decrease in myocardial function) and volume overload to the left side of the heart cause CHF during the first week of life. Therefore, chest radiographs show cardiomegaly and increased pulmonary vascularity. Unless hypoxia and acidosis are corrected, the condition of these infants deteriorates rapidly. Hypoxia and acidosis stimulate the carotid and cerebral chemoreceptors, causing hyperventilation and a low Pco$_2$ in the pulmonary circulation. Other metabolic problems encountered are hypoglycemia, which is probably secondary to pancreatic islet hypertrophy and hyperinsulinism, and a tendency toward hypothermia. The electrocardiogram (ECG) shows right ventricular hypertrophy (RVH), but RVH may be difficult to diagnose in the first days of life because of the normal dominance of the RV at this age. Usually no heart murmur is noted in a neonate with D-TGA, although a murmur is commonly found in other forms of cyanotic heart defects. The S2 is single, mainly because the pulmonary valve is farther from the chest wall, causing the P2 to be
inaudible. A deeply cyanotic newborn with increased pulmonary vascular markings and cardiomegaly without heart murmur can be considered to have TGA until proved otherwise.

**FIGURE 11-6** Diagrammatic presentation of the hemodynamic abnormalities in transposition of the great arteries with a large ventricular septal defect (VSD) (A) and with VSD and pulmonary stenosis. (B) Numbers within the diagram denote oxygen saturation values, and those outside the diagram denote pressure values. Abbreviations are the same as those in Figure 11-5.

The presence of a large atrial septal defect (ASD) is most desirable in infants with TGA. When a large ASD is present, infants have good arterial oxygen saturation (as high as 80% to 90%) because of good mixing (Fig. 11-5, B). Therefore, hypoxia and metabolic acidosis are not the problems in these children. In fact, the idea of the balloon atrial septostomy (Rashkind procedure) was derived from the natural history of infants with TGA and large ASDs. However, the frequency of a large ASD occurring naturally in TGA is low. Infants who have had successful balloon atrial septostomies behave like those with naturally occurring ASDs. As the PVR falls after birth, PBF increases, with an increase in the size of the LA and LV. Although these infants are not hypoxic or acidotic, CHF develops because of volume overload to the left side of the heart. Because the RV is the systemic ventricle, RVH becomes evident on the ECG.

When associated with a large ventricular septal defect (VSD), only minimal arterial desaturation is present, and cyanosis may be missed (Fig. 11-6, A). Therefore, metabolic acidosis does not develop, but left-sided heart failure results within the first few weeks of life as the PBF increases with decreasing PVR. Chest radiographs reflect this, showing cardiomegaly with increased pulmonary vascularity. The ECG may show biventricular hypertrophy (BVH) when the VSD is large: RVH because of the systemic RV and left ventricular hypertrophy (LVH) because of volume overload of the left side of the heart. A heart murmur of VSD is present, and the S2 is single because the P2 is inaudible or pulmonary hypertension is present.

When the VSD is associated with pulmonary stenosis (PS) in infants with TGA, although the VSD helps good mixing, the volume of fully saturated blood returning from the lungs is inadequate (see Fig. 11-6, B). Likewise, even after a well-performed Rashkind procedure, the arterial oxygen saturation does not increase much because of the decreased PBF. These infants have severe hypoxia and acidosis and may succumb early in life. This is a good illustration of how the magnitude of PBF affects the arterial oxygen
saturation in a given cyanotic congenital heart defect. Because PBF is not increased, the left cardiac chambers are not under increased volume work; therefore, cardiac enlargement and CHF do not develop. Chest radiographs, therefore, show normal heart size and normal or decreased pulmonary vascularity. The ECG shows evidence of BVH; LVH is present because of PS, and RVH is present because of the nature of TGA. Physical examination reveals a PS murmur and a single S2 in addition to cyanosis.

**FIGURE 11-7** Diagrammatic presentation of persistent truncus arteriosus (A) and a common form of single ventricle (B). AO, aorta; LA, left atrium; LV, left ventricle; PA, pulmonary artery; PV, pulmonary vein; RA, right atrium; RV, right ventricle; SV, single ventricle; TA, truncus arteriosus; VC, vena cava.

**Persistent Truncus Arteriosus and Single Ventricle**

In persistent truncus arteriosus (Fig. 11-7, A), a single arterial blood vessel (truncus arteriosus) arises from the heart. The PA or its branches arise from the truncus arteriosus, and the truncus continues as the aorta. A large VSD is always present in this condition. In single ventricle (also called “double-inlet ventricle”) (Fig. 11-7, B), two atrioventricular (AV) valves empty into a single ventricular chamber from which a great artery (either the aorta or PA) arises. The other great artery arises from a rudimentary ventricular chamber attached to the main ventricle. The opening between the single ventricle and the rudimentary chamber is called the “bulboventricular foramen.” No ventricular septum of significance is present (see Fig. 14-61).

The following similarities exist between persistent truncus arteriosus and single ventricle from a hemodynamic point of view:
1. There is almost complete mixing of systemic and pulmonary venous blood in the ventricle, and the oxygen saturation of blood in the two great arteries is similar.
2. Pressures in both ventricles are identical.
3. The level of oxygen saturation in the systemic circulation is proportional to the magnitude of PBF.
In addition to the level of PVR, the magnitude of PBF is determined by the caliber of the PA in the case of persistent truncus arteriosus and by the presence or absence of PS and the size of the VSD (i.e., the bulboventricular foramen) in the case of single ventricle. When the PBF is large, the patient is minimally cyanotic but may develop CHF because of an excessive volume overload placed on the ventricle. In contrast, when the PBF is small, the patient is severely cyanotic and does not develop CHF because there is no volume overload. This latter group of patients and those with TOF share similar clinical pictures.

Physical examination reveals varying degrees of cyanosis, depending on the magnitude of PBF. A heart murmur of the VSD is rarely audible because of the presence of a huge defect. There may be an ejection systolic murmur caused by the stenosis of the pulmonary valve or of the PA branches. An early diastolic murmur of truncal valve regurgitation may be heard. The ECG usually shows BVH in both conditions. In single ventricle, the QRS complexes of all precordial leads (i.e., V1–V6) are recorded over one ventricle, and therefore, they are similar (with poor R/S progression), suggestive of BVH. Chest radiographic findings are determined by the magnitude of PBF—if the magnitude of the PBF is large, the heart size is large, and the pulmonary vascularity increases; if the magnitude is small, the heart size is small, and the pulmonary vascularity decreases. With increased PBF and resulting pulmonary hypertension, CHF and later pulmonary vascular obstructive disease (i.e., Eisenmenger’s syndrome) may develop.

**FIGURE 11-8** Hemodynamics of acyanotic (A) and cyanotic (B) tetralogy of Fallot. Numbers within the diagram denote oxygen saturation values, and those outside the diagram denote pressure values. In both conditions, the systolic pressure in the right ventricle (RV) is identical to that in the left ventricle (LV) and the aorta (AO) and there is a significant pressure gradient between the RV and the pulmonary artery (PA). Whereas in the acyanotic form (A), pulmonary blood flow is slightly to moderately increased, in the cyanotic form (B), pulmonary blood flow is decreased. Other abbreviations are the same as those in Figure 11-5.

**Tetralogy of Fallot**

The classic description of TOF includes the following four abnormalities: VSD, pulmonary stenosis (PS), right ventricular hypertrophy (RVH), and overriding of the aorta. From a physiologic point of view, TOF requires only two abnormalities—a VSD large enough to equalize systolic pressures in both ventricles and a stenosis of the right ventricular outflow tract (RVOT) in the form of infundibular stenosis, valvular stenosis, or both. RVH is secondary to PS, and the degree of overriding of the aorta varies widely...
and it is not always present. The severity of the RVOT obstruction determines the direction and the magnitude of the shunt through the VSD. With mild stenosis, the shunt is left to right, and the clinical picture resembles that of a VSD. This is called *acyanotic* or *pink TOF* (Fig. 11-8, A). With a more severe stenosis, the shunt is right to left, resulting in “cyanotic” TOF (Fig. 11-8, B). In the extreme form of TOF, the pulmonary valve is atretic, with right-to-left shunting of the entire systemic venous return through the VSD. In this case, the PBF is provided through a patent ductus arteriosus (PDA) or multiple collateral arteries arising from the aorta. In TOF, regardless of the direction of the ventricular shunt, the systolic pressure in the RV equals that of the LV and the aorta (see Fig. 11-8, A and B). The mere combination of a small VSD and a PS is not TOF; the size of the VSD must be nearly as large as the annulus of the aortic valve to equalize the pressure in the RV and LV.

In *acyanotic TOF*, a small to moderate left-to-right ventricular shunt is present, and the systolic pressures are equal in the RV, LV, and aorta (see Fig. 11-8, A). There is a mild to moderate pressure gradient between the RV and PA, and the PA pressure may be slightly elevated (because of a less severe stenosis of the right ventricular outflow tract). Because the presence of the PS minimizes the magnitude of the left-to-right shunt, the heart size and the pulmonary vascularity increase only slightly to moderately. These increases are indistinguishable from those of a small to moderate VSD. However, unlike VSDs, the ECG always shows RVH because the RV pressure is always high. Occasionally, LVH is also present. The heart murmurs are caused by the PS and the VSD. Therefore, the murmur is a superimposition of an ejection systolic murmur of PS and a regurgitant systolic murmur of a VSD. The murmur is best audible along the lower left and mid-left sternal borders, and it sometimes extends to the upper left sternal border. Therefore, in a child who has physical and radiographic findings similar to those of a small VSD, the presence of RVH or BVH on the ECG should raise the possibility of acyanotic TOF. (A small VSD is associated with LVH or a normal ECG rather than with RVH or BVH). Right aortic arch, if present, confirms the diagnosis. Infants with acyanotic TOF become cyanotic over time, usually by 1 or 2 years of age, and have clinical pictures of cyanotic TOF, including exertional dyspnea and squatting.

**FIGURE 11-9** Comparison of ejection systolic murmurs in tetralogy of Fallot (A) and isolated pulmonary valve stenosis (B) (see text). EC, ejection click.
In infants with classic cyanotic TOF, the presence of severe PS produces a right-to-left shunt at the ventricular level (i.e., cyanosis) with decreased PBF (see Fig. 11-8, B). The PAs are small, and the LA and LV may be slightly smaller than normal because of a reduction in the pulmonary venous return to the left side of the heart. Therefore, chest radiograph films show a normal heart size with decreased pulmonary vascularity. The systolic pressures are identical in the RV, LV, and aorta. The ECG demonstrates RVH because of the high pressure in the RV. The right-to-left ventricular shunt is silent, and that the heart murmur audible in this condition originates in the PS (ejection-type murmur). The ejection systolic murmur is best audible at the mid-left sternal border (over the infundibular stenosis) or occasionally at the upper left sternal border (in patients with pulmonary valve stenosis). The intensity and the duration of the heart murmur are proportional to the amount of blood flow through the stenotic valve. When the PS is mild, a relatively large amount of blood goes through the stenotic valve (with a relatively small right-to-left ventricular shunt), thereby producing a loud, long systolic murmur (Fig. 11-9, A). However, with severe PS, there is a relatively large right-to-left ventricular shunt that is silent, and only a small amount of blood goes through the PS, thereby producing a short, faint systolic murmur (see Fig. 11-9, A). In other words, the intensity and duration of the systolic murmur are inversely related to the severity of the PS. These findings are in contrast to those seen in isolated PS (Fig. 11-9, A and B). Because of low pressure in the PA, the P2 is soft and often inaudible, resulting in a single S2. The heart size on chest radiograph films is normal in TOF because none of the heart chambers handle an increased amount of blood. If a cyanotic infant has a large heart on the chest radiograph films, especially with an increase in pulmonary vascularity, TOF is extremely unlikely unless the child has undergone a large systemic-to-PA shunt operation. Another important point is that an infant with TOF does not develop CHF. This is because no cardiac chamber is under volume overload, and the pressure overload placed on the RV (not higher than the aortic pressure, which is under baroreceptor control) is well tolerated.

The extreme form of TOF is that associated with pulmonary atresia, in which the only source of PBF is through a constricting PDA or through multiple aortic collateral arteries (feeding into pulmonary arteries). All systemic venous return is shunted right to left at the ventricular level, resulting in a marked systemic arterial desaturation. Probably the more important reason for such severe cyanosis is the markedly reduced PBF, with resulting reduction of pulmonary venous return to the left side of the heart. Unless the patency of the ductus is maintained, the infant may die. Infusion of prostaglandin E1 has been successful in keeping the ductus open in this and other forms of cyanotic congenital heart defects that rely on the patency of the ductus arteriosus for PBF. Heart murmur is absent, or a faint murmur of PDA is present. RVH is present on the ECG as in other forms of TOF. Chest radiographs show a small heart and a markedly reduced PBF.
It is important to understand what determines the amount of PBF, which in turn determines the degree of cyanosis, in patients with TOF because this concept relates to the mechanism of the “hypoxic” spell of TOF. Because the VSD of TOF is large enough to equalize systolic pressures in both ventricles, the RV and LV may be viewed as a single chamber that ejects blood to the systemic and pulmonary circuits (Fig. 11-10). The ratio of flows to the pulmonary and systemic circuits (Qp/Qs) is related to the ratio of resistance offered by the right ventricular outflow obstruction (shown as pulmonary resistance [PR] in Fig. 11-10) and the systemic vascular resistance (SVR). Either an increase in the pulmonary resistance or a decrease in the SVR will increase the degree of the right-to-left shunt, producing a more severe arterial desaturation. On the contrary, more blood passes through the right ventricular outflow obstruction when the SVR increases or when the pulmonary resistance decreases. Although controversies exist over the role of the spasm of the RVOT as an initiating event for the hypoxic spell, there is no evidence that the spasm actually occurs as a primary event. Pulmonary valve stenosis has a fixed resistance and does not produce spasm. The infundibular stenosis, which consists of disorganized
muscle fibers intermingled with fibrous tissue, is almost nonreactive to sympathetic stimulation or catecholamines. Hypoxic spell also occurs in patients with TOF with pulmonary atresia in which the presence or absence of spasm would have no role in the spell. Therefore, it is more likely that changes in the SVR plays a primary role in controlling the degree of the right-to-left shunt and the amount of PBF. A decrease in the SVR increases the right-to-left shunt and decreases the PBF with a resulting increase in cyanosis. In this case, the RVOT dimension may decrease, but it is likely secondary to the decreased amount of blood flowing through it rather than primary spasm. Conversely, an increase in SVR decreases the right-to-left shunt and forces more blood through the stenotic RVOT. This results in an improvement in the arterial oxygen saturation. Therefore, the likelihood of the RVOT spasm initiating the right-to-left shunt is remote. Also, excessive tachycardia or hypovolemia can increase the right-to-left shunt through the VSD, resulting in a fall in the systemic arterial oxygen saturation. The resulting hypoxia can initiate the hypoxic spell. Tachycardia or hypovolemia may narrow down the RVOT, and hypovolemia with reduction of blood pressure can initiate a hypoxic spell by increasing right-to-left ventricular shunt. Slowing of the heart rate by β-adrenergic blockers, volume expansion, or interventions that increase the SVR have all been used to terminate the hypoxic spell.

The hypoxic spell, also called the cyanotic spell, tet spell, or hypercyanotic spell, occurs in young infants with TOF. It consists of hyperpnea (i.e., rapid and deep respiration), worsening cyanosis, and disappearance of the heart murmur. This occasionally results in complications of the CNS and even death. Any event such as crying, defecation, or increased physical activity that suddenly lowers the SVR or produces a large right-to-left ventricular shunt may initiate the spell and, if not corrected, establishes a vicious circle of hypoxic spells (Fig. 11-11). The sudden onset of tachycardia or hypovolemia can also cause the spell as discussed earlier. The resulting fall in arterial $\text{Po}_2$, in addition to an increase in $\text{Pco}_2$ and a fall in pH, stimulates the respiratory center and produces hyperpnea. The hyperpnea, in turn, makes the negative thoracic pump more efficient and results in an increase in the systemic venous return to the RV. In the presence of fixed resistance at the RVOT (i.e., pulmonary resistance) or decreased SVR, the increased systemic venous return to the RV must go out the aorta. This leads to a further decrease in the arterial oxygen saturation, which establishes a vicious circle of hypoxic spells (see Fig. 11-11).
FIGURE 11-11 Mechanism of hypoxic spell. A decrease in the arterial $P_O_2$ stimulates the respiratory center, and hyperventilation results. Hyperpnea increases systemic venous return. In the presence of a fixed right ventricular outflow tract (RVOT), the increased systemic venous return results in increased right-to-left (R-L) shunt, worsening cyanosis. A vicious circle is established. SVR, systemic vascular resistance.

Treatment of hypoxic spells is aimed at breaking this circle by using one or more of the following maneuvers:
1. Picking up the infant in such a way that the infant assumes the knee–chest position and traps systemic venous blood in the legs, thereby temporarily decreasing systemic venous return and helping to calm the baby. The knee–chest position may also increase SVR by reducing arterial blood flow to the lower extremities.
2. Morphine sulfate suppresses the respiratory center and abolishes hyperpnea.
3. Sodium bicarbonate ($NaHCO_3$) corrects acidosis and eliminates the respiratory center-stimulating effect of acidosis.
4. Administration of oxygen may slightly improve arterial oxygen saturation.
5. Vasoconstrictors such as phenylephrine raise SVR and improve arterial oxygen saturation.
6. Ketamine is a good drug to use because it simultaneously increases SVR and sedates the patient. Both effects are known to help terminate the spell.
7. Propranolol has been used successfully in some cases of hypoxic spell, both acute and chronic. Its mechanism of action is not entirely clear. When administered for acute cases, propranolol may slow the heart rate and perhaps reduce the spasm of the RVOT (although not likely as discussed earlier). More important, propranolol may also increase SVR by antagonizing the vasodilating effects of β-adrenergic stimulation. The successful
use of propranolol in the prevention of hypoxic spells is more likely the result of the drug’s peripheral action. The drug may stabilize vascular reactivity of the systemic arteries, thereby preventing a sudden decrease in SVR (see Chapter 14).

Infants and toddlers with untreated TOF often assume a squatting position after playing hard. During playing, these infants become tachypneic and dusky. When they assume a squatting position and rest a little while, these symptoms disappear, and then they resume playing. What is the mechanism of recovery from these symptoms during squatting? The squatting position is the same as the knee–chest position (which is used to treat hypoxic spells). Squatting or the knee–chest position increases systemic arterial oxygen saturation as shown in an experimental study (Fig. 11-12). Three mechanisms may be involved. First, reduction of the systemic venous return by trapping venous blood in the lower extremities reduces right-to-left shunt at the ventricular level (evidenced by a reduced arterial lactate levels in Fig. 11-12). Second, a reduced arterial blood flow to the legs reduces venous washout from the leg muscles. Third, squatting might also increase SVR, a known mechanism to reduce right-to-left ventricular shunt.

**Tricuspid Atresia**

In tricuspid atresia, the tricuspid valve and a portion of the RV do not exist (Fig. 11-13). Because no direct communication exists between the RA and RV, systemic venous return to the RA must be shunted first to the LA through an ASD or PFO. There is usually a VSD (or PDA) for the pulmonary arteries to receive some blood for survival. For the right-to-left shunt to occur, the RA pressure is elevated in excess of the LA pressure, and enlargement of the RA results (i.e., right atrial hypertrophy [RAH] on the ECG and right atrial enlargement on chest radiographs). The LA and LV receive both systemic and pulmonary venous returns and thereby dilate (i.e., enlargement of the LA and LV on chest radiographs). The volume overload placed on the LV is unopposed by the hypoplastic RV, with resulting LVH on the ECG. Therefore, the ECG shows RAH and LVH, and the chest radiographs show an enlargement of the RA, LA, and LV. In addition, a “superior” QRS axis is a characteristic ECG finding in tricuspid atresia, as in endocardial cushion defect. Embryologically there is a similarity between these two defects; tricuspid atresia results from an abnormal development of the endocardial cushion tissue, that is, an incomplete shift of the common atrioventricular (AV) canal to the right. Developmental abnormalities in the endocardial cushion tissue may explain the similar QRS axis in both conditions.
Oxygen saturation values are equal in the aorta and the PA because there is a complete mixing of systemic and pulmonary venous blood in the LV, from which both the systemic and the pulmonary circulations receive blood. The level of arterial saturation directly relates to the magnitude of PBF. Anatomically, the great arteries are normally related in about 70% of cases and transposed in about 30% of cases (Fig. 11-13, A and B). In patients with normally related great arteries (see Fig. 11-13, A), the PBF is generally reduced because it comes through a small VSD, hypoplastic RV, or small PAs. Therefore, arterial oxygen saturation is low, and the infant is notably cyanotic. In infants with transposed great arteries (see Fig. 11-13, B) the PBF is usually increased. Therefore, these infants are only mildly cyanotic; their heart size is large, and their pulmonary vascular markings are increased. However, because of an interplay of other factors such as the size of the VSD, the presence or absence of PS or pulmonary atresia, as well as the patency of the ductus
arteriosus, some infants with normally related great arteries may have increased PBF, and some infants with TGA may have decreased PBF. The magnitude of PBF determines not only the level of arterial oxygen saturation but also the degree of enlargement of the cardiac chambers.

No physical findings are characteristic of tricuspid atresia. These infants have varying degrees of cyanosis, and most have a heart murmur of VSD. A PS murmur, if present, is characteristic. In patients with increased PBF, an increased amount of blood passing through the mitral valve may produce an apical diastolic rumble. The liver may be enlarged because of increased pressure in the RA, which may result from an inadequate interatrial communication or heart failure.

In summary, tricuspid atresia is the most likely diagnosis if a cyanotic infant has an ECG that shows a “superior” QRS axis, RAH, and LVH and chest radiographic films that show enlargement of the RA (with or without left atrial enlargement), a concave PA segment, and decreased pulmonary vascularity.

**Pulmonary Atresia**

In pulmonary atresia, direct communication between the RV cavity and the PA does not exist; the PDA (or collateral arteries) is the major source of blood flow to the lungs. The systemic venous return to the RA must go to the LA through an ASD or a PFO. The RA enlarges and hypertrophies to maintain a right-to-left atrial shunt (resulting in right atrial enlargement on radiographic films and RAH on the ECG). The RV is usually hypoplastic with a thick ventricular wall, but occasionally the RV is normal in size; tricuspid regurgitation (TR) is usually present in the latter situation. Systemic and pulmonary venous returns mix in the LA and go to the LV to supply the body and the lungs (Fig. 11-14). The volume load placed on the left side of the heart (i.e., LA and LV) is proportionally related to the magnitude of PBF. Because the PDA is the major source of PBF and it may close after birth, the PBF is usually decreased. When multiple collateral arteries are the only source of PBF, they are usually not adequate and PBF is reduced. Therefore, the infant is severely cyanotic, and the overall heart size is normal or only slightly increased. The hypoplasia of the RV and possible volume overload to the LV produce LVH on the ECG.

The infant is usually notably cyanotic, and the S2 is single because there is only one semilunar valve to close. A faint, continuous murmur of PDA may be present. Closure of the ductus results in a rapid deterioration of the infant’s condition unless there are enough collateral arteries supplying PBF. Reopening or maintaining the patency of the ductus arteriosus with infusion of prostaglandin E₁ increases the PBF, improves cyanosis, and stabilizes the infant’s condition.
In summary, a severely cyanotic newborn with decreased pulmonary vascularity and normal or slightly enlarged heart size on chest radiographic films and RAH or biatrial hypertrophy (BAH) and LVH on the ECG may have pulmonary atresia. The QRS axis is usually normal, in contrast to the “superior” QRS axis seen in tricuspid atresia. Either a faint, continuous murmur of PDA or a soft regurgitant systolic murmur of TR may be present.

**Total Anomalous Pulmonary Venous Return**

In total anomalous pulmonary venous return (TAPVR), the pulmonary veins drain abnormally to the RA, either directly or indirectly through its venous tributaries. An ASD is usually present to send blood from the RA to the LA and LV. Depending on the drainage site, TAPVR may be divided into the following three types (see Fig. 14-30):

1. **Supracardiac:** The common pulmonary vein drains to the superior vena cava through the vertical vein and the left innominate vein.
2. **Cardiac:** The pulmonary veins empty into the RA directly or indirectly through the coronary sinus.
3. **Infracardiac (or subdiaphragmatic):** The common pulmonary vein traverses the diaphragm and drains into the portal or hepatic vein or the inferior vena cava.
Physiologically, however, TAPVR may be divided into two types, obstructive and nonobstructive, depending on the presence or absence of an obstruction to the pulmonary venous return. The infracardiac type is usually obstructive, and the majority of the cardiac and supracardiac types are nonobstructive.

The hemodynamics of the nonobstructive types of TAPVR are similar to those of a large ASD. The amount of blood that goes to the LA through the ASD, rather than to the RV, is determined by the size of the interatrial communication and the relative compliance of the ventricles. Because right ventricular compliance normally increases after birth, with a rapid fall in PVR, and the ASD may be inadequate in size, more blood enters the RV than the LA. Thus, volume overload of the right side of the heart and the pulmonary circulation results, with enlargement of the RA, RV, PA, and pulmonary veins (Fig. 11-15, A). Chest radiographs show this as an enlargement of the RA and RV, a prominent PA segment, and increased pulmonary vascular markings. The pressures in the RA, RV, and PA are slightly elevated. The ECG shows right bundle branch block or RVH, as in secundum ASD, and occasional RAH. Because there is complete mixing of systemic and pulmonary venous blood in the RA, oxygen saturation values are almost identical in the aorta and the PA. Cardiac examination reveals an ejection systolic murmur of PS (at the upper left sternal border) and a diastolic murmur of tricuspid stenosis, because the pulmonary and tricuspid valves handle three arrows (see Fig. 11-15, A). The S2 splits widely for the same reasons as it does for ASD. This contributes to the characteristic “quadruple” rhythm of TAPVR, which consists of an S1, a widely split S2, and an S3 or S4. Children with large PBF are only minimally desaturated, and cyanosis is often missed because the arterial oxygen saturation ranges from 85% to 90% (see Fig. 11-15, A).

If there is an obstruction to the pulmonary venous return, the hemodynamic consequences are notably different from those without pulmonary venous obstruction. The obstruction to the pulmonary venous return causes pulmonary venous hypertension and secondary PA and RV hypertension (see Fig. 11-15, B), a situation similar to that seen.
in mitral stenosis (see Fig. 10-4). Pulmonary edema results when the hydrostatic pressure in the capillaries exceeds the osmotic pressure of the blood. As long as a large ASD permits a right-to-left shunt, the RV cavity remains relatively small (i.e., smaller than one arrow). This is because the RV hypertension prevents the RV compliance from increasing, and the PVR remains elevated. Therefore, chest radiographs show a relatively small heart and characteristic patterns of pulmonary venous congestion or pulmonary edema (i.e., “ground-glass” appearance). The ECG reflects the high pressure in the RV (i.e., RVH).

The oxygen saturation values are equal in the aorta and the PA because of the complete mixing of systemic and pulmonary venous return at the RA level, and the arterial saturation is much lower than that found in patients without obstruction. The degree of arterial desaturation or cyanosis inversely relates to the amount of PBF. Infants with obstruction have severe cyanosis and respiratory distress. The latter results from pulmonary edema and may cause pulmonary crackles on auscultation. The pulmonary valve closure sound (P2) is loud because of pulmonary hypertension, which results in a single, loud S2. The heart murmur may be absent or soft because of normal or decreased flow through the pulmonary or tricuspid valve (i.e., smaller than one arrow) (see Fig. 11-15, B).

Full comprehension of the relationship between the magnitude of PBF and the systemic arterial oxygen saturation helps in understanding and managing most cyanotic congenital heart defects. The two extreme examples of TAPVR shown in Figure 11-15 discuss this relationship.

If the PBF is three times as great as the systemic blood flow (i.e., Qp/Qs = 3:1), as in most nonobstructive cases (see Fig. 11-15, A), the arterial oxygen saturation is close to 90%, and cyanosis does not become obvious. This figure is derived as follows. An assumed pulmonary vein saturation of 96% and a vena caval saturation of 60% result in an average mixed venous saturation of 87%. Of course, the aortic saturation will be 87% in this case.

\[
\text{Arterial saturation} = 90\% \\
\text{Venous saturation} = 87\%
\]

The difference in the arterial and venous oxygen saturation is kept at 27% to indicate the absence of heart failure (see Fig. 11-15, A).

If an obstruction to the pulmonary venous return exists and the PBF is small, a marked arterial desaturation results, based on the following calculation. It assumed that the PBF is 70% of the systemic flow (i.e., Qp/Qs = 0.7:1) and the pulmonary vein saturation is 96%. The RA saturation (and thus the aortic saturation) will be 56%.

\[
\text{Arterial oxygen saturation} = 56\% \\
\text{Venous saturation} = 96\%
\]

It is also assumed that the infant is not experiencing heart failure (i.e., the systemic AV difference is 28%) (see Fig. 11-15, B).

This relationship holds true for other forms of cyanotic congenital heart defects. For a given defect, an increase in the magnitude of PBF results in a rise in the systemic arterial
oxygen saturation; a decrease in PBF results in a decrease in the arterial oxygen saturation. An improvement in cyanosis after a systemic-to-PA shunt operation in a cyanotic infant with decreased PBF is an example of this relationship. (Of course, in infants with obstructive pulmonary venous return, a systemic-to-PA shunt operation is not the right operation; it make the situation worse.) Conversely, infants with a single ventricle may be in CHF from a large PBF but not be cyanotic. CHF improves after a PA banding operation (which decreases PBF and lowers PA pressure), but the arterial oxygen saturation usually decreases, and cyanosis may appear.
## PART 4
Specific Congenital Heart Defects

### OUTLINE

<table>
<thead>
<tr>
<th>Introduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>12. Left-to-Right Shunt Lesions</td>
</tr>
<tr>
<td>13. Obstructive Lesions</td>
</tr>
<tr>
<td>14. Cyanotic Congenital Heart Defects</td>
</tr>
<tr>
<td>15. Miscellaneous Congenital Cardiac Conditions</td>
</tr>
<tr>
<td>16. Vascular Ring</td>
</tr>
<tr>
<td>17. Chamber Localization and Cardiac Malposition</td>
</tr>
</tbody>
</table>
Specific Congenital Heart Defects

The next three chapters discuss common left-to-right shunt lesions, obstructive lesions, and cyanotic cardiac defects. Other chapters in this part discuss aortic arch anomalies, primarily “vascular ring” and cardiac malposition. Miscellaneous, rare anomalies that do not belong to these categories are briefly discussed in another chapter. These chapters are intended to be used as a quick reference; therefore, descriptions are brief.
This chapter discusses common left-to-right shunt lesions such as atrial septal defect (ASD), ventricular septal defect (VSD), patent ductus arteriosus (PDA), endocardial cushion defect (ECD), and partial anomalous pulmonary venous return (PAPVR).
Atrial Septal Defect

Prevalence

Atrial septal defect (ostium secundum defect) occurs as an isolated anomaly in 5% to 10% of all congenital heart defects (CHDs). It is more common in females than in males (male-to-female ratio of 1:2). About 30% to 50% of children with CHDs have an ASD as part of the cardiac defect.

Pathology

1. Three types of ASDs exist: secundum defect, primum defect, and sinus venosus defect. Patent foramen ovale (PFO) does not ordinarily produce intracardiac shunts (see Chapter 15).
2. Ostium secundum defect is the most common type of ASD, accounting for 50% to 70% of all ASDs. This defect is present at the site of fossa ovalis, allowing left-to-right shunting of blood from the left atrium (LA) to the right atrium (RA) (Fig. 12-1). Anomalous pulmonary venous return is present in about 10% of cases.
3. Ostium primum defects occur in about 30% of all ASDs, if those that occur as part of complete ECD are included (see Fig. 12-1). Isolated ostium primum ASD occurs in about 15% of all ASDs. This is discussed in greater detail in the section on partial ECD.
4. Sinus venosus defect occurs in about 10% of all ASDs. The defect is most commonly located at the entry of the superior vena cava (SVC) into the RA (superior vena caval type) and rarely at the entry of the inferior vena cava (IVC) into the RA (inferior vena caval type). The former is commonly associated with anomalous drainage of the right upper pulmonary vein (into the RA), and the latter is often associated with anomalous drainage of the right lung into the IVC (“scimitar syndrome”) (see Chapter 15).
5. In coronary sinus ASD, there is a defect in the roof of the coronary sinus and the LA blood shunts through the defect and empties into the RA through the coronary sinus ostium, producing clinical pictures similar to other types of ASDs.
6. Mitral valve prolapse (MVP) occurs in 20% of patients with either ostium secundum or sinus venosus defects.

Clinical Manifestations

History

Infants and children with ASDs are usually asymptomatic.

Physical Examination (Fig. 12-2)

1. A relatively slender body build is typical. (The body weight of many is less than the 10th percentile.)
2. A widely split and fixed S2 and a grade 2 to 3 of 6 systolic ejection murmur are characteristic findings of ASD in older infants and children. With a large left-to-right shunt, a mid-diastolic rumble resulting from relative tricuspid stenosis may be audible at the lower left sternal border.

3. Classic auscultatory findings (and electrocardiographic [ECG] and radiography...
findings) of ASD are not present unless the shunt is reasonably large (at least Qp/Qs of 1.5 or greater). The typical auscultatory findings may be absent in infants and toddlers, even in those with a large defect because the RV is poorly compliant.

**Electrocardiography (Fig. 12-3)**

Right axis deviation of +90 to +180 degrees and mild right ventricular hypertrophy (RVH) or right bundle branch block (RBBB) with an rsR' pattern in V1 are typical ECG findings. In about 50% of patients with sinus venosus ASD, the P axis is less than +30 degrees.

**Radiography Studies (Fig. 12-4)**

1. Cardiomegaly with enlargement of the RA and right ventricle (RV) may be present.
2. A prominent pulmonary artery (PA) segment and increased pulmonary vascular markings are seen when the shunt is significant.

![](image)

**FIGURE 12-4** Posteroanterior and lateral views of chest roentgenograms from a 10-year-old child with atrial septal defect. The heart is mildly enlarged with involvement of the right atrium (best seen in the posteroanterior view) and the right ventricle (best seen in the lateral view with obliteration of the retrosternal space). Pulmonary vascularity is increased, and the main pulmonary artery segment is slightly prominent.

![](image)

**FIGURE 12-5** Diagram of two-dimensional echocardiography of the three types of atrial septal defects (ASDs). The subcostal transducer position provides the most diagnostic view. **A**, Sinus venosus defect. The defect is located in the posterosuperior atrial septum, usually just beneath the orifice of the superior vena cava. This defect is often associated with partial anomalous return of the right upper pulmonary vein. **B**, Secundum ASD. The defect is located in the middle portion of the atrial septum. **C**, Primum ASD. The defect is located in the anteroinferior atrial septum, just over the inflow portion of each atrioventricular valve. LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle.

**Echocardiography**
1. A two-dimensional echocardiographic study is diagnostic. The study shows the position as well as the size of the defect, which can best be seen in the subcostal four-chamber view (Fig. 12-5). In secundum ASD, a dropout can be seen in the midatrial septum. The primum type shows a defect in the lower atrial septum; the SVC type of sinus venosus defect shows a defect in the posterosuperior atrial septum.

2. Indirect signs of a significant left-to-right atrial shunt include RV enlargement and RA enlargement, as well as dilated PA, which often accompanies an increased flow velocity across the pulmonary valve. These findings indicate the functional significance of the defect.

3. Pulsed Doppler examination reveals a characteristic flow pattern with the maximum left-to-right shunt occurring in diastole. Color-flow mapping enhances the evaluation of the hemodynamic status of the ASD.

4. M-mode echocardiography may show increased RV dimension and paradoxical motion of the interventricular septum, which are signs of RV volume overload.

5. In older children and adolescents, especially in those with overweight, adequate imaging of the atrial septum may not be possible with the ordinary transthoracic echocardiographic study. Transesophageal echocardiography (TEE) may be used as an alternative.

**Natural History**

1. Earlier reports have indicated that spontaneous closure of the secundum defect occurs in about 40% of patients in the first 4 years of life (reported rates vary between 14% and 55% of patients). The defect may decrease in size in some patients. However, a more recent report indicates the overall rate of spontaneous closure to be 87%. In patients with an ASD smaller than 3 mm in size diagnosed before 3 months of age, spontaneous closure occurs in 100% of patients at 1½ years of age. Spontaneous closure occurs more than 80% of the time in patients with defects between 3 and 8 mm before 1½ years of age. An ASD with a diameter larger than 8 mm rarely closes spontaneously. Spontaneous closure is not likely to occur after 4 years of age.

   It may be that “small ASDs” detected by color Doppler studies are not the true ASD; they may simply be incompetent foramen ovale which resolved to competent PFO without shunt. (Spontaneous closure of VSD is associated with high velocities across the defect with resulting platelet adhesion to a jet lesion on the septal leaflet of the tricuspid valve. Such hemodynamic abnormalities do not exist with ASD.)

2. Most children with an ASD remain active and asymptomatic. Rarely, congestive heart failure (CHF) can develop in infancy.

3. If a large defect is untreated, CHF and pulmonary hypertension begin to develop in adults who are in their 20s and 30s, and it becomes common after 40 years of age.

4. With or without surgery, atrial arrhythmias (flutter or fibrillation) may occur in adults. The incidence of atrial arrhythmias increases to as high as 13% in patients older than 40 years of age.

5. Infective endocarditis does not occur in patients with isolated ASDs.
6. Cerebrovascular accident, resulting from paradoxical embolization through an ASD, is a rare complication.

**Management**

**Medical**

1. Exercise restriction is unnecessary.
2. In infants with CHF, medical management (with a diuretic) is recommended because of its high success rate and the possibility of spontaneous closure of the defect.

**Nonsurgical Closure**

Nonsurgical closure using a catheter-delivered closure device has become a preferred method, provided the indications are met. Several closure devices that can be delivered through cardiac catheters have been shown to be safe and efficacious for secundum ASD closure. In the United States, currently only the Amplatzer septal occluder (AGA Medical) and Helex septal occluder (W.L. Gore and Associates) are approved for secundum ASD closure. Currently, there are no transcatheter devices designed for closure of sinus venosus, primum, or coronary sinus ASDs.

The use of the closure device may be indicated to close a secundum ASD measuring 5 mm or more in diameter (but less than 32 mm for Amplatzer device and less than 18 mm for Helex device) and a hemodynamically significant L-R shunt with clinical evidence of RV volume overload (i.e., Qp/Qs ratio of 1.5:1 or greater or RV enlargement). There must be enough rim (4 mm) of septal tissue around the defect for appropriate placement of the device, although some newer devices no longer require a septal rim present along the entire margin of the defect. The size of the rim around the ASD can be estimated by two-dimensional echocardiographic study as diagrammatically shown in Figure 12-6. The rim size is estimated in four directions: anterosuperior, anteroinferior, posterosuperior, and posteroinferior (Magni et al, 1997).

The timing of the device closure for secundum ASD is not entirely clear. Considering the possibility of spontaneous closure, it is wise not to use the device in infancy unless the patient is symptomatic with heart failure. ASD closure devices can be implanted successfully in children younger than 2 years of age, although common practice suggests that a weight greater than 15 kg may offer some technical advantages and simplify the procedure (Feltes et al, 2011). Closure rates are excellent with small residual shunts seen in fewer than 5% of patients at 1 year of follow-up.
Complications are extremely rare. The overall risk of the procedure is 7.2% with the major complication rate of 1.6%, including device embolism with surgical removal. Other reported complications may include the following.

1. Early ECG abnormalities are common within the first 24 hours after implant, but most of these resolve quickly.

2. Probably the most feared complication with the Amplatzer device (but not with the Helex device) is early or late erosion of the device into the aortic root, with subsequent pericardial tamponade and rare death. It may be related to the oversizing of devices and deficiency of the anterosuperior (or retroaortic) rim (see Fig. 12-6).

3. Rarely thrombus formation in the right and left atrium occurs (2%-3%), but cerebral embolism is not more frequent than after surgical closure of the defect.

4. Release of nickel from the device (with peak at 1 month after implant) is a rare cause of significant allergic reaction.

Advantages of nonsurgical closure include a complete avoidance of cardiopulmonary bypass with its attendant risk, avoidance of pain and residual thoracotomy scars, a less than 24-hour hospital stay, and rapid recovery. All of these devices are associated with a higher rate of small residual leak than is operative closure.

Postdevice Closure Follow-up

The patients are prescribed aspirin 81 mg per day for 6 months. Postprocedure echocardiographic studies check for a residual atrial shunt and unobstructed flow of pulmonary veins, coronary sinus, and venae cavae, and proper function of the mitral and tricuspid valves. If 1-month and 1-year follow-up echocardiographic findings are normal,
yearly or biennial follow-up will suffice. Some cardiologists prescribe aspirin 81 mg for patients with residual shunt to prevent paradoxical embolization, but most cardiologists do not.

**Surgical Closure**

**Indications and Timing**

Surgical closure is indicated only when device closure is not considered appropriate. Therefore, most patients with secundum ASD are not candidates for surgical closure of the defect.

1. A left-to-right shunt with a pulmonary-to-systemic blood flow ratio (Qp/Qs ratio) of 1.5:1 or greater is a surgical indication. Surgery is usually delayed until 2 to 4 years of age because the possibility of spontaneous closure exists.
2. If CHF does not respond to medical management, surgery is performed during infancy, again if device closure is considered inappropriate.
3. High pulmonary vascular resistance (PVR) (i.e., >10 units/m$^2$, >7 units/m$^2$ with vasodilators) may be a contraindication for surgery (or device closure).

**Procedure**

For secundum ASD, the defect is traditionally repaired through a midsternal incision under cardiopulmonary bypass by either a simple suture or a pericardial or Teflon patch. Recently, so-called minimally invasive cardiac surgical techniques with smaller skin incisions have become popular, especially for female patients. For ASDs (including simple primum ASDs and sinus venosus defects), one of the following techniques can be used: midline short transxiphoid incision with minimal sternal split (preferred), transverse inframammary incision with vertical or transverse sternotomy, or small lower midline skin incision with either partial or full median sternotomy. The benefit of this technique appears to be an improved cosmetic result; it does not reduce pain, hospital stay, or surgical stress.

For a sinus venosus defect without associated anomalous pulmonary venous return, the defect is closed using an autologous pericardial patch. When it is associated with pulmonary venous anomaly, a tunnel is created between the anomalous pulmonary vein and the ASD by using a Teflon or pericardial patch. A plastic or pericardial gusset is placed in the SVC to prevent obstruction to the SVC. Alternatively, one may use the Warden procedure. In this procedure, the SVC is divided above the level of the pulmonary venous entry. The cardiac end of the SVC is oversewn, and a pericardial baffle is placed in such a way to drain the pulmonary venous blood through the sinus venosus ASD into the LA. The proximal SVC is sewn to the right atrial appendage to drain the SVC blood to the RA.

For coronary sinus ASD, the ostium of the coronary sinus is closed with an autologous pericardium with care to avoid conduction tissues, provided it is not associated with persistent left SVC. This will result in drainage of coronary sinus blood into the left
Mortality
Fewer than 0.5% of patients die; however, there is a greater risk for small infants and those with increased PVR.

Complications
Cerebrovascular accident and postoperative arrhythmias may develop in the immediate postoperative period.

Postoperative Follow-up
1. Cardiomegaly on chest radiographs and enlarged RV dimension on echo as well as the wide splitting of the S2 may persist for 1 or 2 years after surgery. The ECG typically demonstrates RBBB (or RV conduction disturbance).
2. Atrial or nodal arrhythmias occur in 7% to 20% of postoperative patients. Occasionally, sick sinus syndrome, which occurs especially after the repair of a sinus venosus defect, may require antiarrhythmic drugs, pacemaker therapy, or both.
Ventricular Septal Defect

Prevalence
Ventricular septal defect is the most common form of CHD and accounts for 15% to 20% of all such defects, not including those occurring as part of cyanotic CHDs.

Pathology

1. The ventricular septum may be divided into a small membranous portion and a large muscular portion (Fig. 12-7, A). The muscular septum has three components: the inlet septum, the trabecular septum, and the outlet (infundibular or conal) septum. The trabecular septum (also simply called the muscular septum) is further divided into anterior, posterior, mid, and apical portions. Therefore, VSD may be classified as a membranous, inlet, outlet (or infundibular), midtrabecular (or midmuscular), anterior trabecular (or anterior muscular, posterior trabecular (or posterior muscular), and apical muscular defect (Fig. 12-7, B).

   a. The membranous septum is a relatively small area immediately beneath the aortic valve. The membranous defect involves varying amounts of muscular tissue adjacent to the membranous septum (perimembranous VSD). According to the accompanying defect in the adjacent muscular septum, perimembranous VSDs have been called perimembranous inlet (atrioventricular [AV] canal type), perimembranous trabecular, or perimembranous outlet (tetralogy type) defects. Perimembranous defects are most common (70%).

   b. Outlet (infundibular or conal) defects account for 5% to 7% of all VSDs in the Western world and about 30% in Far Eastern countries. The defect is located within the outlet (conal) septum, and part of its rim is formed by the aortic and pulmonary annulus. An aortic leaflet can prolapse through the VSD and cause aortic insufficiency (see later for further discussion). It has been called a supracristal, conal, subpulmonary, or subarterial defect.

   c. Inlet (or AV canal) defects account for 5% to 8% of all VSDs. The defect is located posterior and inferior to the perimembranous defect beneath the septal leaflet of the tricuspid valve (see Fig. 12-7, B).

   d. Trabecular (or muscular) defects account for 5% to 20% of all VSDs. They frequently appear to be multiple when viewed from the right side. A midmuscular defect is posterior to the septal band. An apical muscular defect is near the cardiac apex and is difficult to visualize and repair. The anterior (marginal) defects are usually multiple, small, and tortuous. The “Swiss cheese” type of multiple muscular defect (involving all components of the ventricular septum) is extremely difficult to close surgically.
2. The defects vary in size, ranging from tiny defects without hemodynamic significance to large defects with accompanying CHF and pulmonary hypertension.

3. The bundle of His is related to the posteroinferior quadrant of perimembranous defects and the superoanterior quadrant of inlet muscular defects. Defects in other parts of the septum are usually unrelated to the conduction tissue.
Cardiac findings of a large ventricular septal defect. A classic holosystolic regurgitant murmur is audible at the lower left sternal border. A systolic thrill is also palpable at the same area (dots). There is usually a mid-diastolic rumble, resulting from relative mitral stenosis, at the apex. The S2 is narrowly split, and the P2 is accentuated in intensity. Occasionally, an ejection click (EC) may be audible in the upper left sternal border when associated with pulmonary hypertension. The heart murmurs shown without solid borders are transmitted from other areas and are not characteristic of the defect. Abnormal sounds are shown in black. Insp, inspiration.

In an infundibular defect, the right coronary cusp of the aortic valve may herniate through the defect. This may result in an actual reduction of the VSD shunt but may produce aortic regurgitation (AR) and cause an obstruction in the RV outflow tract (RVOT). A similar herniation of the right or noncoronary cusp occasionally occurs through perimembranous defects.

Clinical Manifestations

History

1. With a small VSD, the patient is asymptomatic with normal growth and development.
2. With a moderate to large VSD, delayed growth and development, decreased exercise tolerance, repeated pulmonary infections, and CHF are relatively common during infancy.
3. With long-standing pulmonary hypertension, a history of cyanosis and a decreased level of activity may be present.

Physical Examination (Figs. 12-8 and 12-9)

1. Infants with small VSDs are well developed and acyanotic. Before 2 or 3 months of age, infants with large VSDs may have poor weight gain or show signs of CHF. Cyanosis and clubbing may be present in patients with pulmonary vascular obstructive disease (Eisenmenger’s syndrome).
2. A systolic thrill may be present at the lower left sternal border. Precordial bulge and hyperactivity are present with a large-shunt VSD.
3. The intensity of the P2 is normal with a small shunt and moderately increased with a large shunt. The S2 is loud and single in patients with pulmonary hypertension or pulmonary vascular obstructive disease. A grade 2 to 5 of 6 regurgitant systolic murmur is audible at the lower left sternal border (see Figs. 12-8 and 12-9). It may be holosystolic or early systolic. An apical diastolic rumble is present with a moderate to large shunt.
(caused by an increased flow through the mitral valve during diastole) (see Fig. 12-9).

FIGURE 12-10 Tracing from a 3-month-old infant with a large ventricular septal defect, patent ductus arteriosus, and pulmonary hypertension. The tracing shows biventricular hypertrophy with left dominance. Note that V2 and V4 are in ½ standardization.

FIGURE 12-11 Posteroanterior and lateral views of chest roentgenograms of a ventricular septal defect with a large shunt and pulmonary hypertension. The heart size is moderately increased, with enlargement on both right and left sides of the heart. Pulmonary vascular markings are increased, with a prominent main pulmonary artery segment.

4. With infundibular VSD, a grade 1 to 3 of 6 early diastolic decrescendo murmur of AR may be audible. This murmur may be caused by herniation of an aortic cusp.

**Electrocardiography**

1. With a small VSD, the ECG findings are normal.
2. With a moderate VSD, left ventricular hypertrophy (LVH) and occasional left atrial hypertrophy (LAH) may be seen.
3. With a large defect, the ECG shows biventricular hypertrophy (BVH) with or without LAH (Fig. 12-10).
4. If pulmonary vascular obstructive disease develops, the ECG shows RVH only.

**Radiography (Fig. 12-11)**
Cardiomegaly of varying degrees is present and involves the LA, left ventricle (LV), and sometimes RV. Pulmonary vascular markings increase. The degree of cardiomegaly and the increase in pulmonary vascular markings directly relate to the magnitude of the left-to-right shunt.

**FIGURE 12-12** Selected two-dimensional echo views of the ventricular septum. These schematic drawings are helpful in determining the site of a ventricular septal defect (VSD). Different shading has been used for easy recognition of different parts of the ventricular septum. In the standard parasternal long-axis view (A1), the ventricular septum consists of (from the aortic valve toward the apex) the infracristal outlet (Inf-C outlet) septum (the VSD of tetralogy of Fallot is seen here) and the trabecular (mid- and apical) septum. In the parasternal right ventricular outlet tract (RVOT) view (A2), the septum consists of supracristal outlet (Sup-C outlet) septum and the trabecular septum. In the parasternal short-axis view showing the aortic valve (B1), the membranous septum is toward the 10 o'clock direction, the infracristal outlet septum at the 12 o'clock direction, and the supracristal outlet septum immediately adjacent to the pulmonary valve. The ventricular septum at the mitral valve (B2), the posterior muscular septum is inlet (INLET) septum. The ventricular septum at the papillary muscle (B3) is all trabecular septum, so that one can easily classify the defect into anterior (ANT), mid- (MID), and posterior (POST) trabecular defects. In the apical four-chamber view showing the coronary sinus (C1), the ventricular septum is the posterior (POST) trabecular septum. In the apical four-chamber view showing both atrioventricular (AV) valves (C2), the septum immediately beneath the tricuspid valve is the inlet septum (INLET) and the remainder is the mid- and apical septa. The thin septum between the insertion of the mitral and tricuspid valves is the AV septum (C2), a defect which can result in a left ventricle (LV)–to–right atrium (RA) shunt. In the standard apical four-chamber view,
the membranous septum is not visible. In the apical “five-chamber” view (C3), the membranous (MEMB) septum is seen beneath the aortic valve, and below it is the infracristal outlet (Inf-C outlet) septum. The ventricular septum seen in the subcostal four-chamber view (D1) is similar to the apical four-chamber view (C2). With anterior angulation of the horizontal transducer, the LV outflow tract (LVOT) is seen (D2), and the septum seen here is similar to the apical “five-chamber” view (C3). With further anterior angulation, the RVOT is seen (D3). The superior part is the supracristal outlet (Sup-C outlet) septum, and the inferior part is the anterior (ANT) trabecular septum (D3). The subcostal short-axis view showing the RVOT (E1) is orthogonal to the standard subcostal four-chamber view and is an important view for evaluating the site and size of a VSD. In this view, both supracristal outlet (Sup-C outlet) and infracristal outlet (Inf-C outlet) septa (in that order) are seen beneath the pulmonary valve and the trabecular septum (ANT and POST) is seen apical ward. The ventricular septum seen at the papillary muscle (E2) is all trabecular septum and is similar to the parasternal short axis view (B3).

2. In pulmonary vascular obstructive disease, the main PA and the hilar PAs enlarge noticeably, but the peripheral lung fields are ischemic. The heart size is usually normal.

**Echocardiography**

Two-dimensional and Doppler echocardiographic studies can identify the number, size, and exact location of the defect; estimate PA pressure by using the modified Bernoulli equation; identify other associated defects; and estimate the magnitude of the shunt. Because the ventricular septum is a large, complex structure, examination for a VSD should be carried out in a systematic manner to be able to specify the exact location and size of the defect. When possible, more than one view should be obtained, preferably a combination of the long- and short-axis views.

The cardiac valves serve as markers of specific types of VSDs except for the trabecular septum. The membranous VSD is closely related to the aortic valve, the inlet VSD to the tricuspid (or AV) valve, and the infundibular VSD to the semilunar valves. Figure 12-12 is a collection of selected views of parasternal, apical, and subcostal views, which are useful in locating the site of VSDs.

The **membranous septum** is closely related to the aortic valve. In the apical and subcostal “five-chamber” views, it is seen in the LV outflow tract (LVOT) just under the aortic valve (Fig. 12-12, C3). In the parasternal short-axis view at the level of the aortic valve, it is seen adjacent to the tricuspid valve (Fig. 12-12, B1). These are the best views to confirm the membranous VSD. The membranous VSD is not visible in the standard parasternal long-axis view, but by tilting the transducer slightly to the right, away from the aorta, the membranous VSD becomes visible. Figure 12-13 shows a membranous VSD imaged in the apical “five-chamber” view.

The **inlet septum** is best imaged in the apical or subcostal four-chamber view beneath the AV valves (Fig. 12-12, C2 and D1). It can also be seen equally well in the parasternal short-axis view in the posterior interventricular septum at the levels between the mitral valve and the papillary muscle (Fig. 12-12, B2). Simple inlet VSD (not that associated with AV canal defect) is seen beneath the AV valve, but a small amount of tissue remains under the valves. In the AV canal type of VSD, the AV valves are at the same level. There may be straddling or overriding.

The **infundibular (or outlet) septum** lies inferior to the semilunar valves. The subpulmonary, supracristal infundibular VSD lies under the pulmonary valve (Fig. 12-12, A2 and D3), and the subaortic infracristal VSD (tetralogy of Fallot [TOF] type, also called
The trabecular septum is the largest portion of the ventricular septum and extends from the membranous septum to the cardiac apex. The four types of trabecular VSDs are (1) anterior, (2) midmuscular, (3) apical, (4) posterior. Echocardiographic views that show the locations of different types of trabecular VSDs are shown in Figure 12-12. The apical VSD occurs near the cardiac apex (Fig. 12-12, A1, A2, C2, C3, D1, and D2). The entire ventricular septum seen at the papillary muscle level is the trabecular septum (Fig. 12-12, B3 and E2). For imaging of an apical muscular VSD, the transducer must be maximally angled toward the cardiac apex.

Natural History
Understanding the natural history of a VSD is important when planning its management.
1. Spontaneous closure of perimembranous and muscular VSDs can occur. It occurs more frequently with small defects and during the first 6 months of life. About 60% of small to moderate muscular VSDs close spontaneously but not after 8 years of age. About 35% of small perimembranous VSDs close spontaneously but not after 5 years of age. These VSDs do not become bigger with age; rather, they decrease in size. However, inlet defects and outlet (infundibular) defects do not become smaller or close spontaneously.
2. CHF develops in infants with large VSDs but usually not until 6 to 8 weeks of age.
3. Pulmonary vascular obstructive disease may begin to develop as early as 6 to 12 months of age in patients with large VSDs, but the resulting right-to-left shunt usually does not develop until the teenage years.
4. Infundibular stenosis may develop in some infants with large defects and result in a
decrease in the magnitude of the left-to-right shunt (i.e., acyanotic TOF), with an occasional occurrence of a right-to-left shunt.

Management

Medical

1. Treatment of CHF, if it develops, is indicated with diuretics (with or without) digoxin (see Chapter 27) for 2 to 4 months to see if growth failure can be improved. Some centers do not use digoxin. Addition of spironolactone may be helpful to minimize potassium loss from diuretics. Concomitant use of an afterload reducing agent, such as captopril, has gained popularity. Angiotensin-converting enzyme (ACE) inhibitors may raise the serum potassium level, and spironolactone or potassium supplementation should be discontinued. Frequent feedings of high-calorie formulas, either by nasogastric tube or oral feeding, may help. Anemia, if present, should be corrected by oral iron therapy. These measures often allow delay of surgical treatment and may promote spontaneous reduction or closure of the VSD.

2. No exercise restriction is required in the absence of pulmonary hypertension.

3. Nonsurgical device closure of selected muscular VSDs is possible in selected patients when the defect is not too close to cardiac valves and when it is difficult to access surgically. Some centers have used so-called hybrid procedures through left thoracotomy incision and performing “percutaneous” device closure without the use of cardiopulmonary bypass to close muscular VSD in the operating room. Device closure is not popular for the perimembranous VSD because of the unacceptable rate of postprocedure heart block.

Surgical

Indications and Timing

1. Small infants who have large VSDs and develop CHF with growth retardation are managed with diuretics and afterload reducing agents, with or without digoxin. If growth failure cannot be improved by medical therapy, the VSD should be operated on within the first 6 months of life, preferably by 3 to 4 months of age. Surgery should be delayed for infants who respond to medical therapy.

2. Infants who have small VSDs and have reached the age of 6 months without CHF or evidence of pulmonary hypertension are usually not candidates for surgery.

3. If the PA pressure is more than 50% of systemic pressure, surgical closure should be done by the end of the first year.

4. After 1 year of age, a significant left-to-right shunt with Qp/Qs ratio of at least 2:1 indicates that surgical closure is needed, regardless of PA pressure. Surgery is not indicated for small VSD with Qp/Qs ratio less than 1.5:1.

5. Older infants with large VSDs and evidence of elevated PVR should be operated on as soon as possible.
6. Surgery is contraindicated in patients with a pulmonary to systemic vascular resistance ratio of greater than 0.5 or with pulmonary vascular obstructive disease with a predominant right-to-left shunt.

**Procedure**

1. PA banding as a palliative procedure is no longer performed unless additional lesions make complete repair difficult.
2. Direct closure of the defect is carried out under hypothermic cardiopulmonary bypass, preferably without right ventriculotomy. Most perimembranous and inlet VSDs are repaired by a transatrial approach. Outlet (conal) defects are best approached through an incision in the main pulmonary artery. Apical VSD may require apical right ventriculotomy.

   As with the closure of ASDs, minimally invasive surgical techniques with smaller skin incisions are becoming popular for the closure of VSDs. The major benefit of this approach appears to be cosmetic.

**Mortality**

The surgical mortality rate is less than 1%. The mortality rate is higher for small infants younger than 2 months of age, infants with associated defects, and infants with multiple VSDs.

**Complications**

1. RBBB is frequent in patients repaired via right ventriculotomy. This is usually caused by the disruption of the Purkinje fibers, but it can also be caused by direct injury to the right bundle itself.
2. RBBB and left anterior hemiblock, which occurs in fewer than 10% of patients, is a controversial cause of sudden death. Complete heart block requiring pacemaker occurs in 1% to 2% of patients.
3. Residual shunt occurs in fewer than 5%. Intraoperative TEE echocardiography has reduced the incidence of the residual shunt.
4. The incidence of neurologic complications is directly related to the circulatory arrest time.

**Surgical Approaches for Special Situations**

1. **VSD and PDA.** If the PDA is large, the ductus alone may be closed in the first 6 to 8 weeks in the hope that the VSD is restrictive. If the VSD is large and not restrictive, PDA should be ligated at the time of VSD repair through the median sternotomy.
2. **VSD and coarctation of the aorta (COA).** A VSD is present in 15% to 20% of patients with COA. Several options exist in this controversial situation.
   a. Initial repair of the COA alone if the VSD appears relatively small. The VSD is closed later, if indicated.
   b. Coarctation repair and PA banding when the VSD appears unrestrictive.
c. Repair of both defects at the same time using one or two incisions.

3. **VSD and AR syndrome.** The prolapsed aortic cusp, with resulting AR, is usually associated with outlet VSD and occasionally with perimembranous VSD. It occurs in about 5% of patients with VSD, but the prevalence is much higher in Far Eastern countries (15%–20%). The adjacent (i.e., right or noncoronary) aortic valve cusps prolapse through the defect into the RVOT, actually reducing the VSD shunt. When AR appears, it gradually worsens. Surgery is usually performed promptly when AR is present even if the Qp/Qs ratio is less than 2:1, so that progression of AR (by Venturi effect through the open VSD) is either aborted or abolished. Some centers close the VSD even in the absence of AR if the aortic prolapse is demonstrated. When AR is trivial or mild, the VSD alone is closed. When AR is moderate or severe, the aortic valve is repaired or replaced. Not every case of VSD and AR results from the prolapsed aortic cusps; it may be the result of a VSD and bicuspid aortic valve.

**Postoperative Follow-up**

1. Office examination should be scheduled every 1 to 2 years.
2. Activity should not be restricted unless complications have resulted from surgery.
3. The ECG will show RBBB in 50% to 90% of patients who had VSD repair through right ventriculotomy and up to 40% of the patients who had repair through a right atrial approach.
4. Although rare these days, patients who had VSD and mild pulmonary hypertension and repair of the VSD after 3 years of age should be checked for possible progressive pulmonary vascular disease.
5. A patient with a postoperative history of transient heart block with or without pacemaker therapy requires long-term follow-up.
Patent Ductus Arteriosus

Prevalence
Patent ductus arteriosus occurs in 5% to 10% of all CHDs, excluding premature infants. It is more common in females than in males (male-to-female ratio of 1:3). PDA is a common problem in premature infants and will be presented under a separate heading in this chapter.

Pathology
1. There is a persistent patency of a normal fetal structure between the PA and the descending aorta, that is, about 5 to 10 mm distal to the origin of the left subclavian artery.
2. The ductus is usually cone shaped with a small orifice to the PA, which is restrictive to blood flow. The ductus may be short or long, straight, or tortuous.

Clinical Manifestations

History
1. Patients are usually asymptomatic when the ductus is small.
2. A large-shunt PDA may cause a lower respiratory tract infection, atelectasis, and CHF (accompanied by tachypnea and poor weight gain).
3. Exertional dyspnea may be present in children with a large-shunt PDA.

Physical Examination (Fig. 12-14)
1. Tachycardia and tachypnea may be present in infants with CHF.
2. Bounding peripheral pulses with wide pulse pressure (with elevated systolic pressure and lower diastolic pressure) are characteristic findings of a large PDA. With a small shunt, these findings do not occur.
3. With a large shunt, the precordium is hyperactive. A systolic thrill may be present at the upper left sternal border. The P2 is usually normal, but its intensity may be accentuated if pulmonary hypertension is present. A grade 1 to 4 of 6 continuous ("machinery") murmur is best audible at the left infraclavicular area or upper left sternal border. An apical diastolic rumble may be heard when the PDA shunt is large. Patients with small ductus do not have the above findings.
4. If pulmonary vascular obstructive disease develops, a right-to-left ductal shunt results in cyanosis only in the lower half of the body (i.e., differential cyanosis).

Electrocardiography
The ECG findings in PDA are similar to those in VSD. A normal ECG or LVH is seen with small to moderate PDA. BVH is seen with large PDA. If pulmonary vascular obstructive disease develops, RVH is present.
Radiography
Radiographs are also similar to those of VSD.
1. Chest radiographs may be normal with a small-shunt PDA.
2. Cardiomegaly of varying degrees occurs in moderate-to large-shunt PDA with enlargement of the LA, LV, and ascending aorta. Pulmonary vascular markings are increased.
3. With pulmonary vascular obstructive disease, the heart size becomes normal, with a marked prominence of the PA segment and hilar vessels.

Echocardiography
Echocardiography has emerged as the procedure of choice in confirming the diagnosis and assessing functional significance.
1. The PDA can be imaged in most patients. Its size can be assessed by two-dimensional echo in a high parasternal view or in a suprasternal notch view (Fig. 12-15).
2. Doppler studies that are performed with the sample volume in the PA immediately proximal to the ductal opening provide important functional information (see discussion in PDA in Preterm Neonates).

3. The dimensions of the LA and LV provide an indirect assessment of the magnitude of the left-to-right ductal shunt. The larger the shunt, the greater the dilatation of these
Natural History

1. Unlike PDA in premature infants, spontaneous closure of a PDA is rare in full-term infants and children. This is because the PDA in term infants results from a structural abnormality of the ductal smooth muscle rather than a decreased responsiveness of the ductal smooth muscle to oxygen.

2. CHF or recurrent pneumonia develops if the shunt is large.

3. Pulmonary vascular obstructive disease may develop if a large PDA with pulmonary hypertension is left untreated.

4. Although rare, an aneurysm of PDA may develop and possibly rupture in adult life.

Differential Diagnosis

The following conditions occur with a heart murmur, which is similar to the continuous murmur of PDA or with bounding pulses, and they require differentiation from PDA:

1. **Coronary arteriovenous fistula:** A continuous murmur is usually maximally audible along the right sternal border, not at the left infraclavicular area or upper left sternal border.

2. **Systemic arteriovenous fistula:** A bounding pulse with a wide pulse pressure and signs of CHF may develop without continuous murmur over the precordium. A continuous murmur is present over the fistula (i.e., head or liver).

3. **Pulmonary arteriovenous fistula:** A continuous murmur is audible over the back. Cyanosis and clubbing are present in the absence of cardiomegaly.

4. **Venous hum:** A venous hum is maximally audible in the right or left infraclavicular and supraclavicular areas when the patient is examined in a sitting position. It usually disappears when the patient lies in a supine position.

5. **Collaterals in COA:** A continuous murmur is audible in the intercostal spaces, usually bilaterally.

6. **VSD with AR:** A to-and-fro murmur, rather than a continuous murmur, is audible at the mid-left sternal border or lower left sternal border.

7. **Absence of the pulmonary valve:** A to-and-fro murmur ("sawing wood" sound) is audible at the upper left sternal border. Large hilar PAs on radiographic films and RVH on the ECG are characteristic. These patients are frequently cyanotic because this defect is usually associated with TOF.

8. **Persistent truncus arteriosus:** A continuous murmur is occasionally audible at the second right intercostal space or at the back in a cyanotic infant rather than in the upper left sternal border. The ECG may show BVH, and chest radiographic films show varying degrees of cardiomegaly and increased pulmonary vascularity. A right aortic arch is frequently found.

9. **Aortopulmonary septal defect (aortopulmonary window):** This extremely rare condition produces a bounding pulse, but the murmur resembles that of a VSD. CHF
develops in early infancy.

10. **Peripheral PA stenosis:** A continuous murmur is audible all over the thorax. The ECG may show RVH if the stenosis is severe. This often accompanies Williams syndrome or rubella syndrome.

11. **Ruptured sinus of Valsalva aneurysm:** The sudden onset of chest pain and signs of severe heart failure with dyspnea develop. A continuous murmur or a to-and-fro murmur is present at the base. This condition is more commonly seen in patients with Marfan’s syndrome.

12. **Total anomalous pulmonary venous return (TAPVR) draining into the RA:** A murmur that sounds similar to a venous hum may be heard along the right sternal border in a child with mild cyanosis. The ECG shows RVH in the presence of cardiomegaly and increased pulmonary vascular markings on chest radiographic films.

**Management**

**Medical**

1. Unlike in premature infants with PDAs, indomethacin is ineffective in term infants and should not be used.
2. No exercise restriction is needed in the absence of pulmonary hypertension.
3. Nonsurgical occlusion of PDA has become a standard of care at many centers except in patients with very low birth weight.

**Nonsurgical Closure**

Large series of nonsurgical ductal closure in the United States and Europe reported 95% to 100% success rates.

1. Indications of PDA closure are as follows (Feltes TF, et al, 2011).
   a. Closure of PDA is definitely indicated in patients with hemodynamically significant PDA with CHF, failure to thrive, pulmonary overcirculation, or enlargement of the LA and LV.
   b. It is reasonable to close a small PDA when the murmur of PDA is audible by standard auscultation techniques.
   c. There is controversy related to occlusion of so-called silent ductus. There are few data on the benefits of occluding the silent ductus because of lack of significant endothelial damage to cause endocarditis.
   d. Ductal closure is contraindicated in patients with Eisenmenger’s syndrome or pulmonary vascular obstructive disease. The response of PVR to balloon occlusion or pulmonary vasodilators (e.g., oxygen or nitric oxide) is tested in the cardiac catheterization laboratory. If a good response is obtained, closure is advised. If the response is poor or equivocal, closure may not be recommended. A device closure (without additional surgical insult) may be considered in this setting. The presence of severe pulmonary hypertension with irreversible pulmonary vascular obstructive disease is a contraindication to surgery.
2. Procedure. Small ductus (<3 mm in diameter) are closed by various kinds of coils and larger ones by the Amplatzer PDA device.
   a. Gianturco stainless steel coils have become the standard device for closure of PDA for all children with ducts smaller than 3 mm in diameter in the United States. In optimal candidates for the device, the ductus is 2.5 mm in size, but the use of multiple coils can close a ductus up to 5 mm. A retrograde approach is used from the femoral artery. The residual shunt rate is 5% to 15% at 12 months of follow-up. Overall, the procedure has 97% or greater success with zero mortality.
   b. For larger PDA but smaller than 12 mm in diameter, specialized devices, such as the Amplatzer duct occluder, are available for catheter-based closure. The devices are implanted antegrade from the femoral vein. Although original recommendations from the manufacturer exclude patients who weigh less than 6 kg, successful use in infants as small as 2.5 kg has been reported. There is a 98% or greater closure rate at 6 months with minimal complications and no mortality.

The advantages of nonsurgical closure of the ductus include no need for general anesthesia, shorter hospital stay and convalescent period, and elimination of a thoracotomy scar. Disadvantages and potential complications include residual leaks, pulmonary artery coil embolization, hemolysis, left PA stenosis, aortic occlusion with the Amplatzer device, and femoral vessel occlusion.

**Surgical Closure**

**Indications and Timing**
Surgical closure is reserved for patients in whom a nonsurgical closure technique is not considered applicable. An interventional device rather than surgery is used to close small ductus with no hemodynamic significance by many centers.

**Procedure**
1. Ligation and division through left posterolateral thoracotomy without cardiopulmonary bypass is the standard procedure.
2. The technique of video-assisted thoracoscopic surgery (VATS) clip ligation has become the standard of care for surgical management of ductus with adequate length (to allow safe ligation), which is performed through three small ports in the fourth intercostal space.

**Mortality**
The surgical mortality rate is 0% for both techniques.

**Complications**
Complications are rare. Injury to the recurrent laryngeal nerve (hoarseness), the left phrenic nerve (paralysis of the left hemidiaphragm), or the thoracic duct (chylothorax) is possible. Recanalization (reopening) of the ductus is possible, although rare, occurring
after ligation alone (without division).
Patent Ductus Arteriosus in Preterm Neonates

Prevalence

Clinical evidence of PDA appears in 45% of infants with a birth weight less than 1750 g and in about 80% of infants with a birth weight less than 1200 g. Significant PDA with CHF occurs in 15% of premature infants with a birth weight less than 1750 g and in 40% to 50% of those with a birth weight less than 1500 g.

Pathophysiology

1. PDA is a special problem in premature infants who are recovering from hyaline membrane disease. With improvement in oxygenation, the PVR falls rapidly, but the ductus remains patent because its responsiveness to oxygen is immature in premature newborns (see Chapter 8). The resulting large left-to-right shunt makes the lung stiff, and weaning the infant from the ventilator and oxygen therapy becomes difficult.
2. If the infant must remain on a ventilator and oxygen therapy for a long time, bronchopulmonary dysplasia develops, with resulting pulmonary hypertension (cor pulmonale) and right-sided heart failure.
3. Premature infants with significant left-to-right shunt may suffer from the consequences of prolonged hypoperfusion to many organs, which may include intracranial hemorrhage, renal dysfunction, myocardial ischemia, and necrotizing enterocolitis. Early recognition and appropriate management of PDA are keys to improving the prognosis of these infants.

Clinical Manifestations

1. The history is important in suspecting a significant PDA in a premature neonate. Typically, a premature infant with hyaline membrane disease shows some improvement during the first few days after birth. This is followed by an inability to wean the infant from the ventilator or a need to increase ventilator settings or oxygen requirements in 4- to 7-day-old premature infants. Episodes of apnea or bradycardia may be the initial sign of PDA in infants who are not on ventilators.
2. The physical examination commonly reveals bounding peripheral pulses, a hyperactive precordium, and tachycardia with or without gallop rhythm. The classic continuous murmur at the left infraclavicular area or upper left sternal border is diagnostic, but the murmur may be only systolic and is difficult to hear in infants who are on ventilators. Premature infants who are fluid overloaded or retaining fluid may also present with findings of PDA as described earlier (hyperdynamic precordium, systolic ejection murmur, bounding pulses, and wide pulse pressures), requiring differentiation from PDA.
3. The ECG is not diagnostic. It usually is normal but occasionally shows LVH.
4. Chest radiographs show cardiomegaly in larger premature infants who are not intubated. The infant may have evidence of pulmonary edema or increased pulmonary
vascular markings, but these may be difficult to assess in the presence of hyaline membrane disease. In infants who are intubated and on high ventilator settings, chest x-ray films may show the heart to be either of normal size or only mildly enlarged.

5. Two-dimensional echocardiographic and color-flow Doppler studies provide accurate anatomic and functional information.
   a. Two-dimensional echo provides anatomic information about the diameter, length, and shape of the ductus (see Fig. 12-15).
   b. Doppler studies of the ductus (with the sample volume placed at the pulmonary end of the ductus) provide important functional information, such as ductal shunt patterns (pure left-to-right, bidirectional, or predominant right-to-left shunt), pressures in the PA, and magnitude of the ductal shunt or pulmonary perfusion status:
      1) **Ductal shunt pattern.** A continuous positive flow indicates a pure left-to-right shunt with the PA pressure lower than the aortic pressure. In pure right-to-left shunts, flow is continuously negative away from the PA, indicating that the PA pressure is suprasystemic. A bidirectional shunting pattern (with an early negative flow in systole followed by a late positive flow in diastole) is found in infants with PDA and severe pulmonary hypertension.
      2) **Estimation of PA pressures.** A high ductal flow velocity indicates a low PA pressure, and a low flow velocity indicates a high PA pressure. The pressure drop may be underestimated in patients with a small pulmonary end of the ductus, tortuous PDAs, or tunnel-like PDAs with diameters smaller than 3 mm and lengths longer than 10 mm (because of viscous energy loss). However, the easiest and most accurate estimate of the PA systolic pressure is obtained from the peak velocity of the TR, when it is present.
      3) **Perfusion status.** Increased flow velocity in the left PA suggests a large left-to-right shunt through the ductus. High PA pressure and a lower flow velocity (with a pressure drop of <5 mm Hg) indicate poor perfusion of the lungs, which is a bad prognostic sign during the first 24 to 36 hours.

**Management**

For symptomatic infants, either pharmacologic or surgical closure of the ductus is indicated. A small PDA that does not cause symptoms should be followed medically for 6 months without surgical ligation because of the possibility of spontaneous closure.

**Medical**

1. Fluid restriction to 120 mL/kg per day and a diuretic (e.g., furosemide, 1 mg/kg two to three times a day) may be tried for 24 to 48 hours, but these regimens have a low success rate. Digoxin is not used because it has little hemodynamic benefit and a high incidence of digitalis toxicity.
2. Pharmacologic closure of the PDA can be achieved with indomethacin (a prostaglandin synthetase inhibitor). Indications and dosages vary from center to center (see later
One popular approach is to give indomethacin (Indocin) 0.2 mg/kg intravenously every 12 hours for up to three doses in selected cases. A second course of indomethacin treatment is occasionally necessary to achieve adequate ductal closure. Contraindications to the use of indomethacin include high blood urea nitrogen (>25 mg/dL) or creatinine (>1.8 mg/dL) levels, low platelet count (<80,000/mm³), bleeding tendency (including intracranial hemorrhage), necrotizing enterocolitis, and hyperbilirubinemia.

Many dosage regimens exist and dose is dependent on postnatal age of the infant at time of first dose; one example is as follows. The dose is given intravenously every 12 hours a total of 3 doses. For infants less than 48 hours old, 0.2 mg/kg is followed by 0.1 mg/kg times 2. For infants 2 to 7 days old, 0.2 mg/kg times 3 is given, and for infants older than 7 days old, 0.2 mg/kg followed by 0.25 mg/kg times 2 is given.

A multicenter prospective study from Europe showed that intravenous ibuprofen (10 mg/kg followed at 24-hour intervals by two doses of 5 mg/kg) starting on the third day of life was as effective in closing the ductus in preterm newborns as indomethacin. Ibuprofen had a significantly lower incidence of oliguria, and it does not appear to have a deleterious effect on cerebral blood flow. Ibuprofen significantly reduces plasma concentrations of prostaglandin. An earlier study from Canada reported that intravenous ibuprofen 10 mg/kg given at 3 hours of age followed by 5 mg/kg given at 24 and 48 hours of age was effective in reducing the incidence of PDA without causing notable adverse drug reactions. Thus, ibuprofen appears to be a valuable alternative to indomethacin for both the treatment and the prophylaxis of PDA in preterm newborns. Ibuprofen may prove to be a better choice than indomethacin. A recent dose-finding study conducted in Europe confirmed the dosage of 10-5-5 mg/kg to be correct for ductal closure (Desfrere et al, 2005). Recent reports from Europe concluded that prophylactic use of ibuprofen in small preterm infants was not useful because, although it reduced the occurrence and the need for surgical ligation of the ductus, it did not reduce the frequency of intraventricular hemorrhage, mortality, or morbidity.

**Surgical**

If medical treatment is unsuccessful or if the use of indomethacin is contraindicated, surgical ligation of the ductus is indicated. The standard operative approach to PDA is through a posterolateral thoracotomy. The PDA is simply ligated or hemoclipped (without division). Many centers now perform PDA ligation in the neonatal intensive care unit at the bedside. The operative mortality rate is 0% to 3%.

Recently, the use of minimally invasive VATS has been reported for the management of PDA in low-birth-weight infants. This technique allows PDA interruption without the muscle cutting or rib spreading of a standard thoracotomy. Reduced compromise of respiratory mechanics and less chest wall deformity associated with a large thoracotomy incision may also be advantages.
Complete Endocardial Cushion Defect

Prevalence

Complete ECD (also known as AV canal defect, complete AV canal defect, or AV communis) occurs in 2% of all CHDs. Of patients with complete ECD, about 70% are children with Down syndrome. Of children with Down syndrome, about 40% have CHDs, and 50% of the defects are ECD. ECD is also a component of heart defects in asplenia and polysplenia syndromes (see Chapter 14).

Pathology

1. Abnormalities seen in complete ECD affect the structures normally derived from the endocardial cushion tissue. Ostium primum ASD, VSD in the inlet ventricular septum, and clefts in the anterior mitral valve and the septal leaflet of the tricuspid valve (forming the common AV valve) are all present in the complete form of ECD (Fig. 12-16). The combination of these defects may result in interatrial and interventricular shunts, LV-to-RA shunt, and AV valve regurgitation. Although rare, the entire atrial septum may be absent (common atrium). When two AV valve orifices are present without an interventricular shunt, the defect is called partial ECD or ostium primum ASD (which is presented under a separate heading in this chapter).

2. Both complete and partial forms of ECD are characterized by a deficiency of the inlet portion of the ventricular septum, with a “scooped-out” appearance of the muscular septum and an excessively long infundibular septum, as well as by an abnormal position of the aortic valve (i.e., displaced anterosuperiorly rather than being wedged between the right and left AV valves). The latter results in lengthening and narrowing of the LVOT, thereby producing the characteristic “goose-neck deformity” on angiocardiogram (see Fig. 12-21).

3. Whereas in complete ECD, a single valve orifice connects the atrial and ventricular chambers, in the partial form, there are separate mitral and tricuspid orifices. The common AV valve usually has five leaflets (see Fig 12-16). The arrangement of the LV papillary muscles may be abnormal in that either they are closer together or only one papillary muscle is present in the LV, which makes surgical repair difficult.

**FIGURE 12-16** Diagram of the atrioventricular (AV) valve and cardiac septa in partial and complete endocardial cushion defect (ECDs). **A,** Normal AV valve anatomy with no septal defect. **B,** Partial ECD with clefts in the mitral and tricuspid valves and an ostium primum atrial septal defect (ASD) (solid arrow). **C,** Complete ECD. There is a
common AV valve with large anterior and posterior bridging leaflets. An ostium primum ASD (solid arrow) and an inlet ventricular septal defect (open arrow) are present. LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle.

FIGURE 12-17 Rastelli’s classification of complete endocardial cushion defect. A, Type A. B, Type B. C, Type C. (See text for descriptions.) LV, left ventricle; RA, right atrium; RV, right ventricle.

4. In the majority of complete ECD cases, the AV orifices are equally committed to the RV and LV (“balanced” AV canal). In some patients, however, the orifices are committed primarily to one ventricle, with hypoplasia of the other ventricle (i.e., “unbalanced” AV canal with RV or LV dominance). Hypoplasia of one ventricle may necessitate one ventricular repair (i.e., Fontan operation).

5. A universally accepted classification for complete ECD does not exist. The Rastelli classification was based on the relationships of the anterior bridging leaflets to the crest of the ventricular septum or RV papillary muscles (Fig. 12-17). In type A, the anterior bridging leaflet is tightly tethered to the crest of the ventricular septum, occurring in 50% to 70%. This type is commonly associated with Down syndrome. In type B (3%), the anterior bridging leaflet is not attached to the ventricular septum; rather, it is attached to an anomalous RV papillary muscle and is almost always associated with unbalanced AV canal with right dominance. In type C (30%), a free-floating anterior leaflet is attached to the anterior papillary muscle. This type is often seen in visceral heterotaxia and conotruncal malformations.

6. Additional cardiac anomalies include TOF (called “canal tet,” occurring in 6% of patients), DORV with more than 50% overriding of the aorta (occurring in 6%), and transposition of the great arteries (occurring in 3%). Associated defects are rare in children with Down syndrome.

Clinical Manifestation

History

Failure to thrive, repeated respiratory infections, and signs of CHF are common.

Physical Examination (Fig. 12-18)

1. Infants with ECD are usually undernourished and have tachycardia and tachypnea (signs of CHF). This defect is common in infants with Down syndrome.
2. Hyperactive precordium with a systolic thrill at the lower left sternal border is common (shown as the area with dots in Fig. 12-18).

3. The S1 is accentuated. The S2 narrowly splits, and the P2 increases in intensity. A grade 3 to 4 of 6 holosystolic murmur is usually audible along the lower left sternal border. The systolic murmur may transmit well to the left axilla and be heard well at the apex when mitral regurgitation (MR) is significant. A mid-diastolic rumble may be present at the lower left sternal border or at the apex as a result of relative stenosis of the tricuspid or mitral valve.

4. Signs of CHF (e.g., hepatomegaly, gallop rhythm) may be present.

**Electrocardiography**

1. “Superior” QRS axis with the QRS axis between −40 and −150 degrees is characteristic of the defect (Fig. 12-19).

2. Most of the patients have a prolonged PR interval (first-degree AV block).

3. RVH or RBBB is present in all cases, and many patients have LVH, too.

**Radiography**

Cardiomegaly is always present and involves all four cardiac chambers. Pulmonary vascular markings are increased, and the main PA segment is prominent.

**Echocardiography**

Two-dimensional and Doppler echocardiographic studies allow imaging of all components of complete ECD and an assessment of the severity of these components. The following surgically important information can be gained: size of the ASD and VSD, size of the AV valve orifices, anatomy of leaflets, chordal attachment, relative and absolute size of the RV and LV (balance of the canal), and papillary muscle architecture (one vs. two) in the LV.

1. The apical and subcostal four-chamber views are most useful in evaluating the anatomy and the functional significance of the defect. These views show both an ostium primum ASD and an inlet muscular VSD (Fig. 12-20). Either the anterior bridging leaflet crosses the ventricular septum or the right and left AV valve leaflets can be seen at the same level from the crest of the ventricular septum. The full extent of the ASD and VSD can be imaged during systole when the common anterior leaflet is closed.

2. A combined use of the subcostal transducer position (i.e., about 45 degrees clockwise from a standard four-chamber view) and the parasternal short-axis examination may show a cleft in the mitral valve, the presence of bridging leaflets, the number of AV valve orifices (e.g., double orifice mitral valve), and the AV valve leaflets. These views may also image the abnormal position of the anterolateral papillary muscle, which is displaced posteriorly from its normal position, and the number (i.e., single or triple) of papillary muscles.

3. The subcostal “five-chamber” view may image a goose-neck deformity, which is characteristic of an angiocardiographic finding (Fig. 12-21).
4. In real time, the subcostal and apical four-chamber views can image the chordal attachment of the anterior bridging leaflet to the crest of the ventricular septum (type A), to the right side of the septum (type B), or to a papillary muscle at the apex of the RV or on its free wall (type C).

**FIGURE 12-18** Cardiac findings of complete endocardial cushion defect, which resemble those of a large ventricular septal defect. An apical holosystolic murmur (caused by mitral regurgitation) may transmit toward the left axilla. A systolic thrill may be present at the lower left sternal border (dotted area), where the systolic murmur is loudest. Insp., inspiration.

**FIGURE 12-19** Tracing from a 5-year-old boy with Down syndrome and complete atrioventricular canal. Note the “superior” QRS axis (–110 degrees) and right ventricular hypertrophy.

**Natural History**

1. Patients with complete ECD develop heart failure 1 to 2 months after birth, and recurrent pneumonia is common.
2. Without surgical intervention, most patients die by the age of 2 to 3 years.
3. In the latter half of the first year of life, survivors begin to develop pulmonary vascular obstructive disease. These survivors usually die in late childhood or as young adults. Infants with Down syndrome are particularly prone to the early development of pulmonary vascular obstructive disease during infancy. Therefore, surgery should be performed during infancy.
Figures 12-20 and 12-21 depict echocardiographic views of patients with endocardial cushion defects.

**Figure 12-20** Apical four-chamber views in systole (A) and diastole (B) from a patient with a complete endocardial cushion defect. In systole, an ostium primum defect and an inlet ventricular septal defect are imaged. The atrioventricular (AV) valve appears to be attached to the crest of the ventricular septum by chordae (type A). When the AV valve opens in diastole, a large deficiency in the center of the heart is visible. Note that there is a common AV valve, instead of two separate AV valves. LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle. (From Snider AR, Serwer GA: Echocardiography in Pediatric Heart Disease. St Louis, Mosby, 1990.)

**Figure 12-21** Frontal view of a left ventriculogram of a patient with partial endocardial cushion defect showing a goose-neck deformity. The left ventricular outflow tract is elongated and narrowed. The arrows point to the mitral cleft. AO, aorta; LV, left ventricle.

### Management

#### Medical

1. In small infants with CHF, anticongestive management with diuretics and ACE inhibitors should be started. Digoxin may also be used (see Chapter 27).
2. Nutrition should be optimized.

#### Surgical
**Indications**
The presence of complete ECD indicates the need for surgery because an important hemodynamic derangement is usually present. Most of these infants have CHF that is unresponsive to medical therapy, and some have elevated PVR.

**Timing**
Although timing varies among institutions and with the hemodynamics of the defect, most centers perform the repair at 2 to 4 months of age. Early surgical repair is especially important for infants with Down syndrome with complete ECD because of their known tendency to develop early pulmonary vascular obstructive disease.

**Procedures**

**Palliative**
Bandung of the PA in early infancy is no longer recommended unless other associated abnormalities make complete repair a high-risk procedure, such as those with “unbalanced” AV canal. The mortality rate for PA banding can be as high as 15%.

**Corrective**
Given two ventricles of suitable size and no additional defects, closure of the primum ASD and inlet VSD and construction of two separate and competent AV valves are carried out under cardiopulmonary bypass, deep hypothermia, or both. Some surgeons use a single patch to close the ASD and VSD and reconstruction of the left AV valve as a bileaflet valve; others use a two-patch technique, one patch for the VSD and a second for the ASD (Fig. 12-22). The left AV valve is allowed to persist as a trileaflet structure. A schematic drawing of the surgery is shown in Figure 12-21. This figure illustrates the complexity of the anatomy of the AV canal. Mitral valve replacement may become necessary in a few patients.

Patients with an unbalanced AV canal (with hypoplasia of RV or LV) may be treated by an earlier PA banding and later by a modified Fontan operation.

**Mortality**
The mortality rate has been 3% to 10%. The survival rate is the same for patients with and without Down syndrome. Factors that increase the surgical risk are young age, severe AV valve regurgitation, hypoplasia of the LV, increased and fixed PVR, and severe preoperative symptoms. Other defects (e.g., double-orifice mitral valve, single left-sided papillary muscle, additional muscular VSD) increase the surgical risk. The hospital mortality rate for complete ECD and TOF (“canal tet”) is around 10%.
Complications
1. MR becomes persistent or worsens 10% of the time.
2. Sinus node dysfunction resulting in bradyarrhythmias may occur.
3. Although complete heart block occurs rarely (in <5% of patients), it occurs more frequently when mitral valve replacement is required (up to 20% of patients).
4. Postoperative arrhythmias occur and are usually supraventricular.

Special Situations
1. Because of the early development of pulmonary vascular obstructive disease in patients with Down syndrome and complete ECD, cardiac catheterization should be performed before 3 months of age, and elective surgery should follow shortly thereafter. Down syndrome itself is not a risk factor.
2. Patients with “unbalanced” AV canal with severe hypoplasia of the LV and low PA pressure may receive a combination of the Damus-Kaye-Stansel operation (similar to Fig. 14-62) and a Fontan-type operation. The proximal PA is anastomosed end to side to the ascending aorta, and systemic venous return is channeled to the right PA, bypassing the RV.
3. In patients with TOF and complete ECD (i.e., “canal tet”) who are severely cyanotic, a systemic-to-PA shunt is carried out during infancy. A complete repair is done between 2 and 4 years of age.
4. Parachute deformity of the mitral valve may result in an obstructed mitral orifice. If there is a significant MR, valve replacement may be required.
5. Double-orifice mitral valve (found in 4%) is usually left alone. Incision of the valve may create more problems with MR.

Postoperative Follow-up
1. An office evaluation should be given every 6 months to 1 year.
2. Medications (e.g., diuretics, captopril, digoxin) may be required if residual hemodynamic abnormalities are present.
3. Some restriction of activities may be necessary if significant MR or other complications exist.
Partial Endocardial Cushion Defect

Prevalence
Partial ECD (partial AV canal defect or ostium primum ASD) occurs in 1% to 2% of all CHDs, which is considerably less than the prevalence of secundum ASD.

Pathology
1. In partial ECD, there is a defect in the lower part of the atrial septum near the AV valves without an interventricular communication (see Fig. 12-1). The anterior and posterior bridging leaflets are fused by a connecting tongue to form separate right and left AV orifices (see Fig. 12-16). There are “clefts” in the septal leaflets of the mitral and tricuspid valves. The conjoined leaflets are displaced into the ventricle and are usually firmly attached to the crest of the ventricular septum. The aortic valve and AV valves are distanced from one another, which accounts for the characteristic “goose-neck” deformity in angiograms (see Fig. 12-21).
2. Less common forms of partial ECD include common atrium, VSD of the inlet septum (i.e., AV canal-type VSD), and isolated cleft of the mitral valve. A common atrium, in which the atrial septum is virtually absent, is either a characteristic lesion in patients with the Ellis-van Creveld syndrome or a component of complex cyanotic heart defects such as those associated with asplenia or polysplenia syndrome.
3. Occasional associated anomalies include secundum ASD and persistent left SVC that drains into the coronary sinus.

Clinical Manifestations

History
1. Patients with ostium primum ASD are usually asymptomatic during childhood.
2. History of symptoms such as dyspnea, easy fatigability, recurrent respiratory infections, and growth retardation may be present early in life if associated with major MR or common atrium.

Physical Examination
1. Cardiac findings are the same as those of secundum ASD (see Fig. 12-2), with the exception of a regurgitant systolic murmur of MR (owing to a cleft mitral valve), which may be present at the apex.
2. Mild cyanosis and clubbing may be present in patients with a common atrium.

Electrocardiography
1. “Superior” QRS axis with the QRS axis ranging from −30 to −150 degrees is characteristic of the condition (see Fig. 12-19).
2. RVH or RBBB (with rsR' pattern in V1) is present, as in secundum ASD.
3. First-degree AV block (i.e., prolonged PR interval) is present in about 50% of cases.

**Radiography**

The radiography findings are the same as those of a secundum ASD (see Fig. 12-4) except for enlargement of the LA and LV when MR is significant. A characteristic “goose-neck” deformity is seen on a left ventriculogram (see Fig. 12-21).

**Echocardiography**

1. Two-dimensional and Doppler echocardiography allows accurate diagnosis of primum ASD. The defect is in the lower atrial septum (see Fig. 12-5). No visible or Doppler-detectable VSD is present. The septal portions of the AV valves insert at the same level on the crest of the ventricular septum.
2. A cleft in the anterior leaflet of the mitral valve is commonly imaged (which is directed toward the inlet septum or 9 o’clock direction in the parasternal short-axis view). (In case of “isolated mitral cleft,” the cleft is directed toward the LVOT or 11 o’clock direction in the short-axis view.) Rare abnormalities of the mitral valve include double-orifice mitral valve and parachute mitral valve.
3. The atrial septum may be completely absent (common atrium) in patients with Ellis-van Creveld syndrome.
4. Color-flow and Doppler studies are useful in the detection of stenosis or regurgitation of the AV valve and in the assessment of the RV and PA pressures.

**Natural History**

1. Spontaneous closure of the defect does not occur.
2. CHF may develop in childhood earlier than with secundum ASD. CHF is related to major MR or other associated defects.
3. Pulmonary hypertension (i.e., pulmonary vascular obstructive disease) develops in adulthood.
4. Arrhythmias occur in 20% of patients.

**Management**

**Medical**

1. No exercise restriction is indicated.
2. Anticongestive therapy with diuretics and ACE inhibitors may be indicated for some patients.
3. Device closure of the defect cannot be done.

**Surgical**

**Indications and Timing**
The presence of a partial AV canal (or primum ASD) is an indication for surgical repair. Elective surgery can be performed in asymptomatic children between 2 and 4 years of age. Surgery can be performed earlier in infants with CHF, failure to thrive, MR, or a common atrium.

**Procedure**

Under cardiopulmonary bypass, the primum ASD is closed, and the cleft mitral and tricuspid valves are reconstructed. Some surgeons leave the mitral valve as a trileaflet valve (without suturing the cleft) by performing various mitral annuloplasties. Recently, minimally invasive cardiac surgical techniques with smaller skin incisions have become popular, especially for female patients (discussed under Atrial Septal Defect).

**Mortality**

The surgical mortality rate is approximately 3%. Risk factors include the presence of CHF or cyanosis, failure to thrive, and moderate to severe MR.

**Complications**

1. Reoperation is needed in about 15% of the patients who have residual or worsening MR.
2. Atrial or junctional (nodal) arrhythmias occasionally occur.
3. Complete heart block rarely results and requires a permanent cardiac pacemaker.
4. Although rare, subaortic stenosis can develop after surgery.

**Postoperative Follow-up**

1. Usually no restriction in activity is indicated.
2. Sinus node dysfunction may require permanent pacemaker therapy.
3. Periodic echocardiographic evaluation for the development of subaortic stenosis and for worsening of MR should be performed. Subaortic stenosis develops more frequently after repair of partial ECD than complete ECD.
Partial Anomalous Pulmonary Venous Return

Prevalence

Partial anomalous pulmonary venous return occurs in less than 1% of all CHDs.

![FIGURE 12-23 Common types of partial anomalous pulmonary venous return. A, The right pulmonary veins drain anomalously to the superior vena cava (SVC). Sinus venosus atrial septal defect (ASD) is usually present. B, The right lower pulmonary vein drains anomalously into the inferior vena cava (IVC), usually without an associated ASD. C, The left pulmonary veins drain into the left innominate vein. D, The left pulmonary veins drain into the coronary sinus (CS). LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle.]

Pathology

1. One or more (but not all) pulmonary veins drain into the RA or its venous tributaries such as the SVC, IVC, coronary sinus, and left innominate vein. The right pulmonary veins are involved twice as often as the left pulmonary veins.
2. The right pulmonary veins may drain into the SVC, which is often associated with a sinus venosus defect (Fig. 12-23, A), or drain into the IVC (Fig. 12-23, B) in association with an intact atrial septum and bronchopulmonary sequestration (see simitar syndrome in Chapter 15).
3. The left pulmonary veins either drain into the left innominate vein (Fig. 12-23, C) or into the coronary sinus (Fig. 12-23, D). ASD is usually present with anomalous drainage of the left pulmonary veins.

Pathophysiology

1. Hemodynamic alterations are similar to those in ASD. Pulmonary blood flow increases as a result of recirculation through the lungs.
2. The magnitude of the pulmonary recirculation is determined by the number of anomalous pulmonary veins, the presence and size of the ASD, and the PVR.

Clinical Manifestations

History

Children with PAPVR are usually asymptomatic.
Physical Examination
1. Cardiac findings are similar to those of ASD (see Fig. 12-2).
2. When associated with ASD, the S2 is split widely and fixed. When the atrial septum is intact, the S2 is normal. A grade 2 to 3 of 6 midsystolic murmur is present at the upper left sternal border. A mid-diastolic rumble, resulting from relative tricuspid stenosis, may be present.

Electrocardiography
Right ventricular hypertrophy, RBBB, or a normal ECG may be seen.

Radiography
The findings are similar to those of secundum ASD (see Fig. 12-4).
1. Cardiomegaly involving the RA and RV, prominence of the PA segment, and increased pulmonary vascularity are all present.
2. Occasionally a dilated SVC, a crescent-shaped vertical shadow in the right lower lung (scimitar syndrome), or a distended vertical vein may suggest the site of anomalous drainage.

Echocardiography
The diagnosis of PAPVR requires a high index of suspicion. A systematic attempt to visualize each pulmonary vein should be made during any routine echocardiographic studies.
1. The inability to visualize all four pulmonary veins in the presence of mild dilatation of the RA and RV strongly suggests the diagnosis of PAPVR, especially in the presence of a demonstrable ASD.
2. PAPVR is frequently found in patients with ASD of any type and in those with persistent left SVC.
3. In sinus venosus defect, the chance of anomalous drainage of the right upper pulmonary vein is high.

Cardiac Magnetic Resonance Imaging
Cardiac magnetic resonance imaging can make correct diagnosis of partial anomalous pulmonary venous return, alternative to the invasive cardiac catheterization with exposure to radiation.

Natural History
1. Cyanosis and exertional dyspnea may develop during the third and fourth decades of life. This results from pulmonary hypertension and pulmonary vascular obstructive disease.
2. Pulmonary infections are common in patients with anomalous drainage of the right pulmonary veins to the IVC.
Management

Medical
1. No medical treatment is needed when asymptomatic.
2. Exercise restriction is not required.

Surgical

Indications and Timing
Indications for surgery include a significant left-to-right shunt with a Qp/Qs ratio of greater than 2:1 and, if the anatomy is uncomplicated, a ratio of greater than 1.5:1. Surgery is indicated in patients with scimitar syndrome with severe hypoplasia of the right lung even with a Qp/Qs ratio less than 2:1. Surgery is carried out between the age of 2 and 5 years. Isolated single-lobe anomaly without an ASD is usually not corrected.

Procedures
Surgical correction is carried out under cardiopulmonary bypass. The procedure to be performed depends on the site of the anomalous drainage.
1. **To the RA.** The ASD is widened, and a patch is sewn in such a way that the anomalous pulmonary veins drain into the LA (similar to that shown in Fig. 14-33, B).
2. **To the SVC.** A tunnel is created between the anomalous vein and the ASD through the SVC and the RA by using a Teflon or pericardial patch. A plastic or pericardial gusset is placed in the SVC to prevent obstruction to the SVC.
3. **To the IVC.** In scimitar syndrome, the resection of the involved lobe(s) may be indicated without connecting the anomalous vein to the heart. When the anomalous venous drainage is an isolated lesion, the vein is reimplanted to the RA, and an intraatrial tunnel is created to drain into the LA.
4. **To the coronary sinus.** This defect is repaired in the same manner as for TAPVR to the coronary sinus (see Fig. 14-33, C).

Mortality
Surgical mortality occurs less than 1% of the time.

Complications
1. SVC obstruction for those patients with anomalous drainage into the SVC.
2. Postoperative arrhythmias (usually supraventricular) occur.

Postoperative Follow-up
1. An examination should be done every 1 to 2 years or at longer intervals.
2. No restriction in activities is indicated.
Obstructive Lesions

Lesions that produce obstruction to ventricular outflow such as pulmonary stenosis (PS), aortic stenosis (AS), and coarctation of the aorta (COA) are discussed in this chapter.
Pulmonary Stenosis

Prevalence
Isolated PS occurs in 8% to 12% of all congenital heart defects (CHDs). PS is often associated with other CHDs, such as tetralogy of Fallot (TOF), single ventricle, and others.

Pathology
1. PS may be valvular, subvalvular (infundibular), supravalvular, or within the RV cavity (i.e., “double-chambered RV”).
2. In valvular PS, the pulmonary valve is thickened, with fused or absent commissures and a small orifice (Fig. 13-1, A). Although the RV is usually normal in size, it is hypoplastic in infants with critical PS (with a nearly atretic valve). Dysplastic valves (consisting of thickened, irregular, immobile tissue and a variably small pulmonary valve annulus) are frequently seen with Noonan’s syndrome.
3. Isolated infundibular PS is rare; it is usually associated with a large ventricular septal defect (VSD), as seen in TOF (see Fig. 13-1, B).
4. Aberrant hypertrophied muscular bands (running between the ventricular septum and the anterior wall) divide the right ventricular (RV) cavity into a proximal high-pressure chamber and a distal low-pressure chamber (double-chambered RV). A “dimple” in the ordinarily smooth RV surface is found during surgery (see Chapter 15).
5. Supravalvular PS (or stenosis of the pulmonary arteries), isolated or in association with other CHDs, occurs in 2% to 3% of all patients with CHD. The stenosis may be single, involving the main pulmonary artery (PA) (see Fig. 13-1) or either of its branches, or multiple, involving both the main and several smaller peripheral PA branches (not shown). Commonly associated defects are pulmonary valve stenosis, VSD, and TOF. Peripheral PA stenosis is often seen in association with congenital syndromes; such as Williams syndrome, Noonan’s syndrome, Alagille syndrome, Ehlers-Danlos syndrome, and Silver-Russell syndrome or congenital rubella syndrome. PA stenosis is discussed further in Chapter 15.

Clinical Manifestations

History
1. Children with mild PS are completely asymptomatic. Exertional dyspnea and easy fatigability may be present in patients with moderately severe cases. Heart failure or exertional chest pain may develop in severe cases.
2. Newborns with critical PS may present with poor feeding, tachypnea, and cyanosis.

Physical Examination (Fig. 13-2)
1. Most patients are acyanotic and well developed. Newborns with critical PS are cyanotic
and tachypneic.

2. A right ventricular tap and a systolic thrill may be present at the upper left sternal border (and occasionally in the suprasternal notch).

![Figure 13-1](image1.png)

**FIGURE 13-1** Anatomic types of pulmonary stenoses (PSs). **A**, Valvular stenosis. **B**, Infundibular stenosis. **C**, Supravalvular PS (or stenosis of the main pulmonary artery (PA)). Abnormalities are indicated by arrows. AO, aorta; LV, left ventricle; RA, right atrium; RV, right ventricle.

3. A systolic ejection click is present at the upper left sternal border only with valvular stenosis. The S2 may split widely, and the P2 may be diminished in intensity. An ejection-type systolic murmur (grade 2–5 of 6) is best audible at the upper left sternal border, and it transmits well to the back, too. The louder and longer the murmur, the more severe the stenosis is.

4. Hepatomegaly may be present if congestive heart failure (CHF) develops.

5. In newborns with critical PS, cyanosis may be present (caused by a right-to-left atrial shunt), and signs of CHF with hepatomegaly and peripheral vasoconstriction may be found.

6. In patients with peripheral PA stenosis, a midsystolic murmur in the pulmonary valve area is well transmitted to the axillae and back. Occasionally, a continuous murmur is audible over the involved lung field.

**Electrocardiography**

1. The electrocardiogram (ECG) findings are normal in mild cases.
2. Right-axis deviation (RAD) and right ventricular hypertrophy (RVH) are present in moderate PS.

3. Right atrial hypertrophy (RAH) and RVH with “strain” may be seen in severe PS.

4. Neonates with critical PS may show left ventricular hypertrophy (LVH) because of a hypoplastic RV and relatively large left ventricle (LV).

**Radiography**

1. Heart size is usually normal, but the main PA segment may be prominent with valvular stenosis (caused by poststenotic dilatation) ([Fig. 13-3](#)). Cardiomegaly is present only if CHF develops.

2. Pulmonary vascular markings are usually normal but may decrease with severe PS.

3. In neonates with critical PS, lung fields are oligemic with a varying degree of cardiomegaly.

**Echocardiography**

1. Two-dimensional echocardiography in the parasternal short-axis view (see [Fig. 5-2](#)) shows thick pulmonary valve cusps with restricted systolic motion (doming). The subcostal long-axis view (see [Fig. 5-5](#)) may show similar findings. The size of the pulmonary valve annulus can be estimated. The main PA is often dilated (poststenotic dilatation).

![FIGURE 13-3](https://example.com/figure13-3.png)

**FIGURE 13-3**  Posteroanterior view of chest radiograph in pulmonary valve stenosis. Note a marked poststenotic dilatation (arrow) and normal pulmonary vascularity. (Courtesy Dr. Ewell Clarke, San Antonio, TX.)

2. The Doppler study can estimate the pressure gradient across the stenotic valve by the simplified Bernoulli equation. Multiple echocardiographic views, including parasternal...
short-axis and subcostal long-axis views, should be used to obtain the maximum flow velocity. The instantaneous pressure gradient estimated by Doppler echo is slightly greater than the peak-to-peak systolic pressure gradient obtained by cardiac catheterization. The severity of PS (by Doppler gradient) may be classified as follows.

a. **Mild:** A pressure gradient less than 35 to 40 mm Hg (or RV systolic pressure <50% of the LV pressure).

b. **Moderate:** A valve pressure gradient of 40 to 70 mm Hg (or RV pressure 50%–75% of the LV pressure).

c. **Severe:** A pressure gradient greater than 70 mm Hg (or RV pressure ≥75% LV pressure).

3. Dysplastic valves are characterized by a noticeably thickened and immobile leaflet and hypoplasia of the pulmonary valve annulus.

4. In neonates, Doppler pressure gradient may underestimate the severity of PS because the PA pressure may be higher than normal, especially in those with PDA with a left-to-right shunt.

**Natural History**

1. The severity of stenosis is usually not progressive in mild PS. For example, more than 95% of patients with an initial Doppler gradient less than 25 mm Hg did not need operation over a 25-year period. The majority of the patients with mild PS (<35 mm Hg) do well without intervention.

2. In moderate or severe PS, the severity tends to progress with age.

3. CHF may develop in patients with severe stenosis. Sudden death is possible in patients with severe stenosis during heavy physical activities.

4. Without appropriate management, most neonates with critical PS die (see Management).

**Management**

**Medical**

1. Newborns with critical PS and cyanosis require emergency treatment to reduce mortality.

   a. These babies may temporarily improve with prostaglandin E₁ infusion, which reopens the ductus arteriosus, and other supportive measures.

   b. Balloon valvuloplasty is the procedure of choice in critically ill neonates. Immediate reduction in pressure gradient can be achieved in more than 90% of these neonates.

   c. Some of these infants are not able to maintain effective forward flow through the pulmonary valve because of noncompliant or hypoplastic RV. Some of them may need one of the following: (1) a prolonged prostaglandin (PG) infusion (for 3 weeks), (2) ductal stenting, or (3) systemic-to-pulmonary shunt surgery.

   d. In neonates, complications of the balloon procedure are more common than in older patients, with a mortality rate of up to 3%, a major complication rate of 3.5%, and a
minor complication rate of 15%.
e. About 15% of the patients require reintervention (either repeat valvuloplasty or surgery for infundibular stenosis or dysplastic valve) at a later time.
f. Even dysplastic valves appear to mature after the balloon procedure.

2. Balloon valvuloplasty is the procedure of choice for the valvular stenosis at all ages.
a. Indications for the balloon procedure may include the following.
   1) A resting pressure gradient of greater than 40 mm Hg with the patient sedated in the catheterization laboratory.
   2) If the catheterization gradient is 30 to 39 mm Hg, the balloon procedure may be reasonable.
   3) Symptoms attributable to PS with a catheterization gradient greater than 30 mm Hg. The symptoms may include angina, syncope or presyncope, and exertional dyspnea.
   4) The procedure is useful and reasonable in patients with dysplastic pulmonary valve, as commonly seen in Noonan’s syndrome. It has a lower success rate with the valvuloplasty (65%). If balloon valvuloplasty is unsuccessful, surgery is indicated.

b. Results: The balloon procedure carries an extremely low risk, is painless, is less costly than surgery, and shortens hospital stay.
   1) A good outcome is achieved in 85% of patients with valvular stenosis. Restenosis after balloon dilatation is extremely rare.
   2) Pulmonary regurgitation (PR) after balloon dilatation is common, occurring in 10% to 40% of patients. PR is usually well tolerated, although rarely some of these patients may become candidates for pulmonary valve implantation. Therefore, a balloon smaller than previously recommended (i.e., 120%–140% of the annulus) may be preferable.
   3) After relief of severe PS (either by balloon or surgery), a hypertrophied dynamic infundibulum may cause a persistent pressure gradient, with rare occurrences of fatal outcome (“suicidal right ventricle”). Propranolol may be given to reduce hyperdynamic infundibular obstruction. The reduction of this gradient occurs gradually over weeks.

3. Restriction of activity is not necessary in children with this condition except in cases of severe PS (Doppler gradient >70 mm Hg).

**Surgical**

**Indications and Timing**

1. Surgical valvotomy should be limited to patients with more complex lesions or those in whom balloon procedure is contraindicated or failed.
2. Other types of obstructions (e.g., infundibular stenosis, anomalous RV muscle bundle) with significant pressure gradients require surgery on an elective basis.
3. If balloon valvuloplasty is unsuccessful or unavailable, infants with critical PS and CHF require surgery on an urgent basis.
Procedure
1. Through a midsternal incision, pulmonary valvotomy is performed for pulmonary valve stenosis under cardiopulmonary bypass. The approach is through the PA. Neonates with critical PS may require a transventricular valvotomy or the insertion of a transannular patch (or both) while receiving prostaglandin E\textsubscript{1} infusion. If severe infundibular hypoplasia is present, a systemic-to-PA shunt is also performed.
2. Dysplastic valves often require complete excision of the valves. Simple valvotomy may be ineffective.
3. Infundibular stenosis requires resection of the infundibular muscle and patch widening of the right ventricular outflow tract.
4. Stenosis at the main PA level requires patch widening of the narrow portion.
5. Anomalous muscle bundles require surgical resection.

Mortality
Surgical mortality occurs in fewer than 1% of older children. The rate is about 10% in critically ill infants.
Aortic Stenosis

Prevalence

Left ventricular outflow tract obstruction (LVOTO), which includes stenosis at, below, or above the aortic valve, represents up to 10% of all CHDs. Valvular AS is the most frequent (71%) followed by subvalvular stenosis (23%) and supravalvular stenosis (6%). Aortic valve stenosis occurs more often in males (male-to-female ratio of 4:1).

Pathology

1. Stenosis may be at the valvular, subvalvular, or supravalvular level (Fig. 13-4).
2. Valvular AS may be caused by a bicuspid aortic valve, a unicuspid aortic valve, or stenosis of the tricuspid (or tricommissural) aortic valve (see Fig. 13-4, B). A bicuspid aortic valve with a fused commissure and an eccentric orifice accounts for the most common form of aortic valve stenosis (75%) (Fig. 13-5, B). Less common is the unicuspid valve with one lateral attachment (see Fig. 13-5, A). A valve that has three unseparated cusps with a stenotic central orifice is the least common form (see Fig. 13-5, C). Many bicuspid aortic valves are nonobstructive during childhood and become stenotic in adult life because of calcification of the valve.

3. Symptomatic neonates with so-called critical neonatal aortic valve stenosis have primitive, myxomatous valve tissue, with a pinhole opening. The aortic valve ring and ascending aorta are almost always hypoplastic. Hypoplasia of the mitral valve, LV cavity, or LVOT and a VSD are also frequently found, often requiring one-ventricular repair (Norwood operation followed by Fontan operation).

4. Supravalvular AS is an annular constriction at the upper margin of the sinus of Valsalva (see Fig. 13-4, C). Occasionally, the ascending aorta is diffusely hypoplastic. This is often associated with Williams syndrome (which includes mental retardation, characteristic facies, and multiple PA stenosis).

5. Subvalvular (subaortic) stenosis may be in the form of a discrete narrowing or a long tunnel-like fibromuscular narrowing of the LVOT.
   a. Discrete stenosis occurs more often than tunnel stenosis and accounts for about 10% of all AS cases. It may be simple membranous ridge or collar (more common) or fibromuscular ridge with or without membrane. Some subaortic stenosis is believed to develop as the result of turbulence in an abnormally shaped LVOT, which causes endocardial injury and subsequent proliferation and fibrosis.
      1) Two thirds of the patients have associated cardiac lesions, such as VSD, patent ductus arteriosus (PDA), or COA.
      2) In one third of the patients, the stenosis is isolated; familial isolated subaortic membrane has been reported.
      3) In some patients, there is history of surgical intervention, such as membranous VSD closure or PA banding (9 months to 8 years before the development of the membrane).
   b. Tunnel-like subaortic stenosis is often associated with hypoplasia of the ascending aorta and aortic valve ring, as well as thickened aortic valve leaflets. It is usually associated with other LV anomalies, including Shone complex (comprising...
supramitral ring, parachute mitral valve, subaortic stenosis, and COA). Another type of subvalvular stenosis is idiopathic hypertrophic subaortic stenosis (see Fig. 13-4, E), a primary disorder of the heart muscle (discussed in Chapter 18).

**Clinical Manifestations**

**History**

1. Neonates with critical or severe stenosis of the aortic valve may develop signs of hypoperfusion or respiratory distress caused by pulmonary edema within days to weeks after birth.
2. Most children with mild to moderate AS are asymptomatic. Occasionally, exercise intolerance may be present.
3. Exertional chest pain, easy fatigability, or syncope may occur in a child with severe degree of obstruction.

**Physical Examination (Fig. 13-6)**

1. Infants and children with AS are acyanotic and are normally developed.
2. Except for neonates with critical AS, blood pressure is normal in most patients, but a narrow pulse pressure is present in severe AS. Patients with supravalvular AS may have a higher systolic pressure in the right arm than in the left (caused by the jet of stenosis directed into the innominate artery, the so-called Coanda effect).

3. A systolic thrill may be palpable at the upper right sternal border, in the suprasternal notch, or over the carotid arteries.
4. An ejection click may be heard with valvular AS. The S2 splits either normally or a bit narrowly. The S2 may split paradoxically in severe AS (see Fig. 13-6). A harsh, grade 2 to 4 of 6, midsystolic murmur is best heard at the second right or left intercostal space, with good transmission to the neck and apex. A high-pitched, early diastolic decrescendo murmur, which results from aortic regurgitation (AR), may be audible in patients with bicuspid aortic valve and in those with discrete subvalvular stenosis.
5. Peculiar “elfin facies,” mental retardation, and friendly “cocktail party” personalities may be associated with supravalvular AS (e.g., Williams syndrome).
6. Newborns with critical AS may develop signs of reduced peripheral perfusion (with weak and thready pulses, pale cool skin, and slow capillary refill) triggered by ductal constriction. The clinical picture may mimic overwhelming sepsis with low cardiac output. The heart murmur may be absent or faint but becomes louder when CHF improves.

**Electrocardiography**

In mild cases, the ECG is normal. LVH with or without strain pattern may be present in severe cases (Fig. 13-7). Correlation of the severity of AS and the ECG abnormalities is relatively poor.

**Radiography**

1. The heart size is usually normal in children, but a dilated ascending aorta or a prominent aortic knob may be seen occasionally in valvular AS, resulting from poststenotic dilatation.
2. Significant cardiomegaly does not develop unless CHF occurs later in life or if AR becomes substantial.

**Echocardiography**

1. Valvular AS
   a. In the parasternal short-axis view of the two-dimensional (2D) echocardiogram, normal aortic valves are tricuspid, with three cusps of approximately equal size. In diastole, the normal aortic cusp margins form a Y pattern (Fig. 13-8). In systole, a bicuspid aortic valve appears as a noncircular (i.e., football-shaped) orifice (see Fig. 13-8). Stenosis of the tricuspid aortic valve appears as a heavy Y pattern in diastole and as a small, centrally located orifice in systole, with three thickened commissures distinctly visible. A unicommissural aortic valve, which is seen often in infants with critical AS, is seen as a circular orifice positioned eccentrically within the aortic root and without visible distinct cusps.

![Figure 13-7](image-url) Tracing from a 7-year-old boy with severe aortic stenosis. It shows left ventricular hypertrophy, with a probable “strain” pattern.
b. In the parasternal long-axis view of the 2D echocardiogram, doming of the thick aortic valve with restriction to the opening is seen in systole. Reverse doming during diastole commonly occurs in the unicuspid valve, occurs less frequently in the bicuspid valve, and does not occur in the tricuspid aortic valve.

c. Doppler pressure gradient is best obtained from the apical five-chamber view with the cursor placed distal to the stenotic aortic valve in the sinus of Valsalva.

d. Doppler studies can estimate the severity of the stenosis by using the simplified Bernoulli equation (see Chapter 5). However, the Doppler-derived gradient (i.e., instantaneous gradient) may be approximately 20% higher than the peak-to-peak systolic pressure gradient obtained under sedation during cardiac catheterization. The severity of AS by Doppler peak (and mean) gradient and by peak-to-peak gradient may be classified as follows (Graham et al, 2005).

1) **Mild:** A peak Doppler of less than 40 mm Hg (mean Doppler <25 mm Hg) or peak-to-peak gradient of less than 30 mm Hg

2) **Moderate:** A peak Doppler of 40 to 70 mm Hg (mean Doppler of 25–40 mm Hg) or peak-to-peak gradient of 30 to 50 mm Hg

3) **Severe:** A peak Doppler of greater than 70 mm Hg (mean Doppler of >40 mm Hg) or peak-to-peak gradient of greater than 50 mm Hg

2. Subvalvular AS

a. The type of subaortic stenosis is best imaged in the parasternal long-axis view, apical long-axis view, and apical five-chamber view just beneath the aortic valve.

b. One should note whether the stenosis is membrane, fibromuscular ridge, or diffuse tunnel-like fibromuscular narrowing (tunnel stenosis).

c. For the membranous type, one should note (1) the length of the membrane, (2) the pressure gradient across the obstruction, (3) the distance of the membrane from the hinge point of the aortic valve, (4) extension of the membrane onto the aortic or mitral valve, (5) the presence of aortic regurgitation, and (6) associated cardiac lesion. Some of these have been linked to the risk of recurrence requiring surgery.

d. The pressure gradient across the subaortic stenosis is best obtained in the apical five-chamber view with the cursor placed immediately distal to the obstruction but proximal to the aortic valve.

3. Supravalvular AS is seen as a narrowing of the ascending aorta in the parasternal long-axis view and apical long-axis view. The suprasternal view best shows diffuse hypoplasia of the ascending aorta. Doppler pressure gradient is obtained with the cursor distal to the stenosis in the ascending aorta.
FIGURE 13-8  Diagram of parasternal short-axis scan showing normal tricuspid (left column) and bicuspid aortic valves (three right columns) during diastole and systole. Three nearly equal-sized aortic cusps are imaged in a normal aortic valve, which opens widely during systole. The systolic opening pattern distinguishes a raphe from a commissure. With a bicuspid aortic valve, various commissural orientations are imaged. The most common pattern demonstrates commissures at the 4 or 5 o’clock and the 9 or 10 o’clock positions, with raphe at the 1 or 2 o’clock position (46%). (Modified from Brandenburg RO Jr, Tajik AJ, Edwards WD, et al: Accuracy of 2-dimensional echocardiographic diagnosis of congenitally bicuspid aortic valve: Echocardiographic-anatomic correlation in 115 patients. Am J Cardiol 51:1469-1473, 1983.)
Natural History

1. Chest pain, syncope, and even sudden death (1%–2% of cases) may occur in children with severe AS.
2. Heart failure occurs with severe AS during the newborn period or later in adult life.
3. Bicuspid aortic valve, the most common type of AS, becomes frequently more severe with time in a significant number of patients. Isolated AR tends to occur in younger patients. Early signs of calcification occur in the second to third decades of life with worsening of AS and eventual worsening of AR. Valve replacement may be required in many adult patients.
4. Progressive worsening of AR is possible in discrete subaortic stenosis. The jet of the subaortic stenosis damages the aortic valve with resulting AR.

Management

Medical

1. For critically ill newborns with CHF, the patients are stabilized before surgery or balloon valvuloplasty by the use of rapidly acting inotropic agents (usually dopamine) and diuretics to treat CHF and intravenous infusion of prostaglandin E\(_1\) to reopen the ductus. Mechanical ventilation may be useful. Neonates and young infants with CHF from critical AS require the balloon valvuloplasty (or surgery) on an urgent basis.
2. For asymptomatic patients with mild to moderate stenosis a serial echo-Doppler ultrasound evaluation is needed at approximately 1- to 2-year intervals. It is needed more often in children with severe stenosis because AS, of all severities, tends to worsen with time.
3. Exercise stress test (EST) may be indicated in asymptomatic children with peak gradients above 50 mm Hg or mean Doppler gradient above 30 mm Hg who are interested in athletic participation or in becoming pregnant.
4. Balloon valvuloplasty
   a. Indications: Percutaneous balloon valvuloplasty has replaced open surgical valvotomy as the treatment of choice for children with moderate to severe congenital aortic valve stenosis in the majority of centers. For subaortic stenosis, the balloon procedure is not effective. The following may be indications for the procedure according to the American Heart Association (*Feltes et al, 2011*).
      - In newborns with isolated critical valvar AS who are ductal dependent
      - In children with isolated valvar AS who have depressed LV systolic function
      - In children with isolated valvar AS who have a resting peak-to-peak systolic gradient of 50 mm Hg or greater by cardiac catheterization
      - In children with isolated valvar AS who have a resting peak systolic gradient 40 mm Hg or greater, if there are symptoms of angina or syncope or ischemic ST-T wave changes on ECG at rest or with exercise
   b. Results of the valvuloplasty: Although the results of aortic balloon valvuloplasty are promising, they are not as good as those for PS. A technically adequate balloon
dilatation will typically reduce the catheter peak-to-peak systolic gradient to 20 to 35 mm Hg. The optimal ratio of balloon-annulus diameter is 0.9 to 1.0. Larger balloon diameter is associated with a greater risk of developing AR after the procedure. The long-term outcome after a successful valve dilatation is good, but late restenosis and aortic valve regurgitation eventually necessitate reintervention in the majority of patients. The freedom from reintervention was 67% after 5 years in children; it was lower (48%) in newborns (Feltes et al, 2011). Serious complications (e.g., major hemorrhage, loss of the femoral artery pulse, avulsion of part of the aortic valve leaflet, perforation of the mitral valve or left ventricle) can occur.

5. Activity restrictions (Graham et al, 2005)
   a. No limitation in activity is required for mild AS.
   b. For patients with moderate AS, varying levels of activity restriction are required as suggested below.
      1) Those with mild or no LVH by echo, no LV strain on ECG, and normal EST findings may participate in competitive sports in class IA, IB, and IIA.
      2) Those with supraventricular tachycardia (SVT) or multiple or complex ventricular tachycardia (VT) at rest or with exercise may participate only in low-intensity competitive sports in class IA and IB (see Fig. 34-1).
   c. Patients with severe AS should not participate in any competitive sports.

Surgical

Indications and Timing

1. Valvular AS: If the balloon valvuloplasty has failed to relieve the pressure gradient or if severe AR results after the balloon procedure.
2. Subaortic membrane: Most commonly accepted indications for surgical intervention are a peak gradient greater than 35 mm Hg and at least mild AR. Occasionally, the presence of one of them may be an indication for intervention. Most centers accept the onset of AR as an indication for surgical removal of the membrane.
   Patients with the following are considered low risk and are recommended for medical follow-up rather than surgical intervention: those with (1) no or trace AR, (2) Doppler gradient of 30 mm Hg or less, (3) the membrane not in proximity to the aortic valve (>6 mm), and (4) thin and mobile aortic valve. The risk of recurrence after surgical removal of the membrane has been a concern (see later for further discussion).
3. Tunnel-type subaortic stenosis: A gradient of 50 mm Hg or greater is considered an indication for surgery.
4. Supravalvular AS: Surgery is advisable for patients with supravalvular AS when there is a peak pressure gradient across the stenosis greater than 50 to 60 mm Hg, severe LVH, or appearance of new AR.

Procedures (and Mortality)

1. Closed aortic valvotomy, using calibrated dilators or balloon catheters without
cardiopulmonary bypass, may be performed in sick infants. This procedure has a low surgical mortality rate.

2. Newborns with “critical AS” (with hypoplasia of the aortic annulus, ascending aorta, and mitral annulus, small LV cavity, and MR from papillary muscle infarction) have a poor prognosis. The Norwood procedure (see Chapter 14) may be preferable (for future Fontan operation) to aortic valvotomy. A mortality rate for sick neonates with critical AS has decreased to around 10%, although it was much higher in the past, up to 40% to 50%.

3. Valvular AS: The following procedures are performed for aortic valve stenosis: aortic valve commissurotomy, aortic valve replacement, or the Ross procedure.
   a. Aortic valve commissurotomy is usually tried if stenosis is the predominant lesion. Fused commissures are divided with a knife to within 1 mm of the aortic wall. Only commissures with adequate leaflet attachments to the aortic wall are opened because division of rudimentary commissures produces severe AR.
   b. Aortic valve replacement may be necessary if AR is the predominant lesion. Valve replacement is done by using a mechanical prosthetic valve or homografts. The advantage of the mechanical valve is durability, but it has the tendency of thrombus formation on the valve with a potential embolization. Because of this tendency, patients require warfarin, with its attendant risks of bleeding, in addition to aspirin. Homografts have the advantage of a lower incidence of thromboembolism, but deterioration of the homograft (caused by generation and calcification) is likely to occur within a decade or two.
   c. Because of accelerated degeneration of homograft or bioprosthetic valves, a mechanical valve is usually used in adolescents. For adolescent girls or women in whom pregnancy is desired, homografts may be a good alternative until the childbearing years are completed because of the known teratogenic effects of warfarin. A recent study in adults suggests that increased serum cholesterol level (>200 mg/dL) may be a risk factor for bioprosthetic valve calcification, so lowering cholesterol levels is recommended.
   d. In the Ross procedure (pulmonary root autografts), the autologous pulmonary valve replaces the aortic valve, and an aortic or a pulmonary allograft replaces the pulmonary valve. The Ross procedure is more complex than simple aortic valve replacement because it requires coronary artery implantation (Fig. 13-9). The pulmonary valve autograft has the advantage of documented long-term durability; it does not require anticoagulation and remains uncompromised by host reactions. There is evidence of the autograft’s growth, making it an attractive option for aortic valve replacement in infants and children. Mild regurgitation of the neoaortic valve occurs frequently, which may result from a preexisting pulmonary valve regurgitation. The patient’s own aortic valve may be used for pulmonary position after aortic valvotomy (“double” Ross procedure). An early mortality rate for the Ross procedure (and the Ross/Konno procedure) is less than 5%.
FIGURE 13-9 Ross procedure (pulmonary root autograft). A, The two horizontal lines on the aorta (AO) and pulmonary artery (PA) and two broken circles around the coronary artery ostia are lines of proposed incision. The pulmonary valve, with a small rim of right ventricle (RV) muscle, and the adjacent PA are removed. B, The aortic valve and the adjacent aorta have been removed, leaving buttons of aortic tissue around the coronary arteries. C, The pulmonary autograft is sutured to the aortic annulus and to the distal aorta, and the coronary arteries are sutured to openings made in the PA. The pulmonary valve is replaced with either an aortic or a pulmonary allograft. LV, left ventricle; RA, right atrium.

4. Subvalvular AS
   a. Excision of the membrane is done for discrete subvalvular AS. There is a tendency for recurrence after surgical excision. The recurrence rate is as high as 25% to 30%. Risk factors for recurrence include (a) younger age (<4 year), (b) high-pressure gradient (>50 mm Hg), (c) proximity of the membrane to the aortic valve (<6 mm), and (d) extension of the membrane to the aortic or mitral valves. Some centers delay surgery until after 10 years of age because recurrence is very rare at this age. More aggressive resection of the membrane and extensive myectomy reduced the recurrence but resulted in higher complication of atrioventricular block (14%). The surgical mortality rate for subaortic membrane is near 0%.
   b. For complex LVOT obstruction (e.g., aortic stenosis combined with a diffuse subaortic stenosis or hypoplastic annulus), the Ross procedure can be combined with Konno operation (the Ross-Konno procedure) (Fig. 13-10). The mortality for tunnel subaortic stenosis is less than 5%.

4. Supravalvular AS: With the most common hourglass type of supravalvular AS, a reconstructive surgery is done using a Y-shaped patch. For the diffuse form of obstruction, the patch is extended superiorly into the transverse arch to relieve all obstruction. Death occurs for supravalvular stenosis in fewer than 1% of cases, although diffuse narrowing of the ascending aorta is a risk factor.

Postballoon and Postoperative Follow-up

1. Annual follow-up examination is necessary for all patients who had the aortic valve balloon procedure or surgery to detect development of stenosis or regurgitation. In 10% to 30% of patients, significant AR develops after valvotomy or the balloon procedure.
2. Recurrence of discrete subaortic stenosis occurs in 25% to 30% after surgical resection of the membrane and as long as 17 years after the initial procedure, requiring a long, periodic follow-up. Some of these patients require reoperation at a later age.
3. Anticoagulation is needed after a prosthetic mechanical valve replacement. The
The international normalized ratio (INR) should be maintained between 2.5 and 3.5 for the first 3 months and 2.0 to 3.0 beyond that time. Low-dose aspirin (75–100 mg/day for adolescents) is also indicated in addition to warfarin (American College of Cardiology/American Heart Association [ACC/AHA] 2006 Guidelines).

4. After aortic valve replacement with bioprosthesis and no risk factors, aspirin (75–100 mg), but not warfarin, is indicated. When there are risk factors (which include atrial fibrillation, previous thromboembolism, LV dysfunction, and hypercoagulable state), warfarin is indicated to achieve an INR of 2.0 to 3.0 (ACC/AHA 2006 Guidelines).

**FIGURE 13-10** The Ross-Konno procedure. A, Intended incision in the ascending aorta and around the aortic annulus and excision boundaries for the pulmonary artery and right ventricle (RV) are shown. Intended incisions to harvest buttons of aortic wall around the coronary artery ostia are also shown. B, The pulmonary artery autograft has been harvested (with an extra portion of the RV, not shown) for the Ross procedure. The aortic root and aortic valve are completely excised. C, The small obstructed left ventricular outflow tract (LVOT) is shown. The intended incision in the LVOT and the interventricular septum is noted by the dotted line, which will result in a V-shaped widening of the LVOT. D, The posterior portion of the pulmonary autograft is sutured to the original LVOT. E, The LVOT is reconstructed by suturing the extra portion of the RV to the widened V-shaped LVOT. The coronary arteries have been reimplanted. F, The RVOT is reconstructed by inserting a pulmonary homograft between the RV body and the distal end of the pulmonary artery. LCA, left coronary artery; LVOT, left ventricular outflow tract; RCA, right coronary artery; SVC, superior vena cava. Other abbreviations used are the same as in Figure 13-9.
Coarctation of the Aorta

Prevalence
Coarctation of the aorta occurs in 8% to 10% of all cases of CHD. It is more common in males than in females (male-to-female ratio of 2 to 1). Among patients with Turner’s syndrome, 30% have COA.

Pathology
1. The usual location of COA is juxtaductal, just distal to the left subclavian artery; less often it is proximal to the origin of the left subclavian artery.
2. The most common associated anomaly is bicuspid aortic valve, which occurs in more than 50% and up to 85% of all patients with COA.
3. COA also occurs as part of other CHDs, such as transposition of the great arteries and double-outlet right ventricle (e.g., Taussig-Bing abnormality).
4. Intracerebral aneurysm (berry aneurysm) is present in approximately 10% of patients with COA (Connolly et al, 2003).
5. In symptomatic infants with COA, other associated cardiac defects such as aortic hypoplasia, abnormal aortic valve, VSD, and mitral valve anomalies are often present. In these infants, during fetal life, the descending aorta is supplied mostly via right-to-left ductal flow because the amount of antegrade flow through the relatively small aortic arch and isthmus is reduced (see Fig. 10-3). With ductal closure, a reduced antegrade aortic flow to the descending aorta produces symptoms early in life. Good collateral circulation has not developed in these infants (see Chapter 10). Occasionally, infants without associated defects may become symptomatic because of LV failure, which results from a sudden increase in pressure work in early postnatal life.
6. In asymptomatic infants and children with COA, during fetal life, the descending aorta is supplied by both normal amount of antegrade aortic flow through the aortic isthmus and normal ductal flow because associated cardiac defects are rare in these children except for bicuspid aortic valve. Good collateral circulation gradually develops between the proximal aorta and the distal aorta during fetal life.
7. Major collateral circulation between the aortic segments proximal and distal to the coarctation comprises (1) the internal mammary artery anteriorly, (2) arteries arising from the subclavian artery by way of the intercostal arteries, and (3) the anterior spinal artery (Fig. 13-11).
FIGURE 13-11  Collateral circulation in coarctation of the aorta. Anteriorly, the internal mammary artery leads to the epigastric arteries for the supply to the lower extremity. The arteries arising from the subclavian artery and supplying the scapula communicate, by way of intercostal arteries, with the descending aorta, thereby supplying blood to the abdominal organs. The anterior spinal artery is also enlarged. a., artery; Coarc, coarctation; Inf., inferior; Lat., lateral; Sup, superior. (From Moller JH, Amplatz K, Edwards JE: Congenital Heart Disease. Kalamazoo, MI, Upjohn, 1971.)

The presentation of patients with COA occurs in a bimodal distribution: newborn infants with circulatory symptoms in the first weeks of life and asymptomatic infants and children. Clinical manifestation and management are quite different in these two groups; therefore, they are presented under separate headings.

## Symptomatic Infants

### Clinical Manifestations

#### History

Poor feeding, dyspnea, or signs of acute circulatory shock may develop in the first 6 weeks of life. **Figure 13-12** provides an explanation for hemodynamic deterioration in the
newborn period. The newborn discharge examination may have been normal as a result of incomplete obliteration of the aortic end of the ductus, which would permit blood flow to the descending aorta. After ductal obliteration, the aortic lumen narrows with loss of the space provided by the aortic end of the ductus.

**Physical Examination**

1. Infants with COA are pale and experience varying degrees of respiratory distress. Oliguria or anuria, general circulatory shock, and severe acidemia are common. Differential cyanosis may be present; for example, only the lower half of the body is cyanotic because of a right-to-left ductal shunt (particularly after prostaglandin E$_1$ [PGE$_1$] infusion).

2. Peripheral pulses may be weak and thready as a result of CHF. A blood pressure differential may become apparent only after improvement of cardiac function with administration of rapidly acting inotropic agents.

3. The S2 is single and loud; a loud S3 gallop is usually present. No heart murmur is present in 50% of sick infants. A nonspecific ejection systolic murmur is audible over the precordium. The heart murmur may become louder after treatment.

**Electrocardiography**

A normal or rightward QRS axis and RVH or right bundle branch block (RBBB) are present in most infants with COA rather than LVH; LVH is seen in older children (see Chapter 10) (Fig. 13-13).

**FIGURE 13-12** Explanation for hemodynamic deterioration seen in some infants with coarctation of the aorta (COA) in the first days of life. **A**, Coarctation is at the juxtaductal position, so that space is added to the narrowed aorta (AO) by the ductus. **B**, After ductal obliteration, the added lumen is lost, and the aorta becomes severely obstructed, although the severity of the coarctation is unchanged. PA, pulmonary artery.
**Radiography**

Marked cardiomegaly and pulmonary edema or pulmonary venous congestion are usually present.

**Echocardiography**

Two-dimensional echocardiography and color-flow Doppler studies usually show the site and extent of the coarctation (Fig. 13-14).

1. In the suprasternal notch view, a thin wedge-shaped “posterior shelf” is imaged in the posterolateral aspect of the upper descending aorta, which is distal to the left subclavian artery.

2. Varying degrees of isthmic hypoplasia are present. The third percentile value of normal internal dimension of the aortic isthmus at 40-week gestation is 5.4 mm.

3. The transverse aortic arch may be hypoplastic also. Poststenotic dilatation of the descending aorta is usually imaged. Bicuspid aortic valve is frequently present. Other associated defects such as VSD can be imaged.

4. Echocardiographic diagnosis of neonatal COA in the presence of patent ductus arteriosus is difficult. Ramaciotti et al (1993) suggested the following diagnostic criteria for neonatal COA: an aortic isthmus 3 mm or smaller without PDA or 4 mm or smaller in the presence of PDA. The ratio of the aortic isthmus to the descending aorta at the diaphragm smaller than 0.64 is also a reliable sign of COA in the presence of PDA.

5. Doppler studies above and below the coarctation site should be obtained, as shown in Figure 13-14, in assessing the severity of the coarctation (see Chapter 5 for further discussion).

6. Delayed rate of systolic upstroke and diastolic flow in the abdominal aorta may hint the presence of coarctation.

**Other Imaging**

Magnetic resonance imaging (MRI) has become the imaging modality of choice after echocardiographic diagnosis of the condition. Cardiac catheterization is no longer needed for anatomic assessment. It is performed primarily for interventional treatment.

**Natural History**

About 20% to 30% of all patients with COA develop CHF by 3 month of age. If COA is undetected and untreated in a symptomatic infant, early death may result from CHF and renal shutdown.
Management

Medical

1. In symptomatic neonates, PGE₁ infusion should be started to promote ductal patency and establish flow to the descending aorta and the kidneys.
2. Intensive anticongestive measures with short-acting inotropic agents (e.g., dopamine, dobutamine), diuretics, and oxygen should be started.

3. Metabolic disturbances (e.g., acidosis and hypoglycemia) should be recognized and treated promptly.
4. When the patient is stabilized, either surgical repair or balloon procedure should be performed because the improvement from anticongestive measures is usually temporary.
5. Although surgical repair has been the primary treatment for COA at most centers, balloon angioplasty with or without stent implantation has emerged as a less invasive alternative to surgery for sick infants. This is controversial, however. Balloon angioplasty appears to be associated with a higher rate of recoarctation than surgical repair, and the rate of complications (including femoral artery injury) is high during infancy. Some centers use cutting balloons or low-profile stents in very sick infants, which do not require overexpansion of the coarctation segment and thus are less likely to produce aneurysms. When stents are used in small infants, they are usually not expandable to adult size, requiring surgical removal at a later date.

Surgical

Indications and Timing

1. If CHF or circulatory shock develops early in life, surgical repair (extended resection with an end-to-end anastomosis) should be performed on an urgent basis. A short period of medical treatment, as described earlier, improves the patient’s condition before surgery.
2. If there is a large associated VSD, which occurs in 17% to 33% of patients with COA,
one of the following procedures may be performed:
  a. COA and VSD can be repaired in the same operative setting if the VSD is nonrestrictive. Both are performed through a median sternotomy.
  b. Only coarctation repair is performed if the VSD appears restrictive. Approximately 40% of restrictive VSDs close spontaneously. If CHF cannot be managed medically, VSD is surgically closed within days or weeks after the initial coarctation surgery.
  c. PA banding is performed if the PA pressure remains high after completing COA surgery. Later the VSD is closed, and the PA band is removed between 6 and 24 months of age.

Procedures
The choice of surgical procedures varies greatly from institution to institution, but the following procedures are popular (Fig. 13-15).
1. Extended resection and end-to-end anastomosis is preferred to other surgical options. It consists of resecting the coarctation segment and anastomosing the proximal and distal aortas (Fig. 13-15, top). Because most of symptomatic neonatal COA is associated with hypoplasia of the isthmus and occasionally of the aortic arch, extended resection with end-to-end anastomosis has been performed with a lower recurrence rate (<10%).
2. Subclavian flap aortoplasty consists of dividing the distal subclavian artery and inserting a flap of the proximal portion of this vessel between the two sides of the longitudinally split aorta throughout the coarctation segment (see Fig. 13-15, middle). The vertebral artery is ligated to avoid subclavian steal. The recurrence rate is lower (10%–40%) than that with the patch aortoplasty.
3. With patch aortoplasty, the aorta is opened longitudinally through the coarctation segment and extending to the left subclavian artery, and the fibrous shelf and any existing membrane are excised. An elliptic woven Dacron patch is inserted to expand the diameter of the lumen (see Fig. 13-15, bottom). Patch aortoplasty has the highest recurrence rate (≤50%).
4. A conduit insertion between the ascending and descending aorta may be performed for severe, long-segment COA (not shown).

Mortality
The mortality rate for COA surgery is less than 5%. The mortality rate for repair of COA and VSD at the same time is less than 10%.

Complications
1. Postoperative renal failure is the most common cause of death.
2. Residual obstruction or recoarctation occurs in 6% to 33% of all patients, but the recurrence rate is lower after surgery than that after balloon angioplasty.

Postoperative Follow-up
1. An examination every 6 to 12 months to check for recurrence of COA is necessary, especially when surgery is performed in the first year of life.
FIGURE 13-15  Surgical techniques for repair of coarctation of the aorta (COA). Top, End-to-end anastomosis. A segment of coarctation is resected, and the proximal and distal aortas are anastomosed end to end. Middle, Subclavian flap procedure. The distal subclavian artery is divided, and the flap of the proximal portion of this vessel is used to widen the coarcted segment. Bottom, Patch aortoplasty. An elliptic woven Dacron patch is inserted to expand the diameter of the lumen. Regardless of the type of operative procedure, the ductus arteriosus is always ligated and divided.

FIGURE 13-16  Cardiac findings of coarctation of the aorta. A systolic thrill may be present in the suprasternal notch (area shown by dots). EC, ejection click.

2. Balloon angioplasty (with or without stent) may be performed if a significant recoarctation develops.
3. Physicians should watch for and treat systemic hypertension.

Asymptomatic Infants and Children

Clinical Manifestations

History
Most children are asymptomatic. Occasionally, a child complains of weakness or pain (or both) in the legs after exercise.

**Physical Examination (Fig. 13-16)**
1. Patients grow and develop normally.
2. Arterial pulses in the leg are either absent or weak and delayed. There is hypertension in the arm or the leg systolic pressure is equal to or lower than the arm systolic pressure. In normal children, the oscillometric systolic pressure in the thigh or calf is 5 to 10 mm Hg higher than that in the arm. With use of the auscultatory method, the leg systolic pressure may be as much as 20 mm Hg higher than in the arm in normal children (see Chapter 2).
3. A systolic thrill may be present in the suprasternal notch. The S2 splits normally, and the A2 is accentuated. An ejection click is frequently audible at the apex or at the base (or both), which may originate in the associated bicuspid aortic valve or from systemic hypertension. An ejection systolic murmur grade 2 to 4 of 6 is heard at the upper right sternal border and mid-or lower left sternal border. A well-localized systolic murmur is also audible in the left interscapular area in the back. Occasionally, an early diastolic decrescendo murmur of AR from the bicuspid aortic valve may be audible in the third left intercostal space (see Fig. 13-16).

**Electrocardiography**
Leftward QRS axis and LVH are commonly found. The ECG is normal in approximately 20% of patients.

**Radiography**
1. The heart size may be normal or slightly enlarged.
2. Dilatation of the ascending aorta may be seen.
3. An E-shaped indentation on the barium-filled esophagus or a “3 sign” on overpenetrated films suggests COA (see Fig. 4-10).
4. Rib notching between the fourth and eighth ribs may be seen in older children but rarely in children younger than 5 years of age (see Fig. 4-9).

**Echocardiography**
1. The suprasternal notch 2D echo demonstrates a discrete shelf-like membrane in the posterolateral aspect of the descending aorta. Associated findings such as isthmus hypoplasia, poststenotic dilatation, and diminished pulsation in the descending aorta may be present. Bicuspid aortic valve is frequently present.
2. Doppler examination often demonstrates a pattern of diastolic runoff, especially in patients with robust collaterals or tight stenosis. Continuous-wave Doppler flow profile distal to the coarctation is composed of two superimposed signals representing low-velocity flow in the proximal descending aorta and high-velocity flow across the coarctation. As discussed earlier, a more accurate estimation of the gradient is obtained
by the expanded Bernoulli equation, in which the peak velocities obtained from the segments proximal and distal to the coarctation site are used. This is because the flow velocity proximal to the coarctation is often higher than 1.5 m/sec and it cannot be ignored in the Bernoulli equation. In severe COA with extensive collaterals, the Doppler-estimated gradient may underestimate the severity of the coarctation because the blood flow through the coarctation site is decreased.

Other Imaging
Magnetic resonance imaging with three-dimensional reconstruction supplemented by gadolinium contrast has become the imaging modality of choice. Cardiac catheterization is no longer needed for anatomic assessment.

Natural History
1. LV failure, rupture of the aorta, intracranial hemorrhage (i.e., rupture of a berry aneurysm of the arterial circle of Willis), hypertensive encephalopathy, and hypertensive cardiovascular disease are rare complications seen in adulthood.
2. A bicuspid aortic valve may cause stenosis or regurgitation with age.

Management
Medical
1. Children with mild COA should be watched regularly for hypertension in the arm and for increasing pressure differences between the arm and leg. Reduced BP readings in the lower extremities may be caused by femoral artery injuries resulting from previous surgeries or interventional procedures.
2. Balloon angioplasty for native unoperated coarctation is controversial, although most centers perform balloon dilatation for recurrent coarctation. Some centers continue to use the balloon procedure for the native COA, but other centers prefer a surgical approach.

   Indications for balloon intervention include the following according to a recent recommendation by the AHA (Feltes et al, 2011):
   • Transcatheter systolic gradient across COA of greater than 20 mm Hg and suitable anatomy, irrespective of patients’ age.
   • Transcatheter systolic gradient of less than 20 mm Hg with suitable angiographic anatomy:
     a. In the presence of significant collateral vessels
     b. In patients with univentricular heart
     c. In patients with significant LV dysfunction
   • It may be reasonable to consider the procedure for native coarctation as a palliative procedure at any age when the patient has severe LV dysfunction, severe mitral regurgitation, or systemic disease affected by the cardiac condition.

   The most common acute complication of the balloon angioplasty has been femoral
artery injury and thrombosis, especially in small children. There is a possibility of aortic aneurysm formation with serious late complications. A recent single center analysis of balloon angioplasty versus surgical repair of native coarctation in children ages 3 to 20 years suggests the superiority of surgical repair over balloon procedure in terms of aortic aneurysm formation (0% vs. 35%), with some aneurysms developing 5 years after the procedure (Cowley et al, 2005).

3. A balloon-expandable stainless-steel stent implanted concurrently with balloon angioplasty is gaining popularity. Currently, the aortic stent is used for older children (at least 8 to 10 years old), and the stent used should be expandable to an adult size (minimum of 20 mm in diameter).

Advantages of the use of the expandable stent may include the following: (1) it does not require overexpansion of the coarcted segment, thereby reducing the chance of the development of aortic aneurysm; (2) it produces better results with greater reduction of pressure gradient than the balloon procedure alone; and (3) it can be reexpanded to the adult size, avoiding repeat surgical procedures.

Current recommendations for stent placement in native COA and recoarctation of the aorta are as follows according to the recent recommendations by the AHA (Feltes et al, 2011).

- For recoarctation, stent placement is indicated in patients who have a transcatheter systolic coarctation gradient greater than 20 mm Hg and are of sufficient size for safe stent placement which can be expanded to an adult size.
- For initial treatment of native COA or recurrent coarctation, it is reasonable to consider stent placement if there is:
  a. A transcatheter systolic coarctation gradient of >20 mm Hg
  b. A transcatheter systolic gradient of <20 mm Hg with systolic hypertension caused by the narrowing of the aorta
  c. A long segment coarctation with a transcatheter systolic gradient >20 mm Hg
- For patients in whom balloon angioplasty has failed in the treatment of native or recurrent COA, it is reasonable to use stent placement.

4. Absorbable metal stent is in the experimental stage. The Magnesium Biocorrodible Stent (Biotroniks, Nulach, Switzerland) is an innovative stent made of a magnesium alloy (that also contains zirconium, yttrium, and rare earths), that can be deliverable through a 5-French sheath (Peuster et al, 2001). This could be used in infants and small children in whom repeat dilatation of the stent may be necessary.

**Surgical**

**Indications and Timing**

1. Significant narrowing of the aorta with pressure gradient greater than 20 to 30 mm Hg is considered an indication for surgery in asymptomatic children.
   a. Blood pressure measurement showing hypertension in the arm with a large systolic pressure gradient of 20 to 30 mm Hg or greater by Doppler echocardiography or blood pressure measurement may be a relatively weak indication.
b. Reduction of aortic diameter by 50% at the level of COA in the presence of pressure gradient of more than 20 to 30 mm Hg is considered an absolute indication for surgery. The dimension of the coarctation segment can be determined by an echocardiographic study, but MRI may be a better choice for older children and adolescents.

c. Children with mild COA (<20 mm Hg gradient) may be considered for surgery if a prominent gradient develops with exercise.

2. The preferred age for surgery varies from center to center; some centers prefer ages of 2 and 3 years, and others prefer delaying it until 4 to 5 years of age. A lower incidence of hypertension is found in patients who had COA repair before 1 year of age. However, early surgery (i.e., before 1 year of age) appears to increase the chance of recoarctation. The risk of late recurrence of coarctation is low if the surgery is performed after 2 years of age. Older children are operated on soon after the diagnosis is made.

**Procedures**

1. Through a left thoracotomy incision, extended resection of the coarctation segment and end-to-end anastomosis is the procedure of choice for discrete COA in children (see Fig. 13-15).

2. Occasionally, subclavian artery aortoplasty or circular or patch grafts may be performed.

**Mortality**

The mortality rate is less than 1% in older children.

**Complications**

1. Spinal cord ischemia producing paraplegia may develop after cross-clamping of the aorta during surgery, which is probably related to limited collateral circulation. This develops in 0.4% of cases.

2. Rebound hypertension may occur in the immediate postoperative period as a result of an increased sympathetic activity (with elevated norepinephrine level).

3. Other rare complications may include recurrent laryngeal nerve injury, chylothorax, bleeding, and infection.

**Postoperative Follow-up**

1. During childhood, annual examinations should pay attention to the following.
   a. Blood pressure differences in the arm and leg, which suggest recoarctation. Again, consider the possibility of femoral artery damage from previous procedures as the cause of the blood pressure differential.
   b. Persistence or resurgence of hypertension in the arm and legs in some of the patients. The cause of the hypertension is not completely understood. Its occurrence appears to be proportional to the age of the child at the time of the operative repair.
   c. Associated abnormalities such as bicuspid aortic valve or mitral valve disease.
d. Persistent myocardial dysfunction that was present before surgery.
e. Subaortic stenosis evolving years after the initial surgery in some patients.

2. Lifelong follow-up is indicated because of COA-related complications and frequent association of bicuspid aortic valve.
   a. Systemic hypertension is common in adults and may predispose cerebral aneurysms in these patients to rupture with resulting stroke. Hypertension should be treated with beta-blockers.
   b. Aneurysm formation and likelihood of dissection and rupture. Magnetic resonance angiography or computed tomography (CT) imaging is better than echocardiographic studies, performed perhaps every 2 to 5 years.
   c. All patients with bicuspid aortic valve require a regular follow-up because some of these patients may require aortic valve surgery.
   d. For a recurrence of the COA after either a surgical repair or a balloon angioplasty for native COA, a balloon angioplasty may be performed.
   e. Coarctation stenting decreases recoil after the angioplasty and may reduce the late incidence of aneurysm formation, but this can be done only in older children and adolescents because it requires a large arterial (8 or 9 French) sheath.

---

**FIGURE 13-17** Three types of aortic arch interruptions. **A,** Type A. **B,** Type B. **C,** Type C (see text). AO, aorta; LCC, left common carotid; LS, left subclavian; MPA, main pulmonary artery; PDA, patent ductus arteriosus; RCC, right common carotid; RS, right subclavian.
Interrupted Aortic Arch

Prevalence
Interrupted aortic arch accounts for about 1% of all critically ill infants who have CHDs.

Pathology
1. This is an extreme form of COA in which the aortic arch is atretic or a segment of the arch is absent.
2. Depending on the location of the interruption, the defect is divided into the following three types (Fig. 13-17):
   a. **Type A**: The interruption is distal to the left subclavian artery (occurring in 30% of cases).
   b. **Type B**: The interruption is between the left carotid and left subclavian arteries (occurs in 43% of cases). An aberrant right subclavian artery is common. DiGeorge syndrome is reported in about 50% of patients with type B.
   c. **Type C**: The interruption is between the innominate and left carotid arteries (occurs in 17% of cases).
3. Interrupted aortic arch is usually associated with PDA and VSD (occurring in >90% of cases). A bicuspid aortic valve occurs in 60% of all cases. Often there is mitral valve deformity (10% of cases), persistent truncus arteriosus (10% of cases), or subaortic stenosis (20% of cases).
4. DiGeorge syndrome occurs in at least 15% of these patients.

Clinical Manifestations
1. Respiratory distress, variable degrees of cyanosis, poor peripheral pulses, and signs of CHF or circulatory shock develop during the first days of life. Differential cyanosis is uncommon because of the frequent association of VSD.
2. Chest radiographs show cardiomegaly, increased pulmonary vascular markings, and pulmonary venous congestion or pulmonary edema. The upper mediastinum may be narrow because of the absence of the thymus, as is commonly found with DiGeorge syndrome. The ECG may show RVH in uncomplicated cases.
3. Echocardiography is useful in the diagnosis of the interruption and associated defects. Cardiac CT and MRI are used more frequently than angiography to clarify the anatomy before surgery.

Management
1. Medical treatment consists of PGE₁ infusion (preferably before 4 days of age) with intubation and oxygen administration. Workup for DiGeorge syndrome (i.e., serum calcium) should be done. Hyperventilation that causes respiratory alkalosis and tetany should be avoided, and citrated blood (which causes hypocalcemia by chelation) should
not be transfused in patients with DiGeorge syndrome. Blood should be irradiated before the transfusion.

2. Primary complete repair of the interruption and the VSD is recommended if the interruption is associated with a simple VSD. If it is associated with complex anomalies, the initial procedures should be banding the PA and repairing the interruption. Debanding and repair of the VSD and other cardiac anomalies should be done at a later date. A primary anastomosis, Dacron vascular graft, or venous homograft may be used to repair the interruption. The surgical mortality rate can be as low as 10% for initial surgery.
Cyanotic Congenital Heart Defects

Most cyanotic congenital heart defects (CHDs) manifest during the neonatal period, requiring a correct diagnosis for appropriate management. Detection of cyanosis has been made much easier in recent years by routine use of pulse oximetry in asymptomatic newborns. Pulse oximetry helps detect most cyanotic CHDs as well as some noncyanotic critical CHDs. Critical CHDs include defects that depend on the patency of the ductus arteriosus for survival, such as hypoplastic left heart syndrome (HLHS), aortic arch atresia, critical aortic stenosis (AS), pulmonary stenosis (PS) or atresia, tricuspid atresia, and others.

However, pulse oximetry cannot detect all cases of critical CHDs or cyanotic CHDs. Hypoxemia may not be present in some patients with HLHS, AS, and coarctation of the aorta (COA) before discharge from the hospital. In addition, not all cyanotic CHDs manifest with detectable hypoxemia in the nursery. For example, some patients with double outlet right ventricle (RV), Ebstein’s anomaly, and acyanotic tetralogy of Fallot (TOF) may not manifest with detectable hypoxemia in early days of life. Therefore, a negative test result does not exclude the possibility of serious heart defects.

Many investigators believe that pulse oximetry in newborns should be done after 24 hours of life and before hospital discharge and be taken in lower extremities to be able to detect defects with right-to-left ductal shunt and that the cutoff point of abnormal oxygen saturation be set at 95% or less. Arterial saturation is expected to be lower in high altitudes (especially above 5000 ft), but the cutoff point has not been established (Mahle et al, 2009).

Hypoxemia does not necessarily mean a heart defect is present; it may be caused by pulmonary disease or central nervous system (CNS) depression. After hypoxemia (or central cyanosis) is detected, the cause of hypoxemia must be determined.
Approach to a Cyanotic Neonate

Three common causes of central cyanosis (or hypoxemia) are cardiac disease, pulmonary disease, and CNS depression. Clinical findings often direct physicians to the correct system that causes cyanosis. Table 14-1 lists some of the differentiating clinical findings of central cyanosis associated with the three common causes of cyanosis. Crying may improve the cyanosis caused by lung diseases or CNS depression; however, crying usually worsens cyanosis in patients with cyanotic heart defects.

Box 14-1 lists some of the traditional tools used in the investigation of cyanotic newborns. Some of the steps could be skipped when cardiology consultation is readily available, but they are discussed for the sake of completeness.

1. **Electrocardiography (ECG) and chest radiography.** Although the routine tools of cardiac evaluation (physical examination, ECG, and chest radiography) are not very helpful in diagnosing a specific cyanotic heart defect, these tools are often useful in reducing the diagnostic possibilities. Besides being cyanotic, a neonate may have dyspnea, tachypnea, abnormal heart sounds, heart murmurs, or abnormal peripheral pulses. A midline liver may be palpable (or seen on radiography). Chest radiography may show abnormal lung fields (e.g., increased vascularity, oligemic lung fields, or other abnormalities) and abnormal cardiac shadow (abnormal size or abnormal silhouette). The ECG findings may include abnormal rhythm and rate, abnormal QRS axis, atrial hypertrophy, or ventricular hypertrophy. The more of these abnormalities the patient has, the greater the chance of having CHDs. Cardiology consult should be considered at this time.

<table>
<thead>
<tr>
<th>TABLE 14-1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CAUSES AND CLINICAL FINDINGS OF CENTRAL CYANOSIS</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Systems</th>
<th>Causes</th>
<th>Clinical Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNS depression</td>
<td>Perinatal asphyxia</td>
<td>Shallow irregular respiration</td>
</tr>
<tr>
<td>CNS depression</td>
<td>Heavy maternal sedation</td>
<td>Cyanosis that disappears when the patient is stimulated or oxygen is given</td>
</tr>
<tr>
<td>CNS depression</td>
<td>Intrauterine fetal distress</td>
<td>Poor muscle tone</td>
</tr>
<tr>
<td>Pulmonary disease</td>
<td>Parenchymal lung disease (e.g., hyaline membrane disease)</td>
<td>Tachypnea and respiratory distress with retraction and expiratory grunting</td>
</tr>
<tr>
<td>Pulmonary disease</td>
<td>Pneumothorax or pleural effusion</td>
<td>Crackles or decreased breath sounds on auscultation</td>
</tr>
<tr>
<td>Pulmonary disease</td>
<td>Diaphragmatic hernia</td>
<td>Chest radiography may reveal causes (e.g., those listed under causes in this table)</td>
</tr>
<tr>
<td>Pulmonary disease</td>
<td>PPHN</td>
<td>Oxygen administration may improve or abolishes cyanosis</td>
</tr>
<tr>
<td>Cardiac disease</td>
<td>Cyanotic CHD with right-to-left shunt</td>
<td>Tachypnea usually without retraction</td>
</tr>
<tr>
<td>Cardiac disease</td>
<td></td>
<td>Lack of crackles or abnormal breath sounds unless CHF supervenes</td>
</tr>
<tr>
<td>Cardiac disease</td>
<td></td>
<td>Heart murmurs may be absent in serious forms of cyanotic CHD</td>
</tr>
<tr>
<td>Cardiac disease</td>
<td></td>
<td>A continuous murmur (of PDA) is audible in a cyanotic neonate</td>
</tr>
<tr>
<td>Cardiac disease</td>
<td></td>
<td>Chest radiography may show cardiomegaly, abnormal cardiac silhouette, increased or decreased pulmonary vascular markings</td>
</tr>
<tr>
<td>Cardiac disease</td>
<td></td>
<td>Little or no increase in Po2 with oxygen administration</td>
</tr>
</tbody>
</table>

CHD, congenital heart defect; CHF, congestive heart failure; CNS, central nervous system; PDA, patent ductus arteriosus; PPHN, persistent pulmonary hypertension of the newborn.
1. Chest radiography
   Chest radiography may reveal pulmonary causes of cyanosis and the urgency of the problem.
   It can also hint at the presence or absence of cardiac defects and the type of defect.
2. ECG if cardiac origin of cyanosis is suspected.
3. Arterial blood gases in room air
   Arterial blood gases in room air confirm or reject central cyanosis.
   An elevated PCO$_2$ suggests pulmonary or CNS problems.
   A low pH may be seen in sepsis, circulatory shock, or severe hypoxemia.
4. Hyperoxitest: Repeating arterial blood gases while the patient breathes 100% oxygen helps separate cardiac causes of cyanosis from pulmonary or CNS causes.
5. Umbilical artery line: A Po$_2$ value in a preductal artery (e.g., the right radial artery) that is 10 to 15 mm Hg higher than that in a postductal artery (an umbilical artery line) suggests a right-to-left ductal shunt.
6. PGE$_1$: If a cyanotic defect is suspected that depends on the patency of the ductus for survival, PGE$_1$ (Prostin VR Pediatric) should be started or made available.

CNS, central nervous system; ECG, electrocardiography; PGE$_1$, prostaglandin E$_1$.

2. **Hyperoxitest.** This test helps differentiate cyanosis caused by cardiac disease from that caused by pulmonary diseases. When central cyanosis has been confirmed by arterial Po$_2$, one tests the response of arterial Po$_2$ to 100% oxygen inhalation (hyperoxitest). Oxygen should be administered through a plastic hood (e.g., an Oxyhood) for at least 10 minutes to completely fill the alveolar space with oxygen. With pulmonary disease, arterial Po$_2$ usually rises to greater than 100 mm Hg. When there is a significant intracardiac right-to-left shunt, the arterial Po$_2$ does not exceed 100 mm Hg, and the rise is usually not more than 10 to 30 mm Hg (see Chapter 11 for details). Exceptions exist in patients with large pulmonary blood flow and those with severe lung pathology.

3. **Arterial Po$_2$ in preductal and postductal arteries.** It is important that one obtain arterial blood samples from the right upper body (right radial, brachial, or temporal artery), rather than from the descending aorta, to detect (true) cyanotic CHDs. If a low arterial Po$_2$ is obtained from an umbilical artery line (or from a lower extremity site), another sample from the right upper body should be obtained, and the Po$_2$ values from the two sites should be compared to see if there is a right-to-left ductal shunt. Arterial Po$_2$ from
the right radial artery that is 10 to 15 mm Hg higher than that from an umbilical artery catheter is significant. In severe cases of right-to-left ductal shunt, differential cyanosis may be noticeable, with a pink upper and a cyanotic lower body. Such a right-to-left ductal shunt is caused not only by persistent pulmonary hypertension of the newborn (PPHN) but also by other serious cardiovascular conditions, including severe obstructive lesions of the left ventricle (LV) (e.g., severe AS) or aortic obstructive lesions (e.g., interrupted aortic arch, COA).

4. **Prostaglandin E$_1$ (PGE1) infusion.** If a cyanotic CHD or a ductus-dependent cardiac defect (e.g., pulmonary atresia with or without ventricular septal defect [VSD], tricuspid atresia, HLHS, interrupted aortic arch, severe COA) is suspected or confirmed, a PGE$_1$ (Prostin VR Pediatric) intravenous (IV) infusion should be started. At the same time, cardiology consultation should be requested on an urgent basis. The starting dose of Prostin is 0.05 to 0.1 µg/kg per minute administered in a continuous IV drip. When the desired effects (increased Po$_2$, increased systemic blood pressure, improved pH) are achieved, the dose should be reduced step by step to 0.01 µg/kg per minute. When the initial starting dose has no effect, it may be increased up to 0.4 µg/kg per minute. Three common side effects of IV infusion of PGE$_1$ are apnea (12%), fever (14%), and flushing (10%). Less common side effects include tachycardia or bradycardia, hypotension, and cardiac arrest.
Complete Transposition of the Great Arteries

Prevalence
Complete transposition of the great arteries (TGA) occurs in about 5% to 7% of all CHDs. It is more common in males than in females (male-to-female ratio of 3:1).

Pathophysiology
1. In complete TGA, the aorta arises anteriorly from the RV carrying desaturated blood to the body, and the pulmonary artery (PA) arises posteriorly from the LV carrying oxygenated blood back to the lungs. In the classic complete TGA, the aorta is located anteriorly and to the right (dextro) of the PA. This is why the prefix $D$ is used and thus the condition is called $D$-transposition (D-TGA). (When the transposed aorta is located to the left of the PA, it is called $L$-transposition, to be discussed later in this chapter.)
2. The result of D-TGA is complete separation of the pulmonary and systemic circulations. This results in hypoxemic blood circulating throughout the body and hyperoxemic blood circulating in the pulmonary circuit, which is not compatible with survival (see Fig. 11-4). Defects that permit mixing of the two circulations (e.g., atrial septal defect [ASD], VSD, and patent ductus arteriosus [PDA]) are necessary for survival.
3. About half of these infants do not have associated defects other than a patent foramen ovale (PFO) or a small PDA (i.e., simple TGA).
4. In about 5% of the patients, left ventricular outflow tract (LVOT) obstruction (or subpulmonary stenosis) occurs. The obstruction may be dynamic or fixed. Dynamic obstruction of the LVOT, which occurs in about 20% of such patients, results from bowing of the interventricular septum to the left because of a high RV pressure. Anatomic (or fixed) subpulmonary stenosis or abnormal mitral chordal attachment rarely causes obstruction of the LVOT.

5. VSD is present in 30% to 40% of patients with D-TGA and may be located anywhere in the ventricular septum. A combination of VSD and significant LVOT obstruction (or PS) occurs in about 10% of all patients with D-TGA. Infants with TGA and VSD more
commonly have associated defects than those without associated VSD. Such associated defects may include COA, interrupted aortic arch, pulmonary atresia, and an overriding or straddling of the atrioventricular (AV) valve.

**Overriding** is an abnormal relationship between the AV valve annulus and the ventricular septum. The AV valve annulus commits to both ventricular chambers, and it is the result of malalignment of the atria and ventricular septa. **Straddling** is present when the chordae tendineae insert into the contralateral ventricle through a septal defect. Type A straddling is a mild form in which the chordae insert near the crest of the ventricular septum. In type B, the insertion is along the ventricular septum. In type C straddling, the chordae insert into the free wall of the contralateral ventricle. Overriding and straddling may occur independently or coexist in the same valve.

**Clinical Manifestations**

**History**
1. History of cyanosis from birth is always present.
2. Signs of congestive heart failure (CHF) with dyspnea and feeding difficulties develop during the newborn period.

**Physical Examination** *(Fig. 14-1)*
1. Moderate to severe cyanosis is present, especially in large male newborns. Such an infant is tachypneic but without retraction unless CHF supervenes.
2. The S2 is single and loud. No heart murmur is heard in infants with an intact ventricular septum. An early or holosystolic murmur of VSD may be audible in less cyanotic infants with associated VSD. A soft midsystolic murmur of PS (LVOT obstruction) may be audible.
3. If CHF supervenes, hepatomegaly and dyspnea develop.

**Laboratory Studies**
1. Severe arterial hypoxemia usually with acidosis is present. Hypoxemia does not respond to oxygen inhalation. (See the discussion of the hyperoxitest in an early section of this chapter.)
2. Hypoglycemia and hypocalcemia are occasionally present.

**Electrocardiography** *(Fig. 14-2)*
1. Right ventricular hypertrophy (RVH) is usually present after the first few days of life. The QRS voltages and the QRS axis may be normal in many newborns with the defect. After 3 days of life, an upright T wave in V1 may be the only abnormality suggestive of RVH.
2. Biventricular hypertrophy (BVH) may be present in infants with large VSD, PDA, or pulmonary vascular obstructive disease because all of these conditions produce an additional left ventricular hypertrophy (LVH).
3. Occasionally, right atrial hypertrophy (RAH) is present.

**Radiography**
1. Cardiomegaly with increased pulmonary vascularity is typically present.
2. An egg-shaped cardiac silhouette with a narrow, superior mediastinum is characteristic (Fig. 14-3).

**Echocardiography**

Two-dimensional echocardiography and color-flow Doppler studies usually provide all the anatomic and functional information needed for the management of infants with D-TGA.

1. In the parasternal long-axis view, the great artery arising from the posterior ventricle (LV) has a sharp posterior angulation toward the lungs, which suggests that this artery is the PA (Fig. 14-4, A). In contrast to the normal intertwining of the great arteries, the proximal portion of the great arteries runs parallel. Unlike in a normal heart, there is a fibrous continuity between the pulmonary and mitral valves, and subaortic conus is present. (In normal hearts, there is aortic–mitral fibrous continuity with subpulmonary conus.)

2. In the parasternal short-axis view, the “circle and sausage” appearance of the normal great arteries is not visible. Instead, the great arteries appear as “double circles” (Fig. 14-4, B). The PA is in the center of the heart, and the coronary arteries do not arise from this great artery. The aorta is usually anterior and slightly to the right of the PA, and the coronary arteries arise from the aorta.

3. In the apical and subcostal five-chamber views, the PA (i.e., the artery that bifurcates) is seen to arise from the LV, and the aorta arises from the RV.

4. The status of atrial communication, both before and after balloon septostomy, is best evaluated in the subcostal view. Doppler examination and color-flow mapping should aid in the functional evaluation of the atrial shunt.

5. Frequently, associated defects such as VSD, LVOT obstruction (dynamic or fixed), or
The coronary arteries can be imaged in most patients in the parasternal and apical views (Fig. 14-5).

Other Studies
Cardiac catheterization is performed only for the purpose of balloon atrial septostomy to improve mixing at the atrial level. Rarely, it is performed to look for associated anomalies such as abnormal coronary artery, collateral circulation, or a small aortic isthmus.

Natural History
1. Progressive hypoxia, acidosis, and heart failure result in death in the newborn period. Without surgical intervention, death occurs in 90% of patients before they reach 6 months of age.
2. Infants with an intact ventricular septum are the sickest group but demonstrate the most dramatic improvement after Rashkind balloon atrial septostomy.
3. Infants with VSD are the least cyanotic group but the most likely to develop CHF and pulmonary vascular obstructive disease. Many infants with TGA and a large VSD develop moderate pulmonary vascular obstructive disease by 3 to 4 months of age. Thus, surgical procedures are recommended before that age.
4. Infants with a significant PDA are similar to those with a large VSD in terms of their development of CHF and pulmonary vascular obstructive disease.
5. The combination of VSD and PS allows considerably longer survival without surgery because the pulmonary vascular bed is protected from developing pulmonary hypertension, but this combination carries a high surgical risk for correction.
FIGURE 14-5  Diagram of the coronary artery anatomy in 32 patients with transposition of the great arteries (TGA). The orientation of the figures is that of a parasternal short-axis echocardiographic view. LAD, left anterior descending artery; LCCA, left circumflex coronary artery; RCA, right coronary artery. (From Pasquini L, Sanders SP, Parness IA, et al: Diagnosis of coronary artery anatomy by two-dimensional echocardiography in patients with transposition of the great arteries. Circulation 75:557–564, 1987.)

Management

Medical

1. The following measures should be carried out to stabilize the patient before an emergency cardiac catheterization (if performed) or a surgical procedure is carried out:
   a. Arterial blood gases and pH should be obtained, and metabolic acidosis should be corrected. Hypoglycemia and hypocalcemia, if present, should be treated.
   b. PGE₁ infusion should be started to improve arterial oxygen saturation by reopening the ductus (see Appendix E for the dosage). This should be continued throughout the cardiac catheterization or until the time of surgery.
   c. Oxygen should be administered for severe hypoxia. Oxygen may help lower pulmonary vascular resistance (PVR) and increase pulmonary blood flow (PBF),
which in turn increases systemic arterial oxygen saturation.

2. Before surgery, cardiac catheterization and a balloon atrial septostomy (i.e., the Rashkind procedure) are often carried out to have some flexibility in planning surgery. If adequate interatrial communication exists and the anatomic diagnosis of TGA is clear by echocardiographic examination, the patient may go to surgery without cardiac catheterization or the balloon atrial septostomy. The need for the balloon septostomy may be determined by inadequate atrial mixing through the PFO (evidenced with a high Doppler flow velocity of >1 m/sec) or a lack of readiness for surgical intervention.

In the balloon atrial septostomy, a balloon-tipped catheter is advanced into the left atrium (LA) through the PFO. The balloon is inflated with diluted radio-opaque dye and abruptly and forcefully withdrawn to the right atrium (RA) under fluoroscopic or echocardiographic monitoring. This procedure creates a large defect in the atrial septum through which an improved intracardiac mixing occurs. An increase in the oxygen saturation of 10% or more and a minimal interatrial pressure gradient are considered satisfactory results of the procedure.

3. CHF may be treated with diuretics (and digoxin).

**Surgical**

**Palliative Procedure**

No palliative procedure is performed unless an arterial switch operation (ASO) cannot be performed early in life.

**Definitive Repair**

Historically, definitive surgeries performed for TGA were procedures that switched right-and left-sided blood at three levels: the atrial level (intraatrial repair surgeries such as the Senning or Mustard operation), the ventricular level (i.e., Rastelli operation), and the great artery level (ASO). At this time, ASO is clearly the procedure of choice, and intraatrial repair surgeries are very rarely performed only under unusual situations. The Damus-Kaye-Stansel operation in conjunction with the Rastelli operation can be performed in patients with VSD and subaortic stenosis. Because of a relatively poor long-term result of the Rastelli operation, other options such as the Nikaidoh operation or REV (réparation à l’étage ventriculaire) procedure have become more popular recently.

**Procedures**

1. **Atrial baffle operations** (Mustard and Senning operations)

   These procedures reroute pulmonary and systemic venous returns at the atrial level with resulting physiologic correction. The pulmonary venous blood eventually goes to the aorta, and the systemic venous blood goes to the PA (see Fig. 14-6 for the hemodynamic results of atrial baffle operation). The Mustard operation uses a pericardial or a prosthetic baffle, and the Senning operation uses the patient’s own atrial septal flap and the RA free wall to redirect the venous returns.
A number of long-term problems have been reported, including superior vena cava (SVC) obstruction (<5% of all cases), baffle leak (<20%), absence of sinus rhythm (>50%), frequent atrial and ventricular arrhythmias with occasional sudden death, tricuspid valve insufficiency (rare), and RV (i.e., systemic ventricular) dysfunction or failure. The ASO has largely replaced the atrial baffle operation. There are, however, rare indications for atrial baffle operations, including a situation in which relative contraindications of the ASO exist (e.g., coronary arteries that are difficult to transfer).

2. Rastelli operation. In patients with VSD and severe PS, redirection of the pulmonary and systemic venous blood is carried out at the ventricular level. The LV is directed to the aorta by creating an intraventricular tunnel between the VSD and the aortic valve. A valved conduit or a homograft is placed between the RV and the PA (Fig. 14-7). Most surgeons prefer to delay this procedure until after the first year of life. The mortality rate is between 10% and 29%.

FIGURE 14-6 Atrial baffle operation. The hemodynamic results of the Mustard and Senning operations are shown. Systemic venous blood (shaded) is redirected at the atrial level to the anatomic left atrium (LA) and left ventricle (LV) and eventually to the pulmonary circulation. Pulmonary venous blood is redirected at the atrial level to the anatomic right atrium (RA) and right ventricle (RV) through the tricuspid valve and to the aorta. AO, aorta; IVC, inferior vena cava; PA, pulmonary artery; P.V. atrium, pulmonary venous atrium; S.V. atrium, systemic venous
atrium; SVC, superior vena cava.

**FIGURE 14-7** The Rastelli operation. *A*, In patients with D-transposition of the great arteries (D-TGA), ventricular septal defect (VSD) and severe pulmonary stenosis (PS), the pulmonary artery (PA) is divided from the left ventricle (LV), and the cardiac end is oversewn (arrow). *B*, An intracardiac tunnel (arrow) is placed between the large VSD and the aorta (AO) so that the LV communicates with the aorta. *C*, The right ventricle (RV) is connected to the divided PA by a valved conduit or an aortic homograft. RA, right atrium.

Complications after the Rastelli operation include conduit obstruction (especially in those containing porcine heterograft valves) and complete heart block (which rarely occurs). The conduit needs to be replaced as the child grows. Occasionally, LVOT obstruction occurs at the level of the VSD or at the level of the intraventricular tunnels. More importantly, the long-term results are not optimal, with the 20-year survival rate at about 50%. Two alternative procedures are now available, the REV procedure and the Nikaidoh procedure (see later discussion of these procedures).

3. **Arterial switch operation**

   The ASO is now firmly established as the procedure of choice. There are almost no situations which would justify the performance of a Senning or Mustard procedure for D-TGA. The coronary arteries are transplanted to the PA, and the proximal great arteries are connected to the distal end of the other great artery, resulting in an anatomic correction (Fig. 14-8). This procedure has advantages over the atrial baffle operations because it is an anatomic (not physiologic) correction, and long-term complications are infrequent. This procedure is indicated not only for simple TGA but also TGA with other associated anomalies (e.g., VSD or PDA) and the Taussig-Bing type of double outlet right ventricle (DORV) with subpulmonary VSD. The operative mortality rate for neonates with TGA and intact ventricular septum is down to around 6%.
Complications after the ASO are infrequent. Normal sinus rhythm is usually present, arrhythmias are extremely rare, and LV function is usually normal. The following complications may occur after the ASO:

a. Coronary artery obstruction, which may lead to myocardial ischemia, infarction, and even death, is a serious but a rare complication.

b. Supravalvular PS at the anastomosis site (~12%) is the most common cause for reoperation, although the incidence has decreased.

c. Neoaortic valvular regurgitation and supravalvular neoaortic stenosis are rare complications.

The following factors are important for a successful ASO.

1) **LV pressure.** An LV that can support the systemic circulation after surgery must exist. The LV pressure should be near systemic levels at the time of surgery so that the ASO should be performed shortly after birth. The time limit is 3 weeks of age (although some suggest an upper limit of 8 week of age).

2) **Coronary artery anatomy.** Almost all coronary artery patterns in TGA are amenable to the ASO. However, the risk is slightly higher when either one or both coronary arteries passes between the great arteries. The single coronary artery is transferable by various surgical techniques.

Currently, other associated anomalies are repaired at the time of the ASO in the neonatal period.

a. For patients with associated VSD, the VSD is repaired through the atrial approach or through the pulmonary valve. The mortality rate is around 6%.

b. For patients with PDA and VSD, the PDA is ligated, and the VSD is closed.

c. Mild pulmonary valve stenosis or dynamic subpulmonary stenosis does not preclude a successful ASO.

**Two-stage switch operation.** In patients whose LV pressure is low (because of missing the chance for an early ASO), it can be raised by PA banding, either with or without a shunt procedure, for 7 to 10 days (in cases of a “rapid two-stage switch operation”) or for several months before undertaking the switch operation. LV pressure greater than 85% of the RV pressure appears to be satisfactory for the switch operation. The rapid switch is preferable to a longer waiting period, which results in scarring and adhesions of the PA after PA banding. Scarring makes PA reconstruction and anastomosis of the great arteries difficult, and adhesions obscure coronary artery anatomy.
Réparation à l’étage l’ventriculare (REV) procedure for patients with D-transposition of the great arteries (D-TGA), ventricular septal defect (VSD), and severe pulmonary stenosis (PS). A, A schematic drawing of D-TGA with VSD and severe PS (with a relatively small pulmonary artery [PA]). The broken lines indicate the planned aortic and right ventricular (RV) incision sites. The broken circle indicates a VSD. B, The aorta and PA have been transected, and the right pulmonary artery (RPA) is brought anterior to the aorta (Lecompte maneuver). The proximal PA has been oversewn. The VSD is exposed through the right ventriculotomy. (Note that these figures have expanded ventriculotomy to allow visualization of intracardiac structures.) Dotted semi-circular lines indicate the portion of the infundibular septum to be excised to enlarge the VSD. C, The aortic valve is well shown by retractors. The broken line indicates the planned site of a patch placement for the LV–aorta (AO) connection. The transected aorta has been reconnected behind the RPA. D, The completed LV-to-AO tunnel is shown (marked LVOT [left ventricular outflow tract] patch). The superior portion of the right ventriculotomy is sutured directly to the posterior portion of the main PA. E, A pericardial or synthetic patch is used to complete the RV-to-PA reconstruction (marked RVOT [right ventricular outflow tract] patch).

Staged conversion to ASO. Some patients who received an atrial baffle operation develop RV failure with severe tricuspid valve regurgitation. For these patients, staged conversion to ASO can be done. Initially, a PA band is placed to raise the LV pressure. This is followed by an ASO with a higher mortality rate (≈25%–33%). Alternatively, after PA band, the Damus-Kaye-Stansel operation can be performed, which does not require transfer of coronary arteries. Transfer of coronary arteries is much more difficult in these patients because of dense adhesions.

4. REV procedure. This procedure, first reported by Lecompte, may be performed for patients with D-TGA associated with VSD and severe PS, instead of the Rastelli operation. The procedure consists of (1) infundibular resection to enlarge the VSD, (2) intraventricular baffle to direct LV output to the aorta, (3) aortic transection to perform the Lecompte maneuver (by which the right pulmonary artery (RPA) is brought anterior to the ascending aorta), and (4) direct RV-to-PA reconstruction by using an anterior patch (Fig. 14-9). This may require fewer reoperations than the Rastelli procedure. Lecompte reported 50 cases (4 mo–15 yr) with an 18% operative mortality rate.

5. Nikaidoh procedure. This procedure is another surgical option for patients with D-TGA, VSD, and severe PS. In this procedure, the aortic root is mobilized and translocated
to the pulmonary position. The repair consists of the following: (1) harvesting the aortic root from the RV (with attached coronary arteries in the original procedure), (2) relieving the LVOT obstruction (by enlarging the VSD by means of dividing the outlet septum and excising the pulmonary valve), (3) reconstructing the LVOT (with posteriorly translocated aortic root and the VSD patch), and (4) reconstructing the right ventricular outflow tract (RVOT) (with a pericardial patch or a homograft). In the modified Nikaidoh procedure, one or both coronary arteries are moved to a more favorable position as necessary (not shown), and the Lecompte maneuver is also performed (Fig. 14-10). The hospital mortality is less than 10%.

**FIGURE 14-10** Nikaidoh procedure (for patients with D-transposition of the great arteries [D-TGA], ventricular septal defect [VSD], and severe pulmonary stenosis [PS]). A, Schematic drawing of D-TGA with VSD and severe PS (with relatively small pulmonary artery [PA]) is shown. The circular broken line around the aorta is the planned incision site for aortic root mobilization. The smaller broken circle indicates a VSD. B, The aortic root has been mobilized by a circular incision around the aortic root, which leaves an opening in the right ventricular (RV) free wall. The main PA is also transected. Through the opening, part of the VSD, the ventricular septum, and the hypoplastic PA stump are seen. The dotted vertical line in the ventricular septum (in the smaller inset in B) is the planned incision through the infundibular septum. C, In the inset, the incision in the infundibular septum has created a large opening, which includes the PA annulus and stump and the VSD. D, In the large inset, the posterior portion of the aorta is directly sutured to the PA stump, which results in a large VSD. This completes translocation of the aorta to the original PA position. The thick oval-shaped broken line that goes through the front of the transected aortic root is the planned site for placement of the left ventricular (LV) outflow tract (LVOT) patch, which will direct the LV flow to the aorta. E, The completed tunnel is shown (marked LVOT patch, which directs the LV flow to the aorta). The distal segment of the main PA is fixed to the aorta. Some surgeons use the Lecompte maneuver to bring the right pulmonary artery (RPA) in front of the ascending aorta (as shown here). F, A pericardial patch is oversewn to complete the RV-to-PA connection (marked RVOT [RV outflow tract] patch).

6. **Damus-Kaye-Stansel operation.** Infants with a large VSD and significant subaortic stenosis may receive the Damus-Kaye-Stansel operation at 1 to 2 years of age. In this procedure, the coronary arteries are not transferred to a neoaorta. Instead, the subaortic stenosis is bypassed by connecting the proximal PA trunk to the ascending aorta. The VSD is closed, and a conduit is placed between the RV and the distal PA (Fig. 14-11). The
The mortality rate is considerable, ranging from 15% to 30%.

The Damus-Kaye-Stansel operation is also applicable in patients with single ventricle and TGA with an obstructive bulboventricular foramen (BVF) or DORV with subaortic stenosis (see Fig. 14-62).

Surgical management for patients with TGA and various associated defects is summarized in Figure 14-12.

**Follow-up After Arterial Switch Operation**

Although the complication rate is much lower for arterial switch than for atrial baffle repair, regular follow-up is needed to detect possible complications, such as stenosis of the PA or aorta in the supravalvular regions, coronary artery obstruction with myocardial ischemia or infarction, ventricular dysfunction, arrhythmias, and semilunar valve regurgitation. These complications are, for the most part, hemodynamically insignificant or infrequent.

**FIGURE 14-11** Damus-Kaye-Stansel operation for complete transposition of the great arteries (D-TGA) + ventricular septal defect (VSD + subaortic stenosis). A, D-TGA with VSD and subaortic stenosis is illustrated. The main pulmonary artery (MPA) is transected near its bifurcation. An appropriately positioned and sized incision is made in the ascending aorta (AO). B, The proximal MPA is anastomosed end to side to the ascending aorta using either a Dacron tube or Gore-Tex. This channel will direct left ventricular blood to the aorta. The aortic valve is either closed or left unclosed. The VSD is closed (through a right ventriculotomy). C, A valved conduit is placed between the right ventricle (RV) and the distal pulmonary artery (PA). This channel will carry RV blood to the PA. LV, left ventricle; RA, right atrium.

**FIGURE 14-12** Surgical approaches to transposition of the great arteries with various associated defects. ASO, arterial switch operation; BT, Blalock-Taussig; PDA, patent ductus arteriosus; PS, pulmonary stenosis; REV,
Coronary artery obstruction after the surgery is a concern. In one study, about 5% of postoperative arterial switch patients had coronary arterial abnormalities by coronary angiography; some of them had no signs of ischemia by history, ECG, and echocardiographic studies. A periodic follow-up is recommended with ECG, echocardiography, exercise stress test (in older children), magnetic resonance imaging (MRI) or computed tomography (CT), or coronary angiography. MRI can provide a comprehensive anatomic and functional evaluation for coronary ischemia noninvasively, including myocardial perfusion and viability information.
Congenitally Corrected Transposition of the Great Arteries

Prevalence

Congenitally corrected transposition of the great arteries (or L-TGA) occurs in fewer than 1% of all patients with CHDs.

**FIGURE 14-13** Diagram of congenitally corrected transposition of the great arteries (L-TGA). There is an inversion of ventricular chambers with their corresponding atrioventricular valves. The great arteries are transposed, but functional correction results, with oxygenated blood going to the aorta. Unfortunately, a high percentage of the patients with L-TGA have associated defects, some of which may cause cyanosis. AO, aorta; LA, left atrium; LV, left ventricle; PA, pulmonary artery; RA, right atrium; RV, right ventricle.

Pathology

1. In this condition, the viscerocarial relationship is normal, but there is ventricular inversion. The RA is to the right of the LA and receives systemic venous blood. The RA
empties into the anatomic LV through the mitral valve, and the LA empties into the RV through the tricuspid valve. For this to occur, the RV is located to the left of the LV (or the LV is located to the right of the RV), which is called ventricular inversion (Fig. 14-13). The great arteries are transposed, with the aorta rising from the RV and the PA rising from the LV. The aorta is located anterior to and left of the PA; thus, the prefix of L is used, and the condition is called L-TGA (see Fig. 17-4, D). The result is functional correction in that oxygenated blood coming into the LA goes to the anatomic RV and then flows out to the aorta. This is why the term corrected is used to describe this condition.

2. Theoretically, no functional abnormalities exist, but unfortunately, most cases are complicated by associated intracardiac defects, AV conduction disturbances, and arrhythmias.
   a. VSD occurs in 80% of all cases.
   b. PS, both valvular and subvalvular, occurs in 50% of patients and is usually associated with VSD.
   c. Systemic AV valve (tricuspid valve) regurgitation occurs in 30% of patients.
   d. Occasionally, complex associated defects are present with hypoplastic ventricle, AV valve abnormalities, or multiple VSDs.
   e. Both varying and progressive degrees of AV block and paroxysmal supraventricular tachycardia (SVT) frequently occur.

3. The cardiac apex is in the right chest (dextrocardia) in about 50% of cases.

4. The coronary arteries show a mirror-image distribution. The right coronary artery supplies the anterior descending branch and gives rise to a circumflex; the left coronary artery resembles a right coronary artery.

**Clinical Manifestations**

**History**

1. Patients are asymptomatic when L-TGA is not associated with other defects.
2. During the first months of life, most patients with associated defects become symptomatic with cyanosis resulting from VSD and PS or CHF resulting from a large VSD.
3. Exertional dyspnea and easy fatigability may develop with regurgitation of the systemic AV valve (i.e., anatomic tricuspid valve).

**Physical Examination**

1. The patient is cyanotic if PS and VSD are present.
2. Hyperactive precordium occurs in the presence of a large VSD. Systolic thrill occurs in the presence of PS with or without VSD.
3. The S2 is loud and single at the upper left or right sternal border. A grade 2 to 4 of 6 harsh, holosystolic murmur along the lower left sternal border indicates the presence of VSD or systemic AV valve regurgitation. A grade 2 to 3 of 6 ejection systolic murmur is present at the upper left or right sternal border if PS is present. An apical diastolic rumble may be audible if a large VSD or significant tricuspid regurgitation (TR) is present.
4. Bradycardia, tachycardia, or irregular rhythm requires an investigation for AV conduction disturbances or arrhythmias.

**Electrocardiography**

1. The absence of Q waves in V5 and V6 or the presence of Q waves in V4R or V1 is characteristic of the condition ([Fig. 14-14](#)). This is because the direction of ventricular septal depolarization is from the embryonic LV to RV.
2. Varying degrees of AV block are common. First-degree AV block is present in about 50% of patients. Second-degree AV block may progress to complete heart block.
3. Atrial arrhythmias and Wolff-Parkinson-White (WPW) preexcitation are occasionally present.
4. Atrial or ventricular hypertrophy (or both) may be present in complicated cases.

**Radiography**

1. A straight, left upper cardiac border, formed by the ascending aorta, is a characteristic finding ([Fig. 14-15](#)).
2. Cardiomegaly and increased pulmonary vascular markings are present when the condition is associated with VSD.
3. Pulmonary venous congestion and LA enlargement may be seen with severe left-sided AV valve regurgitation.
4. Positional abnormalities (e.g., dextrocardia, mesocardia) may be present.

**Echocardiography**
With use of the segmental approach (see Chapter 17), the diagnosis of L-TGA can be made easily, and associated anomalies can be detected and quantitated.

1. The parasternal long-axis view is obtained from a more vertical and leftward scan than with a normal heart. The aorta, which arises from the posterior ventricle, is not in fibrous continuity with the AV valve.

2. In the parasternal short-axis scan, a “double circle” of the semilunar valves is imaged instead of the normal “circle and sausage” pattern. The posterior circle is the PA without demonstrable coronary arteries. The aorta is usually anterior to and left of the PA. The LV, which has two well-defined papillary muscles, is seen anteriorly and on the right and is connected to the characteristic “fish mouth” appearance of the mitral valve.

3. In the apical and subcostal four-chamber views, the LA is connected to the tricuspid valve (which has a more apical attachment to the ventricular septum than the other) and the RA is connected to the mitral valve. The anterior artery (aorta) arises from the left-sided morphologic RV, and the posterior artery with bifurcation (PA) arises from the right-sided morphologic LV.

4. The situs solitus of the atria is confirmed by the drainage of systemic veins (i.e., inferior vena cava [IVC] and SVC) to the right-sided atrium and the drainage of pulmonary veins to the left-sided atrium.

5. The following associated abnormalities should be looked for, and their functional significance should be assessed by the Doppler and color-flow studies: type and severity of PS, size and location of VSD, straddling of the AV valve, and so on.

**Other Studies**

Occasionally, angiography may be necessary to image coronary artery anatomy, although CT or MRI may provide this information noninvasively.

**Natural History**
The clinical course is determined by the presence or absence of associated defects and complications.

1. Some palliative surgeries are usually needed in infancy when L-TGA is associated with other defects (e.g., PA banding for a large VSD or a systemic-to-PA shunt for severe PS). Without these procedures, 20% to 30% of patients die in the first year. CHF is the most common cause of death.

2. Regurgitation of the systemic AV valve (anatomic tricuspid valve) develops in about 30% of patients. This is often associated with dysplastic or Ebstein-like tricuspid valves.

3. Progressive AV conduction disturbances may occur, including complete heart block in up to 30% of cases. These disturbances occur more often in patients without VSD than in those with VSD. Sudden death rarely occurs.

4. Occasional adult patients without major associated defects are asymptomatic.

**Management**

**Medical**

1. Treatment with anticongestive agents is necessary if CHF develops.

2. Antiarrhythmic agents are used for arrhythmias.

![Surgical summary of congenitally corrected transposition of the great arteries (L-TGA). AO, aorta; ASO, arterial switch operation; PA, pulmonary artery; RV, right ventricle; PS, pulmonary stenosis (= LV outflow tract obstruction); TGA, transposition of the great arteries; TR, tricuspid regurgitation (= left-sided AV valve regurgitation); VSD, ventricular septal defect.](image)

**Surgical**

**Palliative Procedures**
1. A modified Blalock-Taussig (BT) shunt is necessary for patients with severe PS (usually associated with VSD).
2. PA banding may be needed for uncontrollable CHF in early infancy.

**Definitive Procedures**

There are two major approaches to surgical management of L-TGA, classic repair and anatomic repair. Patients with regurgitation of the tricuspid valve (systemic AV valve) or RV dysfunction need the anatomic repair in which the LV is made the systemic ventricle. The surgical approach for L-TGA is summarized in Figure 14-16.

1. Classic repair leaves the anatomic RV as the systemic ventricle. A competent tricuspid valve (or left AV valve) and good RV function are required. Even after repair, progressive TR and RV failure may develop.
   a. In patients with VSD, the VSD is closed through an atrial approach. Complete heart block is a complication of the surgery, occurring 15% to 30% of the time. The mortality rate is 5% to 10%, which is higher than that for a simple VSD.
   b. In patients with VSD and PS (or LVOT obstruction), the VSD is closed and an LV-to-PA conduit is placed. The surgical mortality rate is higher (10%–15%).
2. Anatomic repair makes the anatomic LV the systemic ventricle, which may reduce the likelihood of TR and RV failure. This repair is technically more difficult than the classic repair and carries a higher risk, but this procedure is a better choice for patients with TR or RV dysfunction.
   a. A combination of Senning procedure (which is an atrial switch operation; see Fig. 14-6) and ASO (see Fig. 14-8), called a “double switch” operation, is performed in patients with VSD. A PA banding is initially placed to delay the procedure until after 1 year of age. Closure of VSD, if present, is performed through the RA. The hospital mortality rate for the “double switch” operation is approximately 10%, with complete heart block occurring 0% to 23% of the time.
   b. In patients with VSD and PS (or LVOT obstruction), a combination of the Senning operation and Rastelli operation is performed. VSD is closed through a right ventriculotomy in such a way to connect the VSD to the aorta. Enlargement of the VSD is often necessary. RV-to-PA continuity is established with an extracardiac valved conduit. The hospital mortality rate is around 10%. TR improves after the procedure.
3. Fontan-type operation. In patients with complex intracardiac anatomies, including hypoplasia of one ventricle, straddling AV valves, or multiple VSDs, bidirectional Glenn operation or a full Fontan procedure is indicated.
4. Other procedures
   a. **Valve replacement.** For patients with significant TR, valve replacement is required in about 15%, including those without other associated defects.
   b. **Pacemaker implantation** is required for either spontaneous or postoperative complete heart block.
   c. **Cardiac transplantation.** Some patients with complex L-TGA eventually become candidates for cardiac transplantation.
Postoperative Follow-up

1. Follow-up every 6 to 12 months is required for a possible progression of AV conduction disturbances, arrhythmias, or worsening of anatomic tricuspid valve regurgitation.
2. Routine pacemaker care, if a pacemaker is implanted, should be conducted.
3. Activity restriction is indicated if significant hemodynamic abnormalities persist.
Prevalence
Tetralogy of Fallot occurs in 5% to 10% of all CHDs. This is probably the most common cyanotic heart defect.

Pathology
1. The original description of TOF included the following four abnormalities: a large VSD, RVOT obstruction, RVH, and overriding of the aorta. In actuality, only two abnormalities are required, a VSD large enough to equalize pressures in both ventricles and an RVOT obstruction. The RVH is secondary to the RVOT obstruction, and the overriding of the aorta varies (Fig. 14-17).
2. The VSD in TOF is a large perimembranous defect with extension into the subpulmonary region.
3. The RVOT obstruction is most frequently in the form of infundibular stenosis (45%). The obstruction is rarely at the pulmonary valve level (10%). A combination of the two may also occur (30%). The pulmonary valve is atretic in the most severe form of the anomaly (15%), which is discussed under a separate heading in this chapter.
4. The pulmonary annulus and main PA are variably hypoplastic in most patients. The PA branches are usually small, although marked hypoplasia is uncommon. Stenosis at the origin of the branch PAs, especially the left PA, is common. Occasionally, systemic collateral arteries feed into the lungs, especially in severe cases of TOF.
5. Right aortic arch is present in 25% of cases, with some of them having symptoms of vascular ring.
6. In about 5% of TOF patients, abnormal coronary arteries are present. The most common abnormality is the anterior descending branch arising from the right coronary artery and passing over the RVOT, which prohibits a surgical incision in the region.
7. Complete AV canal defect occurs in approximately 2% of patients with TOF, more commonly among patients with Down syndrome, called “canal tet.” In these patients, the VSD has a large outlet component in addition to the inlet portion associated with the AV canal.
FIGURE 14-17  Pathologic anatomy of tetralogy of Fallot viewed with the right ventricular (RV) free wall removed. A large ventricular septal defect (VSD) is present underneath the aortic valve. Hypertrophied parietal and septal bands produce infundibular stenosis (marked x). A stenotic and hypoplastic main pulmonary artery (PA) is shown. The RV muscle is hypertrophied. TV, tricuspid valve. (Hirsch JC, Bove EL. Tetralogy of Fallot. In Mavroudis C. Pediatric Cardiac Surgery, 3rd ed. Philadelphia, Mosby, 2003. Reproduced with permission).

FIGURE 14-18  Cardiac findings in cyanotic tetralogy of Fallot. A long ejection systolic murmur at the upper and mid left sternal border and a loud, single S2 are characteristic auscultatory findings of TOF. EC, ejection click.

Clinical Manifestations
History
1. A heart murmur is audible at birth.
2. Most patients are symptomatic with cyanosis at birth or shortly thereafter. Dyspnea on exertion, squatting, or hypoxic spells develop later even in mildly cyanotic infants (see Chapter 11).
3. Occasional infants with acyanotic TOF may be asymptomatic or may show signs of CHF from a large left-to-right ventricular shunt.

Physical Examination (Fig. 14-18)
1. Varying degrees of cyanosis, tachypnea, and clubbing (in older infants and children) are present.
2. An RV tap along the left sternal border and a systolic thrill at the upper and mid-left sternal borders are commonly present (50%).
3. An ejection click that originates in the aorta may be audible. The S2 is usually single because the pulmonary component is too soft to be heard. A long, loud (grade 3 to 5 of 6) ejection-type systolic murmur is heard at the mid-and upper left sternal borders. This murmur originates from the PS but may be easily confused with the holosystolic regurgitant murmur of a VSD. The more severe the obstruction of the RVOT, the shorter and softer the systolic murmur.
4. In the acyanotic form, a long systolic murmur, resulting from VSD and infundibular stenosis, is audible along the entire left sternal border, and cyanosis is absent. Thus, auscultatory findings resemble those of a small-shunt VSD (but, unlike VSD, the ECG shows RVH or BVH).

Electrocardiography
1. Right-axis deviation (RAD) (+120 to +150 degrees) is present in cyanotic TOF. In the acyanotic form, the QRS axis is normal.
2. RVH is usually present, but the strain pattern is unusual (because RV pressure is not suprasystemic). BVH may be seen in the acyanotic form. RAH is occasionally present.

Radiography

Cyanotic Tetralogy of Fallot
1. The heart size is normal or smaller than normal, and pulmonary vascular markings are decreased. “Black” lung fields are seen in TOF with pulmonary atresia.
2. A concave main PA segment with an upturned apex (i.e., “boot-shaped” heart or coeur en sabot) is characteristic (Fig. 14-19).
3. RA enlargement (25%) and right aortic arch (25%) may be present.

Acyanotic Tetralogy of Fallot
Radiographic findings of acyanotic TOF are indistinguishable from those of a small to moderate VSD (but patients with TOF have RVH rather than LVH on the ECG).
Echocardiography

Two-dimensional echocardiography and Doppler studies usually make the diagnosis and quantitate the severity of TOF.

1. A large, perimembranous infundibular VSD and overriding of the aorta are readily imaged in the parasternal long-axis view (Fig. 14-20).

2. Anatomy of the RVOT, the pulmonary valve, the pulmonary annulus, and the main PA and its branches is imaged in the parasternal short-axis and subcostal short-axis views. These views allow systematic evaluation of the severity of obstruction at different levels.

3. Doppler studies estimate the pressure gradient across the RVOT obstruction.

4. Anomalous coronary artery distribution can be imaged accurately by echocardiographic studies (Fig. 14-21). The major concern is to rule out any branch of the coronary artery crossing the RVOT. Thus, preoperative cardiac catheterization solely for the diagnosis of coronary artery anatomy is not necessary.

5. Associated anomalies such as ASD and persistence of the left superior vena cava (LSVC) can be imaged.

Other Studies

Two-dimensional echocardiographic and Doppler studies are the primary methods of evaluation before surgery. Cardiac catheterization is reserved only for patients with specific unanswered questions after echocardiographic study.
FIGURE 14-20  Parasternal long-axis view in a patient with tetralogy of Fallot. Note a large subaortic ventricular septal defect (arrow) and a relatively large aorta (AO) overriding the interventricular septum (IVS). AV, aortic valve; LA, left atrium; LV, left ventricle; MV, mitral valve; RV, right ventricle.

FIGURE 14-21  Patterns of coronary artery anatomy in tetralogy of Fallot (TOF) as imaged from the parasternal short-axis view. The percentage of each pattern seen in 598 patients with TOF is indicated in the lower left corner of each box. Ant, anterior; CX, left circumflex branch; L, left; LAD, left anterior descending coronary artery; R, right; RCA, right coronary artery; Post, posterior. (From Need LR, Powell AJ, del Nido P, Geva T: Coronary echocardiography in tetralogy of Fallot: Diagnostic accuracy, resource utilization and surgical implications over 13 years. J Am Coll Cardiol 36:1371–1377, 2000.)
1. Infants with acyanotic TOF gradually become cyanotic. Patients who are already cyanotic become more cyanotic as the infundibular stenosis worsens and polycythemia develops.
2. Polycythemia develops secondary to cyanosis.
3. Physicians need to watch for the development of relative iron-deficiency states (i.e., hypochromia) (see Chapter 11).
4. Hypoxic spells may develop in infants (see Chapter 11).
5. Growth retardation may be present if cyanosis is severe.
6. Brain abscess and cerebrovascular accident rarely occur (see Chapter 11).
7. Subacute bacterial endocarditis (SBE) is occasionally a complication.
8. Some patients, particularly those with severe TOF, develop aortic regurgitation (AR).
9. Coagulopathy is a late complication of a long-standing cyanosis.

Hypoxic Spell

Hypoxic spells (also called cyanotic spells, hypercyanotic spells, “tet” spells) of TOF are not as common as they used to be because many of the patients with TOF receive surgery before they develop the spells. However, it is very important for physicians to be able to immediately recognize and treat the spells appropriately because they can lead to serious complications of the CNS.

Hypoxic spells are characterized by a paroxysm of hyperpnea (i.e., rapid and deep respiration), irritability and prolonged crying, increasing cyanosis, and decreasing intensity of the heart murmur. Hypoxic spells occur in infants, with a peak incidence between 2 and 4 months of age. These spells usually occur in the morning after crying, feeding, or defecation. A severe spell may lead to limpness, convulsion, cerebrovascular accident, or even death. There appears to be no relationship between the degree of cyanosis at rest and the likelihood of having hypoxic spells (see Chapter 11).

Treatment of the hypoxic spell strives to break the vicious circle of the spell (see Fig. 11-11). Physicians may use one or more of the following to treat the spell.
1. The infant should be picked up and held in a knee–chest position.
2. Morphine sulfate, 0.2 mg/kg administered subcutaneously or intramuscularly, suppresses the respiratory center and abolishes hyperpnea (and thus breaks the vicious cycle).
3. Oxygen is usually administered, but it has little demonstrable effect on arterial oxygen saturation.
4. Acidosis should be treated with sodium bicarbonate (NaHCO₃), 1 mEq/kg administered IV. The same dose can be repeated in 10 to 15 minutes. NaHCO₃ reduces the respiratory center–stimulating effect of acidosis.

With the preceding treatment, the infant usually becomes less cyanotic, and the heart murmur becomes louder, which indicates an increased amount of blood flowing through the stenotic RVOT. If the hypoxic spells do not fully respond to these measures, the following medications can be tried:
1. Ketamine, 1 to 3 mg/kg (average, 2 mg/kg) administered IV over 60 seconds, works
well. It increases the systemic vascular resistance (SVR) and sedates the infant.
2. Propranolol, 0.01 to 0.25 mg/kg (average, 0.05 mg/kg) administered by slow IV push, reduces the heart rate and may reverse the spell.

Management

Medical

1. Physicians should recognize and treat hypoxic spells (see the preceding section and Chapter 11). It is important to educate parents to recognize the spells and know what to do.
2. Oral propranolol therapy, 0.5 to 1.5 mg/kg every 6 hours, is occasionally used to prevent hypoxic spells while waiting for an optimal time for corrective surgery in the regions where open heart surgical procedures are not well established for small infants.
3. Balloon dilatation of the RVOT and pulmonary valve, although not widely practiced, has been attempted to delay repair for several months.
4. Relative iron-deficiency states should be detected and treated. Iron-deficient children are more susceptible to cerebrovascular complications. Normal hemoglobin or hematocrit values or decreased red blood cell indices indicate an iron-deficiency state in cyanotic patients.

Surgical

Palliative Shunt Procedures

Indications

Shunt procedures are performed to increase PBF (Fig. 14-22). Indications for shunt procedures vary from institution to institution. Many institutions, however, prefer primary repair without a shunt operation regardless of the patient’s age. However, when the following situations are present, a shunt operation may be chosen rather than primary repair.
1. Neonates with TOF and pulmonary atresia
2. Infants with hypoplastic pulmonary annulus, which requires a transannular patch for complete repair
3. Children with hypoplastic PAs
4. Unfavorable coronary artery anatomy
5. Infants younger than 3 to 4 months old who have medically unmanageable hypoxic spells
6. Infants weighing less than 2.5 kg

Procedures, Complications, and Mortality

Although several other procedures were performed in the past (see Fig. 14-22), a modified BT (Gore-Tex interposition) shunt is the only procedure performed at this time.
1. Classic BT shunt, anastomosed between the subclavian artery and the ipsilateral PA, is
usually performed for infants older than 3 months because the shunt is often thrombosed in young infants. A right-sided shunt is performed in patients with left aortic arch; a left-sided shunt is performed for right aortic arch.

2. With a modified BT shunt, a Gore-Tex interposition shunt is placed between the subclavian artery and the ipsilateral PA. This is the most popular procedure for any age, especially for infants younger than 3 months of age. Whereas a left-sided shunt is preferred for patients with left aortic arch, a right-sided shunt is preferred for patients with a right aortic arch. The surgical mortality rate is 1% or less.

3. The Waterston shunt, anastomosed between the ascending aorta and the right PA, is no longer performed because of a high incidence of surgical complications. Complications resulting from this procedure included too large a shunt leading to CHF or pulmonary hypertension and narrowing and kinking of the right PA at the site of the anastomosis. This created difficult problems in closing the shunt and reconstructing the right PA at the time of corrective surgery.

![Diagram of shunt procedures](image)

**FIGURE 14-22** Palliative procedures that can be performed in patients with cyanotic cardiac defect with decreased pulmonary blood flow. The Gore-Tex interposition shunt (or modified Blalock-Taussig shunt) is the most popular systemic–to–pulmonary artery (PA) shunt procedure. AO, aorta; LV, left ventricle; RA, right atrium; RV, right ventricle.
4. The Potts operation, anastomosed between the descending aorta and the left PA, is no longer performed either. It may result in heart failure or pulmonary hypertension, as in the Waterston operation. A separate incision (i.e., left thoracotomy) is required to close the shunt during corrective surgery, which is performed through a midsternal incision.

**Complete Repair Surgery**

Timing of this operation varies from institution to institution, but early surgery is generally preferred.

**Indications and Timing**

1. Oxygen saturation less than 75% to 80% is an indication of surgery by most centers. The occurrence of hypoxic spells is generally considered an indication for operation.
2. Symptomatic infants who have favorable anatomy of the RVOT and PAs may have primary repair at any time after 3 to 4 months of age, with some centers performing it even before 3 months of age. Most centers prefer primary elective repair by 1 to 2 years of age even if they are asymptomatic, acyanotic (i.e., “pink tet”), or minimally cyanotic.
   
   Advantages cited for early primary repair include diminution of hypertrophy and fibrosis of the RV, normal growth of the PAs and alveolar units, and reduced incidence of postoperative ventricular arrhythmias, and sudden death.
3. Mildly cyanotic infants who have had previous shunt surgery may have total repair 1 to 2 years after the shunt operation.
4. Asymptomatic children with coronary artery anomalies may have the repair after 1 year of age, because a conduit placement may be required between the RV and the PA.

**Procedure**

Total repair of the defect is carried out under cardiopulmonary bypass, circulatory arrest, and hypothermia. The procedure includes patch closure of the VSD, preferably through transatrial and transpulmonary artery approach (rather than right ventriculotomy, which is shown in Fig. 14-23); widening of the RVOT by division or resection of the infundibular tissue; and pulmonary valvotomy, avoiding placement of a fabric patch whenever possible (see Fig. 14-23). Widening of the RVOT without placement of patch is more likely to be accomplished if the repair is done in early infancy. However, if the pulmonary annulus and main PA are hypoplastic, transannular patch placement is unavoidable. Whereas some centers advocate placement of a monocusp valve at the time of initial
repair, others advocate pulmonary valve replacement at a later time if indicated.

The surgical approach in patients with TOF is summarized in Figure 14-24.

Mortality
For patients with uncomplicated TOF, the mortality rate is 2% to 3% during the first 2 years. Patients at risk are those younger than 3 months and older than 4 years, as well as those with severe hypoplasia of the pulmonary annulus and trunk. Other risk factors may include multiple VSDs, large aortopulmonary collateral arteries, and Down syndrome.

![Figure 14-24](image)

**FIGURE 14-24** Surgery approaches for tetralogy of Fallot (TOF). BT, Blalock-Taussig; RVOT, right ventricular outflow tract; RV-PA, right ventricle–to–pulmonary artery; VSD, ventricular septal defect.

Complications
1. Bleeding problems may occur during the postoperative period, especially in older polycythemic patients.
2. Pulmonary valve regurgitation may occur, but mild regurgitation is well tolerated.
3. Right bundle branch block (RBBB) on the ECG caused by right ventriculotomy, which occurs in more than 90% of patients, is well tolerated.
4. Complete heart block (i.e., <1%) and ventricular arrhythmia are both rare.

**Anomalous coronary artery**
Anomalous anterior descending coronary artery arising from the right coronary artery is considered a contraindication to a primary repair because it may require placement of a conduit between the RV and PA, which is usually performed after 1 year of age. However, it is often possible to enlarge the outflow tract through a transatrial approach and by placing a short outflow patch either above or below the anomalous coronary artery. Alternatively, when a small conduit is necessary between the RV and the PA, the native outflow tract should be made as large as possible through an atrial approach, so that a “double outlet” (the native outlet and the conduit) results from the RV.

Postoperative Follow-up
1. Long-term follow-up with office examinations every 6 to 12 months is recommended,
especially for patients with residual VSD shunt, residual obstruction of the RVOT, residual PA obstruction, arrhythmias, or conduction disturbances.

2. Significant pulmonary regurgitation (PR) may develop after repair of TOF. Although the PR is well tolerated for a decade or two, moderate to severe PR may eventually develop with significant RV dilatation and dysfunction, requiring surgical insertion of a homograft pulmonary valve. Severe PR left untreated may result in irreversible anatomic and functional changes in the RV, but the ideal timing of the valve replacement has been controversial. RV function is best investigated by MRI; if MRI is contraindicated because of the presence of metallic objects or cardiac pacemaker, CT should be used. The following are suggested criteria for surgical pulmonary valve replacement.
   a. Recommended criteria by Geva T (2006) is primarily based on RV regurgitant fraction:
      1) RV regurgitation fraction ≥25% PLUS
      2) Two or more of the following criteria
         a) RV end-diastolic volume index ≥160 mL/m$^2$ (normal, <108 mL/m$^2$)
         b) RV end-systolic volume index ≥70 mL/m$^2$ (normal, <47 mL/m$^2$)
         c) LV end-diastolic volume index ≥65 mL/m$^2$
         d) RV ejection fraction ≤45%
         e) RV outflow tract aneurysm
         f) Clinical criteria: exercise intolerance, syncope, presence of heart failure, sustained ventricular tachycardia, or QRS duration ≥180 msec (two last ones are known risk factors for sudden death)
      3) The following are modifiers to the above criteria.
         a) Presence of moderate to severe TR, residual ASD or VSD, and severe AR may trigger valve replacement.
         b) If the PR is associated with the stenosis of the main or branch pulmonary arteries (natural or secondary to shunt operations), the PA stenosis should be relieved first by a balloon and/or stent procedure, which may improve PR.
         c) In patients who underwent TOF repair at age 3 years or older, the valve replacement may be indicated in the presence of less severe RV dilatation and dysfunction than those 6 listed above. [Old age at surgery is an independent risk factor for impaired clinical status.]
   b. Recently, Lee C. et al (2012) have recommended the following cutoff values for optimal outcome. They found the systolic volume index to be more important than the diastolic volume index in determining the outcome of surgery.
      1) RV end-systolic volume index ≥80 mL/m$^2$ and
      2) RV end-diastolic volume index ≥163 mL/m$^2$.

3. Some patients, particularly those who had Rastelli operation using valved conduit, develop valvular stenosis or regurgitation. Valvular stenosis may improve after balloon dilatation, but PR may worsen. A nonsurgical percutaneous pulmonary valve implantation technique developed by Bonhoeffer et al (2000) has been used successfully. It is marketed as the Melody transcatheter pulmonary valve (Medtronic, Minneapolis,
4. Some children develop late arrhythmias, particularly ventricular tachycardia, which may result in sudden death. Arrhythmias are primarily related to persistent RVH as a result of unsatisfactory repair.
5. Pacemaker therapy is indicated for surgically induced complete heart block or sinus node dysfunction.
6. Varying levels of activity limitation may be necessary.
7. For patients who have residual defects or have prosthetic material for repair, SBE prophylaxis should be observed throughout life.
Tetralogy of Fallot with Pulmonary Atresia (Pulmonary Atresia and Ventricular Septal Defect)

Prevalence

Pulmonary atresia occurs in about 15% to 20% of patients with TOF.

Pathology

1. The intracardiac pathology resembles that of TOF in all respects except for the presence of pulmonary atresia, the extreme form of RVOT obstruction. The atresia may be at the infundibular or valvular level.
2. The PBF is most commonly mediated through a PDA (70%) and less commonly through multiple systemic collaterals (30%), which are referred to as multiple aortopulmonary collateral arteries (MAPCAs). Both PDA and collateral arteries may coexist as the source of PBF.
3. The central PAs are usually confluent in patients with PDA (70%). In patients with MAPCAs, the central PA is frequently nonconfluent, with the right upper lobe frequently supplied by a collateral from the subclavian artery and the left lower lobe by a collateral from the descending aorta. The subgroup of the patients with MAPCAs is designated as pulmonary atresia and ventricular septal defect (PA-VSD).
4. PA anomalies are common in the form of hypoplasia, nonconfluence, and abnormal distribution.
   a. The central PAs are confluent in 85% of patients; they are nonconfluent in 15%.
   b. The central and branch PAs are hypoplastic in most patients, but this occurs more frequently in patients with MAPCAs than in those with PDA. The degree of PA hypoplasia is importantly related to the success of surgery (see below for further discussion of PA hypoplasia).
   c. Incomplete arborization (distribution) of one or both PAs is found in 50% of patients with confluent PAs and in 80% of patients with nonconfluent PAs.
5. Collateral arteries arise most commonly from the descending aorta (occurring in two thirds of patients), less commonly from the subclavian arteries, and rarely from the abdominal aorta or its branches.
6. The ductus is small and long and arises from the transverse aortic arch and courses downward (“vertical” ductus) (Fig. 14-25).
7. The McGoon ratio and the Nakata index are used to quantitate the degree of PA hypoplasia. Small values of these measurements may adversely affect the outcome of surgeries in patients with small pulmonary arteries.
   a. The McGoon ratio is the ratio of the sum of the diameter of the immediately prebranching portion of the RPA plus left pulmonary artery (LPA) divided by the diameter of the descending aorta just above the diaphragm. Normal values of the McGoon ratio are 2.0 to 2.5. Most survivors of TOF with pulmonary atresia have a ratio greater than 1. Good Fontan candidates should have a ratio greater than 1.8.
b. The Nakata index is the cross-sectional area of the RPA and LPA (in mm\(^2\)) divided by the body surface area (BSA). The average diameter of both RPA and LPA are measured at the points immediately proximal to the origin of the first lobar branches at maximal and minimal during one cardiac cycle in the anteroposterior view of the pulmonary arteriogram. The cross-sectional area is calculated by using the formula, \( \pi \times r^2 \times \text{magnification coefficient} \) (where \( r \) is the radius or 1/2 of the measured PA diameters). A normal Nakata index is 330 ± 30 mm\(^2\)/BSA. Patients with TOF with PS should have an index greater than 100 for survival. A good Fontan candidate should have an index greater than 250, and a good Rastelli candidate should have an index greater than 200. (Those with an index less than 200 should have a shunt operation rather than the Rastelli.)

**Clinical Manifestations**

1. These patients are cyanotic at birth. The degree of cyanosis depends on whether the ductus is patent and how extensive the systemic collateral arteries are.
2. Usually a heart murmur cannot be heard. However, a faint, continuous murmur may be audible from the PDA or collaterals. The S2 is loud and single. A systolic click is occasionally present.
3. The ECG shows RAD and RVH.
4. Chest radiography shows a normal heart size. The heart often appears as a boot-shaped silhouette (see Fig. 14-19), and the pulmonary vascularity is usually markedly decreased (i.e., “black” lung field). Rarely, children with MAPCAs have excessive PBF, and CHF may develop.
5. Echocardiographic studies show all the anatomic findings of TOF plus the absence of a direct connection between the RV and the PA. In this case, a careful examination of the central PA is necessary with measurements of the size of central and branch PAs. The small branch PAs and “vertical ductus” (see Fig. 14-25) are well imaged from a high parasternal or suprasternal transducer position. Some of the multiple collateral arteries are also imaged by echocardiography and Doppler.

![FIGURE 14-25](image)

Anatomy of the ductus arteriosus in pulmonary atresia. The size and direction of the ductus arteriosus are different between a normal fetus and a fetus with pulmonary atresia. **A**, In a normal fetus, the ductus is large and joins the aorta (AO) at an obtuse angle. The aortic isthmus (the portion of the aorta between the left subclavian artery and the ductus) is narrower than the descending aorta. **B**, In pulmonary atresia, the ductus is small because flow to the descending aorta does not go through the ductus. Furthermore, because flow is from the
aorta to the pulmonary artery, the connection of the ductus with the aorta has an acute inferior angle (sometimes called “vertical” ductus). The aortic isthmus has the same diameter as the descending aorta. This type of ductus arteriosus is also found in some patients with tricuspid atresia. LPA, left pulmonary artery; MPA, main pulmonary artery; RPA, right pulmonary artery.

6. Cardiac catheterization and angiograms are sometimes needed for a complete delineation of the collaterals. Alternatively, MRI, rather than CT, is chosen for complete anatomic delineation of the aortic collaterals and PA branches.

**Natural History**

1. Without immediate attention to the establishment of PBF during the newborn period, most neonates who have this condition die during the first 2 years of life; however, infants with extensive collaterals may survive for a long time, perhaps for more than 15 years.
2. Occasionally, patients with excessive collateral circulation develop hemoptysis during late childhood.

**Management**

**Medical**

1. PGE1 infusion should be started as soon as the diagnosis is made or suspected to keep the ductus open for additional studies and to prepare for surgery. The starting dose of alprostadil (Prostin VR Pediatric) solution is 0.05 to 0.1 µg/kg per minute. When the desired effect is obtained, the dosage should be gradually reduced to 0.01 µg/kg per minute.
2. Emergency cardiac catheterization or MRI study is usually needed to delineate the anatomy of the PAs and systemic arterial collaterals.

**Surgical**

A connection must be established between the RV and true PA as early in life as possible. This may allow tiny central PAs to enlarge rapidly during the first year of life with improved arborization (distribution) of the pulmonary arteries with concurrent development of alveolar units. To achieve this goal, some centers initially use a central shunt procedure, and others proceed with an RV–PA connection.

1. Central shunt operation. Some centers use a central shunt directly connecting the ascending aorta and the hypoplastic main PA to achieve growth of the peripheral PAs (Mee procedure) (Fig. 14-26). A classic or modified BT shunt is avoided because it is difficult to perform on tiny PAs and may cause stenosis or distortion. This is then followed by unifocalization (see below for explanation), RV-PA connection, and closure of VSD. Other centers skip the shunt procedure and proceed with the connection of the RV and the main PA (see below).
2. RV-to-PA connection
   a. **Single-stage repair.** Complete, primary surgical repair in patients with TOF and
pulmonary atresia is possible only when (1) the true PAs provide most or all PBF (with \(O_2\) saturation of >75%) or (2) the central PA connects without obstruction to sufficient regions of the lungs (i.e., at least equal to one whole lung). If additional major collaterals are identified, test the level of arterial \(O_2\) saturation after occlusion of the collateral in the catheterization laboratory. If the \(O_2\) saturation remains greater than 70% to 75%, coil occlusion of the collaterals is then carried out.


Primary repair of this condition consists of closing the VSD, establishing a continuity between the RV and the unifocalized PA (see below for unifocalization procedure) using either aortic or pulmonary homograft (9- to 10-mm internal diameter), and interrupting collateral circulation. The mortality rate varies between 5% and 20%. Good candidates for the repair are those with a Nakata index above 200. If the index is below 200, a shunt procedure is preferable.

b. **Multiple-stage repair.** When the requirements for single-stage repair are not met, three consequential steps are used to repair this condition. These steps are summarized in **Figure 14-27**.

1. **Stage 1.** RV-to-hypoplastic PA conduit, using a relatively small homograft conduit (6- to 8-mm internal diameter) (see Fig. 14-27). The major goal of this operation is to make the central PA grow to an adequate size for eventual repair surgery. Interventional catheterization is carried out 3 to 6 months later to identify and coil occlude remaining aortic collaterals, to define PA distribution, and to identify if certain bronchopulmonary segments are receiving a duplicate blood supply.

2. **Stage 2.** A unifocalization procedure is carried out. Unifocalization is a surgical procedure in which aortopulmonary collaterals are divided from their aortic origin and are anastomosed to the true pulmonary arteries or main PA conduit (see Fig. 14-27).
FIGURE 14-27 Diagram of multiple-stage repair. Upper row (confluent pulmonary artery [PA] and collaterals): A, A hypoplastic but confluent central PA and multiple other collateral arteries are shown. B, A small right ventricle–to–PA (RV-to-PA) connection is made with pulmonary homograft (shown shaded), with collaterals left alone. C, The pulmonary arteries have grown to a larger size, and a larger pulmonary homograft has replaced the earlier small one. Collateral arteries are now anastomosed (unifocalized) to the originally hypoplastic PA branches. The ventricular septal defect (VSD) may be closed at a later time usually 1 to 3 years of age. The pulmonary homograft is usually replaced with a larger graft at this time. Bottom row (nonconfluent PA and multiple collaterals): A, Absent central PA and multiple aortic collaterals are shown. B, A small pulmonary homograft (6–8 mm internal diameter, shown shaded) is used to establish the RV-to-PA connection with some collaterals connected to it (unifocalized) (performed at 3–6 mo). Some collaterals are not unifocalized at this time. C, The homograft conduit has been replaced with a larger one. Remaining collateral arteries are anastomosed to the pulmonary homograft to complete unifocalization procedure. The VSD is closed with or without fenestration, usually at 1 to 3 years.

Post-unifocalization catheterization is carried out 3 to 6 months later (a) to identify multiple peripheral stenosis in both the true as well as the unifocalized collaterals and to do balloon dilatation with or without stenting and (b) to assess the need for further unifocalization procedures.

(3) **Stage 3.** Closure of VSD with or without fenestration, usually at 1 to 3 years of age (see Fig. 14-27). The homograft conduit may need to be replaced at the same time. If the RV pressure is 10% to 20% greater than systemic pressure, a central fenestration 3 to 4 mm is created. Multiple ballooning and stenting procedures are often necessary to reduce RV pressure to less than 50% systemic if possible.

Surgical steps used in patients with TOF with pulmonary atresia are summarized in Figure 14-28.

**Postoperative Follow-up**

1. Frequent follow-up is needed to assess the palliative surgery and decide on appropriate times for further surgeries.
2. Valved conduits or homografts may develop valve degeneration requiring conduit replacement at a later time. Valvular stenosis can be dilated with a balloon to reduce the pressure gradient but often result in significant valve regurgitation, eventually leading to RV dysfunction. Many of these patients require surgical replacement of the conduit.
3. Recently, Bonhoeffer and his colleagues (2000) have developed a technique in which a dysfunctional conduit or homograft valve can be replaced by percutaneous replacement of pulmonary valve, and more children and adults have successfully had this procedure done (Khambadkone et al, 2005). A bovine jugular venous valve was mounted into the platinum stent and loaded in the delivery system. The assembly was delivered (implanted) in the RVOT according to standard stent-placeing technique using an 18-Fr long sheath through a right femoral approach. This valve is marketed as the Melody transcatheter pulmonary valve. The other commercially available valve for use in the RVOT is the Edwards SAPIEN valve (Edwards Lifescience, Irvine, CA), a balloon-expandable stainless steel stent containing a bovine pericardial valve. Experience with this valve is extremely limited.

4. Survivors of the defect may need antibiotic prophylaxis for SBE for an indefinite period.

5. A certain level of activity restriction is needed because many of these children have exercise intolerance. Most survivors after complete repair are in New York Heart Association (NYHA) class I or II symptomatically.
Tetralogy of Fallot with Absent Pulmonary Valve

Prevalence

Tetralogy of Fallot with an absent pulmonary valve occurs in approximately 2% of patients with TOF.

Pathology and Pathophysiology

1. The pulmonary valve leaflets are either completely absent or have an uneven rim of rudimentary valve tissue present. The annulus of the valve is stenotic and displaced distally. A massive aneurysmal dilatation of the PAs is present. This anomaly is usually associated with a large VSD, similar to that seen in TOF. It rarely occurs with an intact ventricular septum.

2. The massive PA aneurysm (Fig. 14-29) develops during fetal life resulting from severe PR and an associated increase in RV stroke volume. The aneurysmal PAs compress anteriorly the lower end of the developing trachea and bronchi throughout fetal life, producing hypoplasia of the compressed airways. This produces signs of airway obstruction and respiratory distress during infancy. Pulmonary complications (e.g., atelectasis, pneumonia), rather than the intracardiac defect, are the usual causes of death.

3. The ductus arteriosus is frequently (but not invariably) absent in patients with more severe aneurysmal dilatation of the PAs.

4. Because the stenosis at the pulmonary valve ring is only moderate, an initial bidirectional shunt becomes predominantly a left-to-right shunt after the newborn period.

5. In some infants, tufts of PAs entwine and compress the intrapulmonary bronchi, resulting in reduced numbers of alveolar units. This may preclude successful surgical correction.

Clinical Manifestations

1. Mild cyanosis may be present as a result of a bidirectional shunt during the newborn period when the PVR is relatively high. Cyanosis disappears, and signs of CHF may develop after the newborn period. Respiratory symptoms vary greatly, ranging from neonates with severe respiratory compromise, those with wheezing or frequent respiratory infection, and those with no respiratory symptoms at all.

2. A to-and-fro murmur (with “sawing-wood” sound) at the upper and mid-left sternal borders is a characteristic auscultatory finding of the condition. This murmur occurs because of mild PS and free PR. The S2 is loud and single. The RV hyperactivity is palpable.

3. The ECG shows RAD and RVH.
4. Chest radiography images reveal a noticeably dilated main PA and hilar PAs. The heart size is either normal or mildly enlarged, and pulmonary vascular markings may be slightly increased. The lung fields may show hyperinflated areas, representing partial airway obstruction (see Fig. 14-29, A).

5. Echocardiographic studies reveal a large, subaortic VSD with overriding of the aorta, distally displaced pulmonary annulus (with thick ridges instead of fully developed pulmonary valve leaflets), and gigantic aneurysm of the PA and its branches. The RV is markedly dilated, often with paradoxical motion of the ventricular septum. Doppler studies reveal evidence of stenosis at the annulus and PR. Cardiac catheterization and angiocardiography (see Fig. 14-29, B) are usually unnecessary for accurate anatomic assessment of the PAs.

6. CT or MRI scan can define the relationship between sites of airway obstruction and dilatation of the central PA. Bronchoscopy provides the degree of airway compression.

**Natural History**

1. More than 75% of infants with severe pulmonary complications (e.g., atelectasis, pneumonia) die during infancy if treated only medically. The surgical mortality rate of infants with pulmonary complications is 20% to 40%.

2. Infants who survive infancy without serious pulmonary problems do well for 5 to 20 years and have fewer respiratory symptoms during childhood. They become symptomatic later and die from intractable right-sided heart failure.

**Management**

**Medical**

In the past, medical management was preferred because of poor surgical results in newborns; however, the mortality rate of medical management is much higher than surgical management. After the pulmonary symptoms appear, neither surgical nor medical management has good results.
**Surgical**
Symptomatic neonates should have corrective surgery on an urgent basis. Even asymptomatic children should have elective surgery in the first 3 to 6 month of life.

**Primary Repair**
Complete primary repair is the procedure of choice. VSD is closed through right ventriculotomy (across the pulmonary annulus). In symptomatic neonates, a pulmonary homograft is used to replace the dysplastic pulmonary valve and the dilated main and branch PAs. Alternatively, a valved conduit may be used to restore competence of the pulmonary valve, and the aneurysmal PAs are plicated. Some surgeons advocate aortic transection to achieve good exposure of the PAs for an extensive pulmonary arterioplasty into the hila of both lungs. An early surgical mortality rate is as high as more than 20% with a 1-year survival rate of 75%.
Total Anomalous Pulmonary Venous Return

Prevalence

Total anomalous pulmonary venous return (TAPVR) accounts for 1% of all CHDs. There is a marked male preponderance for the infracardiac type (male-to-female ratio of 4:1).

Pathology and Pathophysiology

1. No direct communication exists between the pulmonary veins and the LA. Instead, they drain anomalously into the systemic venous tributaries or into the RA. Depending on the drainage site of the pulmonary veins, the defect may be divided into the following four types (Fig. 14-30).
   a. **Supracardiac**: This type accounts for 50% of TAPVR patients. The common pulmonary venous sinus drains into the right SVC through the left vertical vein and the left innominate vein (see Fig. 14-30, A).
   b. **Cardiac**: This type accounts for 20% of TAPVR patients. The pulmonary veins enter the RA separately through four openings (only two openings are illustrated in Fig. 14-30, B), or the common pulmonary venous sinus drains into the coronary sinus (see Fig. 14-30, C).
   c. **Infracardiac**: This type accounts for 20% of TAPVR patients. The common pulmonary venous sinus drains to the portal vein, ductus venosus, hepatic vein, or IVC. The common pulmonary vein penetrates the diaphragm through the esophageal hiatus (see Fig. 14-30, D).
   d. **Mixed type**: This type, which is a combination of the other types, accounts for 10% of TAPVR patients.


2. Many patients with supracardiac and cardiac types of TAPVRs and most patients with the infracardiac type have pulmonary hypertension secondary to obstruction of the pulmonary venous return. Either the length of the venous channels or the resistance caused by the hepatic sinusoids is the cause of obstruction.
3. In patients with pulmonary venous obstruction, pulmonary arterial hypertension develops. These patients develop progressive pulmonary venous congestion, hypoxemia, and systemic hypoperfusion.
4. An interatrial communication, either an ASD or PFO, is necessary for survival. Most
patients do not have restricted flow across the atrial septum.
5. The left side of the heart is relatively small.

Clinical Manifestations
Clinical manifestations differ, depending on whether there is obstruction to the pulmonary venous return.

Without Pulmonary Venous Obstruction

History
1. CHF with growth retardation and frequent pulmonary infection is common in infancy.
2. A history of mild cyanosis from birth is present.

Physical Examination
1. The infant is undernourished and mildly cyanotic. Signs of CHF (e.g., tachypnea, dyspnea, tachycardia, hepatomegaly) are present.
2. A precordial bulge with hyperactive RV impulse is present. The cardiac impulse is maximal at the xyphoid process and the lower left sternal border.
3. Characteristic quadruple or quintuple rhythm is present. The S2 is widely split and fixed, and the P2 may be accentuated. A grade 2 to 3 of 6 ejection systolic murmur is usually audible at the upper left sternal border. A mid-diastolic rumble is always present at the lower left sternal border (because of increased flow through the tricuspid valve) (Fig. 14-31).

FIGURE 14-31  Cardiac findings of total anomalous pulmonary venous return without obstruction to pulmonary venous return.
FIGURE 14-32  Posteroanterior view of plain chest film demonstrating the “snowman” sign (A) and an angiocardiogram demonstrating anatomic structures that participate in the formation of the “snowman” sign (B). The vertical vein (left superior vena cava), the dilated left innominate vein, and the right superior vena cava are opacified.

Electrocardiography
Right ventricular hypertrophy of the so-called volume overload type (i.e., rsR’ in V1) and occasional RAH are present.

Radiography
1. Moderate to marked cardiomegaly involving the RA and RV is present with increased pulmonary vascular markings.
2. The “snowman” sign or figure-of-8 configuration may be seen in the supracardiac type but rarely before 4 months of age (Fig. 14-32).

With Pulmonary Venous Obstruction

History
1. Marked cyanosis and respiratory distress develop in the neonatal period with failure to thrive.
2. Cyanosis worsens with feeding, especially in infants with the infracardiac type, resulting from compression of the common pulmonary vein by the food-filled esophagus.

Physical Examination
1. Moderate to marked cyanosis and tachypnea with retraction are present in newborns and undernourished infants.
2. Cardiac findings may be minimal. A loud, single S2 and gallop rhythm are present. Heart murmur is usually absent. If present, however, it is usually a faint ejection-type systolic murmur at the upper left sternal border.
3. Pulmonary crackles and hepatomegaly are usually present.

Electrocardiography
Invariably, RVH in the form of tall R waves in the right precordial leads is present. RAH
is occasionally present.

**Radiography**
The heart size is normal or slightly enlarged. The lung fields reveal findings of pulmonary edema (i.e., diffuse reticular pattern and Kerley’s B lines). These findings may be confused with pneumonia or hyaline membrane disease.

**Echocardiography**
Echocardiography and Doppler studies are usually diagnostic of the condition and can identify associated anomalies.

**Features Common to All Types**
1. A large RV with a compressed LV (i.e., relative hypoplasia of the LV) is the most striking initial finding. A large RA and a small LA, with deviation of the atrial septum to the left and dilated PAs, are also present.
2. An interatrial communication is usually present. PFO occurs in 70% of patients, and secundum ASD occurs in 30%.
3. A large common chamber (i.e., common pulmonary venous sinus) may be imaged posterior to the LA in the parasternal long-axis view.
4. M-mode echocardiography may show paradoxical or flat motion of the interventricular septum as a sign of RV volume overload.
5. Doppler studies reveal an increased flow velocity in the PA, an increased flow velocity or continuous flow at the site of the pulmonary venous drainage, and findings suggestive of pulmonary hypertension.

**Features of the Supracardiac Type**
The most common site of connection is the left SVC (i.e., left vertical vein), with subsequent drainage to the dilated left innominate vein and right SVC. These abnormal pathways can be imaged in the suprasternal notch short-axis view. Color-flow mapping and Doppler ultrasonography are helpful in defining the direction of the flow in the left SVC.

**Features of the Cardiac Type**
The most common site of entry is to the coronary sinus, occurring in 15% of cases. A dilated coronary sinus, best imaged in the parasternal long-axis view and the apical four-chamber view, may be the first clue to this condition.

**Features of the Infracardiac Type**
A dilated vein descending to the abdominal cavity through the diaphragm is imaged using the subcostal sagittal and transverse scans. All four pulmonary veins that connect to the confluence must be imaged. They are best imaged on the subcostal coronal scan or
the suprasternal notch short-axis view.

**Possibility of the Mixed Type**

Unless it is demonstrated that all four pulmonary veins connect to the confluence, the possibility of the mixed type of TAPVR cannot be eliminated. In the most common mixed type, the left lung, usually the upper lobe, drains to the left SVC, and the remaining pulmonary veins in both lungs drain to the coronary sinus. When the mixed type is suspected, either MRI or cardiac catheterization needs to be performed.

**Other Studies**

Echocardiography is usually diagnostic and can identify the subtypes. Cardiac catheterization is rarely performed for diagnostic purposes; it is occasionally done to perform atrial septostomy to improve atrial shunt or to identify a complex mixed type of pulmonary venous return. Alternatively, MRI or cardiac CT can be used for diagnosis in case of complex mixed type; the former is preferable because it does not use ionizing radiation.

**Natural History**

1. CHF occurs in both types of TAPVRs with growth retardation and repeated pneumonias.
2. Without surgical repair, two thirds of the infants without obstruction die before reaching 1 year of age. They usually die from superimposed pneumonia.
3. Patients with the infracardiac type rarely survive for longer than a few weeks without surgery. Most die before 2 months of age.

**Management**

**Medical**

1. Intensive anticongestive measures with diuretics should be provided for infants without pulmonary venous obstruction.
2. Metabolic acidosis, if present, should be corrected.
3. Infants with severe pulmonary edema (resulting from the infracardiac type and from other types with obstruction) should be intubated and receive ventilator support with oxygen and positive end-expiratory pressure, if necessary, before cardiac catheterization or surgery.
4. In some patients with pulmonary hypertension, such as those with the infracardiac type, PGE₁ can increase systemic flow by keeping the ductus open.
5. If the size of the interatrial communication appears small and immediate surgery is not indicated, balloon atrial septostomy or blade atrial septostomy may be performed to enlarge the communication.
Surgical

Indications and Timing
Corrective surgery is necessary for all patients with this condition. No palliative procedure exists.
1. All infants with pulmonary venous obstruction should be operated on soon after diagnosis in the newborn period.
2. Infants who do not have pulmonary venous obstruction but do have heart failure that is difficult to control are usually operated on between 4 and 6 months of age.

Procedures
Although procedures vary with the site of the anomalous drainage, all procedures are intended to redirect the pulmonary venous return to the LA (Fig. 14-33). Surgical techniques used vary from surgeon to surgeon; some use the RA approach to reach the LA, and others reach the posterior wall of the LA directly. Some favor use of deep hypothermic (18°–20°C) circulatory arrest.

**Supracardiac type.** A large, side-to-side anastomosis is made between the common pulmonary venous sinus and the LA. The vertical vein is ligated. The ASD is closed with a cloth patch (see Fig. 14-33, A).

**TAPVR to the RA.** The atrial septum is excised, and a patch is sewn in such a way that the pulmonary venous return is diverted to the LA (see Fig. 14-33, B). The ASD may have to be enlarged.

**TAPVR to the coronary sinus.** An incision is made in the anterior wall of the coronary sinus (“unroofing”) to make a communication between the coronary sinus and the LA. A single patch closes the original ASD and the ostium of the coronary sinus. This results in the drainage of coronary sinus blood with low oxygen saturation into the LA (see Fig. 14-33, C).

**Infracardiac type.** A large vertical anastomosis is made between the common pulmonary venous sinus and the LA. The common pulmonary vein, which descends vertically to the abdominal cavity, is ligated above the diaphragm (see Fig. 14-33, D).

**FIGURE 14-33** Surgical approaches to various types of total anomalous pulmonary venous returns. **A,** in the supracardiac type, a large side-to-side anastomosis is made between the common pulmonary venous sinus and the LA and the ASD is closed with a patch. **B,** in the cardiac type, the atrial septum is excised and a patch is sewn in such a way that all pulmonary venous return is diverted to the LA. **C,** for the coronary sinus type, an incision is made in the anterior wall of the coronary sinus to make a communication between the coronary sinus and the LA. The original ASD and the ostium of the coronary sinus are closed by a single patch. **D,** for the infracardiac type, a large anastomosis is made between the common pulmonary venous sinus and the LA and the common pulmonary
Mortality rate. The surgical mortality rate is between 5% and 10% for infants with the unobstructed type. This rate can be as high as 20% for infants with the infracardiac type. Two common causes of death are postoperative paroxysms of pulmonary hypertension and the development of pulmonary vein stenosis.

Complications
1. Paroxysms of pulmonary hypertension, which relate to a small and poorly compliant left heart, with resulting cardiac failure and pulmonary edema, may require prolonged respiratory support postoperatively.
2. Postoperative arrhythmias are usually atrial.
3. Obstruction at the site of anastomosis or stenosis of the pulmonary veins rarely occurs.

Postoperative Follow-up
1. An office evaluation every 6 to 12 months is recommended for such late complications as pulmonary vein obstruction and atrial arrhythmias.
2. Pulmonary vein obstruction at the anastomosis site or delayed development of pulmonary vein stenosis may occur in about 10% of patients and requires reoperation. These complications are usually evident within 6 to 12 months after the repair. The possibility of pulmonary vein stenosis requires cardiac catheterization and angiocardiography. If present, it is nearly impossible to correct.
3. Some patients develop atrial arrhythmias, including sick sinus syndrome, that require medical treatment or pacemaker therapy.
4. Activity restriction is usually unnecessary unless pulmonary venous obstruction occurs.
Tricuspid Atresia

Prevalence
Tricuspid atresia accounts for 1% to 3% of CHDs.

Pathology
1. The tricuspid valve is absent, and the RV is hypoplastic, with absence of the inflow portion of the RV. The associated defects such as ASD, VSD, or PDA are necessary for survival.
2. Tricuspid atresia is usually classified according to the presence or absence of PS and TGA (Fig. 14-34). The great arteries are normally related in about 70% of cases and are transposed in 30% of cases. In 3% of cases, the L form of transposition occurs.
3. In patients with normally related great arteries, the VSD is usually small, PS is present with resulting hypoplasia of the pulmonary arteries, and the pulmonary blood flow is reduced. This is the most common type, occurring in about 50% of all patients with tricuspid atresia. Occasionally, the VSD is large with normal-sized PAs or the ventricular septum is intact with pulmonary atresia.
4. When TGA is present, the pulmonary valve is normal with increased PBF in two thirds of cases. In one third of cases, it is either stenotic or atretic with decreased PBF. Patients with TGA need a fairly large VSD to maintain normal systemic cardiac output. Less than adequate size or spontaneous reduction of the VSD creates problems with a decreased systemic cardiac output.
5. COA or interrupted aortic arch is a frequently associated anomaly that is more commonly seen in patients with TGA.

Clinical Manifestations

History
1. Cyanosis is usually severe from birth. Tachypnea and poor feeding usually manifest.
2. History of hypoxic spells may be present in infants with this condition.
FIGURE 14-34  Anatomic classification of tricuspid atresia. In about 70% of cases, the great arteries are normally related, and there is a small ventricular septal defect (VSD) with associated hypoplasia of the pulmonary artery (PA). When the great arteries are transposed, the VSD is usually large, and the PAs are large with increased pulmonary blood flow. AS, aortic stenosis; D-TGA, complete transposition of the great arteries; L-TGA, congenitally corrected TGA; PA, pulmonary atresia; PS, pulmonary stenosis; sub AS, subaortic stenosis; sub PS, subpulmonary stenosis; TGA, transposition of the great arteries; VSD, ventricular septal defect. (Data from Keith JD, Rowe RD, Vlad P: Heart Disease in Infancy and Childhood, 3rd ed. New York, Macmillan, 1978.)

FIGURE 14-35  Cardiac findings of tricuspid atresia associated with patent ductus arteriosus and ventricular septal defect. “Superior” QRS axis on the electrocardiogram and cyanosis are characteristic of the defect.
Physical Examination (Fig. 14-35)

1. Cyanosis is usually present. Older infants may have clubbing.
2. A systolic thrill is rarely palpable when associated with PS.
3. The S2 is single. A grade 2 to 3 of 6 holosystolic (or early systolic) murmur of VSD is usually present at the lower left sternal border. A continuous murmur of PDA is occasionally present. An apical diastolic rumble is rarely audible in patients with large PBF.
4. Hepatomegaly may indicate an inadequate interatrial communication or CHF.

FIGURE 14-36  Tracing from a 6-month-old girl with tricuspid atresia showing “superior QRS axis” or left anterior hemiblock (~30 degrees), right atrial hypertrophy, and left ventricular hypertrophy.

FIGURE 14-37  Posteroanterior view of chest roentgenogram in an infant with tricuspid atresia with normally related great arteries. The heart is minimally enlarged. The pulmonary vascular markings are decreased, and the main pulmonary artery segment is somewhat concave.
**Electrocardiography**

1. “Superior” QRS axis (between 0 and –90 degrees) is characteristic. It appears in most patients without TGA (Fig. 14-36). The “superior” QRS axis is present in only 50% of patients with TGA.

2. LVH is usually present; RAH or biatrial hypertrophy is common.

**Radiography**

The heart size is normal or slightly increased, with enlargement of the RA and LV. Pulmonary vascularity decreases in most patients (Fig. 14-37), although it may increase in infants with TGA. Occasionally, the concave PA segment may produce a boot-shaped heart, similar to the radiographic findings of TOF.

**Echocardiography**

Two-dimensional echocardiography readily establishes the diagnosis of tricuspid atresia.

1. Absence of the tricuspid orifice, a large RA, marked hypoplasia of the RV, and a large LV can be imaged in the apical four-chamber view. The size of the LA is determined by the magnitude of pulmonary blood flow.

2. The bulging of the atrial septum toward the left and the size of the interatrial communication are easily imaged in the subcostal four-chamber view.

3. The size of the VSD, the presence and severity of PS, and the presence of TGA should all be investigated.

4. Patients with TGA should be examined for possible subaortic stenosis and aortic arch anomalies, especially the COA.

**Other Studies**

Echocardiographic and color-flow Doppler studies can delineate most anatomic and physiologic issues related to the condition. However, cardiac catheterization with interventional balloon atrial septostomy is indicated when atrial communication is inadequate. Cardiac catheterization is generally recommended before a planned surgical intervention other than the BT shunt or PA banding. Specific information on the PA anatomy, pressure, and LV function is necessary before any Fontan-type operation.

**Natural History**

1. Few infants with tricuspid atresia and normally related great arteries survive beyond 6 months of age without surgical palliation.

2. Occasionally, patients with increased PBF develop CHF and eventually pulmonary vascular obstructive disease.

3. For patients who survive into their second decade of life without a Fontan-type operation, the chronic volume overload of the LV usually results in LV systolic dysfunction, which is a known risk factor for the Fontan operation. (The Fontan procedure should be performed before LV dysfunction develops.)
Management

Initial Medical Management

1. PGE₁ should be started in neonates with severe cyanosis to maintain the patency of the ductus before planned cardiac catheterization or cardiac surgery.
2. The Rashkind procedure (balloon atrial septostomy) may be performed as part of the initial catheterization to improve the RA-to-LA shunt, especially when the interatrial communication is considered inadequate by echocardiographic studies.
3. Treatment of CHF is rarely needed in infants with TGA and without PS.
4. Infants with normally related great arteries and adequate PBF through a VSD do not need any other procedures; rather, they need to be closely watched for decreasing oxygen saturation resulting from spontaneous reduction of the VSD.

Surgical

Most infants with tricuspid atresia require one or more palliative procedures before a Fontan-type operation, the definitive surgery, can be performed. Staged palliative surgical procedures are aimed at producing ideal candidates for future Fontan candidates. Ideal candidates for a Fontan-type operation are those who have normal LV function and low pulmonary resistance.

1. Normal LV function results from prevention of excessive volume or pressure loading of the LV by:
   a. Preventing excessive volume load by using a relatively small systemic-to-pulmonary shunt (e.g., 3.5 mm for neonates).
   b. Avoiding ventricular hypertrophy (e.g., by relieving the LV outflow obstruction).
2. Low pulmonary resistance may result from:
   a. Providing adequate PBF, which promotes the growth of PA branches (with a resulting increase in the cross-sectional area of the pulmonary vascular bed).
   b. Preventing distortion of the central pulmonary arteries. Shunt operation is preferably done on the right PA, which can be incorporated into a Fontan operation.
   c. Protecting the pulmonary vascular bed from overflow or pressure overload (by PA band when PBF is increased).

Palliative surgical procedures described below and the Fontan procedure are not just for tricuspid atresia but are also performed for other CHDs with a functionally single ventricle, such as single ventricle (double inlet ventricle), some cases of pulmonary atresia with an intact ventricular septum, unbalanced AV canal, complicated DORV, HLHS, and heterotaxia (splenic syndromes). Because the Fontan operation is applicable to so many other defects, a staged approach to the Fontan operation is summarized in Box 14-2 for quick reference.

Stage 1. The most frequently performed first-stage operation is the BT shunt. Under special circumstances, other procedures (e.g., the Damus-Kaye-Stansel operation) may have to be combined with the BT shunt. On rare occasion, a PA banding is indicated for infants with too much pulmonary blood flow.

1. **BT shunt.** Most patients who have tricuspid atresia with decreased PBF need the BT
shunt soon after birth when the PVR is still high (see Fig. 14-22). This procedure results in the volume load on the LV because the LV supplies blood to both the systemic and pulmonary circulations. Thus, the shunt should be relatively small (e.g., 3.5 mm) and should not be left alone too long (before proceeding to stage 2 operation). The B-T shunt is done on the right PA.

2. **Damus-Kaye-Stansel and shunt operation.** For infants with tricuspid atresia with TGA and restrictive VSD, the Damus-Kaye-Stansel procedure may be performed in addition to a systemic-to-PA shunt. In the Damus-Kaye-Stansel operation, the main PA is transected, and the distal PA is sewn over. The proximal PA is connected end to side to the ascending aorta (see Fig. 14-11). A systemic-to-PA shunt is created to supply blood to the lungs. A Fontan-type operation is performed at a later time. This procedure also results in the volume overload to the LV, and a stage 2 operation should be performed as early as possible.

3. **PA banding.** PA banding is rarely necessary for infants with CHF resulting from increased PBF. PA banding protects the pulmonary vasculature from developing pulmonary hypertension, and it may be performed at any age with a mortality rate of less than 5%.

**Follow-up Medical Management.** After the stage 1 operation, the infant should be watched carefully until the time of the stage 2 palliation with emphasis on the following:

a. Cyanosis (with $O_2$ saturation <75%) should be investigated by cardiac catheterization or MRI.

b. Poor growth may indicate too large a PBF, and tightening of the PA band should be considered.

---

**BOX 14-2  Fontan Pathway**

**Stage I** One of the following procedures is done in preparation for a future Fontan operation.

1. The Blalock-Taussig shunt, when PBF is small
2. PA banding when PBF is excessive
3. Damus-Kaye-Stansel + shunt operation (for TA + TGA + restrictive VSD)

**Medical follow-up** after stage I. Watch for:

a. Cyanosis ($O_2$ saturation <75%): cardiac catheterization or MRI to find out the cause of it

b. Poor weight gain (CHF from too much PBF): tightening of PA band may be necessary

**Stage II** (at 3 mo or by 6 mo)

1. BDG operation or
2. The hemi-Fontan operation

**Medical follow-up** after stage II. Watch for the following:

a. A gradual decrease in $O_2$ saturation (<75%) may be caused by:

   (1) Opening of venous collaterals
(2) Pulmonary AV fistula (caused by the absence of hepatic inhibitory factor): Perform cardiac catheterization (to find and occlude collaterals) or proceed with Fontan operation.

b. Transient hypertension: 1–2 wk postoperatively: May use ACE inhibitors

c. Cardiac catheterization by 12 mo after stage II.

The following are risk factors. Presence of ≥2 is a high-risk situation.

1. Mean PA pressure >18 mm Hg (or PVR >2 U/m²)
2. LV end-diastolic pressure <12 mm Hg (or EF >60%)
3. AV valve regurgitation
4. Distorted PAs secondary to previous shunt operation

**Stage III (Fontan operation): within 1–2 yr after stage II operation**

1. “Lateral tunnel” Fontan (with 4 mm fenestration)
2. An extracardiac conduit (with or without fenestration)

ACE, angiotensin-converting enzyme; AV, atrioventricular; CHF, congestive heart failure; EF, ejection fraction; LV, left ventricle; MRI, magnetic resonance imaging; PA, pulmonary artery; PBF, pulmonary blood flow; PVR, pulmonary vascular resistance; TA, truncus arteriosus; TGA, transposition of the great arteries; VSD, ventricular septal defect.

**Stage 2.** As a stage 2 operation, either a bidirectional Glenn shunt or the hemi-Fontan operation is performed in preparation for the final Fontan operation.

1. **Bidirectional Glenn operation.** An end-to-side SVC-to-RPA shunt (also called bidirectional superior cavopulmonary shunt) can be performed by 2.5 to 3 months of age (Fig. 14-38, A). By this time, the PVR is sufficiently low to allow venous pressure to be the driving force for the pulmonary circulation. There appears to be no advantage in further delaying the second stage operation beyond 6 months. For this procedure to be successful, the PVR has to be relatively low because the SVC blood flows passively into the pulmonary arteries. Any previous systemic-to-PA shunt is taken down at the time of the procedure. The azygos vein and, when present, the hemiazygos are divided. The IVC blood still bypasses the lungs.

   This procedure satisfactorily increases oxygen saturation, which averages 85%, without adding volume work to the LV. The mortality rate for this procedure is between 5% and 10%.

2. **The hemi-Fontan operation.** An incision is made along the most superior part of the RA appendage, and it is extended into the SVC (Fig. 14-39). A connection is made between this opening and the lower margin of the central portion of the PA. An intraatrial baffle is placed to direct the SVC blood to the pulmonary arteries. The BT shunt is taken down, and the native pulmonary valve is oversewn.
FIGURE 14-38  A modified Fontan operation. **A**, Bidirectional Glenn operation or superior vena cava (SVC)–to–right pulmonary artery anastomosis (state 2 operation). **B**, Completion of the Fontan operation by cavocaval baffle–to–pulmonary artery (PA) connection, with or without fenestration (stage 3 operation). See text for description of these procedures. AO, aorta; IVC, inferior vena cava; LV, left ventricle; RA, right atrium; RV, right ventricle.

FIGURE 14-39  Hemi-Fontan operation. **A**, A Blalock-Taussig (BT) shunt is taken down (arrow). An incision is made in the superior aspect of the right atrial appendage (RAA) extending it into the superior vena cava (SVC), and a horizontal incision is made in the right pulmonary artery (RPA). **B**, The lower margin of the RPA incision and the adjacent margin of the incision in the RAA and SVC are connected. **C**, The connection is completed using pulmonary allograft. An intraatrial patch is placed to direct SVC blood to the pulmonary arteries. AO, aorta; RA, right atrium.

The advantages of the hemi-Fontan operation are that it allows supplementation of the central PA area so as to optimize flow to the left lung, and it simplifies the subsequent Fontan operation. A major disadvantage may be that it involves extensive surgery in the region of the sinus node and sinus node artery, which may result in late sinus node dysfunction.

Medical follow-up after the stage 2 operation should focus on the following (see Box 14-2).

a. A remarkable improvement in $O_2$ saturation ($\approx 85\%$) results after the procedure. However, a gradual deterioration in $O_2$ saturation may occur in the months after surgery, which may be caused by:

1) Opening of venous collaterals which decompress the upper body
2) The development of pulmonary arteriovenous fistula, which may be related to an absence of hepatic inhibitory factor
Pulmonary arteriovenous fistulas develop commonly after the SVC-to-PA connection, in which hepatic venous blood does not reach the pulmonary circulation. It has been postulated that the liver may produce vasoconstrictor PGs, which prevent pulmonary vasodilation and development of pulmonary arteriovenous fistula. Vasoconstrictor PGs in blood from the liver bypassing the pulmonary circulation may lead to the pulmonary arteriovenous fistulas. **Song and colleagues (1996)** reported that long-term aspirin (a cyclooxygenase inhibitor) therapy has successfully prevented the development of cyanosis, possibly by preventing pulmonary arteriovenous fistula formation. A similar pulmonary arteriovenous fistula also occurs, with the clinical manifestation of cyanosis in patients with liver dysfunction (hepatopulmonary syndrome). The diagnosis of pulmonary arteriovenous malformation requires pulmonary angiography or, even better, a bubble-contrast echocardiography with injection into branch pulmonary arteries.

b. If a child’s $O_2$ saturation is 75% or less, it is preferable to proceed with Fontan operation. Alternatively, cardiac catheterization may be performed to find a cause of desaturation (e.g., missed left SVC, which can be coil occluded).

c. A pre-Fontan cardiac catheterization is performed by 12 months after the second-stage operation.

**Stage 3.** A modified Fontan operation is the definitive procedure for patients with tricuspid atresia. The whole premise of the Fontan operation is directing the entire systemic venous blood to the pulmonary arteries without an intervening pumping chamber. The Fontan operation is usually completed when the child is around 2 years of age. This procedure can even be performed on infants.

The following are risk factors for the Fontan operation: The presence of two or more of these risk factors constitutes a high-risk situation.

a. High PVR (>2 U/m$^2$) or high mean PA pressure (>18 mm Hg)
b. Distorted PAs secondary to previous shunt operations
c. Poor systolic or diastolic ventricular function, with LV end-diastolic pressure greater than 12 mm Hg or an ejection fraction less than 60%
d. AV valve regurgitation

The surgical technique of completing a modified Fontan operation varies according to the type of the second-stage operation performed (bidirectional Glenn operation or hemi-Fontan operation).

1. **After the bidirectional Glenn procedure**

An intraatrial tubular pathway is created from the orifice of the IVC to the orifice of the SVC (termed cavocaval baffle or a lateral tunnel). The cardiac end of the SVC is anastomosed to the undersurface of the RPA to complete the operation (see **Fig. 14-38, B**).

Some centers routinely use “fenestration” (4–6 mm) in the baffle, but others use it only in high-risk patients. The fenestration needs to be closed later, usually with an ASD closure device in the catheterization laboratory. Cited advantages of fenestration include decompression of the systemic venous circulation and augmentation of cardiac output in the early postoperative period. Disadvantages include systemic arterial desaturation with possible systemic embolization from the systemic veins and the later need to close the fenestration. An alternative to the above-described procedure, an extracardiac conduit,
may be used to complete the Fontan operation (see Fig. 14-41, H). Fenestration is not necessary for the extracardiac conduit, but some surgeons create the fenestration with this approach.

**FIGURE 14-40** From the hemi-Fontan to Fontan connection. A, A vertical incision (heavy broken line) is made in the anterior right atrial (RA) wall. B, The intraatrial patch is removed, and a lateral tunnel is constructed to direct the inferior vena cava (IVC) blood to the existing conglomerate of RA and right pulmonary artery (RPA). C, The direction of blood flow from the superior vena cava (SVC) and IVC is shown.

Early survival rates have improved to more than 90%. In a large series of 500 Fontan operations, the probability of survival was 85% at 1 month, about 80% at 1 and 5 years, and 70% at 10 years.

2. **After the hemi-Fontan operation**

The intraatrial patch that was used to direct SVC blood to the PAs is excised, and a lateral atrial tunnel is constructed, directing flow from the IVC to the previously created amalgamation of the SVC with the RPA (Fig. 14-40).

Timing for surgery is the same as for the cavocaval baffle-to-PA anastomosis. The mortality rate for the Fontan procedure for children who have undergone a hemi-Fontan operation is reportedly lower than those who had the bidirectional Glenn operation.

**Complications of the Fontan-Type Operation**

**Early Complications.**

Early postoperative complications may include the following.

1. Low cardiac output, heart failure, or both are early postoperative complications.
2. Persistent pleural effusion. This is a troublesome complication. Prolonged pleural drainage may lead to protein-losing enteropathy, which carries a poor prognosis. It may be the result of a sudden rise in the systemic venous or RA pressure. It occurs more often on the right side. The presence of aortopulmonary collaterals increases the risk of prolonged pleural effusion. Coil occlusion of these vessels before surgery can ameliorate this problem.

The extracardiac conduit was associated with increased pleural drainage than the intraatrial lateral tunnel, although the former may have a theoretical benefit for a lower incidence of late arrhythmias (Rogers et al, 2012). On the other hand, creation of fenestration was associated with a decreased incidence of prolonged effusion. Among
patients who received extracardiac conduit, Gupta et al (2008) found that lower preoperative oxygen saturation, smaller conduit size, and longer duration of cardiopulmonary bypass were associated with persistent pleural effusion.

The following treatments can be used for this complication: prolonged chest tube drainage, a low-fat diet with a medium-chain triglyceride oil supplement or total parenteral nutrition, chemical or talc pleurodesis, a pleuroperitoneal shunt, and thoracic duct ligation (which is a major surgery).

3. Thrombus formation in the systemic venous pathways may result from a sluggish blood flow, which can be diagnosed by transesophageal echocardiography. Treatment consists of warfarin, thrombolysis with streptokinase, or surgical removal. The risk is highest in the first several weeks to months after the Fontan operation, although the risk is present for the lifetime.

4. Although rare, acute liver dysfunction with alanine transaminase (ALT) greater than 1000 U/L can occur during the first week after surgery, possibly resulting from hepatic hypoperfusion (caused by low cardiac output).

Late Complications.

Regular follow-up is necessary to detect the following late complications:

1. Prolonged hepatomegaly and ascites require treatment with diuretics, afterload-reducing agents, and digitalis.

2. Supraventricular arrhythmia is one of the most troublesome complications. Early-onset arrhythmias occur in 15% of patients. The incidence of late-onset supraventricular arrhythmia continues to increase with longer follow-up after the Fontan procedure (6% at 1 year, 12% at 3 years, and 17% at 5 years). Extracardiac conduit (instead of intraatrial lateral tunnel) may help reduce the incidence of late cardiac arrhythmias (see Fig. 14-41, H).

3. A progressive decrease in arterial oxygen saturation may result from obstruction of the venous pathways, leakage in the intraatrial baffle, or development of pulmonary arteriovenous fistula.

4. Protein-losing enteropathy can result from increased systemic venous pressure that subsequently causes lymphangiectasis. Prolonged pleural drainage is an unfavorable sign to develop this condition. Increased PVR, decreased cardiac index, and increased ventricular end-diastolic pressure were coincidental findings with the condition. The incidence of protein-losing enteropathy among survivors is 4%. The prognosis is poor; about half of patients die within 5 years, regardless of the type of treatment, medical or surgical. Heart transplantation should be considered for these patients.

5. Thromboembolism can occur in up to 10% of patients after the Fontan operation. Some reports suggest stroke occurring in as high as 19% of the patients. Therefore, long-term thromboprophylaxis is required (see below).

The following are considered an increased risk for thromboembolism: a known hypercoagulable state, presence of intracardiac prosthetic materials, intracardiac shunt (fenestration), dilated atrium, atrial arrhythmias, ventricular dysfunction, low-flow states, stasis in the venous pathways, protein-losing enteropathy, and PA distortion. The use of
an extracardiac conduit may reduce the risk of thromboembolism.
Results of Fontan Operation

Currently, the operative mortality rate of the Fontan procedure is less than 3%. Mean PA pressure of 15 mm Hg or above was associated with prolonged hospital stay and unfavorable outcomes (Rogers et al, 2012). The overall survival rate after the Fontan operation is above 95% at follow-up of 50 months (Hirsch et al, 2008).
1. Patients should maintain a low-salt diet.

2. Medications
   a. Some patients need continued digoxin and diuretic therapy.
   b. An angiotensin-converting enzyme (ACE) inhibitor is generally recommended. Although not proved, it may augment LV output with consequent improvement in pulmonary blood flow.
   c. Aspirin or even warfarin is used to prevent thrombus formation. Controversy exists as to whether aspirin is adequate for thrombus prophylaxis compared with warfarin. A recent international report suggests that aspirin (5 mg/kg/day) is as good as properly controlled warfarin therapy (with a target international normalized ratio [INR] of 2.0–3.0) (McCrindle et al, 2013). Earlier studies have also reported the same finding. An important new finding by McCrindle et al (2013) is that when the INR levels were inadequately controlled (<2.0), the risk of thrombosis was higher than with aspirin. Anticoagulation activity is minimal with an INR below 2.0, and it is almost nonexistent with an INR below 1.5. Achieving and maintaining a target level of INR (>2.0) is important but difficult, especially in children, because of individual and genetic factors, interactions with multiple drugs and foods, and noncompliance. The ease of aspirin administration and the attendant higher compliance appear to make the antiplatelet dose of aspirin a better choice than warfarin.

3. Some centers recommend device closure of the fenestration a year or so after the Fontan procedure. However, about 20% to 40% of fenestrations will close spontaneously over the first year or two postoperatively.

4. Patients should not participate in competitive, strenuous sports.

5. Antibiotic prophylaxis against SBE should be observed when indications arise.

6. Among patients with tricuspid atresia, the 5-year survival rate is 80%, and the 10-year survival rate is 70%. During years 11 to 16 after surgery, the majority of patients have shown acceptable results, with 48% in NYHA class I, and 16% in class II (see Appendix A, Table A-3).
Evolution of the Fontan-Type Operation

The Fontan-type operation applies to many complex CHDs, most of which are otherwise uncorrectable. Therefore, this procedure can be considered a major advancement in pediatric cardiac surgery during the past 4 decades. Castaneda (1992) has written an excellent review article on the historical aspect of the Fontan-type operations. Many modifications have been made since the original Fontan operation in 1971. The results of animal experiments conducted in the 1940s and 1950s suggested that the RV could be successfully bypassed (i.e., systemic venous pressure was an adequate force for pulmonary blood flow). The Glenn shunt (1958), which is an end-to-end anastomosis of the SVC to the distal end of the right PA, was the first such example, although it involved only one lung.

The original Fontan operation consisted of a Glenn shunt, connection of the RA and the right PA with insertion of an aortic homograft, insertion of another allograft valve in the IVC–RA junction, and closure of the ASD (Fig. 14-41, A). At that time, RA contractions were thought to be important in pulsatile assistance to the pulmonary circulation. It became evident later that inlet and outlet valves were more problematic than beneficial.

Kreutzer and associates (1973) made a direct anastomosis between the RA appendage and the PA trunk using either a homograft or the patient’s own pulmonary valve. The ASD was closed (see Fig. 14-41, B). Subsequently, modifications of the connection were made between the RA and RV (see Fig. 14-41, C), as well as between the RA and the main or right PA (see Fig. 14-41, D), by direct anastomosis of the two structures or by the use of patches or conduits with or without an interposed valve. It became evident later that a direct connection between the RA appendage and the right PA without an interposed valve provided equally good hemodynamic results and that the incorporation of a portion of the RV was not beneficial.

Kawashima and associates (1984) reported a new operation in four children with complex single ventricle. These children also had interrupted IVC with either azygous continuation to the right SVC or hemiazygous continuation to the left SVC and they were palliated earlier with B-T shunts. Either the right or left SVC, which received blood from the entire systemic venous system, was successfully connected end to side to the ipsilateral PAs (in Fig. 14-41, E, azygous continuation is shown). This procedure proved for the first time that the entire systemic venous return could be put into the pulmonary circulation, completely bypassing the right side of the heart.

De Leval and associates (1988) have shown that the interposition of a compliant RA chamber between the systemic vein and the PA is a major cause of energy loss in the RA, and they have shown that a cavocaval baffle-to-PA anastomosis, the latest modification of the Fontan operation (see Fig. 14-41, F), has significant hemodynamic advantages over earlier attempts to use the RA (as in Fig. 14-41, D) as part of the venous pathway.

A two-stage Fontan operation was recommended for high-risk patients. Initially, a bidirectional Glenn shunt was performed. This was later followed by the completion of the cavocaval baffle-to-right PA anastomosis. After the first procedure, there was often a
noticeable improvement in oxygen saturation and symptoms to the point that raised questions about the necessity of the second procedure.

**FIGURE 14-41** Modifications of the Fontan operation. 

A, The original Fontan operation (Fontan and Baudet, 1971) consisted of an end-to-end anastomosis of the right pulmonary artery (RPA) to the superior vena cava (SVC), an end-to-end anastomosis of the right atrial appendage (RAA) to the proximal end of the RPA by means of an aortic valve homograft, closure of the atrial septal defect (ASD), insertion of a pulmonary valve homograft into the inferior vena cava (IVC), and ligation of the main pulmonary artery (PA). 

B, Modification by Kreutzer et al (1973) consisted of an anastomosis of the RAA and the main PA with its intact pulmonary valve (which was excised from the right ventricle [RV]) after closure of the ASD and ventricular septal defect. A Glenn operation was not performed, and no IVC valve was used. 

C, A later modification by Bjork et al (1979) consisted of a direct anastomosis between the RAA and the right ventricular outflow tract in patients with a normal pulmonary valve using a roof of pericardium to avoid a synthetic tube graft. 

D, Direct anastomosis of the right atrium (RA) to the RPA. 

E, Kawashima et al (1983) first showed that systemic venous returns could be directly connected to the pulmonary circulation without passing through the right heart. 

F and G, Separate anastomosis of the two ends of the divided SVC to the RPA and insertion of IVC to SVC intraatrial baffle (total cavopulmonary connection) with (G) and without (F) fenestration. 

H, Extracardiac conduit between the IVC and the RPA and a bidirectional Glenn operation. 

AO, aorta; LPA, left pulmonary artery; LV, left ventricle.

A fenestrated Fontan operation has been recommended for high-risk patients (see Fig. 14-41, G). Reported advantages of fenestration include a lower early surgical mortality rate; reduced incidence or duration of postoperative pleural effusion; shorter hospital stay; and right-to-left shunt through the fenestration, which may help maintain cardiac output if blood flow through the lungs decreases. The possible disadvantages are paradoxical embolization and stroke, lower arterial oxygen saturation, and the need to close the fenestration.

Extracardiac right heart bypass with an IVC-to-right PA Dacron conduit and SVC-to-PA PA anastomosis has also been performed (see Fig. 14-41, H). This procedure is performed a little later than the standard intraatrial lateral tunnel operation in order to place a larger conduit. An extracardiac conduit appears to be better than the intraatrial lateral tunnel procedure with a very low operative mortality rate, a lower incidence of early and late arrhythmias, improved hemodynamics, and fewer postoperative complications (Backer et al, 2011), but the conduit does not have growth potential. However, a recent report by Rogers et al (2012) found an association between extracardiac conduit and
prolonged period of pleural drainage.
Surgical approaches in tricuspid atresia are summarized in Figure 14-42.
Prevalence

Pulmonary atresia with an intact ventricular septum accounts for fewer than 1% of all CHDs. It accounts for 2.5% of the critically ill infants with CHDs.

![Diagram of surgical approaches in tricuspid atresia](image)

**FIGURE 14-42** Surgical approaches in tricuspid atresia. BDG, bidirectional Glenn; BT, Blalock-Taussig; op, operation; PA, pulmonary artery; PBF, pulmonary blood flow; TA, tricuspid atresia; TGA, transposition of the great arteries; VSD, ventricular septal defect.

![Schematic diagrams of right ventriculograms](image)

**FIGURE 14-43** Schematic diagrams of right ventriculograms that illustrate three types of pulmonary atresia with intact ventricular septum. A, Normal right ventricle (RV). B, Tripartite type that shows all three portions (inlet, trabecular, and infundibular) of the RV. C, Bipartite type in which only the inlet and infundibular portions are present. D, Monopartite type in which only the inlet portion of the RV is present.

Pathology

1. In 80% of these patients, the pulmonary valve is atretic with a diaphragm-like membrane. The infundibulum is atretic in 20% of these patients. The valve ring and the main PA are hypoplastic. The PA trunk is rarely atretic. The ventricular septum remains intact.
2. RV size varies and relates to survival. In 1982, Bull and associates divided this condition into three types based on the presence or absence of the three portions of the RV: inlet, trabecular, and infundibular portions (Fig. 14-43). All three of these portions are present, and the RV is almost normal in size in the *tripartite type* of pulmonary atresia. In the *bipartite type*, the inlet and infundibular portions are present, but the trabecular portion is obliterated. The inlet is the only portion present, and the RV size is
diminutive in the *monopartite type*. The RV size is highly correlated with the size of the tricuspid valve. A rare type of pulmonary atresia that is not included in the above classification is that associated with tricuspid insufficiency, less thickened but dilated RV cavity, and dilated RA.

3. This condition is frequently associated with important anomalies of the coronary arteries. The high pressure in the RV is decompressed through dilated coronary microcirculation (i.e., ventriculocoronary connection, coronary sinusoids, or RV-dependent coronary circulation) into the left or right coronary artery (see Fig. 14-44 for right ventriculograms showing coronary sinusoids). Often the proximal coronary arteries are obstructed (≈10%). Rarely, proximal portion(s) of the right or left coronary artery are absent. Sinusoid channels are demonstrable by a right ventriculogram in 30% to 50% of cases. If proximal coronary artery obstruction is present, coronary circulation is perfused entirely by desaturated RV blood (RV-dependent coronary circulation). Tricuspid valve z score less than –2.5 is a helpful predictor of coronary fistulas and RV-dependent coronary circulation. Such coronary sinusoids occur only in patients with hypertensive RV and not in patients with tricuspid regurgitation.

4. Confluent pulmonary arteries are usually present with PBF provided through a PDA. Rarely, nonconfluent pulmonary arteries are supplied by bilateral ductus arteriosus or multiple aortopulmonary collaterals.

5. An interatrial communication (i.e., either ASD or PFO) and PDA (or collateral arteries) are necessary for the patient to survive.

6. RV myocardium shows varying degrees of ischemia, infarction, fibrosis, and endocardial fibroelastosis, with poorly compliant RV, which may contribute to surgical mortality.

**Clinical Manifestations**

**History**

A history of severe cyanosis since birth is present.

**Physical Examination**

1. Severe cyanosis and tachypnea are seen in distressed neonates.
2. The S2 is single. A heart murmur is usually absent, but a soft murmur of either TR or a soft continuous murmur of PDA may be audible.
3. Inadequate interatrial communication causes hepatomegaly.

**Electrocardiography**

1. The QRS axis is normal (i.e., +60 to +140 degrees) in contrast to the superiorly oriented QRS axis seen in tricuspid atresia.
2. LVH is usually present. Occasionally, RVH is seen in infants with a relatively large RV cavity. RAH is common, occurring in 70% of cases.
Radiography
The heart size may be normal or large, resulting from RA enlargement. Pulmonary vascular markings are decreased with dark lung fields. The main PA segment is concave.

Echocardiography
1. Diagnostic features of the condition include (a) a thickened, immobile, atretic pulmonary valve with no Doppler evidence of blood flow through it; (b) a hypertrophied RV wall with a small cavity; (c) a patent, but small, tricuspid valve; (d) a right-to-left atrial shunt through an ASD demonstrated by color flow and Doppler studies; (e) and ductus arteriosus running vertically from the aortic arch to the PA (i.e., “vertical ductus”) (see Fig. 14-25).
2. The size of the tricuspid valve should be carefully measured because this measurement correlates well with the size of the RV cavity and thus determines whether a biventricular or univentricular repair is suitable (see Table D-5, Appendix D, for tricuspid and other valve annulus dimensions in the neonates). The most severely stenotic tricuspid valve is associated with the most underdeveloped RV and with likelihood of RV-dependent coronary circulation.
3. Images of the proximal coronary arteries help detect coronary artery anomalies. A coronary AV fistula is not easy to detect, but dilated or tortuous proximal coronary arteries suggest an RV-dependent coronary circulation. Color Doppler flow mapping may show retrograde flow in a proximal coronary artery. Absence of normal origin of a coronary artery may also suggest the presence of a fistulous connection to that coronary artery.
4. The right and left PA branches are usually well developed.

Cardiac Catheterization
Cardiac catheterization and angiocardiography are required for proper management in most patients with pulmonary atresia. A right ventriculogram demonstrates the size of the RV cavity and the presence or absence of coronary sinusoids (Fig. 14-44). An ascending aortogram identifies stenosis or interruption of the coronary arteries. Both are important in surgical decision making, whether to go for univentricular or biventricular repair.
Natural History

Without appropriate management (which includes PGE\textsubscript{1} infusion and surgery), the prognosis is exceedingly poor. About 50\% of these patients die by the end of the first month if not managed properly; about 80\% die by 6 months of age. Death usually coincides with the spontaneous closure of the ductus arteriosus.

Management

Medical

1. PGE\textsubscript{1} (Prostin VR Pediatric solution) infusion should begin as soon as the diagnosis is suspected or confirmed, so that the patency of the ductus arteriosus is maintained. Infusion is continued during cardiac catheterization and surgery. The starting dose of Prostin is 0.05 to 0.1 µg/kg per minute. When the desired effect is achieved, the dosage is gradually reduced to 0.01 µg/kg per minute.
2. For small premature infants, a prolonged course of PGE\textsubscript{1} infusion may be necessary before surgery is undertaken.
3. In neonates with monopartite RV, who are not likely to be candidates for two-ventricular repair and are likely to require bidirectional Glenn operation or hemi-Fontan in a few months, some centers advocate using PDA stenting instead of the BT shunt. PDA stenting is less reliable and shorter lasting than the BT shunt but is likely to last to the time of bidirectional Glenn or hemi-Fontan procedure (Feltes et al, 2011).
4. A balloon atrial septostomy may be performed as part of the cardiac catheterization to improve the right-to-left atrial shunt, but it is recommended only when a two-ventricular repair is considered not possible (e.g., the presence of RV sinusoids or too small an RV cavity).
5. In patients with membranous atresia, a laser-assisted pulmonary valvotomy with balloon pulmonary valvuloplasty may be a useful alternative to a surgical procedure that establishes an RV-to-PA continuity (Cheung et al, 2002). Infundibular atresia is unsuitable for catheter intervention.

Surgical

The size of the RV (or that of the tricuspid valve) and the presence or absence of coronary sinusoids or coronary artery anomalies dictate surgical procedures for infants with
pulmonary atresia with intact ventricular septum. Surgical options are as follows.

1. **Two-ventricular repair**, which is the ultimate goal whenever feasible, is possible only when there is an adequate size of the RV cavity with adequate RVOTs.
2. One and one-half ventricular repair may be chosen when the RV size is judged to be borderline for a two-ventricular repair but too good to be abandoned for Fontan-type repair.
3. One-ventricular repair (Fontan operation) is used when (a) an RV-dependent coronary circulation is present or (b) a monopartite RV (with a tricuspid valve z score $\leq -4$ to $-5$) is present.
4. Cardiac transplantation is a possible option.

### Procedures

1. **Staged two-ventricular repair**: For the two-ventricular repair, the initial procedure consists of establishing a connection between the RV and the PA (to promote growth of the RV) and a systemic-to-PA shunt created at the same time. The second-stage operation consists of reconstruction of the RVOT.

   a. **First-stage operation**: One of the following is done.
      1. Placement of a transannular RV outflow patch and a systemic-to-PA shunt seems most promising for a two-ventricular repair at a later date (Fig. 14-45). Balloon atrial septostomy is not recommended with this approach, so that a high RA pressure is maintained to maximize the forward RV output. The mortality rate is about 20%.
      2. For a patient with a well-formed pulmonary valve and adequate infundibulum, a closed transpulmonary valvotomy (without cardiopulmonary bypass) and a left-sided modified BT shunt procedure are performed. The mortality rate of these procedures is less than 5%.
      3. An alternative to the closed surgical valvotomy is the use of laser wire and radiofrequency-assisted valvotomy and balloon dilatation during cardiac catheterization (Cheung et al, 2002). The mortality rate of the procedure is about 5%.

   b. **Follow-up**: After one of the above first-stage procedures, the growth of the RV is monitored in the following manner.
      1. Echocardiographic studies showing growth of the tricuspid valve size (to larger than z score $>-2$), evidence of growth of the RV size, and stable $O_2$ saturation are positive signs for future two-ventricular repair.
      2. Cardiac catheterization is performed within 6 to 18 months after the initial surgery. An arterial $O_2$ saturation greater than 70%, a greater RV volume, and evidence of a good forward flow through the pulmonary valve are all positive signs.
      3. If the patient tolerates balloon occlusion of the shunt during cardiac catheterization, the patient is considered a candidate for a two-ventricular repair.
c. The second-stage operation: RVOT reconstruction and closure of the ASD are carried out under cardiopulmonary bypass. The systemic-to-PA shunt is closed at the time of surgery. The mortality rate is about 15%.

2. One and one-half ventricular repair: This may be performed when the RV size is not quite large enough to have two-ventricular repair but the RV is too good to be abandoned for one-ventricular repair. This type of repair consists of the following.
   a. A bidirectional Glenn anastomosis is created to bring the SVC blood directly to the pulmonary artery, bypassing the RV.
   b. The IVC blood goes to the lungs via the normal pathway through the RV which is large enough to handle half of the systemic venous return.

   ![FIGURE 14-45](image)

   **FIGURE 14-45**  Initial surgery for tripartite or bipartite type of pulmonary atresia. **A**, A longitudinal incision is made across the pulmonary annulus. The pulmonary valve is incised, and the right ventricular outflow tract is carefully widened. **B**, A piece of pericardium is used for the transannular patch. A left-sided Gore-Tex shunt is made between the left subclavian artery and the left pulmonary artery (PA). AO, aorta; LV, left ventricle; RA, right atrium; RV, right ventricle.

   After this procedure, the size of the tricuspid valve and the RV may actually increase with an adequate RV function. Complications associated with Fontan procedure (e.g., arrhythmias, protein-losing enteropathy) do not occur after this procedure. The surgical mortality rate is between 0% and 12% (similar to Fontan).

3. One-ventricular repair (Fontan operation): For patients with monopartite RV (with or without coronary sinusoids), a two-ventricular repair is not possible. These patients need one-ventricular repair (Fontan operation).
   a. A systemic-to-PA shunt without the RV outflow patch is recommended as the initial procedure. Some institutions use PDA stenting, instead of the BT shunt until the time of bidirectional Glenn or hermi-Fontan operation (at 3–6 months of age).
   b. A staged Fontan operation is performed at a later time (see Tricuspid Atresia for a full description of the Fontan operation).
   c. For patients who have rudimentary RV (with high RV pressure) and sinusoidal
channels, there are two options.

1. The sinusoids are left alone without decompression, and a systemic-to-PA shunt is performed for a future Fontan-type operation. Decompression of the RV by valvotomy or an outflow patch cannot be done because it results in a reversal of coronary flow into the RV, thereby producing myocardial ischemia.

2. Alternatively, the tricuspid valve is closed (converting it to tricuspid atresia, the Starnes procedure) and a systemic-to-PA shunt is created for a future Fontan operation.

4. When the proximal portion of the coronary arteries is not identified or severe anomalies of the coronary circulation are present, cardiac transplantation may be an option.

The surgical approach to pulmonary atresia with intact ventricular septum is illustrated in Figure 14-46.

![Figure 14-46](image)

**FIGURE 14-46** Surgical approach to pulmonary atresia with intact ventricular septum. BDG, bidirectional Glenn; BT, Blalock-Taussig; op, operation; RV, right ventricle; RVOT, right ventricular outflow tract; RV-PA conn, right ventricle–to–pulmonary artery connection.

**Postoperative Follow-up**
Most patients require close follow-up because none of the surgical procedures available is curative.
Hypoplastic Left Heart Syndrome

Prevalence
Hypoplastic left heart syndrome occurs in 1 in 5000 live births. About 2000 infants are born annually with the defect in the United States. About 10% of cases are associated with genetic syndromes such as Turner syndrome, trisomy 18, Jacobsen’s syndrome, and others.

Pathology
1. HLHS includes a group of closely related anomalies characterized by hypoplasia of the LV, atresia or critical stenosis of the aortic or mitral valves, and hypoplasia of the ascending aorta and aortic arch. The LV is small and nonfunctional or totally atretic.
2. The atrial septum may be intact with a normal foramen ovale, or the patient may have a true ASD (15%). A VSD appears in about 10% of patients. COA frequently is an associated finding (up to 75%).
3. A high prevalence of brain abnormalities has been reported. Up to 29% of the patients had a CNS abnormality. Overt CNS malformations (e.g., agenesis of the corpus callosum, holoprosencephaly) were seen in 10% of these infants. Micrencephaly was found in 27% of the infants, and an immature cortical mantle was seen in 21% of the patients. The presence or absence of dysmorphic physical features did not predict CNS malformations (Glauser et al, 1990).

Pathophysiology
1. During fetal life, the PVR is higher than the SVR, and the dominant RV maintains normal perfusing pressure in the descending aorta and the placenta through the ductal right-to-left shunt. The proximal aorta and the coronary and cerebral circulations are adequately perfused retrogradely. Fetuses tolerate this serious cardiac anomaly well in utero.
2. Difficulties arise after birth for two reasons: reduction of PVR (with the onset of respiration) and closure of the ductus arteriosus. The result is a marked reduction in the aortic perfusing pressure and systemic hypoperfusion, producing circulatory shock and metabolic acidosis.
3. Maintenance of adequate systemic blood flow (and thus survival of these infants) depends on an adequate size of the ductus arteriosus and maintenance of a high PVR to permit the RV to send an adequate amount of blood flow to the aorta. Large pulmonary blood flow increases pulmonary venous return to the LA. An adequate interatrial communication is necessary to decompress the LA. In the presence of a large ASD that permits a left-to-RA shunt, pulmonary edema is not severe, and the arterial oxygen saturation may be in the 80s. With an inadequate atrial septal communication, pulmonary edema is severe, and the arterial oxygen saturation is low. Without treatment, the infant usually dies shortly after birth.
Clinical Manifestations

1. A neonate with HLHS becomes critically ill within the first few hours to the first few days of life. Tachycardia, dyspnea, pulmonary crackles, weak peripheral pulses, and vasoconstricted extremities are characteristic. The patient may not have severe cyanosis but has a grayish blue color of the skin with poor perfusion.

2. The S2 is loud and single. Heart murmur usually is absent. Occasionally, a grade 1 to 2 of 6 nonspecific ejection systolic murmur may be heard over the precordium. Signs of CHF develop, with hepatomegaly and gallop rhythm.

3. The ECG almost always shows RVH. Rarely, the ECG suggests LVH with large R waves in V5 and V6 (because these leads are placed over the dilated RV, not over the hypoplastic LV).

4. Chest radiography characteristically shows pulmonary venous congestion or pulmonary edema (Fig. 14-47, A). The heart is moderately or markedly enlarged.

5. Arterial blood gas levels reveal a slightly decreased Po$_2$ and a normal Pco$_2$. Severe metabolic acidosis out of proportion to the Pco$_2$ (caused by markedly decreased cardiac output) is characteristic of the condition.

6. Echocardiographic findings are diagnostic and usually obviate the need for cardiac catheterization and angiocardiography.
   a. The LV cavity is diminutive, but the RV cavity is markedly dilated, and the tricuspid valve is large.
   b. Imaging usually reveals severe hypoplasia of the aorta and aortic annulus and an absent or distorted mitral valve. COA frequently is an associated anomaly.
   c. The patient may have an ASD or a PFO with a left-to-right shunt. The patient occasionally has a VSD with a relatively large LV, aortic annulus, and ascending aorta.
   d. Color-flow mapping and Doppler studies reveal retrograde blood flow in the aortic arch and ascending aorta (to perfuse the head and the coronary circulation).
Natural History

Pulmonary edema and CHF develop in the first week of life. Circulatory shock and progressive hypoxemia and acidosis result in death, usually in the first month of life.

Management

Presurgical Medical Management

1. The patient should be intubated and ventilated appropriately with oxygen, and metabolic acidosis is corrected.
2. IV infusion of PGE$_1$ (Prostin VR Pediatric) may temporarily improve HLHS by reopening the ductus arteriosus (for the dosage, see Appendix E).
3. Balloon atrial septostomy may help decompress the LA and improve oxygenation but produces only a temporary benefit.
4. Support therapy only without surgical procedure is no longer acceptable in most parts of the world.
5. Infants with HLHS should have careful genetic, ophthalmologic, and neurologic evaluations, including imaging of their intracranial anatomy, and long-term follow-up because of a high prevalence of neurodevelopmental abnormalities seen with the condition.

Surgical

Three options are available in the management of these infants: (1) the Norwood operation (followed by a Fontan-type operation), (2) a hybrid operation (followed by a Fontan-type operation), and (3) cardiac transplantation. The surgical procedure of choice remains controversial, but the Norwood operation is more popular than cardiac transplantation. A hybrid operation is being done in increasing numbers, but its long-term advantages are not clear at this time. A rare subgroup of patients with normal-sized LV (because of a large VSD) can have a two-ventricular repair rather than the Fontan operation.

![Schematic diagram of the Norwood procedure. A, The heart with aortic atresia with a hypoplastic ascending aorta and aortic arch, along with a large pulmonary artery (PA) and ductus arteriosus, are shown. The main PA is transected. B, An incision that extends around the aortic arch to the level of the ductus is made in the ascending aorta. The distal PA is closed with a patch. The ductus arteriosus is ligated and divided. C, A modified right Blalock-Taussig shunt is created between the right subclavian artery and the right PA (RPA) as the sole](image-url)
source of pulmonary blood flow. Alternatively, a homograft conduit may be placed between the right ventricle (RV) and PA bifurcation as shown in the figure (Sano modification). Note that only one of these two procedures is performed but not both. By the use of an aortic or PA allograft (striped area), the main PA is anastomosed to the ascending aorta and the aortic arch to create a large new arterial trunk. The Norwood procedure also includes widening of the atrial communication which is not shown in the illustration. LPA, left pulmonary artery; RA, right atrium.

**Staged Surgical Approach**

1. The first-stage (Norwood) operation is performed initially and followed later by the Fontan-type operation.
   a. The Norwood operation is performed in the neonatal period. The operation consists of the following procedures (Fig. 14-48).
      (1) The main PA is divided, the distal stump is closed with a patch, and the ductus arteriosus is ligated.
      (2) Using an aortic or PA allograft, one connects the proximal PA and the hypoplastic ascending aorta and aortic arch.
      (3) Pulmonary blood flow is established by one of the following procedures.
         (a) A right-side modified BT shunt is created (using a 4- to 5-mm Gore-Tex tube) to provide pulmonary blood flow while preventing CHF and pulmonary hypertension.
         (b) An RV-to-PA shunt (using polytetrafluorethylene graft) was first used by Sano and colleagues (4 mm for patients weighing <2 kg and 5 mm for those weighing >2 kg) (Sano modification).
      The Sano central shunt may be an advantage over the modified BT shunt for the following reasons. Although the central shunt requires a right ventriculotomy to complete the shunt, (1) it promotes symmetrical growth of the pulmonary arteries, and (2) it provides a higher aortic diastolic pressure and thus a higher coronary artery perfusion pressure than the BT shunt does. The BT shunt, on the other hand, provides continuous forward flow to the PA during both systole and diastole, causing diastolic retrograde flow in the central aorta, which may cause “coronary steal” during diastole.
      (4) The atrial septum is excised to allow adequate interatrial mixing.
   b. The Norwood procedure carries the highest surgical mortality rate among common cyanotic CHD, ranging from 7% to 19%. In addition, between the Norwood operation and the second-stage operation, 4% to 15% of infants die. A recent report shows that survival rate after the first-stage (Norwood) operation was significantly higher in infants who had a Sano modification than those who had a modified BT shunt (74% vs. 64%) (Ohye et al, 2010).
   c. Post-Norwood medical management. Most patients are placed on the following medications after the Norwood operation (and most of them are continued throughout their lives even after the final Fontan operation).
      (1) Small-dose diuretic therapy (not to produce hypovolemia).
      (2) Digoxin is given by some centers.
      (3) Captopril, an afterload-reducing agent, is given (to increase systemic blood flow, thereby possibly to reduce pulmonary blood flow).
Aspirin is given to prevent shunt thrombosis.
Nutritional support is very important, if necessary, including nasogastric feeding or a gastrostomy tube feeding.

2. Second-stage operation for HLHS is either the bidirectional Glenn procedure or the hemi-Fontan procedure. These procedures are performed at 3 to 6 months of age.
   a. Cavopulmonary shunt (also called the bidirectional Glenn operation) is an end-to-side anastomosis of the SVC to the right PA (see Fig. 14-38, A) performed at 3 to 6 months of age in an effort to reduce the volume overload to the systemic RV. The mortality rate for this procedure is less than 5%.
   b. The hemi-Fontan operation. This procedure includes augmentation of the central PA without dividing the SVC while excluding IVC blood from the pulmonary arteries by means of a temporary intraatrial patch (see Fig. 14-39).

3. A modified Fontan operation is performed at 1 to 2 years of age (see Fig. 14-38, B). Five important hemodynamic and anatomic features considered essential to successful Fontan operation include (1) unrestrictive interatrial communication, (2) competence of the tricuspid valve, (3) unobstructed PA-to-descending aorta anastomosis (with pressure gradient <25 mm Hg), (4) undistorted PAs and low PVR, and (5) preservation of RV function.
   Currently, the operative mortality rate of the Fontan procedure is less than 3%.
   Patients with HLHS have a higher likelihood of prolonged pleural effusion and hospital stay than those with tricuspid atresia. Mean PA pressure of 15 mm Hg or greater was associated with prolonged hospital stay and unfavorable outcomes (Rogers et al, 2012). Significant TR appears to be an important predictor of poor outcome of the Fontan operation. The overall survival rate after the Fontan operation is better than 95% at follow-up of 50 months (Hirsch et al, 2008).

Hybrid Approach
A hybrid approach followed later by the Fontan-type operation was first reported in 2008 (Galantowicz et al, 2008). Many centers now use this procedure as an alternative to the Norwood (stage I) procedure for high-risk HLHS and single-ventricle patients or as a bridge to heart transplantation in infants with HLHS.
   The advantages of this approach are that (1) it creates a stable, balanced circulation without the use of open heart surgery using cardiopulmonary bypass, which carries a relatively high risk, and (2) it delays the open heart procedure until later in life when a bidirectional Glenn or hemi-Fontan operation can be safely performed (3–6 months of age).
   a. A hybrid procedure is performed in the first weeks of life. The procedure consists of (1) bilateral PA banding through a small median sternotomy using a 1- to 2-mm ring from a 3.5-mm Gore-Tex tube graft (3.0-mm tube for patients <2.5 kg) to provide adequate pulmonary blood flow but without causing pulmonary hypertension or heart failure and (2) insertion of a PDA stent in the same setting through a sheath placed (through purse string) in the main PA to ensure adequate systemic and coronary perfusion (see Fig. 14-49). The surgical mortality rate is 2.5%, which is much lower than that for the Norwood
operation (7%-19%). As a separate procedure, atrial septostomy with or without balloon dilatation is performed to establish a reliable atrial shunt.

b. Comprehensive stage 2 surgery is performed at 3 to 6 months of age with a surgical mortality rate of 8%. The second-stage procedures combine the Norwood operation and bidirectional Glenn operation. Thus, the stage 2 procedures include (1) removal of PDA stent and PA bands, (2) repair of aortic arch and the pulmonary arteries (especially the LPA if necessary), (3) reimplantation of the diminutive ascending aorta into the pulmonary root, (4) atrial septostomy, and (5) bidirectional Glenn operation.

c. A Fontan-type operation is performed at the age of 2 years, the same as that described under the staged Norwood approach.

Other Surgical Approaches

1. Infants with aortic atresia and normal-sized LV caused by a large VSD can have a biventricular repair, rather than a Fontan approach. The VSD is tunneled to the PA. The main pulmonary artery (MPA) is divided, and the proximal MPA is connected to the ascending aorta. The RV is connected to the distal MPA using a valved conduit or a homograft.
2. Some centers considered cardiac transplantation the procedure of choice in the past. If the diameter of the ascending aorta is smaller than 2.5 mm, cardiac transplantation, rather than the Norwood operation, was believed to provide a better result. The surgical technique of cardiac transplantation is presented in Chapter 35.

For patients placed on a transplantation algorithm, it is necessary to keep the ductus open and to increase the size of the interatrial communication. A hybrid procedure may be used as a bridge to cardiac transplantation, in which an endovascular stent is placed in closing ductus to keep the ductus open and PA branches are banded to control pulmonary blood flow. Blade atrial septostomy followed by balloon dilatation has been performed for decompression of the LA.

At this time, not all cardiac centers offer orthotopic heart transplantation. The availability of the donor heart is limited, and the overall mortality rate while awaiting transplantation is 21% to 37%. Furthermore, this approach requires lifelong immunosuppression with the attendant risks of rejection, infection, graft atherosclerosis, and malignancies. Some patients may require subsequent retransplantation caused by allograft vasculopathy and graft dysfunction.

**Postoperative Follow-up Plan**

After the second-stage operation and the final Fontan operation, the follow-up plans are similar to those described for tricuspid atresia (also refer to Box 14-2).

**Figure 14-50** summarizes surgical approaches used in the management of patients with HLHS.

![Figure 14-50](image-url)

**FIGURE 14-50** Surgery for hypoplastic left heart syndrome. BDG, bidirectional Glenn; BT, Blalock-Taussig; PA, pulmonary artery; PDA, patent ductus arteriosus.
Diagram of Ebstein’s anomaly of the tricuspid valve. There is an apicalward displacement of the tricuspid valve, usually the septal and posterior leaflets, into the right ventricle (RV). Part of the RV is incorporated into the right atrium (RA) (“atrialized” portion of the RV). Regurgitation of the tricuspid valve results in RA enlargement. An atrial septal defect (ASD) is usually present. CS, coronary sinus; IVC, inferior vena cava; LPA, left pulmonary artery; PA, pulmonary artery; RPA, right pulmonary artery; SVC, superior vena cava.
Ebstein’s Anomaly

Prevalence

Ebstein’s anomaly of the tricuspid valve occurs in less than 1% of all CHDs.

Pathology

1. There is downward displacement of the septal and posterior leaflets of the tricuspid valve into the RV cavity, so that a portion of the RV is incorporated into the RA (i.e., atrialized RV), and functional hypoplasia of the RV results (Fig. 14-51). Tricuspid regurgitation is usually present, and redundant tricuspid valve tissues can rarely obstruct the RVOT, which results in dilatation and hypertrophy of the RA.
2. An interatrial communication (e.g., PFO, true ASD) with a right-to-left shunt is present in all patients.
3. The RV free wall is often dilated and thin. Fibrosis is present in both RV and LV free walls; this may be responsible for severe symptoms early in life and LV dysfunction in later life.
4. WPW preexcitation is frequently associated with the anomaly and predisposes the patient to SVT.
5. PS, pulmonary atresia, TOF, VSD, and other defects are occasionally associated with the anomaly.

Clinical Manifestations

History

1. In severe cases, cyanosis and CHF develop during the first few days of life. Some subsequent improvement coincides with reduction of the PVR.

**FIGURE 14-52** Cardiac findings of Ebstein’s anomaly. Quadruple rhythm and a soft, regurgitant systolic murmur (of tricuspid regurgitation) are characteristic of the defect.
2. Children with milder cases may complain of dyspnea, fatigue, cyanosis, or palpitation on exertion.
3. A history of SVT is occasionally present.

**Physical Examination**
1. Mild to severe cyanosis is present, as well as clubbing of the fingers and toes in older infants and children.
2. Characteristic triple or quadruple rhythm is audible. This rhythm consists of a widely split S2, split S1, S3, and S4. A soft holosystolic (or early systolic) murmur of TR is usually audible at the lower left sternal border (Fig. 14-52). A soft, scratchy, mid-diastolic murmur is present at the same location.
3. Hepatomegaly is usually present.

**Electrocardiography**
1. Characteristic ECG findings of RBBB and RAH are present in most patients with this condition (Fig. 14-53).
2. First-degree AV block is frequent, occurring in 40% of patients. A WPW pattern of preexcitation is present in 15% to 20% of patients (with occasional episodes of SVT).

**Radiography**
In mild cases, the heart is almost normal in size and has normal pulmonary vascular markings. In severe cases, an extreme cardiomegaly (principally involving the RA) with a balloon-shaped heart and decreased pulmonary vascular markings is present. Some of the largest heart sizes are found in newborns with this condition (Fig. 14-54).

**Echocardiography**
Two-dimensional echocardiography with color-flow Doppler study is the procedure of choice for the diagnosis and functional assessment of Ebstein’s anomaly; cardiac catheterization and angiography are not needed.
1. The single most diagnostic feature is apical displacement of the hinge point of the septal leaflet of the tricuspid valve (Fig. 14-55). Normally, the septal leaflet of the tricuspid valve inserts on the ventricular septum slightly below the insertion of the mitral valve. In patients with Ebstein’s anomaly, this normal displacement is exaggerated. A
diagnosis of Ebstein’s anomaly is made when the tricuspid valve is displaced toward the apex by more than 8 mm/m² of BSA from the mitral valve insertion. This displacement is best seen in the apical four-chamber view.

FIGURE 14-54 Posteroanterior view (A) and diagram (B) of chest roentgenogram from a 2-week-old infant with severe Ebstein’s anomaly. Note extreme cardiomegaly involving primarily the right atrium (RA) and diminished pulmonary vascularity. Ao, aorta; ARV, atrialized right ventricle; LV, left ventricle; PA, pulmonary artery; RV, right ventricle.

FIGURE 14-55 Echocardiogram (A) and diagram (B) of an apical four-chamber view in a patient with Ebstein’s anomaly. The septal leaflet is displaced into the right ventricle (RV; large dark arrow) and thus forms an atrialized RV (aRV). The anterior tricuspid leaflet is elongated. Both leaflets are tethered to underlying myocardium (small arrows). The tricuspid annulus and the right atrium (RA) are dilated. AS, atrial septum; fRV, functional right ventricle; LA, left atrium; LV, left ventricle; mv, mitral valve; tv, tricuspid valve; VS, ventricular septum. (From Shiina A, Serwer JB, Edwards WD, et al: Two-dimensional echocardiographic spectrum of Ebstein’s anomaly: Detailed anatomic assessment. J Am Coll Cardiol 3:356–370, 1984.)

2. The tricuspid valve leaflets are elongated, redundant, and dysplastic with abnormal chordal attachment.
3. A large RA, including the atrialized RV, and a small functional RV represent anatomic severity. Evidence of tricuspid valve regurgitation and tricuspid stenosis (TS) is present.
4. RVOT obstruction may occur owing to the redundant anterior leaflet of the tricuspid valve.
5. A nonrestrictive ASD is commonly imaged.
6. Other anomalies may include mitral valve prolapse and LV dysfunction.

Other Studies. Cardiac catheterization is rarely necessary in patients with Ebstein’s anomaly. In patients who had a BT shunt, it may be indicated to exclude distortion of the PA or pulmonary hypertension before planning cavopulmonary shunts and Fontan-type operations.

Natural History
1. Some 18% of symptomatic newborns die in the neonatal period; 30% of patients die before the age of 10 years, usually from CHF.
2. Cyanosis tends to improve as the PVR falls during the newborn period. Cyanosis may reappear later.
3. Patients with a less severe anomaly may be either asymptomatic or mildly symptomatic.
4. Hemodynamic deterioration with increasing cyanosis, CHF, and LV dysfunction develops later in life. These developments foretell early death.
5. Attacks of SVT with associated WPW preexcitation occur in 15% to 20% of all patients. Sudden, unexpected death can occur, probably as a result of arrhythmias.
6. Other possible complications include infective endocarditis, brain abscess, and cerebrovascular accident.

Management

Medical
1. In severely cyanotic newborns, intensive treatment with mechanical ventilation, PGE\textsubscript{1} infusion, inotropic agents, and correction of metabolic acidosis may be necessary before proceeding with emergency surgery.
2. In infants who appear to have a mild form of Ebstein’s anomaly and to be improving with the above management, treatment with PGE\textsubscript{1} and inotropic support is gradually withdrawn to observe the effect of ductal closure.
3. Asymptomatic children with mild Ebstein’s anomaly require only regular observation. If CHF develops, anticongestive measures, including digoxin and diuretics, are indicated.
4. Acute episodes of SVT may be treated most effectively with adenosine (see Chapter 24). Beta-blockers are the most appropriate first-line preventive therapy for SVT. For patients with recurrent SVT caused by AV reentrant mechanism, radiofrequency catheter ablation techniques have been successful.
5. Varying degrees of activity restriction may be necessary for children with this condition.

Surgical

Indications
Although surgical indications for Ebstein’s anomaly are not completely defined, they may include the following:
1. Critically ill neonates who show symptoms within the first week of life (after a period of intensive medical treatment)
2. Occurrence of moderately severe or progressive cyanosis (arterial saturation of ≤80%), polycythemia (hemoglobin level of ≥16 g/dL), or CHF
3. RVOT obstruction by redundant tricuspid valve
4. Severe activity limitation (i.e., NYHA functional class III or IV) (see Appendix A, Table A-3)
5. History of paradoxical embolus
6. Repeated, life-threatening arrhythmias in patients with associated WPW syndrome

Procedures
Controversy exists concerning the types and timing of surgical procedures.
1. Palliative procedures. For critically ill neonates, if medical management does not show signs of improvement, surgical intervention is indicated to avoid certain death.
   a. BT shunt (with enlargement of ASD). This procedure can be lifesaving when there are obstructive lesions between the RV and the PA or stenotic tricuspid valve. Good LV function (with adequate LV size) is required to survive the procedure. A Fontan-type operation is performed later (see Fig. 14-38).
   b. If the LV is “pancaked” by large RV or RA, a procedure to reduce the RV or RA may be considered, such as the Starnes operation (pericardial closure of the tricuspid valve) or plication of large RA (atrialized RV), enlargement of ASD, and a BT shunt using a 4-mm tube. A Fontan-type operation (see Fig. 14-38) is performed later.
   c. Classic Glenn anastomosis (SVC to right PA end-to-end anastomosis) or its modification may be considered in severely cyanotic infants.

2. Definitive procedures. Children with good RV size and function are candidates for biventricular repair (with tricuspid valve repair or replacement). An inadequate RV size
or function requires Fontan operation.

a. **Two-ventricular repair:** Reconstruction of the tricuspid valve (e.g., Danielson and Carpentier procedure) is preferable to valve replacement. ASD is closed at the time of surgery.

1. **Danielson technique:** For repair of the tricuspid valve, this technique is the most desirable and best tested, although it is frequently limited by anatomy. This technique can be applied in about 60% of patients (Fig. 14-56). It plicates the atrialized portion of the RV, narrows the tricuspid orifice in a selective manner, and results in a monoleaflet valve (by the anterior leaflet of the tricuspid valve). Two other leaflets are often severely hypoplastic and cannot be made to function as a leaflet. The mortality rate is about 5%, which is lower than that for valve replacement.

2. **Carpentier technique:** As an alternative, Carpentier reconstructive surgery may be used. This repair also plicates the atrialized portion of the RV and the tricuspid annulus but in a direction that is at right angles to those used by Danielson. This repair can be applied in most patients with Ebstein’s anomaly. The surgical mortality rate is 15%.

3. **Tricuspid valve replacement and closure of the ASD** are a less desirable surgical approach but may be necessary for 20% to 30% of patients with Ebstein’s anomaly who are not candidates for reconstructive surgery. The replacement valve of choice is a stented, antibiotically treated semilunar valve allograft or a heterograft valve. A pulmonary allograft valve mounted in a short Dacron sleeve can be used in younger children. The surgical mortality rate ranges from 5% to 20%.

b. **One-ventricular repair:** For patients with inadequate size of the RV, a Fontan-type operation is usually performed in stages following the initial palliative procedures such as a bidirectional Glenn operation or hemi-Fontan operation (see Fig. 14-38).

3. **Other procedures.** For patients with WPW syndrome and recurrent SVT, surgical interruption at the time of surgery or radiofrequency ablation of the accessory pathway is recommended.

**Complications**

1. Complete heart block is a rare complication.
2. Supraventricular arrhythmias persist in 10% to 20% of patients after surgery.

**Postoperative Follow-up**

1. Frequent follow-up is necessary because of the persistence of arrhythmias after surgery, which occurs in 10% to 20% of patients, and because of possible problems associated with tricuspid valve surgery that require reoperation.
2. The patient should not participate in competitive or strenuous sports.
Surgical approaches for Ebstein’s anomaly are shown in Figure 14-57.

**FIGURE 14-57** Surgical approaches for Ebstein’s anomaly of the tricuspid valve. ASD, atrial septal defect; BDG, bidirectional Glenn; BT, Blalock-Taussig; LV, left ventricle; RA, right atrium; RV, right ventricle; RVOT, right ventricular outflow tract; TV, tricuspid valve.

**FIGURE 14-58** The anatomic type of persistent truncus arteriosus (TA) is determined by the branching patterns of the pulmonary arteries. A, In type I, the main pulmonary artery (PA) arises from the truncus and then divides into the right (RPA) and left pulmonary artery (LPA) branches. B, In type II, the RPA and LPA arise separately from the posterior aspect of the truncus. C, In type III, the PAs arise separately from the lateral aspects of the truncus. D, In type IV, or pseudotruncus arteriosus, arteries arising from the descending aorta (AO) supply the lungs. LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle.

Surgical approaches for Ebstein’s anomaly are shown in Figure 14-57.
Persistent Truncus Arteriosus

Prevalence
Persistent truncus arteriosus occurs in fewer than 1% of all CHDs.

Pathology
1. Only a single arterial trunk with a truncal valve leaves the heart and gives rise to the pulmonary, systemic, and coronary circulations. A large perimembranous, infundibular VSD is present directly below the truncus (Fig. 14-58). The truncal valve may be bicuspid, tricuspid, or quadricuspid, and it is often incompetent.
2. According to Collett and Edwards' classification, this anomaly is divided into four types by how the pulmonary arteries arise from the truncus arteriosus (see Fig. 14-58 for the description of each type). Types I and II constitute 85% of cases. Type IV is not a true persistent truncus arteriosus; rather, it is a severe form of TOF with pulmonary atresia (i.e., pseudo-truncus arteriosus), with aortic collaterals supplying the lungs.
3. The pulmonary blood flow is increased in type I, nearly normal in types II and III, and decreased in type IV.
4. Coronary artery abnormalities are common and may contribute to the high surgical mortality rate. The anomalies include stenotic coronary ostia, high and low takeoff of coronary arteries, and abnormal branching and course of the coronary arteries.
5. Interrupted aortic arch is seen in 13% of cases (this is type A4 of van Praagh classification). In this case, the interruption occurs distal to the takeoff of the left carotid artery and lower extremity flow is accomplished through the PDA.
6. A right aortic arch is present in 30% of patients.
7. Evidence of DiGeorge syndrome with hypocalcemia is present in 33% of patients.

Clinical Manifestations

History
1. Cyanosis may be seen immediately after birth.
2. Signs of CHF develop within several days to weeks after birth.
3. A history of dyspnea with feeding, failure to thrive, and frequent respiratory infections is usually present in infancy.

Physical Examination
1. Varying degrees of cyanosis and signs of CHF with tachypnea and dyspnea are usually present.
2. The peripheral pulses are bounding, with a wide pulse pressure. The precordium is hyperactive, and the apical impulse is displaced laterally.
3. A systolic click is frequently audible at the apex and upper left sternal border. The S2 is single. A harsh (grade 2 to 4 of 6), regurgitant systolic murmur, which suggests VSD,
usually audible along the left sternal border. An apical diastolic rumble with or without gallop rhythm may be present when the PBF is large. A high-pitched, early diastolic, decrescendo murmur of truncal valve regurgitation may be audible.

**Electrocardiography**
The QRS axis is normal (+50 to +120 degrees). BVH is present in 70% of cases; RVH or LVH is less common. Left atrial hypertrophy (LAH) is occasionally present.

**Radiography**
Cardiomegaly is usually present, with increased pulmonary vascularity. A right aortic arch is seen in 30% of cases.

**Echocardiography**
Two-dimensional and Doppler echocardiography show the following. The first three findings are diagnostic.
1. A large VSD is imaged directly under the truncal valve, similar to that seen in TOF.
2. A large, single great artery arises from the heart (i.e., truncus arteriosus). The type of persistent truncus arteriosus can be identified, and the size of the PAs can be determined. An artery, branching posteriorly from the truncus, is the PA.
3. The pulmonary valve cannot be imaged; only one semilunar valve (i.e., truncal valve) is imaged.
4. Cross-sectional imaging may determine the number of sinuses (usually three, although it may be two or four) of the truncal valve and the presence or absence of stenosis or regurgitation of the valve.
5. Right aortic arch is frequently present (in ≈35%). Interruption of the aortic arch is occasionally present, which is difficult to image.

**Other Studies**
Preoperative cardiac catheterization is now rarely necessary in neonates. However, with late diagnosis of the condition, cardiac catheterization may be performed to evaluate PA pressure and PVR.

**Natural History**
1. Most infants present with CHF during the first 2 weeks. A total of 85% of untreated children die by 1 year of age.
2. Clinical improvement occurs if the infant develops pulmonary vascular obstructive disease, which may begin to occur by 3 to 4 months of age. Death occurs around the third decade of life.
3. Truncal valve insufficiency worsens with time.

**Management**
Medical

1. Vigorous anticongestive measures with diuretics and ACE inhibitors should be pursued before an operation is undertaken.
2. Because of the frequent association of DiGeorge syndrome:
   a. Serum calcium and magnesium levels should be checked; supplementation may be indicated.
   b. Only irradiated blood product should be used for an urgent surgery (because of an insufficient time for evaluation of immune status accurately).
   c. Because of the thymus-based immune deficiency, treatment and prophylaxis against pneumococcal and streptococcal infections are important.
   d. Immunization with live vaccine should be avoided.
3. Prophylaxis against SBE should be observed when indications arise.

Surgical

Palliative Procedures
Although PA banding was performed in the past in small infants with large PBF and CHF, primary repair of the defect is currently recommended by many centers. The banding produces distortion of the PAs and does not necessarily prevent pulmonary vascular obstructive disease. The procedure is associated with a high mortality rate, as high as 30%.

Definitive Procedure
1. Various modifications of the Rastelli procedure are performed. Ideally, surgery should be undertaken within the first week of life. When the diagnosis is delayed, surgery should be performed on an urgent basis after 2 to 3 days of medical stabilization.
2. For all types, the VSD is closed in such a way that the LV ejects into the truncus. The surgical mortality rate is 10% to 30%. Careful investigation of coronary artery anomalies and avoidance of surgical interruption of the coronary arteries are important.
   a. For type I, an aortic homograft (with internal diameter of 9–11 mm) is placed between the RV and the PA (Fig. 14-59).
   b. For types II and III, a circumferential band of the truncus, which contains both PA orifices, is removed. This cuff is tailored and then connected to the RV by the use of a homograft. Aortic continuity is restored with a tubular Dacron graft (Fig. 14-60).
   c. When associated with an interrupted aortic arch, aortic reconstruction is done by anastomosis of the proximal and distal aortas. The RPA is brought anterior to the ascending aorta (Lecompte maneuver) to prevent compression on the RPA. Using a homograft, the RV and the PA are connected.
3. The regurgitant truncal valve is almost always amenable to various repair techniques. A prolapsing vestigial leaflet can be supported by suturing to the adjacent leaflet (closure of a commissure). Truncal valve replacement is indicated if there is significant truncal valve insufficiency. It has an extremely high mortality rate of 50% or greater.
FIGURE 14-59  Operative technique for type I truncus arteriosus. A, Truncus arteriosus type I is shown with a large ventricular septal defect (VSD; broken circle) directly under the truncal valve. The vertical broken line on the right ventricle (RV) is the site of the right ventriculotomy. B, The pulmonary artery (PA) trunk has been cut away from the truncal artery, and the opening in the truncal artery is sutured. Patch closure of the VSD (which is visible through the ventriculotomy) is completed in such a way that only left ventricular blood goes out to the truncal artery (creating the left ventricle [LV]–to–truncal artery pathway). C, A valved conduit or homograft is anastomosed to the pulmonary trunk. The posterior half of the proximal conduit is anastomosed to the upper end of the ventriculotomy. A small pericardial patch is trimmed and sutured into place to fill the defect between the allograft and the lower end of the right ventriculotomy. AO, aorta; RA, right atrium.

FIGURE 14-60  Operative technique for types II and III truncus arteriosus. A, Two broken lines on the truncal artery indicate the sites of excision of the pulmonary arteries (PAs). The vertical broken line is the site of the right ventriculotomy. A ventricular septal defect (VSD) is under the truncal valve (broken circle). B, The VSD is closed with a patch through a right ventriculotomy (which is visible through the ventriculotomy) in such a way that the truncal artery receives blood only from the left ventricle (LV) (LV-to-truncus pathway). The cuff of truncal tissue, including the PA orifices, has been excised and trimmed. C, Continuity of the truncal artery, which is now the aorta (AO), has been restored with a Dacron graft. The lower end of a homograft has been anastomosed to the right ventriculotomy, and the upper end of the homograft has been anastomosed to the cuff containing the PAs. RA, right atrium; RV, right ventricle.

Postoperative Follow-up

1. Follow-up every 4 to 12 months is required to detect late complications, either natural or postoperative.
   a. Progressive truncal valve insufficiency may develop, and truncal valve repair or replacement may be needed.
   b. A small conduit needs to be changed to a larger size, usually by 2 to 3 years of age.
   c. Calcification of the valve in the conduit may occur within 1 to 5 years, which requires
reoperation.
d. Ventricular arrhythmias may develop because of right ventriculotomy.
2. Balloon dilatation and stent implantation in the RV-to-PA conduit can prolong conduit longevity and delay the need to surgically replace the conduit.
3. For older children who had received a larger sized conduit and develop valvular regurgitation after balloon dilatation of the conduit valve, a nonsurgical percutaneous pulmonary valve implantation technique has been developed by Bonhoeffer et al (2000), and this technique has been used successfully in Europe (see further discussion under TOF with pulmonary atresia in this chapter).

4. SBE prophylaxis should be observed throughout life.

**FIGURE 14-61** Diagram of the most common form of single ventricle. The single ventricle is an anatomic left ventricle (double-inlet LV). The great arteries are transposed (L-transposition), with the aorta (AO) anterior to and left of the pulmonary artery (PA) and arising from the rudimentary right ventricle (RV). Both atrioventricular valves open into the single ventricle (double-inlet LV). The opening between the main and rudimentary ventricles is the bulboventricular foramen (thick arrow). Stenosis of the pulmonary valve is present in about 50% of cases (shown as thick valves). This type accounts for 70% to 75% of cases of single ventricle. LA, left atrium; MV, mitral valve; RA, right atrium; TV, tricuspid valve.
5. The patient should not participate in strenuous competitive sports.
Single Ventricle

Prevalence

Single ventricle (double-inlet ventricle) occurs in fewer than 1% of all CHDs.

Pathology

1. Both AV valves are connected to a main, single ventricular chamber (i.e., double-inlet ventricle), and the main chamber is in turn connected to a rudimentary chamber through the BVF. One great artery arises from the main chamber, and the other arises from the rudimentary chamber (Fig. 14-61). In about 80% of cases, the main ventricular chamber has anatomic characteristics of the LV (i.e., double-inlet LV). Occasionally, the main chamber has anatomic characteristics of the RV (i.e., double-inlet RV). Rarely does the ventricle have an intermediate trabecular pattern without a rudimentary chamber (i.e., common ventricle). Also, both atria rarely empty via a common AV valve into the main ventricular chamber with either LV or RV morphology (i.e., common-inlet ventricle).

2. Either D-TGA or L-TGA is present in 85% of cases. The most common form of single ventricle is double-inlet LV with L-TGA with the aorta arising from the rudimentary chamber. This type occurs in 70% to 75% of single ventricle (see Fig. 14-61). The mitral valve is right sided; the tricuspid valve is left sided. PS or pulmonary atresia is present in about 50% of cases. COA and interrupted aortic arch are also common. Less commonly, D-TGA is present with the aorta arising from the right and anterior rudimentary chamber.

3. The BVF is frequently obstructive.

4. Anomalies of the AV valves are common, which include stenosis, overriding, or straddling.

5. In double-inlet RV, either right or LA isomerism and straddling or overriding of the AV valves is common.

Pathophysiology

1. Because there is a complete mixing in the single ventricle, the systemic arterial saturation is determined primarily by the amount of PBF.

   a. With PS, PBF is decreased, and cyanosis is present (with arterial oxygen saturation <85%). With pulmonary atresia, cyanosis is intense at birth.

   b. When the pulmonary valve is not stenotic, the PBF is large, and signs of CHF develop within days or weeks without cyanosis; arterial oxygen saturation is nearly 90%.

2. An obstructed BVF may either occur naturally with growth or, for unknown reasons, develop after PA banding. This condition occurs in 70% to 85% of patients who receive PA banding. The occurrence of an obstructed foramen has a profound hemodynamic effect, as well as major surgical implications in patients with the aorta arising from the anterior rudimentary chamber. The obstruction increases PBF and decreases systemic
perfusion. The banding also causes excessive hypertrophy of the main ventricle (LV), resulting in decreased compliance of the ventricle, which places the patient at risk for a future Fontan operation.

Clinical Manifestations

History
1. Cyanosis of varying degrees may be present from birth.
2. History of failure to thrive or pneumonia may be present in infants with increased pulmonary blood flow (signs of CHF).

Physical Examination

Physical findings depend on the magnitude of PBF.
1. With increased PBF, physical findings resemble those of TGA plus VSD or even those of large VSD:
   a. Mild cyanosis and CHF with growth retardation are present in early infancy.
   b. The S2 is single or narrowly split with a loud P2. A grade 3 to 4 of 6 long systolic murmur is audible along the left sternal border. An apical diastolic rumble may be audible. A diastolic murmur of PR may be present along the upper left sternal border as a result of pulmonary hypertension.
2. With decreased PBF, physical findings resemble those of TOF:
   a. Moderate to severe cyanosis is present. CHF is not present. Clubbing may be seen in older infants and children.
   b. The S2 is loud and single. A grade 2 to 4 of 6 ejection systolic murmur may be heard at the upper right or left sternal border.

Electrocardiography
1. An unusual ventricular hypertrophy pattern with similar QRS complexes across most or all precordial leads is common (e.g., RS, rS, or QR pattern).
2. Abnormal Q waves (representing abnormalities in septal depolarization) are also common and take one of the following forms: Q waves in the right precordial leads, no Q waves in any precordial leads, or Q waves in both the right and left precordial leads.
3. Either first- or second-degree AV block may be present.
4. Arrhythmias such as SVT or wandering pacemaker may occur.

Radiography
1. With increased PBF, the heart size enlarges and the pulmonary vascularity increases.
2. When PBF is normal or decreased, the heart size is normal and the pulmonary vascularity is normal or decreased.
3. A narrow upper mediastinum suggests TGA.

Echocardiography
1. The most important diagnostic sign of single ventricle is the presence of a single ventricular chamber into which two AV valves open.
2. The following anatomic and functional information is important from a surgical point of view. Efforts should be made to obtain information on all of these aspects in each patient with single ventricle:
   a. Morphology of the single ventricle (e.g., double-inlet LV? double-inlet RV?).
   b. Location of the rudimentary outflow chamber, which is usually left and anterior.
   c. Size of the BVF and whether there is an obstruction at the foramen. Obstruction of the foramen is considered present if the Doppler gradient is more than 1.5 m/sec or if the area of the foramen is less than $2 \text{ cm}^2/m^2$. A foramen that is nearly as large as the aortic annulus is considered ideal.
   d. Presence or absence of D-TGA or L-TGA, stenosis of the pulmonary or aortic valve, and size of the PAs.
   e. Anatomy of the AV valves. The position of the mitral and tricuspid valves, in addition to the presence of stenosis, regurgitation, hypoplasia, or straddling of these valves, should be checked.
   f. The size of the ASD.
   g. Associated defects such as COA, interrupted aortic arch, or PDA.

Other Studies

Echocardiographic and Doppler studies provide most of the anatomic and hemodynamic information needed for the initial management of single ventricle. Cardiac catheterization is performed only when certain preoperative information is not available before the initial stage of surgical management. It is, however, routinely indicated before stages II and III surgical intervention.

Natural History

1. In patients without PS, CHF and growth failure develop in early infancy in association with pulmonary hypertension. Without surgery, about 50% of these patients die before reaching 1 year of age. The remainder of the patients with increased PBF develop pulmonary vascular obstructive disease after the first year of life with clinical improvement of CHF.
2. In patients with associated PS, cyanosis increases if PS worsens.
3. If the aorta arises from the rudimentary chamber, the BVF is often small or becomes obstructed. This results in increased PBF and decreased systemic perfusion.
4. Progressive AV valve regurgitation is poorly tolerated.
5. Complete heart block develops in about 12% of patients.
6. The cause of death can be CHF, arrhythmias, or sudden death.

Management

Initial Medical Management
1. Newborns with severe PS or pulmonary atresia and those with interrupted aortic arch or coarctation require PGE₃ infusion and other supportive measures before surgery.

2. Anticongestive measures are indicated if CHF develops.

**Surgical**

1. Initial surgical palliative procedures
   a. The purpose of the first-stage operation is to make patients acceptable candidates for bidirectional Glenn or hemi-Fontan operation. Cyanosis with oxygen saturation less than 85% or increased pulmonary blood flow with possible future pulmonary hypertension is an indication for the operation. The presence or absence of PS or of obstructive BVF results in one of the following four situations. PS (or pulmonary atresia) is present in about 50% of the patients. When there is no PS, pulmonary overcirculation can lead to pulmonary hypertension, which jeopardizes future Fontan operation.

   (1) In patients with no PS and large PBF with resulting CHF and pulmonary edema, PA banding may be done, although the banding carries a high mortality rate (≈25% or even higher). The major risk factor for the banding is the presence or development of an obstructed BVF. Most infants with an obstructed foramen do not tolerate the banding well. Therefore, PA banding is performed, only when the BVF is *normal* or *unobstructed*. In addition, these patients should be watched for the development of obstruction after the banding.

   (2) In patients with no PS, if the BVF is too small, the Damus-Kaye-Stansel operation is performed rather than the PA banding. The operation involves a PA-to-aorta anastomosis, which is accomplished by transection of the main PA and anastomosis of the proximal PA to the ascending aorta. This operation is combined with a right-sided BT shunt (Fig. 14-62) or a single ventricle–to–the main PA (Sano) shunt (not shown). A Fontan-type operation can be performed later (see Fig. 14-38, B).

---

**FIGURE 14-62** Damus-Kaye-Stansel anastomosis for single ventricle and subpulmonary stenosis. **A,** The pulmonary artery (PA) is transected proximal to the bifurcation. An appropriately positioned and sized incision is made in the ascending aorta (AO). **B,** The distal end of the PA is oversewn, and the proximal end of the PA is anastomosed to the opening in the aorta. **C,** An appropriately shaped hood (Dacron tube, pericardium, allograft, or Gore-Tex) is added to the anastomosis. A Blalock-Taussig shunt has been completed. Sano
(3) If PS or pulmonary atresia is present (with O\textsubscript{2} saturation <85%), a BT shunt is necessary to improve cyanosis. Shunt to the right PA is preferable because any distortion of the RPA can be incorporated later in the Fontan anastomosis. The mortality rate is low (5%–10%). In PGE\textsubscript{1}-dependent neonates, the PDA is ligated after placement of the shunt.

Recently, a hybrid procedure consisting of PDA stenting, bilateral PA banding, and balloon atrial septostomy (with or without balloon dilatation), as discussed under HLHS, has been used as an alternative to the BT shunt.

(4) If PS is present and the BVF is obstructive, enlargement of the BVF by a transaortic approach and without cardiopulmonary bypass may be performed. The surgical mortality rate is about 15%. An additional BT shunt may be needed to provide adequate pulmonary blood flow.

b. Surgery for interrupted aortic arch or coarctation should be performed, if present.
c. After the first-stage operation, the infant should be watched closely, until the time of the second-stage palliation, for cyanosis (with O\textsubscript{2} saturation <75%) or signs of CHF (too large a pulmonary blood flow for which tightening of the PA band should be considered).

2. Second-stage surgical palliative procedures
   a. A bidirectional Glenn operation (see Fig. 14-38) is carried out between the age of 3 and 6 months, before proceeding with the Fontan operation. Alternatively, a hemi-Fontan procedure can be performed (see Fig. 14-39).
   b. After the second-stage surgical procedure, the child needs to be followed up with attention to the O\textsubscript{2} saturation. The follow-up plans are the same as those described in Box 14-2.

3. Definitive (Fontan) procedures
   The Fontan-type operation is performed at 18 to 24 months of age. Many centers consider the lateral tunnel Fontan procedure the procedure of choice (see Figs. 14-38, B, and 14-40). Some centers make a 4- to 6-mm fenestration in the baffle, and others do not. Some centers prefer the extracardiac conduit modification of the Fontan procedure, which may reduce the incidence of late atrial arrhythmias. If an AV valve is incompetent, it may need to be closed during surgery. The surgical mortality rate of the Fontan-type operation has been reduced to 5% to 10%, similar to that for tricuspid atresia.

The surgical approaches in single ventricle are summarized in Fig. 14-63.
FIGURE 14-63  Surgical approach for single ventricle. BDG, bidirectional Glenn; BVF, bulboventricular foramen; BT, Blalock-Taussig; CHF, congestive heart failure; PBF, pulmonary blood flow; PS, pulmonary stenosis; RPA, right pulmonary artery.

**Postoperative Follow-up**

1. Close follow-up is necessary for early and late complications, which have been discussed in detail under tricuspid atresia.
2. Some survivors of surgery, if performed late, remain symptomatic with cyanosis, dyspnea as a result of ventricular dysfunction, and arrhythmias. These symptoms require regular follow-up. Early surgery as outlined above tends to reduce unfavorable results.
Double-Outlet Right Ventricle

Prevalence

Double-outlet right ventricle (DORV) occurs in fewer than 1% of all CHDs. DORV occurs frequently in patients with heterotaxy in association with other complex cardiac defects.

Pathology

1. Both the aorta and the PA arise from the RV. The only outlet from the LV is a large VSD.
2. The great arteries usually lie side by side. The aorta is usually to the right of the PA, although one of the great arteries may be more anterior than the other. The aortic and pulmonary valves are at the same level. Conus septum is present between the aorta and the PA. The subaortic and subpulmonary coni separate the aortic and pulmonary valves from the tricuspid and mitral valves, respectively. This means that there is no fibrous continuity between the semilunar valves and the AV valves. In a normal heart, the aortic valve is lower than the pulmonary valve, and the aortic valve is in fibrous continuity with the mitral valve.
3. The position of the VSD and the presence or absence of PS (or RVOT obstruction) influence hemodynamic alterations and form the basis for dividing the defect into the following types of DORV (Fig. 14-64):
   a. Subaortic VSD. The VSD is closer to the aortic valve than to the pulmonary valve and lies to the right of the conus septum (see Fig. 14-64, A). This is the most common type, occurring in 55% to 70% of cases.
   b. Fallot type. In about 50% of patients with subaortic VSD, RVOT obstruction occurs (Fig. 14-64, B). RVOT obstruction is most commonly caused by infundibular stenosis, but rarely pure valvular PS can occur with small annulus.
   c. Subpulmonary VSD (i.e., Taussig-Bing anomaly) (see Fig. 14-64, C). The VSD is closer to the pulmonary valve than to the aortic valve, and it usually lies above the crista supraventricularis and to the left of the conus septum. This type accounts for approximately 10% to 30% of cases.

FIGURE 14-64  Diagram of three representative types of double outlet right ventricle, viewed with the free wall of the right ventricle (RV) removed. A, Subaortic ventricular septal defect (VSD). B, Subaortic VSD with pulmonary
d. Doubly committed VSD. The VSD is closely related to both semilunar valves and is usually above the crista supraventricularis (<5% of cases).
e. Noncommitted (or remote) VSD. The VSD is clearly away from the semilunar valves (≈10% of cases). It most commonly represents the AV canal-type VSD and occasionally an isolated muscular VSD. Atrial isomerism is commonly seen with this type.

4. Sometimes surgeons’ and pathologists’ definitions of DORV are different and are the source of confusion. Some cases of TOF with marked overriding of the aorta may be called DORV by surgeons because the mitral–aortic fibrous continuity is not always clear in the operating room. Surgeons use the so-called 50% rule: when the aortic annulus overlies the RV by at least 50%, it is called DORV.

**Pathophysiology and Clinical Manifestations**

The pathophysiology and clinical manifestations of DORV are determined primarily by the position of the VSD and the presence or absence of PS. Each type is presented separately.

1. Subaortic VSD without PS. In subaortic VSD, oxygenated blood from the LV is directed to the aorta, and desaturated systemic venous blood is directed to the PA, thereby producing mild or no cyanosis (see Fig. 14-64, A). The PBF increases in the absence of PS, and CHF may result. Therefore, the clinical pictures of this type resemble those of a large VSD with pulmonary hypertension and CHF.
   a. Growth retardation, tachypnea, and other signs of CHF are usually present. A hyperactive precordium, a loud S2, and a VSD-type (holosystolic or early systolic) murmur are present. An apical diastolic rumble may be audible.
   b. The ECG often resembles that of complete endocardial cushion defect (ECD). “Superior” QRS axis (i.e., −30 to −170 degrees) may be found in this type. RVH or BVH, as well as LAH, is common. Occasionally, first-degree AV block is present.
   c. Chest radiography shows cardiomegaly with increased pulmonary vascular markings and a prominent PA segment.

2. Subaortic VSD with PS (Fallot type). Even though the VSD is subaortic, in the presence of PS (or RVOT obstruction), some desaturated blood goes to the aorta. This causes cyanosis and a decrease in PBF. The clinical pictures resemble those of TOF (see Fig. 14-64, B).
   a. Growth retardation and cyanosis are common. The S2 is loud and single. A grade 2 to 4 of 6 midsystolic (ejection) murmur along the left sternal border is present, either with or without a systolic thrill.
   b. The ECG shows RAD, RAH, RVH, or RBBB. First-degree AV block is frequent.
   c. Chest radiography shows normal heart size with an upturned apex. Pulmonary vascularity is decreased.
3. Subpulmonary VSD (Taussig-Bing malformation). In subpulmonary VSD, or Taussig-Bing malformation, oxygenated blood from the LV is directed to the PA, and desaturated blood from the systemic vein is directed to the aorta. This results in severe cyanosis (see Fig. 14-64, C). The PBF increases with the fall of the PVR. Clinical pictures resemble those of complete TGA.

   a. Growth retardation and severe cyanosis with or without clubbing are common findings. The S2 is loud, and a grade 2 to 3 of 6 systolic murmur is audible at the upper left sternal border. An ejection click and an occasional PR murmur (as a result of pulmonary hypertension) may be audible.
   b. The ECG shows RAD, RAH, and RVH. LVH may be seen during infancy.
   c. Chest radiography shows cardiomegaly with increased pulmonary vascular markings and a prominent PA segment.

4. Doubly committed or noncommitted VSD. With the VSD close to both semilunar valves (called doubly committed VSD) or remotely located from these valves (noncommitted VSD), cyanosis of a mild degree is present, and the PBF increases.

**Echocardiography**

Three diagnostic signs of DORV are the origin of both great arteries from the anterior RV, the absence of LV outflow other than the VSD, and the discontinuity of the mitral and semilunar valves.

1. In the parasternal long-axis view, all three diagnostic features of DORV are imaged. Typical subaortic or subpulmonary VSD can be demonstrated in this view for most patients (Fig. 14-65). No great artery is seen to arise from the posterior ventricle. The great arteries arising from the anterior ventricle are seen in parallel orientation. In addition, a mass of echocardiography-positive tissue, usually larger than 5 mm in length, is present between the mitral valve annulus and the semilunar valve (i.e., mitral–semilunar discontinuity).

2. In the parasternal short-axis view, a double circle, rather than the normal circle and sausage appearance of the great arteries, may be seen. Either the great arteries are side by side with the aorta to the right or the aorta is anterior and slightly to the right of the PA.

3. The size and position of the VSD should be determined in relation to the great arteries.
   a. Typical subpulmonary or subaortic VSD can be demonstrated by parasternal long-axis scanning in most patients (see Fig. 14-65).
   b. In the subcostal four-chamber view, the subaortic VSD is located to the right of the conus septum just beneath the aortic valve. The subpulmonary VSD is located to the left of the conus septum just beneath the pulmonary valve.
c. Doubly committed VSD is recognized in the parasternal or the apical long-axis view.
d. Noncommitted (remote) VSDs, either endocardial cushion type or apical muscular VSD, are best recognized in the apical four-chamber view.

4. Associated anomalies such as valvular or subvalvular PS and other left-to-right shunt lesions (e.g., ASD, PDA) should be looked for.
5. Occasionally, differentiation of DORV from TOF with a marked overriding of the aorta or from TGA is necessary. There is mitral–semilunar continuity in TOF and TGA (i.e., mitral–aortic continuity in TOF and mitral–pulmonary continuity in TGA), but no mitral–semilunar continuity is present in DORV.

Other Studies
Cardiac catheterization and angiography are not necessary for initial surgical management of the condition with PA banding or BT shunt. They are indicated to perform atrial septostomy in patients with Taussig-Bing malformation with inadequate atrial septal mixing. They are usually indicated before later stage operations.

Natural History
1. Infants without PS may develop severe CHF and later pulmonary vascular obstructive disease if left untreated. Spontaneous closure of VSD, which is fatal, is rare.
2. When PS is present, complications common to cyanotic CHDs (e.g., polycythemia, cerebrovascular accident) may develop.
3. In patients with the Taussig-Bing malformation, severe pulmonary vascular obstructive disease develops early in life, as seen in patients with D-TGA.
4. Associated anomalies (e.g., COA, LV hypoplasia) also contribute to the poor prognosis.

Management
Treatment of CHF with diuretics, ACE inhibitors, and digoxin is indicated.

Surgical

Palliative Procedures
1. PA banding for symptomatic infants with increased PBF and CHF is occasionally performed in infants with multiple muscular VSD or a remote VSD. However, this procedure is not recommended for infants with subaortic VSD or doubly committed VSD. Primary repair is a better choice.
2. For infants with the Taussig-Bing type, enlarging the interatrial communication is important for better mixing and for decompressing the LA, which causes pulmonary venous congestion. Balloon or blade atrial septostomy should be considered.
3. In infants with PS and decreased PBF with cyanosis, a systemic-to-PA shunt procedure is occasionally indicated.

Definitive Surgeries
1. Subaortic or doubly committed VSD. An intraventricular tunnel between the VSD and the subaortic outflow tract is created by means of a Dacron patch. This procedure is performed early in life, preferably during the neonatal period or at least in early infancy, without preliminary PA banding. Sometimes the RVOT may have to be augmented with an outflow patch if the VSD–AO tunnel obstructs the RV outflow tract. The mortality rate is less than 5% for simple subaortic VSD; it is slightly higher for doubly committed VSD.
2. Fallot type. There are three surgical options. Surgical repair is generally advised by 6 months of age, preferably during the neonatal period. However, if the patient’s condition is poor or if there are major associated noncardiac anomalies, an initial shunt operation is an option.
   a. Tunnel VSD closure + Rastelli operation. An intraventricular tunnel between the VSD and the aorta is established, and a Rastelli operation is performed to relieve PS using either a pulmonary or aortic homograft conduit.
   b. REV procedure. So-called reparation a l’etage ventriculare (REV), which is similar to ASO, may be performed. In the REV procedure, the proximal ascending aorta and main PA are transected, and the proximal stump of the PA is oversewn (see Fig. 14-9, which is performed for D-TGA + VSD + PS, a situation very similar to this one). The pulmonary arteries are translocated anterior to the aorta (Lecompte maneuver), and the ascending aorta is reconnected. The distal PA is anastomosed directly to the upper margin of the infundibular incision. Autologous pericardium forms the anterior portion of the pathway. The hospital mortality rate is 18%.
   c. Nikaidoh procedure. This combines the principle of the Ross procedure and the Konno operation. The aortic root including the aortic valve is detached in the same manner as done to the pulmonary root in the Ross procedure. The PA is divided, and the pulmonary valve is excised. The pulmonary root is divided, and the conal septum
above the VSD is excised, which creates a large opening to the LV cavity. The aortic root is translocated posteriorly and sutured to the open orifice of the pulmonary annulus. A pericardial patch is used to connect the lower margin of the VSD and the anterior circumference of the harvested aortic root, completing the LV to AO connection. A pericardial gusset completes the connection of the RV and the distal end of the MPA (see Fig. 14-10, which has been described for D-TGA + VSD + PS).

3. Taussig-Bing anomaly (subpulmonary VSD). There are four possible surgical approaches. These operations should be carried out by 3 to 4 months of age or sooner because of the rapid development of pulmonary vascular obstructive disease in this subtype.
   a. The procedure of choice is the creation of an intraventricular tunnel between the VSD and the PA (resulting in TGA), which is then corrected by the ASO. The mortality rate is between 5% and 15%.
   b. Creation of an intraventricular tunnel between the VSD and the PA is followed by the Senning operation. This is a less desirable approach because of a high mortality rate (>40%) and a higher late complication rate associated with the Senning procedure.
   c. An intraventricular tunnel between the VSD and the aorta is desirable but often technically impossible. The surgical mortality rate is about 15%.
   d. Creation of a VSD-to-PA tunnel followed by the Damus-Kaye-Stansel operation and RV–to-PA conduit is another possibility.

4. Noncommitted VSD. When possible, an intraventricular tunnel procedure between the AV canal-type VSD and the aorta is performed, but the mortality rate is high (30%–40%). PA banding is usually needed in infancy to control CHF, and the surgery may be delayed until 2 to 3 years of age. The surgical approach for patients with DORV is summarized in Figure 14-66.

**Postoperative Follow-up**

Long-term, regular follow-up at 6- to 12-month intervals is necessary to detect and manage late complications of surgery.

1. In general, patients who had subaortic VSD without PS have an excellent long-term outlook.
2. Ventricular arrhythmia should be treated because it may cause sudden death.
3. About 20% of patients require reoperation of the intraventricular tunnel.
Heterotaxia (Atrial Isomerism, Splenic Syndromes)

There is a failure of differentiation into right- and left-sided organs in heterotaxia (splenic syndrome or atrial isomerism), with resulting congenital malformations of multiple organs systems, including complex malformation of the cardiovascular system. Asplenia syndrome (Ivemark’s syndrome, RA isomerism) is associated with absence of the spleen, which is a left-sided organ, and a tendency for bilateral right-sidedness. In polysplenia syndrome (LA isomerism), multiple splenic tissues are present, with a tendency for bilateral left-sidedness.

There is a striking tendency for symmetrical development of normally asymmetrical organs or pairs of organs. Members of paired organs, such as the lungs, commonly show pronounced isomerism; unpaired organs, such as the stomach, seem to be located in a random fashion. Table 14-2 compares cardiovascular abnormalities in asplenia and polysplenia syndromes. Although the types and severity of cardiovascular malformations differ as a group between the two syndromes, the same types of defects are present in both. The abnormalities that help differentiate the two are shown with asterisks, but probably the most significant differential power is the IVC, which is almost always normal with asplenia syndrome but is interrupted (with azygous continuation) with polysplenia. In general cardiovascular abnormalities are much more severe in patients with asplenia than in those with polysplenia.

Some noncardiac findings suggest heterotaxia. Because of the symmetry of paired organs, normally different right- and left-sided organs show the same morphology. Some clinical findings available to general physicians that may lead to the recognition of heterotaxia include the following.
1. Symmetric “midline” liver (on palpation or radiography)
2. Discordant cardiac apex and stomach bubble (on chest radiography)
3. Biliary atresia in a neonate with CHDs
4. Symmetric mainstem bronchi on chest radiography
5. Superior P axis (or coronary sinus rhythm) on the ECG

It is important to know which type of isomerism one has from the point of prophylaxis against bacterial infection, asplenia or polysplenia syndrome. Patients with asplenia syndrome are prone to fulminating sepsis and should be given daily antibiotic prophylaxis and vaccinated against pneumococcus, *Haemophilus influenzae* type b (Hib), and meningococcus (see below).
Asplenia Syndrome

Prevalence

Asplenia syndrome occurs in 1% of newborns with symptomatic CHDs. This syndrome occurs more often in boys than girls.

<table>
<thead>
<tr>
<th>Structure</th>
<th>Asplenia Syndrome</th>
<th>Polysplenia Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic veins</td>
<td>Bilateral SVC (65%); single SVC usually right (35%)</td>
<td>Bilateral SVC (33%); single SVC right or left (66%)</td>
</tr>
<tr>
<td></td>
<td>Normal IVC in all but may be left-sided (35%)</td>
<td>†Interrupted IVC (absent hepatic segment of IVC) with azygos continuation right or left (85%)</td>
</tr>
<tr>
<td></td>
<td>(Interrupted IVC extremely rare)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>†IVC and aorta on the same side, either right or left</td>
<td>Juxtaposition of IVC and aorta occasionally</td>
</tr>
<tr>
<td></td>
<td>Normal hepatic veins to IVC (75%)</td>
<td>Bilateral, common hepatic vein to RA or LA</td>
</tr>
<tr>
<td>Pulmonary veins</td>
<td>†TAPVR with extracardiac connection: supracardiac or infracardiac (&gt;80%), often with PV obstruction</td>
<td>†Normal PV return (50%)</td>
</tr>
<tr>
<td>Coronary sinus</td>
<td>Absent coronary sinus (most)</td>
<td>Absent coronary sinus (most)</td>
</tr>
<tr>
<td>Atrium and atrial septum</td>
<td>Bilateral right atria (with bilateral sinus node)</td>
<td>Bilateral, left atria</td>
</tr>
<tr>
<td></td>
<td>†Absent atrial septum (common atrium) common; primum ASD (100%), secundum ASD (66%)</td>
<td>Single (or common) atrium, primum ASD (60%), or secundum ASD (25%)</td>
</tr>
<tr>
<td>AV valve</td>
<td>†Common (single) AV valve (90%); Complete AV canal, usually</td>
<td>Normal AV valve (50%); single AV valve rare</td>
</tr>
<tr>
<td></td>
<td>VSD always present</td>
<td>Partial ECD common (with large primum defect)</td>
</tr>
<tr>
<td></td>
<td>†Single ventricle (50%) usually morphologic RV or undetermined; two ventricles (50%)</td>
<td>VSD frequent but not always</td>
</tr>
<tr>
<td></td>
<td>DORV (&gt;80%)</td>
<td>†Two ventricles usually present; VSD (65%); DORV (20%)</td>
</tr>
<tr>
<td></td>
<td>Left apex (60%); right apex (40%)</td>
<td>Left apex (60%); right apex (40%)</td>
</tr>
<tr>
<td>Semilunar valves</td>
<td>†Stenosis (40%) or atresia (40%) of PV</td>
<td>Normal PV (60%); PS or pulmonary atresia (40%)</td>
</tr>
<tr>
<td>Great arteries</td>
<td>†Transposition (70%), either D- or L-</td>
<td>†Normal great arteries (85%); transposition (15%)</td>
</tr>
<tr>
<td>ECG</td>
<td>Normal P axis or in the +90 to +180 degree quadrant</td>
<td>†Superior P axis (70%)</td>
</tr>
</tbody>
</table>

ASD, atrial septal defect; AV, atrioventricular; DORV, double-outlet right ventricle; IVC, inferior vena cava; PS, pulmonary stenosis; PV, pulmonary venous or vein; RA, right atrium; RV, right ventricle; SVC, superior vena cava; TAPVR, total anomalous pulmonary venous return; VSD, ventricular septal defect.

* Extremely important differentiating points.
† Important differentiating points.

Pathology

1. The spleen is absent in asplenia syndrome. A striking tendency for bilateral right-sidedness characterizes malformations of the major organ systems. Bilateral, three-lobed lungs with bilateral, eparterial bronchi (Fig. 14-67); various gastrointestinal malformations (occurring in 20% of cases); a symmetrical, midline liver; and malrotation of the intestines are all present. The stomach may be located on either the right or the left.

2. Complex cardiac malformations are always present. Cardiovascular malformations involve all parts of the heart, systemic and pulmonary veins, and great arteries. Two sinoatrial nodes are present. Table 14-2 summarizes and compares these malformations with those of polysplenia syndrome. Cardiovascular anomalies that help distinguish
asplenia syndrome from polysplenia syndrome include the following:

a. A normal IVC is present in asplenia syndrome, but the hepatic portion of the IVC is commonly absent (with azygous continuation draining into the SVC) in polysplenia syndrome.

b. TGA with PS or pulmonary atresia occurs in about 80% of asplenia syndrome cases, thereby producing severe cyanosis during the newborn period. TGA is present in only 15% of patients with polysplenia syndrome.

c. Single ventricle and common AV valve occur with greater frequency in asplenia syndrome. In polysplenia syndrome, two ventricles are usually present.

d. TAPVR to extracardiac structures occurs in more than 75% of cases of asplenia syndrome, although it is difficult to diagnose. Pulmonary venous return is normal in 50% of patients with polysplenia syndrome.

Pathophysiology

1. Complete mixing of systemic and pulmonary venous blood usually occurs because of the multiple cardiovascular abnormalities associated with this syndrome.
2. PBF is reduced because of stenosis or atresia of the pulmonary valve. This results in severe cyanosis shortly after birth.
3. Although rare, the absence of PS may result in CHF early in life.

Clinical Manifestations

Physical Examination

1. Cyanosis is usually the presenting sign and is often severe.
2. Auscultation of the heart is nonspecific. Heart murmurs of PS and VSD are frequently audible.
3. A symmetrical liver (midline liver) is palpable.

Electrocardiography

1. A “superior” QRS axis is present, as a result of the presence of ECD.
2. The P axis is either normal (0 to +90 degrees) or alternating between the lower left and lower right quadrants. This occurs because two sinus nodes alternate the pacemaker function.
3. RVH, LVH, or BVH is present.

**Radiography**
1. The heart size is usually normal or slightly increased, with decreased pulmonary vascular markings.
2. The heart is in the right chest, left chest, or midline (mesocardia).
3. A symmetrical liver is a striking feature (see Fig. 4-8).
4. Tracheobronchial symmetry with bilateral, eparterial bronchi is usually identified.

**Echocardiography**
When the systematic approach is used, two-dimensional echocardiography and color-flow Doppler studies can detect all or most of the anomalies described in the section on pathology. The anatomy of the IVC and great arteries and the presence or absence of PS or pulmonary atresia are important in differentiating the two splenic syndromes.

**Other Imaging Modalities**
Cardiac MRI or CT is usually indicated because almost all of the patients with asplenia syndromes have complex anomalies of pulmonary and systemic venous returns, which cannot be accurately imaged by echocardiographic studies.

**Laboratory Studies**
1. Howell-Jolly and Heinz bodies seen on the peripheral smear suggest asplenia syndrome. However, these bodies may be found in some normal newborns and in septic infants.
2. A splenic scan may be useful in older infants but is of limited value in extremely ill neonates.

**Natural History**
Without palliative surgical procedures, more than 95% of patients with asplenia syndrome die within the first year of life. Fulminating sepsis is one cause of death.

**Management**

**Medical**
1. In severely cyanotic newborns, PGE\textsubscript{1} infusion is given to reopen the ductus. (If obstructive anomalous pulmonary venous return is suspected, pulmonary angiography should be obtained while the ductus is open by PGE\textsubscript{1} infusion.)
2. The risk of fulminating infection, especially by *Streptococcus pneumoniae*, is high (Red
Continuous oral antibiotic therapy is recommended regardless of immunization status. Oral penicillin V (125 mg, twice a day for children younger than 5 years, and 250 mg, twice a day for children 5 years of age and older) is recommended. Some experts recommend amoxicillin (20 mg/kg per day, divided into two doses). Erythromycin (250 mg twice daily) is an alternate choice in patients who are allergic to penicillin. Prophylactic penicillin can be discontinued at 5 years of age, but some experts continue prophylactic penicillin throughout childhood and into adulthood.

3. Asplenic infants and children have a high risk of fulminant bacteremia, especially associated with encapsulated bacteria. *Streptococcus pneumoniae* is the most common pathogen that causes bacteremia in asplenic children. Less common causes of bacteremia include Hib, *Neisseria meningitidis*, and many others.
   a. Pneumococcal conjugate and polysaccharide vaccines are indicated for all children with asplenia at the recommended age (*Red Book, 2012*). After administration of an appropriate number of doses of PCV13, pneumococcal polysaccharide vaccine (PPSV23) should be given starting at 24 months of age. A second dose should be administered 6 years later. For children 2 through 5 years of age with a complete PCV7 series who have not received PCV13, a supplemental dose of PCV13 should be administered. For asplenic people 6 through 18 years of age who have not received a dose of PCV13, a supplemental dose of PCV13 should be considered (*Red Book, 2012*).
   b. Hib immunization should be initiated at 2 months of age, as recommended for otherwise healthy children.
   c. Two primary doses of quadrivalent meningococcal conjugate vaccine should be administered 2 months apart to children 2 years through adolescence, and a booster dose should be given every 5 years, although its efficacy has not been established.

**Surgical**

1. A systemic-to-PA shunt is usually necessary during the newborn period or infancy. Surgical mortality for the shunt is higher in asplenia patients than in those with other defects, and it is probably related to regurgitation of the common AV valve and undiagnosed obstructive TAPVR.
   a. Patients with a common AV valve, especially those with regurgitation of the valve, do not tolerate the volume overload that results from the shunt.
   b. Patients with the obstructive type of TAPVR may show evidence of the anomalous return, with signs of pulmonary edema, only after the systemic-to-PA shunt. The surgical mortality rate for both the shunt and repair of the TAPVR is unacceptably high in that death occurs in more than 90% of cases.
   c. Identification of infants with obstructive TAPVR by pulmonary angiography with PGE$_1$ infusion before surgery is important. In infants with the infracardiac type of TAPVR, a successful connection can be made between the pulmonary venous confluence and the RA with the use of a partial exclusion clamp and without cardiopulmonary bypass.

2. A Fontan-type operation can be performed with the overall mortality rate as high as 65%. Regurgitation of the AV valve is a high-risk factor, requiring repair or replacement.
of the valve.
Polysplenia Syndrome

Prevalence

Polysplenia syndrome (LA isomerism) occurs in fewer than 1% of all CHDs. It occurs usually in females (70%).

Pathology

1. Multiple splenic tissues are present. A tendency for bilateral left-sidedness characterizes this syndrome. Noncardiovascular malformations include bilateral, bilobed lungs (i.e., two left lungs); bilateral, hyparterial bronchi (see Fig. 14-67); a symmetrical liver (25%); occasional absence of the gallbladder; and some degree of intestinal malrotation (80%).

2. Cardiovascular malformations are similar to those seen in asplenia syndrome but have a lower frequency of pulmonary valve stenosis or atresia. Occasionally, a normal heart or minimal malformation of the heart is present in patients with polysplenia syndrome (≈13%). Cardiovascular malformations are summarized and compared with those of asplenia syndrome in Table 14-2. Important features of polysplenia syndrome that distinguish it from asplenia syndrome include the following:
   a. Absence of the hepatic segment of the IVC with azygous (right side) or hemiazygous (left side) continuation is seen in 85% of patients. This abnormality is rarely present in asplenia syndrome.
   b. Two ventricles are usually present. On the contrary, single ventricle with a common AV valve is common in asplenia syndrome.
   c. TGA, PS or pulmonary atresia, and TAPVR occur less often than they do in asplenia syndrome.
   d. The ECG shows a superiorly oriented P axis (i.e., ectopic atrial rhythm), resulting from absence of the sinus node (Fig. 14-68).
   e. Polysplenia syndrome occurs more often in females (70%).

Pathophysiology

Because PS or pulmonary atresia occurs less frequently, cyanosis is not intense, if it is present at all. Rather, CHF often develops because of increased PBF.

Clinical Manifestations

Physical Examination

1. Cyanosis is either absent or mild. Signs of CHF may develop during the neonatal period.
2. Heart murmur of VSD may be audible. A symmetrical liver is usually palpable.

Electrocardiography (see Fig. 14-68)
1. Ectopic atrial rhythm with a superiorly oriented P axis (−30 to −90 degrees) is seen in more than 70% of patients because there is no sinus node when two LA are present.
2. A “superior” QRS axis is present as a result of the presence of ECD.
3. RVH or LVH is common.
4. Complete heart block occurs in about 10% of patients.

**Radiography**
Mild to moderate cardiomegaly with increased pulmonary vascular markings; midline liver (see Fig. 4-8); and bilateral, hyparterial bronchi may be present.

**Laboratory Studies**
1. Some patients with splenic hypoplasia and hypofunction may have Howell-Jolly bodies but not in an excessive number.
2. The radioactive splenic scan may show multiple splenic tissues.

**Echocardiography**
Two-dimensional and Doppler echocardiographic studies reveal all or most of the cardiovascular malformations listed in Table 14-2 and help differentiate this syndrome from asplenia syndrome.

**Other Imaging Modalities**
Cardiac MRI or CT is often indicated because many patients with polysplenia syndromes have complex anomalies of pulmonary and systemic venous returns.

**Natural History**
1. The first-year mortality rate is 60% compared with greater than 95% in asplenia syndrome.
2. Most infants with severe cardiac malformations die within the first year without surgical palliation or repair.
3. The heart rate is lower than in normal children (because of the absence of sinus node). Excessive junctional bradycardia may develop, resulting in CHF.

**Management**

**Medical**
If present, CHF should be treated.
Surgical

1. PA banding should be performed if intractable CHF develops with large PBF.
2. Occasionally, pacemaker therapy is required for children with excessive junctional bradycardia and CHF.
3. Total correction of the defect is possible in some children. If total correction is not possible, at least a Fontan-type operation can be performed. The surgical mortality rate of the Fontan-type operation in this group of children is about 25%, which is lower than that for asplenia but higher than that for tricuspid atresia.

Postoperative Follow-up

Periodic follow-up is necessary because of continuing medical and surgical problems.
1. Although most patients are in NYHA class I or II (see Appendix A, Table A-3), persistent ascites or edema occurs frequently and requires medications such as digoxin, diuretics, and others for several years after the Fontan-type operation.
2. Cardiac arrhythmias, usually supraventricular, are present in 25% of patients. Some require antiarrhythmic medications.
Persistent Pulmonary Hypertension of the Newborn

Prevalence
Persistent pulmonary hypertension of the newborn (or persistence of the fetal circulation) occurs in approximately one in 1500 live births.

Pathology and Pathophysiology
1. This neonatal condition is characterized by persistence of pulmonary hypertension, which in turn causes a varying degree of cyanosis from a right-to-left shunt through the PDA or PFO. No other underlying CHD is present.
2. Various causes have been identified, but they can be divided into three groups by the anatomy of the pulmonary vascular bed:
   a. Intense pulmonary vasoconstriction in the presence of a normally developed pulmonary vascular bed
   b. Hypertrophy (of the medial layer) of the pulmonary arterioles
   c. Developmentally abnormal pulmonary arterioles with decreased cross-sectional area of the pulmonary vascular bed (see Box 14-3 for further description)

BOX 14-3 Causes of Persistent Pulmonary Hypertension of the Newborn
Pulmonary vasoconstriction in the presence of a normally developed pulmonary vascular bed may be caused by or seen in:
- Alveolar hypoxia (meconium aspiration syndrome, hyaline membrane disease, hypoventilation caused by CNS anomalies)
- Birth asphyxia
- LV dysfunction or circulatory shock
- Infections (e.g., group B hemolytic streptococcal infection)
- Hyperviscosity syndrome (polycythemia)
- Hypoglycemia and hypocalcemia
- Increased pulmonary vascular smooth muscle development (hypertrophy) may be caused by:
  - Chronic intrauterine asphyxia
  - Maternal use of prostaglandin synthesis inhibitors (aspirin, indomethacin) resulting in early ductal closure
- Decreased cross-sectional area of pulmonary vascular bed may be seen in association with:
  - Congenital diaphragmatic hernia
  - Primary pulmonary hypoplasia
  - CNS, central nervous system; LV, left ventricular.
In general, pulmonary hypertension caused by the first group is relatively easy to reverse, and that caused by the second group is more difficult to reverse than that caused by the first group. Pulmonary hypertension caused by the third group is most difficult or impossible to reverse.

3. Varying degrees of myocardial dysfunction often occur in association with PPHN.

**Clinical Manifestations**

1. Symptoms begin 6 to 12 hours after birth, with cyanosis and respiratory difficulties (with retraction and grunting). The idiopathic form usually affects full-term or postterm neonates. The patient usually has a history of meconium staining or birth asphyxia. A history of maternal ingestion of nonsteroidal antiinflammatory drugs (in the third trimester) may be elicited.

2. A prominent RV impulse and a single and loud S2 are usually found. Occasional gallop rhythm (from myocardial dysfunction) and a soft regurgitant systolic murmur of TR may be audible. Severe cases of myocardial dysfunction may manifest with systemic hypotension.

3. Arterial desaturation is found in blood samples obtained from an umbilical artery catheter. Arterial Po$_2$ may be lower in the descending aorta (the umbilical artery line) than in the preductal arteries (the right radial, brachial, or temporal artery) by 5 to 10 mm Hg because of a right-to-left ductal shunt. In severe cases, differential cyanosis may appear (with a pink upper body and a cyanotic lower body). If there is a prominent right-to-left intracardiac shunt, usually through the PFO, the preductal and postductal arteries may not show a Po$_2$ difference.

4. The ECG usually is normal for age, but occasional RVH is present. T-wave abnormalities suggestive of myocardial dysfunction may be seen.

5. Chest radiography reveals a varying degree of cardiomegaly. The lung fields may be free of abnormal findings or may show hyperinflation or atelectasis. The pulmonary vascular markings may appear normal, increased, or decreased.

6. Echocardiographic and Doppler studies are indicated to rule out CHDs and to identify patients with myocardial dysfunction. Patients with PPHN have no evidence of cyanotic or acyanotic CHDs. The only structural abnormality is the presence of a large PDA with a right-to-left or bidirectional shunt. The RV is enlarged with a flattened interventricular septum. There is evidence of increased RA pressures (with the atrial septum bulging toward the left) with or without an ASD or PFO. The LV dimension may be increased, and its systolic function (fractional shortening or ejection fraction) may be decreased.

7. Cardiac catheterization usually is not indicated. If the diagnosis is unclear or the patient does not respond to therapy, cardiac catheterization and pulmonary arteriography rarely are considered.

**Management**

The goals of therapy are to (1) lower the PVR and PA (PA) pressure through the
administration of oxygen, the induction of respiratory alkalosis, and the use of pulmonary vasodilators; (2) correct myocardial dysfunction; and (3) stabilize the patient and treat associated conditions. Detailed description of management for each goal is beyond the scope of this book; only principles of management will be presented.

1. General supportive therapy includes monitoring oxygen saturation; detecting and treating hypoglycemia, hypocalcemia, hypomagnesemia, and polycythemia; and maintaining body temperature between 98° and 99°F (36.6° and 37.2°C).

2. To increase arterial Po$_2$ levels, 100% oxygen is administered, initially without intubation. If this is not successful, intubation plus continuous positive airway pressure at 2 to 10 cm of water may be effective.

3. If the previous measures are not successful, mechanical ventilation with 100% oxygen is used to produce respiratory alkalosis. Ventilator settings are initially set to achieve Po$_2$ of 50 to 70 mm Hg and P$_{CO_2}$ of 50 to 55 mm Hg. The patient usually is paralyzed with pancuronium (Pavulon) at 0.1 mg/kg IV. However, use of paralytic agents is controversial because it may promote atelectasis of dependent lung regions with resulting ventilation–perfusion mismatch.

4. Maintaining a normal or alkaline pH level can also be achieved with the use of sodium bicarbonate or tromethamine (THAM) infusion may promote pulmonary vasodilatation and improve oxygenation.

5. Tolazoline (Priscoline), a nonselective α-adrenergic antagonist, is sometimes used. Tolazoline, being a nonselective vasodilator, also lowers SVR, resulting in systemic hypotension. Other side effects of tolazoline include increased gastric secretion, gastrointestinal bleeding, decreased platelet counts, and decreased urine output. Cimetidine (a histamine H$_2$ receptor antagonist) is not recommended because it may block the action of histamine, which is a known pulmonary vasodilator.

6. For myocardial dysfunction, dopamine is used with tolazoline to improve cardiac output. Correction of acidosis, hypocalcemia, and hypoglycemia helps improve myocardial function. Diuretics may be included in the regimen. For chronic myocardial dysfunction, digoxin may be added at a later stage.

7. A high-frequency oscillatory ventilator is effective in patients with severe PPHN. Through the use of this device, about 40% of patients who would be candidates for extracorporeal membrane oxygenation (ECMO) can avoid this procedure.

8. Inhalation nitric oxide (iNO) is a potent and selective pulmonary vasodilator. The usual starting dose is 20 ppm. Prolonged low-dose NO therapy has caused sustained improvement in oxygenation without systemic hypotension. Most newborn infants require iNO for fewer than 5 days. The use of iNO in PPHN has decreased the need for ECMO by approximately 40%. When administered by inhalation, NO diffuses to vascular smooth muscle, stimulating the production of cyclic guanosine monophosphate and causing vasodilatation.

9. ECMO has been shown to be effective in the management of selected patients with severe PPHN. However, this treatment may require ligation of a carotid artery and the jugular vein, and cerebrovascular accidents have been reported.
Prognosis

1. Prognosis generally is good for neonates with mild PPHN who respond quickly to therapy. Most of these neonates recover without permanent lung damage or neurologic impairment.
2. For those requiring a maximal ventilator setting for a prolonged time, the chance of survival is smaller, and many survivors develop bronchopulmonary dysplasia and other complications.
3. Patients with developmental decreases in cross-sectional areas of the pulmonary vascular bed usually do not respond to therapy, and their prognosis is poor.
4. Neurodevelopmental abnormalities may manifest. Patients have a high incidence of hearing loss (≤50%). Abnormal electroencephalogram findings (≤80%) and cerebral infarction (45%) have been reported.

* This occurs in all types of cyanotic CHDs.
In this chapter, congenital heart defects (CHDs) with a relatively low prevalence that have not been discussed previously are presented briefly.
Aneurysm of the Sinus of Valsalva

In aneurysm of the sinus of Valsalva (congenital aortic sinus aneurysm), there is a gradual downward protrusion of the aneurysm into a lower pressure cardiac chamber that eventually ruptures. Most of the aneurysm arises from the right coronary sinus (80%) and less frequently from the noncoronary cusp (20%). When a sinus of Valsalva aneurysm ruptures, a sinus of Valsalva fistula is formed. The fistula communicates most frequently with the right ventricle (RV) (75%) and less frequently with the right atrium (RA) (25%). Associated anomalies are common and include ventricular septal defect (VSD) (50%), aortic regurgitation (AR) (20%), and coarctation of the aorta. This rare anomaly has been reported primarily in the Asian population.

Unruptured aneurysm produces no symptoms or signs. A small sinus of Valsalva fistula may develop without symptoms. The aneurysm usually ruptures during the third or fourth decade of life. The rupture is often characterized by sudden onset of chest pain, dyspnea, a continuous heart murmur over the right or left sternal border, and bounding peripheral pulses. Severe congestive heart failure (CHF) eventually develops. Chest radiography shows cardiomegaly and increased pulmonary vascularity. The ECG may show biventricular hypertrophy (BVH), first- or second-degree atrioventricular (AV) block, or junctional rhythm.

Patients with small- to moderate-sized unruptured aneurysms probably do not need surgery. Unruptured aneurysms of the sinus of Valsalva that produce hemodynamic derangement should be repaired. When the aneurysm of the congenital sinus of Valsalva has ruptured or is associated with a VSD with or without aortic regurgitation, prompt operation is advisable.
Anomalous Origin of the Left Coronary Artery from the Pulmonary Artery (Bland-White-Garland Syndrome, ALCAPA Syndrome)

In anomalous origin of the left coronary artery from the pulmonary artery (PA), the left coronary artery arises abnormally from the PA. Patients usually are asymptomatic in the newborn period until the PA pressure falls to a critical level after birth. The direction of blood flow is from the right coronary artery, through intercoronary collaterals retrogradely, to the left coronary artery, and into the PA. This results in left ventricular insufficiency or infarction.

Symptoms appear at 2 to 3 months of age and consist of recurring episodes of distress (anginal pain), marked cardiomegaly, and CHF. Significant heart murmur usually is absent, with a rare exception of a heart murmur of mitral regurgitation secondary to myocardial infarction. The electrocardiogram (ECG) shows an anterolateral myocardial infarction pattern consisting of abnormally deep and wide Q waves, inverted T waves, and an ST segment shift in leads I and aVL and the left precordial leads (see Fig. 3-27). Chest radiography may show cardiomegaly (of the left atrium [LA] and left ventricle [LV]) with or without pulmonary edema in advanced cases. Cardiac enzyme changes probably occur, but the relatively slow development of myocardial infarction and the uncertainty of the exact time of infarction may make it difficult to interpret laboratory data. However, knowledge of cardiac enzyme changes seen in adult cases of myocardial infarction helps in the diagnosis of this condition (see Fig. A-2). Cardiac troponin I levels may also increase. The normal level of cardiac troponin I in children is 2 ng/mL or less and is frequently below the level of detection for the assay.

Two-dimensional echocardiography with color-flow mapping is diagnostic and has replaced cardiac catheterization. The presence of normal origin of both the right and left coronary arteries from the aorta should be routinely checked in every echocardiographic
study, especially in newborns. The absence of a normal left coronary artery raises the possibility of the condition and thus the diagnosis can be made in the newborn period before symptoms develop. Color Doppler examination may show retrograde flow into the proximal main PA (Fig. 15-1). The right coronary artery may be seen enlarged. The echocardiographic study also shows the size and function of the left heart. Increased echogenicity of papillary muscles and adjacent endocardium suggests fibrosis and fibroelastosis.

Computed tomography (CT) scans show high-resolution definition of coronary artery anatomy. The use of rapid acquisition (64-detector) scanners and pharmacologic slowing of the heart rate (with beta-blockers), especially in small infants, may be necessary to increase the ability to diagnose the condition.

**Management**

Medical treatment alone carries an unacceptably high mortality (80%–100%). Therefore, all patients with this diagnosis need operation. The optimal operation in infancy remains controversial, but most centers prefer definitive surgery unless the patient is critically ill.

**Palliative Surgery**

In critically ill infants, simple ligation of the anomalous left coronary artery close to its origin from the PA may be performed to prevent steal into the PA. This should be followed by a later elective bypass procedure (as described below).

**Definitive Surgery**

Even for infants who are critically ill, many centers prefer to create a two-coronary system by performing one of the following procedures.

---

**FIGURE 15-2** Intrapulmonary artery tunnel repair for anomalous origin of the left coronary artery (LCA) from the pulmonary artery (PA) (Takeuchi repair). A, Two dashed lines on the anterior wall of the PA are the proposed incision sites to create a flap of the PA. B, An aortopulmonary shunt is created after a punch hole (5–6 mm in size) is made in the contiguous wall of the aorta (Ao) and PA. C, The flap of the PA is sutured in place to form the convex roof of a tunnel through which aortic blood passes to the anomalous orifice of the left coronary artery. D, A piece of pericardium is used to close the opening in the anterior wall of the PA. E, Cross-sectional view of the tunnel operation when completed. LV, left ventricle; RA, right atrium; RV, right ventricle.
Intrapulmonary Tunnel Operation (Takeuchi Repair)

Intrapulmonary tunnel operation is the most popular among two-coronary repair surgeries (Fig. 15-2). Two circular openings are made in the contiguous wall of the aorta and the pulmonary trunk, and a 5- to 6-mm aortopulmonary window is created by suturing together these two openings. Two horizontal incisions are made in the anterior wall of the PA directly over the aortopulmonary window to create the flap of the PA wall. The flap is sutured in the posterior wall of the PA, and a tunnel is created that connects the opening of the aortopulmonary window and the orifice of the anomalous left coronary artery. The opening in the anterior wall of the PA is closed by a piece of pericardium. The mortality rate is near 0% but as high as more than 20% has been reported. Late complications of the procedure include supravalvular PA stenosis (75%), baffle leak (52%) causing coronary–PA fistula, and aortic insufficiency.

Left Coronary Artery Implantation

Left coronary artery implantation, with direct transfer of the anomalous left coronary artery into the aortic root, appears to be the most advisable procedure, but it is not always possible. The anomalous coronary artery is excised from the PA along with a button of PA wall, and the artery is reimplanted into the anterior aspect of the ascending aorta. If the direct implantation may result in excessive tension in the coronary artery, flaps can be developed from the anterior main PA wall and ascending aorta. These flaps are sutured to form a tube extension for the left coronary artery, which is then implanted to the aorta. The early surgical mortality rate is 15% to 20%.

Tashiro Repair

Tashiro and colleagues (1993) reported a repair technique that was performed in adult patients. In this procedure, a narrow cuff of the main PA, including the orifice of the left coronary artery, is transected; the upper and lower edges of the cuff are closed to form a new left main coronary artery; and the aorta and the newly created left coronary artery are anastomosed side to end. The divided main PA is anastomosed end to end. This creates no obstruction to the PA. This technique has a potential application in the pediatric population, including small infants.

Subclavian–to–Left Coronary Artery Anastomosis

In subclavian–to–left coronary artery anastomosis, the end of the left subclavian artery is turned down and anastomosed end to side to the anomalous left coronary artery through a left thoracotomy approach. Aortic cross-clamping, which could be the source of ventricular impairment with postoperative low cardiac output and a high mortality rate, is avoided.
The need for simultaneous mitral valve reconstruction at the time of definitive surgery is controversial because spontaneous improvement of mitral regurgitation (MR) occurs after surgical revascularization. After successful two-coronary artery repair, LV systolic function and heart failure improve markedly, and the severity of the MR also decreases. Even the infarct pattern on ECG may eventually disappear.
Aortopulmonary Septal Defect

In aortopulmonary septal defect (also known as aortopulmonary window, aortopulmonary fenestration), a large defect is present between the ascending aorta and the main PA (Fig. 15-3). This condition results from failure of the spiral septum to completely divide the embryonic truncus arteriosus.

Hemodynamic abnormalities are similar to those of persistent truncus arteriosus and are more severe than those of patent ductus arteriosus (PDA). CHF and pulmonary hypertension appear in early infancy. Peripheral pulses are bounding, but the heart murmur is usually of the systolic ejection type (rather than continuous murmur) at the base.

The natural history of this defect is similar to that of a large untreated PDA, with development of pulmonary vascular disease in surviving patients. This defect has no known tendency to close spontaneously. Prompt surgical closure of the defect under cardiopulmonary bypass is indicated when the diagnosis is made. The surgical mortality rate is very low.
Coronary artery fistulas are the most common congenital anomalies of the coronary artery, representing nearly half of all coronary artery anomalies. It can be isolated or associated with other CHDs, such as tetralogy of Fallot (TOF), atrial septal defect (ASD), PDA, and VSD. The right coronary artery is much more frequently involved than the left, and rarely both coronary arteries are involved.

These fistulas occur in one of two patterns.

1. **“True” coronary arteriovenous fistula.** This pattern occurs in only 7% of the cases of coronary fistulas (Fig. 15-4). This fistula involves a branching tributary from a coronary artery coursing along a normal anatomic distribution and eventually entering into the coronary sinus.

2. **Coronary artery fistula (or coronary-cameral fistula).** In the majority of cases (>90% of patients), the coronary fistula results from an abnormal coronary artery system with aberrant termination rather than true arteriovenous fistula. The right coronary is most commonly involved in coronary artery fistula. In more than 90% of reported cases, the fistula terminates in the right side of the heart (either to the RV or the PA; less commonly to the RA). It rarely terminates in the left side of the heart, but when it does, the majority enters the LA.

Patients usually are asymptomatic. However, congestive heart failure may develop if the shunt through the fistula is large. With a significant shunt, a continuous murmur, similar to the murmur of PDA, is audible over the precordium (rather than in the left infraclavicular area). The ECG usually is normal but may show right ventricular hypertrophy (RVH) or left ventricular hypertrophy (LVH) if the fistula is large. Chest radiography shows a normal heart size.

**FIGURE 15-4** Aortogram showing coronary arteriovenous fistula in the distribution of the left circumflex artery (solid arrows). **A,** Anteroposterior projection. **B,** Lateral projection. The fistula empties through the coronary sinus (cs) and eventually into the right atrium (RA). The point of entry into the RA is marked by an open arrow. AO, aorta.
Echocardiographic studies usually suggest the sites and types of the fistulas. The presence of a massively dilated proximal portion of one coronary artery while the other coronary artery is of normal size suggests coronary artery or arteriovenous fistula. The dilatation is usually uniform. One can follow the course of the dilated coronary artery to its site of entry. The site of entry can usually be located with the help of color Doppler echocardiography by the detection of either continuous or diastolic high-velocity flow. Often selective coronary artery angiography is necessary for an accurate diagnosis before the intended intervention. If the flow through the fistula is large, then the chamber or vessel receiving the fistula will be dilated.

A tiny coronary artery fistula to the PA (coronary artery–to-PA fistula) that produces no symptom can only be detected incidentally by an echocardiographic study. Most children with this condition are asymptomatic. Spontaneous closure may occur in small fistulae. However, some patients may present with symptoms of dyspnea on exertion, increased fatigability, and possibly signs of high-output congestive heart failure. Rarely, adult patients may present with angina, palpitation, or signs of exercise-related coronary insufficiency.

Small fistulous connections in the asymptomatic patient may be monitored. For a moderate or large coronary artery fistula, transcatheter occlusion is reasonable using coils or other occluding devices. Elective surgery is indicated if not amenable to catheter occlusion. Using cardiopulmonary bypass, the fistula is ligated as proximal as can be done without jeopardizing flow in the normal arteries, and it is ligated near its entrance to the cardiac chamber. The surgical mortality rate is 0% to 5%.
Arteriovenous Fistula, Pulmonary

In this condition, the pulmonary arteries and veins communicate directly, bypassing the pulmonary capillary circulation. The fistulas may take the form of either multiple tiny angiomas (telangiectasis) or a large PA–to–pulmonary vein (PV) communication. About 60% of patients with pulmonary arteriovenous fistulas have hereditary hemorrhagic telangiectasis (Rendu-Osler-Weber syndrome), and 5% to 15% of patients with the syndrome have the fistula (see Table 2-1). Patients who have undergone a bidirectional Glenn operation are at risk of developing multiple pulmonary arteriovenous fistulas, although these malformations rarely occur after completion of a Fontan operation. This finding suggests that pulmonary circulation requires as yet undetermined hepatic factors, possibly vasoconstrictor prostaglandins, to suppress the development of arteriovenous malformations. Similarly, chronic liver disease can rarely be the cause of the arteriovenous fistula.

Desaturated systemic blood from the PAs reaches the PVs, bypassing the lung tissue, resulting in systemic arterial desaturation, cyanosis, and clubbing. The pulmonary blood flow and pressure remain unchanged, and there is no volume overload to the heart, unlike in systemic AV fistulas.

Physical examination may reveal cyanosis and clubbing. The peripheral pulses are not bounding. A faint systolic or continuous murmur may be audible over the affected lung in about 50% of patients. Polycythemia usually is present, and arterial oxygen saturation runs between 50% and 85%. Chest radiography shows normal heart size because there is no volume overload to the heart in pulmonary AV fistulas. One or more rounded opacities of variable size may be present in the lung fields. The ECG usually is normal. Occasional complications include stroke, brain abscess, rupture of the fistula with hemoptysis or hemothorax, and infective endocarditis.

The diagnosis can be made through contrast two-dimensional echocardiography by the appearance of microcavitations (bubbles) in the LA. In this technique, 4 to 10 mL of saline that has been agitated is injected into a peripheral vein while the appearance of bubbles in the atria is monitored. The bubbles appear first in the RA, and within 2 cardiac cycles, they appear in the LA. CT typically shows one or more enlarged arteries feeding a serpiginous or lobulated mass and one or more draining veins. Magnetic resonance imaging (MRI) has not been studied as much as CT in children. Pulmonary angiography remains the gold standard to determine the position and structure of abnormal vascular lesions in the lung before treatment.

Transcatheter occlusion is recommended for all symptomatic patients and for asymptomatic patients with discrete lesions with feeding arteries 3 mm or larger in diameter. Transcatheter occlusion has been proved to be effective with excellent long-term results. Diffuse microscopic pulmonary AV malformations are not amenable to transcatheter occlusion. Surgical resection of the lesions, with preservation of as much healthy lung tissue as possible, may be attempted in symptomatic children, but the progressive nature of the disorder calls for a conservative approach.
Systemic arteriovenous fistulas may be limited to small cavernous hemangiomas or may be extensive. In large AV fistulas, there is direct communication (either a vascular channel or angiomas) between the artery and a vein without the interposition of the capillary bed. The two most common sites of systemic arteriovenous fistulas are the brain and liver. In the brain, it is usually a large type occurring in newborns in association with a vein of Galan malformation. In the liver, either localized or generalized hemangioendotheliomas (densely vascular benign tumors) are more common than fistulous arteriovenous malformations. With a large fistula, because of decreased peripheral vascular resistance, an increase in stroke volume (with a wide pulse pressure) and tachycardia result, leading to increased cardiac output, volume overload to the heart, and even CHF.

Physical examination reveals a systolic or continuous murmur over the affected organ. An ejection systolic murmur may be present over the precordium because of increased blood flow through the semilunar valves. The peripheral pulses may be bounding during the high-output state but weak when CHF develops. A gallop rhythm may be present with CHF. Chest radiography may show cardiomegaly and increased pulmonary vascular markings with a large fistula. The ECG may show hypertrophy of either or both ventricles.

Most patients with large cerebral arteriovenous fistulas and CHF die in the neonatal period, and surgical ligation of the affected artery to the brain is rarely possible without infarcting the brain. Surgical treatment of hepatic fistulas is often impossible because they are widespread throughout the liver. However, hemangioendotheliomas often eventually disappear completely. Large liver hemangiomas have been treated with corticosteroids, aminocaproic acid, local radiation, or partial embolization, but the beneficial effects of these management options are not fully established. Catheter embolization is becoming the treatment of choice for many symptomatic patients with AV fistula.
Atrial Septal Aneurysm

An aneurysmal tissue is present in part or all of the atrial septum that shows phasic septal excursion (of 10–15 mm in an adult) protruding into either atria. Atrial septal aneurysm (ASA) is present in 4% of the neonate using a different criterion (of marked mobility of the atrial septum). The prevalence of ASA varies between 0.2% and 1.9% of normal adult patients and up to 8% to 15% of adult stroke patients by transesophageal echocardiographic studies. It is commonly associated with patent foramen ovale (PFO), and together they might play a role in cryptogenic stroke in adult patients. ASA may prove to be a cause of atrial arrhythmias in some patients. See the section on PFO later in this chapter for further discussion of PFO or ASA versus stroke.
Cervical Aortic Arch

In this rare anomaly, the aortic arch is elongated, usually into the neck above the level of the clavicle. The aortic arch is usually right-sided and sometime with the descending aorta on the left, producing an anatomical vascular ring. Sometimes it is associated with arch hypoplasia or abnormal branching of the arch (e.g., anomalous subclavian artery, separate origin of the internal and external carotid arteries, and common origin of both carotid arteries). Rarely, discrete aortic coarctation or stenosis or atresia of the left subclavian artery is seen.

Infants with this condition may present with stridor, dyspnea, or repeated lower respiratory infection, similar to the signs of vascular ring. In adults, dysphagia is a common presenting complaint. A pulsating mass with associated thrill is present in the right supraclavicular fossa. A presumptive diagnosis of cervical aortic arch is made by noting loss of femoral pulses during brief compression of the pulsating mass. Chest radiographs may show a wide upper mediastinum with absence of the aortic knob. Echocardiography, CT, and MRI may be diagnostic. However, an aortogram is often necessary to make an accurate diagnosis of the condition with arch vessel abnormalities.

Treatment is necessary if the cervical arch is complicated by arch hypoplasia; symptomatic vascular ring; or rarely, aneurysm of the cervical arch itself.
Isolated cleft of the mitral valve is a very uncommon defect. There is a cleft in the septal leaflet of the mitral valve, not associated with endocardial cushion defect (ECD). About two thirds of cases are associated with other cardiac defects such as VSD (50%), left ventricular outflow tract (LVOT) obstructive lesions including aortic stenosis (AS) and subaortic stenosis (40%), secundum ASD (20%), and others. About 60% of the patients have syndromes, including trisomy 21, CHARGE association (see Table 2-1), heterotaxia, and others.

On the parasternal view of two-dimensional echocardiography, the cleft is seen in the septal mitral leaflet, directed toward the LVOT (11 o’clock direction) and associated with a varying degree of MR. This contrasts with the cleft associated with ECD that is directed toward the inlet (or posterior) septum (9 o’clock direction) in the same view.

More than half of these patients required surgical repair of the cleft because of an increasing severity of MR. During surgery, the cleft is usually buttressed by means of a Kaye anuloplasty or an anuloplasty band, depending on the age of the patient (Zhu et al, 2009).
Common Atrium (or Single Atrium)

In common atrium (single atrium, cor triloculare biventriculare), either the atrial septum is completely absent or only the vestigial element of a poorly developed atrial septum is present. This is a form of ECD with cleft mitral valve. Patients with asplenia syndrome (with other complex heart defects) have common atrium. This condition is also commonly seen with Ellis-van Creveld syndrome (see Table 2-1).

Symptoms may include shortness of breath and easy fatigability. Occasional infants may be critically ill with heart failure. Cyanosis varies from obvious to very mild, presenting only with exertion. The ECG shows left anterior hemiblock (“superior QRS axis”), as in ECD, and an rsR′ pattern in the right precordial leads, as in ASD. Surgery should be performed early in life because the patients usually have symptoms and are at risk for developing pulmonary vascular obstructive disease. Successful creation of a polyvinyl septum is possible.
Cor Triatriatum

Cor triatriatum is a rare congenital cardiac anomaly in which the LA is divided into two compartments by an abnormal fibromuscular septum with an opening (Fig. 15-5, A), producing varying degrees of obstruction of pulmonary venous return. Pulmonary venous and pulmonary arterial hypertension may result. Embryologically, this condition results from failure of incorporation of the embryonic common PV into the LA. Therefore, the upper compartment (accessory LA) is a dilated common PV, and the lower compartment is the true LA. Hemodynamic abnormalities of this condition are similar to those of mitral stenosis in that both conditions produce pulmonary venous and pulmonary arterial hypertension (see Chapter 10).

Important physical findings include dyspnea, basal pulmonary crackles, a loud S2, and a nonspecific systolic murmur. The ECG shows right-axis deviation and severe RVH and occasional right atrial hypertrophy. Chest radiography shows evidence of pulmonary venous congestion or pulmonary edema, a prominent PA segment, and right-sided heart enlargement. Echocardiography demonstrates a linear structure within the LA cavity (see Fig. 15-5, B). Surgical correction is always indicated. Pulmonary hypertension regresses rapidly in survivors if the correction is made early.
Double-chambered RV (anomalous muscle bundle of the RV) is characterized by aberrant hypertrophied muscle bands that divide the RV cavity into a proximal high-pressure chamber and a distal low-pressure chamber. In the majority of patients, VSD or pulmonary valve stenosis is also present.

Clinical manifestations closely resemble those of pulmonary valvular or infundibular stenosis: a loud, grade 3 to 5 of 6 ejection systolic murmur along the upper and mid-left sternal border is present. Two-dimensional echocardiography is usually diagnostic in this lesion. The anomalous muscle bundle can be visualized best from either the subcostal or parasternal view. Color-flow Doppler assesses the severity and identifies the site of the obstruction. MRI may provide the same information as two-dimensional echocardiography. Cardiac catheterization and right ventriculogram should be performed before any intervention. Surgical resection of the bundle, as well as repair of other anomalies, is usually indicated as soon as the diagnosis is made.

**FIGURE 15-5** Cor triatriatum. **A**, Diagram of cor triatriatum. **B**, Subcostal four-chamber view of an echocardiogram demonstrating a membrane (small arrows) in the left atrium (LA). AO, aorta; LV, left ventricle; PA, pulmonary artery; PV, pulmonary vein; RA, right atrium; RV, right ventricle; VC, vena cava.
Ectopia Cordis

In this extremely rare condition, the heart is partially or totally outside the thorax. Most reported cases of ectopia cordis are either thoracic (60%) or thoracoabdominal (40%); rarely, a case may be cervical or abdominal. The thoracic type is characterized by a sternal defect, absence of the parietal pericardium, cephalic orientation of the cardiac apex, epigastric omphalocele, and a small thoracic cavity. The thoracoabdominal type has partial absence or cleft of the lower sternum, an anterior diaphragmatic defect through which a portion of the ventricle protrudes into the abdominal cavity, a defect of the parietal pericardium, and an omphalocele. Intracardiac abnormalities are very common but not invariable; ASD, VSD, TOF, and tricuspid atresia are the most common intracardiac defects. One reported case of the abdominal type (1806) was a healthy French soldier, the father of three children, who died of pyelonephritis.

The treatment and prognosis of the defect are determined by the location of the defect, the extent of the cardiac displacement, and the presence or absence of intracardiac anomalies. Simple sternal cleft with minimal cardiac protrusion can be successfully treated in early infancy. However, in more severe cases, most surgical efforts to put the heart into the thorax have failed because of the smallness of the thorax and kinking of the blood vessels. Patients without omphalocele or intracardiac defects may remain largely asymptomatic and can undergo surgical repair later in childhood.
In hemitruncus arteriosus (origin of one PA from the ascending aorta), one of the PAs, usually the right PA, arises from the ascending aorta (Fig. 15-6). Associated defects such as PDA, VSD, and TOF are occasionally present. Hemodynamically, one lung receives blood directly from the aorta, as in PDA, with resulting volume or pressure overload, and the other lung receives the entire RV output, resulting in volume overload of that lung. Therefore, pulmonary hypertension of both lungs develops. CHF develops early in infancy, with respiratory distress and poor weight gain. A continuous murmur and bounding pulses may be present. The ECG shows BVH, and chest radiography shows cardiomegaly and increased pulmonary vascular markings.

![Aortogram showing the right pulmonary artery (large arrow) originating anomalously from the ascending aorta (AO) and coronary arteries (small arrows).](image)

**FIGURE 15-6** Hemitruncus. Aortogram showing the right pulmonary artery (large arrow) originating anomalously from the ascending aorta (AO). Coronary arteries are also opacified (small arrows).

Definitive diagnosis is made by echocardiography, angiography, or other imaging modalities. Cardiac catheterization is needed to define the anatomy and assess pulmonary vascular resistance. Early surgical correction (anastomosis of the anomalous PA to the main PA) is indicated.
In idiopathic dilatation of the PA (congenital pulmonary insufficiency), pulmonary regurgitation is present in the absence of pulmonary hypertension in asymptomatic children or adolescents. Many regard this as a very mild pulmonary valve stenosis with resulting poststenotic dilatation but subsequent loss of pressure gradient across the pulmonary valve.

A characteristic auscultatory finding is a grade 1 to 3 of 6 low-frequency, decrescendo diastolic murmur at the upper and mid-left sternal borders. The S2 is normal. The ECG usually is normal, but occasional right bundle branch block is present. Chest radiography shows a prominent main PA segment with normal peripheral pulmonary vascularity. Echocardiographic studies reveal a poststenotic dilatation of the main PA and varying degree of pulmonary regurgitation with little or no pressure gradient across the pulmonary valve but with a whirling of blood flow in the PA. The prognosis is generally good, but right-sided heart failure may occur in adult life.
Kartagener’s Syndrome

Kartagener’s syndrome consists of the triad of situs inversus (with dextrocardia), paranasal sinusitis, and bronchiectasis. This disorder is inherited as an autosomal recessive trait; males and females are affected with equal frequency. The dextrocardia is a mirror image of normal and is functionally normal. Bronchiectasis is believed to result from a functional defect of the mucociliary epithelium with immotility of the cilia. In addition, affected males are infertile as a result of immobile spermatozoa.
Parachute Mitral Valve

Parachute mitral valve is a severe form of congenital mitral valve stenosis. In this anomaly, all chordae tendineae are thickened and shortened, and they attach to a single posteriorly located papillary muscles, producing severe mitral stenosis. The anterior papillary muscle is usually absent. The diagnosis can be suspected by two-dimensional echocardiography on the parasternal views. In the parasternal short-axis view, only one papillary muscle is imaged. Commonly associated conditions include supramitral ring, subvalvular or valvular AS and COA or the complete “Shone complex,” which is the combination of all or some of these abnormalities.
Patent Foramen Ovale

Patent foramen ovale is a tunnel between the septum secundum and the superior margin of the septum primum. The septum secundum is a thick, concave, muscular structure that expands from the posterosuperior wall and partially partitions the atria. The septum primum, a thin flap, extends from inferiorly and makes a tunnel. During fetal life, the tunnel (foramen ovale) is open and allows a direct flow of inferior vena cava (IVC) blood into the LA, sending blood with higher oxygen saturation to the LA (and eventually to the brain and coronary circulation).

Postnatally, when the pressure in the LA exceeds that in the RA as the result of lung expansion, and resulting increase in pulmonary venous return, the thin flap of the superior end of the septum primum is forced to shut against the septum secundum, thereby resulting in functional closure of the foramen. In most individuals, the foramen ovale is sealed shortly after birth, but for some reason, functional closure does not always occur, resulting in a small left-to-right atrial shunt detectable by color Doppler study. This condition is called “incompetent foramen ovale” (IFO) and is quite common in newborns, presenting in 75% of neonates. Probe patency of a competent foramen ovale is found in 25% of normal adults.

Patent Foramen Ovale Versus Stroke

There are controversies regarding the management of PFO, which has been proposed as a potential cause of cryptogenic stroke in adult patients. Some retrospective observational reports have shown a strong association (but not cause-and-effect relationship) between cryptogenic strokes and both PFO and ASA in adults. The prevalence of PFO was four times higher in stroke patients (40%) than in control participants (10%), and it was much higher (33 times) in patients with both PFO and ASA. Thus, paradoxical embolism via a PFO has been postulated as a possible cause of stroke. The proponents of the hypothesis of paradoxical embolization have advocated closing PFO for secondary prevention of stroke in patients with PFO and in high-risk adult patients without stroke.

However, some evidence casts doubts about this hypothesis, and thus the rationale of closing PFO to prevent recurrence of stroke remains controversial.
1. In these earlier observational studies, transient atrial fibrillation (with LA thrombus formation), emboli from aortic atherosclerotic plaques, and the hypercoagulable state were not ruled out (although the ability to rule out the hypercoagulable state is quite limited at this time).
2. Several recent studies (including a meta-analysis [Overell et al, 2000], a prospective case control study [Mas et al, 2001]), and a prospective population study [Meissner et al, 2006]) suggest that PFO alone does not appear to increase the odd ratio for stroke. ASA alone or in combination with PFO does not appear to substantially increase the odds ratio of stroke. In patients with isolated ASA (without PFO), paradoxical embolization cannot be the cause of stroke.
3. However, patients with ASA have been found to have a higher vulnerability to atrial fibrillation than those without it (Berthet et al, 2000). Atrial fibrillation, even a transient one, is a known cause of cardiogenic embolism.

4. Unless the RA pressure is elevated and frequent venous thrombus formation is demonstrated, hemodynamics do not favor paradoxical embolization in normal individuals with normal RA pressure.

Given these findings, the cause of stroke is more likely systemic embolization rather than paradoxical embolization through PFO; thus, closing of an isolated PFO may not be an effective or justifiable procedure for prevention of stroke. In fact, there is no evidence that closure of PFO (surgical or by device) is superior to medical management (aspirin, warfarin, or both) in preventing recurrence of strokes.

A recent guideline from the American Heart Association and American Stroke Association (Goldstein et al, 2006), which has been endorsed by the American Academy of Neurology, does not support closure of PFO for prevention of recurrent stroke at this time. Rather, it recommends antithrombotic therapy with aspirin or warfarin. PFO closure may be considered for patients with recurrent cryptogenic stroke despite medical therapy.

In the absence of convincing evidence for PFO as a cause of paradoxical embolization in adult patients and the absence of a superiority of PFO closure to medical therapy in adult patients, the rationale for closing PFOs in pediatric patients is at best controversial and may not be justified. It appears prudent to wait until this controversy is cleared before adopting the practice of closing PFOs in pediatric patients.
Pericardial Defect, Congenital

This rare congenital anomaly of the pericardium may be partial or complete. The majority of these cases occurs on the left side (85%), and they are more often complete (65%) than partial. About 30% to 50% of cases are associated with congenital anomalies of the heart (PDA, ASD, TOF, and mitral stenosis), lung, chest wall, or diaphragm. Pleural defect is almost always present.

Unless an associated cardiac anomaly is present, most patients are asymptomatic. Occasionally, a partial defect may produce chest pain, syncope, or systemic embolism secondary to herniation and strangulation of the left atrial appendage. A complete defect may produce vague positional discomfort in the supine or left lateral position.

Congenital pericardial defects are difficult to diagnose preoperatively. Occasionally, chest radiography may show a prominence of the left hilum or the PA caused by herniation of these structures through the partial defect. Complete absence of the left pericardium may be characterized by leftward displacement of the heart and aortic knob or a prominent PA. Echocardiography findings of complete absence of the left pericardium include an unusual cardiac hypermobility (cardioptosis), abnormal swing motion of the heart with each cardiac beat, and an abnormal systolic anterior motion of the ventricular septum (on M-mode). (These findings are similar to the echocardiographic findings of the transplanted heart, in which the donor heart is untethered and is placed in a large potential space.) Traditionally, the appearance of pneumopericardium after the introduction of air into the left pleural cavity was diagnostic. CT or MRI now permits better visualization of absence of the pericardium.

Surgical treatment is recommended only for symptomatic patients. Surgical procedures used in this condition include longitudinal pericardiotomy; partial pericardiectomy; primary closure; partial appendectomy (of the left atrial appendage); and pericardioplasty with pleural flaps, Teflon, or porcine pericardium.
Pseudocoarctation of the aorta is a condition in which the distal portion of the aortic arch and the proximal portion of the descending aorta are abnormally elongated and tortuous, with narrowing of the aortic isthmus but without significant obstruction. The elongation of the arch frequently produces an increased distance between the origin of the left common carotid and the left subclavian artery. Unlike cervical aortic arch, the aortic arch stays below the level of the clavicle. A variety of CHDs have been reported in association with pseudocoarctation. Physical examination and the ECG are normal when it is not associated with other cardiac defects.

Pseudocoarctation is not a benign entity as once believed because there is tendency for dilatation and aneurysm formation related to turbulent flow across the kink, and it may progress to show a substantial obstruction. Therefore, a close follow-up is required for asymptomatic patients who are without any associated anomalies. Cardiac catheterization (with measurement of pressure gradient) and angiography provide a definitive diagnosis for this condition. Similarly, CT is very helpful in the diagnosis. Surgical intervention may be required if dilatation compresses surrounding structures (e.g., esophagus), or aneurysm formation is present.
Pulmonary Artery Stenosis

Incidence
PA stenosis accounts for more than 3% of all CHDs.

Pathology
1. Stenosis of the PA occurs either at the main PA or in the peripheral pulmonary arteries. The most frequent site of stenosis is near the bifurcation as an isolated anomaly. More often it is seen with other CHDs such as valvular pulmonary stenosis, ASD, VSD, PDA, or TOF (in which 20% of the patients have associated peripheral PA stenosis).
2. When associated with cyanotic CHDs (e.g., pulmonary atresia with intact ventricular septum or TOF with pulmonary atresia), the stenosis usually involves multiple branches and multiple sites.
3. It may also be seen in association with other conditions such as rubella syndrome, Williams syndrome, and Alagille syndrome.
4. Some PA stenosis is secondary to surgical procedures, such as previous systemic-to-PA shunts.

Clinical Manifestation
1. Mild stenosis of the PAs causes no symptoms. If the stenosis is severe, the RV may hypertrophy.
2. An ejection systolic murmur grade 2 to 3 of 6 is audible at the upper left sternal border, with good transmission to the ipsilateral axilla and back. Occasionally, a continuous murmur is audible with severe stenosis. The S2 is either normal or more obviously split.
3. The ECG is normal with mild stenosis, but it shows RVH with severe stenosis.
4. Chest radiography findings usually are normal.
5. The echocardiogram may show stenosis in the main PA or near the bifurcation, but those in smaller branches cannot be imaged by echocardiography.
   a. Significant PA stenosis is clearly present when (1) there is measurable pressure gradient of greater than 20 to 30 mm Hg, (2) RV or main PA pressure is higher than 50% of systemic pressure, or (3) lung perfusion scan shows a relative flow discrepancy between two lungs of 35%/65% or worse. (The normal right-to-left perfusion ratio was found to be 52.5 to 47.5 [±2.1%] rather than the often quoted 55/45 split, which was found to be more than 1 standard deviation greater than the mean [Cheng et al, 2006].)
   b. Many significant stenoses may not be demonstrable by pressure gradient because of discrepant blood flow away from the stenotic area or because of low pulmonary flow situation (e.g., with Glenn shunt and Fontan circulation).
   c. Lung perfusion scintigraphy had been a useful noninvasive method for determining relative pulmonary flows. However, washout effects from additional blood supply to
the lung can make flow quantification inaccurate. Currently, MRI represents the gold standard for assessing differential blood flow to the lungs as derived by flow calculation in the branch pulmonary arteries. In patients with multiple previous stenting of the pulmonary tree, contrast-enhanced CT imaging is preferred. Angiocardiography is the best invasive tool in the diagnosis of peripheral PA stenosis.

**Management**

1. Mild to moderate PA stenosis usually does not require treatment, but severe cases require some form of treatment.
2. The central (extraparenchymal) type is surgically amenable but the peripheral (intraparenchymal) type is not correctable by surgery; catheter therapy is often the only option.
3. For peripheral PA stenosis, treatment modalities include the use of standard balloon angioplasty, a cutting balloon, and the placement of endovascular stent.
   a. Balloon angioplasty using low-pressure inflations has only a limited success rate, approximately 50%, with a 16% recurrence rate. Using high-pressure balloons (that can be inflated to 20–25 atm) appears to improve the effectiveness.
   b. Using cutting balloons: Vessels resistant to high-pressure balloon angioplasty respond to either cutting balloon angioplasty alone or that followed by high-pressure ballooning. These techniques are best suited for small, lobar PA branches not amenable to stenting. Cutting balloons have three or four microsurgical blades with a cutting depth of 0.15 mm, which are activated when the balloons are inflated.
   c. In contrast, stainless-steel balloon-expandable stents can overcome an obstruction, with an acute success rate close to 100% and a recurrence rate of only 2% to 3%. These stents are balloon dilatable to potential adult diameters of the vessel. This technique has become the primary mode of therapy for branch PA stenosis.
Pulmonary Vein Stenosis

Pulmonary vein stenosis is a very rare anomaly that can be either congenital (or “primary”) or acquired. The primary type is one that occurs without any inciting event, and the acquired type follows either a surgical or interventional procedure.

Congenital (“Primary”) Pulmonary Vein Stenosis

The congenital or “primary” form of stenosis can be isolated to a single PV but most often occurs in multiple veins simultaneously and the severity can be progressive, leading to partial or even total obstruction of flow. The stenosis can be a relatively discrete shelf, a longer segment of narrowing, or a diffuse hypoplasia of PVs. More than 50% of patients with PV stenosis have associated cardiac defects. On the other hand, nearly half of patients with PV stenosis have no associated cardiac anomalies (Latson et al, 2007). The disease may possibly be caused by abnormal proliferation of myofibroblasts in the PV.

Obstruction to pulmonary venous return results in pulmonary edema, pulmonary arterial hypertension, and increased pulmonary vascular resistance, similar to mitral stenosis. The number and severity of the stenosis of the PVs involved determine the timing and severity of symptoms. Most patients with the primary form of the disease present early in infancy with a history of significant respiratory symptoms (with tachypnea and recurrent pneumonias). If only one or two veins are involved, the manifestation may be delayed or the patient may remain asymptomatic for a long time. As the disease progresses, signs of pulmonary hypertension appear. Chest radiography may show localized or diffuse pulmonary edema depending on the number of PVs involved. Hemothypsis may develop in older surviving children.

Diagnosis

Signs of pulmonary hypertension in the absence of a readily recognizable cause should raise the possibility of PV stenosis (Latson et al, 2007).

1. Echocardiographic study can visualize all PVs in nearly all patients. The finding of turbulent flow on color Doppler should raise the suspicion of PV stenosis. Monophasic flow or flow velocities above 1.7 m/sec indicate functionally significant stenosis. Normally, early diastolic flow velocity is less than 1 m/sec, and systolic flow velocity is much less than that.
2. MRI has been shown to be very useful in evaluation of PVs, although its applicability is limited by long acquisition time.
3. Multidetector CT angiography is an excellent technique for detailed analysis of the PVs.
4. Angiography provides the most selective detailed views of the PVs. It can be done by selective injection of contrast dye into the major branch or small branches of the PA.
5. Radionuclide imaging may demonstrate reduced flow to the affected portion of the
lung that drains by affected PV(s).

**Treatment and Prognosis**

The prognosis is exceedingly poor in patients with involvement of most or all of the PVs, and long-term survival is rare without treatment. Most of the death is caused by pulmonary hypertensive crisis. Patients with only one or two PVs involved have much more benign courses. Patients with involvement of only one PV survive much longer.

Surgical as well as catheter intervention have a uniformly bad long-term outcome. Surgery can widen the narrowed veins, and interventional procedures can stretch the vessels, but the result is usually short-term solution because the stenosis typically recurs within 1 month to 6 weeks.

1. **Surgical relief of stenosis by various techniques (including so-called sutureless techniques) has not improved survival significantly because of progression of the disease. Only 50% of patients survive for 5 years after surgery.**
2. **Catheter intervention offers only limited success. Balloon angioplasty with low-pressure dilatation follows quick recurrence in most of the patients. High-pressure balloon angioplasty or angioplasty with a cutting balloon may offer a better result. Use of stent has reported no better medium- or long-term results than cutting balloon angioplasty.**
3. **Pneumonectomy may be necessary for hemoptysis.**
4. **Lung transplantation can be an option in selected patients.**
5. **Use of chemotherapy drugs, such as Avastin or Gleevec (alone or in conjunction, depending on the child’s specific disease) is in experimental stage, which may inhibit proliferation of myofibroblast.**

**Acquired Pulmonary Vein Stenosis**

Pulmonary vein stenosis may be secondary to surgery for anomalous pulmonary venous return. Significant stenosis of the PVs occurs in about 10% of patients after surgical repair of total anomalous pulmonary venous return. Rare causes of PV stenosis in adults include neoplasm growth, sarcoidosis, and fibrosing mediastinitis. The most common cause of PV stenosis in adults is radiofrequency ablation procedures done for treatment of atrial fibrillation. These patients usually present with shortness of breath.

In adults, balloon angioplasty of the involved vessels usually leads to a reasonably good initial result, but restenosis occurs in more than 50% of patients within 1 year. Use of cutting balloon angioplasty and further dilatation of stents has been successful in some cases. Use of drug (paclitaxel or zotarolimus)-eluting stents is gaining experience in adult patients with the condition; it appears to offer an excellent stent patency rate (De Potter et al, 2011).
Scimitar Syndrome

All or some of the PVs from the lower lobe and sometimes the middle lobe of the right lung drain anomalously into the IVC, either just above or below the diaphragm. The appearance of chest radiography resembles a curved Turkish sword, a scimitar, with vertical radiographic shadow along the lower right cardiac border.

In symptomatic infants, associated anomalies (e.g., ASD, PDA, hypoplasia of the right lung and right PA, pulmonary venous obstruction, sequestration of right lung tissue receiving arterial supply from the aorta) are frequent. Left-sided obstructive lesions (e.g., hypoplastic LV, subaortic stenosis, aortic arch obstruction) also are frequently present. Anomalous systemic arterial supply originates in the descending aorta, usually supplies the right lung, and rarely supplies the left lung (pulmonary sequestration). Dextrocardia or mesocardia also is frequently found secondary to hypoplasia of the right lung.

For symptomatic infants, embolization or ligation of the systemic arterial supply to the right lung, if present, may result in improvement of pulmonary hypertension and signs of CHF. In infants with associated ASD, a pericardial tunnel of synthetic patch may be used to direct flow from the scimitar vein through the RA and into the LA. For most symptomatic infants with additional associated defects, the surgical mortality rate is high (up to near 50%).

Children and adults with the syndrome are either minimally symptomatic or asymptomatic, probably because they have a low incidence of associated anomalies. For older children, the anomalous pulmonary venous return can be redirected to the LA, but in patients with associated pulmonary sequestration, the involved lobes of the right lung may need to be resected. In selected older children and adult patients, the anomalous pulmonary venous return can be connected to the LA through a right thoracotomy without the use of cardiopulmonary bypass (Schwill et al, 2010).
A wide variety of abnormalities appears in the systemic venous system; some of these have little physiologic importance, and others produce cyanosis. Recent developments in the diagnosis and treatment of cardiovascular disorders have brought these anomalies to the attention of cardiologists and thoracic surgeons. Some of these abnormalities produce difficulties in the manipulation of catheters during cardiac catheterization, and preoperative knowledge of systemic venous anomalies is important in cardiac surgery. Therefore, the search for common abnormalities of the systemic veins has become routine in the evaluation of pediatric cardiac patients during echocardiographic and cardiac catheterization.

Two well-known anomalies of systemic veins are persistent left superior vena cava (SVC) and infrahepatic interruption of the IVC with azygos continuation. Rarely, either a persistent left SVC or interrupted IVC drains into the LA, producing cyanosis.

**Anomalies of the Superior Vena Cava**

Persistent left SVC occurs in 3% to 5% of children with CHDs. The persistent left SVC is connected to the RA in 92% of cases and to the LA (producing cyanosis) in the remainder.

**Persistent Left Superior Vena Cava Draining into the Right Atrium**

In the most common type, the left SVC is connected to the coronary sinus (Fig. 15-7, A). As a rule, persistent left SVC is part of a bilateral SVC, but rarely the right SVC is absent (see Fig. 15-7, B). A bridging innominate vein is present in 60% of cases.

Isolated persistent left SVC (see Fig. 15-7) does not produce symptoms or signs. Cardiac examination is entirely normal. Chest radiography may show the shadow of the left SVC along the upper left border of the mediastinum. A high prevalence of leftward P axis (+15 degrees or less) has been reported on the ECG. Imaging of a enlarged coronary sinus is often the first clue to the diagnosis of persistent left SVC. Echocardiographic
Persistent Left Superior Vena Cava Draining into the Left Atrium

Rarely (in 8% of cases), a persistent left SVC drains into the LA, resulting in systemic arterial desaturation (Figs. 15-7, C and D). This is due to failure of invagination between the left sinus horn and LA; therefore, the coronary sinus is absent. Associated cardiac anomalies almost invariably are present. Complex defects, such as cor biloculare, conotruncal abnormalities, and asplenia syndrome, are commonly found. Defects of the atrial septum (single atrium, secundum ASD, primum ASD) are also frequently found.

Clinical manifestations are dominated by the associated complex cardiac defects. In the absence of complex defects, cyanosis is more marked when there is no atrial communication (see Fig. 15-7, C) than when there is an ASD. When there is an ASD (see Fig. 15-7, D), clinical findings resemble those of ASD with left-to-right shunt, with only mild arterial desaturation. Echocardiographic study with color-flow mapping usually provides an adequate diagnosis. MRI is increasingly used to establish the diagnosis of the condition. Cardiac catheterization and selective left SVC angiography establish the diagnosis.

Surgical correction is necessary. When there is an adequate-size bridging vein that connects two SVCs, simple ligation of the left SVC is performed. If the right SVC is absent or a bridging vein is inadequate, the left SVC is transposed to the RA.

Anomalies of the Inferior Vena Cava

Many abnormalities in the formation of the IVC have been reported. Among the significant anomalies are infrahepatic interruption of the IVC with azygos continuation and anomalous drainage of the IVC into the LA, producing cyanosis (Fig. 15-8).

Interrupted IVC with azygos continuation (see Fig. 15-8, A) has been reported in about 3% of children with CHDs. The IVC below the level of the renal veins is normal, but the hepatic portion of the IVC is absent. Instead of receiving the hepatic veins and entering the RA, the IVC drains via an enlarged azygos system into the right SVC and eventually to the RA. The hepatic veins connect directly to the RA. Bilateral SVC also is common. Azygos continuation of the IVC often is associated with complex cyanotic heart defects, such as polysplenia syndrome, double-outlet RV, cor biloculare, and anomalies of pulmonary venous return. Less often, a simple cardiac defect is associated. No case has been reported in association with asplenia syndrome. This defect creates difficulties during cardiac catheterization and can complicate surgical correction of an underlying cardiac defect. This condition is readily diagnosed by echocardiographic studies as well as by MRI. No specific treatment of this condition is indicated.
**FIGURE 15-8**  Schematic diagram of selected abnormalities of the inferior vena cava (IVC).  

A, Interrupted IVC with azygos continuation, the most common abnormality of the IVC. The hepatic veins (HVs) connect directly to the right atrium (RA).  

B, Right IVC draining into the left atrium (LA).  

C, Absence of the lower right IVC. The IVC drains into the LA through the left superior vena cava (SVC), and the RA drains through the hepatic portion of the IVC.  

D, Complete absence of the right IVC with communicating vein draining to the azygos vein. L, liver.  

**IVC connecting to the LA** (see Fig. 15-8, B) is an extremely rare condition in which the IVC receives the hepatic veins, curves toward the LA, and makes a direct connection with the chamber. Pathologic persistence of the eustachian valve can result in a clinically similar situation in which a membrane completely excludes the IVC from the RA, with the IVC blood shunted to the LA through either an ASD or a PFO.  

Two other extremely rare cases of IVC abnormalities are shown in Figure 15-8. In one of them, the lower end of the right IVC is absent, and the dominant left IVC drains into the LA (producing cyanosis) through the (left-sided) hemiazygos system and persistent left SVC (see Fig. 15-8, C). In the other case, the lower end of the right IVC is absent, and the left IVC drains through the (right-sided) azygos system (see Fig. 15-8, D).
Vascular Ring

Prevalence
Vascular ring reportedly represents less than 1% of all congenital cardiovascular anomalies, but this may be an underestimate because some conditions are asymptomatic.

Pathology
Vascular ring refers to a group of anomalies of the aortic arch that cause respiratory symptoms or feeding problems. A rare anomaly of the left pulmonary artery L(PA) that causes symptoms is also included in this group, although it does not involve the aortic arch. The vascular ring may be divided into two groups, complete (or true) and incomplete.

1. **Complete vascular ring** refers to conditions in which the abnormal vascular structures or their remnants form a complete circle around the trachea and esophagus. Double aortic arch and right aortic arch with left ligamentum arteriosum are examples of complete vascular ring.

2. **Incomplete vascular ring** refers to vascular anomalies that do not form a complete circle around the trachea and esophagus but do compress the trachea or esophagus. These include anomalous innominate artery, aberrant right subclavian artery, and anomalous left PA (“vascular sling” or “pulmonary sling”).

Five major vascular rings will be discussed in this chapter.

1. **Double aortic arch** is the most common vascular ring (40%) (Fig. 16-1). This anomaly is caused by a failure of regression of both the right and left fourth branchial arches, resulting in right and left aortic arches, respectively. These two arches completely encircle and compress the trachea and esophagus, producing respiratory distress and feeding problems in early infancy. The right arch gives off two arch vessels, the right common carotid and the right subclavian arteries, and the left arch gives off the left common carotid and left subclavian arteries (see Fig. 16-1). The right aortic arch is usually larger than the left arch (seen in 75% of patients), but on rare occasions, partial obstruction or complete atresia of the left arch (with a ligamentous remnant) may occur. Double aortic arch is commonly an isolated anomaly but is rarely associated with a variety of congenital heart defects (CHDs) such as transposition of the great arteries, ventricular septal defect (VSD), persistent truncus arteriosus, tetralogy of Fallot (TOF), and coarctation of the aorta (COA).

2. **Right aortic arch with left ligamentum arteriosum**. One of the major components of most vascular rings is a right aortic arch. Vascular ring with a right arch with left ligamentum arteriosum has several different forms; two common types are described here. Although rare, right aortic arch may occur without forming a vascular ring if the
aorta stays and descends on the right of the vertebrae.

a. In the most frequent form of vascular ring with right aortic arch with left ligamentum arteriosum (occurring in ≈65% of cases), the right arch first gives off the left carotid artery, then the right carotid artery followed by the right subclavian artery, and last, the left subclavian artery (see Fig. 16-1). The aberrant left subclavian artery often arises from a retroesophageal diverticulum (called diverticulum of Kommerell). The ring is completed by a left-sided ductus arteriosus (or its remnant ligamentum arteriosum) passing from the subclavian artery to the proximal LPA (see Fig. 16-1). The descending aorta usually courses to the left of the vertebral column to pass through the diaphragm in the usual location of the aortic hiatus. About 10% of this type of vascular ring is associated with an intracardiac defect.

<table>
<thead>
<tr>
<th>Anatomy</th>
<th>Ba-Esophag.</th>
<th>Chest Film</th>
<th>Symptoms</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Double aortic arch</td>
<td>PA lat Post.</td>
<td>Anterior compression of trachea</td>
<td>Respiratory difficulties in early infancy Swallowing dysfunction</td>
<td>Surgical division of a smaller arch</td>
</tr>
<tr>
<td>Right aortic arch with left ligamentum arteriosum</td>
<td>Aber. rt. subclav. Mirror-image</td>
<td>Right aortic arch</td>
<td>Mild respiratory difficulties in infancy Swallowing dysfunction</td>
<td>Surgical division of left lig. arteriosum</td>
</tr>
<tr>
<td>Anomalous innominate artery</td>
<td>Normal</td>
<td>Anterior compression of trachea</td>
<td>Stridor or cough in infancy</td>
<td>Conservative management Surgical suturing of the artery to the sternum (±)</td>
</tr>
<tr>
<td>Aberrant right subclavian artery</td>
<td></td>
<td></td>
<td>Occasional swallowing dysfunction</td>
<td>Usually no treatment is necessary</td>
</tr>
<tr>
<td>“Vascular sling”</td>
<td></td>
<td>Right-sided emphysema or atelectasis Posterior compression of trachea</td>
<td>Wheezing and cyanotic episodes since birth</td>
<td>Surgical division of the anomalous LPA (from the RPA) and anastomosis to the MPA</td>
</tr>
</tbody>
</table>

As a rare variant of this type, an aberrant innominate artery, rather than subclavian artery, may arise from the upper descending, and the ligamentum arteriosum connects the base of the innominate artery and the proximal left PA completing a vascular ring. Clinical manifestations are similar to the one described above.

b. In the second type of vascular ring with right aortic arch and ligamentum arteriosum (occurring in ≈35%), the left innominate artery originates from the right arch in mirror image fashion as the first branch followed by the right carotid and right subclavian arteries. A left-sided ductus or ligamentum arteriosum passes between the descending aorta and the proximal LPA (see Fig. 16-1). More than 90% of patients with this type of vascular ring have associated intracardiac defects, notably TOF and truncus arteriosus.
3. Anomalous innominate artery occurs in about 10% of patients with vascular ring (see Fig. 16-1). If the innominate artery takes off too far to the left from the aortic arch or more posteriorly, it may compress the trachea, producing mild respiratory symptoms. This anomaly is commonly associated with other congenital heart defects such as VSD.

4. Aberrant right subclavian artery is the most common arch anomaly (accounting for 0.5% of the general population, but its true incidence may be higher if asymptomatic patients are included). Most cases are asymptomatic. When the right subclavian artery arises independently from the descending aorta, it courses behind the esophagus, compressing the posterior aspect of the esophagus and producing mild feeding problems (Figs. 16-1 and 16-2). Often, a larger compression is found behind the esophagus by an aortic diverticulum at the take-off of the right subclavian artery. This anomaly usually is an isolated anomaly, but it has a high association with coarctation of the aorta or interrupted aortic arch. Its incidence is very high (38%) in patients with Down syndrome with CHDs.

5. Anomalous left PA (also called “vascular sling”) is a rare anomaly in which the left PA arises from the right PA (Figs. 16-1 and 16-3). To reach the left lung, the anomalous artery courses over the proximal portion of the right mainstem bronchus, behind the trachea, and in front of the esophagus to the hilum of the left lung. Therefore, both respiratory symptoms and feeding problems (e.g., coughing; wheezing; stridor; episodes of choking, cyanosis, or apnea) may occur. About 10% to 20% of patients with this anomaly have associated cardiac defects, such as patent ductus arteriosus, VSD, atrial septal defect (ASD), atrioventricular canal, single ventricle, or aortic arch anomalies.
Clinical Manifestations

History

1. Inspiratory stridor and feeding problems of varying severity are present, beginning at different ages. In double aortic arch, symptoms tend to appear in the newborn period or in early infancy (before 3 months of age), and they are more severe than those in right aortic arch with left ligamentum arteriosum. Symptoms often are made worse by feeding. Affected infants frequently hyperextend their necks to reduce tracheal compression.

2. Respiratory symptoms or feeding problems are milder with incomplete forms of vascular ring than with the complete form.

3. A history of pneumonia frequently is elicited.

4. A history of atelectasis, emphysema, or pneumonia of the right lung is found with “vascular sling.”

Physical Examination

1. Physical examination is not revealing except for a varying degree of rhonchi when the vascular ring is an isolated anomaly.

2. Cardiac examination is usually normal except in about 25% of patients in whom
associated cardiac anomalies are present.

**Electrocardiography**
The electrocardiography findings are normal unless the vascular ring is associated with other CHDs.

**Diagnosis**
The diagnosis of vascular ring is accomplished by using the following imaging techniques; some are routinely available and others are specialized.

1. **Chest radiography:** Because patients usually present with symptoms of respiratory difficulty, chest radiography is always the first and most commonly performed test.
   a. One looks for right aortic arch. In right aortic arch, the trachea is deviated to the left of the midline rather than to the right as seen in the presence of a normal left arch. If a right aortic arch is identified, a vascular ring is highly likely. If only a left arch is identified, a vascular right is much less likely but not excluded.
   b. An ill-defined aortic arch location is often observed in patients with double aortic arch.
   c. With the complete form of vascular ring, compression of the air-filled trachea may be visible on posteroanterior or lateral chest radiography.
   d. Aspiration pneumonia may be present. Hyperinflation or atelectasis of the right lung may be a suggestive sign of anomalous LPA ("vascular sling").

2. **Barium esophagography:** If plain chest radiography suggests vascular rings, barium esophagography is the next logical step, which is usually diagnostic of most vascular rings (see Fig. 16-1). Patients with normal esophagography findings do not have a significant vascular ring.
   a. In double aortic arch, two large indentations are present in both sides (with the right one usually larger) on the posteroanterior view, and a large posterior indentation is seen on the lateral view (see Fig. 16-1).
   b. In right aortic arch with left ligamentum arteriosum, a large right-sided indentation and a much smaller left-sided indentation are present. A posterior indentation, either small or large, also is present on the lateral view. A large posterior indentation suggests the presence of diverticulum of Kommerell (see Fig. 16-1).
   c. In aberrant right subclavian artery, there is a small oblique indentation extending toward the right shoulder on the posteroanterior view. There is a small posterior indentation on the lateral view (see Figs. 16-1 and 16-2). Indentations may be large if the compression is made by an aortic diverticulum.
   d. In "vascular sling," an anterior indentation of the esophagus seen in the lateral view at the level of the carina is characteristic. This is the only vascular ring that produces an anterior esophageal indentation (see Fig. 16-1). A right-sided indentation usually is seen on the posteroanterior view. The right lung is either hyperlucent or atelectatic with pneumonic infiltrations.
   e. Barium esophagography findings are normal in anomalous left innominate artery.
3. **Echocardiography and color-flow Doppler**: Echo and color-flow Doppler studies are very helpful, both for diagnosing vascular ring and for excluding associated intracardiac defects. One should perform a careful segmental investigation of the aortic arch and arch vessels. The suprasternal notch views are especially useful in establishing the diagnosis. However, there are limitations to echocardiographic study in the diagnosis of vascular ring. Structures without a lumen, such as a ligamentum arteriosum or an atretic arch, have no blood flow and are difficult to identify with color-flow echocardiography. Also, identification of compressed midline structures and their relationship to encircling vascular anomalies is difficult to detect with echo studies.

4. **Computed tomography (CT) scan, magnetic resonance imaging (MRI), and digital subtraction angiography**: These radiologic studies are often used in the diagnosis of vascular rings and may eliminate the need for invasive aortography.
   - CT and MRI are useful diagnostic tools because they reveal not only the position of vascular structures but also of the tracheobronchial and esophageal structures and their relationships to the vascular structures. These studies do not show ligamentum arteriosum either. MRI has been proposed as an excellent substitute for angiography.
   - These radiologic techniques have advantages and disadvantages. The major advantage of CT is the rapidity with which data can be acquired, in many cases without the need for sedation. Its disadvantage is the use of radiation and need for intravenous contrast media. MRI, on the other hand, does not use radiation or iodinated intravenous contrast media but does have longer imaging times, requiring sedation in most pediatric patients; sedation may be particularly risky in young children with airway obstruction, and general anesthesia with intubation might be required.

5. **Aortic angiography and cardiac catheterization**: In the past, diagnostic aortography was performed in delineating anomalous arch vasculatures. However, it is more invasive and does not have tomographic or multiplanar capability. Echo with color Doppler studies, CT, or MRI can usually provide the required information before surgery. Therefore, when a choice is available, MRI and CT angiography are preferable for detailed diagnosis and preoperative assessment.

6. **Tracheography and bronchoscopy** usually add little information and may be hazardous in some patients. However, these tests may be useful in delineating tracheobronchial malacia associated with vascular ring in some patients.

### Management

#### Medical

1. Asymptomatic patients need no surgical treatment even when the anomalies are found incidentally.
2. Medical management for infants with mild symptoms includes careful feeding with soft foods and aggressive treatment of pulmonary infections.
Surgical

Indications and Timing
Respiratory distress and a history of recurrent pulmonary infections and apneic spells are indications for surgical intervention. The timing of surgery depends on the severity of symptoms, and surgery may be performed during infancy.

Procedures and Mortality Rate

1. **Double aortic arch**: Division of the smaller of the two arches (usually the left) is performed through a left thoracotomy. Knowing which arch is the dominant arch is very important because thoracotomy is typically performed on the side of the nondominant arch. The surgical mortality rate is less than 5%.

2. **Right aortic arch and left ligamentum arteriosum**: Ligation and division of the ligamentum are performed through a left thoracotomy. If a Kommerell diverticulum is found, the diverticulum is resected, and the left subclavian artery is transferred to the left carotid artery. The mortality rate is less than 5%.

3. **Anomalous innominate artery**: Through a right anterolateral thoracotomy, the innominate artery is suspended to the posterior sternum. Asymptomatic patients do not require surgery; only 10% of the patients with the anomaly require surgery.

4. **Aberrant right subclavian artery**: Surgical interruption of the aberrant artery is performed rarely only in symptomatic patients with dysphagia. The procedure consists of division of the aberrant artery and translocation to the right common carotid artery.

5. **Anomalous LPA**: Surgical division and reimplantation of the left PA to the main PA is performed, usually through a median sternotomy and with the use of cardiopulmonary bypass. The surgical mortality rate is near 0%.

Complications
In infants who have had surgery for severe symptoms, airway obstruction may persist for weeks or months. Careful respiratory management is required in the postoperative period. A period of months to 1 year may be required before disappearance of the noisy respiration, which is caused by preexisting tracheomalacia. This fact should be anticipated and clearly explained to the parents preoperatively. This complication is more likely in patients who have had double aortic arch, vascular sling, or right aortic arch with left ligamentum arteriosum.

Variants of Aortic Arch Branching
Although the most common aortic arch branching pattern is three-vessel branching pattern in humans, up to about 30% of patients have a two-vessel branching pattern, which is a normal variant. The two-vessel branching pattern has incorrectly been called the “bovine aortic arch” in humans. True bovine aortic arch branching has no resemblance to the two-vessel branching patterns seen in humans. Thus, the use of
misnomers such as “bovine arch” should be avoided. Instead, one should use descriptive branching patterns as described below or simply call it a two-vessel branching pattern if further branching information is not known (Layton et al, 2006).

The following describes standard aortic arch branching and its normal variants in humans (Fig. 16-4).

1. The most common aortic arch branching pattern (standard aortic arch branching) in humans consists of three great arteries originating from the aortic arch. The first branch is the innominate artery, the second one the left common carotid artery, and the third one the left subclavian artery (Fig. 16-4, A). This pattern is present in about 70% of patients.

2. A common variant of the standard aortic arch is the one in which two great arteries originate from the aortic arch. This occurs in about 30% of patients, more commonly observed in Africans. In one group of these patients, the innominate artery and the left carotid artery share the common trunk, which occurs in about 13% of patients (correctly described as “common origin of the innominate artery and left common carotid artery”) (Fig. 16-4, B). In the other group of the two-vessel branching variant, the left common carotid artery branches from the innominate artery (rather than sharing the common trunk). This variant occurs in about 9% of patients (correctly described as “origin of the left carotid artery from the innominate artery”) (Fig. 16-4, C).

![FIGURE 16-4 Variants in the aortic arch branching pattern in humans and the bovine aortic arch.](image)


In the true bovine aortic arch, there is only one great artery originating from the arch. It has no resemblance to any of the branching patterns seen in humans. The single trunk, called the “brachiocephalic trunk,” gives rise to both subclavian arteries and a bicarotid trunk. The bicarotid trunk then bifurcates into the left and right common carotid arteries (Fig. 16-4, D).
In this chapter, clinical methods of locating cardiac chambers using chest radiography, electrocardiography (ECG), and echocardiography are discussed. This is followed by application of a principle that may aid in the anatomic diagnosis of the heart in the right chest (dextrocardia) or in the midline (mesocardia). Although these methods are valid, many false-positive and false-negative results are possible. Two-dimensional echocardiography usually reveals the correct diagnosis, but occasionally additional studies such as magnetic resonance imaging (MRI) or angiography may be needed.
Chamber Localization

The heart and great arteries can be viewed as three separate segments: the atria, the ventricles, and the great arteries. These three segments can vary from their normal positions either independently or together, resulting in many possible sets of abnormalities. The *segmental approach* of Van Praagh is useful in determining the relationship at each segment. This approach also simplifies the description of complex cardiac defects and abnormal positions of the heart (e.g., dextrocardia, levocardia, mesocardia).

Localization of the Atria

The atria can be localized accurately by three noninvasive methods: chest radiography, ECG, and echocardiography. The radiographic method relies on the fact that the atrial situs is almost always the same as the type of visceral situs; the right atrium (RA) is on the same side as the liver or on the opposite side of the stomach bubble. The ECG method is based on the principle that the sinus node is always located in the RA and that the site of the sinus node can be determined by the P axis. Echocardiography clarifies the relationship between systemic and pulmonary veins and the atria.

**Chest radiography.** The clinician should locate the liver shadow and the stomach bubble.

1. A right-sided liver shadow and left-sided stomach bubble (situs solitus) indicate situs solitus of the atria (with the RA on the right of the left atrium [LA], as in normal) ([Fig. 17-1](#)), A). A left-sided liver shadow and right-sided stomach bubble (situs inversus) indicate situs inversus of the atria (with the RA on the left of the LA) ([Fig. 17-1](#), B).
2. A midline (symmetrical) liver shadow with a variable location of stomach bubble suggests heterotaxia (or splenic syndromes) in which either two RAs or two LAs (situs ambiguus) and other associated complex cardiac anomalies are present ([Fig. 17-1](#), C; see also sections on heterotaxia in *Chapter 14*).

**Electrocardiography.** The sinus node is always located in the anatomic RA. Therefore, the P axis of the ECG can be used to locate the atria; the RA is located on the opposite side of the P axis.

1. When the P axis is in the lower left quadrant of the hexaxial reference system (0 to +90 degrees), the RA is on the right side (with the RA to the right of the LA, or situs solitus of the atria) ([Fig. 17-2](#)).
2. When the P axis is in the lower right quadrant (+90 to +180 degrees), the RA is on the left side (with the RA on the left of the LA, or situs inversus of the atria) (see Fig. 17-2).

3. With heterotaxia, the P axis may be superiorly directed (as seen with polysplenia syndrome) or may change between the lower left quadrant and lower right quadrant from time to time (as seen with asplenia syndrome, in which two sinus nodes are present).

**Two-dimensional echocardiography and other methods.** Two-dimensional echocardiography identifies the inferior vena cava (IVC), pulmonary veins, or both. The atrial chamber that is connected to the IVC is the RA, and the atrium that receives the pulmonary veins is the LA. Cardiac MRI, angiocardiology, surgical inspection, and autopsy findings aid further in the diagnosis of atrial situs.
Localization of the Ventricles

Ventricles can be localized noninvasively by the ECG and two-dimensional echocardiography (or by MRI or angiocardiography).

**Electrocardiography.** The ECG method of localizing the ventricle is based on the fact that the depolarization of the ventricular septum moves from the embryonic left ventricle (LV) to the right ventricle (RV). This produces Q waves in the precordial leads that lie over the anatomic LV.

1. If Q waves are present in V5 and V6 but not in V1, D-loop of the ventricle, as in the normal person, is likely (Fig. 17-3, A).
2. If Q waves are present in V4R, V1, and V2 but not in V5 and V6, L-loop of the ventricles is likely (ventricular inversion) (see Fig. 17-3, B).

**Two-dimensional echocardiography.** The anatomic RV and LV are identified by the facts that the tricuspid valve leaflet usually inserts on the interventricular septum in a more apical position than the mitral septal leaflet and that the LV is invariably attached to the mitral valve and the RV to the tricuspid valve. A ventricular chamber that has two papillary muscles is the LV.

**Magnetic resonance imaging or ventriculography.** The anatomic RV is coarsely trabeculated and triangular, and the anatomic LV is finely trabeculated and ellipsoid.

---

**FIGURE 17-3** Locating the ventricles from the electrocardiogram (ECG). The left ventricle (LV) is usually located on the same side as the precordial leads that show Q waves. If V6 shows a Q wave, the LV is on the left side (A). If V4R and V1 show a Q wave, the LV is to the right of the anatomic right ventricle (RV) (B). Note that Q waves are also present in V1 in severe right ventricular hypertrophy. (From Park MK, Guntheroth WG: How to Read Pediatric ECGs, 4th ed. Philadelphia, Mosby, 2006.)

**FIGURE 17-4** Four types of relationships between the great arteries, viewed in the horizontal section. A, Solitus (S) relationship is present when the aortic valve is posterior and to the right of the pulmonary valve. B, In inversus (I) relationship, the aortic valve is posterior to and left of the pulmonary valve (mirror-image of normal). C, Complete transposition (D) is present when the aortic valve is anterior and to the right of the pulmonary valve. D, Congenitally corrected transposition (L) is present when the aortic valve is anterior and to the left of the pulmonary valve. AO, aorta; PA, pulmonary artery.
Localization of the Great Arteries

One can accurately determine the relationship between the two great arteries and the relationship of the great arteries to the ventricles noninvasively through echocardiography or MRI (and invasively through angiocardiography). The ECG and chest radiography are not very helpful in determining the relationship between the great arteries and the ventricles. In many cases, however, one can deduce the relationship through the loop rule (of Van Praagh). The loop rule states that the D-loop of the ventricle (with the anatomic RV to the right of the LV) usually is associated with normally related great arteries or with complete transposition of the great arteries (D-TGA). The L-loop of the ventricle (with the anatomic RV to the left of the anatomic LV) usually is associated with the mirror image of normally related great arteries or with congenitally corrected transposition of the great arteries (L-TGA).

There are four types of relationships between the two great arteries: (1) solitus, (2) inversus, (3) D-transposition, and (4) L-transposition (Fig. 17-4). One can deduce the relationship of the great artery. For example, when the situs solitus of the atria and the D-loop of the ventricle are confirmed, a situs solitus relationship is present if the patient is not cyanotic; if the patient is cyanotic, a D-TGA is present.

Segmental Expression

The following symbols are used in describing the segmental relationship of cardiac chambers and great arteries:

1. Visceroatrial relationship: S (solitus), I (inversus), or A (ambiguus)
2. Ventricular loop: D (D-loop), L (L-loop), or X (uncertain or indeterminate)
3. Great arteries: S (solitus), I (inversus), D (D-transposition), or L (L-transposition)

With these symbols, the segmental relationship of the heart can be expressed by three letters. The first letter signifies the visceroatrial relationship; the second letter, the ventricular loop; and the third letter, the relationship of the great arteries. The segmental approach to the diagnosis of cardiac malposition is independent of the location of the cardiac apex. Consequently, this approach applies to normally located hearts (levocardia in situs solitus) as well as to abnormally located hearts, such as dextrocardia and mesocardia. A few examples of normal and well-known abnormal segmental relationships can be expressed as follows:

Normal heart with situs solitus: S, D, S
Normal heart with situs inversus (mirror image of normal): I, L, I
D-TGA: S, D, D
D-TGA with situs inversus: I, L, L
L-TGA with situs solitus: S, L, L
A normally formed heart that is displaced to the right side of the chest secondary to hypoplasia of the right lung (“dextroversion”): S, D, S
Dextrocardia and Mesocardia

*Dextrocardia* refers to a condition in which the heart is located on the right side of the chest. *Mesocardia* indicates that the heart is located approximately on the midline of the thorax; that is, the heart lies predominantly neither to the right nor to the left on the posteroanterior chest radiograph. The terms *dextrocardia* and *mesocardia* express the position of the heart as a whole but do not specify the segmental relationship of the heart.

The four common types of dextrocardias are classic mirror-image dextrocardia (Fig. 17-5, A), normal heart displaced to the right side of the chest (Fig. 16-5, B), L-TGA (Fig. 17-5, C), and single ventricle. Less commonly, asplenia and polysplenia syndromes with situs ambiguous and complicated cardiac defects cause dextrocardia (Fig. 17-5, D). All of these abnormalities may result in mesocardia.

With chest radiography studies and the ECG, one can deduce the location of the atria and the ventricles in dextrocardia (as well as in mesocardia). One can gain a more conclusive diagnosis of the segmental relationship through two-dimensional echocardiography or MRI (or invasively with angiocardiography).

1. **Classic mirror-image dextrocardia** (I, L, I) (see Fig. 17-5, A) shows:
   a. The liver shadow on the left and the stomach bubble on the right on radiography and the P axis between +90 and +180 degrees on the ECG (situs inversus)
   b. Q waves in V5R and V6R (V5R and V6R are right-sided precordial leads, the mirror-image positions of V5 and V6, respectively)

2. **Normal heart shifted toward the right side of the chest with the normal right-to-left relationship maintained (dextroversion)** (S, D, S) (see Fig. 17-5, B) shows:
   a. The liver shadow on the right and the stomach bubble on the left on radiography and the P axis between 0 and +90 degrees on the ECG (situs solitus)
   b. Q waves in V5 and V6

3. **L-TGA with situs solitus** (S, L, L) (see Fig. 17-5, C) shows:
   a. Situs solitus of abdominal viscera on radiography and the P axis in the normal quadrant (0 to +90 degrees) on the ECG
   b. Q waves in V5R and V6R

![Figure 17-5](https://example.com/figure17-5.png)

**FIGURE 17-5** Examples of common conditions in which the apex of the heart is in the right chest. A, Classic mirror-image dextrocardia. B, Normally formed heart shifted toward the right side of the chest. C, Congenitally corrected transposition of the great arteries (L-TGA) with situs solitus. D, Situs ambiguous seen with splenic syndromes. LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle. (From Park MK, Guntheroth WG: How to Read Pediatric ECGs, 4th ed. Philadelphia, Mosby, 2006.)
4. Undifferentiated cardiac chambers (see Fig. 17-5, D) are often associated with complicated cardiac defects and may show:
   a. Midline liver on radiography and shifting P axis or superiorly oriented P axis on the ECG
   b. Abnormal Q waves in the precordial leads (similar to those described for single ventricle; see Chapter 14)
# PART 5
## Acquired Heart Disease

### OUTLINE

<table>
<thead>
<tr>
<th>Introduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>18. Primary Myocardial Disease</td>
</tr>
<tr>
<td>19. Cardiovascular Infections</td>
</tr>
<tr>
<td>20. Acute Rheumatic Fever</td>
</tr>
<tr>
<td>21. Valvular Heart Disease</td>
</tr>
<tr>
<td>22. Cardiac Tumors</td>
</tr>
<tr>
<td>23. Cardiovascular Involvement in Systemic Diseases</td>
</tr>
</tbody>
</table>

Acquired Heart Disease

Among acquired heart diseases, emphasis is placed on the more common pediatric diseases, such as cardiomyopathies; cardiovascular infections, including myocarditis and infective endocarditis; acute rheumatic fever; and valvular heart disease. Although the cause of Kawasaki’s disease is not entirely clear, it is discussed in the chapter on cardiovascular infection. Mitral valve prolapse is discussed in the chapter on valvular heart disease. A chapter on cardiac involvement in some systemic diseases also is presented.
Primary Myocardial Disease

Cardiomyopathies are structural or functional abnormalities of the myocardium not secondary to congenital, valvular, hypertensive, pulmonary, or coronary heart diseases. Cardiomyopathy has been classified into three types based on anatomic and functional features; hypertrophic, dilated, and restrictive (Fig. 18-1).

1. In hypertrophic cardiomyopathy (HCM), there is massive ventricular hypertrophy with a smaller than normal ventricular cavity. Contractile function of the ventricle is enhanced, but ventricular filling is impaired by relaxation abnormalities.

2. Dilated cardiomyopathy (DCM) is characterized by decreased contractile function of the ventricle associated with ventricular dilatation. Endocardial fibroelastosis (seen in infancy) and doxorubicin cardiomyopathy (seen in children who have received chemotherapy for malignancies) have clinical features similar to those of DCM.

3. Restrictive cardiomyopathy denotes a restriction of diastolic filling of the ventricles (usually infiltrative disease). Contractile function of the ventricle may be normal, but there is marked dilatation of both atria.

Recently, two new ones have been added to the classification, arrhythmogenic cardiomyopathy and left ventricular (LV) noncompaction. The two new types of cardiomyopathies are presented later in this chapter. The original three types of cardiomyopathies are functionally different from one another, and demands of therapy also are different. Table 18-1 summarizes clinical characteristics and treatment of the original three types of cardiomyopathies.
Hypertrophic cardiomyopathy is a heterogeneous, usually familial disorder of heart muscle. In about 50% of cases, HCM is inherited as a Mendelian autosomal dominant trait and is caused by mutations in one of 10 genes encoding protein components of the cardiac sarcomere (e.g., β-myosin heavy chain, myosin binding protein C, and cardiac troponin-T). The remainder of the cases occurs sporadically. HCM usually is seen in adolescents and young adults, with equal gender distribution. It is the most common cause of sudden cardiac death in teens and young adults, especially among athletes. It may be seen in children with LEOPARD syndrome (see Table 2-1). A usually transient form of HCM occurs in infants of mothers with diabetes, which will be presented under a separate heading in this chapter.

Pathology and Pathophysiology

1. The most characteristic abnormality is the hypertrophied LV, with the ventricular cavity usually small or normal in size. Although asymmetrical septal hypertrophy, a condition formerly known as idiopathic hypertrophic subaortic stenosis (Fig. 18-2), is most common, the hypertrophy may be concentric or localized to a small segment of the septum (Fig. 18-3). Microscopically, an extensive disarray of hypertrophied myocardial cells, myocardial scarring, and abnormalities of the small intramural coronary arteries are present.

2. In some patients, an intracavitary pressure gradient develops during systole, either at subaortic or rarely at mid-cavity. This subset is called hypertrophic obstructive cardiomyopathy (HOCM).
   a. The subaortic obstruction is commonly caused by systolic anterior motion (SAM) of the mitral valve against the hypertrophied septum (see Fig. 18-2). The SAM probably is created by the high outflow velocities and Venturi forces with frequent association of mitral regurgitation (MR).
   b. Midcavity obstruction is caused by anomalous insertion of anterolateral papillary muscle into the anterior mitral leaflet.
   c. In so-called apical HCM, hypertrophy is confined to the LV apex without intracavitary obstruction (and with giant negative T waves on the electrocardiogram (ECG). This subtype is present in about 25% of patients in Japan and fewer than 10% in other parts of the world.
3. The myocardium itself has an enhanced contractile state, but diastolic ventricular filling is impaired by abnormal stiffness of the LV, which may lead to left atrial enlargement and pulmonary venous congestion, producing congestive symptoms (exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea).

4. A unique aspect of HOCM is the variability of the degree of obstruction from moment to moment; the intensity of the heart murmur varies from time to time. Because the obstruction of the LVOT results from SAM of the mitral valve against the hypertrophied ventricular septum, any influence that reduces the LV systolic volume (e.g., positive inotropic agents, reduced blood volume, or lowering of the systemic vascular resistance) increases the obstruction. On the other hand, any influence that increases the LV systolic volume (e.g., negative inotropic agents, leg raising, blood transfusion, or increasing systemic vascular resistance) lessens the obstruction.

5. A large portion of the stroke volume (≈80%) is ejected during the early part of systole when there is little or no obstruction, producing a sharp upstroke in the arterial pulse, a characteristic finding of HOCM. The obstruction occurs late in systole, producing a late systolic murmur.

6. Patients with severe hypertrophy and obstruction may experience anginal chest pain, lightheadedness, near syncope, or syncope. Patients also are prone to develop arrhythmias, which may lead to sudden death (presumably from ventricular tachycardia or fibrillation). Nearly 30% of children with HCM have myocardial bridging (seen on coronary angiograms) with narrowing of the anterior descending coronary artery, which may have a key role in the development of ventricular arrhythmias. These patients may be more prone to sudden death. (Normally, the large epicardial coronary arteries run on the surface of the heart, with only their terminal branches penetrating the myocardium.)
When parts of the epicardial artery dip beneath the epicardial muscle so that there is a muscle bridge over the artery, they are called myocardial bridges.

**FIGURE 18-2**  Systolic anterior motion of the mitral valve. A, Diagram of systolic anterior motion in the presence of an asymmetrical septal hypertrophy. The Venturi effect may be important in the production of systolic anterior motion. B, M-mode echocardiography of the mitral valve in a patient with hypertrophic cardiomyopathy. Systolic anterior motion of the anterior leaflet of the mitral valve is indicated by arrows. AO, aorta; IVS, interventricular septum; LA, left atrium; LV, left ventricle; LVPW, LV posterior wall; mv, mitral valve; RV, right ventricle.

**FIGURE 18-3**  Morphologic variability in hypertrophic cardiomyopathy seen on parasternal short-axis view of two-dimensional echo. In type I hypertrophy, relatively mild left ventricular hypertrophy confined to the anterior portion of the ventricular septum (VS) is present. In type II, hypertrophy of the anterior and posterior septum is present in the absence of free wall thickening. In type III, there is diffuse hypertrophy of substantial portions of both the ventricular septum and the anterolateral free wall (ALFW). In type IV, the M-mode echocardiography beam (M) does not traverse the thickened portions of the left ventricle (LV) in the posterior septum and anterolateral free wall. A or ANT, anterior; AML, anterior mitral leaflet; L, left; LVFW, left ventricular free wall; P or POST, posterior; PML, posterior mitral leaflet; R, right. (From Maron BJ: Asymmetry in hypertrophic cardiomyopathy: The septal to free wall thickness ratio revisited [editorial]. Am J Cardiol 55: 835-838, 1985.)

| TABLE 18-1 |
| SUMMARY OF CLINICAL CHARACTERISTICS OF CARDIOMYOPATHIES |
Clinical Features | Hypertrophic | Dilated | Restrictive
--- | --- | --- | ---
Cause | Inherited (AD in ≥50%) Sporadic (new mutation ±) | Pluricausal (e.g., toxic, metabolic, infectious, alcohol, doxorubicin) | Myocardial fibrosis, hypertrophy, or infiltration (amyloid, hemochromatosis)
Hemodynamic dysfunction | Diastolic dysfunction (with normal systolic function) (abnormally stiff LV with impaired ventricular filling) | Diastolic dysfunction (with normal systolic function) (abnormally stiff LV with impaired ventricular filling) | Diastolic dysfunction (rigid ventricular walls impede ventricular filling)
Echocardiography (morphology) | Thickened LV (and occasionally RV) wall Small or normal LV chamber dimension | Biventricular dilatation (ILVDD, ILVSD) Atrial enlargement in proportion to ventricular enlargement | Biatrial enlargement Normal LV and RV volume Normal LV systolic function until advanced stage
Doppler | HOCM, ASH, or both Reduced relaxation pattern (see Fig. 18-6) | Apical thrombus (±) Reduced relaxation pattern (see Fig. 18-6) “Restrictive” pattern (see Fig. 18-6) | Atrial thrombus (±) Diuretics Anticoagulants (±) Corticosteroids (±)
Treatment | β-Adrenoceptor blockers Calcium antagonists (Digitalis, catechols, and nitrates contraindicated) (Diuretics may worsen symptoms) | Vasodilator therapy Digitalis plus diuretics β-Adrenoceptor blockers (±) | Anticoagulants Antiarrhythmics (±) Cardiac transplantation (±)

AD, autosomal dominant; ASH, asymmetrical septal hypertrophy; HOCM, hypertrophic obstructive cardiomyopathy; LV, left ventricle; LVDD, left ventricular diastolic dimension; LVEDP, left ventricular end-diastolic pressure; LVSD, left ventricular systolic dimension; RV, right ventricle.

Clinical Manifestations

History
1. Easy fatigability, dyspnea, palpitation, dizziness, syncope, or anginal pain may be present.
2. Family history is positive for the disease in 30% to 60% of patients.

Physical Examination
1. A sharp upstroke of the arterial pulse is characteristic (in contrast to a slow upstroke seen with fixed aortic stenosis [AS]). An LV lift and a systolic thrill at the apex or along the lower left sternal border may be present.
2. The S2 is normal, and an ejection click is generally absent. A grade 1 to 3 of 6 ejection systolic murmur of medium pitch is most audible at the mid-and lower left sternal borders or at the apex. A soft holosystolic murmur of MR is often present. The intensity
and even the presence of the murmur vary from examination to examination.

**Electrocardiography**
The ECG is abnormal in the majority of patients. Common ECG abnormalities include left ventricular hypertrophy (LVH), ST-T changes, and abnormally deep Q waves (owing to septal hypertrophy) with diminished or absent R waves in the left precordial leads (Fig. 18-4). Occasionally, “giant” negative T waves are seen in the left precordial leads, which may suggest apical HCM. Other ECG abnormalities may include cardiac arrhythmias and first-degree AV block.

**Radiography**
Mild LV enlargement with a globular-shaped heart may be present. The pulmonary vascularity usually is normal.

**Echocardiography**
1. Echocardiography is diagnostic. Two-dimensional echocardiography demonstrates the wide morphologic spectrum of the disease; including concentric hypertrophy (Fig. 18-5), localized segmental hypertrophy, and asymmetrical septal hypertrophy (see Fig. 18-3). Apical HCM may be missed by two-dimensional echocardiography. (If apical HCM is suspected, a cardiac MRI should be obtained.)

---

**FIGURE 18-4**  Tracing from a 17-year-old girl with hypertrophic obstructive cardiomyopathy with marked septal hypertrophy. Note the prominent Q waves with absent R waves in V5 and V6.
2. The diastolic LV wall thickness 15 mm or larger (or on occasion, 13 or 14 mm), usually with LV dimension smaller than 45 mm, is accepted for the clinical diagnosis of HCM in adults. For children, z-score of 2 or more relative to body surface area is theoretically compatible with the diagnosis.

The heart of some highly trained athletes may show hypertrophy of the LV wall, making the differentiation between the physiologic hypertrophy and HCM difficult. An LV wall thickness of 13 mm or larger is very uncommon in highly trained athletes, and it is always associated with an enlarged LV cavity (with LV diastolic dimension >54 mm, with ranges 55 to 63 mm). Therefore, athletes with LV wall thickness greater than 16 mm and a nondilated LV cavity are likely to have HCM (Pelliccia et al, 1991).

3. M-mode echocardiography may demonstrate an asymmetrical septal hypertrophy of the interventricular septum (with the septal thickness 1.4 times greater than the posterior LV wall) and occasionally SAM of the anterior mitral valve leaflet in the obstructive type (see Fig. 18-2).

4. Mitral inflow Doppler tracing demonstrates diastolic dysfunction with decreased E-wave velocity, increased deceleration time, and decreased E/A ratio of the mitral valve (usually <0.8) (Fig. 18-6). LV systolic function is normal or supernormal.

5. Doppler peak gradient in the LVOT of 30 mm Hg or greater indicates an obstructive type.
**Natural History**

1. The obstruction may be absent, stable, or slowly progressive. Genetically predisposed individuals often show striking increases in wall thickness during childhood.
2. Death is often sudden and unexpected and typically is associated with sports or vigorous exertion. Sudden death may occur most commonly in patients between 10 and 35 years of age. The incidence of sudden death may be as high as 4% to 6% a year in children and adolescents and 2% to 4% a year in adults. Ventricular fibrillation is the cause of death in the majority of sudden deaths. Even brief episodes of asymptomatic ventricular tachycardia on ambulatory ECG may be a risk factor for sudden death. Patients with myocardial bridging (occurring in about 30%) may be at risk for sudden death.
3. Atrial fibrillation (AF) may cause stroke or heart failure. AF results from left atrium (LA) enlargement with loss of the atrial “kick” needed for filling the thick LV.
4. In a minority of patients, heart failure with cardiac dilatation (“burned-out” phase of the disease) may develop later in life.

**Management**

The goal of treatment is to reduce ventricular contractility, increase ventricular volume, increase ventricular compliance, and increase LV outflow tract (LVOT) dimensions. In the obstructive form of the condition, reduction of the LVOT pressure gradient is important. However, unfortunately, most of therapeutic modalities used do not appear to significantly reduce the mortality rate. Surgical implantation of an automatic defibrillator may prove to be a very important modality to reduce sudden death.

**Medical**

1. **General management**
   a. Moderate restriction of physical activity is recommended. Patients with the diagnosis of HCM should avoid strenuous exercise and competitive sports, regardless of age, gender, symptoms, LVOT obstruction, or treatment.
   b. Digitalis is contraindicated because it increases the degree of obstruction. Other cardiotonic drugs and vasodilators should be avoided because they tend to increase the pressure gradient. Diuretics usually are ineffective and can be harmful. However, judicious use can help improve congestive symptoms (e.g., exertional dyspnea, orthopnea) by reducing LV filling pressure.
   c. Clinical screening of first-degree relatives and other family members should be encouraged.
   d. Annual evaluation of adolescence (12–18 years of age) is recommended, regardless of symptoms, with physical examination, ECG, and two-dimensional echocardiography studies.
2. **Patients with symptoms** (dyspnea, chest discomfort, disability)
   Exertional dyspnea and disability are caused by diastolic dysfunction with impaired
filling caused by increased LV stiffness. Chest pain is probably caused by myocardial ischemia of severely hypertrophied LV. Beta-blockers and calcium channel blockers are effective therapies in children with HCM. These agents reduce hypercontractile systolic function and improve diastolic filling.

a. A β-adrenergic blocker (e.g., propranolol, atenolol, or metoprolol) appears to be a preferred drug for symptomatic patients with outflow gradient, which develops only with exertion. Beta-blockers reduce the degree of outflow tract obstruction, decrease the incidence of anginal pain, and have antiarrhythmic effects.

In small children, propranolol is the drug of choice because of liquid formulation and low side effect profile. The dosage is 2 to 5 mg/kg/day given in three divided doses, with the heart rate goal of 80 to 100 beats/min. In older children, atenolol is typically used. In patients with excessive LVH and severe LVOT obstruction, a combination therapy with atenolol and verapamil may be considered.

b. Calcium channel blockers (principally verapamil) may be equally effective in both the nonobstructive and obstructive forms. Adverse hemodynamic effects may occur presumably as the result of vasodilating properties predominating over negative inotropic effects.

3. Asymptomatic patients. Prophylactic therapy with either β-adrenergic blockers or the calcium channel blocker verapamil is controversial in asymptomatic patients without LV obstruction. Some favor prophylactic administration of these drugs to prevent sudden death or to delay progression of the disease process; others limit prophylactic drug therapy to young patients with a family history of premature sudden death and those with particularly marked LVH. The efficacy of empiric prophylactic drug treatment with the above agents is unresolved.

4. Drug-refractory patients with obstruction. When standard pharmacologic therapy fails, there are limited options. In small children with persistent LVOT obstruction, the Morrow’s myectomy is the only option. In adults, alcohol septal ablation has been used but not in children. In patients with syncope, ventricular arrhythmias, or other high-risk factors, implantable cardioverter-defibrillator (ICD) implantation should be considered.

a. Morrow’s myotomy–myectomy. Transaortic LV septal myotomy—myectomy (the Morrow operation) is the procedure of choice for drug-refractory patients with LVOT obstruction. This operation is performed through an aortotomy without the benefit of complete direct visualization. Two vertical and parallel incisions are made (≈1 cm apart, 1–1.5 cm deep) into the hypertrophied ventricular septum. A third transverse incision connects the two incisions at their distal extent, and the bar of rectangular septal muscle is excised. Indications for the procedure is the presence of a resting pressure gradient of greater than 50 mm Hg by continuous wave Doppler study in patients who are symptomatic despite medical management.

The mortality rate, including children, is 1% to 3%. Partial or complete left bundle branch block (LBBB) always results. Symptoms improve in most patients, but patients may later die of congestive symptoms and arrhythmias caused by the cardiomyopathy. Serious complications of the surgery such as complete heart block requiring permanent pacemaker and surgically induced ventricular septal defect have become uncommon.
b. **Percutaneous alcohol septal ablation.** For adult patients with persistent LVOT obstruction, the introduction of absolute alcohol into a target septal perforator branch of the left anterior descending coronary artery produces myocardial infarction within the proximal ventricular septum. This is analogous to surgical myomectomy. A decrease in pressure gradient occurs after 6 to 12 months. A large proportion of patients demonstrate subjective improvement in symptoms and in quality of life. The increasing popularity of the procedure is probably unjustifiable. This procedure should not be considered a routine invasive procedure because selection of the appropriate perforator branch is crucially important.

The procedure-related mortality rate is 1% to 4%. Permanent pacemaker implantation occurs in 1% to 4%. This procedure commonly results in right bundle branch block (RBBB) rather than LBBB seen with surgical myotomy.

c. **Pacemaker implantation.** Dual-chamber pacing was shown in earlier studies to reduce symptoms and the pressure gradient across the LVOT, but more recent studies did not support earlier findings. There are currently no data to support the contention that pacing improves survival or quality of life. Therefore, pacing is not recommended as the primary treatment for most symptomatic patients with obstruction.

5. **ICD.** Recently, HCM has become one of the most frequent indications for ICD implantation in children with proven efficacy to prevent sudden death from arrhythmias. ICD implantation is warranted when risk for sudden death is judged to be unacceptably high. The following are risk factors for sudden death in HCM.
   a. Prior cardiac arrest (ventricular fibrillation)
   b. Spontaneous sustained ventricular tachycardia (3 beats/min or more or at least 120 beats/min)
   c. Family history of premature sudden death
   d. Unexplained syncope, particularly in young patients
   e. LV thickness of 30 mm or greater, particularly in adolescents and young adults
   f. Abnormal exercise blood pressure (attenuated response or hypotension)
   g. Nonsustained ventricular tachycardia

   Special consideration may be given to adolescents for ICD implantation because it is the period of life consistently showing the greatest predilection for sudden death.

6. **Cardiac arrhythmias**
   a. Ventricular arrhythmias may be treated with propranolol, amiodarone, and other standard antiarrhythmic agents guided by serial ambulatory ECG monitoring.
   b. AF occurs more often in patients with LA enlargement. AF can possibly trigger ventricular arrhythmias in certain patients. For new-onset AF, electrical cardioversion followed by anticoagulation with warfarin (superior to aspirin) is recommended. Amiodarone is generally considered to be the most effective agent for preventing recurrence of AF.

7. In patients with heart failure from either diastolic or systolic dysfunction, therapy is similar to that for DCM, including an angiotensin-converting enzyme (ACE) inhibitor
plus beta-blocker with or without diuretic and digoxin. Enalapril plus carvedilol is the most common ACE-inhibitor–β-blocker combination used.

8. Mitral valve replacement. Mitral valve replacement with a low-profile prosthetic valve may be indicated in selected patients with symptomatic mitral regurgitation. The operative mortality rate is about 6%. About 70% of patients show symptomatic improvement, but complications related to the prosthetic valve occur.
Infants of Mothers with Diabetes

Prevalence
At least 1.3% of pregnancies are complicated by diabetes mellitus.

Pathology
1. The teratogenic action of diabetes mellitus is generalized, affecting multiple organ systems. The prevalence of major congenital malformations in infants of mothers with diabetes is as high as 6% to 9% (i.e., three to four times that found in the general population). Neural tube defects (anencephaly, myelomeningocele), congenital heart defects, and sacral dysgenesis or agenesis are common ones. Infants born to mothers with insulin-dependent diabetes are at highest risk for developing congenital malformations; infants born to mothers with non–insulin-dependent, well-controlled diabetes do not appear to have an increased risk of congenital malformations.

2. Infants of mothers with diabetes have a high prevalence of congenital heart defects, cardiomyopathy, and persistent pulmonary hypertension of the newborn (PPHN).
   a. The risk of congenital heart defect is three to four times greater than that in the general population, with ventricular septal defect, transposition of the great arteries, truncus arteriosus, tricuspid atresia, and coarctation of the aorta (COA) among the more common defects.
   b. HCM with or without obstruction is seen in 10% to 20% of these infants. The weight of the heart is increased by the increased myocardial fiber size and number (rather than by excess glycogen, as once thought); the hypertrophy is thought to be caused by hyperinsulinemia. Although free walls of both ventricles and the ventricular septum are hypertrophied, the ventricular septum characteristically is more hypertrophied than the LV posterior wall (asymmetrical septal hypertrophy) (Fig. 18-7).
   c. Infants of mothers with diabetes also have an increased risk of PPHN. They often are affected by conditions that promote the persistence of pulmonary hypertension, such as hypoglycemia, perinatal asphyxia, respiratory distress, and polycythemia.

Clinical Manifestations
The clinical manifestations of only cardiomyopathy are presented in this section. Congenital heart defects and PPHN are discussed under specific headings.
1. The history usually reveals gestational or insulin-dependent diabetes mellitus in the mother. The patient often has a history of progressive respiratory distress with tachypnea (80–100 breaths/min) from birth.
2. These large-for-gestational-age babies often are plethoric and mildly cyanotic and may have tachypnea and tachycardia (>160 beats/min). Signs of CHF with gallop rhythm may be found in 5% to 10% of these babies. The patient may have a systolic murmur along the left sternal border, which may be caused by an outflow tract obstruction or an associated
defect.
3. Chest radiography may reveal a varying degree of cardiomegaly. Pulmonary vascular markings are normal or mildly increased due to pulmonary venous congestion.

![Image of chest radiograph and diagram]

**FIGURE 18-7** Parasternal long-axis view of 2-D echocardiogram of an infant of a diabetic mother. There is asymmetrical hypertrophy of the interventricular septum (IVS), which is at least two times as thick as the posterior wall of the left ventricle (LV). AO, aorta; LA, left atrium; RV, right ventricle.

4. The ECG usually is nonspecific, but a long QT interval caused by a long ST-segment secondary to hypocalcemia may be found. Occasionally, RVH, LVH, or biventricular hypertrophy (BVH) may be seen.
5. Echocardiography may show the following:
   a. The ventricular septum often is disproportionately thicker than the LV free wall, but even free walls are thicker than normal (see Fig. 18-7).
   b. Supernormal contractility of the LV and evidence of LVOT obstruction appear in about 50% of infants with cardiomyopathy.
   c. Rarely, the LV is dilated, and its contractility is decreased.

**Management**
1. General supportive measures are provided, such as intravenous fluids, correction of hypoglycemia and hypocalcemia, and ventilatory assistance, if indicated.
2. In most cases, the hypertrophy spontaneously resolves within the first 6 to 12 months of life. β-Adrenergic blockers, such as propranolol, may help the LVOT obstruction, but treatment usually is not necessary. Digitalis and other inotropic agents are contraindicated because they may worsen the obstruction.
3. If the LV is dilated with decreased LV contractility, the usual anticongestive measures (e.g., digoxin, diuretics) are indicated.
Other Rare Forms of Hypertrophic Cardiomyopathies

The following are some examples of HCM that manifest in syndromic forms.

1. **Pompe disease** (type II glycogen storage disease). In this autosomal recessive inherited disease, deficiency of $\alpha$-1,4-glucosidase results in massive accumulation of glycogen in various organs, leading to an enlarged tongue, striking hepatomegaly, hypotonia, and HCM and congestive heart failure (CHF). The ECG typically shows gigantic QRS voltages and short PR interval. The disease typically manifests during the first 5 months of life, and patients usually die before their second year of life unless they receive enzyme replacement. Enzyme therapy with Myozyme (alglucosidase alfa) is now possible.

2. **Fabry disease.** Fabry disease is an X-linked recessive disorder with skin manifestations (angiokeratomas), corneal clouding, peripheral neuropathy, renal failure, and anhidrosis. It is caused by mutations in the gene encoding the enzyme $\alpha$ galactosidase A. Deposits of glycosphingolipids on various tissues, particularly the kidneys and coronary arteries, cause the most important disease manifestations. The diagnosis of the condition is often delayed until the adolescence or adulthood; the average age of first symptoms is 11 years, but the diagnosis is usually further delayed. Primary cardiac manifestations in affected males are HCM and MR. The ECG shows a short PR interval. Replacement enzyme infusion is now approved by the U.S. Food and Drug Administration for treatment of this condition. This treatment resulted in clearance of pathological GL-3 deposits in the kidneys.
Dilated Cardiomyopathy

Cause

1. DCM, previously called congestive cardiomyopathy, is the most common form of cardiomyopathy. The causes of DCM are heterogeneous.
2. The most common cause of DCM is idiopathic (≈50%). About 20% to 35% of patients with idiopathic cardiomyopathy have been shown to have inherited familial DCM (Judge, 2009). Among the familial type, an autosomal dominant inheritance pattern is most frequent (occurring in 30%–50%); X-linked, autosomal recessive, and mitochondrial inheritance patterns are less common. There are at least 35 different genes in which mutation have been reported to cause DCM (Judge, 2009).
3. The most common known causes of DCM are myocarditis (46%) and neuromuscular diseases (≈25%) followed by familial cardiomyopathy, active myocarditis, and other causes. Some cases of idiopathic DCM may be the result of subclinical myocarditis.
4. The most frequently recognized familial form is Duchenne muscular dystrophy.
5. Other rare causes of DCM include infectious causes other than viral infection (bacterial, fungal, protozoan, rickettsial), as well as endocrine–metabolic disorders (hyper- and hypothyroidism, excessive catecholamines, diabetes, hypocalcemia, hypophosphatemia, glycogen storage disease, mucopolysaccharidoses) and nutritional disorders (kwashiorkor, beriberi, carnitine deficiency).
6. Some of the patients with the idiopathic type may have tachycardia-induced cardiomyopathy, which is related to chronic tachycardia (usually atrial or supraventricular tachycardia). (Resolution of ventricular dysfunction in 3 weeks after successful therapy may suggest the diagnosis, but echocardiography improvement may take 3 to 20 weeks.)
7. Cardiotoxic agents such as doxorubicin and systemic diseases such as connective tissue diseases can also cause DCM.

Pathology and Pathophysiology

1. In DCM, a weakening of systolic contraction is associated with dilatation of all four cardiac chambers. Dilatation of the atria is in proportion to ventricular dilatation. The ventricular walls are not thickened, although heart weight is increased.
2. Intracavitary thrombus formation is common in the apical portion of the ventricular cavities and in atrial appendages and may give rise to pulmonary and systemic emboli.
3. Histologic examinations from endomyocardial biopsies show varying degrees of myocyte hypertrophy and fibrosis. Inflammatory cells are usually absent, but a varying incidence of inflammatory myocarditis has been reported.

Clinical Manifestations

History
1. A history of fatigue, weakness, and symptoms of left-sided heart failure (dyspnea on exertion, orthopnea) may be elicited.
2. A history of prior viral illness occasionally is obtained.

**Physical Examination**

1. Signs of CHF (tachycardia, pulmonary crackles, weak peripheral pulses, distended neck veins, hepatomegaly) are present. The apical impulse usually is displaced to the left and inferiorly.
2. The S2 may be normal or narrowly split with accentuated P2 if pulmonary hypertension develops. A prominent S3 is present with or without gallop rhythm. A soft regurgitant systolic murmur (caused by MR or tricuspid regurgitation [TR]) may be present.

**Electrocardiography**

1. Sinus tachycardia, LVH, and ST-T changes are the most common findings. Left or right atrial hypertrophy (left atrial hypertrophy [LAH] or right atrial hypertrophy [RAH]) may be present. Rarely, a healed anterior myocardial infarction pattern may be present.
2. Atrial or ventricular arrhythmias and atrioventricular (AV) conduction disturbances may be seen.

**Radiography**

Generalized cardiomegaly is usually present, with or without signs of pulmonary venous hypertension or pulmonary edema.

**Echocardiography**

Echocardiography is the most important tool in the diagnosis of the condition and is important in the longitudinal follow-up of patients.

1. Two-dimensional echocardiography shows a marked LV enlargement and poor contractility (Fig. 18-8). The LA may also be enlarged. Occasionally, an intracavitary thrombus may be found, especially in the left atrial appendage and cardiac apex. Pericardial effusion may be seen.
2. On M-mode echocardiography, the end-diastolic and end-systolic dimensions of the LV are increased, with a markedly reduced fractional shortening and ejection fraction of the LV (Fig. 18-9). The M-mode measurement provides a valuable technique for serial assessment of patients with DCM.
3. Mitral inflow Doppler tracing demonstrates a reduced E velocity and a decreased E/A ratio (ratio of E-wave to A-wave velocity) (see Fig. 18-6).
Other Laboratory Tests
1. Urine for organic and amino acids; 3-methylglutaconic acid (i.e., Barth syndrome)
2. Blood studies for lactate, calcium, magnesium, carnitine, and acylcarnitine

Cardiac Catheterization
Catheterization can be helpful to (1) exclude anomalous coronary artery; (2) predict etiology and prognosis by obtaining endomyocardial biopsy; and (3) evaluate for cardiac transplantation, including measurement of pulmonary vascular resistance. Endomyocardial biopsy typically shows varying degrees of myocyte hypertrophy and fibrosis without significant lymphocytic infiltration.

Natural History
1. Progressive deterioration is the rule rather than the exception. About two thirds of patients die from intractable heart failure within 4 years after the onset of symptoms of CHF. In one report in children, the 1- and 5-year rates of death or transplantation were 31% and 46%, respectively.

2. Atrial and ventricular arrhythmias develop with time (in ≈50% of patients studied by 24-hour Holter) but are not predictive of outcome.

3. Systemic and pulmonary embolism resulting from dislodgment of intracavitary thrombi occurs in the late stages of the illness.

4. Causes of death are CHF, sudden death resulting from arrhythmias, and massive embolization.

**FIGURE 18-9** M-mode echocardiogram in a child with dilated cardiomyopathy (DCM). A, M-mode echocardiogram from a 9-year-old normal child. The left ventricular (LV) diastolic dimension (d) is 36 mm, and the LV systolic dimension (s) is 24 mm, with resulting fractional shortening of 33%. B, M-mode echocardiogram from an 8-year-old child with DCM with a markedly decreased LV contractile function. The LV diastolic dimension (62 mm) and LV systolic dimension (52 mm) are markedly increased, with a marked decrease in the fractional shortening (16%). IVS, interventricular septum; LVPW, LV posterior wall; RV, right ventricle.

### Management

If no identifiable and treatable cause of DCM is found, therapy is supportive and consists of (1) an anticongestive regimen, (2) control of significant arrhythmias, and (3) minimizing the risk of thromboembolic complications.

1. An integral part of medical treatment for underlying heart failure consists of diuretics (furosemide, spironolactone), digoxin, and ACE inhibitors (captopril, enalapril), as well as bed rest or restriction of activity.

2. Antiplatelet agents (aspirin) should be initiated. The propensity for thrombus formation in patients with dilated cardiac chambers and blood stasis may prompt the use of anticoagulation with warfarin. If thrombi are detected, they should be treated aggressively with heparin initially and later switched to long-term warfarin therapy.

3. Patients with arrhythmias may be treated with amiodarone or other antiarrhythmic
agents. Amiodarone is effective and relatively safe in children. For symptomatic bradycardia, a cardiac pacemaker may be necessary. An ICD may be considered, but there is limited experience with this device in children.

4. Recently, the use of β-adrenergic blocker therapy in children with chronic heart failure has been shown to improve LV ejection fraction. Carvedilol is a β-adrenergic blocker with additional vasodilating action. The beneficial effects of β-adrenergic blocking agents (somewhat unorthodox, given poor contractility) have been reported in adult patients. Similar beneficial effects of beta-blockers have been reported in children with DCM of various causes. Recent evidence suggests that activation of the sympathetic nervous system may have deleterious cardiac effects (rather than being an important compensatory mechanism, as traditionally thought). β-Adrenergic blockers may exert beneficial effects by a negative chronotropic effect with reduced oxygen demand, reduction in catecholamine toxicity, inhibition of sympathetically mediated vasoconstriction, or reduction of potentially lethal ventricular arrhythmias. Further discussion on the use of β-adrenergic blockers is presented in Chapter 27.

5. If carnitine deficiency is considered as the cause for the cardiomyopathy, carnitine supplementation should be started.

6. After an interesting observation by Fazio and colleagues (1996), several small studies have shown beneficial effects of growth hormone in adult patients with DCM. Some of these studies reported that treatment with growth hormone for 3 to 6 months resulted in increased LV wall thickness, reduction of the chamber size, and improved cardiac output. However, some other studies did not find the same salutary effect of the hormone. A small study involving children (McElhinney et al, 2004) reported that administration of recombinant human growth hormone (0.025–0.04 mg/kg/day for 6 months) showed a trend toward improved LV ejection fraction along with significant acceleration of somatic growth. Whether growth hormone treatment will finally find a place in the treatment of congestive cardiomyopathy remains to be established.

7. The utility of immunosuppressive agents, including steroids, cyclosporine, and azathioprine, remains unproved.

8. Children with severe decompensation may require mechanical circulatory support therapy with a ventricular assist device, intraaortic balloon counterpulsation, or extracorporeal membrane oxygenation. In children, mechanical circulatory support commonly is a bridge to transplantation.

9. Many of these children with DCM may become candidates for cardiac transplantation.

Prognosis
Review of the literature in children suggests that approximately one third die, one third recover completely, and one third improve with some residual cardiac dysfunction.
Endocardial Fibroelastosis

Prevalence
The prevalence of the nonfamilial form of endocardial fibroelastosis is extremely rare. The prevalence has declined in the past 3 decades for unknown reasons; in the past, it accounted for 4% of cardiac autopsy cases in children.

Pathology
1. Primary endocardial fibroelastosis is a form of DCM seen in infants. The condition is characterized by diffuse changes in the endocardium with a white, opaque, glistening appearance. The heart chambers, primarily the LA and LV, are notably dilated and hypertrophied. Involvement of the right-sided heart chambers is rare. Deformities and shortening of the papillary muscles and chordae tendineae (resulting in MR) are often present late in the course. Similar pathology appears secondary to severe congenital obstructive lesions of the left heart, such as AS, COA, and hypoplastic left heart syndrome (called secondary fibroelastosis).
2. The cause of primary fibroelastosis is not known. It may be the result of a process of reaction to many different insults, rather than a specific disease. Viral myocarditis and a sequel to interstitial myocarditis have received more attention than other proposed causes, including systemic carnitine deficiency and genetic factors. Several decades ago, mumps virus was considered the possible causal agent for the disease. Recently, the mumps virus genome was found in the myocardium in a significant number of patients with the diagnosis, suggesting that endocardial fibroelastosis is a complication of myocarditis caused by the mumps virus.

Clinical Manifestations
1. Symptoms and signs of CHF (feeding difficulties, tachypnea, sweating, irritability, pallor, failure to thrive) develop in the first 10 months of life.
2. Patients have tachycardia and tachypnea. No heart murmur is audible in the majority of patients, although a gallop rhythm usually is present. Occasionally, a heart murmur of MR is audible. Hepatomegaly frequently is present.
3. The ECG typically shows LVH with “strain.” Occasionally, myocardial infarction patterns, arrhythmias, and varying degrees of AV block may be seen.
4. Chest radiographs show marked generalized cardiomegaly with normal or congested pulmonary vascularity.
5. Echocardiography characteristically shows a markedly dilated and poorly contracting LV in the absence of structural heart defects. The LA also is markedly dilated. Bright endocardial echoes are typical of the condition.

Management
1. Early diagnosis and long-term (for years) treatment with digoxin, diuretics, and afterload-reducing agents are mandatory. Digoxin is continued for a minimum of 2 to 3 years and is then gradually discontinued if symptoms are absent, heart size is normal, and the ECG has reverted to normal.
2. An afterload-reducing agent may be beneficial.

**Prognosis**

When proper treatment is instituted, about one third of patients deteriorate and die of CHF. Another third survive but experience persistent symptoms. The remaining third exhibit complete recovery. Operative procedures are not available.
Doxorubicin Cardiomyopathy

Prevalence
Anthracyclines remain among the most widely used and effective anticancer agents. Unfortunately, life-threatening anthracycline cardiomyopathy continues to develop among survivors of cancer. Its prevalence is nonlinearly dose related, occurring in 2% to 5% of patients who have received a cumulative dose of 400 to 500 mg/m$^2$ of doxorubicin (Adriamycin) and up to 50% of patients who have received more than 1000 mg/m$^2$ of the drug. It may be seen occasionally in patients who received only 220 mg/m$^2$. When radiation therapy is combined with doxorubicin, the risk of cardiac damage is even greater.

Cause
1. C-13 anthracycline metabolites, which are inhibitors of adenosine triphosphatases of sarcoplasmic reticulum, mitochondria, and sarcolemma, have been implicated in the mechanism of cardiotoxicity causing cardiomyopathy.
2. Risk factors for developing doxorubicin cardiomyopathy may include the following.
   a. Cumulative dose of anthracyclines greater than 360 mg/m$^2$ are 40 times more likely to die than those who received less than 240 mg/m$^2$.
   b. Age younger than 4 years.
   c. A dosing regimen with larger and less frequent doses has been raised as a risk factor but not proved.
   d. Concomitant cardiac irradiation.

Pathology and Pathophysiology
1. Dilated LV, decreased contractility, elevated filling pressures of the LV, and reduced cardiac output characterize pathophysiologic features.
2. Microscopically, interstitial edema without evidence of inflammatory changes, loss of myofibrils within the myocyte, vacuolar degeneration, necrosis, and fibrosis are present.

Clinical Manifestations
1. Patients are usually asymptomatic until signs of heart failure develop. Patients have a history of receiving doxorubicin, with the onset of symptoms 2 to 4 months, and rarely years, after completion of therapy. Tachypnea and dyspnea made worse by exertion are the usual presenting complaints. Occasionally, palpitation, cough, and substernal discomfort are complaints.
2. Signs of CHF develop, with hepatomegaly and distended neck veins. Gallop rhythm may be present, with occasional soft murmur of MR or TR.
3. Radiography shows cardiomegaly with or without pulmonary congestion or pleural effusion.
4. The ECG shows sinus tachycardia. T-wave flattening or inversion is nonspecific evidence of cardiac involvement.
5. Echocardiography abnormalities of chronic cardiomyopathy occur within 1 year after doxorubicin treatment and may include the following:
   a. The LV size is slightly increased, and the LV wall thickness is slightly decreased.
   b. LV contractility (either ejection fraction or fractional shortening) is decreased.
   c. Indices of diastolic function may be more sensitive for subclinical cardiac dysfunction.
6. During doxorubicin therapy, acute ECG changes may include a prolonged QT interval occurring in 40% of patients immediately after a single dose. Echocardiography may show reduced LV systolic function (ejection fraction or fractional shortening) during therapy. Stopping therapy based on these changes may not be justified.

Management

1. Attempts to prevent anthracycline cardiotoxicity have been directed toward (a) anthracycline dose limitation, (b) method of drug administration, (c) developing less cardiotoxic analogs, and (d) concurrently administering cardioprotective agents to attenuate the cardiotoxic effects of anthracycline to the heart.
   a. Restriction of the total dose is controversial. Limiting the total cumulative dose to 400 to 500 mg/m\(^2\) reduces the incidence of CHF to 5%, but this dose may not be effective in treating some malignancies.
   b. Continuous slow infusion therapy may reduce cardiac injury by avoiding peak levels. At least one study recommends infusion over 6 hours. However, a more recent study (Lipshultz et al, 2012) has reported no long-term cardioprotection of continuous infusion over bolus infusion.
   c. The analog of doxorubicin, such as idarubicin and epirubicin, has similar cardiotoxicity to that of doxorubicin. There is some suggestion of lower rate of clinical and subclinical heart failure in patients treated with liposomal encapsulated doxorubicin preparation.
   d. Concurrent administration of the cardioprotective agents, such as dexrazoxane (an iron chelator), carvedilol (a β-receptor antagonist with antioxidant property), and coenzyme Q10, has shown varying levels of protective effects. Among these, dexrazoxane appears to be most cardioprotective, and some authorities recommend dexrazoxane to be included in the pediatric oncology protocol.
2. Unfortunately, no effective treatment for established doxorubicin cardiomyopathy is presently available. Currently, the following medications are used.
   a. Digoxin, diuretics, and afterload-reducing agents (ACE inhibitors, e.g., enalapril) are useful. It is unclear whether these agents improve clinical outcome.
   b. Beta-blockers have been shown to be beneficial in some children with chemotherapy-induced cardiomyopathy, similar to what has been reported in adults. Carvedilol, a nonselective beta-blocker, also has vasodilator effect and antioxidant activity. Carvedilol (12.5 mg once daily) given for 6 months to patients concurrently
receiving Adriamycin or epirubicin was shown to prevent ventricular dilatation and maintain their ejection fraction at approximately 70% (Kalay et al, 2006). Metoprolol (starting at 0.1 mg/kg per dose twice a day and increasing to a maximal dose of 0.9 mg/kg per day) increases LV fractional shortening and ejection fraction and improves symptoms.

3. Cardiac transplantation may be an option for selected patients.

Prognosis
Symptomatic cardiomyopathy carries a high mortality rate. The 2-year survival rate is about 20%, and all patients die by 9 years after the onset of the illness.
Carnitine Deficiency

Carnitine deficiency is a rare cause of cardiomegaly in infants and small children. Carnitine is an essential cofactor for transport of long-chain fatty acids into mitochondria, where oxidation takes place. Carnitine deficiency leads to depressed mitochondrial oxidation of fatty acids, resulting in storage of fat in muscle and functional abnormalities of cardiac and skeletal muscle. It is synthesized predominantly in the liver.

**Primary carnitine deficiency** is an uncommon inherited disorder. The condition has been classified as either systemic or myopathic.

The **systemic form** of the disease manifests with low concentrations of carnitine in plasma, muscle, and liver. Symptoms are variable but include muscle weakness, cardiomyopathy, abnormal liver function, encephalopathy, impaired ketogenesis, and hypoglycemia during fasting. In systemic carnitine deficiency, patients may present with acute hepatic hypoglycemia and encephalopathy during the first year of life before the cardiomyopathy becomes symptomatic. Both hypertrophic and dilated cardiomyopathies have been reported with carnitine deficiency.

**Myopathic disease** is characterized primarily by muscle weakness. Fatty infiltration of muscle fiber is found at biopsy. The most common manifestation of myopathic carnitine deficiency is progressive cardiomyopathy with or without skeletal muscle weakness that begins at 2 to 4 years of age.

The patients with cardiomyopathy may show bizarre T-wave spiking on the ECG. These children may die suddenly presumably from arrhythmias.

**Secondary forms of carnitine deficiency** have been reported in renal tubular disorders (with excessive excretion of carnitine), chronic renal failure (excessive loss of carnitine from hemodialysis), inborn errors of metabolism with increased concentrations of organic acids, and occasional patients receiving total parenteral nutrition. Diagnosis of the condition is established by extremely low levels of carnitine in plasma and skeletal muscle.

**Treatment**

1. Treatment with oral carnitine (L-carnitine: 50–100 mg/kg/day orally divided twice or three times a day; maximum daily dose, 3 g) may improve myocardial function, reduce cardiomegaly, and improve muscle weakness.
2. A recent multicenter study has shown that treatment of various forms of cardiomyopathy with L-carnitine, especially those with suggestive evidence of disorders of metabolism, provided clinical benefits.
3. The benefits of carnitine administration have been reported for other conditions with myocardial dysfunction, including prevention of diphtheric myocarditis in children, and potential protective and therapeutic effects on doxorubicin-induced cardiomyopathy in rats.
Barth Syndrome

Barth syndrome is a sex-linked cardioskeletal myopathy with abnormal mitochondria and neutropenia. This disorder typically presents in male infants as CHF associated with neutropenia (cyclic) and 3-methylglutaconic acidemia. Echocardiography shows LV dysfunction with LV dilatation, endocardial fibroelastosis, or a dilated hypertrophic LV. Some infants die from CHF, ventricular tachycardia, or sepsis caused by leukocyte dysfunction. Most children survive infancy and do well clinically, although DCM usually persists. Some require cardiac transplantation.

Kearns-Sayre Syndrome

This mitochondrial myopathy is characterized by ptosis, chronic progressive external ophthalmoplegia, abnormal retinal pigmentation, DCM, and cardiac conduction defects. Approximately 20% of patients with Kearns-Sayre syndrome have cardiac involvement, and the majority have conduction defect causing progressive AV block, requiring pacemaker therapy.
Restrictive Cardiomyopathy

Prevalence and Cause
Restrictive cardiomyopathy is an extremely rare form of cardiomyopathy, accounting for 5% of cardiomyopathy cases in children. It may be idiopathic or may be associated with a systemic infiltrative disease (e.g., scleroderma, amyloidosis, and sarcoidosis) or an inborn error of metabolism (mucopolysaccharidosis). Malignancies or radiation therapy may result in restrictive cardiomyopathy.

Pathology and Pathophysiology
1. This condition is characterized by markedly dilated atria and generally normal ventricular dimensions. Ventricular diastolic filling is impaired, resulting from excessively stiff ventricular walls. Contractile function of the ventricle is normal. Therefore, this condition resembles constrictive pericarditis in clinical presentation and hemodynamic abnormalities.
2. There are areas of myocardial fibrosis and hypertrophy of myocytes, or the myocardium may be infiltrated by various materials. Infiltrative restrictive cardiomyopathy may be caused by conditions such as amyloidosis, sarcoidosis, hemochromatosis, glycogen deposit, Fabry’s disease (with deposition of glycosphingolipids), or neoplastic infiltration.

Clinical Manifestations
1. The patients may have a history of exercise intolerance, weakness and dyspnea, or chest pain.
2. Jugular venous distention, hepatomegaly, a loud pulmonary component of S2 (P2), gallop rhythm, and a systolic murmur of AV valve regurgitation may be present.
3. Chest radiography shows cardiomegaly, pulmonary venous congestion, and occasional pleural effusion.
4. The ECG usually shows LAH, RAH, or both. It may show AF and paroxysms of supraventricular tachycardia. AV block may be present in familial restrictive cardiomyopathy.
5. Echocardiography studies reveal:
   a. Characteristic biatrial enlargement with normal dimension of the LV and right ventricle (RV) is almost diagnostic.
   b. LV systolic function is normal (until the late stage of the disease).
   c. Atrial thrombus may be present.
   d. Findings of diastolic dysfunction are present (see Fig. 18-6); the mitral inflow Doppler tracing shows an increased E velocity, shortened deceleration time, and increased E/A ratio.
   e. Differentiation from constrictive pericarditis can pose difficulties. In constrictive pericarditis, echocardiography shows a thickened pericardium, and Doppler studies...
show a marked respiratory variation in the filling phase. Doppler studies also show
similar findings of diastolic dysfunction as those seen in restrictive pericarditis.
6. Cardiac catheterization should be performed. It shows elevated LV and RV end-
diastolic pressures and frequent pulmonary hypertension (with elevated pulmonary
vascular resistance). Endomyocardial biopsy reveals myocyte hypertrophy and interstitial
fibrosis; it may also reveal a specific cause.

Management

Treatment is nonspecific and directed at alleviating symptoms. In general, medical
therapy does not improve survival. The prognosis is poor.
1. Diuretics are beneficial to relieve congestive symptoms, but they should be used
judiciously because they can reduce end-diastolic pressure, making symptoms worse.
Digoxin is not indicated because systolic function is unimpaired. ACE inhibitors may
reduce systemic blood pressure without increasing cardiac output and therefore should
probably be avoided.
2. Calcium channel blockers may be used to increase diastolic compliance.
3. Anticoagulants (warfarin) and antiplatelet drugs (aspirin and dipyridamole) may help
prevent thrombosis.
4. Corticosteroids and immunosuppressive agents have been suggested.
5. A permanent pacemaker is indicated for complete heart block.
6. Surgical options are limited to cardiac transplantation. Early transplantation is
preferable before severe pulmonary hypertension develops. In patients with systemic
disease (e.g., sarcoidosis), recurrence is a major concern after transplantation, and it may
not be a viable option.
Arrhythmogenic Cardiomyopathy

This cardiomyopathy is also known as arrhythmogenic RV dysplasia, arrhythmogenic RV cardiomyopathy, RV dysplasia, or RV cardiomyopathy.

**Cause**

1. Most cases appear to be sporadic, although familial occurrences have been reported. Whether the disease is congenital or acquired is unknown, although recent evidence favors an acquired degenerative process.
2. An inflammatory process, possibly infection (by coxsackievirus B3 and adenovirus) has been implicated as a cause.
3. The prevalence of the disease is not known, but it is estimated to range from 1 in 1000 to 1 in 5000 population.

**Pathology**

1. This is a rare abnormality of unknown cause in which the myocardium of the RV is partially or totally replaced by fibrous or adipose tissue. The RV wall may assume a paper-thin appearance because of the total absence of myocardial tissue, but in others, RV wall thickness is normal or near normal. The LV is also often affected.
2. Histologic sections show a variable reduction in myofibrils and inflammation associated with interstitial infiltration by histocytes and lymphocytes.

**Clinical Manifestations**

1. The onset is in infancy, childhood, or adulthood (but usually before the age of 20 years) with a history of palpitation, syncopal episodes, or both. Sudden death may be the first sign of the disease.
2. The physical examination is usually normal. An irregular rhythm or signs of heart failure may occasionally be present.
3. The ECG is helpful. Tall P waves in lead II (RA hypertrophy) and decreased RV forces may be present. Inverted T waves in the right precordial leads (V1–V4) may be significant (although this pattern is normally seen in young children). It may show premature ventricular contractions or ventricular tachycardia with LBBB morphology. An incomplete RBBB pattern may be present (in >30% of the cases).
4. Chest radiography usually show no or minimal cardiomegaly. Pulmonary vascular markings are usually normal.
5. Echocardiography shows selective RV enlargement and often systolic bulging or areas of akinesia or dyskinesia.
6. Cardiac MRI can visualize RV enlargement, aneurysm, systolic bulging of the RV free wall, myocardial fibrosis, and inflammation. Cardiac MRI is emerging as a more definite diagnostic tool than endomyocardial biopsy because the ventricular septum may lack the
characteristic histologic changes.
7. Cardiac catheterization may show an elevated right atrial “a” wave. An RV angiogram usually shows RV systolic dysfunction. The hallmark of the disease is systolic bulging of the RV free wall. Endomyocardial biopsy of the RV septum shows classic pathologic changes in more than 90% of the patients but with a high false-negative rate.
8. A substantial portion of patients die before 5 years of age from CHF and intractable ventricular tachycardia.

Management
1. Various antiarrhythmic agents may be tried, but they are often unsuccessful in abolishing ventricular tachycardia.
2. Surgical intervention (ventricular incision or complete electrical disarticulation of the RV free wall) may be tried if antiarrhythmic therapy is unsuccessful.
3. An ICD may be indicated in selected cases.
Noncompaction cardiomyopathy, also known as LV noncompaction, LV hypertrabeculation, or spongy myocardium, results from an intrauterine arrest of normal compaction of the loose interwoven meshwork of the ventricular myocardium (which normally occurs during the first month of fetal life). Mutations in the gene G4.5 on Xq28 may be responsible for noncompaction.

**Clinical Manifestations**

1. Most of the patients with this disorder are asymptomatic. Occasionally, they may present with signs and symptoms of heart failure during infancy. Familial occurrence has been reported in up to 25% with a less severe form of the disease. Evaluation of all members of the family has been recommended.

2. Physical examination findings may be entirely normal in some patients. Associated dysmorphic facial features may be seen in 14%. Nearly 30% of the patients have neurologic disorders, including seizures, hypotonia, myopathy, or mental or motor retardation. Patients with dysmorphic features or neuromuscular disorders may have associated metabolic disorders. It may coexist with various congenital heart defects. Signs of LV dysfunction may be present when the diagnosis is made; if not, most of them will eventually develop CHF.

3. The ECG may show giant QRS complexes, sometimes with Wolff-Parkinson-White preexcitation. Chest radiography findings are usually normal.

4. Echocardiography findings
   a. Characteristic echocardiography findings are segmental thickening of the LV wall consisting of two layers with a thin, compacted epicardial layer and an extremely thickened noncompacted endocardial layer with prominent trabeculations and deep recesses. The apical and midventricular segment of both the inferior and lateral walls are most commonly affected (Fig. 18-10).
   b. The LV is uniformly affected, resulting in systolic and diastolic dysfunction and clinical heart failure. The RV is rarely affected, but it is difficult to demonstrate by echocardiographic study. In pediatric patients, LV systolic dysfunction is seen in 35% to 90% at diagnosis and during follow-up.

5. When echocardiography studies are inconclusive, cardiac MRI should be obtained. MRI not only helps establish the diagnosis but can also find RV dysfunction in 16% of patients.

6. The disease is usually progressive with worsening of heart failure despite optimal treatment. Arrhythmias and thromboembolic events are mostly seen in adults, but they may also be seen in children.

**Treatment**

Treatment should be directed toward its complications. The most common complication
of the disease is heart failure. Less common complications are thromboembolic events and ventricular arrhythmias, more frequently seen in adult patients.

1. Anticongestive measures with digoxin, diuretics, and afterload-reducing agents are usually used.

2. In addition to the usual anticongestive measures, the use of carvedilol, a beta-blocker, should be considered in patients with LV dysfunction. Carvedilol has been shown to improve LV dysfunction.

3. All patients should be on an antiplatelet dose of aspirin. If thrombosis is detected, anticoagulation with Coumadin should be started.

4. Appropriate antiarrhythmic therapy is indicated. Implantation of an ICD may be considered for life-threatening ventricular arrhythmias.

5. Patients with dysmorphic features or neurologic manifestations may need detailed metabolic screening (e.g., fatty acid oxidation disorder or mitochondrial disease).

6. Heart transplantation is a possible option for selected patients.

Cardiovascular Infections

Included in this chapter are infective endocarditis (IE), myocarditis, pericarditis, Lyme carditis, and postperfusion syndrome. Other conditions in which the cause is not well established but the host’s immune response to an infective agent is thought to play a role are also included, such as Kawasaki’s disease and postpericardiotomy syndrome. Cardiac manifestations of human immunodeficiency virus (HIV) are also included.
Infective Endocarditis

Prevalence
Infective endocarditis accounts for 0.5 to 1 of every 1000 hospital admissions, excluding postoperative endocarditis.

Pathogenesis
1. Two factors are important in the pathogenesis of IE: (1) a damaged area of endothelium and (2) bacteremia, even transient. The presence of structural abnormalities of the heart or great arteries, with a significant pressure gradient or turbulence, produces endothelial damage. Such endothelial damage induces thrombus formation with deposition of sterile clumps of platelet and fibrin (nonbacterial thrombus). Prosthetic valves or prosthetic materials used in surgery also promote deposition of sterile thrombus. Nonbacterial thrombus provides a nidus for bacteria to adhere and eventually form infected vegetation. Platelets and fibrin are deposited over the organisms, leading to the enlargement of the vegetation.
2. Almost all patients who develop IE have a history of congenital or acquired heart disease. Drug addicts may develop endocarditis in the absence of known cardiac anomalies.
3. All congenital heart defects (CHDs), with the exception of secundum-type atrial septal defect (ASD), predispose to endocarditis. More frequently encountered defects are tetralogy of Fallot (TOF), ventricular septal defect (VSD), aortic valve disease, transposition of the great arteries (TGA), and systemic-to-PA shunt. Those with a prosthetic heart valve or prosthetic material in the heart are at particularly high risk of developing endocarditis. Patients with mitral valve prolapse (MVP) with mitral regurgitation (MR) and those with rheumatic MR also are vulnerable to IE.
4. Bacteremia resulting from dental procedures can cause IE. Bacteremia also occurs with activities such as chewing or brushing the teeth. Chewing with diseased teeth or gums may be the most frequent cause of bacteremia. Therefore, good dental hygiene is very important in the prevention of IE.

Pathology
Vegetation of IE is usually found on the low-pressure side of the defect, either around the defect or on the opposite surface of the defect where endothelial damage is established by the jet effect of the defect. For example, vegetations are found in the PA in patent ductus arteriosus (PDA) or systemic-to-PA shunts, on the atrial surface of the mitral valve in MR, on the ventricular surface of the aortic valve and mitral chordae in aortic regurgitation (AR), and on the superior surface of the aortic valve or at the site of a jet lesion in the aorta in patients with aortic stenosis (AS).

Microbiology
1. In the past, *Streptococcus viridans*, enterococci, and *Staphylococcus aureus* were responsible for more than 90% of the cases. In recent years, this frequency has decreased to 50% to 60%, with a concomitant increase in cases caused by fungi and HACEK organisms (*Haemophilus, Actinobacillus, Cardiobacterium, Eikenella*, and *Kingella* spp.). HACEK organisms are particularly common in neonates and immunocompromised children, accounting for 17% to 30% of cases.

2. α-Hemolytic streptococci (*S. viridans*) are the most common cause of endocarditis in patients who have had dental procedures or in those with carious teeth or periodontal disease.

3. Enterococci are the organisms most often found after genitourinary or gastrointestinal (GI) surgery or instrumentation.

4. The organisms most commonly found in postoperative endocarditis are staphylococci.

5. Intravenous (IV) drug abusers are at risk for IE caused by infection with *S. aureus*.

6. Fungal endocarditis (which has a poor prognosis) may occur in sick neonates, in patients who are on long-term antibiotic or steroid therapy, or after open heart surgery. Fungal endocarditis is often associated with very large friable vegetations; emboli from these vegetations frequently produce serious complications.

7. IE associated with indwelling vascular catheters, prosthetic material, and prosthetic valves is frequently caused by *S. aureus* or coagulase-negative staphylococci.

8. Among newborn infants, *S. aureus*, coagulase-negative staphylococci, and *Candida* spp. are the most common causes of IE.

9. A diagnosis of culture-negative endocarditis is made when a patient has clinical or echocardiographic evidence of endocarditis but persistently negative blood culture results. The most common cause of culture-negative endocarditis is current or recent antibiotic therapy or infection caused by a fastidious organism that grows poorly in vitro. Fungal endocarditis is a rare cause of culture-negative endocarditis. At times, the diagnosis can be made only by removal of vegetation (during surgery). In the United States, about 5% to 7% have culture-negative endocarditis.

**Clinical Manifestations**

**History**

1. Most patients have a history of an underlying heart defect. However, some patients with bicuspid aortic valve may not have been diagnosed with the defect before the onset of the endocarditis.

2. A history of a recent dental procedure or tonsillectomy is occasionally present, but a history of toothache (from dental or gingival disease) is more frequent than a history of a procedure.

3. Endocarditis is rare in infancy; at this age, it usually follows open heart surgery.

4. The onset is usually insidious with prolonged low-grade fever and somatic complaints, including fatigue, weakness, loss of appetite, pallor, arthralgia, myalgias, weight loss, and diaphoresis.
Physical Examination

1. Heart murmur is universal (100%). The appearance of a new heart murmur and an increase in the intensity of an existing murmur are important. However, many innocent heart murmurs are also of new onset.
2. Fever is common (80%–90%). Fever fluctuates between 101° and 103°F (38.3° and 39.4°C).
3. Splenomegaly is common (70%).
4. Skin manifestations (50%) (either secondary to microembolization or as an immunologic phenomenon) may be present in the following forms:
   a. Petechiae on the skin, mucous membranes, or conjunctivae are the most frequent skin lesions.
   b. Osler’s nodes (tender, pea-sized red nodes at the ends of the fingers or toes) are rare in children.
   c. Janeway’s lesions (small, painless, hemorrhagic areas on the palms or soles) are rare.
   d. Splinter hemorrhages (linear hemorrhagic streaks beneath the nails) also are rare.
5. Embolic or immunologic phenomena in other organs are present in 50% of cases:
   a. Pulmonary emboli may occur in patients with VSD, PDA, or a systemic-to-PA shunt.
   b. Seizures and hemiparesis are the result of embolization to the central nervous system (CNS) (20%) and are more common with left-sided defects such as aortic and mitral valve disease or with cyanotic heart disease.
   c. Hematuria and renal failure may occur.
   d. Roth’s spots (oval, retinal hemorrhages with pale centers located near the optic disc) occur in fewer than 5% of patients.
6. Carious teeth or periodontal or gingival disease is frequently present.
7. Clubbing of fingers in the absence of cyanosis develops rarely in more chronic cases.
8. Signs of heart failure may be present as a complication of the infection.
9. The clinical manifestations in a neonate with IE are nonspecific (respiratory distress, tachycardia) and may be indistinguishable from septicemia or congestive heart failure (CHF) from other causes. Embolic phenomena (such as osteomyelitis, meningitis, pneumonia) are common. They may have neurologic signs and symptoms (seizures, hemiparesis, apnea).

Laboratory Studies

1. Positive blood cultures are found in more than 90% of patients in the absence of previous antimicrobial therapy. Antimicrobial pretreatment reduces the yield of positive blood culture to 50% to 60%.
2. A complete blood cell count shows anemia, with hemoglobin levels lower than 12 g/100 mL (present in 80% of patients), and leukocytosis with a shift to the left. Patients with polycythemia preceding the onset of IE may have normal hemoglobin.
3. The sedimentation rate is increased unless there is polycythemia.
4. Microscopic hematuria is found in 30% of patients.
Echocardiography

Two-dimensional echocardiography is the main modality for detecting endocardial infection (Fig. 19-1). It detects the site of infection, extent of valvular damage, and cardiac function. Baseline evaluation of ventricular function and cardiac chamber dimension is important for comparison later in the course of the infection. Color Doppler is a sensitive modality for the detection of valvular regurgitation.

1. Certain echocardiographic findings are included as major criteria in the modified Duke criteria. They include:
   a. Oscillating intracardiac mass on valves or supporting structures, in the path of regurgitation jets, or on implanted material
   b. Abscesses
   c. New partial dehiscence of prosthetic valve
   d. New valvular regurgitation

2. Although standard transthoracic echocardiography (TTE) is sufficient in most clinical circumstances, transesophageal echocardiography (TEE) may be an important adjunct to TTE in the obese or very muscular adolescents, in postcardiac surgery patients, or in the presence of compromised respiratory function or pulmonary hyperinflation. TEE may be superior to TTE in identifying vegetations on prosthetic valves, detecting complications of LV outflow tract endocarditis (either valvular or subvalvular), and detecting aortic root abscess and involvement of sinus of Valsalva.

3. The absence of vegetations on echocardiography does not in itself rule out IE. Both TTE and TEE may produce false-negative results if vegetations are small or have already embolized, and they may miss initial perivalvular abscess. Repeat examinations are indicated if suspicion exists without diagnosis of IE or worrisome clinical course during early treatment of IE.

4. Conversely, a false-positive diagnosis is possible. An echogenic mass may represent a sterile thrombus, sterile prosthetic material, normal anatomic variation, an abnormal uninfected valve (previous scarring, severe myxomatous changes), or improper gain of the echocardiography machine. Echocardiographic evidence of vegetation may persist for months or years after bacteriologic cure.

5. Certain echocardiographic features suggest a high-risk case or a need for surgery:
   a. Large vegetations (greatest risk when the vegetation is >10 mm)
   b. Severe valvular regurgitation
   c. Abscess cavities
   d. Pseudoaneurysm
   e. Valvular perforation or dehiscence
   f. Decompensated heart failure
FIGURE 19-1  Echoes of aortic valve vegetation. A, Parasternal long-axis view of a young adult patient with a bicuspid aortic valve demonstrating vegetation on the aortic valve (arrow). Severe aortic regurgitation was present, with a dilated left ventricle (LV). B, Five-chamber transverse plane of a transesophageal echocardiographic image on the same patient that demonstrates vegetations and aortic valve anatomy more clearly than the ordinary two-dimensional echocardiography. Ao, aorta; LA, left atrium; RV, right ventricle.

**Diagnosis**

Recently, the American Heart Association (Baddour et al, 2005) has recommended the modified Duke Criteria in the diagnosis and management of IE. The usefulness of the criteria has been validated in clinical studies.

There are three categories of diagnostic possibilities using the modified Duke criteria: definite, possible, and rejected (Box 19-1).

1. A diagnosis of “definite” IE is made by pathological evidence and fulfillment of certain clinical criteria.
   a. Pathological evidence of IE includes (1) demonstration of microorganism by culture, (2) histology in a vegetation or from an embolic sites or an intracardiac abscess, or histologic evidence of active endocarditis demonstrated in vegetation or intracardiac abscess.
   b. Fulfillment of clinical criteria is met by the presence of two major criteria, one major and three minor criteria, or five minor criteria as described in Box 19-2. Major clinical criteria are (1) positive blood cultures for acceptable microorganism and (2) evidence of endocardial involvement, demonstrated by echocardiographic findings. A positive echocardiographic finding is considered a major criterion.

2. The category of “possible” IE is made when one of the following is present:
   a. One major criterion and one minor criterion
   b. Three minor criteria

3. The other category of diagnosis is “rejected” IE, which is made:
   a. When an alternative diagnosis is established
   b. When clinical manifestations of IE have resolved within 4 days of antibiotic therapy
Definition of Infective Endocarditis According to the Modified Duke Criteria

**Definite Infective Endocarditis**

**A. Pathological criteria**
- 1. Microorganisms demonstrated by culture or histologic examination of a vegetation, a vegetation that has embolized, or an intracardiac abscess specimen or
- 2. Pathological lesions; vegetation or intracardiac abscess confirmed by histologic examination showing active endocarditis

**B. Clinical criteria**
- 1. Two major criteria or
- 2. One major criterion and three minor criteria or
- 3. Five minor criteria

**Possible Infective Endocarditis**
- 1. One major criterion and one minor criterion or
- 2. Three minor criteria

**Rejected**
- 1. Firm alternative diagnosis explaining evidence of IE or
- 2. Resolution of IE syndrome with antibiotic therapy for <4 days or
- 3. No pathological evidence of IE at surgery or autopsy with antibiotic therapy for <4 days or
- 4. Does not meet criteria for possible IE as above

IE, infective endocarditis.


c. No pathological evidence is found on direct examination of the vegetation obtained from surgery or autopsy after antibiotic therapy for less than 4 days
d. When criteria for possible IE are not met

**Management**

1. Blood cultures are indicated for all patients with fever of unexplained origin and a pathologic heart murmur, a history of heart disease, or previous endocarditis.
   a. Usually three blood cultures are drawn by separate venipunctures over 24 hours unless the patient is very ill. In 90% of cases, the causative agent is recovered from the first two cultures.
   b. If there is no growth by the second day of incubation, two more may be obtained. There is no value in obtaining more than five blood cultures over 2 days unless the patient received prior antibiotic therapy.
   c. It is not necessary to obtain the cultures at any particular phase of the fever cycle.
   d. Adequate volume of blood must be obtained: 1 to 3 mL in infants and young children and 5 to 7 mL in older children are optimal.
   e. Aerobic incubation alone suffices because it is rare for IE to be caused by anaerobic bacteria.
2. It is highly recommended that consultation from a local infectious disease specialist be obtained when IE is suspected or confirmed because antibiotics of choice are continually changing, and there may be special situation pertaining to the local area.

3. Initial empirical therapy is started with the following antibiotics while awaiting the results of blood cultures:
   a. The usual initial regimen is an antistaphylococcal semisynthetic penicillin (nafcillin, oxacillin, or methicillin) and an aminoglycoside (gentamicin). This combination covers against *S. viridans*, *S. aureus*, and gram-negative organisms. Some experts add penicillin to the initial regimen to cover against *S. viridans*, although a semisynthetic penicillin is usually adequate for initial therapy.
   b. If a methicillin-resistant *S. aureus* is suspected, vancomycin should be substituted for the semisynthetic penicillin.

**BOX 19-2**

**Definition of Terms Used in the Modified Duke Criteria for the Diagnosis of Infective Endocarditis**

**Major Criteria**

A. Blood culture positive for IE
   1. Typical microorganisms consistent with IE from two separate blood cultures: Viridans streptococci, *Streptococcus bovis*, HACEK group, *Staphylococcus aureus*; or community-acquired enterococci in the absence of a primary focus or
   2. Microorganisms consistent with IE from persistently positive blood cultures defined as follows: at least two positive cultures of blood samples drawn >12 h apart or all of three or a majority of four or more separate cultures of blood (with first and last sample drawn at least 1 h apart)
   3. Single positive blood culture for *Coxiella burnetii* or anti-phase 1 IgG antibody titer >1:800

B. Evidence of endocardial involvement

   Echocardiogram positive for IE (TEE is recommended for patients with prosthetic valves, rated at least “possible IE” by clinical criteria, or complicated IE [paravalvular abscess]; TTE as first test in other patients) defined as follows:
   1. Oscillating intracardiac mass on valve or supporting structures, in the path of regurgitant jets, or on implanted material in the absence of an alternative anatomic explanation or
   2. Abscess or
   3. New partial dehiscence of prosthetic valve or
   4. New valvular regurgitation (worsening or changing or preexisting murmur not sufficient)

**Minor Criteria**

1. Predisposition, predisposing heart condition, or IDU
2. Fever, temperature >38°C
3. Vascular phenomena: major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, and Janeway’s lesions
4. Immunologic phenomena: glomerulonephritis, Osler’s nodes, Roth’s spots, and rheumatoid factor
5. Microbiologic evidence: positive blood culture but does not meet a major criterion as noted above or serologic evidence of active infection with organism consistent with IE

HACEK, *Haemophilus, Actinobacillus, Cardiobacterium, Eikenella*, and *Kingella* spp.; IE, infective endocarditis; IDU, injection drug user; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography.

*Excludes single positive cultures for coagulase-negative staphylococci and organisms that do not cause endocarditis.*

c. Vancomycin can be used in place of penicillin or a semisynthetic penicillin in penicillin-allergic patients.

4. The final selection of antibiotics depends on the organism isolated and the results of an antibiotic sensitivity test.
   a. Streptococcal IE
      (1) In general, patients with native cardiac valve IE caused by a highly sensitive *S. viridans* can be successfully treated with IV penicillin (or ceftriaxone given once daily) for 4 weeks. Alternatively, penicillin, ampicillin, or ceftriaxone combined with gentamicin for 2 weeks may be used.
      (2) For IE caused by penicillin-resistant streptococci, 4 weeks of penicillin, ampicillin, or ceftriaxone combined with gentamicin for the first 2 weeks is recommended.
   b. Staphylococcal endocarditis
      (1) The drug of choice for native valve IE by methicillin-susceptible staphylococci is one of the semisynthetic β-lactamase–resistant penicillins (nafcillin, oxacillin, or methicillin) for a minimum of 6 weeks (with or without gentamicin for the first 3–5 days).
      (2) Patients with methicillin-resistant native valve IE are treated with vancomycin for 6 weeks (with or without gentamicin for the first 3–5 days).
   c. Enterococcus-caused native valve endocarditis usually requires a combination of IV penicillin or ampicillin together with gentamicin for 4 to 6 weeks. If patients are allergic to penicillin, vancomycin combined with gentamicin for 6 weeks is required.
   d. HACEK organisms have begun to become resistant to ampicillin. Ceftriaxone or another third-generation cephalosporin alone or ampicillin plus gentamicin for 4 weeks is recommended. IE caused by other gram-negative bacteria (such as *Escherichia coli*, *Pseudomonas aeruginosa*, or *Serratia marcescens*) is treated with piperacillin or ceftazidime together with gentamicin for a minimum of 6 weeks.
   e. Amphotericin B is the most effective agent for most fungal infections.
   f. For culture-negative endocarditis, treatment is directed against staphylococci, streptococci, and the HACEK organisms using ceftriaxone and gentamicin. When staphylococcal IE is suspected, nafcillin should be added to the above therapy.

5. Patients with prosthetic valve endocarditis should be treated for 6 weeks based on the organism isolated and the results of the sensitivity test. Operative intervention may be necessary before the antibiotic therapy is completed if the clinical situation warrants (e.g., progressive CHF, significant malfunction of prosthetic valves, persistently positive blood cultures after 2 weeks of therapy). Bacteriologic relapse after an appropriate course of therapy also calls for operative intervention.

Prognosis
The overall recovery rate is 80% to 85%; it is 90% or better for *S. viridans* and enterococci and about 50% for *Staphylococcus* organisms. Fungal endocarditis is associated with a very poor outcome.

### Prevention

In 2007, the American Heart Association (AHA) made a major change in the antibiotic prophylaxis against IE (*Wilson et al, 2007*). The same was recommended jointly by the American College of Cardiology (ACC) and the AHA in 2008 in a focused practice guideline (*Nishimura et al, 2008*). The following are the main reasons for the change in the long-standing tradition of antibiotic prophylaxis in patients with most of the CHDs.

1. An exceedingly small number of IE that could be caused by bacteremia-producing dental procedures. The estimated frequency of bacteremia during routine daily activities (e.g., chewing, toothbrushing, flossing, use of toothpicks, use of water irrigation devices, and other activities) far exceeds that occurring during dental procedures. For example, tooth brushing and flossing result in bacteremia 20% to 40% of the time and chewing food results in bacteremia 7% to 51% of the time. The cumulative risk over time of bacteremia from routine daily activities is estimated to be greater than 100,000 times compared with that resulting from dental procedures.

2. Besides, the ability of antibiotic therapy to prevent or reduce bacteremia is controversial, and nonfatal adverse reactions (e.g., rash, diarrhea, and GI upset) also occur frequently.

Therefore, an emphasis should be on maintaining good oral hygiene and eradicating dental disease to decrease the frequency of bacteremia from routine daily activities. The new guidelines recommend antibiotic prophylaxis only for cardiac conditions listed in Box 19-3. Procedures for which antibiotic prophylaxis is recommended and those for which it is not recommended are listed in Box 19-4. Note that prophylaxis is no longer recommended for routine bronchoscopy; it is recommended for tonsillectomy and adenoidectomy only in high-risk patients (see Box 19-4). Prophylaxis is no longer recommended for GI or genitourinary procedures, such as diagnostic esophagogastroduodenoscopy or colonoscopy. Regimens for dental and oral procedures are given in Table 19-1.

### Special Situations

1. Patients already receiving antibiotics
   - Rheumatic fever prophylaxis: Rather than using a higher dose of the same antibiotic, use other antibiotics, such as clindamycin, azithromycin, or clarithromycin.
   - If possible, delay a dental procedure until at least 10 days after completion of the antibiotic therapy.

### TABLE 19-1

<table>
<thead>
<tr>
<th>PROPHYLACTIC REGIMENS FOR DENTAL PROCEDURES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Situation</td>
</tr>
<tr>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>Oral</td>
</tr>
<tr>
<td>Unable to take oral medications</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Allergic to penicillin or ampicillin—oral</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Allergic to penicillin or ampicillin and unable to take oral medication</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

IM, intramuscular; IV, intravenous.

* Or other first- or second-generation oral cephalosporin in equivalent adult or pediatric dosage.

† Cephalosporins should not be used in an individual with a history of anaphylaxis, angioedema, or urticaria with penicillin or ampicillin.

**BOX 19-3** Cardiac Conditions for Which Prophylaxis with Dental Procedures is Recommended

1. Patients with prosthetic cardiac valve or prosthetic material used for cardiac valve repair
2. Patients with previous IE
3. Patients with CHD:
   a. Unrepaired cyanotic CHD, including palliative shunts and conduits
   b. Completely repaired CHD with prosthetic material or device, whether placed by surgery or by catheter intervention, during the first 6 months after the procedure*
   c. Repaired CHD with residual defects at the site or adjacent to the site of a prosthetic patch or prosthetic device (which inhibits endothelialization)
4. Cardiac transplantation recipients with valve regurgitation caused by a structurally abnormal valve

CHD, congenital heart disease; IE, infective endocarditis.

* Prophylaxis is recommended because endothelialization of prosthetic material occurs within 6 months after the procedure.
Procedures for Which Endocarditis Prophylaxis is Recommended

1. Dental procedures
   All dental procedures that involve manipulation of gingival tissue of the periapical region of teeth or perforation of the oral mucosa. Antibiotic choices and dosages for dental procedures are shown in Table 19-1.

2. Respiratory tract procedures
   a. Prophylaxis is recommended for the procedures that involve incision or biopsy of the respiratory mucosa, such as tonsillectomy and adenoidectomy.
   b. Prophylaxis is not recommended for bronchoscopy (unless it involves incision of the mucosa, such as for abscess or empyema).

3. GI or GU procedures
   a. No prophylaxis is used for diagnostic esophagogastroduodenoscopy or colonoscopy.
   b. Prophylaxis is reasonable in patients with infected GI or GU tract (with amoxicillin or ampicillin to cover against enterococci).

4. Skin, skin structure, or musculoskeletal tissue
   a. Prophylaxis is recommended for surgical procedures that involve infected skin, skin structure, or musculoskeletal tissue (with antibiotics against staphylococcus and β-hemolytic streptococcus, such as antistaphylococcal penicillin or a cephalosporin).
   b. Vancomycin or clindamycin is administered if unable to tolerate β-lactam or if infection is caused by methicillin-resistant staphyloccoccus.

GI, gastrointestinal; GU, genitourinary.

2. Patients who undergo cardiac surgery: A careful preoperative dental evaluation is recommended so that required dental treatment may be completed whenever possible before cardiac valve surgery or replacement or repair of a CHD. Prophylaxis at the time of surgery should be directed primarily against staphylococci and should be of short duration. Prophylaxis should be initiated immediately before the operative procedure, repeated during prolonged procedures to maintain serum concentrations intraoperatively, and continued for no more than 48 hours postoperatively.
Myocarditis

Prevalence
Myocarditis severe enough to be recognized clinically is rare, but the prevalence of mild and subclinical cases is probably much higher.

Pathology
1. The principal mechanism of cardiac involvement in viral myocarditis is believed to be a cell-mediated immunologic reaction, not merely myocardial damage from viral replication. Isolation of virus from the myocardium is unusual at autopsy.
2. The inflamed myocardium is soft, flabby, and pale, with areas of scarring on gross examination. Microscopic examination reveals patchy infiltrations by plasma cells, mononuclear leukocytes, and some eosinophils during the acute phase and giant cell infiltration in the later stages.

Cause
1. In North America, viruses are probably the most common causes of myocarditis. Among viruses, adenovirus, coxsackievirus B, and echoviruses are the most common agents. Many other viruses (e.g., poliomyelitis, mumps, measles, rubella, cytomegalovirus [CMV], HIV, arboviruses, influenza) can cause myocarditis. In South America, Chagas’ disease (caused by Trypanosoma cruzi, a protozoan) is a common cause of myocarditis. Rarely, bacteria, rickettsia, fungi, protozoa, and parasites are the causative agents.
2. Immune-mediated diseases, including acute rheumatic fever and Kawasaki’s disease, may be the cause.
3. Collagen vascular diseases can cause myocarditis.
4. Toxic myocarditis (from drug ingestion, diphtheria exotoxin, and anoxic agents) occurs.

Clinical Manifestations

History
1. Older children may have a history of an upper respiratory infection.
2. The illness may have a sudden onset in newborns and small infants, with anorexia, vomiting, lethargy, and occasionally circulatory shock.

Physical Examination
1. The presentation depends on the patient’s age and the acute or chronic nature of the infection. In neonates and infants, signs of CHF may be present; these include poor heart tone, tachycardia, gallop rhythm, tachypnea, and (rarely) cyanosis. In older children, a gradual onset of CHF and arrhythmia are commonly seen.
2. A soft, systolic heart murmur and irregular rhythm caused by supraventricular or ventricular ectopic beats may be audible.
3. Hepatomegaly (evidence of viral hepatitis) may be present.

**Electrocardiography**
Any one or a combination of the following may be seen: low QRS voltages, ST-T changes, PR prolongation, prolongation of the QT interval, and arrhythmias (especially premature contractions).

**Radiography**
Cardiomegaly of varying degrees is the most important clinical sign of myocarditis.

**Echocardiography**
Echocardiography reveals cardiac chamber enlargement and impaired left ventricle (LV) function, often regional in nature. Occasionally, increased wall thickness and LV thrombi are found.

**Laboratory Studies**
1. Cardiac troponin levels (troponin I and T) and myocardial enzymes (creatine kinase [CK], MB isoenzyme of CK [CK-MB]) may be elevated. In children, the normal value of cardiac troponin I has been reported to be 2 ng/mL or less, and it is frequently below the level of detection for the assay. Troponin levels may be more sensitive than the cardiac enzymes.
2. Radionuclide scanning (after administration of gallium-67 or technetium-99m pyrophosphate) may identify inflammatory and necrotic changes characteristic of myocarditis.
3. Myocarditis can be confirmed by an endomyocardial biopsy.

**Natural History**
1. The mortality rate is as high as 75% in symptomatic neonates with acute viral myocarditis.
2. The majority of patients, especially those with mild inflammation, recover completely.
3. Some patients develop subacute or chronic myocarditis with persistent cardiomegaly (with or without signs of CHF) and ECG evidence of left ventricular hypertrophy (LVH) or biventricular hypertrophy (BVH). Clinically, these patients are indistinguishable from those with dilated cardiomyopathy. Myocarditis may be a precursor to idiopathic dilated cardiomyopathy in some cases.

**Management**
1. One should attempt virus identification by viral cultures from the blood, stool, or
throat washing. Acute and convalescent sera should be compared for serologic titer rise.

2. Bed rest and limitation in activities are recommended during the acute phase (because exercise intensifies the damage from myocarditis in experimental animals).

3. Anticongestive measures include the following:
   a. Rapid-acting diuretics (furosemide or ethacrynic acid, 1 mg/kg, each one to three times a day)
   b. Rapid-acting inotropic agents, such as dobutamine or dopamine, are useful in critically ill children.
   c. Oxygen and bed rest are recommended. Use of a “cardiac chair” or “infant seat” relieves respiratory distress.
   d. Digoxin may be given cautiously using half of the usual digitalizing dose (see Table 27-5) because some patients with myocarditis are exquisitely sensitive to the drug.

4. Recently, beneficial effects of high-dose gamma globulin (2 g/kg over 24 hours) have been reported. Gamma globulin was associated with better survival during the first year after presentation, echocardiographic evidence of smaller LV diastolic dimension, and higher fractional shortening compared with the control group. Myocardial damage in myocarditis is mediated in part by immunologic mechanisms, and a high dose of gamma globulin is an immunomodulatory agent, shown to be effective in myocarditis secondary to Kawasaki’s disease.

5. Angiotensin-converting enzyme inhibitors, such as captopril, may prove beneficial in the acute phase (as demonstrated in animal experiments).

6. Arrhythmias should be treated aggressively and may require the use of IV amiodarone.

7. The role of corticosteroids is unclear at this time except in the treatment of severe rheumatic carditis.

8. Specific therapies include antitoxin in diphtheritic myocarditis.
Pericarditis

Cause
1. Viral infection is probably the most common cause of pericarditis, particularly in infancy. Many viruses similar to those listed in the section on myocarditis can cause pericarditis.
2. Acute rheumatic fever is a common cause of pericarditis, especially in certain parts of the world (see also Chapter 20).
3. Bacterial infection (purulent pericarditis) is a rare, serious form of pericarditis. Commonly encountered are S. aureus, Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis, and streptococci.
4. Tuberculosis is an occasional cause of constrictive pericarditis with an insidious onset.
5. Heart surgery is a possible cause (see Postpericardiotomy Syndrome).
6. Collagen disease such as rheumatoid arthritis (see Chapter 23) can cause pericarditis.
7. Pericarditis can be a complication of oncologic disease or its therapy, including radiation.
8. Uremia (uremic pericarditis) is a rare cause.

Pathology
The parietal and visceral surfaces of the pericardium are inflamed. Pericardial effusion may be serofibrinous, hemorrhagic, or purulent. Effusion may be completely absorbed or may result in pericardial thickening or chronic constriction (constrictive pericarditis).

Pathophysiology
The pathogenesis of symptoms and signs of pericardial effusion is determined by two factors: the speed of fluid accumulation and the competence of the myocardium. A rapid accumulation of a large amount of pericardial fluid produces more serious circulatory embarrassment. A slow accumulation of a relatively small amount of fluid may result in serious circulatory embarrassment (cardiac tamponade) if the extent of myocarditis is significant. Slow accumulation of a large amount of fluid may be accommodated by stretching of the pericardium if the myocardium is intact.

With the development of pericardial tamponade, several compensatory mechanisms are triggered, including systemic and pulmonary venous constriction to improve diastolic filling, an increase in systemic vascular resistance to raise falling blood pressure, and tachycardia to improve cardiac output.

Clinical Manifestations

History
1. The patient may have a history of upper respiratory tract infection.
2. Precordial pain (dull, aching, or stabbing) with occasional radiation to the shoulder and neck may be a presenting complaint. The pain may be relieved by leaning forward and may be made worse by the supine position or deep inspiration.

3. Fever of varying degrees may be present.

**Physical Examination**

1. Pericardial friction rub (a grating, to-and-fro sound in phase with the heart sounds) is the cardinal physical sign.
2. The heart is quiet and hypodynamic in the presence of a large amount of pericardial effusion.
3. Pulsus paradoxus is characteristic of pericardial effusion with tamponade (see Chapter 2 and Fig. 2-2).
4. Heart murmur is usually absent, although it may be present in acute rheumatic carditis (see Chapter 20).
5. In children with *purulent pericarditis*, septic fever (101°F–105°F [38.3°C–40.5°C]), tachycardia, chest pain, and dyspnea are almost always present.
6. Signs of *cardiac tamponade* may be present: distant heart sounds, tachycardia, pulsus paradoxus, hepatomegaly, venous distention, and occasional hypotension with peripheral vasoconstriction. Cardiac tamponade occurs more commonly in purulent pericarditis than in other forms of pericarditis.

**Electrocardiography**

1. The low-voltage QRS complex caused by pericardial effusion is characteristic but not a constant finding.
2. The following time-dependent changes secondary to myocardial involvement may occur (see Fig. 3-25):
   a. Initial ST segment elevation
   b. Return of the ST segment to the baseline with inversion of T waves (2–4 weeks after onset)

**Chest Radiography**

1. A varying degree of cardiomegaly is present.
2. A pear-shaped or water-bottle-shaped heart is characteristic of a large effusion.
3. Pulmonary vascular markings may be increased if cardiac tamponade develops. Tamponade may occur without enlargement of the cardiac silhouette if it develops quickly.

**Echocardiography**

Echocardiography is the most useful tool in establishing the diagnosis of pericardial effusion. It appears as an echo-free space between the epicardium (visceral pericardium) and the parietal pericardium.

1. Pericardial effusion first appears posteriorly in the dependent portion of the
The presence of a small amount of effusion posteriorly without anterior effusion suggests a small pericardial effusion. A small amount of fluid, which appears only in systole, is normal.

2. With larger effusion, the fluid also appears anteriorly. The larger the echo-free space, the larger the pericardial effusion. With very large effusions, the swinging motion of the heart may be imaged.

3. In patients with chronic effusion, fibrinous strands and other organized materials can be seen in the pericardial fluid, which may lead to fluid loculations.

4. Echocardiography is very helpful in detecting cardiac tamponade. Helpful two-dimensional echocardiographic findings of tamponade are as follows:
   a. Collapse of the right atrium (RA) in late diastole (Fig. 19-2) (because the pressure in the pericardial sac exceeds the pressure within the RA at end diastole when the atrium has emptied)
   b. Collapse or indentation of the right ventricular (RV) free wall, especially the outflow tract

Management

1. Pericardiocentesis or surgical drainage to identify the cause of the pericarditis is mandatory, especially when purulent or tuberculous pericarditis is suspected. A drainage catheter may be left in place with intermittent low-pressure drainage.

2. Pericardial fluid studies include cell counts and differential, glucose, and protein concentrations; histologic examination of cells; Gram and acid-fast stains; and viral, bacterial, and fungal cultures.

3. For cardiac tamponade, urgent decompression by surgical drainage or pericardiocentesis is indicated. While getting ready for the procedure, fluid push with Plasmanate should be given to increase central venous pressure and thereby improve cardiac filling, which can provide temporary emergency stabilization.

4. Urgent surgical drainage of the pericardium is indicated when purulent pericarditis is suspected. This must be followed by IV antibiotic therapy for 4 to 6 weeks.

5. There is no specific treatment for viral pericarditis.

6. Treatment focuses on the basic disease itself (e.g., uremia, collagen disease).
7. Salicylates are given for precordial pain and nonbacterial or rheumatic pericarditis.  
8. Corticosteroid therapy may be indicated in children with severe rheumatic carditis or postpericardiotomy syndrome.
Constrictive Pericarditis

Although rare in children, constrictive pericarditis may be associated with an earlier viral pericarditis, tuberculosis, incomplete drainage of purulent pericarditis, hemopericardium, mediastinal irradiation, neoplastic infiltration, or connective tissue disorders. In this condition, a fibrotic, thickened, and adherent pericardium restricts diastolic filling of the heart.

Diagnosis of constrictive pericarditis is suggested by the following clinical findings:
1. Signs of elevated jugular venous pressure occur.
2. Hepatomegaly with ascites and systemic edema may be present.
3. Diastolic pericardial knock, which resembles the opening snap, is often heard along the left sternal border in the absence of heart murmur.
4. Chest radiograph may show calcification of the pericardium, enlargement of the superior vena cava (SVC) and left atrium (LA), and pleural effusion.
5. The ECG may show low QRS voltages, T-wave inversion or flattening, and left atrial hypertrophy (LAH). Atrial fibrillation occasionally is seen.
6. M-mode echocardiography may reveal two parallel lines representing the thickened visceral and parietal pericardia or multiple dense echoes. Two-dimensional echocardiography shows (a) a thickened pericardium, (b) a dilated inferior vena cava and hepatic vein, and (c) paradoxical septal motion and abrupt displacement of the interventricular septum during early diastolic filling (“septal bounce”) (not specific for this condition). Doppler examination of the mitral inflow reveals findings of diastolic dysfunction (see Fig. 18-6) and a marked respiratory variation in diastolic inflow tracings.
7. Cardiac catheterization may document the presence of constrictive physiology.
   a. The RA and LA pressures, ventricular end-diastolic pressures, and PA wedge pressure are all elevated and usually equalized.
   b. Ventricular pressure waveforms demonstrate the characteristic “square root sign” (in which there is an early rapid fall in diastolic pressure followed by a rapid rise to an elevated diastolic plateau).

The treatment for constrictive pericarditis is complete resection of the pericardium; symptomatic improvement occurs in 75% of patients.
Kawasaki’s Disease

Cause and Epidemiology

1. The cause of Kawasaki’s disease (also called mucocutaneous lymph node syndrome) is not known. Most investigators believe that the disease is related to, if not caused by, an infectious disease. The disease is probably driven by abnormalities of the immune system initiated by the infectious insult.
2. Children of all racial and ethnic groups are affected, although it is more common in Asians and Pacific islanders. The male-to-female ratio is 1.5 to 1. In the United States, Kawasaki’s disease is more common during the winter and early spring months.
3. It occurs primarily in young children, with a peak incidence between 1 and 2 years of age; 80% of patients are younger than 4 years of age, and 50% are younger than 2 years of age. Cases in children older than 8 years and younger than 3 months of age are uncommon.

Pathology

1. During the first 10 days after the onset of fever, generalized microvasculitis occurs throughout the body, with a predilection for the coronary arteries. Other arteries such as the iliac, femoral, axillary, and renal arteries are less frequently involved.
2. Coronary artery aneurysm develops in 15% to 20% during the acute phase and persists for 1 to 3 weeks. It tends to develop most frequently in the proximal segment of the major coronary arteries and may assume fusiform, saccular, cylindrical, or beads-on-a-string appearance.
3. During the acute phase, there is pancarditis, with inflammation of the atrioventricular (AV) conduction system (which can produce AV block), myocardium (myocardial dysfunction, CHF), pericardium (pericardial effusion), and endocardium (with aortic and mitral valve involvement).
4. Late changes (after 40 days) consist of healing and fibrosis in the coronary arteries, with thrombus formation and stenosis in the postaneurysmal segment and myocardial fibrosis from old myocardial infarction (MI).
5. The elevated platelet count seen in this condition contributes to coronary thrombosis.

Clinical Manifestations

The clinical course of the disease can be divided into three phases: acute, subacute, and convalescent. Each phase of the disease is characterized by unique symptoms and signs. Only clinical features seen in the acute phase are important in making the diagnosis of the disease, and they are discussed in depth.

Acute Phase (First 10 Days)

1. Six signs that compose the principal clinical features of Kawasaki’s disease are present
during the acute phase (Box 19-5).

a. The onset of illness is abrupt, with a high fever, usually above 39°C (102°F) and in many cases above 40°C (104°F). Fever persists for a mean of 11 days without treatment. With appropriate therapy, the fever usually resolves within 2 days of treatment. Within 2 to 5 days after the onset of fever, other principal features develop.

b. Conjunctivitis occurs shortly after the onset of fever. It is not associated with exudate, being different from that seen in other conditions such as measles, Stevens-Johnson syndrome, or viral conjunctivitis. Conjunctivitis resolves rapidly.

c. Changes in the lips and oral cavity include (1) erythema, dryness, fissuring, peeling, cracking, and bleeding of the lips; (2) “strawberry tongue” that is indistinguishable from scarlet fever; (3) diffuse erythema of the oropharyngeal mucosa. Oral ulceration and pharyngeal exudates are not seen.

d. Changes in the hands and feet consist of erythema of the palms and soles, firm edema, and sometimes painful induration. Desquamation of hands and feet takes place within 2 to 3 weeks.

e. The rash usually appears within 5 days of the onset of fever and may take many forms (except bullous and vesicular eruptions) even in the same patient. The most common is a nonspecific, diffuse maculopapular eruption. Its distribution is extensive involving the trunk and extremities, with accentuation in the perineal region (where early desquamation may occur); desquamation usually occurs by days 5 to 7.

f. Cervical lymph node enlargement is the least common of the principal clinical features, occurring in approximately 50% of patients. The firm swelling is usually unilateral, involves more than one node measuring larger than 1.5 cm in diameter, and is confined to the anterior cervical triangle.

2. Cardiovascular abnormalities result from involvement of the pericardium,
myocardium, endocardium, valves, and coronary arteries, with some or all of the following manifestations:

a. Tachycardia, gallop rhythm, or other signs of heart failure
b. LV dysfunction with cardiomegaly (myocarditis)
c. Pericardial effusion
d. Mitral valve regurgitation murmur
e. Chest radiographs may show cardiomegaly if myocarditis or significant coronary artery abnormality or valvular regurgitation is present.
f. ECG changes may include arrhythmias, prolonged PR interval (occurring in up to 60%), and nonspecific ST-T changes. Abnormal Q waves (wide and deep) in the limb leads or precordial leads suggest MI.
g. Coronary artery abnormalities are seen initially at the end of the first week through the second week of illness (see below for further discussion).

3. Involvement of other organ systems is also frequent during the acute phase.

a. Musculoskeletal system: Arthritis or arthralgia of multiple joints (30%) involving small joints as well as large joints
b. Genitourinary system: Sterile pyuria (60%)
c. GI system: Abdominal pain with diarrhea (20%), liver dysfunction (40%), hydrops of the gallbladder (10%, demonstrable by abdominal ultrasonography) with jaundice
d. CNS: Irritability, lethargy or semicoma, aseptic meningitis (25%), and sensory neuronal hearing loss

4. Laboratory studies: Even though laboratory results are nonspecific, they provide diagnostic support of the disease during the acute phase. For example, Kawasaki’s disease is unlikely if acute phase reactants and platelet counts are normal after 7 days of the illness.

a. Marked leukocytosis with a shift to the left and anemia are common.
b. Acute phase reactant levels (C-reactive protein [CRP] levels, erythrocyte sedimentation rate [ESR]) are always elevated, which are uncommon with viral illnesses. An elevated ESR (but not CRP) can be caused by intravenous immunoglobulin (IVIG) infusion per se.
c. Thrombocytosis (usually ≥450,000/mm³) occurs after day 7 of the illness, sometimes reaching 600,000 to greater than 1 million/mm³ during the subacute phase. A low platelet count suggests viral illnesses.
d. Pyuria (caused by urethritis) is common on microscopic examination.
e. Liver enzymes are moderately elevated (more than two times the upper limit of normal) in 40% of patients, hypoalbuminemia, and mild hyperbilirubinemia may be present in 10%.
f. Elevated serum cardiac troponin I may occur, which suggests myocardial damage.
g. Lipid abnormalities are common. Decreased levels of high-density lipoprotein are present during the illness and follow-up for more than 3 years, especially in patients with persistent coronary artery abnormalities. The total cholesterol level is normal, but the triglyceride level tends to be high. Repeat measurement is recommended 1 year later in patients with abnormal lipid profiles.
5. Echocardiography: The main purpose of an echocardiographic study during the acute phase is to detect coronary artery aneurysm and other cardiac dysfunction.
   a. Coronary artery aneurysm rarely occurs before day 10 of illness. During this period, other echocardiographic findings may suggest cardiac involvement.
      (1) Perivascular brightness and ectasia (dilatation) may represent coronary arteritis (before aneurysm formation)
      (2) Decreased LV systolic function with increased LV dimensions
      (3) Mild mitral valve regurgitation (presumably from myocarditis, MI, or coronary artery occlusion)
      (4) Pericardial effusion
   b. Multiple echocardiographic views should be obtained to visualize all major coronary artery segments (left main coronary artery [LMCA], left anterior descending [LAD], left circumflex coronary artery [LCX], and right coronary artery [RCA]).
   c. The configuration (saccular, fusiform, ectatic), size, and number of aneurysm and the presence or absence of intraluminal or mural thrombi should be assessed. Aneurysms are classified as saccular (nearly equal axial and lateral diameters), fusiform (symmetric dilatation with gradual proximal and distal tapering), and ectatic (dilated without segmental aneurysm). “Giant” aneurysm is present when the diameter of the aneurysm is 8 mm or larger. Figure 19-3 shows a large saccular aneurysm of the RCA.
   Clinical findings seen during the subacute phase and convalescent phase are not important in diagnosis or planning management, but they are more or less useful in confirming the diagnosis at a later time.

**Subacute Phase (11–25 Days after Onset)**
1. Desquamation of the tips of the fingers and toes is characteristic.
2. Rash, fever, and lymphadenopathy disappear.
3. Significant cardiovascular changes, including coronary aneurysm, pericardial effusion, CHF, and MI, occur in this phase. Approximately 20% of patients manifest coronary artery aneurysm on echocardiography.
4. Thrombocytosis also occurs during this period, peaking at 2 weeks or more after the onset of the illness.
Convalescent Phase

This phase lasts until the elevated ESR and platelet count return to normal. Deep transverse grooves (Beau’s lines) may appear across the fingernails and toenails.

Diagnosis

There is no specific diagnostic test or pathognomonic clinical feature of Kawasaki’s disease. The diagnosis of Kawasaki’s disease relies on clinical criteria. Box 19-5 lists the principal clinical features that establish the diagnosis. In cases with less than full criteria for the disease (incomplete Kawasaki’s disease), other clinical and laboratory findings (as discussed earlier) may aid physicians in making decision to initiate treatment. One could also consider the Harada score (see below) in the decision making to initiate treatment.

1. The presence of fever for 5 days or longer and at least four of the five principal criteria (see Box 19-5) are required to make the diagnosis of Kawasaki’s disease. More than 90% of patients have fever plus the first four of the five signs, but only about 50% of patients have lymphadenopathy.

2. However, patients with fever for 5 days or longer and fewer than four criteria can be diagnosed as having Kawasaki’s disease when a coronary artery abnormality is detected. Indeed, a substantial fraction of children with Kawasaki’s disease with coronary artery anomalies never meet the diagnostic criteria. However, coronary aneurysm rarely occurs before day 10 of Kawasaki’s disease. During this period, perivascular brightness or ectasia (dilatation) of the coronary artery, decreased LV systolic function, mild MR, or pericardial effusion may be present instead.

3. In the presence of four or more principal criteria plus fever, a diagnosis of Kawasaki’s
disease can be made on day 4 of illness rather than waiting until day 5 of illness. (However, there appears to be no advantage giving IVIG before 5 days of illness in preventing coronary artery aneurysm.)

4. Incomplete (preferable to “atypical”) Kawasaki’s disease with two or three principal clinical features creates a management problem. Incomplete Kawasaki’s disease is more common in young infants than older children. Given the potential serious consequences of missing the diagnosis of Kawasaki’s disease in patients with incomplete manifestations of the principal clinical features, together with the efficiency and safety of early treatment with IVIG, physicians should not wait for full manifestations of the disease but should consider other clinical manifestations and laboratory findings in deciding whether or not to initiate treatment.

a. When incomplete Kawasaki’s disease is suspected, some laboratory tests should be obtained because their results are similar to those found in complete cases.
   (1) Abnormal acute phase reactants (CRP ≥3.0 mg/dL and ESR ≥40 mm/hr) are very helpful.
   (2) Other helpful supplemental laboratory tests (with their abnormal values shown in parentheses) are serum albumin (≤3.0 g/dL), anemia for age, alanine aminotransferase (>50 or 60 U/L), platelets after 7 days (≥450,000/mm$^3$), white blood cell count (≥15,000/mm$^3$), and urine white blood cell count (≥10 cells/high-power field).
   (3) Patients with positive acute phase reactants plus three or more abnormal supplemental laboratory test results may be given treatment along with echocardiographic studies. Even if there are fewer than three abnormal laboratory test results, patients with abnormal echocardiographic findings qualify for treatment.

b. Echocardiographic studies should also be obtained, especially in young infants with fever for longer than 7 days.

5. The detection of coronary artery abnormalities relies on the measurement of the proximal coronary artery segments. Kurotobi et al (2002) published the mean and prediction limits of 2 and 3 standard deviations (SDs) of major coronary artery segments in normal infants and children and those with Kawasaki’s disease, which are shown in Appendix D (Table D-6). One must measure the dimension at a specific point as shown in the figure in Table D-6. The LMCA is measured at a point between the ostium and the first bifurcation of the artery, the LAD distal to and away from the bifurcation of the branch from the LMCA and the RCA in the relatively straight section of the artery just after rightward turn from the initial anterior course of the artery. A coronary dimension that is greater than +3 SD in one of the three proximal segments (LMCA, LAD, and RCA) or one that is greater than +2.5 SD in two proximal segments is highly unusual in the normal population (Kurotobi et al, 2002).

6. The Harada score has been devised to predict increased risk of developing coronary aneurysm. According to this score, when assessed in the first 9 days of the illness, the presence of four of the following criteria indicates a case at high risk for future development of coronary artery aneurysm: (a) white blood cell count above 12,000/mm$^3$,..
(b) platelet count above 350,000/mm$^3$, (c) CRP greater than +3, (d) hematocrit less than 35%, (e) albumin less than 3.5 g/dL, (f) age 12 months or younger, and (g) male sex. These criteria have been adopted by the AHA Committee.

**Differential Diagnosis**

One must rule out diseases with similar manifestations through appropriate cultures and the use of laboratory tests (Box 19-6). Measles and group A β-hemolytic streptococcal infection most closely mimic Kawasaki’s disease. Children with Kawasaki’s disease are extremely irritable (often inconsolable). In addition, children with Kawasaki’s disease are less likely to have exudative conjunctivitis, pharyngitis, generalized lymphadenopathy, or discrete intraoral lesions (Koplik’s spot) and are more likely to have a perineal distribution of their rash. Other diseases with findings similar to Kawasaki’s disease, such as viral exanthems, drug reactions, juvenile rheumatoid arthritis, and Rocky Mountain spotted fever, require differentiation. Viral illness is more likely if acute phase reactants and platelet counts are normal after 7 days of the illness.

**Management**

No specific therapy is available. Two goals of therapy are reduction of inflammation within the coronary artery and in the myocardium (by IV gamma globulin) and prevention of thrombosis by inhibition of platelet aggregation (by aspirin).

1. A high-dose (2 g/kg), single infusion (given in a 10- to 12-hour infusion) of IVIG with aspirin (80–100 mg/kg per day) given within 10 days and, if possible, within 7 days of illness is considered the treatment of choice.
2. IVIG, not aspirin, significantly reduces the prevalence of coronary artery abnormalities. Aspirin only helps reduce thrombus formation but does not reduce coronary artery aneurysm.

   a. After IVIG infusion, two thirds of patients become afebrile by 24 hours after completion of infusion; 90% are afebrile by 48 hours.
   b. A repeat dose (2 g/kg) of IVIG is indicated in children with a persistent fever.
   c. IVIG given before 5 days of illness appears no more likely to prevent coronary aneurysm but was associated with increased need for retreatment with gamma globulin for persistent or recrudescent fever.
   d. Gamma globulin should be given even after day 10 of illness if the patient has persistent fever, aneurysms, or ongoing systemic inflammation (by ESR or CRP).
   e. Measles and varicella immunization should be deferred for 11 months after a child receives high-dose IVIG.

**BOX 19-6 Differential Diagnosis of Kawasaki’s Disease**

- Viral infections (e.g., measles, adenovirus, enterovirus, Epstein-Barr virus)
- Scarlet fever
3. Aspirin has antiinflammatory effects at high doses (80–100 mg/kg/day) and an antiplatelet action at low doses (3–5 kg/day).
   a. The initial high dose of aspirin is reduced to 3 to 5 mg/kg/day in a single dose after the child has been afebrile for 48 to 72 hours. Some physicians continue high-dose aspirin until day 14 of illness and for 48 to 72 hours or more after fever cessation.
   b. Aspirin is continued until the patient shows no evidence of coronary changes by 6 to 8 weeks after the onset of illness.
   c. For children who develop coronary abnormalities, aspirin may be continued indefinitely.
   d. Some Japanese authorities recommend the antiplatelet dose of aspirin from the onset because the high dose does not have antiplatelet action; does not appear to reduce coronary aneurysm; and may result in increased frequency of hepatotoxicity, GI irritation and bleeding, and Reye’s syndrome.

4. A concomitant use of corticosteroids has been reported to reduce the duration of fever and possibly the incidence of coronary aneurysm (Okada et al, 2003). An earlier study, before IVIG was available, suggested that corticosteroids exert a detrimental effect with increased incidence of coronary aneurysm. Therefore, the usefulness of steroids in the initial treatment of Kawasaki’s disease is not well established at this time.

5. Recently, the administration of infliximab, another antiinflammatory agent, has increased in the United States despite the absence of clinical evidence of its efficacy (Son et al, 2009). Infliximab, a monoclonal antibody to tumor necrosis factor α (TNF-α), blocks the attachment of TNF-α to T cells, ameliorating the inflammatory response. Because TNF-α has inflammatory and thrombotic properties, blocking its actions appears to be a logical approach. Infliximab has been approved by the Food and Drug Administration (FDA) for use in children with Crohn’s disease.

6. For patients who continue to be febrile after IVIG (occurring in about 10% of patients), repeat IVIG (2 g/kg) is generally recommended. If the patient continues to have fever despite two or more courses of IVIG, the use of corticosteroid therapy may be tried.

7. In patients with large coronary artery aneurysm, administration of abciximab, a platelet glycoprotein IIb/IIIa receptor inhibitor, was associated with greater regression of
the aneurysm compared with patients who received only the standard treatment (γ-globulin, aspirin) at 4 to 6 months of follow-up (Williams et al, 2002).

8. In patients with coronary artery aneurysm, therapeutic regimens used depend on the severity of coronary involvement.
   a. For mild and stable disease, low-dose aspirin may be appropriate.
   b. With increasing severity and extent of coronary involvement, the combination of aspirin with other antiplatelet agents (e.g., dipyridamole [Persantine], clopidogrel [Plavix]) may be more effective in suppressing platelet activation.
   c. For giant aneurysm or the combination of stenosis and aneurysm, low-dose aspirin together with warfarin (with international normalized ratio maintained at 2.0–2.5) should be used.

Natural History
Kawasaki’s disease is a self-limited disease for most patients. Cardiovascular involvement is the most serious complication.
1. Coronary aneurysm develops in 15% to 25% of untreated patients and is responsible for MI (<5%) and mortality (1%–5%). Significantly higher temperature (101.3°F [38.5°C] on days 9–12) and longer duration of fever (more than 14 days) appear to be risk factors for coronary aneurysm. Despite prompt treatment with high-dose IVIG, at least transient coronary artery abnormalities develop in 5% of the patients and giant aneurysm in 1%.
2. Angiographic resolution of aneurysm 1 to 2 years after the illness occurs in 50% to 67% of the patients, but these arteries do not dilate in response to exercise or coronary vasodilators. In some patients, stenosis, tortuosity, and thrombosis of the coronary arteries result. The resolution appears to be more likely to occur with a smaller aneurysm, age at onset younger than 1 year, fusiform rather than saccular aneurysm, and aneurysm located at a distal coronary segment.
3. More than 70% of MIs occur in the first year after onset of the disease without warning symptoms or signs. Giant aneurysm (>8 mm) is associated with a greater morbidity and mortality (because of thrombotic occlusion or stenotic obstruction and subsequent MI).
4. If the coronary arteries remain normal throughout the first month after onset, subsequent development of a new coronary lesion is extremely unusual.

Long-Term Follow-up
Serial cardiology follow-up is important for evaluation of the cardiac status. The recommendations of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, American Heart Association (2004) are summarized in Table 19-2.
1. For children with no or transient coronary abnormalities, aspirin is discontinued after 6 to 8 weeks. No follow-up diagnostic tests are indicated. Only periodic counseling is recommended.
2. If the patient has a coronary aneurysm, low-dose aspirin is continued indefinitely. With a large aneurysm, a combination of aspirin and warfarin is indicated.
3. Varying levels of activity restriction are indicated in patients who have coronary artery aneurysm (see Table 19-2).

4. Echocardiography: In the absence of coronary artery abnormalities in the first 6 to 8 weeks, follow-up echocardiograms are not indicated. If significant abnormalities of the coronary vessels, LV dysfunction, or valvular regurgitation are found, the echocardiogram should be repeated at 6- to 12-month intervals.

5. Exercise stress testing or myocardial perfusion evaluation is indicated in children with coronary artery aneurysms at 1- to 2-year intervals.

6. Occasionally, coronary angiography may be indicated in infants with large aneurysms or stenosis, in patients with symptoms suggestive of ischemia, in patients with positive exercise tests or thallium study findings, and those with evidence of MI.

7. Rarely, for patients with evidence of reversible ischemia from coronary artery stenosis (demonstrable on stress imaging tests), percutaneous intervention, such as balloon angioplasty, rotational atherectomy, stenting, or a combination of these procedures may be indicated (Ishii et al, 2002). On rare occasions, coronary artery bypass surgery may be indicated. The internal mammary artery graft may be used for bypass surgery.
Lyme Carditis

Prevalence
Lyme carditis occurs in about 10% of patients with Lyme disease.

Cause and Pathology
1. Lyme disease is the leading tickborne illness in North America and Europe. The disease is endemic in three U.S. regions: the Northeast (most commonly in coastal areas from Maryland to northern Massachusetts), the upper Midwest (Wisconsin and Minnesota), and the Far West (California and Oregon). The disease has been reported from every part of the world, including most of the United States. The disease is named after the town of Old Lyme, Connecticut, where a number of cases were identified in 1975.
2. It is caused by the spirochete *Borrelia burgdorferi*, which is carried by hard-bodied ticks (e.g., *Ixodes dammini*). The spirochete initially produces a characteristic skin lesion (erythema chronicum migrans) and then spreads through the lymphatics and bloodstream and disseminates to other organs, including the heart and the central and peripheral nervous system.
3. The organism can be found in the heart and other parts of the body and is responsible for the clinical symptoms and signs.

| TABLE 19-2 |
| FOLLOW-UP RECOMMENDATIONS ACCORDING TO THE DEGREE OF CORONARY ARTERY INVOLVEMENT |
Clinical Manifestations

1. Most cases are identified during the summer months, and a history of tick bites may be elicited.

2. Lyme disease can be divided into three stages.
   a. **Stage 1** (localized erythema migrans) begins 3 to 30 days after the tick bite with the onset of influenza-like symptoms (fever, headache, myalgia, arthralgias, malaise) and the characteristic rash, *erythema chronicum migrans*. The skin lesion, seen in 60% to 80% of patients at the site of the tick bite, begins as a macule or papule followed by progressive expansion of an erythematous ring over approximately 7 days. The ring may be as large as 15 cm with red borders and central clearing, most often appearing on the thigh, groin, or axilla. Erythema migrans lesions usually fade within 3 to 4 weeks, but they may recur.
   b. **Stage 2** (disseminated infection) starts 2 to 12 weeks after the tick bite. Neurologic (10% to 15%) and cardiac (10%) manifestations occur in this stage. The classic triad of Lyme neuroborreliosis includes aseptic meningitis, cranial nerve palsies (most commonly, unilateral or bilateral Bell’s palsy), and peripheral radiculoneuropathy. The most common cardiac manifestation is fluctuating AV block (see later discussion), although myocarditis, pericarditis, and LV dysfunction can occur.
   c. **Stage 3** (persistent infection) manifests as large-joint arthritis weeks to years after stage 2 and is seen in about 50% of the patients not previously treated. In general,
joint manifestation is self-limited but may recur in patients who do not receive appropriate antibiotic therapy.

3. Cardiac manifestations occur in about 10% of cases. They generally appear 4 to 8 weeks after the initial illness, but their appearance can vary from 4 days to 7 months. The most common cardiac manifestation is varying degrees of AV block, occurring in up to 87% of cases. More than 95% of these patients show first-degree AV block at some time in their course. Up to 50% develop complete heart block, and some of them develop permanent heart block. First-degree AV block can change to complete heart block within minutes.

**Diagnosis**

1. The diagnosis is suggested by the presence of the distinctive erythema chronicum migrans and other features of Lyme disease. A history of tick exposure (e.g., travel to an endemic area) and any of the manifestations of stages 2 and 3 are important clues to the disease. The presence of AV block alone is not specific for Lyme carditis; it can be caused by other infective agents, such as viral infections (coxsackievirus A and B, echovirus, mumps, polio), rickettsial infections, *Treponema pallidum*, *Yersinia enterocolitica*, toxoplasmosis, diphtheria, and Chagas’ disease.

2. Although cultivation or visualization of *B. burgdorferi* is the most reliable technique to confirm the diagnosis, this test is rarely positive.

3. Enzyme-linked immunosorbent assays (ELISAs) are probably more accurate than indirect immunofluorescence assays. The diagnosis of Lyme disease is confirmed if there is a single titer greater than 1:256 or a fourfold increase in antibody titer over time and compatible clinical symptoms.

**Management**

1. Doxycycline (100 mg twice a day orally for 14–21 days) is the drug of choice for children older than 8 years of age. For children younger than 8 years of age, amoxicillin (25–50 mg/kg per day orally divided into two doses for 2 to 3 weeks) is the drug of choice. For patients allergic to penicillin, cefuroxime axetil is an alternative.

2. If antibiotic therapy is begun in stage 1, the duration of the skin lesion is shortened, and subsequent complications can be averted. Antibiotic treatment also improves cardiac and neurologic symptoms.

3. Heart block responds to antibiotic treatment, usually within 6 weeks, and has a good prognosis.

4. For high-level AV block, temporary pacing may be indicated (in up to one third of patients).

5. Recently, a Lyme disease vaccine (LYMERix, SmithKline Beecham) was licensed by the U.S. FDA for persons 15 to 70 years of age. The vaccine seems to be safe and effective, but its cost effectiveness has yet to be determined.
Postpericardiotomy Syndrome

Postpericardiotomy syndrome is a febrile illness with inflammatory reaction of the pericardium and pleura that develops after surgery involving pericardiotomy. It is believed to be an autoimmune response to damaged myocardium or pericardium or blood in the pericardial sac. There is also possibility of anti-heart antibodies created idiomatically or caused by concurrent cross-reactivity of the antibodies produced against viral antigens. However, the latter assumption is not fully proven because of conflicting studies. The incidence is about 25% to 30% of patients who receive pericardiotomy. A nonsurgical example of this syndrome is seen after MI (Dressler’s syndrome) and traumatic hemopericardium. It can occur after percutaneous coronary intervention or after pacemaker or pacemaker wire placement.

Clinical Manifestations

1. The onset of the syndrome is a few weeks to a few months (median, 4 weeks) after cardiac surgery that involves pericardiotomy. It is rare in infants younger than 2 years of age.
2. The syndrome is characterized by fever and chest pain. Fever may be sustained or spike up to 104°F (40°C). Chest pain may be severe, caused by both pericarditis and pleuritis. Chest pain resulting from pericardial effusion radiates to the left side of the chest and shoulder and worsens in a supine position. Pleural pain worsens on deep inspiration. On physical examination, pericardial and pleural friction rubs and hepatomegaly are usually present. Tachycardia, tachypnea, rising venous pressure, and falling arterial pressure with a paradoxical pulse are signs of cardiac tamponade.
3. Chest radiographs show an enlarged cardiac silhouette and pleural effusion, especially on the left. The ECG shows persistent ST-segment elevation and flat or inverted T waves in the limb leads and left precordial leads.
4. Echocardiography is the most reliable test in confirming the presence and amount of pericardial effusion and in evaluating evidence of cardiac tamponade.
5. Leukocytosis with a shift to the left and an elevated ESR rate are present. Acute phase reactant (ESR, CRP) levels are elevated.
6. Although the disease is self-limited, its duration is highly variable; the median duration is 2 to 3 weeks. Recurrences are common, appearing in 21% of patients.

Management

1. Bed rest is all that is needed for mild cases.
2. Nonsteroidal antiinflammatory agents, such as ibuprofen or indomethacin, may be effective in most cases.
3. In severe cases, moderate doses of corticosteroids may be indicated for a few days if the diagnosis is secure and infection has been ruled out. A more prompt response is seen with steroid therapy, but a serious drawback is the tendency for the condition to rebound.
after withdrawal of the drug, with some patients becoming steroid bound.
4. Emergency pericardiocentesis may be required if signs of cardiac tamponade are present.
5. Diuretics may be used for pleural effusion.
6. Pericardiectomy may be necessary in patients with recurrent effusion.
Postperfusion Syndrome

Postperfusion syndrome, which occurs only after open-heart surgery using a pump oxygenator, is caused by CMV infection. The virus may be transmitted to the patient from a viremia from healthy donors. The syndrome has almost disappeared because freshly drawn blood is no longer used except in patients with severe cyanotic heart defects.

Clinical Manifestations

1. The onset is 4 to 6 weeks after cardiac surgery using cardiopulmonary bypass.
2. The syndrome is characterized by the triad of fever, splenomegaly, and atypical lymphocytosis. Hepatomegaly is also common. Low-grade fever, with elevations to 100° to 102°F (37.7°–38.8°C) occur. Malaise and anorexia are commonly present.
3. The fever and atypical lymphocytosis are short-term manifestations (lasting about 2 weeks), but splenomegaly usually lasts 3 to 4 weeks to 3 to 4 months. No recurrence has been reported.
4. The white blood cell count may be normal, but atypical lymphocytes are seen in the peripheral smears. CMV may be demonstrated in the urine, or a changing titer to the virus may be demonstrated in the serum.

Management

1. No specific treatment is available.
2. The syndrome is self-limited, lasting for a week to a few months.
Infection with HIV has become a major pediatric health concern in the United States and around the world. The clinical manifestations of HIV infection are well known to primary care physicians, but the significance of cardiovascular manifestations (cardiomyopathy) is less well known.

**Clinical Manifestations**

1. Initial symptoms may be subtle or nonspecific. Recurrent infections by opportunistic infective agents and by encapsulated organisms are common (occurring in 20%). GI candidiasis, periodontal disease, oral or esophageal ulcerations, and chronic or recurrent diarrhea with failure to thrive are frequent. Elevation of hepatic transaminases with or without cholestasis occasionally occurs. Anemia (occurring in 20%–70%), leukopenia, neutropenia, and thrombocytopenia (occurring in 10%–20%) may be seen. In contrast to adults, malignancies (non-Hodgkin’s lymphoma, primary CNS lymphoma, and leiomyosarcoma) are infrequent in children (2% of cases).

2. CNS involvement in perinatally infected children occurs in 40% to 90%, with a median age of 19 months. Progressive encephalitis is the most common form of CNS manifestation, with loss of motor development, cognitive deterioration, and acquired microcephaly. Imaging may show cerebral atrophy (in 85%), increased ventricular size, and basal ganglia calcifications.

3. In children, the prevalence of cardiovascular manifestations is about 20%, and these manifestations are importantly related to prognosis. HIV RNA transcripts have been found in the myocardium of patients with cardiomyopathy. The virus may infect the structure directly or may have an indirect role in the pathogenesis of myocardial manifestations. Coinfection with other viruses, such as Epstein-Barr virus and CMV; malnutrition; and wasting may also contribute to the cardiac-related morbidity and mortality and the overall mortality.

   Common cardiovascular manifestations include cardiomyopathy, myocarditis, pericarditis, cardiac arrhythmias, and chronic CHF. The ECG and echocardiographic studies are helpful in detecting preclinical abnormalities of the cardiovascular system.

   a. Cardiac examination may reveal sinus tachycardia (in 64% of cases), gallop rhythm, tachypnea, and hepatosplenomegaly—all signs of CHF.

   b. Besides tachycardia, the ECG may show atrial and ventricular ectopic beats and second-degree AV block.

   c. Echocardiographic studies may demonstrate diminished LV contractility (in 26%), with some patients having dilated cardiomyopathy and others having hypertrophy of the LV. Pericardial effusions are frequent (26%), caused by opportunistic viral and bacterial infections, including mycobacteria. Occasionally, cardiac tamponade develops, which requires emergency pericardiocentesis. Calcification of cardiac valves also occurs. The incidence of these abnormalities is higher in vertically infected children than in an uninfected cohort from HIV-infected mothers.
d. The presence of pericardial effusion correlates highly with pleural effusion and ascites. Thus, in children with pleural effusion or ascites, pericardial effusion and cardiac abnormalities should be suspected.

**Prognosis**

The disease progresses more rapidly in children than in infected adults. Cardiac dysfunction is a predictor of poor prognosis. In children, the 1-year mortality rate after the diagnosis of CHF is about 70%, and most children with CHF die within 2 years of the diagnosis. If cardiac abnormalities are diagnosed early, preventive and therapeutic strategies for progressive LV dysfunction can be applied.

**Management**

1. It has been shown that monthly IV infusion of immune globulin improves LV function in HIV-infected patients. This suggests that the LV dysfunction may be immunologically mediated.
2. An early study indicates that zidovudine neither worsens nor ameliorates progressive cardiac changes in HIV-infected patients.
3. Antibiotics are indicated when there is a bacterial infection of the pericardium or other structures.
4. Emergency pericardiocentesis may be required when tamponade is present.
5. If CHF develops, anticongestive measures, including diuretics, inotropic agents, and afterload-reducing agents, are indicated.
Acute Rheumatic Fever

Prevalence
Acute rheumatic fever is relatively uncommon in the United States but is a common cause of heart disease in less developed countries. However, in the past few decades, new outbreaks have occurred, and new sporadic cases are being reported in the United States.

Cause
1. Acute rheumatic fever is believed to be an immunologic response that occurs as a delayed sequela of group A streptococcal infection of the pharynx but not of the skin. The attack rate of acute rheumatic fever after streptococcal infection varies with the severity of the infection, ranging from 0.3% to 3%.
2. Important predisposing factors include family history of rheumatic fever, low socioeconomic status (poverty, poor hygiene, medical deprivation), and age between 6 and 15 years (with a peak incidence at 8 years of age).

Pathology
1. The inflammatory lesion is found in many parts of the body, most notably in the heart, brain, joints, and skin.
2. Rheumatic carditis was considered to be pancarditis, with myocarditis being the most important element. It is now recognized that the valvular component may be as important as or much more important than myocardial and pericardial involvement. In rheumatic myocarditis, myocardial contractility is rarely impaired, and the serum level of troponin is not elevated. It is not only the valve leaflets that are heavily involved with fibrinous vegetations on the coapting surfaces, but the entire mitral valve apparatus is also involved (with annular dilatation and stretching of chordae tendineae).
3. Valvular damage most frequently and most severely involves the mitral, less commonly the aortic, and rarely the tricuspid and pulmonary valves.
4. Aschoff bodies in the atrial myocardium are believed to be characteristic of rheumatic fever. These consist of inflammatory lesions associated with swelling, fragmentation of collagen fibers, and alterations in the staining characteristics of connective tissue, now believed to be necrotic myocardial cells.

Clinical Manifestations
Acute rheumatic fever is diagnosed by the use of revised Jones criteria (updated in 1993; see Box 20-1). The criteria are three groups of important clinical and laboratory findings: (1) five major manifestations, (2) four minor manifestations, and (3) supporting evidence of an antecedent group A streptococcal infection. These and other important clinical
findings are presented here.

**History**

1. History of streptococcal pharyngitis, 1 to 5 weeks (average, 3 weeks) before the onset of symptoms, is common. The latent period may be as long as 2 to 6 months (average, 4 months) in cases of isolated chorea.

### BOX 20-1 Guidelines for the Diagnosis of Initial Attack of Rheumatic Fever

<table>
<thead>
<tr>
<th>MAJOR MANIFESTATIONS</th>
<th>MINOR MANIFESTATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carditis</td>
<td>Clinical Findings</td>
</tr>
<tr>
<td>Polyarthritis</td>
<td>Arthralgia</td>
</tr>
<tr>
<td>Chorea</td>
<td>Fever</td>
</tr>
<tr>
<td>Erythema marginatum</td>
<td>Laboratory Findings</td>
</tr>
<tr>
<td>Subcutaneous nodule</td>
<td>Elevated acute-phase reactants (ESR, CRP)</td>
</tr>
<tr>
<td></td>
<td>Prolonged PR interval</td>
</tr>
</tbody>
</table>

**Supporting Evidence of Antecedent Group A Streptococcal Infection**

- Positive throat culture or rapid streptococcal antigen test result
- Elevated or rising streptococcal antibody titer

---

* If supported by evidence of preceding group A streptococcal infection, the presence of two major manifestations or of one major and two minor manifestations indicates a high probability of acute rheumatic fever.

From Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki’s Disease of the Council of Cardiovascular Disease in the Young, American Heart Association: Circulation 87:302-307, 1993.

2. Pallor, malaise; easy fatigability; and other history, such as epistaxis (5%–10%) and abdominal pain, may be present.

**Major Manifestations**
Five major criteria of acute rheumatic fever are discussed below.

**Arthritis**

Arthritis, the most common manifestation of acute rheumatic fever (70% of cases), usually involves large joints (e.g., knees, ankles, elbows, wrists). Often more than one joint is involved, either simultaneously or in succession, with a characteristic migratory nature of the arthritis. Swelling, heat, redness, severe pain, tenderness, and limitation of motion are common. If the patient was given salicylate-containing analgesics, these signs of inflammation may be mild. The arthritis responds dramatically to salicylate therapy; if patients treated with salicylates (with documented therapeutic levels) do not improve in 48 hours, the diagnosis of acute rheumatic fever probably is incorrect.

**Carditis**

Carditis occurs in 50% of patients. Signs of carditis include some or all of the following.

1. Tachycardia (out of proportion to the degree of fever) is common; its absence makes the diagnosis of myocarditis unlikely.
2. A heart murmur of mitral regurgitation (MR) or aortic regurgitation (AR) (or both) is almost always present. Although the American Heart Association’s Jones criteria recommend not to make the diagnosis of acute rheumatic carditis without audible murmurs of MR or AR, this is debatable. Significant echocardiographic abnormalities may be present in the absence of heart murmur.

   Echocardiographic examination can determine the severity of cardiac enlargement, the presence and degree of MR and AR, and the presence of pericardial effusion more objectively than auscultation can. Inclusion of echocardiographic abnormalities may enhance the correct diagnosis of acute rheumatic carditis (Vijayalakshmi et al, 2005). However, a hemodynamically insignificant echocardiographic finding of MR alone is considered insufficient to diagnose myocarditis. Gross prolapse of the mitral valve or the presence of posterolateral (not central) MR jet by color-flow mapping may be significant. (With chronic rheumatic MR, fusion of the leaflets and cordae and contracture of these structures occur, and the regurgitation jets tends to become more central.) Other abnormal echocardiographic findings may include pericardial effusion, increased left ventricular (LV) dimension, or impaired LV function.
3. Pericarditis (with friction rub, pericardial effusion, chest pain, and electrocardiographic [ECG] changes) may be present. Pericarditis does not occur without mitral valve involvement in rheumatic fever. Pericardial effusion is usually of small amount and almost never causes cardiac tamponade.
4. Cardiomegaly on chest radiograph is indicative of severity of rheumatic carditis (or valvulitis) or congestive heart failure (CHF).
5. Signs of CHF (gallop rhythm, distant heart sounds, cardiomegaly) are indications of severe cardiac dysfunction.

**Erythema Marginatum**
Erythema marginatum occurs in fewer than 10% of patients with acute rheumatic fever. The characteristic nonpruritic serpiginous or annular erythematous rashes are most prominent on the trunk and the inner proximal portions of the extremities; they are never seen on the face. The rashes are evanescent, disappearing on exposure to cold and reappearing after a hot shower or when the patient is covered with a warm blanket. They seldom are detected in air-conditioned rooms.

**Subcutaneous Nodules**
Subcutaneous nodules are found in 2% to 10% of patients, particularly in cases with recurrences; it is almost never present as a sole manifestation of rheumatic fever. They are hard, painless, nonpruritic, freely movable, swelling, and 0.2 to 2 cm in diameter. They usually are found symmetrically, singly or in clusters, on the extensor surfaces of both large and small joints, over the scalp, or along the spine. They are not transient, lasting for weeks, and have a significant association with carditis. Subcutaneous nodules are not exclusive to rheumatic fever. They occur in 10% of children with rheumatoid arthritis, and benign subcutaneous nodules have been described in children and adults. In adults, they occur with rheumatoid arthritis, systemic lupus erythematosus (SLE), and other diseases.

**Sydenham’s Chorea**
Sydenham’s chorea (St. Vitus’ dance) is found in 15% of patients with acute rheumatic fever. It occurs more often in prepubertal girls (8–12 years) than in boys. It is a neuropsychiatric disorder consisting of both neurologic signs (choreic movement and hypotonia) and psychiatric signs (e.g., emotional lability, hyperactivity, separation anxiety, obsessions, and compulsions). It begins with emotional lability and personality changes. These are soon replaced (in 1–4 weeks) by the characteristic spontaneous, purposeless movement of chorea (which lasts 4–18 months), followed by motor weakness. The distractability and inattentiveness outlast the choreic movements. The adventitious movements, weakness, and hypotonia continue for an average of 7 months (up to 17 months) before slowly waning in severity. Recently, elevated titers of “antineuronal antibodies” recognizing basal ganglion tissues have been found in more than 90% of patients. The levels of the antineuronal antibody titer are positively related to the severity of choreic movements. These findings suggest that chorea may be related to dysfunction of basal ganglia and cortical neuronal components.

**Minor Manifestations**
The following are four minor criteria for the diagnosis of acute rheumatic fever.
1. Arthralgia refers to joint pain without the objective changes of arthritis. It must not be considered a minor manifestation when arthritis is used as a major manifestation in making the diagnosis of rheumatic fever.
2. Fever (usually with a temperature of at least 102°F [38.8°C]) is present early in the course of untreated rheumatic fever.
3. In laboratory findings, elevated acute-phase reactants (elevated C-reactive protein [CRP] levels and elevated erythrocyte sedimentation rate [ESR]) are objective evidence of an inflammatory process.
4. A prolonged PR interval on the ECG is neither specific for acute rheumatic fever nor an indication of active carditis.

**Evidence of Antecedent Group A Streptococcal Infection**

1. A history of sore throat or of scarlet fever unsubstantiated by laboratory data is not adequate evidence of recent group A streptococcal infection.
2. Positive throat cultures or rapid streptococcal antigen tests for group A streptococci are less reliable than antibody tests because they do not distinguish between recent infection and chronic pharyngeal carriage.
3. Streptococcal antibody tests are the most reliable laboratory evidence of antecedent streptococcal infection capable of producing acute rheumatic fever. The onset of the clinical manifestations of acute rheumatic fever coincides with the peak of the streptococcal antibody response.
   a. Antistreptolysin 0 (ASO) titer is well standardized and therefore is the most widely used test. It is elevated in 80% of patients with acute rheumatic fever and in 20% of normal individuals. Only 67% of patients with isolated chorea have an elevated ASO titer. ASO titers of at least 333 Todd units in children and 250 Todd units in adults are considered elevated. A single low ASO titer does not exclude acute rheumatic fever. If three antistreptococcal antibody tests (antistreptolysin O, antideoxyribonuclease B, and antihyaluronidase tests) are obtained, a titer for at least one antibody test is elevated in more than 95% of patients.
   b. The antideoxyribonuclease B titers of 240 Todd units or greater in children and 120 Todd units or greater in adults are considered elevated.
   c. A slide agglutination test (Streptozyme test, Wampole Laboratories, Cranbury, NJ) that detects antibodies, is a relatively simple slide agglutination test, but it is less standardized and less reproducible than the other antibody tests. It should not be used as a diagnostic test for evidence of antecedent group A streptococcal infection.

**Other Clinical Features**

1. Abdominal pain, a rapid sleeping heart rate, tachycardia out of proportion to fever, malaise, anemia, epistaxis, and precordial pain are relatively common but not specific.
2. A positive family history of rheumatic fever also may heighten the suspicion.

**Diagnosis**

1. The revised Jones criteria are used for the diagnosis of acute rheumatic fever (see Box 20-1). A diagnosis of acute rheumatic fever is highly probable when either two major manifestations or one major and two minor manifestations, plus evidence of antecedent
streptococcal infection, are present. The absence of supporting evidence of a previous group A streptococcal infection makes the diagnosis doubtful (see later discussion for exceptions).

2. The following tips help in applying the Jones criteria:
   a. Two major manifestations are always stronger than one major plus two minor manifestations.
   b. Arthralgia or a prolonged PR interval cannot be used as a minor manifestation when using arthritis and carditis, respectively, as major manifestations.
   c. The absence of evidence of an antecedent group A streptococcal infection is a warning that acute rheumatic fever is unlikely (except when chorea is present).
   d. The vibratory innocent (Still’s) murmur is often misinterpreted as a murmur of MR and thereby is a frequent cause of misdiagnosis (or overdiagnosis) of acute rheumatic fever. The murmur of MR is a regurgitant-type systolic murmur (starting with the S1) caused by MR, but the innocent murmur is low pitched and an ejection type. A cardiology consultation during the acute phase minimizes the frequency of misdiagnosis.
   e. The possibility of the early suppression of full clinical manifestations should be sought during the history taking. Subtherapeutic doses of aspirin or salicylate-containing analgesics (e.g., Bufferin, Anacin) may suppress full manifestations.

3. Exceptions to the Jones criteria include the following three specific situations:
   a. Chorea may occur as the only manifestation of rheumatic fever.
   b. Indolent carditis may be the only manifestation in patients who come to medical attention months after the onset of rheumatic fever.
   c. Occasionally, patients with rheumatic fever recurrences may not fulfill the Jones criteria.

Differential Diagnosis

1. Juvenile rheumatoid arthritis is often misdiagnosed as acute rheumatic fever. The following findings suggest juvenile rheumatoid arthritis rather than acute rheumatic fever: involvement of peripheral small joints, symmetrical involvement of large joints without migratory arthritis, pallor of the involved joints, a more indolent course, no evidence of preceding streptococcal infection, and the absence of prompt response to salicylate therapy within 24 to 48 hours.

2. Other collagen vascular diseases (SLE, mixed connective tissue disease); reactive arthritis, including poststreptococcal arthritis; serum sickness; and infectious arthritis (such as gonococcal) occasionally require differentiation.

3. Virus-associated acute arthritis (rubella, parvovirus, hepatitis B virus, herpesviruses, enteroviruses) is much more common in adults.

4. Hematologic disorders, such as sickleemia and leukemia, should be considered in the differential diagnosis.

Clinical Course
1. Only carditis can cause permanent cardiac damage. Signs of mild carditis disappear rapidly in weeks, but those of severe carditis may last for 2 to 6 months.
2. Arthritis subsides within a few days to several weeks, even without treatment, and does not cause permanent damage.
3. Chorea gradually subsides in 6 to 7 months or longer and usually does not cause permanent neurologic sequelae.

Management

1. When acute rheumatic fever is suggested by history and physical examination, one should obtain the following laboratory studies: complete blood count, acute-phase reactants (ESR and CRP), throat culture, ASO titer (and a second antibody titer, particularly with chorea), chest radiographs, and ECG. Cardiology consultation is indicated to clarify whether there is cardiac involvement; two-dimensional echocardiographic and Doppler studies are usually performed at that time.
2. Benzathine penicillin G, 0.6 to 1.2 million units intramuscularly, is given to eradicate streptococci. This serves as the first dose of penicillin prophylaxis as well (see later discussion). In patients who are allergic to penicillin, erythromycin, 40 mg/kg per day in two to four doses for 10 days, may be substituted for penicillin.
3. Antiinflammatory or suppressive therapy with salicylates or steroids must not be started until a definite diagnosis is made. Early suppressive therapy may interfere with a definite diagnosis of acute rheumatic fever by suppressing full development of joint manifestations and suppressing acute-phase reactants.
4. When the diagnosis of acute rheumatic fever is confirmed, one must educate the patient and parents about the need to prevent subsequent streptococcal infection through continuous antibiotic prophylaxis.
5. Bed rest of varying duration is recommended. The duration depends on the type and severity of the manifestations and may range from 1 week (for isolated arthritis) to several weeks for severe carditis. Bed rest is followed by a period of indoor ambulation of varying duration before the child is allowed to return to school. The ESR is a helpful guide to the rheumatic activity and therefore to the duration of restriction of activities. Full activity is allowed when the ESR has returned to normal, except in children with significant cardiac involvement. Table 20-1 is a general guide to the period of bed rest and indoor ambulation.

<table>
<thead>
<tr>
<th></th>
<th>Arthritis Alone</th>
<th>Mild Carditis*</th>
<th>Moderate Carditis†</th>
<th>Severe Carditis‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bed rest</td>
<td>1–2 wk</td>
<td>3–4 wk</td>
<td>4–6 wk</td>
<td>As long as congestive heart failure is present 2–3 mo</td>
</tr>
<tr>
<td>Indoor</td>
<td>1–2 wk</td>
<td>3–4 wk</td>
<td>4–6 wk</td>
<td></td>
</tr>
</tbody>
</table>

**Table 20-1**

GENERAL GUIDELINES FOR BED REST AND INDOOR AMBULATION
* Questionable cardiomegaly.
† Definite but mild cardiomegaly.
‡ Marked cardiomegaly or heart failure.

### TABLE 20-2
**RECOMMENDED ANTIINFLAMMATORY AGENTS**

<table>
<thead>
<tr>
<th></th>
<th>Arthritis Alone</th>
<th>Mild Carditis</th>
<th>Moderate Carditis</th>
<th>Severe Carditis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prednisone</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2–6 wk*</td>
</tr>
<tr>
<td>Aspirin</td>
<td>1–2 wk</td>
<td>3–4 wk†</td>
<td>6–8 wk</td>
<td>2–4 mo</td>
</tr>
</tbody>
</table>

**Dosages:** Prednisone: 2 mg/kg/day in four divided doses. Aspirin: 100 mg/kg/day in four to six divided doses.

* The dose of prednisone should be tapered and aspirin started during the final week.
† Aspirin may be reduced to 60 mg/kg/day after 2 weeks of therapy.

6. Therapy with antiinflammatory agents should be started as soon as acute rheumatic fever has been diagnosed.
   a. For mild to moderate carditis, aspirin alone is recommended in a dose of 90 to 100 mg/kg per day in four to six divided doses. An adequate blood level of salicylates is 20 to 25 mg/100 mL. This dose is continued for 4 to 8 weeks, depending on the clinical response. After improvement, the therapy is withdrawn gradually over 4 to 6 weeks while monitoring acute-phase reactants.
   b. For arthritis, aspirin therapy is continued for 2 weeks and gradually withdrawn over the following 2 to 3 weeks. Rapid resolution of joint symptoms with aspirin within 24 to 36 hours is supportive evidence of the arthritis of acute rheumatic fever.
   c. Prednisone (2 mg/kg per day in four divided doses for 2 to 6 weeks) is indicated only in cases of severe carditis (Table 20-2).

7. Treatment of CHF includes the following (also see Chapter 27):
   a. Complete bed rest with orthopneic position and moist, cool oxygen
   b. Prednisone for severe carditis of recent onset (see Table 20-2)
   c. Digoxin is used with caution, beginning with half the usual recommended dose, because some patients with rheumatic carditis are supersensitive to digitalis) (see Table 27-5).
   d. Furosemide, 1 mg/kg every 6 to 12 hours, if indicated

8. Management of Sydenham’s chorea:
   a. Reduce physical and emotional stress and use protective measures as indicated to prevent physical injuries.
   b. Give benzathine penicillin G, 1.2 million units, initially for eradication of
streptococci and every 28 days for prevention of recurrence, just as in patients with other rheumatic manifestations. Without the prophylaxis, about 25% of patients with isolated chorea (without carditis) develop rheumatic valvular heart disease in 20-year follow-up.

c. Antiinflammatory agents are not needed in patients with isolated chorea.

d. For severe cases, any of the following drugs may be used: phenobarbital (15–30 mg every 6–8 hours), haloperidol (starting at 0.5 mg and increasing every 8 hours to 2 g), valproic acid, chlorpromazine (Thorazine), diazepam (Valium), or steroids.

e. Results of plasma exchange (to remove antineuronal antibodies) and intravenous immune globulin therapy (to inactivate the effects of the antineuronal antibodies) are promising in decreasing the severity of chorea and they were better than prednisone (Garvey et al, 2005).

| TABLE 20-3 |
| RECOMMENDED DURATION OF PROPHYLAXIS FOR RHEUMATIC FEVER |

<table>
<thead>
<tr>
<th>Category</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatic fever without carditis</td>
<td>At least for 5 years or until age 21 years, whichever is longer</td>
</tr>
<tr>
<td>Rheumatic fever with carditis but without residual heart disease (no valvular disease)</td>
<td>At least for 10 years or well into adulthood, whichever is longer</td>
</tr>
<tr>
<td>Rheumatic fever with carditis and residual heart disease (persistent valvular disease)</td>
<td>At least 10 years since last episode and at least until age 40 years; sometimes lifelong prophylaxis</td>
</tr>
</tbody>
</table>


Prognosis

The presence or absence of permanent cardiac damage determines the prognosis. The development of residual heart disease is influenced by the following three factors.

1. **Cardiac status at the start of treatment:** The more severe the cardiac involvement at the time the patient is first seen, the greater the incidence of residual heart disease.
2. **Recurrence of rheumatic fever:** The severity of valvular involvement increases with each recurrence.
3. **Regression of heart disease:** Evidence of cardiac involvement at the first attack may disappear in 10% to 25% of patients 10 years after the initial attack. Valvular disease resolves more frequently when prophylaxis is followed.

Prevention

**Primary Prevention**

Primary prevention of rheumatic fever is possible with a 10-day course of penicillin therapy for streptococcal pharyngitis. However, primary prevention is not possible in all patients because about 30% of the patients develop subclinical pharyngitis and therefore do not seek medical treatment. Another 30% of patients develop acute rheumatic fever
without symptoms of streptococcal pharyngitis (30%).

**Secondary Prevention**

1. Who should receive prophylaxis?
   Patients with documented histories of rheumatic fever, including those with isolated chorea and those without evidence of rheumatic heart disease, must receive prophylaxis.

2. For how long?
   Ideally, patients should receive prophylaxis indefinitely. For patients who had acute rheumatic fever without carditis, the prophylaxis should continue for at least 5 years or until the person is 21 years of age, whichever is longer. For patients who are in a high-risk occupation (e.g., schoolteachers, physicians, nurses), prophylaxis should be continued for a longer period of time. The chance of recurrence is highest in the first 5 years after acute rheumatic fever. If the patient had rheumatic carditis or residual valvular disease as a result of rheumatic fever, the duration of prophylaxis should be longer (Table 20-3).

3. Method of prophylaxis
   The method of choice for secondary prevention is benzathine penicillin G, 1.2 million units given intramuscularly every 28 days (not once a month). Alternative methods, although not as effective, are the following:
   a. Oral penicillin V, 250 mg, twice daily
   b. Oral sulfadiazine 1 g or sulfisoxazole 0.5 g once daily
   c. Oral erythromycin ethyl succinate, 250 mg, twice daily
Valvular Heart Disease

Valvular heart diseases are either congenital or acquired in origin. The pathophysiology and clinical manifestations are similar for both entities and are discussed in Chapter 10, Pathophysiology of Obstructive and Valvular Regurgitant Lesions. Congenital stenoses of the aortic and pulmonary valves are discussed in depth in the section on obstructive lesions in Chapter 13.

In this chapter, mitral stenosis (MS), mitral regurgitation (MR), and aortic regurgitation (AR) of both congenital and acquired etiology are discussed if they are isolated or the major lesion. Although the cause of mitral valve prolapse (MVP) is not entirely clear, it is discussed in this chapter because it involves a cardiac valve. Isolated congenital pulmonary regurgitation (PR), tricuspid regurgitation, and tricuspid stenosis of significance are exceedingly rare and therefore are not discussed. PR after tetralogy of Fallot (TOF) surgery is discussed under TOF in Chapter 14. Tricuspid regurgitation is most frequently seen with Ebstein’s anomaly and is discussed under that condition.

Most acquired valvular heart diseases are of rheumatic etiology. They are, however, rare in the industrialized countries, although they still occur frequently in less developed countries. Among rheumatic heart disease, mitral valve involvement occurs in about three fourths and aortic valve involvement in about one fourth of the cases. Stenosis and regurgitation of the same valve usually occur together. Isolated aortic stenosis (AS) of rheumatic origin without mitral valve involvement is extremely rare. Rheumatic involvement of the tricuspid and pulmonary valves almost never occurs.
Mitral Stenosis

Prevalence

Isolated congenital MS is very rare. It is usually associated with other anomalies such as Shone complex. MS of rheumatic origin is rare in children (because it requires 5 to 10 years from the initial attack to develop the condition), but it is the most common valvular involvement in adult rheumatic patients in areas where rheumatic fever is still prevalent.

Pathology and Pathophysiology

1. Congenital MS usually is associated with obstruction at more than one level. The stenosis may be at the level of the valve leaflets (fusion of the leaflets), papillary muscle (single papillary muscle seen with parachute mitral valve), chordae (thickened and fused chordae seen in single papillary muscle), or supravalvar region (supravalvar mitral ring), and it may be caused by hypoplasia of the valve ring itself (as seen with hypoplastic left heart syndrome).
2. In rheumatic MS, thickening of the leaflets and fusion of the commissures dominate the pathologic findings. Calcification with immobility of the valve results over time.
3. Regardless of the etiology, a significant MS results in the enlargement of the left atrium (LA), pulmonary venous hypertension, and PA hypertension with resulting enlargement and hypertrophy of the right side of the heart.
4. In patients with severe pulmonary venous hypertension, pulmonary congestion and edema, fibrosis of the alveolar walls, hypertrophy of the pulmonary arterioles, and loss of lung compliance result.

Clinical Manifestations

History

1. Patients with mild MS are asymptomatic.
2. In infants with severe MS, symptoms develop early in life with shortness of breath and failure to thrive.
3. Dyspnea with or without exertion is the most common symptom in older children. Orthopnea, nocturnal dyspnea, or palpitation is present in more severe cases.

Physical Examination (Fig. 21-1)

1. An increased right ventricular (RV) impulse is palpable along the left sternal border. Neck veins are distended if right-sided heart failure supervenes.
2. A loud S1 at the apex and a narrowly split S2 with accentuated P2 are audible if pulmonary hypertension is present. An opening snap (a short snapping sound accompanying the opening of the mitral valve) may be audible in rheumatic MS. A low-frequency mitral diastolic rumble is present at the apex (see Fig. 21-1). A crescendo presystolic murmur may be audible at the apex. Occasionally, a high-frequency diastolic
murmur of PR (Graham Steell’s murmur) is present at the upper left sternal border, but it is difficult to distinguish from AR.

**Electrocardiography**

Right-axis deviation, left atrial hypertrophy (LAH), and right ventricular hypertrophy (RVH) (caused by pulmonary hypertension) are common. Atrial fibrillation (AF) is rare in children.

**Chest Radiography**

1. The LA and RV are usually enlarged, and the main pulmonary artery (PA) segment is usually prominent.
2. Lung fields show pulmonary venous congestion, interstitial edema shown as Kerley’s B lines (dense, short horizontal lines most commonly seen in the costophrenic angles), and redistribution of pulmonary blood flow with increased pulmonary vascularity to the upper lobes.

**Echocardiography**

Echocardiography is the most accurate noninvasive tool for the detection of MS.

1. A two-dimensional echocardiographic study should define structural abnormalities of the valve, supravalvar region, chordae, and papillary muscles.
2. It shows a dilated LA. The main PA, RV, and right atrium (RA) also are dilated.
3. Doppler studies can estimate the pressure gradient and thus the severity of stenosis. A mean Doppler gradient of less than 4 to 5 mm Hg results from mild stenosis, 6 to 12 mm Hg is seen with moderate stenosis, and a mean gradient greater than 13 mm Hg is seen with severe stenosis. RV systolic pressure can be estimated from the TR jet velocity (by Bernoulli equation), which may be elevated.
4. In patients with rheumatic MS, an M-mode echocardiogram may show a diminished E to F slope (reflecting a slow diastolic closure of the anterior mitral leaflet), anterior movement of the posterior leaflet during diastole, multiple echoes from thickened mitral leaflets, and large LA dimension.

![FIGURE 21-1](image) Cardiac findings of mitral stenosis. Abnormal sounds are shown in black and include a loud S1, an ejection click (EC), a loud S2, and an opening snap (OS). Also note the mid-diastolic rumble and presystolic murmur. The murmur of pulmonary regurgitation indicates long-standing pulmonary hypertension.
Natural History

1. Infants with significant MS with failure to thrive require either balloon or surgical intervention.
2. Most children with mild MS are asymptomatic but become symptomatic with exertion.
3. Recurrence of rheumatic fever worsens the stenosis.
4. Atrial flutter or fibrillation and thromboembolism (related to the chronic atrial arrhythmias) are rare in children.
5. Hemoptysis can develop from the rupture of small vessels in the bronchi as a result of long-standing pulmonary venous hypertension.

Management

Medical

1. Mild and moderate MS is managed with anticongestive measures (diuretics).
2. Balloon dilatation of the valve should be considered in infants with failure to thrive and with repeated respiratory infections. It may delay surgical intervention. Balloon dilatation is an effective and safe option for children with rheumatic MS.
3. If AF develops, propranolol, verapamil, or digoxin may be used to slow the atrioventricular (AV) conduction. Intravenous procainamide may be used for conversion to sinus rhythm in hemodynamically stable patients. For patients with chronic AF, anticoagulation with warfarin should be started 3 weeks before cardioversion to prevent systemic embolization of atrial thrombus. Anticoagulation is continued for 4 weeks after restoration of sinus rhythm (see Chapter 24 for further discussion). Quinidine may prevent recurrence.
4. Good dental hygiene and antibiotic prophylaxis against subacute bacterial endocarditis (SBE) are important.
5. Varying degrees of restriction of activity may be indicated.
6. Recurrence of rheumatic fever should be prevented with penicillin or sulfonamide (see Chapter 20).

Surgical

Indications

According to the American College of Cardiology/American Heart Association (ACC/AHA) 2006 Guidelines, the indications for mitral valve surgery for congenital MS in adolescents and young adults are as follows.
1. Surgery is indicated in patients with congenital MS who have symptoms (New York Heart Association [NYHA] functional class III or IV) and mean Doppler MV gradient greater than 10 mm Hg. (Symptoms may include angina, syncope, or dyspnea on exertion.)
2. Surgery is reasonable in mildly symptomatic patients with congenital MS (NYHA functional class I) and a mean Doppler MV gradient greater than 10 mm Hg.

3. Surgery is reasonable in asymptomatic patients with PA pressure of 50 mm Hg or greater and a mean MV gradient of 10 mm Hg or greater.

For infants and children with severe MS, the following indications may also apply.
1. Symptomatic infants or children with failure to gain weight, dyspnea on exertion, pulmonary edema, or paroxysmal dyspnea may be candidates for surgery (or balloon dilatation).
2. Failed balloon dilatation or severe MR resulting from the balloon procedure is an indication for surgery.
3. Recurrent AF, thromboembolic phenomenon, and hemoptysis may be indications for surgery in children.

**Procedures and Mortality**

1. Resection of a supravalvar mitral ring or splitting of thickened and fused chordae is an option depending on the nature of the lesion.
2. For rheumatic MS, if balloon dilatation is unsuccessful, closed or open mitral commissurotomy remains the procedure of choice for those with pliable mitral valves without calcification or MR. The operative mortality rate is less than 1%.
3. Mitral valve replacement: A prosthetic valve (Starr-Edwards, Bjork-Shiley, St. Jude) is inserted either in the annulus or in a supra-annular position. The surgical mortality rate is 0% to 19%. All mechanical valves require anticoagulation with warfarin with its long-term risk, and reoperation may become necessary because of valve entrapment by pannus formation. The bioprostheses (porcine valve, heterograft valve) do not require anticoagulation therapy but require low-dose aspirin. Bioprostheses tend to deteriorate more rapidly because of calcific degeneration in children.
4. In patients with a parachute mitral valve, creation of fenestration among the fused chordae may increase effective orifice area and improve symptoms dramatically. MV replacement may occasionally be necessary but is especially problematic in patients with a hypoplastic mitral annulus in whom an annulus-enlarging operation may be necessary.
5. Rarely, a valved conduit can be placed between the LA and the apex of the left ventricle (LV).

**Complications**

1. Postoperative congestive heart failure (CHF) is the most common cause of early postoperative death.
2. Arterial embolization is a rare complication.
3. Bleeding diathesis is possible with anticoagulation therapy for an implanted prosthetic valve.

**Postoperative Follow-up**

1. Regular checkups every 6 to 12 months with echocardiography and Doppler studies
should be done for possible dysfunction of the repaired or replaced valve.

2. After replacement with a mechanical valve with no risk factors, warfarin is indicated to achieve an international normalized ratio (INR) of 2.5 to 3.5. Low-dose aspirin is also indicated. After replacement with a bioprosthesis and risk factors (which may include AF, previous thromboembolism, LV dysfunction, and hypercoagulable state), warfarin is also indicated.

3. When there are no risk factors after bioprosthesis placement, aspirin alone is indicated at 75 to 100 mg/day (see the ACC/AHA 2006 Guidelines).
Mitral Regurgitation

Prevalence
Mitral regurgitation is more common than MS. It is most often congenital and associated with AV canal defect. MR of rheumatic origin is rare but is the most common valvular involvement in children with rheumatic heart disease.

Pathology
1. Mitral valve regurgitation associated with AV canal occurs frequently through the cleft in the mitral valve. When the valve annulus is dilated from any causes that dilate the LV (e.g., aortic regurgitation (AR) or dilated cardiomyopathy), central regurgitation occurs.
2. In rheumatic heart disease, mitral valve leaflets are shortened because of fibrosis, resulting in MR.
3. With increasing severity of MR, dilatation of the LA and LV results, and the mitral valve ring may become dilated. Pulmonary hypertension may eventually develop as with MS.

Clinical Manifestations

History
1. Patients are usually asymptomatic with mild MR.
2. Rarely, fatigue (caused by reduced forward cardiac output) and palpitation (caused by AF) develop.

Physical Examination (Fig. 21-2)
1. The jugular venous pulse is normal in the absence of CHF. A heaving, hyperdynamic apical impulse is palpable in severe MR.
2. The S1 is normal or diminished. The S2 may split widely as a result of shortening of the LV ejection and early closure of the aortic valve. The S3 commonly is present and loud. The hallmark of MR is a regurgitant systolic murmur starting with S1, grade 2 to 4 of 6, at the apex, with good transmission to the left axilla (best demonstrated in the left decubitus position). A short, low-frequency diastolic rumble may be present at the apex (see Fig. 21-2).

Electrocardiography
1. ECG findings are normal in mild cases.
2. Left ventricular hypertrophy (LVH) or LV dominance, with or without LAH, is usually present.
3. AF is rare in children but often develops in adults.

Chest Radiography (Fig. 21-3)
1. The LA and LV are enlarged to varying degrees.
2. Pulmonary vascularity usually is within normal limits, but a pulmonary venous congestion pattern may develop if CHF supervenes.

**FIGURE 21-2** Cardiac findings of mitral regurgitation. The arrow near the apex indicates the direction of radiation of the murmur toward the left axilla.

**FIGURE 21-3** Posteroanterior (A) and lateral (B) views of chest radiographs in a patient with moderately severe mitral regurgitation of rheumatic origin. The lateral view was obtained with barium swallow. The cardiothoracic ratio is increased (0.64), and the apex is displaced downward and laterally in the posteroanterior view. The lateral view shows an indentation of the barium-filled esophagus by an enlarged left atrium, and the left ventricle is displaced posteriorly.

**Echocardiography**

1. Two-dimensional echocardiography shows dilated LA and LV; the degree of dilatation is related to the severity of MR.
2. Color-flow mapping of the regurgitant jet into the LA and Doppler studies can assess the severity of the regurgitation.
3. The echocardiogram can distinguish eccentric regurgitation through the cleft mitral valve from central regurgitation (associated with annular dilatation).

**Natural History**
1. Patients are relatively stable for a long time with mild regurgitation.
2. Infective endocarditis is a rare complication.
3. LV failure and consequent pulmonary hypertension may occur in adult life.

**Management**

**Medical**
1. Prophylaxis against recurrence of rheumatic fever (see Chapter 20) is important.
2. Activity need not be restricted in most mild cases.
3. Afterload-reducing agents are particularly useful in maintaining the forward cardiac output.
4. Anticongestive therapy (with diuretics and digoxin) is provided if CHF develops.
5. If AF develops (rare in children), digoxin is indicated to slow the ventricular response. For further discussion of the management of AF, see Chapter 24.

**Surgical**

**Indications**
The indications for valve repair surgery are not so stringent because surgery can significantly improve the regurgitation. Indications for valve surgery in adolescents and young adults with severe MR are as follows, according to the ACC/AHA 2006 Guidelines (Circulation 2006).

The following are noninvasive findings of severe MR: vena contracta width larger than 0.7 cm with large central MR jet (area >40% of LA size) or with a wall-impinging jet of any size, swirling in LA, or enlargement of the LA and LV size.
1. Symptomatic patients with severe congenital MR with NYHA functional class III or IV. (see earlier discussion for noninvasive findings of severe MR).
2. Asymptomatic patients with severe congenital MR (see earlier discussion) and LV systolic dysfunction (ejection fraction [EF] ≤0.6).
3. Surgery may be considered in patients with preserved LV function if the likelihood of successful repair without residual MR is great.

Some centers consider an LV diastolic dimension of 60 mm in adults an indication for mitral valve replacement. For children, intractable CHF, progressive cardiomegaly with symptoms, and pulmonary hypertension may be indications.

**Procedures and Mortality**
Mitral valve repair or replacement is performed under cardiopulmonary bypass.
1. Valve repair surgery is preferred over valve replacement, performed usually beyond infancy and during childhood. For cleft leak, repair of the cleft is performed. For central regurgitation with dilated annulus, anuloplasty is performed by commissuroplasty (not using an anuloplasty ring, which restricts growth potential). Valve repair has a lower mortality rate (<1%), and anticoagulation is not necessary.
2. Valve replacement is rarely necessary for unrepairable regurgitation. Frequently used low-profile prostheses are the Bjork-Shiley tilting disk and the St. Jude pyrolytic carbon valve. The surgical mortality rate is 2% to 7% for valve replacement. If a prosthetic valve is used, anticoagulation therapy must be continued.

**Complications**
Complications are similar to those listed for MS.

**Postoperative Follow-up**
1. Valve function (of either the repaired natural valve or the replacement valve) should be checked by echocardiography and Doppler studies every 6 to 12 months.
2. After replacement with a mechanical valve with no risk factors, warfarin is indicated to achieve an INR of 2.5 to 3.5 along with low-dose aspirin. After replacement with a bioprosthesis with no risk factors, aspirin alone is indicated at the dose of 75 to 100 mg/day; when there are risk factors (e.g., AF, previous thromboembolism, LV dysfunction, hypercoagulable state), warfarin is also indicated.
Aortic Regurgitation

Prevalence
Aortic regurgitation is more often congenital than rheumatic in origin. AR of rheumatic origin is almost always associated with mitral valve disease.

Pathology
1. Congenital causes of AR include the following:
   a. Congenital bicuspid aortic valve
   b. After balloon dilatation of aortic valve
   c. Associated with ventricular septal defect (VSD, either subpulmonary or membranous)
   d. Secondary to subaortic stenosis
   e. In association with dilated aortic root (Marfan’s syndrome or Ehlers-Danlos syndrome)
2. Rarely, rheumatic heart disease is a cause of AR.

Clinical Manifestations

History
1. Patients with mild regurgitation are asymptomatic.
2. Exercise tolerance is reduced with more severe AR or CHF.

Physical Examination (Fig. 21-4)
1. With moderate or severe AR, the precordium may be hyperdynamic with a laterally displaced apical impulse. A diastolic thrill occasionally is present at the third left intercostal space. A wide pulse pressure and a bounding water-hammer pulse may be present with severe AR.
2. The heart sounds are normal with mild AR. The S1 is decreased in intensity with moderate to severe AR. The S2 may be normal or single. A high-pitched diastolic decrescendo murmur, best audible at the third or fourth left intercostal space, is the auscultatory hallmark. This murmur is more easily audible with the patient sitting and leaning forward. The longer the murmur, the more severe the regurgitation (see Fig. 21-4). A systolic murmur of varying intensity may be present at the second right intercostal space because of relative AS caused by an increased stroke volume. The combination of the diastolic and systolic murmurs gives rise to a to-and-fro murmur in patients with severe AR. A mid-diastolic mitral rumble (Austin Flint murmur) may be present at the apex when the AR is severe.
Electrocardiography

The ECG is normal in mild cases. In severe cases, LVH usually is present. LAH may be present in long-standing cases.

Chest Radiography

Cardiomegaly of varying degree involving the LV is present. A dilated ascending aorta and a prominent aortic knob frequently are present. Pulmonary venous congestion develops if LV failure supervenes.

Echocardiography

The LV dimension is increased, but the LA remains normal in size. The LV diastolic dimension is proportional to the severity of AR. Color-flow and Doppler examination can aid in estimating the severity of the regurgitation. LV systolic dysfunction develops at a later stage in severe AR.

Natural History

1. Patients with mild to moderate AR remain asymptomatic for a long time, but when symptoms begin to develop, many patients deteriorate rapidly.
2. Anginal pain, CHF, and multiple premature ventricular contractions are unfavorable signs occurring with severe AR.
3. Infective endocarditis is a rare complication.

Management

Medical

1. In case of a rheumatic cause, prophylaxis should be continued against the recurrence of rheumatic fever with penicillin or sulfonamides (see Chapter 20).
2. Activity need not be restricted in mild cases, but varying degrees of restriction are indicated in more severe cases. Aerobic exercise is a better form of exercise, and
weightlifting exercise should be discouraged.
3. When used on a long-term basis, the angiotensin-converting enzyme inhibitors have been shown to reduce (or even reverse) the dilatation and hypertrophy of the LV in children with AR but without CHF.
4. If CHF develops, digoxin, diuretics, and afterload-reducing agents may be beneficial, but the benefits are rarely maintained.

**Surgical**

**Indications**

A major clinical decision in AR is the timing of aortic valve replacement. Ideally, it should be performed before irreversible dilatation of the LV develops, but there is no reliable method of detecting that point. According to ACC/AHA 2006 Guidelines, the following are surgical indications in adolescents and adult patients with chronic severe AR. (Chronic severe AR is considered present when central jet width >86% LV outflow tract or Doppler vena contracta width >0.6 cm is present.) Similar indications may apply for younger children.

1. Symptomatic patients (with angina, syncope, or dyspnea on exertion) with severe AR
2. Asymptomatic patients with LV systolic dysfunction (EF <0.5) on serial studies 1 to 3 months apart
3. Asymptomatic patients with progressive LV enlargement (end-diastolic dimension > mean +4 standard deviation)

**Procedure and Mortality**

Aortic valve repair is favored over valve replacement whenever possible. Valve replacement does not incorporate growth potential except for the Ross procedure. Surgery is performed under cardiopulmonary bypass. The mortality rate for valve repair is near 0%, and that for valve replacement is about 2% to 5%.

1. Valve repair may include repair of simple tears or valvuloplasty for prolapsed cusps and so on.
2. Valve replacement surgery
   a. The antibiotic-sterilized aortic homograft has been widely used and appears to be the device of choice.
   b. The porcine heterograft has the risk of accelerated degeneration.
   c. The Bjork-Shiley and St. Jude prostheses require anticoagulation therapy and are less suitable for young patients.
3. A pulmonary root autograft (Ross procedure) may be an attractive alternative to the conventional valve replacement surgery (see Fig. 13-9) in selected adolescents and young adults. In this procedure, the patient’s own pulmonary valve and the adjacent PA are used to replace the diseased aortic valve and the adjacent aorta. The coronary arteries are detached from the aorta and implanted into the PA. The surgical mortality rate is near 0%. This procedure does not require anticoagulant therapy, the autograft may last longer
than a porcine bioprosthesis, and there is a growth potential for the autograft pulmonary valve.

**Complications**

1. Postoperative acute cardiac failure is the most common cause of death.
2. Thromboembolism, chronic hemolysis, and anticoagulant-induced hemorrhage may occur with a prosthetic valve.
3. Porcine valves tend to develop early calcification in children.
4. Prosthetic valve endocarditis is a rare complication.

**Postoperative Follow-up**

1. Regular follow-up of valve function should be done every 6 to 12 months by echocardiography and Doppler studies.
2. Anticoagulation is needed after a prosthetic mechanical valve replacement. INR should be maintained between 2.5 and 3.5 for the first 3 months and 2.0 to 3.0 beyond that time. Low-dose aspirin (75–100 mg/day for adolescents) is also indicated in addition to warfarin ([ACC/AHA 2006 Guidelines](https://www.acc.org)).
3. After aortic valve replacement with bioprosthesis and no risk factors, aspirin (75–100 mg) is indicated, but warfarin is not indicated. When there are risk factors (which include AF, previous thromboembolism, LV dysfunction, and hypercoagulable state), warfarin is indicated to achieve an INR of 2.0 to 3.0 ([ACC/AHA 2006 Guidelines](https://www.acc.org)).
4. After the Ross procedure, anticoagulation is not indicated.
5. The importance of good oral hygiene and antibiotic prophylaxis against SBE should be emphasized.
Mitral Valve Prolapse

Prevalence
The reported incidence of MVP of 2% to 5% in the pediatric population probably is an overestimate. The prevalence of MVP increases with age. This condition usually occurs in older children and adolescents (it is more common in adults) and has a female preponderance (male-to-female ratio of 1:2).

Pathology
1. MVP is generally sporadic but is associated with disorders of the connective tissue, including Marfan syndrome, Ehlers-Danlos syndrome, osteogenesis imperfecta, and others. Secondary cases of MVP can be caused by other conditions, including rupture or dysfunction of the papillary muscles caused by myocardial infarction or ischemia, rupture of chordae tendineae caused by infective endocarditis, or abnormal LV wall motion associated with ischemia or primary myocardial disease. Only primary MVP is discussed in this chapter.
2. In the primary form of MVP, thick and redundant mitral valve leaflets bulge into the mitral annulus (caused by myxomatous degeneration of the valve leaflets, chordae, or both). The posterior leaflet is more commonly and more severely affected than the anterior leaflet.
3. MVP is associated with several of the most common heritable disorders of connective tissue disease, such as Marfan’s syndrome, Ehlers-Danlos syndrome, Stickler syndrome, and polycystic kidney disease in adults. Nearly all patients with Marfan’s syndrome have MVP.
4. A congenital heart defect is present in one third of patients with MVP. Secundum atrial septal defect is most common; VSD and Ebstein’s anomaly are found rarely.

Clinical Manifestations

History
1. MVP usually is asymptomatic, but a history of nonexertional chest pain; palpitation; and, rarely, syncope may be elicited. Chest discomfort may be typical of anginal pain but more atypical in that it is not related to exertion and is often brief attacks or stabbing pain at the apex. Whether the chest pain is actually cardiac in origin (from papillary muscles) has not been fully determined, but the discomfort could be secondary to abnormal tension on papillary muscle. Palpitation may be related to cardiac arrhythmias. Syncope or presyncope may be caused by arrhythmias or a manifestation of an orthostatic phenomenon.
2. The patient occasionally has a family history of MVP.

Physical Examination (Fig. 21-5)
1. An asthenic build with a high incidence of thoracic skeletal anomalies (80%), including pectus excavatum (50%), straight back (20%), and scoliosis (10%), is common. *(Straight-back syndrome)* is a condition in which the normal dorsal curvature of the spine is lost, resulting in a shortening of the chest’s anteroposterior diameter.

2. The midsystolic click with or without a late systolic murmur is the auscultatory hallmark of this syndrome and is best audible at the apex (see Fig. 21-5). The presence or absence of the click and murmur, as well as their timing, varies from one examination to the next.

   a. The click and murmur may be brought out by held expiration, left decubitus position, sitting, standing, or leaning forward. They may disappear on inspiration.
   
   b. Various maneuvers can alter the timing of the click and the murmur:
      
      (1) The click moves toward the S1 and the murmur lengths with maneuvers that decrease the LV volume, such as standing, sitting, Valsalva’s strain phase, tachycardia, and the administration of amyl nitrite.
      
      (2) The click moves toward the S2, and the murmur shortens with maneuvers that increase the LV volume, such as squatting, hand grip exercise, Valsalva’s release phase, bradycardia, and the administration of pressor agents or propranolol.

![Diagram of auscultatory findings in mitral valve prolapse and the effect of various maneuvers on the timing of the midsystolic click (MC) and the murmur. The maneuvers that reduce ventricular volume enhance leaflet redundancy and move the click and murmur earlier in systole. An increase in left ventricular dimension has the opposite effect.](image)

**FIGURE 21-5** Diagram of auscultatory findings in mitral valve prolapse and the effect of various maneuvers on the timing of the midsystolic click (MC) and the murmur. The maneuvers that reduce ventricular volume enhance leaflet redundancy and move the click and murmur earlier in systole. An increase in left ventricular dimension has the opposite effect.

**Electrocardiography**

1. The ECG findings are usually normal, but a superiorly directed T vector (with flat or inverted T waves in II, III, and aVF) occurs in 20% to 60% of patients (Fig. 21-6).

2. Arrhythmias are relatively uncommon and include supraventricular tachycardia, premature atrial contractions, and premature ventricular contractions.

3. First-degree AV block and right bundle branch block are occasionally present.

4. The incidence of Wolff-Parkinson-White preexcitation or prolonged QT interval is
higher in patients with MVP than in the general population.
5. LVH or LAH rarely is present.

**Chest Radiography**
1. Chest radiographs are unremarkable except for LA enlargement in patients with severe MR.
2. Thoracoskeletal abnormalities (e.g., straight back, pectus excavatum, scoliosis) may be present.

**Echocardiography**
Echocardiographic findings for adult patients with MVP have been established, but those for pediatric patients are not clearly defined.
1. Two-dimensional echocardiography shows prolapse of the mitral valve leaflet(s) superior to the plane of the mitral valve. The parasternal long-axis view is most reliable. The superior displacement seen only on the apical four-chamber view is not diagnostic because more than 30% of preselected normal children show this finding. The “saddle-shaped” mitral valve ring explains the superior displacement of the mitral valve seen in normal people in the apical four-chamber view.
2. In adults, one or both mitral valve leaflets bulge by at least 2 mm into the LA during systole in the parasternal long-axis view. Thickening of the involved leaflet to more than 5 mm supports the diagnosis. In more severe myxomatous disease, leaflet redundancy, chordal elongation, and dilatation of the mitral annulus may be present.
3. Some pediatric patients with the characteristic body build and auscultatory findings of the condition do not show the adult echocardiographic criterion of MVP; they may only show thickened mitral leaflets with systolic straightening or systolic superior doming and some posterosuperior displacement of the coaptation point of the mitral valve, some even with mild MR. It may be because MVP is a progressive disease that shows its full manifestations only in adult life.

4. A large number of first-degree relatives of patient with MVP have echocardiographic findings of MVP.

**Natural History**
1. The majority of patients are asymptomatic, particularly during childhood.
2. Complications that are reported in adult patients, although rare in childhood, include sudden death (probably from ventricular arrhythmias), SBE, spontaneous rupture of chordae tendineae, progressive MR, CHF, arrhythmias, and conduction disturbances.

**Management**

1. Asymptomatic patients require no treatment or restriction of activity.
2. Antibiotic prophylaxis against bacterial endocarditis is recommended when significant MR is present by auscultation or by echo studies.
3. β-Adrenergic blockers (propranolol or atenolol) are often used in the following situations.
   a. Patients who are symptomatic (with palpitation, lightheadedness, dizziness, or syncope) secondary to ventricular arrhythmias. Symptomatic patients suspected to have arrhythmias should undergo ambulatory ECG monitoring, treadmill exercise testing, or both. Although beta-blockers are the drug of choice, other drugs, such as calcium blockers, quinidine, or procainamide, may prove to be effective in some patients.
   b. Patients with self-terminating episodes of supraventricular tachycardia may also receive beta-blockers.
   c. Patients with chest discomfort may also be treated with propranolol. (It is not relieved by nitroglycerin but may worsen it.)
4. Physical activities that require prolonged periods of straining, such as weightlifting, push-ups, pull-ups, sit-ups, and hanging on monkey bars, are discouraged; these activities add stress to the mitral valve apparatus.
5. Reconstructive surgery or mitral valve replacement rarely may be indicated in patients with severe MR. MVP is the most common cause of isolated MR requiring surgical treatment in the United States.
Cardiac Tumors
Prevalence

Cardiac tumors in the pediatric age group are extremely rare. A primary cardiac tumor was diagnosed in 0.001% to 0.003% of admissions at large children’s referral centers. The male-to-female distribution is equal.
### Types and Frequency of Tumors

Table 22-1 shows the relative incidence of cardiac tumors in infants and children (Becker, 2000). Becker’s data include 55 cases from Armed Forces Institute of Pathology, Washington, DC, series 3f, and 21 cases from the Cardiovascular Pathology Registry in the Academic Medical Center, Amsterdam, Netherlands. Data in Table 22-1 show the following:

1. A large portion of primary heart tumors in the pediatric age group presents at less than 1 year of age.
2. The most common cardiac tumor in the pediatric age group is rhabdomyoma. In infants younger than 1 year old, more than 50% of tumors are rhabdomyomas followed by fibromas (25%). In children 1 to 16 years of age, nearly 40% of benign tumors are fibromas and myxomas (see Table 22-1). Rhabdomyomas accounted for only 8% of benign tumor in this age group.
3. More than 90% of primary tumors are benign in infants. Although primary malignant tumors are extremely rare in infants (≈5%), approximately 40% of primary tumors were malignant in children older than 1 year of age. Malignant tumors reported in children include rhabdomyosarcoma, leiomyosarcoma, angiosarcoma, fibrosarcoma, and many others.

Recently, 120 operated cases of cardiac tumors in infants and children were reported by Bielefeld et al (2012). Although the data are not presented according to two age groups, younger than 12 months and older than 12 months, a similar trend exists with earlier reports. Rhabdomyomas were the most frequent, representing 35% of pediatric cardiac tumors (mean age, 7 months). Myxomas were the second most frequent (23%) with a mean age of 9 years. Fibromas represented 20% of the cases with a mean age of 3.25 years. These three tumor types accounted for three fourths of all surgically treated pediatric cardiac tumors.
Pathology of Individual Cardiac Tumor

Common pediatric cardiac tumors are briefly summarized in this chapter.

**Rhabdomyoma**

1. Rhabdomyomas are by far the most frequent tumors in the pediatric age group, accounting for about half the cases of cardiac tumors.
2. They usually are multiple, ranging in size from several millimeters to several centimeters. The most common location is in the ventricles, either in the ventricular septum or free wall, but they may rarely appear in the atrium.

<table>
<thead>
<tr>
<th>Table 22-1</th>
<th>Relative Incidence of Cardiac Tumors in Infants and Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tumors</strong></td>
<td><strong>Incidence (%)</strong></td>
</tr>
<tr>
<td>Infants (younger than 12 months) (n = 52)</td>
<td>Children (1–16 years of age) (n = 25)</td>
</tr>
<tr>
<td>Benign Tumors (94%)</td>
<td>Benign Tumors (58%)</td>
</tr>
<tr>
<td>Rhabdomyoma</td>
<td>52</td>
</tr>
<tr>
<td>Fibroma</td>
<td>25</td>
</tr>
<tr>
<td>Hemangioma or angiomyoma</td>
<td>6</td>
</tr>
<tr>
<td>Teratoma</td>
<td>2</td>
</tr>
<tr>
<td>Others</td>
<td>8</td>
</tr>
<tr>
<td>Malignant Tumors (6%)</td>
<td>Others</td>
</tr>
<tr>
<td>Rhabdomyosarcoma</td>
<td>2</td>
</tr>
<tr>
<td>Leiomyosarcoma</td>
<td>4</td>
</tr>
<tr>
<td>Other</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>


3. More than half the children with multiple rhabdomyomas have tuberous sclerosis (e.g., with adenoma of the sebaceous glands, mental retardation, seizures).
4. Tumors regress in size or number or both in most patients younger than 4 years of age (but less so in older patients) (Nir et al, 1995). Spontaneous complete regression may occur.
5. The tumors may produce symptoms of obstruction to blood flow, arrhythmias (usually ventricular tachycardia, occasionally supraventricular tachycardia), or sudden death.
6. Cardiac rhabdomyomas are associated with a higher incidence of Wolff-Parkinson-White (WPW) preexcitation and may increase the risk for arrhythmias.

**Fibroma**

1. Fibroma is the second most common tumor type encountered in infants and small children.
2. Cardiac fibromas usually occur as a single solid tumor, most commonly in the ventricular septum, although they may also occur in the wall of any cardiac chamber. The
size of the tumor varies from several millimeters to centimeters. Occasionally, the tumor calcifies.
3. The tumor may obstruct blood flow and disturb atrioventricular (AV) or ventricular conduction.
4. In some cases, the tumor can be removed completely, but in others, the tumor intermingles with myocardial tissue so that complete resection is not possible. The tumors probably represent hamartomatous lesions that may eventually regress. This has led to a tendency for a less aggressive surgical resection to reduce potential risks for complications.

**Myxoma**
1. Myxomas are the most common type of cardiac tumors in adults, accounting for about 30% of all primary cardiac tumors, but they are very rare in infants and children.
2. The majority of myxomas arise in the left atrium, 25% arise in the right atrium, and very few arise in the ventricles.
3. Myxomas can produce hemodynamic disturbances, commonly interfering with mitral valve function or producing thromboembolic phenomena in the systemic circulation. With right atrial myxoma, similar effects on the tricuspid valve and thromboembolic phenomena in the pulmonary circulation may be found. Rarely, patients may have symptoms while sitting and standing, but their symptoms improve when they lie down because of the intermittent protrusion of the tumor through the mitral valve.
4. Surgical removal usually is successful.

**Teratoma**
1. Teratomas contain elements from all three germ layers.
2. Most of the tumors are intrapericardial and are attached to the root of the aorta and pulmonary trunk, but the heart wall can be involved, and occasionally they may present as an intracardiac mass.
3. Surgical excision is usually possible.

**Cardiac Angioma**
1. This is a relatively rare tumor in infants and children.
2. They show preference for the epicardium, in which they may produce hemopericardium. Intramyocardial location may cause myocardial dysfunction, AV block, or both.
3. They do not grow rapidly, and spontaneous involution has been documented.
Clinical Manifestations

1. Cardiac tumors usually are found on routine echocardiographic studies when the diagnosis is not suspected, especially in small infants.
2. Syncope or chest pain may be a presenting complaint in older children. Sudden unexpected death may be the first manifestation. Rarely, symptoms vary with posture in cases of pedunculated tumors (e.g., myxoma).
3. Clinical manifestations of cardiac tumors often are nonspecific and vary primarily with the location and the size of the tumor.
   a. Tumors near cardiac valves may produce heart murmurs of stenosis or regurgitation of valves. So-called tumor plop may occur with a pedunculated and sessile tumor, such as a left atrial myxoma.
   b. Tumors involving the conduction tissue may manifest with arrhythmias or conduction disturbances (such as seen with fibromas).
   c. Intracavitary tumors may produce inflow or outflow obstruction (such as seen with rhabdomyoma), with clinical findings similar to those of mitral or semilunar valve stenosis.
   d. Involvement of the myocardium (mural tumors) may result in heart failure or cardiac arrhythmias.
   e. Pericardial tumors, which may signal malignancy, can produce pericardial effusion and cardiac tamponade or features simulating infective pericarditis.
3. Fragmentation of intracavitary tumors may lead to embolism of the pulmonary or systemic circulations (as seen with myxoma).
4. Occasionally, for unknown reasons, fever and general malaise may manifest, especially with myxomas.
5. The ECG may show nonspecific ST-T changes, an infarct-like pattern, low-voltage QRS complexes, or WPW preexcitation. Various arrhythmias and conduction disturbances have been reported.
6. Chest radiographs occasionally may reveal altered contour of the heart with or without changes in pulmonary vascular markings.
1. Two-dimensional Doppler echocardiography is the primary tool for the evaluation of cardiac tumors in pediatric patients. Echocardiography and Doppler studies allow accurate determination of the extent and location of the tumor as well as the hemodynamic significance of the lesion.

   a. Multiple intraventricular tumors in infants and children most likely are rhabdomyomas (Fig. 22-1).

   b. A solitary tumor of varying size, arising from the ventricular septum or the ventricular wall, is likely to be a fibroma (Fig. 22-2).

   c. Left atrial tumors, especially when pedunculated, usually are myxomas (Fig. 22-3).

   d. An intrapericardial tumor arising near the great arteries most likely is a teratoma.

   e. Pericardial effusion suggests a secondary malignant tumor.

**FIGURE 22-1** Parasternal long-axis view (A) and diagram (B) of multiple rhabdomyomas (T) in a newborn. There is a round, mobile mass in the left ventricular outflow tract, with resulting obstruction. One large and at least two other smaller tumor masses are imaged in the right ventricle (RV). The tumor in the left ventricular outflow tract was surgically removed because of the obstructive nature of the mass. AO, aorta; IVS, interventricular septum; LA, left atrium.

**FIGURE 22-2** Apical four-chamber view (apex up) (A) and diagram (B) of a large solitary tumor in the left ventricular (LV) cavity in a newborn. The mass is attached to the LV free wall. Because of symptoms, a surgical attempt was made to remove the mass, but the infant died. Pathologic examination revealed the mass to be fibroma. AO, aorta; LA, left atrium; RA, right atrium; RV, right ventricle.
2. Transesophageal echocardiography can provide more precise delineation of the tumor before and during surgery.

3. Magnetic resonance imaging (MRI) also provides the same information as the two-dimensional echo study does. MRI techniques have certain advantages over echocardiographic study.
   a. MRI provides high-resolution images of cardiac cavitary, valvular, myocardial, pericardial, and extracardiac masses in addition to its relationship with mediastinal and other intrathoracic structures.
   b. MRI can provide spatial relationship of the tumor mass to the coronary arteries, which may help guide surgical management.
   c. MRI allows differentiation of tumors from myocardium and differentiation of the type of tumor, such as cardiac hemangiomas from rhabdomyomas and fibromas.
   d. MRI is better than echocardiography in detecting apical tumors.

4. Cardiac catheterization and angiography are usually not necessary. Attempts at tissue diagnosis can be risky because of possible embolization of tumor fragment.
Management

Surgery is the only treatment for cardiac tumors that require intervention. Surgery is indicated in patients with inlet or outlet obstruction and in patients with symptoms of cardiac failure or ventricular arrhythmias refractory to medical treatment.

1. Rhabdomyomas: Spontaneous regression of these tumors has been well established so that surgical intervention is no longer indicated unless the tumors produce obstruction or arrhythmias refractory to medical treatment.

2. Fibromas: A successful complete resection of a fibroma is possible. In some cases, the tumor intermingles with myocardial tissue so that complete resection is not possible without causing damage to the myocardium or conduction tissues. Fibromas accounted for the highest surgical mortality rate (33%). Currently, there is a tendency for less than radical surgical resection because cardiac fibromas probably represent hamartomatous lesions that may regress spontaneously.

3. Surgical removal is a standard procedure for myxomas and has a favorable outcome. The stalk of the tumor should be removed completely to prevent recurrence.

4. If myocardial involvement is extensive, surgical treatment is not possible. Cardiac transplantation may be an option in such cases.
Cardiovascular Involvement in Systemic Diseases

Many collagen, neuromuscular, endocrine, and other systemic diseases may have important cardiovascular manifestations. The involvement of the cardiovascular system usually becomes evident when the diagnosis of the primary disease is well established, but occasionally cardiac manifestations may precede evidence of the basic disease. Cardiac manifestations of selected systemic diseases are briefly described here.
Acute Glomerulonephritis

Clinically evident myocardial involvement is found in 30% to 40% of patients with acute poststreptococcal glomerulonephritis. Pulmonary edema, systemic venous congestion, and cardiomegaly also are common, resulting from salt and water retention. Systemic hypertension, sometimes appearing with hypertensive encephalopathy, is a frequent manifestation and may be responsible for signs of congestive heart failure (CHF) in some, but not all, patients. Although hypertension probably reflects fluid expansion (secondary to impaired salt and water excretion), peripheral resistance has been found to be elevated. Increased renin activity may be responsible for the latter. The acute phase generally resolves within 6 to 8 weeks.

Treatment is directed toward lowering blood pressure and inducing diuresis. Sodium restriction, diuresis usually with intravenous Lasix, and antihypertensive therapy with calcium channel antagonists, vasodilators, or angiotensin-converting enzyme (ACE) inhibitors are standard treatment.
DiGeorge Syndrome

The same syndrome has been described by different researchers in different areas of expertise. Angelo DiGeorge, an endocrinologist, reported DiGeorge syndrome in the 1960s, and Robert Shprintzen, PhD, a speech pathologist, reported velocardiofacial syndrome in the 1970s. A Japanese cardiologist group called it conotruncal anomaly face (CTAF) syndrome in 1978. These syndromes share a common genetic cause in most cases, a chromosome 22q11 deletion; therefore, the term “22q11 deletion syndrome” is currently used. The great majority of patients with these syndromes have serious congenital heart defects (CHDs).

DiGeorge syndrome occurs in both males and females. Clinical features in these syndromes include abnormal facies, CHDs, and absence or hypoplasia of the thymus (with congenital immune deficiency and increased susceptibility to infection) and parathyroid gland (with hypocalcemia). Clinical features of the syndrome are collectively grouped under the acronym of CATCH-22 (cardiac, abnormal facies, thymic hypoplasia, cleft palate, and hypocalcemia resulting from 22q11 deletion).

Approximately 90% of patients have a deletion of the long arm of chromosome 22 (22q11.2) detectable with current cytogenetic and fluorescence in situ hybridization (FISH) techniques. In 90% of cases, the disorder occurs as the result of a new mutation. In 10%, the disorder is inherited from a parent in an autosomal dominant fashion. Rarely, the syndrome may be caused by other chromosomal abnormalities or maternal environmental factors (e.g., alcohol, retinoids).

Clinical Manifestations

1. **Abnormal facies**: Abnormal facies is characterized by hypertelorism; micrognathia; a short philtrum with a fish-mouth appearance; an antimongoloid slant; and telecanthus with short palpebral fissures and low-set ears, often with defective pinna.

2. **Cardiac**: Many patients (85%) have cardiac defects. The most common cardiac anomalies include tetralogy of Fallot (TOF) (25%); interrupted aortic arch (15%); ventricular septal defect (VSD), usually perimembranous (15%); persistent truncus arteriosus (9%); and isolated aortic arch anomalies (5%). Less common anomalies include pulmonary stenosis (PS), atrial septal defect (ASD), atrioventricular (AV) canal defect, and transposition of the great arteries.

3. **Cleft**: Anomalies in the palate are common (70%–80%), with speech and feeding disorders. The palatal abnormalities may be overt or submucosal cleft. Occasionally, a bilateral cleft lip and palate may be present. Velopharyngeal insufficiency with delayed and hypernasal speech may occur.

4. **Metabolic**: Hypocalcemia (observed in 60%) is caused by hypoparathyroidism.

5. **Immunologic**: Thymic hypoplasia or aplasia leads to a mild to moderate decrease in T-cell number. Occasionally, humoral deficits, including IgA deficiency, have been observed (~10%).

6. **Recurrent infections** are common, an important cause of later mortality.
7. General: Short stature, mental retardation, and hypotonia in infancy are frequent. Occasionally, psychiatric disorders (e.g., schizophrenia and bipolar disorder) develop.
8. Lateral view of chest radiograph shows a defective thymic shadow.
9. Cytogenetic analysis detects only 20% of the deletion in the region. The deletion is best identified by FISH.

Management
1. Correction of cardiac malformation as discussed in other sections. Cardiac defects are major causes of early death.
2. Irradiated, cytomegalovirus-negative blood products must be administered because of the risk of graft-versus-host disease with nonirradiated products.
3. Monitoring of serum calcium levels and supplementation of calcium and vitamin D are important.
   a. Calcium gluconate (Kalcinate), 500 to 750 mg/kg/day, orally (PO) four times a day (QID), QID or calcium carbonate (Oscal, Titralac, Oystercal, Caltrate), 112.5 to 162.5 mg/kg/day, given QID.
   b. Ergocalciferol (vitamin D2), 25,000 to 2000,000 U PO every day.
4. Live vaccines are contraindicated in patients with DiGeorge syndrome and in household members because of the risk of shedding live organism.
5. Usual prophylactic regimen for T- and B-cell deficiency.
6. Early thymus transplantation may promote successful immune reconstitution.

Prognosis
The prognosis depends on cardiac and immune system disorders. The prognosis is poor with complex cyanotic heart defects, with a 1-month mortality rate of 55% and 6-month mortality rate of 86%.
Friedreich’s Ataxia

Friedreich’s ataxia is inherited as an autosomal recessive trait. The onset of ataxia usually occurs before age 10 years, and it progresses slowly, involving the lower extremities to a greater extent than the upper extremities. Explosive dysarthric speech and nystagmus are characteristic, but intelligence is preserved.

Echocardiographic studies reveal evidence of cardiomyopathy in approximately 30% of the cases. Concentric hypertrophy of the left ventricle (LV) with normal LV systolic function is the most common finding. In advanced stages, the LV enlarges, and the LV wall thickness decreases with decreasing fractional shortening, suggesting the presence of fibrosis in the myocardium (Weidemann et al, 2012). Diastolic dysfunction of the LV may be present. The thickness of the interventricular septum correlates well with LV mass determined by magnetic resonance imaging (MRI). Microscopically, diffuse interstitial fibrosis and fatty degeneration of the myocardium, with compensatory hypertrophy of the remaining cells, frequently are found. CHF is the terminal event with most patients dying before 40 years of age.

Cardiac symptoms (e.g., dyspnea, chest pain) are common. Because of physical disability, cardiac problems may not be recognized until arrhythmias or signs of CHF develop. Importantly, there appears to be no clear correlation between the severity of myocardial involvement and that of neurologic dysfunction. A systolic murmur may be audible at the upper left sternal border. Electrocardiographic (ECG) abnormalities are very common. The most common finding is the T-vector change in the limb leads or left precordial leads. Occasionally, left ventricular hypertrophy (LVH), right ventricular hypertrophy (RVH), abnormal Q waves, or short PR interval is found. Chest radiographs usually are normal.

Treatments are the same as those described under different types of cardiomyopathies.
Hyperthyroidism: Congenital and Acquired

The thyroid hormones increase oxygen consumption, stimulate protein synthesis and growth, and affect carbohydrates and lipid metabolism. On the cardiovascular system, the thyroid hormones (1) increase heart rate, cardiac contractility, and cardiac output; (2) increase systolic pressure and decrease diastolic pressure, with mean pressure unchanged; and (3) may increase myocardial sensitivity to catecholamines. Hyperthyroidism results from excess production of triiodothyronine (T₃), thyroxine (T₄), or both.

**Congenital hyperthyroidism** most often is caused by increased thyroid-stimulating immunoglobulin in infants of mothers who had Graves’ disease during pregnancy. A newborn infant with congenital hyperthyroidism often is premature and usually has a goiter. The baby appears anxious, restless, alert, and irritable. The eyes are widely open and appear exophthalmic.

**Juvenile hyperthyroidism** is believed to be caused by thyroid-stimulating antibodies and often is associated with lymphocytic thyroiditis and other autoimmune disorders. The incidence of juvenile hyperthyroidism peaks during adolescence, with girls affected more often than boys. These children become hyperactive, irritable, and excitable. The thyroid gland is enlarged.

Both congenital and acquired hyperthyroidism manifests with tachycardia, full and bounding pulses, and increased systolic and pulse pressures. A nonspecific systolic murmur may be audible. Bruits may be audible over the enlarged thyroid in children but not in newborns. In severely affected patients, cardiac enlargement and cardiac failure may develop, requiring prompt recognition and treatment.

Chest radiographs usually are normal but may show cardiomegaly and increased pulmonary vascularity, especially in the presence of heart failure. ECG abnormalities may include sinus tachycardia, peaked P waves, various arrhythmias (supraventricular tachycardia, junctional rhythm), complete heart block, RVH, LVH, or biventricular hypertrophy (but arrhythmias are rare in acquired (juvenile) hyperthyroidism. Echocardiographic studies reveal a hyperkinetic state with increased fractional shortening.

In severely affected patients, a β-adrenergic blocker, such as propranolol, is indicated to reduce the effect of catecholamines. It is interesting to note that some actions of T₃ on the heart are similar to those of β-adrenergic stimulation and that essentially all beta-blockers can alleviate many of the symptoms of hyperthyroidism. The mechanism of the similarity between these two is unclear; it may involve increased beta-adrenergic receptor density or it may occur independently of β-adrenergic receptor stimulation. Treatment of hyperthyroidism consists of oral administration of antithyroid drugs, propylthiouracil, or methimazole (Tapazole). If CHF develops, treatment with anticongestive medications is indicated (see Chapter 27).
Hypothyroidism results from deficient production of thyroid hormone or a defect in its receptor. The disorder may manifest from birth or may be acquired.

**Congenital hypothyroidism**, formerly known as cretinism, most often is caused by a developmental defect of the thyroid gland. Hypothyroidism may not be apparent until 3 months of age. The typical picture includes a protuberant tongue, cool and mottled skin, subnormal temperature, carotenemia, and myxedema. Untreated children become mentally retarded and slow in physical development. In the congenital type, patent ductus arteriosus and pulmonary stenosis are frequently found.

The patient may have significant bradycardia, a weak arterial pulse, hypotension, and nonpitting facial and peripheral edema. ECG abnormalities occur in more than 90% of patients and consist of some or all of the following: (1) low QRS voltages, especially in the limb leads; (2) low T-wave amplitude, not affecting the T axis; (3) prolongation of PR and QT intervals; and (4) dome-shaped T wave with an absent ST segment (“mosque” sign) (Fig. 23-1). Echocardiographic studies may show cardiomegaly, pericardial effusion, hypertrophic cardiomyopathy, or asymmetric septal hypertrophy in addition to CHDs, if present. Sodium-l-thyroxine given orally is the treatment of choice.

**Acquired (or juvenile) hypothyroidism** most often results from lymphocytic thyroiditis (Hashimoto’s disease or autoimmune thyroiditis). Hypothyroidism may result from subtotal or complete thyroidectomy or from protracted ingestion of goitrogens, iodides, or cobalt medications. Rarely, amiodarone can cause hypothyroidism. Serum levels of thyroxine and triiodothyronine are low or borderline.

The heart rate is relatively slow, and the heart sounds may be soft. A weak arterial pulse and hypotension may be present. Myxedema may be present. There is an increased occurrence of hypercholesterolemia. Echocardiographic studies frequently show pericardial effusion and asymmetric septal hypertrophy. The ECG, chest radiograph, and echocardiographic findings of juvenile hypothyroidism are the same as for congenital
hypothyroidism. Treatment of hypothyroidism corrects the lipid abnormalities.
Marfan’s Syndrome

Marfan’s syndrome is a generalized connective tissue disease with clinical features involving skeletal, cardiovascular, and ocular systems. It is inherited as an autosomal dominant pattern with variable expressivity.

Skeletal features include tall stature with long slim limbs, little subcutaneous fat and muscle hypotonia, arachnodactyly, joint laxity with scoliosis and kyphosis, pectus excavatum or carinatum, and narrow facies. Eye manifestations may include lens subluxation, increased axial global length, myopia, and retinal detachment.

Clinically evident cardiovascular involvement occurs in more than 50% of patients by the age of 21 years. Microscopic changes probably are present in almost all patients even during infancy and childhood. A wide spectrum of cardiovascular abnormalities is seen in Marfan’s syndrome

1. The common abnormalities include dilatation of the sinus of Valsalva, dilatation of the ascending aorta (with or without dissection or rupture), and aortic regurgitation (AR). Microscopic examination of the proximal aorta (and the proximal coronary arteries) reveals disruption of the elastic media, with fragmentation and disorganization of the elastic fibers. Large accumulations of dermatan sulfate, heparan sulfate, and chondroitin sulfate have been reported in the media of the aorta.
2. Mitral valve abnormalities are more common in children and young adults than aortic lesions. The mitral valve and left atrial (LA) endocardium often undergo a fibromyxoid degeneration, resulting in dilatation of the mitral valve annulus, mitral regurgitation (MR) and mitral valve prolapse (MVP).
3. Aneurysm of the pulmonary artery (PA) is less frequently seen.
4. Rarely, myocardial fibrosis and infarction, rupture of chordae tendineae, aneurysm of the abdominal aorta, and aneurysmal dilatation of the proximal coronary arteries have been reported.

Auscultatory findings of MR and MVP appear in more than 50% of patients (see Chapter 21). Rarely, the murmur of AR is audible. The S2 may be accentuated in many patients, especially in those with thin chest walls or dilated PAs. The ECG findings may include LVH; T-wave inversion in leads II, III, aVF, and left precordial leads; and first-degree AV block. Chest radiographs may show cardiomegaly, either generalized or involving only the LV and LA, or a prominence of the ascending aorta, aortic knob, or the main PA segment.

Echocardiographic studies show an increased dimension of the aortic root with or without AR and a “redundant” mitral valve or MVP with thickened valve leaflets and MR. Periodic examination of the aortic root dimension and the status of the MR and MVP are important. As to the diagnosis of MVP in children, however, the adult criteria of MVP are met infrequently, probably because MVP is a progressive disease, and a full manifestation of the disease does not occur until adulthood.

Early death in individuals with this syndrome is most commonly precipitated by aortic dissection, chronic AR, or severe MR. Early and improved surgery and the use of beta-blockers have significantly increased the life expectancy of these patients in recent years.
1. Beta-blockers (atenolol, propranolol) are effective in slowing the rate of aortic dilatation and reducing the development of aortic complications. Recently, enalapril was reported to reduce the rate of increase in the aortic root diameter (Yetman et al, 2005). Thus, beta-blockers or ACE inhibitors (or both) should be administered to children when the aortic root size exceeds the upper limit of normal for age.

2. Certain physical activities are discouraged to reduce the damage to the aortic root and regurgitant aortic and mitral valves. Exercises, such as weightlifting, rowing, push-ups, pull-ups, sit-ups, and hanging on a monkey bar, should be avoided.

3. Surgery should be considered when the diameter of the aortic root increases significantly. However, there is controversy as to what is considered significant enlargement of the aortic root to require surgery. Some centers recommend surgery when the aortic root diameter is greater than 3.5 cm (Kim et al, 2005), others recommend surgery when the aortic root equals approximately twice the average measurement for that age group, and still others recommend surgery when the diameter reaches near 6.5 cm (Gott et al, 1999). Recently, a maximum sinus dimension of 5 cm or a rapid increase in dimension (>1 cm/year) have been suggested as indications for surgery (Tweddell et al, 2012). Normal two-dimensional echocardiographic dimensions of the aortic root and the aorta are presented in Table D-3 in Appendix D.

4. Valve-sparing aortic root reconstruction appears to be preferable to composite graft surgery.

5. Cardiac failure caused by severe MR is treated with mitral valve repair or valve replacement.

6. Aortic root dilatation or aortic aneurysm may occur in other connective tissue diseases, and similar surgical procedures may become necessary. The conditions may include, in addition to Marfan’s syndrome, Ehlers-Danlos syndrome, Turner syndrome, Loeys-Dietz syndrome, and others. Dilatation of the ascending aorta or the aortic root can also occur after surgery for CHDs, such as aortic stenosis (AS), TOF, and truncus arteriosus.
The mucopolysaccharidoses (MPS) are a diverse group of inherited metabolic disorders in which excessive amounts of glycosaminoglycans (previously called mucopolysaccharides) accumulate in various tissues, including the myocardium and coronary arteries. Stored glycosaminoglycans vary with different types and include chondroitin sulfate, heparan sulfate, keratan sulfate, dermatan sulfate, and hyaluronan. Hurler (type IH), Hunter (II), Scheie (IS), Sanfilippo (III), and Morquio (IV) are well-known eponyms. A wide variety of clinical manifestations occur, including growth and mental retardation, skeletal abnormalities, a clouded cornea, upper airway obstruction, and cardiac abnormalities. In most cases, the cause of death is cardiorespiratory failure secondary to cardiac involvement and upper airway obstruction.

Echocardiographic studies show involvement of mitral and aortic valves (most frequently valve regurgitation) in more than 50% of the cases; about 25% of the cases show cardiomyopathy. The prevalence of these abnormalities increases as the patient becomes older.

1. MR is present in approximately 30% of the patients. It is more frequent in types IH (38%) than other types (24% in type II and 20% in type III). Thickening of the mitral valve is common.
2. Aortic regurgitation is present in about 15% of the cases, often with thickening of the valve. It is more common in type II (56%) and type IV (24%).
3. Myocardial abnormalities, such as asymmetric septal hypertrophy, hypertrophic cardiomyopathy, dilated cardiomyopathy, and endocardial thickening, are present in about 25% of the cases.
4. Occasionally, systemic hypertension is present.
5. Rarely, myocardial infarction can occur.

Heart murmur may represent cardiac valve involvement. Chest radiographs may show cardiomegaly in severe cases of valve regurgitation. The ECG may show a prolonged QT interval, RVH, LVH, or left atrial hypertrophy (LAH). Management depends on the abnormalities present.
Muscular Dystrophy

Duchenne’s muscular dystrophy is a sex-linked recessive disease. Involvement of the pelvic muscles leads to lordosis, a waddling gait, a protuberant abdomen, and difficulty rising. Becker’s muscular dystrophy is the same fundamental disease as Duchenne’s dystrophy, but it follows a milder and more protracted course.

Cardiac enlargement, with occasional endocardial thickening of the LV and LA, is found on gross examination. Fatty degeneration and lymphocytic infiltration are found on microscopic examination. Dystrophic changes in the papillary muscles may be evident, with MR or MVP.

Exertional dyspnea and tachypnea are common symptoms. The P2 may be loud if pulmonary hypertension is present. One may hear either a systolic ejection murmur at the base or a regurgitant apical systolic murmur of MR. CHF is an ominous terminal sign.

Electrocardiographic abnormalities occur in 90% of teenagers with Duchenne’s type, and RVH and right bundle branch block (RBBB) are the most common abnormalities. Deep Q waves frequently are seen in the left precordial leads. A short PR interval is occasionally seen. T-vector changes may be seen in the limb leads or left precordial leads.

Echocardiographic studies show significant cardiac involvement in the form of dilated cardiomyopathy in both Duchenne’s and Becker’s types of muscular dystrophies and manifests clinically during adolescence. In the early stages of the disease, only diastolic dysfunction (of reduced diastolic relaxation pattern) may be present. Systolic dysfunction appears later in the disease process. Echocardiographic features of MR or MVP may be seen.

Treatment is the same as that described for dilated cardiomyopathy (see Chapter 18). Recent reports suggest that a more aggressive treatment with ACE inhibitors (e.g., perindopril) appears to lead to improved LV function and possible delay of progression of the disease (Duboc et al, 2005). Although prospective treatment may be better, the treatment appears to improve LV function even if started after abnormal echocardiographic findings appear. Addition of carvedilol (0.5–1 mg/kg twice daily) to the standard treatment was shown to prevent dilatation of the ventricle over baseline and to increase fractional shortening (Kajimoto et al, 2006). Recently, Viollet et al (2012) reported that treatment with of an ACE inhibitor (lisinopril) with or without additional beta-blockers (metoprolol) in 42 patients significantly improved the myocardial function. Beta-blockers were added to the ACE inhibitor when average heart rate exceeded 100 beats/min on a 24-hr Holter monitoring.
Myotonic dystrophy is the second most common muscular dystrophy. This disease is characterized by myotonia (increased muscular irritability and contractility with decreased power of relaxation) combined with muscular weakness. This autosomal dominant disease causes dysfunction in multiple organ systems, including the musculoskeletal, gastrointestinal, cardiovascular, endocrine, and immunologic systems.

In infancy, myotonic dystrophy presents with feeding difficulties. Later in life, developmental retardation, poor coordination, and muscle weakness are evident. During childhood, the trunk and proximal muscle groups are involved, and in late in life, the distal muscle groups and facial and neck muscles are involved. A “hatchet” face is characteristic with an open mouth, drooling, and lack of expression.

Cardiac abnormalities are frequent with involvement of the AV conduction and structural abnormalities. Fatty infiltration in the myocardium and fibrofatty degeneration in the sinus node and AV conduction system may be responsible for the manifestations.

1. The ECG may show first-degree AV block and intraventricular conduction delay. As the disease progresses, second-degree and complete heart block may develop. In addition, atrial fibrillation and flutter, abnormal Q waves, and ventricular arrhythmias may develop. Sudden death is frequent and attributable to conduction abnormalities or arrhythmias.

2. MVP may develop, usually by adulthood.

3. LV systolic dysfunction may appears with advancing age. Rarely, LVH, LA dilatation, and regional wall motion abnormalities are seen.

Patients with symptoms or evidence of dysrhythmias should be considered for pacemaker treatment. LV dysfunction, if present, should be treated.
Noonan Syndrome

Noonan syndrome, once referred to as “male Turner syndrome,” is an autosomal dominant genetic disorder, occurring in both males and females. It is associated with normal chromosomes. It was first described by Dr. Jacqueline A. Noonan, a pediatric cardiologist, in the early 1960s. Noonan syndrome occurs in about one in 1000 to 2500 live births.

The diagnosis of Noonan syndrome is suspected by distinctive facial features, short stature, chest deformity, and CHD (Romano et al, 2010).

1. The facial appearance is most characteristic in infancy and early to middle childhood. It includes a large head, wide-spaced eyes, prominent epicanthal folds, horizontal or down-slanting palpebral fissures, low-set ears, and a short and broad nose with a depressed root. The neck is short with excess skin (webbed neck) and a low posterior hairline (55%).
2. Cubitus valgus is found in more than half of the patients. Hyperextensibility is common.
3. A characteristic pectus deformity of the chest with pectus carinatum superiorly and pectus excavatum inferiorly is seen in many children with the syndrome. Scoliosis is reported in 10% to 15% of patients.
4. Although some clinical features are similar to Turner syndrome, patients with Noonan syndrome are often mentally retarded, and normal sexual maturation usually occurs, although it is delayed.
5. Cardiovascular abnormalities: More than 80% of patients with the syndrome have an abnormality of the cardiovascular system.
   a. Pulmonary valve stenosis is the most common one. The valve may be dysplastic in 25% to 35% of the cases.
   b. Secundum ASD is often associated with pulmonary valve stenosis.
   c. Hypertrophic cardiomyopathy is present in approximately 20% of patients. The condition may resolve, become rapidly progressive, or remain stable.
6. Abnormal ECG findings are present in about 50% of patients with LAD, LVH, and abnormal Q waves.

Management

1. For significant PS, initial treatment is usually pulmonary balloon valvuloplasty, but it may be unsuccessful if the valve is dysplastic. With severe dysplasia, a pulmonary valvectomy or pulmonary homograft may be needed in childhood.
2. Patients with hypertrophic cardiomyopathy may require the use of beta-blockers or surgical myomectomy to reduce outflow obstruction.
3. Individuals without heart disease on their initial evaluation should be followed every 5 years because of the possible late appearance of cardiac problems.
4. Patients should be followed by endocrinologists for:
   a. Possible growth failure, which may require growth hormone therapy
b. Thyroid hormone replacement for hypothyroidism
c. Possible pubertal induction with estrogen (for females) or testosterone (for males) for absence of breast development in girls by the age of 13 years or no testicular enlargement in boys by 14 years of age.
Rheumatoid arthritis represents an autoimmune disease in which the synovium is the principal target of inappropriate immune attack. Autopsy cases may exhibit multiple hemorrhages on parietal and visceral pericardial surfaces with dense fibrous adhesion. The myocardium may be hypertrophied with infiltration of inflammatory cells, and irregular nodular thickening may be seen on cardiac valves.

In clinical settings, the following cardiac manifestations may occur.
1. Pericarditis is the most common finding, occurring in about 50% of cases. Chest pain and friction rub signify pericarditis. It is most frequent in systemic-onset juvenile rheumatoid arthritis (JRA), occasionally in patients with polyarticular-onset JRA and very rarely in pauciarticular-onset JRA. Small pericardial effusion occurs without symptoms, but large effusion may cause symptoms. Cardiac tamponade only rarely occurs.
2. Myocarditis occurs infrequently (1%–10%) in JRA but can lead to life-threatening CHF and arrhythmias.
3. Rarely, MR and AR with thickening of these valves occur.
4. Occasionally, LV systolic dysfunction (decreased ejection fraction and fractional shortening) with dilated LV occurs.
5. ECG abnormalities occur in 20% of cases, with the most common findings being nonspecific ST-T changes. Rarely, involvement of the conduction system with heart block can occur.

Asymptomatic and mild pericarditis may be treated with nonsteroidal antiinflammatory agents (e.g., naproxen 15 mg/kg/day in two divided doses). Symptomatic or severe pericarditis may require treatment with corticosteroids for 8 to 16 weeks. Prednisone 0.5 to 2 mg/kg/day for 1 week is gradually reduced by approximately 20%. Tamponade is treated with pericardiocentesis.
Sickle Cell Anemia

In sickle cell anemia, erythrocytes become rigid and “sickled,” leading to capillary occlusion and sickle cell “crisis.” The increased stroke volume of the heart compensates for anemia, and the heart gradually dilates and hypertrophies. Heart failure may be a late complication.

Most of the clinical manifestations reflect anemia. The arterial pulse is brisk, and the precordium is hyperactive. The diastolic pressure is low with a wide pulse pressure. An ejection systolic murmur usually is audible along the upper right and left sternal borders. Rarely, one may hear an apical rumble and a gallop rhythm. ECG abnormalities may include first-degree AV block, LVH, and nonspecific T-wave changes. Chest radiographs show generalized cardiomegaly in nearly all patients. Echocardiographic findings include increased LV dimension and vigorous LV contraction, but the ejection fraction and systolic time intervals are within normal limits.
Systemic Lupus Erythematosus

This chronic multisystem autoimmune disease can affect the cardiovascular system. The condition most commonly affects girls older than 8 years of age (78%), with a girl-to-boy ratio of 6.3:1.

The most common symptoms of lupus include constitutional complaints (fever, fatigue, anorexia, weight loss), joint pain and stiffness with or without swelling (commonly finger joints), skin rash (typical malar “butterfly” rash, seen only in 50%), and chest pain (from pleuritis or pericarditis). Evidence of renal involvement, hypertension, and Raynaud’s phenomenon are also frequent. Chorea may be the sole presenting manifestation, requiring differentiation from acute rheumatic fever.

A positive antinuclear antibody (ANA) test result is present in more than 95% of the cases, making it the most helpful initial screening test. However, a positive ANA test result is not diagnostic of the disease, particularly if the titer is low. A positive ANA test result is seen in other connective tissue diseases, such as JRA (but not in systemic-onset type), dermatomyositis, scleroderma, Sjögren’s syndrome, and mixed connective tissue disease) and in some healthy children and adults. If the ANA test result is positive, further screening by a rheumatologist should be carried out.

Cardiovascular manifestations occur in about 30% to 40% of patients with lupus erythematosus, a higher rate than with other connective tissue diseases. Pathologically, varying degrees of immune-mediated changes occur in all layers of the heart, including the pericardium (patchy infiltration of inflammatory cells, fibrous adhesion), myocardium (mild to moderate acute and chronic inflammatory foci, perivasculitis of intramural arteries, increased interstitial connective tissue, myocardial cell atrophy), and cardiac valves (classical verrucous Libman-Sacks lesions).

1. Pericarditis with pericardial effusion is the most common manifestation (≈25%) and is often asymptomatic. Tamponade is rare, and constrictive pericarditis is extremely rare.
2. Clinically evident myocarditis occurs in 2% to 25%, with resting tachycardia.
3. The classic verrucous endocarditis (Libman-Sacks) is found most commonly on the mitral valve, less commonly on the aortic valve, and only rarely on the tricuspid and pulmonary valves. Echocardiographic studies show irregular vegetations 2 to 4 mm in diameter on the valve or subvalvular apparatus (seen in ≈10%). Rarely, embolization of the vegetations can occur to a coronary or cerebral artery. Recent studies indicate that, instead of verrucous lesion, the mitral or aortic valve may exhibit diffuse thickening with or without regurgitation.

Anterior chest pain may occur with pericarditis. Apical systolic murmur of MR frequently is found, but pericardial friction rub rarely is audible. The ECG shows nonspecific ST-T changes, arrhythmias, or conduction disturbances. With pericarditis, T-wave inversion and ST segment elevation may develop.

If active valvulitis is suspected, corticosteroid therapy may be warranted. Anticoagulation therapy should also be considered.
Turner Syndrome

Turner syndrome occurs in about one of 2000 live female births. Standard karyotyping shows a missing X chromosome in more than 50% of the patients (45,X); others have a combination of monosomy X and normal cells (45,X/46,XX), called mosaic Turner syndrome.

Diagnosis of Turner syndrome is suspected at birth by a characteristic edema of the dorsa of the hands and feet and loose skin folds at the nape of the neck. Clinical manifestations in childhood include webbing of the neck, a broad chest with wide-spaced nipples, cubitus valgus, and small stature. Cardiac abnormalities are found in about 35% of patients with Turner syndrome.

Important cardiac abnormalities are as follows:
1. Bicuspid aortic valve (BAV), coarctation of the aorta (COA), and aortic wall abnormalities (ascending aortic dilatation, aneurysm formation, and aortic dissection) are more commonly found in patients with webbing of the neck. BAV may lead to clinically significant AS or AR.
2. Less common CV anomalies include the following.
   a. Elongated transverse arch is present, which may be prone to dilatation and perhaps dissection.
   b. Partial anomalous pulmonary venous return involving the left upper PV is found in 13%.
   c. Persistent left SVC (13%).
3. The ECG may show right axis deviation, T-wave abnormalities, accelerated AV conduction, and QTc prolongation.
4. Two-dimensional echocardiography and color Doppler studies usually detect most cardiovascular abnormalities, but MRI should also be performed to evaluate other abnormalities when it can be done without sedation.

The following are suggested in the follow-ups according to the organ systems (Bondy, 2007).
1. Cardiac follow-up is required with attention to the following.
   a. Monitoring blood pressure for hypertension. Hypertension is treated with beta-blockers.
   b. Aortic dimension should be determined on a regular basis. If the aorta is enlarged, the patient should be treated with beta-blockers.
   c. Also monitor for diabetes and dyslipidemia.
   d. MRI may be advised to evaluate the aortic dimension every 5 to 10 years.
2. They should be followed by pediatric endocrinologists.
   a. Growth hormone is indicated as early as possible and through puberty to attain normal adult height. Optimal age for starting growth hormone is not established, but it may be as early as 9 months of age.
   b. Puberty induction with estrogen therapy at around 12 years of age, if pubertal development is absent (although 30% will have spontaneous pubertal development). Spontaneous pregnancies occur in 2% to 5% of patients.
3. Cautions with regard to pregnancy:
   a. Aortic dissection during pregnancy and the postpartum period is possible.
   b. If pregnancy is being considered, cardiology evaluation with MRI of the aorta is indicated.
   c. A history of surgically repaired cardiovascular defect, BAV, aortic dilatation, and systemic hypertension are relative contraindications of pregnancy.

4. Exercise: Regular moderate aerobic activity is emphasized. Highly competitive sports and very strenuous or isometric exercise are not recommended for patients with a dilated aortic root.
Williams Syndrome

Williams syndrome is a rare genetic condition, occurring in one per 7500 to 20,000 births; most cases are sporadic. It occurs with equal prevalence in males and females. A microdeletion in the chromosomal region 7q11.23 near the elastin gene (ELN) is identified in virtually all individuals with Williams syndrome. Elastin is a protein that allows blood vessels and other tissues in the body to stretch. Elastin arteriopothy is generalized, but it most commonly affects the ascending aorta and the pulmonary arteries.

Important cardiovascular pathology includes the following.
1. Supravalvular AS and pulmonary artery stenosis are the two most common defects, occurring singly or together, in 55% to 80% of the patients. Pulmonary artery stenosis has been reported in up to 83% of cases (in some reports).
2. Less common defects include COA, hypoplastic aortic arch, ASD, VSD, TOF, complete AV canal, and hypertrophic cardiomyopathy.
3. High pressure in the sinus of Valsalva may lead to coronary ostial narrowing and coronary artery stenosis and may result in an increased risk for sudden death.
4. There may also be renal artery stenosis with resulting hypertension.

Patients with Williams syndrome have multisystem manifestations, including cardiovascular disease, developmental delay, learning disability, mental retardation, hearing loss, severe dental disease, ocular problems, nephrolithiasis, and bowel and bladder diverticula.
1. Many children have history of failure to thrive, poor weight gain, colic, or delayed motor development during early life.
2. Most young children with the syndrome have similar characteristic features. These features include a small upturned nose, a long philtrum (upper lip length), wide mouth, full lips, a small chin, a stellate pattern in the iris (seen in 50%), and puffiness around the eyes. They have personality trait of being very friendly, trusting strangers, fearing loud sounds, and being interested in music. They are also hyperactive, inattentive, and easily distracted (attention deficit disorder). Other findings include a hoarse voice, joint hyperelasticity, contractures, kyphoscoliosis, and lordosis.
3. Cardiac examination may show systolic ejection murmur (arising from supravalvular AS or pulmonary artery stenosis).
4. Systemic hypertension may be present or develop in approximately 50% of the patients.
5. The ECG may show LVH in severe cases of supravalvular AS. BVH or RVH may be present with severe PA stenosis. Rarely, ST-T-wave abnormalities may be present.
6. Echocardiography may show most of the known cardiac abnormalities (as described earlier).
7. Renal ultrasonography may find anatomic abnormalities (found in 15%–20%) or nephrolithiasis (caused by hypercalcemia).
8. Hypercalcemia, which is noted in approximately 15% of infants with Williams syndrome, is frequently asymptomatic and resolves in the first few years of life but can
be lifelong.

The diagnosis of the syndrome is suspected by facial characteristics and cardiac abnormalities (supravalvular AS or pulmonary artery stenosis). Most deletions are detected through FISH, not through standard karyotyping.

A less well-recognized fact is an increased chance of sudden death (Bird et al, 1996). It has been estimated that sudden death can occur in patients with Williams syndrome at a rate 25- to 100-fold higher than in age-matched control subjects. Deaths have been reported after the use of anesthesia or sedation or during invasive procedures (e.g., cardiac catheterization and heart surgery). Sudden deaths with no apparent instigating event have also been reported. Several factors have been cited as the potential causes of sudden death.

1. Severe supravalvular AS or severe pulmonary stenosis leading to ventricular hypertrophy and myocardial ischemia
2. Coronary artery stenosis secondary to exposure to a high systolic pressure in the sinus of Valsalva
3. Recently, prolongation of the QTc interval has been raised as a possibility. Collins et al (2010) have reported a much higher prevalence of prolonged QTc interval in patients with the syndrome. Prolonged QTc interval (≥460 ms) was found in 13.6% of the patients compared with 2.0% in control participants. Whereas JTc prolongation (>340 ms) was found in 11.7% in the patients, it was found in 1.8% in control participants. Thus, prolonged cardiac repolarization seen in this condition may be a cause of sudden death.

Management may include the following.

1. Hypercalcemia should be treated, if present. Patients should avoid taking extra calcium and vitamin D.
2. Annual cardiology evaluation is indicated with assessment of the cardiac conditions, measurement of blood pressure, and checking the QTc interval.
3. When planning a procedure, the patient’s history should be evaluated carefully for syncope, angina, fatigue or dyspnea, and hemodynamic instability during previous anesthesia or sedation.
4. Management of cardiac defects is described under specific defects; supravalvular AS in Chapter 13 and PA stenosis in Chapter 15.
PART 6
Arrhythmias and Atrioventricular Conduction Disturbances

OUTLINE

Introduction
24. Cardiac Arrhythmias
25. Disturbances of Atrioventricular Conduction
26. Cardiac Pacemakers and Implantable Cardioverter-Defibrillators in Children
This part discusses cardiac arrhythmias, atrioventricular conduction disturbances, and cardiac pacemakers and implantable cardioverter-defibrillators in children.
The frequency and clinical significance of arrhythmias are different in children compared with adults. Although arrhythmias are relatively infrequent in infants and children, the common practice of monitoring cardiac rhythm in children requires primary care physicians, emergency department physicians, and intensive care physicians to be able to recognize and manage basic arrhythmias.

The normal heart rate varies with age: The younger the child, the faster the heart rate. Therefore, the definitions of bradycardia (<60 beats/min) and tachycardia (>100 beats/min) used for adults do not apply to infants and children. Tachycardia is defined as a heart rate beyond the upper limit of normal for the patient’s age, and bradycardia is defined as a heart rate slower than the lower limit of normal. Normal resting heart rates by age are presented in Table 24-1.

This chapter discusses basic arrhythmias according to the origin of their impulse. Each arrhythmia is described along with its causes, significance, and treatment.
Rhythms Originating in the Sinus Node

All rhythms that originate in the sinoatrial (SA) node (sinus rhythm) have two important characteristics (Fig. 24-1). Both are required for a rhythm to be called sinus rhythm.

1. P waves precede each QRS complex with a regular PR interval. (The PR interval may be prolonged, as in first-degree atrioventricular [AV] block); in this case, the rhythm is sinus with first-degree AV block).
2. The P axis falls between 0 and +90 degrees, an often neglected criterion. This produces upright P waves in lead II and inverted P waves in aVR. (See Chapter 3 for a detailed discussion of sinus rhythm.)

Regular Sinus Rhythm

Description. The rhythm is regular, and the rate is normal for age. The two characteristics of sinus rhythm described previously are present (see Fig. 24-1).

Significance. This rhythm is normal at any age.

Management. No treatment is required.

Sinus Tachycardia

Description. Characteristics of sinus rhythm are present (see previous description). The rate is faster than the upper limit of normal for age (see Table 24-1). A rate above 140 beats/min in children and above 170 beats/min in infants may be significant. The heart rate usually is below 200 beats/min in sinus tachycardia (see Fig. 24-1).

Causes. Anxiety, fever, hypovolemia or circulatory shock, anemia, congestive heart failure (CHF), administration of catecholamines, thyrotoxicosis, and myocardial disease are possible causes.

Significance. Increased cardiac work is well tolerated by healthy myocardium.

Management. The underlying cause is treated.

Sinus Bradycardia

Description. The characteristics of sinus rhythm are present (see previous description), but the heart rate is slower than the lower limit of normal for the age (see Table 24-1). A rate slower than 80 beats/min in newborn infants and slower than 60 beats/min in older children may be significant (see Fig. 24-1).
FIGURE 24-1 Normal and abnormal rhythms originating in the sinoatrial node. (From Park MK, Guntheroth WG: How to Read Pediatric ECGs, 4th ed. Philadelphia, Mosby, 1992.)

TABLE 24-1
NORMAL RANGES OF RESTING HEART RATE

<table>
<thead>
<tr>
<th>Age</th>
<th>Mean (range)</th>
<th>Age (yr)</th>
<th>Mean (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newborn</td>
<td>145 (90–180)</td>
<td>4</td>
<td>108 (72–135)</td>
</tr>
<tr>
<td>6 months</td>
<td>145 (105–185)</td>
<td>6</td>
<td>100 (65–135)</td>
</tr>
<tr>
<td>1 year</td>
<td>132 (105–170)</td>
<td>10</td>
<td>90 (65–130)</td>
</tr>
<tr>
<td>2 year</td>
<td>120 (90–150)</td>
<td>14</td>
<td>85 (60–120)</td>
</tr>
</tbody>
</table>


**Causes.** Sinus bradycardia may occur in normal individuals and trained athletes. It may occur with vagal stimulation, increased intracranial pressure, hypothyroidism, hypothermia, hypoxia, hyperkalemia, and administration of drugs such as β-adrenergic blockers.

**Significance.** In some patients, marked bradycardia may not maintain normal cardiac output.

**Management.** The underlying cause is treated.

**Sinus Arrhythmia**

**Description.** There is a phasic variation in the heart rate caused by respiratory influences on the autonomic nervous system, increasing during inspiration and decreasing during expiration. The arrhythmia occurs, with maintenance of characteristics of sinus rhythm (see Fig. 24-1).
Causes. This is a normal phenomenon and is caused by phasic variation in the firing rate of cardiac autonomic nerves with the phases of respiration.

Significance. Sinus arrhythmia has no significance because it is a normal finding in children and a sign of good cardiac reserve.

Management. No treatment is indicated.

Sinus Pause

Description. In sinus pause, the sinus node pacemaker momentarily ceases activity, resulting in absence of the P wave and QRS complex for a relatively short time (see Fig. 24-1). Sinus arrest is of longer duration and usually results in an escape beat (see later discussion) by other pacemakers, such as the AV junctional or nodal tissue (junctional or nodal escape beat).

Causes. Increased vagal tone, hypoxia, sick sinus syndrome, and digitalis toxicity are possible causes. Well-conditioned athletes may have bradycardia and sinus pause of greater than 2 seconds because of prominent vagal influence.

Significance. Sinus pause of less than 2 seconds are normal in young children and adolescents. It usually has no hemodynamic significance but may reduce cardiac output in patients with frequent and long period of sinus pause.

Management. Treatment is rarely indicated except in sinus node dysfunction (or sick sinus syndrome; see later discussion).

Sinoatrial Exit Block

Description. A P wave is absent from the normally expected P wave, resulting in a long RR interval. The duration of the pause is a multiple of the basic PP interval. An impulse formed within the sinus node fails to propagate normally to the atrium.

Causes. Excessive vagal stimulation, myocarditis or fibrosis involving the atrium, and drugs such as quinidine, procainamide or digitalis.

Significance. It is usually transient and has no hemodynamic significance. Rarely, the patient may have syncope.

Management. The underlying cause is treated.

Sinus Node Dysfunction (Sick Sinus Syndrome)

Description. In sinus node dysfunction, the sinus node fails to function as the dominant pacemaker of the heart or performs abnormally slowly, resulting in a variety of arrhythmias. These arrhythmias may include profound sinus bradycardia, sinus pause or arrest, sinus node exit block, slow junctional escape beats, and ectopic atrial or nodal rhythm. Clear documentation is not always possible. Long-term recording with Holter is better in documenting overall heart rate variation and the prevalence of abnormally slow and fast rhythm.

Bradytachyarrhythmia occurs when bradycardia and tachycardia alternate. Whereas
Bradycardia may originate in the sinus node, atria, AV junction, or ventricle, tachycardia is usually caused by atrial flutter or fibrillation and less commonly by reentrant supraventricular tachycardia (SVT). When these arrhythmias are accompanied by symptoms such as dizziness or syncope, sinus node dysfunction is referred to as sick sinus syndrome.

**Causes**

1. Injury to the sinus node caused by extensive cardiac surgery, particularly involving the atria (e.g., the Senning operation, Fontan procedure, or surgery for partial or total anomalous pulmonary venous return or endocardial cushion defect) are possible causes.
2. Some cases of sick sinus syndrome are idiopathic, involving an otherwise normal heart without structural defect.
3. Rarely, myocarditis, pericarditis, or rheumatic fever is a cause.
4. Congenital heart defects (CHDs) (e.g., sinus venosus atrial septal defect [ASD], Ebstein’s anomaly, left atrial isomerism [polysplenia syndrome])
5. Secondary to antiarrhythmic drugs (e.g., digitalis, propranolol, verapamil, quinidine)
6. Hypothyroidism

**Significance**

Bradytachyarrhythmia is the most worrisome. Profound bradycardia after a period of tachycardia (overdrive suppression) can cause presyncope, syncope, and even death.

**Management**

1. For severe bradycardia:
   a. Acute symptomatic bradycardia is treated with intravenous (IV) atropine (0.04 mg/kg IV every 2–4 hours) or isoproterenol (0.05–0.5 μg/kg IV) or transcutaneous pacing. Temporary transvenous or transesophageal pacing can be used until a permanent pacing system can be implanted.
   b. Chronic medical treatment using drugs has not been uniformly successful and is not accepted as standard treatment of sinus node dysfunction.
   c. Symptomatic bradycardia is treated with permanent pacing. Asymptomatic patients with heart rate under 40 beats/min or pauses longer than 3 seconds are less clear indications for permanent pacing.
   d. Permanent implantation is the treatment of choice in symptomatic patients, especially those with syncope. Most patients receive atrial demand pacing. Patients with any degree of AV nodal dysfunction receive dual chamber pacemakers. Ventricular demand pacemakers may be used.
2. For symptomatic tachycardia:
   a. Antiarrhythmic drugs, such as propranolol or quinidine, may be given to suppress tachycardia, but they are often unsuccessful.
   b. Digoxin may help to decrease AV conduction of rapid tachycardia.
   c. Catheter ablation of arrhythmia substrates (often requiring concomitant surgical revision of previous surgeries) may be indicated.
e. Patients with tachycardia–bradycardia syndrome may benefit from antitachycardia pacemakers.
Rhythms Originating in the Atrium

Rhythms that originate in the atrium (ectopic atrial rhythm) are characterized by the following (Fig. 24-2):  
1. P waves have an unusual contour, which is caused by an abnormal P axis or an abnormal number of P waves per QRS complex.  
2. QRS complexes are usually of normal configuration, but occasional bizarre QRS complexes caused by aberrancy may occur (see later discussion).

Premature Atrial Contraction

**Description.** The QRS complex appears prematurely. The P wave may be upright in lead II when the ectopic focus is high in the atrium. The P wave is inverted when the ectopic focus is low in the atrium (so-called coronary sinus rhythm). The compensatory pause is incomplete; that is, the length of two cycles, including one premature beat, is less than the length of two normal cycles (see Fig. 24-2).

An occasional premature atrial contraction (PAC) is not followed by a QRS complex (i.e., a nonconducted PAC; see Fig. 24-2). A nonconducted PAC is differentiated from a second-degree AV block by the prematurity of the nonconducted P wave (P’ in Fig. 24-2). The P’ wave occurs earlier than the anticipated normal P wave, and the resulting PP’ interval is shorter than the normal PP interval for that individual. In second-degree AV block, the P wave that is not followed by the QRS complex occurs at the anticipated time, maintaining a regular PP interval.

**Causes.** PAC appears in healthy children, including newborns. It also may appear after cardiac surgery and with digitalis toxicity.

**Significance.** PAC has no hemodynamic significance.

**Management.** Usually no treatment is indicated except in cases of digitalis toxicity.

Wandering Atrial Pacemaker

**Description.** Wandering atrial pacemaker is characterized by gradual changes in the shape of P waves and PR intervals (see Fig. 24-2). The QRS complex is normal.
Causes. Wandering atrial pacemaker is seen in otherwise healthy children. It is the result of a gradual shift of the site of impulse formation in the atria through several cardiac cycles.

Significance. Wandering atrial pacemaker is a benign arrhythmia and has no clinical significance.

Management. No treatment is indicated.

Ectopic (or Autonomic) Atrial Tachycardia

Description. There is a narrow QRS complex tachycardia (in the absence of aberrancy or preexisting bundle branch block) with visible P waves at an inappropriately rapid rate. The P axis is different from that of sinus rhythm. When the ectopic focus is near the sinus node, the P axis may be the same as in sinus rhythm. The usual heart rate in older children is between 110 and 160 beats/min, but the tachycardia rate varies substantially during the course of a day, reaching 200 beats/min with sympathetic stimuli. This arrhythmia is sometimes difficult to distinguish from the re-entrant AV tachycardia, and thus it is included under SVT. It represented 18% of SVT in one study.
Holter monitoring may demonstrate a characteristic gradual acceleration of the heart rate, the so-called warming up period, rather than abrupt onset and termination seen with reentrant AV tachycardia. The P waves of ectopic atrial tachycardia may not conduct to the ventricle, especially during sleep, when parasympathetic tone is heightened.

**Causes.** Ectopic atrial tachycardia originates from a single focus in the atrium. This arrhythmia is believed to be secondary to increased automaticity of nonsinus atrial focus.

1. Most patients have structurally normal heart (idiopathic).
2. Myocarditis, chronic cardiomyopathy, AV valve regurgitation, atrial dilatation, atrial tumors, and previous cardiac surgery involving atria (e.g., Senning operation, Fontan procedure) may be the cause.
3. Occasionally, respiratory infections caused by mycoplasma or viruses may trigger the arrhythmia.

**Significance.** The chronic nature of the arrhythmia at a relatively low heart rate (<150 beats/min) can escape detection, and CHF is common at presentation. There is a high association of this tachycardia with tachycardia-induced cardiomyopathy.

**Management.** It is refractory to medical therapy and cardioversion. Drugs that are effective in reentrant atrial tachycardia (e.g., adenosine) do not terminate the tachycardia. Cardioversion is ineffective because the ectopic rhythm resumes immediately.

1. Drugs to slow the ventricular rate are not usually successful. There are conflicting reports regarding the efficacy of digoxin and beta-blockers in slowing down the ventricular rate. Class IC (e.g., flecainide) and class III (e.g., amiodarone) antiarrhythmic agents are generally most effective (up to 75%).
2. Radiofrequency ablation may prove to be effective in 95% to 100%. In children, a majority of the foci are found in the left atrium near the pulmonary veins and the atrial appendage in contrast to the right atrium found in adults.

**Chaotic (or Multifocal) Atrial Tachycardia**

**Description.** This is an uncommon tachycardia characterized by three or more distinct P-wave morphologies. The PP and RR intervals are irregular with variable PR intervals. The arrhythmia may be misdiagnosed as atrial fibrillation (AF).

**Causes.** Most patients with the condition are infants; it is very rare after 5 years of age. About 30% to 50% have respiratory illness. Myocarditis and birth asphyxia have been described. Structural heart disease may or may not be present.

**Significance.** The mechanism of this arrhythmia has been poorly defined. Cardiac enlargement or reduced left ventricular (LV) systolic function may be present at the diagnosis. Sudden death has been reported in up to 17% while on therapy. Spontaneous resolution frequently occurs.

**Management.** This arrhythmia is refractory to cardiac pacing, cardioversion, and adenosine.

1. When there is no evidence of cardiac dysfunction, observation on a regular basis may be reasonable.
2. Drugs that slow AV conduction (propranolol or digoxin) and those that decrease
automaticity (e.g., class IA or IC or class III) have not been very effective.
3. Concurrent illness should be treated.
4. If the patient has cardiac dysfunction, medical therapy with amiodarone should be begun. Amiodarone appears to be the current treatment of choice.

Atrial Flutter

Description. The pacemaker lies in an ectopic focus, and “circus movement” in the atrium is the mechanism of this arrhythmia.
1. Typical atrial flutter is characterized by an atrial rate (F wave with “sawtooth” configuration) of about 300 (ranges, 240–360) beats/min, a ventricular response with varying degrees of block (e.g., 2:1, 3:1, 4:1), and normal QRS complexes (see Fig. 24-2).
2. Another form of atrial flutter may be seen in children who have undergone atrial surgery with multiple suture lines. Atrial flutter is secondary to a reentry mechanism within the scarred atrial muscle (called incisional intraatrial reentrant tachycardia). In this situation, the atrial rates are commonly 250 beats/min or slower, and the P-wave morphology is variable without the usual sawtooth F waves, and the P wave is often difficult to detect. Either 2:1 or 1:1 AV conduction is present.

Causes. Atrial flutter usually suggests a significant cardiac pathology, although most fetuses and neonates with atrial flutter have normal hearts, and spontaneous conversion is common. Structural heart disease with dilated atria, acute infectious illness, myocarditis or pericarditis, digitalis toxicity, and thyrotoxicosis are possible causes. Previous surgical procedures involving atria (e.g., Senning operation for transposition, Fontan operation, and other CHDs) may cause incisional intraatrial reentrant tachycardia.

Significance. The ventricular rate determines eventual cardiac output. With a reasonable ventricular rate, the arrhythmia is well tolerated for a long time. A too-rapid ventricular rate may decrease cardiac output and result in heart failure. Thrombus formation may lead to embolic events. Uncontrolled atrial flutter may precipitate heart failure. The flutter may be associated with syncope, presyncope, or chest pain.

Management. Management of atrial flutter is divided into acute conversion, chronic suppression of the arrhythmia, control of ventricular rate, prevention of recurrences, and for refractory cases.
1. Acute situation
   a. Adenosine does not convert the arrhythmia to sinus rhythm, although it may be helpful in confirming the diagnosis of atrial flutter by temporarily blocking AV conduction.
   b. Immediate synchronized DC cardioversion is the treatment of choice for atrial flutter of short duration if the infant or child is in severe CHF.
   c. Transesophageal atrial overdrive pacing may be used for the same purpose. Pacing stimuli are delivered at rates 20% to 25% faster than the flutter rate until the flutter circuit is captured.
   d. In children, IV amiodarone (class III) or IV procainamide (class IA) may be
2. **For chronic cases:** For long-standing atrial flutter or fibrillation (of 24–48 hours) or those with an unknown duration, thrombus formation may lead to cerebral embolic events, especially when the atrial arrhythmia is terminated.
   a. It is essential to rule out atrial thrombi, preferably by echocardiography. Transesophageal echocardiography may define atrial thrombi better than transthoracic echocardiography.
   b. If a thrombus is found or its absence is uncertain, anticoagulation with warfarin (with an international normalized ratio between 2.0 and 3.0) is started and cardioversion delayed for 2 to 3 weeks. After conversion to sinus rhythm, anticoagulation is continued for an additional 3 to 4 weeks.

3. **For rate control:** For control of ventricular rate, calcium channel blockers appear to be the drug of choice. Propranolol may be equally effective. In the past, digoxin was popular for this purpose.

4. **For prevention of recurrences:** Class I and class III antiarrhythmic drugs have been shown to be successful in preventing recurrences in some cases. However, class IA drugs (procainamide, quinidine, disopyramide) also have anticholinergic effects that may produce a faster conduction through the AV node, worsening the situation. Therefore, they should be used with drugs that offset the anticholinergic effect, such as digoxin, beta-blockers, or diltiazem. Amiodarone and ibutilide (class III) have also been shown to be effective in treating atrial flutter. For a quick review of antiarrhythmic drugs, readers should see **Tables A-4 and A-5 in Appendix A**.

5. **For refractory cases:** For incisional intraatrial reentry tachycardia, radiofrequency ablation to interrupt the flutter circuit may be indicated. The success rate for this condition is not as high as in typical atrial flutter (with an acute success rate of 75% and a recurrence rate as high as 50%).

### Atrial Fibrillation

**Description.** Atrial fibrillation (AF) is the most common arrhythmia seen in adults, but it is rare in children and is less common than atrial flutter in children. The mechanism of this arrhythmia is “circus movement,” as in atrial flutter. AF is characterized by an extremely fast atrial rate (f wave at a rate of 350–600 beats/min) and an “irregularly irregular” ventricular response with narrow QRS complexes (see **Fig. 24-2**).

**Causes.** AF usually is associated with structural heart diseases with dilated atria, such as seen with mitral stenosis and regurgitation, Ebstein’s anomaly, tricuspid atresia, ASD, or previous intraatrial surgery. Thyrotoxicosis, pulmonary emboli, and pericarditis should be suspected in a previously normal child who develops AF.

**Significance.** The rapid ventricular rate, in addition to the loss of coordinated contraction of the atria and ventricles, decreases the cardiac output, as occurs in atrial tachycardia. AF usually suggests a significant cardiac pathology.

**Management.** Some part of medical management for AF is similar to that described under a trial flutter (see previous discussion).
1. If AF has been present for more than 48 hours, anticoagulation with warfarin for 2 to 3 weeks is recommended to prevent systemic embolization of atrial thrombus if the conversion can be delayed. Anticoagulation is continued for 3 to 4 weeks after the restoration of sinus rhythm. If cardioversion cannot be delayed, IV heparin should be started and cardioversion performed when activated partial thromboplastin time (aPTT) reaches 1.5 to 2.5 times control levels (in 5–10 days), with subsequent oral anticoagulation with warfarin. An alternative to anticoagulation is transesophageal echocardiography to rule out atrial thrombus.

2. Propranolol, verapamil, or digoxin may be used to slow the ventricular rate.

3. Class I antiarrhythmic agents (e.g., quinidine, procainamide, flecainide) and the class III agent amiodarone may be used, but the success rate in rhythm conversion is disappointingly low. Tables A-4 and A-5 in Appendix A provide a quick review of antiarrhythmic drugs.

4. In patients with chronic AF, anticoagulation with warfarin should be considered to reduce the incidence of thromboembolism. In chronic cases, rate control, rather than conversion, is increasingly used.

5. In the Cox maze procedure (or the “cut-and-sew-maze”), multiple surgical incisions are made in the right and left atria that are then repaired in an attempt to minimize the formation of reentrant loop. The procedure showed greater than a 96% cure rate 10 years after the surgery in adult patients. Freedom from stroke has generally been reported as exceeding 99% for Cox maze procedures.

6. Radiofrequency ablation to electrically isolate the pulmonary veins from the left atrium or directly ablating the ectopic focus within the pulmonary veins has shown better results than pharmacologic agents in rhythm control in adults.

### Supraventricular Tachycardia

#### Description

Supraventricular tachycardia (SVT) is a general term that refers to any rapid heart rhythm originating above the ventricular tissue. In general, SVTs are caused by two separate mechanisms. The first mechanism is reentry, and the second is automaticity. The majority of SVTs are caused by reentrant (or reciprocating) AV tachycardia rather than rapid firing of a single focus in the atria. Examples of reentry (reciprocating) SVT include AV reentrant (or reciprocating) tachycardia and nodal reentrant AV tachycardia. Examples of automatic types of SVTs are atrial ectopic tachycardia and junctional ectopic tachycardia (JET). These arrhythmias share a number of clinical, electrocardiographic, and therapeutic similarities. Most of the discussion here focuses on the reentry type of SVTs; others are discussed under specific headings.

#### Reentrant (Reciprocating) Type of SVT

In the reentry type of SVT, the heart rate is extremely rapid and regular (usually 240 ± 40 beats/min). The P wave usually is invisible. When visible, the P wave has an abnormal P
axis and either precedes or follows the QRS complex (see Figs. 24-2 and 24-3). The QRS complex is usually normal (narrow), but occasionally, aberrancy increases the QRS duration, making differentiation from ventricular tachycardia (VT) difficult (see later discussion).

**AV reentrant (or reciprocating) tachycardia** is not only the most common mechanism of SVT but also the most common tachyarrhythmia seen in the pediatric age group. This arrhythmia was formerly called paroxysmal atrial tachycardia (PAT) because the onset and termination of this arrhythmia were characteristically abrupt. In SVT caused by reentry, two pathways are involved; at least one of these is the AV node, and the other is an accessory pathway. The accessory pathway may be an anatomically separate bypass tract, such as the bundle of Kent (which produces accessory reciprocating AV tachycardia [RAVT]; see Fig. 24-3, A and B), or only a functionally separate bypass tract, such as in a dual AV node pathway (which produces nodal RAVT; see Fig. 24-3, C and D). Patients with accessory pathways frequently have Wolff-Parkinson-White (WPW) preexcitation.

Figure 24-3 shows the mechanism of RAVT in relation to electrocardiographic (ECG) findings. If a PAC occurs, the prematurity of the extrasystole may find the accessory bundle refractory, but the AV node may conduct, producing a normal QRS complex; when the impulse reaches the bundle of Kent from the ventricular side, the bundle will

**FIGURE 24-3** Diagram showing the mechanism of reciprocating atrioventricular tachycardia (RAVT) in relation to electrocardiographic (ECG) findings. A, Orthodromic accessory RAVT is the most common mechanism of supraventricular tachycardia in patients with Wolff-Parkinson-White syndrome. Antegrade conduction through the normal, slow atrioventricular (AV) node produces a normal QRS complex, and the retrograde conduction through the bypass tract creates inverted P waves after the QRS complex (with a short RP interval). B, In antidromic accessory RAVT, the antegrade conduction through the bypass tract produces a wide QRS complex. Retrograde P waves precede the wide QRS complex with a short PR interval (and a long RP interval). C, In orthodromic nodal RAVT (common form), the retrograde P waves are usually concealed in the QRS complex of normal duration. The ECG is similar to that of orthodromic accessory RAVT, and differentiation between these two is possible only when the tachyarrhythmia terminates by the presence of preexcitation in the accessory RAVT. D, In antidromic nodal RAVT (uncommon), narrow QRS complexes are preceded by retrograde P waves, with a short PR interval. The ECG is similar to that of ectopic atrial tachycardia. LV, left ventricle; RV, right ventricle. (From Park MK, Guntheroth WG: How to Read Pediatric ECGs, 4th ed. Philadelphia, Mosby, 1992.)
have recovered and allows reentry into the atrium, producing a superiorly directed P wave that is difficult to detect. In turn, the cycle is maintained by reentry into the AV node, with a very fast heart rate. When there is an antegrade conduction through the AV node (slow pathway); the rhythm is called orthodromic reciprocating atrioventricular tachycardia (see Fig. 24-3, A).

Less common is a widened QRS complex with antegrade conduction into the ventricle via the accessory (fast) pathway and retrograde conduction through the (slower) AV node (antidromic reciprocating AV tachycardia; see Fig. 24-3, B). A premature ventricular contraction (PVC) could initiate this arrhythmia if the recovery time of the two limbs is ideal for the initiation of the reentry.

Dual pathways in the AV node are more common than accessory bundles, at least as functional entities. For SVT to occur, the two pathways would have to have, at least temporarily, different conduction and recovery rates, creating the substrate for a reentry tachycardia. When the normal, slow pathway through the AV node is used in antegrade conduction to the bundle of His (orthodromic), the resulting QRS complex is normal with an abnormal P vector, but the latter is unrecognizable because it is superimposed on the QRS complex (see Fig. 24-3, C). The resulting tachycardia could be the same as that seen with SVT associated with WPW syndrome. The two can be differentiated only after conversion from the SVT; after conversion, the patient with accessory bundle would have WPW preexcitation. In antidromic nodal reentrant AV tachycardia (see Fig. 24-3, D), which is uncommon, the fast tract of the AV node transmits the antegrade impulse to the bundle of His, and the normal, slow pathway of the AV node transmits the impulse retrogradely. The resulting SVT demonstrates normal QRS duration, a short PR interval, and an inverted P wave.

In general, nodal RAVT is more influenced by increased sympathetic tone than accessory RAVT. Nodal RAVT is more likely triggered by physical activity, emotional stress, and abrupt changes in body position. In addition, nodal RAVT is less likely to be incessant (and therefore rarely causing tachycardia-induced cardiomyopathy). SVT, seen in the first year of life but few afterward, is more likely to have accessory RAVT, and an adolescent who has first SVT is more likely to have nodal RAVT.

Any type of AV block is incompatible with reentrant tachycardia; AV block would abruptly terminate the tachycardia, at least temporarily. This is the reason that adenosine, which transiently blocks AV conduction, works well for this type of arrhythmia.

**Automatic Type of SVT**

Ectopic (or nonreciprocating) atrial tachycardia is a rare mechanism of SVT in which rapid firing of a single focus in the atrium is responsible for the tachycardia (see previous section). Unlike in reciprocating atrial tachycardia, in ectopic atrial tachycardia, the heart rate varies substantially during the course of a day, and second-degree AV block may develop. In contrast, in reentrant tachycardia, second-degree AV block terminates the SVT. Nodal ectopic tachycardia may superficially resemble atrial tachycardia because the P wave is buried in the T waves of the preceding beat and becomes invisible but the rate of
nodal tachycardia is relatively slower (120–200 beats/min) than the rate of ectopic atrial tachycardia. These two arrhythmias are further discussed under separate headings.

**Causes**

1. WPW preexcitation is present in 10% to 20% of cases, which is evident only after conversion to sinus rhythm. Approximately 10% of WPW patients have multiple (two to four) accessory pathways.
2. No heart disease is found in about half of patients. This idiopathic type of SVT occurs more commonly in young infants than in older children.
3. Patients with some CHDs (e.g., Ebstein’s anomaly, single ventricle, congenitally corrected transposition of the great arteries) are more prone to this arrhythmia.
4. SVT may occur after cardiac surgeries.

**Significance**

1. Many infants tolerate SVT well. If the tachycardia is sustained for 6 to 12 hours, signs of CHF usually develop in infants. Clinical manifestations of CHF include irritability, tachypnea, poor feeding, and pallor. When CHF develops, the infant’s condition can deteriorate rapidly.
2. Older children may complain of chest pain, palpitation, shortness of breath, lightheadedness, and fatigue. A pounding sensation in the neck (i.e., neck pulsation) is fairly unique to the reentrant-type SVT and considered to be the result of cannon waves when the atrium contracts against a simultaneously contracting ventricle.

**Management**

**Acute Treatment of SVT**

1. Vagal stimulatory maneuvers (unilateral carotid sinus massage, gagging, pressure on an eyeball) may be effective in older children but rarely effective in infants. Placing an ice-water bag on the face (for up to 10 seconds) is often effective in infants (by diving reflex). In children, a headstand often successfully interrupts the SVT.

![FIGURE 24-4](image_url) Adenosine can uncover the mechanism of supraventricular tachycardia. A 3-month-old infant developed an extremely fast, narrow QRS complex tachycardia and a heart rate of 220 beats/min after insertion of a central line through a jugular vein. Adenosine produced a transient atrioventricular block and unmasked very rapid atrial fibrillation waves (570 beats/min).
2. If the vagal maneuver is ineffective, adenosine is considered the drug of choice. It has negative chronotropic, dromotropic, and inotropic actions with a very short duration of action (half-life <10 seconds) and minimal hemodynamic consequences. Adenosine is effective for almost all reciprocating SVT (in which the AV node forms part of the reentry circuit) of both narrow- and wide-complex regular tachycardia. It is not effective for irregular tachycardia. It is not effective for non-reciprocating atrial tachycardia, atrial flutter or AF, and VT, but it has differential diagnostic ability. Its transient AV block may unmask atrial activities by slowing the ventricular rate and thus help clarify the mechanism of certain supraventricular arrhythmias (see Fig. 24-4).

Adenosine is given by rapid IV bolus followed by a saline flush, starting at 50 µg/kg, increasing in increment of 50 µg/kg, every 1 to 2 minutes. The usual effective dose is 100 to 150 µg/kg with maximum dose of 250 µg/kg. Adenosine is 90% to 100% effective.

3. If the infant is in severe CHF and adenosine is not readily available, emergency treatment is directed at immediate cardioversion. The initial dose of 0.5 joule/kg is increased in steps up to 2 joule/kg.

4. IV administration of propranolol may be used to treat SVT in the presence of WPW syndrome. IV verapamil should be avoided in infants younger than 12 months of age because it may produce extreme bradycardia and hypotension in infants. Esmolol, other beta-adrenergic blockers, verapamil, and digoxin also have been used with some success.

5. Overdrive suppression (by transesophageal pacing or by atrial pacing) may be effective in children who have been digitalized.

Prevention of Recurrence of SVT

1. In infants without WPW preexcitation, oral propranolol for 12 months is effective.
2. Verapamil can also be used, but it should be used with caution in patients with poor LV function and in young infants.
3. In infants or children with or without WPW preexcitation on the ECG, beta-blockers such as atenolol or nadolol are often the medication of choice in the long-term management. In the presence of WPW preexcitation, digoxin or verapamil may increase the rate of antegrade conduction of the impulse through the accessory pathway and therefore should be avoided.
4. For children who have infrequent episodes of SVT that result in little hemodynamic compromise, observation is indicated. They should be taught how to apply vagal maneuvers (e.g., gagging, headstands). If not effective, adenosine is used to correct the rhythm. Alternatively, the use of a beta-blocker or calcium channel blocker can be effective in slowing and terminating the SVT.
5. Radiofrequency catheter ablation or surgical interruption of accessory pathways should be considered if medical management fails or frequent recurrences occur. Ablation therapy is controversial for asymptomatic patients with WPW preexcitation. Ablation is
not recommended in infants 1 to 2 years of age because of a possibility of spontaneous resolution of SVT.

Radiofrequency ablation can be carried out with a high degree of success and a low complication rate. The success rate of the procedure for accessory pathway ablation is between 90% and 95%; the highest success rates are found in patients with left-sided accessory pathways. Patients with para-Hisian pathways have the lowest success rate because of more cautious applications (fearing risk of AV block). A risk of heart block is 1.2% with a risk as high as 10.4% for patients with a midseptal ablation site. The overall risk of complication is 3% to 4%.
Rhythms Originating in the Atrioventricular Node

Rhythms that originate in the AV node are characterized by the following findings (Fig. 24-5):
1. The P wave may be absent, or inverted P waves may follow the QRS complex.  
2. The QRS complex usually is normal in duration and configuration.  
   Only the lower part (NH region) of the AV node has pacemaker ability. The upper (AN region) and middle (N region) parts do not function as pacemakers but delay the conduction of an impulse, either antegrade or retrograde.

Junctional (or Nodal) Premature Beats

Description. A normal QRS complex occurs prematurely. P waves usually are absent, but inverted P waves may follow QRS complexes (see Fig. 24-5). The compensatory pause may be complete or incomplete.

Causes. Nodal premature beats usually are idiopathic in an otherwise normal heart; they may result from cardiac surgery and digitalis toxicity.

Significance. Nodal premature beats usually have no hemodynamic significance.

Management. Treatment is not indicated unless the cause is digitalis toxicity.

Junctional (or Nodal) Escape Beats

Description. When the SA node impulse fails to reach the AV node, the NH region of the AV node initiates an impulse (junctional or nodal escape beat). The resulting QRS complex occurs later than the anticipated normal beat. The P wave may be absent, or an inverted P wave follows the QRS complex (see Fig. 24-5). The duration and configuration of QRS complexes are normal.
Causes. Nodal escape beats may occur after cardiac surgery involving the atria (the Senning procedure or Fontan operation) or in otherwise healthy children.

Significance. Nodal escape beats have little hemodynamic significance.

Management. Generally, no specific treatment is required.

Nodal (or Junctional) Rhythm

Description. If the SA node consistently fails, the AV node may function as the main pacemaker of the heart, producing a relatively slow rate (40–60 beats/min). Nodal rhythm is characterized by no P waves or inverted P waves after QRS complexes and normal (narrow) QRS complexes with a rate of 40 to 60 beats/min (see Fig. 24-5).

Causes. Nodal or junctional rhythm may occur in an otherwise normal heart, increased vagal tone (increased intracranial pressure, pharyngeal stimulation), and digitalis toxicity or as a result of cardiac surgery. Rarely, it may be seen in children with polysplenia syndrome (left atrial isomerism).

Significance. The slow heart rate may significantly decrease cardiac output and produce symptoms.

Management. No treatment is indicated if the patient is asymptomatic. Known causes such as digitalis toxicity should be treated. Atropine or electric pacing is indicated if the patient is symptomatic from bradycardia.

Accelerated Nodal Rhythm

Description. When the patient has a normal sinus rate and AV conduction and the AV node (NH region) has enhanced automaticity and captures the pacemaker function at a faster rate (60–120 beats/min) than the normal junctional rate (40–60 beats/min), the rhythm is called accelerated nodal (or AV junctional) rhythm. P waves are either absent or inverted P waves follow the normal QRS complexes.

Causes. Accelerated nodal rhythm may be idiopathic, may result from digitalis toxicity or myocarditis, or may occur after cardiac surgery.

Significance. Accelerated nodal rhythm has little hemodynamic significance.

Management. No treatment is necessary unless caused by digitalis toxicity.

Junctional Ectopic Tachycardia (Nodal Tachycardia)

Description. Either the P waves are absent or inverted P waves follow QRS complexes (see Fig. 24-5). The ventricular rate varies from 140 to 240 beats/min. The QRS complex is usually normal, but aberration may occur on rare occasions, as in atrial tachycardia. JET is sometimes difficult to separate from other types of SVTs.

Causes. Enhanced automaticity of the junctional area is the suspected mechanism of the arrhythmia. There are two types, postoperative and congenital.
The postoperative type is the most common form of junctional autonomic rhythm in children. It is a transient disorder seen immediately after open heart surgery lasting 24 to 48 hours. Trauma, stretch, or ischemia to the AV node and electrolyte imbalances resulting from surgical procedures may be responsible for the rhythm abnormality. The rare congenital form may occur without a heart defect or may be associated with a cardiac malformation (up to 50%). Developmental abnormalities of the AV node and superimposed fibrosis, inflammation, and focal degeneration may be the underlying causes.

**Significance.** In the postoperative type, there is a loss of AV synchrony in the presence of a fast rate (nearly 200 beats/min), which compromises cardiac output, leading to a fall in blood pressure. Increased endogenous catecholamine levels and administered inotropic support (to maintain adequate blood pressure and renal perfusion) may result in peripheral vasoconstriction leading to a raise in the core temperature. The rising core temperature exacerbates the tachycardia, worsening ventricular performance.

In the congenital form, most patients present before 6 months of age, usually with congestive heart failure. The overall mortality rate is about 35% for this form of tachycardia.

**Management.** A number of complementary measures are used to treat postoperative JET. They are aimed at correcting pathophysiology of the postoperative tachycardia.

1. A heart rate less than 170 beats/min is well tolerated, but the rate faster than 170 to 190 beats/min needs to be slowed. Atrial overdrive pacing (typically 10 beats/min higher than the rate) often restores AV synchrony.
2. Mild systemic hypothermia is induced, usually a core temperature of 34° to 35°C. At a core temperature below 32°C, ventricular function may be impaired.
3. Cardiac output should be maximized by carefully titrating fluid and electrolyte balance, inotropic support, and pain management.
4. IV amiodarone appears to be the drug of choice as antiarrhythmic therapy. Digoxin, used in the past, has little place in treatment.
5. As an alternative, extracorporeal membrane oxygenation can be used for this arrhythmia.

For the congenital type, amiodarone appears to be the drug of choice. Amiodarone in a
high dose was effective in 85% of the patients with almost a 75% survival rate. If amiodarone is not effective, ablation therapy may be tried.
Rhythms Originating in the Ventricle

Rhythms that originate in the ventricle (ventricular arrhythmias) are characterized by the following (Fig. 24-6):
1. Bizarre and wide QRS complexes
2. T waves pointing in directions opposite of QRS complexes
3. QRS complexes randomly related to P waves, if visible

Premature Ventricular Contraction

Description
A bizarre, wide QRS complex appears earlier than anticipated, and the T wave points in the opposite direction. A full compensatory pause usually appears; that is, the length of two cycles, including the premature beat, is the same as that of two normal cycles (see Fig. 24-6). The presence of a full compensatory pause indicates that the sinus node is not prematurely discharged by the PVC. If the retrograde impulse discharges and resets the sinus node prematurely, it produces a pause that is not fully compensatory.

PVCs may be classified into several types, depending on their interrelationship, similarities, timing, and coupling intervals.

Interrelationship
1. **Ventricular bigeminy or coupling:** Each abnormal QRS complex regularly alternates with a normal QRS complex.
2. **Ventricular trigeminy:** Each abnormal QRS complex regularly follows two normal QRS complexes.
3. **Couplets:** Two abnormal QRS complexes appear in sequence.
4. **Triplets:** Three abnormal QRS complexes appear in sequence. Three or more successive PVCs arbitrarily are termed *ventricular tachycardia.*
**FIGURE 24-7** Types of premature ventricular contractions (PVCs) according to timing in the cardiac cycle. 

- **A**, Regular sinus rhythm. 
- **B**, Interpolated PVC followed by a slightly prolonged PR interval. 
- **C**, Early PVC, which results in a retrogradely conducted P wave (P') with a less than full compensatory pause. The first postectopic beat is a ventricular escape beat (E). 
- **D**, Early PVC with a retrogradely conducted P wave (P') with a less than full compensatory pause. A ventricular fusion beat (F) resumes the cardiac cycle. 
- **E**, Late PVC, which results in a full compensatory pause; presumably, retrograde discharge of the sinus node did not occur. 
- **F**, Ventricular fusion beat with a full compensatory pause.

**Similarities among PVCs**

Depending on the similarities of the bizarre QRS complex, PVCs may be classified into the following types:

1. **Uniform (monomorphic or unifocal) PVCs**: Abnormal QRS complexes have the same configuration in a single lead. They are assumed to originate from a single focus.
2. **Multiform (polymorphic or multifocal) PVCs**: Abnormal QRS complexes have different configurations in a single lead. They are assumed to originate from different foci.

**Timing in the cardiac cycle**
Depending on their timing in the cardiac cycle, PVCs may be classified into several types (Fig. 24-7):

1. **Interpolated PVC**: The PVC appears between two conducted sinus beats. Sinus rhythm is not interrupted, and there is no compensatory pause after the PVC. The PR interval after the PVC is slightly increased (see Fig. 24-7, B).

2. **Early PVC**: The PVC appears shortly after the normal T wave of the preceding beat. A compensatory pause may appear. If the sinus rate is slow and a retrograde atrial conduction prematurely discharges the sinus node, a noncompensatory pause results. Either a ventricular escape beat or a fusion beat resumes the cardiac cycle (see Fig. 24-7, C and D).

3. **Late PVC**: The PVC appears slightly before the normal P wave of the next beat. A full compensatory pause results (see Fig. 24-7, E).

4. **Fusion beats**: The PVC occurs so late in the cardiac cycle that a normal sinus pacemaker impulse has already penetrated the AV node and started to depolarize the ventricle. The resulting QRS complex appears midway between the patient’s normal conducted beat and the pure ectopic ventricular beat because it is produced partly by a normally conducted supraventricular impulse and partly by an ectopic ventricular impulse (see Fig. 24-7, F). The presence of a “fusion” complex is a reliable sign of PVC and helps differentiate VT from a supraventricular arrhythmia with aberrant ventricular conduction (see later discussion).

**Coupling Interval**

1. **Fixed coupling**: PVCs appear at a constant interval after the QRS complex of the previous cardiac cycle. This suggests ventricular reentry within the Purkinje system as the underlying mechanism. Most PVCs in children have a fixed coupling interval and a uniform left bundle branch block (LBBB) morphology.
2. **Varying coupling.** When coupling intervals vary by more than 80 msec, the PVCs may result from parasystole. If the intervals between ectopic beats can be factored so that each interval is a multiple of a single basic interval (within 0.08 second), ventricular parasystole is diagnosed. Ventricular parasystole consists of an impulse-forming focus in the ventricle that is independent of the sinus node-generated impulse and is protected from depolarization (entrance block) by sinus impulses.

### Causes

1. PVC may appear in otherwise healthy children. Up to 50% to 70% of normal children may show PVCs on 24-hour ambulatory ECGs.
2. A link has been found between LV false tendon and PVCs. False tendons are thin, chordal strands that extend from the ventricular septum to either the LV free wall or an LV papillary muscle; they are detectable by two-dimensional echocardiography (Fig. 24-8). False tendons contain Purkinje fibers, which may be the source of the arrhythmia.
3. Myocarditis, myocardial injury or infarction, cardiomyopathy (dilated or hypertrophic), and cardiac tumors are possible causes.
4. Arrhythmogenic right ventricular dysplasia (right ventricular [RV] cardiomyopathy) may be the cause in children with symptomatic tachycardia. (See the section on primary myocardial disease in Chapter 18.)
5. Long QT syndrome (LQTS; see later section)
6. Congenital or acquired heart disease, preoperative or postoperative
7. Drugs such as catecholamines, theophylline, caffeine, amphetamines, digitalis toxicity,
and some anesthetic agents are possible causes.
8. Mitral valve prolapse (MVP) is a possible cause.

**Significance**
1. Occasional PVCs are benign in children, particularly if they are uniform and disappear or become less frequent with exercise.
2. PVCs are more significant if the following are true:
   a. They are associated with underlying heart disease (preoperative or postoperative status, MVP, cardiomyopathy).
   b. There is a history of syncope or a family history of sudden death.
   c. They are precipitated by or become more frequent with activity.
   d. They are multiform, particularly couplets.
   e. There are runs of PVCs with symptoms.
   f. There are incessant or frequent episodes of paroxysmal VT (more likely myocardial tumors).
3. Ventricular parasystole does not appear to have any consequences in children.

**Management**
1. In children with otherwise normal hearts, occasional isolated uniform PVCs that are suppressed by exercise do not require extensive investigation or treatment. ECG, echocardiography studies, and 24-hour Holter monitoring suffice.
   a. ECGs are used to detect QTc prolongation, ST-T changes, and other abnormalities.
   b. Echocardiography studies detect structural heart disease or functional abnormalities.
   c. 24-Hour ambulatory ECG (Holter monitoring) or event recorder detects the frequency and severity of the arrhythmia.
2. Children with uniform PVCs, including ventricular bigeminy and trigeminy, do not need to be treated if the echocardiography findings and exercise stress test results are normal. Arrhythmias that are potentially related to exercise are significant and require documentation of the relationship. The induction or exacerbation of arrhythmia with exercise may be an indication of underlying heart disease. In children, PVCs characteristically are reduced or eliminated by exercise.
3. Asymptomatic children with multiform PVCs and ventricular couplets should have 24-hour Holter monitoring, even if they have structurally normal hearts, to detect the severity and extent of ventricular arrhythmias.
4. All children with symptomatic ventricular arrhythmias and those with complex PVCs (multiform PVCs, ventricular couplets, unsustained VT) should be treated. Tables A-4 and A-5 in Appendix A provide a quick review of antiarrhythmic drugs.
   a. Beta-blockers (e.g., atenolol, 1–2 mg/kg orally in a single daily dose) are effective for cardiomyopathy and occasionally for RV dysplasia.
   b. Other antiarrhythmic drugs, such as phenytoin sodium (Dilantin) and mexiletine, may be effective. Antiarrhythmic agents that prolong the QT interval, such as those
of class IA (quinidine, procainamide), class IC (encainide, flecainide), and class III (amiodarone, bretylium), should be avoided (Box 24-1).
c. Frequent PVCs occasionally require treatment with an IV bolus of lidocaine (1 mg/kg per dose) followed by an IV drip of lidocaine (20–50 µg/kg/min).
5. For patients with symptomatic ventricular arrhythmias or sustained VT and seemingly normal hearts, magnetic resonance imaging (MRI) may be indicated to investigate for RV dysplasia.
6. Children with multiform PVCs and runs of PVCs (VT) with or without symptoms need to be evaluated by an electrophysiologist. Invasive electrophysiologic studies with RV endomyocardial biopsy may be indicated.

**Accelerated Ventricular Rhythm**

**Description**
1. Accelerated ventricular rhythm (AVR) is also known by many other names, such as slow VT, idioventricular tachycardia, slow ventricular rhythm, and nonparoxysmal VT.
2. A wide QRS complex rhythm of short duration is present (usually several beats but can be longer than 120 beats).
3. The ventricular rate approximates the patient’s sinus rate, within ±10% to 15% of the sinus rate (*isochronicity*). The *isochronicity* with sinus rhythm is more important than the rate per minute.
4. The ventricular rate is usually 120 beats/min or less in children (and 140–180 beats/min in newborns). The rate helps differentiate AVR from VT (with a rate >120 bpm).
5. The QRS morphology is LBBB pattern in the great majority.

**Causes**
1. In the majority of the patients, AVR is usually an isolated finding. Rarely, it may be associated with underlying heart disease, such as CHD, myocarditis, digitalis toxicity, hypertension, cardiomyopathy, metabolic abnormalities, postoperative state, or myocardial infarction (in adults).
2. The mechanism of AVR is unknown; an ectopic ventricular focus may accelerate its rate enough to overcome sinus rate.

**Box 24-1**

**Acquired Causes of QT Prolongation**

**Drugs**
- Antibiotics: erythromycin, clarithromycin, telithromycin, azithromycin, trimethoprim-sulfamethoxazole
- Antifungal agents: fluconazole, itraconazole, ketoconazole
- Antiprotozoal agents: pentamidine isethionate
- Antihistamines: astemizole, terfenadine (Seldane) (Seldane has been
Antidepressants: tricyclics such as imipramine (Tofranil), amitriptyline (Elavil), desipramine (Norpramin), and doxepin (Sinequan)
Antipsychotics: haloperidol, risperidone, phenothiazines such as thioridazine (Mellaril) and chlorpromazine (Thorazine)
Antiarrhythmic agents
Class I A (sodium channel blockers): quinidine, procainamide, disopyramide
Class III (prolong depolarization): amiodarone (rare), bretylium, dofetilide, N-acetyl-procainamide, sotalol
Lipid-lowering agent: probucol
Antiangular agent: bepridil
Diuretics (through K loss): furosemide (Lasix), ethacrynic acid (Edecrin)
Oral hypoglycemic agents: glibenclamide, glyburide
Organophosphate insecticides
Promotility agents: cisapride
Vasodilators: prenylamine

**Electrolyte Disturbances**

Hypokalemia: diuretics, hyperventilation
   Hypocalcemia
   Hypomagnesemia

**Underlying Medical Conditions**

Bradycardia: complete atroventricular block, severe bradycardia, sick sinus syndrome
   Myocardial dysfunction: anthracycline cardiotoxicity, congestive heart failure, myocarditis, cardiac tumors
   Endocrinopathy: hyperparathyroidism, hypothyroidism, pheochromocytoma
   Neurologic: encephalitis, head trauma, stroke, subarachnoid hemorrhage
   Nutritional: alcoholism, anorexia nervosa, starvation

*A more exhaustive updated list of medications that can prolong QTc interval is available at the University of Arizona Center for Education and Research on Therapeutics’ website ([www.torsades.org](http://www.torsades.org) or [www.qtdrugs.org](http://www.qtdrugs.org)).

**Significance**

1. It is hemodynamically insignificant, usually asymptomatic, and benign. It is rarely
seen in patients with syncope, presyncope, or palpitation.
2. Sometimes it is found by routine ECG or Holter monitoring in asymptomatic patients.
3. Exertional sinus tachycardia usually converts it to sinus rhythm.

Management
1. In children, AVR is generally considered benign.
2. AVR is notably resistant to antiarrhythmic agents (no treatment is required).
3. Follow-up Holter monitoring is useful and it usually shows resolution of AVR.

Ventricular Tachycardia

Description
1. VT is a series of three or more PVCs with a heart rate of 120 to 200 beats/min. QRS complexes are wide and bizarre, with T waves pointing in opposite directions (see Fig. 24-6).
2. VT may be classified in various ways by its onset, duration, and morphology.
   a. The onset may be paroxysmal (sudden) or nonparoxysmal.
   b. By duration, VT may be (1) a salvo of VT (a few beats in a row), (2) nonsustained VT (a duration of <30 seconds), (3) sustained VT (longer than 30 seconds), and (4) incessant VT (lengthy, sustained VT that dominates the cardiac rhythm).
   c. By morphology, it may be (1) monomorphic (one dominant QRS form), (2) polymorphic (a beat-to-beat change in the QRS shape), or (3) “bidirectional VT” (a specific form of polymorphic VT in which the QRS axis shifts across the baseline).
3. Torsades de pointes (meaning “twisting of the points”) is characterized by a paroxysm of VT during which there are progressive changes in the amplitude and polarity of QRS complexes separated by a narrow transition QRS complex. It is a distinct form of polymorphic VT, occurring in patients with marked QT prolongation.
4. Differentiating VT from SVT with aberrant conduction (see later discussion) is sometimes difficult. However, in children, almost all wide QRS tachycardias are VT. They should be treated as such until proven otherwise.

Causes
1. VT may occur in patients with structural heart diseases such as tetralogy of Fallot (TOF), aortic stenosis, hypertrophic or dilated cardiomyopathy, or MVP.
2. Postoperative CHDs (e.g., TOF, dextrotransposition of the great arteries, or double-outlet RV).
3. Myocarditis, cardiomyopathies, Chaga’s disease (trypanosomiasis in South America), myocardial tumors, myocardial ischemia, and infarction
4. Pulmonary hypertension
5. Arrhythmogenic RV dysplasia (in patients of southern European ancestry), Brugada syndrome (young men from Southeast Asia), and LQTS
6. Metabolic causes include hypoxia, acidosis, hyperkalemia, hypokalemia, and
hypomagnesemia.
7. Mechanical irritation from an intraventricular catheter
8. Pharmacologic and chemical causes include catecholamine infusion, digitalis toxicity, cocaine, and organophosphate insecticides. Most antiarrhythmic drugs (especially classes IA, IC, and III) are also proarrhythmic.
9. Certain drugs that prolong the QT interval may cause VT, including antiarrhythmic drugs (especially class IA [quinidine, procainamide], class IC [encainide, flecainide], class III [amiodarone, bretylium]), antipsychotic agents (phenothiazines [chlorpromazine, thioridazine], tricyclic antidepressants (imipramine, desipramine), and certain antibiotics (erythromycin, trimethoprim-sulfamethoxazole) (see Box 24-1). Class II and IV antiarrhythmic agents do not prolong the QT interval. For a quick review of antiarrhythmic drugs, readers should refer to Tables A-4 and A-5 in Appendix A.
10. VT may occur in healthy children who have structurally and functionally normal hearts. This group is discussed under a separate heading (see later discussion).

Significance
1. VT may signify a serious myocardial pathology or dysfunction and can be a cause of sudden cardiac death. These events are, however, unusual in patients with structurally normal hearts.
2. Presenting symptoms may be dizziness, syncope, palpitation, or chest pain. The family history may be positive for ventricular arrhythmia or sudden death.
3. With a fast heart rate, cardiac output may decrease notably, and the rhythm may deteriorate to ventricular fibrillation (VF), in which effective cardiac output does not occur.
4. Chronic low-rate VT may lead to a tachycardia-mediated cardiomyopathy.
5. A condition called accelerated ventricular rhythm is similar to VT, but the heart rate is slower (<120 beats/min) and occurs in patients with structurally normal hearts. (This is discussed later in this chapter under a separate heading.)
6. Polymorphic VTs are more significant than monomorphic ones.
7. Those associated with abnormal cardiac structure (pre- and postoperative) or function are more significant than those seen in patients with structurally and functionally normal hearts.
8. Some VTs are provoked by exercise, but others are suppressed by exercise. The former is usually more significant than the latter.
9. VTs associated with certain forms of cardiomyopathy (arrhythmogenic RV dysplasia, hypertrophic or dilated cardiomyopathy) and genetic electrical heart diseases (LQTS; Brugada syndrome) can be a cause of sudden death.

Management
1. The following investigations may be indicated.
   a. A history of congenital or acquired heart disease or substance abuse and a family history of syncope, seizure, sudden cardiac death, or familial arrhythmia are important.
b. Echocardiography and Doppler studies identify most conditions that may cause sudden cardiac death, such as cardiomyopathies (hypertrophic, dilated, noncompaction), myocarditis, coronary artery anomalies (congenital, Kawasaki’s disease), primary pulmonary hypertension, and various CHDs (pre- and postoperative).

A structurally and functionally normal heart on echocardiography studies may include a group of benign conditions as well as some potentially lethal conditions, including the following:

(1) Right ventricular outflow tract (RVOT) VT, right bundle branch block (RBBB) VT (Belhassen’s type), and accelerated ventricular rhythm (AVR) are generally benign conditions. These conditions are discussed further under separate headings.

(2) Electrical myopathies: LQTS, Brugada syndrome, and RV dysplasias are potentially fatal conditions. The ECG usually suggests these conditions.

c. Holter monitoring may be useful for assessing the frequency of PVCs or VTs.

d. Exercise stress test is useful for detecting exercise-induced VT and for assessing the effectiveness of therapy (either medical or ablation).

e. MRI is useful to rule out arrhythmogenic RV dysplasia.

f. Electrophysiologic investigation may be indicated for:
   (1) Those with high-density PVCs and symptoms suspicious for tachyarrhythmia
   (2) Those with underlying heart disease, especially those in postoperative status, with potentially life-threatening inducible sustained VT
   (3) To target the VT focus or reentry circuit for ablation
   (4) To check for the effectiveness of orally administered antiarrhythmic therapy

2. Acute therapy

a. Symptomatic VT must be treated promptly with synchronized DC cardioversion (0.5–1 joule/kg) if the patient is unconscious or has cardiovascular instability with clinical evidence of low cardiac output.

b. Rarely, if the patient is conscious, an IV bolus of lidocaine (1 mg/kg per dose over 1–2 minutes) followed by an IV drip of lidocaine (20–50 µg/kg per minute) may be effective. Lidocaine or procainamide is often initiated after cardioversion in an attempt to suppress reinitiation of the tachycardia.

c. IV amiodarone is used in patients with drug-refractory VT, particularly as seen in postoperative patients. The mechanism of action of amiodarone appears to be by reducing transmural heterogeneity of repolarization in the ventricular muscle.

d. IV injection of magnesium sulfate is reportedly an effective and safe treatment for torsades de pointes in adults (2 g in an IV bolus).

e. A trial of adenosine may be helpful in some patients with structurally normal hearts. VT with RBBB and superior axis (LV septal origin) may be calcium channel dependant and respond to a slow IV push of verapamil.

3. The physician should research for reversible conditions contributing to the initiation of VT (e.g., hypokalemia, hypoxemia, postoperative TOF with severe pulmonary regurgitation) and correct the conditions if possible.
4. Chronic therapy
   a. Conservative management may be safe for those asymptomatic patients with repetitive nonsustained VT in the absence of any evidence of ventricular dysfunction.
   b. Antiarrhythmic drug treatment: Complete pharmacologic suppression may not be achieved without serious complications. Therefore, controlling the rate to an asymptomatic level may be adequate. A combination of 24-hour Holter monitoring and treadmill exercise testing is the best noninvasive means of evaluating drug effectiveness.

   (1) Virtually all classes of antiarrhythmic agents have been used for various types of VTs, including all class I and III drugs, with varying levels of success. Tables A-4 and A-5 in Appendix A provide a quick review of antiarrhythmic drugs.

   FIGURE 24-9  Tracing from a 4-year-old girl who is asymptomatic even while having ventricular tachycardia (VT). The child is on atenolol. In this figure, P waves are not identifiable in front of each QRS complex. The QRS duration is wide (0.10 second), and ventricular tachycardia is present with the ventricular rate of 160 beats/min. The QRS complexes have left bundle branch block morphology, indicating the right ventricle (RV) as the ectopic focus, and the axis of VT is directed inferiorly. Spontaneous temporary interruption of VT occurred while recording the V4, V5, and V6 leads.

   (2) Beta-blockers may be very effective for patients who have no underlying heart disease and those who have exercise-provokable monomorphic VT from the RVOT or LV outflow tract. Beta-blockers have fewer side effects than most other antiarrhythmic agents.
   (3) In patients with reduced LV function, digitalis and an afterload reducer may be beneficial (to improve LV function).

   c. Patients with LQTS are treated with beta-blockers, which alleviate symptoms in 75% to 80% of patients. An implantable cardioverter-defibrillator (ICD) is sometimes recommended as initial therapy.
   d. Catheter ablation is most successful in patients with structurally normal hearts with
a focal origin of the tachycardia. Patients with underlying heart disease are more likely to have reentry circuits and have lower effectiveness than those with focal origin of VT.

e. ICD has become the established standard for treating many, if not most, forms of VT, which are potentially lethal. ICDs that can be used without thoracotomy are gaining experience in the young.

Ventricular Arrhythmias in Children with Normal Hearts

Although recurrent sustained VT usually signals an organic cause of the arrhythmia, some VTs are seen in healthy adolescents and young adults with structurally and functionally normal hearts. The prognosis is good. So-called RVOT VT and RBBB VT are examples of this group of VT.

1. **RVOT VT**: This special form of VT seen in children with structurally and functionally normal hearts originates from the RV conal septum and thus has inferior QRS axis and LBBB morphology (Fig. 24-9). This is usually benign tachycardia. It may manifest as PVCs or short runs or salvos of VT, but many children are asymptomatic or minimally symptomatic. Exercise stress may not completely abolish the tachycardia. Beta-blockers are sufficient for treatment. Verapamil and other agents may also prove to be effective. Radiofrequency ablation can be curative.

2. **RBBB VT (Belhassen’s tachycardia)**: It appears to arise from the septal surface of the LV and is less common than RVOT VT. It is characterized by RBBB morphology and superior QRS axis. They may be calcium channel dependent and respond to a slow IV push of verapamil or adenosine. Long-term treatment with verapamil can prevent recurrences. When refractory to medical therapy, radiofrequency ablation or surgery is effective. The long-term outcome is excellent.

Aberration

When a supraventricular impulse prematurely reaches the AV node or bundle of His, it may find one bundle branch excitable and the other still refractory. Therefore, the resulting QRS complex resembles a bundle branch block pattern. The right bundle branch usually has a longer refractory period than the left bundle branch, producing QRS complexes similar to those of RBBB. The following features help in differentiating aberrant ventricular conduction from ectopic ventricular impulses:

1. An rsR’ pattern in V1 that resembles QRS complexes of RBBB suggests aberration. In ventricular ectopic beats, the QRS morphology is bizarre and does not resemble the classic form of RBBB or LBBB.
2. Occasional wide QRS complexes after P waves with regular PR intervals suggest an aberration.
3. The presence of a ventricular “fusion” complex (see previous discussion) is a reliable sign of ventricular ectopic rhythm.
Ventricular Fibrillation

**Description.** Ventricular fibrillation is rare in the pediatric population. It is characterized by bizarre QRS complexes of varying sizes and configurations. The rate is rapid and irregular (see Fig. 24-6). The arrhythmia is maintained by multiple reentrant circuits because portions of the myocardium are depolarizing constantly.

**Causes.** All of the causes listed for VT can cause VF. Predisposing factors include electrolyte abnormalities, proarrhythmic medications, increased sympathetic activities or catecholamine infusion, hypoxia, or ischemia. Certain CHD (pre- and postoperative) and hereditary conditions are possible causes.

Abrupt VF after blunt chest wall trauma that typically occurs in young participants in sports (notably, ice hockey, lacrosse, baseball, and softball) can cause the arrhythmia (called commotio cordis).

**Significance.** VF usually is a degeneration of VT and is terminal arrhythmia because it results in ineffective circulation. Immediate resuscitation must be provided.

**Management.** Resuscitation from VF is successful if performed in a timely fashion; the longer the myocardium is allowed to fibrillate, the more difficult conversion to a sinus rhythm. Electric shocks (delivered in an asynchronous fashion) are aimed at depolarizing the myocardium to terminate fibrillating rhythm and allow an intrinsic cardiac pacemaker to resume control.

1. **Acute care**
   a. Immediate cardiopulmonary resuscitation (CPR), providing the ABCs (airway, breathing, and circulation), airway management with 100% oxygen, and rhythm monitoring, is essential.
   b. Defibrillation with 2, 4, and 6 joule/kg if needed
   c. Administration of epinephrine via IV or intrasosseous (IO) route, 0.01 mg/kg (1:10,000 solution, 0.1 mL/kg) or via an endotracheal (ET) tube 0.1 mg/kg (1:1000 solution, 0.1 mL/kg)
   d. One should identify and treat causes, including the metabolic environment (hypoxia, acidosis).
   e. One of the following antiarrhythmic agents may be used:
      (1) Amiodarone 5 mg/kg bolus, IV or IO
      (2) Lidocaine 1 mg/kg IV, or IO, or ET
      (3) Magnesium sulfate 25 to 50 mg/kg IV or IO (not to exceed 2 g) for torsades de pointes or hypomagnesemia

2. A child with susceptibility to VF and those resuscitated from the arrhythmia should have a comprehensive pediatric electro-physiology evaluation.

3. An ICD is often indicated in patients who survive VF. This device can be deployed through epicardial patch or transvenous lead placement.

Long QT Syndrome

Long QT syndrome is a genetic disorder of myocardial repolarization characterized by a
prolonged QT interval on the ECG and ventricular arrhythmias, usually torsades de pointes, that may result in sudden death. There are four groups of patients with congenital types of LQTS: those with Jervell and Lange-Nielsen syndrome, those with Romano-Ward syndrome, those with a sporadic form of Romano-Ward syndrome, and those with two new rare forms of the condition.

1. Jervell and Lange-Nielsen (1957) first described families in Norway in whom a long QT interval on the ECG was associated with congenital deafness, syncopal spells, and a family history of sudden death. This syndrome is transmitted in an autosomal recessive manner.

2. Roman-Ward syndrome, reported independently by Romano and colleagues in Italy (1963) and Ward in Ireland (1964), has all of the features of Jervell and Lange-Nielsen syndrome but without deafness. This syndrome transmits in an autosomal dominant mode and is much more common than Jervell and Lange-Nielsen syndrome.

3. A significant number of individuals with Romano-Ward syndrome (with normal hearing) appear to represent sporadic cases, with a negative family history of the syndrome.

4. Two additional syndromes, Anderson-Tawil syndrome and Timothy syndrome, have been added recently (Table 24-2). Anderson-Tawil syndrome is sometimes designated as LQT7, in which the QU interval, rather than the QT interval, is prolonged, along with muscle weakness (periodic paralysis), ventricular arrhythmias, and developmental abnormalities. Timothy syndrome is associated with webbed fingers and toes and long QT measurement.

### Causes

The QT prolongation may be congenital or acquired.

1. Congenital LQTS is a heterogeneous disorder. LQTS is caused by mutations of cardiac ion channel genes. Recent advances in molecular biology have revealed that ion channels that govern the electrical activity of the heart are defective in congenital LQTS. Based on genetic background, six types of Romano-Ward syndromes and two types of Jervell-Lange Nielsen syndromes are identified. Two additional syndromes (Anderson-Tawil syndrome and Timothy syndrome) are considered different subgroups. Table 24-2 lists molecular genotypes, frequency, chromosomes involved, mutant genes, and defective ionic channels according to subtypes of congenital LQTS. This discussion focuses on congenital LQTS.

2. Acquired prolongation of the QT interval can be caused by a number of drugs, electrolyte disturbances, and other underlying medical conditions (see Box 24-1). In the acquired type of LQTS, a similar ionic mechanism may be involved as is observed in congenital LQTS. Individuals who manifest acquired LQTS are believed to be genetically predisposed for the condition.

### TABLE 24-2

**CONGENITAL CAUSES OF LONG QT SYNDROME**
Pathophysiology

Prolonged QT interval on the ECG represents prolonged recovery from electrical excitation that contributes to an increased likelihood of dispersion of refractoriness with some parts of the myocardium remaining refractory to subsequent depolarization. Consequently, the wave of excitation may pursue a distinctive pathway around a focal point in myocardium (circus reentry rhythm), leading to VT.

Clinical Manifestations

1. The family history is positive in about 60% of patients, and deafness is present in 5% of patients with the syndrome.
2. Presenting symptoms may be syncope (26%), seizure (10%), cardiac arrest (9%), presyncope, or palpitation (6%). The majority of these symptoms occurs during exercise or with emotion. Symptoms of LQTS are related to ventricular arrhythmias. The first symptom of the syndrome appears usually in the first decade but by the end of the second decade of life. The first manifestation may be cardiac arrest.
3. Syncope occurs in the setting of intense adrenergic arousal, intense emotion, and during or after rigorous exercise. Swimming appears to be a particular trigger among exercises. Abrupt auditory signals such as a loud doorbell, alarm clock, telephone, or security alarm can trigger symptoms.
4. The ECG shows the following:
   a. A prolonged QT interval with a corrected QT interval (QTc) usually longer than 0.46 second (Fig. 24-10); the upper limit of normal is 0.44 second.
   b. Abnormal T-wave morphology (bifid, diphasic, or notched) is frequent.
   c. Bradycardia (20%), second-degree AV block, multiform PVCs, and monomorphic or polymorphic VT (10%–20%) may be present. All of these ECG findings are

<table>
<thead>
<tr>
<th>Molecular Genotype</th>
<th>Frequency (%)</th>
<th>Chromosomes Involved</th>
<th>Mutant Genes</th>
<th>Defective Ionic Channel</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Romano-Ward Syndrome (Autosomal Dominant) with Normal Hearing</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LQT1</td>
<td>42</td>
<td>11p15.5</td>
<td>KCNQ1/KVLQT1</td>
<td>Potassium channel (I_{Ks})</td>
</tr>
<tr>
<td>LQT2</td>
<td>45</td>
<td>7q35-36</td>
<td>KCNH2/HERG</td>
<td>Potassium channel (I_{Kr})</td>
</tr>
<tr>
<td>LQT3</td>
<td>8</td>
<td>3p21-24</td>
<td>SCN5A</td>
<td>Sodium channel (I_{Na})</td>
</tr>
<tr>
<td>LQT4</td>
<td>?</td>
<td>4q25-27</td>
<td>AKNB</td>
<td>Na/Ca exchanger (I_{Na-Ca})</td>
</tr>
<tr>
<td>LQT5</td>
<td>3</td>
<td>21q22.2-22.2</td>
<td>KCNE1/mink</td>
<td>Potassium channel (I_{Ks})</td>
</tr>
<tr>
<td>LQT6</td>
<td>2</td>
<td>21q22.2-22.2</td>
<td>KCNE2/MIRP1</td>
<td>Potassium channel (I_{Ks})</td>
</tr>
</tbody>
</table>

**Jervell and Lange-Nielsen Syndrome (Autosomal Recessive) with Deafness**

| JLN1 | 80 | 11p15.5 | KCNQ1/KVLQT1 | Potassium channel (I_{Ks}) |
| JLN2 | 20 | 21q22.1-22.2 | KCNE1/mink | Potassium channel (I_{Ks}) |

**Anderson-Tawil Syndrome (Autosomal Dominant)**

| ATS1 | 50 | 17q23 | KCNJ2 | Inward rectifier potassium channel (I_{Kr}) |

**Timothy Syndrome (Sporadic)**

| TS1 | ? | 1q42-q43 | CACNA1C | Cardiac L-type calcium channel (I_{Ca,L}) |

considered risk factors for sudden death.
5. Echocardiographic studies usually show a structurally and functionally normal heart.

FIGURE 24-10  Electrocardiogram from a patient with Romano-Ward syndrome at age 6 years demonstrates the longest QTc interval (0.56 second). The precordial leads are not shown. Two negative P waves in aVF suggest a junctional mechanism. This child received 10 mg of propranolol four times a day until the age of 13 years, with complete cessation of syncopal attacks. There were seven cases of sudden death associated with syncopal attacks on the maternal side of the family. His mother (age 27 years) and sister (age 5 years) had moderate prolongation of QTc interval but experienced no syncopal attacks.

Diagnosis
Correct diagnosis and treatment are important to prevent sudden death. However, the diagnosis of this disease, which has a poor prognosis, should not be made lightly because it implies a lifelong commitment to treatment.

Any child who has a prolonged QTc of 0.46 sec or longer or a compelling borderline QTc interval with symptoms, family history, or unusual T waves (T wave alternans or notched T waves) should be carefully evaluated.

1. Accurate measurement of the QTc interval is necessary for the diagnosis of LQTS. A 12-lead ECG is the current screening tool for the identification of LQTS.

   a. Lead II is the preferred lead to measure the QT interval because a q wave is usually present in this lead, but precordial leads (V1, V3, or V5) may also be used because they provide better definition of T waves.

   b. The QTc interval is calculated by using Bazett’s formula (see Chapter 3). The QTc interval represents the QT interval normalized for a heart rate of 60 beats/min.

   c. The presence of sinus arrhythmia creates problems in measuring an accurate and reliable QTc interval because the QTc interval varies with the R-R interval. It has been recommended that the longest QTc interval after the shortest R-R interval be used. By this method, it is rare to have LQTS with a QTc of 0.46 msec or less (Martin et al, 1995). This recommendation is still controversial. The Bazett’s formula is reliable only for the steady state, but sinus arrhythmia is not steady state. In
addition, there is a phenomenon called QT hysteresis in which the QT interval adapts slowly to changing heart rate and certainly not in one beat. Therefore, it may be worthwhile repeating the measurement of the QTc interval in a tracing that does not have marked sinus arrhythmia.

d. In patients with prolonged QRS duration (as seen in bundle branch block), the QT interval may be prolonged secondary to the lengthening of the QRS duration even in the absence of repolarization abnormalities; the QT interval includes both depolarization and repolarization. In such cases, the JT interval may be a more sensitive predictor of repolarization abnormalities than the QTc interval. The JT interval is measured from the J point (the junction of the S wave and the ST segment) to the end of the T wave. Rate correction is accomplished by the use of Bazett’s formula (Berul et al, 1994). A normal JTc interval (mean ± SD) is 0.32 ± 0.02 second with the upper limit of normal of 0.34 second in children and adolescents.

2. The diagnosis of LQTS is clear cut when there is a marked prolongation of the QTc interval with positive family history of the syndrome. However, many cases are at borderline, making it difficult to make or reject the diagnosis. Schwartz et al refined the diagnostic criteria in 1993. A point system is used to distinguish the likelihood of a patient having disease. The criteria take into account the ECG findings, clinical history, and family history and rank the findings by points based on the “importance” of the findings (Table 24-3). According to these criteria, the scoring of the probability of LQTS is done as follows.

≤1 point = Low probability of LQTS
2 to 3 points = Intermediate probability of LQTS
≥4 points = High probability LQTS

3. Initial diagnostic strategy: Initially, the following five steps are considered in making the diagnosis of LQTS.
   a. History of presyncope, syncope, seizure, or palpitation and family history are carefully examined.
   b. Causes of acquired LQTS are excluded (see Box 24-1).
   c. ECG is examined for the QTc interval and morphology of the T waves. ECGs are also obtained from immediate family members
   d. The LQTS score is calculated (see Table 24-3), and the diagnostic possibility is graded as described earlier

| TABLE 24-3 |
| SCHWARTZ DIAGNOSTIC CRITERIA FOR LONG QT SYNDROME |

<table>
<thead>
<tr>
<th>Findings</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>History of presyncope, syncope, seizure, or palpitation and family history are carefully examined</td>
<td>1</td>
</tr>
<tr>
<td>Causes of acquired LQTS are excluded</td>
<td>2</td>
</tr>
<tr>
<td>ECG is examined for the QTc interval and morphology of the T waves. ECGs are also obtained from immediate family members</td>
<td>3</td>
</tr>
<tr>
<td>The LQTS score is calculated</td>
<td>4</td>
</tr>
</tbody>
</table>
Patients with an LQTS score of 4 or above or abnormal exercise test results are considered to have LQTS; an LQTS score of 1 or below is excluded from the diagnosis. Patients with an LQTS score of 2 or 3 are followed up for possible LQTS. For borderline cases, some centers carry out additional testing, such as Holter monitoring, exercise testing, pharmacologic testing, or electrophysiology study. However, the interpretation and significance of these tests are controversial.

a. **Holter monitoring**: This may detect intermittent QT prolongation with changing heart rate (with QTc prolongation at a faster rate), bradyarrhythmia, macrovolt T-wave alternans, and T-wave notching. It may also detect VT. However, the results of Holter monitoring should be interpreted with caution because the standards for QTc on ambulatory monitoring are not established. The QTc interval is longer during sleep; therefore, Holter monitoring may show the QTc interval to be 0.05 second longer than the interval on a standard ECG. Tape speed of the monitor may vary according to the device used. Accordingly, comparison of the Holter with a standard ECG for the QTc interval may be inaccurate.

b. **Exercise testing**: Some centers routinely perform exercise testing. In most children and young adults, the QT intervals shortens with exercise with an increasing heart rate. However, in patients with LQTS, the QT interval may fail to shorten or may lengthen at higher heart rates and with exertion. A lack of appropriate shortening of the QTc duration and abnormal T-wave morphology are most often seen in LQTS patients. Ventricular arrhythmias may develop during the test in up to 30% of patients.

c. **Epinephrine test**: Continuous ECG monitoring during an infusion of IV epinephrine
at escalating doses (0.025–0.3 mcg/kg per min) usually shortens the QT interval in normal subjects. The QTc prolongs in all patients with LQT subgroups. The prolongation is greatest in patients with LQT1 (141 msec in LQT1 compared with 69 and 3 msec for LQT2 and LQT3, respectively).

5. Genetic testing may identify genotypes of the LQTS. Commercially available genetic testing can identify the five most common gene mutations, all in Romano Ward syndrome, including KCNQ1, KCNE1, KCNH2, KCNE2, and SCN5A. The genetic testing has limitations, though. It is important to realize that the testing can identify a particular mutation, but it cannot rule out LQTS; a negative genetic test result does not rule out LQTS.

**Management**

1. The known risk factors should be considered when making a treatment plan for the congenital type of LQTS.
   a. Known risk factors for sudden death include:
      (1) Bradycardia for age (from sinus bradycardia, junctional escape rhythm, or second-degree AV block)
      (2) An extremely long QTc interval (>0.55 second)
      (3) Symptoms at presentation (syncope, seizure, cardiac arrest)
      (4) Young age at presentation (<1 month)
      (5) Documented torsades de pointes or VF
   b. T-wave alternation (major changes in T-wave morphology) is a relative risk factor.
   c. Noncompliance with medication is an important risk factor for sudden death.

2. General measures
   a. Physicians should be aware of the conditions and medications that prolong the QT interval (see Box 24-1). Physicians should avoid prescribing QT-prolonging medications (and discontinue those medications if possible).
   b. A list of drugs that are known to prolong the QT interval (see Box 24-1) along with the websites for it (www.qtdrugs.org) should be given to the parents.
   c. Catecholamines and sympathomimetic drugs should also be avoided if possible because they can potentially trigger torsades de pointes in patients with LQTS.
   d. A no competitive sports policy applies. This is particularly important in patients with LQT1. Physicians should also advise against swimming.
   e. Alarm clocks and bedside telephones should be removed because these are known triggers of VT in patients with LQTS.
   f. The patients and the parents should be educated about the importance of being compliant with their medication because noncompliance can result in sudden death.

3. Treatment of congenital LQTS: For congenital LQTS, the initial treatment is aimed at interrupting sympathetic input to the myocardium with beta-blockers. An ICD may be needed in some patients who continue to have symptoms while taking beta-blockers. Left cardiac sympathetic denervation is no longer popular because of the availability of other options, such as pacing and ICD.
   a. Beta-blockers: The present therapy of choice is treatment with beta-blockers. The
protective effect of beta-blockers is related to their ability to reduce both syncope and sudden cardiac death. There is a consensus that all symptomatic children with LQTS should be treated with propranolol or other beta-blockers (e.g., atenolol, metoprolol). Moderate doses of beta-blockers may be better than larger doses because moderate doses lessen the trend toward bradycardia, a known risk factor for sudden death, especially in patients with sinus or AV node disorders.

Beta-blockers are effective in preventing cardiac events in approximately 70% of patients; cardiac events continue to occur despite beta-blocker therapy in the remaining 30% of patients. Even with treatment with beta-blockers, sudden death can occur. More than 80% of cases of sudden death occur while patients are on medications; some of these cases of sudden death are caused by noncompliance.

Whether to start beta-blockers on asymptomatic children with QTc prolongation has been controversial. Any patients who scores 4 or greater on the Schwartz diagnostic criteria should be treated regardless of symptoms. However, it may be prudent to follow asymptomatic children whose QTc intervals are at borderline (0.46–0.47). Symptoms are more likely to occur in patients with QTc intervals longer than 0.48 second. In addition, beta-blocker treatment may be dangerous to some patients with the syndrome because treatment tends to produce bradycardia, a known risk factor for sudden death. Definitive treatment of asymptomatic patients with congenital LQTS has been suggested by Schwartz (1997) in the following circumstances: (1) newborns and infants, (2) patients with sensorineuronal hearing loss, (3) affected siblings with LQTS and sudden cardiac death, (4) extremely long QTc (>0.60 sec) or T-wave alternans, and (5) to prevent family or patient anxiety.

b. Cardiac pacemakers: Implantation of cardiac pacemakers (with continuous ventricular or dual chamber pacing) has been considered helpful because pacing eliminates arrhythmogenic bradycardia which may result from high doses of beta-blockers. In this situation, a maximally tolerated dose of beta-blockers (e.g., atenolol 50–200 mg/day, metoprolol to 50 to 200 mg/day, propranolol 60–120 mg/day) may be used because the pacemaker is expected to prevent bradycardia from occurring. However, pacemakers did not provide complete protection from sudden death (occurring in 16% of patients) because the pacemaker lacks defibrillation capability. In view of the availability of an ICD that can defibrillate as well as pace when bradycardia develops, cardiac pacemakers are no longer popular in this condition.

c. Left cardiac sympathetic denervation: Left cardiac sympathetic denervation is another method to reduce cardiac events in patients who continue to have symptoms by reducing sympathetic discharge. After a high thoracic sympathectomy, there was a dramatic reduction in the incidence of cardiac events, although sudden death still occurred (8%). Beta-blockers are usually continued after the surgical procedure. Because of the availability of other options, such as pacing and ICD, this procedure is rarely performed.

d. ICD: Implantation of an ICD appears to be the most effective therapy for high-risk
patients, defined as those with aborted cardiac arrests or recurrent cardiac events despite conventional therapy (with beta-blockers), and those with extremely prolonged QTc intervals (e.g., >0.60 second). An ICD is expected not only to prevent bradycardia (a risk factor, which may result from a high dose of beta-blockers) but also to convert ventricular arrhythmias. ICD has been shown to be safe and effective in preventing sudden death in limited clinical experience with children. These patients should be kept on beta-blockers.

Complications to the ICD placement may include infection, lead fracture and dislodgement, inappropriate discharge, psychiatric sequelae, and electrical storm.

e. **Targeted pharmacologic therapy** has reported some success. The sodium channel blocker mexiletine was used in patients with mutations in the sodium channel gene \( SCN5A \) (LQT3) with significant shortening of the QTc. In patients with LQT2 (with potassium channel abnormalities), potassium supplementation in combination with spironolactone was associated with a significant reduction in QTc and some improvement in T-wave morphology.

f. **“Gene-specific” approach:** Gene or gene-specific therapy has not gained wide clinical application at this time.

### Treatment of Acquired Long QT Syndrome

The management of acquired LQTS involves acute treatment of arrhythmias (with IV magnesium), discontinuation of any precipitating drug, and correction of any metabolic abnormalities (e.g., hypokalemia or hypomagnesemia).

### Prognosis

Long QT syndrome is a serious disease, and treatment is at best only partially effective. The prognosis is very poor in untreated patients, with an annual mortality rate as high as 20% and 10-year mortality rate of 50%. Beta-blockers may reduce mortality to some extent, but they do not completely protect patients from sudden death. An ICD appears promising in improving prognosis.

### Short QT Syndrome

Recently, a familial short QT interval has been reported to be a cause of sudden death. Short QT syndrome is characterized by a very short QTc (≤300 msec), symptoms of palpitation, dizziness or syncope, and family history of sudden death. The cause of death is believed to be VF. Symptoms including syncope and cardiac arrest occur most often during periods of rest or sleep. Although it usually occurs in the adult (median age 30 years), a sudden cardiac death was observed in infancy. This syndrome is transmitted in an autosomal dominant manner and a few affected families have been identified. Recently, the use of an antiarrhythmic agent, particularly quinidine (which prolongs the QT interval) has been suggested. An ICD may become standard practice.
Brugada Syndrome

This inherited arrhythmogenic disorder with a high risk of sudden cardiac death occurring during sleep, resulting from ventricular tachyarrhythmias, appears to be inherited as an autosomal dominant pattern. It is primarily a disease of men seen most commonly in Southeast Asian men (with a reported mean age at sudden death of 40 years). However, this syndrome has also been demonstrated in children and infants. No male preponderance is observed in children, raising a possibility of high level of androgen in the occurrence of the fatal event. Mutations in the sodium channel (SCN5A) appear to be the cause of the condition, at least in 20% of sufferers.

The ECG is abnormal but without demonstrable structural abnormalities of the heart. The ECG typically shows concave ST-segment elevation (>2 mm) with J-point elevation followed by a negative T wave in the right precordial leads (V–V3) and RBBB appearance. This so-called type 1 ECG pattern may be present either spontaneously or after provocation with ajmaline or flecainide. The PR interval is frequently prolonged. Fever is an important precipitating factor of syncope, including one that develops after vaccination. SVT, including atrial flutter, is also frequent. The patient may present with complaints of syncope or palpitations. Most syncope takes place at rest (90%). There may be a family history of sudden death. Cardiac examination findings are usually normal.

The diagnosis is suspected based on the ECG appearance, which may not always be present. The condition can carry a poor prognosis, particularly in those who are symptomatic (i.e., at least a 10% death rate per year). Beta-blockers do not appear to reduce the risk of death in these patients. In many centers, an ICD is standard practice to prevent sudden cardiac death. Hydroquinidine has been shown to be a good alternative to ICD implantation in adult patients, and it appears to be effective in preventing syncope in children also (Probst et al, 2007).
Disturbances of Atrioventricular Conduction

Atrioventricular (AV) block is a disturbance in conduction between the normal sinus impulse and the eventual ventricular response. The block is assigned to one of three classes, depending on the severity of the conduction disturbance. First-degree AV block is a simple prolongation of the PR interval, but all P waves are conducted to the ventricle. In second-degree AV block, some atrial impulses are not conducted into the ventricle. In third-degree AV block (or complete heart block), none of the atrial impulses is conducted into the ventricle (Fig. 25-1). Holter monitoring often reveals patterns not apparent in the relatively short electrocardiogram.
**First-Degree Atrioventricular Block**

**Description.** The PR interval is prolonged beyond the upper limits of normal for the patient’s age and heart rate (see Table 3-2 and Fig. 25-1). The PR interval includes the time required for depolarization of the atrial myocardium (PA interval), the delay of conduction in the AV node (AH interval), conduction through the bundle of His, and the time of onset of ventricular depolarization (HV interval).

**Causes.** First-degree AV block can appear in otherwise healthy children and young adults, particularly in athletes, mediated through excessive parasympathetic tone. Other causes include congenital heart diseases (CHDs) (e.g., endocardial cushion defect, atrial septal defect [ASD], Ebstein’s anomaly), infectious disease, inflammatory conditions (rheumatic fever), cardiac surgery, and certain drugs (e.g., digitalis, calcium channel blockers).

**Significance.** Slow intraatrial or AV nodal conjunction is almost always the mechanism for first-degree AV block. First-degree AV block does not produce hemodynamic disturbance. Exercise, both recreational and during stress testing, induces parasympathetic withdrawal, resulting in normalization of AV conduction and the PR interval. The PR interval can be very long, but in the absence of heart disease, it usually does not progress.

**Management.** No treatment is indicated except when the block is caused by drugs.
Second-Degree Atrioventricular Block

Some, but not all, P waves are followed by QRS complex (dropped beats). There are three types: Mobitz type I (Wenckebach phenomenon), Mobitz type II, and high-grade (or advanced) second-degree AV block.

Mobitz Type I (Wenckebach)

**Description.** The PR interval becomes progressively prolonged until one QRS complex is dropped completely (see Fig. 25-1).

**Causes.** Mobitz type I AV block appears in otherwise healthy children. Other causes include myocarditis, cardiomyopathy, myocardial infarction, congenital heart defect, cardiac surgery, and digitalis toxicity.

**Significance.** The block is at the level of the AV node (with prolonged AH interval). It usually does not progress to complete heart block. It occurs in individuals with vagal dominance.

**Management.** The underlying causes are treated.

Mobitz Type II

**Description.** The AV conduction is “all or none.” AV conduction is either normal or completely blocked (see Fig. 25-1).

**Causes.** Causes are the same as for Mobitz type I.

**Significance.** The block usually occurs below the AV node (at the level of the bundle of His). It is more serious than type I block because it may progress to complete heart block.

![Figure 25-1: Atrioventricular (AV) block.](From Park MK, Guntheroth WG: How to Read Pediatric ECGs, 4th ed. Philadelphia, Mosby, 2006.)
Two to One (or Higher) Atrioventricular Block

**Description.** A QRS complex follows every second, third, or fourth P wave, resulting in 2:1, 3:1, or 4:1 AV block (see Fig. 25-1). When two or more consecutive P waves are nonconducted, the rhythm is called advanced or high-grade second-degree AV block. In contrast to third-degree complete AV block, some P waves continue to be conducted to the ventricle, and the PR interval of conducted beats is constant.

**Causes.** Causes are similar to those of other second-degree AV blocks.

**Significance.** The block is usually at the bundle of His, alone or in combination with the AV nodal block. It may progress to complete heart block. Higher grade second-degree AV block should always be regarded as abnormal. The implications of high-grade AV block appear to be similar to those of complete AV block.

**Management.** The underlying causes are treated. Electrophysiologic studies may be necessary to determine the level of the block. Symptomatic second-degree AV block, although uncommon, can be acutely treated with atropine, isoproterenol, and temporary pacing. Pacemaker therapy is indicated for symptomatic advanced second-degree AV block.
Third-Degree Atrioventricular Block (Complete Heart Block)

Description
In third-degree AV block, atrial and ventricular activities are entirely independent of each other (see Fig. 25-1).
1. The P waves are regular (regular PP interval), with a rate comparable to the normal heart rate for the patient’s age. The QRS complexes also are regular (regular R-R interval), with a rate much slower than the P rate.
2. In congenital complete heart block (and some acquired types), the duration of the QRS complex is normal because the pacemaker for the ventricular complex is at a level higher than the bifurcation of the bundle of His. The ventricular rate is faster (50–80 beats/min) than that in the acquired type, and the ventricular rate is somewhat variable in response to varying physiologic conditions.
3. In surgically induced (and in some acquired) complete heart block, the QRS duration is prolonged because the pacemaker for the ventricular complex is at a level below the bifurcation of the bundle of His. The ventricular rate is in the range of 40 to 50 beats/min (idioventricular rhythm), and the ventricular rate is relatively fixed.

Causes
Congenital type. In the absence of CHD, 60% to 90% of cases of congenital heart block are caused by neonatal lupus erythematosus. Maternal antibodies for autoimmune connective diseases cross the placenta to the fetus, causing the heart block. In 25% to 33%, it is associated with CHDs, most commonly with L-transposition of the great arteries, single ventricle, or polysplenia syndrome. Neonatal myocarditis and several genetic disorders such as familial ASD and Kearns-Sayre syndrome have been identified.

Acquired type. Cardiac surgery is the most common cause of acquired complete heart block in children. Other rare causes include severe myocarditis, Lyme carditis, acute rheumatic fever, mumps, diphtheria, cardiomyopathies, tumors in the conduction system, myocardial infarction, and overdoses of certain drugs. These causes produce either temporary or permanent heart block.

Significance
1. Complete heart block can be diagnosed by fetal bradycardia during fetal echocardiographic study between 18 and 28 weeks of gestation. Complications in utero may include hydrops fetalis, myocarditis, and fetal death.
2. Congestive heart failure (CHF) may develop in infancy, particularly when there are associated congenital heart defects.
3. About 40% of congenital heart blocks do not present until childhood (mean age, 5–6 years). Those who survive infancy are usually asymptomatic and achieve normal growth and development for 5 to 10 years. Presenting symptoms may include reduced exercise
tolerance, presyncope, syncope, or slow pulse detected during routine examination. Chest radiography may show cardiomegaly (from large stroke volume needed to compensate for the slow heart rate).

4. Syncopal attacks (Stokes-Adams attacks) may occur with a heart rate below 40 to 45 beats/min. A sudden onset of acquired heart block may result in death unless treatment maintains the heart rate in the acceptable range.

**Management**

1. When detected in utero, steroid therapy may be applied if associated with anti-Ro/SSA and anti-La/SSB.
2. Atropine or isoproterenol is indicated in symptomatic children and adults until temporary ventricular pacing is secured.
3. A temporary transvenous ventricular pacemaker is indicated in patients with heart block, or it may be given prophylactically in patients who might develop heart block.
4. No treatment is required for children with asymptomatic congenital complete heart block with an acceptable rate, a narrow QRS complex, and normal ventricular function. Most of these patients ultimately require pacemaker placement.
5. Pacemaker therapy is indicated under the following situations:
   a. If the patient is symptomatic or develops CHF. Dizziness or lightheadedness may be an early warning sign of the need for a pacemaker
   b. If an infant has a ventricular rate below 50 to 55 beats/min or if the infant has a CHD with a ventricular rate below 70 beats/min
   c. If the patient has a wide QRS escape rhythm, complex ventricular ectopy or ventricular dysfunction
6. A permanent artificial ventricular pacemaker is indicated in patients with surgically induced heart block that is not expected to resolve or persists at least 7 days after cardiac surgery.
7. A variety of problems may arise after a pacemaker is placed in children. Stress placed on the lead system by the linear growth of the child, fracture of the lead system in a physically active child, electrode malfunction (scarring of the myocardium around the electrode, especially in infants), and the limited life span of the pulse generator require follow-up of children with an artificial pacemaker.

**Atrioventricular Dissociation**

Atrioventricular dissociation should not be confused with third-degree AV block. AV
dissociation results from a marked slowing of the sinus node or atrial bradycardia or acceleration of the AV node. Whereas in AV dissociation, the atrial rate is slower than the ventricular rate, in complete heart block, the ventricular rate is usually slower than the atrial rate. In AV dissociation, an atrial impulse may conduct to the AV node if it comes at the right time (Fig. 25-2). The conducted beat can be recognized by its relative prematurity.
A pacemaker is a device that delivers battery-supplied electrical stimuli over leads to electrodes that are in contact with the heart. It primarily treats bradycardia. An implantable cardioverter-defibrillator (ICD) is a multiprogrammable antiarrhythmic device for treating ventricular tachycardia and ventricular fibrillation. ICDs also possess pacemaking capability to treat bradycardia. The electrical leads are placed either directly over the epicardium or inserted transvenously into the cardiac chambers. Electronic circuitry regulates the timing and characteristics of the stimuli. The power source is usually a lithium–iodine battery.

Physicians encounter an increasing number of children with either temporary or permanent pacemakers. Basic knowledge about the pacemaker and the pacemaker rhythm strip is essential in taking care of these children. This chapter presents examples of electrocardiography (ECG) rhythm strips from children with various types of pacemakers and elementary information regarding pacemaker and ICD therapy in children.
Electrocardiograms of Artificial Cardiac Pacemakers

The need to recognize the rhythm strips of artificial pacemakers has increased in recent years, especially in intensive care and emergency room settings. The position and number of the pacemaker spikes on the ECG rhythm strip are used to recognize different types of pacemakers. Thus, a pacemaker may be classified as a ventricular pacemaker, atrial pacemaker, or P wave–triggered ventricular pacemaker.

1. When the pacemaker stimulates the atrium, the resulting P wave demonstrates an abnormal P axis.
2. When the pacemaker stimulates the ventricle, wide QRS complexes result.
3. The ventricle that is stimulated (or the ventricle on which the pacemaker electrode is placed) can be identified by the morphology of the QRS complexes. With the pacing electrode on the right ventricle, the QRS complex resembles a left bundle branch block (LBBB) pattern; with the pacemaker placed on the left ventricle, a right bundle branch block (RBBB) pattern results.

Ventricular Pacemaker (Ventricular Sensing and Pacing)

This mode of pacing is recognized by vertical pacemaker spikes that initiate ventricular depolarization with wide QRS complexes (Fig. 26-1, A). The electronic spike has no fixed relationship with atrial activity (P wave). The pacemaker rate may be fixed (as in Fig. 26-1, A), or it may be on a demand (or standby) mode in which the pacemaker fires only after a long pause between the patient’s own ventricular beats.

[Figures A, B, and C showing examples of pacemakers]
Atrial Pacemaker (Atrial Sensing and Pacing)

The atrial pacemaker is recognized by a pacemaker spike followed by an atrial complex; when atrioventricular (AV) conduction is normal, a QRS complex of normal duration follows (see Fig. 26-1, B). This type of pacemaker is indicated in patients with sinus node dysfunction with bradycardia. When the patient has high-degree or complete AV block in addition to sinus node dysfunction, an additional ventricular pacemaker may be required (AV sequential pacemaker, not illustrated in Fig. 26-1). The AV sequential pacemaker is recognized by two sets of electronic spikes—one before the P wave, and another before the wide QRS complex.

P Wave–Triggered Ventricular Pacemaker (Atrial Sensing, Ventricular Pacing)

This pacemaker may be recognized by pacemaker spikes that follow the patient’s own P waves at regular PR intervals and with wide QRS complexes (see Fig. 26-1, C). The patient’s own P waves are sensed and trigger a ventricular pacemaker after an electronically preset PR interval. This type of pacemaker is the most physiologic and is indicated when the patient has advanced AV block but a normal sinus mechanism. Advantages of this type of pacemaker are that the heart rate varies with physiologic need, and the atrial contraction contributes to ventricular filling and improves cardiac output.
Pacemaker Therapy in Children

Remarkable technologic advances have been made in pacemaker design and function. Surgical corrections of cardiac defects and their late sequelae have increased the need for pacemaker therapy in children. New permanent pacemakers (physiologic pacemakers) are capable of closely mimicking normal cardiac rhythm, and most of them are small enough to be implanted in an infant.

Indications

The indications for permanent pacemaker implantation in children are continually evolving as the reliability of pacing systems improves and clinical experience increases. Box 26-1 lists conditions for which pacemaker therapy is or is not indicated based on the 2008 joint recommendations of the American College of Cardiology (ACC), American Heart Association (AHA), and Heart Rhythm Society (HRS) (Epstein et al, 2008). In the guidelines, class I conditions are those for which there is general agreement that the device will be beneficial, and class II conditions are those for which there is ambivalence regarding whether the device will be beneficial. Class IIa conditions are those for which the weight of evidence or opinion is in favor of usefulness or efficacy, and class IIb conditions are those for which usefulness or efficacy is less well established. Class III conditions are those for which there is agreement that the device will not be useful. Each recommendation is accompanied by the weight of evidence as follows. Level A if the data were derived from multiple randomized clinical trials, level B when data were derived either from a limited number of trials or nonrandomized studies, level C when the consensus of experts was the primary source of the recommendation.

BOX 26-1

Recommendations for Permanent Pacing in Children, Adolescents, and Patients with Congenital Heart Disease

Class I (is indicated)

1. For advanced second- or third-degree associated with symptomatic bradycardia, ventricular dysfunction, or low cardiac output (level of evidence: C)
2. For sinus node dysfunction with correlation of symptoms during age-inappropriate bradycardia; the definition of bradycardia varies with the patient’s age and expected heart rate (level of evidence: B)
3. For postoperative advanced second- or third-degree AV block that is not expected to resolve or that persists at least 7 days after cardiac surgery (level of evidence: B)
4. For congenital third-degree AV block with a wide QRS escape rhythm,
complex ventricular ectopy, or ventricular dysfunction (level of evidence: B)
5. For congenital third-degree AV block in an infant with a ventricular rate less than 55 beats/min or with congenital heart disease and a ventricular rate less than 70 beats/min (level of evidence: C)

### Class IIa (is reasonable)
1. For patients with congenital heart disease and sinus bradycardia for the prevention of recurrent episodes of intraatrial reentrant tachycardia; sinus node dysfunction may be intrinsic or secondary to antiarrhythmic treatment (level of evidence: C)
2. For congenital third-degree AV block beyond the first year of life with an average heart rate less than 50 beats/min, abrupt pauses in ventricular rate that are two or three times the basic cycle length, or associated with symptoms caused by chronotropic incompetence (level of evidence: B)
3. For sinus bradycardia with complex congenital heart disease with a resting heart rate less than 40 beats/min or pauses in ventricular rate longer than 3 seconds (level of evidence: C)
4. For patients with congenital heart disease and impaired hemodynamics caused by sinus bradycardia or loss of AV synchrony (level of evidence: C)
5. For unexplained syncope in the patient with prior congenital heart surgery complicated by transient complete heart block with residual fascicular block after a careful evaluation to exclude other causes of syncope (level of evidence: B)

### Class IIb (may or might be reasonable)
1. For transient postoperative third-degree AV block that reverts to sinus rhythm with residual bifascicular block (level of evidence: C)
2. For congenital third-degree AV block in asymptomatic children or adolescents with an acceptable rate, a narrow QRS complex, and normal ventricular function (level of evidence: B)
3. For asymptomatic sinus bradycardia after biventricular repair of congenital heart disease with a resting heart rate less than 40 beats/min or pauses in ventricular rate longer than 3 seconds (level of evidence: C)

### Class III (is not indicated)
1. For transient postoperative AV block with return of normal AV conduction in an otherwise asymptomatic patient (level of evidence: B)
2. For asymptomatic bifascicular block with or without first-degree AV block after surgery for congenital heart disease in the absence of prior transient complete AV block (level of evidence: C)
3. For asymptomatic type I second-degree AV block (level of evidence: C)
4. For asymptomatic sinus bradycardia with the longest relative risk interval less than 3 seconds and a minimum heart rate more than 40 beats/min (level of evidence: C)
In general, the most common indications for permanent pacemaker implantation in children, adolescents, and patients with congenital heart disease fit into one of three categories: (1) symptomatic sinus bradycardia (with symptoms of syncope, dizziness, exercise intolerance, or congestive heart failure); (2) the bradycardia–tachycardia syndrome (caused by overdrive suppression after a period of tachycardia); and (3) advanced second- or third-degree AV block, either congenital or postsurgical.

Bradycardia is the most common and noncontroversial indication for permanent pacemaker therapy in both children and adults. The primary criterion for pacemaker implantation for bradycardia is the concurrent observation of a symptom (e.g., syncope) with bradycardia (e.g., heart rate less than 40 beats/min or asystole longer than 3 seconds). In children, significant bradycardia with syncope or near syncope results most commonly from extensive surgery involving the atria (e.g., the Senning operation, the Fontan operation, and surgery for atrial septal defect or total anomalous pulmonary venous return). Another noncontroversial indication is surgically acquired heart block that lasts more than 2 weeks after surgery. The risk of death from surgically acquired heart block is as high as 35% in unpaced patients. Most children with congenital heart block will eventually require pacemaker implantation. Those patients with additional CHDs will require pacemaker therapy at an earlier age than those without heart defects.

Temporary pacing is indicated for (1) patients with advanced second-degree or complete heart block secondary to overdose of certain drugs, myocarditis, or myocardial
Types of Pacing Devices

The North American Society of Pacing and Electrophysiology and the British Pacing and Electrophysiology Group devised a generic letter code to describe the types and functions of pacemakers, and it was updated in 2002 (Table 26-1). The first three letters are used exclusively for antibradyarrhythmia functions.

1. The letter in the first position identifies the chamber paced (O, none; A, atrium; V, ventricle; D, dual chamber; or both A and V).
2. The second is the chamber sensed (O, none; A, atrium; V, ventricle; D, dual).
3. The third letter corresponds to the response of the pacemaker to an intrinsic cardiac event (O, none; I, inhibited; T, triggered; D, dual [I + T]).
4. The fourth letter indicates both programmability and rate modulation.
5. The fifth position of the code is used to indicate whether multisite pacing is present.

Some examples of the first three letters (and their indications) are shown below.

1. A VOO device provides ventricular pacing, no sensing, and no response to an intrinsic cardiac event. This type of pacemaker is commonly used as emergency pacing.
2. An AOO device provides atrial pacing with no sensing.
3. A VVI device is ventricle stimulated and ventricle sensed; it inhibits paced output if endogenous ventricular activity occurs (thus preventing competition with native QRS activity). This type is commonly used for episodic AV block or bradycardia in small infants.
4. An AAI device paces and senses the atrium and is inhibited by the patient’s own atrial activity. This type is commonly used in sinus node dysfunction with intact AV conduction.
5. A DDD device is a dual-chamber pacemaker that is capable of pacing either chamber, sensing activity in either chamber, and either triggering or inhibiting paced output (with resulting AV synchrony). This type is used in AV block where AV synchrony is important.
6. A DVI device paces the ventricle, senses both chambers, and inhibits ventricular pacing. This type allows AV synchrony and is commonly used in patients with atrial arrhythmias.

Selection of Pacing Mode

The pacemaker choice is based on several factors, including the presence or absence of underlying cardiac disease, the size of the patient, and the relevant hemodynamic factors (including the need for atrial contribution in cardiac output).

1. A patient who has sinus node dysfunction but an intact AV node function may receive a single-chamber atrial pacemaker or ventricular pacemaker if AV synchrony is not necessary.
2. In patients with AV block, if AV synchrony is not necessary, a single-chamber
ventricular pacing may be implanted.

3. If the sinus node and AV node are both dysfunctional, a dual-chamber device is implanted.

Rate-adaptive pacemakers have the ability to increase the pacing rate through sensors that monitor physiological processes such as activity (activity sensing with vibration detection by piezoelectric crystal or accelerometer) and minute ventilation.

**Battery, Leads, and Route**

Lithium anode batteries are used almost exclusively. The most widely used type of lithium battery is the lithium iodide. Battery longevity depends on several factors, such as battery size, stimulation frequency, and output per stimulation. Battery life varies from 3 years for a dual-chamber pacemaker used in a small child to 15 years for a large single-chamber device needed infrequently.

There are two types of leads, unipolar and bipolar. The unipolar lead (in which the tip of the lead is the negative pole and the pacemaker itself is the positive pole) has the advantages of a smaller size and a larger sensing circuit, which amplifies low-voltage P waves. The bipolar lead (which possesses a tip electrode [ - ] and a ring electrode [ + ] near the end of the pacing catheter) can screen pectoral muscle “noise,” has a lower likelihood of external muscle stimulation, and can function even if the pacemaker is out of contact with the body.

Historically, epicardial pacing was more common in children, but transvenous implantation is the method of choice. With improved technology, generators and leads have become smaller and more advanced, allowing transvenous pacing systems in small children. In general, the transvenous route is a reasonable approach for children weighing at least 10 kg, although others have reported successful transvenous pacing in neonates without complications. Transvenous implantation is performed on the side contralateral to the dominant hand. Transvenous implantation has several advantages over epicardial implantation: Both atrial and ventricular capture thresholds generally are lower, and pacing problems are significantly fewer than with epicardial implantation. Epicardial implantation is performed through a xyphoid approach and is chosen when a transvenous implantation is precluded, when the patient is a neonate or a small infant (<10 kg), and when the transvenous approach is not possible (after the Fontan operation or superior vena cava obstruction).
Implantable Cardioverter-Defibrillator Therapy

An ICD is used in patients at risk for recurrent, sustained ventricular tachycardia or fibrillation. The efficacy of ICD therapy in saving the lives of patients at high risk of sudden death has been shown convincingly. Multiple studies have shown ICDs to be superior to antiarrhythmic drug therapy in patients with a history of life-threatening ventricular tachyarrhythmias (i.e., ventricular tachycardia or fibrillations).

All ICDs also have a built-in pacemaker. Pacing may be necessary for bradycardia, which may follow an electrical shock delivered by the ICD. The pacemaker also corrects certain tachycardia by overdrive suppression.

The ICD automatically detects, recognizes, and treats tachyarrhythmias and bradyarrhythmias using tiered therapy (i.e., bradycardia pacing, overdrive tachycardia pacing, low-energy cardioversion, high-energy shock defibrillation). They also offer a host of other sophisticated functions (e.g., storage of detected arrhythmic events and the ability to do “noninvasive” electrophysiologic testing). ICDs can discharge voltages ranging from less than 1 V for pacing to 750 V for defibrillation.

The ICD is implanted beneath the skin over the left chest (for right-handed persons) pectoralis muscle and it is then connected to the leads. Virtually all ICD systems are implanted transvenously. The longevity of the ICD depends on the frequency of shock delivery, the degree of pacemaker dependency, and other programmable options, but most are expected to last from 5 to 10 years.

The most common problem with ICDs is inappropriate shocks, which are usually the result of detection of a supraventricular tachycardia, most commonly atrial fibrillation. In adult patients, inappropriate shock has been reported in up to 20% of patients within the first year and 40% by 2 years after implantation, causing pain and anxiety generated by this complication.

**Indications**

Indications for ICD implantation include patients with life-threatening arrhythmias; aborted sudden death; family history of the same disease that can cause sudden death; those with dilated and hypertrophic cardiomyopathy, especially when unexplained fainting episodes have occurred; and other conditions that may increase sudden arrhythmic death risk. The ICD usually is recommended as initial therapy in patients who present with sustained VT or resuscitated cardiac arrest. Box 26-2 lists recommendations for ICD therapy according to the 2008 ACC/AHA/HRS Guidelines (Epstein et al, 2008).

Fewer than 1% of all ICD implantations are performed in pediatric patients.

1. Two most common indications for ICD implantation in children are hypertrophic cardiomyopathy and long QT syndrome.
2. Other potential indications include idiopathic dilated cardiomyopathy, Brugada syndrome, and arrhythmogenic right ventricular (RV) dysplasia.
3. A family history of sudden death may influence the decision to use an ICD in a
pediatric patient.

4. Some postoperative CHDs with ventricular tachycardia, such as tetralogy of Fallot and transposition of the great arteries are rare indications for ICD implantation.

**Living with a Pacemaker or Implantable Cardioverter-Defibrillator**

Electromagnetic interference (EMI) can cause malfunction of the pacemaker or ICD by rate alteration, sensing abnormalities, reprogramming, and other functions, which may result in malfunction of the device or even damage to the pulse generator. EMI is defined as any signal—biological or nonbiological—that is within a frequency spectrum detectable by the sensing circuitry of the pacemaker or ICD.

**BOX 26-2 Recommendations for Implantable Cardioverter-Defibrillators in Pediatric Patients and Patients with Congenital Heart Disease**

**Class I (is indicated)**

1. In the survivors of cardiac arrest after evaluation to define the cause of the event and to exclude any reversible causes (*level of evidence: B*)
2. For patients with symptomatic sustained VT in association with congenital heart disease who have undergone hemodynamic and electrophysiological evaluation; catheter ablation or surgical repair may offer possible alternatives in carefully selected patients (*level of evidence: C*)

**Class IIa (is reasonable)**

1. For patients with CHD with recurrent syncope of undetermined origin in the presence of either ventricular dysfunction or inducible ventricular arrhythmias at electrophysiological study (*level of evidence: B*)

**Class IIb (may or might be reasonable)**

1. For patients with recurrent syncope associated with complex CHD and advanced systemic ventricular dysfunction when thorough invasive and noninvasive investigations have failed to define a cause (*level of evidence: C*)

**Class III (is not indicated). The same as in adults**

1. For patients who do not have a reasonable expectation of survival with an acceptable functional status for at least 1 year even if they meet ICD implantation criteria specific in class I, IIa, and IIb recommendation above (*level of evidence: C*)
2. For patients with incessant VT or VF (*level of evidence: C*)
3. In patients with significant psychiatric illness that may be aggravated by
device implantation or that may preclude systemic follow-up (level of evidence: C)

4. For NYHA class IV patients with drug-refractory congestive heart failure who are not candidates for cardiac transplantation or CTR-D (level of evidence: C)

5. For syncope of undetermined cause in a patient without inducible ventricular tachycardias and without structural heart disease (level of evidence: C)

6. When VF or VT is amenable to surgical or catheter ablation (e.g., atrial arrhythmias associated with the WPW syndrome, RV or LV outflow tract VT, idiopathic VT, or fascicular VT in the absence of structural heart disease (level of evidence: C)

7. For patients with ventricular tachyarrhythmias caused by a completely reversible disorder in the absence of structural heart disease (e.g., electrolyte imbalance, drugs, or trauma) (level of evidence: B)

CHD, Congenital heart disease; CRT-D, cardiac resynchronization therapy device incorporating both pacing and defibrillation capabilities. LV, left ventricular; NYHA, New York Heart Association; RV, right ventricular; VF, ventricular fibrillation; VT, ventricular tachycardia; WPW, Wolff-Parkinson-White.


Patients should be well educated to avoid situations that may cause malfunction or damage to the device. EMI can occur within or outside the hospital. The patient with pacemakers or ICDs should wear a medical identification bracelet or necklace to show that he or she has a pacemaker or ICD in case of emergency. The following lists some common situations which may or may not affect pacemakers or ICDs.

1. Most home appliances will not interfere with the pacemaker signal. The following home appliances are safe to use.
   a. Kitchen appliances (microwave ovens, blenders, toaster ovens, electric knives)
   b. Televisions, stereos, FM and AM radios, ham radios, and CB radios
   c. Electric blankets, heating pads,
   d. Electric shavers, hair dryers, curling irons
   e. Garage door openers, gardening electric trimmers
   f. Computers, copying and fax machines
   g. Properly grounded shop tools (except power generator or arc welding equipment)

2. The patient must use caution in the following situations.
a. Security detectors at airport and government buildings such as courthouse. The patient should not stay near the electronic article surveillance (EAS) system longer than is necessary and should not lean against the system.

b. Cellular phones: one should not carry a cell phone in the breast pocket when the ICD is implanted in the left upper chest. Keep the cell phone at least 6 inches away from the ICD. When talking on the cell phone, hold it on the opposite side of the body from the ICD.

c. Avoid working with, holding, or carrying magnets near the pacemaker.

d. Turn off large motors such as cars or boats when working on them. Do not use a chainsaw.

e. Avoid industrial welding equipment. Most welding equipment used for hobby welding should not cause any significant problem.

f. Avoid high-tension wires, radar installations, smelting furnaces, electric steel furnaces, and other high-current industrial equipment.

g. Abstain from diathermy (the use of heat to treat muscles).

h. Contact sports are not recommended for children with pacemakers or ICDs.

3. Hospital sources of potentially significant EMI are as follows.

a. Electrocautery during surgical procedures: Notify the surgeon or dentist so that electrocautery will not be used to control bleeding. ICD therapy should be deactivated before surgery and reinitiated after surgery by a qualified professional. Alternatively, a magnet can be placed over the pacemaker throughout the procedure.

b. For cardioversion or defibrillation: Paddles should be placed in the anteroposterior position, keeping the paddles at least 4 inches from the pulse generator. A qualified pacemaker programmer should be available.

c. Magnetic resonance imaging is considered a relative contraindication in patients with a pacemaker or ICD.

Follow-up for Pacemaker and Implantable Cardioverter-Defibrillator

Patients with pacemakers and ICDs must be followed on a regular schedule. Many of the same considerations are relevant to both pacemaker and ICD follow-up. The follow-up schedule varies from institution to institution, but one popular approach is to see the child 2 weeks after cardiac pacemaker implantation to make sure that the incisions are healing well and there is no electrode dislodgement. A repeat follow-up appointment is scheduled at 6 weeks. Subsequent visits are scheduled at 3 months, 6 months, and 1 year. Thereafter, visits are usually done once every 12 months for single-chamber pacemakers and once every 6 months for dual-chamber pacemakers.

After the initial pacemaker follow-ups, some physicians prefer regular office assessment, others prefer transtelephonic follow-up, and still others prefer a combination of the two techniques. Monthly transtelephonic pacing system evaluation is simple, convenient, and relatively inexpensive, allowing follow-up with fewer cardiology office visits. Transtelephonic assessment includes a collection of (1) a nonmagnet ECG
strip, (2) an ECG strip with magnet applied to the pacemaker, and (3) measurement of magnet rate (see below for a discussion of an ECG with magnet application) and pulse duration. (Pulse duration is measured on both atrial and ventricular channels for dual-chamber pacemaker.) During an office visit, the clinical status of the patient is assessed, and the same information as described for transtelephonic assessment should be collected.

**ECG and magnet application.** The 12-lead ECG with and without a magnet (placed over a pacemaker generator) is a useful tool in pacemaker follow-up assessment.
1. The integrity of atrial and ventricular pacing can be quickly identified with magnet placement. Without the magnet, the patient’s intrinsic rhythm inhibits pacer firing.
2. With the magnet on, it begins to pace at a fixed rate in an asynchronous mode (or “magnet mode”). It does not sense the patient’s own rhythm (i.e., it paces at a fixed rate regardless of what the patient’s own heart rhythm is).
3. The fixed rate that a pacemaker paces at after magnet placement is termed the magnet rate. A decrease in the magnet rate (e.g., from the fixed pacing rate of 85 beats/min to 75 beats/min) over time is indicative of a pacemaker battery that is beginning to wear down.
4. It will help locate the side of the ventricle paced (i.e., RBBB pattern with left ventricular pacing and LBBB pattern with RB pacing. Whereas a superior QRS axis suggests leads in the RV apex, an intermediate or inferiorly directed QRS axis suggests leads high on the septum or in the outflow tract.

In many institutions, ICD follow-up is similar to pacemaker follow-up. For an ICD follow-up, the following specific information is collected and assessed. Many cardiologists follow up every 3 to 6 months for the first 3 to 4 years, after which follow-up frequency increases.
1. History: specific emphasis on awareness of delivered therapy and any tachycardia events
2. Device interrogation
3. Assessment of battery status and charge time
4. Retrieval and assessment of stored diagnostic data, such as the cycle length or rate of the detected tachyarrhythmias and ECGs of detected arrhythmias
5. Periodic radiographic assessment
6. Periodic arrhythmia induction in the electrophysiology laboratory to assess defibrillation threshold and efficacy
PART 7
Special Problems

OUTLINE

Introduction
27. Congestive Heart Failure
28. Systemic Hypertension
29. Pulmonary Hypertension
30. Child with Chest Pain
31. Syncope
32. Palpitation
33. Dyslipidemia and Other Cardiovascular Risk Factors
34. Athletes with Cardiac Problems
35. Cardiac Transplantation
Special Problems

This part explores common pediatric cardiac problems not discussed in previous chapters. The topics include congestive heart failure, systemic hypertension, pulmonary hypertension, child with chest pain, syncope, palpitation, dyslipidemia and other cardiovascular risk factors, athletes with cardiac problems, and cardiac transplantation.
Congestive Heart Failure
Definition

Congestive heart failure (CHF) is a clinical syndrome in which the heart is unable to pump enough blood to the body to meet its needs, to dispose of systemic or pulmonary venous return adequately, or a combination of the two.
The heart failure syndrome may arise from diverse causes. Common causes of CHF are volume or pressure overload (or both) caused by congenital or acquired heart disease and myocardial diseases. Tachyarrhythmias and heart block can also cause heart failure at any age. By far the most common causes of CHF in infancy result from congenital heart defects (CHDs). Beyond infancy, myocardial dysfunctions of various etiologies are important causes of CHF. Among the rare causes of CHF are metabolic and endocrine disorders, anemia, pulmonary diseases, collagen vascular diseases, systemic or pulmonary hypertension, neuromuscular disorders, and drugs such as anthracyclines.

**Congenital Heart Disease**

Volume overload lesions, such as ventricular septal defect (VSD), patent ductus arteriosus (PDA), and endocardial cushion defect (ECD), are the most common causes of CHF in the first 6 months of life. In infancy, the time of the onset of CHF varies predictably with the type of defect. Table 27-1 lists common CHDs according to the age at which CHF develops. When looking at the table, the following should also be noted:
1. Children with tetralogy of Fallot (TOF) do not develop CHF unless they have received a large systemic-to-pulmonary artery shunt procedure (e.g., too large a Gore-Tex interposition shunt).
2. Atrial septal defect (ASD) rarely causes CHF in the pediatric age group, although it causes CHF in adulthood.
3. Large left-to-right shunt lesions, such as VSD and PDA, do not cause CHF before 6 to 8 weeks of age because the pulmonary vascular resistance does not fall low enough to cause a large left-to-right shunt until this age. The onset of CHF resulting from these left-to-right shunt lesions may be earlier in premature infants (within the first month) because of an earlier fall in the pulmonary vascular resistance in these infants.

**Acquired Heart Disease**

Acquired heart disease of various causes can lead to CHF. With acquired heart disease, the age at onset of CHF is not as predictable as with CHD, but the following generalities apply:
1. Dilated cardiomyopathy is probably the most common cause of CHF beyond infancy. It may cause CHF at any age during childhood and adolescence. The cause of the majority of dilated cardiomyopathy is idiopathic, but it may be caused by infectious, endocrine, or metabolic disorders; autoimmune diseases; or after antineoplastic treatment (e.g., anthracycline).
2. Doxorubicin cardiomyopathy may manifest months to years after the completion of chemotherapy for malignancies in children.

**TABLE 27-1**
## Causes of Congestive Heart Failure Resulting from Congenital Heart Disease

<table>
<thead>
<tr>
<th>Age of Onset</th>
<th>Cause</th>
</tr>
</thead>
<tbody>
<tr>
<td>At birth</td>
<td>HLHS</td>
</tr>
<tr>
<td></td>
<td>Volume overload lesions:</td>
</tr>
<tr>
<td></td>
<td>Severe tricuspid or pulmonary insufficiency</td>
</tr>
<tr>
<td></td>
<td>Large systemic arteriovenous fistula</td>
</tr>
<tr>
<td>First week</td>
<td>TGA</td>
</tr>
<tr>
<td></td>
<td>PDA in small premature infants</td>
</tr>
<tr>
<td></td>
<td>HLHS (with more favorable anatomy)</td>
</tr>
<tr>
<td></td>
<td>TAPVR, particularly those with pulmonary venous obstruction</td>
</tr>
<tr>
<td></td>
<td>Others</td>
</tr>
<tr>
<td></td>
<td>Systemic arteriovenous fistula</td>
</tr>
<tr>
<td></td>
<td>Critical AS or PS</td>
</tr>
<tr>
<td>1–4 wk</td>
<td>COA with associated anomalies</td>
</tr>
<tr>
<td></td>
<td>Critical AS</td>
</tr>
<tr>
<td></td>
<td>Large left-to-right shunt lesions (VSD, PDA) in premature infants</td>
</tr>
<tr>
<td></td>
<td>All other lesions previously listed</td>
</tr>
<tr>
<td>4–6 wk</td>
<td>Some left-to-right shunt lesions such as ECD</td>
</tr>
<tr>
<td>6 wk–4 mo</td>
<td>Large VSD</td>
</tr>
<tr>
<td></td>
<td>Large PDA</td>
</tr>
<tr>
<td></td>
<td>Others such as anomalous left coronary artery from the PA</td>
</tr>
</tbody>
</table>

**AS**, Aortic stenosis; **COA**, coarctation of the aorta; **ECD**, endocardial cushion defect; **HLHS**, hypoplastic left heart syndrome; **PA**, pulmonary artery; **PDA**, patent ductus arteriosus; **PS**, pulmonary stenosis; **TAPVR**, total anomalous pulmonary venous return; **TGA**, transposition of the great arteries; **VSD**, ventricular septal defect.

3. Cardiomyopathies associated with muscular dystrophy and Friedreich’s ataxia may cause CHF in older children and adolescents.
4. Myocarditis associated with Kawasaki’s disease is seen in children 1 to 4 years of age.
5. Patients who received surgery for some types of CHDs (e.g., Fontan operation, surgery for TOF, transposition of the great arteries and other cyanotic defects) may remain in or develop CHF after varying period of time.
6. Viral myocarditis tends to be more common in small children older than 1 year. It occurs occasionally in the newborn period, with a fulminating clinical course with poor prognosis.
7. Acute rheumatic carditis is an occasional cause of CHF that occurs primarily in school-age children.
8. Rheumatic valvular heart diseases, usually volume overload lesions such as mitral regurgitation (MR) or aortic regurgitation (AR), cause CHF in older children and adults. These diseases are uncommon in industrialized counties.
9. Endocardial fibroelastosis, a rare primary myocardial disease, causes CHF in infancy; 90% of cases occur in the first 8 months of life.

### Miscellaneous Causes

Miscellaneous causes of CHF includes the following:
1. Metabolic abnormalities (severe hypoxia and acidosis, as well as hypoglycemia and hypocalcemia) can cause CHF in newborns.
2. Endocrinopathy such as hyperthyroidism.
3. Supraventricular tachycardia (SVT) causes CHF in early infancy.
4. Complete heart block associated with structural heart defects causes CHF in the
newborn period or early infancy.
5. Severe anemia may be a cause of CHF at any age. Hydrops fetalis may be a cause of CHF in the newborn period and severe sickleemia at a later age.
6. Bronchopulmonary dysplasia seen in premature infants causes predominantly right-sided heart failure in the first few months of life.

![Diagram](https://example.com/diagram.png)

**FIGURE 27-1** Effects of anticongestive medications on the Frank-Starling relationship for ventricular function. In persons with normal heart, cardiac output increases as a function of ventricular filling pressure (preload; see the upper curve). In patients with heart failure, the normal relationship between cardiac output (or stroke volume) and filling pressure (preload) is shifted lower and to the right such that a low-output state and congestive symptoms may coincide. Congestive symptoms (dyspnea, tachypnea) may appear even in normal hearts if the filling pressure reaches a certain point. At one extreme, the addition of a pure inotropic agent, such as digoxin, primarily increases the stroke volume with minimal impact on filling pressure (so that the patient may still have congestive symptoms). Conversely, the addition of a diuretic primarily decreases the filling pressure (with improved congestive symptoms) but without improving cardiac output. Clinically, it is common to use multiple classes of agents (usually a combination of inotropic agents, diuretics, and vasodilators) to produce both increased cardiac output and decreased filling pressure. (Adapted from Cohn JN, Franciosa JS. Vasodilator therapy of cardiac failure [first of two parts]. N Engl J Med 1977; 297:27-31).

7. Primary carnitine deficiency (plasma membrane carnitine transport defect) causes progressive cardiomyopathy with or without skeletal muscle weakness that begins at 2 to 4 years of age.
8. Acute coronary pulmonale caused by acute airway obstruction (such as seen with large tonsils) can cause CHF at any age but most commonly during early childhood.
9. Acute systemic hypertension, as seen in acute postinfectious glomerulonephritis, causes CHF in school-age children. Fluid retention with poor renal function is important as a cause of hypertension in this condition.
Cardiac output is determined by preload, afterload, myocardial contractility, and heart rate. Cardiac output is proportional to filling pressure (preload) and inversely proportional to the resistance against which the heart pumps (afterload).

**Preload**
According to the Frank-Starling law, as the ventricular end-diastolic volume (or preload) increases, the healthy heart increases cardiac output until a maximum is reached and cardiac output can no longer be augmented (see Figure 27-1, which appears in the section on Management in this chapter). This is a built-in property of the heart that normally allows it to pump out automatically whatever amount of blood flows into the heart. When the left ventricular (LV) end-diastolic pressure reaches a certain point, however, pulmonary congestion develops with congestive symptoms (tachypnea and dyspnea). Congestive symptoms occur even with a normally functioning myocardium if the end-diastolic pressure is greatly increased, such as seen with infusion of a large amount of fluid or blood. An increase in the stroke volume is also achieved in the failing heart when the preload is increased but the failing heart does not achieve the same level of maximal cardiac output as seen in the normal heart. The increased stroke volume obtained in this manner increases the myocardial oxygen consumption.

**Afterload**
Afterload is the force that resists myofibril shortening during systole, which contributes to total myocardial wall stress (or tension). A decrease in afterload increases cardiac output, and an acute increase in afterload results in decreases in stroke volume and ejection fraction. Indices of afterload include aortic pressure, total systemic vascular resistance, arterial impedance, and myocardial peak wall stress. Afterload reducing increases cardiac output without increasing oxygen consumption.

**Wall Stress**
According to the law of Laplace, wall tension is the product of pressure and radium.

The Laplace law, although an oversimplification, emphasizes the following two points: (1) the bigger the LV and the greater the radius, the greater the wall stress, and (2) at any given radius (LV size), the greater the pressure developed in the LV, the greater the wall stress. Thus, dilated ventricles require more tension in the wall and thus increased oxygen demand to generate the same pressure. A relationship exists between wall stress and preload as well as afterload. Preload can be defined as the wall stress at the end of diastole. The afterload, being the load on the contracting myocardium, is the wall stress.
during LV ejection.

The increased wall tension in the dilated ventricle leads to ventricular hypertrophy that tends to keep the wall tension low. Well-trained athletes develop cardiac hypertrophy, which helps reduce wall stress, according to Laplace’s law. A failing heart will also hypertrophy to reduce the increase in wall stress, but the hypertrophy in the failing heart is abnormal because it occurs as part of ventricular remodeling secondary to neurohormonal compensatory mechanisms. (Cardiac remodeling is defined as genomic expression resulting in molecular, cellular, and interstitial changes that are manifested clinically as changes in size, shape, and function of the heart after cardiac injury.) Although hypertrophy may tend to lower wall tension, abnormally hypertrophied ventricles may interfere with synthesis of some of the contractile proteins and leads to collagen damage, including fibrosis. It is also possible that capillary growth does not keep up with the growth of the muscle fibers, causing difficulties in supplying energy.

**Compensatory Mechanisms**

In the early stages of heart failure, various compensatory mechanisms are evoked to maintain normal metabolic function. Among the compensatory responses are the activation of the sympathetic nervous system and the renin–angiotensin–aldosterone system. Although these responses are an attempt to preserve cardiovascular homeostasis and thus beneficial initially, chronic stimulation of these systems may be deleterious in the natural history of myocardial dysfunction.

1. One major compensatory mechanism for increasing cardiac output is an increase in sympathetic tone secondary to increased adrenal secretion of circulating epinephrine and increased neural release of norepinephrine. The initial beneficial effects of adrenergic stimulation include increased heart rate and myocardial contractility with a resulting increase in cardiac output. However, chronic adrenergic stimulation eventually leads to adverse myocardial effects, including increased afterload, hypermetabolism, arrhythmogenesis, and direct myocardial toxicity.
   a. Catecholamines are toxic to cardiac muscle, perhaps by producing calcium overload or by inhibiting the synthesis of contractile proteins.
   b. High catecholamine levels decrease the density of β-adrenergic receptors on the surfaces of the myocardial cell, which may be the major cause of the functional loss of the catecholamine-mediated positive inotropic response.

   In clinical settings, the reduction of adrenergic stimulation by the use of β-adrenergic blockers has resulted in clinical improvement in patients with dilated cardiomyopathy, in whom increased levels of catecholamines have been shown to be present.

2. The reduced blood flow to the kidneys in patients with CHF causes a marked increase in renin output, and this in turn causes the formation of angiotensin II. Angiotensin II leads to a further increase in reabsorption of both water and salt from the renal tubules. Angiotensin II may cause a trophic response in vascular smooth muscle (with vasoconstriction) and myocardial hypertrophy. Angiotensin II also promotes myocardial fibrosis. Thus, although a hypertrophic response is adaptive by attempting to restore wall
stress to normal, angiotensin II plays a maladaptive role in CHF by initiating fibrosis and altering ventricular compliance.

Thus, the reasons for using β-adrenergic blockers and angiotensin-converting enzyme (ACE) inhibitors in the treatment of CHF are to block the maladaptive role of adrenergic and renin–angiotensin–aldosterone systems.
Diagnosis

The diagnosis of CHF relies on several sources of clinical findings, including history, physical examination, chest radiographs, and echocardiographic studies. No single test is specific for CHF. In addition to physical findings discussed later, cardiomegaly on a chest film (or echocardiographic study) is nearly a prerequisite sign of CHF. An electrocardiogram (ECG) is perhaps the least important test for the diagnosis of CHF, although it may help identify the cause of heart failure. Echocardiographic studies are most helpful noninvasive study that confirms the diagnosis of heart failure and estimates the severity of heart failure. It may also help identify the cause of heart failure.

Plasma levels of natriuretic peptides, atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), are increased in most adult patients with heart failure. They are important makers of heart failure and may help distinguish dyspnea caused by heart failure and pulmonary disease in adult patients. ANP is stored mainly in the RA and is released when the atrial distending pressure increases. BNP is stored in ventricular myocardium and appears to be released when the ventricular filling pressure increases. Both peptides exhibit vasodilating effects and natriuretic effects on the kidneys and counteract the water-retaining effects of the renin–angiotensin–aldosterone system. The plasma levels of these peptides are elevated in newborns and in the first weeks of life but decrease to the levels observed in normal adults. Increased levels of BNP and the N-terminal segment of its prohormone (NT-ProBNT) have been reported in most children with either pressure or volume overload cardiac lesions compared with the levels seen in normal children (Nir et al, 2005). However, the usefulness of the levels of these peptides appears limited because an appropriate reference range has not been established. The levels of these peptides are different depending on the commercial testing kits used.

History

1. Poor feeding of recent onset, tachypnea that worsens during feeding, poor weight gain, and cold sweat on the forehead suggest CHF in infants.
2. Older children may complain of shortness of breath, especially with activities, early fatigability, puffy eyelids, or swollen feet.

Physical Examination

Physical findings of CHF may be classified as follows, depending on their pathophysiologic mechanisms. The more common findings are in italics.

1. The following are found as compensatory responses to impaired cardiac function:
   a. Tachycardia, gallop rhythm, and weak and thready pulses are common.
   b. Cardiomegaly is almost always present. Chest radiographs are more reliable than physical examination in demonstrating cardiomegaly.
   c. There are signs of increased sympathetic discharges (e.g., growth failure; perspiration, cold and wet skin).


2. Pulmonary venous congestion (from left-sided failure) results in the following manifestations:
   a. *Tachypnea* is common and is an early manifestation of CHF in infants.
   b. Dyspnea on exertion (equivalent to poor feeding in small infants) is common in children.
   c. Orthopnea may be seen in older children.
   d. Wheezing and pulmonary crackles are occasionally audible.

3. Systemic venous congestion (caused by right-sided failure) results in the following:
   a. Hepatomegaly is common, but it is not always indicative of CHF. A large liver may be palpable in conditions that cause hyperinflated lungs (asthma, bronchiolitis, during hypoxic spells) and in infiltrative liver disease. Conversely, the absence of hepatomegaly does not rule out CHF; hepatomegaly may be absent in (early) left-sided failure.
   b. Puffy eyelids are common in infants.
   c. Distended neck veins and ankle edema, which are common in adults, are not seen in infants.
   d. Splenomegaly is not indicative of CHF; it usually indicates infection.

**Radiography**

The presence of cardiomegaly should be demonstrated by chest radiographs. The absence of cardiomegaly almost rules out the diagnosis of CHF. The only exception to this rule is when the pulmonary venous return is obstructed; in such cases, the lung parenchyma will show pulmonary edema or venous congestion.

**Electrocardiography**

Electrocardiography helps determine the type of heart defect causing heart failure but is not helpful in determining whether CHF is present.

**Echocardiography**

Echocardiographic studies may confirm enlargement of ventricular chambers and impaired LV systolic function (decreased fractional shortening or ejection fraction) as well as impaired diastolic function by the use of Doppler techniques. A more important role of echocardiography may be its ability to determine the cause of CHF. Echocardiography is also helpful in serial evaluation of the efficacy of therapy. Normal echocardiographic values for LV diastolic and systolic dimensions are found in Table D-1 in Appendix D.

**Tissue Diagnosis**

Endomyocardial biopsy obtained during cardiac catheterization offers a new approach to specific diagnosis of the cause of CHF, such as inflammatory disease, infectious process,
or metabolic disorder. When viral myocarditis is suspected, the polymerase chain reaction provides a means of isolating the offending viral agent from biopsy specimens. In a patient with dilated cardiomyopathy, evaluation of biopsy specimens, including genetic analysis, may provide data permitting the diagnosis of specific metabolic causes, such as carnitine deficiency.
Management

The treatment of CHF consists of (1) elimination of the underlying causes, (2) treatment of the precipitating or contributing causes (e.g., infection, anemia, arrhythmias, fever), and (3) control of heart failure state. Eliminating the underlying causes is the most desirable approach whenever possible. Surgical correction of CHDs is such an approach. Every patient with CHF should receive maximal medical treatment, but continuing with long-term anticongestive measures is unwise when the heart defect can be safely repaired through surgery. The heart failure state is controlled by the use of multiple drugs, including inotropic agents, diuretics, and afterload-reducing agents, along with general supportive measures.

Treatment of Underlying Causes or Contributing Factors

1. When surgically feasible, surgical correction of underlying CHDs and valvular heart disease is the best approach for complete cure.
2. If hypertension is the underlying cause of CHF, antihypertensive treatment should be given.
3. If arrhythmias or advanced heart block is the cause of or contributing factor to heart failure, antiarrhythmic agents or cardiac pacemaker therapy is indicated.
4. If hyperthyroidism is the cause of heart failure, this condition should be treated.
5. Fever should be controlled with antipyretics.
6. When there is a concomitant infection, it should be treated with appropriate antibiotics.
7. For anemia, a packed cell transfusion is given to raise the hematocrit to 35% or higher.

General Measures

General support to improve congestive symptoms and nutritional support are important.
1. A “cardiac chair” or “infant seat” is used to keep infants in a semiupright position to relieve respiratory distress.
2. Oxygen (40%–50%) with humidity is administered to infants with respiratory distress if pulse oximetry indicates compromise of blood oxygenation.
3. Adequate calories and fluid should be provided to permit appropriate weight gain. Infants in CHF need significantly higher caloric intakes than recommended for average children. The required calorie intake may be as high as 150 to 160 kcal/kg/day for infants in CHF. Compounding this problem is that these infants typically cannot take in needed calories even for normal growth owing to tachypnea, increased work of breathing, diminished strength of sucking, and difficulty with coordination of sucking and swallowing.
   a. Increasing caloric density of feeding may be required and it may be accomplished with fortification of feeding (Table 27-2).
   b. Frequent small feedings are better tolerated than large feeding in infants.
c. If oral feedings are not well tolerated, intermittent or continuous nasogastric (NG) feeding is indicated. To promote normal development of oral-motor function, infants may be allowed to take calorie-dense oral feeds throughout the day and then be given continuous NG feeds overnight.
d. Salt restriction in the form of a low-salt formula and severe fluid restriction are not indicated in infants. Use of diuretics has replaced these measures.
e. Parents should be taught proper feeding techniques.

### TABLE 27-2
**INCREASING CALORIC DENSITY OF FEEDINGS**

<table>
<thead>
<tr>
<th>Step</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Human milk fortifier (Enfamil, Mead Johnson), 1 packet per 25 mL of breast milk = 24 kcal/oz</td>
</tr>
<tr>
<td>2.</td>
<td>Formula concentration to 24 kcal/oz by:</td>
</tr>
<tr>
<td></td>
<td>a. 1 cup powdered formula + 3 cups water or</td>
</tr>
<tr>
<td></td>
<td>b. 4 oz ready-to-feed + ½ scoop powdered formula</td>
</tr>
<tr>
<td>3.</td>
<td>Supplementation of formula to 26–30 kcal/oz is accomplished in the following manner:</td>
</tr>
<tr>
<td></td>
<td>a. Fat modular products</td>
</tr>
<tr>
<td></td>
<td>(1) MCT oil (Mead Johnson), 8 kcal/mL</td>
</tr>
<tr>
<td></td>
<td>(2) Microlipid (safflower oil emulsion, Mead Johnson), 4.5 kcal/mL</td>
</tr>
<tr>
<td></td>
<td>b. Low-osmolality polymers</td>
</tr>
<tr>
<td></td>
<td>(1) Polyose (Ross), 23 kcal/tablespoon</td>
</tr>
<tr>
<td></td>
<td>(2) Moducal (Mead Johnson), 30 kcal/tablespoon</td>
</tr>
<tr>
<td>4.</td>
<td>PediaSure (Ross), 30 kcal/oz ready-to-feed formula (for children older than 1 year of age)</td>
</tr>
</tbody>
</table>

MCT, Medium-chain triglyceride.

### TABLE 27-3
**DIURETIC AGENTS AND DOSAGES**

<table>
<thead>
<tr>
<th>Preparation</th>
<th>Route</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thiazide Diuretics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlorothiazide (Diurol)</td>
<td>PO</td>
<td>20–40 mg/kg/day in 2–3 divided doses</td>
</tr>
<tr>
<td>Hydrochlorothiazide</td>
<td>PO</td>
<td>2–4 mg/kg/day in 2–3 divided doses</td>
</tr>
<tr>
<td>(HydroDIURIL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Loop Diuretics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Furosemide (Lasix)</td>
<td>IV</td>
<td>1 mg/kg/dose</td>
</tr>
<tr>
<td></td>
<td>PO</td>
<td>2–3 mg/kg/day in 2–3 divided doses</td>
</tr>
<tr>
<td>Ethacrynic acid (Edecrin)</td>
<td>IV</td>
<td>1 mg/kg/dose</td>
</tr>
<tr>
<td></td>
<td>PO</td>
<td>2–3 mg/kg/day in 2–3 divided doses</td>
</tr>
<tr>
<td><strong>Aldosterone Antagonist</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spironolactone (Aldactone)</td>
<td>PO</td>
<td>1–3 mg/kg/day in 2–3 divided doses</td>
</tr>
</tbody>
</table>
4. In older children, salt restriction (<0.5 g/day) and avoidance of salty snacks (chips, pretzels) and table salt are recommended. Bed rest remains an important component of management. The availability of a television screen and computer games for entertainment ensures bed rest in older children.

5. If respiratory failure accompanies cardiac failure, intubation and positive-pressure ventilation are occasionally required. Respiratory failure usually signifies that surgical intervention will be needed for CHDs when the patient is stabilized.

6. Daily weight measurement is essential in hospitalized patients.

**Drug Therapy**

Three major classes of drugs are commonly used in the treatment of CHF in children: inotropic agents, diuretics, and afterload-reducing agents. Rapid-acting inotropic agents (dopamine, dobutamine) are used in critically or acutely ill infants and children. Diuretics are usually used with inotropic agents. Afterload-reducing agents, such as ACE inhibitors, have gained popularity because they can increase cardiac output without increasing myocardial oxygen consumption. Recently, low-dose β-adrenergic blockade has been added to the treatment of dilated cardiomyopathy with encouraging results.

**Diuretics**

Diuretics remain the principal therapeutic agent to control pulmonary and systemic venous congestion. Diuretics only reduce preload and improve congestive symptoms, but do not improve cardiac output or myocardial contractility (see Fig. 27-1). Patients with mild CHF may improve rapidly after a dose of fast-acting diuretics, such as ethacrynic acid or furosemide, even without inotropic agents. Table 27-3 shows dosages of commonly available diuretic preparations. There are three main classes of diuretics that are commercially available.

1. Thiazide diuretics (e.g., chlorothiazide, hydrochlorothiazide), which act at the proximal and distal tubules, are no longer popular.
2. Rapid-acting diuretics, such as furosemide and ethacrynic acid, are the drugs of choice. They act primarily at the loop of Henle (“loop diuretics”).
3. Aldosterone antagonists (e.g., spironolactone) act on the distal tubule to inhibit sodium-potassium exchange. The serum aldosterone level is significantly increased in patients with persistent CHF, contributing to fluid and salt retention. Patients with increased levels of circulating aldosterone have a diminished response to diuretic agents because aldosterone increases tubular reabsorption of sodium and water at a site distal to the sites of action of other diuretic agents (thiazides or furosemide). Aldosterone antagonists have value in preventing hypokalemia produced by other diuretics and thus are used in conjunction with a loop diuretic. However, when ACE inhibitors are used, spironolactone should be discontinued to avoid hyperkalemia.
### Suggested Starting Dosages of Catecholamines

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage and Route</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epinephrine (Adrenalin)</td>
<td>0.1–1 µg/kg/min IV</td>
<td>Hypertension, arrhythmias</td>
</tr>
<tr>
<td>Isoproterenol (Isuprel)</td>
<td>0.1–0.5 µg/kg/min IV</td>
<td>Peripheral and pulmonary vasodilatation</td>
</tr>
<tr>
<td>Dobutamine (Dobutrex)</td>
<td>2–8 µg/kg/min IV</td>
<td>Little tachycardia and vasodilatation, arrhythmias</td>
</tr>
<tr>
<td>Dopamine (Intropin)</td>
<td>5–10 µg/kg/min IV</td>
<td>Tachycardia, arrhythmias, hypertension or hypotension</td>
</tr>
</tbody>
</table>

Dose-related cardiovascular effects (µg/kg/min):
- Renal vasodilatation: 2–5
- Inotropic: 5–8
- Tachycardia: >8
- Mild vasoconstriction: >10
- Vasoconstriction: 15–20

/IV, Intravenous.

### Side Effects of Diuretic Therapy
Diuretic therapy alters the serum electrolytes and acid–base equilibrium.

1. Hypokalemia is a common problem with diuretic therapy except when used with spironolactone. It is more profound with potent loop diuretics. Hypokalemia may increase the likelihood of digitalis toxicity.
2. Hypochloremic alkalosis may result because the loss of chloride ions is greater than the loss of sodium ions through the kidneys, with a resultant increase in bicarbonate levels. Alkalosis also predisposes to digitalis toxicity.

### Rapidly Acting Inotropic Agents
In critically ill infants with CHF, in those with renal dysfunction (e.g., infants with coarctation of the aorta), or in postoperative cardiac patients with heart failure, rapidly acting catecholamines with a short duration of action are preferable to digoxin. This class of agents includes dopamine, dobutamine, isoproterenol, and epinephrine. These agents possess inotropic and vasodilator actions and thus are useful in acute situations.

Dobutamine has fewer chronotropic effects than dopamine. Dopamine in high doses causes α-receptor stimulation with vasoconstriction and reduction of renal blood flow. There is an added beneficial effect when an inotropic agent has vasodilating action as in dopamine. Inotropic agents in general increase the contractile property of the myocardium toward the normal curve (see Fig. 27-1). Dosages for intravenous drip of these catecholamines are suggested in Table 27-4.

Amrinone is a noncatecholamine agent that exerts its inotropic and vasodilator effects by inhibiting phosphodiesterase. Thrombocytopenia is a side effect; the drug should be discontinued if the platelet count falls below 150,000/mm³. Amrinone is useful in patients with severe CHF (dilated cardiomyopathy) who have received prolonged treatment with β-stimulants (see Appendix E, Table E-2 for dosage).

### Digitalis Glycosides

#### Usage of Digoxin
The popularity of digoxin in the treatment of heart failure has waxed and waned. Until
the early 1980s, there were only two classes of drugs available to treat CHF; cardiac glycosides and diuretics (thiazide diuretics, loop diuretics, or aldosterone antagonist). During that period of time, open heart surgeries carried a high mortality rate in small infants with CHDs; thus, maximum pharmacologic efforts were made using digoxin and diuretics to delay the surgeries in small infants with heart failure from CHDs.

Afterload-reducing agents, mainly ACE inhibitors, became available in the 1980s. At that time, it became apparent that many infants with large left-to-right shunt lesions had congestive symptoms, but their LV systolic function remained normal, the so-called pulmonary overcirculation state. With increasing popularity of ACE inhibitors and new understanding of pathophysiology of congestive symptoms (with normal LV systolic function) in infants with large left-to-right shunt lesions, the benefits of digoxin in these infants were questioned, and the use of digoxin became controversial. Salutary effects of combined use of diuretics and afterload-reducing agents, without digoxin, were reported. Thereafter, the use of digoxin in small infants with congestive symptoms from large left-to-right shunt lesions gradually lost popularity.

**TABLE 27-5**

**ORAL DIGOXIN DOSAGE FOR CONGESTIVE HEART FAILURE**

<table>
<thead>
<tr>
<th>Age</th>
<th>Total Digitalizing Dose (µg/kg)</th>
<th>Maintenance Dose* (µg/kg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Premature infants</td>
<td>20</td>
<td>5</td>
</tr>
<tr>
<td>Newborn infants</td>
<td>30</td>
<td>8</td>
</tr>
<tr>
<td>&lt;2 yr</td>
<td>40–50</td>
<td>10–12</td>
</tr>
<tr>
<td>&gt;2 yr</td>
<td>30–40</td>
<td>8–10</td>
</tr>
</tbody>
</table>

*The maintenance dose is 25% of the total digitalizing dose in two divided doses. The intravenous dose is 75% of the oral dose.


However, studies have shown that digoxin improves symptoms in these infants with pulmonary overcirculation, perhaps because of other actions of digoxin (Berman et al, 1983). In addition to inotropic action, digoxin also has parasympathomimetic action with slowing of heart rate, reducing sinoatrial firing, and slowing the atrioventricular (AV) conduction. Several earlier studies have shown that digoxin reduces circulating norepinephrine, renin, and aldosterone levels. Digoxin is a diuretic agent as well. Thus, digoxin can increase inotropy without increasing myocardial oxygen consumption. Research has shown that myocardial oxygen consumption is increased in the normal heart by the positive inotropic action of glycosides; oxygen consumption is actually reduced or remains constant in the failing heart (Braunwald, 1985). Therefore, some cardiologists still favor the use of digoxin in infants with CHF from large-shunt lesions. A usual approach may be that a diuretic and an afterload-reducing agent are initially started, and digoxin is added later if further improvement is needed.

With regard to the patients with dilated LV with decreased systolic function, such as those with dilated cardiomyopathy, inotropic agents clearly increase the cardiac output (or contractile state of the myocardium), thereby resulting in an upward and leftward
shift of the ventricular function curve relating cardiac output to filling volume of pressure (see Fig. 27-1). When inotropic agents are used with a vasodilator or a diuretic, a much greater improvement is seen both in the contractile state and in congestive symptoms than when a single class of agent was used (see Fig. 27-1). Thus, the use of a combination of inotropic agents, diuretics, and vasodilators has become popular.

**Dosage of digoxin**

The total digitalizing dose and maintenance dosages of digoxin in treating CHF by oral and intravenous routes are shown in Table 27-5. A higher dose may be needed in treating SVT, in which the goal of treatment is to delay AV conduction. The maintenance dose is more closely related to the serum digoxin level than is the digitalizing dose, which is given to build a sufficient body store of the drug and to shorten the time required to reach the pharmacokinetic steady state.

The pediatric dosage of digoxin is much larger than the adult dosage on the basis of body weight. Pharmacokinetic studies indicate that infants and children require larger doses of digoxin than adults to attain comparable serum levels, primarily because of a larger volume of distribution and, less important, a more rapid renal clearance, including tubular secretion. The volume of distribution of digoxin is 7.5 L/kg in neonates, 16 L/kg in infants and children, and 4 L/kg in adults. Much higher concentrations of digoxin are found in the myocardium and skeletal muscles from young patients.

**How to digitalize**

Loading doses of the total digitalizing doses are given over 12 to 18 hours followed by maintenance doses. This results in a pharmacokinetic steady state in 3 to 5 days. The intravenous route is preferred over the oral route, particularly when dealing with infants in severe heart failure. The intramuscular route is not recommended because absorption of the drug from the injection site is unreliable. When an infant is in mild heart failure, the maintenance dose may be administered orally without loading doses; this results in a steady state in 5 to 8 days.

**BOX 27-1  Electrocardiographic Changes Associated with Digitalis**

**Effects**

- Shortening of QTc, the earliest sign of digitalis effect
  - Sagging ST segment and diminished amplitude of T wave (the T vector does not change)
  - Slowing of heart rate

**Toxicity**

- Prolongation of PR interval: sometimes a prolonged PR interval is seen in
children without digitalis, making a baseline ECG mandatory; the prolongation may progress to second-degree AV block

Profound sinus bradycardia or sinoatrial block

Supraventricular arrhythmias, such as atrial or nodal ectopic beats and tachycardias (particularly if accompanied by AV block), which are more common than ventricular arrhythmias in children

Ventricular arrhythmias such as ventricular bigeminy and trigeminy, which are extremely rare in children, although they are common in adults with digitalis toxicity; isolated PVCs, which are not uncommon in children, is a sign of toxicity

AV, Atrioventricular; ECG, electrocardiographic; PVC, premature ventricular contraction.

The following is a suggested step-by-step method of digitalization:

1. Obtain a baseline ECG (rhythm and PR interval) and baseline levels of serum electrolytes. Changes in ECG rhythm and PR interval are important signs of digitalis toxicity (see later discussion). Hypokalemia and hypercalcemia predispose to digitalis toxicity.

2. Calculate the total digitalizing dose (see Table 27-5).

3. Give half the total digitalizing dose immediately followed by one fourth and then the final fourth of the total digitalizing dose at 6- to 8-hour intervals.

4. Start the maintenance dose 12 hours after the final total digitalizing dose. Obtaining an ECG strip before starting the maintenance dose is advised.

Monitoring for digitalis toxicity by ECG

Digitalis toxicity is best detected by monitoring with ECGs, not serum digoxin levels, during the first 3 to 5 days after digitalization. Box 27-1 lists signs of digitalis effects and toxicity. In general, whereas the digitalis effect is confined to ventricular repolarization, toxicity involves disturbances in the formation and conduction of the impulse. One should assume that any arrhythmia or conduction disturbance occurring with digitalis is caused by digitalis until proved otherwise.

Serum digoxin levels

Therapeutic ranges of serum digoxin levels for treating CHF are 0.8 to 2 ng/mL. Levels obtained during the first 3 to 5 days after digitalization tend to be higher than those obtained when the pharmacokinetic steady state is reached. Blood for serum digoxin levels should be drawn at least 6 hours after the last dose or just before a scheduled dose; samples obtained earlier than 6 hours after the last dose will give a falsely elevated level.

Determining serum digoxin levels frequently and using those levels for therapeutic goals are neither justified nor practical; occasional determination of the levels is
adequate. Determination of the serum digoxin levels is useful in evaluating possible toxicity (see later section), determining the patient’s compliance, and detecting abnormalities in absorption and excretion is mandatory in managing accidental overdoses.

Serum digoxin levels may be elevated when administered concomitantly with other drugs such as quinidine, verapamil, amiodarone, beta-blockers, tetracycline, and erythromycin. Lower serum levels have been noted with rifampin, kaolin-pectin, neomycin, and cholestyramine.

**BOX 27-2**

**Factors That May Predispose to Digitalis Toxicity**

**High Serum Digoxin Level**
- High-dose requirement, as in treatment of certain arrhythmias
- Decreased renal excretion
- Premature infants
- Renal disease
- Hypothyroidism
- Drug interaction (e.g., quinidine, verapamil, amiodarone)

**Increased Sensitivity of Myocardium (without High Serum Digoxin Level)**
- Status of myocardium
  - Myocardial ischemia
  - Myocarditis (rheumatic, viral)
- Systemic changes
- Electrolyte imbalance (hypokalemia, hypercalcemia)
- Hypoxia
- Alkalosis
- Adrenergic stimuli or catecholamines
- Immediate postoperative period after heart surgery under cardiopulmonary bypass

**Digitalis toxicity**

Digitalis toxicity may result during treatment with digoxin or from an accidental overdose of digoxin. With the relatively low dosage recommended in Table 27-5, digitalis toxicity is unlikely to develop. However, one should beware of possible digitalis toxicity in every child receiving digitalis preparations. Patients with conditions listed in Box 27-2...
are more likely to develop toxicity. The diagnosis of digitalis toxicity is a clinical decision and usually is based on the following clinical and laboratory findings:
1. The patient has a history of accidental ingestion.
2. Noncardiac symptoms appear in digitalized children; these symptoms include anorexia, nausea, vomiting, diarrhea, restlessness, drowsiness, fatigue, and visual disturbances in older children.
3. Heart failure worsens.
4. ECG signs of toxicity probably are more reliable and appear early (see Box 27-1).
5. An elevated serum level of digoxin (>2 mg/mL) is likely to be associated with toxicity in a child if the clinical findings suggest digitalis toxicity.

**Afterload-Reducing Agents**

Vasoconstriction that occurs as a compensatory response to reduced cardiac output seen in CHF may be deleterious to the failing ventricle. Vasoconstriction is produced by a rise in sympathetic tone and circulating catecholamines and an increase in the activity of the renin–angiotensin system. Reducing afterload tends to augment the stroke volume without a great change in the contractile state of the heart and therefore without increasing myocardial oxygen consumption (see Fig. 27-1). When a vasodilator is used with an inotropic agent, the degree of improvement in the inotropic state as well as in congestive symptoms is much greater than when a vasodilator alone is used. Combined use of an inotropic agent, a vasodilator, and a diuretic produces most improvement in both inotropic state and congestive symptoms (Fig. 27-1).

Afterload-reducing agents now occupy a prominent role in the treatment of infants with CHF secondary to a large left-to-right shunt lesions (e.g., VSD, AV canal, PDA). Infants with large left-to-right shunts have been shown to benefit from captopril and hydralazine. Beneficial effects of afterload-reducing agents are also seen in dilated cardiomyopathy, Adriamycin-induced cardiomyopathy, myocardial ischemia, postoperative cardiac status, severe MR or AR, and systemic hypertension. These agents usually are used in conjunction with diuretics and often with digitalis glycosides for a maximal benefit.

Afterload-reducing agents may be divided into three groups based on the site of action: arteriolar vasodilators, venodilators, and mixed vasodilators. Dosages of these agents are presented in Table 27-6.
1. Arteriolar vasodilators (hydralazine) augment cardiac output by acting primarily on the arteriolar bed, with resulting reduction of the afterload. Hydralazine often is administered with propranolol because it activates the baroreceptor reflex, with resulting tachycardia.
2. Venodilators (nitroglycerin, isosorbide dinitrate) act primarily by dilating systemic veins and redistributing blood from the pulmonary to the systemic circuit (with a resulting decrease in pulmonary symptoms). Venodilators are most beneficial in patients with pulmonary congestion but may have adverse effects when preload has been restored to normal by diuretics or sodium restriction.
3. Mixed vasodilators include ACE inhibitors (captopril, enalapril), nitroprusside, and
prazosin. These agents act on both arteriolar and venous beds. ACE inhibitors are popular in children with chronic severe CHF, but sodium nitroprusside is used primarily in acute situations such as after cardiac surgery under cardiopulmonary bypass, especially in patients who had pulmonary hypertension and those with postoperative rises in pulmonary artery pressure. When nitroprusside is used, blood pressure must be monitored continuously. ACE inhibitors reduce systemic vascular resistance by inhibiting angiotensin II generation and augmenting the production of bradykinin.

**TABLE 27-6**

**DOSAGES OF VASODILATORS**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Route and Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Arteriolar Vasodilator</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydralazine (Apresoline)</td>
<td>IV: 0.15—0.2 mg/kg/dose every 4–6 hr (maximum, 20 mg/dose) Oral: 0.75–3 mg/kg/day, in 2–4 doses (maximum, 200 mg/day)</td>
<td>May cause tachycardia; may be used with propranolol May cause GI symptoms, neutropenia, and lupus-like syndrome</td>
</tr>
<tr>
<td><strong>Venodilators</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nitroglycerin</td>
<td>IV: 0.5–1 μg/kg/min (maximum, 6 μg/kg/min)</td>
<td>Start with small dose and titrate based on effects</td>
</tr>
<tr>
<td><strong>Mixed Vasodilators</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Captopril (Capoten)</td>
<td>PO: Newborn: 0.1–0.4 mg/kg, TID–QID Infants: Initially 0.15–0.3 mg/kg QD–QID; titrate upward if needed; maximum dose, 6 mg/kg/24 hr Children: Initially 0.3–0.5 mg/kg BID–TID; titrate upward if needed; maximum, 6 mg/kg/24 hr Adolescents and adults: Initially 12.5–25 mg, BID–TID; increase weekly if needed by 25 mg/dose to maximum dose of 450 mg/24 hr</td>
<td>May cause hypotension, dizziness, neutropenia, and proteinuria Dose should be reduced in patients with impaired renal function</td>
</tr>
<tr>
<td>Enalapril (Vasotec)</td>
<td>PO: 0.1 mg/kg QD or BID</td>
<td>Patient may develop hypotension, dizziness, or syncope</td>
</tr>
<tr>
<td>Nitroprusside (Nipride)</td>
<td>IV: 0.3–0.5 μg/kg/min; titrate to effect; maximum dose, 10 μg/kg/min</td>
<td>May cause thiocyanate or cyanide toxicity (e.g., fatigue, nausea, disorientation), hepatic dysfunction, or light sensitivity</td>
</tr>
</tbody>
</table>

BID, Twice a day; GI, gastrointestinal; IV, intravenous; PO, oral; QD, once a day; QID, four times a day; TID, three times a day.
Other Drugs

β-Adrenergic blockers

Beneficial effects of β-adrenergic blockers were reported in adult patients with dilated cardiomyopathy. Recent studies suggest that adrenergic overstimulation often seen in patients with chronic CHF may have detrimental effects on the hemodynamics of heart failure by inducing myocyte injury and necrosis rather than being a compensatory mechanism, as traditionally thought. Small-scale, uncontrolled pediatric studies have shown similar beneficial effects of β-adrenergic blockers in some children with chronic CHF who were symptomatic despite being treated with standard anticongestive drugs (digoxin, diuretics, ACE inhibitors).

In 1999, Shaddy et al reported on the use of metoprolol in children. Metoprolol was added to standard anticongestive medicines in patients with chronic CHF from dilated cardiomyopathy. Metoprolol increased LV fractional shortening and ejection fraction and improved symptoms. The starting dose was 0.1 to 0.2 mg/kg per dose twice a day and slowly increased over a period of weeks to a dose of 1.1 mg/kg/day (range, 0.5–2.3 mg/kg/day) (Shaddy et al, 1999).

Carvedilol, when added to standard medical therapy for CHF, has been shown to be beneficial in children with dilated cardiomyopathy (Bruns et al, 2001). The patients included in the study were those with idiopathic dilated cardiomyopathy, chemotherapy-induced cardiomyopathy, postmyocarditis myopathy, or muscular dystrophy and those who had chronic heart failure after surgeries for CHDs (e.g., Fontan or Senning operation). The initial dose was 0.09 mg/kg twice daily, and the dose was increased gradually to 0.36 and 0.75 mg/kg as tolerated, up to the maximum adult dose of 50 mg/day. Side effects of the drug include dizziness, hypotension, and headache (also see the discussion of dilated cardiomyopathy).

Carvedilol and metoprolol have been studied most often. There is a theoretical advantage of carvedilol over metoprolol. Carvedilol is a nonselective beta-blocker that inhibits β1-, β2-, and α1-adrenoceptors with additional vasodilatory and antioxidant properties. Metoprolol is a selective β1- (and β2- at high dose) adrenoceptor blocker that does not have vasodilator or antioxidant properties (Foerster et al, 2008). The improvement in the LV fractional shortening appeared slightly better with carvedilol than with metoprolol.

However, β-adrenergic blockers should not be given to those with decompensated heart failure. Their use should be deferred until reestablishment of good fluid balance and stable blood pressure and should be started with a small dose and gradually increased. Contraindications to the use of β-adrenergic blockers include symptomatic bradycardia or heart block, significant hypotension, active asthma, and severe bronchial disease.

Although earlier noncontrolled studies have implied effectiveness of carvedilol and other β-adrenoceptors in the treatment of pediatric heart failure, a more recent, 26 multicenter large-scale, prospective, randomized trials on 150 patients did not reach the same conclusion (Shaddy et al, 2007). In that study, the patients were divided into three
groups; placebo group and low and high doses of carvedilol groups (0.4 mg and 0.8 mg/kg/day, respectively). All patients were on standard treatment with ACE inhibitors and diuretics. The study found no significant differences among the three groups in terms of symptoms and echocardiographic indices over the 6-month period of follow-up. However, it has found a surprising number of patients showing spontaneous improvement in all three groups. It also found a trend to better outcome in patients who have morphologic LVs (as seen in patients with tricuspid atresia).

**Carnitine**

Carnitine, which is an essential cofactor for transport of long-chain fatty acids into mitochondria for oxidation, has been shown to be beneficial in some cases of cardiomyopathy, especially those with suggestive evidence of disorders of metabolism (Helton et al, 2000). Most of these patients had dilated cardiomyopathy. The dosage of $L$-carnitine was 50 to 100 mg/kg/day, given twice a day or three times a day orally (maximum daily dose, 3 g). It improved myocardial function, reduced cardiomegaly, and improved muscle weakness. Animal studies suggest potential protective and therapeutic effects on doxorubicin-induced cardiomyopathy in rats.

**Surgical Management**

If medical treatment with the previously mentioned regimens does not improve CHF caused by CHDs within a few weeks to months, one should consider either palliative or corrective cardiac surgery for the underlying cardiac defect when technically feasible.

Cardiac transplantation is an option for a patient with progressively deteriorating cardiomyopathy despite maximal medical treatment.
Systemic Hypertension
Definition

For adults, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7 Report, 2003) has recommended the following classification of blood pressure (BP) levels. BP level of 120/80 mm Hg, previously considered normal, is now classified as prehypertension; levels lower than 120/80 are now considered normal. Systolic pressure of 140 mm Hg and greater or diastolic pressure of 90 mm Hg and greater are now considered hypertension. Hypertension is further classified as stage 1 and stage 2 depending on the level of abnormalities (Table 28-1).

In children, hypertension is defined statistically because BP levels vary with age and gender and because outcome-based data are not available for children. The Fourth Report of the National High Blood Pressure Education Program (NHBPEP) Working Group on High Blood Pressure in Children and Adolescents (2004) has recommended the following definition (also see Table 28-1).

1. **Hypertension** is defined as systolic or diastolic pressure levels that are greater than the 95th percentile for age and gender on at least three occasions. As in adults, adolescents with BP levels of 120/80 mm Hg or above by auscultatory method are considered hypertensive even if they are below the 95th percentile.

2. **Prehypertension** is defined as an average systolic or diastolic pressure between the 90th and 95th percentiles for age and gender.

3. When the BP reading is above the 95th percentile, one further classifies the hypertension into stages 1 and 2 as follows.
   a. Stage 1 hypertension is present when BP readings are between the 95th and 99th percentiles.
   b. Stage 2 hypertension is present when BP readings are 5 mm Hg or more above the 99th percentile values.

4. **White-coat hypertension** is present when BP readings in health care facilities are greater than the 95th percentile but are normotensive outside a clinical setting. This condition may not be as benign as once thought to be, and regular follow-up is now recommended. This topic is discussed further later in this chapter.

<table>
<thead>
<tr>
<th>BP Classification</th>
<th>Adults*</th>
<th>Children* and Adolescents*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Systolic BP (mm Hg)</td>
<td>Diastolic BP (mm Hg)</td>
</tr>
<tr>
<td>Normal</td>
<td>&lt;120</td>
<td>&lt;80</td>
</tr>
<tr>
<td>Prehypertension</td>
<td>120–139</td>
<td>80–89</td>
</tr>
<tr>
<td>Stage 1 hypertension</td>
<td>140–159</td>
<td>90–99</td>
</tr>
<tr>
<td>Stage 2 hypertension</td>
<td>≥160</td>
<td>≥100</td>
</tr>
</tbody>
</table>

BP, blood pressure.

A prerequisite to the use of the above definition for pediatric hypertension is the availability of reliable normative BP standards. An unfortunate part of the problem is that there are no reliable evidence-based BP standards for children. The BP tables recommended by the Working Group of the NHBPEP are not as good as they were made to believe because (1) the BP data are not derived by the methodology recommended by the working group, (2) expressing BP levels by age and height percentiles is statistically unsound and unjustified, and (3) additional computation of BP levels by height percentile on such highly variable office BP readings are impractical and unproductive for busy practitioners (see Blood Pressure Measurement in Chapter 2 for further discussion). The NHBPEP’s statistical efforts on unscientifically obtained data do not improve their validity.

In addition, it is important to know that the BP standards of the NHBPEP cannot be used when BP is measured by an oscillometric device. BPs measured by the auscultatory method are not interchangeable with those measured by the oscillometric method, which is being used in increased frequency. In San Antonio Children’s Blood Pressure Study (SACBPS) using both the auscultatory and an oscillometric device (Dinamap Model 8100), BP levels obtained by Dinamap, an oscillometric device, were on average 10 mm Hg higher for the systolic pressure and 5 mm Hg higher for the diastolic pressures than those obtained by the auscultatory method (Park et al, 2001). Therefore, when BPs are obtained by an oscillometric device, one should not use the BP standards provided by the NHBPEP, which are based on the auscultatory method. Only normative BP standards by Dinamap Monitor are those from the SACBPS (Park et al, 2005), and they are presented in Appendix B (Tables B-6 and B-7) according to age and gender.

Kaelber et al (2009) have recommended a simplified table of BP levels according to age and gender (without height percentiles), above which further evaluation should be carried out for possible hypertension (see left half of Table 28-2). This is a more practical approach because in some BP screening sites, height is not always measured and because the inclusion of height percentile in BP evaluation has no statistical validity (as discussed in Chapter 2). Auscultatory BP levels presented in Table 28-2 agree very closely with the normative auscultatory standards reported by the SACBPS (Park et al, 2005). Because BP levels obtained by an oscillometric device are not interchangeable with those obtained by the auscultatory method, BP levels in the prehypertensive range by the oscillometric (Dinamap) method (Park et al, 2005) are shown in the right half of Table 28-2 for the same reasons.
Hypertension is classified into two general types, essential (or primary) hypertension, in which a specific cause cannot be identified, and secondary hypertension, in which a cause can be (Box 28-1).

1. The exact prevalence of essential hypertension in children and adolescents is not known. It is estimated that about 60% of pediatric patients with hypertension have essential hypertension. Among the patients with essential hypertension 75% of them are obese. Thus, the most common cause of pediatric hypertension appears to be obesity; about 10% to 30% of obese children are reported to have hypertension.

2. Among patients with secondary hypertension, more than 90% of the cases are caused by three conditions: renal parenchymal disease and renovascular diseases (both accounting for 70%) and coarctation of the aorta (COA) (20%). Fewer than 10% of secondary hypertension is caused by endocrine and other disorders.

3. In newborns, the causes of hypertension may include renal artery thrombosis, congenital renal malformation, and COA. Transient hypertension may be found in neonates with bronchopulmonary dysplasias, which resolves when oxygenation improves.

### Table 28-2
**Blood Pressure Values Requiring Further Evaluation According to Age and Gender**

<table>
<thead>
<tr>
<th>Age (yr)</th>
<th>Male</th>
<th>Female</th>
<th>Age (yr)</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Syst</td>
<td>Diast</td>
<td>Syst</td>
<td>Diast</td>
<td>Syst</td>
</tr>
<tr>
<td>3</td>
<td>100</td>
<td>59</td>
<td>100</td>
<td>61</td>
<td>3</td>
</tr>
<tr>
<td>4</td>
<td>102</td>
<td>62</td>
<td>101</td>
<td>64</td>
<td>4</td>
</tr>
<tr>
<td>5</td>
<td>104</td>
<td>65</td>
<td>103</td>
<td>66</td>
<td>5</td>
</tr>
<tr>
<td>6</td>
<td>105</td>
<td>68</td>
<td>104</td>
<td>68</td>
<td>6</td>
</tr>
<tr>
<td>7</td>
<td>106</td>
<td>70</td>
<td>106</td>
<td>69</td>
<td>7</td>
</tr>
<tr>
<td>8</td>
<td>107</td>
<td>71</td>
<td>108</td>
<td>71</td>
<td>8</td>
</tr>
<tr>
<td>9</td>
<td>109</td>
<td>72</td>
<td>110</td>
<td>72</td>
<td>9</td>
</tr>
<tr>
<td>10</td>
<td>111</td>
<td>73</td>
<td>112</td>
<td>73</td>
<td>10</td>
</tr>
<tr>
<td>11</td>
<td>113</td>
<td>74</td>
<td>114</td>
<td>74</td>
<td>11</td>
</tr>
<tr>
<td>12</td>
<td>115</td>
<td>74</td>
<td>116</td>
<td>75</td>
<td>12</td>
</tr>
<tr>
<td>13</td>
<td>117</td>
<td>75</td>
<td>117</td>
<td>76</td>
<td>13</td>
</tr>
<tr>
<td>14</td>
<td>120</td>
<td>75</td>
<td>119</td>
<td>77</td>
<td>14</td>
</tr>
<tr>
<td>15</td>
<td>120</td>
<td>76</td>
<td>120</td>
<td>78</td>
<td>15</td>
</tr>
<tr>
<td>16</td>
<td>120</td>
<td>78</td>
<td>120</td>
<td>78</td>
<td>16</td>
</tr>
<tr>
<td>17</td>
<td>120</td>
<td>80</td>
<td>120</td>
<td>78</td>
<td>17</td>
</tr>
</tbody>
</table>

Diast, diastolic; Syst, systolic.

*From Kaelber DC, Pickett F: Simple table to identify children and adolescents needing further evaluation of blood pressure. Pediatrics 123(6):e972, 2009. For adolescents age 14 years and older, systolic pressure of 120 mm Hg is in prehypertensive range, as in adults.*
In general, children with essential hypertension are older than 10 years of age, have mild hypertension, and are often obese. Secondary hypertension is suggested by a younger age, levels of hypertension (varying from mild to severe, especially stage 2 hypertension), and presence of clinical signs that suggest systemic conditions. Children with secondary hypertension are rarely obese and are often less than normal height. Table 28-3 lists the common causes of hypertension by age group in children. Box 28-1 lists the causes of secondary hypertension.
Diagnosis and Workup

Steps to Confirm the Diagnosis

1. The diagnosis of hypertension relies on accurate BP measurement and comparing the reading with reliable BP standards. In evaluating for possible diagnosis of hypertension, it is very important to remember that (a) the most common cause of high BP readings, especially of a single BP reading, in a health care facility is anxiety, called the white-coat phenomenon, and (b) BPs measured by the auscultatory and oscillometric methods are significantly different and thus are not interchangeable (as mentioned earlier). The following is one way of handling a case of high BP reading in the office setting.

   a. If an abnormal reading is the result of single reading, two additional measurements should be made to help reduce the effects of anxiety associated with a visit to the doctor’s office.

   b. If BP is still high, a repeat set of three readings at the end of the office visit may help identify some of the children with the white-coat phenomenon.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newborns</td>
<td>Renal artery thrombosis, renal artery stenosis, congenital renal malformation, COA, bronchopulmonary dysplasia</td>
</tr>
<tr>
<td>&lt;6 yr</td>
<td>Renal parenchymal disease, COA, renal artery stenosis</td>
</tr>
<tr>
<td>6–10 yr</td>
<td>Renal artery stenosis, renal parenchymal disease, primary hypertension</td>
</tr>
<tr>
<td>&gt;10 yr</td>
<td>Primary hypertension, renal parenchymal disease</td>
</tr>
</tbody>
</table>

COA, coarctation of the aorta.


**BOX 28-1**

Causes of Secondary Hypertension

**Renal**
- Renal parenchymal disease
  - Glomerulonephritis, acute and chronic
  - Pyelonephritis, acute and chronic
  - Congenital anomalies (polycystic or dysplastic kidneys)
  - Obstructive uropathies (hydronephrosis)
  - Hemolytic-uremic syndrome
  - Collagen disease (periarteritis, lupus)
  - Renal damage from nephrotoxic medications, trauma, or radiation

**Renovascular disease**
- Renal artery disorders (e.g., stenosis, polyarteritis, thrombosis)
- Renal vein thrombosis

**Cardiovascular**
- Coarctation of the aorta
- Conditions with large stroke volume (patent ductus arteriosus, aortic insufficiency, systemic
### Endocrine
- Hyperthyroidism (systolic hypertension)
- Excessive catecholamine levels
  - Pheochromocytoma
  - Neuroblastoma
- Adrenal dysfunction
  - Congenital adrenal hyperplasia
    - 11-β-Hydroxylase deficiency
    - 17-Hydroxylase deficiency
  - Cushing’s syndrome
  - Hyperaldosteronism
    - Primary
      - Conn’s syndrome
      - Idiopathic nodular hyperplasia
      - Dexamethasone-suppressible hyperaldosteronism
    - Secondary
      - Renovascular hypertension
      - Renin-producing tumor (juxtaglomerular cell tumor)
- Hyperparathyroidism (and hypercalcemia)

### Neurogenic
- Increased intracranial pressure (any cause, especially tumors, infections, trauma)
  - Poliomyelitis
  - Guillain-Barré syndrome
  - Dysautonomia (Riley-Day syndrome)

### Drugs and chemicals
- Sympathomimetic drugs (nose drops, cough medications, cold preparations, theophylline)
  - Amphetamines
  - Corticosteroids
  - Nonsteroidal antiinflammatory drugs
  - Oral contraceptives
  - Heavy-metal poisoning (mercury, lead)
  - Cocaine, acute or chronic use
  - Cyclosporine
  - Thyroxine
  - Tacrolimus

### Miscellaneous
- Hypervolemia and hypernatremia
- Stevens-Johnson syndrome
- Bronchopulmonary dysplasia (newborns)

c. Even if these BP readings are still high, a possibility of white-coat hypertension still exists. The diagnosis of hypertension should not be made until one confirms persistently elevated BP levels greater than the 95th percentile on three or more separate office visits over a period of time.
d. One should consider ways to identify cases of white coat hypertension by measuring BPs outside the health care facility.
   (1) Some physicians advocate the use of the ambulatory BP measurement to rule out white-coat hypertension. Ambulatory BP measurement is costly, and it
reflects BP readings on a single day; BPs vary from day to day.

(2) Having reliable school nurses to take daily BP for 3 to 4 weeks may be a cost-effective way to get the same information.

(3) Home BP monitoring can be an option. For adult patients, new position papers from the United States and Europe recommend home BP monitoring as a routine part of diagnosis and management of hypertension. They recommend recording an average of two (or three) BP readings taken in the morning and at night for 1 week, with a total of at least 12 readings being averaged to make clinical decisions. It is reasonable to try home BP measurement in children under certain circumstances using a protocol similar to the one described for adults.

(4) For home BP monitoring, the monitor should be checked for its accuracy, and the patient should be taught correct measurement technique and correct BP cuff size. Wrist monitors are not acceptable because the readings will reflect peripheral amplification of systolic pressure. In evaluating home BP readings, one should not use BP standards by NHBPEP, which are based on the auscultatory method. One may use the oscillometric BP data from the San Antonio Children’s Blood Pressure Study. Appendix B provides normative oscillometric BP values (Table B-6 for boys; Table B-7 for girls).

2. If multiple BP readings obtained outside the health care facility show persistently elevated BP levels above the 95th percentile most of the time, one could make a tentative diagnosis of hypertension and proceed with initial investigation for hypertension (as described below).

3. If the repeated BP measurements fall between the 90th and 95th percentiles (prehypertension), the patient should be followed on a regular basis (every 3 to 6 months) with repeat BP measurements.

4. When the diagnosis of hypertension is established:
   a. One should evaluate the history (present, past, and family), perform careful physical findings, and proceed with initial investigation to look for the cause of hypertension.
   b. The initial investigation should include urinalysis, serum electrolytes, renal function tests, uric acid, and electrocardiography (ECG) or echocardiography. The diagnosis of essential hypertension is made when the cause of hypertension is not found in a hypertensive patient older than 10 years of age.
   c. One should also assess additional cardiovascular risk factors, including obesity, which is the most common associated finding in children with essential hypertension. Currently recognized cardiometabolic risk factors include:
      (1) Family history of premature cardiovascular disease
      (2) Obesity
      (3) Dyslipidemias, such as hypercholesterolemia, hypertriglyceridemia, and low levels of high-density lipoprotein cholesterol (<40 mg/100 mL)
      (4) Cigarette smoking
      (5) Diabetes mellitus or prediabetic state
      (6) Physical inactivity
History

Past and Present History

1. Present history
   a. Most children with mild hypertension are asymptomatic, and hypertension is diagnosed as the result of routine BP measurement, highlighting the importance of accurate measurement of BP.
   b. Children with acute severe hypertension may be symptomatic, such as that seen with acute glomerulonephritis (with headache, dizziness, nausea and vomiting, irritability, or personality changes). Occasionally, neurologic manifestations, congestive heart failure, renal dysfunction, and stroke may be the presenting symptoms.
   c. Weakness and muscle cramp from hypokalemia may be seen with primary aldosteronism.
   d. A history of palpitation, headache, and excessive sweating may suggest increased catecholamine levels.
   e. Tachycardia with systolic hypertension may suggest hyperthyroidism or catecholamine excess.

2. Neonatal: Use of umbilical artery catheters (a possible cause of renovascular hypertension)

3. Cardiovascular: History of COA or surgery for it

4. Renal: History of obstructive uropathies; urinary tract infection; and radiation, trauma, or surgery to the kidney area

5. Medications: Corticosteroids, amphetamines, antiasthmatic drugs, cold medications, oral contraceptives, nephrotoxic antibiotics (e.g., aminoglycosides, sulfonamides, amphotericin B, trimethoprim, and others), cyclosporin, cocaine use, excessive dose of thyroxin, ingestion of large quantity of licorice. (Licorice inhibits 11β-hydroxysteroid dehydrogenase with a resulting increase in cortisol levels and producing hypokalemia.)

6. Habits: Smoking or consumption of excessive amount of coffee or tea

Family History

1. Essential hypertension, atherosclerotic heart disease, and stroke

2. Familial or hereditary renal disease (polycystic kidney, cystinuria, familial nephritis)

Physical Examination

1. Accurate measurement of BP is essential.

2. Complete physical examination also is essential, with emphasis on the following:
   a. Delayed growth (renal disease)
   b.Bounding peripheral pulse (patent ductus arteriosus or aortic regurgitation)
   c. Weak or absent femoral pulses or BP differential between the arms and legs (COA).
      In normal children, systolic pressure in the lower limbs is more than 5 to 10 mm Hg higher than that in the upper limbs.
Initial Investigation

1. The initial investigations should be directed toward detecting renal parenchymal disease and COA and therefore include the following (Table 28-4).
   a. **Urinalysis**: Abnormal urinalysis with red blood cells or white blood cells suggests nephritis or infectious processes. Urine culture is indicated if urinalysis suggests infectious processes. Urinalysis is normal in essential hypertension, renovascular hypertension, and endocrine hypertension.
   b. **Serum electrolytes**: Low potassium levels suggest aldosterone excess, either from primary aldosteronism or secondary hyperaldosteronism (including renovascular hypertension). Serum electrolyte changes also occur in endocrine disorders causing hypertension; hypokalemia may be seen with Cushing’s syndrome or certain (not all) types of congenital adrenal hyperplasias (11-β hydroxylase deficiency and 17-hydroxylase deficiency). Hypercalcemia suggests hyperparathyroidism.
   c. **Blood urea nitrogen (BUN) and creatinine**: Abnormal values suggest renal parenchymal or renovascular disease, although renal function is usually not affected in renovascular hypertension. Normal BUN and creatinine do not rule out renovascular hypertension.
   d. **Uric acid level**: Uric acid level above 5.5 mg/dL was found in 89% of subjects with primary hypertension, 30% of children with secondary hypertension, and 0% of children with white-coat hypertension and normal control participants. This finding suggests that uric acid level might have a role in the pathogenesis of primary hypertension (Feig et al, 2003). Furthermore, there is independent association between uric acid level and the severity of hypertension.
   e. **ECG, chest radiographs, and echocardiography**: Echocardiography is useful in ruling out COA and evaluating end-organ damage, such as left ventricular (LV) mass.

2. When obesity is the likely cause of hypertension, metabolic aspects of risk factors should be evaluated (including fasting lipid profile, liver function test, blood glucose, and so on). Renal Doppler ultrasonography adds very little in obese children. The presence of metabolic abnormalities may help in convincing patients to adopt a healthy lifestyle.

3. In a nonobese child, younger than 10 years of age, who has moderate to severe hypertension, one should consider the possibility of renovascular hypertension. A history of umbilical catheterization and abdominal radiation is an important clue to renovascular hypertension. The following preliminary screening tests may be indicated.
   a. Renal ultrasonography and renal Doppler sonography
b. Plasma renin activity (PRA)
c. 24-Hour urine collection for catecholamines and their metabolites
4. Thyroid function test (TSH, thyroxine) may be indicated when a rapid heart rate and hypertension coexist.
5. Depending on the results of the routine tests, more specialized tests have been used in the diagnosis of secondary hypertension (see Specialized Studies). The decision to undertake special tests and procedures depends on the availability of and familiarity with the procedure, severity of hypertension, age of the patient, and history and physical findings suggestive of a certain cause. For example:
   a. Nonobese children younger than 10 years of age with sustained hypertension require extensive evaluation because identifiable, and potentially curable causes are more likely to be found.
   b. Adolescents with mild hypertension and a positive family history of essential hypertension are more likely to have essential hypertension, and extensive studies are not cost effective.
   c. In obese children with mild hypertension, renal Doppler ultrasound study does not add any clinical value.
6. When renovascular or renoparenchymal hypertension is a possibility, nephrology consultation is indicated because most of the specialized tests belong to the domain of nephrology. Consultation with endocrinology should be obtained when endocrine disorders are suspected to be the cause of hypertension.

**TABLE 28-4**
INITIAL AND SPECIAL LABORATORY TESTS AND THEIR SIGNIFICANCE

<table>
<thead>
<tr>
<th>Investigations</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urinalysis, urine culture, BUN, creatinine, uric acid</td>
<td>Renal parenchymal disease</td>
</tr>
<tr>
<td>Serum electrolytes (hypokalemia)</td>
<td>Hyperaldosteronism (primary or secondary)</td>
</tr>
<tr>
<td>ECG, chest radiography, and possibly echocardiography</td>
<td>Adrenogenital syndrome</td>
</tr>
<tr>
<td>Ultrasonography, radionuclide studies, CT or MRI of the kidneys, or IVP</td>
<td>Renal parenchymal disease</td>
</tr>
<tr>
<td>Plasma renin activity (peripheral)</td>
<td>Renovascular hypertension</td>
</tr>
<tr>
<td>24-hr urine collection for 17-ketosteroid and 17-hydroxycorticosteroids</td>
<td>Tumors (neuroblastoma, Wilms’ tumor)</td>
</tr>
<tr>
<td>Plasma renin activity (peripheral)</td>
<td>High-renin hypertension (renovascular hypertension, renin-producing tumors, some Cushing syndrome, some essential hypertension)</td>
</tr>
<tr>
<td>24-hr urine collection for catecholamine levels and VMA</td>
<td>Low-renin hypertension (adrenogenital syndrome, primary hyperaldosteronism)</td>
</tr>
<tr>
<td>Aldosterone</td>
<td>Hyperaldosteronism (primary or secondary)</td>
</tr>
<tr>
<td>Renal vein plasma renin activity</td>
<td>Unilateral renal parenchymal disease</td>
</tr>
<tr>
<td>Abdominal aortogram</td>
<td>Renovascular hypertension</td>
</tr>
<tr>
<td>Intra-arterial digital subtraction angiography</td>
<td>Renovascular hypertension</td>
</tr>
</tbody>
</table>

BUN, blood urea nitrogen; CT, computed tomography; ECG, electrocardiogram; HT, hypertension; IVP, intravenous pyelography; MRI, magnetic resonance imaging; VMA, vanillylmandelic acid.
Specialized Studies

The following specialized studies may be indicated for the detection of causes of secondary hypertension (see Table 28-4).

1. Renal ultrasonography can provide a comparison of kidney size; the thickness and echogenicity of the renal cortex, medulla, and pyramids; and anatomic information of the collecting system. A smaller kidney may be seen with irreversible renal disease. The yield of this test in adolescents with obesity-associated hypertension is very low and not very cost effective (Tuli et al, 2005), although the test is definitely indicated in younger children with significant hypertension. This study has replaced intravenous pyelography.

2. Peripheral PRA is a useful screening test for a renal cause of hypertension. Whereas an elevated value (high-renin hypertension) suggests renal parenchymal or renovascular diseases, a suppressed value (low-renin hypertension) suggests excess mineralocorticoid effects such as seen with hyperaldosteronism. The usefulness of captopril-stimulated PRA is controversial at best.

3. A radionuclide renal scan is useful in distinguishing variation in perfusion and scarring of the two kidneys. Decreased flow to one kidney suggests arterial occlusion of that kidney.

4. Renal Doppler ultrasonography can demonstrate lesions in the main renal arteries and in the segmental branches. Computed tomography (CT) angiography and magnetic resonance (MR) angiography have higher sensitivity and specificity than Doppler ultrasonography for renovascular hypertension. However, renal arteriography is considered the gold standard for the diagnosis of renovascular hypertension.

5. PRA in blood collected from both renal veins and the inferior vena cava, at the time of angiography, is helpful in diagnosing unilateral or bilateral kidney disease.

6. Aldosterone levels in serum and urine are indicated in patients with hypokalemia for possible hyperaldosteronism.
   a. High plasma aldosterone levels seen in primary aldosteronism are caused by a benign adrenal adenoma (Conn’s syndrome) or bilateral idiopathic adrenal hyperplasia.
   b. Secondary hyperaldosteronism is caused by overactivity of the renin–angiotensin system. Examples of secondary hyperaldosteronism include juxtaglomerular cell tumor and renal artery stenosis (which increases renin levels). Other conditions, such as liver cirrhosis, heart failure, nephrotic syndrome, or a very low sodium diet may also increase aldosterone levels.

7. 24-Hour urine collection for catecholamine levels and their metabolites (metanephrine, normetanephrine, and vanillylmandelic acid [VMA]) is indicated when a catecholamine-secreting tumor (e.g., pheochromocytoma, neuroblastoma) is suspected. Collection of urine for 24 hours is preferable to plasma for the detection of increased levels of catecholamines or their metabolites because plasma levels of these fluctuate throughout the day.

8. 24-Hour urine collection for free cortisol and 17-ketosteroid: The former is elevated in Cushing’s syndrome, and the latter is elevated in congenital adrenal hyperplasia.
(adrenogenital syndrome).
Management of Essential Hypertension

Nonpharmacologic intervention
Nonpharmacologic intervention should be started as an initial treatment. Counseling should encourage weight reduction if the patient is overweight or obese, healthful diets, low-salt (and potassium-rich) foods, regular aerobic exercise, and avoidance of smoking and oral contraceptives.

Pharmacologic intervention
Drug therapy is not recommended initially. Drugs are used when nonpharmacologic approaches have not been found to be effective because the possible adverse effects of long-term drug therapy on growing children have not been evaluated adequately and because many antihypertensive agents have side effects.

Indications for drug therapy
Although there are no clear guidelines for identifying those who should be treated with antihypertensive drugs, the following are generally considered indications for initiating drug therapy in hypertensive children.
1. Severe symptomatic hypertension should be treated with intravenous (IV) antihypertensive medications.
2. Significant secondary hypertension, such as caused by renovascular and renoparenchymal diseases
3. Persistent hypertension despite nonpharmacologic measures
4. Hypertensive target-organ damage: LV hypertrophy; increased LV mass, and so on
5. Diabetes (types 1 and 2)
6. Family history of early complications of hypertension
7. Child who has dyslipidemia and other coronary artery risk factors

End-Organ Damage
The most reliable evidence of end-organ damage at this time appears to be the presence of LV hypertrophy revealed by echocardiographic studies. Increased LV mass by echocardiography may be an indication of LV hypertrophy, but the values are not very reproducible, and controversies exist as to how to express LV mass (i.e., by 2.7 power of height or by body surface area [BSA]). Other valuable markers of end-organ damage include carotid intima-media thickening and urinary albumin excretion. Although the latter two are frequently used in the evaluation of adult hypertension, they are infrequently used in the evaluation of pediatric hypertension. Carotid intima-media thickening is nonspecific and is also seen in children with familial hypercholesterolemia and obesity. Urinary albumin excretion is a sign of hypertension-related renal damage. Normal M-mode–derived LV mass data indexed by 2.7 power of height are available in Table D-7 in Appendix D. Normal two-dimensional echocardiography-derived LV mass
data indexed by BSA are provided in Table D-8.

The Choice of Drug

In the past, most comparative studies in adult populations found that moderate doses of all classes of antihypertensive agents provided similar efficacy. However, more recent studies in adults suggest that beta-blockers are not as effective as other classes of antihypotensive agents. European studies have shown the superiority of calcium channel blockers (CCBs) over beta-blockers in lowering BP. Other studies have found that angiotensin-converting enzyme (ACE) inhibitors are definitely better than diuretics and are as effective as CCBs. It is known that diuretics and beta-blockers tend to raise blood glucose levels. Thus, CCBs and ACE inhibitors appear preferable to beta-blockers and diuretics, especially for overweight patients at risk of developing diabetes. Besides the BP-lowering effect of the drugs, ACE inhibitors and angiotensin receptor blockers (ARBs) are especially renoprotective and thus are recommended for patients with diabetes and other kidney diseases.

Currently, many adult cardiologists, especially those from European countries, strongly favor using ACE inhibitors (or ARBs) or CCBs as the choice of initial therapy in adult patients with hypertension. Some pediatric authorities now recommend ACE inhibitors (or ARBs) or CCBs as the initial drug for the treatment of hypertension in children and adolescents. Because ACE inhibitors are contraindicated in pregnancy, CCBs may be a better choice for female adolescents with hypertension. CCBs appear to be better choices for African Americans.

1. Adolescent boys
   a. ACE inhibitors or ARBs: These agents alone or in combination with CCB (e.g., Lotrel, the combination of amlodipine and benazepril) are good choice in obese children with high glucose and triglyceride levels.
   b. CCB are equally good as ACE inhibitors as the initial antihypertensive agent. CCBs do not raise blood glucose.
   c. ACE inhibitors plus diuretics are a good combination because diuretics enhance ACE inhibitors’ effects. However, this combination is not recommended in obese patients with acanthosis nigricans because it could cause diabetes.

2. Adolescent girls and women of childbearing age
   a. CCBs (e.g., amlodipine [Norvasc] or extended-release nifedipine) are good choices in women as they lack teratogenic effects.
   b. Diuretics and beta-blockers are probably safe. However, blood glucose levels should be checked regularly because they raise glucose levels.
   c. ACE inhibitors or ARBs should not be used in female adolescents because they are known teratogens. If one becomes pregnant, the drug should be discontinued; it may be resumed at the end of the third trimester if needed.

3. Coexisting conditions: The choice of initial therapy has been influenced by other conditions that frequently coexist with hypertension. Preferences, contraindications, and side effects of different classes of antihypertensive agents are summarized in Table 28-5, which may help in choosing the drug for initial therapy. Most of the information has...
been derived from adult experiences.

a. Migraine patients: Beta-blockers or CCBs are preferred. Beta-blockers appear to be more effective in the prevention of migraines than CCBs.

b. Patients with asthma: CCBs may be the drug of first choice. ARBs and diuretics may work well. ACE inhibitors may cause persistent dry cough in 10% of 20% of patients with asthma, and this may possibly cause bronchospasm. Beta-blockers are contraindicated in patients with asthma because they may cause bronchospasm.

c. Hyperthyroidism or hyperdynamic hypertension with fast heart rates: Beta-blockers are preferred. Beta-blockers are used as treatment adjuncts in hyperthyroidism.

d. Patients with diabetes: ACE inhibitors or ARBs are preferred. Thiazide diuretics and beta-blockers should not be used because they increase blood glucose levels.

e. Renal failure: CCBs or ACE inhibitors are preferred.

After the most appropriate agent for initial therapy has been selected, a relatively small dose of a single drug should be started, aiming for BP reduction of 5 to 10 mm Hg at each step of the dosage until the full dosage or the target BP is reached. If the first drug is not effective, a second drug may be added to, or substituted for, the first drug, starting with a small dose and proceeding to a full dose. In many situations, however, more than one drug is needed to control severely elevated BPs such as those seen in

<table>
<thead>
<tr>
<th>Drug Classes</th>
<th>Preferred In</th>
<th>Contraindicated In (Not to Use In)</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thiazide diuretics</td>
<td>Asthma (+)</td>
<td>Not to use in: Diabetic or prediabetic (increases glucose level)</td>
<td>Hypokalemia, hyponatremia (±) May increase glucose May increase uric acid Increases glucose Increases triglycerides Rarely hypoglycemia</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>Migraine</td>
<td>Contraindicated in: Asthma and diabetes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hyperthyroidism</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hyperdynamic hypertension</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Coarctation of the aorta</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACE inhibitors (ACEIs)</td>
<td>Male adolescents</td>
<td>Contraindicated in: Pregnancy (because of teratogenic effects)</td>
<td>Hyperkalemia Azotemia Angioedema Dry cough Rash, loss of taste, and leukopenia Angioedema rarely (but no cough)</td>
</tr>
<tr>
<td></td>
<td>Diabetic or prediabetic</td>
<td>Not to use in: Patients with asthma (can cause cough)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Obese males (may be used in combination with the CCB Lorcet)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Renal failure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angiotensin receptor blockers (ARBs)</td>
<td>Male adolescents</td>
<td>Contraindicated in: Pregnancy (because of teratogenic effects)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diabetic or prediabetic</td>
<td>Not to use in: Childbearing aged women</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Renal failure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium channel blockers (CCBs)</td>
<td>Female adolescents</td>
<td>Contraindicated in: Heart block</td>
<td>Occasional headache, flushing, ankle edema</td>
</tr>
<tr>
<td></td>
<td>Male adolescents</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>African Americans</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Migraine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Asthma</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Renal failure</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Classes of Antihypertensive Drugs

Diuretics
Diuretics are the oldest class of antihypertensive drugs. The thiazide diuretics (hydrochlorothiazide and chlorthalidone) have the longest history of being used in the treatment of hypertension, sometimes in combination with a potassium-sparing diuretic. The action of thiazide diuretics is related to a decrease in extracellular and plasma volume initially, and later the action is related to a decline in peripheral resistance. An important side effect of thiazide diuretics in children is hypokalemia, occasionally requiring potassium supplementation in the diet or as potassium salt. They may also increase glucose, insulin, and cholesterol levels. One should check serum electrolytes and glucose levels initially and periodically.

TABLE 28-6
ORAL DOSAGES OF SELECTED ANTIHYPERTENSIVE DRUGS FOR CHILDREN
Aldosterone antagonists (or aldosterone receptor blockers), such as spironolactone, are weak potassium-sparing diuretics. Spironolactone antagonizes the action of aldosterone at mineralocorticoid receptors, with resulting inhibition of sodium resorption in the collecting duct of the nephron in the kidneys (by interfering with Na/K exchange with reduction of urinary potassium loss). This group of drugs is often used as adjunctive therapy, in combination with other drugs, for the management of chronic heart failure. It is also used in the management of hyperaldosteronism (including Conn’s syndrome).

Sodium channel blockers, such as triamterene (Dyrenium) and amiloride, are potassium-sparing diuretics used in combination with thiazide diuretics for the treatment of hypertension and edema. It directly blocks the epithelial sodium channel on the lumen side of the collecting tubule. Potassium-sparing diuretics (spironolactone, triamterene) may cause hyperkalemia, especially if given with ACE inhibitors or ARBs.

### Adrenergic Inhibitors

The mechanism of action of beta-blockers is not fully understood. It may involve...
suppressing cardiac contractility, decreasing systemic vascular resistance, or suppressing the renin–angiotensin system. Beta-blockers appear to be less effective than other classes of antihypertensives. β-Adrenergic blockers are contraindicated in patients with asthma (because of bronchospasm) and diabetes mellitus (because of hyperglycemic effects). Propranolol (Inderal) is a short-acting form requiring dosing three times a day. Atenolol (Tenormin) has the advantage of being a longer acting beta-blocker requiring only a single daily dose.

**Angiotensin converting enzyme inhibitors**

Captopril is a short-acting ACE inhibitor widely used in the treatment of pediatric hypertension. Enalapril and lisinopril are long-acting ACE inhibitors that have also been shown to be effective in children with hypertension. A diuretic clearly enhances the effectiveness of ACE inhibitors. Side effects of ACE inhibitors include rash, loss of taste, and leukopenia. Occasional side effects include cough, angioedema, hyperkalemia, and azotemia. If cough appears, an ARB may be used. ACE inhibitors are contraindicated in pregnancy because of their known teratogenic effects. Serum electrolytes and creatinine should be checked for hyperkalemia and azotemia.

**Angiotensin receptor blockers**

are new class of antihypertensive agents that act by displacing angiotensin II from its receptor, antagonizing all of angiotensin’s known effects with a resulting decrease in peripheral resistance. Cough is not a side effect, although angioedema can occur.

**Calcium channel blockers**

CCBs are being used increasingly in the treatment of adult hypertension. Nifedipine has the greatest peripheral vasodilatory action, with little effect on cardiac automaticity, conduction, or contractility. Concomitant dietary sodium restriction or the use of a diuretic agent may not be necessary because calcium antagonists cause natriuresis by producing renal vasodilatation. Recently, the safety and efficacy of amlodipine (Norvasc) have been reported for children with various forms of hypertension (Flynn et al, 2004). Occasional side effects include headache, flushing, and local ankle edema.

**Vasodilators**

Hydralazine (Apresoline), a direct-acting vasodilator, is popular in the treatment of acute hypertension in children. When used alone, it produces side effects related to increased cardiac output (flushing, headache, tachycardia, palpitation) and salt retention. Therefore, the concomitant use of a β-adrenergic blocker and a diuretic is recommended. Hydralazine can cause lupus-like syndrome. Minoxidil, a less commonly used vasodilator, can cause hypertrichosis when used on a chronic basis.

**Follow-up Evaluation of Patients with Chronic Hypertension**
1. Follow-up examinations should include ongoing monitoring of BP levels, target-organ damage, periodic serum electrolyte determination in children treated with ACE inhibitors or diuretics, counseling regarding other cardiovascular risk factors, and adherence with a newly adopted healthy lifestyle.

2. Goals of treatment
   a. For children with uncomplicated primary hypertension without hypertensive end-organ damage, the goal of the treatment is reduction of BP to below the 95th percentile.
   b. For children with chronic renal disease, diabetes, or hypertensive target organ damage, the goal is reduction of BP to below the 90th percentile.

3. A “step-down” therapy or cessation of therapy may be considered in selected patients with uncomplicated primary hypertension that is well under control, especially overweight children who successfully lose weight. Such patients require ongoing follow-up of their BP levels and their weight status.
Management of Secondary Hypertension

Treatment of secondary hypertension should be aimed at removing the cause of hypertension whenever possible. Table 28-7 lists curable causes of systemic hypertension.

**Cardiovascular causes.** Hypertension caused by mild coarctation is treated with beta-blockers. Surgical or catheter interventional correction may be indicated for COA.

**Renal parenchymal disease.** In nephritis, medical management should be instituted to lower BP in the same manner as has been discussed for essential hypertension. Salt restriction, avoidance of excessive fluid intake, and antihypertensive drug therapy can control hypertension caused by most renal parenchymal diseases. Concomitant antibiotic therapy for infectious processes and general supportive measures may be indicated, depending on the nature of the renal disease. If hypertension is difficult to control and the disease is unilateral, unilateral nephrectomy may be considered.

**TABLE 28-7**

<table>
<thead>
<tr>
<th><strong>CURABLE FORMS OF HYPERTENSION</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Organ or System</strong></td>
</tr>
<tr>
<td>Renal</td>
</tr>
<tr>
<td>Cardiovascular</td>
</tr>
<tr>
<td>Renal artery abnormalities (e.g., stenosis, aneurysm, fibromuscular dysplasia, thrombosis)</td>
</tr>
<tr>
<td>Adrenal</td>
</tr>
<tr>
<td>Cushing syndrome (caused by adrenocortical or pituitary tumor)</td>
</tr>
<tr>
<td>Primary aldosteronism</td>
</tr>
<tr>
<td>Miscellaneous</td>
</tr>
<tr>
<td>Oral contraceptives</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
</tr>
</tbody>
</table>

**Renovascular disease.** Renovascular disease may be cured by successful renal artery balloon angioplasty or surgery, such as reconstruction of a stenotic renal artery, autotransplantation, or unilateral nephrectomy. Further discussion of this topic follows.

**Adrenal glands.** Hyperaldosteronism caused by bilateral adrenal hyperplasia is treated with the mineralocorticoid antagonist, such as spironolactone or eplerenone. Hypertension caused by tumors that secrete vasoactive substances, such as pheochromocytoma and neuroblastoma, are treated primarily by surgery. Further discussion of this topic follows.
White-Coat Hypertension

White-coat hypertension is defined as persistent hypertension in a health care facility with concomitant normal BP during usual daily life. The prevalence of white-coat hypertension in children and adolescents is estimated to be about 30% to 50%.

White-coat hypertension may not be as benign as it was once thought to be. Several recent studies in adults and children suggest that about 30% to 40% of patients with white-coat hypertension spontaneously evolve into having hypertension with accompanying end-organ damage (e.g., increase in LV mass or increase in carotid intima-media thickness). Thus, white-coat hypertension can be considered a prehypertension. Therefore, it is important to identify individuals with white-coat hypertension before labeling them as hypertensive or dismissing them as normotensives. Patients with white-coat hypertension should be followed up on a regular basis.

How are individuals with white-coat hypertension identified, and how should they be followed? One needs a reliable way of accurately measuring BPs outside of health care facilities. There are at least two ways of identifying patients with white-coat hypertension.

1. Twenty-four-hour ambulatory BP measurements provide reliable BP readings outside the doctor’s office. The ambulatory BP values can then be compared with available ABP standards, such as those reported by Wühl and colleagues (2002), which provide both the 90th and 95th percentiles (see Table B-8 in Appendix B). It is noteworthy that the left ventricular mass index (LVMI) correlates well with ambulatory systolic pressures only but not well with ambulatory diastolic pressures or clinic BPs (Sorof et al, 2002). Ambulatory diastolic BP does not change much with increasing age. Drawbacks of ambulatory BP are that it is costly and reflects BP changes for only 1 day, but there are day-to-day variations in BP readings.

2. Another way of getting BP readings outside the doctor’s office is by having reliable outside persons, such as school nurses, to take daily BP measurements for 3 to 4 weeks. One then examines the overall distribution of BP readings and compares them with clinic BP readings as well as with normative BP standards to see if the readings are in the hypertensive range.

3. Home BP monitoring with an oscillometric device is controversial because the accuracy of many commercially available BP measuring devices is questionable. Besides, those that take BP on the wrist are more likely to cause confusion than solving the problem because of the well-known peripheral amplification of systolic pressure (discussed in depth in Chapter 2). The radial artery systolic BP is expected to be higher than the brachial artery BP, and there are no normal BP values for the wrist. Physicians should never recommend or use the wrist device.
Secondary Hypertension

Among patients with secondary hypertension, more than 90% of the cases of secondary hypertension are caused by chronic renal disease, renovascular diseases, and COA. The remaining 10% of cases are caused by other diseases and conditions listed in Box 28-1. In this section, renovascular hypertension and pheochromocytoma are discussed in some detail. Management of hypertension caused by COA is discussed in Chapter 13.

Renovascular Hypertension

Renovascular hypertension results from a lesion that impairs blood flow to a part or all of one or both kidneys. It is the second most common cause of correctable secondary hypertension, second only to COA. It accounts for 3% to 10% of children with hypertension.

Pathogenesis of Renovascular Hypertension

The renin–angiotensin–aldosterone system (RAAS) is involved in the pathogenesis of renovascular hypertension. Angiotensin and aldosterone together influence arterial pressure and cardiac output. Therefore, knowledge of the RAAS is essential in the management of renovascular hypertension by using such drugs as ACE inhibitors, ARBs, and aldosterone antagonists (see Fig. 28-1).

1. Renin is stored and released from juxtaglomerular (JG) cells associated with the afferent arteriole entering the glomerulus. Renin release from the JG cells of the kidney is stimulated by a reduction in BP in the afferent arteriole, such as is seen with renal artery stenosis or systemic hypotension; its release is inhibited by increased BP (see Fig. 28-1).

2. Renin causes the cleavage of angiotensinogen in circulation to form angiotensin I, which has no known biological activity. Angiotensin I is further broken down to angiotensin II by ACE. Angiotensin II is a potent vasoconstrictor, constricting arteries and veins and increasing BP.

3. Angiotensin II acts on the adrenal cortex to stimulate the secretion of aldosterone. Aldosterone in turn acts on the kidneys to increase the reabsorption of sodium and fluid retention, which may help sustain BP and lead to secondary suppression of renin release. Aldosterone stimulates the excretion of potassium in the distal tubule with resulting hypokalemia.

Causes

1. Fibromuscular dysplasia is the most common cause of renovascular hypertension, accounting up to 70% of the patients, in whom the media of the arterial wall is primarily affected. If the intima is most affected, the term intimal hyperplasia is used, which shows a “string of beads” appearance on angiography.

2. Rarely, renal artery stenosis is also seen in other systemic or inherited conditions, including Williams’ syndrome, Marfan’s syndrome, Kawasaki’s disease, and Takayasu’s
Clinical Manifestations
Many children with renovascular hypertension are asymptomatic, and when symptoms are present, they are frequently nonspecific. However, when any or some of the following are found on workup, one should consider a possibility of renovascular hypertension.
1. Young age, usually younger than 10 years of age
2. History of umbilical catheterization in the newborn period or history of abdominal irradiation
3. Serum electrolyte abnormalities, notably hypokalemia, but occasionally hyponatremia may also be found. However, an absence of electrolyte abnormalities does not preclude the possibility of severe renovascular hypertension.
4. Some normal children may have abdominal bruit.
5. Severe hypertension or worsening of hypertension refractory to medical treatment. However, hypertension is not always severe in renovascular hypertension.
6. Unexplained impaired renal function in the presence of hypertension
7. Unequal kidney size on any clinical study. The affected kidney is usually smaller.
8. Rarely, polyuria and polydipsia may be present.

Diagnostic Workup
When renovascular hypertension is a possible cause, one generally needs most of the investigations listed earlier (see Table 28-4) except for endocrine tests.

1. BUN and creatinine are usually normal in renovascular hypertension unless there is severe renal artery involvement or accelerated hypertension.
2. There may be some hypokalemia caused by secondary hyperaldosteronism.
3. It is not uncommon to find a normal size and shape of the kidneys in renal ultrasonography.
4. PRA is increased in most (but not all) cases of patients with renovascular disease or pyelonephritic scarring. ACE inhibitors stimulate PRA selectively in patients with renovascular hypertension (“captopril-stimulated PRA test”), but the specificity of the test is controversial. Low PRA in a hypertensive child suggests mineralocorticoid excess or a salt and water overload for other reasons.
5. Renal vein renin measurement is an important diagnostic procedure and helps in identifying surgically curable forms of renal hypertension.
6. Doppler ultrasonography, CT angiography, and MR angiography are safe tests with high sensitivity and specificity for renovascular hypertension. However, renal arteriography is still considered the gold standard for the diagnosis of renovascular hypertension. The procedure is mandatory if surgical or transluminal angioplasty is being considered.

**Management**

1. While waiting for intervention, antihypertensive medication should be started to lower the BP.
   a. ACE inhibitors are most effective, which minimizes the ischemia-induced rise in the angiotensin production. One needs to closely monitor renal function because ACE inhibitors can cause a drop in the glomerular filtration rate. ARBs may be equally effective.
   b. CCBs provide control of hypertension in patients with less impaired function of the ischemic kidney. They may have beneficial long-term effects, but this remains uncertain.
2. Restoration of adequate renal blood flow can be accomplished by percutaneous transluminal angioplasty with or without stenting. This is a relatively safe procedure with a success rate up to 90%.
3. Surgical revascularization by using bypass graft may be performed. However, the widespread nature of the disease in children will not offer a benefit to many children. In adults, surgical revascularization was found to offer better long-term results than endovascular revascularization (Ham et al, 2010).

**Pheochromocytoma**

Pheochromocytoma is a catecholamine-secreting tumor that arises from chromaffin cells. The most common site of the tumor is the adrenal medulla, but it can occur anywhere along the abdominal sympathetic chain. It may be inherited as an autosomal dominant
Hypertension results from excess secretion of norepinephrine and epinephrine. Paroxysmal hypertension typically suggests the disease, but hypertension in children is usually more sustained than paroxysmal. During attacks, the patient complains of headache, palpitation, abdominal pain, dizziness, vomiting, pallor, and sweating. Convulsion and other manifestations of hypertensive emergency may occur. Because of hypermetabolism, growth failure is striking, with frequent polydipsia and polyuria. BP may rise to 180 to 220 mm Hg.

The diagnosis is made by demonstration of increased levels of blood and urine catecholamines and their metabolites. Urinary excretion of VMA and metanephrine is increased. Adrenal tumors are easily detected by sonography, CT scan, or MR imaging, and they are often bilateral. However, in children, it often occurs in extraadrenal sites and in multiple sites, and thus, it may be difficult to detect and remove all tumors. Removal of these tumors results in cure, but the operation is very high risk. Preoperative α- and β-adrenergic blockade and fluid loading are required.
Hypertensive Crisis

In hypertensive crisis, BP is rapidly rising or a high BP level is associated with neurologic manifestations, heart failure, or pulmonary edema.

Classification

Hypertensive crisis may be loosely divided into the following subgroups.

1. **Hypertensive emergencies**
   Situations in which immediate reduction of BP (within minutes) is needed, usually with parenteral therapy

2. **Hypertensive urgencies**
   Situations in which reduction of BP is needed within hours, usually with oral agents

3. **Accelerated malignant hypertension**
   Situations in which papilledema, hemorrhage, and exudate are associated with a markedly elevated BP; the diastolic pressure is usually above 140 mm Hg

4. **Hypertensive encephalopathy**
   Situations in which markedly elevated BP is associated with severe headache and various alterations in consciousness. Hypertensive encephalopathy may be seen in a previously normotensive patient who suddenly becomes hypertensive, such as children with acute glomerulonephritis or young women with eclampsia. Chronically hypertensive patients less commonly develop encephalopathy and only at much higher pressures.

Treatment

Aggressive parenteral administration of antihypertensive drugs is indicated to lower BP.

1. Labetalol (alpha- and beta-blocker) 0.2 to 2 mg/kg/hour IV drip, diazoxide (Hyperstat), 3 to 5 mg/kg as an IV bolus, or nitroprusside (Nipride), 1 to 3 µg/kg per minute as an IV drip, is the treatment of choice.

2. If hypertension is less severe, hydralazine (Apresoline), 0.15 mg/kg IV or intramuscularly (IM), may be used. The onset of action is 10 minutes after an IV dose and 20 to 30 minutes after an IM dose. The dose may be repeated at 4- to 6-hour intervals. Nifedipine, 0.2 to 0.5 mg/kg (maximum, 10 mg), may be given orally every 4 to 6 hours in severe cases.

3. A rapid-acting diuretic, such as furosemide (1 mg/kg), is given IV to initiate diuresis.

4. Fluid balance must be controlled carefully, so intake is limited to urine output plus insensible loss.

5. Seizures may be treated with slow IV infusion of diazepam (Valium), 0.2 mg/kg, or
another anticonvulsant medication.
6. When a hypertensive crisis is under control, oral medications replace the parenteral medications (see Table 28-5 for oral dosages of antihypertensive drugs).
Pulmonary Hypertension
When measured directly in the cardiac catheterization laboratory, the normal pulmonary artery (PA) systolic pressure of children and adults is 30 mm Hg or below, and the mean PA pressure is 25 mm Hg or below. A diagnosis of pulmonary hypertension can be made when the mean PA pressure is 25 mm Hg or above in a resting individual at sea level. The PA pressure is higher at high elevations.

The noninvasive Doppler method, however, often overestimates the PA pressure in people with normal PA pressure. Using tricuspid regurgitation jet velocity and the modified Bernoulli equation and adding assumed a right atrial (RA) pressure of 10 mm Hg will usually overestimate the right ventricular (RV) systolic pressure. The assumed RA pressure of 10 mm Hg is too high unless RV dysfunction or severe tricuspid regurgitation (TR) is present. The directly measured RA pressure is normally 3 to 5 mm Hg in infants and children. Using this assumption, the mean PA systolic pressure (± standard deviation [SD]) was found to be 28.3 ± 4.9 mm Hg (range, 15–57 mm Hg) in infants and adults, higher values than previously reported using invasive methods (McQuillan et al, 2001). The estimated upper 95% limit for PA systolic pressure by the Doppler method was 37.2 mm Hg. (This results from a TR jet velocity of 2.7 m/sec in the absence of pulmonary stenosis [PS].) Thus, Doppler-estimated PA systolic pressure of 36 to 40 mm Hg has been assumed as the cut-off value for mild PA hypertension. Thus, the Doppler estimates are relatively imprecise and are not a substitute for cardiac catheterization.

There is a wide range of severity in pulmonary hypertension; in some, it reaches or surpasses the systemic pressure. The status of pulmonary hypertension also varies; in some, it is static, and in others, it is dynamic.
Causes

Pulmonary hypertension is a group of conditions with multiple causes rather than a single one. Pathogenesis and management differ among entities. Box 29-1 lists, according to pathogenesis, conditions that cause pulmonary hypertension of a temporary or permanent, acute or chronic nature.

The causes of pulmonary hypertension can be grouped into the following five. Some oversimplification is inevitable in dividing this diverse group into five categories.

1. Increased PBF seen in congenital heart defects (CHDs) with large left-to-right shunts (hyperkinetic pulmonary hypertension)
2. Alveolar hypoxia
3. Increased pulmonary venous pressure
4. Primary pulmonary vascular disease
5. Other diseases that involve pulmonary parenchyma or pulmonary vasculature, directly or indirectly

Although a new classification of pulmonary hypertension was proposed in Dana Point in 2008, it is not better than the one used here because it is difficult to apply in some cases of pediatric pulmonary hypertension.

<table>
<thead>
<tr>
<th>BOX 29-1 Causes of Pulmonary Hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Large left-to-right shunt lesions (hyperkinetic pulmonary hypertension): ventricular septal defect, patent ductus arteriosus, endocardial cushion defect</td>
</tr>
<tr>
<td>2. Alveolar hypoxia</td>
</tr>
<tr>
<td>a. Pulmonary parenchymal disease</td>
</tr>
<tr>
<td>(1) Extensive pneumonia</td>
</tr>
<tr>
<td>(2) Hypoplasia of lungs (primary or secondary, such as that seen in diaphragmatic hernia)</td>
</tr>
<tr>
<td>(3) Bronchopulmonary dysplasia</td>
</tr>
<tr>
<td>(4) Interstitial lung disease (Hamman-Rich syndrome)</td>
</tr>
<tr>
<td>(5) Wilson-Mikity syndrome</td>
</tr>
<tr>
<td>b. Airway obstruction</td>
</tr>
<tr>
<td>(1) Upper airway obstruction (large tonsils, macroglossia, micrognathia, laryngotracheomalacia, sleep-disordered breathing)</td>
</tr>
<tr>
<td>(2) Lower airway obstruction (bronchial asthma, cystic fibrosis)</td>
</tr>
<tr>
<td>c. Inadequate ventilatory drive (central nervous system diseases, obesity hypoventilation syndrome)</td>
</tr>
<tr>
<td>d. Disorders of chest wall or respiratory muscles</td>
</tr>
<tr>
<td>(1) Kyphoscoliosis</td>
</tr>
<tr>
<td>(2) Weakening or paralysis of skeletal muscle</td>
</tr>
<tr>
<td>e. High altitude (in certain hyperreouters)</td>
</tr>
</tbody>
</table>
3. Pulmonary venous hypertension: mitral stenosis, cor triatriatum, total anomalous pulmonary venous return with obstruction, chronic left heart failure, left-sided obstructive lesions (aortic stenosis, coarctation of the aorta); rarely, congenital pulmonary vein stenosis cause incurable pulmonary hypertension

4. Primary pulmonary vascular disease
   a. Persistent pulmonary hypertension of the newborn
   b. Primary pulmonary hypertension (rare, fatal form of pulmonary hypertension with obscure cause)

5. Other diseases that involve pulmonary parenchyma or pulmonary vasculature, directly or indirectly.
   a. Thromboembolism: ventriculoatrial shunt for hydrocephalus, sickle cell anemia, thrombophlebitis
   b. Connective tissue disease: scleroderma, systemic lupus erythematosus, mixed connective tissue disease, dermatomyositis, rheumatoid arthritis
   c. Disorders directly affecting the pulmonary vasculature: schistosomiasis, sarcoidosis, histiocytosis X
   d. Portal hypertension (hepatopulmonary syndrome)
   e. HIV infection
The basics of physiology of pulmonary circulation and pulmonary vascular responses are summarized below for a quick review.

1. **Vascular endothelium:** Normally, balanced release of vasodilators and vasoconstrictors by endothelial cells is a key factor in the regulation of the pulmonary vascular tone. Three endothelium signaling cascades are known: (a) nitric oxide (NO)–cyclic guanosine monophosphate (cGMP) cascade, (b) prostanoids, and (c) endothelin-1 (ET-1). The most widely used drug therapy of pulmonary hypertension works by altering one of these signaling cascades (see Management):
   a. NO, a vasodilator, is produced in the vascular endothelium by the enzyme endothelial nitric oxide synthase (eNOS) from the precursor L-arginine. After formation, NO diffuses into the adjacent smooth muscle cell and produces cGMP (by activation of guanylate cyclase), which results in smooth muscle relaxation. cGMP is broken down by a family of phosphodiesterases, which is prominent in the pulmonary circulation. Blocking breakdown of cGMP helps maintain vasodilation.
   b. Arachidonic acid metabolism within vascular endothelial cells results in the production of prostaglandin I\(_2\) (PGI\(_2\) or prostacyclin) and thromboxane (TXA\(_2\)). PGI\(_2\) is a vasodilator, and TXA\(_2\) is a vasoconstrictor.
   c. ET-1, the dominant isoform of ET, is produced by vascular endothelial cells. ET-1 is a potent vasoconstrictor.

2. The lung is unique in its response to hypoxia. Alveolar oxygen tension in the alveolar capillary region is the major physiologic determinant of pulmonary arteriolar tone. Alveolar hypoxia causes vasoconstriction in the lungs. In all other tissues, hypoxia causes vasodilation. In hypoxia-induced vasoconstriction, NO production is reduced, and ET production is increased. High altitude (with low alveolar oxygen tension) is associated with pulmonary vasoconstriction (and pulmonary hypertension) of varying degrees. There is a large species and individual variation in the reactivity of the pulmonary arteries to low alveolar oxygen tension.

3. Pulmonary vascular resistance (PVR) is primarily determined by the cross-sectional area of small muscular arteries and arterioles. With stenosis or thrombosis of the pulmonary arteries, PVR will increase. Other determinants of PVR include blood viscosity, total mass of the lungs (pneumonectomy or hypoplasia), and extramural compression on the vessels. Normal PVR is 1 Wood unit (or 67 ± 23 [SD] dyne-sec/cm\(^5\)), which is one tenth of systemic vascular resistance.

4. With exercise, a large increase in pulmonary blood flow (PBF) is accomplished by only a small increase in PA pressure because of recruitment of near collapsed capillaries. The increase in the left atrial (LA) pressure appears to account for most of the increase in PA pressure.
Pathogenesis of Pulmonary Hypertension

Pressure (P) is related to both flow (F) and vascular resistance (R), as shown in the following formula:

\[ P = F \times R \]

An increase in flow, vascular resistance, or both can result in pulmonary hypertension. Regardless of its cause, pulmonary hypertension eventually involves constriction of the pulmonary arterioles, resulting in an increase in PVR and hypertrophy of the RV.

Pathogenesis of pulmonary hypertension is discussed according to the (first four) general categories of causes because each is distinctly different from the other.

**Hyperkinetic Pulmonary Hypertension**

Pulmonary hypertension associated with large left-to-right shunt lesions, such as ventricular septal defect (VSD), patent ductus arteriosus (PDA), is called *hyperkinetic pulmonary hypertension*. It is the result of an increase in PBF, a direct transmission of the systemic pressure to the PA, and an increase in PVR by compensatory pulmonary vasoconstriction. If no vasoconstriction occurs, the increase in PBF will be much larger, and intractable congestive heart failure (CHF) will result. Defects in the vasodilation machinery of the endothelial cell, such as overproduction of vasoconstrictor elements, have been implicated in this form of pulmonary hypertension. Hyperkinetic pulmonary hypertension is usually reversible if the cause is eliminated before permanent changes occur in the pulmonary arterioles (see later section).

If large left-to-right shunt lesions (e.g., VSD, PDA, complete atrioventricular canal) are left untreated, irreversible changes take place in the pulmonary vascular bed, with severe pulmonary hypertension and cyanosis caused by a reversal of the left-to-right shunt. This stage is called Eisenmenger’s syndrome or pulmonary vascular obstructive disease (PVOD). Surgical correction is not possible at this stage. The time of onset of PVOD varies, ranging from infancy to adulthood, but the majority of patients develops PVOD during late childhood or early adolescence. It develops even later in patients with atrial septal defect (ASD). Many patients with uncorrected transposition of the great arteries (TGA) begin to develop PVOD within the first year of life for reasons not entirely clear. Children with Down syndrome with large left-to-right shunt lesions tend to develop PVOD much earlier than other children with similar lesions.

**Alveolar Hypoxia**

An acute or chronic reduction in the oxygen tension (Po$_2$) in the alveolar capillary region (alveolar hypoxia) elicits a strong pulmonary vasoconstrictor response, which may be augmented by acidosis. Hypoxia in the alveolar space elicits a much stronger vasoconstrictor effect than low Po$_2$ in the PA.
The mechanisms of the pulmonary vasoconstrictor response to alveolar hypoxia are not completely understood, but studies in animals and humans suggest that ET and NO, the two important vascular endothelium-released vasoactive substances, are the strongest candidates responsible for the response. Normally, balanced release of NO and ET by endothelial cells regulates the pulmonary circulation. Whereas a reduction in NO production occurs in chronically hypoxic animals, prolonged inhalation of NO attenuates hypoxic pulmonary vasoconstriction and vascular remodeling (proliferation) in these animals. Conversely, plasma levels of ET-1 are increased in association with hypoxia in humans. ET receptor antagonists have been demonstrated to reduce hypoxic pulmonary vasoconstriction and vascular remodeling in animals. A number of other growth factors (including platelet-derived growth factors and vascular endothelial growth factor) also mediate pulmonary vascular remodeling in response to hypoxia.

Alveolar hypoxia may be an important basic mechanism of many forms of pulmonary hypertension, including that seen in pulmonary parenchymal disease, airway obstruction, inadequate ventilatory drive (central nervous system diseases), disorders of chest wall or respiratory muscles, and high altitude. Even a small area of affected lung may produce vasoconstriction throughout the lungs, possibly through a circulating humoral agent. Pulmonary hypertension caused by alveolar hypoxia is usually reversible when the cause is eliminated.

**Pulmonary Venous Hypertension**

Increased pressures in the pulmonary veins produce reflex vasoconstriction of the pulmonary arterioles, raising PA pressure to maintain a high enough pressure gradient between the PA and the pulmonary vein. This pressure gradient maintains a constant forward flow in the pulmonary circulation. There is a marked individual variation in the degree of reactive pulmonary arteriolar vasoconstriction. For example, when the pulmonary venous pressure is elevated in excess of 25 mm Hg from mitral stenosis, marked reactive pulmonary hypertension occurs only in less than one third of patients. The mechanism for the vasoconstriction is not entirely clear, but a neuronal component may be present. Moreover, an elevated pulmonary venous pressure may also narrow or close small airways, resulting in alveolar hypoxia, which may contribute to the vasoconstriction. Mitral stenosis, total anomalous pulmonary venous return (TAPVR) with obstruction (of pulmonary venous return to the LA), and chronic left-sided heart failure are examples of this entity. Pulmonary hypertension with increased pulmonary venous pressure is usually reversible when the cause is eliminated, with the exception of congenital pulmonary vein stenosis, for which no curative intervention is available.

**Primary Pulmonary Vascular Disease**

Primary pulmonary hypertension is characterized by progressive, irreversible vascular changes similar to those seen in Eisenmenger’s syndrome but without intracardiac lesions. There is a decrease in the cross-sectional area of the pulmonary vascular bed
caused by pathologic changes in the vascular tissue itself, thromboembolism, platelet aggregation, or a combination of these. This condition is extremely rare in pediatric patients; it is a condition of adulthood and is more prevalent in women. The familial form of the disease has been reported worldwide in approximately 6% of the cases with primary pulmonary hypertension. It has a poor prognosis.

The pathogenesis of primary pulmonary hypertension is not fully understood, but endothelial dysfunction of the pulmonary vascular bed and enhanced platelet activities may be important factors. In a normal pulmonary vascular bed, the endothelial cells modulate the tone of vascular smooth muscles (by synthesizing prostacyclin, NO, and ET), control the potential proliferation of smooth muscle cells, and interact with platelets to release anticlotting factors in the blood to maintain a nonthrombotic state (by releasing prostacyclin, an inhibitor of platelet function). These delicate functions are themselves influenced by factors such as shear stress, hypoxia, and tissue metabolism.

The striking features of the pulmonary vasculature in patients with primary pulmonary hypertension are marked intimal proliferation (and in some vessels with complete vascular occlusion) and in situ thrombosis of the small pulmonary arteries. Interactions among ET, growth factors, platelets, and the vascular wall may play a fundamental role in the pathologic processes seen in this condition. ET is overproduced in pulmonary hypertension, and this excess ET is associated with not only vasoconstriction but also cell proliferation, inflammation, medial hypertrophy, and fibrosis. Endothelium receptor antagonists (e.g., bosentan) produce vasodilation.

Other Disease States
Pulmonary hypertension associated with other disease states has similar pathophysiologies described in the above four categories, singly or in combination.
Pathology of Pulmonary Hypertension

Regardless of the initial events that lead to PA hypertension, elevated PA pressure eventually induces varying severity of anatomic changes in the pulmonary vessels. The triad of well-established pulmonary hypertension is vasoconstriction, cell proliferation, and thrombosis through the action of ET, serotonin, and TXA$_2$.

1. Hyperkinetic pulmonary hypertension is the result of CHDs with left-to-right shunts. Heath and Edwards classified the changes into six grades (Fig. 29-1). Grade 1 consists of hypertrophy of the medial wall of the small muscular arteries; grade 2, hyperplasia of the intima; and grade 3, hyperplasia and fibrosis of the intima with narrowing of the vascular lumen. Changes up to grade 3 are considered reversible if the cause is eliminated. In grade 4, dilatation and so-called plexiform lesion of the muscular pulmonary arteries and arterioles are present. Grade 5 changes include complex plexiform, angiomatous, and cavernous lesions and hyalinization of intimal fibrosis. Grade 6 is characterized by the presence of necrotizing arteritis. These advanced changes seen in grades 4 through 6 are considered “irreversible,” and they augment the hypertension and sustain it even when the original stimulus is removed. Thus, the presence of irreversible pulmonary vascular changes precludes surgical repair of CHDs.

2. The progressive vascular changes that occur in primary pulmonary hypertension are identical to those that occur with CHDs.

3. With pulmonary venous hypertension, the pulmonary arteries may show severe medial hypertrophy and intimal fibrosis. However, the changes are limited to grades I through III of the Heath and Edwards classification, and they are often reversible when the cause is eliminated.
<table>
<thead>
<tr>
<th>CHANGE(S)</th>
<th>GRADE</th>
<th>MORPHOLOGY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal or Thin Walled</td>
<td>0</td>
<td><img src="image1" alt="Diagram" /></td>
</tr>
<tr>
<td>Medial Thickening (MT)</td>
<td>I</td>
<td><img src="image2" alt="Diagram" /></td>
</tr>
<tr>
<td>MT + Intimal Thickening (IT)</td>
<td>II</td>
<td><img src="image3" alt="Diagram" /></td>
</tr>
<tr>
<td>MT + IT + Plexiform Lesion</td>
<td>III</td>
<td><img src="image4" alt="Diagram" /></td>
</tr>
</tbody>
</table>

FIGURE 29-1  Heath-Edwards grading of the morphologic changes in the pulmonary arteries of patients with pulmonary hypertension (see text). (From Roberts WC: Congenital Heart Disease in Adults. Philadelphia, FA Davis, 1979.)
Pathophysiology

1. The normally thin RV cannot sustain sudden pressure loads over 40 to 50 mm Hg. If severe pulmonary hypertension develops suddenly in the presence of an unprepared (nonhypertrophied) RV, right-sided heart failure develops. Examples include infants who develop acute upper airway obstruction and adult patients who develop massive pulmonary thromboembolism.

2. However, if pulmonary hypertension develops slowly, the RV hypertrophies, and it can tolerate mild pulmonary hypertension (with a systolic pressure of about 50 mm Hg) without producing clinical problems. The RV pressure rises gradually with accompanying RV hypertrophy, and the PA pressure may eventually exceed the systemic pressure.

3. In patients with pulmonary hypertension, a decrease in cardiac output may result from at least two mechanisms:
   a. A volume and pressure overload of the RV impairs cardiac function, primarily by impaired coronary perfusion of the hypertrophied and dilated RV and decreased left ventricular (LV) function. The LV dysfunction results from the dramatic leftward shift of the interventricular septum caused by the increasing RV volume. The dilated RV also alters LV structures and decreases the compliance of the LV, resulting in an increase in both LV end-diastolic pressure and LA pressure and thus worsening pulmonary vasoconstriction.
   b. A sudden increase in PVR may decrease pulmonary venous return to the LA, with resulting hypotension in the absence of a right-to-left intracardiac shunt.

4. Pulmonary edema can occur without elevation of LA pressure. Direct disruption of the walls of the small arterioles proximal to the hypoxically constricted arterioles may be responsible (a mechanism similar to that proposed for high-altitude pulmonary edema). The disruption is more likely if there is no hypertrophy of the smooth muscles in the media of these vessels.

5. Deterioration of arterial blood gas levels may occur. Hypoxemia, acidosis, and occasionally hypercapnia may result from pulmonary venous congestion or edema, compression of small airways, or intracardiac shunts, which may worsen pulmonary hypertension.
Clinical Manifestations

Regardless of the cause, the clinical manifestations of pulmonary hypertension are similar when significant hypertension exists.

History

1. Exertional dyspnea and fatigue are the earliest and most frequent complaints. Some patients may have history of headache.
2. Syncope, presyncope, or chest pain also occur on exertion, which generally represent more advanced disease with a fixed cardiac output.
3. History of a heart defect or CHF in infancy is present in most cases of Eisenmenger’s syndrome.
4. Patients with underlying lung disease may also complain of frequent episodes of cough or wheezing.
5. Hemoptysis (associated with pulmonary infarction secondary to thrombosis) is a late and sometimes fatal development.

Physical Examination

1. Cyanosis with or without clubbing may be present. The neck veins are distended, with a prominent a wave.
2. An RV lift or tap (on the left parasternal area) is present on palpation.
3. There is a single S2, or it splits narrowly; the P2 is loud. An ejection click and an early diastolic decrescendo murmur of pulmonary regurgitation (PR) are usually present along the mid-left sternal border. A holosystolic murmur of TR may be audible at the lower left sternal border.
4. Signs of right-sided heart failure (e.g., hepatomegaly, ankle edema) may be present.
5. Arrhythmias occur in the late stage.
6. Patients with associated illness often have clinical findings of that disease.

Electrocardiography

1. Right-axis deviation and RV hypertrophy with or without “strain” are seen with severe pulmonary hypertension.
2. RA hypertrophy is frequently seen late.

Radiographic Studies

1. The heart size is normal or only slightly enlarged with or without RA enlargement. Cardiomegaly appears when CHF supervenes.
2. A prominent PA segment and dilated hilar vessels with clear lung fields are characteristic.
3. With acute exacerbation, pulmonary edema may be seen.
Echocardiography

Echo usually demonstrates the following.
1. Enlargement of the RA and RV with normal or small LV dimensions
2. Thickened interventricular septum and abnormal septal motion (as a result of the RV pressure overload)
3. Thickened RV free wall and RV dysfunction are difficult to demonstrate and quantitate. Semiquantitative estimation of PA pressures can be obtained using various methods, such as M-mode or two-dimensional echocardiography, and Doppler examination. It should be noted, however, that Doppler estimated PA pressure and that measured in the cardiac catheterization laboratory are not interchangeable (as discussed earlier in this chapter). These noninvasive methods of estimating the severity of pulmonary hypertension are presented below.

1. **Abnormal valve motion on M-mode echocardiography:** An absent or diminished a wave, a reduced EF slope, and a midsystolic closure (notching) indicate pulmonary hypertension (Fig. 29-2). However, these abnormalities are not quantitative and not always present, and a false-positive result occurs rarely.

2. **Two-dimensional echocardiography:** With an elevated RV pressure, the interventricular septum shifts toward the LV and appears flattened at the end of systole. An inspection of the septal curvature at the end of systole provides an estimate of the RV systolic pressure (Fig. 29-3).

3. **Doppler echocardiography**
   a. Peak TR velocity determined by continuous-wave Doppler is used to estimate the systolic pressure in the PA. The simplified Bernoulli equation ($\Delta P = 4V^2$) is used to estimate a systolic pressure drop across the tricuspid valve; a normal central venous pressure of 10 mm Hg is added to the result to estimate PA systolic pressure. In the absence of PS, the systolic pressure in the RV equals that in the PA. (Note that the normal Doppler-derived values are different from those obtained by invasive methods; the upper limit of normal PA systolic pressure is 36 to 40 mm Hg by the Doppler method.)

![FIGURE 29-2](image)

**FIGURE 29-2** M-mode echocardiography of the pulmonary valve in pulmonary hypertension. **A**, Normal M-mode echocardiography. **B**, Pulmonary hypertension demonstrating an absent a wave, diminished or negative EF slope, and midsystolic notch or flutter (arrow).
FIGURE 29-3  Parasternal short-axis stop frames of interventricular septal configurations of normal patients and patients with right ventricular (RV) hypertension. The top row represents the end-diastolic frames, the middle row represents the midsystolic frames, and the bottom row represents the end-systolic frames. In normal children (left column), the typical rounded configuration of the interventricular septum is demonstrated throughout the cardiac cycle. In moderate pulmonary hypertension (middle column), the interventricular septum becomes progressively flattened from the end of diastole to the end of systole. When RV pressure is suprasystemic (right column), the interventricular septum is flattened at the end of diastole; at the end of systole, it reverses its curvature to become convex toward the left ventricle. (Modified from King ME, Braun H, Goldblatt A, et al: Interventricular septal configuration as a predictor of right ventricular systolic hypertension in children: A cross-sectional echocardiographic study. Circulation 68:68–75, 1983.)

b. With a shunt lesion, such as VSD, PDA, or systemic-to-PA shunt, the peak systolic velocity across the shunt can be used to estimate systolic pressure in the RV or PA. The systolic pressure in the LV (which is equal to the aortic pressure) estimated by systolic pressure in the arm minus the systolic pressure drop across the VSD or PDA estimates RV and PA systolic pressures, respectively. Note that the systolic pressure in the arm is a little higher (5–10 mm Hg) than the LV systolic pressure because of the peripheral amplification of systolic pressure (see Chapter 2).

c. The end-diastolic velocity of PR can be used to estimate the diastolic pressure in the PA. The end-diastolic (not early diastolic) velocity is measured and entered into the modified Bernoulli equation, and a normal central venous pressure of 10 mm Hg is added.

Exercise Testing
A symptom-limited exercise, such as the 6-minute walk test, has been found to be useful in the evaluation of adult patients with pulmonary hypertension (see Stress Testing in Chapter 6 for the 6-minute walk test). At this time, reference values for healthy children and adolescents are not available, but the test is useful for following disease progression or measuring the response to medical interventions.
Diagnosis

1. Cardiac catheterization is necessary to confirm the presence and severity of pulmonary hypertension.
2. After the diagnosis of pulmonary hypertension is confirmed, it is critical to test whether the elevated PVR is due to active vasoconstriction (“responders”) or to permanent changes in the pulmonary arterioles (“nonresponders”). The protocol for vasodilator testing varies from center to center. NO inhalation (20 ppm) with or without increased oxygen concentration for 10 minutes is commonly used. One may also use tolazoline (Priscoline, α-adrenoceptor blocker), intravenous (IV) prostacyclin, or the administration of oxygen.

   Acute “responders” should show a decrease of 10 mm Hg or greater in the mean PA pressure with a mean PA pressure of 40 mm Hg or less or a decrease in 20% or greater in the mean PA pressure or PVR with an unchanged or increased cardiac output.

3. Characteristic angiographic findings of advanced pulmonary hypertension secondary to CHD include sparseness of arborization, abrupt tapering of small arteries, and reduced background capillary filling.
4. Lung biopsies have been used in an attempt to evaluate the “operability” of patients with pulmonary hypertension and CHD. Unfortunately, pulmonary vascular changes are not uniformly distributed, and the biopsy findings correlate poorly with the natural history of the disease or the operability. Hemodynamic data appear to predict the survival better than biopsy findings.
1. Pulmonary hypertension secondary to the upper airway obstruction is usually reversible when the cause is eliminated.
2. Chronic conditions that produce alveolar hypoxia have a relatively poor prognosis. Pulmonary hypertension of variable degree persists with right-sided heart failure. Superimposed pulmonary infection may be an aggravating factor.
3. Pulmonary hypertension with large left-to-right shunt lesions (hyperkinetic type) or associated with pulmonary venous hypertension improves or disappears after surgical repair of the cause if treatment of the condition is possible and performed early.
4. Primary pulmonary hypertension is progressive and has a fatal outcome, usually 2 to 3 years after the onset of symptoms.
5. Pulmonary hypertension associated with Eisenmenger’s syndrome, collagen disease, and chronic thromboembolism is usually irreversible and has a poor prognosis but may be stable for 2 to 3 decades.
6. Right-sided heart failure and atrial and ventricular arrhythmias may occur late.
7. The two most frequent causes of death are progressive RV failure and sudden death (probably secondary to arrhythmias).
8. Cerebrovascular accident from paradoxical embolization is a rare complication.
Management
Most cases of pulmonary hypertension are difficult to treat and impossible to reverse unless the cause can be eliminated. The primary emphasis must be on the prevention and elimination of causes whenever possible.

Treating Underlying Causes
Measures to remove or treat the underlying cause include the following.
1. Timely corrective surgery for congenital defects, such as large-shunt VSD, endocardial cushion defect, or PDA, before obstructive anatomic changes occur in the pulmonary vessels
2. Tonsillectomy and adenoidectomy when the cause of pulmonary hypertension is the upper airway obstruction
3. Treatment of underlying diseases, such as cystic fibrosis, asthma, pneumonia, obstructive sleep apnea, or bronchopulmonary dysplasia

General Measures
General measures are aimed at preventing further elevation of PA pressure or treating its complications.
1. Avoidance or limitation of strenuous exertion, isometric activities (weight lifting), trips to high altitudes, and possibly flights on commercial aircraft
2. Oxygen supplementation is provided as needed.
3. Avoidance of vasoconstrictor drugs, including decongestants with α-adrenergic properties
4. Patients should be strongly advised to avoid pregnancy. Pregnancy increases circulating blood volume and oxygen consumption, may increase the risk of pulmonary embolism from deep vein thrombosis or amniotic fluid, and may cause syncope and cardiac arrest. Oral contraceptives worsen pulmonary hypertension (surgical contraception is preferred).
5. CHF is treated with chronic administration of digoxin and diuretics and a low-salt diet. Digoxin may improve RV contractility against the elevated afterload and is also useful if there is coexisting LV dysfunction. Diuretics provide marked benefit in symptom relief by reducing intravascular volume, hepatic congestion, and pulmonary congestion.
6. Cardiac arrhythmias are treated with antiarrhythmic drugs.
7. Partial erythropheresis is performed for polycythemia and headache.
8. Annual flu shots are recommended.
9. The use of nitroglycerine for anginal pain is avoided because it may worsen the pain.

Anticoagulation
Oral anticoagulation is widely used because the numerous studies have implicated
thrombosis as contributing to the progression of the disease.

1. Anticoagulation with warfarin (Coumadin) is widely recommended in patients with thromboembolic disease and may be beneficial in patients with pulmonary hypertension from other causes. The international normalized ratio of 2.0 to 2.5 is the goal of therapy.

2. Some recommend antiplatelet drugs (aspirin) instead of warfarin to prevent microembolism in the pulmonary circulation. Unlike in patients with a prosthetic mechanical heart valve, concomitant use of aspirin is not recommended because it may increase the effects of warfarin.

Pharmacologic Treatment of Chronic Pulmonary Hypertension

The main determinant of treatment of chronic pulmonary hypertension is the response to vasodilator testing at cardiac catheterization (see Diagnosis). The pulmonary vasodilators are used in “responders.” For nonresponders, vasodilators have limited success. Vasodilators should not be used without testing first in the catheterization laboratory.

Drugs that are used to relieve pulmonary vasoconstriction can be divided into endothelial-based and smooth muscle-based drugs (Oishi et al, 2011).

- **Endothelial-based drugs** act on endothelial mechanisms that cause vasoconstriction or induce vasodilatation.
  - NO inhalation
  - Phosphodiesterase type 5 inhibitors (sildenafil, tadalafil)
  - Prostacyclin analogues (epoprostenol, treprostinil)
  - ET receptor antagonists (bosentan, sitaxsentan, ambrisentan)

- **Smooth muscle–based drugs** act directly on the smooth muscle.
  - Calcium channel blockers

For “responders.”

1. Nifedipine, a calcium channel blocking agent, is one of the oldest drugs used with beneficial effects seen in 40% of children with primary pulmonary hypertension who have shown vasodilator responses during cardiac catheterization. The oral dose of nifedipine is 0.2 mg/kg every 8 hours. Barst et al (1999) showed that 5-year survival rates improved significantly among responders. Calcium channel blockers could worsen the underlying pulmonary hypertension because of negative inotropic effects and their reflex sympathetic stimulation. The major side effect is systemic hypotension. In adults, only very large doses (not the conventional dose) of the agent were shown to be salutary.

2. Prostacyclin is a potent pulmonary and systemic vasodilator with antiplatelet activity. Prostacyclin analogues have been shown to improve quality of life and survival in patients with primary pulmonary hypertension, Eisenmenger’s syndrome, and chronic lung disease.
   - a. Epoprostenol is a synthetic prostacyclin and has a very short half-life (1–2 min),
necessitating a continuous IV infusion through a central venous line and delivered by an ambulatory infusion system. (The starting dose of epoprostenol was 2 ng/kg/min with increments of 2 ng/kg/min every 15 minutes until desired effects appeared; the average final dose was 9 to 11 ng/kg/min.) Barst et al (1999) have shown improved survival rates, with a 4-year survival rate of 94% compared with 38% in untreated patients. Thrombosis, pump malfunction (with rebound pulmonary hypertension), flushing, headache, nausea, diarrhea, and jaw discomfort are reported complications and side effects.

b. Several prostacyclin analogs have been used in adults, which can be administered IV (Treprostinil), by inhalation (Iloprost) at the dose of 5 mcg every 2 to 3 hours, or orally (Beraprost).

3. The ET receptor antagonists bosentan and sitaxsentan have been used in both primary pulmonary hypertension and Eisenmenger’s syndrome. Two receptors, ET \(_A\) and ET \(_B\) receptors, are known. Whereas both ET \(_A\) and ET \(_B\) receptors on vascular smooth muscle mediate vasoconstriction, ET \(_B\) receptors on endothelial cells cause release of NO and prostacyclin and act as clearance receptors for circulating ET-1 (Tissot et al, 2010).

a. Bosentan, a nonselective ET receptor blocker, given orally in a dose of 125 mg twice a day for 16 weeks, has resulted in a significant improvement in the level of exercise capability in adult patients. Similarly, beneficial effects have been reported in pediatric patients. In children with primary pulmonary hypertension or Eisenmenger’s syndrome, oral bosentan in the dose of 31.25 mg twice a day for children who weigh less than 20 kg, 62.5 mg twice a day for children who weigh 20 to 40 kg, and 125 mg twice a day for children who weigh more than 40 kg (with or without concomitant IV prostacyclin therapy) for a median duration of 14 months resulted in a significant functional improvement in about 50% of the cases (Barst et al, 2003; Maiya et al, 2006; Rosensweig et al, 2005). A rare side effect of the drug is increased liver enzyme.

b. Sitaxsentan, a selective endothelin-A (ET \(_A\)) receptor antagonist given orally once daily at a dose of 100 mg (for mostly adult patients and children older than 12 years), resulted in improved exercise capacity after 18 weeks’ treatment (Barst et al, 2006). Elevation of aspartate aminotransferase and alanine aminotransferase was a rare side effect.

c. Ambrisentan is another oral selective ET \(_A\) receptor, but little data are available for children.

4. Sildenafil, a phosphodiesterase inhibitor, prevents the breakdown of cyclic cGMP, resulting in pulmonary vasodilatation. Given orally, it has been shown to be a potent and selective pulmonary vasodilator with equal efficacy to that of inhaled NO in adult patients. A small pediatric study with sildenafil for 12 months resulted in improvement in hemodynamics and exercise capacity in children with primary pulmonary hypertension and secondary pulmonary hypertension from CHDs. The dosage used was 0.25 to 1 mg/kg four times daily, starting with the lower dose (Humpl et al, 2005). Adverse effects include headache, flushing, exacerbation of nosebleed, and rare systemic hypotension or
erections. Tadalafil is also a selective phosphodiesterase inhibitor, but no data are available in children.

5. NO inhalation is effective in lowering PA pressure in adult respiratory distress syndrome, primary pulmonary hypertension, and persistent pulmonary hypertension of the newborn. NO can be administered only by inhalation because it is inactivated by hemoglobin. Rebound pulmonary hypertension is problematic.

For “nonresponders.”

The following measures can be used in patients with fixed PVR and severe pulmonary hypertension, including primary pulmonary hypertension.

1. NO inhalation and continuous IV or possibly nebulized prostacyclin (PGI₂) may provide selective pulmonary vasodilatation.
2. Atrial septostomy or septectomy (either by catheter or surgery) improves survival rates and abolishes syncope or intractable right heart failure by providing a right-to-left atrial shunt and thereby helping to maintain cardiac output but with increased hypoxemia.
3. Lung or heart–lung transplantation remains the only available treatment for patients unresponsive to vasodilator treatment. It was believed initially that because of severe RV dysfunction, heart–lung transplantation was the only option. However, bilateral or single-lung transplantation has been shown to reduce PVR and improve RV function. Bilateral lung transplantation is preferred at most centers because of a greater pulmonary vascular reserve, but some centers prefer single-lung transplantation because of its simpler surgical technique and shorter waiting time for the organ procurement.
Child with Chest Pain

A complaint of chest pain is frequently encountered in children in the office and emergency department (ED). Although chest pain does not indicate serious disease of the heart or other systems in most pediatric patients, in a society with a high prevalence of atherosclerotic cardiovascular disease, it can be alarming to the child and parents. Physicians should be aware of the differential diagnosis of chest pain in children and should make every effort to find a specific cause before making a referral to a specialist or reassuring the child and the parents of the benign nature of the complaint. Making a routine referral to a cardiologist is not always a good idea; it may increase the family’s concern and may result in a prolonged and costly cardiac evaluation.

Cause and Prevalence

Chest pain occurs in children of all ages and equally in male and female patients, with an average age of presentation at 13 years. Most of the data on the frequency of causes of chest pain in children come from studies performed in pediatric ED and cardiology clinics. Chest pain accounts for approximately 0.3% to 0.6% of pediatric ED visits. Table 30-1 lists the frequency of the causes of chest pain in children according to the organ systems based on data from 6 published reports from pediatric emergency departments or pediatric clinics and data from 4 pediatric cardiology clinics (Thull-Freedman, 2011). According to the table, trauma or muscle strain of the chest wall, costochondritis, and respiratory illness are the three most frequent causes of the pain. Gastrointestinal and psychogenic causes are identified in fewer than 10% of cases, and a cardiac cause is found infrequently (5% or less). In another report, chest wall pathology, including costochondritis, was the cause of the pain in 64% of patients seen in an ED and in 88% of the patients seen in cardiology clinic (Massin et al, 2004). Whereas children younger than 12 years of age were two times more likely to have an organic cause, adolescents were 2.5 times more likely to have a psychogenic cause. Box 30-1 is a partial list of possible causes of noncardiac and cardiac chest pain in children.

Clinical Manifestations

**Idiopathic Chest Pain**

No cause can be found in 12% to 85% of patients even after a moderately extensive investigation. In many children with chronic chest pain, an organic cause is less likely to be found. In some of these children, chest pain is resolved spontaneously, and some of them are eventually referred for specialty evaluation.

**Noncardiac Causes of Chest Pain**

Most cases of pediatric chest pain originate in the organ systems other than the
cardiovascular system. Identifiable noncardiac causes of chest pain are found in 56% to 86% of reported cases. Causes of chest pain are found most often on the thorax and respiratory system.

**Costochondritis.** Costochondritis causes chest pain in 9% to 22% of children with such pain. A single study reported rates as high as 79%. It is more common in girls than boys. Pain is generally sharp, anterior chest pain and usually unilateral but occasionally bilateral. Pain is usually exaggerated by physical activity or breathing. A specific position may also cause the pain. The pain may radiate to the remainder of the chest, back, and abdomen. The pain may be preceded by exercise, an upper respiratory infection, or physical activity. Physical examination is diagnostic; the clinician finds a reproducible tenderness on palpation over the chondrosternal or costochondral junctions. It is a benign condition, but the pain may persist for several months.

### Table 30-1

**FREQUENCY OF CAUSES OF CHEST PAIN IN CHILDREN**

<table>
<thead>
<tr>
<th>Causes</th>
<th>Pediatric Emergency Department or Pediatric Clinic (Data from Six Reports) (%)</th>
<th>Cardiology Clinic (Data from Four Reports) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Idiopathic or cause unknown</td>
<td>12–61</td>
<td>37–54</td>
</tr>
<tr>
<td>Musculoskeletal or costochondritis</td>
<td>7–69</td>
<td>1–89</td>
</tr>
<tr>
<td>Respiratory or asthma</td>
<td>13–24</td>
<td>1–12</td>
</tr>
<tr>
<td>Gastrointestinal or gastroesophageal reflux disease</td>
<td>3–7</td>
<td>3–12</td>
</tr>
<tr>
<td>Psychogenic</td>
<td>5–9</td>
<td>4–19</td>
</tr>
<tr>
<td>Cardiac</td>
<td>2–5</td>
<td>3–7</td>
</tr>
</tbody>
</table>


### Box 30-1

**Selected Causes of Chest Pain**

**Noncardiac Causes**

**Musculoskeletal**
- Costochondritis
  - Trauma to chest wall (from sports, fights, or accident)
  - Muscle strains (pectoral, shoulder, or back muscles)
  - Overused chest wall muscle (from coughing)
  - Abnormalities of the rib cage or thoracic spine
  - Tetze’s syndrome
  - Slipping rib syndrome
  - Precordial catch (Texidor’s twinge or stitch in the side)

**Respiratory**
- Reactive airway disease (exercise-induced asthma)
  - Pneumonia (viral, bacterial, mycobacterium, fungal, or parasitic)
- Pleural irritation (pleural effusion)
Pneumothorax or pneumomediastinum
Pleurodynia (devil’s grip)
Pulmonary embolism
Foreign bodies in the airway

**Gastrointestinal**
Gastroesophageal reflux
Peptic ulcer disease
Esophagitis
Gastritis
Esophageal diverticulum
Hiatal hernia
Foreign bodies (e.g., coins)
Cholecystitis
Pancreatitis

**Psychogenic**
Life stressor (death in family, family discord, divorce, failure in school, nonacceptance from peers, sexual molestation)
Hyperventilation
Conversion symptoms
Somatization disorder
Depression
Bulimia nervosa (esophagitis, esophageal tear)

**Miscellaneous**
Sickle cell disease (vaso-occlusive crisis)
Mastalgia
Herpes zoster

**Cardiac Causes**

**Ischemic Ventricular Dysfunction**
Structural abnormalities of the heart (severe aortic or pulmonary stenosis, hypertrophic obstructive cardiomyopathy, Eisenmenger syndrome
Mitral valve prolapse
Coronary artery abnormalities (previous Kawasaki disease, congenital anomaly, coronary heart disease, hypertension, sickle cell disease)
Cocaine abuse
Aortic dissection and aortic aneurysm (Turner’s, Marfan’s, and Noonan’s syndromes)

**Inflammatory Conditions**
Pericarditis (viral, bacterial, or rheumatic)
Postpericardiotomy syndrome
Tietze’s syndrome is a rare form of costochondritis characterized by a large, tender, fusiform (spindle-shaped), nonsuppurative swelling at the chondrosternal junction. It usually affects the upper ribs, particularly the second and third costochondral junctions.

**Musculoskeletal.** Musculoskeletal chest pain is also common in children. The pain is caused by strains of the pectoral, shoulder, or back muscles after exercise; overused chest wall muscle for coughing; or because of trauma to the chest wall from sports, fights, or accidents. A history of vigorous exercise, weightlifting, or direct trauma to the chest and the presence of tenderness of the chest wall or muscles clearly indicate muscle strain or trauma. Abnormalities of the rib cage or thoracic spine can cause mild, chronic chest pain in children.

**Respiratory.** Respiratory problems are responsible for about 10% to 20% of cases of pediatric chest pain, which may result from lung pathology, pleural irritation, or pneumothorax. A history of severe cough, with tenderness of intercostal or abdominal muscles, is usually present. The presence of crackles, wheezing, tachypnea, retraction, or fever on examination suggests a respiratory cause of chest pain. Pleural effusion may cause pain that is worsened by deep inspiration. Radiographic examination may confirm the diagnosis of pleural effusion, pneumonia, or pneumothorax.

**Exercise-induced asthma.** The prevalence of exercise-induced asthma is probably underestimated. Exercise triggers bronchospasm in up to 80% of individuals with asthma. The response of the patient with asthma to exercise is quite characteristic. Running for 1 to 2 minutes often causes bronchodilatation in patients with asthma, but strenuous exercise for 3 to 8 minute’s duration causes bronchoconstriction in virtually all subjects with asthma, especially when the heart rate rises to 180 beats/min. Symptoms range from mild to severe and may include coughing; wheezing; dyspnea; and chest congestion, constriction, or pain. They also complain of limited endurance during exercise. Environmental factors such as cold temperature, pollens, and air pollution, as well as viral respiratory infection, can worsen exercise-induced asthma. Exercise-induced bronchospasm provocation test is diagnostic, which is described under Stress Tests in Chapter 6.

**Gastrointestinal.** Some gastrointestinal disorders, including gastroesophageal reflux disease (GERD), may present as chest pain in children. In addition to chest pain, children with GERD may complain of abdominal pain, frequent sore throat, gagging or choking,
extreme pickiness about foods, frequent respiratory problems (e.g., bronchitis, wheezing, asthma), and poor weight gain. The onset and relief of pain in relation to eating and diet may help clarify the diagnosis. The incidence of GERD is higher in patients with Down syndrome, cerebral palsy, and other causes of developmental delay. Esophagitis resulting from gastroesophageal reflux should be suspected in a child who complains of burning substernal pain that worsens with a reclining posture or abdominal pressure or that worsens after certain foods are eaten. Cholecystitis presents with postprandial pain referred to the right upper quadrant of the abdomen and part of the chest.

Young children sometimes ingest foreign bodies, such as coins, which lodge in the upper esophagus, or they may ingest caustic substances that burn the entire esophagus. In such cases, the history makes the diagnosis obvious.

**Psychogenic.** Psychogenic disturbances account for 5% to 17% of cases and are seen in both boys and girls at equal rates. Often a recent major stressful event parallels the onset of the chest pain such as a death, divorce or separation in the family, a serious illness, a disability, a recent move, failure in school, or sexual molestation. However, a psychological cause of chest pain should not be lightly assigned without a thorough history taking and a follow-up evaluation. Psychological or psychiatric consultation may reveal conversion symptoms, a somatization disorder, or even depression.

**Miscellaneous**
- The *precordial catch* (Texidor’s twinge or stitch in the side), a one-sided chest pain, lasts a few seconds or minutes and is associated with bending or slouching. The cause is unclear, but the pain is relieved by straightening and taking a few shallow breaths or one deep breath. The pain may recur frequently or remain absent for months.
- *Slipping rib syndrome* results from excess mobility of the 8th to 10th ribs, which do not directly insert into the sternum. In many cases, the ligaments that hold these ribs to the upper ribs are weak, resulting in slippage of the ribs, causing pain.
- Some male and female adolescents complain of chest pain caused by breast masses (*mastalgia*). These tender masses may be cysts (in postpubertal girls) or may be part of normal breast development in pubertal boys and girls.
- *Pleurodynia* (devil’s grip), an unusual cause of chest pain caused by coxsackievirus infection, is characterized by sudden episodes of sharp pain in the chest or abdomen.
- *Herpes zoster* is another unusual cause of chest pain.
- *Spontaneous pneumothorax* and *pneumomediastinum* are serious but rare respiratory causes of acute chest pain in children; children with asthma, cystic fibrosis, or Marfan’s syndrome are at risk. Inhalation of cocaine can provoke pneumomediastinum and pneumothorax with subcutaneous emphysema.
- *Pulmonary embolism*, although extremely rare in children, has been reported in female adolescents who use oral contraceptives or have had elective abortions. It has also been reported in male adolescents with recent trauma of the lower extremities and in children with shunted hydrocephalus. It may occur in children with hypercoagulation syndromes. Affected patients usually have dyspnea, pleuritic pain, fever, cough, and hemoptysis.
- *Hyperventilation* can produce chest discomfort and is often associated with paresthesia and lightheadedness.
Cardiovascular Causes of Chest Pain

Cardiovascular disease is identified as the cause of pediatric chest pain in 0% to 5% of cases. Cardiac chest pain may be caused by ischemic ventricular dysfunction, pericardial or myocardial inflammatory processes, or arrhythmias. A typical anginal pain in adults is located in the precordial or substernal area and radiates to the neck, jaw, either or both arms, the back, or the abdomen. The patient describes the pain as a deep, heavy pressure; the feeling of choking; or a squeezing sensation. Older adolescents are expected to describe the pain this way, but young children may not. Exercise, cold stress, emotional upset, or a large meal typically precipitates anginal pain. Table 30-2 summarizes clinical findings of cardiac causes of chest pain in children for practitioners.

If a noncardiac cause of chest pain is not found and the nature of the pain is consistent with that of cardiac origin, cardiology consultation should be considered. Children with exertional chest pain, especially if it is associated with dizziness or palpitation, should be considered for a possible cardiac cause of chest pain. The electrocardiographic (ECG) and echocardiographic study should demonstrate or rule out most of the chest pain of cardiac origin, except for those associated with cardiac arrhythmias or substance abuse.

Ischemic Myocardial Dysfunction. Congenital heart defects. Severe obstructive lesions, such as aortic stenosis (AS), subaortic stenosis, severe pulmonary stenosis (PS), and pulmonary vascular obstructive disease (Eisenmenger’s syndrome), may cause chest pain. Mild stenotic lesions do not cause ischemic chest pain. Chest pain from severe obstructive lesions results from increased myocardial oxygen demands from tachycardia and increased pressure work by the ventricle. Therefore, the pain is usually associated with exercise and is a typical anginal pain. Cardiac examination often reveals a loud heart murmur best audible at the upper right or left sternal border, usually with a thrill, except in patients with Eisenmenger’s syndrome. The ECG usually shows ventricular hypertrophy with or without “strain” pattern. Chest radiographs may be abnormal in patients with AS or PS with a prominent ascending aorta or main pulmonary artery trunk, respectively. Chest films are definitely abnormal in patients with Eisenmenger’s syndrome, with a marked prominence of the main pulmonary artery segment. Echocardiography and Doppler studies permit accurate diagnosis of the type and severity of the obstructive lesion.

Mitral valve prolapse. Chest pain associated with mitral valve prolapse (MVP) has been reported in about 20% of patients with the condition. The pain is usually a vague, nonexertional pain of short duration located at the apex without a constant relationship to effort or emotion. The pain is presumed to result from abnormal tension on papillary muscles, but the causal relationship between chest pain and MVP remains unclear in children. Occasionally, supraventricular or ventricular arrhythmias may result in cardiac symptoms, including chest discomfort. Thoracoskeletal deformities commonly occur in these children and may cause chest pain. Nearly all patients with Marfan’s syndrome have MVP.

**TABLE 30-2**
<table>
<thead>
<tr>
<th>Conditions</th>
<th>History</th>
<th>Physical Findings</th>
<th>ECG</th>
<th>Chest Radiograph</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe AS</td>
<td>History of CHD (+)</td>
<td>Loud (&gt;grade 3/6 SEM at URSB with radiation to neck)</td>
<td>LVH with or without strain</td>
<td>Prominent ascending aorta and aortic knob</td>
</tr>
<tr>
<td>Severe PS</td>
<td>History of CHD (+)</td>
<td>Loud (grade &gt;3/6) SEM at ULSB</td>
<td>RVH with or without strain</td>
<td>Prominent PA segment</td>
</tr>
<tr>
<td>HOCM</td>
<td>Positive FH in one third of cases</td>
<td>Variable heart murmurs</td>
<td>LVH</td>
<td>Mild cardiomegaly with globular-shaped heart</td>
</tr>
<tr>
<td>MVP</td>
<td>Positive FH (±)</td>
<td>Midsystolic click with or without late systolic murmur</td>
<td>Inverted T waves in aVF (±)</td>
<td>Normal heart size Straight back (±) Narrow AP diameter (±)</td>
</tr>
<tr>
<td>Eisenmenger syndrome</td>
<td>History of CHD (+)</td>
<td>Cyanosis and clubbing RV impulse</td>
<td>RVH</td>
<td>Markedly prominent PA with normal heart size</td>
</tr>
<tr>
<td>Anomalous origin of left coronary artery</td>
<td>Recurrent episodes of distress in early infancy</td>
<td>Soft or no heart murmur</td>
<td>Anterolateral MI pattern</td>
<td>Moderate to marked cardiomegaly Normal heart size or mild cardiomegaly</td>
</tr>
<tr>
<td>Sequelae of Kawasaki's or other coronary artery diseases</td>
<td>History of Kawasaki's disease (±) Typical exercise-related anginal pain</td>
<td>Usually negative Continuous murmur in coronary fistula</td>
<td>ST-segment elevation (±) Old MI pattern (±)</td>
<td>Normal heart size in acute cases</td>
</tr>
<tr>
<td>Cocaine abuse</td>
<td>History of substance abuse (±)</td>
<td>Hypertension</td>
<td>ST-segment elevation (±)</td>
<td>Normal heart size Cardiomegaly of varying degree</td>
</tr>
<tr>
<td>Pericarditis and myocarditis</td>
<td>History of URI (±)</td>
<td>Friction rub</td>
<td>Low QRS voltages ST-segment shift Arrhythmias (±)</td>
<td>Cardiomegaly of varying degree</td>
</tr>
<tr>
<td>Postpericardiotomy syndrome</td>
<td>History of recent heart surgery, pain, and dyspnea</td>
<td>Muffled heart sounds</td>
<td>Persistent ST-segment elevation (±)</td>
<td>Cardiomegaly of varying degree</td>
</tr>
<tr>
<td>Arrhythmias (and palpitation)</td>
<td>History of WPW syndrome (±) FH of long QT syndrome (±)</td>
<td>Friction rub May be negative Irregular rhythm (±)</td>
<td>WFP preexcitation (±) Long QTc interval (&gt;0.46 sec)</td>
<td>Normal heart size Normal heart size</td>
</tr>
</tbody>
</table>

+, Positive; ±, may be present; AP, anteroposterior; AS, aortic stenosis; CHD, congenital heart disease; FH, family history; HOCM, hypertrophic obstructive cardiomyopathy; LPLs, left precordial leads; LVH, left ventricular hypertrophy; MI, myocardial infarction; MVP, mitral valve prolapse; PA, pulmonary artery; PS, pulmonary stenosis; RV, right ventricle; RVH, right ventricular hypertrophy; SEM, systolic ejection murmur; ULSB, upper left sternal border; URI, upper respiratory infection; URSB, upper right sternal border; WPW, Wolff-Parkinson-White.

Cardiac examination reveals a midsystolic click with or without a late systolic murmur. The midsystolic click becomes more prominent on standing. The ECG may
show T-wave inversion in the inferior leads. Two-dimensional echocardiographic findings of MVP in adults are well established, but diagnostic echocardiographic findings of MVP have not been established in children (see Chapter 21).

**Cardiomyopathy.** Hypertrophic and dilated cardiomyopathies can cause chest pain from ischemia, with or without exercise, or from rhythm disturbances. Cardiac examination reveals no diagnostic findings, but the ECG or chest radiographs are abnormal, leading to further studies. Echocardiographic studies are diagnostic of the conditions (see Chapter 18).

**Coronary artery disease.** Coronary artery anomalies rarely cause chest pain. They include rare cases of anomalous origin of the left coronary artery from the pulmonary artery (usually symptomatic during early infancy), single coronary artery, coronary artery fistula, aneurysm or stenosis of the coronary arteries as a result of Kawasaki’s disease, or coronary insufficiency secondary to previous cardiac surgery involving the coronary arteries or the vicinity of these arteries.

The pain caused by coronary artery abnormalities is expected to be typical of anginal pain. Cardiac examination may be normal or may reveal a heart murmur (systolic murmur of mitral regurgitation or continuous murmur of coronary artery fistula). The ECG may show myocardial ischemia (ST-segment elevation) or old myocardial infarction. Chest radiographs may reveal abnormalities suggestive of these conditions. Although echo can be helpful, computed tomography or coronary angiography is usually indicated for the definitive diagnosis.

**Cocaine abuse.** Even children with normal hearts are at risk of ischemia and myocardial infarction if cocaine is used. Cocaine blocks the reuptake of norepinephrine in the central nervous system and peripheral sympathetic nerves. An increase in the sympathetic output and circulating level of catecholamines causes coronary vasoconstriction. Cocaine also induces the activation of platelets in some patients and causes increased production of endothelin and decreased production of nitric oxide. The resulting increase in heart rate and blood pressure, increase in myocardial oxygen consumption, possible increase in platelet activation, and myocardial electrical abnormalities may collectively produce anginal pain, infarction, arrhythmias, or sudden death. History and drug screening help physicians in the diagnosis of cocaine-induced chest pain.

**Aortic dissection or aortic aneurysm.** Aortic dissection or aortic aneurysm rarely causes chest pain. Children with Turner’s, Marfan’s, and Noonan’s syndrome are at risk.

**Pericardial or Myocardial Disease. Pericarditis.** Irritation of the pericardium may result from inflammatory pericardial disease; pericarditis may have a viral, bacterial, or rheumatic origin. In a child who had recent open-heart surgery, the cause of the pain may be postpericardiotomy syndrome. Older children with pericarditis may complain of a sharp, stabbing precordial pain that worsens when lying down and improves after sitting and leaning forward. Examination may reveal distant heart sounds, neck vein distention, friction rub, and paradoxical pulse. The ECG may reveal low QRS voltages and ST-T changes, and chest radiographs may show varying degrees of cardiac enlargement and changes in the cardiac silhouette. Diagnosis of pericardial effusion with or without
tamponade can be accurately made by echo examination.

**Myocarditis.** Acute myocarditis often involves the pericardium to a certain extent and can cause chest pain. Examination may reveal fever, respiratory distress, distant heart sounds, neck vein distention, and friction rub. Chest radiographs and the ECG may suggest the correct diagnosis, which can be confirmed by echo examination (see Chapter 19).

**Arrhythmias.** Chest pain may result from a variety of arrhythmias, especially with sustained tachycardia resulting in myocardial ischemia. Even without ischemia, children may consider palpitation or forceful heartbeats as chest pain. When chest pain is associated with dizziness and palpitation, a resting ECG and a 24-hour Holter monitor should be obtained. Alternatively, an event recorder with telephone transmission device may be used to record the ECG rhythm while the patient experiences symptoms.

**Diagnostic Approach**

The first goal of evaluating children with a complaint of chest pain is to rule out a cardiac cause of chest pain, which is usually the main concern to the child and parents, and to look for three common noncardiac causes of chest pain—costochondritis, musculoskeletal causes, and respiratory diseases—which account for 45% to 65% of chest pain in children.

A thorough history taking and careful physical examination suffice to rule out cardiac causes of chest pain and often to find a specific cause of the pain. To rule out cardiac causes of chest pain, physicians need chest radiographs and an ECG. (Cardiologists, in addition, obtain an echocardiogram to accomplish the same.) Cardiac causes of chest pain can be ruled out by the nonexertional nature of the pain, negative cardiac examination findings, and normal results of other investigations, with the exception of cardiac arrhythmia as the cause of the pain. Even if physicians cannot find a specific cause of chest pain, it is relatively easy to rule out cardiac causes of chest pain by following the steps outlined below. Most patients and parents will be relieved and satisfied to learn that the heart is not the cause of chest pain. Finding a specific, benign, or noncardiac cause of pain establishes the diagnosis of noncardiac chest pain.

**History of Present Illness**

The initial history should be directed at determining the nature of the pain in terms of the duration, intensity, frequency, location, and points of radiation. An important history is whether the chest pain occurred during or after heavy physical activities, at rest, or while sitting in class. It is important to remember that ischemic cardiac chest pain is described as a pressure or squeezing sensation, not a sharp pain. Associated symptoms, concurrent or precipitating events, and relieving factors may help clarify the origin of the pain.

The following are some examples of questions to ask.

- When did the pain begin?
- Acute onset of pain (within 48 hours) is more likely to have an organic etiology.
In young children, a sudden onset of chest pain should raise the possibility of a foreign body (coin or button battery) in the esophagus.

Those with chronic pain are more likely to be idiopathic or psychogenic, although some children with costochondritis may have chronic pain.

How often have you had similar pain (frequency and chronicity)?

What is the location (e.g., specific point, localized or diffuse)?

How severe is the pain?

What is the pain like (e.g., sharp, pressure sensation, squeezing)?

The character of the pain is usually nonspecific in children and does not help much in identifying the cause.

Although the classic description of cardiac pain in adults is that of pressure, crushing, or a squeezing sensation, it is uncertain whether this classic description is typical in pediatric cases.

How long does the pain last (seconds, minutes)?

What triggers the pain (e.g., exercise, eating, trauma, emotional stress)?

Chest pain precipitated by running or exercise may relate to cardiac disease or more commonly exercise-induced asthma.

Midsternal or precordial pain that worsens after eating or when lying down may be esophageal.

History of recent workouts, trauma, or fighting may point to the musculoskeletal system.

A recent stressful event may be an important clue to a psychogenic etiology of pain (after ruling out organic causes).

What makes the pain better or worse?

Pain that worsens with moving, deep breathing, or cough may suggest chest wall pain, pleural pain, or lung pathology.

Pain that improves by sitting up and leaning forward may be caused by pericarditis.

Are there associated symptoms, such as cough, fever, syncope, dizziness, or palpitation?

Pain associated with palpitation or syncope may suggest arrhythmia or other cardiac disease.

History of fever suggests an infectious process (e.g., pneumonia, myocarditis, pericarditis).

Has there been an injury while playing, or have the arms been used excessively for any reason?

Is there any important medical history, such as Kawasaki’s disease, asthma, sickle cell disease, diabetes, or Marfan’s syndrome (or other connective tissue disease)?

Is there a family history of heart disease, sudden death, or other conditions?

What treatments for the pain have been tried?

Past and Family Histories

After gaining some idea about the nature of the pain, the clinician should focus on important past and family histories. Examples of questions are as follows.
1. Does the child have any known medical conditions (e.g., congenital or acquired heart disease, cardiac surgery, infection, asthma)?
2. Is the child taking medicines, such as asthma medicines or birth control pills?
3. Has there been recent heart disease, chest pain, or a cardiac death in the family?
4. Does any disease run in the family?
5. What is the patient or family member concerned about?
6. Has the child been exposed to drugs (cocaine) or cigarettes?

**Physical Examination**

1. A careful general physical examination should be performed before the focus turns to the chest. The clinician should note whether the child is in severe distress from pain, is in emotional stress, or is hyperventilating.
2. The skin and extremities should be examined for trauma or chronic disease. Bruising elsewhere on the body may indicate chest trauma that cannot be seen.
3. The abdomen should be carefully examined because it may be the source of pain referred to the chest.
4. The chest should be carefully inspected for trauma and asymmetry. The chest wall should be palpated for signs of tenderness and subcutaneous air. Special attention should be paid to the possibility of costochondritis as the cause of chest pain, which is a quite common identifiable cause of the pain. Physicians should use the soft part of the terminal phalanx of a middle finger to palpate each costochondral and chondrosternal junction, not with the palm of a hand; using the palm may frequently miss the diagnosis. The pectoralis muscles and shoulder muscles should be examined for tenderness, which may be caused by excessive weightlifting or other work requiring the use of these muscles.
5. The heart and lungs should be auscultated for arrhythmias, heart murmurs, rubs, muffled heart sounds, gallop rhythm, crackles, wheezes, or decreased breath sounds.
6. Finally, the child’s psychological state should be assessed.

**Other Investigations**

If the three common causes or other identifiable causes of chest pain are not found by physical examination, the clinician should obtain chest radiographs and an ECG and direct his or her attention to the cardiac causes of chest pain listed in Table 30-2, which summarizes important history, physical findings, and abnormalities of chest x-ray films and ECGs for cardiac causes of chest pain.

1. Cardiac examination is done to detect a pathological heart murmur. One must be careful not to interpret commonly occurring innocent murmurs as pathologic.
2. Chest radiographs should be evaluated for pulmonary pathology, cardiac size and silhouette, and pulmonary vascularity.
3. A resting 12-lead ECG should be evaluated for cardiac arrhythmias, hypertrophy, conduction disturbances (including Wolff-Parkinson-White preexcitation), abnormal T and Q waves, and an abnormal QTc interval.
If the pain is nonexertional, the family history is negative for hereditary heart disease (e.g., long QT syndrome, cardiomyopathies, unexpected sudden death), the history is negative for heart disease or Kawasaki’s disease, the cardiac examination is unremarkable, and the ECG and chest radiographs are normal, the chest pain is not likely to be of cardiac origin unless palpitation or dizziness is a prominent accompanying symptom. At this point, the clinician can reassure the patient and family of the probable benign nature of the chest pain. If any of the above aspects are found, a formal cardiac consultation may be indicated. An echocardiographic examination is usually obtained by cardiologists and will most likely rule in or out cardiac causes of chest pain.

If a cardiac cause and the three common noncardiac causes of chest pain are not found, the pain is likely due to a condition in other systems, such as gastrointestinal or respiratory systems, including psychogenic or idiopathic origin. Simple follow-up may clarify the cause. Drug screening for cocaine may be worthwhile in adolescents who have acute, severe chest pain and distress with an unclear cause.

Referral to Cardiologists
The following are some of the indications for referral to a cardiologist for cardiac evaluation.
1. When the history reveals that chest pain is triggered or worsened by physical activities, the pain suggests anginal pain, or chest pain is accompanied by other symptoms such as palpitation, dizziness, or syncope.
2. When there are abnormal findings in the cardiac examination or when abnormalities occur in the chest radiographs or ECG, cardiology referral is clearly indicated. The examiner’s ability to recognize common innocent heart murmurs minimizes the frequency of such referrals.
3. When there is a positive family history for cardiomyopathy, long QT syndrome, sudden unexpected death, or other hereditary diseases commonly associated with cardiac abnormalities
4. High levels of anxiety in the family and patient and a chronic, recurring nature of the pain are also important reasons for referral to a cardiologist.

Management
When a specific cause of chest pain is identified, treatment is directed at correcting or improving the cause.
1. Costochondritis can be treated by reassurance and occasionally by nonsteroidal antiinflammatory drugs (NSAIDs, e.g., ibuprofen) or acetaminophen. Ibuprofen is better than acetaminophen because the former is an antiinflammatory agent and the latter is only analgesic.
   a. Ibuprofen 1 mg/kg three to four times a day for 7 days often improves the pain. The same course may be repeated two or three times with a 1-week period of no medicine in between the courses.
   b. The weight of backpacks should be reduced to a minimum.
c. Physical activities requiring the use of shoulder girdle muscles should be avoided, which may include sports using arms, push-ups, pull-ups, certain house chores, and others.

2. Most musculoskeletal and nonorganic causes of chest pain can be treated with rest, acetaminophen, or NSAIDs.

3. If respiratory causes of chest pain are found, treatment is directed at those causes. Referral to a pulmonologist should be considered.

4. Exercise-induced asthma is most effectively prevented by inhalation of a $\beta_2$-agonist 10 to 15 minutes before exercise. Inhaled albuterol usually affords protection for 4 hours. Other antiasthmatic agents have also been reported to be effective as well. Use of a muffler or cold weather mask to warm and humidify air before inhalation also is effective.

5. If gastritis, gastroesophageal reflux, or peptic ulcer disease is suspected, trials of antacids, hydrogen ion blockers, or prokinetic agents (e.g., metoclopramide [Reglan]) are helpful therapeutically (as well as diagnostically).

6. If serious cardiac anomalies, arrhythmias, or exercise-induced asthma is diagnosed, a referral is made to the cardiology or pulmonary service. Cardiac evaluation requires further specialized studies such as echocardiography, an exercise stress test, Holter monitoring, event recorder, or even cardiac catheterization or electrophysiologic study. Depending on the cause, treatment may be surgical or medical.

7. If organic causes of chest pain are not found and a psychogenic etiology is suspected, psychological consultation may be considered.

8. When cocaine-associated chest pain is suspected, one should follow the recent guidelines from the American Heart Association (McCord et al, 2008). If cocaine intoxication is suspected, benzodiazepines are recommended as the primary treatment for anxiety, tachycardia, and hypertension. Aspirin and nitrates continue to be strongly recommended. However, beta-blockers (including agents with mixed $\alpha$-adrenergic antagonist effects, such as labetalol) are considered contraindicated because the unopposed $\alpha$-adrenergic effect leads to worsening coronary vasoconstriction and increasing blood pressure. Calcium channel blockers are not recommended; they might increase mortality rates. Early percutaneous coronary intervention is indicated if myocardial infarction is likely the diagnosis.
Prevalence

The prevalence of syncope and near syncope in children is unknown, but it is estimated that as many as 15% of children and adolescents will have a syncopal event between the ages of 8 and 18 years. The incidence may be as high as 3% of emergency department visits in some areas. Before age 6 years, syncope is unusual except in the setting of seizure disorders, breath holding, and cardiac arrhythmias.
Definition

• Syncope is a transient loss of consciousness and muscle tone that result from inadequate cerebral perfusion.
• Presyncope is the feeling that one is about to pass out but remains conscious with a transient loss of postural tone. It is usually less serious than syncope and is often a manifestation of a benign condition.
• Dizziness is the most common prodromal symptom to the above. It is a nonspecific symptom that may include vertigo and lightheadedness. The patient may say “My head is spinning” or “The room is whirling” to describe vertigo (a manifestation of vestibular disorder). Lightheadedness often accompanies hyperventilation and is frequently associated with psychological distress, including anxiety, depression, and panic attacks.
• Although most of these complaints are benign in the pediatric age group, any of these complaints could represent a serious cardiac condition that could cause sudden death.

Causes

The normal function of the brain depends on a constant supply of oxygen and glucose. Significant alterations in the supply of oxygen and glucose may result in a transient loss or near loss of consciousness with manifestations of syncope, presyncope, or dizziness. The differential diagnosis of syncope is rather broad. It may be due to noncardiac causes (usually autonomic dysfunction), cardiac conditions, neuropsychiatric conditions, and metabolic disorders. Box 31-1 lists possible causes of syncope.

In contrast to adults, in whom most cases of syncope are caused by cardiac problems, in children and adolescents, most incidents of syncope are benign, resulting from vasovagal episodes (probably the most common cause), orthostatic intolerance syndromes, dehydration (or inadequate hydration), hyperventilation, and breath holding. However, the primary purpose of the evaluation of patients with syncope is to determine whether the patient is at increased risk for death.

In this chapter, only circulatory causes of syncope are discussed in some detail. Discussion of the metabolic and neuropsychiatric causes of syncope is beyond the scope of this book.

Noncardiac Causes of Syncope

Orthostatic Intolerance

Orthostatic intolerance encompasses disorders of blood flow, heart rate, and blood pressure (BP) regulation that are most easily demonstrable during orthostatic stress yet are present in all positions. Improved understanding of changes in these parameters is the result of the recently popularized head-up tilt test. Three easily definable entities of orthostatic intolerance include vasovagal syncope, orthostatic hypotension, and postural orthostatic tachycardia syndrome (POTS).
Causes of Syncope

Autonomic (Noncardiac)

Orthostatic intolerance Group
Vasovagal syncope (also known as simple syncope, neurocardiogenic syncope, or neutrally mediated syncope)
  Orthostatic (postural) hypotension (dysautonomia)
  Postural orthostatic tachycardia syndrome

Exercise-related syncope
Uncited

Situational syncope
Breath holding
  Cough, micturition, defecation, and so on
  Carotid sinus hypersensitivity

Excess vagal tone
Uncited

Cardiac

Arrhythmia
Tachycardia: SVT, atrial flutter or fibrillation, VT (seen with long QT syndrome, arrhythmogenic RV dysplasia, Brugada syndrome)
  Bradycardias: sinus bradycardia, asystole, complete heart block, pacemaker malfunction

Obstructive lesions
Outflow obstruction: AS, PS, hypertrophic cardiomyopathy, pulmonary hypertension
  Inflow obstruction: MS, tamponade, constrictive pericarditis, atrial myxoma

Myocardial
Coronary artery anomalies, hypertrophic cardiomyopathy, dilated cardiomyopathy, MVP, arrhythmogenic RV dysplasia.

Neuropsychiatric
Anxiety disorders: panic disorders, agoraphobia (fear of open space or uncontrollable social situations)
  Hyperventilation
  Seizure disorders
  Migraine
Vasovagal Syncope

Vasovagal syncope (also called simple fainting or neurocardiogenic or neurally mediated syncope) is the most common type of syncope in otherwise healthy children and adolescents. This syncope is uncommon before 10 to 12 years of age but quite prevalent in adolescent girls. It is characterized by a prodrome (warning symptoms and signs) lasting a few seconds to 1 minute; the prodrome may include dizziness, nausea, pallor, diaphoresis, palpitation, blurred vision, headache, or hyperventilation. The prodrome is followed by loss of consciousness and muscle tone. The patient usually falls without injury, the unconsciousness does not last more than 1 minute, and the patient gradually awakens. The syncope may occur after rising in the morning; after taking a morning shower; or in association with prolonged standing, anxiety or fright, pain, blood drawing or the sight of blood, fasting, hot and humid conditions, or crowded places. It may occur after prolonged exercise (if it is stopped suddenly).

The pathophysiology of vasovagal syncope is not completely understood. The following is a popular hypothesis (although dismissed by some). In normal individuals, an erect posture without movement shifts blood to the lower extremities and pelvis and causes a decrease in venous return, thus decreasing stroke volume and BP. This reduced filling of the ventricle places less stretch on the mechanoreceptor (i.e., C fibers) and causes a decrease in afferent neural output to the brain stem, reflecting hypotension. This decline in neural traffic from the mechanoreceptors and a decreased arterial pressure elicit an increase in sympathetic output, resulting in an increase in heart rate and peripheral vasoconstriction to restore BP to the normal range. Thus, the normal responses to the assumption of an upright posture are a reduced cardiac output (by 25%), an increase in heart rate, an unchanged or slightly diminished systolic pressure (Fig. 31-1), and an increase in diastolic pressure to ensure coronary artery perfusion. Cerebral blood flow decreases by approximately 6% with cerebrovascular autoregulation functioning near its
maximal limit.

FIGURE 31-1  Schematic drawing of changes in heart rate (HR) and blood pressure (BP) observed during the head-up tilt test. Thin arrows mark the start of orthostatic stress. Large unfilled arrows indicate the appearance of symptoms with changes seen in HR and BP. In normal individuals, the HR increases slightly with no change or a slight reduction in BP. In patients with vasovagal syncope, both the HR and BP drop precipitously with the appearance of symptoms. Postural hypotension is characterized by a drop in BP by 10 to 15 mm Hg as symptoms appear within 3 minutes of standing. Postural hypotension may not occur in the presence of good hydration. In POTS, the HR increases significantly by more than 30 beats/min (or the HR is 120 beats/min or higher) with development of symptoms within 10 minutes of standing. POTS, postural orthostatic tachycardia syndrome.

In susceptible individuals, however, a sudden decrease in venous return to the ventricle produces a large increase in the force of ventricular contraction; this causes activation of the left ventricular mechanoreceptors, which normally respond only to stretch (Fig. 31-2). The resulting paroxysmal increase in neural traffic to the brain stem somehow mimics the conditions seen in hypertension and thereby produces a paradoxical withdrawal of sympathetic activity and vagal activation. Withdrawal of sympathetic activity leads to a peripheral vasodilatation, hypotension, and bradycardia. Vagal activation results in bradycardia (see Fig. 31-2). Characteristically, the reduction of BP and especially the heart rate are severe enough to decrease cerebral perfusion, resulting in either presyncope or syncope (with loss of consciousness). Vasovagal syncope always occurs while the patient is in a standing position. Hypovolemia (or dehydration) is often a predisposing factor. “Stress” may also be a possible predisposing factor in the pathogenesis of syncope. With respect to the pharmacologic approach to prevent vasovagal syncope, α-adrenergic agonists, beta-blockers, serotonin reuptake inhibitors, anticholinergic muscarinic blockers, and volume expansion have been used successfully, and their presumed points of action are shown Figure 31-2.

History is most important in establishing the diagnosis of vasovagal syncope. Tilt testing of various protocols is useful in diagnosing vasovagal syncope, but it has not been well standardized, and its specificity and reproducibility are questionable.

Placing the patient in a supine position until the circulatory crisis resolves may be all that is indicated. If the patient feels the prodrome to a faint, he or she should be told to lie down with the feet raised above the chest; this usually aborts the syncope. Success in preventing syncope has been reported with medications, such as fludrocortisone.
Orthostatic Hypotension (Dysautonomia)

The normal response to standing is reflex arterial and venous constriction and a slight increase in heart rate. In orthostatic hypotension, the normal adrenergic vasoconstriction of the arterioles and veins in the upright position is absent or inadequate, resulting in hypotension without a reflex increase in heart rate (see Fig. 31-1). In contrast to the prodrome seen with vasovagal syncope, in orthostatic hypotension, patients experience only lightheadedness. Orthostatic hypotension is usually related to medication (see later discussion) or dehydration, but it can be precipitated by prolonged bed rest, prolonged standing, and conditions that decrease the circulating blood volume (e.g., bleeding, dehydration). Drugs that interfere with the sympathetic vasomotor response (e.g., calcium channel blockers, antihypertensive drugs, vasodilators, phenothiazines) and diuretics may exacerbate orthostatic hypotension. Dysautonomia may also be seen during an acute infectious disease or in peripheral neuropathies such as Guillain-Barré syndrome.

In patients suspected of having orthostatic hypotension, BP should be measured in the supine and standing positions. The American Autonomic Society has defined orthostatic hypotension as a persistent fall in systolic/diastolic pressure of more than 20/10 mm Hg.
within 3 minutes of assuming the upright position without moving the arms or legs with no increase in the heart rate but without fainting. Orthostatic hypotension may only be demonstrable in the presence of dehydration. In a well-hydrated state when the individual is seen in an office setting, orthostatic hypotension may not occur. Patients with orthostatic hypotension also have a positive tilt test result but do not display the autonomic nervous system signs of vasovagal syncope, such as pallor, diaphoresis, and hyperventilation.

The same management as that given for vasovagal syncope is sometimes successful. Elastic stockings, a high-salt diet, sympathomimetic amines, and corticosteroids have been used with varying degrees of success. The patient should be told to move to an upright position slowly.

**Postural Orthostatic Tachycardia Syndrome**

This relatively new syndrome is a form of orthostatic intolerance that is most often observed in young women. Venous pooling associated with assuming a standing position predominantly affects the lower extremities. This leads to a reduced venous return, a resulting increase in sympathetic discharge, and a significant degree of tachycardia. An increased level of adrenomedullin, a potent vasodilator with natriuretic and diuretic effects, has been observed in some children with the syndrome, possibly as a result of endothelial dysfunction (Zhang et al, 2012).

Patients with POTS experience difficulties with daily routines such as housework, shopping, eating, attending work or school, and complaints of chronic fatigue. Children (and adults) with the syndrome often have symptoms of syncope, dizziness, chest discomfort or pain, headache, palpitation, nausea, fatigue, and exercise intolerance. This may be related to chronic fatigue syndrome and may be misdiagnosed as having panic attacks or chronic anxiety. The general physical examination is often unrevealing.

For the diagnosis of POTS, heart rate and BP are measured in the supine, sitting, and standing positions. POTS is defined as the development of orthostatic symptoms that are associated with at least a 30-beat/min increase in heart rate (or a heart rate of ≥120 beats/min) that occurs within the first 10 minutes of standing or upright tilt. An exaggerated increase in heart rate is often accompanied by hypotension in association with the symptoms described above (see Fig. 31-1). Occasional patients develop swelling of the dependent lower extremities with purplish discoloration of the dorsum of the foot and ankle. Tilt table testing is often useful as a standardized measure of response to postural change.

The same approaches of management as vasovagal syncope are used with varying level of success. One should check if any medications the patient may be taking could be contributing to the problem (e.g., vasodilators, tricyclic antidepressants, monoamine oxidase inhibitors, or alcohol). The patient is advised to avoid extreme heat and dehydration and to increase salt and fluid intake. Pharmacologic agents such as fludrocortisone, midodrine (a peripheral vasoconstrictor, at a dose of 5–10 mg three times a day), or venlafaxine (a selective serotonin reuptake inhibitor) are useful in many patients.
Exercise-Related Syncope
Sudden unconsciousness that occurs during or after strenuous physical activities or sports may signal an organic cause such as cardiopulmonary diseases, including cardiac arrhythmia. However, in most cases, exercise-related syncope is not an indicator of serious underlying cardiopulmonary or metabolic disease. It occurs more often because of a combination of venous pooling in vasodilated leg muscles, inadequate hydration, and high ambient temperature. Hyperventilation with hypocapnia (with tingling or numbness of extremities) secondary to strenuous activities may also cause syncope. To prevent venous pooling, athletes should keep moving after running competitions.

Rare Causes of Syncope
Micturition syncope is a rare form of orthostatic hypotension. In this condition, rapid bladder decompression results in decreased total peripheral vascular resistance with splanchnic stasis and reduced venous return to the heart, resulting in postural hypotension.

Cough syncope occurs after paroxysmal nocturnal coughing in children with asthma. The patient's face become plethoric and cyanotic, and the child perspires, becomes agitated, and is frightened. Loss of consciousness is associated with muscle contractions lasting for several seconds. Urinary incontinence is frequent. Consciousness is regained within a few minutes. Paroxysmal coughing produces a marked increase in intrapleural pressure with a reduced venous return and reduced cardiac output, resulting in altered cerebral blood flow and loss of consciousness. Treatment is aimed at preventing bronchoconstriction with aggressive asthma treatment plans.

Cardiac Causes of Syncope
Cardiac causes of syncope may include obstructive lesions; myocardial dysfunction; and arrhythmias, including long QT syndrome and Brugada syndrome. A cardiac cause of syncope is suggested by the occurrence of syncope even in the recumbent position, syncope provoked by exercise, chest pain associated with syncope, a history of unoperated or operated heart disease, or a family history of sudden death.

Obstructive Lesions
Patients with severe obstructive lesions, such as aortic stenosis (AS), pulmonary stenosis (PS), or hypertrophic obstructive cardiomyopathy (HOCM), as well as those with pulmonary hypertension, may have syncope. Exercise often precipitates syncope associated with these conditions. Peripheral vasodilatation secondary to exercise is not accompanied by an adequate increase in cardiac output because of the obstructive lesion, which results in diminished perfusion to the brain. Patients may also complain of chest pain, dyspnea, and palpitation.

Myocardial Dysfunction
Although rare, myocardial ischemia or infarction secondary to congenital anomalies of the coronary arteries or acquired disease of the coronary arteries (e.g., Kawasaki’s disease or atherosclerotic heart disease) may cause syncope. Patients with dilated cardiomyopathy may have episodes of syncope associated with self-terminating episodes of ventricular tachycardia, which can lead to cardiac arrest. Syncope is a major risk factor for subsequent sudden cardiac death in hypertrophic cardiomyopathy, particularly if it is repetitive and occurs with exertion. Arrhythmogenic RV dysplasia often develops ventricular tachycardia caused by myocyte replacement by adipose tissue or fibrosis.

**Arrhythmias**

Either extreme tachycardia or bradycardia can decrease cardiac output and lower the cerebral blood flow below the critical level, causing syncope. The occurrence of syncope in the sitting or recumbent position suggests cardiac arrhythmias (or seizure) as the cause of syncope. Commonly encountered rhythm disturbances include supraventricular tachycardia (SVT), ventricular tachycardia, sick sinus syndrome, and complete heart block. Simple bradycardia is usually well tolerated in children, but the combination of tachycardia followed by bradycardia (overdrive suppression) is more likely to produce syncope. Arrhythmias may or may not be associated with structural heart defects.

**No identifiable structural defects.** Syncope from arrhythmias in children with structurally normal hearts may be seen in the following conditions.

1. Long QT syndrome is characterized by syncope caused by ventricular arrhythmias, prolongation of the QT interval on the electrocardiogram (ECG), and occasionally a family history of sudden death. Congenital deafness is also a component of Jervell and Lange-Nielsen syndrome but not of Romano-Ward syndrome.
2. Short QT syndrome.
3. Wolff-Parkinson-White (WPW) preexcitation may cause SVT.
4. Right ventricular (RV) dysplasia (RV cardiomyopathy) is a rare anomaly of the myocardium and is associated with repeated episodes of ventricular tachycardia (see Chapter 18).
5. Brugada syndrome is a rare cause of sudden death by ventricular arrhythmias, seen mostly in the Southeast Asian men. Syncope typically occurs at rest (90%). The ECG typically shows right bundle branch block with J-point elevation and concave ST elevation in V1.

**Structural heart defects.** The following congenital and acquired heart conditions, unoperated or operated, are associated with arrhythmias that may result in syncope.

1. Preoperative congenital heart defects (CHDs), such as Ebstein’s anomaly, mitral stenosis (MS), and mitral regurgitation (MR), and congenitally corrected transposition of the great arteries (L-TGA), may cause arrhythmias.
2. Postoperative CHDs may cause arrhythmias, especially after repairs of tetralogy of Fallot (TOF) and transposition of the great arteries (TGA) and after the Fontan operation. These children may have sinus node dysfunction (sick sinus syndrome), SVT or ventricular tachycardia, or complete heart block.
3. Dilated cardiomyopathy can cause sinus bradycardia, SVT, or ventricular tachycardia.
4. Hypertrophic cardiomyopathy is a rare cause of ventricular tachycardia and syncope.
5. Mitral valve prolapse (MVP) is an extremely rare cause of ventricular tachycardia.
Evaluation of a Child with Syncope

Most children who present with presyncope (without loss of consciousness) or even syncope have vasovagal phenomena or other benign causes of syncope. However, the goal of the evaluation of a patient with syncope (or presyncope) is to identify high-risk patients with underlying heart disease, which may include ECG abnormalities (such as seen in long QT syndrome, WPW preexcitation, Brugada syndrome), cardiomyopathy (hypertrophic or dilated), or structural heart diseases. The evaluation of pediatric patients with syncope may extend to other family members when a genetic condition is suspected or identified.

History

Because physical examinations of patients are almost always normal long after the event, accurate history taking is most important in determining a cost-effective diagnostic workup for each patient. Sometimes a complete history cannot be obtained owing to amnesia about the event, but witness accounts are useful. The following are some important aspects of history taking.

1. About the syncopal event
   a. The time of the day
      • Syncope occurring after rising in the morning or after morning shower suggests vasovagal syncope.
      • Hypoglycemia is a very rare cause of syncope, occurring in a fasting state in the morning.
   b. The patient’s position (supine, standing, or sitting)
      • Syncope while sitting or recumbent suggests arrhythmias or seizures.
      • Syncope after standing for some time suggests orthostatic intolerance group, including vasovagal syncope.
   c. Relationship to exercise
      • Syncope occurring during exercise suggests arrhythmias.
      • Syncope occurring immediately after cessation of physical activities suggests venous pooling in the leg (with reduced venous return and cardiac output).
      • Estimating vigorousness and duration of the activity, relative hydration status, and ambient temperature at the time of syncope is important.
   d. Associated symptoms sometimes are helpful in suspecting the cause of syncope.
      • Palpitation or a racing heart rate suggests tachycardia or arrhythmias.
      • Chest pain suggest possible myocardial ischemia (e.g., obstructive lesions, cardiomyopathy, carditis).
      • Shortness of breath or tingling or numbness of the extremities suggests hyperventilation.
      • Nausea, epigastric discomfort, and diaphoresis suggest vasovagal syncope.
      • Headache or visual changes suggest vasovagal syncope.
   e. The duration of syncope
• A syncopal duration less than 1 min suggests vasovagal syncope, postural hypotension, or hyperventilation.
• A longer duration of syncope suggests convulsive disorders, migraine, or arrhythmias.
  f. The patient’s appearance during and immediately after the episode
  • Pallor indicates hypotension.
  • Abnormal movement or posturing, confusion, focal neurologic signs, amnesia, or muscle soreness suggests the possibility of seizure.

2. History of a cardiac, endocrine, neurologic, or psychological disorders may suggest a disorder in that system.
3. Medication history, including prescribed, over-the-counter, and recreational drugs, should be checked.
4. Family history should include:
   a. Coronary heart disease risk factors, including history of myocardial infarction in family members younger than 30 years of age
   b. Cardiac arrhythmia, CHD, cardiomyopathies, long QT syndrome, seizures, metabolic and psychological disorders
   c. A positive family history of fainting is common in patients with vasovagal syncope.
5. Social history is important in assessing whether there is a possibility of substance abuse, pregnancy, or factors leading to a conversion reaction.

**Physical Examination**

Although the results of the physical examination are usually normal, a complete physical examination should always be performed, focusing on the patient’s cardiac and neurologic status.
1. If orthostatic intolerance group is suspected, the heart rate and BP should be measured repeatedly while the patient is supine and after standing without moving for up to 10 minutes. In a well-hydrated state, positive test results for vasovagal syncope or postural hypotension in the office setting are uncommon.
2. Careful auscultation is carried out to detect a heart murmur or an abnormally loud second heart sound.
3. Neurologic examination should include a funduscopic examination, test for Romberg’s sign, gait evaluation, test of deep tendon reflexes, and test of cerebellar function.

**Diagnostic Studies**

History and physical examinations guide practitioners in choosing the diagnostic tests that apply to a given patient with syncope. A complete cardiac evaluation is indicated if there is a heart murmur, a family history of sudden death or cardiomyopathy, or an abnormal ECG finding.
1. Serum glucose and electrolytes is of limited value because the patients are seen hours or days after the episode.
2. In suspected cases of arrhythmia as the cause of syncope, the following may be
a. **ECG:** All patients presenting with syncope should have an ECG. The ECG should be inspected for heart rate (bradycardia), arrhythmias, WPW preexcitation, heart block, and long QTc interval, as well as abnormalities suggestive of cardiomyopathies and myocarditis.

b. **Ambulatory ECG monitoring:** A correlation between the patient’s symptoms and a diagnostic arrhythmia confirms the arrhythmic cause of syncope. Symptoms without arrhythmia probably exclude an arrhythmic cause of syncope.
   1. A Holter monitor usually records ECG for up to 24 hours.
   2. Loop memory event recorders with extended monitoring (usually for 1 month) may increase the diagnostic yield.
   3. A nonlooping event recorder can be used for symptoms lasting for a few minutes (usually for a month).
   4. An implantable loop recorder (implanted in the left pectoral region) is a device that can be used to record ECGs for a period much longer than 1 month.

c. **Exercise stress test:** If the syncopal event is associated with exercise, a treadmill exercise stress test should also be performed with full ECG and BP monitoring (see Chapter 6, Noninvasive Techniques).

3. **Echocardiographic studies:** These studies identify structural abnormalities that can cause of syncope and chest pain. Identifiable structural causes include severe obstructive lesions (e.g., AS, PS, HOCM), pulmonary hypertension, certain CHDs (Ebstein’s anomaly, mitral stenosis or regurgitation, L-TGA), and the status of postoperative CHDs (e.g., TOF, TGA, Fontan operation).

4. **Head-up tilt table test:** If patients with syncope have autonomic symptoms (e.g., pallor, diaphoresis, or hyperventilation), tilt table testing is useful (see subsequent section for full discussion).

5. **Cardiac catheterization and electrophysiologic testing** may rarely be indicated in some equivocal cases. Because of the low yield of electrophysiologic testing in patients without underlying heart disease, this test is not routinely recommended in such cases.

6. **Neurologic consultation:** Patients exhibiting prolonged loss of consciousness, seizure activity, and a postictal phase with lethargy or confusion should be referred for neurologic consultation and electroencephalography. Without the above history, the reported positive yield of electroencephalography or imaging studies is very low.

   **Head-up tilt table test:** The goal of tilt table testing is to provoke the patient’s symptoms exactly during orthostatic stress while being closely monitored, with demonstration of the cardiac rhythm and rate and BP responses associated with symptoms. Orthostatic stress is created by a tilting table with the patient placed in an upright position to obtain the necessary pooling of blood to the lower extremities.

   Patients lie supine on an electric tilt table and have an intravenous line established. ECG monitoring and automated BP measurements are performed. Some laboratories perform autonomic challenge test, which includes deep breathing to accentuate sinus arrhythmia, carotid massage (not done in adults, especially elderly adults), Valsalva maneuver, and the application of ice to the face to induce the “diving reflex.” Patients are
then tilted into the 60- to 80-degree head-up position for a period of up to 30 minutes. These patients remain upright, with recording of BP every 1 or 2 minutes and continuous heart rate and rhythm monitoring. If a patient becomes symptomatic or the 30-minute time elapses, the tilt table is immediately returned to the supine position. If the tilt test alone result is not positive, the procedure is repeated with an infusion of isoproterenol, starting at \(0.02\ \mu g/kg\) per minute and increasing to \(1\ \mu g/kg\) per minute for 15 minutes. The use of isoproterenol in the evaluation of patients with vasovagal syncope remains somewhat controversial. Some believe that responses to isoproterenol are nonspecific. Positive responses commonly include lightheadedness, dizziness, nausea, visual changes, and frank syncope. Sinus bradycardia, junctional bradycardia, and asystole for as long as 30 seconds are common. Hypotension generally is manifested by systolic BPs of less than 70 mm Hg, with frequently immeasurable diastolic BPs. Returning these patients to the supine position produces resolution of symptoms rapidly, with a return of normal sinus rhythm, usually with a reactive tachycardia. Patients frequently comment that they “had a spell” and that they feel tired and weak.

Several distinct abnormal patterns have been identified after head-up tilt table tests (see Fig. 31-1).
1. **Vasovagal:** An abrupt decrease in BP usually with bradycardia
2. **Dysautonomia (or postural hypotension):** A gradual decrease in BP leading to syncope
3. **POTS:** An excessive heart rate increase to maintain an adequate BP to prevent syncope

After a positive tilt test result, many laboratories begin a therapeutic trial of a short-acting beta-blocker, such as an esmolol infusion, and repeat the tilt test. If the patient does not become symptomatic during the tilt test, an oral beta-blocker is prescribed (see subsequent discussion). If the patient is again symptomatic, he or she is tested with infusion of an \(\alpha\)-agonist (phenylephrine) with a repeat tilt table test. Finally, the patient is tested with a bolus of 1 L of normal saline. If the patient remains asymptomatic during the test, the patient is treated with volume expansion therapy using a mineralocorticoid (Florinef) and salt supplementation (see later discussion).

There are, however, serious questions about the sensitivity, specificity, diagnostic yield, and day-to-day reproducibility of the tilt test. In adults, the overall reproducibility of syncope by the tilt test is disappointingly low (62%), which causes doubt about the specificity of the test for diagnosis and the validity of evaluating the effect of oral drug treatment by a repeat tilt test. About 25% of adolescents with no prior fainting history fainted during the tilt test. Moreover, among habitual fainters, 25% to 30% did not faint during the test on a given day.
Treatment

The same preventive measures are used for all orthostatic intolerance group of conditions. Beginning the therapy empirically without performing a head-up tilt table test is not unreasonable. Most patients show spontaneous resolution of syncope in 6 to 12 months; therefore, long-term medical prophylaxis is usually not necessary.

Orthostatic Intolerance Syndromes (including vasovagal syndrome)

1. Maintaining adequate intravascular volume is the most important element in the prevention of syncope.
   a. The patient is recommended to drink 60 to 90 oz of water a day. Physical activities, especially in a hot environment, require much more fluid intake, preferably electrolyte-containing fluids (e.g., Gatorade).
   b. Drinking “sport drinks” with additional sodium is an option.
   c. Liberal use of salt with meals and nonfatty salted snacks (e.g., pretzels, popcorn without butter) are recommended.
   d. Caffeinated beverages should be avoided (because of their renal diuretic effect).
   e. Wearing elastic support hose (waist high) is useful in some patients with postural hypotension.

2. Success in preventing syncope has been reported with the following medications. Their mechanism of action is shown in Figure 31-2.
   a. Fludrocortisone (Florinef), a mineralocorticoid, increases intravascular volume and also produces both venous and arterial vasoconstriction. It can be given in a low dosage (0.1 mg by mouth once or twice a day; adult dose ≈0.2 mg/day) with increased salt intake or a salt tablet (1 g daily). Average preadolescents or adolescents commonly gain 1 or 2 kg of water weight into their circulating volume within 2 or 3 weeks. The increased vascular volume allows these patients to maintain cerebral BP despite the normal episodic parasympathetic-mediated venodilatation.
   b. Beta-blocker therapy is used commonly, especially in adolescents and young adults, to modify the feedback loop. Atenolol (1–1.2 mg/kg/day orally every day; maximum dose, 2 mg/kg/day) and metoprolol (1.5 mg/kg/day given orally in two or three doses) are most commonly used.
   c. α-Agonist therapy using pseudoephedrine or an ephedrine–theophylline combination (Marax) stimulates the heart rate and increases the peripheral vascular tone, preventing reflex bradycardia and vasodilation. Pseudoephedrine, 60 mg, given orally twice a day, has been reported to be beneficial in some older children and adolescents.

3. Less commonly used medications include:
   a. Disopyramide 150 mg three times a day orally has been reported to be effective in mostly adult patients with severe cases of vasovagal syncope. Disopyramide may owe its beneficial effects to its negative inotropic properties, vasoconstricting action,
and anticholinergic action.
b. The efficacy of serotonin agonists (sertraline [Zoloft]) has also been described in the
treatment of patients with refractory syncope.
4. Cardiac Pacemaker. Beneficial effects of an implanted pacemaker for vasovagal
syncope have been reported by some investigators but not by others. It is generally not
indicated in pediatric patients. In a recent double-blind, randomized trial in adult
patients, recurrent syncope still occurred; even though the pacemaker maintained the
heart rate, BP dropped, and symptoms still occurred (Connolly et al, 2003).

Cardiac Arrhythmias
Patients with primary cardiac arrhythmias presenting as syncopal events may require
antiarrhythmic medications. Most arrhythmias respond to antiarrhythmic therapy.
Patients with long QT syndrome are treated with beta-blockers, pacemakers, or
implantable cardioverter-defibrillators (see Chapter 24). Propranolol or other
antiarrhythmic drugs may be indicated in patients with symptomatic MVP syndrome.
Occasionally, catheter ablation may be indicated in some patients (e.g., in patients with
WPW syndrome causing frequent SVT).
Differential Diagnosis

A thorough history taking usually directs the physician to the correct diagnosis and thereby reduces the number of unnecessary tests.

**Epilepsy.** Patients with epilepsy may have incontinence, marked confusion in the postictal state, and abnormal electroencephalograms. Patients are rigid rather than limp and may have sustained injuries. Patients do not experience the prodromal symptoms of syncope (e.g., dizziness, pallor, palpitation, diaphoresis). The duration of unconsciousness is longer than that typically seen with syncope (<1 minute).

**Hypoglycemia.** Hypoglycemia has characteristics similar to syncope, such as pallor, perspiration, abdominal discomfort, lightheadedness, confusion, unconsciousness, and possible subsequent occurrence of seizures. However, hypoglycemic attacks differ from syncope in that the onset and recovery occur more gradually, they do not occur during or shortly after meals, and the presyncopal symptoms do not improve in the supine position.

**Hyperventilation.** Hyperventilation is believed to produce hypocapnia, resulting in intense cerebral vasoconstriction, and causes syncope. A recent study, however, demonstrates that hyperventilation alone is not sufficient to cause syncope, suggesting that it may also have a psychological component. A typical spell usually begins with an apprehensive feeling and “deep sighing respirations” that the patient rarely notices. The patient often experiences air hunger, shortness of breath, chest tightness, abdominal discomfort, palpitations, dizziness, numbness or tingling of the face and extremities, and rarely loss of consciousness. It often is associated with emotional disturbances. The supine position may help the patient relax and may stop the anxiety–hyperventilation cycle. The syncopal episode can be reproduced in the office when the patient hyperventilates.

**Hysteria.** Syncope resulting from hysteria is not associated with injury and occurs only in the presence of an audience. A teenager may be able to give an accurate presyncopal history, but during these attacks, he or she does not experience the pallor and hypotension that characterize true syncope. The attacks may last longer (up to 1 hour) than a brief syncopal spell. Episodes usually occur in an emotionally charged setting and are rare before 10 years of age. Spells are not consistently related to postural changes and are not improved by the supine position.
Palpitation
Definition

Palpitation is an unpleasant subjective awareness of one’s own heartbeats. This usually occurs as a sensation in the chest of rapid, irregular, or unusually strong heartbeats. The patient describes it as pounding, jumping, racing, irregularity of the heartbeat, a “flip flopping” or “rapid fluttering” in the chest, or pounding in the neck. Palpitation can be felt in the chest, throat, or neck. The pulse rate may become faster or rarely slower than normal. The term *palpitation* is used so loosely that specific questions must be asked to determine the exact nature of the symptom.
Causes

Palpitation is one of the most common cardiac symptoms encountered in medical practice, but it poorly corresponds to demonstrable abnormalities. Many palpitations are not serious. However, palpitation may indicate the possible presence of serious cardiac arrhythmias.

Box 32-1 lists causes of palpitation. The differential diagnosis can range from benign etiologies to life-threatening arrhythmias.

- A high percentage of patients with palpitation have no cause that can be established.
- Caffeine, a common stimulant, is found in many foods and drinks, such as coffee, tea, hot cocoa, soda, chocolate, and some medicines. Most energy drinks (e.g., Venom, Whoopass, Red Bull, Adrenalin Rush), which are the latest popular fad among youth, contain large doses of caffeine and other legal stimulants, including ephedrine, guarana, taurine, and ginseng.
- Certain drugs and substances can be identified as causes of palpitation.
- Some medical conditions, such as hyperthyroidism, anemia, and hypoglycemia, may be the cause of palpitation.
- Although relatively rare, cardiac arrhythmias and structural heart disease should be looked into as a cause of palpitation. However, most palpitations are not accompanied by arrhythmias, and most arrhythmias are not perceived and reported as palpitations.
- Rarely, slow heart rates may cause palpitation.
- Occasionally, a psychogenic or psychiatric cause for the symptoms can be suspected. Some adult patients and adolescents with palpitations have panic disorder or panic attack. Panic attack and arrhythmias may be difficult to distinguish clinically because both may present as palpitations, shortness of breath, and lightheadedness.
Evaluation

History

In a child who is old enough to provide a detailed history, careful history taking often suggests possible causes. Palpitation usually occurs without other symptoms. However, the presence of additional symptoms such as dizziness, fainting, nausea, sweating, chest pain, shortness of breath, and so on may be more significant.

1. The nature and onset of palpitation may suggest causes.
   a. Isolated “jumps” or “skips” suggest premature beats.
   b. A sudden start and stop of rapid heartbeat or a pounding of the chest suggests supraventricular tachycardia (SVT). Some children appear sweaty or pale with SVT.

---

**BOX 32-1  Causes of Palpitation**

**Normal Physiologic Events**
- Exercise, excitement, fever

**Psychologic or Psychiatric**
- Fear, anger, stress, anxiety disorders, panic attack or panic disorder

**Certain Drugs and Substances**
- Stimulants: caffeine (coffee, tea, soda, chocolate), some energy drinks, smoking.
- Over-the-counter drugs: decongestants, diet pills, and so on
- Drugs that cause tachycardia: catecholamines, theophylline, hydralazine, minoxidil, cocaine
- Drugs that cause bradycardia: beta-blockers, antihypertensive drugs, calcium channel blockers
- Drugs that cause arrhythmias: antiarrhythmics (some of which are proarrhythmic), tricyclic antidepressants, phenothiazines

**Certain Medical Conditions**
- Anemia
- Hyperthyroidism
- Hypoglycemia
- Hyperventilation
- Poor physical condition

**Heart Diseases**
- Certain congenital heart defects that are prone to arrhythmias or that result in a poor physical condition
- After surgeries for congenital heart disease: Fontan connection, Senning operation
- Mitral valve prolapse
- Hypertrophic cardiomyopathy
- Dilated cardiomyopathy
- Valvular disease: aortic stenosis
- Cardiac tumors or infiltrative diseases

**Cardiac Arrhythmias**
- Tachycardia
- Bradycardia
- Premature atrial contractions
- Premature ventricular contractions
- Supraventricular tachycardias
- Ventricular tachycardias
- Atrial fibrillation
- Wolff-Parkinson-White preexcitation
- Sick sinus syndrome
c. A gradual onset and cessation of palpitation suggest sinus tachycardia or anxiety state.
d. When the rate is known to be normal and the rhythm is regular, an anxiety state is the cause.
e. Palpitation characterized by slow heart rate may be caused by atrioventricular (AV) block or sinus node dysfunction.

2. Relationship to exertion:
   a. A history of palpitation during strenuous physical activity may be a normal phenomenon (caused by sinus tachycardia), although it could also be caused by exercise-induced arrhythmias.
   b. Nonexertional palpitation may suggest atrial flutter or fibrillation, febrile state, thyrotoxicosis, hypoglycemia, or anxiety state.
   c. A rapidly developing palpitation, although not abrupt, unrelated to exertion or excitement, may occur with hypoglycemia or tumor of adrenal medulla.
   d. Palpitation on standing suggests postural hypotension (or orthostatic intolerance).

3. Associated symptoms:
   a. Symptoms of dizziness or fainting associated with palpitation may indicate ventricular tachycardia.
   b. The presence of other symptoms, such as chest pain, sweating, nausea, or shortness of breath, maybe more significant and may increase the likelihood of identifiable causes of palpitation.

4. Personal and family history may help identify the cause.
   a. Ask about eating and drinking habits, such as sodas, coffee, tea, hot cocoa, and chocolates, which contain caffeine.
   b. Ask if the patient is taking energy drinks.
   b. Ask about prescription and over-the-counter medications that could cause palpitation.
   c. Ask about medical or heart conditions that may cause tachycardia or palpitation (listed in Box 32-1).
   d. Ask about family history of syncope, sudden death, or arrhythmias.

Physical Examination
1. Most children with palpitation have normal physical examinations except for those with hyperthyroidism.
2. Cardiac examination may reveal findings of mitral valve prolapse (MVP), obstructive lesions, or possibly cardiomyopathy.

Recording of Electrocardiography Rhythm
Recording of electrocardiography (ECG) rhythm that coincides with the timing of the
patient’s complaint of palpitation is a certain way of making a diagnosis of arrhythmia or ruling it out as the cause of palpitation. A number of different ECG recording techniques are available.

1. Routine ECG during office visit: Check for prolonged QTc interval, delta waves (Wolff-Parkinson-White preexcitation), and AV block.
2. When palpitation occurs almost daily, especially when associated with symptoms, 24-hour Holter monitoring is usually most helpful in making the diagnosis of the rhythm abnormality. This may clarify the diagnosis and secure management plans. Some children actually complain of palpitation during sinus tachycardia.
3. When palpitation occurs infrequently, long-term event monitor recording (up to 30 days) is indicated. With infrequent palpitations that are fairly long lasting, handheld or patient-activated event recorders are indicated. However, with infrequent short-lasting palpitation, external loop recorders are indicated.
4. Implantable loop recorder (inserted under the skin at about the second rib on the left front of the chest) can be used to monitor for a period longer than 1 month (may be up to 1 year). This can be worn during swimming or other vigorous exercises.
5. Continuous outpatient telemetry monitoring is a new monitoring modality available at most tertiary care facilities. The patient is fitted with a transmitter that sends the ECG data to the area of hospital where the telemetry monitoring occurs. The patient can move around within the device’s transmitting range.
6. If the symptoms occur during exercise, an exercise stress test may be helpful in making the diagnosis.
7. If there is a high suspicion of ventricular tachycardia, sometimes provocative electrophysiologic studies may be indicated.

**Echocardiography**

Echocardiography studies help identify possible structural heart disease that may cause arrhythmias, such as hypertrophic cardiomyopathy, dilated cardiomyopathy, cardiac tumors, MVP, and other structural abnormalities of the heart.

**Laboratory Studies**

When other medical conditions are suspected as a cause of palpitation, a complete blood count (for anemia), electrolytes, blood glucose, and thyroid function testing may be indicated.
1. If the rhythm recorded on the 24-hour Holter monitoring shows sinus tachycardia during the complaint of palpitation, all one has to do is to reassure the parent and child of the normal, benign nature of palpitation. Some parents are unaware of the fact that children’s heart rates are faster than adults’ heart rates and that children’s heartbeats are easily palpable when they place their palms over the child’s chest.

2. For isolated premature atrial contractions or premature ventricular contractions, nothing needs to be done except to avoid stimulants such as caffeine, excessive amounts of soda, or energy drinks. If they are so frequent that they are a hindrance to normal daily living, a beta-blocker could be tried.

3. When a significant cardiac arrhythmia or an AV conduction disturbance is the suspected cause of palpitation, further evaluation and therapy are guided by recommendations discussed in Chapters 24 and 25.

4. Examination of all medications that the patient is taking may be helpful in the diagnosis and in modifying the dosage or schedule or changing it to other medications.

5. If palpitation is associated with symptoms, such as fainting, dizziness, chest pain, pallor, or diaphoresis, further evaluation is guided as described in Chapters 30 and 31.
Dyslipidemia and Other Cardiovascular Risk Factors

Atherosclerotic cardiovascular (CV) disease is a major cause of morbidity and mortality and is responsible for more than 50% of all the deaths in the United States and other Western countries. The best and longest known risk factor for coronary artery disease (CAD) is hypercholesterolemia. Other types of dyslipidemia, obesity, smoking, hypertension, and diabetes mellitus are among the known CV risk factors. Although most of the clinical burden of CV disease occurs in adulthood, these risk factors can develop during childhood and adolescence. In fact, there is now clear evidence that atherosclerosis begins during childhood. To reduce CV death, we need to turn our attention to preventing and correcting these risk factors before adulthood when atherosclerotic processes may have progressed too far to be reversible by therapy.

Unfortunately, the importance of preventing heart disease in the pediatric population is not well perceived by pediatricians and pediatric cardiologists. When pediatricians and pediatric cardiologists are asked about heart disease in children, they think about congenital heart defects (CHD). Although CHD is associated with the highest mortality rate of any congenital defects, only 0.4% of deaths from CV diseases are caused by CHDs in the United States. The great majority of CV death is from CAD (54%), stroke (18%), congestive heart failure (6%), and hypertension (5%) (Lauer et al, 2006). Therefore, preventive cardiology is and should be in the pediatric domain. The primary purpose of this chapter is to raise physicians’ attention to the emerging importance of practicing medicine to prevent future CV disease (and type II diabetes) during childhood.

The strongest CV risk factors include a high concentration of low-density lipoprotein (LDL) cholesterol and triglycerides, a low concentration of high-density lipoprotein (HDL), elevated blood pressure, diabetes mellitus, cigarette smoking, and obesity. The prevalence of obesity has increased rapidly in recent decades, which is now known to be an independent risk factor for CV disease and diabetes. Obesity is often associated with other CV risk factors such as atherogenic dyslipidemia. Therefore, early detection and treatment of dyslipidemias and obesity during childhood and adolescence may help reduce CV mortality and morbidity in adulthood.

This chapter discusses the following topics in the order listed below. Hypertension, another CV risk factor, is discussed in a separate chapter (Chapter 28).
1. Evidence of childhood onset of atherosclerotic heart disease
2. Identification of standard CV risk factors and the diagnosis of metabolic syndrome in children
3. In-depth discussion of dyslipidemia in children, including lipid screening and diagnosis and treatment of dyslipidemia. Dyslipidemia includes hypercholesterolemia, hypertriglyceridemia, and low HDL cholesterol.
4. Diagnosis and principles of management of childhood obesity
5. Strategies for smoke cessation
6. The summary table of the American Heart Association (AHA) Guidelines on practice of pediatric preventive cardiology
Atherosclerotic lesions start to develop in early childhood and progress to irreversible lesions in adolescence and adulthood. The strongest evidence of childhood onset of CAD comes from the Bogalusa Heart Study (Berenson et al, 1998) and the Pathological Determinants of Atherosclerosis in Youth (PDAY) Research Group (Strong et al, 1995; McGill et al, 2002). Autopsy studies of the aorta and coronary arteries in the youth after unexpected deaths in the Bogalusa Heart Study and in the study by the PDAY Research Group have found that atherosclerosis originates in childhood, with a rapid increase in the prevalence of coronary pathology during adolescence and young adulthood.

These studies have found the following:
1. Fatty streak, the earliest lesion of the atherosclerosis, occurred by 5 to 8 years of age, and fibrous plaque, the advanced lesion, appeared in the coronary arteries in subjects in their late teens.
2. Fibrous plaque was found in more than 30% of 16- to 20-year-old patients, and the prevalence of the lesion reached nearly 70% by age 26 to 39 years.
3. The extent of pathological changes in the aorta and coronary arteries increased with age and so did the number of known CV risk factors that the individual had at the time of death.

Therefore, one strategy of reducing CAD in adults is to prevent or correct CV risk factors in children and adolescents.
Box 33-1 lists major risk factors for CV disease, according to the Third Report of the National Cholesterol Education Program (NCEP) (Circulation, 2002).

Cardiovascular risk factors include a positive family history of coronary heart disease, smoking, high levels of cholesterol, hypertension, being overweight, smoking, and diabetic or prediabetic states. These risk factors are all associated with an increased prevalence and extent of atherosclerosis. Obtaining a history of these CV risk factors should be a routine process in the practice of medicine.

A family history of premature CAD in first-degree relatives (parents and siblings) has been found to be the single best predictor of CV risk for adults. For children, however, family history includes the first- and second-degree relatives (including parents, siblings, grandparents, or blood-related aunts and uncles) who have or had CAD before age 55 years for boys and before age 60 years for girls. The reason that the second-degree relatives are included in family history for children is because some children’s parents are too young to have developed clinical CAD when their children are examined.

The relationship between obesity and CAD has been a subject of some dispute for many years. However, more recent studies have shown that obesity is a risk factor for CAD independently of the standard risk factors, probably through the emerging risk factors. The emerging risk factors, which are commonly found in obese persons, include atherogenic dyslipidemia (also known as the “lipid triad” consisting of raised level of triglycerides; small, dense LDL particles; and low levels of HDL-C), insulin resistance (hyperinsulinemia), a proinflammatory state (elevation of serum high-sensitivity C-reactive protein [CRP]), and a prothrombotic state (increased amount of plasminogen activator inhibitor-1 [PAI-1]).

**BOX 33-1**  
**Major Risk Factors for Coronary Heart Disease**

- Family history of premature coronary heart disease, cerebrovascular or occlusive peripheral vascular disease (with onset before age 55 years for men and 65 years for women in parents or grandparents)
  - Cigarette smoking
  - Hypercholesterolemia
  - Hypertension (blood pressure >140/90 mm Hg or on antihypertensive medication)
  - Low levels of high-density lipoprotein (<40 mg/100 mL)
  - Diabetes mellitus (as a coronary heart disease risk equivalent)

The cluster of the above risk factors occurring in one person is known as “the metabolic syndrome.” In the metabolic syndrome, LCL-C levels may not be elevated, but apoprotein B (apo B) and small, dense LDL particles are elevated; the smallest particles in the LDL fraction are known to have the greatest atherogenicity (see a later section for further discussion on small, dense LDL particles). This syndrome occurs more commonly in individuals with abdominal (visceral) obesity. The exact mechanism for the role of visceral adiposity is not completely understood, but it appears to be closely related to insulin resistance. It has been assumed that obese adipose tissue releases an excess of fatty acids and cytokines that induce insulin resistance. With increasing adiposity, the lipid triad becomes more pronounced. Hispanics and South Asians seem to be particularly susceptible to the syndrome. Black men have a lower frequency of the syndrome than do white men, likely because of a lower prevalence of atherogenic dyslipidemia.

Clinically identifiable components of the metabolic syndrome for adults are listed in Box 33-2. The presence of at least three of the risk factors is required to make the diagnosis of the metabolic syndrome in adults. Evidence has supported that waist circumference (WC) (reflecting visceral adiposity) is a better predictor of CV disease than body mass index (BMI). Although LCL-C may not be elevated, small, dense LDL particles present in this syndrome are highly atherogenic. Other components of metabolic syndrome, such as proinflammatory and prothrombotic states, are not routinely measured in clinical practice. CRP of 3 mg/L or above may be significant in adults.

A direct association between obesity and insulin resistance also exists in children. Several definitions for use in the clinical setting for diagnosis of the metabolic syndrome in children exist. One in particular, Cook and coworkers’ (Cook et al, 2003) definition, includes triglycerides of 110 mg/dL or above and fasting glucose of 110 mg/dL or above. On the other hand, the International Diabetes Federation (2007) has proposed different cutoff points for these two, 150 mg/dL or above for triglycerides and 100 mg/dL or above for fasting glucose. The triglyceride level of 150 mg/dL is more appropriate according to more recent NHANES (National Health and Nutrition Examination Survey) data (collected between 1988 and 2002); the 90th percentile of triglyceride is much higher than 110 mg/dL (Jolliffe, 2006). Note that the new values for triglycerides and fasting glucose proposed by International Diabetes Federation are the same as in adults (see Box 33-2).

As in adults, the presence of at least three of the risk factors is required to make the diagnosis of the metabolic syndrome in children. It is important to note that LDL-cholesterol (LDL-C) levels may not be elevated, but this is because the LDL is mostly made up by small, dense LDL particles, which are much more atherogenic than large LDL particles. The prevalence of the metabolic syndrome in adolescents has been reported to be about 4%, but it increases to 30% to 50% in overweight adolescents (Singh, 2006).

**BOX 33-2** Definitions of the Metabolic Syndrome in...
As in adults, WC is preferable to BMI for children as well, which represents abdominal (visceral or central) obesity. Ethnicity- and gender-specific WC percentiles are now available for children from the NHANES III (Fernandez et al, 2004) (see Tables C-1 through C-3, Appendix C). There are significant differences in WC according to ethnicity and gender. In general, Mexican American boys and girls have higher WCs than other ethnic groups. Note that the 75th percentile of WC of African American and Mexican American girls 16 and 17 years old exceed the WC values of 88 cm (35 inches) identified as the cutoff point for increased risk of obesity-related comorbidities in women.

The mainstay of the treatment of the metabolic syndrome for both adults and children is weight control through dietary intervention and promotion of an active lifestyle to achieve and maintain optimum weight, normal blood pressure, and normal lipid profile for age. The pharmacologic intervention is usually not required in children, but drugs may be used in selected high-risk patients. Each component of the syndrome present should be treated aggressively because the presence of the syndrome indicates a higher risk for CV diseases and diabetes.

Metformin (Glucophage) therapy may be effective in preventing or delaying the development of type 2 diabetes in patients with the metabolic syndrome. In conjunction with low-intensity weight control efforts, 6 months of metformin therapy has shown modest but favorable effects on the features of the syndrome, including reduction of weight, BMI, body fat mass (but not intraabdominal adipose tissue), and total cholesterol levels. It also improved fasting plasma glucose and insulin resistance (Yanovski et al, 2011). The principles of managing obesity are presented in the section of obesity in this chapter. Treatment of dyslipidemias is presented in some detail in the section on dyslipidemia.

There appears to be a difference in susceptibility to different risk factors for different
populations when they gain weight (Grundy, 2002). For example:
1. The white population of European origin appears to be more predisposed to atherogenic dyslipidemia than other populations when they gain weight.
2. Blacks of African origin are prone to hypertension when they gain weight; they also appear to be susceptible to type 2 diabetes. On the other hand, they develop less atherogenic dyslipidemia than do whites with same degree of weight gain.
3. Native Americans and Hispanics are especially susceptible to type 2 diabetes but less likely to develop hypertension than are blacks.
4. People of South and Southeast Asia also have a high frequency of insulin resistance and type 2 diabetes. They appear more susceptible to CAD than are East Asians.
Dyslipidemia

The pathogenesis of atherosclerosis and death from the coronary atherosclerosis are importantly related to high levels of total cholesterol and LDL-C levels and low levels of HDL-cholesterol (HDL-C) levels. Multiple trials in adults have demonstrated that cholesterol reduction results in reduced angiographic progression of CAD and even modest regression in some cases. Recently, a link has been established between increased levels of triglycerides and coronary heart disease. It is timely for physicians and other health care providers to review and update their knowledge on dyslipidemia.

Quick Review

Biochemistry of Lipids and Lipoproteins

Lipids represent an essential constituent of our daily diet. Four major lipids of plasma are cholesterol, triglycerides, phospholipids, and free fatty acids. Triglycerides form an important energy source for cellular metabolism. Phospholipids are, because of their amphophilic behavior, excellent emulsifiers of fats and constitute the predominant element of all biological membranes. Cholesterol has an ambivalent nature: on the one hand, it is necessary for the stabilization of biological membrane structure and an essential precursor of hormones and bile acids in hepatic metabolism; on the other hand, a surplus of cholesterol is considered to trigger atherosclerosis.

Plasma lipids that are hydrophobic do not circulate freely but rather circulate in the form of lipid-protein macromolecular complexes known as lipoproteins. The nonpolar lipids (cholesterol esters and triglycerides) are present in the lipoprotein core surrounded by a monolayer composed of specific proteins (apos) and the polar lipids (unesterified or free cholesterol and phospholipids). This monolayer allows the lipoprotein to remain miscible in plasma. Lipoproteins function as transport vehicles for water-insoluble lipid fractions and lead them to their sites of metabolism or deposition. Free fatty acids are bound to albumin.

The plasma lipoproteins have been classified into four major groups based on their density: chylomicrons, very low-density lipoprotein (VLDL), LDL, and HDL. Most cholesterol in plasma is transported by LDL (~65%) with the remainder on HDL (25%) and VLDL (10%). Triglycerides (TGs) are transported primarily by chylomicron and VLDL.

The lipoproteins can be divided into two by the type of apos in the lipoprotein. Apos serve as enzymatic cofactors and recognition elements in binding to specific receptors.

- The apo B lipoproteins are atherogenic and include chylomicrons, LVDL, LDL, and lipoprotein(a) [Lp(a)].
- The apo A-I-containing lipoproteins are associated with reduced CV disease and include HDL and their subfractions.

Small, dense LDL. Recent studies have shown that it is the size of the LDL particles, not the total concentration of LDL, that is more important in the pathogenesis of CAD. Small, dense LDL particles are expected to be better able to penetrate through the intima...
of the coronary arteries to deposit in the subendothelial space, where plaque forms. They are also more readily oxidized; only oxidized LDL can enter the macrophages in the lining of the arteries and form cholesterol-rich plaques. The small, dense LDL phenotype usually occurs associated with elevated TG levels (>140 mg/dL) and a decreased HDL level (<40 mg/dL in men; <50 mg/dL in women). These are typical features of obesity, the metabolic syndrome, insulin resistance, and type 2 diabetes mellitus.

Lipid and Lipoprotein Metabolism
A review of simplified lipid and lipoprotein metabolism is presented in Figure 33-1 for readers who wish to quickly refresh the metabolism of lipid and lipoproteins before reading clinical aspects of dyslipidemia. The figure legend provides a shorter summary of the topic.

Exogenous Pathway
After ingestion of fat-containing foods, TGs and cholesterol are absorbed into intestinal cells as fatty acids and free cholesterol. Within the intestinal wall, free fatty acids and cholesterol are reesterified to form TGs and cholesteryl ester, respectively. These lipids are then combined with phospholipids and apos A-I, A-IV, and B-48 to form TG-rich chylomicron particles. Apo B-48 is an obligatory protein.

Chylomicrons rapidly enter plasma via the thoracic duct. In the circulation, chylomicrons acquire additional apos (mainly apo E and several forms of apo C). TG-rich chylomicrons are hydrolyzed by the enzyme lipoprotein lipase (LPL) at the capillary endothelium, leaving a smaller and denser, remnant particle because they have lost much of their TGs. (The free fatty acid products of this hydrolysis are transferred primarily to adipose tissues for storage as TGs or to muscle for β-oxidation.) This particle is called chylomicron remnant and is rich in cholesterol and has gained apo E from HDL (and lost apo A and apo C to HDL).

These remnants are bound and internalized in part via hepatic membrane receptors specific for apo E on the particle. By this mechanism, dietary cholesterol is delivered to the liver, where it plays a role in the regulation of hepatic cholesterol metabolism. In normal persons, chylomicron and chylomicron remnants are very short lived in the circulation, and none of them exists in the plasma after a 12-hour fast. Chylomicron and chylomicron remnants may be atherogenic. Delayed clearance of chylomicron occurs in inherited deficiency of LPL or its activator, apo C-II (type I hypertriglyceridemia).
FIGURE 33-1  Endogenous and exogenous pathways of plasma lipid and lipoprotein metabolism. Free fatty acid (FA) and cholesterol (C) are esterified in the intestinal mucosa to form triglyceride (TG) and cholesteryl ester (CE), respectively. They combine with apoprotein (apo) A and apo B-48 to form chylomicron and are secreted into the circulation. The clear portion in the circles represents TG, and the shaded portion represents CE. Chylomicron undergoes lipolysis in the capillary endothelium near adipose tissue and muscle tissue, losing TG via lipoprotein lipase (LPL). The resulting chylomicron remnants are taken up by hepatic apo E receptors for degradation by lysosomes. In the liver, TG and CE are combined with apo B-100, apo C, and apo E and then secreted as very low-density lipoprotein (VLDL). The clear portion of the circle represents TG and the shaded portion CE. VLDL undergoes lipolysis in the capillary endothelium near adipose tissue and muscle tissue, losing TG via LPL, similar to what happens with chylomicron remnants. The resulting VLDL remnants (or intermediate-density lipoprotein [IDL]) are either converted to low-density lipoprotein (LDL) for transport to peripheral cells via LDL receptor-mediated uptake or are taken up by hepatic receptors. The other major class of lipoprotein, high-density lipoprotein (HDL), participates in the conversion of free cholesterol from peripheral tissues to cholesteryl ester by the action of lecithin–cholesterol acyltransferase (LCAT). Cholesteryl esters are then directly taken up by the HDL receptors in the liver or are transferred to VLDL remnants and LDL by cholesteryl ester transfer protein (CETP), to be ultimately taken up by the liver. This process is known as reverse cholesterol transport. (Modified from Goldstein JL, Kita T, Brown MS: Defective lipoprotein receptors and atherosclerosis: Lessons from an animal counterpart of familial hypercholesterolemia. N Engl J Med 309:288-295, 1983.)

Endogenous Pathway

Triglycerides synthesized in the liver are packaged with cholesteryl esters and apos B-100, C, and E and then secreted as VLDL. The synthesis of VLDL by the liver is increased by excess carbohydrate, alcohol, or caloric intake and is decreased in the fasting state. In the capillary beds, TG in the core of the VLDL is hydrolyzed by LPL, with a cofactor apo C-II, to produce a smaller denser particle called VLDL remnant or intermediate-density lipoprotein (IDL), which is analogous to chylomicron remnant. (The surface components, except for apos B-100 and E, are transferred to HDL.) Free fatty acids generated by hydrolysis of TG are delivered to adipose tissue and muscle. Compared with VLDL, VLDL remnants have more cholesterol ester and less TG.

Some of these remnant particles (IDLs) are taken up by the hepatic receptors specific for apo E, and some others undergo conversion to LDL by hepatic TG lipase. Elevation of VLDL remnants may predispose the patient to premature CAD and peripheral artery disease (characteristically seen in Frederickson’s type III hyperlipoproteinemia).
Low-density lipoprotein is usually formed by means of enhanced conversion of VLDL remnants (see Fig. 33-1) or by direct hepatic production of apo B–containing lipoproteins. LDLs are almost entirely made up of cholesteryl esters and apo B-100.

The content of cholesterol ester in the LDL particle may vary as much as 40%. LDL particles that contain lower amounts of cholesterol ester are known as small, dense LDL particles. Patients with increased amounts of small, dense LDL particles are at increased risk for CAD. Small, dense LDL is commonly associated with male gender, diabetes, low HDL-C levels, high TG levels, and familial combined hyperlipidemia (FCH).

Low-density lipoproteins are transported to peripheral cells or liver cells. Apo B-100, the only protein found in LDL, is recognized by a high-affinity LDL receptor on the surfaces of hepatic and certain nonhepatic cells, where LDLs are internalized into the cells. By this mechanism, LDL particles can deliver cholesterol to extrahepatic tissues for use in membrane or steroid hormone synthesis. LDL receptor expression by the liver is a major regulator of plasma LDL-C levels. LDL particles have a half-life of 3 to 4 days.

The liver and small intestine secrete HDL as nascent discoid particles composed primarily of phospholipids and apolipoproteins (nascent HDL). (Whereas nascent HDL particles secreted by the intestine are rich in apo A-I and apo A-IV, those secreted by the liver contain predominantly apo A-I and apo A-II.) Nascent lipid-poor apo A-I accepts free (unesterified) cholesterol from tissues, and the free cholesterol transferred to the surface of HDL is esterified by the action of enzyme lecithin–cholesterol acyltransferase (LCAT).

High-density lipoprotein cholesteryl esters may be directly transferred to and selectively taken up by the liver via a hepatic HDL receptor called scavenger receptor class BI (SR-BI). Alternatively, HDL cholesteryl esters may transfer from HDL to VLDL and LDL by the cholesteryl ester transfer protein (CETP), after which it may be taken up by the liver or redistributed to peripheral tissues. Thus, HDLs have two pathways by which they return tissue-derived cholesterol to the liver. The removal of cholesterol from cells by HDL for ultimate disposal in the liver has been termed reverse cholesterol transport. These reactions may explain how HDL and apo A-I can protect against the development of atherosclerosis.

Among the several subtypes of HDL particles, HDL$_2$ and HDL$_3$ are clinically important. HDL$_2$ is closely associated with protection against premature atherosclerosis. Alcohol consumption predominantly increases the HDL$_3$ subfraction. Lower levels of both subfractions are associated with male gender, hypertriglyceridemia, diabetes mellitus, obesity, uremia, smoking, and the use of androgens and progesterones. Estrogen raises HDL levels.

Cholesterol returning to the liver is converted into bile acids by the enzymatic hydroxylation of cholesterol, or cholesterol and phospholipids are excreted directly into the bile. A large portion of secreted bile acid is reabsorbed in the enterohepatic circulation and recycled. Bile acid sequestrants reduce the reabsorption of secreted bile acids, eventually reducing serum cholesterol levels by increasing the conversion of hepatic cholesterol to bile acids, thus reducing the cholesterol content of the hepatocytes. The reduced hepatic cholesterol stimulates the production of surface receptors for LDL-
C, clearing more LDL from the serum.

The hepatic and extrahepatic cells can control their own cholesterol content through a feedback control system. In conditions of cellular cholesterol excess, the cell can (1) suppress endogenous cholesterol production by inhibiting the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol synthesis; (2) decrease its input of cholesterol by suppressing the production of LDL surface receptors through a feedback mechanism; and (3) promote the removal of cholesterol by increasing its movement to the plasma membrane for efflux. The “statins” work through the first mechanism to reduce endogenous cholesterol production.

**Diagnosis of Dyslipidemia**

The diagnosis of dyslipidemia is made by measuring blood lipid, lipoproteins, or apolipoprotein factors. If any of the measurements are abnormal, the diagnosis of a specific dyslipidemia is made, such as elevated total cholesterol, LDL-C, apo B, non–HDL-C, and TGs or a lower than normal level of HDL-C.

**Measurement of Lipid and Lipoproteins**

A lipoprotein analysis is obtained after an overnight fast of 12 hours. The routine lipid profile typically includes total cholesterol, HDL-C, LDL-C, and TGs. An extended profile may also include VLDL cholesterol (VLDL-C), non–HDL-C, and the ratio of total cholesterol to HDL.

The LDL level is usually estimated by the Friedewald formula:

\[
\text{LDL} = \text{TC} - \text{HDL} - \left( \frac{\text{TG}}{5} \right)
\]

This formula is not accurate if the child is not fasting, if the TG level is above 400 mg/100 mL, or if chylomicrons or dysbetalipoproteinemia (type III hyperlipoproteinemia) is present. Methods are currently available to measure LDL-C directly, which allow LDL-C determination on specimens with the TG level above 400 mg/dL. Direct LDL-C measurement does not require a fasting specimen.

The following derivatives of lipid profile may be useful in the assessment of risks for CV disease.

1. **Non–HDL-C cholesterol**: Serum non–HDL-C (Total cholesterol – HDL-C) is considered a better screening tool than LDL-C for the assessment of CAD risk because it includes all classes of atherogenic (apo B–containing) lipoproteins; it includes VLDL-C, IDLs, LDL-C, and lipoprotein (a) (or Lp[a]). It was found in adults that increased level of non-HDL-C by 1 mg/dL increases the risk of death from CV disease by 5%.

2. **TC to HDL-C ratio**: The total cholesterol to HDL-C (TC to HDL-C) ratio is a useful parameter for assessing risk for CV disease. The usual TC to HDL-C ratio in children is approximately 3 (based on TC of 150 mg/dL and an HDL-C of 50 mg/dL). According to the Framingham study, the ratio for average risk was 5.0 for men and 4.2 for women. The higher the ratio, the higher the risk of developing CV disease. The ratio of 3.4 halves the
risk of developing CV disease for both men and women.

3. **Small, dense LDL particles**: In recent years, small, dense LDL particles have been shown to be more important than the total LDL levels in CAD. The size of LDL particles is not routinely measured because the presence of this phenotype is predictable. It occurs in association with elevated TG levels (>140 mg/dL) and a decreased HDL level (<40 mg/dL in men; <50 mg/dL in women). Although not routinely measured, small, dense LDL can be measured directly by various methods in commercial laboratories (including Berkeley HeartLab, Inc. [www.bhlinc.com]; Atherotec, Inc. [www.thevaptest.com]; and LipoScience, Inc. [www.lipoprofile.com]).

### Normal Levels of Lipids and Lipoproteins

Table 33-1 shows normal, borderline, and abnormal levels of lipid and lipoprotein levels in children, and Table 33-2 shows those values for young adults. Note that to convert total cholesterol, LDL-C, and HDL-C levels in milligrams per deciliter to millimoles per liter, one divides the mg/dL number by a factor of 38.67. To convert TGs in milligrams per deciliter to millimoles per liter, one divides the mg/dL number by a factor of 88.5.

#### TABLE 33-1

<table>
<thead>
<tr>
<th>Category</th>
<th>Low</th>
<th>Acceptable</th>
<th>Borderline</th>
<th>High</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cholesterol</td>
<td>—</td>
<td>&lt;170</td>
<td>170–199</td>
<td>≥200</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>—</td>
<td>&lt;110</td>
<td>110–129</td>
<td>≥130</td>
</tr>
<tr>
<td>Non-HDL-C</td>
<td>—</td>
<td>&lt;120</td>
<td>120–144</td>
<td>≥145</td>
</tr>
<tr>
<td>Triglycerides: 0–9 years</td>
<td>—</td>
<td>&lt;75</td>
<td>75–99</td>
<td>≥100</td>
</tr>
<tr>
<td>10–19 years</td>
<td>—</td>
<td>&lt;90</td>
<td>90–129</td>
<td>≥130</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>&lt;40</td>
<td>&gt;45</td>
<td>40–45</td>
<td>—</td>
</tr>
<tr>
<td>Apolipoprotein A-1</td>
<td>&lt;115</td>
<td>&gt;120</td>
<td>115–120</td>
<td>—</td>
</tr>
<tr>
<td>Apolipoprotein B</td>
<td>—</td>
<td>&lt;90</td>
<td>90–109</td>
<td>≥110</td>
</tr>
</tbody>
</table>

**HDL**, High-density lipoprotein; **LDL**, Low-density lipoprotein.


#### TABLE 33-2

**Recommended Cut Points for Lipid and Lipoprotein Levels IN Young Adults (mg/dL)**

<table>
<thead>
<tr>
<th>Category</th>
<th>Low</th>
<th>Borderline Low</th>
<th>Acceptable</th>
<th>Borderline High</th>
<th>High</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cholesterol</td>
<td>—</td>
<td>—</td>
<td>&lt;190</td>
<td>190–224</td>
<td>≥225</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>—</td>
<td>—</td>
<td>&lt;120</td>
<td>120–159</td>
<td>≥160</td>
</tr>
<tr>
<td>Non-HDL cholesterol</td>
<td>—</td>
<td>—</td>
<td>&lt;150</td>
<td>150–189</td>
<td>≥190</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>—</td>
<td>—</td>
<td>&lt;1155</td>
<td>115–149</td>
<td>≥150</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>&lt;40</td>
<td>40–44</td>
<td>&gt;45</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>
**Classification of Dyslipidemia**

Dyslipidemias were traditionally classified by patterns of elevation in lipids and lipoproteins (Fredrickson phenotypes), but a more practical system is to classify them as primary (genetic) or secondary dyslipidemia.

1. Primary dyslipidemia is caused by single or multiple gene mutations that result in either overproduction or defective clearance of TGs and LDL-C or in underproduction or excessive clearance of HDL-C (see later discussion). This entity is much less common than secondary dyslipidemia.

2. Secondary dyslipidemia is caused by associated diseases or conditions and is much more common than primary dyslipidemia (see further discussion later). The majority of the cases found during screening are secondary forms.

Screening of all family members is recommended to determine whether the disorder is a familial one. Family screening is important not only to detect dyslipidemia in other members of the family but also to emphasize the need for all family members to change their eating patterns. Young patients with elevated LDL levels are more likely to have a familial disorder of LDL metabolism. Secondary dyslipidemia can occur in any age group.

**Secondary Dyslipidemia**

Box 33-3 lists the causes of secondary dyslipidemia. The most common cause of pediatric dyslipidemia is obesity. Medications such as oral contraceptives, isotretinoin (Accutane),
anabolic steroids, diuretics, beta-blockers, and estrogens are uncommon causes of dyslipidemia. Medical conditions that include hypothyroidism, renal failure, nephrotic syndrome, and alcohol usage are less common causes of secondary dyslipidemia. Evidence of accelerated atherosclerosis from secondary causes of dyslipidemia is as impressive as that of primary causes.

**TABLE 33-3**

Lipid Profile in Major Lipid Disorders in Children and Adolescents

<table>
<thead>
<tr>
<th>Primary Lipid Disorders</th>
<th>LDL</th>
<th>VLDL</th>
<th>TG</th>
<th>HDL</th>
<th>Others</th>
</tr>
</thead>
<tbody>
<tr>
<td>Familial hypercholesterolemia:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>homozygous</td>
<td>†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>heterozygous</td>
<td>†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FCH: type IIa</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type IV</td>
<td>†</td>
<td></td>
<td>†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type IIb</td>
<td>†</td>
<td></td>
<td>†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Types IIb and IV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>†</td>
</tr>
<tr>
<td>Familial hypertriglyceridemia (200–1000 mg/dL)</td>
<td>†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severe hypertriglyceridemia (&gt;1000 mg/dL)</td>
<td>†</td>
<td></td>
<td>†</td>
<td></td>
<td>† Chylomicron</td>
</tr>
<tr>
<td>Familial hypoalphalipoproteinemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>† LDL</td>
</tr>
<tr>
<td>Dysbetalipoproteinemia (TC: 250–500 mg/dL; TGL: 50–600 mg/dL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>† Chylomicron remnant</td>
</tr>
</tbody>
</table>

FCH, Familial combined hyperlipidemia; HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; VLDL, very low-density lipoprotein.


Most secondary causes of dyslipidemia raise TGs and often lower HDL-C levels, with the exception of estrogen excess with which HDL-C levels increase.

Each child with dyslipidemia should have certain blood tests to help rule out secondary causes of dyslipidemia. The blood tests should include fasting blood glucose and tests of kidney, liver, and thyroid function. When the diagnosis of secondary dyslipidemia is made, one should treat the associated disorder producing the dyslipidemia first, such as diabetes, obesity, or nephritic syndrome, and then treat dyslipidemia using the same guidelines as in primary dyslipidemia.

**Selected Primary Dyslipidemias**

Primary or inherited dyslipidemia is less commonly found in the screening process. Major primary dyslipidemias found in children include familial hypercholesterolemia (FH), FCH, familial hypertriglyceridemia, and several others. Table 33-3 summarizes changes in the lipid profile seen with primary lipid disorders.

**Familial hypercholesterolemia.** FH is autosomal dominant condition caused by a lack of or a reduction in LDL receptors. Whereas heterozygotes have about a 50% reduction in LDL receptors, homozygotes have little or no receptor activity. FH results in extreme
elevation of LDL-C that may distinguish the condition from other primary and most secondary causes of dyslipidemia. Genetic testing remains the criterion standard for diagnosis of the condition, although it is not widely used.

1. Heterozygous disorder. Familial hypercholesterolemia heterozygous disorder is fairly common, occurring in one of every 500 people. It is inherited in an autosomal dominant mode. An evaluation of family members is important in the diagnosis of this condition. In this condition, 50% of siblings and one parent have elevated total and LDL-C levels, but unaffected first-degree relatives have completely normal levels.

In heterozygotes, total cholesterol and LDL-C levels are two to three times higher than normal, present at birth or early in life. Their total cholesterol levels are most often above 240 mg/100 mL, with an average of 300 mg/dL, and their LDL-C levels are above 160 mg/100 mL, with an average of 240 mg/dL. HDL-C is reduced, and TG levels are usually normal. The presence of xanthomas of the extensor tendon in the parents of such children almost confirms the diagnosis. A heterozygous child or adolescent has normal physical findings. Tendon xanthomas are rarely found before the age of 10 years; they develop in the second decade, primarily in the Achilles tendons and extensor tendons of the hands, in only 10% to 15% of patients. These patients are likely to develop premature CV disease; rarely, angina pectoris develops in the late teenage years.

Treatment of heterozygotes includes a diet low in saturated fat and cholesterol and high in water-soluble fibers. Bile acid sequestrants are safe and moderately effective but difficult to tolerate over the long term because of their gritty texture and gastrointestinal (GI) complaints. Statins are safe, effective, and well tolerated and are considered the drug of choice (see later section). The addition to the statin of a bile acid sequestrant or a cholesterol absorption inhibitor (CAI) is often necessary to achieve LDL-C goals. Niacin is generally not used to treat FH heterozygous children.

2. Homozygous disorder. Homozygosity occurs in children who inherit a mutant allele for FH from both parents; it occurs in about one in a million children. The total cholesterol and LDL-C levels in these children are five to six times greater than normal. Such children have cholesterol levels that average 700 mg/dL but may reach higher than 1000 mg/dL. Clinical signs such as planar xanthomas, which are flat, orange-colored skin lesions, may be present by the age of 5 years in the webbing of the hands and over the elbows and buttocks. Tendon xanthomas, arcus corneae, and clinically significant coronary heart disease are often present by the age of 10 years. The generalized atherosclerosis often affects the aortic valve, with resulting aortic stenosis.

Familial hypercholesterolemia homozygous children respond somewhat to high doses of potent statins and to niacin. CAIs also lowers LDL-C in FH homozygotes, especially in combination with a more potent statin. However, most FH homozygotes invariably require LDL apheresis (with extracorporeal affinity LDL absorption column and plasma reinfusion) every 2 weeks to lower LDL to a range that is less atherogenic. The Liposorber system is an example, which selectively binds apo B–containing lipoproteins (LDL, Lp[a], and VLDL).

**Familial combined hyperlipidemia.** FCH is an autosomal dominant disorder seen three times more frequently than FH. It occurs in one of every 200 to 300 people. It is
characterized by variable lipid phenotypic expression: elevated LDL level alone, elevated LDL with hypertriglyceridemia, or normal LDL with hypertriglyceridemia. Clinically, it may be difficult to separate this entity from FH. The diagnosis of FCH is suspected when a first-degree family member (often a parent or sibling) has a different lipoprotein phenotype than the proband. Levels of total and LDL-C are somewhat lower than in patients with FH, and LDL-C levels fluctuate from time to time, with TG levels fluctuating in the opposite direction. These children usually have plasma total cholesterol levels between 190 and 220 mg/dL. The LDL-C level is usually normal or only mildly elevated. In FCH, most patients lack tendon xanthomas, and extreme hyperlipidemia is absent in childhood. It may occur in children of survivors of myocardial infarction. Their phenotypes often have other characteristics such as hyperinsulinemia, glucose intolerance, hypertension, and visceral obesity. The combined expression of three or more of these traits constitutes the metabolic syndrome (see earlier section).

A cornerstone of management should be aimed at a fat- and cholesterol-restricted diet and a simple carbohydrate-restricted diet (low glycemic index foods) together with attention to other CV lifestyle changes (control of overweight and regular aerobic exercise). Low glycemic index foods are important in reducing carbohydrate-induced hypertriglyceridemia. The statins are the most effective in lowering LDL-C and the total number of atherogenic small, dense LDL particles. Fibric acid and niacin, which are effective in adults, are not ordinarily used in pediatric patients. Drug therapy is reasonable in patients with persistently elevated TGs levels (>350 mg/dL), aimed primarily at preventing an episode of pancreatitis. Metformin has been used to treat obese hyperinsulinemic adolescents with the metabolic syndrome. Metformin may enhance insulin sensitivity and reduce fasting blood glucose, insulin levels, plasma lipids, free fatty acids, and leptin.

**Familial hypertriglyceridemia.** In children, this autosomal dominant disorder is caused by LPL deficiency, resulting in hepatic overproduction of VLDL-C. TG levels are typically increased. Cholesterol levels are not increased. Eruptive xanthomas and lipemia retinalis (a creamy appearance of the retinal veins and arteries caused by a high concentration of lipids in the blood) can also be found. Metabolic consequences of hypertriglyceridemia include (1) a lowering of HDL-C; (2) production of smaller, denser LDL particles with more atherogenicity; and (3) a hypercoagulable state.

Treatment is based first on a diet very low in fat and simple sugar and lifestyle modification, including increasing exercise, withdrawing hormones (estrogen, progesterone), and limiting alcohol intake. When the level of TGs is between 200 and 500 mg/dL, the goal of the treatment is to reduce CAD. When TG levels reach 500 to 1000 mg/dL, pancreatitis is a major concern. One may consider using drugs such as fibrate or niacin (see later sections for the use of these antilipidemic agents). If pancreatitis develops, which is usually characterized by severe abdominal pain, and elevated plasma levels of amylase and lipase, the patient should be admitted to a hospital for care with intravenous fluid.

**Dysbetalipoproteinemia (type III hyperlipoproteinemia).** This familial disorder is a
rare genetic disorder caused by a defect in apo E, which results in increased accumulation of chylomicron remnants and VLDL remnants. This autosomal recessive disorder is characterized by elevation of both cholesterol and TG equally to greater than 300 mg/dL, but this disorder is not usually seen in childhood. Clinical manifestations may include palmar xanthoma. Patients with this disorder have a moderately increased risk of CV disease. A low-fat diet, a low glycemic index diet, and drug treatment (fibric acid or statin) are very effective.

**Familial hypoalphalipoproteinemia (low HDL syndrome).** This condition is associated with autosomal dominant inheritance. The underlying mechanism is decreased concentration of apo A-I and apo A-II and absent apo C-III. This condition is associated with isolated low HDL-C levels and mild to moderately increased risk of premature CAD. In Tangiers disease, HDL-C is nearly absent (with markedly enlarged yellow tonsils).

Although specific drug therapy is not routinely recommended in pediatric age groups, a low-carbohydrate and low-fat diet is indicated in children with inherited disorders of HDL metabolism. Exercise and weight loss are also helpful. The most effective way to reduce CV risk in these patients is to maintain low LDL-C levels.
Lipid Screening

Past Recommendations

The NCEP Expert Panel (1991) recommended selective screening of children and adolescents with a family history of premature CV disease or at least one parent with high serum cholesterol levels. This selective screening was somewhat controversial because several studies published in the pediatric literature have indicated that about 50% of children with high LDL levels will be missed by following this recommendation. A major reason for this is that there is no reliable family history available on adopted children and because parents of children (and some grandparents) are still too young to have experienced premature coronary heart disease. Universal screening should theoretically detect all children with high LDL-C levels, but no pediatric organizations have recommended universal screening.

In 2008, the American Academy of Pediatrics made the following updated recommendations (Daniels, 2008), but universal lipid screening was not included. The recommendations for lipid screening include (1) children and adolescents with a positive family history of premature CV disease in parents or grandparents; (2) those with family history of dyslipidemia occurring in parents; (3) those whose family history is not known; and (4) those with other CV risk factors such as overweight, obesity, hypertension, cigarette smoking, or diabetes mellitus.

Current Recommendations

In 2011, however, the Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents convened by the National Heart Lung and Blood Institute (NHLBI) has made major changes in the recommendation (Pediatrics, 2011).

1. A universal screening for children between the ages of 9 and 11 years (late childhood)
2. Selective screening for children in other age groups who have certain CV risk factors
3. An additional universal screening between the ages of 17 and 21 years

The reasons for choosing the age 9 to 11 years are that there is the strongest statistical correlation between results in late childhood (around 10 years of age) and in the adult life and that cholesterol levels decrease as much as 10% to 20% during puberty. The Expert Panel believed that, in the absence of clinical or historic markers, the identification of lipid disorders that predispose to accelerated atherosclerosis requires universal lipid assessment. Age-specific descriptions of the recommended screening are shown in Box 33-4.

In this recommendation, either a nonfasting lipid profile (non-FLP) or a fasting lipid panel (FLP) is acceptable. A non-FLP is more convenient because it can be obtained at the time of the office visit without fasting. In this case, non–HDL-C is calculated from the nonfasting blood samples (by subtracting HDL-C from total cholesterol) because non–HDL-C has been shown to be as powerful a predictor of atherosclerosis as any other
lipoprotein cholesterol measurement in children and adolescents. If non-HDL-C is abnormal (≥145 mg/dL), then two FLP measurements are obtained.

**BOX 33-4**

**Recommendations for Lipid Assessment According to Age Group**

<table>
<thead>
<tr>
<th>Category</th>
<th>Low</th>
<th>Acceptable</th>
<th>Borderline</th>
<th>High</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cholesterol</td>
<td>—</td>
<td>&lt;170</td>
<td>170–199</td>
<td>≥200</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>—</td>
<td>&lt;110</td>
<td>110–129</td>
<td>≥130</td>
</tr>
<tr>
<td>Non-HDL-C</td>
<td>—</td>
<td>&lt;120</td>
<td>120–144</td>
<td>≥145</td>
</tr>
<tr>
<td>Triglycerides: 0–9 years</td>
<td>—</td>
<td>&lt;75</td>
<td>75–99</td>
<td>≥100</td>
</tr>
<tr>
<td>10–19 years</td>
<td>—</td>
<td>&lt;90</td>
<td>90–129</td>
<td>≥130</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>&lt;40</td>
<td>&gt;45</td>
<td>40–45</td>
<td>—</td>
</tr>
<tr>
<td>Apolipoprotein A-1</td>
<td>&lt;115</td>
<td>&gt;120</td>
<td>115–120</td>
<td>—</td>
</tr>
<tr>
<td>Apolipoprotein B</td>
<td>—</td>
<td>&lt;90</td>
<td>90–109</td>
<td>≥110</td>
</tr>
</tbody>
</table>

BMI, body mass index; FLP, fasting lipid panel; HDL, high-density lipoprotein; LDL, low-density lipoprotein; non-FLP, non-fasting lipid profile; TC, total cholesterol.


For children who belong to other age groups who do not require universal screening (i.e., ages 2–8 and 12–16 years), selective screening is recommended if the following apply (see Box 33-4). For these children who need selective screening, FLP is measured. The average of two measurements is used.

1. Positive family history (Box 33-5)
2. Parent(s) with total cholesterol (TC) of 240 mg/dL or above or known dyslipidemia
3. Child who has moderate- to high-level risk factors, such as diabetes, hypertension, BMI at the 85th percentile or above, or smokes cigarettes (see Box 33-5)
4. Child who has a moderate- or high-risk medical condition (e.g., diabetes, chronic renal disease, posttransplant patients, Kawasaki’s disease, HIV infection, nephritic syndrome, and others) (see Box 33-5)

**What to Do with the Results of the Screening**

1. When non-FLP is obtained, an abnormal level of non-HDL-C is 145 mg/dL or above. In this case, one needs to obtain two FLPS to get LDL-C and TG levels. The average of the two LDL-C and TG levels determine what steps to take.
2. Abnormal levels of LDL-C and TG levels that need attention are as follows:
   - LDL-C: >130 mg/dL
   - TGs: >100 mg/dL for children younger than 10 years old; 130 mg/dL for those who are 10 to 19 years old
3. Management plans for children with dyslipidemia are presented in the sections to
Initially, dietary management and lifestyle change are recommended for children with high levels of LDL-C and TG. The first step is to employ the Cardiovascular Health Integrated Lifestyle Diet (CHILD)-1 for 3 to 6 months. If CHILD-1 is ineffective, CHILD-2 is used for 3 to 6 months.

If unsuccessful in lowering LDL-C levels by dietary management, the use of lipid-lowering drugs (statins) is considered. Indications for the use of “statins” depend not only on the level of lipid abnormalities but also on the presence or absence of a positive family history, coexisting risk factors, or medical conditions.

**Box 33-5 Cardiovascular Risk Factor Categories**

**Positive Family History**
Parent, grandparent, aunt or uncle, or sibling with myocardial infarction; angina; coronary artery bypass graft, stent, or angioplasty; or sudden cardiac death at <55 yr for men or <65 yr for women

**Risk Factors**

**High-Level Risk Factors**
- Hypertension that requires drug therapy (BP ≥99th percentile + 5 mm Hg)
- Current cigarette smoker
- BMI ≥97th percentile
- Presence of high-risk conditions, including diabetes mellitus (see below)

**Moderate-Level Risk Factors**
- Hypertension that does not require drug therapy
- BMI at the ≥95th percentile or <97th percentile
- HDL cholesterol <40 mg/dL
- Presence of moderate-risk conditions (see below)

**Special Risk Conditions**

**High-Risk Conditions**
- Type 1 and 2 diabetes mellitus
- Chronic kidney disease, end-stage renal disease, postrenal transplant
- Post–orthotopic heart transplant
- Kawasaki disease with current aneurysm

**Moderate-Risk Conditions**
- Kawasaki disease with regressed coronary aneurysm
- Chronic inflammatory disease (systemic lupus erythematosus, juvenile rheumatoid arthritis)
- HIV infection
- Nephrotic syndrome

BP, blood pressure; BMI, body mass index; FLP, fasting lipid panel; HDL, high-density lipoprotein; LDL, low-density lipoprotein; non-FLP, non-fasting lipid profile; TC, total cholesterol.

c. For high levels of TG, dietary therapy is used as the primary tool. Continued use of the CHILD-2-TG diet, weight control efforts, reduction of sugar consumption, and increased consumption of fish (or omega-3 fish oil) are added to the effort.

4. Children with LDL-C of 250 mg/dL or above and those with TGs of 500 mg/dL or above should be referred to lipid specialists.
Dietary Management of Hypercholesterolemia

Reduced intake of saturated fat and cholesterol is most basic to the dietary therapy of hypercholesterolemia. The efficacy and safety of dietary therapy have been demonstrated in adults as well as children. Diet therapy is prescribed in two steps that progressively reduce the intake of saturated fats and cholesterol. Physicians should follow the algorithm shown in Figure 33-2 for managing high LCL-C levels.

1. The CHILD-1 diet is the first stage in dietary change for children with dyslipidemia, overweight and obesity, risk-factor clustering, and high-risk medical conditions (Table 33-4). The CHILD-1 diet is also the recommended diet for children with a positive family history of premature CV disease, dyslipidemia, obesity, hypertension, diabetes mellitus, or exposure to smoking in the home. This diet is very similar to what has been recommended for the general population of the United States to consume by the Dietary Guidelines for Americans 2010. The use of dietary adjuncts such as plant sterol or stanol esters has shown short-term benefits.

<table>
<thead>
<tr>
<th>Nutrients (% total calories)</th>
<th>CHILD-1</th>
<th>CHILD-2-LDL</th>
<th>CHILD-2-TG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total fat</td>
<td>&lt;30%</td>
<td>25%–30%</td>
<td>25%–30%</td>
</tr>
<tr>
<td>Saturated fat</td>
<td>7%–10%</td>
<td>≤7%</td>
<td>≤7%</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>300 mg/day</td>
<td>&lt;200 mg/day</td>
<td>&lt;200 mg/day</td>
</tr>
<tr>
<td>Mono- and polyunsaturated fatty acids</td>
<td>20%</td>
<td>&lt;10%</td>
<td>~10%</td>
</tr>
<tr>
<td>Carbohydrate</td>
<td>50%–55%</td>
<td>Avoid trans fat as much as possible</td>
<td>Decrease sugar intake</td>
</tr>
<tr>
<td>Protein</td>
<td>15%–20%</td>
<td></td>
<td>Increase intake of complex carbohydrates</td>
</tr>
<tr>
<td>Others</td>
<td>Reduce trans fat intake</td>
<td>Increase dietary fish (omega-3 fatty acids)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>May add plant sterol, or plant sterol esters, water-soluble fiber psyllium</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CHILD, Cardiovascular Health Integrated Lifestyle Diet; LDL, low-density lipoprotein; TG, triglyceride.

2. If this diet fails to achieve the minimal goal of the dietary therapy for LDL-C (≤130 mg/dL) in 6 months, a more stringent diet with saturated fat at 7% or less of total calories and dietary cholesterol of less than 200 mg/day (CHILD-2-LDL) is used, which has been shown to be safe and effective. A registered dietitian or other qualified nutrition professional should be consulted.

3. If the dietary intervention with CHILD-2-LDL fails, one may proceed with drug therapy.

Indications for Drug Therapy
When dietary management with lifestyle changes of 6 to 12 months’ duration fails to lower LCL-C levels to the target level (≤130 mg/dL), the use of medication should be considered. Decisions regarding the need for medication therapy should be based on the average of results from at least two FLPs obtained at least 2 weeks but no more than 3 months apart, and it should be in consultation with the patient and the family.

1. The following are indications for consideration of drug therapy (Box 33-6 and Fig. 33-2).

a. LCL-C of 190 mg/dL or greater after a 6-month trial of lifestyle management (CHILD-1 followed by CHILD-2-LDL) for children 10 years of age or older

b. LCL-C 160 to 189 mg/dL after a 6-month trial of lifestyle and diet management (CHILD-2-LDL) in a child 10 years of age or older with a positive family history of premature CVD or events in first-degree relatives or at least one high-level risk factor or risk condition or at least two moderate-level risk factors or risk conditions (see Box 33-5)

c. LDL-C 130 to 159 mg/dL in a child 10 years of age or older with a negative family history of premature CVD but with at least two high-level risk factors or risk conditions or at least one high-level risk factor or risk condition together with at least two moderate-level risk factors or risk conditions

**BOX 33-6  Indications for Drug Therapy for Hypercholesterolemia in Children and Adolescents**

- Failure of diet therapy and lifestyle management for 6 to 12 mo plus
- Age ≥10 yr with one of the following lipid profiles or risk factors:
  a. LDL cholesterol ≥190 mg/dL
  b. LDL cholesterol 160–189 mg/dL with a positive family history of premature CV disease or events in first-degree relatives, at least one high-level risk factor or risk condition, or at least two moderate-level risk factors or risk conditions
  c. LDL cholesterol 130–159 mg/dL with at least two high-level risk factors or risk conditions or at least one high-level risk factor or risk condition together with at least two moderate-level risk factors or risk conditions (Box 33-5).

OR

- Children age 8 or 9 years with LDL cholesterol level persistently ≥190 mg/dL together with multiple first-degree family members with premature CV disease or events or the presence of at least one high-level risk factor or risk condition or the presence of at least two moderate-level risk factors or risk conditions

CV, cardiovascular; LDL, low-density lipoprotein.


d. For children age 8 or 9 years with LDL-C persistently 190 mg/dL or above with multiple first-degree family members with premature CVD or events or the presence of at least one high-level risk factor or risk conditions or the presence of at least two moderate-level risk factors or risk conditions

e. LDL-C 130 to 189 mg/dL in a child 10 years of age or older with a negative family history of premature CVD in first-degree relatives and no high- or moderate-level
risk factor or risk condition should continue with lifestyle changes (CHILD-2-LDL), plus weight management if the BMI is at the 85th percentile or above.

2. Children with homozygous FH and extremely elevated LDL-C levels (>500 mg/dL) have undergone effective LDL-lowering therapy with biweekly LDL apheresis under the care of lipid specialists.

**Lipid-Lowering Drugs**

Five well-known classes of lipid-lowering drugs have been used for adults with dyslipidemia. They are bile acid sequestrants, HMG-CoA reductase inhibitors (“statins”), CAIs, nicotinic acid (niacin, vitamin B₃), and fibric acid derivatives. The mechanisms of action, side effects, and ranges of adult dosages of the lipid-lowering agents are presented in Table 33-5.

Experience in children is quite limited, especially with drugs other than the statins, and consensus recommendations are lacking with regard to the use of other lipid-lowering drugs, such as fibrate and niacin.

1. It has been established that the HMG-CoA reductase inhibitors (statins) are the most effective in lowering LDL-C in adults as well as in children and adolescents. A further discussion is presented in the section to follow.

2. The bile acid sequestrants (cholestyramine, colestipol) are other lipid-lowering drugs approved for use in children older than 10 years of age. However, these agents are not used widely because they are associated with a low compliance rate (because of their gritty texture and GI complaints), and they provide only a modest reduction of LDL-C level. No further discussion follows on this topic.

3. Ezetimibe, a CAI, is effective in lowering blood cholesterol levels. Contrary to earlier belief, they are absorbed through the enterohepatic circulation and may have systemic effects, such as rare liver toxicity. Even though ezetimibe decreases cholesterol levels, the results of two major, high-quality clinical trials in adults (in 2008 and 2009) showed a lack of clinically significant improvement in CV events. No further discussion follows on this topic.

**TABLE 33-5**

Summary of Lipid-lowering Drugs
4. Nicotinic acid and fibrates have been shown to lower LDL-C and TG levels and increase HDL levels in adults. Although they are frequently used in adults with hypercholesterolemia as a second line of drug, they are not frequently used in adolescents because of limited data available.

The “Statins”

At this time, a statin is recommended as first-line treatment in adolescents with hypercholesterolemia (McCrindle et al, 2007). The statins inhibit HMG-CoA reductase, which is the rate-limiting step in the endogenous production of cholesterol in the hepatic cells.
Initiation, Titration, and Monitoring of Statin Therapy in Children and Adolescents

- Measure baseline CK, ALT, and AST levels.
- Start with lower dose given once orally (see text for dosage).
- Monitor for potential adverse effects.
  - Instruct the patient to report immediately all potential adverse effects, especially myopathy (muscle cramps, weakness, asthenia, and more diffuse symptoms).
  - If myopathy is present, its relationship to recent physical activities should be assessed, the medication stopped, and CK assessed.
  - The patient should be monitored for resolution of myopathy and any associated increases in CK.
  - Consideration can be given to restarting the medication after symptoms and laboratory abnormalities have resolved.
  - Advise female patients about concerns with regard to pregnancy and the need for appropriate contraception if warranted.
- After 4 weeks, measure fasting lipoprotein profile, CK, ALT, and AST
  - The threshold for worrisome level of CK is 10 times above the upper limit of reported normal; consider the impact of physical activity.
  - The threshold for worrisome level of ALT or AST is three times above the upper limit of reported normal.
  - Target level for LDL: minimal, <130 mg/dL; ideal, 110 mg/dL
- At 4-week follow-up:
  - If target LDL levels are achieved and no laboratory abnormalities are noted:
    - Continue therapy and recheck in 8 wk and then 3 mo.
  - If laboratory abnormalities are noted or symptoms reported:
    - Temporarily withhold the drug and repeat the blood work in ≈2 wk.
    - When anomalies return to normal, the drugs may be restarted with close monitoring.
  - If target LDL levels not achieved:
    - Increase the dose by 10 mg and repeat the blood work in 4 wk.
    - Continue stepped titration up to the maximum recommended dose until target LDL levels are achieved or there is evidence of toxicity.
- Repeat laboratory tests every 3 to 6 mo: fasting lipoprotein profile, CK, ALT, and AST.
- Continue counseling on:
  - Compliance with medications and reduced fat diets
  - Other risk factors, such as weight gain, smoking, and inactivity
  - Counsel female adolescents about statin contraindication in pregnancy and the need for appropriate contraception. Seek referral to an
Adverse Effects of Statins

Adverse effects of statins are infrequent but may include GI upset; elevation of liver transaminases; and myopathy ranging in severity from asymptomatic increases in creatine kinase (CK), muscle aches or weakness, to fatal rhabdomyolysis. Myopathy and elevated liver enzymes are the main concerns.

• More than a 10-time increase in CK levels and more than three times an increase in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels above the upper limits of normal are worrisome levels. Therefore, periodic measurements of ALT, AST (preferred because it is also found in muscles), and CK should be done for possible adverse effects of the statins at the same time lipid levels are measured. Box 33-7 provides step-by-step instruction on initiation, titration, and monitoring of statin therapy (McCrindle et al, 2007).

• Patients should be instructed to report immediately any potential signs and symptoms of myopathy (e.g., muscle cramps, weakness, or more diffuse symptoms). Asymptomatic transient increases in CK, although unusual, have been reported. Practitioners should be aware that an increase in CK may be related to vigorous exercise, particularly contact sports or weightlifting. Myopathy is defined as a serum CK level 10 times the upper limit of normal with or without muscle weakness or pain. Rhabdomyolysis is defined as unexplained muscle pain or weakness with a serum CK level more than 40 times the upper limit of normal.

The likelihood of myopathy increases with high doses, especially of simvastatin (80 mg in adults), and when used concomitantly with other medications, such as cyclosporine, erythromycin, gemfibrozil, niacin, azole antifungal agents, or antiretroviral agents (Egan, 2011).

• Increases in liver enzymes up to three times the upper limits of normal have been reported in several patients treated with high doses of simvastatin (40 mg/day) and atorvastatin (20 mg/day). Liver transaminases are not likely to increase in patients taking pravastatin and rosuvastatin.

• The statins are also teratogenic, and female patients should be advised about appropriate contraception if warranted.

Dosages of the “Statins”
Numerous studies have demonstrated the safety and efficacy of the statins in male and female adolescents with FH (Holmes et al, 2005). Five statins—atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin—are currently approved by the Food and Drug Administration (FDA) for use in adolescents. A recent double-blind, placebo-controlled trial with 2 years of pravastatin treatment has shown not only significant reduction of LDL-C but also regression of carotid atherosclerosis in children and adolescents with FH (Wiegman et al, 2004).

Based on recently published clinical trials in children and adolescents, the following may be a reasonable pediatric dosage of the statins that are approved for pediatric use (Holmes et al, 2005). The Expert Panel has recommended to start with the lowest available dose given once daily at bedtime. The starting doses listed below are the lowest available doses for each statin, except for simvastatin (with 5 mg as the lowest available dose).

• Atorvastatin (Lipitor): The starting dose of 10 mg is increased to 20 mg at 3 months and further to a dose of 40 mg/day (maximum adult dose, 80 mg/day).
• Fluvastatin (Lescol): The starting dose is 20 mg. The maintenance dose ranges from 20 to 40 mg.
• Lovastatin (Mevacor): The starting dose is 10 mg with a 10-mg increase every 3 months to a maximum of 40 mg/day.
• Pravastatin (Pravachol): The starting dose of 10 mg is increased to 20 or 40 mg/day.
• Simvastatin (Zocor): The starting dose is 10 mg. It is increased in increments of 10 mg every 3 months to a maximum of 40 mg/day. Note that 80 mg of the drug carries a high risk of myopathy or rhabdomyolysis in adults.

The dose of statin is increased by 10 mg every 3 months to the half or even full dose of the upper range dosage with periodic measurements of cholesterol levels. The maintenance dosage of the drug is decided by periodic determinations of cholesterol levels. The minimal target level for LDL-C is less than 130 mg/dL, and the ideal target level is 110 mg/dL. If the target level is not reached, a second agent such as a bile acid sequestrant or CAI may be added under the direction of a lipid specialist.
Hypertriglyceridemia

High TG levels are a marker for atherogenic remnant lipoproteins, such as VLDL-C. Recent studies have found that hypertriglyceridemia is an independent risk factor for major coronary events after controlling for LDL-C and HDL-C. According to the Helsinki Heart Study (1987), people with hypertriglyceridemia alone (without other risk factors for heart disease) had about a 50% increased risk for CAD compared with people with normal TG levels. When high LDL-C coexisted with elevated TG levels, there was a 300% greater risk for CAD.

Management of Hypertriglyceridemia

There are different cutoff points for the treatment of hypertriglyceridemia in children and adults; 100 mg/dL for children younger than 10 years of age, 130 mg/dL for ages 10 to 19 years, and 150 mg/dL for young adults (see Tables 33-1 and 33-2). An algorithm for managing hypertriglyceridemia is shown in Figure 33-3.

1. Diet therapy is the primary tool in treating high TG level, using a low-fat diet and low glycemic index foods, such as CHILD-2-TG (see Table 33-4). Reduction of simple carbohydrate intake (and increased intake of complex carbohydrate), reduced saturated fat intake, and weight loss are associated with decreased TG levels. It is important for physicians to know that both a high-fat diet and a high-carbohydrate diet raise TG levels. fact, a high-carbohydrate diet may be a more important source of hypertriglyceridemia than high fat intake. The best established metabolic disturbance attributable to high dietary sugar intake may be a rise in plasma lipids, not in plasma glucose (Hellerstein, 2002). A rise in TG levels after consuming high carbohydrate is known as carbohydrate-induced hypertriglyceridemia. The increase in TG is worse with a high glycemic index diet than with a low glycemic index diet. Therefore, all refined carbohydrate foods such as sugary drinks, cookies, ice cream, and desserts, should be avoided and complex carbohydrates such as whole-grain products should be consumed more often.

2. Lifestyle changes with increased physical activity (at least 30 minutes of moderate-intensity exercise 5 days a week) and weight control help reduce TG levels. Exercise also helps decrease LDL-C and increase HDL-C.

3. Increasing dietary fish (to increase omega-3 fatty acids) may be effective.
   a. Children with increased TG levels (100–200 mg/dL) after a trial of lifestyle and diet management with CHILD-2-TG should increase dietary fish consumption.
   b. Children with fasting TG levels of 200 to 499 mg/dL or above, non-HDL levels of greater than 145 mg/dL, after a trial of lifestyle and diet management with CHILD-2-TG and increased fish intake may be considered for fish oil supplementation.
Omega-3 fatty acids in fish oils lower plasma TGs levels by inhibiting the synthesis of VLDL-C and TGs in the liver. They also have antithrombotic properties. A review of human studies (Harris, 1997) concluded that approximately 4 g/day of omega-3 fatty acids reduced serum TG concentrations by 25% to 30%, increased LDL-C levels by 5% to 10%, and increased HDL-C levels by 1% to 3%. Total cholesterol was not significantly affected by omega-3 fatty acids. A prescription omega-3 fatty acid product (e.g., Omacor) 4 g/day and 8 g/day may be used. (Most fish oil capsules contain omega-3 fatty content, only one third of that contained in Omacor.)

4. Children with average fasting TG levels of 500 mg/dL or above or any single measurement of 1000 mg/dL or above should be treated in conjunction with a lipid specialist. For these patients, in addition to the dietary management with CHILD-2-TG and fish oil, use of fibrate or niacin should be considered to prevent pancreatitis (see below for other lipid-lowering drugs, fibrates and niacin).

Fibrates have the effect of both lowering TGs and raising HDL-C. Side effects seen in adults include myalgia, myositis, myopathy, rhabdomyolysis, liver toxicity, gallstones, and glucose intolerance. Safety and efficacy data in children are limited. Therefore, CK level and liver enzymes should be monitored every 3 months.

Niacin is the best known drug that raises HDL-C, but it also reduces TG levels. Adverse effects of niacin include liver toxicity, GI tract upset, and facial flushing. Less commonly seen side effects are hyperuricemia and glucose intolerance. Extended-release preparations produce less flushing, but they are more likely to produce liver toxicity. Niacin is rarely used to treat the pediatric population because of reported poor tolerance and the potential for very serious adverse effects. Liver transaminases should be checked every 3 months.
Low levels of HDL-C represent a major CV risk factor. Despite the presence of desirable total cholesterol levels, patients with low HDL-C may be at very high risk of developing a subsequent CV event. In the Framingham study, approximately 50% of primary myocardial infarctions occurred in subjects with total cholesterol levels of 250 mg/dL, and 20% of them had desirable cholesterol levels (200 mg/dL). In the Helsinki Heart Study, HDL-C elevation independently reduced CV event rate. An increase in HDL-C is associated with a reduction in the CV events. It is estimated that a rise of 1 mg/dL in HDL lowers the risk of fatal MI by about 3%.

HDL-C has a number of antiatherogenic effects. The best known of these relates to the ability of HDL-C to promote the efflux of cholesterol from macrophages in the arterial wall through reverse cholesterol transport. Other antiatherogenic potentials of HDL-C include antioxidant, antithrombotic, and antiinflammatory effects.

Low HDL level is defined as less than 40 mg/dL in adolescent boys and girls. In adults, low level is defined as less than 40 mg/dL in men and less than 50 mg/dL in women.

### Treatment of Low Levels of High-Density Lipoprotein Cholesterol

The primary approach in managing low levels of HDL-C is lifestyle change and diet therapy. Drugs used for this condition (niacin, fibrates) have unacceptable side effects. The following has been suggested for adult patients with low levels of HDL-C (Ashen et al, 2005; others).

1. **Lifestyle change** is the best way to deal with low levels of HDL-C. Regular exercise (for 30 minutes of brisk aerobic exercise every day or every other day) is recommended. Weight control (and quitting smoking) is equally important.

2. **Dietary intervention**
   a. A diet low in saturated fat and rich in the polyunsaturated fatty acids is recommended. This is because the most effective way to reduce CV risk in patients with low HDL levels is to maintain low LDL-C levels, not because it raises HDL levels.
   b. Omega-3 fatty acids may help raise HDL levels.
   c. Restrict consumption of high glycemic index foods. Consumption of carbohydrates, especially simple carbohydrates, is associated with low HDL levels. Some studies have found that a low-carbohydrate diet can raise HDL levels.
   d. Mild to moderate consumption of alcohol (1–2 drinks a day) in adults resulted in a rise of 4 mg/dL (not for those with liver or addiction problems).

3. **Current pharmacologic options** for adults include nicotinic acid (niacin), fibrates, and statins, but none is without major adverse effects. The use of drug should be considered only when all nonpharmacologic measures do not achieve the goal of raising HDL-C level in pediatric patients.

- Among these medications, niacin (nicotinic acid or vitamin B₃) is known to be most...
effective medication for raising HDL-C (raising HDL level by 20% to 35%). However, niacin is rarely used in the pediatric population because of the potential for very serious adverse effects.

One of the major adverse effects of niacin is severe flushing. Flushing is a major reason people stop taking the medication. The flushing problem has been substantially reduced by the development of a newer extended-release formulation of niacin (Niaspan) but it is more likely to increase liver toxicity. Flushing (which may involve prostaglandin D2) can be blocked by taking 300 mg of aspirin half an hour before taking niacin.

- Fibrate therapy is also effective, producing an average increase of 10% to 25%.
- Statins are the least effective of the three drug classes in raising HDL levels (by 2%–15%).
- When used in combination, low-dose statins and high-dose niacin have been shown to produce benefits of 21% to 26%.
Elevated Triglyceride and Low High-Density Lipoprotein

A subgroup of patients with a combination of elevated TG and low HDL-C need special attention. This combination of dyslipidemia is typically seen in patients with obesity, the metabolic syndrome, and diabetes and in some patients with FCH. Although LDL-C may not be elevated, this phenotype is usually associated with small, dense LDL particle, which are much more atherogenic than large LDL particles.

Treatment of the Subgroup of High Triglycerides and Low High-Density Lipoprotein

For this subgroup of patients, the following are recommended.
1. Lifestyle change, in particular with adequate exercise, is probably the most important approach for this subgroup of patients.
2. Low-carbohydrate and low-fat diets. Low glycemic index diets appear to be more beneficial to these patients than low-fat diets, which are traditionally known to lower LDL levels.
3. Cholesterol-lowering drugs that impact small, dense LDL are nicotinic acid and the fibric acid derivatives in adult patients. No consensus guidelines exist for pediatric patients. Of note is that the statin drugs do not appear to affect particle composition, although they lower LDL concentration.
Other CV risk factors beside dyslipidemia need attention in order to prevent CV disease and diabetes. In this section, a brief discussion is presented on the topics of obesity and smoking. Another risk factor, hypertension, is presented in Chapter 28.

**Obesity**

Information provided in this section should only be used to assist health care providers in making diagnoses of overweight and obesity, recognizing complications of obesity, providing the basic knowledge needed in patient counseling, and helping them with appropriate time for referral to a weight management specialist. This section is not meant to describe in detail treatment of obesity; successful treatment of obesity requires special skills and facilities with the availability of a multidisciplinary team consisting of registered dietitians, specialized nurses, psychologists, and exercise specialists. Such specialized programs are costly and, unfortunately, are insufficient in number.

**Prevalence**

Obesity is one of the most pressing public health issues today in the United States. Between 1980 and 2002, obesity prevalence doubled in adults and overweight prevalence tripled in children and adolescents age 6 to 19 years (Hedley et al, 2004). According to the most recent national statistics (from the National Health and Nutrition Examination Survey conducted in 2007 and 2008), 16.9% of children and adolescents (2–19 years old) and 33.8% of adults in the United States are obese. In addition, approximately 30% of children and adolescents are overweight. Therefore, nearly half of all American children and adolescents are either overweight or obese.

**Pathogenesis**

The pathogenesis of obesity may be, in part, inherited, but genetics alone cannot account for the rapid increases in overweight in the US population. Environmental factors appear importantly related to the recent rise in the prevalence of obesity in this country. Increased consumption of calorie-dense foods and a decrease in physical activity and an increased time spent on TV and video games may be causally related to the increasing prevalence of obesity seen in children and adolescents (Gortmaker et al, 1996).

The concept of energy balance applies to the pathogenesis of obesity (Fig. 33-4). When energy intake exceeds energy expenditure on a chronic basis, obesity results. When energy intake is less than energy expenditure, weight loss may result. All energy intake comes from the ingestion of macronutrients. Whereas the caloric value of fat is 9 kcal/g, that of protein and carbohydrate is 4 kcal/g; this is an important reason for recommending reduced fat intake to control weight. A large portion of energy expenditure is the resting metabolic rate (RMR) accounting for 60% to 75% of energy expenditure. Approximately 10% of energy expenditure is dissipated through the thermic effect of food (TEF), which is mainly the result of the energy cost of nutrient absorption,
processing, and storage. Energy expenditure resulting from physical activity is relatively small, accounting for only 10% to 15% of the total energy expenditure. This component is least affected by genetics, and it varies greatly from individual to individual depending on the level of physical activities. The level of energy expenditure from RMR and TEF may be predominantly determined by genetic factors.

By measure, 3500 calories is equivalent to 1 lb. A relatively small positive energy balance can lead to significant weight gain over time. For example, an excess intake of only 100 calories per day will lead to a 10 lb of weight gain over 1 year.

**Health Consequences of Obesity**

A number of disease states are associated with obesity in adults, which are not only risk factors for heart disease and diabetes but also responsible for significant health care costs: approximately 5% of total health care costs (more than $100 billion) can be attributed to obesity. Common conditions associated with adult obesity include hyperlipidemia, heart disease, hypertension, type 2 diabetes, stroke, and osteoarthritis. Obesity also increases the prevalence of some cancers, gallbladder disease, sleep disorders, gout, and mood disorders.

![Energy balance diagram](image)

**FIGURE 33-4** Energy balance. To maintain a stable weight, energy intake (protein, carbohydrate, and fat) of a person should be equal to energy expenditure, which is composed of resting metabolic rate (RMR), the thermic effect of food (TEF), and expenditure associated with physical activities. When intake is greater than expenditure, weight gain will result; when expenditure of energy is greater than the intake, weight loss may result.

The health consequences of obesity in children are somewhat different from those seen in obese adults (Dietz, 1998).

   a. Cardiovascular risk factors (data from Becque, 1998; Srinivasan et al, 1999)
b. Glucose intolerance, which is linked to the recent increase in the prevalence of type 2 diabetes in children.
c. Hypertension is present in 10% to 30% of overweight children.
d. Asthma is more common in obese children and is more difficult to control than in nonobese children.
e. Acanthosis nigricans (∼25%), an indication of hyperinsulinemia
f. Hepatic steatosis (fatty degeneration) with elevated liver enzymes (seen in >10% of overweight children), cholelithiasis (caused by increased cholesterol synthesis), and cholecystitis (occurring more often with weight reduction).

2. Less common medical consequences of obesity
   a. Pseudotumor cerebri (with manifestations of headache, visual impairment or blindness, papilledema, occurring before adolescence) requires aggressive treatment. About 50% of children with the condition are obese.
   b. Sleep apnea occurs in less than 7% of obese children. This requires an aggressive treatment including tonsillectomy and adenoidectomy or weight reduction.
   c. Orthopedic complications: Blount disease (bowing of the tibia and femur with resulting overgrowth of the medial aspect of the proximal tibial metaphysis) or slipped capital femoral epiphysis
   d. Polycystic ovary disease: Menstrual abnormalities and hirsutism in association with obesity, acanthosis, hyperinsulinemia, and hyperandrogenemia suggest this condition.

3. Psychosocial consequences
   a. Early discrimination (in childhood)
   b. Negative self-esteem (in adolescence)
   c. Inappropriate expectation to be more mature because of their large size. This may lead to frustration, a sense of failure, and social isolation.
   d. Learning difficulties
   e. Eating disorders (in white girls)
   f. Obese men tend to attain lower socioeconomic status and social achievement. Obese women tend to have lower educational level, family income, and rates of marriage and higher rates of living in poverty.

Evaluation of Obese Children

1. The BMI (weight in kilograms divided by square of the height in meters \([kg/m^2]\)) is a simple, valid measure of relative weight and is recommended in clinical diagnosis of overweight states. Although parents tend to better understand the term *relative weight* (the child’s weight divided by the ideal weight of the child for his or her height), physicians should use BMI percentile in following up overweight children. Age- and gender-specific BMI percentile curves for the US pediatric population have been published by the Centers for Disease Control and Prevention (CDC) (see Appendix C,
2. **Classification:** In adults, obesity is present when BMI is above 30 and overweight is present when BMI is between 25.0 and 29.9. For children, statistical definition of overweight is used. Children whose BMIs are between the 85th and 95th percentile are “overweight,” and children whose BMIs are at or greater than the 95th percentile are “obese.” A large BMI does not always indicate an increase in body fat; lean, muscular individuals may have large BMIs. Percent body fat may be more accurate in determining obesity than BMI, but the method of determining body fat is cumbersome and is not routinely used in clinical practice.

3. Physicians should consider identifiable underlying causes of obesity, such as genetic or endocrine disorders
   a. Genetic causes: Prader-Willi, Bardet-Biedl, and Alström syndromes all have severe early onsets of obesity. Most of the genetic conditions associated with obesity have in common mental retardation and short stature, often with dysmorphic features.
   b. Endocrine abnormalities, such as hypothyroidism, Cushing’s syndrome, and generalized hypothalamic dysfunction, should be considered. Children with hypothyroidism and cortisol excess have short stature and delayed puberty rather than tall stature and early puberty seen in most obese children. When questions arise, determination of free thyroxine and thyroid-stimulating hormone and 24-hour urinary free cortisol or diurnal salivary cortisol levels should clarify the questions.

4. Check for the presence of other risk factors for CV disease, diabetes, and metabolic syndrome (see Box 33-2).
   a. Blood pressure measurement
   b. Lipoprotein analysis, fasting insulin, and blood glucose
   c. Glycosylated hemoglobin ($\text{HbA}_{1c}$) may also be useful.

5. Search for possible obesity-related complications by history and physical examination, such as those listed below.
   a. Acanthosis nigricans is associated with hyperinsulinemia and a higher risk of developing type 2 diabetes.
   b. Thyroid enlargement may be associated with hypothyroidism.
   c. History of nighttime snoring, breathing difficulties, or daytime somnolence may indicate obstructive sleep apnea or obesity hypoventilation syndrome.
   d. Hip or knee pain may be a manifestation of slipped capital femoral epiphysis.
   e. Abdominal pain or tenderness may be associated with gallbladder disease.
   f. Headaches and blurred optic disk margins may indicate pseudotumor cerebri.
   g. Hepatomegaly may be associated with hepatic steatosis.
   h. Oligomenorrhea, amenorrhea, striae, or hirsutism may indicate polycystic ovary disease or Cushing’s syndrome.
   i. Signs of depression, bulimia nervosa, binge-eating disorder, or other serious psychological disorders require further evaluation and treatment by a child psychiatrist or psychologist.
All successful pediatric weight management programs include four components: (1) dietary component, (2) exercise, (3) behavior modification, and (4) family component. Among these, dietary intervention and regular exercise combined are the cornerstones of weight management. Only through behavior modification can long-term healthy eating and activity patterns can be established; attempts at using diet and exercise for quick weight loss usually fail. Without involvement of the parents and family, behavior modification of children and adolescents is difficult to achieve. Currently, no pharmacologic agents have been shown to be safe and effective for long-term weight management in children and adolescents. Presently, the FDA has approved only two drugs, sibutramine (Meridia) and orlistat (Xenical), that may be used for treating severely obese children. Consultations with registered dietitians, psychologists, and exercise specialists may be sought or a referral to a multidisciplinary weight management program may become necessary.

Assessment of usual diet and activity patterns of overweight children and adolescents is important. Selected questions (or assessments) and appropriate counseling are listed below.

1. **Diet**
   a. The following questions are helpful in assessing the dietary habits of the child and family.
      (1) How often vegetables and fruits are eaten as main meal or snack
      (2) How often high calorie drinks (soda pops, fruit punches, fruit juices) are consumed
      (3) Numbers and types of fast foods eaten per week
      (4) How often the child eats fish, chicken, and red meats
      (5) Type of milk, bread, and butter consumed
      (6) How often fried foods are eaten in a week
   b. The counseling should include at least the following:
      (1) The diet of choice is a diet low in saturated fat and cholesterol and includes five
or more daily servings of vegetables and fruits and 6 to 11 servings of whole-grain and other complex carbohydrate foods.

(2) A new Food Guide System, MyPlate, should be introduced. Half of a plate is filled with fruits and vegetables, a quadrant with grains (e.g., bread, wheat, rice), and the last quadrant with protein (e.g., meat, poultry, fish, soy).

(3) To help people better understand what constitutes healthy habits for controlling obesity, some simple guidelines have been developed, such as the “5-2-1-0” message (which includes physical activity). This message developed by the New Hampshire Health Department has been endorsed by the American Academy of Pediatrics as basic healthy lifestyle counseling tool. The message is simple to understand and remember and can be given in a few minutes. The 5-2-1-0 message stands for:
- 5: Eating at least five servings of fruits and vegetables most days.
- 2: Limiting screen time to 2 hours or less daily.
- 1: Participating in at least 1 or more hours of physical activity every day.
- 0: Encouraging no soda and sugar-sweetened drinks. Instead, drink water and low-fat or fat-free milk.

c. Physicians may consider using the following as handout materials for counseling.
   (1) Box 33-8 (dietary strategies) and Box 33-9: Tips for parents
   (2) Table C-4, Appendix C: Specific foods to choose and to decrease
   (3) Table C-5, Appendix C: Serving size of various food groups according to age and gender

d. Physicians may recommend parents to read about the new food guide system (MyPlate) recommended by the US Department of Agriculture (http://teamnutrition.usda.gov/myplate.html).

2. Physical activity
Exercise is another integral part of weight management. Without regular exercise, dietary modification alone is insufficient for successful weight management. Physicians should first assess the level of physical activity of overweight children and use their influential position to counsel children and their family to adopt a healthy lifestyle.

a. The following questions are useful in assessing physical activity in children.
   (1) Amount of time regularly spent walking, bicycling, swimming, and in backyard play
   (2) Use of stairs, playgrounds, and gymnasiums and interactive physical play with other children

---

**BOX 33-9** Tips for Parents to Implement American Heart Association Pediatric Dietary Guidelines

- Reduce added sugars, including sugar-sweetened drinks and juices.
- Use canola, soybean, corn oil, safflower oil, or other unsaturated oils in place of solid fats during food preparation.
- Use recommended portion sizes on food labels when preparing and serving food.
- Use fresh, frozen, and canned vegetables and fruits and serve them at every meal; be careful with added sauces and sugar.
- Introduce and regularly serve fish as an entrée.
• Remove the skin from poultry before eating.
• Use only lean cuts of meat and reduced-fat meat products.
• Limit high-calorie causes such as Alfredo, cream sauces, cheese sauces, and hollandaise sauce.
• Eat whole-grain breads and cereals rather than refined products; read labels and ensure that “whole grain” is the first ingredient on the food label of these products.
• Eat more legumes (beans) and tofu in place of meat for some entrées.
• Breads, breakfast cereals, prepared foods, including soups, may be high in salt or sugar; read food labels for content and choose high-fiber, low-salt, and low-sugar alternatives.


3. Behavior modification is essential for permanent changes in dietary and exercise habits.

  a. Promotion of long-term permanent changes in behavior patterns, rather than short-
term diet or exercise program for rapid weight loss, should be the goal of treatment. b. Emphasis should be on small and gradual behavior changes. 

4. **Early intervention and family involvement:** Physicians should also talk about the importance of early intervention (beginning before adolescence) and family involvement for successful weight management.
   a. The importance of early intervention includes:
      (1) Many lifestyle habits (eating and exercise habits) are established early in childhood. Parents have much control of their children’s behaviors in the early school years. 
      (2) There is a tracking of CV risk factors from childhood to adulthood. About 80% of obese adolescents became obese adults. After it is established, obesity is difficult to cure. 
   b. Family involvement is very important in pediatric weight management programs. 
      (1) Willingness on the part of both child and family to participate and involvement of the entire family and other caregivers are important. 
      (2) Parents need to learn certain skills and commit themselves to the program. 
         (a) Parent role modeling of healthful dietary and activity habits
         (b) Understanding the new food guide system (MyPlate)
         (c) Ability to read food labels
         (d) Appropriate ways of praising and rewarding good progress
         (e) Changes in family environment, such as removing high-calorie foods, reducing the number of meals eaten outside of the home, serving portion-controlled meals to the child, promoting active lifestyles, and discouraging a sedentary lifestyle
         (f) Inclusion of activities to help families monitor their eating and physical activity behaviors and establishing formal routine exercise program at a scheduled time each day or evening

   Primary emphasis in weight control efforts should be the lifestyle change; the weight loss itself is of secondary importance. An active lifestyle improves risk factors even when weight loss is minimal. When a weight loss goal is set, it should be realistic and should not attempt to fully normalize weight. In children without complications of obesity, maintenance of the current weight or modest weight loss, while children continue to grow in height, reduces their degree of overweight. Children with complications of obesity (e.g., hypertension, hyperlipidemias, insulin resistance, hepatic steatosis) should attempt to lose weight to correct those complications.

**Cigarette Smoking**

Cigarette smoking has been called the chief single avoidable cause of death in our society and one of the most important public health issues of our time, costing more than $167 billion a year. Cigarette smoking is a powerful independent risk factor for myocardial infarction, sudden death, and peripheral vascular disease. Even passive exposure to smoke causes alterations in the risk factors in children.
Prevalence. The prevalence of cigarette smoking nationwide among high school students (grades 9–12) increased during the 1990s, peaking in 1996 and 1997, and then declining slightly since, but a significant number of children and adolescents continue to be smokers. An estimated 6.4 million children younger than 18 years of age who are living today will die prematurely as adults because they began to smoke cigarettes during adolescence.

Some important statistics on the prevalence of smoking among the youth are presented below, based on the 2006 CDC and other recent reports.

1. Current use of any tobacco product (cigarettes, cigars, pipes, smokeless tobacco) ranges from 13% among middle school students to 28% among high school students. Among college students, 33% are current users of tobacco products, and nearly 50% used tobacco product in the past year (Rigotti et al, 2000). More recent CDC data show some decline in the numbers; 20% of high school students and 12% of middle school students. Tobacco use was significantly higher among white students than black students. Cigarette smoking was the most prevalent, and cigar smoking was the second most prevalent form of tobacco use.

2. Approximately 80% of tobacco users initiate use before age 18 years.

3. There were smokers in the household in 72% of middle school student smokers and in 58% among high school student smokers.

4. Nearly 50% of middle school student smokers and 62% of high school student smokers reported a desire to stop smoking cigarettes, and most of them have made at least one cessation attempt during the past 12 months. On the other hand, among students who have never smoked cigarettes, 21% of middle school students and 23% of high school students were susceptible to initiating cigarette smoking in the next year.

Pathophysiologic effects of smoking. The following are some pathophysiologic effects of smoking on the CV system (Lu et al, 2004), all of which appear likely to be involved in accelerating atherosclerosis in the coronary artery and peripheral arteries or increasing the probability of thrombosis (with the potential for stroke). Physicians could use this information in counseling session with smokers.

1. Smoking causes atherogenic dyslipidemia
   a. It increases levels of LDL and VLDL-C and TGs.
   b. It lowers HDL-C levels.
   
   These effects are greater in children and adolescents than in adults. Even passive smoking lowers HDL-C.

2. Smoking contributes to a prothrombotic predisposition.
   a. It increases levels of fibrinogen, factor VII, and other factors involved in the fibrin clotting cascade and decreases the concentration of plasminogen.
   b. It activates platelets, increasing their ability to adhere to the vessel wall.

3. Smoking increases blood viscosity by increasing hemoglobin levels (through carbon monoxide–induced increase in carboxyhemoglobin) and by an elevation of plasma fibrinogen levels.

4. Smoking accelerates the atherosclerotic process by:
   a. Increasing monocyte adhesion to endothelial cell (the initial step in atherogenesis)
b. Decreasing nitric oxide synthesis (with resulting endothelial dysfunction)
c. Decreasing synthesis of prostacycline

5. Smoking causes peripheral arterial disease through endothelial dysfunction. Smoking raises blood pressure transiently, raises heart rate, and increases myocardial contractility and myocardial oxygen consumption (by stimulation of the sympathetic nervous system).

Psychosociology of smoking. Physicians should be aware of the psychosociology of initiating smoking to help prevent smoking in children.
1. Most smoking starts during adolescence. The high-risk period is the transition from elementary school to middle school and the first and second years of middle school. This should be the target age group to counsel individually or through school systems.
2. Known predictors of smoking include peer influence (the most important), family members who smoke (siblings and parents), less educated parents, being a more independent and rebellious child, and having less academic success.
3. Cited reasons for starting to smoke include wanting to fit into a group, to lose weight, and to appear more mature.

Management
Physicians and health care professionals should assess the status of smoking, provide smoking prevention messages, help counsel parents and children about smoking cessation, and encourage school and community antismoking efforts.
1. Physician should assess the status of smoking during office visits.
   a. Smoking history should be obtained in all children older than 8 years of age during routine health assessments and updated. History regarding any siblings and friends who smoke should also be obtained.
   b. For current smokers, onset of smoking; number and type of cigarette smoked per day, week, or month; and whether they want to quit smoking and need help to quit the habit should be determined.
   c. Smoking history should also be obtained for parents and be updated.
2. Parents who smoke should be encouraged to quit. Physicians should emphasize the adverse effects of passive smoking on their children and to be role models for their children. Physicians should refer parent smokers to community smoking cessation programs.
3. Physicians’ offices should be nonsmoking environments (without ashtrays); antismoking posters, pamphlets, and videos in the waiting room may be productive.
4. Counseling techniques may vary with the age of the child.
   a. For elementary school children, antismoking messages at each well-child assessment may counterbalance any negative pro-smoking influences exerted by friends or family. Emphasize the harmful physical consequences of smoking and the addictive nature of cigarettes. Parental assistance in the child’s cessation of smoking should also be sought.
   b. For adolescents, emphasis should be on the current negative physiological and social effects of smoking rather than long-term health consequences. Adolescents understand the health consequences of smoking but see them as remote and
irrelevant. More immediate negative effects include bad breath, smelling like smoke, yellow-stained fingers, smell from clothing and hair, increasing heart rate and blood pressure, lack of stamina for sports, shortness of breath, and so on.

5. Some adolescents quit smoking on the advice of their physicians, and cessation message as brief as 3 minutes may be effective. Many adolescents require repeated efforts to quit smoking. Physicians should also encourage activities that tend to preclude cigarette smoking, such as regular physical activity and a variety of school and after-school activities.

   **Pharmacologic approach.** For established adult smokers, if counseling is ineffective, physicians may try nicotine replacement and bupropion to help them quit smoking.

1. Nicotine replacement (by nicotine polacrilex gum or transdermal patch) delivers less nicotine than does cigarette smoking, which delivers a bolus of nicotine. It also eliminates carbon monoxide inhalation.

2. Bupropion, an antidepressant, stimulates dopamine release and curbs the severe withdrawal symptoms of smoking cessation.
Practice of Preventive Cardiology

The primary mission of pediatrics has been the prevention of disease and ensuring normal growth and development. It is natural for pediatricians to pay attention to early detection of children at risk of developing CV disease (and type 2 diabetes) and provide counseling, intervention, and treatment whenever possible.

Atherosclerotic CV disease, the leading cause of both death and disability in this country, has an early onset, and its presence and extent correlate positively and significantly with established CV risk factors, namely, LCL-C, TGs, blood pressure, BMI, and presence of cigarette smoking (see Box 33-1). There is a disturbing increase in the prevalence of obesity during childhood, and it is closely related to the development of other risk factors for CAD and diabetes, which is known as the metabolic syndrome (see Box 33-2).

Acquisition of behaviors associated with risk factors occurs in childhood, such as dietary habits, physical activity behaviors, and the use of tobacco. Intervention to reduce the risk factors in childhood has been successful with low-calorie diets, smoking prevention, increasing physical activities, and family-based weight control programs. Some risk factors are detectable, modifiable, or treatable.

1. Family history of CV disease is very important in assessing a child’s risk of developing CAD later in life. Although it is not modifiable, its presence is a marker for a high risk of heart disease. A history of premature CAD in the first- or second-degree relatives (parents, grandparents, blood-related aunts and uncles, or siblings) before age 55 years for men and before age 60 years for women should prompt physicians to check on other risk factors.

2. Hypercholesterolemia is one of the major risk factors that are identifiable and treatable.

3. Hypertension is also an identifiable and treatable risk factor (see Chapter 28).

4. Other risk factors, such as smoking, consumption of atherogenic diets, and physical inactivity, are all modifiable by behavior changes.

5. Obesity is easily detectable. Although treatment of obesity can be frustrating to both patients and physicians, patient education and behavior modification can be productive.

6. Inclusion of HbA1c should be considered in the screening protocol to detect diabetic and prediabetic states.

The American Heart Association has published a guideline for the prevention of CV disease. Table 33-6 is a handy summary that presents goals and recommendations for reducing risks in children and adolescents for future CV disease.

<table>
<thead>
<tr>
<th>TABLE 33-6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Summary Guidelines for Preventive Pediatric Cardiology</td>
</tr>
</tbody>
</table>

---
<table>
<thead>
<tr>
<th>Risk Identification</th>
<th>Treatment Goals</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood cholesterol</td>
<td>Goals:</td>
<td>If LDL-C is above goals, initiate additional therapeutic lifestyle changes, including diet (&lt;7% of calories from saturated fat, &lt;200 mg cholesterol per day), in conjunction with a trained diettian.</td>
</tr>
<tr>
<td>Total cholesterol:</td>
<td>LDL-C: &lt;130 mg/dL (110 mg/dL is even better)</td>
<td>Consider LDL-lowering dietary options (increase soluble fiber by using age [in years] plus 5–10 g up to age 15 years, when the total remains at 25 g per day) in conjunction with a trained diettian.</td>
</tr>
<tr>
<td>&gt;170 mg/dL is borderline;</td>
<td>For patients with diabetes, LDL-C &lt;100 mg/dL</td>
<td>Emphasize weight management and increased physical activity.</td>
</tr>
<tr>
<td>&gt;200 mg/dL is elevated</td>
<td></td>
<td>If LDL-C is persistently above goals, evaluate for secondary causes (TSH, LFTs, renal function tests, urinalysis).</td>
</tr>
<tr>
<td>LDL-C:</td>
<td></td>
<td>Consider pharmacologic therapy for individuals with LDL &gt;190 mg/dL with no other risk factors for CVD or &gt;160 mg/dL with other risk factors present (BP elevation, diabetes, obesity, strong family history of premature CVD) (see Figure 33-2).</td>
</tr>
<tr>
<td>&gt;110 mg/dL is borderline;</td>
<td></td>
<td>Pharmacologic intervention for dyslipidemia should be accomplished in collaboration with a physician experienced in the treatment of disorders of cholesterol in pediatric patients.</td>
</tr>
<tr>
<td>&gt;130 mg/dL is elevated</td>
<td></td>
<td>Elevated fasting TG and reduced HDL-C are often seen in the context of overweight with insulin resistance. Therapeutic lifestyle change should include weight management with appropriate energy intake and expenditure. Decrease intake of simple sugars.</td>
</tr>
<tr>
<td>Other lipids and lipoprotein</td>
<td>Goals:</td>
<td>If fasting TG are persistently elevated, evaluate for secondary causes such as diabetes, thyroid disease, renal disease, and alcohol abuse.</td>
</tr>
<tr>
<td>TGs:</td>
<td>Fasting TGs:</td>
<td>No pharmacologic interventions are recommended in children for isolated elevation of fasting TG unless this is very marked. Treatment may be initiated at TG &gt;400 mg/dL to protect against postprandial TG of 1000 mg/dL or greater, which may be associated with an increased risk of pancreatitis.</td>
</tr>
<tr>
<td>&gt;100 mg/dL is elevated</td>
<td>&lt;75 mg/dL for &lt;10 yr; &lt;90 mg/dL for &gt;10 yr</td>
<td>Promote achievement of appropriate weight.</td>
</tr>
<tr>
<td>&gt;130 mg/dL is elevated</td>
<td>HDL-C &gt;40 mg/dL</td>
<td>Reduce sodium in the diet.</td>
</tr>
<tr>
<td>&lt;10 yr</td>
<td></td>
<td>Emphasize increased consumption of fruits and vegetables.</td>
</tr>
<tr>
<td>HDL-C:</td>
<td></td>
<td>If BP is persistently above the 95th percentile, consider possible secondary causes (e.g., renal disease, coarctation of the aorta).</td>
</tr>
<tr>
<td>&lt;40 mg/dL is reduced</td>
<td></td>
<td>Consider pharmacologic therapy for individuals above the 95th percentile if lifestyle modification brings no improvement and there is evidence of target organ changes (LVH, microalbuminuria, retinal vascular abnormalities). Start BP medication individualized to other patient requirements and characteristics (e.g., age, race, need for drugs with specific benefits).</td>
</tr>
<tr>
<td>BP</td>
<td>Goal:</td>
<td>Pharmacologic management of hypertension should be accomplished in collaboration with a physician experienced in pediatric hypertension.</td>
</tr>
<tr>
<td>Systolic and diastolic</td>
<td>Systolic and diastolic BP &lt;95th percentile for age, sex, and height</td>
<td></td>
</tr>
<tr>
<td>pressure &gt;95th percentile</td>
<td></td>
<td></td>
</tr>
<tr>
<td>for age, sex, and height</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Weight</strong></td>
<td><strong>Goal:</strong></td>
<td>**For children who are overweight (&gt;85th percentile) or obese (&gt;95th percentile), a weight management program should be initiated with appropriate energy balance achieved through changes in diet and physical activity. Use the “5-2-1-0” message and MyPlate for education and counseling. For children of normal height, a secondary cause of obesity is unlikely. Weight management should be directed at all family members who are overweight using a family-centered behavioral management approach. Weight management should be done in collaboration with a trained dietician. Management of type 1 and type 2 diabetes in children and adolescents should be accomplished in collaboration with a pediatric endocrinologist. For type 2 diabetes, the first step is weight management with improved diet and exercise. Because of risk for accelerated vascular disease, other risk factors (e.g., blood pressure, lipid abnormalities) should be treated more aggressively in patients with diabetes. Advise every tobacco user (patients and children) to quit and be prepared to provide assistance with this (counseling or referral to develop a plan for quitting using available community resources to help with smoking cessation).</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>BMI:</td>
<td>Achieve and maintain BMI &lt;95th percentile for age and sex</td>
<td></td>
</tr>
<tr>
<td>&gt;85th percentile is overweight; &gt;90th percentile is obese</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **Diabetes** | **Goals:** | **Fasting plasma glucose:**
≥126 mg/dL |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Goal:</strong></td>
<td>Near normal fasting plasma glucose (&lt;120 mg/dL) Near normal HbA₁c (&lt;7%)</td>
<td></td>
</tr>
</tbody>
</table>

| **Cigarette smoking** | **Goal:** | Complete cessation of smoking for children and parents who smoke |

---

*BMI*, Body mass index; *BP*, blood pressure; *CV*, cardiovascular; *HDL*, high-density lipoprotein; *LDL*, low-density lipoprotein; *LFT*, liver function test; *LVH*, left ventricular hypertrophy; *TG*, triglyceride; *TSH*, thyroid-stimulating hormone. Modified from Kavey RW, Daniels SR, Lauer RM, et al: American Heart Association Guidelines for Primary Prevention of Atherosclerotic Cardiovascular Disease Beginning in Childhood. Circulation 107:1562-1566, 2003.
Athletes with Cardiac Problems

Competitive athletes are those who participate in an organized team or individual sport that requires regular competition against others. This definition is most easily applied to high school, college, and professional sports. Athletic competitions substantially increase the sympathetic drive, and the resulting increase in catecholamine levels increases blood pressure (BP), heart rate, and myocardial contractility, thereby increasing myocardial oxygen demand. The increase in sympathetic tone can cause arrhythmias and may aggravate existing myocardial ischemia. An athlete with a cardiac problem is at an increased risk of developing serious morbidity and even sudden death during athletic competition compared with nonathletes with similar cardiac problems.

Almost all U.S. states require some type of preparticipation screening of participants in organized sports. The most important reason to screen for heart disease is to prevent sudden unexpected death. Heart disease may also lead to sudden incapacity, which may result in injuries, and preexisting heart disease may be exacerbated by exercise. There are also legal and insurance requirements.

Most physicians encounter this issue in association with high school and college sports; therefore, physicians should be aware of cardiac conditions that may cause problems and have the knowledge base required to accomplish a physician’s role in school sports clearance. In addition, physicians should have a general understanding of the eligibility guidelines and the participation eligibility for patients with specific cardiovascular conditions.

The recommendations presented are mostly from the 36th Bethesda conference published in 2005 (36th Bethesda Conference, 2005). The following major areas will be presented in a table format for easy access of information.
1. Causes of sudden expected death
2. The American Heart Association’s (AHA’s) 12-point screening procedure, including the responsibilities of the general physician
3. Classification of sports according to the type and intensity to help physicians select allowable types of sports
4. Participation eligibility for athletes with different types of cardiovascular problems, presented in a table form for easy access of information
5. Guidelines for athletes with hypertension
Sudden unexpected death in athletes is estimated to occur in about 1 per 200,000 high school sports participants per academic year. Most cases of unexpected sudden death in athletes are caused by unrecognized cardiovascular disease. Although rare, when a sudden unexpected death of an athlete due to a cardiac condition occurs, the public becomes disbelieving, suspicious, and even angry. Sometimes, these feelings have been directed at the physicians involved. It is, therefore, important for primary care physicians to have a good understanding of cardiac conditions that can result in sudden death in order to reduce that possibility and to know his or her responsibilities in recommending sports clearance.

Among a variety of congenital or acquired heart diseases that can cause sudden death during athletic competition, hypertrophic cardiomyopathy (HCM) and coronary artery anomalies or diseases are the two most important groups, accounting for nearly 2/3 of the cases. Table 34-1 shows previously implicated diseases for sudden cardiac death, which is derived from 690 cases of cardiovascular causes of sudden death (Maron et al, 2009).

1. Hypertrophic cardiomyopathy. The single most common cardiovascular abnormality among the causes of sudden death in young athletes is HCM (36%) and its variants (8%), accounting for nearly half of the cases (see Table 34-1).
2. Congenital anomalies and acquired diseases of the coronary arteries are the next important group of causes of sudden death, accounting nearly 25%, including congenital anomalies of the coronary artery and acquired coronary artery diseases such as atherosclerotic coronary artery disease or coronary artery stenosis resulting from Kawasaki disease.
3. Myocarditis. Sudden cardiac death has been reported at rest and during exercise with both acute and chronic myocarditis (up to 6% of sudden death) by way of ventricular arrhythmias.
4. Cardiac arrhythmias (from long QT syndrome, Wolff-Parkinson-White [WPW] syndrome, sinus node dysfunction, arrhythmogenic right ventricular dysplasia [ARVD]) are rare causes of sudden death.
5. Other rare causes of sudden death in athletes include severe obstructive lesions (e.g., aortic stenosis, pulmonary stenosis), Marfan’s syndrome (from ruptured aortic aneurysm), mitral valve prolapse (MVP), dilated cardiomyopathy, primary pulmonary hypertension (PH), unexpected blow to the chest (by such objects as baseball or hockey puck, termed commotion cordis), sarcoidosis, and sickle cell trait.

Some patients die while they are sedentary or during mild exertion, but many collapse during or just after vigorous physical activity. On occasion, athletes may die suddenly without evidence of structural heart disease on autopsy. In such instances, it may be due to a noncardiac cause such as drug abuse.
Preparticipation Screening

The objective of preparticipation screening is to detect “silent” cardiovascular disease that can cause sudden cardiac death. There are, however, no cost-effective practical guidelines for the screening that have been proved to be effective in identifying the potential candidates for sudden death at this time. Prospective cardiovascular screening of a large athletic population is impractical. The total number of competitive athletes in the United States may be in the range of 8 to 10 million. Even with the use of specialized tools available to cardiologists, complete prevention of such death is nearly impossible, given the rarity of some of the causes of sudden expected death. Consequently, medical clearance for sports does not necessarily imply the absence of cardiovascular disease or complete protection from sudden death.

**TABLE 34-1**

**CARDIOVASCULAR CAUSES OF SUDDEN DEATH IN YOUNG ATHLETES (N = 690)**

<table>
<thead>
<tr>
<th>Cause</th>
<th>Proportion of all Causes (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertrophic cardiomyopathy</td>
<td>36</td>
</tr>
<tr>
<td>Coronary artery anomalies</td>
<td>17</td>
</tr>
<tr>
<td>Possible hypertrophic cardiomyopathy*</td>
<td>8</td>
</tr>
<tr>
<td>Myocarditis</td>
<td>6</td>
</tr>
<tr>
<td>Arrhythmogenic right ventricular cardiomyopathy</td>
<td>4</td>
</tr>
<tr>
<td>Ion channel disease</td>
<td>4</td>
</tr>
<tr>
<td>Mitral valve prolapse</td>
<td>3</td>
</tr>
<tr>
<td>Bridged left anterior descending coronary artery</td>
<td>3</td>
</tr>
<tr>
<td>Atherosclerotic coronary artery disease</td>
<td>3</td>
</tr>
<tr>
<td>Aortic rupture</td>
<td>3</td>
</tr>
<tr>
<td>Aortic stenosis</td>
<td>2</td>
</tr>
<tr>
<td>Dilated cardiomyopathy</td>
<td>2</td>
</tr>
<tr>
<td>Wolff-Parkinson-White syndrome</td>
<td>2</td>
</tr>
<tr>
<td>Others</td>
<td>5</td>
</tr>
</tbody>
</table>

* Findings suggestive but not diagnostic of hypertrophic cardiomyopathy.


Customary screening for U.S. high school and college athletes is confined to history taking and physical examination, which is known to be limited in its power to consistently identify important cardiovascular abnormalities. The AHA has recommended its 12-point screening procedure as shown in Box 34-1. As can be seen, eight of the 12 points are related to the history, and the remaining four are physical examination. Although the European Society of Cardiology (ESC) has recommended electrocardiography (ECG) with each evaluation, the AHA did not recommend other testing on a routine basis. The ESC believes that ECGs will detect most cases of HCM. Although that may be true, the AHA believes that the cost of doing ECGs versus the yield is prohibitive and that the cost of evaluating false-positive results is too great to make this practice cost effective. Currently, there are no comparative data using the two approaches, and there are few data to support that either approach significantly reduces the risk of sudden athletic death.

History and Physical Examination
History and Physical Examination

Although simple history and physical examination can raise the suspicion of cardiovascular disease in some at-risk athletes, they do not have sufficient power to guarantee detection of many critical cardiovascular abnormalities. However, the AHA’s screening method has the capability of raising the clinical suspicion of several cardiovascular abnormalities.

1. History of syncope, chest pain, dyspnea, and fatigue, particularly when associated with exertion, is important.
2. Family history of premature cardiac death, sudden unexpected death, and heritable diseases should be noted.
3. Physical examination detects significant aortic or pulmonary stenosis or coarctation of the aorta.

**BOX 34-1 American Heart Association Consensus Panel Recommendations for Preparticipation Athlete Screening**

**Family History**
1. Premature sudden cardiac death
2. Heart disease in surviving relative younger than 50 years old

**Personal History**
3. Heart murmur
4. Systemic hypertension
5. Fatigue
6. Syncope or near syncope
7. Excessive or unexplained exertional dyspnea
8. Exertional chest pain

**Physical Examination**
9. Heart murmur (supine or standing*)
10. Femoral arterial pulses (to exclude coarctation of the aorta)
11. Stigmata of Marfan syndrome
12. Brachial blood pressure measurement (sitting)

* In particular, to identify heart murmur consistent with dynamic obstruction to the left ventricular outflow tract.

4. Identification of HCM by the standard history and physical examination is unreliable because (a) most patients with HCM have the nonobstructive form of the disease (and thus no audible heart murmur), and (b) most athletes with HCM do not experience exertional syncope or have a family history of the disease or premature sudden death.

If cardiovascular abnormalities are suspected by the AHA’s screening procedure, a physician should request specialty consultation or order additional testing. The athlete should be temporarily withdrawn from activities until the issue can be resolved. The utility of ECG and an echocardiographic study are briefly outlined below, although they are not routinely recommended by the AHA.

**Electrocardiography**

The 12-lead ECG is a practical and cost-effective strategic alternative to routine echocardiography.

1. The ECG findings are abnormal in up to 75% to 95% of patients with HCM. Common ECG abnormalities in HCM include left ventricular hypertrophy (LVH), ST-T changes, and abnormally deep Q waves (owing to septal hypertrophy) with diminished or absent R waves in the left precordial leads. Occasionally, “giant” negative T waves are seen in the left precordial leads. Cardiac arrhythmias and first-degree atrioventricular (AV) block may be seen occasionally.
2. Coronary artery abnormalities may show ST-T wave abnormalities or abnormal Q waves.
3. It will also identify other abnormalities such as the long QT syndrome (prolonged QTc interval >0.46 sec), Brugada syndrome (right bundle branch block [RBBB] with ST-segment elevation), and other inherited syndromes associated with ventricular arrhythmias.
4. It may also raise suspicion of myocarditis (premature ventricular contractions [PVCs], ST-T changes), or arrhythmogenic right ventricular (RV) cardiomyopathy (by T-wave inversion in leads V1 through V3, tall P waves, decreased RV potentials).
5. However, abnormal ECG findings are seen in about 40% of trained athletes, and this may be the source of confusion. ECG abnormalities seen in trained athletes include increased R- or S-wave voltages, Q-wave and repolarization abnormalities, and frequent or complex ventricular tachyarrhythmias on Holter ECG monitors.
6. On the other hand, normal ECG does not necessarily rule out significant cardiac abnormalities.

**Echocardiography**

Echocardiographic study is the principal diagnostic imaging modality for clinical identification of HCM and other cardiac abnormalities.

1. HCM can be reliably diagnosed by two-dimensional echocardiography. Diastolic left ventricular (LV) wall thickness of 15 mm or greater (or on occasion, 13 or 14 mm), usually with LV dimension of less than 45 mm, is accepted for the clinical diagnosis of HCM in
adults. For children, z-score of 2 or more relative to body surface area is theoretically compatible with the diagnosis.

The hearts of some highly trained athletes may show hypertrophy of the LV wall, making the differentiation between the physiologic hypertrophy and HCM difficult. An LV wall thickness of 13 mm or greater is very uncommon in highly trained athletes and is always associated with an enlarged LV cavity (with LV diastolic dimension >54 mm, ranging from 55–63 mm). Therefore, athletes with LV wall thickness greater than 16 mm and a nondilated LV cavity are likely to have HCM (Pelliccia et al, 1991).

2. Echocardiography is also expected to detect other congenital structural abnormalities, such as valvular heart disease (aortic stenosis, pulmonary stenosis), Marfan’s syndrome (aortic root dilatation, MVP), myocarditis, and dilated cardiomyopathy (LV dysfunction or enlargement).

3. Definitive diagnosis of congenital coronary artery anomalies may not be accomplished by echo studies; it may require other tests such as computed tomography or coronary angiography.

Although the primary obligation of a physician to the athletes is their best medical interest, the physician must avoid unnecessary exclusion from sports. The physician should seek consultations from a specialist or order additional testing (e.g., ECG, echocardiography) to minimize unnecessary disqualification. The athlete should be temporarily withdrawn from activities until the issue can be resolved. After evaluation by a specialist, if the general physician and the specialist both agree that the patient’s condition requires disqualification, then they should not hesitate to disqualify the individual from participation. Such decisions, if based on a reasonable preparticipation evaluation, have generally been upheld in court cases. Also, there seems to be little liability risk if an asymptomatic condition is missed.

The physician should resist pressure from competing interest such as the athlete, the family, the coach, and administrative officials of the educational institution. The importance of the player to the team should be a secondary factor; it is the player’s safety that should be the primary factor in making recommendations. After a decision has been made, the physician should report only to the patient and his or her parents; the referring doctor; and in some cases, the institutional officials when an institution is paying for the medical evaluation.
Classification of Sports

If cardiovascular or other abnormalities are found when evaluating an individual, the next step is to estimate how much physical exercise can be safely tolerated. Depending on the cardiac condition, the athlete may be able to safely engage in less demanding athletic activities. This requires knowledge of the type of exercise the individual will be doing, how much static and dynamic exertion is required, and how vigorous the training program is.

For the purpose of making recommendations on athletes’ participation eligibility, Task Force 8 of the 36th Bethesda Conference (Fig. 34-1) has presented the following classification of sports. Sports can be classified according to the type and intensity of exercise performed and with regard to the danger of bodily injury from collision as well as the consequences of syncope. Sports are divided into two broad types, dynamic and static, and each sport is categorized by the level of intensity (low, medium, or high). This should not be regarded as a rigid classification but rather a spectrum in which some athletes in the same sport could possibly deserve placement in different categories.

![Figure 34-1](image)

**FIGURE 34-1** Classification of sports. Max O$_2$, maximal oxygen uptake; MVC, maximal voluntary contraction; *Danger of bodily collision; †Increased risk if syncope occurs. Modified from Mitchel JH, Haskel W, Snell P, Van Camp SP: Task Force 8: Classification of sports. J Am Coll Cardiol 45:1364-1367, 2005.

Dynamic (isotonic) exercise involves changes in muscle length and joint movement with rhythmic contractions that develop relatively small intramuscular force; static (isometric) exercise involves development of relatively large intramuscular force with little or no change in muscle length or joint movement. Most sports activities are a combination of static and dynamic exercises. The terms *dynamic* and *static* exercise
characterize activity on the basis of the mechanical action of the muscles involved and are different from the terms *aerobic* and *anaerobic* exercise. The latter characterizes activity on the basis of the type of muscle metabolism.

Dynamic exercise causes a marked increase in oxygen consumption with a substantial increase in cardiac output, heart rate, stroke volume, and systolic BP and a decrease in diastolic pressure and systemic vascular resistance. Static exercise, in contrast, causes a small increase in oxygen consumption, cardiac output, and heart rate and no change in stroke volume. There is a marked increase in systolic, diastolic, and mean arterial pressures and no appreciable change in total peripheral resistance. Thus, whereas dynamic exercise primarily causes a volume load on the left ventricle, static exercise causes a pressure load.
Eligibility Determination of Athletes with Cardiovascular Diseases

For the purpose of eligibility recommendations for athletes with cardiovascular abnormalities, recommendations for each specific condition are presented in table format for easy access of information.

1. Acyanotic congenital heart defects (CHDs)
2. Cyanotic congenital heart defects
3. Coronary artery anomalies
4. Valvular heart disease
5. Cardiomyopathy, pericarditis, and other select cardiovascular diseases
6. Cardiac arrhythmias
7. AV or intraventricular block
8. Systemic hypertension

Most of the recommendations are excerpts from the 36th Bethesda Conference (2005). These recommendations apply to athletes in high school and college. For middle school and elementary school children, less strict restriction may apply because of less strenuous training and sports activities. However, the above guidelines are still useful in making final recommendations for this group of athletes as well.

It should be noted that beta-blockers that are used to treat certain heart conditions and arrhythmias are expressly banned in sports like riflery (class IA) and archery (class IIA) in which the athlete would benefit from a slow heart rate. Putting athletes on beta-blockers would risk their having a positive drug test result.

Acyanotic Congenital Heart Defects

The participation eligibility of athletes with acyanotic heart diseases (which include left-to-right shunt lesions and obstructive lesions) is importantly determined by the level of pulmonary artery (PA) systolic pressure and the status of LV systolic function. Note that pressure levels shown below are those obtained in the cardiac catheterization laboratory (i.e., peak-to-peak pressure gradient): Doppler-derived pressure gradients are higher than these (see Chapter 29).

1. PA systolic pressure
   a. When PA systolic pressure is 30 mm Hg or less (or Doppler-estimated PA systolic pressure is <36 to 40 mm Hg), full participation in all competitive sports is allowed.
   b. When PA systolic pressure is greater than 30 mm Hg (or Doppler-estimated PA systolic pressure of >36 to 40 mm Hg), a full evaluation will determine limitations in participation eligibility. With mild PH, low-intensity sports (IA) are permitted. With pulmonary vascular obstructive disease (PVOD), no competitive sports are allowed.

2. Left ventricular (LV) systolic function
   a. When LV systolic function is normal (with ejection fraction [EF] ≥50%), full participation is allowed.
   b. With mild LV dysfunction (EF 40%–50%), low-intensity static sports (class IA, IB,
and IC) are allowed.
c. With moderate to severe LV dysfunction (EF <40%), no competitive sports are allowed.

Detailed participation recommendations for specific left-to-right shunt lesion and obstructive lesion are presented in Table 34-2.

**Cyanotic Congenital Heart Defects**

In patients with arterial oxygen desaturation from cyanotic CHD, moderate to severe restriction in sports participation is recommended.
1. Patients with cyanotic CHDs, which are unoperated or for which palliative procedures have been done, can only participate in low-intensity competitive sports, such as class IA.
2. Most patients with cyanotic CHDs for which surgical repair have been done can only participate in low-intensity sports.
3. Patients who have received an excellent result from the surgical repair of tetralogy of Fallot or arterial switch operation for transposition of the great arteries may participate in all competitive sports.

Detailed recommendations are provided for specific cyanotic heart defects in Table 34-3.

**Coronary Artery Abnormalities**

For most patients with congenital abnormalities of the coronary arteries or after Kawasaki’s disease, moderate to severe restriction in sports participation is recommended. Children who had no coronary artery involvement during the acute phase of Kawasaki’s disease may participate in all sports 6 to 8 weeks after the illness. Stress testing is often required before prescribing participation eligibility. Detailed participation recommendations for specific conditions with coronary artery abnormalities are presented in Table 34-4.

**Valvular Heart Diseases**

The severity of the valvular lesion determines the eligibility of participation in competitive sports.
1. With mild valvular lesions (e.g., mitral stenosis, mitral regurgitation, atrial stenosis, and atrial regurgitation), participation in all competitive sports is allowed.
2. With moderate valvular lesions, participation is limited to low to moderate-intensity sports.
3. With severe obstructive lesions such as atrial stenosis, participation in competitive sports is not permitted.
4. With valvular lesions that produce significant PH, no participation in competitive sports is permitted.
5. For patients with prosthetic valve and taking warfarin, no sports involving the risk of
bodily contact is allowed.

Detailed participation recommendations for specific valvular heart disease are presented in Table 34-5.

### Table 34-2

**PARTICIPATION RECOMMENDATIONS FOR ACYANOTIC CONGENITAL HEART DEFECTS**
<table>
<thead>
<tr>
<th>Heart Defect</th>
<th>Clinical Status</th>
<th>Can Participate in</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASD, untreated</td>
<td>Small ASD with normal PA pressure Moderate to large ASD with mild PH Large ASD with severe PH (cyanosis)</td>
<td>All competitive sports, Class IA sports, No competitive sports</td>
</tr>
<tr>
<td>ASD, closed by surgery or device</td>
<td>Postclosure ASD in the absence of PH, symptomatic arrhythmias, or second- or third-degree AV block Athletes with PH, arrhythmias, or AV block</td>
<td>All sports (3–6 mo after closure)</td>
</tr>
<tr>
<td>VSD, untreated</td>
<td>VSD with normal PA pressure Large VSD (without marked PH) requires surgery</td>
<td>All competitive sports, All competitive sports (3–6 mo after surgical repair)</td>
</tr>
<tr>
<td>VSD, closed</td>
<td>Asymptomatic, no or small residual defect, and no PH Symptomatic arrhythmias, or second- or third-degree AV block Persistent severe PH</td>
<td>All sports (3–6 mo after closure), See Table 34-7 recommendations</td>
</tr>
<tr>
<td>PDA</td>
<td>Small PDA Moderate to large PDA: requires surgery</td>
<td>No competitive sports, All competitive sports (3–6 mo after surgical repair)</td>
</tr>
<tr>
<td>PDA, closed</td>
<td>Residual PH Moderate or large PDA with severe PH and cyanosis Asymptomatic with no PH and no LV enlargement</td>
<td>No competitive sports, All sports (after 3 mo), Class IA or no competitive sports</td>
</tr>
<tr>
<td>PS, untreated</td>
<td>Mild PS (peak Doppler gradient &lt;40 mm Hg) and normal RV function Moderate PS (peak Doppler gradient, 40–60 mm Hg) and severe PS (peak gradient &gt;60 mm Hg)</td>
<td>Class IA and IB, All competitive sports, annual reevaluation needed</td>
</tr>
<tr>
<td>PS, treated</td>
<td>No or mild residual PS and normal ventricular function Residual Doppler gradient &gt;40 mm Hg Severe PR with marked RV enlargement</td>
<td>All competitive sports (2–4 wk after balloon valvuloplasty is performed)</td>
</tr>
<tr>
<td>AS, untreated</td>
<td>Mild AS (peak Doppler gradient &lt;40 mm Hg), with normal ECG, normal EST, no symptoms, and no symptomatic arrhythmias Moderate AS (peak Doppler gradient, 40–70 mm Hg), asymptomatic, with mild or no LVH (echocardiography), no strain pattern on ECG, normal EST Moderate AS with SVT or multiple or complex ventricular arrhythmias at rest or with exercise Severe AS (peak Doppler gradient &gt;70 mm Hg)</td>
<td>All competitive sports, Class IA, IB, and IIA, Class IA and IB</td>
</tr>
<tr>
<td>AS, treated by surgery or balloon</td>
<td>Residual mild, moderate, or severe AS Moderate to severe AR</td>
<td>No competitive sports, Same as untreated AS, See Table 34-5 recommendations</td>
</tr>
<tr>
<td>COA, untreated</td>
<td>Mild COA (no aortic root dilatation, normal EST, arm-to-leg SP gradient at rest &lt;20 mm Hg, and arm SP &lt;230 mm Hg with exercise)</td>
<td>All competitive sports, Only class IA until treated</td>
</tr>
<tr>
<td>COA, treated by surgery or balloon</td>
<td>Arm-to-leg SP gradient &gt;20 mm Hg or exercise-induced hypertension with arm SP &gt;230 mm Hg Arm-to-leg SP gradient &lt;20 mm Hg at rest and normal arm SP during rest and exercise Significant aortic dilatation, wall thinning, or aneurysm formation</td>
<td>All competitive sports 3 mo after repair, Class IA and IB</td>
</tr>
</tbody>
</table>

AS, Aortic (valve) stenosis; ASD, atrial septal defect; AV, atrioventricular; COA, coarctation of the aorta; EST, exercise stress test; LV, left ventricle; MR, mitral regurgitation; PA, pulmonary artery; PDA, patent ductus arteriosus; PH, pulmonary hypertension; PR, pulmonary regurgitation; PS, pulmonary (valve) stenosis; RV, right ventricle; SP, systolic pressure; SVT, supraventricular arrhythmia; VSD, ventricular septal defect.

<table>
<thead>
<tr>
<th>TABLE 34-3</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARTICIPATION RECOMMENDATIONS FOR CYANOTIC CONGENITAL HEART DEFECTS</td>
</tr>
<tr>
<td>Heart Defect</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Cyanotic CHD, unoperated</td>
</tr>
</tbody>
</table>
| Cyanotic CHD, palliated                         | Palliated patients with the following criteria:  
- Arterial $O_2$ saturation $>80\%$  
- No history of syncope or presyncope from tachyarrhythmias  
- Absence of moderate or severe ventricular dysfunction (EF $<40\%$)  

Residual problems with the following findings:  
- Marked PR and RV volume overload  
- Residual RV hypertension ($RV \text{ SP} \geq 50\%$ systemic pressure)  
- Atrial or ventricular tachyarrhythmias                                                                 | Class I A sports                                      |
| TOF, postoperative                               | Excellent repair with the following findings:  
- Normal or near normal RV pressure  
- No or only mild RV volume overload  
- No significant residual shunt  
- No atrial or ventricular tachyarrhythmias on ambulatory ECG or exercise testing  

Residual problems with the following findings:  
- Marked FR and RV volume overload  
- Residual RV hypertension (RV SP $\geq 50\%$ systemic pressure)  
- Atrial or ventricular tachyarrhythmias                                                                 | All competitive sports                                |
| TGA, post-atrial repair surgery (Senning)        | Athletes with the following findings:  
- Mild or no cardiac chamber enlargement on chest radiography  
- No history of atrial flutter, SVT, or ventricular tachyarrhythmias  
- Normal EST (normal duration, workload, heart rate, ECG, and BP response)  

Athletes not in the above category                                                                                                 | Class I A and IIA sports                              |
| TGA, post-arterial switch operation              | Athletes with normal ventricular function, normal EST, no atrial or ventricular tachyarrhythmias  

Athletes with more than mild hemodynamic abnormalities or ventricular dysfunction but with normal EST findings | Class I A, I B, I C, and I IIA sports                 |
| Congenitally corrected TGA                      | Asymptomatic patients without other cardiac abnormalities with the following findings:  
- No systemic ventricular enlargement  
- No atrial or ventricular tachyarrhythmias on ambulatory ECG or exercise testing, or  
- Normal EST findings  

Periodic reevaluation is required to detect arrhythmias or systemic ventricular dysfunction, and systemic AV valve regurgitation | Not allowed in class I I I A, I I I B, or I I I C or power weightlifting |
| Fontan operation, postoperative                 | Post-Fontan patients  

Post-Fontan patients with normal ventricular function and $O_2$ saturation                                                                 | Class I A sports                                      |
| Ebstein's anomaly, postoperative               | Mild Ebstein's anomaly (with no cyanosis, normal RV size, no atrial or ventricular arrhythmias)  

Moderate TR but no arrhythmia on Holter ECG other than isolated premature contractions  

Severe Ebstein's anomaly  
- Mild or no TR with  
- No cardiac chamber enlargement  
- No symptomatic atrial or ventricular arrhythmias  

Excellent hemodynamics after repair                                                             | No competitive sports                                  |

AV, Atrioventricular; BP, blood pressure; CHD, congenital heart defects; ECG, electrocardiogram; EF, ejection fraction; EST, exercise stress test; LV, left ventricle; PR, pulmonary regurgitation; RV, right ventricle; SP, systolic pressure; SVT,
supraventricular tachycardia; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; TR, tricuspid regurgitation; VSD, ventricular septal defect.

### TABLE 34-4
PARTICIPATION RECOMMENDATIONS FOR CORONARY ANOMALIES

<table>
<thead>
<tr>
<th>Heart Condition</th>
<th>Clinical Status</th>
<th>Can Participate in</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congenital CA anomalies</td>
<td>Presurgery: CA arising from wrong sinus, passing between great arteries</td>
<td>Exclusion from all competitive sports</td>
</tr>
<tr>
<td></td>
<td>Postsurgery: without ischemia, ventricular dysfunction, or arrhythmia during maximal EST</td>
<td>All competitive sports (3 mo after successful surgery)</td>
</tr>
<tr>
<td>Kawasaki’s disease</td>
<td>No CA abnormalities or transient CA ectasia resolving during the convalescent phase</td>
<td>All competitive sports (after 6–8 weeks)</td>
</tr>
<tr>
<td></td>
<td>Regressed aneurysm with no evidence of exercise-induced ischemia by EST with myocardial perfusion scan</td>
<td>All competitive sports</td>
</tr>
<tr>
<td></td>
<td>Isolated small- to medium-sized aneurysm in one or more CAs (but with normal LV function, no exercise-induced ischemia, or arrhythmia)</td>
<td>Class IIA, IIB, IIIA, and IIIB sports (EST every 1–2 yr)</td>
</tr>
<tr>
<td></td>
<td>One or more large CA aneurysms or multiple or complex aneurysm, with or without obstruction to coronary blood flow, with normal LV function, and no exercise-induced arrhythmias</td>
<td>Class IA and IIIA sports</td>
</tr>
<tr>
<td>Recent MI or revascularization</td>
<td>1. Those with normal LV function and EST, no reversible ischemia on myocardial perfusion scan, no exercise-induced arrhythmia</td>
<td>No competitive sports for 6–8 wks</td>
</tr>
<tr>
<td></td>
<td>2. Those with LV EF &lt;40%, exercise intolerance, or exercise-induced ventricular arrhythmia</td>
<td>1. Class IA and IB sports</td>
</tr>
<tr>
<td></td>
<td>Patients with CA lesions and taking warfarin and/or aspirin</td>
<td>2. No competitive sports</td>
</tr>
</tbody>
</table>

CA, Coronary artery; EF, ejection fraction; EST, exercise stress test; LV, left ventricle; MI, myocardial infarction.


### TABLE 34-5
PARTICIPATION RECOMMENDATIONS FOR VALVULAR HEART DISEASE
<table>
<thead>
<tr>
<th>Heart Condition</th>
<th>Clinical Status</th>
<th>Can Participate in</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitral stenosis (MS)</td>
<td>Mild MS (valve area &gt; 1.5 cm²; rest PA SP ≤ 20 mm Hg)</td>
<td>All competitive sports</td>
</tr>
<tr>
<td></td>
<td>Moderate MS (valve area 1.0–1.5 cm²; rest PA SP ≤ 50 mm Hg)</td>
<td>Class IA, IB, IIA, and IIB sports</td>
</tr>
<tr>
<td></td>
<td>Severe MS (valve area &lt; 1.0 cm²; rest PA SP &gt; 50 mm Hg)</td>
<td>No participation in any competitive sports</td>
</tr>
<tr>
<td></td>
<td>MS of any severity with AF or history of AF (with anticoagulation)</td>
<td>No participation in any competitive sports</td>
</tr>
<tr>
<td>Mitral regurgitation (MR)</td>
<td>Mild to moderate MR with sinus rhythm, normal LV size and function, and normal PA pressure</td>
<td>All competitive sports</td>
</tr>
<tr>
<td></td>
<td>Mild to moderate MR with sinus rhythm, normal LV systolic function, and mild LV enlargement (≤ 60 mm)</td>
<td>Class IA, IB, IC, IIA, IIB, and IIC sports</td>
</tr>
<tr>
<td></td>
<td>Severe MR + definite LV enlargement (≥ 60 mm), PH, or any degree of LV systolic dysfunction at rest</td>
<td>No participation in any competitive sports</td>
</tr>
<tr>
<td></td>
<td>Patients in AF or history of AF receiving anticoagulation</td>
<td>No participation in any competitive sports</td>
</tr>
<tr>
<td>Aortic stenosis (AS)</td>
<td>Mild AS (mean gradient &lt; 25 mm Hg)</td>
<td>All competitive sports</td>
</tr>
<tr>
<td></td>
<td>Moderate AS (mean gradient 25–40 mm Hg) with abnormalities in any of the above categories</td>
<td>Class IA sports</td>
</tr>
<tr>
<td></td>
<td>Moderate AS with EST performed to the level comparable to a competitive sport with no symptoms, ST depression or ventricular arrhythmias, and normal BP response</td>
<td>Class IA, IB, and IIA sports</td>
</tr>
<tr>
<td></td>
<td>Severe AS (mean gradient &gt; 40 mm Hg) or symptomatic patients</td>
<td>No participation in any competitive sports</td>
</tr>
<tr>
<td>Aortic regurgitation (AR)</td>
<td>Mild or moderate AR (with slight or no LVE)</td>
<td>All competitive sports</td>
</tr>
<tr>
<td></td>
<td>Mild to moderate AR (with moderate LVE) but with good EST to the level of that sport with no symptoms or ventricular arrhythmia</td>
<td>Class IA, IB, IC, IIA, IIB, and IIC sports</td>
</tr>
<tr>
<td></td>
<td>Mild to moderate AR with asymptomatic nonsustained ventricular tachycardia</td>
<td>Class IA sports</td>
</tr>
<tr>
<td></td>
<td>Severe AR and LVE (&gt; 65 mm) or those with mild to moderate AR and symptoms</td>
<td>No participation in any competitive sports</td>
</tr>
<tr>
<td></td>
<td>AR and significant dilatation of the proximal ascending aorta (&gt; 45 mm) who do not have Marfan’s syndrome</td>
<td>Only in class IA sports</td>
</tr>
<tr>
<td>Bicuspid aortic valve (BAV)</td>
<td>No aortic root dilatation and no significant AS or AR</td>
<td>All competitive sports</td>
</tr>
<tr>
<td></td>
<td>BAV with dilated aortic root (40–45 mm)</td>
<td>Class IA, IB, IIA, and IIB sports</td>
</tr>
<tr>
<td>Prosthetic heart valves</td>
<td>Bioprosthetic mitral valve, not taking warfarin, and with normal valve function and normal or near normal LV function</td>
<td>Class IA, IB, IIA, and IIB sports</td>
</tr>
<tr>
<td></td>
<td>Mechanical or bioprosthetic aortic valve with normal valve function and normal LV function</td>
<td>Class IA, IB, and IIA sports</td>
</tr>
<tr>
<td></td>
<td>Those with prosthetic aortic or mitral valve taking warfarin</td>
<td>No sports involving the risk of bodily contact</td>
</tr>
</tbody>
</table>
### Aortic Stenosis (AS)
- Mild AS (mean gradient <25 mm Hg)
- Moderate AS (mean gradient 25–40 mm Hg) with abnormalities in any of the above categories
- Moderate AS with EST performed to the level comparable to a competitive sport with no symptoms, ST depression or ventricular arrhythmias, and normal BP response
- Severe AS (mean gradient >40 mm Hg) or asymptomatic patients

### Aortic Regurgitation (AR)
- Mild or moderate AR (with slight or no LVE)
- Mild to moderate AR (with moderate LVE) but with good EST to the level of that sport with no symptom or ventricular arrhythmia
- Mild to moderate AR with asymptomatic nonsustained ventricular tachycardia
- Severe AR and LVE (>65 mm) or those with mild to moderate AR and symptoms

### Bicuspid Aortic Valve (BAV)
- No aortic root dilatation and no significant AS or AR
- BAV with dilated aortic root (40–45 mm)

### Prosthetic Heart Valves
- Bioprosthetic mitral valve, not taking warfarin, and with normal valve function and normal or near normal LV function
- Mechanical or bioprosthetic aortic valve with normal valve function and normal LV function
- Those with prosthetic aortic or mitral valve taking warfarin

### Cardiomyopathy, Pericarditis, and Other Myocardial Diseases

Detailed participation recommendations for specific disorders of the myocardium, pericardium, and other related cardiovascular diseases are presented in Table 34-6.  
1. Athletes who have either confirmed or probable diagnosis of HCM or arrhythmogenic RV dysplasia are excluded from most competitive sports, with the possible exception of...
class IA sports.
2. Athletes with myocarditis or pericarditis of any etiology should be excluded from all competitive sports during the acute phase. After complete recovery from these illnesses, they may gradually participate in sports.

TABLE 34-6
PARTICIPATION RECOMMENDATIONS FOR CARDIOMYOPATHY, PERICARDITIS, AND OTHER SELECTED CARDIOVASCULAR DISEASES
<table>
<thead>
<tr>
<th>Heart Condition</th>
<th>Clinical Status</th>
<th>Can Participate in</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertrophic cardiomyopathy (HCM)</td>
<td>Probable or definite diagnosis of HCM (regardless of age, gender, symptoms, LVOT obstruction, prior drug treatment, or ICD)</td>
<td>Exclude from most competitive sports, with the possible exception of class IA sports</td>
</tr>
<tr>
<td>Arrhythmogenic RV dysplasia</td>
<td>Diagnosis of arrhythmogenic RV dysplasia</td>
<td>No competitive sports, with the possible exception of class IA sports</td>
</tr>
<tr>
<td>Myocarditis</td>
<td>Probable or definite myocarditis When the following occurs:</td>
<td>Exclude from all competitive sports</td>
</tr>
<tr>
<td></td>
<td>• Normal LV function</td>
<td>May return to training or competition</td>
</tr>
<tr>
<td></td>
<td>• No arrhythmias on ambulatory ECG</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• No serum markers of inflammation and heart failure</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Normal 12-lead ECG</td>
<td></td>
</tr>
<tr>
<td>Pericarditis</td>
<td>Pericarditis, regardless of etiology</td>
<td>No competitive sports during the acute phase</td>
</tr>
<tr>
<td>Mitral valve prolapse (MVP)</td>
<td>Athletes with MVP without any of the following features:</td>
<td>All competitive sports</td>
</tr>
<tr>
<td></td>
<td>• Prior syncope judged to be caused by arrhythmia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Sustained or nonsustained SVT or complex VT on ambulatory ECG</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Severe MR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• LV systolic dysfunction (EF &lt;50%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Prior embolic event</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• FH of MVP-related sudden death</td>
<td></td>
</tr>
<tr>
<td>Marfan’s syndrome</td>
<td>If patients with Marfan’s syndrome do not have the following:</td>
<td>Class IA and II A sports (repeat echocardiography every 6 mo to measure aortic root dimension)</td>
</tr>
<tr>
<td></td>
<td>• Aortic root dilatation (≥2 SD from mean in children; ≥40 mm in adults)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Moderate to severe MR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• FH of dissection or sudden death</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Athletes with aortic root dilatation (≥40 mm), prior aortic root reconstruction, moderate to severe MR, FH of dissection or sudden death</td>
<td>Class IA sports only</td>
</tr>
<tr>
<td>Ehlers-Danlos syndrome</td>
<td>Diagnosis of Ehlers-Danlos syndrome</td>
<td>No competitive sports</td>
</tr>
<tr>
<td>Myocardial bridging</td>
<td>Myocardial bridging without evidence of myocardial ischemia at rest or during exercise</td>
<td>All competitive sports</td>
</tr>
<tr>
<td></td>
<td>Myocardial bridging with objective evidence of myocardial ischemia or prior MI</td>
<td>Class IA sports only</td>
</tr>
<tr>
<td></td>
<td>Asymptomatic athletes who had surgical resection or stenting for myocardial bridging should undergo EST if the EST findings are normal 6 months after the procedure</td>
<td>All competitive sports</td>
</tr>
</tbody>
</table>

EF, Ejection fraction; EST, exercise stress testing; FH, family history; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter-defibrillator; LV, left ventricle; LVOT, left ventricular outflow tract; MI, myocardial infarction; MR, mitral regurgitation; MVP, mitral valve prolapse; RV, right ventricle; SD, standard deviation; SVT, supraventricular tachycardia; VT, ventricular tachycardia.

3. Athletes with Marfan’s syndrome can participate only in class IA or IB sports.
4. Athletes with MVP who have any symptoms or abnormalities in ECG, LV function, or arrhythmias are permitted to participate only in low-intensity sports.
5. Athletes with myocardial bridging without ischemia at rest and during exercise may participate in all sports.

Detailed participation recommendations for specific valvular heart disease are presented in Table 34-6.
Cardiac Arrhythmias and Sports

Although sudden unexpected death in young athletes is rare, a significant portion of these deaths occurs in relation to exercise, and it is probably related to cardiac arrhythmias. Cardiac arrhythmias occurring while playing sports, however, manifest more often with syncope or near syncope than sudden death. A cardiac arrhythmia should be considered a possible cause of syncope, particularly when it occurs during or immediately after exercise, and a thorough evaluation is required. Although syncope may signal the presence of a serious cardiac problem, it may also be due to a benign mechanism such as vasovagal syncope, which is a common finding in highly trained athletes. However, the diagnosis of such a benign mechanism should not be made without first excluding underlying structural disease or electrical disorders (see Chapter 31 for further description).

Arrhythmias may be associated with a variety of structural heart disease. In the absence of identifiable structural abnormalities of the heart, it may be due to primary electrical disorders, such as an supraventricular tachycardia (SVT) associated with WPW preexcitation or ventricular tachycardia (VT) secondary to long QT syndrome. A number of stimulant-containing drinks that are popular among young athletes can trigger certain arrhythmias. Abuse with drugs such as cocaine or ephedra can precipitate life-threatening arrhythmias.

Young athletes with an arrhythmia who are permitted to engage in athletic activities should be reevaluated at 6- to 12-month intervals to determine whether the training process affected the arrhythmia. Follow-up evaluation should be done to check on compliance of antiarrhythmic drugs. Use of certain drugs, such as β-adrenergic blocking agents, is banned in some competitive sports, such as archery and riflery, in which athletes benefit from slow heart rates.

Diagnostic Workup

In general, all athletes with possible cardiac arrhythmias being considered for athletic activity should have a careful history and cardiac examination, a 12-lead ECG, and an echocardiogram. In most cases, a 24-hour Holter recording and exercise stress testing (EST) are also indicated.

History

The screening questionnaires recommended by the AHA (see Box 34-1) are useful starting points in eligibility evaluation. However, review of athlete’s medical history and careful cardiac examination are often negative. The following are some important findings from the history, which should prompt one to consider the possibility of arrhythmia in an athlete.

- History of syncope, near syncope, dizziness or lightheadedness, seizures, palpitation, chest pain, or pallor
- History of known heart disease (congenital or acquired) and medications or surgery for
Family history of arrhythmias or sudden death
Certain medications or drugs of abuse (e.g., tricyclic antidepressant, inhalants, or cocaine)

Physical Examination
Physical examination may reveal an irregularity of the heart rate, but a regular heart rate on examination does not rule out arrhythmias.

Recording of the Electrocardiogram
Normal ambulatory ECG monitoring findings do not provide absolute safety or absence of arrhythmias because arrhythmias are commonly evanescent, often disappearing unpredictably for long periods of time in some cases.

Although most high school and college athletes are not fully trained athletes, it is important to understand the range of normal heart rate and rhythm for trained athletes recorded on 24-hour Holter ECG recordings.
1. Heart rates of 25 beats/min and sinus pauses for longer than 2 seconds may be found.
2. Mobitz type I second-degree AV block and single uniform PVCs each may occur in about 40% of trained athletes.
3. Complex ventricular arrhythmias (including multiform PVCs, couplets, and nonsustained VT) are rarely present without adverse clinical events (Marion et al, 2006).

Exercise Stress Test
An EST is often needed to document the appearance or disappearance of arrhythmias with exercise. Arrhythmias that disappear or reduce in their frequency during exercise are usually benign. Those that appear with exercise or those that increase their frequency are more significant. EST may be indicated to document the efficacy of medical treatment or ablation of arrhythmias.

Eligibility Recommendations for Cardiac Arrhythmias
Detailed participation recommendations are provided in Table 34-7 for arrhythmias based on the 36th Bethesda Conference (Zipes et al, 2005). The following are general statements regarding participation eligibility for athletes with cardiac arrhythmias.
1. The presence of a symptomatic cardiac arrhythmia requires exclusion from physical activity until this problem can be adequately evaluated and controlled by a cardiologist.
2. Sinus arrhythmias and premature atrial contractions (PACs) are benign if the heart is structurally normal; these individuals can participate in all competitive sports.
3. Asymptomatic athletes with atrial flutter or fibrillation and structurally normal hearts may participate in competitive sports when the arrhythmias are fully under control either by medication or ablation.
4. Athletes with SVT and structurally normal hearts may participate in all competitive sports when the SVT is in full control with medication or after successful ablation.
5. For athletes with structurally normal hearts who have PVCs or more complex arrhythmias, an EST is a useful technique. If the PVCs disappear when the heart rate reaches 140 to 150 beats/min, the PVCs are benign, and full participation may be permitted.

6. Athletes with VT who had successful treatment to prevent recurrence of the arrhythmias may participate in sports, provided that VT is not inducible by EST or electrophysiologic study (EPS).

7. Asymptomatic adult athletes with WPW preexcitation with no history of SVT may participate in all competitive sports, but children with the same diagnosis require in-depth evaluation.

8. Athletes with long QT syndrome can only participate in class IA sports.

9. Athletes who had a successful ablation for any of the arrhythmias may participate in all competitive sports after verification of the success by appropriate tests.

Eligibility Recommendations for Atrioventricular Block and Intraventricular Blocks

Detailed participation recommendations are provided in Table 34-8 for AV and intraventricular blocks. The following are general statements regarding participation eligibility for athletes with these abnormalities.

1. Athletes with first-degree AV block or Mobitz type 1 second-degree AV block can participate in all sports provided the block does not worsen with exercise.

### TABLE 34-7

**ELIGIBILITY RECOMMENDATIONS FOR ATHLETES WITH CARDIAC ARRHYTHMIAS**
<table>
<thead>
<tr>
<th>Arrhythmia</th>
<th>Clinical Situation</th>
<th>Can Participate in</th>
</tr>
</thead>
</table>
| Sinus node dysfunction             | Bradycardia, structurally normal heart, and appropriate increase in HR by physical activity  
Bradycardia, structural HD, and appropriate increase in HR by physical activity  
Symptomatic bradycardia (syncope or near syncope)  
Tachycardia–bradycardia syndrome, with no structural HD: should be treated  
Athlete with pacemakers            | All competitive sports  
Limitation determined by the nature of the structural HD  
No sports until the cause has been determined and treated and the patient is asymptomatic  
All competitive sports (when asymptomatic for 2–3 mo after successful treatment)  
No sports with danger of bodily collision; protective padding for soccer, basketball, baseball, softball, and so on |  
| Premature atrial contraction (PAC) | Asymptomatic PACs, structurally normal heart  
Atrial flutter, normal heart, appropriate ventricular rate response during exercise (receiving no therapy or AV nodal blocking agents)  
Atrial flutter, structural HD, no recurrence for 2–4 wk  
Atrial flutter, normal heart, postablation with no recurrence for 2–4 wk  
Atrial flutter, on anticoagulation | All competitive sports  
Class IA sports only  
Full participation allowed only when no recurrence after 2–3 mo of treatment (note: beta-blockers are prohibited in some sports)  
Class IA sports |  
| Atrial flutter                      | Atrial flutter, normal heart, appropriate ventricular rate response during exercise (receiving no therapy or AV nodal blocking agents)  
Atrial flutter, structural HD, no recurrence for 2–4 wk  
Atrial flutter, normal heart, postablation with no recurrence for 2–4 wk  
Atrial flutter, on anticoagulation | All competitive sports  
No sports with danger of bodily collision  
All competitive sports (note: beta-blockers are prohibited in some sports)  
Sports consistent with the limitation of the structural heart disease  
All competitive sports |  
| Atrial fibrillation (AF)           | Asymptomatic AF, normal heart, appropriate ventricular rate response during exercise (receiving no therapy or AV nodal blocking agents)  
AF, structural HD (receiving no therapy or AV nodal blocking agents)  
AF in normal heart, postablation with no recurrence for 4–6 wk (or EPS confirmed success)  
AF on anticoagulation | All competitive sports  
No sports with danger of bodily collision  
The same as those for sinus node dysfunction  
All competitive sports |  
| AV junctional escape beats or rhythm or premature AV junctional complexes | Usually associated with sinus node dysfunction  
Structurally normal heart, normal HR response without sustained tachycardia | The same as those for sinus node dysfunction  
All competitive sports |  
| AV junctional tachycardia           | Asymptomatic AVJT, normal heart, appropriate ventricular rate response during activity (with or without therapy)  
Asymptomatic AVJT, structural HD or incompletely controlled ventricular rate  
Inappropriately rapid ventricular rate, successful treatment to control ventricular rate with or without HD | All competitive sports  
Class IA sports  
With normal heart: class IA sports  
Structural HD: limitation consistent with the structural heart disease |
<table>
<thead>
<tr>
<th>Condition</th>
<th>Criteria</th>
<th>Sports Restrictions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supraventricular tachycardia (SVT)</td>
<td>Asymptomatic patients with normal hearts whose reproducible exercise-induced SVT has been successfully treated and verified by appropriate testing Patients with sporadic recurrences of SVT (but without exercise-induced SVT) after successful treatment to prevent recurrence Asymptomatic with episodes of SVT lasting &lt;5–15 sec, no worsening with exercise Syncope, near-syncpe, or significant symptoms, structural HD Normal heart, successful catheter or surgical ablation with no recurrence for 2–4 wk (or EPS-confirmed success)</td>
<td>All competitive sports</td>
</tr>
<tr>
<td>WPW syndrome</td>
<td>Young adults (20–25 years old), normal heart, no history of palpitation or tachycardia Younger patients, normal heart, no history of palpitation or tachycardia Episodes of reciprocating SVT with the shortest cycle length &lt;250 msec should undergo ablation Episodes of AF/flutter (with rate &gt;240 beats/min), syncope or near syncope: should receive catheter ablation Normal heart, successful catheter or surgical ablation, asymptomatic</td>
<td>All competitive sports</td>
</tr>
<tr>
<td>Premature ventricular complexes (PVCs)</td>
<td>Normal heart, asymptomatic PVCs at rest and during exercise, normal exercise test results Normal heart, PVCs increasing in frequency or becoming symptomatic: during exercise (near syncope, significant fatigue or dyspnea) Structural HD, PVCs (with or without treatment)</td>
<td>All competitive sports Class IA sports only</td>
</tr>
<tr>
<td>Ventricular tachycardia (VT)</td>
<td>Normal heart, monomorphic nonsustained or sustained VT with a specific site of origin: catheter ablation Normal heart, monomorphic VT; treated with drugs; VT not inducible by exercise, EST, or EPS VT with structural HD regardless of whether VT is suppressed or ablated Normal heart, asymptomatic, brief episodes of VT (&lt;8–10 consecutive monomorphic VT) with VT rate &lt;150 beats/min, suppression or no worsening of VT during EST compared to the baseline ICD implantation (athlete's desire to continue sports is not an indication for ICD implantation)</td>
<td>All competitive sports after successful ablation Class IA sports only All competitive sports</td>
</tr>
<tr>
<td>Ventricular flutter and VT</td>
<td>Generally requires ICD implantation</td>
<td>Class IA sports, only after no episodes for more than 6 mo</td>
</tr>
<tr>
<td>Type of AV Block</td>
<td>Clinical Situation</td>
<td>Can Participate in</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>First-degree AV block</td>
<td>Normal heart, first-degree AV block that does not worsen with exercise</td>
<td>All competitive sports</td>
</tr>
<tr>
<td>Second-degree AV block, Mobitz type 1</td>
<td>Normal heart, type 1 AV block that does not worsen with exercise</td>
<td>All competitive sports</td>
</tr>
<tr>
<td>Second-degree AV block, Mobitz type 2</td>
<td>Structural HD, type 1 AV block that does not worsen with exercise</td>
<td>As determined by the limitation of the cardiac abnormality</td>
</tr>
<tr>
<td>Congenital complete heart block</td>
<td>Structural HD, type 1 AV block that worsens during or after exercise</td>
<td>Further evaluation (may require a pacemaker)</td>
</tr>
<tr>
<td></td>
<td>The same as in acquired complete heart block: should receive a pacemaker</td>
<td>No sports with danger of bodily collision</td>
</tr>
<tr>
<td></td>
<td>Normal heart, normal ventricular function, no syncope or near syncope; narrow QRS complex; ventricular rate &gt;40–50 beats/min; HR increasing appropriately with exercise</td>
<td>Permanent pacing before any athletic activity</td>
</tr>
<tr>
<td></td>
<td>Ventricular arrhythmia, symptoms of fatigue, syncope or near-syncope: should receive a pacemaker</td>
<td>All competitive sports</td>
</tr>
<tr>
<td>Second-degree AV block, Mobitz type 2</td>
<td>Structural HD (such as shunt lesions): should receive a pacemaker</td>
<td>No sports with danger of bodily collision</td>
</tr>
<tr>
<td>Complete RBBB</td>
<td>Should receive a pacemaker</td>
<td>Sports category to be determined after EST</td>
</tr>
<tr>
<td>Complete LBBB</td>
<td>Asymptomatic, no ventricular arrhythmias, who do not develop AV block with exercise</td>
<td>All competitive sports</td>
</tr>
<tr>
<td></td>
<td>Adult athletes with acquired LBBB follow the same recommendations as RBBB</td>
<td>All competitive sports</td>
</tr>
<tr>
<td></td>
<td>Normal HV interval and normal AV conduction response to pacing</td>
<td>All competitive sports</td>
</tr>
<tr>
<td></td>
<td>Abnormal AV conduction with HV interval &gt;90 msec or His-Parkinje block should have pacemaker</td>
<td>All competitive sports</td>
</tr>
</tbody>
</table>

**AF, Atrial fibrillation; AV, atrioventricular; EPS, electrophysiologic study; HD, heart disease; HR, heart rate; ICD, implantable cardioverter-defibrillator; LQTS, long QT syndrome; VT, ventricular tachycardia; WPW, Wolff-Parkinson-White.**

2. Athletes with Mobitz type 2 second-degree AV block or complete heart block usually require pacemaker implantation before being permitted to participate in any sports.

3. Athletes who have a pacemaker implanted and those who are on anticoagulation (usually for atrial flutter or fibrillation) should not be permitted to engage in activities with danger of bodily collision. Participation in class IA sports is usually permitted.

4. Asymptomatic athletes with RBBB or left bundle branch block (LBBB) who do not have ventricular arrhythmias or develop AV block during exercise can participate in all sports. However, patients with LBBB who have an abnormal prolongation of HV interval on EPS should receive pacemakers.
Athletes with Systemic Hypertension

Reports of cerebrovascular accident during maximal exercise have raised concerns that the rise in BP accompanying strenuous activity may cause harm. However, changes in BP depend on the type of exercise in which they are engaged. For example:

1. Dynamic exercise causes a substantial increase in systolic pressure, heart rate, stroke volume, and cardiac output. A moderate increase in mean arterial pressure and a decrease in diastolic pressure occur, with a marked decrease in total peripheral resistance.
2. Static exercise, in contrast, causes a small increase in cardiac output and heart rate and no change in stroke volume. There is a marked increase in systolic, diastolic, and mean arterial pressures and no appreciable change in total peripheral resistance.

Correct diagnosis of hypertension is very important before recommending restrictions. On each occasion, two or more BP readings should be taken, and when the readings vary by greater than 5 mm Hg, additional readings should be taken until two consecutive readings are close. When the initial office BP readings are high, an out-of-office measurement of BP may be needed to exclude “white-coat” hypertension. The diagnosis of hypertension should be made only after several elevated BP readings are obtained on separate occasions. When the diagnosis of hypertension is confirmed, an evaluation including a history, thorough physical examination, and appropriate laboratory testing should be performed (see Chapter 28).

Task Force 5: Systemic Hypertension, 36th Bethesda Conference on Eligibility Recommendations for competitive sports has recommended the following (Kaplan et al, 2005).

1. Athletes with prehypertension (BP levels between the 90th and 95th percentiles or 120–139/80–89 mm Hg):
   a. May participate in physical activity but should be encouraged to modify their lifestyles
   b. If prehypertension persists, echocardiography studies are done to see if there is LVH (beyond that seen with “athletes’ heart”).
   c. If LVH is present, athletic participation is limited until the BP is normalized by appropriate drug therapy.

2. Athletes with stage 1 hypertension (BP levels between the 95th and 99th percentiles or 140–159/90–99 mm Hg):
   a. May participate in any competitive sports in the absence of target organ damage, including LVH or concomitant heart disease. However, hypertension should be checked every 2 to 4 months (or more frequently) to monitor the impact of exercise.
   b. If LVH is present, athletic participation is limited until the BP is normalized by appropriate drug therapy.

3. Athletes with stage 2 (severe) hypertension (BP level ≥5 mm Hg above the 99th percentile or >160/100 mm Hg): Even in the absence of target organ damage (e.g., LVH), athletic participation should be restricted, particularly from high-static sports (class IIIA, IIIB, and IIIC), until the hypertension is controlled by either lifestyle modification or...
drug therapy.
All drugs being taken must be registered with appropriate governing bodies to obtain a therapeutic exemption. When hypertension coexists with another cardiovascular disease, eligibility for participation in competitive sports is usually based on the type and severity of the associated condition.

With respect to the treatment of hypertension, beta-blockers are not banned for most sports, including football and basketball, but they are banned for riflery or archery. However, athletes with essential hypertension do not tolerate beta-blockers well because they reduce their maximum performance. Therefore, one should avoid treating hypertensive athletes with beta-blockers. Instead, angiotensin-converting enzyme (ACE) inhibitors or calcium channel blockers are preferred. One should be aware of the potential teratogenic effects of ACE inhibitors if they are taken during pregnancy.
Lower and Shumway at Stanford University performed the first successful orthotopic heart transplantation in a dog in 1960. Barnard in South Africa unexpectedly performed the first successful human heart transplantation in 1966. This was followed by an explosive interest in heart transplantation but almost uniformly poor results because of organ rejection. Introduction of cyclosporine in 1980 markedly improved the results of adult heart transplantation. This success has extended to pediatric patients, and the first infant cardiac transplantation was carried out by Bailey at Loma Linda University in 1985. Although some ethical and medical issues exist, cardiac transplantation will continue to contribute to the treatment of children with some heart diseases.

Physicians may have a chance to participate in the care of cardiac transplant recipients. Therefore, practitioners should have some basic knowledge on the topic, and that is the aim of this chapter. This chapter is not intended to review up-to-date advances or to provide management guidelines on transplant patients. Cardiac transplantation is done by transplantation centers with multidisciplinary teams of professionals and supporting staff who are primarily responsible for follow-up of their posttransplant patients according to the management protocol established by the center.
Indications

Pediatric heart transplantation is a treatment option for children with intractable heart failure or congenital heart defects (CHDs) not amenable to surgical palliation. Several decades ago, when the surgical mortality rate was very high, hypoplastic left heart syndrome (HLHS) was a major indication for heart transplantation. With improved surgical outcome, HLHS is no longer considered a major indication for heart transplantation.

The majority of pediatric transplant patients are those with pre- and postoperative complex CHDs and those with cardiomyopathies. In infants younger than 12 months of age, who account for about 23% of pediatric cardiac transplantation, HLHS is still the most common indication followed by dilated cardiomyopathy. In children, cardiomyopathies (dilated, hypertrophic, and restrictive) account for about 60% of the cases. Most of the other indications for the transplant are patients who had surgical repairs for complex CHDs (e.g., single ventricle, atrioventricular canal defect, truncus arteriosus, L-transposition of the great arteries). Rarely, patients with unresectable cardiac tumor are candidates for transplantation. Significant cardiac allograft vasculopathy and chronic graft dysfunction of a previous heart transplant are rare indications for heart transplantation.
Careful selection of appropriate recipients remains the most important determinant of a favorable outcome. Multidisciplinary evaluation of the recipient includes assessment of cardiopulmonary, renal, hepatic, neurologic, and infectious disease status and socioeconomic assessment. In general, the recipient should satisfy the following selection criteria:

1. Terminal heart disease with death expected within 6 to 12 months
2. The presence of adequate dimension of hilar pulmonary arteries. If the pulmonary vascular resistance (PVR) is high or if severe hypoplasia or stenosis of the pulmonary arteries is present, the patient may be a candidate for heart and lung transplantation.
3. Other general requirements:
   a. Normal function or reversible dysfunction of the kidneys and liver
   b. Lack of systemic infection
   c. Malignancy under complete remission for longer than 1 year
   d. Lack of systemic disease (e.g., diabetes and degenerative neuromuscular disease) that would limit recovery or survival
   e. Lack of drug addiction
   f. Lack of mental deficiency
4. Equally important for successful pediatric heart transplantation are a family history of stability, past history of compliance, and evidence of strong motivation for the transplant as assessed by physicians and social workers. The child and parents should demonstrate sufficient responsibility, resources, and psychological strength to cope with multiple outpatient clinic visits, routine endomyocardial biopsy, and a lifetime of vigilance of the immunosuppressed state.
5. Unique to pediatric transplantation is the requirement of a reliable caregiver for the recipient child. The caregiver identified need not be a parent but must have legal responsibility for total care and be prepared to deal with the strict medical regimen required.

   Cardiac transplantation is contraindicated:
   1. If PVR is 6 Wood units/m² or greater or
   2. Transpulmonary gradient (TPG = Pulmonary artery [PA] pressure – PA wedge pressure) is 15 mm Hg or greater, which does not respond to vasodilators.

   After the decision has been made for heart transplantation and after complete multidisciplinary evaluation, the patient is placed on the cardiac transplantation waiting list (to the United Network of Organ Sharing [UNOS] and the Regional Organ Bank). Each listing is specific for ABO blood type and the recipient’s weight.
Evaluation and Management of the Cardiac Donor

1. The cardiac donor must meet the legal definition of brain death. Most neonatal donors are victims of sudden infant death syndrome or birth asphyxia. Most older children donors are victims of car accidents or violence.

2. The screening of donor is accomplished in three phases.
   a. Primary screening is done by organ procurement specialists to obtain information on body size, ABO blood type, serologic data on hepatitis B and human immunodeficiency virus (HIV), cause of death, clinical course, and routine laboratory data.
   b. Secondary screening is performed by cardiac surgeons or cardiologists, who pay attention to the extent of other (especially thoracic) injuries, the extent of treatment required to sustain acceptable hemodynamic status, electrocardiogram (ECG), chest radiographs, arterial blood gas analysis, and echocardiogram.
   c. Tertiary screening is inspection of the heart by a “harvesting” surgeon to ensure that there is no evidence of a palpable thrill over the heart and great arteries, obvious arteriosclerotic heart disease, or myocardial contusion.

3. Donor heart should have:
   a. No evidence of cardiac abnormalities by echocardiography, ECG, or myocardial enzyme tests
   b. Left ventricular fractional shortening greater than 28%, regardless of inotropic support

4. Specific compatibility should exist between the donor and recipient in three aspects
   a. ABO blood group compatibility
   b. The donor’s body weight should be within 20% of the recipient’s weight; a larger donor heart is better tolerated than a smaller one.
   c. The donor should be within close geographic range so that the donor heart can be harvested, transported, and implanted within 4 hours (up to 9 hours for infants).

5. Medical management of donor heart before transplantation: The donor should be managed in the intensive care unit with routine monitoring. The systolic blood pressure should be maintained in the normal range (>100 mg Hg for adults). Inotropic support and fluid resuscitation may be necessary. Normal serum electrolyte levels, acid–base balance, and oxygenation should be maintained. The hematocrit should be above 30%.
FIGURE 35-1  “Right atrial” technique of cardiac transplantation. A, The recipient cardiectomy has been completed, leaving the anastomosis to be performed in the following sequence: (1) left atrium (LA), (2) aorta (Ao), (3) right atrium (RA), and (4) pulmonary artery (PA). B, The completed transplant. From Backer CL, Mavroudis C: Pediatric transplantation, Part A: Heart transplantation. In Stuart FP, Abecassis MM, Kaufman DB (eds): Organ transplantation, Georgetown, TX, Landes Bioscience, 2000.
The public often misunderstands what transplantation can accomplish. The recipient and parents must fully understand the short- and long-term implications of transplantation by knowing the following facts, which are not well publicized:

1. Unlike most cardiac surgeries, cardiac transplantation is not a cure for the condition for which it is being considered. It can be viewed as another medical problem that will require lifelong medical attention, including frequent hospital visits or admissions for noninvasive and invasive procedures, frequent adjustments of immunosuppressive and antibiotic medications, varying degrees of limitations in activity, and adjustments in lifestyle.

2. There is always a threat of rejection and infection throughout the patient’s life. Even with full compliance, rejection can occur, resulting in death or a need for retransplantation.

3. The heart received will not last for an indefinite period; it will eventually develop allograft coronary artery disease (CAD), requiring consideration of retransplantation.

4. Immunosuppressive therapy may cause malignancies (especially lymphoma in children) and an increased risk of infection.

5. Lifelong medical attention will place a tremendous financial, emotional, and social burden on the family. A dysfunctional family could result.
Operative Technique

There are currently two surgical techniques used in cardiac transplantation: the right atrial (RA) technique and the bicaval technique. The latter is a more recent technique and has become more popular than the former.

In the RA cardiac transplantation, when the native heart is explanted, the posterior walls of both atria of the recipient heart are left in place and are anastomosed to the donor heart. End-to-end anastomoses are also made between the donor and recipient aortas and pulmonary arteries (Fig. 35-1). This technique is similar to those described by Lower and Shumway in 1960. The hospital mortality rate is 10% to 15%.

A modification of the above, called “bicaval” cardiac transplantation, has become popular in some institutions (Fig. 35-2). In this technique, the RA is also explanted from the recipient, leaving only the posterior wall of the left atrium (LA) with four pulmonary veins attached. Anastomoses are made between the venae cavae, the aorta, the PA, and the LA.

FIGURE 35-2  “Bicaval” technique of cardiac transplantation. A, The recipient cardiectomy has been completed. Note that the entire right atrium has been removed. The sequence of the anastomosis is (1) left atrium (LA), (2) aortic (Ao), (3) inferior vena cava, (4) pulmonary artery (PA), and (5) superior vena cava. B, The completed transplant. From Backer CL, Mavroudis C: Pediatric transplantation, Part A: Heart transplantation. In Stuart FP, Abecassis MM, Kaufman DB (eds): Organ transplantation, Georgetown, TX, Landes Bioscience, 2000.
For patients with HLHS who are placed on a transplantation algorithm, it is necessary to keep the ductus arteriosus open and to increase the size of the interatrial communication. A hybrid procedure as described under HLHS (in Chapter 14) may be used as a bridge to cardiac transplantation, in which an endovascular stent is placed in the closing ductus to keep the ductus open and PA branches are banded to control pulmonary blood flow (see Fig. 14-49). Blade atrial septostomy followed by balloon dilatation is performed to increase the size of the interatrial communication.

For most babies with HLHS, the donor cardiectomy is modified in that the entire aortic arch is harvested well beyond the insertion of the ligamentum arteriosum to augment the ascending aorta and aortic arch, such as those shown in Figure 35-3.
Posttransplant Management

This section is not meant to describe how to take care of patients after heart transplantation. Medical professionals and support staff of the transplantation center are the providers of appropriate care for these children. This section is intended to show what is involved in the proper care of posttransplant patients for physicians who may become involved in their care. Very close follow-ups are required by frequent clinic visits and a number of investigations to detect possible rejection or infection.

Frequency of Clinic Visits and Investigations

The early postoperative period is the period of highest risk and requires a very close follow-up with frequent clinic visits and laboratory tests and other investigations. In general, the frequency of clinic visits and investigation is most intense in the first year after the transplant, and it decreases gradually thereafter. The following is an excerpt of the posttransplant follow-up plans at the Loma Linda University Children’s Hospital (Chinnock, 2012). It should be pointed out, however, that each institution has a detailed management plan established by the transplantation team, which may be somewhat different from the Loma Linda’s.

1. Office visit twice weekly for 6 weeks; then monthly visit for the first year. It is then reduced to every 3 months thereafter.
2. Echocardiography study is done twice weekly for 4 weeks; then reduced to monthly to coincide with the clinic visit.
3. ECG is done monthly for 3 months, then every 3 months for the first year, and then every 6 months thereafter.
4. Chest radiography is performed monthly for 3 months, at 12 months, and then annually.
5. Blood levels of immunosuppressive agents are obtained twice weekly for 2 weeks, weekly for 4 weeks, monthly for the first year, and then every 3 months thereafter. See a later section for target trough levels of each immunosuppressive agent.
6. Complete blood count and platelets are obtained every 2 weeks, then monthly for the first year, and then every 3 months thereafter.
7. Cytomegalovirus (CMV) immunoglobulin titer is assessed at 6 and 12 months and then annually until conversion. Epstein-Barr virus (EBV) polymerase chain reaction is assessed every 3 months. HIV and the surface antigen of the hepatitis B virus (HBsAg) tests are obtained at 6 months.
8. Isotopic glomerular filtration rate is assessed at 3 and 12 months and every year thereafter for patients who received transplant during infancy. For those who received transplant after infancy, it is assessed every 2 years.
9. Renal ultrasonography is performed at 3 and 12 months and every other year thereafter.
10. Endomyocardial biopsy is obtained annually for newborns and children 2 years or younger. For children 2 to 8 years of age, it is obtained at 1, 3, and 12 months and annually thereafter. For children 9 years of age and older, it is obtained at 1, 2, 3, 6, and 12 months and annually thereafter.
11. Coronary angiography is performed annually starting at the first anniversary of transplantation.
12. Intravascular echocardiography is performed at age 6 years and every other year thereafter.
13. All routine vaccinations, except for live virus vaccines (e.g., oral polio, varicella, and measles–mumps–rubella vaccines) should be administered, starting as early as 6 weeks after transplantation.

Overview of Immunosuppressive Therapy
Successful immunosuppression depends on a delicate balance between suppression of the host mechanisms that would reject the foreign graft and preservation of the mechanisms of the immune response that protect against bacterial, fungal, and viral invasion.

The so-called triple-drug therapy consists of three classes of medications.
1. Calcineurin inhibitors (e.g., cyclosporine [Neoral], tacrolimus [Prograf, FK506]) block T-cell cytokine gene expression.
2. Corticosteroids (methylprednisolone or prednisone) suppress cell-mediated immunity as well as the humoral immunity.
3. Antiproliferative agents (e.g., azathioprine [Imuran], mycophenolate mofetil [CellCept]) prevent rejection by interfering with purine synthesis, resulting in antiproliferative effects on T and B cells.

Calcineurin Inhibitors
Cyclosporine. Cyclosporine is the most commonly used agent for maintenance therapy. The first dose of cyclosporine (10 mg/kg) is administered before surgery because it may be most effective when given before the antigenic challenge (Table 35-1). Target trough levels of cyclosporine are as follows; 250 to 300 ng/mL for 6 months, 200 to 250 ng/mL for 6 to 12 months, and 125 to 150 ng/mL thereafter. Cyclosporine is continued for as long as the patient lives.

The drug’s primary toxic effects are hypertension and associated renal insufficiency. Other side effects of the drug include hyperlipidemia, hirsutism, gingival hyperplasia, and facial dysmorphism (with widening of the nose, thickening of the nares and lips, and prominence of the supraorbital ridge and eyebrows).

Tacrolimus (Prograf), a newer agent in the same class as cyclosporine, is being used increasingly by some centers as a primary calcineurin agent. It has remarkably lower rates of hypertension and hyperlipidemia and does not cause hirsutism, gingival hyperplasia, or the facial dysmorphism associated with cyclosporine.

Corticosteroids
Methylprednisolone (10 mg/kg for children) is administered intravenously (IV) as the sternotomy is made. After cardiopulmonary bypass has been discontinued, a 2-mg/kg IV dose is given every 8 hours, totaling three doses. After 24 hours, prednisone is administered in high doses (1 mg/kg per day by mouth). After about 3 weeks, the dose is tapered to 0.2 mg/kg per day by 3 months after surgery (see Table 35-1). Further tapering or discontinuation depends on the institution’s protocol and the presence or absence of rejection. Some centers discontinue it after 6 months, particularly in neonates and...
infants. Most centers aim to establish a steroid-free regimen in selected patients by 1 year after the transplantation to minimize the risk of steroid-associated morbidity.

Antiproliferative Agents

Azathioprine. It is given immediately after the transplantation surgery. The starting dose is 1 to 2 mg/kg per day to produce a peripheral white blood cell count around 5000/mm$^3$. If the count falls below 4000/mm$^3$, the drug is reduced, or it is stopped if the reduction is severe (see Table 35-1). The major toxicity of azathioprine is bone marrow depression and less frequently hepatotoxicity. The drug is generally continued indefinitely.

Mycophenate mofetil (CellCept) is a new agent in the antiproliferative agent group. A clinical study has demonstrated a lower rate of rejection rates than azathioprine when used with cyclosporine and corticosteroids. This agent also allowed reduction of the dosage of cyclosporine and tacrolimus, which may potentially reduce the side effects of these drugs. The dose is 600 mg/m$^2$/dose orally twice a day. Its side effects include gastrointestinal (GI) symptoms (in 30%), bone marrow suppression (anemia), hypertension, headache, fever, and increased risk of developing lymphomas or other malignancies.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Preoperative Dosage</th>
<th>Early Postoperative Dosage</th>
<th>Late Postoperative Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclosporine$^*$</td>
<td>10 mg/kg IV</td>
<td>0.5–1 mg/kg/day IV</td>
<td>3–6 mg/kg/day PO$^*$</td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td>10 mg/kg IV</td>
<td>2 mg/kg IV q8h x 3</td>
<td>Taper to 0.2 mg/kg/day PO by 3 mo; stop by 6 mo</td>
</tr>
<tr>
<td>Prednisone</td>
<td></td>
<td>1 mg/kg/day PO</td>
<td>1–2 mg/kg/day (adjust according to white blood cell count)</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>1–2 mg/kg PO or IV</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

$^*$ Adjust cyclosporine dosage by PO twice-a-day dosing (or q8h dosing for infants younger than 6 mo of age) to maintain target trough level as follows:


Early Posttransplantation Follow-Up

The highest risk of dying is in the first 6 months after transplantation. In the early postoperative period, acute graft dysfunction and technical issues account for more than 50% of the deaths. The two most common causes of death in the early posttransplant period are acute rejection (26%) and infection (16%).
Acute Rejection

Identification
1. Subtle symptoms may be the only indication of the beginning of a rejection episode. These symptoms include unexplained fever, tachycardia, fatigue, shortness of breath, joint pain, and personality changes.
2. Echocardiographic techniques rely on a physiologic abnormality of the rejecting heart (myocardial edema or decreased left ventricular contractility) (see a later section for further discussion).
3. Endomyocardial biopsy remains the most important method for identifying acute rejection. The endomyocardial biopsy is graded according to the International Society of Heart and Lung Transplantation (ISHLT) scale (2005) (Table 35-2).

Treatment. Rejection treatment depends on the grade of rejection. Generally, specific antirejection therapy is initiated only for moderate or severe rejection (grade 2R or greater).
1. Methylprednisolone (1000 mg for adults; 15 mg/kg for children weighing <50 kg) given IV or prednisone (100 mg for adults) given orally for 3 days is followed by tapering to the baseline dose over the next 2 weeks.
2. If rejection does not respond to steroids or if hemodynamic compromise occurs, antithymocyte sera such as antithymocyte globulin (ATG) or the monoclonal antibody to T3 lymphocytes (OKT3) are used for 5 or 10 days, respectively.
3. If all measures prove ineffective, retransplantation is considered.

Infection
Immunosuppressive medications used to prevent allograft rejection increase the risk of infection. There are two peak incidences for infection after transplantation.
1. An “early” infection, occurring within the first month of transplantation, is dominated by nosocomial, often catheter-related, infection caused by Staphylococcus spp. and gram-negative organisms.
2. A “late” infection, occurring within 2 to 5 months, is caused by opportunistic infections from organisms such as CMV, Pneumocystis spp., and fungal pathogens (see later section). The lung is the most common site of infection in heart transplant recipients followed by the blood, urine, GI tract, and sternal wound.

Table 35-2
INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION CARDIAC BIOPSY GRADING SCHEME FOR THE DIAGNOSIS OF ACUTE CELLULAR REJECTION

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0R</td>
<td>No rejection</td>
</tr>
<tr>
<td>1R</td>
<td>Interstitial or perivascular infiltrate with up to one focus of myocyte damage</td>
</tr>
<tr>
<td>2R</td>
<td>Two or more foci of infiltrate-associated myocyte damage</td>
</tr>
<tr>
<td>3R</td>
<td>Diffuse infiltrate with multifocal myocyte damage ± edema ± hemorrhage ± vasculitis</td>
</tr>
</tbody>
</table>
Late Posttransplantation Follow-Up

Late follow-up examinations are intended to detect rejection, infection, and the side effects of immunosuppression. Infection and rejection remain the most common causes of death after heart transplantation. For those who survive beyond 1 year after transplantation, acute rejection (30%), allograft vasculopathy (24%), and infection (12%) account for most of the deaths. Graft failure, lymphoma, and CAD are responsible for the remaining deaths.

Rejection

Although the risk of rejection is greatest in the first 3 months after transplantation, continued surveillance for rejection is necessary. A high index of suspicion is necessary to detect rejection because many rejections occur without symptoms. Endomyocardial biopsy at regular intervals is required to detect rejection.

1. Clinically evident cardiac dysfunction or congestive heart failure (CHF) is usually absent. Nonspecific clinical signs and symptoms (e.g., fever, tachycardia, malaise, personality changes, gallop rhythm, arrhythmias, hypotension) may be the only indications of rejection. These symptoms are often caused by infection rather than rejection. Decreased ECG voltages and decreased ventricular function (by echocardiography) are late signs of acute rejection.

2. Some centers have used serial echocardiography to assess rejection, but this method has not been universally accepted.

3. Endomyocardial biopsies are the criterion standard and are graded according to the criteria of the ISHLT, with treatment generally occurring only for biopsy samples that demonstrate a 2R or greater histology. Patients with no or mild rejection (grade 0R or 1R) on the biopsy receive no change in drug dosage.

Infection

Infection is a common cause of death and is probably related to the immunosuppressive therapy. Infection after the immediate posttransplantation period is caused by opportunistic infective agents such as CMV, Pneumocystis organisms, and fungi. The average mortality rate from infection is about 12%; that of fungal infection is about 36%. The lung is the most commonly infected organ; the mortality rate of patients with infected lungs is 22%. CMV remains the most common single infection, but the specific antiviral agent for CMV, ganciclovir, does not appear to reduce the incidence of primary CMV infection. The efficacy of pyrimethamine and trimethoprim–sulfamethoxazole has been proved for the prophylaxis of toxoplasmosis and Pneumocystis infection, respectively. The risk-to-benefit ratio of using influenza vaccines after transplantation remains controversial.

Most researchers agree that children receiving immunosuppressive therapy, as well as
their siblings, should not receive all live vaccines, including varicella, measles, mumps, rubella, and oral polio. Because of their immunosuppressed status, there is an increased risk that these patients will develop active disease from the vaccine strains.

**Allograft Coronary Artery Disease**

An unusual, accelerated form of CAD, probably an immune-mediated disease, is the third most common cause of death after infection and rejection. CAD is the major determinant of long-term survival. Virtually all adult patients have some histopathologic evidence of CAD by 1 year after transplantation. It may occur in up to 40% of transplanted hearts in 3 years and in more than 50% in 5 years. This disease also occurs in pediatric patients, perhaps to a lesser degree, but 28% of pediatric patients surviving 6 months to 6 years after transplantation develop CAD.

Most patients with transplanted, denervated hearts fail to experience typical chest pain. Life-threatening ventricular arrhythmias, CHF, silent myocardial infarction, and sudden death may result. Coronary angiography (or computed tomography [CT] coronary angiography) is necessary to diagnose the disease. The unique angiographic hallmark of this disease is diffuse, concentric, longitudinal, and rapid pruning and obliteration of distal branch vessels. Many centers recommend performing the first coronary angiography (or CT coronary angiography) within 2 to 4 weeks of transplantation to obtain a baseline; some centers also recommend performing an exercise stress test, if appropriate for the patient’s age, and coronary angiography (or CT coronary angiography) 1 year after transplantation to evaluate graft function and to detect premature and aggressive coronary atherosclerosis. The only effective treatment of allograft CAD is retransplantation.

**Side Effects of Immunosuppression**

1. Cyclosporine. Hypertension and renal toxicity are common side effects, and malignancies are rare side effects of cyclosporine therapy. Less severe adverse side effects of the drug include reversible hepatotoxicity, fluid retention, hirsutism, gum hypertrophy, and GI symptoms. Rarely (10% of patients), lymphoma develops with a larger dose of the drug.

Hypertension occurs in 50% to 90% of heart transplant recipients who take cyclosporine. The mechanisms of cyclosporine-associated hypertension include nephrotoxicity, increased sympathetic tone, volume expansion, increased endothelin levels, and stimulation of the renin–angiotensin system. Calcium channel blockers, angiotensin-converting enzyme inhibitors, and beta- and alpha-blockers have been used with varying degrees of success.

Another side effect of chronic immunosuppressive treatment is the development of malignant neoplasms, occurring in 1% to 2% of patients each year, or 12.5% during a mean follow-up period of 50 months. A unique form of lymphoma, posttransplant lymphoproliferative disease, is the most common tumor reported (80%) with cyclosporine-based immunosuppression; it occurs more frequently in young patients. Most of these
tumors are thought to be the result of EBV infection. The use of OKT3 and ATG, as well as higher initial doses of cyclosporine and prednisone, appears to increase the risk of posttransplant lymphoproliferative disease. About 40% of patients respond to a reduction in immunotherapy, but chemotherapy and radiation therapy may be needed.

2. Corticosteroids. Growth retardation may occur with large doses of steroids. The dosage of steroids is kept at a minimum, or steroids are not given at all.

3. Azathioprine may produce bone marrow depression (e.g., thrombocytopenia, leukocytopenia, anemia), alopecia, and GI symptoms. Cutaneous malignancy (squamous cell and basal cell carcinoma) is the most common tumor associated with the use of azathioprine, perhaps related to the drug’s enhanced photosensitivity. The mortality rate from posttransplant tumors is high (38%).

**Physiology of the Transplanted Heart**

In following posttransplantation patients, physicians should first be aware of the unique physiology of the transplanted heart, which responds differently to exercise and to certain medications. The transplanted heart remains largely, but not entirely, denervated throughout the life of the recipient.

1. The response of the transplanted heart to exercise or stress is less than normal but adequate for most activities. With exercise, the heart rate accelerates slowly, and it parallels the rise in circulating catecholamine levels.

2. Most patients with denervated hearts experience no chest pain even with significant CAD.

3. Transplant recipients are supersensitive to catecholamines, in part because of the upregulation of β-adrenergic receptors and in part because of a loss of norepinephrine uptake in sympathetic neurons.

4. Coronary vasodilator response may be abnormal if allograft CAD has developed.
Prognosis

Recent data from the ISHLT Registry (2009) revealed that the overall 20-year survival rate for all pediatric heart transplant recipients is 40%. The 1-, 5-, and 10-year survival rates are 80%, 68%, and 58%, respectively. Another recent study (Zuppen et al, 2009) reported similar overall survivals of 85% at 1 year, 75% at 5 years, and 65% at 10 years. Newborns and infants appear to have better survival rates after transplantation; the 5-year actuarial survival rate is 80%.
# APPENDIX A

## Miscellaneous

### TABLE A-1

**RECURRENCE RISKS GIVEN ONE SIBLING WHO HAS A CARDIOVASCULAR ANOMALY**

<table>
<thead>
<tr>
<th>Anomaly</th>
<th>Suggested Risk (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ventricular septal defect</td>
<td>3.0</td>
</tr>
<tr>
<td>Patent ductus arteriosus</td>
<td>3.0</td>
</tr>
<tr>
<td>Atrial septal defect</td>
<td>2.5</td>
</tr>
<tr>
<td>Tetralogy of Fallot</td>
<td>2.5</td>
</tr>
<tr>
<td>Pulmonary stenosis</td>
<td>2.0</td>
</tr>
<tr>
<td>Coarctation of the aorta</td>
<td>2.0</td>
</tr>
<tr>
<td>Aortic stenosis</td>
<td>2.0</td>
</tr>
<tr>
<td>Transposition of the great arteries</td>
<td>1.5</td>
</tr>
<tr>
<td>Atrioventricular canal (complete endocardial cushion defect)</td>
<td>2.0</td>
</tr>
<tr>
<td>Endocardial fibroelastosis</td>
<td>4.0</td>
</tr>
<tr>
<td>Tricuspid atresia</td>
<td>1.0</td>
</tr>
<tr>
<td>Ebstein’s anomaly</td>
<td>1.0</td>
</tr>
<tr>
<td>Persistent truncus arteriosus</td>
<td>1.0</td>
</tr>
<tr>
<td>Pulmonary atresia</td>
<td>1.0</td>
</tr>
<tr>
<td>Hypoplastic left heart syndrome</td>
<td>2.0</td>
</tr>
</tbody>
</table>


### TABLE A-2

**AFFECTED OFFSPRING GIVEN ONE PARENT WITH A CONGENITAL HEART DEFECT**

<table>
<thead>
<tr>
<th>Defect</th>
<th>Mother Affected (%)</th>
<th>Father Affected (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aortic stenosis</td>
<td>13.0–18.0</td>
<td>3.0</td>
</tr>
<tr>
<td>Atrial septal defect</td>
<td>4.0–4.5</td>
<td>1.5</td>
</tr>
<tr>
<td>Atrioventricular canal (complete endocardial cushion defect)</td>
<td>14.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Coarctation of the aorta</td>
<td>4.0</td>
<td>2.0</td>
</tr>
<tr>
<td>Patent ductus arteriosus</td>
<td>3.5–4.0</td>
<td>2.5</td>
</tr>
<tr>
<td>Pulmonary stenosis</td>
<td>4.0–6.5</td>
<td>2.0</td>
</tr>
<tr>
<td>Tetralogy of Fallot</td>
<td>6.0–10.0</td>
<td>1.5</td>
</tr>
<tr>
<td>Ventricular septal defect</td>
<td>6.0</td>
<td>2.0</td>
</tr>
</tbody>
</table>


### TABLE A-3

**NEW YORK HEART ASSOCIATION FUNCTIONAL CLASSIFICATION**

<table>
<thead>
<tr>
<th>Classification</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>None detected by physical exertion, no dyspnea (NYHA)</td>
</tr>
<tr>
<td>II</td>
<td>Dyspnea on mild exertion (NYHA)</td>
</tr>
<tr>
<td>III</td>
<td>Dyspnea on less than mild exertion (NYHA)</td>
</tr>
<tr>
<td>IV</td>
<td>Unable to do any work (NYHA)</td>
</tr>
</tbody>
</table>

*Indicates classification based on symptoms alone.*
This is a classification of functional impairment in exercise capacity based on symptoms of dyspnea and fatigue. It is simple and useful in the evaluation of cardiac patients.

### TABLE A-4
SUMMARY OF ANTIARRHYTHMIC AGENTS

<table>
<thead>
<tr>
<th>Class</th>
<th>Mechanism of Action</th>
<th>Examples</th>
<th>Remarks</th>
</tr>
</thead>
</table>
| I     | Sodium channel blockers  
Delayed phase 0 of the action potential and slows conduction velocity in the tissue | Quinidine  
Procaïnamide | Has a significant proarrhythmic effect |
| IA    | Slows the rate of rise of phase 0 and prolongs the refractory period | Lidocaine  
Mexiletine | Major effect on QTC and QRS prolongation |
| IB    | Minimal effect on phase 0 and refractory period | | Least proarrhythmic among class I agents |
| IC    | Marked depression in conduction velocity with minimal effects on refractoriness | Flecainide  
Propafenone | Major effect on PR and QRS duration |
| II    | Beta-blockers | Propranolol  
(β1 + β2)  
Atenolol (β1)  
Nadolol (β1 + β2)  
Esmolol (β1) | Minor effects on ECG |
| III   | K-channel blockers  
Delaying repolarization | Amiodarone  
Sotalol  
Dofetilide  
Ibutilide | Has a significant proarrhythmia  
Major effect on QT prolongation |
| IV    | Ca-channel blockers (slows inward Ca²⁺ current)  
Slows conduction velocity and increases refractoriness in the AV node | Verapamil  
Diltiazem | Minor effects on ECG |

AV, Atrioventricular; ECG, electrocardiogram.

### TABLE A-5
EFFECTS OF ANTIARRHYTHMIC AGENTS ON THE ECG
<table>
<thead>
<tr>
<th>Class</th>
<th>Drug</th>
<th>PR</th>
<th>QRS</th>
<th>QT</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Quinidine</td>
<td>±</td>
<td>III</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Procainamide</td>
<td>±</td>
<td>I</td>
<td>II</td>
</tr>
<tr>
<td>IB</td>
<td>Lidocaine</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>IC</td>
<td>Mexiletine</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>III</td>
<td>Flecaïnide</td>
<td>I</td>
<td>I</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>Propafenone</td>
<td>I</td>
<td>I</td>
<td>±</td>
</tr>
<tr>
<td></td>
<td>Amiodarone</td>
<td>Acu</td>
<td>Acu</td>
<td>Acu</td>
</tr>
<tr>
<td></td>
<td>Sotalol</td>
<td>I</td>
<td>±</td>
<td>III</td>
</tr>
<tr>
<td></td>
<td>Dofetilide</td>
<td>±</td>
<td>±</td>
<td>III</td>
</tr>
<tr>
<td></td>
<td>Ibutilide</td>
<td>±</td>
<td>±</td>
<td>III</td>
</tr>
</tbody>
</table>

Acu, Acute effect; Chr, chronic effect

**TABLE A-6**

**OXYGEN CONSUMPTION PER BODY SURFACE AREA**
<table>
<thead>
<tr>
<th>Age (yr)</th>
<th>50</th>
<th>60</th>
<th>70</th>
<th>80</th>
<th>90</th>
<th>100</th>
<th>110</th>
<th>120</th>
<th>130</th>
<th>140</th>
<th>150</th>
<th>160</th>
<th>170</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male Patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>155</td>
<td>159</td>
<td>163</td>
<td>167</td>
<td>171</td>
<td>175</td>
<td>178</td>
<td>182</td>
<td>186</td>
<td>190</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>149</td>
<td>152</td>
<td>156</td>
<td>160</td>
<td>163</td>
<td>168</td>
<td>171</td>
<td>175</td>
<td>179</td>
<td>182</td>
<td>186</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>141</td>
<td>144</td>
<td>148</td>
<td>151</td>
<td>155</td>
<td>159</td>
<td>162</td>
<td>167</td>
<td>171</td>
<td>174</td>
<td>178</td>
<td>181</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>136</td>
<td>141</td>
<td>145</td>
<td>148</td>
<td>152</td>
<td>156</td>
<td>159</td>
<td>163</td>
<td>167</td>
<td>171</td>
<td>175</td>
<td>178</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>130</td>
<td>134</td>
<td>139</td>
<td>142</td>
<td>146</td>
<td>149</td>
<td>153</td>
<td>157</td>
<td>160</td>
<td>165</td>
<td>169</td>
<td>172</td>
<td>176</td>
</tr>
<tr>
<td>12</td>
<td>128</td>
<td>132</td>
<td>136</td>
<td>140</td>
<td>144</td>
<td>147</td>
<td>151</td>
<td>155</td>
<td>158</td>
<td>162</td>
<td>167</td>
<td>170</td>
<td>174</td>
</tr>
<tr>
<td>14</td>
<td>127</td>
<td>130</td>
<td>134</td>
<td>137</td>
<td>142</td>
<td>146</td>
<td>149</td>
<td>153</td>
<td>157</td>
<td>160</td>
<td>165</td>
<td>169</td>
<td>172</td>
</tr>
<tr>
<td>16</td>
<td>125</td>
<td>129</td>
<td>132</td>
<td>136</td>
<td>141</td>
<td>144</td>
<td>148</td>
<td>152</td>
<td>155</td>
<td>159</td>
<td>162</td>
<td>167</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>124</td>
<td>127</td>
<td>131</td>
<td>135</td>
<td>139</td>
<td>143</td>
<td>147</td>
<td>150</td>
<td>154</td>
<td>157</td>
<td>161</td>
<td>166</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>123</td>
<td>126</td>
<td>130</td>
<td>134</td>
<td>137</td>
<td>142</td>
<td>145</td>
<td>149</td>
<td>153</td>
<td>156</td>
<td>160</td>
<td>165</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>120</td>
<td>124</td>
<td>127</td>
<td>131</td>
<td>135</td>
<td>139</td>
<td>143</td>
<td>147</td>
<td>150</td>
<td>154</td>
<td>157</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>118</td>
<td>122</td>
<td>125</td>
<td>129</td>
<td>133</td>
<td>136</td>
<td>141</td>
<td>145</td>
<td>148</td>
<td>152</td>
<td>155</td>
<td>159</td>
<td>163</td>
</tr>
<tr>
<td>35</td>
<td>116</td>
<td>120</td>
<td>124</td>
<td>127</td>
<td>131</td>
<td>135</td>
<td>139</td>
<td>143</td>
<td>147</td>
<td>150</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>115</td>
<td>119</td>
<td>122</td>
<td>126</td>
<td>130</td>
<td>133</td>
<td>137</td>
<td>141</td>
<td>145</td>
<td>149</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female Patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>150</td>
<td>153</td>
<td>157</td>
<td>161</td>
<td>165</td>
<td>169</td>
<td>172</td>
<td>176</td>
<td>180</td>
<td>183</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>141</td>
<td>145</td>
<td>149</td>
<td>152</td>
<td>156</td>
<td>159</td>
<td>163</td>
<td>168</td>
<td>171</td>
<td>175</td>
<td>179</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>130</td>
<td>134</td>
<td>137</td>
<td>142</td>
<td>146</td>
<td>149</td>
<td>153</td>
<td>156</td>
<td>160</td>
<td>165</td>
<td>168</td>
<td>172</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>125</td>
<td>129</td>
<td>133</td>
<td>136</td>
<td>141</td>
<td>144</td>
<td>148</td>
<td>152</td>
<td>155</td>
<td>159</td>
<td>163</td>
<td>167</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>118</td>
<td>122</td>
<td>125</td>
<td>129</td>
<td>133</td>
<td>136</td>
<td>141</td>
<td>144</td>
<td>148</td>
<td>152</td>
<td>155</td>
<td>159</td>
<td>163</td>
</tr>
<tr>
<td>12</td>
<td>115</td>
<td>119</td>
<td>122</td>
<td>126</td>
<td>130</td>
<td>133</td>
<td>137</td>
<td>141</td>
<td>145</td>
<td>149</td>
<td>152</td>
<td>156</td>
<td>160</td>
</tr>
<tr>
<td>14</td>
<td>112</td>
<td>116</td>
<td>120</td>
<td>123</td>
<td>127</td>
<td>131</td>
<td>134</td>
<td>133</td>
<td>143</td>
<td>146</td>
<td>150</td>
<td>153</td>
<td>157</td>
</tr>
<tr>
<td>16</td>
<td>109</td>
<td>114</td>
<td>118</td>
<td>121</td>
<td>125</td>
<td>128</td>
<td>132</td>
<td>136</td>
<td>140</td>
<td>144</td>
<td>148</td>
<td>151</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>107</td>
<td>111</td>
<td>116</td>
<td>119</td>
<td>123</td>
<td>127</td>
<td>130</td>
<td>134</td>
<td>137</td>
<td>142</td>
<td>146</td>
<td>149</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>106</td>
<td>109</td>
<td>114</td>
<td>118</td>
<td>121</td>
<td>125</td>
<td>128</td>
<td>132</td>
<td>136</td>
<td>140</td>
<td>144</td>
<td>148</td>
<td>148</td>
</tr>
<tr>
<td>25</td>
<td>102</td>
<td>106</td>
<td>109</td>
<td>114</td>
<td>118</td>
<td>121</td>
<td>125</td>
<td>128</td>
<td>132</td>
<td>136</td>
<td>140</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>99</td>
<td>103</td>
<td>106</td>
<td>110</td>
<td>115</td>
<td>118</td>
<td>122</td>
<td>125</td>
<td>129</td>
<td>133</td>
<td>136</td>
<td></td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>97</td>
<td>100</td>
<td>104</td>
<td>107</td>
<td>111</td>
<td>116</td>
<td>119</td>
<td>123</td>
<td>127</td>
<td>130</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>94</td>
<td>98</td>
<td>102</td>
<td>105</td>
<td>109</td>
<td>112</td>
<td>117</td>
<td>121</td>
<td>124</td>
<td>128</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* In (mL/min)/m².

FIGURE A-1  Body surface area nomogram.

FIGURE A-2  Time course of elevation of selected serum markers after acute myocardial infarction in an adult. This figure summarizes the relative timing, rate of rise, peak values, and duration of elevation above the upper limit of normal for the serum markers. Myoglobin rises quickly soon after the onset of infarction but it is not specific for cardiac muscle; it may also come from skeletal muscles. Total creatine kinase (CK) rises within 4 to 8 hours, reaches a peak at 24 hours, and declines to normal levels within 2 to 3 days. There are three isoenzymes (BB, MM,
and MB) of CK identified by electrophoresis. The CK-MB isoenzyme occurs primarily in cardiac muscles, the BB enzyme occurs primarily in the brain and kidneys, and the MM isoenzyme occurs in cardiac and skeletal muscles. Lactate dehydrogenase (LDH) elevation occurs several days after the onset of myocardial infarction. False elevation of LDH occurs in patients with hemolysis, leukemia, liver disease or congestion, renal disease, pulmonary embolism, skeletal muscle disease, shock, and myocarditis. Cardiac-specific troponin I may be useful for the diagnosis of infarction even 3 to 4 days after the event. In children, the normal value of cardiac troponin I has been reported to be 2 ng/mL or less, and it is frequently below the level of detection for the assay. (From Antman EM: General hospital management. In Julian DG, Barunwald E [eds]: Management of Acute Myocardial Infarction. London, WB Saunders, 1994, p 63.)

**FIGURE A-3**  Action potential of human ventricular myocyte of subepicardial origin.

- Phase 0 (rapid depolarization) is the result of sudden increase in membrane conductance to Na$^+$ ion.
- Phase 1 (early rapid repolarization) is caused by transient outward K$^+$ current.
- Phase 2 (plateau) is maintained by the competition between outward current carried by K$^+$ and Cl$^-$ ions and inward current carried by Ca$^{2+}$ ions.
- Phase 3 (final rapid repolarization) is caused by activation of repolarizing outward K$^+$ current, and
- Phase 4 (the resting potential or diastolic depolarization) is caused by the Na-K pump that maintains high K$^+$ concentration and low intracellular Na$^+$ concentration by pumping K$^+$ inward and Na$^+$ outward.
**APPENDIX B**

Blood Pressure Values

**TABLE B-1**

BLOOD PRESSURE LEVELS FOR BOYS BY AGE AND HEIGHT PERCENTILE (NHBPEP)
<table>
<thead>
<tr>
<th>Age</th>
<th>BP Percentile</th>
<th>5th</th>
<th>10th</th>
<th>25th</th>
<th>50th</th>
<th>75th</th>
<th>90th</th>
<th>95th</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>50th</td>
<td>80</td>
<td>81</td>
<td>83</td>
<td>85</td>
<td>87</td>
<td>88</td>
<td>89</td>
</tr>
<tr>
<td></td>
<td>90th</td>
<td>94</td>
<td>95</td>
<td>97</td>
<td>99</td>
<td>100</td>
<td>102</td>
<td>103</td>
</tr>
<tr>
<td></td>
<td>95th</td>
<td>98</td>
<td>99</td>
<td>101</td>
<td>103</td>
<td>104</td>
<td>106</td>
<td>106</td>
</tr>
<tr>
<td></td>
<td>99th</td>
<td>105</td>
<td>106</td>
<td>108</td>
<td>110</td>
<td>112</td>
<td>113</td>
<td>114</td>
</tr>
<tr>
<td>2</td>
<td>50th</td>
<td>84</td>
<td>85</td>
<td>87</td>
<td>88</td>
<td>90</td>
<td>92</td>
<td>92</td>
</tr>
<tr>
<td></td>
<td>90th</td>
<td>97</td>
<td>99</td>
<td>100</td>
<td>102</td>
<td>104</td>
<td>105</td>
<td>106</td>
</tr>
<tr>
<td></td>
<td>95th</td>
<td>101</td>
<td>102</td>
<td>104</td>
<td>106</td>
<td>108</td>
<td>109</td>
<td>110</td>
</tr>
<tr>
<td></td>
<td>99th</td>
<td>109</td>
<td>110</td>
<td>111</td>
<td>113</td>
<td>115</td>
<td>117</td>
<td>117</td>
</tr>
<tr>
<td>3</td>
<td>50th</td>
<td>86</td>
<td>87</td>
<td>89</td>
<td>91</td>
<td>93</td>
<td>94</td>
<td>95</td>
</tr>
<tr>
<td></td>
<td>90th</td>
<td>100</td>
<td>101</td>
<td>103</td>
<td>105</td>
<td>107</td>
<td>108</td>
<td>109</td>
</tr>
<tr>
<td></td>
<td>95th</td>
<td>104</td>
<td>105</td>
<td>107</td>
<td>109</td>
<td>110</td>
<td>112</td>
<td>113</td>
</tr>
<tr>
<td></td>
<td>99th</td>
<td>111</td>
<td>112</td>
<td>114</td>
<td>116</td>
<td>118</td>
<td>119</td>
<td>120</td>
</tr>
<tr>
<td>4</td>
<td>50th</td>
<td>88</td>
<td>89</td>
<td>91</td>
<td>93</td>
<td>95</td>
<td>96</td>
<td>97</td>
</tr>
<tr>
<td></td>
<td>90th</td>
<td>102</td>
<td>103</td>
<td>105</td>
<td>107</td>
<td>109</td>
<td>110</td>
<td>111</td>
</tr>
<tr>
<td></td>
<td>95th</td>
<td>106</td>
<td>107</td>
<td>109</td>
<td>111</td>
<td>112</td>
<td>114</td>
<td>115</td>
</tr>
<tr>
<td></td>
<td>99th</td>
<td>113</td>
<td>114</td>
<td>116</td>
<td>118</td>
<td>120</td>
<td>121</td>
<td>122</td>
</tr>
<tr>
<td>5</td>
<td>50th</td>
<td>90</td>
<td>91</td>
<td>93</td>
<td>95</td>
<td>96</td>
<td>98</td>
<td>98</td>
</tr>
<tr>
<td></td>
<td>90th</td>
<td>104</td>
<td>105</td>
<td>106</td>
<td>108</td>
<td>110</td>
<td>111</td>
<td>112</td>
</tr>
<tr>
<td></td>
<td>95th</td>
<td>108</td>
<td>109</td>
<td>110</td>
<td>112</td>
<td>114</td>
<td>115</td>
<td>116</td>
</tr>
<tr>
<td></td>
<td>99th</td>
<td>115</td>
<td>116</td>
<td>118</td>
<td>120</td>
<td>121</td>
<td>123</td>
<td>123</td>
</tr>
<tr>
<td>6</td>
<td>50th</td>
<td>91</td>
<td>92</td>
<td>94</td>
<td>96</td>
<td>98</td>
<td>99</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>90th</td>
<td>105</td>
<td>106</td>
<td>108</td>
<td>110</td>
<td>111</td>
<td>113</td>
<td>113</td>
</tr>
<tr>
<td></td>
<td>95th</td>
<td>109</td>
<td>110</td>
<td>112</td>
<td>114</td>
<td>115</td>
<td>117</td>
<td>117</td>
</tr>
<tr>
<td></td>
<td>99th</td>
<td>116</td>
<td>117</td>
<td>119</td>
<td>121</td>
<td>123</td>
<td>124</td>
<td>125</td>
</tr>
<tr>
<td>7</td>
<td>50th</td>
<td>92</td>
<td>94</td>
<td>95</td>
<td>97</td>
<td>99</td>
<td>100</td>
<td>101</td>
</tr>
<tr>
<td></td>
<td>90th</td>
<td>106</td>
<td>107</td>
<td>109</td>
<td>111</td>
<td>113</td>
<td>114</td>
<td>115</td>
</tr>
<tr>
<td></td>
<td>95th</td>
<td>110</td>
<td>111</td>
<td>113</td>
<td>115</td>
<td>117</td>
<td>118</td>
<td>119</td>
</tr>
<tr>
<td></td>
<td>99th</td>
<td>117</td>
<td>118</td>
<td>120</td>
<td>122</td>
<td>124</td>
<td>125</td>
<td>125</td>
</tr>
<tr>
<td>8</td>
<td>50th</td>
<td>94</td>
<td>95</td>
<td>97</td>
<td>99</td>
<td>100</td>
<td>102</td>
<td>102</td>
</tr>
<tr>
<td></td>
<td>90th</td>
<td>107</td>
<td>109</td>
<td>110</td>
<td>112</td>
<td>114</td>
<td>115</td>
<td>116</td>
</tr>
<tr>
<td></td>
<td>95th</td>
<td>111</td>
<td>112</td>
<td>114</td>
<td>116</td>
<td>118</td>
<td>119</td>
<td>120</td>
</tr>
<tr>
<td></td>
<td>99th</td>
<td>119</td>
<td>120</td>
<td>122</td>
<td>123</td>
<td>125</td>
<td>127</td>
<td>127</td>
</tr>
<tr>
<td>9</td>
<td>50th</td>
<td>95</td>
<td>96</td>
<td>98</td>
<td>100</td>
<td>102</td>
<td>103</td>
<td>104</td>
</tr>
<tr>
<td></td>
<td>90th</td>
<td>109</td>
<td>110</td>
<td>112</td>
<td>114</td>
<td>115</td>
<td>117</td>
<td>118</td>
</tr>
<tr>
<td></td>
<td>95th</td>
<td>113</td>
<td>114</td>
<td>116</td>
<td>118</td>
<td>120</td>
<td>121</td>
<td>121</td>
</tr>
<tr>
<td></td>
<td>99th</td>
<td>120</td>
<td>121</td>
<td>123</td>
<td>125</td>
<td>127</td>
<td>128</td>
<td>129</td>
</tr>
<tr>
<td>10</td>
<td>50th</td>
<td>97</td>
<td>98</td>
<td>100</td>
<td>102</td>
<td>103</td>
<td>105</td>
<td>106</td>
</tr>
<tr>
<td></td>
<td>90th</td>
<td>111</td>
<td>112</td>
<td>114</td>
<td>115</td>
<td>117</td>
<td>119</td>
<td>119</td>
</tr>
<tr>
<td></td>
<td>95th</td>
<td>115</td>
<td>116</td>
<td>117</td>
<td>119</td>
<td>121</td>
<td>122</td>
<td>123</td>
</tr>
<tr>
<td>11</td>
<td>50th</td>
<td>99</td>
<td>100</td>
<td>102</td>
<td>104</td>
<td>105</td>
<td>107</td>
<td>107</td>
</tr>
<tr>
<td></td>
<td>90th</td>
<td>113</td>
<td>114</td>
<td>115</td>
<td>117</td>
<td>119</td>
<td>120</td>
<td>121</td>
</tr>
<tr>
<td></td>
<td>95th</td>
<td>117</td>
<td>118</td>
<td>119</td>
<td>121</td>
<td>123</td>
<td>124</td>
<td>125</td>
</tr>
<tr>
<td></td>
<td>99th</td>
<td>124</td>
<td>125</td>
<td>127</td>
<td>129</td>
<td>130</td>
<td>132</td>
<td>132</td>
</tr>
<tr>
<td>12</td>
<td>50th</td>
<td>101</td>
<td>102</td>
<td>104</td>
<td>106</td>
<td>108</td>
<td>109</td>
<td>110</td>
</tr>
<tr>
<td></td>
<td>90th</td>
<td>115</td>
<td>116</td>
<td>118</td>
<td>120</td>
<td>121</td>
<td>123</td>
<td>123</td>
</tr>
<tr>
<td></td>
<td>95th</td>
<td>119</td>
<td>120</td>
<td>122</td>
<td>123</td>
<td>125</td>
<td>127</td>
<td>127</td>
</tr>
<tr>
<td></td>
<td>99th</td>
<td>126</td>
<td>127</td>
<td>129</td>
<td>131</td>
<td>133</td>
<td>134</td>
<td>135</td>
</tr>
<tr>
<td>13</td>
<td>50th</td>
<td>104</td>
<td>105</td>
<td>106</td>
<td>108</td>
<td>110</td>
<td>111</td>
<td>112</td>
</tr>
<tr>
<td></td>
<td>90th</td>
<td>117</td>
<td>118</td>
<td>120</td>
<td>122</td>
<td>124</td>
<td>125</td>
<td>126</td>
</tr>
<tr>
<td></td>
<td>95th</td>
<td>121</td>
<td>122</td>
<td>124</td>
<td>126</td>
<td>128</td>
<td>129</td>
<td>130</td>
</tr>
<tr>
<td></td>
<td>99th</td>
<td>128</td>
<td>130</td>
<td>131</td>
<td>133</td>
<td>135</td>
<td>136</td>
<td>137</td>
</tr>
<tr>
<td>14</td>
<td>50th</td>
<td>106</td>
<td>107</td>
<td>109</td>
<td>111</td>
<td>113</td>
<td>114</td>
<td>114</td>
</tr>
<tr>
<td></td>
<td>90th</td>
<td>120</td>
<td>121</td>
<td>123</td>
<td>125</td>
<td>126</td>
<td>128</td>
<td>128</td>
</tr>
<tr>
<td></td>
<td>95th</td>
<td>124</td>
<td>125</td>
<td>127</td>
<td>128</td>
<td>130</td>
<td>132</td>
<td>132</td>
</tr>
<tr>
<td></td>
<td>99th</td>
<td>131</td>
<td>132</td>
<td>134</td>
<td>136</td>
<td>138</td>
<td>139</td>
<td>140</td>
</tr>
</tbody>
</table>
### TABLE B-2

**BLOOD PRESSURE LEVELS FOR GIRLS BY AGE AND HEIGHT PERCENTILE (NHBPEP)**

<table>
<thead>
<tr>
<th>15</th>
<th>50th</th>
<th>109</th>
<th>110</th>
<th>112</th>
<th>113</th>
<th>115</th>
<th>117</th>
<th>117</th>
<th>61</th>
<th>62</th>
<th>63</th>
<th>64</th>
<th>65</th>
<th>66</th>
<th>66</th>
<th>90th</th>
<th>122</th>
<th>124</th>
<th>125</th>
<th>127</th>
<th>129</th>
<th>130</th>
<th>131</th>
<th>76</th>
<th>77</th>
<th>78</th>
<th>79</th>
<th>80</th>
<th>80</th>
<th>81</th>
</tr>
</thead>
<tbody>
<tr>
<td>90th</td>
<td>126</td>
<td>127</td>
<td>129</td>
<td>131</td>
<td>133</td>
<td>134</td>
<td>135</td>
<td>81</td>
<td>81</td>
<td>82</td>
<td>83</td>
<td>84</td>
<td>85</td>
<td>85</td>
<td>85</td>
<td>95th</td>
<td>134</td>
<td>135</td>
<td>136</td>
<td>138</td>
<td>140</td>
<td>142</td>
<td>142</td>
<td>88</td>
<td>89</td>
<td>90</td>
<td>91</td>
<td>92</td>
<td>93</td>
<td>93</td>
</tr>
<tr>
<td>99th</td>
<td>137</td>
<td>138</td>
<td>140</td>
<td>142</td>
<td>142</td>
<td>88</td>
<td>89</td>
<td>90</td>
<td>91</td>
<td>92</td>
<td>93</td>
<td>94</td>
<td>94</td>
<td>94</td>
<td>94</td>
<td>16</td>
<td>50th</td>
<td>111</td>
<td>112</td>
<td>114</td>
<td>116</td>
<td>118</td>
<td>119</td>
<td>120</td>
<td>63</td>
<td>63</td>
<td>64</td>
<td>65</td>
<td>66</td>
<td>67</td>
</tr>
<tr>
<td>90th</td>
<td>125</td>
<td>126</td>
<td>128</td>
<td>130</td>
<td>131</td>
<td>133</td>
<td>134</td>
<td>78</td>
<td>78</td>
<td>79</td>
<td>80</td>
<td>81</td>
<td>82</td>
<td>82</td>
<td>82</td>
<td>95th</td>
<td>129</td>
<td>130</td>
<td>132</td>
<td>134</td>
<td>135</td>
<td>137</td>
<td>137</td>
<td>82</td>
<td>83</td>
<td>83</td>
<td>84</td>
<td>85</td>
<td>86</td>
<td>87</td>
</tr>
<tr>
<td>99th</td>
<td>136</td>
<td>137</td>
<td>139</td>
<td>141</td>
<td>143</td>
<td>144</td>
<td>145</td>
<td>90</td>
<td>90</td>
<td>91</td>
<td>92</td>
<td>93</td>
<td>94</td>
<td>94</td>
<td>94</td>
<td>17</td>
<td>50th</td>
<td>114</td>
<td>115</td>
<td>116</td>
<td>118</td>
<td>120</td>
<td>121</td>
<td>122</td>
<td>65</td>
<td>66</td>
<td>66</td>
<td>67</td>
<td>68</td>
<td>69</td>
</tr>
<tr>
<td>90th</td>
<td>127</td>
<td>128</td>
<td>130</td>
<td>132</td>
<td>134</td>
<td>135</td>
<td>136</td>
<td>80</td>
<td>80</td>
<td>81</td>
<td>82</td>
<td>83</td>
<td>84</td>
<td>84</td>
<td>84</td>
<td>95th</td>
<td>131</td>
<td>132</td>
<td>134</td>
<td>136</td>
<td>138</td>
<td>139</td>
<td>140</td>
<td>84</td>
<td>85</td>
<td>86</td>
<td>87</td>
<td>87</td>
<td>88</td>
<td>89</td>
</tr>
<tr>
<td>99th</td>
<td>139</td>
<td>140</td>
<td>141</td>
<td>143</td>
<td>145</td>
<td>146</td>
<td>147</td>
<td>92</td>
<td>93</td>
<td>93</td>
<td>94</td>
<td>95</td>
<td>96</td>
<td>96</td>
<td>97</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*BP, Blood pressure; NHBPEP, National High Blood Pressure Education Program.*


BP, Blood pressure; NHBPEP, National High Blood Pressure Education Program.


**TABLE B-3**

AUSCULTATORY BLOOD PRESSURE VALUES FOR BOYS 5 TO 17 YEARS OLD (SAN ANTONIO CHILDREN’S BLOOD PRESSURE STUDY)

<table>
<thead>
<tr>
<th>Age (yr)</th>
<th>5th</th>
<th>10th</th>
<th>25th</th>
<th>Mean</th>
<th>75th</th>
<th>90th</th>
<th>95th</th>
<th>99th*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Systolic Blood Pressure</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>78</td>
<td>81</td>
<td>87</td>
<td>92</td>
<td>98</td>
<td>103</td>
<td>106</td>
<td>112</td>
</tr>
<tr>
<td>6</td>
<td>81</td>
<td>84</td>
<td>89</td>
<td>95</td>
<td>100</td>
<td>105</td>
<td>108</td>
<td>114</td>
</tr>
<tr>
<td>7</td>
<td>82</td>
<td>85</td>
<td>90</td>
<td>96</td>
<td>102</td>
<td>107</td>
<td>110</td>
<td>116</td>
</tr>
<tr>
<td>8</td>
<td>83</td>
<td>86</td>
<td>92</td>
<td>97</td>
<td>103</td>
<td>108</td>
<td>111</td>
<td>117</td>
</tr>
<tr>
<td>9</td>
<td>85</td>
<td>88</td>
<td>93</td>
<td>99</td>
<td>104</td>
<td>109</td>
<td>113</td>
<td>118</td>
</tr>
<tr>
<td>10</td>
<td>86</td>
<td>89</td>
<td>95</td>
<td>100</td>
<td>106</td>
<td>111</td>
<td>114</td>
<td>120</td>
</tr>
<tr>
<td>11</td>
<td>88</td>
<td>91</td>
<td>97</td>
<td>102</td>
<td>108</td>
<td>113</td>
<td>116</td>
<td>122</td>
</tr>
<tr>
<td>12</td>
<td>91</td>
<td>94</td>
<td>99</td>
<td>105</td>
<td>111</td>
<td>116</td>
<td>119</td>
<td>125</td>
</tr>
<tr>
<td>13</td>
<td>94</td>
<td>97</td>
<td>102</td>
<td>108</td>
<td>113</td>
<td>118</td>
<td>122</td>
<td>127</td>
</tr>
<tr>
<td>14</td>
<td>96</td>
<td>99</td>
<td>105</td>
<td>110</td>
<td>116</td>
<td>121</td>
<td>122</td>
<td>130</td>
</tr>
<tr>
<td>15</td>
<td>99</td>
<td>102</td>
<td>107</td>
<td>113</td>
<td>118</td>
<td>124</td>
<td>127</td>
<td>132</td>
</tr>
<tr>
<td>16</td>
<td>100</td>
<td>103</td>
<td>108</td>
<td>114</td>
<td>120</td>
<td>125</td>
<td>128</td>
<td>134</td>
</tr>
<tr>
<td>17</td>
<td>100</td>
<td>103</td>
<td>109</td>
<td>114</td>
<td>120</td>
<td>125</td>
<td>128</td>
<td>134</td>
</tr>
</tbody>
</table>

| **Diastolic Blood Pressure (K5)** |     |      |      |      |      |      |      |       |
| 5        | 34  | 37   | 43   | 49   | 55   | 60   | 63   | 70    |
| 6        | 38  | 41   | 47   | 53   | 59   | 64   | 67   | 73    |
| 7        | 40  | 44   | 49   | 55   | 61   | 66   | 70   | 76    |
| 8        | 42  | 45   | 50   | 56   | 62   | 68   | 71   | 77    |
| 9        | 42  | 45   | 51   | 57   | 63   | 68   | 71   | 77    |
| 10       | 42  | 45   | 51   | 57   | 63   | 68   | 71   | 77    |
| 11       | 42  | 45   | 51   | 57   | 63   | 68   | 71   | 77    |
| 12       | 42  | 45   | 50   | 56   | 62   | 68   | 71   | 77    |
| 13       | 42  | 45   | 51   | 57   | 63   | 68   | 71   | 77    |
| 14       | 42  | 45   | 51   | 57   | 63   | 68   | 71   | 77    |
| 15       | 43  | 46   | 51   | 57   | 63   | 69   | 72   | 78    |
| 16       | 45  | 48   | 53   | 59   | 65   | 71   | 74   | 80    |
| 17       | 47  | 51   | 56   | 62   | 68   | 73   | 77   | 83    |

K5, Korotkoff Phase 5.

* The 99th percentile values were added after publication.
### TABLE B-4

AUSCULTATORY BLOOD PRESSURE VALUES FOR GIRLS 5 TO 17 YEARS OLD (SAN ANTONIO CHILDREN’S BLOOD PRESSURE STUDY)

<table>
<thead>
<tr>
<th>Age (yr)</th>
<th>5th</th>
<th>10th</th>
<th>25th</th>
<th>Mean</th>
<th>75th</th>
<th>90th</th>
<th>95th</th>
<th>99th*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Systolic Blood Pressure</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>79</td>
<td>82</td>
<td>87</td>
<td>92</td>
<td>97</td>
<td>102</td>
<td>105</td>
<td>110</td>
</tr>
<tr>
<td>6</td>
<td>80</td>
<td>83</td>
<td>88</td>
<td>93</td>
<td>98</td>
<td>103</td>
<td>106</td>
<td>111</td>
</tr>
<tr>
<td>7</td>
<td>81</td>
<td>84</td>
<td>89</td>
<td>94</td>
<td>99</td>
<td>104</td>
<td>107</td>
<td>112</td>
</tr>
<tr>
<td>8</td>
<td>83</td>
<td>86</td>
<td>91</td>
<td>96</td>
<td>101</td>
<td>106</td>
<td>109</td>
<td>114</td>
</tr>
<tr>
<td>9</td>
<td>85</td>
<td>88</td>
<td>93</td>
<td>98</td>
<td>103</td>
<td>108</td>
<td>111</td>
<td>116</td>
</tr>
<tr>
<td>10</td>
<td>87</td>
<td>90</td>
<td>95</td>
<td>100</td>
<td>105</td>
<td>110</td>
<td>113</td>
<td>118</td>
</tr>
<tr>
<td>11</td>
<td>89</td>
<td>92</td>
<td>97</td>
<td>102</td>
<td>107</td>
<td>112</td>
<td>115</td>
<td>120</td>
</tr>
<tr>
<td>12</td>
<td>91</td>
<td>94</td>
<td>98</td>
<td>104</td>
<td>109</td>
<td>113</td>
<td>116</td>
<td>122</td>
</tr>
<tr>
<td>13</td>
<td>92</td>
<td>95</td>
<td>100</td>
<td>105</td>
<td>110</td>
<td>115</td>
<td>118</td>
<td>123</td>
</tr>
<tr>
<td>14</td>
<td>93</td>
<td>96</td>
<td>101</td>
<td>106</td>
<td>111</td>
<td>116</td>
<td>119</td>
<td>124</td>
</tr>
<tr>
<td>15</td>
<td>94</td>
<td>97</td>
<td>101</td>
<td>107</td>
<td>112</td>
<td>117</td>
<td>119</td>
<td>125</td>
</tr>
<tr>
<td>16</td>
<td>94</td>
<td>97</td>
<td>102</td>
<td>107</td>
<td>112</td>
<td>117</td>
<td>120</td>
<td>125</td>
</tr>
<tr>
<td>17</td>
<td>95</td>
<td>98</td>
<td>103</td>
<td>108</td>
<td>113</td>
<td>118</td>
<td>121</td>
<td>126</td>
</tr>
<tr>
<td><strong>Diastolic Blood Pressure (K5)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>35</td>
<td>38</td>
<td>44</td>
<td>49</td>
<td>55</td>
<td>60</td>
<td>63</td>
<td>69</td>
</tr>
<tr>
<td>6</td>
<td>38</td>
<td>41</td>
<td>47</td>
<td>52</td>
<td>58</td>
<td>63</td>
<td>66</td>
<td>72</td>
</tr>
<tr>
<td>7</td>
<td>40</td>
<td>41</td>
<td>49</td>
<td>54</td>
<td>60</td>
<td>65</td>
<td>68</td>
<td>74</td>
</tr>
<tr>
<td>8</td>
<td>42</td>
<td>45</td>
<td>50</td>
<td>56</td>
<td>61</td>
<td>67</td>
<td>70</td>
<td>75</td>
</tr>
<tr>
<td>9</td>
<td>43</td>
<td>46</td>
<td>51</td>
<td>56</td>
<td>62</td>
<td>67</td>
<td>70</td>
<td>76</td>
</tr>
<tr>
<td>10</td>
<td>43</td>
<td>46</td>
<td>51</td>
<td>57</td>
<td>63</td>
<td>68</td>
<td>71</td>
<td>77</td>
</tr>
<tr>
<td>11</td>
<td>43</td>
<td>46</td>
<td>51</td>
<td>57</td>
<td>63</td>
<td>68</td>
<td>71</td>
<td>77</td>
</tr>
<tr>
<td>12</td>
<td>43</td>
<td>46</td>
<td>52</td>
<td>57</td>
<td>63</td>
<td>68</td>
<td>71</td>
<td>77</td>
</tr>
<tr>
<td>13</td>
<td>43</td>
<td>47</td>
<td>52</td>
<td>57</td>
<td>63</td>
<td>68</td>
<td>71</td>
<td>77</td>
</tr>
<tr>
<td>14</td>
<td>44</td>
<td>47</td>
<td>52</td>
<td>58</td>
<td>63</td>
<td>68</td>
<td>72</td>
<td>77</td>
</tr>
<tr>
<td>15</td>
<td>44</td>
<td>47</td>
<td>52</td>
<td>58</td>
<td>64</td>
<td>69</td>
<td>72</td>
<td>78</td>
</tr>
<tr>
<td>16</td>
<td>45</td>
<td>48</td>
<td>53</td>
<td>59</td>
<td>64</td>
<td>69</td>
<td>73</td>
<td>78</td>
</tr>
<tr>
<td>17</td>
<td>46</td>
<td>49</td>
<td>54</td>
<td>59</td>
<td>65</td>
<td>70</td>
<td>73</td>
<td>79</td>
</tr>
</tbody>
</table>

*K5, Korotkoff Phase 5.

* The 99th percentile values were added after publication.

<table>
<thead>
<tr>
<th>Age</th>
<th>5th</th>
<th>10th</th>
<th>25th</th>
<th>Mean</th>
<th>75th</th>
<th>90th</th>
<th>95th</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic Blood Pressure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1–3 days</td>
<td>52</td>
<td>56</td>
<td>58</td>
<td>65</td>
<td>71</td>
<td>74</td>
<td>77</td>
</tr>
<tr>
<td>2–3 wks</td>
<td>62</td>
<td>66</td>
<td>71</td>
<td>78</td>
<td>84</td>
<td>89</td>
<td>92</td>
</tr>
<tr>
<td>1–5 mo</td>
<td>76</td>
<td>79</td>
<td>88</td>
<td>94</td>
<td>102</td>
<td>106</td>
<td>111</td>
</tr>
<tr>
<td>6–11 mo</td>
<td>79</td>
<td>84</td>
<td>88</td>
<td>94</td>
<td>99</td>
<td>104</td>
<td>109</td>
</tr>
<tr>
<td>1 yr</td>
<td>80</td>
<td>84</td>
<td>89</td>
<td>94</td>
<td>99</td>
<td>104</td>
<td>108</td>
</tr>
<tr>
<td>2 yr</td>
<td>82</td>
<td>85</td>
<td>91</td>
<td>95</td>
<td>101</td>
<td>106</td>
<td>109</td>
</tr>
<tr>
<td>3 yr</td>
<td>84</td>
<td>87</td>
<td>92</td>
<td>98</td>
<td>103</td>
<td>108</td>
<td>112</td>
</tr>
<tr>
<td>4 yr</td>
<td>86</td>
<td>90</td>
<td>95</td>
<td>100</td>
<td>105</td>
<td>110</td>
<td>114</td>
</tr>
<tr>
<td>5 yr</td>
<td>89</td>
<td>93</td>
<td>96</td>
<td>102</td>
<td>107</td>
<td>113</td>
<td>116</td>
</tr>
<tr>
<td>Diastolic Blood Pressure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1–3 days</td>
<td>31</td>
<td>33</td>
<td>37</td>
<td>41</td>
<td>45</td>
<td>50</td>
<td>52</td>
</tr>
<tr>
<td>2–3 wks</td>
<td>31</td>
<td>37</td>
<td>42</td>
<td>47</td>
<td>53</td>
<td>58</td>
<td>61</td>
</tr>
<tr>
<td>1–5 mo</td>
<td>45</td>
<td>48</td>
<td>53</td>
<td>59</td>
<td>64</td>
<td>71</td>
<td>75</td>
</tr>
<tr>
<td>6–11 mo</td>
<td>41</td>
<td>44</td>
<td>52</td>
<td>57</td>
<td>63</td>
<td>67</td>
<td>69</td>
</tr>
<tr>
<td>1 yr</td>
<td>44</td>
<td>48</td>
<td>52</td>
<td>57</td>
<td>73</td>
<td>67</td>
<td>69</td>
</tr>
<tr>
<td>2 yr</td>
<td>45</td>
<td>47</td>
<td>52</td>
<td>56</td>
<td>61</td>
<td>65</td>
<td>68</td>
</tr>
<tr>
<td>3 yr</td>
<td>44</td>
<td>47</td>
<td>52</td>
<td>56</td>
<td>61</td>
<td>65</td>
<td>69</td>
</tr>
<tr>
<td>4 yr</td>
<td>44</td>
<td>48</td>
<td>52</td>
<td>56</td>
<td>61</td>
<td>65</td>
<td>68</td>
</tr>
<tr>
<td>5 yr</td>
<td>44</td>
<td>48</td>
<td>53</td>
<td>57</td>
<td>62</td>
<td>66</td>
<td>68</td>
</tr>
</tbody>
</table>

**Table B-7**

**DINAMAP (MODEL 8100) BLOOD PRESSURE PERCENTILE FOR GIRLS 5 TO 17 YEARS OLD (SAN ANTONIO CHILDREN’S 5 TO 17 YEARS OLD STUDY)**

<table>
<thead>
<tr>
<th>Age (yr)</th>
<th>5th</th>
<th>10th</th>
<th>25th</th>
<th>Mean</th>
<th>75th</th>
<th>90th</th>
<th>95th</th>
<th>99th*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic Blood Pressure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>90</td>
<td>93</td>
<td>98</td>
<td>104</td>
<td>110</td>
<td>115</td>
<td>118</td>
<td>124</td>
</tr>
<tr>
<td>6</td>
<td>92</td>
<td>95</td>
<td>100</td>
<td>106</td>
<td>112</td>
<td>117</td>
<td>120</td>
<td>126</td>
</tr>
<tr>
<td>7</td>
<td>93</td>
<td>96</td>
<td>102</td>
<td>107</td>
<td>113</td>
<td>118</td>
<td>121</td>
<td>127</td>
</tr>
<tr>
<td>8</td>
<td>94</td>
<td>97</td>
<td>103</td>
<td>108</td>
<td>114</td>
<td>119</td>
<td>123</td>
<td>128</td>
</tr>
<tr>
<td>9</td>
<td>95</td>
<td>99</td>
<td>104</td>
<td>110</td>
<td>115</td>
<td>121</td>
<td>124</td>
<td>130</td>
</tr>
<tr>
<td>10</td>
<td>97</td>
<td>100</td>
<td>105</td>
<td>110</td>
<td>117</td>
<td>122</td>
<td>125</td>
<td>131</td>
</tr>
<tr>
<td>11</td>
<td>99</td>
<td>102</td>
<td>107</td>
<td>113</td>
<td>119</td>
<td>124</td>
<td>127</td>
<td>133</td>
</tr>
<tr>
<td>12</td>
<td>101</td>
<td>104</td>
<td>109</td>
<td>115</td>
<td>121</td>
<td>126</td>
<td>129</td>
<td>135</td>
</tr>
<tr>
<td>13</td>
<td>104</td>
<td>107</td>
<td>112</td>
<td>118</td>
<td>123</td>
<td>129</td>
<td>132</td>
<td>138</td>
</tr>
<tr>
<td>14</td>
<td>106</td>
<td>109</td>
<td>114</td>
<td>120</td>
<td>126</td>
<td>131</td>
<td>134</td>
<td>140</td>
</tr>
<tr>
<td>15</td>
<td>108</td>
<td>111</td>
<td>116</td>
<td>122</td>
<td>128</td>
<td>133</td>
<td>136</td>
<td>141</td>
</tr>
<tr>
<td>16</td>
<td>109</td>
<td>112</td>
<td>117</td>
<td>123</td>
<td>128</td>
<td>134</td>
<td>137</td>
<td>143</td>
</tr>
<tr>
<td>17</td>
<td>109</td>
<td>112</td>
<td>117</td>
<td>123</td>
<td>129</td>
<td>134</td>
<td>137</td>
<td>143</td>
</tr>
</tbody>
</table>

Diastolic Blood Pressure

<table>
<thead>
<tr>
<th>Age (yr)</th>
<th>5th</th>
<th>10th</th>
<th>25th</th>
<th>Mean</th>
<th>75th</th>
<th>90th</th>
<th>95th</th>
<th>99th*</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>46</td>
<td>49</td>
<td>53</td>
<td>58</td>
<td>63</td>
<td>68</td>
<td>71</td>
<td>76</td>
</tr>
<tr>
<td>6</td>
<td>47</td>
<td>49</td>
<td>54</td>
<td>59</td>
<td>64</td>
<td>68</td>
<td>71</td>
<td>76</td>
</tr>
<tr>
<td>7</td>
<td>47</td>
<td>50</td>
<td>54</td>
<td>59</td>
<td>64</td>
<td>69</td>
<td>72</td>
<td>77</td>
</tr>
<tr>
<td>8</td>
<td>48</td>
<td>51</td>
<td>55</td>
<td>60</td>
<td>65</td>
<td>70</td>
<td>72</td>
<td>78</td>
</tr>
<tr>
<td>9</td>
<td>49</td>
<td>51</td>
<td>56</td>
<td>61</td>
<td>66</td>
<td>70</td>
<td>73</td>
<td>78</td>
</tr>
<tr>
<td>10</td>
<td>49</td>
<td>52</td>
<td>56</td>
<td>61</td>
<td>66</td>
<td>71</td>
<td>74</td>
<td>79</td>
</tr>
<tr>
<td>11</td>
<td>49</td>
<td>52</td>
<td>57</td>
<td>62</td>
<td>67</td>
<td>71</td>
<td>74</td>
<td>79</td>
</tr>
<tr>
<td>12</td>
<td>50</td>
<td>52</td>
<td>57</td>
<td>62</td>
<td>67</td>
<td>71</td>
<td>74</td>
<td>79</td>
</tr>
<tr>
<td>13</td>
<td>50</td>
<td>52</td>
<td>57</td>
<td>62</td>
<td>67</td>
<td>71</td>
<td>74</td>
<td>79</td>
</tr>
<tr>
<td>14</td>
<td>50</td>
<td>52</td>
<td>57</td>
<td>62</td>
<td>67</td>
<td>72</td>
<td>74</td>
<td>79</td>
</tr>
<tr>
<td>15</td>
<td>50</td>
<td>52</td>
<td>57</td>
<td>62</td>
<td>67</td>
<td>72</td>
<td>74</td>
<td>79</td>
</tr>
<tr>
<td>16</td>
<td>50</td>
<td>53</td>
<td>57</td>
<td>62</td>
<td>67</td>
<td>72</td>
<td>74</td>
<td>80</td>
</tr>
<tr>
<td>17</td>
<td>50</td>
<td>53</td>
<td>57</td>
<td>62</td>
<td>67</td>
<td>72</td>
<td>75</td>
<td>80</td>
</tr>
</tbody>
</table>

* The 99th percentile values were added after submission of the manuscript.

<table>
<thead>
<tr>
<th>Age (yr)</th>
<th>5th</th>
<th>10th</th>
<th>25th</th>
<th>Mean</th>
<th>75th</th>
<th>90th</th>
<th>95th</th>
<th>99th*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic Blood Pressure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>90</td>
<td>93</td>
<td>98</td>
<td>103</td>
<td>109</td>
<td>114</td>
<td>117</td>
<td>122</td>
</tr>
<tr>
<td>6</td>
<td>91</td>
<td>94</td>
<td>99</td>
<td>104</td>
<td>110</td>
<td>115</td>
<td>118</td>
<td>123</td>
</tr>
<tr>
<td>7</td>
<td>92</td>
<td>95</td>
<td>100</td>
<td>106</td>
<td>111</td>
<td>116</td>
<td>119</td>
<td>125</td>
</tr>
<tr>
<td>8</td>
<td>94</td>
<td>97</td>
<td>102</td>
<td>107</td>
<td>113</td>
<td>118</td>
<td>121</td>
<td>126</td>
</tr>
<tr>
<td>9</td>
<td>95</td>
<td>98</td>
<td>103</td>
<td>109</td>
<td>114</td>
<td>119</td>
<td>122</td>
<td>128</td>
</tr>
<tr>
<td>10</td>
<td>97</td>
<td>100</td>
<td>105</td>
<td>110</td>
<td>116</td>
<td>121</td>
<td>124</td>
<td>129</td>
</tr>
<tr>
<td>11</td>
<td>98</td>
<td>101</td>
<td>106</td>
<td>112</td>
<td>117</td>
<td>122</td>
<td>125</td>
<td>131</td>
</tr>
<tr>
<td>12</td>
<td>100</td>
<td>103</td>
<td>107</td>
<td>113</td>
<td>118</td>
<td>123</td>
<td>126</td>
<td>132</td>
</tr>
<tr>
<td>13</td>
<td>101</td>
<td>104</td>
<td>109</td>
<td>114</td>
<td>120</td>
<td>125</td>
<td>128</td>
<td>133</td>
</tr>
<tr>
<td>14</td>
<td>102</td>
<td>104</td>
<td>109</td>
<td>115</td>
<td>120</td>
<td>125</td>
<td>128</td>
<td>134</td>
</tr>
<tr>
<td>15</td>
<td>102</td>
<td>105</td>
<td>110</td>
<td>115</td>
<td>121</td>
<td>126</td>
<td>129</td>
<td>134</td>
</tr>
<tr>
<td>16</td>
<td>102</td>
<td>105</td>
<td>110</td>
<td>115</td>
<td>121</td>
<td>126</td>
<td>129</td>
<td>134</td>
</tr>
<tr>
<td>17</td>
<td>102</td>
<td>105</td>
<td>110</td>
<td>115</td>
<td>121</td>
<td>126</td>
<td>129</td>
<td>134</td>
</tr>
<tr>
<td>Diastolic Blood Pressure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>46</td>
<td>48</td>
<td>53</td>
<td>59</td>
<td>64</td>
<td>68</td>
<td>71</td>
<td>76</td>
</tr>
<tr>
<td>6</td>
<td>47</td>
<td>49</td>
<td>54</td>
<td>59</td>
<td>64</td>
<td>68</td>
<td>71</td>
<td>76</td>
</tr>
<tr>
<td>7</td>
<td>47</td>
<td>50</td>
<td>54</td>
<td>60</td>
<td>65</td>
<td>69</td>
<td>72</td>
<td>77</td>
</tr>
<tr>
<td>8</td>
<td>48</td>
<td>50</td>
<td>55</td>
<td>60</td>
<td>65</td>
<td>70</td>
<td>73</td>
<td>78</td>
</tr>
<tr>
<td>9</td>
<td>49</td>
<td>51</td>
<td>55</td>
<td>61</td>
<td>66</td>
<td>70</td>
<td>73</td>
<td>78</td>
</tr>
<tr>
<td>10</td>
<td>49</td>
<td>51</td>
<td>56</td>
<td>61</td>
<td>66</td>
<td>71</td>
<td>74</td>
<td>79</td>
</tr>
<tr>
<td>11</td>
<td>49</td>
<td>52</td>
<td>56</td>
<td>62</td>
<td>67</td>
<td>71</td>
<td>74</td>
<td>79</td>
</tr>
<tr>
<td>12</td>
<td>50</td>
<td>52</td>
<td>57</td>
<td>62</td>
<td>67</td>
<td>71</td>
<td>74</td>
<td>79</td>
</tr>
<tr>
<td>13</td>
<td>50</td>
<td>53</td>
<td>57</td>
<td>62</td>
<td>67</td>
<td>71</td>
<td>74</td>
<td>79</td>
</tr>
<tr>
<td>14</td>
<td>50</td>
<td>53</td>
<td>58</td>
<td>62</td>
<td>67</td>
<td>72</td>
<td>74</td>
<td>79</td>
</tr>
<tr>
<td>15</td>
<td>50</td>
<td>54</td>
<td>58</td>
<td>62</td>
<td>67</td>
<td>72</td>
<td>74</td>
<td>79</td>
</tr>
<tr>
<td>16</td>
<td>50</td>
<td>54</td>
<td>58</td>
<td>62</td>
<td>67</td>
<td>72</td>
<td>74</td>
<td>80</td>
</tr>
<tr>
<td>17</td>
<td>50</td>
<td>54</td>
<td>58</td>
<td>62</td>
<td>67</td>
<td>72</td>
<td>75</td>
<td>80</td>
</tr>
</tbody>
</table>

* The 99th percentile values were added after submission of the manuscript.


**TABLE B-8**

AMBULATORY BLOOD PRESSURE STANDARDS FOR DAYTIME AND NIGHTTIME, ACCORDING TO HEIGHT, FOR BOYS
### TABLE B-9
**AMBULATORY BLOOD PRESSURE STANDARDS FOR DAYTIME AND NIGHTTIME, ACCORDING TO HEIGHT, FOR GIRLS**

<table>
<thead>
<tr>
<th>Height (cm)</th>
<th>Systolic BP</th>
<th></th>
<th>Diastolic BP</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Daytime 90th Percentile</td>
<td>Daytime 95th Percentile</td>
<td>Nighttime 90th Percentile</td>
<td>Nighttime 95th Percentile</td>
</tr>
<tr>
<td>120</td>
<td>120.6</td>
<td>123.5</td>
<td>103.7</td>
<td>106.4</td>
</tr>
<tr>
<td>125</td>
<td>121.0</td>
<td>124.0</td>
<td>104.9</td>
<td>107.8</td>
</tr>
<tr>
<td>130</td>
<td>121.6</td>
<td>124.6</td>
<td>106.3</td>
<td>109.5</td>
</tr>
<tr>
<td>135</td>
<td>122.2</td>
<td>125.2</td>
<td>107.7</td>
<td>111.3</td>
</tr>
<tr>
<td>140</td>
<td>123.0</td>
<td>126.0</td>
<td>109.3</td>
<td>113.1</td>
</tr>
<tr>
<td>145</td>
<td>124.0</td>
<td>127.0</td>
<td>110.7</td>
<td>114.7</td>
</tr>
<tr>
<td>150</td>
<td>125.4</td>
<td>128.5</td>
<td>111.0</td>
<td>115.9</td>
</tr>
<tr>
<td>155</td>
<td>127.2</td>
<td>130.2</td>
<td>113.1</td>
<td>117.0</td>
</tr>
<tr>
<td>160</td>
<td>129.2</td>
<td>132.3</td>
<td>114.3</td>
<td>118.0</td>
</tr>
<tr>
<td>165</td>
<td>131.3</td>
<td>134.5</td>
<td>115.5</td>
<td>119.1</td>
</tr>
<tr>
<td>170</td>
<td>133.5</td>
<td>136.7</td>
<td>116.8</td>
<td>120.2</td>
</tr>
<tr>
<td>175</td>
<td>135.6</td>
<td>138.8</td>
<td>118.1</td>
<td>121.2</td>
</tr>
<tr>
<td>180</td>
<td>137.7</td>
<td>140.9</td>
<td>119.2</td>
<td>122.1</td>
</tr>
<tr>
<td>185</td>
<td>139.8</td>
<td>143.0</td>
<td>120.3</td>
<td>123.0</td>
</tr>
</tbody>
</table>

# APPENDIX C

## Cardiovascular Risk Factors

**TABLE C-1**

ESTIMATED VALUE FOR PERCENTILE REGRESSION OF WAIST CIRCUMFERENCE* FOR EUROPEAN AMERICAN CHILDREN AND ADOLESCENTS ACCORDING TO SEX

<table>
<thead>
<tr>
<th>Age (yr)</th>
<th>10th</th>
<th>25th</th>
<th>50th</th>
<th>75th</th>
<th>90th</th>
<th>10th</th>
<th>25th</th>
<th>50th</th>
<th>75th</th>
<th>90th</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>42.9</td>
<td>46.9</td>
<td>47.1</td>
<td>48.6</td>
<td>50.6</td>
<td>43.1</td>
<td>45.1</td>
<td>47.4</td>
<td>49.6</td>
<td>52.5</td>
</tr>
<tr>
<td>3</td>
<td>44.7</td>
<td>48.8</td>
<td>49.2</td>
<td>51.2</td>
<td>54.0</td>
<td>44.7</td>
<td>46.8</td>
<td>49.3</td>
<td>51.9</td>
<td>55.4</td>
</tr>
<tr>
<td>4</td>
<td>46.5</td>
<td>50.6</td>
<td>51.3</td>
<td>53.8</td>
<td>57.4</td>
<td>46.3</td>
<td>48.5</td>
<td>51.2</td>
<td>54.2</td>
<td>58.2</td>
</tr>
<tr>
<td>5</td>
<td>48.3</td>
<td>52.5</td>
<td>53.3</td>
<td>56.5</td>
<td>60.8</td>
<td>47.9</td>
<td>50.2</td>
<td>53.1</td>
<td>56.5</td>
<td>61.1</td>
</tr>
<tr>
<td>6</td>
<td>50.1</td>
<td>54.3</td>
<td>55.4</td>
<td>59.1</td>
<td>64.2</td>
<td>49.5</td>
<td>51.8</td>
<td>55.0</td>
<td>58.8</td>
<td>64.0</td>
</tr>
<tr>
<td>7</td>
<td>46.5</td>
<td>50.6</td>
<td>51.3</td>
<td>53.8</td>
<td>57.4</td>
<td>46.3</td>
<td>48.5</td>
<td>51.2</td>
<td>54.2</td>
<td>58.2</td>
</tr>
<tr>
<td>8</td>
<td>48.3</td>
<td>52.5</td>
<td>53.3</td>
<td>56.5</td>
<td>60.8</td>
<td>47.9</td>
<td>50.2</td>
<td>53.1</td>
<td>56.5</td>
<td>61.1</td>
</tr>
<tr>
<td>9</td>
<td>50.1</td>
<td>54.3</td>
<td>55.4</td>
<td>59.1</td>
<td>64.2</td>
<td>49.5</td>
<td>51.8</td>
<td>55.0</td>
<td>58.8</td>
<td>64.0</td>
</tr>
<tr>
<td>10</td>
<td>46.5</td>
<td>50.6</td>
<td>51.3</td>
<td>53.8</td>
<td>57.4</td>
<td>46.3</td>
<td>48.5</td>
<td>51.2</td>
<td>54.2</td>
<td>58.2</td>
</tr>
<tr>
<td>11</td>
<td>59.1</td>
<td>63.6</td>
<td>65.8</td>
<td>72.2</td>
<td>81.1</td>
<td>57.5</td>
<td>60.2</td>
<td>64.4</td>
<td>70.3</td>
<td>78.3</td>
</tr>
<tr>
<td>12</td>
<td>60.9</td>
<td>65.5</td>
<td>67.9</td>
<td>74.9</td>
<td>84.5</td>
<td>59.1</td>
<td>61.9</td>
<td>66.3</td>
<td>72.6</td>
<td>81.2</td>
</tr>
<tr>
<td>13</td>
<td>62.7</td>
<td>67.4</td>
<td>70.0</td>
<td>77.5</td>
<td>87.9</td>
<td>60.7</td>
<td>63.6</td>
<td>68.2</td>
<td>74.9</td>
<td>84.1</td>
</tr>
<tr>
<td>14</td>
<td>64.5</td>
<td>69.2</td>
<td>72.1</td>
<td>80.1</td>
<td>91.3</td>
<td>62.3</td>
<td>65.3</td>
<td>70.1</td>
<td>77.2</td>
<td>86.9</td>
</tr>
<tr>
<td>15</td>
<td>66.3</td>
<td>71.1</td>
<td>74.1</td>
<td>82.8</td>
<td>94.7</td>
<td>63.9</td>
<td>67.0</td>
<td>72.0</td>
<td>79.5</td>
<td>89.8</td>
</tr>
<tr>
<td>16</td>
<td>68.1</td>
<td>72.9</td>
<td>76.2</td>
<td>85.4</td>
<td>98.1</td>
<td>65.5</td>
<td>68.6</td>
<td>73.9</td>
<td>81.8</td>
<td>92.7</td>
</tr>
<tr>
<td>17</td>
<td>69.9</td>
<td>74.8</td>
<td>78.3</td>
<td>88.0</td>
<td>101.5</td>
<td>67.1</td>
<td>70.3</td>
<td>75.8</td>
<td>84.1</td>
<td>95.5</td>
</tr>
<tr>
<td>18</td>
<td>71.7</td>
<td>76.7</td>
<td>80.4</td>
<td>90.6</td>
<td>104.9</td>
<td>68.7</td>
<td>72.0</td>
<td>77.7</td>
<td>86.4</td>
<td>98.4</td>
</tr>
</tbody>
</table>

* Waist circumference was measured with a tape at just above the uppermost lateral border of the right ilium at the end of normal expiration.


**TABLE C-2**

ESTIMATED VALUE FOR PERCENTILE REGRESSION OF WAIST CIRCUMFERENCE* FOR AFRICAN AMERICAN CHILDREN AND ADOLESCENTS ACCORDING TO SEX

* Waist circumference was measured with a tape at just above the uppermost lateral border of the right ilium at the end of normal expiration.
**Waist circumference was measured with a tape at just above the uppermost lateral border of the right ileum at the end of normal expiration.**


### TABLE C-3
**ESTIMATED VALUE FOR PERCENTILE REGRESSION OF WAIST CIRCUMFERENCE** for Mexican American children and adolescents according to sex

<table>
<thead>
<tr>
<th>Age (yr)</th>
<th>Percentile for boys</th>
<th>Percentile for girls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10th</td>
<td>25th</td>
</tr>
<tr>
<td>2</td>
<td>43.0</td>
<td>44.6</td>
</tr>
<tr>
<td>3</td>
<td>46.1</td>
<td>48.0</td>
</tr>
<tr>
<td>4</td>
<td>47.7</td>
<td>49.7</td>
</tr>
<tr>
<td>5</td>
<td>49.2</td>
<td>51.4</td>
</tr>
<tr>
<td>6</td>
<td>50.8</td>
<td>53.2</td>
</tr>
<tr>
<td>7</td>
<td>52.4</td>
<td>54.9</td>
</tr>
<tr>
<td>8</td>
<td>53.9</td>
<td>56.6</td>
</tr>
<tr>
<td>9</td>
<td>55.5</td>
<td>58.3</td>
</tr>
<tr>
<td>10</td>
<td>57.0</td>
<td>60.0</td>
</tr>
<tr>
<td>11</td>
<td>58.6</td>
<td>61.7</td>
</tr>
<tr>
<td>12</td>
<td>60.2</td>
<td>63.4</td>
</tr>
<tr>
<td>13</td>
<td>61.7</td>
<td>65.1</td>
</tr>
<tr>
<td>14</td>
<td>63.3</td>
<td>66.8</td>
</tr>
<tr>
<td>15</td>
<td>64.8</td>
<td>68.5</td>
</tr>
<tr>
<td>16</td>
<td>66.4</td>
<td>70.3</td>
</tr>
<tr>
<td>17</td>
<td>68.0</td>
<td>72.0</td>
</tr>
<tr>
<td>18</td>
<td>68.0</td>
<td>72.0</td>
</tr>
</tbody>
</table>

*Waist circumference was measured with a tape at just above the uppermost lateral border of the right ileum at the end of normal expiration.*


### TABLE C-4
FOODS TO CHOOSE AND DECREASE FOR THE STEP-ONE AND STEP-TWO DIETS
<table>
<thead>
<tr>
<th>Foods to Choose</th>
<th>Food to Decrease</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Meat, Poultry, and Fish</strong></td>
<td>Beef, pork, lamb—regular ground beef, fatty cuts, spare ribs, organ meats, sausage, regular luncheon meats, wiener, bacon</td>
</tr>
<tr>
<td>Beef, pork, lamb—lean cuts well trimmed before cooking</td>
<td>Poultry with skin, dried chicken</td>
</tr>
<tr>
<td>Poultry without skin</td>
<td>Fried fish, fried shellfish</td>
</tr>
<tr>
<td>Fish, shellfish</td>
<td>Regular luncheon meats (e.g., bologna, salami, sausage, wiener)</td>
</tr>
<tr>
<td>Processed meat—prepared from lean meat (e.g., turkey, ham, tuna wiener)</td>
<td>Egg yolk (if more than four per week on step one or if more than two per week on step two); includes eggs used in cooking</td>
</tr>
<tr>
<td><strong>Eggs</strong></td>
<td>Whole milk (fluid, evaporated, condensed), 2% low-fat milk, imitation milk</td>
</tr>
<tr>
<td>Egg whites (two whites equal one whole egg in recipes), cholesterol-free egg substitute</td>
<td>Whole milk yogurt, whole milk yogurt beverages</td>
</tr>
<tr>
<td><strong>Dairy Products</strong></td>
<td>Regular cheese (American, blue, Brie, cheddar, Colby, Edam, Monterey jack, whole milk mozzarella, Parmesan, Swiss), cream cheese, Neufchâtel cheese</td>
</tr>
<tr>
<td>Milk—skim or 1% fat (fluid, powdered, evaporated), buttermilk</td>
<td>Cottage cheese (4% fat)</td>
</tr>
<tr>
<td>Yogurt—nonfat or low-fat yogurt or yogurt beverages</td>
<td>Ice cream</td>
</tr>
<tr>
<td>Cheese—low-fat natural or processed cheese (part-skim mozzarella, ricotta) with no more than 6 g of fat per ounce on step one or 2 g of fat per ounce on step two</td>
<td>Cream, half and half, whipping cream, nondairy creamer, whipped topping, sour cream</td>
</tr>
<tr>
<td>Cottage cheese—low fat, nonfat, or dry curd (0%–2% fat)</td>
<td>Coconut oil, palm kernel oil, palm oil</td>
</tr>
<tr>
<td>Frozen dairy dessert—ice milk, frozen yogurt (low fat or nonfat)</td>
<td>Butter, lard, shortening, bacon fat</td>
</tr>
<tr>
<td><strong>Fats and Oils</strong></td>
<td>Dressing made with egg yolk, cheese, sour cream, whole milk</td>
</tr>
<tr>
<td>Unsaturated oils—safflower, sunflower, corn, soybean, canola, olive, peanut</td>
<td>Coconut</td>
</tr>
<tr>
<td>Margarine—made from unsaturated oils previously listed, light or diet margarine</td>
<td>Chocolate</td>
</tr>
<tr>
<td>Salad dressings—made with unsaturated oils previously listed, low fat or oil free</td>
<td>Bread in which eggs are a major ingredient, croissants</td>
</tr>
<tr>
<td>Seeds and nuts—peanut butter, other nut butters</td>
<td>Granola made with coconut</td>
</tr>
<tr>
<td>Cocoa powder</td>
<td>Egg noodles and pasta containing egg yolk</td>
</tr>
<tr>
<td><strong>Breads and Cereals</strong></td>
<td>High-fat crackers</td>
</tr>
<tr>
<td>Breads—whole-grain bread, hamburger and hot dog buns, corn tortilla</td>
<td>Commercially baked pastries, muffins, biscuits</td>
</tr>
<tr>
<td>Cereals—oat, wheat, corn, multigrain</td>
<td>Soup containing whole milk, cream, meat fat, poultry fat, or poultry skin</td>
</tr>
<tr>
<td>Pasta</td>
<td>Vegetables prepared with butter, cheese, or cream sauce</td>
</tr>
<tr>
<td>Rice</td>
<td>Fried fruit or fruit served with butter or cream sauce</td>
</tr>
<tr>
<td>Dry beans and peas</td>
<td><strong>Sweets and Modified Fat Desserts</strong></td>
</tr>
<tr>
<td>Crackers—low-fat animal type, graham, saltine</td>
<td>Beverages—fruit-flavored drinks, lemonade, fruit punch</td>
</tr>
<tr>
<td>Homemade baked goods using unsaturated oil, skim or 1% milk, and egg substitute—quick breads, biscuits, cornbread muffins, bran muffins, pancakes, waffles</td>
<td><strong>Fruits</strong></td>
</tr>
<tr>
<td>Soup—chicken or beef noodle, minestrone, tomato, vegetarian, potato</td>
<td>Fruit—fresh, frozen, canned, or dried</td>
</tr>
<tr>
<td><strong>Vegetables</strong></td>
<td>Fruit juice—fresh, frozen, or canned</td>
</tr>
<tr>
<td>Fresh, frozen, or canned vegetables</td>
<td>Vegetables prepared with butter, cheese, or cream sauce</td>
</tr>
<tr>
<td><strong>Fruits</strong></td>
<td>Fried fruit or fruit served with butter or cream sauce</td>
</tr>
</tbody>
</table>
The step one diet has the same nutrient recommendations as the eating pattern recommended for the general population.


**TABLE C-5**

SERVING SIZE OF VARIOUS FOOD GROUPS ACCORDING TO AGE AND GENDER

<table>
<thead>
<tr>
<th>Group</th>
<th>Grains†</th>
<th>Vegetables</th>
<th>Fruits</th>
<th>Dairy</th>
<th>Meat and Beans‡</th>
<th>Fats, Oils, and Sweets</th>
</tr>
</thead>
<tbody>
<tr>
<td>2–3 y</td>
<td>3 oz</td>
<td>1 cup</td>
<td>1 cup</td>
<td>2 cup</td>
<td>2 oz</td>
<td>Use sparingly.</td>
</tr>
<tr>
<td>4–8 yr</td>
<td>4–5 oz</td>
<td>1½ cups</td>
<td>1½ cups</td>
<td>2 cups</td>
<td>3–4 oz</td>
<td>Sugars are quickly absorbed into bloodstream, and unused sugars are stored as fat.</td>
</tr>
<tr>
<td>Girls 9–13 yr</td>
<td>5 oz</td>
<td>2 cups</td>
<td>1½ cups</td>
<td>3 cups</td>
<td>5 oz</td>
<td></td>
</tr>
<tr>
<td>Boys 9–13 yr</td>
<td>6 oz</td>
<td>2½ cups</td>
<td>1½ cups</td>
<td>3 cups</td>
<td>5 oz</td>
<td></td>
</tr>
<tr>
<td>Girls 14–18 yr</td>
<td>6 oz</td>
<td>2½ cups</td>
<td>1½ cups</td>
<td>3 cups</td>
<td>5 oz</td>
<td></td>
</tr>
<tr>
<td>Boys 14–18 yr</td>
<td>7 oz</td>
<td>3 cups</td>
<td>2 cups</td>
<td>3 cups</td>
<td>6 oz</td>
<td></td>
</tr>
</tbody>
</table>

* These guidelines are for children who get about 30 minutes of exercise per day.
† An ounce equals 1 slice of bread, ½ cup of cooked rice or pasta, or ½ cup of oatmeal.
‡ An ounce equals ½ cup of cooked dry beans; ½ cup of tofu; 1 egg; 1 tablespoon of peanut butter; ½ cup of nuts or seeds; or 1 oz of meat, poultry, or fish.

FIGURE C-1  Centers for Disease Control and Prevention (CDC) body mass index percentile curves for boys 2 to 20 years old.
FIGURE C-2  Centers for Disease Control and Prevention (CDC) body mass index percentile curves for girls 2 to 20 years old.
## Normal Echocardiographic Values

### TABLE D-1

**TWO-DIMENSIONAL ECHOCARDIOGRAPHY-DERIVED M-MODE MEASUREMENTS OF THE LEFT VENTRICULAR DIMENSION AND WALL THICKNESS: MEAN (-2 SD TO +2 SD)**

<table>
<thead>
<tr>
<th>Echo Views</th>
<th>BSA</th>
<th>0.2</th>
<th>0.3</th>
<th>0.4</th>
<th>0.5</th>
<th>0.6</th>
<th>0.7</th>
<th>0.8</th>
<th>0.9</th>
<th>1.0</th>
<th>1.2</th>
<th>1.4</th>
<th>1.6</th>
<th>1.8</th>
<th>2.0</th>
<th>2.2</th>
</tr>
</thead>
<tbody>
<tr>
<td>RV ED (D)</td>
<td>(4.5-6.5)</td>
<td>(4.5-6.5)</td>
<td>(4.5-6.5)</td>
<td>(4.5-6.5)</td>
<td>(4.5-6.5)</td>
<td>(4.5-6.5)</td>
<td>(4.5-6.5)</td>
<td>(4.5-6.5)</td>
<td>(4.5-6.5)</td>
<td>(4.5-6.5)</td>
<td>(4.5-6.5)</td>
<td>(4.5-6.5)</td>
<td>(4.5-6.5)</td>
<td>(4.5-6.5)</td>
<td>(4.5-6.5)</td>
<td>(4.5-6.5)</td>
</tr>
<tr>
<td>LV ED (S)</td>
<td>(3.5-5.5)</td>
<td>(3.5-5.5)</td>
<td>(3.5-5.5)</td>
<td>(3.5-5.5)</td>
<td>(3.5-5.5)</td>
<td>(3.5-5.5)</td>
<td>(3.5-5.5)</td>
<td>(3.5-5.5)</td>
<td>(3.5-5.5)</td>
<td>(3.5-5.5)</td>
<td>(3.5-5.5)</td>
<td>(3.5-5.5)</td>
<td>(3.5-5.5)</td>
<td>(3.5-5.5)</td>
<td>(3.5-5.5)</td>
<td>(3.5-5.5)</td>
</tr>
<tr>
<td>RV ED (S)</td>
<td>(1.0-3.0)</td>
<td>(1.0-3.0)</td>
<td>(1.0-3.0)</td>
<td>(1.0-3.0)</td>
<td>(1.0-3.0)</td>
<td>(1.0-3.0)</td>
<td>(1.0-3.0)</td>
<td>(1.0-3.0)</td>
<td>(1.0-3.0)</td>
<td>(1.0-3.0)</td>
<td>(1.0-3.0)</td>
<td>(1.0-3.0)</td>
<td>(1.0-3.0)</td>
<td>(1.0-3.0)</td>
<td>(1.0-3.0)</td>
<td>(1.0-3.0)</td>
</tr>
</tbody>
</table>

**BSA,** Body surface area; **IVS (D),** interventricular septal thickness, end diastolic; **IVS (S),** interventricular septal thickness, end systolic; **LVEDD,** left ventricular end-diastolic dimension; **LVESD,** left ventricular end-systolic dimension; **LVPW (D),** left ventricular posterior wall thickness, end diastolic; **LVPW (S),** left ventricular posterior wall thickness, end systolic; **SD,** standard deviation.

* Values are rounded off to the nearest 0.5 mm.

Values have been derived from graphic data of Lai WW, Mertens LL, Cohen MS, Geva T, (eds): Appendix 1. In Echocardiography in Pediatric and Congenital Heart Disease. Wiley-Blackwell, Oxford (UK), 2010.

### TABLE D-2

**STAND-ALONE M-MODE ECHOCARDIOGRAPHIC MEASUREMENTS: RIGHT VENTRICLE, AORTA, AND LEFT ATRIUM BY BODY SURFACE AREA: MEAN (90% TOLERANCE LIMITS) (IN MM)**

<table>
<thead>
<tr>
<th>Echo Views</th>
<th>BSA</th>
<th>0.2</th>
<th>0.3</th>
<th>0.4</th>
<th>0.5</th>
<th>0.6</th>
<th>0.7</th>
<th>0.8</th>
<th>0.9</th>
<th>1.0</th>
<th>1.2</th>
<th>1.4</th>
<th>1.6</th>
<th>1.8</th>
<th>2.0</th>
<th>2.2</th>
</tr>
</thead>
<tbody>
<tr>
<td>RV (diastolic)</td>
<td>7</td>
<td>9.5</td>
<td>10</td>
<td>10</td>
<td>11 (3-19)</td>
<td>12</td>
<td>13 (4-22)</td>
<td>14</td>
<td>14</td>
<td>16</td>
<td>18</td>
<td>20</td>
<td>22</td>
<td>23</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>LV (diastolic)</td>
<td>(0-16)</td>
<td>(0-17)</td>
<td>(0-17)</td>
<td>(0-17)</td>
<td>(0-17)</td>
<td>(0-17)</td>
<td>(0-17)</td>
<td>(0-17)</td>
<td>(0-17)</td>
<td>(0-17)</td>
<td>(0-17)</td>
<td>(0-17)</td>
<td>(0-17)</td>
<td>(0-17)</td>
<td>(0-17)</td>
<td></td>
</tr>
<tr>
<td>Aorta (diastolic)</td>
<td>10</td>
<td>12</td>
<td>14</td>
<td>14</td>
<td>15</td>
<td>16</td>
<td>17</td>
<td>18</td>
<td>19</td>
<td>20</td>
<td>22</td>
<td>24</td>
<td>24</td>
<td>24</td>
<td>24</td>
<td></td>
</tr>
</tbody>
</table>

**BSA,** Body surface area; **LA,** left atrium; **RV,** right ventricle.

* Values rounded off to the nearest 0.5 mm or measurements <10 mm and to the nearest 1 mm for measurements ≥10 mm.

**TABLE D-3**  
TWO-DIMENSIONAL ECHOCARDIOGRAPHIC MEASUREMENTS OF AORTIC ROOT AND AORTA: MEAN (-2 SD TO +2 SD) (IN MM)

<table>
<thead>
<tr>
<th>Echo Views</th>
<th>BSA</th>
<th>0.2</th>
<th>0.3</th>
<th>0.4</th>
<th>0.5</th>
<th>0.6</th>
<th>0.7</th>
<th>0.8</th>
<th>0.9</th>
<th>1.0</th>
<th>1.2</th>
<th>1.4</th>
<th>1.6</th>
<th>1.8</th>
<th>2.0</th>
<th>2.2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aortic annulus</td>
<td>7.0</td>
<td>5.5</td>
<td>6.0</td>
<td>6.5</td>
<td>7.0</td>
<td>7.5</td>
<td>8.0</td>
<td>8.5</td>
<td>9.0</td>
<td>9.5</td>
<td>10.0</td>
<td>10.5</td>
<td>11.0</td>
<td>11.5</td>
<td>12.0</td>
<td>12.5</td>
</tr>
<tr>
<td>Mean</td>
<td>(5.5-9.0)</td>
<td>(6.0-8.5)</td>
<td>(6.5-9.0)</td>
<td>(7.0-9.5)</td>
<td>(7.5-10.0)</td>
<td>(8.0-10.5)</td>
<td>(8.5-11.0)</td>
<td>(9.0-11.5)</td>
<td>(9.5-12.0)</td>
<td>(10.0-12.5)</td>
<td>(10.5-13.0)</td>
<td>(11.0-13.5)</td>
<td>(11.5-14.0)</td>
<td>(12.0-14.5)</td>
<td>(12.5-15.0)</td>
<td>(13.0-15.5)</td>
</tr>
<tr>
<td>pulmonic annulus</td>
<td>11.0</td>
<td>11.5</td>
<td>12.0</td>
<td>12.5</td>
<td>13.0</td>
<td>13.5</td>
<td>14.0</td>
<td>14.5</td>
<td>15.0</td>
<td>15.5</td>
<td>16.0</td>
<td>16.5</td>
<td>17.0</td>
<td>17.5</td>
<td>18.0</td>
<td>18.5</td>
</tr>
<tr>
<td>Mean</td>
<td>(10.5-11.5)</td>
<td>(11.0-12.0)</td>
<td>(11.5-12.5)</td>
<td>(12.0-13.0)</td>
<td>(12.5-13.5)</td>
<td>(13.0-14.0)</td>
<td>(13.5-14.5)</td>
<td>(14.0-15.0)</td>
<td>(14.5-15.5)</td>
<td>(15.0-16.0)</td>
<td>(15.5-16.5)</td>
<td>(16.0-17.0)</td>
<td>(16.5-17.5)</td>
<td>(17.0-18.0)</td>
<td>(17.5-18.5)</td>
<td>(18.0-19.0)</td>
</tr>
</tbody>
</table>

BSA, Body surface area; SD, standard deviation.

* Values are rounded off to the nearest 0.5 mm.

Values have been derived from graphic data of Lai WW, Mertens LL, Cohen MS, Geva T, (eds): Appendix 1. In Echocardiography in Pediatric and Congenital Heart Disease. Wiley-Blackwell, Oxford (UK), 2010.

**TABLE D-4**  
TWO-DIMENSIONAL ECHOCARDIOGRAPHIC MEASUREMENTS OF THE PULMONARY VALVE AND PULMONARY ARTERIES (IN MM): MEAN (-2 SD TO +2 SD)

<table>
<thead>
<tr>
<th>Echo Views</th>
<th>BSA</th>
<th>0.2</th>
<th>0.3</th>
<th>0.4</th>
<th>0.5</th>
<th>0.6</th>
<th>0.7</th>
<th>0.8</th>
<th>0.9</th>
<th>1.0</th>
<th>1.2</th>
<th>1.4</th>
<th>1.6</th>
<th>1.8</th>
<th>2.0</th>
<th>2.2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary annulus</td>
<td>8.5</td>
<td>7.0</td>
<td>7.5</td>
<td>8.0</td>
<td>8.5</td>
<td>9.0</td>
<td>9.5</td>
<td>10.0</td>
<td>10.5</td>
<td>11.0</td>
<td>11.5</td>
<td>12.0</td>
<td>12.5</td>
<td>13.0</td>
<td>13.5</td>
<td>14.0</td>
</tr>
<tr>
<td>Mean</td>
<td>(6.5-9.0)</td>
<td>(6.5-8.5)</td>
<td>(7.0-9.0)</td>
<td>(7.5-9.5)</td>
<td>(8.0-10.0)</td>
<td>(8.5-10.5)</td>
<td>(9.0-11.0)</td>
<td>(9.5-11.5)</td>
<td>(10.0-12.0)</td>
<td>(10.5-12.5)</td>
<td>(11.0-13.0)</td>
<td>(11.5-13.5)</td>
<td>(12.0-14.0)</td>
<td>(12.5-14.5)</td>
<td>(13.0-15.0)</td>
<td>(13.5-15.5)</td>
</tr>
<tr>
<td>Main PA</td>
<td>7.5</td>
<td>6.0</td>
<td>6.5</td>
<td>7.0</td>
<td>7.5</td>
<td>8.0</td>
<td>8.5</td>
<td>9.0</td>
<td>9.5</td>
<td>10.0</td>
<td>10.5</td>
<td>11.0</td>
<td>11.5</td>
<td>12.0</td>
<td>12.5</td>
<td>13.0</td>
</tr>
<tr>
<td>Mean</td>
<td>(5.5-8.0)</td>
<td>(5.5-6.5)</td>
<td>(6.0-7.0)</td>
<td>(6.5-7.5)</td>
<td>(7.0-8.0)</td>
<td>(7.5-8.5)</td>
<td>(8.0-9.0)</td>
<td>(8.5-9.5)</td>
<td>(9.0-10.0)</td>
<td>(9.5-10.5)</td>
<td>(10.0-11.0)</td>
<td>(10.5-11.5)</td>
<td>(11.0-12.0)</td>
<td>(11.5-12.5)</td>
<td>(12.0-13.0)</td>
<td>(12.5-13.5)</td>
</tr>
<tr>
<td>Right PA</td>
<td>5.0</td>
<td>4.5</td>
<td>5.0</td>
<td>5.5</td>
<td>6.0</td>
<td>6.5</td>
<td>7.0</td>
<td>7.5</td>
<td>8.0</td>
<td>8.5</td>
<td>9.0</td>
<td>9.5</td>
<td>10.0</td>
<td>10.5</td>
<td>11.0</td>
<td>11.5</td>
</tr>
<tr>
<td>Mean</td>
<td>(3.5-6.0)</td>
<td>(4.0-6.5)</td>
<td>(4.5-7.0)</td>
<td>(5.0-7.5)</td>
<td>(5.5-8.0)</td>
<td>(6.0-8.5)</td>
<td>(6.5-9.0)</td>
<td>(7.0-9.5)</td>
<td>(7.5-10.0)</td>
<td>(8.0-10.5)</td>
<td>(8.5-11.0)</td>
<td>(9.0-11.5)</td>
<td>(9.5-12.0)</td>
<td>(10.0-12.5)</td>
<td>(10.5-13.0)</td>
<td>(11.0-13.5)</td>
</tr>
<tr>
<td>Left PA</td>
<td>4.5</td>
<td>4.0</td>
<td>4.5</td>
<td>5.0</td>
<td>5.5</td>
<td>6.0</td>
<td>6.5</td>
<td>7.0</td>
<td>7.5</td>
<td>8.0</td>
<td>8.5</td>
<td>9.0</td>
<td>9.5</td>
<td>10.0</td>
<td>10.5</td>
<td>11.0</td>
</tr>
<tr>
<td>Mean</td>
<td>(3.0-5.5)</td>
<td>(3.5-6.0)</td>
<td>(4.0-6.5)</td>
<td>(4.5-7.0)</td>
<td>(5.0-7.5)</td>
<td>(5.5-8.0)</td>
<td>(6.0-8.5)</td>
<td>(6.5-9.0)</td>
<td>(7.0-9.5)</td>
<td>(7.5-10.0)</td>
<td>(8.0-10.5)</td>
<td>(8.5-11.0)</td>
<td>(9.0-11.5)</td>
<td>(9.5-12.0)</td>
<td>(10.0-12.5)</td>
<td>(10.5-13.0)</td>
</tr>
</tbody>
</table>

* Values are rounded off to the nearest 0.5 mm.

Values have been derived from graphic data of Lai WW, Mertens LL, Cohen MS, Geva T, (eds): Appendix 1. In Echocardiography in Pediatric and Congenital Heart Disease. Wiley-Blackwell, Oxford (UK), 2010.

**TABLE D-5**  
TWO-DIMENSIONAL ECHOCARDIOGRAPHIC MEASUREMENTS OF ATRIOVENTRICULAR VALVES (IN MM): MEAN (-2 SD TO +2 SD)
Values are rounded off to the nearest 0.5 mm.

Values have been derived from graphic data of Lai WW, Mertens LL, Cohen MS, Geva T, (eds): Appendix 1. In Echocardiography in Pediatric and Congenital Heart Disease. Wiley-Blackwell, Oxford (UK), 2010.

### TABLE D-6

**TWO-DIMENSIONAL ECHOCARDIOGRAPHIC MEASUREMENTS OF MEAN AND PREDICTION LIMITS FOR 2 AND 3 STANDARD DEVIATIONS FOR MAJOR CORONARY ARTERY SEGMENTS**

<table>
<thead>
<tr>
<th>Echo Views</th>
<th>BSA</th>
<th>0.2</th>
<th>0.3</th>
<th>0.4</th>
<th>0.5</th>
<th>0.6</th>
<th>0.7</th>
<th>0.8</th>
<th>1.0</th>
<th>1.2</th>
<th>1.4</th>
<th>1.6</th>
<th>1.8</th>
<th>2.0</th>
</tr>
</thead>
<tbody>
<tr>
<td>LAD Mean</td>
<td>1.2</td>
<td>1.4</td>
<td>1.6</td>
<td>1.8</td>
<td>1.9</td>
<td>2.0</td>
<td>2.2</td>
<td>2.3</td>
<td>2.5</td>
<td>2.7</td>
<td>2.0</td>
<td>2.9</td>
<td>3.0</td>
<td>2.9</td>
</tr>
<tr>
<td>Mean + 2 SD</td>
<td>1.5</td>
<td>1.8</td>
<td>2.1</td>
<td>2.3</td>
<td>2.5</td>
<td>2.7</td>
<td>2.8</td>
<td>3.0</td>
<td>3.3</td>
<td>3.5</td>
<td>3.7</td>
<td>4.0</td>
<td>4.2</td>
<td>4.0</td>
</tr>
<tr>
<td>Mean + 3 SD</td>
<td>1.7</td>
<td>2.0</td>
<td>2.3</td>
<td>2.5</td>
<td>2.8</td>
<td>3.0</td>
<td>3.2</td>
<td>3.4</td>
<td>3.8</td>
<td>4.0</td>
<td>4.3</td>
<td>4.5</td>
<td>4.7</td>
<td>4.3</td>
</tr>
<tr>
<td>RCA Mean</td>
<td>1.3</td>
<td>1.4</td>
<td>1.6</td>
<td>1.7</td>
<td>1.8</td>
<td>2.0</td>
<td>2.1</td>
<td>2.3</td>
<td>2.5</td>
<td>2.7</td>
<td>2.8</td>
<td>3.1</td>
<td>3.4</td>
<td>3.6</td>
</tr>
<tr>
<td>Mean + 2 SD</td>
<td>1.9</td>
<td>2.1</td>
<td>2.3</td>
<td>2.4</td>
<td>2.6</td>
<td>2.7</td>
<td>2.8</td>
<td>3.1</td>
<td>3.4</td>
<td>3.6</td>
<td>3.8</td>
<td>4.0</td>
<td>4.3</td>
<td>4.5</td>
</tr>
<tr>
<td>Mean + 3 SD</td>
<td>2.2</td>
<td>2.4</td>
<td>2.6</td>
<td>2.8</td>
<td>3.0</td>
<td>3.1</td>
<td>3.3</td>
<td>3.5</td>
<td>3.8</td>
<td>4.1</td>
<td>4.3</td>
<td>4.5</td>
<td>4.8</td>
<td>4.3</td>
</tr>
<tr>
<td>LMCA Mean</td>
<td>1.7</td>
<td>1.9</td>
<td>2.1</td>
<td>2.3</td>
<td>2.4</td>
<td>2.5</td>
<td>2.7</td>
<td>2.9</td>
<td>3.1</td>
<td>3.3</td>
<td>3.4</td>
<td>3.6</td>
<td>3.7</td>
<td>3.6</td>
</tr>
<tr>
<td>Mean + 2 SD</td>
<td>2.3</td>
<td>2.6</td>
<td>2.8</td>
<td>3.0</td>
<td>3.3</td>
<td>3.4</td>
<td>3.6</td>
<td>3.9</td>
<td>4.2</td>
<td>4.4</td>
<td>4.6</td>
<td>4.8</td>
<td>5.1</td>
<td>4.8</td>
</tr>
<tr>
<td>Mean + 3 SD</td>
<td>2.7</td>
<td>3.0</td>
<td>3.2</td>
<td>3.4</td>
<td>3.7</td>
<td>3.9</td>
<td>4.0</td>
<td>4.3</td>
<td>4.7</td>
<td>4.9</td>
<td>5.2</td>
<td>5.5</td>
<td>5.8</td>
<td>5.5</td>
</tr>
</tbody>
</table>

BSA, Body surface area; LCA, left anterior descending coronary artery; LMCA, left main coronary artery; RCA, right coronary artery; SD, standard deviation.

*Measurements are made from inner edge to inner edge. Values are rounded off to the nearest 0.1 mm.


### TABLE D-7

**LEFT VENTRICULAR MASS AND LEFT VENTRICULAR MASS INDEX BY M-MODE ECHOCARDIOGRAPHY**

<table>
<thead>
<tr>
<th>Boys</th>
<th>Left Ventricular Mass (g)</th>
<th>Left Ventricular Mass Index (g/m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>50th Percentile</td>
<td>90th Percentile</td>
</tr>
<tr>
<td>&lt; 6 mo</td>
<td>10.94</td>
<td>16.28</td>
</tr>
<tr>
<td>0.50 - 2 yr</td>
<td>21.28</td>
<td>22.47</td>
</tr>
<tr>
<td>2 - 4 yr</td>
<td>33.32</td>
<td>45.48</td>
</tr>
<tr>
<td>4 - 6 yr</td>
<td>45.49</td>
<td>59.26</td>
</tr>
<tr>
<td>6 - 8 yr</td>
<td>51.73</td>
<td>70.48</td>
</tr>
<tr>
<td>8 - 10 yr</td>
<td>62.00</td>
<td>84.61</td>
</tr>
<tr>
<td>10 - 12 yr</td>
<td>74.10</td>
<td>105.53</td>
</tr>
<tr>
<td>12 - 14 yr</td>
<td>87.76</td>
<td>138.1</td>
</tr>
<tr>
<td>14 - 16 yr</td>
<td>123.7</td>
<td>187.2</td>
</tr>
<tr>
<td>16 yr</td>
<td>131.5</td>
<td>183.1</td>
</tr>
</tbody>
</table>

*Values are rounded off to the nearest 0.05 mm.*
TABLE D-8

LEFT VENTRICULAR MASS USING THE 5/6AL BY BODY SURFACE AREA: MEAN (±2 SD TO +2 SD)

<table>
<thead>
<tr>
<th>Age</th>
<th>50th Percentile</th>
<th>90th Percentile</th>
<th>95th Percentile</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 6 mo</td>
<td>11.15</td>
<td>16.05</td>
<td>16.50</td>
<td>28.74</td>
</tr>
<tr>
<td>6 mo ≤ 2 yr</td>
<td>22.23</td>
<td>31.98</td>
<td>34.50</td>
<td>35.98</td>
</tr>
<tr>
<td>2 ≤ 4 yr</td>
<td>33.38</td>
<td>43.88</td>
<td>46.10</td>
<td>50.38</td>
</tr>
<tr>
<td>4 ≤ 5 yr</td>
<td>39.67</td>
<td>50.38</td>
<td>57.30</td>
<td>70.84</td>
</tr>
<tr>
<td>5 ≤ 8 yr</td>
<td>48.38</td>
<td>65.54</td>
<td>72.10</td>
<td>89.30</td>
</tr>
<tr>
<td>8 ≤ 10 yr</td>
<td>54.76</td>
<td>75.49</td>
<td>83.00</td>
<td>91.82</td>
</tr>
<tr>
<td>10 ≤ 12 yr</td>
<td>71.66</td>
<td>98.00</td>
<td>102.0</td>
<td>140.1</td>
</tr>
<tr>
<td>12 ≤ 14 yr</td>
<td>92.36</td>
<td>119.8</td>
<td>128.0</td>
<td>155.9</td>
</tr>
<tr>
<td>14 ≤ 16 yr</td>
<td>96.73</td>
<td>130.0</td>
<td>143.0</td>
<td>235.0</td>
</tr>
<tr>
<td>≥ 16 yr</td>
<td>101.6</td>
<td>139.5</td>
<td>154.0</td>
<td>201.4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age</th>
<th>50th Percentile</th>
<th>90th Percentile</th>
<th>95th Percentile</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 6 mo</td>
<td>55.38</td>
<td>73.47</td>
<td>85.60</td>
<td>100.2</td>
</tr>
<tr>
<td>6 mo ≤ 2 yr</td>
<td>42.04</td>
<td>52.86</td>
<td>57.10</td>
<td>61.06</td>
</tr>
<tr>
<td>2 ≤ 4 yr</td>
<td>37.88</td>
<td>47.65</td>
<td>55.30</td>
<td>66.38</td>
</tr>
<tr>
<td>4 ≤ 5 yr</td>
<td>32.29</td>
<td>43.87</td>
<td>44.30</td>
<td>59.25</td>
</tr>
<tr>
<td>5 ≤ 8 yr</td>
<td>20.71</td>
<td>37.73</td>
<td>43.30</td>
<td>54.76</td>
</tr>
<tr>
<td>8 ≤ 10 yr</td>
<td>26.63</td>
<td>34.30</td>
<td>36.00</td>
<td>44.35</td>
</tr>
<tr>
<td>10 ≤ 12 yr</td>
<td>26.11</td>
<td>33.03</td>
<td>35.70</td>
<td>44.48</td>
</tr>
<tr>
<td>12 ≤ 14 yr</td>
<td>26.08</td>
<td>34.65</td>
<td>38.20</td>
<td>43.99</td>
</tr>
<tr>
<td>14 ≤ 16 yr</td>
<td>26.51</td>
<td>34.89</td>
<td>36.90</td>
<td>54.33</td>
</tr>
<tr>
<td>≥ 16 yr</td>
<td>26.35</td>
<td>37.93</td>
<td>40.00</td>
<td>50.74</td>
</tr>
</tbody>
</table>

BSA, Body surface area; LV, left ventricular; SD, standard deviation.

* Values are rounded off to the nearest 1 gram.

Values have been derived from graphic data of Figure Left ventricular mass using the 5/6 × area × length algorithm (5/6AL) versus body surface area from Echocardiography in Pediatric and Congenital Heart Disease, Lai WW, Mertens LL, Cohen MS, and Geva T (editors), Wiley-Blackwell, 2010.
FIGURE D-1  A, Biplane transesophageal echocardiographic views from transgastric position III. B, Biplane transesophageal echocardiographic views at midesophageal position II.C, Biplane transesophageal echocardiography views from the base of the heart at position I. D, Basal views of the heart and great vessels with use of the longitudinal plane probe at position I. A, Anterior; AA, ascending aorta; AML, anterior mitral leaflet; AO, aorta; ASC, ascending; AV, aortic valve; CS, coronary sinus; I, inferior; IAS, interatrial septum; IVC, inferior vena cava; L, left; LA, left atrium; LAA, left atrial appendage; LCA, left coronary artery; LPA, left pulmonary artery; LUPV, left upper pulmonary vein; LV, left ventricle; LVOT, left ventricular outflow tract; MPA, main pulmonary artery; MVO, mitral valve orifice; P, posterior; PML, posterior mitral leaflet; PPM, posterior papillary muscle; PV, pulmonary valve; R, right; RA, right atrium; RAA, right atrial appendage; RCA, right coronary artery; RLPV, right lower pulmonary vein; RPA, right pulmonary artery; RV, right ventricle; RVOT, right ventricular outflow tract; S, superior; SVC, superior vena cava. (From Bansal RC, Shakudo M, Shah PM, Shah PM: Biplane transesophageal echocardiography: Technique, image orientation, and preliminary experience in 131 patients. J Am Soc Echocardiogr 3:348–366, 1990.)
Drugs Used in Pediatric Cardiology

TABLE E-1
DRUG INDEX (FOR DRUGS USED IN PEDIATRIC CARDIOLOGY)
<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Generic Name</th>
<th>Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbokinase</td>
<td>Urokinase</td>
<td>Thrombolytic agent</td>
</tr>
<tr>
<td>Actiq</td>
<td>Fentanyl</td>
<td>Narcotic analgesic</td>
</tr>
<tr>
<td>Adalat</td>
<td>Nifedipine</td>
<td>Calcium channel blocker</td>
</tr>
<tr>
<td>Adalat CC</td>
<td>Nifedipine, sustained release</td>
<td>Calcium channel blocker</td>
</tr>
<tr>
<td>Adenosine</td>
<td></td>
<td>Antiarrhythmic</td>
</tr>
<tr>
<td>Adrenalin</td>
<td>Epinephrine HCl</td>
<td>Nonselective adrenergic stimulator</td>
</tr>
<tr>
<td>Aldactone</td>
<td>Spironolactone</td>
<td>Aldosterone antagonist</td>
</tr>
<tr>
<td>Aldomet</td>
<td>Methyldopa</td>
<td>Antihypertensive</td>
</tr>
<tr>
<td>Alprostadil</td>
<td>Prostaglandin E₁</td>
<td>Vasodilator</td>
</tr>
<tr>
<td>Anacin</td>
<td>Aspirin</td>
<td>Antiplatelet agent, analgesic</td>
</tr>
<tr>
<td>Apresoline</td>
<td>Hydralazine HCl</td>
<td>Peripheral vasodilator</td>
</tr>
<tr>
<td>Aquachloral Suppnettes</td>
<td>Chloral hydrate</td>
<td>Sedative and hypnotic</td>
</tr>
<tr>
<td>Aramine</td>
<td>Metaraminol</td>
<td>β₁-Adrenoceptor stimulant</td>
</tr>
<tr>
<td>Atarax</td>
<td>Hydroxyzine</td>
<td>Sedative</td>
</tr>
<tr>
<td>Atromid-S</td>
<td>Clofibrate</td>
<td>Antilipidemic, triglyceride-lowering agent</td>
</tr>
<tr>
<td>Brevetol</td>
<td>Bretylum isosylate</td>
<td>Class III antiarrhythmic</td>
</tr>
<tr>
<td>Brevibloc</td>
<td>Esmolol</td>
<td>β₁-Selective adrenergic blocking agent, antihypertensive</td>
</tr>
<tr>
<td>Bumex</td>
<td>Bumetanide</td>
<td>Loop diuretic</td>
</tr>
<tr>
<td>Calan</td>
<td>Verapamil</td>
<td>Class IV antiarrhythmic agent</td>
</tr>
<tr>
<td>Capoten</td>
<td>Captiopril</td>
<td>Angiotensin-converting enzyme (ACE) inhibitor</td>
</tr>
<tr>
<td>Cardioquin</td>
<td>Quintidine</td>
<td>Class IA antiarrhythmic agent</td>
</tr>
<tr>
<td>Cardizem</td>
<td>Diltiazem</td>
<td>Calcium channel blocker</td>
</tr>
<tr>
<td>Camitor</td>
<td>Carnitine</td>
<td>L-carnitine</td>
</tr>
<tr>
<td>Colestid</td>
<td>Colestipol</td>
<td>Lipid-lowering agent</td>
</tr>
<tr>
<td>Cordarone</td>
<td>Amiodarone</td>
<td>Class III antiarrhythmic</td>
</tr>
<tr>
<td>Coreg</td>
<td>Carvedilol</td>
<td>Nonselective β adrenergic blocker</td>
</tr>
<tr>
<td>Coreg Tiltab</td>
<td>Carvedilol</td>
<td>Nonselective β adrenergic blocker</td>
</tr>
<tr>
<td>Coumadin</td>
<td>Warfarin</td>
<td>Anticoagulant</td>
</tr>
<tr>
<td>Cozaar</td>
<td>Losartan</td>
<td>Angiotensin receptor blocker</td>
</tr>
<tr>
<td>Demerol</td>
<td>Meperidine</td>
<td>Narcotic analgesic</td>
</tr>
<tr>
<td>Digibind</td>
<td>Digoxin immune Fab (ovine)</td>
<td>Antidigoxin antibody</td>
</tr>
<tr>
<td>Dilacor XR</td>
<td>Diltiazem</td>
<td>Calcium channel blocker</td>
</tr>
<tr>
<td>Dilantin</td>
<td>Phenytoin</td>
<td>Class IB antiarrhythmic</td>
</tr>
<tr>
<td>Dilu</td>
<td>Metolzone</td>
<td>Thiazide-like diuretic</td>
</tr>
<tr>
<td>Durogen</td>
<td>Chlorothiazide</td>
<td>Thiazide diuretic</td>
</tr>
<tr>
<td>Diuril</td>
<td>Chlorothiazide</td>
<td>Thiazide diuretic</td>
</tr>
<tr>
<td>Dobutrex</td>
<td>Dobutamine</td>
<td>Diuretic</td>
</tr>
<tr>
<td>Dopastat</td>
<td>Dopamine</td>
<td>β₁-Adrenergic stimulator</td>
</tr>
<tr>
<td>Duragesic</td>
<td>Fentanyl</td>
<td>Sympathomimetic agent</td>
</tr>
<tr>
<td>Dynacirc</td>
<td>Isradipine</td>
<td>Narcotic analgesic</td>
</tr>
<tr>
<td>Dryenium</td>
<td>Triamterene</td>
<td>Calcium channel blocker</td>
</tr>
<tr>
<td>Edecin</td>
<td>Ethacrylic acid</td>
<td>Loop diuretic</td>
</tr>
<tr>
<td>Esidrix</td>
<td>Thiazide diuretic</td>
<td></td>
</tr>
<tr>
<td>Floctinal</td>
<td>Hydrochlorothiazide Hydro-Par, Oretic</td>
<td>Corticosteroid</td>
</tr>
<tr>
<td>Flohydrofusone</td>
<td>Fludrocortisone acetate</td>
<td>Corticosteroid</td>
</tr>
<tr>
<td>Furosemide</td>
<td>Furosemide</td>
<td>Loop diuretic</td>
</tr>
<tr>
<td>Hyperstat</td>
<td>Diazoxide</td>
<td>Peripheral vasodilator</td>
</tr>
<tr>
<td>HydroDIURIL</td>
<td>Hydrochlorothiazide</td>
<td>Diuretic</td>
</tr>
<tr>
<td>Hydro-Par</td>
<td>Hydrochlorothiazide</td>
<td>Thiazide diuretic</td>
</tr>
<tr>
<td>Imuran</td>
<td>Azathioprine</td>
<td>Immunosuppressive</td>
</tr>
<tr>
<td>Idaral</td>
<td>Propranolol</td>
<td>β-Adreceptor blocker, class II antiarrhythmic agent</td>
</tr>
<tr>
<td>Indocin</td>
<td>Indomethacin</td>
<td>Nonsteroidal antiinflammatory agent</td>
</tr>
<tr>
<td>Inocor</td>
<td>Ammonium lactate</td>
<td>Noncatecholamine inotropic agent with vasodilating effects</td>
</tr>
<tr>
<td>Intopin</td>
<td>Dopamine</td>
<td>Natural catecholamine inotropic agent</td>
</tr>
<tr>
<td>Isoprin</td>
<td>Verapamil</td>
<td>Class IV antiarrhythmic agent</td>
</tr>
<tr>
<td>Isuprel</td>
<td>Isoproterenol</td>
<td>β₁ and β₂ adrenergic stimulator</td>
</tr>
<tr>
<td>Drug</td>
<td>Function</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>Kabikinase</td>
<td>Thrombolytic agent</td>
<td></td>
</tr>
<tr>
<td>Kayexalate</td>
<td>Potassium-lowering agent</td>
<td></td>
</tr>
<tr>
<td>Ketalar</td>
<td>Dissociate anesthetic</td>
<td></td>
</tr>
<tr>
<td>Kionex</td>
<td>Potassium-lowering agent</td>
<td></td>
</tr>
<tr>
<td>Lanoxin</td>
<td>Cardiac glycoside</td>
<td></td>
</tr>
<tr>
<td>Lasix</td>
<td>Loop diuretic</td>
<td></td>
</tr>
<tr>
<td>Levocarnitine</td>
<td>L-carnitine</td>
<td></td>
</tr>
<tr>
<td>Levophed</td>
<td>α- and β-Adrenergic stimulator</td>
<td></td>
</tr>
<tr>
<td>Lipitor</td>
<td>Lipid-lowering agent, “statin”</td>
<td></td>
</tr>
<tr>
<td>Loniten</td>
<td>Peripheral vasodilator</td>
<td></td>
</tr>
<tr>
<td>Lopressor</td>
<td>β-Adrenoceptor blocker</td>
<td></td>
</tr>
<tr>
<td>Lovenox</td>
<td>Low-molecular weight heparin (anticoagulant)</td>
<td></td>
</tr>
<tr>
<td>Mevacor</td>
<td>HMG-CoA reductase inhibitor, lipid-lowering agent</td>
<td></td>
</tr>
<tr>
<td>Mexitil</td>
<td>Class IB antiarrhythmic</td>
<td></td>
</tr>
<tr>
<td>Minipress</td>
<td>Postsynaptic α-adrenergic blocker, antihypertensive</td>
<td></td>
</tr>
<tr>
<td>Mykrox</td>
<td>Thiazide-like diuretic</td>
<td></td>
</tr>
<tr>
<td>Narcan</td>
<td>Narcotine antagonist</td>
<td></td>
</tr>
<tr>
<td>Neo-Calgan</td>
<td>Calcium supplement</td>
<td></td>
</tr>
<tr>
<td>Neo-Synephrine</td>
<td>α-Adrenergic stimulant</td>
<td></td>
</tr>
<tr>
<td>Neoral</td>
<td>Immunosuppressive agent</td>
<td></td>
</tr>
<tr>
<td>Nipride</td>
<td>Peripheral vasodilator</td>
<td></td>
</tr>
<tr>
<td>Nitro-bid</td>
<td>Peripheral vasodilator</td>
<td></td>
</tr>
<tr>
<td>Nitrogest</td>
<td>Peripheral vasodilator</td>
<td></td>
</tr>
<tr>
<td>Nortec</td>
<td>Sedative, hypnotic</td>
<td></td>
</tr>
<tr>
<td>Normodyne</td>
<td>α- and β-Adrenergic antagonist</td>
<td></td>
</tr>
<tr>
<td>Norpace</td>
<td>Class IA antiarrhythmic agent</td>
<td></td>
</tr>
<tr>
<td>Norvac</td>
<td>Calcium channel blocker</td>
<td></td>
</tr>
<tr>
<td>Oretic</td>
<td>Thiazide diuretic</td>
<td></td>
</tr>
<tr>
<td>Phenergan</td>
<td>Sedative, antiemetic</td>
<td></td>
</tr>
<tr>
<td>Pravachol</td>
<td>Lipid-lowering agent, HMG-CoA reductase inhibitor</td>
<td></td>
</tr>
<tr>
<td>Prevalite</td>
<td>Cholesterol-lowering agent</td>
<td></td>
</tr>
<tr>
<td>Primacor</td>
<td>Phosphodiesterase inhibitor, noncatecholamine inotropic, vasodilator</td>
<td></td>
</tr>
<tr>
<td>Prinivil</td>
<td>ACE inhibitor</td>
<td></td>
</tr>
<tr>
<td>Priscoline</td>
<td>α-Adrenoceptor blocker</td>
<td></td>
</tr>
<tr>
<td>Procan SR</td>
<td>Class IA antiarrhythmic</td>
<td></td>
</tr>
<tr>
<td>Procainamide</td>
<td>Calcium channel blocker</td>
<td></td>
</tr>
<tr>
<td>Procardia</td>
<td>Calcium channel blocker</td>
<td></td>
</tr>
<tr>
<td>Procardia XL</td>
<td>Anti hypertensive agent</td>
<td></td>
</tr>
<tr>
<td>Proglycemic</td>
<td>Immunosuppressive agent</td>
<td></td>
</tr>
<tr>
<td>Prograf</td>
<td>Class IA antiarrhythmic</td>
<td></td>
</tr>
<tr>
<td>Prostyn VR</td>
<td>Vasodilator</td>
<td></td>
</tr>
<tr>
<td>Questran</td>
<td>Cholesterol-lowering agent</td>
<td></td>
</tr>
<tr>
<td>Questran Light</td>
<td>Lipid-lowering agent</td>
<td></td>
</tr>
<tr>
<td>Quinidex</td>
<td>Class IA antiarrhythmic</td>
<td></td>
</tr>
<tr>
<td>Quinaglute</td>
<td>Class IA antiarrhythmic</td>
<td></td>
</tr>
<tr>
<td>Regitine</td>
<td>α-Adrenoceptor blocker</td>
<td></td>
</tr>
<tr>
<td>Rogaine</td>
<td>Peripheral vasodilator</td>
<td></td>
</tr>
<tr>
<td>Sandimmune</td>
<td>Immunosuppressive</td>
<td></td>
</tr>
<tr>
<td>Sofaril</td>
<td>Anticoagulating agent</td>
<td></td>
</tr>
<tr>
<td>Streptase</td>
<td>Thrombolytic agent</td>
<td></td>
</tr>
<tr>
<td>Sublimaze</td>
<td>Narcotic analgesic</td>
<td></td>
</tr>
<tr>
<td>Tambocor</td>
<td>Class IC antiarrhythmic</td>
<td></td>
</tr>
<tr>
<td>Tenormin</td>
<td>β1-Adrenoceptor blocker</td>
<td></td>
</tr>
<tr>
<td>Thorazine</td>
<td>Sedative, antiemetic</td>
<td></td>
</tr>
<tr>
<td>Tiazac</td>
<td>Calcium channel blocker</td>
<td></td>
</tr>
<tr>
<td>Tonocard</td>
<td>Class IB antiarrhythmic agent</td>
<td></td>
</tr>
<tr>
<td>Tranlate</td>
<td>α- and β-Adrenergic antagonist</td>
<td></td>
</tr>
</tbody>
</table>
## Table E-2

DOSAGES OF DRUGS USED IN PEDIATRIC CARDIOLOGY

<table>
<thead>
<tr>
<th>Drug</th>
<th>Route and Dosage</th>
<th>Toxicity or Side Effects</th>
<th>How Supplied</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tridil</td>
<td>Nitroglycerin</td>
<td>Peripheral vasodilator</td>
<td></td>
</tr>
<tr>
<td>Valium</td>
<td>Diazepam</td>
<td>Sedative, antianxiety, antiseizure agent</td>
<td></td>
</tr>
<tr>
<td>Vasotec</td>
<td>Enalapril maleate</td>
<td>ACE inhibitor, vasodilator</td>
<td></td>
</tr>
<tr>
<td>Vistaril</td>
<td>Hydroxyzine</td>
<td>Sedative</td>
<td></td>
</tr>
<tr>
<td>VitaCam</td>
<td>Carnitine</td>
<td>L-carnitine</td>
<td></td>
</tr>
<tr>
<td>Xylocaine</td>
<td>Lidocaine</td>
<td>Class IB antiarrhythmic</td>
<td></td>
</tr>
<tr>
<td>Zestril</td>
<td>Lisinopril</td>
<td>ACE inhibitor</td>
<td></td>
</tr>
<tr>
<td>Zecor</td>
<td>Simvastatin</td>
<td>Lipid-lowering agent, HMG-CoA reductase inhibitor</td>
<td></td>
</tr>
<tr>
<td>Zoraxolyn</td>
<td>Metolazone</td>
<td>Thiazide-like diuretic</td>
<td></td>
</tr>
</tbody>
</table>
| Acetazolamide (Diamox) (carbonic anhydrase inhibitor, diuretic) | Children: IV, PO: 5 mg/kg/dose QD–QOD  
Adults: IV, PO: 250–375 mg/dose QD–QOD | GI irritation, paresthesia, sedation, hypokalemia, acidosis, reduced urate secretion, aplastic anemia, polyuria, renal calculi  
Contraindications: hepatic failure, severe renal failure, sulfonamide hypersensitivity | Tab: 125, 250 mg  
Susp: 25, 50 mg/mL  
Caps, sustained release: 500 mg  
Inj: 500 mg/mL  
Tab: 325, 500 mg |
| Acetylsalicylic acid (aspirin) | 
*Children and adults:*

**Antiplatelet therapy:** PO: 3–5 mg/kg QD  
**Antipyretic/analgesic:** PO, PR: 10–15 mg/kg/dose q4–6 hr (Max, 4 g/24 hr)  
**Antiinflammatory:** PO: 80–100 mg/kg/24 hr TID–QID | Rash, nausea, hepatotoxicity, GI bleeding, bronchospasm, GI distress, tinnitus  
Contraindications: hepatic failure, bleeding disorder, hypersensitivity, children <16 yr old with chickenpox or flu symptoms (because of the association with Reye’s syndrome) | Tab, enteric coated: 81, 165, 325, 500, 650 mg  
Tab, chewable: 81 mg  
Supp: 60, 80, 120, 125, 200, 300, 325, 600, 650 mg, and 1.2 g |
| Adenosine (Adenocard) (antiarrhythmic) | **For SVT:**  
Children and adults: IV: 100–200 mcg/kg  
Repeat q1–2 min, with increment of 50 mcg/kg to max of 250 mcg/kg (Max single dose, 12 mg) | Bronchospasm, chest pain, transient asystole, bradycardia and tachycardia  
Transient AV block in atrial flutter or fibrillation (+) | Inj: 3 mg/mL (2, 4 mL) |
| Amiodarone (Cordarone) (class III antiarrhythmic) | **Children:** IV (in emergency situation):  
*Loading:* 5 mg/kg, slow infusion over 30 min followed by infusion of 7 mcg/kg/min (which is calculated to deliver 10 mg/kg/24 hr); switch to oral maintenance dose as soon as clinical condition permits  
PO: 1.0–20 mg/kg/24 hr (infants) or 10 mg/kg/24 hr (children and adolescents) in 2 doses for 5–14 days followed by maintenance dose of 5–7 mg/kg once a day  
*(Therapeutic level: 0.5–2.5 mg/L)*  
**Adults:** PO: *Loading:* 800–1600 mg QD for 1–3 wk; then reduce to 600–800 mg QD for 1 mo  
**Maintenance:** 200–400 mg QD | Progressive dyspnea and cough (pulmonary fibrosis), worsening of arrhythmias, hepatotoxicity, nausea and vomiting, corneal microdeposits, hypotension, heart block, ataxia, hypo- or hyperthyroidism, photosensitivity  
Contraindications: AV block, sinus node dysfunction, sinus bradycardia | Tab: 200, 400 mg  
Susp: 5 mg/mL  
Inj: 50 mg/mL |
<table>
<thead>
<tr>
<th>Drug</th>
<th>For hypertension:</th>
<th>Children:</th>
<th>Adults:</th>
<th>Edema, dizziness, flushing, palpititation, headache, fatigue, nausea, abdominal pain, somnolence</th>
<th>Tab: 2.5, 5, 10 mg Susp: 1 mg/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anlodipine (Norvasc) (calcium channel blocker, antihypertensive)</td>
<td>PO: Initial 0.1 mg/kg dose QD–BID; may be increased gradually to a max. 0.6 mg/kg/24 hr</td>
<td></td>
<td></td>
<td>CNS symptoms (dizziness, tiredness, depression), bradycardia, postural hypotension, nausea and vomiting, rash, blood dyscrasias (agranulocytosis, purpura)</td>
<td>Tab: 25, 50, 100 mg Susp: 2 mg/mL Inj: 0.5 mg/mL (10 mL)</td>
</tr>
<tr>
<td>Atenolol (Tenormin) (β1-adrenoceptor blocker, antihypertensive, antiarrhythmic)</td>
<td>Children: PO: 1–2 mg/kg/dose QD Adults: PO: 25–100 mg/dose QD for 1–2 wk (alone or with diuretic for hypertension); may increase to 200 mg QD</td>
<td></td>
<td></td>
<td>Headache, constipation, diarrhea, elevated liver enzymes, rhabdomyolysis, myopathy</td>
<td>Tab: 10, 20, 40, 80 mg</td>
</tr>
<tr>
<td>Atorvastatin (Lipitor) (antilipemic, “statin,” HMG-CoA reductase inhibitor)</td>
<td>Children: PO: Starting dose, 10 mg QD for 4–6 wk; increase to 20 mg QD and 40 mg QD as needed (Adult max dose, 80 mg/24 hr)</td>
<td></td>
<td></td>
<td>Bone marrow suppression (leukopenia, thrombocytopenia, anemia), GI symptoms (nausea and vomiting)</td>
<td>Tab: 25, 50, 75, 100 mg Susp: 50 mg/mL Inj: 100 mg powder for reconstr</td>
</tr>
<tr>
<td>Azathioprine (Imuran, Azasan) (immunosuppressant)</td>
<td>Children: IV, PO: Initial: 3–5 mg/kg/24 hr QD Maintenance: 1–3 mg/kg/24 hr (to produce WBC count ~5000/mm³); may be reduced if WBC count falls below 4000/mm³</td>
<td></td>
<td></td>
<td>Liver dysfunction, decrease in hemoglobin, fluid retention, heart failure, headache</td>
<td>Tab: 62.5, 125 mg</td>
</tr>
<tr>
<td>Bosentan (Tracleer) (nonsel ective endothelin receptor blocker)</td>
<td>For pulmonary hypertension: Children: PO: &lt;20 kg: 31.25 mg BID 20–40 kg: 62.5 mg BID &gt;40 kg: 125 mg BID Adults: PO: 125 mg BID</td>
<td></td>
<td></td>
<td>Hypotension, cramps, dizziness, headache, electrolyte losses (hypokalemia, hypocalcemia, hyponatremia, hypochloremia), metabolic alkalosis</td>
<td>Tab: 0.5, 1, 2 mg Inj: 0.25 mg/mL</td>
</tr>
<tr>
<td>Bumetanide (Bumex) (loop diuretic)</td>
<td>Children: PO, IM, IV: &gt;6 mo: 0.015–0.1 mg/kg/dose QD–QOD Adults: PO: 0.5–2 mg/dose QD–BID IV: 0.5–1 mg over 1–2 min q2–3 hr PRN (Max, 10 mg/24 hr)</td>
<td></td>
<td></td>
<td></td>
<td>Tab: 0.5, 1, 2 mg Inj: 0.25 mg/mL</td>
</tr>
<tr>
<td><strong>Calcium gluconate (Neo-Calglucon 6.4% elemental calcium)</strong> (calcium supplement)</td>
<td><strong>For neonatal hypocalcemia:</strong></td>
<td><strong>GI irritation, diarrhea, dizziness, headache</strong></td>
<td><strong>Syrup:</strong> 1.8 g/5 mL (480 mL) (1.2 mEq Ca/mL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PO: 1200 mg/kg/24 hr q4–6 hr</td>
<td><strong>Maintenance:</strong></td>
<td><strong>Best absorbed when given before meals</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Infants and children:</strong></td>
<td><strong>Adults:</strong></td>
<td><strong>Neutropenia or agranulocytosis, proteinuria, hypotension and tachycardia, rash, taste impairment, hyperkalemia</strong></td>
<td><strong>Tab:</strong> 12.5, 25, 50, 100 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PO: 600–2000 mg/kg/24 hr QID (max, 9 g/24 hr)</td>
<td>PO: 6–18 g/24 hr QID</td>
<td><strong>Evidence of fetal risk if given during second and third trimesters (same with all other ACE inhibitors)</strong></td>
<td><strong>Susp:</strong> 0.75, 1 mg/mL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Captopril (Capoten) (ACE inhibitor, antihypertensive, vasodilator)</strong></th>
<th><strong>Neonates:</strong></th>
<th><strong>Nausea and vomiting, abdominal cramping, diarrhea, seizure</strong></th>
<th><strong>Tab:</strong> 330, 500 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO: 0.1–0.4 mg/kg/24 hr TID–QID</td>
<td><strong>Infants:</strong></td>
<td><strong>Caps:</strong> 250 mg</td>
<td><strong>Oral sol:</strong> 100 mg/mL (118 mL)</td>
</tr>
<tr>
<td><strong>Children:</strong></td>
<td>PO: Initially 0.15–0.3 mg/kg/dose QD–QID; titrate upward if needed</td>
<td><strong>Inj:</strong> 200 mg/mL (5 mL)</td>
<td></td>
</tr>
<tr>
<td>(Max, 6 mg/kg/24 hr)</td>
<td>(Max, 6 mg/kg/24 hr BID–QID)</td>
<td><strong>(Adjust dose with renal failure)</strong></td>
<td></td>
</tr>
<tr>
<td>Children:</td>
<td><strong>Adolescents and adults:</strong></td>
<td><strong>PO:</strong> Initially 12.5–25 mg/dose BID–TID; increase weekly if needed by 25 mg/dose to max dose, 450 mg/24 hr</td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Dosage Information</td>
<td>Side Effects</td>
<td>Dosage Formulations</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>---------------------</td>
</tr>
</tbody>
</table>
| Carvedilol (Coreg, Coreg CR) (nonselective α- and β-adrenergic blocker) | **Children:** PO: Initial 0.09 mg/kg/dose BID; increase gradually to 0.36 and 0.75 mg/kg as tolerated to adult max dose of 50 mg/24 hr  
**Adults:** PO: 3.125 mg BID for 2 wk; increase slowly to a max dose of 25 mg BID as needed (for heart failure) (Max, 25 mg BID for <85 kg: 50 mg BID for >85 kg) | Dizziness, hypotension, headache, diarrhea, rarely AV block | Tab: 3.125, 6.125, 12.5, 25 mg  
Tab, extended release: 10, 20, 40, 80 mg |
| Chlormedrol (Noctec, Aquachloral) (sedative, hypnotic) | **As sedative:** **Children:** PO, PR: 25–50 mg/kg/dose q6–8 hr  
Sedation for procedures: 25–100 mg (Max dose, 2 g)  
**Adults:** PO, PR: 250 mg/dose q8 hr  
**As hypnotic:** **Adults:** PO, PR: 500–2000 mg/dose | Mucous membrane irritation (laryngospasm if aspirated), GI irritation, excitement or delirium, hypotension  
Contraindicated in hepatic and renal impairment | Caps: 500 mg  
Syrup: 250, 500 mg/5 mL  
Supp: 324, 500, 648 mg |
| Chlorothiazide (Diuril) (diuretic) | **Children:** PO: 20–40 mg/kg/24 hr BID  
IV: 2–8 mg/kg/24 hr BID  
**Adults:** PO, IV: 250–2000 mg/dose QD-BID | Hypercalcemia, hyperbilirubinemia, hyperglycemia, hyperuricemia, hypochloremic alkalosis, hypokalemia, hyponatremia, pre-renal azotemia, hyperlipidemia, rarely pancreatitis, blood dyscrasias, allergic reactions | Tab: 250, 500 mg  
Syr: 250 mg/5 mL (237 mL)  
Inf: 500 mg powder for reconst with 18 mL sterile water |
| Cholestyramine (Questran, Prevalite) (antilipemic, bile acid sequestrant) | **Children:** PO: 250–1500 mg/kg/24 hr BID–QID  
**Adults:** PO: Starting: 1 packet (or scoopful) of Questran powder or Questran Light 1–2 times/day  
Maintenance: 2–4 packets or scoopfuls/24 hr in 2 doses (or 1–6 doses) (Max, 6 packets/24 hr) | Constipation and other GI symptoms, bleeding, hyperchloremic acidosis | Packet of 9-g Questran powder or 5-g Questran Light, each packet containing 4 g of anhydrous cholestyramine resin |
| Clofibrate (Atromid-S) (antilipemic, triglyceride-lowering agent) | **Children:** PO: 0.5–1.5 mg/24 hr BID–TID  
**Adults:** PO: Initial and maintenance: 2 g/24 hr BID–TID | Nausea and other GI symptoms (vomiting, diarrhea, flatulence), headache, dizziness, fatigue, rash, blood dyscrasias, myalgia, arthralgia, hepatic dysfunction | Caps: 500 mg |
<table>
<thead>
<tr>
<th>Drug</th>
<th>Children</th>
<th>Adults</th>
<th>Side Effects</th>
<th>Formulations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clopidogrel (Plavix) (antiplatelet)</td>
<td><strong>Children:</strong> PO: 1 mg/kg/24 hr to max (adult dose) of 75 mg/24 hr</td>
<td><strong>Adults:</strong> PO: 75 mg/dose QD</td>
<td>Bleeding, especially when used with aspirin, neutropenia or agranulocytosis, abdominal pain constipation, rash, syncope, palpitation</td>
<td>Tab: 75 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Packet: 5 g</td>
</tr>
<tr>
<td>Colestipol (Colestid) (antilipemic, bile acid sequestrant)</td>
<td><strong>Children:</strong> PO: 300–1500 mg/24 hr in 2–4 doses</td>
<td><strong>Adults:</strong> PO: Starting dose: 5 g 1–2 times/24 hr; increment of 5 g q1–2 mo Maintenance: 5–30 g/24 hr BID–QID (mix with 3–6 or water or another fluid)</td>
<td>Constipation and other GI symptoms (abdominal distention, flatulence, nausea and vomiting, diarrhea), rarely rash, muscle and joint pain, headache, dizziness</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclosporine, Cyclosporine microemulsion (Sandimmune, Gengraf, Neoral) (immunosuppressant)</td>
<td><strong>Children:</strong> PO: 15 mg/kg as a single dose given 4–12 hr pretransplant; give same daily dose for 1–2 wk posttransplant; then reduce by 5% per wk to 5–10 mg/kg/24 hr QD–BID</td>
<td><strong>Adults:</strong> (Therapeutic level: 100–300 ng/mL) IV: 5–6 mg/kg as a single dose given 4–12 hr pretransplant; administer over 2–6 hr; give same dose posttransplant until patient able to tolerate oral form</td>
<td>Nephrotoxicity, tremor, hypertension, less commonly hepatotoxicity, hyperlipidemia, hirsutism, gum hypertrophy, rarely lymphoma, hypomagnesemia</td>
<td>Oral sol: 100 mg/mL (50 mL) Neoral sol: 100 mg/mL (50 mL) Caps: 25, 50, 100 mg Neoral caps: 25, 100 mg Inj: 50 mg/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diazoxide (Hyperstat IV, Proglycem) (antihypertensive, peripheral vasodilator)</td>
<td><strong>For hypertensive crisis:</strong> <strong>Children and adults:</strong> IV: 1–3 mg/kg (max, 150 mg single dose); repeat q5–15 min; titrate to desired effect</td>
<td><strong>Adults:</strong> Hypotension, transient hyperglycemia, nausea and vomiting, sodium retention (CHF ±)</td>
<td></td>
<td>Inj: 15 mg/mL</td>
</tr>
<tr>
<td>Drug</td>
<td>Children:</td>
<td>AV conduction disturbances, arrhythmias, nausea and vomiting</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digoxin (Lanoxin, Digitale)</td>
<td>PO: Total digitalizing dose:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Premature infants:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>20 mcg/kg;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Full-term newborns:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>30 mcg/kg;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Children 1 mo–2 yr:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>40–50 mcg/kg;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Children &gt;2–10 yr:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>30–40 mcg/kg;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;10 yr and &lt;100 kg:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10–15 mcg/kg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PO: Maintenance:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>25%–30% of TDD/24 hr BID</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IV: 75%–80% of PO dose</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adults:</td>
<td>PO: Loading: 8–12 mcg/kg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maintenance: 0.10–0.25 mg/24 hr</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Therapeutic level:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.8–2 ng/mL</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>Infants and children:</th>
<th>Allergic reaction (rare), hypokalemia, rapid AV conduction in atrial flutter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Digoxin immune Fab (Digibind, Digitab) (antidigoxin antibody)</td>
<td>IV: 1 vial (40 mg) dissolved in 4 mL H₂O over 30 min</td>
<td></td>
</tr>
<tr>
<td>Adults:</td>
<td>IV: 4 vials (240 mg)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>Children:</th>
<th>Dizziness, headache, edema, nausea and vomiting, heart block, and arrhythmias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diltiazem (Cardizem, Cardizem SR, Cardizem CD, Dilacor XR, Tiazac) (calcium channel blocker, antihypertensive)</td>
<td>PO: 1.5–2 mg/kg/24 hr TID–QID</td>
<td>Contraindicated in second- and third-degree AV block, sinus node dysfunction, acute MI with pulmonary congestion</td>
</tr>
<tr>
<td></td>
<td>(Max, 3.5 mg/kg/24 hr)</td>
<td>Maximum antihypertensive effect seen within 2 weeks</td>
</tr>
<tr>
<td>Adolescents:</td>
<td>Immediate release:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PO: 30–120 mg/dose TID–QID, usual range, 180–360 mg/24 hr</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>Extended release:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PO: 120–300 mg/24 hr QD–BID</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(BID dosing with Cardizem SR: QD dosing with Cardizem CD, Dilacor XR, and Tiazac)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>Children:</th>
<th>Vasodilation, rarely dizziness, angina</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dipyridamole (Persantine) (antiplatelet)</td>
<td>PO: 2–6 mg/kg/24 hr TID</td>
<td></td>
</tr>
<tr>
<td>Adults:</td>
<td>PO: 75–100 mg QID</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(As an adjunct to warfarin therapy; not to use with aspirin)</td>
<td></td>
</tr>
</tbody>
</table>

| Drug                          |                                                                 |                                                                                     |
| Elixir                         | 50 mcg/mL (60 mL)                                                      |                                                                                     |
| Tab                            | 125, 250, mcg                                                          |                                                                                     |
| Caps                           | 50, 100, 200 mcg                                                        |                                                                                     |
| Inj                            | 100, 250 mcg/mL                                                        |                                                                                     |
| Inj                            | 38, 40 mg powder for reconst                                             |                                                                                     |
| **Disopyramide**  
| (Norpace)  
| (class IA antiarrhythmic) | **Children:**  
| PO: <1 yr: 10–30 mg/kg/24 hr q6 hr  
| 1–4 yr: 10–20 mg/kg/24 hr q6 hr  
| 4–12 yr: 10–15 mg/kg/24 hr q6 hr  
| 12–18 yr: 6–15 mg/kg/24 hr q6 hr (q12 hr dosing when using regular caps)  
| **Adults:**  
| PO: 150 mg/dose q6 hr or 300 mg (extended release) q12 hr  
| (Max, 1.6 g/24 hr)  
| (Therapeutic level: 3–7 mg/L) | **Heart failure or hypotension, anticholinergic effects (urinary retention, dry mouth, constipation), nausea and vomiting, hypoglycemia**  
| **Caps:** 100, 150 mg  
| Caps, CR: 100, 150 mg  
| Susp: 1 mg/mL, 10 mg/mL |

| **Dobutamine**  
| (Dobutrex)  
| (β-adrenergic stimulator) | **Children:**  
| IV infusion: 2.5–15 mcg/kg/min in D₅W or NS (incompatible with alkali solution)  
| (Max, 40 mcg/kg/min)  
| **Adults:**  
| IV infusion: 2.5–10 mcg/kg/min  
| (Max, 40 mcg/kg/min) | **Tachyarrhythmias, hypertension, nausea and vomiting, headache**  
| **Contraindicated in HOCM and atrial flutter or fibrillation**  
| **Inj:** 12.5 mg/mL  
| (20 mL) |

| **Dopamine**  
| (Intropin, Dopastat)  
| (natural catecholamine inotropic agent) | **Children:**  
| IV: Effects are dose dependent:  
| 2–5 mcg/kg/min: increases RBF and urine output (minimum effects on heart rate and cardiac output)  
| 5–15 mcg/kg/min: increases heart rate, cardiac contractility, and cardiac output  
| >20 mcg/kg/min: α-adrenergic effects with decreased RBF (α)  
| (Incompatible with alkali solution) | **Tachyarrhythmias, nausea and vomiting, hypertension or extravasation (tissue necrosis [treat with local infiltration of phentolamine])**  
| **Inj:** 40, 80, 160 mg/mL  
| (5, 10, 20 mL) |

| **Enalapril, Enalaprilat**  
| (Vasotec)  
| (ACE inhibitor, vasodilator) | **Children:**  
| PO: 0.1 mg/kg/dose QD or BID  
| Increase PRN over 2 wks (Max, 0.5 mg/kg/24 hr)  
| **Adults:**  
| **For CHF:**  
| PO: Start with 2.5 mg QD or BID  
| (Usual range, 5–20 mg/24 hr)  
| **For hypertension:**  
| PO: Start with 5 mg QD  
| (Usual dose, 10–40 mg/24 hr) | **Hypotension, dizziness, fatigue, headache, rash, diminishing taste, neutropenia, hyperkalemia, chronic cough**  
| **Evidence of fetal risk if given during second and third trimesters (same with all other ACE inhibitors)**  
| **Tab:** 2.5, 5, 10, 20 mg  
| (Enalapril)  
| Oral susp: 1 mg/mL  
| Inj: 1.25 mg/mL  
<p>| (Enalaprilat) |</p>
<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage and Administration</th>
<th>Adverse Effects</th>
<th>Formulation</th>
</tr>
</thead>
</table>
| **Enoxaparin**  
(Lovenox)  
(low-molecular-weight heparin, anticoagulant) | **For DVT treatment:**  
- Infants <2 months: SC: 1.5 mg/kg/dose q12 hr  
- Infants ≥2 months to adults: SC: 1 mg/kg/dose q12 hr  
- Adjust dose to achieve target antifactor Xa levels of 0.5–1 units/mL  
**For DVT prophylaxis:**  
- Infants <2 months: SC: 1 mg/kg/dose q12 hr  
- Infants ≥2 mo to 18 yr: SC: 0.5 mg/kg/dose q12 hr  
- Adults: SC: 30 mg BID for 7–10 days | Bleeding  
- Contraindicated in major bleeding and drug-induced thrombocytopenia  
- Protamine sulfate is the antidote; 1 mg protamine sulfate neutralizes 1 mg enoxaparin | Inj: 100 mg/mL (3 mL) |
| **Epinephrine**  
(Adrenalin)  
(α-, β1, and β2-adrenergic stimulator) | **For asystole and bradycardia:**  
- Children: IV/ET: 0.1–0.3 mL/kg of 1:10,000 sol (or 0.01–0.03 mg/kg) q3–5 min | Tachyarrhythmias, hypertension, nausea and vomiting, headache, tissue necrosis (±) | Inj: 0.1 mg/mL  
(1:10,000 sol, 10 mL prefilled syringe)  
1 mg/mL (1:1000 sol, 1, 30 mL) |
| **Esmolol**  
(Brevibloc)  
(β1-selective adrenergic blocking agent, antihypertensive, class II antiarrhythmic) | **Children:**  
- Loading: IV: 100–500 mcg/kg over 1 min  
- Maintenance: IV: 25–100 mcg/kg/min; increase by 25–50 mcg/kg to a max of 300 mcg/kg/min  
(Usual maintenance dose, 50–500 mcg/kg/min) | Bronchospasm, CHF, hypotension, nausea and vomiting | Inj: 10, 20, 250 mg/mL |
| **Ethacrynic acid**  
(Edecrin)  
(loop diuretic) | **Children:**  
- PO: 1 mg/kg/dose QD–TID (Max, 3 mg/kg/24 hr)  
- IV: 1 mg/kg/dose  
**Adults:**  
- PO: 50–100 mg QD (Max, 400 mg)  
- IV: 0.5–1 mg/kg/dose or 50 mg/dose | Dehydration, hypokalemia, prienal azotemia, hyperuricemia, eighth cranial nerve damage (deafness), abnormal LFT, agranulocytosis or thrombocytopenia, GI irritation, rash | Tab: 25 mg  
Inj: 50 mg vial for reconstruction with 50 mL D3W |
<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage and Comments</th>
</tr>
</thead>
</table>
| Flecainide (Tambocor) (class Ic antiarrhythmic) | **For sustained VT:**  
Children: PO: Initial 1–3 mg/kg/24 hr q8 hr  
(Usual range: 3–6 g/kg/24 hr q8 hr)  
Monitor serum level to adjust dose if needed  
Adults: PO: 100 mg/dose BID; may increase by 50 mg q12 hr every 4 days to max dose of 600 mg/24 hr  
(Therapeutic level: 0.2–1 mg/L)  
**Worsening of CHF:**  
bradycardia, AV block, dizziness, blurred vision, dyspnea, nausea, headache, increased PR and QRS duration |
| Fludrocortisone acetate (Florinef, Fludhydroisone) (corticosteroid) | **For syncopal episodes:**  
Children: PO: 0.1 mg/dose QD  
Adults: PO: 0.2 mg/dose QD  
**Hypertension, hypokalemia, acne, rash, bruising, headache, GI ulcers, and growth suppression**  
Weight gain (1–2 kg in 2–3 wk) |
| Furosemide (Lasix, Furoside) (loop diuretic) | **For Children:** IV: 0.5–2 mg/kg/dose BID–Q1D  
PO: 1–2 mg/kg/dose QD–TID  
(Max, 6 mg/kg/dose)  
**Adults:** IV, PO: 20–80 mg/24 hr BID–Q1D  
**Hypokalemia, hyperuricemia, preeclampsia, ototoxicity, rarely bloody dyscrasias, rash** |
| Heparin (anticoagulant)       | **Infants and children:** IV: Initial: 50 U/kg IV bolus  
Maintenance: 10–25 U/kg/hr or 50–100 U/kg q4 hr  
(Adjust dose to give APTT 1.5–2.5 times control, 6–8 hr after IV infusion or 3.5–4 hr after intermittent injection)  
**Adults:** IV: Initial: 10,000 U IV injection  
Maintenance: 5000–10,000 U q4–6 hr  
IV drip: Initial dose: 5000 U followed by 20,000–40,000 U/24 hr  
**Bleeding**  
Antidote: protamine sulfate (1 mg per 100 U heparin used in previous 4 hr) |
|                              | **Tab:** 50, 100, 150 mg  
**Susp:** 5, 20 mg/mL  
**Oral liquid:** 10 mg/mL, 40 mg/5 mL  
**Inj:** 10 mg/mL, 20, 40, 80 mg  
**Inj:** 1000, 2000, 2500, 5000, 7500, 10,000, 20,000, 40,000 U/mL |
<table>
<thead>
<tr>
<th>Drug</th>
<th>Indication</th>
<th>Dosage</th>
<th>Notes</th>
</tr>
</thead>
</table>
| Hydralazine (Apresoline)      | For hypertensive crisis: Children: IM, IV: 0.15–0.2 mg/kg/dose; may be repeated q4–6 hr (Max, 20 mg/dose)  
                                | Hypotension, tachycardia and palpitation, lupus-like syndrome with prolonged use (fever, arthralgia, splenomegaly and positive LE cell preparation), blood dyscrasias  
                                |                                                                                             | Tab: 10, 25, 50, 100 mg  
                                | Oral liquid: 1.25, 2, 4 mg/mL  
                                | Inj: 20 mg/mL                                                                                     |
|                               | Adults: IM, IV: 20–40 mg/dose; repeat q4–6 hr PRN  
                                |                                                                                             |                                                                                                                                  |
|                               | For chronic hypertension: Children: PO: 0.75–3 mg/kg/24 hr  
                                | Same as for chlorothiazide  
                                | Tab: 25, 50, 100 mg  
                                | Caps: 12.5 mg  
                                | Sol: 10 mg/mL (500 mL)                                                                                     |
|                               | BID–QID  
                                |                                                                                             |                                                                                                                                  |
| Hydrochlorothiazide (HydroDI- | Children: PO: 2–4 mg/kg/24 hr BID (Max, 100 mg/24 hr)  
                                | Sepsis, anemia, intraventricular hemorrhage, apnea, GI disorders, renal impairment  
                                |                                                                                             | Inj: 17.1 mg/mL ibuprofen lysine equivalent to 10 mg/mL of ibuprofen (2 mL)  
                                | URL, Estdrix, Hydro-Par, Oretic) (thiazide diuretic)  
                                | Adults: PO: 25–100 mg/24 hr  
                                | Contraindicated in intraventricular hemorrhage, thrombocytopenia, necrotizing enterocolitis, significant renal dysfunction  
                                |                                                                                             |                                                                                                                                  |
|                               | QID–BID (Max, 200 mg/24 hr)  
                                |                                                                                             |                                                                                                                                  |
| Ibuprofen (NeoProfen) (nonsteroidal | For PDA closure in premature infants: Neonates ≤32 weeks (500–1500 g):  
                                | Thrombocytopenia, hypotension, tachyarrhythmias, hepatotoxicity, nausea and vomiting, fever  
                                |                                                                                             | Inj: 5 mg/mL (20 mL)                                                                                     |
| antiinflammatory)             | IV: Initial dose 10 mg/kg followed by two doses of 5 mg/kg after 24 and 48 hr  
                                |                                                                                             |                                                                                                                                  |
|                               | (Hold second and third dose if urine output is <0.6 mL/kg/hr.)  
                                |                                                                                             |                                                                                                                                  |
| Itrimetone (Inocor) (phosphodies- | Children: IV: Loading: 0.75 mg/kg over 2–3 min  
                                |                                                                                             |                                                                                                                                  |
| terase type III inhibitor)    | Maintenance: 5–10 mcg/kg/min  
                                |                                                                                             |                                                                                                                                  |
|                               | Adults: IV: Loading: 0.75 mg/kg over 2–3 min  
                                |                                                                                             |                                                                                                                                  |
|                               | Maintenance: 5–10 mcg/kg/min  
                                |                                                                                             |                                                                                                                                  |
| Indomethacin (Indocin) (Nonsteroidal | For PDA closure in premature infants: IV: <48 hr: 0.2, 0.1, and 0.1 mg/kg/dose q12–24 hr  
                                | GI or other bleeding, GI disturbances, renal impairment, electrolyte disturbances (I-Na, I-K levels)  
                                |                                                                                             | Vial: 1 mg                                                                                     |
| antiinflammatory, antipyretic agent, PG synthesis inhibitor)  
                                | 2–7 days: 0.2, 0.2, and 0.2 mg/kg/dose q12–24 hr  
                                |                                                                                             |                                                                                                                                  |
|                               | >7 days: 0.2, 0.25, and 0.25 mg/kg/dose q12–24 hr  
<p>| | |
|                                                                                             |                                                                                                                                  |</p>
<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage Details</th>
<th>Side Effects</th>
<th>Strength (injection strength)</th>
</tr>
</thead>
</table>
| Isoproterenol (Isuprel) (β<sub>1</sub> and β<sub>2</sub>-adrenergic stimulator) | **Children:** IV: 0.1–2 mcg/kg/min titrated to desired effect  
**Adults:** IV: 2–20 mcg/min titrated to desired effect (incompatible with alkali solution) | Similar to epinephrine                                                         | Inj: 0.2 mg/mL (1:5000 sol: 1, 5 mL) |
| Ketamine (Ketalar) (General anesthetic)    | **For cyanotic spells:**  
**Infants:** IM: 2–3 mg/kg  
Repeat smaller doses q30 min PRN  
IV: 1–3 mg/kg/dose over 60 sec  
Repeat smaller doses q30 min PRN | Hypertension, tachycardia, respiratory depression or apnea, CNS symptoms (dreamlike state, confusion, agitation) | Inj: 10, 50, 100 mg/mL |
| Ketorolac (Toradol) (nonsteroidal antiinflammatory agent) | **Children:** IV, IM: 0.5 mcg/kg/dose q6 hr  
(Max single dose, 30 mg)  
**Adults:** IV, IM: 30 mcg/dose q6 hr  
PO (adults and children ≥50 kg): 10 mcg PRN q6 hr | GI bleeding, nausea, dyspepsia, decreased platelet function, interstitial nephritis  
Consider adding acid blocker with systemic use  
Contraindicated in patients with hepatic or renal failure | Tab: 10 mg, 15 mg/mL (1 mL), 30 mg/mL (1, 2 mL) |
| Labetalol (Normodyne, Trandate) (α- and β-adrenergic antagonist) | **Children:** PO: Initial 4 mg/kg/24 hr BID  
(Max, 40 mg/kg/24 hr)  
IV: (for hypertensive emergency)  
Initial 0.2–1 mg/kg/dose q10 min PRN  
(Max, 20 mg/dose) | Orthostatic hypotension, edema, CHE, bradycardia  
Contraindicated in asthma | Tab: 100, 200, 300 mg, Susp: 10, 40 mg/mL, Inj: 5 mg/mL (20, 40 mL) |
| Lidocaine (Xylocaine) (class IB antiarrhythmic) | **Children:** IV: Loading: 1 mg/kg/dose slow IV q5–10 min PRN  
Maintenance: 30 mcg/kg/min (Range, 20–50 mcg/kg/min)  
**Adults:** IV: Loading: 1 mg/kg/dose q5 min  
Maintenance: 1–4 mg/min (Therapeutic level: 1.5–5 mcg/L) | Seizure, respiratory depression, CNS symptoms  
(anxiety, euphoria or drowsiness), arrhythmias, hypotension or shock | Inj: 0.5%, 1%, 1.5%, 2%, 4%, 10%, 20% (1% = 10 mg/mL) |
| Lisinopril (Zestril, Prinivil) (ACE inhibitor, antihypertensive) | **For hypertension:**  
**Children ≥6 yr:** PO: Initial 0.07 mg/kg/24 hr, (max initial dose, 5 mg/24 hr), increase dose at 1–2 week intervals (Max, 0.6 mg/kg/day or 40 mg/24 hr)  
**Adults:** PO: Initial 10 mg QD; may increase upward as needed to max dose, 80 mg/24 hr | Dry nonproductive cough, rash, hypotension, hyperkalemia, angioedema, rarely bone marrow depression  
Evidence of fetal risk if given during second and third trimesters (same with all other ACE inhibitors) | Tab: 2.5, 5, 10, 20, 30, 40 mg |
<table>
<thead>
<tr>
<th>Drug</th>
<th>For hypertension:</th>
<th>For hypertensive crisis:</th>
<th>Hypotension, dizziness, nasal congestion, muscle cramps</th>
<th>Evidence of fetal risk if given during second and third trimesters</th>
<th>Tab: 25, 50, 100 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lesartan (Cozaar)</td>
<td><em>Children ≥6 yr:</em> FO: 0.7 mg/kg/24 hr QD–BID (Max, 50 mg/24 hr)</td>
<td><em>Children:</em> IX: Start at 2–4 mg/kg/dose q6–8 hr (Max dose, 65 mg/kg/24 hr or 3 g/24 hr whichever is less)</td>
<td><em>Adults:</em> IV: 250–500 mg q6 hr (Max, 1 g q6 hr)</td>
<td>Sedation, orthostatic hypotension and bradycardia, lupus-like syndrome, Coombs (+) hemolytic anemia and leukopenia, hepatitis or cirrhosis, colitis, impotence</td>
<td>Inj: 50 mg/mL (5 mL)</td>
</tr>
<tr>
<td>(angiotensin II receptor blocker)</td>
<td><em>Adults:</em> FO: Initial dose 50 mg QD (Max, 100 mg QD)</td>
<td><em>Adults:</em> IV: 250 mg/dose BID–TID for 2 days (Usual dose: 0.5–2 g/24 hr BID–QID) (Max, 3 g/24 hr)</td>
<td></td>
<td></td>
<td>Susp: 50 mg/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Tab: 25, 50, 100 mg</td>
</tr>
<tr>
<td>Lovastatin (Mevacor) (antilipemic, HMG-CoA reductase inhibitor)</td>
<td>Adolescents: FO: Starting dose, 10 mg/24 hr QD for 6–8 wk; increase to 20 mg/24 hr for 8 wk and then increase to 40 mg/24 hr for 8 wk, as needed.</td>
<td></td>
<td></td>
<td></td>
<td>Tab: 10, 20, 40 mg</td>
</tr>
<tr>
<td>Methyldopa (Aldomet) (antihypertensive)</td>
<td>For hypertension: <em>Children:</em> FO: 10 mg/kg/24 hr BID–QID (Max dose, 65 mg/kg/24 hr or 3 g/24 hr whichever is less)</td>
<td></td>
<td></td>
<td></td>
<td>Inj: 50 mg/mL (5 mL)</td>
</tr>
<tr>
<td></td>
<td><em>Adults:</em> FO: 250 mg/dose BID–TID for 2 days (Usual dose: 0.5–2 g/24 hr BID–QID) (Max, 3 g/24 hr)</td>
<td></td>
<td></td>
<td></td>
<td>Susp: 50 mg/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Tab: 25, 50, 100 mg</td>
</tr>
<tr>
<td>Metoprolol (Lopressor)</td>
<td><em>Children &gt;2 yr:</em> FO: Initially 0.1–0.2 mg/kg/dose BID; gradually increase to 1–3 mg/kg/24 hr</td>
<td></td>
<td></td>
<td></td>
<td>Tab, extended release: 25, 50, 100, 200 mg</td>
</tr>
<tr>
<td>Drug</td>
<td>Children:</td>
<td>Adult:</td>
<td>Formulations:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metolazone (Zaroxolyn, Diulo, Mykrox) (thiazide-like diuretic)</td>
<td><strong>PO:</strong> 0.2–0.4 mg/kg/24 hr QD–TID **May increase to 450 mg/24 hr BID–TID (Usual dose, 100–450 mg/24 hr) (Usually used with hydrochlorothiazide 25–100 mg/24 hr)</td>
<td><strong>PO:</strong> For hypertension: 2.5–5 mg QD  For edema: 5–20 mg QD</td>
<td><strong>Tab:</strong> 0.5 (Mykrox), 2.5, 5, 10 mg <strong>Susp:</strong> 1 mg/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mexiletine (Mexitil) (Class IB antiarrhythmic)</td>
<td><strong>PO:</strong> 6–8 mg/kg/24 hr BID–TID for 2–3 days; then 2–5 mg/kg/dose q6–8 hr Increase 1–2 mg/kg/dose q2–3 days until desired effect achieved (with food or antacid)</td>
<td><strong>PO:</strong> 200 mg q8 hr for 2–3 days Increase to 300–400 mg q8 hr (Usual dose, 200–300 mg q8 hr) (Therapeutic level: 0.75–2 mcg/mL)</td>
<td><strong>Caps:</strong> 150, 200, 250 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Milrinone (Primacor) (phosphodiesterase type III inhibitor)</td>
<td><strong>IV:</strong> Loading: 10–50 mcg/kg over 10 min; then 0.1–1 mcg/kg/min</td>
<td><strong>IV:</strong> Loading: 50 mcg/kg over 10 min 0.5 mcg/kg/min  (Range, 0.375–0.75 mcg/kg/min)</td>
<td><strong>Inj:</strong> 1 mg/mL (5, 10, 20 mL) <strong>Inj, premixed in D5W:</strong> 200 mcg/mL (100, 200 mL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minoxidil (Loniten) (peripheral vasodilator)</td>
<td><strong>Children &lt;12 yr:</strong> <strong>PO:</strong> 0.2 mg/kg/24 hr QD–BID initially Increase 0.1–0.2 mg/kg/24 hr q3 days until desired effect achieved (Usual dose, 0.25–1 mg/kg/24 hr QD–BID; Max, 50 mg/24 hr)</td>
<td><strong>Reflex tachycardia and fluid retention (used with a beta-blocker and diuretic), pericardial effusion, hypertrichosis, rarely blood dyscrasias (leukopenia, thrombocytopenia)</strong></td>
<td><strong>Tab:</strong> 2.5, 10 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Children</td>
<td>Adults</td>
<td>Inj: 0.5, 1, 2, 4, 5, 8, 10, 15, 25, 50 mg/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine sulfate</td>
<td>SC, IM, IV: 0.1–0.2 mg/kg/dose q2–4 hr (Max, 15 mg/dose)</td>
<td>CNS depression, respiratory depression, nausea and vomiting, hypotension, bradycardia</td>
<td>Tab: 500 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(narcotic, analgesic)</td>
<td></td>
<td></td>
<td>Caps: 250 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mycophenolate moletil</td>
<td>PO: 600 mg/m²/dose BID (Max, 2000 mg/24 hr)</td>
<td>Headache, GI symptoms, hypertension, bone marrow suppression (anemia), fever, increased risk of developing lymphomas or other malignancies</td>
<td>Oral susp: 200 mg/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(CellCept)</td>
<td>(Therapeutic level: 5–7 mg/mL)</td>
<td></td>
<td>Inj: 500 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(immunosuppressant)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nifedipine (Procardia, Adalat)</td>
<td>For hypertrophic cardiomyopathy:</td>
<td>Hypotension, peripheral edema, CNS symptoms (headache, dizziness, weakness), nausea</td>
<td>Caps: 10, 20 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(calcium channel blocker)</td>
<td>Children:</td>
<td></td>
<td>Tab, sustained release</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>For hypertension:</td>
<td></td>
<td>(Adalat CC, Procardia XL): 30, 60, 90 mg.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Children:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PO: 0.5–0.9 mg/kg/24 hr TID–QID</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adults:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PO: Initially 10 mg/dose TID</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Titrate up to 20 to 30 mg/dose TID–QID over 7–14 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Usual dose, 10–20 mg TID; max dose, 180 mg/24 hr)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nitroglycerine</td>
<td>IV: 0.5–1 mcg/kg/min Increase 1 mcg/kg/min q20 min to titrate to effect</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Nitro-Bid, Tridil, Nitrostat)</td>
<td>(Max, 6 mcg/kg/min) (Dilute in D₅W or NS with final concentration &lt;400 mcg/mL; light sensitive)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(peripheral vasodilator)</td>
<td>Adults:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IV: Initial dose: 5 mcg/min through infusion pump</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increase 5 mcg/min q3–5 min until desired effect achieved</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Indications</td>
<td>Dosage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Nitroprusside (Nipride) (peripheral vasodilator) | Hypotension, palpitation, and cyanide toxicity (metabolic acidosis earliest and most reliable evidence)  Monitor thiocyanate level when used >48 hr and in patients with renal or hepatic dysfunction. Thiocyanate level should be <50 mg/L; cyanate levels >2 mcg/mL are toxic levels. | Inj: 25 mg/mL (2 mL)
|                                     |                                                                                                | Inj: 50 mg for reconstr with 2–3 mL D₃W                                  |
| Norepinephrine (Levophed, levarterenol) (α₁- and β₁-adrenoceptor stimulant) | Hypertension, bradycardia (reflex), arrhythmias, tissue necrosis (treat with phenolamine infiltration) | Inj: 1 mg/mL (4 mL)                                                      |
| Omega-3-acid ethyl ester (Lovaza; Omzar) | Occasional gastrointestinal complaints (anorexia, belching, constipation, colitis)              | Caps: 1 g soft gelatin capsule (60 caps)                               |
| Phenylephrine (Neo-Synephrine) (α₁-adrenoceptor blocker) | For diagnosis of pheochromocytoma: Children: IM, IV: 0.05–0.1 mg/kg/dose; repeat q5 min until hypertension is controlled; then q2–4 hr PRN  Adults: IM, IV: 2.5–5 mg/dose; repeat q5 min until hypertension is controlled; then q2–4 hr PRN For treatment of extravasated α-adrenergic drugs: SC: Make a solution of 0.5–1 mcg/mL with NS. Inject 1–5 mL (in 5 divided doses) around the site of extravasation (Max, 0.1–0.5 mg/kg or 5 mg total) | Hypotension, tachycardia or arrhythmias, nausea and vomiting Inj: 5 mg powder for reconstr |
| Phenylephrine (Neo-Synephrine) (α₁-adrenoceptor stimulant) | For hypotension: Children: IM, SC: 0.1 mg/kg/dose q1–2 hr PRN (Max dose, 5 mg)  IV: 5–10 mcg/kg/dose IV bolus q10–15 min or 0.1–0.5 mcg/kg/min | Arrhythmias, hypertension, angina Inj: 10 mg/mL |
Phenytoin (Dilan—
tin) (class IB
antiarrhythmic,
anticonvulsant)

**AdulTs:**
IM, SC: 2–5 mg/dose q1–2 hr PRN
(Max dose: 5 mg)
IV: 0.1–0.5 mg/dose IV bolus q10–15 min PRN
Start IV drip at 100–180 mcg/min;
(Usual maintenance dose, 40–60 mcg/min)

**Children:**
IV: 2–4 mg/kg/dose over 5–10 min followed by
PO dose
PO: 2–5 mg/kg/24 hr
BID–TID
(Therapeutic level: 5–18 mcg/mL for arrhyth-
mas, 10–20 mcg/mL for seizures)

**Adults:**
IV: 100 mg q5 min (total, 500 mg)
PO: 250 mg QID for 1 day,
250 mg/dose BID for 2 days, and 300–400
mg/24 hr QD–QID

**Potassium chloride**

**Supplement in diuretic therapy:**
**Children:**
PO: 1–2 mEq/kg/24 hr
TID–QID
(or 0.8–1.5 mL 10% potassium chloride/kg/24
hr, or 0.4–0.7 mL
20% potassium chloride/kg/24 hr
TID–QID)

**Potassium gluconate**

**Supplement in diuretic therapy:**
**Children:**
PO: 1–2 mEq/kg/24 hr
TID–QID or 0.8–1.5 mL/kg/24 hr
TID–QID

**Pravastatin (Pravachol)
(antilipemic, HMG-CoA reductase
inhibitor)**

**Children (8–13 yr):**
PO: Starting dose, 10 mg QD for
4–6 wk
Increase to 20 QD as needed
**Adolescents (14–18 yr):**
PO: 40 mg QD
(Adult max dose, 80 mg/day)

**Rash, Stevens-Johnson
syndrome, CNS symp-
toms (ataxia, dysarthria),
lupus-like syndrome,
bleed dyscrasias, periph-
eral neuropathy, gingival
hypertrophy

**Susp: 125 mg/5 mL
(240 mL)
Tab, chewable: 50 mg
(Infatab)
Caps: 100 mg
Caps, extended release:
30, 100, 200, 300
mg
Inj: 50 mg/mL

**GI disturbances, ulcerations,
hyperkalemia**

**Oral sol: 10% (1.3
mEq/mL), 20% (2.7
mEq/mL)
Caps, sustained release:
8, 10 mEq
Tabs, sustained release:
8, 10, 15, 20 mEq

**Same as for potassium chloride**

**Elixir: 1.3 mEq/mL

**Headache, constipation,
diarrhea, elevated liver
enzymes, rhabdomyolysis,
myopathy

**Tabs: 10, 20, 40, 80 mg**
<table>
<thead>
<tr>
<th>Drug</th>
<th>Children</th>
<th>Adults</th>
<th>CNS symptoms (dizziness, headache, drowsiness), palpitation, nausea</th>
<th>Caps: 1, 2, 5 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prazosin (Minipress)</td>
<td>PO: 5 mcg/kg as a test dose; then 25–150 mcg/kg/24 hr QID</td>
<td>PO: 1 mg/dose BID–TID initially Increase to 20 mg/24 hr BID–QID (Usual dose, 6–15 mg/24 hr)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(postsynaptic α₁-adrenergic blocker, antihypertensive)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procaainamide</td>
<td><strong>Loading:</strong> 2–6 mg/kg/dose over 5 min repeated q10–30 min (Max, 100 mg)</td>
<td><strong>Loading:</strong> 50–100 mg/dose q5 min PRN</td>
<td>Nausea and vomiting, blood dyscrasias, rash, lupus-like syndrome, hypotension, confusion or disorientation</td>
<td>Tab, sustained release: 250, 500, 750, 1000 mg</td>
</tr>
<tr>
<td>(Procanb-id, Pronestyl)</td>
<td><strong>Maintenance:</strong> 20–80 mcg/kg/min (Max, 2 g/24 hr)</td>
<td><strong>Maintenance:</strong> 1–6 mg/min PO: Immediate release 250–500 mg/dose q3–5 hr (sustained release 500–1000 mg/dose q6 hr)</td>
<td></td>
<td>Caps: 250, 375, 500 mg</td>
</tr>
<tr>
<td>(class I antiarrrhythmic)</td>
<td>(Max, 4 g/24 hr)</td>
<td>(Therapeutic level: 4–10 mcg/mL)</td>
<td></td>
<td>Susp: 5, 50, 100 mg/mL</td>
</tr>
<tr>
<td>Propranolol (Inderal)</td>
<td>Tab: 10, 20, 40, 60, 80, 90 mg</td>
<td>Caps, extended release: 60, 80, 120, 160 mg Oral sol: 20, 40 mg/5 mL</td>
<td>Hypotension, syncope, bronchospasm, nausea and vomiting, hypoglycemia, lethargy or depression, heart block</td>
<td>Inj: 1 mg/mL</td>
</tr>
<tr>
<td>(β-adrenoceptor blocker, class II antiarrrhythmic)</td>
<td>For hypertension: Children: PO: 0.5–1 mg/kg/24 hr BID–QID, may increase q 3–5 days (Usual dose, 2–4 mg/kg/24 hr; max dose, 8 mg/kg/24 hr)</td>
<td>For arrhythmias: Children: IV: 0.01–0.15 mg/kg/dose over 10 min; repeat q6–8 hr PRN (Max, 1 mg/dose for infants; 3 mg/dose for children)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adults: IV: 1 mg/dose q5 min (max, 5 mg) PO: 10–20 mg/dose TID–QID; increase PRN (Usual dose, 40–320 mg/24 hr TID–QID)</td>
<td>Adults: IV: 1 mg/dose q5 min (max, 5 mg) PO: 10–20 mg/dose TID–QID; increase PRN (Usual dose, 40–320 mg/24 hr TID–QID)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Effect</td>
<td>Dosing Information</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>--------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostaglandin E₁ or alprostadil (Prostin VR, PGE₁) (vasodilator)</td>
<td>Apnea, flushing, bradycardia, hypotension, fever</td>
<td>Inj: 500 mcg/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protamine sulfate (heparin antidote)</td>
<td>Antidote to heparin overdose</td>
<td>Hypotension, bradycardia, dyspnea, flushing, coagulation problem</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IV: Each 1 mg of protamine neutralizes ≈100 U heparin given in preceding 3–4 hr; slow IV infusion at rate not exceeding 20 mg/min or 50 mg/10 min (Check APTT)</td>
<td>Inj: 10 mg/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quinidine (Cardioquin, Quint dex, Quinaglute) (class IA antiarrhythmic)</td>
<td>Children: Test dose for idiosyncrasy: 2 mg/kg once (PO as sulfate; IM/IV as gluconate)</td>
<td>Nausea and vomiting, ventricular arrhythmias, prolonged QRS complex, depressed myocardial contractility, blood dyscrasias, symptoms of cinchonism</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Therapeutic dose: IV (as gluconate): 2–10 mg/kg/dose q3–6 hr PRN</td>
<td>Gluconate (62% quinidine):</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PO (as sulfate): 15–60 mg/kg/24 hr q6 hr</td>
<td>Tab, slow release:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adults: Test dose: 200 mg once FO/IM</td>
<td>324 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Therapeutic dose: PO (as sulfate, immediate release): 100–600 mg/dose q4–6 hr</td>
<td>Inj: 80 mg/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Begin at 200 mg/dose and titrate to desired effect, or</td>
<td>Sulfate (83% quinidine):</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PO (sulfate, sustained release): 300–600 mg/dose q8–12 hr</td>
<td>Tabs: 200, 300 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PO (as gluconate): 324–972 mg q8–12 hr</td>
<td>Tab, slow release:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IM (as gluconate): 400 mg/dose q4–6 hr</td>
<td>300 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IV (as gluconate): 200–400 mg/dose, infused at a rate of ≤10 mg/min</td>
<td>Susp: 10 mg/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Therapeutic level: 3–7 mg/L)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sildenafil (Revatio, Viagra)</strong> (phosphodiesterase type V inhibitor)</td>
<td><strong>For pulmonary hypertension:</strong></td>
<td><strong>Hypotension, tachycardia, flushing, headache, rash, nausea, diarrhea, priapism, platelet dysfunction, myalgia, paresthesia, blurred vision, epistaxis, dyspnea</strong></td>
<td>Tab: 20, 25, 50, 100 mg</td>
<td></td>
</tr>
<tr>
<td>Children:</td>
<td><strong>PO:</strong> 0.25–1 mg/kg/dose BID–QID</td>
<td><strong>Contraindicated in concurrent use of organic nitrates</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Infants and children:</strong></td>
<td><strong>PO:</strong> 0.25–1 mg/kg/dose q4–6 hr</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adults:</strong></td>
<td><strong>PO:</strong> 20 mg TID</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **Simvastatin** (Zocor) (antilipemic, HMG-CoA reductase inhibitor) | **Children:** | **Headache, constipation, diarrhea, elevated liver enzymes, rhabdomyolysis, myopathy** | Tab: 5, 10, 20, 40, 80 mg |
| **PO:** Starting dose, 10 mg QD | | | |
| Increment of 10 mg q6–8 wk to max dose of 40 mg QD as needed | | | |
| (Adult max, 80 mg/24 hr) | | | |

| **Sirolimus** (Rapamune) (immunosuppressant) | **Children:** | **Hypertension, peripheral edema, chest pain, fever, headache, acne, hirsutism, hypercholesterolemia, neurotoxicity, abdominal pain, anemia, pneumonitis** | Tab: 1, 2 mg |
| **PO:** Loading, 3 mg/m²; maintenance, 1 mg/m²/day QD | **Oral sol:** 1 mg/mL | | |
| **Adults:** | **PO:** Loading, 6 mg; maintenance, 2 mg/day QD | | |
| (Therapeutic level: 6–15 ng/mL) | | | |

| **Sodium polystyrene sulfonate** (Kayexalate, Konsel) (potassium-removing resin) | **For hyperkalemia (slowly effective, taking hours to days):** | **Nausea and vomiting, constipation, severe hypokalemia (muscle weakness, confusion [monitor serum potassium levels, ECG]), hypocalcemia or hyperkalemia (edema)** | Powder: 454, 480 g |
| **Children:** | **PO, NG:** 1 g/kg/dose q6 hr | **Susp:** 15 g/60 mL | |
| **PR:** 1 g/kg/dose q2–6 hr | | | |
| **Adults:** | **PO, NG, PR:** 15 g QD–QID | | |
| (Cation exchange resin with practical exchange rates of 1 mEq potassium per 1 g resin) | (Note: Delivers 1 mEq sodium for each mEq of potassium removed) | | |

| **Sotalol (Betapace)** (class II and III antiarrhythmic) | **For SVT and VT:** | **Chest pain, palpitation, hypoglycemia, hypotension, torsade de pointes, nausea and vomiting, abdominal pain, CNS symptoms (depression, weakness, dizziness), bronchospasm, heart block, bradycardia, negative inotropic effects, QT prolongation (Discontinue if QTc >550 msec)** | Tab: 80, 120, 160, 240 mg |
| **PO:** 80–120 mg/m²/24 hr | **TID (infants) BID (older children and adults)** | | |

| **Spironolactone** (Aldactone) (potassium-sparing diuretic, aldosterone antagonist) | **Children:** | **Hyperkalemia (when given with potassium supplements and ACE inhibitors); GI distress, rash, gynecomastia, agranulocytosis** | Tab: 25, 50, 100 mg |
| **PO:** 3 mg/kg/24 hr BID–TID | **Syrup:** 5 mg/mL | **Contraindicated in renal failure** | |
| **Adults:** | **PO:** 50–100 mg/24 hr | | |
| **TID–QID** | | | |
| (Max, 200 mg/24 hr) | | | |
| **Streptokinase**  
| (Streptase, Kabikinase)  
| (thrombolytic enzyme) | **For thrombolysis:**  
| (Use in consultation with a hematologist)  
| **Children:**  
| IV: 3500–4000 U/kg over 30 min followed by 1000–1500 U/kg/hr, or 2000 U/kg load over 30 min followed by 2000 U/kg/hr  
| (Duration of infusion based on response but generally does not exceed 3 days; obtain tests at baseline and q4 hr: APTI, TT, fibrinogen, PT, hematocrit, platelet count; APTT and TT should be <2 times control) | **Potential for allergic reaction with repeated use; premedicate with acetaminophen and antihistamine and repeat q4–6hr:**  
| Inj: 250,000, 750,000, 1,500,000 IU powder for reconstruction |
| **Tacrolimus**  
| (Prograf)  
| (immunosuppressant) | **Children and adults:**  
| PO: 0.15–0.4 mg/kg/day BID  
| IV: 0.03–0.15 mg/kg/day continuous infusion  
| (Therapeutic level: 5–15 ng/mL) | **Hypertension, hypotension, peripheral edema, myocardial hypertrophy, chest pain, fever, headache, encephalopathy, pruritus, hypercholesterolemia, electrolyte imbalance, neurotoxicity, nephrotoxicity, diarrhea, anemia, dyspnea**  
| **Caps:** 0.5, 1, 5 mg  
| **Susp:** 0.5 mg/mL  
| **Inj:** 5 mg/mL (1 mL) |
| **Tolazoline**  
| (Priscoline)  
| (α-adrenergic blocker) | **For neonatal pulmonary hypertension:**  
| IV: Loading: 1–2 mg/kg over 10 min  
| **Maintenance:** 1–2 mg/kg/hr | **Hypotension and tachycardia, pulmonary hemorrhage, GI bleeding, arrhythmias, thrombocytopenia, leukopenia**  
| **Inj:** 25 mg/mL |
| **Triamterene**  
| (Dyrenium)  
| (potassium-sparing diuretic) | **Children:**  
| PO: 2–4 mg/kg/24 hr  
| QD–BID  
| May increase up to max of 6 mg/kg/24 hr or 300 mg/24 hr  
| **Adults:**  
| PO: 50–100 mg/24 hr  
| QD–BID  
| (Max, 300 mg/24 hr) | **Nausea and vomiting, leg cramps, dizziness, hyperuricemia, rash, prerenal azotemia**  
| **Caps:** 50, 100 mg |
| **Urokinase**  
| (Abbokinase)  
| (thrombolytic enzyme) | **For thrombolysis (in vein thrombosis or pulmonary embolism):**  
| (Should be used in consultation with a hematologist)  
| **Children:**  
| IV: Loading: 4400 U/kg over 10 min | **Bleeding, allergic reactions, rash, fever and chills, bronchospasm**  
| **Inj:** 5000 U/mL |
Maintenance: 4400 U/kg/hr for 6–12 hr. Some patients may require 12–72 hr of therapy. (Monitor same laboratory tests as for streptokinase)

**For occluded IV catheter clearance:**

Aspiration method: Use 5000 U/mL concentrate; instill into the catheter a volume equal to the internal volume of catheter over 1–2 min; leave in place for 1–4 hr; then aspirate; may repeat with 10,000 U/mL if no response; do not infuse into the patient.

IV infusion method: 150–200 U/kg/hr in each lumen for 8–48 hr at a rate of at least 20 mL/hr

**Adults:**

**For pulmonary embolism:**

IV Priming dose:

4400 U/kg

IV infusion: 4400 U/kg/hr for 12 hr by infusion pump

**Verapamil**

(Isoptin, Calan)

(calcium channel blocker,
class IV antiarhythmic)

**For dysrhythmia (SVT):**

**Children:**

IV: 1–15 yr (for SVT):

0.1–0.3 mg/kg over 2 min

May repeat same dose in 15 min

(Max dose, 5 mg first dose; 10 mg second dose)

**Adults:**

IV: 5–10 mg, 10 mg second dose

**For hypertension:**

**Children:**

PO: 4–8 mg/kg/24 hr TID

**Adults:**

PO: 240–480 mg/24 hr TID

**Vitamin K₁**

Antidote to dicumarol or warfarin:

PO/IM/SC/IV: 2.5–10 mg/dose in 1 dose for correction of excessive PT from dicumarol or warfarin overdose

Hypotension, bradycardia, cardiac depression

Tab: 40, 80, 120 mg

Tab, extended release:

120, 180, 240 mg

Caps, extended release:

100, 120, 180, 200, 240, 300, 360 mg

Susc: 50 mg/mL

Inj: 2.5 mg/mL

Tab: 5 mg

Inj: 2, 10 mg/mL
| Warfarin (Coumadin, Safarin) (anticoagulant) | Children: PO: Initial: 0.1–0.2 mg/kg/dose QD in evenin for 2 days (Max dose, 10 mg/dose) (In liver dysfunction, 0.1 mg/kg/day; max, 5 mg/dose) Maintenance: 0.1 mg/kg/24 hr QD (Monitor INR after 3–7 days of new dosage; keep INR at 2.5–3.5 for mechanical prosthetic valve; 2–3 for prophylaxis of DVT, pulmonary emboli) (Heparin preferred initially for rapid anticoagulation; warfarin may be started concomitantly with heparin or may be delayed 3–6 days) Adults: PO: Initial: 5–15 mg/dose QD for 2–5 days Maintenance: 2–10 mg/day (Adjust dosage based on INR) | Bleeding (antidote: vitamin K or fresh-frozen plasma) Increased PT response: salicylates, acetaminophen, alcohol, lipid-lowering agents, phenytoin, ibuprofen, some antibiotics Decreased PT response: antihistamines, barbiturates, oral contraceptives, vitamin C, diet high in vitamin K Onset of action: 36–72 hr. and full effects in 4–5 days Mode of action: inhibits hepatic synthesis of vitamin K–dependent factors (I, VII, IX, X) | Tab: 1, 2, 2.5, 3, 4, 5, 6, 7.5, 10 mg Inj: 5 mg |

ACE, Angiotensin-converting enzyme; APTT, activated partial thromboplastin time; AV, atrioventricular; BID, two times a day; BP, blood pressure; caps, capsule; CHF, congestive heart failure; CK, creatine kinase; CNS, central nervous system; CR, controlled release; D,W, 5% dextrose in water; DVT, deep vein thrombosis; ECG, electrocardiogram; ET, endotracheal; GI, gastrointestinal; HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A; HOCM, hypertrophic obstructive cardiomyopathy; IM, intramuscular; Inj, injection; INR, international normalized ratio; IV, intravenous; LFT, liver function test; max, maximum; NE, norepinephrine; NG, nasogastric; NS, normal saline; PDA, patent ductus arteriosus; PG, prostaglandin; PO, by mouth; PR, per rectum; PRN, as necessary; PT, prothrombin time; q, every; QD, once a day; QID, four times a day; QOD, every other day; RBF, renal blood flow; reconst, reconstitution; SC, subcutaneous; sol, solution; supp, suppository; susp, suspension; tab, tablet; TDD, total digitalizing dose; TID, three times a day; TT, thrombin time; WBC, white blood cell; (±), may occur.
Suggested Readings

General References


Walsh E.P., Saul J.P., Friedman J.K. *Cardiac Arrhythmias in Children and Young Adults with Congenital Heart Disease*. Philadelphia: Lippincott Williams & Wilkins; 2001.

Chapter 1. History Taking


Chapter 2. Physical Examination


Chapter 3. Electrocardiography


Chapter 4. Chest Roentgenography


Chapter 5. Noninvasive Imaging Tools


Chapter 6. Other Noninvasive Investigation Tools

Chapter 7. Invasive Procedures


Chapter 8. Fetal and Perinatal Circulation


Chapter 9. Pathophysiology of Left-to-Right Shunt Lesions;

Chapter 10. Pathophysiology of Obstructive and Valvular Regurgitation Lesions; and
Chapter 11. Pathophysiology of Cyanotic Congenital Heart Defects


Chapter 12. Left-to-Right Shunt Lesions

Atrial Septal Defect


Ventricular Septal Defect


Patent Ductus Arteriosus


Varvarigou A., Bardin C.L., Beharry K. et al. Early ibuprofen administration to prevent patent ductus arteriosus in...

### Endocardial Cushion Defect


### Partial Anomalous Pulmonary Venous Return


### Chapter 13. Obstructive Lesions

#### Pulmonary Stenosis


#### Aortic Stenosis


#### Coarctation of the Aorta


**Chapter 14. Cyanotic Congenital Heart Defects**


**Complete Transposition of the Great Arteries**


**Congenitally Corrected Transposition of the Great Arteries**


**Tetralogy of Fallot**


Kirklin J.W., Blackstone E.H., Jonas R.A. et al. Morphologic and surgical determinant of outcome events after repair of


**Total Anomalous Pulmonary Venous Return**


**Tricuspid Atresia**


Pulmonary Atresia


Hypoplastic Left Heart Syndrome


Ebstein’s Anomaly


Truncus Arteriosus


Single Ventricle


Double-Outlet Right Ventricle


Splenic Syndromes


Persistent Pulmonary Hypertension of Newborn


Chapter 15. Miscellaneous Congenital Cardiac Conditions


### Chapter 16. Vascular Ring


### Chapter 17. Chamber Localization and Cardiac Malposition

Chapter 18. Primary Myocardial Disease


Chapter 19. Cardiovascular Infections


Chapter 20. Acute Rheumatic Fever


Chapter 21. Valvular Heart Disease


Chapter 22. Cardiac Tumors


Chapter 23. Cardiac Involvement in Systemic Diseases


Chapter 24. Cardiac Arrhythmias


Schwartz P.J., Montemero M., Facchini M. et al. The QT interval throughout the first 6 months of life: A prospective
Chapter 25. Disturbances of Atrioventricular Conduction


Chapter 26. Cardiac Pacemakers and Implantable Cardioverter-Defibrillators in Children


Chapter 27. Congestive Heart Failure


Chapter 28. Systemic Hypertension


Chapter 29. Pulmonary Hypertension


King M.E., Braun H., Goldblatt A. et al. Interventricular septal configuration as a predictor of right ventricular systolic


**Chapter 30. Child with Chest Pain**


**Chapter 31. Syncope**


Chapter 32. Palpitation


Chapter 33. Dyslipidemia and Other Cardiovascular Risk Factors

Cardiovascular Risk Factors and Metabolic Syndrome


Dyslipidemia


Gidding S.S., Dennison B.A., Birch L.L. et al. American Heart Association; American Academy of Pediatrics: Dietary...

Obesity

Smoking
Lu J.T., Creager M.A. The relationship of cigarette smoking to peripheral arterial disease. Rev Cardiovasc Med.
Chapter 34. Athletes with Cardiac Problems


Chapter 35. Cardiac Transplantation


Index

Page numbers followed by f indicate figures; t, tables; b, boxes.

A
AAI device, 444
AAO, See Ascending aorta
Abbokinase, See Urokinase
Abciximab, for Kawasaki’s disease, 360
Abdomen, echocardiography subcostal views of, 81f, 84
Abdominal obesity
  measurement of, 595t–596t
  in metabolic syndrome, 522–523
Aberrant right subclavian artery, 308–309, 308f–309f, 311–312
Aberrant ventricular conduction, 427–428
ABPM, See Ambulatory blood pressure monitoring
Abscess, cyanosis causing, 141
Absent pulmonary valve
  PDA compared with, 170
  TOF with
    clinical manifestations of, 236–237, 236f
    management of, 237
    natural history of, 237
    pathology and pathophysiology of, 236, 236f
    prevalence of, 236
Acanthosis nigricans, 16, 544
Accelerated malignant hypertension, 481
Accelerated nodal rhythm, 419
Accelerated ventricular rhythm (AVR), 423–424
Accessory reciprocating AV tachycardia, 415, 415f
ACE inhibitors, See Angiotensin-converting enzyme inhibitors
Acetazolamide (Diamox), 613t–634t
Acetylsalicylic acid, See Aspirin
Acquired pulmonary vein stenosis, 303–304
Acrocytosis, 138
Action potential, of human ventricular myocyte, 585f
Acute glomerulonephritis, cardiovascular involvement in, 392
Acute myocardial infarction, 585f
Acute rheumatic fever
cause of, 367
clinical course of, 371
clinical manifestations of, 367–369
  major, 368–369, 368b
  minor, 368b, 369–370
diagnosis of, 367, 368b, 370–371
differential diagnosis of, 371
evidence of recent group A streptococcal infection and, 370
management of, 371–373, 372t
other clinical features of, 370
pathology of, 367
prevalence of, 367–374
prevention of, 373–374, 373t
prognosis of, 373
Acyanotic congenital heart defects, athletic participation with, 558–559, 560t
Acyanotic TOF, 145–148, 145f–149f
Adalat, See Nifedipine
Adenosine (Adenocard), 613t–634t
  for Ebstein’s anomaly, 266
  stress testing with, 102
  for supraventricular tachycardia, 416, 417f
Adolescents
   Holter monitor findings in, 104
   metabolic syndrome in, 522–523, 522b

Adrenalin, See Epinephrine

β-Adrenergic blockers
   for cardiovascular involvement in hyperthyroidism, 394
   for cardiovascular involvement in Turner syndrome, 401
   for CHF, 455, 454–455, 464
   for DCM, 333, 336
   for Ebstein’s anomaly, 266
   for ectopic atrial tachycardia, 412
   for HCM, 327–328, 330
   for long QT syndrome, 433
   for Marfan’s syndrome, 396
   for muscular dystrophy, 397–398
   for MVP, 386
   for noncompaction cardiomyopathy, 341
   for premature ventricular contraction, 423
   for syncope, 514
   for systemic hypertension, 474–477, 475t–476t
   for TOF hypoxic spells, 147–148, 227–228
   for VT, 427

Aerobic exercise, 558

AF, See Atrial fibrillation

Afterload, in CHF, 454

Afterload-reducing agents, for CHF, 453f, 462–463, 463t

AHA, See American Heart Association

Alagille syndrome, 11t–14t

ALCAPA syndrome, See Anomalous origin of left coronary artery from pulmonary artery
Alcohol septal ablation, for HCM, 328
Alcohol use, history of maternal use of, 3–4
Aldactone, See Spironolactone
Aldomet, See Methyldopa
Aldosterone antagonists
  for CHF, 453f, 458
  for systemic hypertension, 476, 476t
Allograft coronary artery disease, 579–580
Alprostadil, See Prostaglandin E₁
Alveolar hypoxia, pulmonary hypertension due to, 484b, 485–486
Amantadine, ECG effects of, 51
Ambrisentan, for pulmonary hypertension, 493
Ambulatory blood pressure monitoring (ABPM), 105–107, 106t
  standards for daytime and nighttime, according to height, 594t
American Heart Association (AHA), BP measurement method recommended by, 19, 19f
Amiloride, for systemic hypertension, 476
Aminophylline, for pharmacologic stress testing, 102
Amiodarone (Cordarone), 613t–634t
  for atrial flutter, 413
  for cardiomyopathy, 328, 333
  for myocarditis, 351
  for ventricular fibrillation, 428
  for VT, 426
Amitriptyline, ECG effects of, 51
Amlodipine (Norvasc), 613t–634t
  for systemic hypertension, 476t, 477
Amoxicillin
  for asplenia syndrome, 284
  for Lyme carditis, 363
Amphetamines, history of maternal use of, 3
Amphotericin B, for infective endocarditis, 348

Ampicillin
  ECG effects of, 51
  for infective endocarditis, 347–348

Amplatzer duct occluder, 115, 171

Amplatzer septal occluder, 115, 158–159

Amrinone, for CHF, 459

Anaerobic exercise, 558

Anderson-Tawil syndrome, 429, 429t

Anemia, CHF due to, 452

Aneurysm
  aortic, chest pain due to, 499t, 500
  atrial septal, 296
  PA, in TOF with absent pulmonary valve, 236–237, 236f

Aneurysm of sinus of Valsalva, 170, 290

Anginal pain, 498

Angiocardiography, 108
  indications for, 111–112
  preparation and monitoring for, 112–113
  of pulmonary atresia with intact ventricular septum, 254, 255f
  risks of, 110–111
  sedation for, 112
  selective, 110, 110f

Angiography, of vascular ring, 311

Angioma, cardiac, 389

Angioplasty, balloon, See Balloon angioplasty

Angiotensin II receptor antagonists, history of maternal use of, 3

Angiotensin receptor blockers (ARBs)
  for renovascular hypertension, 480
  for systemic hypertension, 474–475, 475t–476t, 477
Angiotensin-converting enzyme (ACE) inhibitors
for aortic regurgitation, 382
for cardiomyopathy, 328, 333, 336
for cardiovascular involvement in acute glomerulonephritis, 392
for CHF, 166, 454–455, 463, 463t
after Fontan-type operation, 250
history of maternal use of, 3
for Marfan’s syndrome, 396
for muscular dystrophy, 397–398
for myocarditis, 351
for persistent truncus arteriosus, 270
for renovascular hypertension, 480
side effects of, 477
for systemic hypertension, 474–475, 475t–476t, 477
Anomalous coronary artery, 230
Anomalous innominate artery, 308, 308f, 311–312
Anomalous left pulmonary artery, 308f, 309, 310f, 311–312
Anomalous origin of left coronary artery from pulmonary artery (ALCAPA syndrome), 290–293, 291f
chest pain due to, 499t, 500
management of, 291–293, 292f
ANP, See Atrial natriuretic peptide
Anterior trabecular septum defects, 160–162, 161f
Anthracycline cardiomyopathy, 335–336
Antiarrhythmic agents
See also specific agents
classification of, 582t
ECG effects of, 50–51, 60
Antibiotics
for asplenia syndrome, 284
ECG effects of, 51
for infective endocarditis, 346–350, 349b, 349t
for Lyme carditis, 363–364
Anticoagulation
  after aortic valve replacement, 194–195, 383
  for cardiomyopathy, 328, 333
  after Fontan-type operation, 250–251
  for mitral stenosis, 377–378
  after mitral valve replacement, 381
  for noncompaction cardiomyopathy, 341
  for PFO patients, 300
  for pulmonary hypertension, 492
  for restrictive cardiomyopathy, 339
Anticonvulsants, history of maternal use of, 3
Antidromic reciprocating AV tachycardia, 415, 415f
Antihistamines, ECG effects of, 51
Antihypertensive agents
  See also specific agents; specific classes
    classes of, 474–477, 475t
    end-organ damage with, 473–474
    indications for, 473–474
    oral dosages of, 475, 476t
Antiproliferative agents, for cardiac transplantation, 576, 577t
Antipsychotics, ECG effects of, 51
Antithymocyte globulin (ATG), 578
AOO device, 444
Aorta
  See also Coarctation of aorta
    body surface area of, 602t
    chest roentgenography of, 73–74, 73f
    overriding of, in TOF, 145–148, 145f–149f
pseudocoarctation of, 301
Aortic aneurysm, 499t, 500
Aortic angiography, of vascular ring, 311
Aortic annulus, measurement of, 604t
Aortic arch
  branching variations of, 312–313, 313f
cervical, 296
double, 307, 308f, 311–312
  right with left ligamentum arteriosum, 307–308, 308f, 311–312
Aortic arch interruptions, See Interrupted aortic arch
Aortic area, systolic heart murmurs at, 26, 32t, 33f
Aortic dilation, chest roentgenography of, 71, 71f
Aortic dissection, chest pain due to, 499t, 500
Aortic isthmus, measurement of, 604t
Aortic regurgitation (AR)
  athletic participation with, 562t–563t
  CHF due to, 452
  clinical manifestations of, 381–382, 381f
  management of, 382–383
  natural history of, 382
  pathology of, 381
  PDA compared with, 170
  prevalence of, 381
  as valvular regurgitant lesion, 136, 136f
  VSD with, 168
Aortic regurgitation murmurs, 35
Aortic root dimensions, 604t
Aortic septal defect, athletic participation with, 560t
Aortic stenosis (AS)
  athletic participation with, 560t, 562t–563t
chest pain due to, 498, 499t
clinical manifestations of, 189–192, 189f–191f
differential diagnosis of, 31t–33t, 33f
management of, 113–114, 192–195, 194f–195f
natural history of, 192–195
pathology of, 188–189, 188f
pathophysiology of, 131–132, 132f
prevalence of, 188
syncope due to, 510
Aortic valve, on echocardiography, 81–82, 78f
Aortic valve commissurotomy, for AS, 193
Aortic valve repair, for aortic regurgitation, 382–383
Aortic valve replacement
  for AS, 193–195
  for aortic regurgitation, 382–383
Aortic valvotomy, 193–195, 194f–195f
Aortoplasty, for COA, 199, 200f
Aortopulmonary collateral arteries
  closure techniques for, 115
  in TOF with pulmonary atresia, 231
Aortopulmonary fenestration, See Aortopulmonary septal defect
Aortopulmonary septal defect, 170, 293, 293f
Apical area, systolic heart murmurs at, 34, 33f, 33t
Apical impulse, palpation of, 17
Apical muscular defect, 160–162, 161f
Apical views, on two-dimensional echocardiography, 79f, 83
Apoproteins, 524, 526
Appearance, inspection of, 9
Apresoline, See Hydralazine
Aquachloral, See Chloral hydrate
AR, See Aortic regurgitation
ARBs, See Angiotensin receptor blockers
Arrhythmias, See Cardiac arrhythmias
Arrhythmogenic cardiomyopathy, 321
  cause of, 339
  clinical manifestations of, 339–340
  management of, 339–340
  pathology of, 339
Arrhythmogenic right ventricular dysplasia, 564t
Arterial oxygen saturation
  in cyanosis, 137–140, 138b, 138f–140f
  in cyanotic congenital heart defects, 151f, 152
  of cyanotic neonate, 207b, 208
Arterial switch operation (ASO)
  for complete TGA, 214–218, 215f
  for congenitally corrected TGA, 222
Arteriohepatic dysplasia, 11t–14t
Arteriolar vasodilators, for CHF, 463, 463t
Arteriovenous fistula
  coronary, 170, 293–294, 294f
  pulmonary, 170, 248, 294–295
  systemic, 170, 295–296
Arthritis
  acute rheumatic fever causing, 368
  cardiovascular involvement in, 399
AS, See Aortic stenosis
ASA, See Atrial septal aneurysm
Ascending aorta (AAO), measurement of, 604t
ASD, See Atrial septal defect
ASO, See Arterial switch operation
Aspirin, 613t–634t
for acute rheumatic fever, 372, 372t
after aortic valve replacement, 194–195, 383
after ASD closure, 159
after bidirectional Glenn operation, 248
for cardiomyopathy, 333, 339
ductus arteriosus closure and, 123
after Fontan-type operation, 250–251
for Kawasaki’s disease, 359–361, 362t
for mitral stenosis, 377, 378
after mitral valve replacement, 381
for noncompaction cardiomyopathy, 341
after Norwood operation, 261
for PFO patients, 300
for pulmonary hypertension, 492
Asplenia syndrome
cardiovascular malformations in, 282–283, 282t
clinical manifestations of, 283–284
management of, 284–285
natural history of, 284
pathology of, 282–283, 283f
pathophysiology of, 283
prevalence of, 281
Asthma, exercise-induced, 497, 503
Atenolol (Tenormin), 613t–634t
for HCM, 327
for Marfan’s syndrome, 396
for MVP, 386
for syncope, 514
for systemic hypertension, 476, 476t
ATG, See Antithymocyte globulin
Atherogenic dyslipidemia, 521–523
Atherosclerosis, family history of, 8
Atherosclerotic cardiovascular disease, childhood onset of, 520–521
Athletes, 553
  with atrioventricular and intraventricular blocks, 566–570, 569t
  with cardiac arrhythmias, 554, 565–570
    diagnostic workup for, 565–570
    eligibility recommendations for, 566, 567t–569t
with cardiomyopathy, pericarditis, and other myocardial diseases, 563–565, 564t
with congenital heart defects, 554
  acyanotic, 558–559, 560t
  cyanotic, 559, 561t
with coronary artery abnormalities, 559, 562t
  eligibility of, 558–565
HCM in, 325, 554, 554t
  preparticipation screening for, 554–557, 555b
  sports classification, 557–558, 557f
  sudden unexpected death in, 553–554, 554t
  with systemic hypertension, 570–571
  with valvular heart disease, 559, 562t–563t
Atorvastatin (Lipitor), 539, 613t–634t
Atrial baffle operations, for complete TGA, 213, 214f
Atrial contraction, premature, 410, 411f
Atrial fibrillation (AF), 411f, 414, 566, 567t–569t
Atrial flutter, 411f, 412–414, 417f, 566, 567t–569t
Atrial hypertrophy, ECG of, 53–54, 53f
Atrial isomerism, See Heterotaxia
Atrial natriuretic peptide (ANP), in CHF, 455
Atrial pacemaker, 441, 441f
Atrial septal aneurysm (ASA), 296
Atrial septal defect (ASD)
  CHF due to, 451
  clinical manifestations of, 124, 125f, 155–158, 156f–157f
  differential diagnosis of, 31t, 33f
  in ECD, 129–130, 130f
  management of, 115, 158–160, 159f
  natural history of, 158
  pathology of, 155, 156f
  pathophysiology of, 124–126, 125f
  prevalence of, 155
  in pulmonary atresia, 150
  in TAPVR, 151–152
  in TGA, 142f, 143
  in tricuspid atresia, 148–149
Atrial septectomy, 493
Atrial septostomy
  balloon and blade, 113, 213
  for pulmonary hypertension, 493
Atrial sound, auscultation of, 27, 27f
Atrial tachycardia
  chaotic, 411f, 412
  ectopic, 411–412, 411f, 414, 416
  paroxysmal, 415
Atrioventricular (AV) block, 436, 437f
  athletic participation with, 566–570, 569t
  CHF due to, 452
  first-degree, 436, 437f, 566–570, 569t
  Mobitz type I, 436–437, 437f, 566–570, 569t
Mobitz type II, 436–437, 437f, 566–570, 569t
pacemaker for, 443
second-degree, 436–437, 437f, 566–570, 569t
syncope with, 510
third-degree (complete), 437f, 438–439
two-to-one (or higher), 436–437, 437f
Atrioventricular (AV) canal defect, See Endocardial cushion defect
Atrioventricular (AV) communis, See Endocardial cushion defect
Atrioventricular (AV) conduction disturbances, 436–439, 437f, 439f
Atrioventricular (AV) dissociation, 439, 439f
Atrioventricular (AV) junctional rhythm, 418f, 419
  accelerated, 419
Atrioventricular (AV) node, rhythms originating in, 418–420, 418f
Atrioventricular (AV) tachycardia, reciprocating, 415–416, 415f
Atrioventricular (AV) valves
  measurements of, 607t
  stenosis of, as obstructive lesions, 134–135, 134f
Atrium
  See also Left atrium; Right atrium
    localization of, 314–315, 315f
    rhythms originating in, 410–418, 411f
Atromid-S, See Clofibrate
Atropine
  for sinus node dysfunction, 410
  stress testing with, 102
Auscultation, 24–25
  of blood pressure, 21f, 20–23, 21f–22f, 28, 34, 466, 467t, 589t–590t
  of extracardiac sounds, 28
  of heart murmurs, 25, 28–39, 29f, 31t–33t, 33f, 35f, 36t, 37f
  of heart rate and regularity, 25
of heart sounds, 25–28, 25f, 26b, 27f

of systolic and diastolic sounds, 25, 27–28, 27f

AV, See Atrioventricular

AVR, See Accelerated ventricular rhythm

Azathioprine (Imuran, Azasan), 613t–634t
  for cardiac transplantation, 577, 577t, 580
BAH, See Biatrial hypertrophy
Balloon angioplasty, 114–115
   for COA, 114, 199, 201–202
   for pulmonary artery stenosis, 302
Balloon atrial septostomy, 113
   for complete TGA, 213
Balloon valvuloplasty, 113–114
   for AS, 113–114, 192–193
   for PS, 110f, 113, 186–187
Barium esophagography, of vascular ring, 308f–309f, 310–311
Barth syndrome, 337
Battery, for cardiac pacemakers, 444–445
BAV, See Bicuspid aortic valve
BBB, See Bundle branch block
Benzathine penicillin, for acute rheumatic fever, 371–372
Betapace, See Sotalol
Biatrial hypertrophy (BAH), ECG of, 53f, 54
Bicarbonate
   for persistent pulmonary hypertension of newborn, 289
   for TOF hypoxic spells, 148, 227
Bicaval cardiac transplantation, 574–575, 575f
Bicuspid aortic valve (BAV), athletic participation with, 562t–563t
Bidirectional Glenn operation
   for Ebstein’s anomaly, 266
   for HLHS, 261–262
   for single ventricle, 275
   for tricuspid atresia, 246b, 247–248, 247f
Bigeminy, 420
Bile acid sequestrants, 526, 536–546, 537t
Bile acids, 526
Biopsy, endomyocardial, for cardiac transplantation, 578–579
Bipartite pulmonary atresia, 253, 253f
Bipolar leads, for cardiac pacemakers, 444
Birth, circulation changes after, 120–123, 121f–122f, 122b
Birth weight, history of, 4
Biventricular hypertrophy (BVH), 56–57, 57f
  in VSD, 163, 163f
Blade atrial septostomy, 113
Blalock-Taussig (BT) shunt
  for Ebstein’s anomaly, 266
  for HLHS, 260, 260f
  for single ventricle, 275
  for TOF, 228–229, 228f
  for tricuspid atresia, 246, 246b
Bland-White-Garland syndrome, See Anomalous origin of left coronary artery from pulmonary artery
Bleeding disorders, cyanosis causing, 141
Blood flow
  cardiac catheterization measurement of, 108–109
  Doppler echocardiography measurement of, 90
Blood pressure (BP)
  ambulatory monitoring of, 105–107, 106t
    standards for daytime and nighttime, according to height, 594t
levels of, by age and height percentiles, 586t–589t
measurement of, 18
  arm and leg value interpretation, 22–23
auscultatory method, 466, 467t
at home, 469
in neonates and small children, 23, 23t
normal standards for, 23, 19, 21f–22f, 465, 465t
oscillometric method of, 21–22, 466, 467t
peripheral amplification of systolic pressure, 23–24, 24f
recommended method for, 19, 19f, 466
stress testing response of, 96, 98–100, 99f, 99t
values of
  ambulatory, 594t
  auscultatory, 589t–590t
  Dinamap percentiles, 591t–593t
Blood urea nitrogen (BUN), for systemic hypertension, 471, 472t
BMI, See Body mass index
BNP, See B-type natriuretic peptide
Body mass index (BMI), 544, 599f–600f
Body surface area
  left ventricular mass by, 609t
  with M-mode echocardiography, 602t
  nomogram for, 584f
  oxygen consumption per, 583t
Bogalusa Heart Study, 521
Boot-shaped heart, in TOF, 225, 225f
Bosentan (Tracleer), 493, 613t–634t
Bovine aortic arch, 313, 313f
BP, See Blood pressure
BP load, 106
BPD, See Bronchopulmonary dysplasia
BPEG, See British Pacing and Electrophysiology Group
Bradycardia
  pacemaker for, 443
  sinus, 407–408, 408f, 408t
  syncope with, 510
Bradycardia–tachycardia syndrome, pacemaker for, 443
Brain abscess, cyanosis causing, 141
Brain death, of cardiac donor, 573
Branch pulmonary artery stenosis, balloon angioplasty for, 114–115
Brevibloc, See Esmolol
British Pacing and Electrophysiology Group (BPEG), 443–444, 443t
Bronchopulmonary dysplasia (BPD), CHF due to, 452
Bronchoscopy, of vascular ring, 311
Bronchospasm, exercise-induced, 102
Brugada syndrome, 435, 510
BT shunt, See Blalock-Taussig shunt
B-type natriuretic peptide (BNP), 455
Bulboventricular foramen, 144
Bumetanide (Bumex), 613t–634t
BUN, See Blood urea nitrogen
Bundle branch block (BBB), 57–62
   See also Left bundle branch block; Right bundle branch block
Bupropion, for smoking cessation, 550
BVH, See Biventricular hypertrophy
CAD, See Coronary artery disease
CAIs, See Cholesterol absorption inhibitors
Calan, See Verapamil
Calcineurin inhibitors, for cardiac transplantation, 576–577, 577t
Calcium, ECG response to, 65, 65f
Calcium carbonate (Os-Cal, Titralac, Oystercal, Caltrate), for DiGeorge syndrome, 393
Calcium channel blockers (CCBs)
  for cardiomyopathy, 327, 339
  for cardiovascular involvement in acute glomerulonephritis, 392
  for MVP, 386
  for pulmonary hypertension, 492
  for renovascular hypertension, 481
  for systemic hypertension, 474–475, 475t–476t, 477
Calcium glubionate (Neo-Calglucon), 613t–634t
Calcium gluconate (Kalcinate), 393
Caloric intake, for CHF, 457, 457t
Caltrate, See Calcium carbonate
Captopril (Capoten), 613t–634t
  for CHF, 166, 463, 463t
  for DCM, 333
  for myocarditis, 351
  after Norwood operation, 261
  for systemic hypertension, 476t, 477
Carbohydrate-induced hypertriglyceridemia, 540
Cardiac arrhythmias, 407, 408t
  accelerated ventricular rhythm as, 423–424
  in athletes, 554
    eligibility recommendations for, 566, 567t–569t
  atrial fibrillation as, 411f, 414
atrial flutter as, 411f, 412–414, 417f
atrial tachycardia as, 411f
  chaotic, 412
  ectopic, 411–412
in Brugada syndrome, 435
chest pain due to, 498, 499t, 500, 503
exercise-induced, 100
HCM with, 328
junctional ectopic tachycardia as, 418f, 419–420
junctional or nodal escape beats as, 418–419, 418f
junctional or nodal premature beats as, 418, 418f
long QT syndrome as, 424b, 428–434, 429t, 430f, 432t
nodal or junctional rhythm as, 418f, 419
  accelerated, 419
originating in atrioventricular node, 418–420, 418f
originating in atrium, 410–418, 411f
originating in sinus node, 407–410, 408t
originating in ventricle, 420–435, 420f
premature atrial contraction as, 410, 411f
premature ventricular contraction as, 420–423, 420f–422f, 424b
short QT syndrome as, 434
sinoatrial exit block as, 409
sinus, 408, 408f
sinus arrhythmia as, 408, 408f
sinus bradycardia as, 407–408, 408f
sinus node dysfunction as, 409–410
sinus pause as, 408f, 409, 418–419, 418f
sinus tachycardia as, 407, 408f
sports and, 565–570
  diagnostic workup for, 565–570
supraventricular tachycardia as, 414–418
  reentrant (reciprocating), 411f, 414–416, 415f
syncope with, 510, 512, 514, 565
ventricular fibrillation as, 420f, 428
ventricular tachycardia as, 420f, 424–427
wandering atrial pacemaker as, 410–411, 411f
Cardiac catheterization
  of DCM, 332
diagnostic, 108
    hemodynamic calculations for, 108–109
    hemodynamic values and, 108, 109f
    indications for, 111–112
    preparation and monitoring for, 112–113
    risks of, 110–111
    sedation for, 112
    selective angiocardiography with, 110, 110f
interventional, 113
  balloon and blade atrial septostomy, 113, 213
  balloon angioplasty, 114–115, 199, 201–202, 302
  balloon valvuloplasty, 110f, 113–114, 186–187, 192–193
  closure techniques, 115
  percutaneous valve replacement, 116
  of pulmonary atresia with intact ventricular septum, 254, 255f
  of vascular ring, 311
Cardiac chambers
  chest roentgenography evaluation of, 69–70, 69f–70f
ehocardiography of, 86f, 87
  in fetus, 119–120, 120f
  localization, 314
    atria, 314–315, 315f
great arteries, 316, 316f
segmental expression, 316–317
ventricles, 315, 316f
Cardiac malposition, 317–318, 317f
Cardiac murmurs, See Heart murmurs
Cardiac output
  cardiac catheterization measurement of, 108–109
  Doppler echocardiography measurement of, 90
  fetal, 120
  pulmonary hypertension and, 488
Cardiac pacemakers, 440
  atrial, 441, 441f
  for AV block, 439
  battery, leads, and route for, 444–445
  for congenitally corrected TGA, 223
  ECG of, 440–441
  electromagnetic interference with, 445–446
  follow-up for, 447–448
  for HCM, 328
  indications for, 441–443, 442b
  living with, 445–447
  for long QT syndrome, 433–434
  rate-adaptive, 444
  selection of, 444
  for syncope, 514
  temporary, 443
  types of, 443–444, 443t
  ventricular, 440, 441f
    P wave–triggered, 441, 441f
Cardiac silhouette, chest roentgenography of, 67–69, 68f–69f
Cardiac tamponade, in pericarditis, 352–354, 353f
Cardiac TAPVR, 151, 238, 238f, 240
Cardiac transplantation, 572
  allograft coronary artery disease after, 579–580
  bicaval, 574–575, 575f
  for congenitally corrected TGA, 223
  contraindications for, 573
  donor evaluation and management for, 573–574
  early posttransplantation follow-up, 578–579, 578t
  history of, 572
  for HLHS, 259–260, 262
  immunosuppressive therapy for, 576–578, 577t
    side effects of, 580
  indications for, 572
  infection after, 578–579, 578t
  informed consent for, 574
  late posttransplantation follow-up, 579–580
  operative technique for, 574–575, 574f–575f
  physiology of heart, 580
  posttransplant management for, 575–580
    clinic visits and investigations, 576
  prognosis for, 580
  recipient selection for, 572–573
  rejection of, 578–579, 578t
  right atrial, 574, 574f
Cardiac tumors
  angioma, 389
  clinical manifestations of, 389
  diagnostic procedures for, 389–391, 390f
  fibroma, 387–389, 390f, 391
management of, 391
myxoma, 387–389, 390f, 391
pathology of, 387–389
prevalence of, 387
rhabdomyoma, 387–389, 390f, 391
teratoma, 389
types and frequency of, 387, 388t
Cardio-limb syndrome, 11t–14t
Cardiomegaly, chest roentgenography of, 67
Cardiomyopathy, 321, 322f, 323t
   See also specific cardiomyopathies
   athletic participation with, 563–565, 564t
catecholamines in, 454
chest pain due to, 499t, 500
CHF due to, 452
Cardioquin, See Quinidine
Cardiothoracic (CT) ratio, 67, 68f
Cardiovascular disease (CVD), atherosclerotic, childhood onset of, 520–521
Cardiovascular infections
   See also Acute rheumatic fever
   HIV, 365–366
   infective endocarditis, 342–350, 344f, 346b–347b, 349b, 349t
   Kawasaki’s disease, 354–361, 355b, 357f, 359b, 362t
   Lyme carditis, 361–364
   myocarditis, 350–352
   pericarditis, 63, 63f, 352–354, 353f
   postperfusion syndrome, 364–365
   postpericardiotomy syndrome, 364
Cardiovascular risk factors
categories, 533b
cigarette smoking, 548–550
management of, 549–550
pathophysiological effects of, 549
prevalence of, 548
psychosociology of, 549
dyslipidemia as
  causes of, 528–531, 528b, 529t
  management of, 534–539, 534f, 535t, 536b, 537t
hypertriglyceridemia, 539–541
carbohydrate-induced, 540
familial, 530–531
low HDL syndrome and, 542
management of, 539–541, 540f
lipids and lipoproteins, 523–524
  measurement of, 526–527
  metabolism of, 524–526, 525f
  screening of, 531–534
low HDL syndrome, 531, 541–542
  high triglycerides with, 542
  hypertriglyceridemia and, 542
  treatment of, 541–542
metabolic syndrome and, 521–523, 521b–522b
obesity as, 521–522, 542–548
  evaluation of, 544–545
  health consequences of, 543–544
  management of, 545–548, 546b–547b
  pathogenesis of, 543, 543f
  percentile regression of waist circumference for, 595t–596t
  prevalence of, 543
preventive cardiology and, 550, 551t–552t
Cardiovascular structure dimensions, echocardiography of, 85, 86f, 87
Cardioversion, for VT, 426
Carditis, acute rheumatic fever causing, 368–369
Cardizem, See Diltiazem
Carnitine (Carnitor), 613t–634t
  for CHF, 464
Carnitine deficiency
  CHF due to, 453
  DCM caused by, 337
Carnitor, See Carnitine
Carotid bruit, auscultation of, 36t, 37f, 38–39
Carpenter’s syndrome, 11t–14t
Carpentier technique, for Ebstein’s anomaly, 267
Carvedilol (Coreg), 613t–634t
  for CHF, 464
  for DCM, 333, 336
    for doxorubicin cardiomyopathy prevention, 336
    for HCM, 328
    for muscular dystrophy, 397–398
    for noncompaction cardiomyopathy, 341
Catecholamines
  in cardiomyopathy, 454
  for CHF, 453f, 459, 459t
    peripheral amplification of systolic pressure and, 24
Catheterization, See Cardiac catheterization
Cavopulmonary shunt, See Bidirectional Glenn operation
CCBs, See Calcium channel blockers
Ceftazidime, for infective endocarditis, 348
Ceftriaxone, for infective endocarditis, 347–348
Cefuroxime axetil, for Lyme carditis, 363
CellCept, See Mycophenolate mofetil

Central cyanosis, 137–138, 206, 207t

See also Cyanosis

Central nervous system (CNS)

cyanosis effects on, 141

malformations of, 15t

Central shunt operation, for TOF with pulmonary atresia, 233, 233f

Cerebro-hepato-renal syndrome, 11t–14t

Cervical aortic arch, 296

CETP, See Cholesteryl ester transfer protein

Chambers, See Cardiac chambers

Chaotic atrial tachycardia, 412

CHARGE association, 11t–14t

CHD, See Congenital heart disease

Chest

inspection of, 16

palpation of, 17–18

Chest pain, 495

causes of, 495–504, 496b, 496t

    cardiac, 496b, 498–500, 499t

    noncardiac, 495–498, 496b

clinical manifestations of, 495–500

diagnostic approach to, 499t, 500–503

history of, 5–6, 501–502

idiopathic, 495

management of, 503–504

prevalence of, 495–504

Chest roentgenography, 67

of AS, 190

of aortic regurgitation, 382
of ASD, 124, 125f, 156–157, 157f
of asplenia syndrome, 283
atria localization using, 314, 315f
cardiac silhouette on, 67–69, 68f–69f
of COA, 198, 201
of complete TGA, 210, 210f
of congenitally corrected TGA, 220, 221f
of cyanotic neonate, 206–207, 207b
of DCM, 331
of Ebstein’s anomaly, 264, 265f
of ECD, 129–130, 130f, 176, 180
great arteries size on, 70–71, 71f
of HCM, 324
heart size on, 67, 68f
of HLHS, 259, 259f
individual chamber enlargement on, 69–70, 69f–70f
of mitral regurgitation, 379–380, 379f
of mitral stenosis, 376
of MVP, 385
of myocarditis, 351
of PAPVR, 182–183
of PDA, 128–129, 128f, 169
    in preterm neonates, 172
of pericarditis, 353
of persistent truncus arteriosus, 269
of polysplenia syndrome, 286
of PS, 185, 186f
of pulmonary atresia with intact ventricular septum, 254
pulmonary vascular markings on, 71
    decreased pulmonary blood flow, 71
increased pulmonary blood flow, 71
normal pulmonary vasculature, 72
pulmonary venous congestion, 72
of single ventricle, 273
systematic approach to, 72
aorta identification, 73–74, 73f
liver and stomach gas bubble location, 72, 72f
pulmonary parenchyma, 74
skeletal aspect, 72, 73f
upper mediastinum, 74, 74f
of TAPVR, 239–240, 239f
of TOF, 225, 225f
of tricuspid atresia, 244, 244f
of vascular ring, 310
of VSD, 126–128, 126f, 163–165, 163f
CHF, See Congestive heart failure
CHILD-1 diet, 534–535, 535t, 597t–598t
CHILD-2-LDL diet, 535, 597t–598t
CHILD-2-TG diet, 535t, 540, 597t–598t
Chloral hydrate (Noctec, Aquachloral), 613t–634t
for invasive procedure sedation, 112
Chlorothiazide (Diuril), 613t–634t
for CHF, 453f, 458
Chlorpromazine (Thorazine)
for acute rheumatic fever, 372
ECG effects of, 51
for invasive procedure sedation, 112
Cholecystitis, chest pain due to, 497
Cholesterol, 523–524
disorders of
primary, 529–531, 529t
secondary, 528–531, 528b
measurement of, 526–527
in metabolic syndrome, 521–523, 521b–522b
metabolism of, 524–526, 525f
normal levels of, 527, 527t–528t
omega-3 fatty acids and, 540–541
reverse transport of, 525f, 526
Cholesterol absorption inhibitors (CAIs), 536–546, 537t
Cholesteryl ester, 525
Cholesteryl ester transfer protein (CETP), 525f, 526
Cholestryamine (Questran, Prevalite), 536, 537t, 613t–634t
Chondroectodermal dysplasia, 11t–14t
Chromosomal syndromes, inspection of, 9–10, 11t–14t
Chylomicron remnants, 524–525, 525f
Chylomicrons, 524–525, 525f
Cigarette smoking, See Smoking
Cimetidine, for persistent pulmonary hypertension of newborn, 289
Circulation
  fetal, 119–120, 120f
  perinatal, 120–123, 121f–122f, 122b
  of premature newborns, 123
Circumoral cyanosis, 138
Classic vibratory murmur
  auscultation of, 36t, 37, 37f
  differential diagnosis of, 32t–33t, 33f
Cleft mitral valve, 296
Clofibrate (Atromid-S), 613t–634t
Clopidogrel (Plavix), 613t–634t
  for Kawasaki’s disease, 360
Closure techniques, 115
Clubbing
  cyanosis causing, 141
  inspection of, 10, 15f
CMV, See Cytomegalovirus
CNS, See Central nervous system
Coarctation of aorta (COA)
  asymptomatic
    clinical manifestations of, 200–201, 200f
    management of, 201–202
    natural history of, 201
  athletic participation with, 560t
  balloon angioplasty for, 114, 199
  differential diagnosis of, 31t, 33f
  hypertension with, 466, 477, 478t
  pathology of, 195–197, 196f
  pathophysiology of, 132–133, 133f
  PDA compared with, 170
  prevalence of, 195
  symptomatic
    clinical manifestations of, 197–198, 197f–198f
    management of, 198–200, 200f
    natural history of, 198
  VSD with, 168, 199
Cocaine abuse, chest pain due to, 499t, 500, 504
Cockayne’s syndrome, 11t–14t
Coenzyme Q10, for doxorubicin cardiomyopathy prevention, 336
Colesevelam (WelChol), 536, 537t
Colestipol (Colestid), 536, 537t, 613t–634t
Collateral arteries
aortopulmonary
closure techniques for, 115
in TOF with pulmonary atresia, 231
closure techniques for, 115
in COA, 184, 184, 196f
PDA compared with, 170
Color, inspection of, 10
Color-flow mapping, 91
Common atrium, 296–297
Complete ECD
clinical manifestations of, 129–130, 130f, 175–177, 176f–178f
management of, 178–180, 179f
natural history of, 177–178
pathology of, 174–175, 175f
prevalence of, 174
Complete TGA, See Dextroposition transposition of the great arteries
Complete vascular ring, 307
Computed tomography (CT), 92–95, 93b
of asplenia syndrome, 284
of polysplenia syndrome, 286
of vascular ring, 311
Conal septum defects, See Outlet septum defects
Congenital heart disease (CHD)
See also specific diseases
affected offspring with, 581t
in athletes, 554, 558–559, 560t
cardiac catheterization for, 111–112
chest pain due to, 498, 499t
CHF due to, 451
in chromosomal syndromes, 9–10, 11t–14t
cyanotic, in athletes, 559, 561t
family history of, 7–8
fetal echocardiography of, 91–92, 91b
in hereditary and nonhereditary syndromes and system malformations, 10, 11t–15t
maternal history of, 4
recurrence risk of, 581t
stress testing response in, 97
syncope due to, 510
Congenital pericardial defect, 300–301
Congenital pulmonary vein stenosis, 302–303
Congenitally corrected TGA, See Levotransposition of the great arteries
Congestive heart failure (CHF), 451
causes of, 451, 451–453, 452t
compensatory mechanisms in, 454–455
diagnosis of, 455–456
management of, 456–464
  β-adrenergic blockers for, 454, 464
  afterload-reducing agents for, 453f, 462–463, 463t
  approach to, 456
carnitine for, 464
carvedilol for, 464
digitalis glycosides for, 453f, 459–462, 460t, 461b–462b
diuretics for, 453f, 458, 458t
general measures in, 457–458, 457t
metoprolol for, 464
rapidly acting inotropic agents for, 453f, 459, 459t
surgical, 464
treatment of underlying causes or contributing factors, 457
pathophysiology of, 453–455
Constrictive pericarditis, 354
Continuous heart murmurs, auscultation of, 35f, 36
Contrast agents, in angiocardiography, 110
Contrast echocardiography, 91
Cor triatriatum, 297, 297f
Cor triloculare biventriculare, 296–297
Cordarone, See Amiodarone
Coreg, See Carvedilol
Cornelia de Lange’s syndrome, 11t–14t
Coronary arteries
  anatomy of
    in TGA patients, 212f
    in TOF patients, 226f
  on echocardiography, 75
    two-dimensional echocardiography of, 607t
Coronary arteriovenous fistula, 170, 293–294, 294f
Coronary artery anomalies, athletic participation with, 559, 562t
Coronary artery disease (CAD)
  allograft, 579–580
  chest pain due to, 499t, 500
  childhood onset of, 520–521
Coronary artery fistula, 293
Coronary pulmonale, CHF due to, 453
Coronary sinus
  on echocardiography, 75, 79f
  TAPVR to, 241, 241f
Coronary sinus ASD, 155
Coronary-cameral fistula, 293
Corticosteroids
  for cardiac transplantation, 576, 577t, 580
  for cardiovascular involvement in rheumatoid arthritis, 399
for Kawasaki’s disease, 360
for myocarditis, 351
for pericarditis, 354
for postpericardiotomy syndrome, 364
Cystoschondritis, chest pain due to, 495–497, 503
Cough syncope, 509
Coumadin, See Warfarin
Couplets, 420
Coupling, 420–422
Cozaar, See Losartan
Craniofacial dysostosis, 11t–14t
Creatinine, for systemic hypertension, 471, 472t
Cri du chat syndrome, 11t–14t
Crouzon’s disease, 11t–14t
CT, See Computed tomography
CT ratio, See Cardiothoracic ratio
CVD, See Cardiovascular disease
Cyanosis
  approach to, 206–208, 207b, 207t
  of cardiac vs. pulmonary origin, 138–139, 139f
  causes of, 138, 138b, 207t
  consequences and complications of, 140–141
  detection of, 137
  hemoglobin dissociation curve and, 139–140, 140f
  hemoglobin level influence on, 137, 138f
  history of, 4–5
  inspection for, 10
  with pulmonary hypertension, 488
Cyanotic congenital heart defects, 206
  See also specific defects
athletic participation with, 559, 561t

Cyanotic spells, See Hypoxic spells

Cyanotic TOF, 145–148, 145f–149f

Cyclosporine (Sandimmune, Gengraf, Neoral), 577, 577t, 580, 613t–634t

Cytomegalovirus (CMV), after cardiac transplantation, 578–579
D

Damus-Kaye-Stansel operation
  for complete TGA, 217, 218f
  for single ventricle, 274–275, 275f
  for tricuspid atresia, 246, 246b

Danielson technique, for Ebstein’s anomaly, 267, 267f

DCM, *See* Dilated cardiomyopathy

DDD device, 444

de Lange’s syndrome, 11t–14t

Defibrillation, for ventricular fibrillation, 428

Deletion 5p syndrome, 11t–14t

Demerol, *See* Meperidine

Dental procedures, antibiotic prophylaxis for, 348–350, 349b, 349t

Dependent shunt, 126

Development, history of, 4

Devil's grip, chest pain due to, 498

Dexrazoxane, for doxorubicin cardiomyopathy prevention, 336

Dextrocardia, 317–318, 317f

Dextroposition transposition of the great arteries (D-TGA), 316, 316f
  clinical manifestations of, 209–211, 209f–212f
  management of, 212–218, 214f–218f
  natural history of, 211–212
  pathophysiology of, 142–144, 142f–143f, 208–209
  prevalence of, 208

Diabetes, maternal, 11t–14t
  HCM caused by, 328–330, 329f

Diagnostic procedures, *See* Invasive procedures, Noninvasive imaging

Diamox, *See* Acetazolamide

Diastolic function, Doppler echocardiography of, 90–91, 90f

Diastolic heart murmurs
in AS, 189f, 190
in aortic regurgitation, 136, 381–382, 381f
in ASD, 156
auscultation of, 35, 35f
  early diastolic decrescendo murmurs, 35, 35f
  mid-diastolic murmurs, 35, 35f
  presystolic (or late diastolic) murmurs, 35, 35f
in COA, 200f, 201
in mitral stenosis, 376, 376f
in persistent truncus arteriosus, 269
in pulmonary regurgitation, 136
in single ventricle, 273
in TAPVR, 151–152, 238, 239f
in TGA, 220
in VSD, 163
Diastolic opening snap, 27f, 28
Diastolic sounds, auscultation of, 25, 27–28, 27f
Diastolic thrill, in aortic regurgitation, 381, 381f
Diazepam (Valium)
  for acute rheumatic fever, 372
  for hypertensive crisis, 482
  for invasive procedure sedation, 112
Diazoxide (Hyperstat, Proglycem), 613t–634t
  for hypertensive crisis, 481
Diet
  for CHF, 457, 457t
  for hypercholesterolemia, 534–535, 534f, 535t
  for hypertriglyceridemia, 527t–528t, 535t, 540
  for low HDL syndrome, 541
  for obesity management, 545–546, 546b–547b
DiGeorge syndrome, 11t–14t, 204–205, 269–270
   cardiovascular involvement in, 392–393
Digibind, See Digoxin immune Fab
DigiFab, See Digoxin immune Fab
Digital subtraction angiography, of vascular ring, 311
Digitalis
   HCM and, 327
   toxicity effects of, 50–51, 62–63
Digitalis glycosides, for CHF, 459–462
   dosage of, 460, 460t
   method for administration of, 460–461, 460t
   monitoring of, 461, 461b
   toxicity of, 460t, 462, 462b
Digitalization, 460–461, 460t
Digitek, See Digoxin
Digoxin (Lanoxin, Digitek), 459–462, 613t–634t
   for acute rheumatic fever, 372
   for aortic regurgitation, 382
   for CHF
      dosage of, 460, 460t
      method for administration of, 460–461, 460t
      monitoring of, 461, 461b
      toxicity of, 460t, 462, 462b
      in VSD, 166
   for DCM, 333, 336
   for ectopic atrial tachycardia, 412
   for endocardial fibroelastosis, 335
   after Fontan-type operation, 250
   for HCM, 328
for mitral regurgitation, 380
for mitral stenosis, 377
for myocarditis, 351
for noncompaction cardiomyopathy, 341
after Norwood operation, 261
for PDA, 173
for persistent pulmonary hypertension of newborn, 289
for sinus node dysfunction, 410
Digoxin immune Fab (Digibind, DigiFab), 613t–634t
Dilacor XR, See Diltiazem
Dilantin, See Phenytoin
Dilatation of aorta, chest roentgenography of, 71, 71f
Dilated cardiomyopathy (DCM), 321, 322f
  Barth syndrome, 337
carnitine deficiency causing, 337
cause of, 330–331
CHF due to, 451
clinical characteristics of, 323t
clinical manifestations of, 331–332, 332f–333f
doxorubicin causing, 335–336
endocardial fibroelastosis, 334–335
Kearns-Sayre syndrome, 337–338
management of, 333–334
natural history of, 332–333
pathology and pathophysiology of, 331
prognosis of, 334
syncope due to, 510
Diltiazem (Cardizem, Dilacor XR, Tiazac), 613t–634t
Dinamap, 466
  blood pressure measurement by, 20–23, 23t, 591t–593t
Diphenhydramine, for invasive procedure sedation, 112
Dipyridamole (Persantine), 613t–634t
  for Kawasaki’s disease, 360
  for restrictive cardiomyopathy, 339
  stress testing with, 102
Disopyramide (Norpace), 613t–634t
  for syncope, 514
Diulo, See Metolazone
Diuretics
  for AS, 192
  for aortic regurgitation, 382
  for cardiovascular involvement in acute glomerulonephritis, 392
  for CHF, 453f, 458, 458t
    in VSD, 166
  for COA, 198
  for DCM, 333, 336
  for endocardial fibroelastosis, 335
  after Fontan-type operation, 250
  for HCM, 327–328
  for mitral regurgitation, 380
  for mitral stenosis, 377
  for myocarditis, 351
  for noncompaction cardiomyopathy, 341
  after Norwood operation, 261
  for PDA, 173
  for persistent pulmonary hypertension of newborn, 289
  for persistent truncus arteriosus, 270
  for postpericardiotomy syndrome, 364
  for restrictive cardiomyopathy, 339
  side effects of, 459
for systemic hypertension, 475–476, 475t–476t
for TAPVR, 241
Diuril, See Chlorothiazide
Dobutamine (Dobutrex), 613t–634t
  for CHF, 459, 459t
  for COA, 198
  for myocarditis, 351
  stress testing with, 102
Dopamine (Intropin, Dopastat), 613t–634t
  for AS, 192
  for CHF, 459, 459t
  for COA, 198
  for myocarditis, 351
  for persistent pulmonary hypertension of newborn, 289
Doppler echocardiography, 87–91, 88t, 89f–90f
  of AS, 191
  of COA, 198, 198f, 201
  of PDA in preterm neonates, 169f, 173
  of PS, 186
  of vascular ring, 311
DORV, See Double-outlet right ventricle
Dosages, for drugs used in pediatric cardiology, 613t–634t
Double aortic arch, 307, 308f, 311–312
Double switch operation, for congenitally corrected TGA, 222
Double-chambered right ventricle, 297–298
Double-inlet ventricle, See Single ventricle
Double-outlet right ventricle (DORV)
  echocardiography of, 278–279, 278f
  management of, 279–280, 281f
  natural history of, 279
pathology of, \textit{276–277, 277f}
pathophysiology and clinical manifestations of, \textit{277–279, 277f}
prevalence of, \textit{276}
Doubly committed VSD, \textit{277–280, 281f}
Down syndrome, \textit{11t–14t}
Doxorubicin cardiomyopathy, \textit{335–336}
  
  CHF due to, \textit{451}
Doxycycline, for Lyme carditis, \textit{363}
Drugs
  history of maternal use of, \textit{3–4}
  history of patient use of, \textit{7}
  in pediatric cardiology, \textit{611t–613t}
    dosages of, \textit{613t–634t}
D-TGA, \textit{See Dextroposition transposition of the great arteries}
Duchenne’s muscular dystrophy, \textit{11t–14t}
Ductus arteriosus
  \textit{See also Patent ductus arteriosus}
    closure of, \textit{121–123}
    in fetal circulation, \textit{119, 120f}
    in premature newborns, \textit{123}
    reopening of, \textit{123}
    responses to various stimuli by, \textit{123}
Ductus venosus, in fetal circulation, \textit{119, 120f}
Duke Criteria, for infective endocarditis, \textit{345–346, 346b–347b}
DVI device, \textit{444}
DynaCirc, \textit{See Isradipine}
Dynamic exercise, \textit{96, 557f, 558}
Dyrenium, \textit{See Triamterene, Trimethadione}
Dysautonomia, \textit{507–508, 507f}
Dysbetalipoproteinemia, \textit{531}
Dyslipidemia
causes of
  primary, 529–531, 529t
  secondary, 528–531, 528b
classification of, 528–531
lipids and lipoproteins, 523–524
  measurement of, 526–527
  metabolism of, 524–526, 525f
  screening of, 531–534
management of, 534–539, 534f, 535t, 536b, 537t
in metabolic syndrome, 521–531, 521b–522b

Dyspnea
  history of, 5
  inspection of, 15
Early diastolic decrescendo murmurs, 35, 35f
Early repolarization, 62, 63f
Early systolic heart murmurs, 29f, 30
Ebstein's anomaly
  athletic participation with, 561t
  clinical manifestations of, 263–265, 264f–265f
  management of, 266–268, 267f–268f
  natural history of, 266
  pathology of, 263, 263f
  prevalence of, 263
ECD, See Endocardial cushion defect
ECG, See Electrocardiography
Echocardiography (echo), 77–92
  See also Doppler echocardiography
  of AS, 190–192, 191f
  of ALCAPA syndrome, 291, 291f
  of aortic regurgitation, 382
  of ASD, 157–158, 157f
  of asplenia syndrome, 283–284
  for athletes, 556–557
  atria localization using, 315
  of cardiac tumors, 389–391, 390f
  of COA, 198, 198f, 201
  color-flow mapping, 91
  of complete TGA, 210–211, 211f–212f
  of congenitally corrected TGA, 220–221
  contrast, 91
  of DCM, 331–332, 332f–333f
  of DORV, 278–279, 278f
of Ebstein’s anomaly, 264–265, 265f
of ECD, 176–177, 177f–178f, 180–181
fetal, 91–92, 91b
of HCM, 324–326, 325f–326f
of infective endocarditis, 344–345, 344f
intravascular, 92
of mitral regurgitation, 380
of mitral stenosis, 376–377
M-mode, 86–87, 86f, 608t
    measurements derived from, 602t
of MVP, 385–386
of myocarditis, 351
normal values for, 601–610
of PAPVR, 183
of PDA, 169–170, 169f
    in preterm neonates, 169f, 173
of pericarditis, 353, 353f
of persistent truncus arteriosus, 269–270
of polysplenia syndrome, 286
of PS, 185–186
of pulmonary artery stenosis, 302
of pulmonary atresia with intact ventricular septum, 254
of single ventricle, 273–274
for systemic hypertension, 471–472, 472t
of TAPVR, 240
of TOF, 225–226, 226f
transesophageal, 92, 609f
of tricuspid atresia, 244–245
two-dimensional, 77–79
    apical views on, 79f, 83
measurements derived from, 604t–605t, 607t
parasternal views on, 78f, 79
quantitative values derived from, 85–86
subclavicular views on, 82f, 85
subcostal views on, 80f–81f, 84
suprasternal views on, 81f, 84–85
of vascular ring, 311
ventricle localization using, 315
of VSD, 164f–166f, 165–166
Ectopia cordis, 298
Ectopic atrial tachycardia, 411–412, 411f, 414, 416
Edecrin, See Ethacrynic acid
Edema, pulmonary, pulmonary hypertension and, 483
Edwards SAPIEN valve, 116, 235
Edward’s syndrome, 11t–14t
Ehlers-Danlos syndrome, 11t–14t
    athletic participation with, 564t
Eisenmenger’s syndrome, 127–129, 162, 171
    chest pain due to, 498, 499t
Ejection click, 27–28, 27f
    in AS, 189f, 190
    in COA, 200f, 201
    in PS, 185, 185f
    in TOF, 224–225, 224f
Ejection fraction, 87
Ejection systolic murmurs, 28–30, 29f
    in ASD, 156
    in COA, 200f, 201
    in obstructive lesions to ventricular output, 131–133, 132f
    in PS, 185, 185f
in TAPVR, 151–152, 238–239, 239f
in TGA, 220
in TOF, 145–146, 146f, 224–225, 224f

Electrocardiography (ECG)

of AS, 190, 190f
of aortic regurgitation, 382
of ASD, 156, 156f
of asplenia syndrome, 283
for athletes, 556
  with cardiac arrhythmias, 566
atria localization using, 314, 315f
atrial hypertrophy on, 53–54, 53f
basic measurements and normal/abnormal values on
  heart rate, 46–47, 46f–47f
  intervals, 49–51, 50f, 50t–51t
  P-wave duration and amplitude, 51
  QRS amplitude, R/S ratio, and Q waves, 51–53, 52t–53t
  QRS axis, T axis, and QRS-T angle, 47–49, 48f, 49t
  rhythm, 45–46, 46f
  ST segment and T waves, 53
of cardiac pacemakers, 440–441
of COA, 197, 197f, 201
of complete TGA, 209–210, 210f
of congenitally corrected TGA, 220, 220f
of cyanotic neonate, 206–207, 207b
of DCM, 331
of Ebstein’s anomaly, 264, 264f
of ECD, 176, 176f, 180
electrolyte disturbances on, 65–66, 65f–66f
of HCM, 324, 325f
long-term recording of, 103
  event recorders, 104–105
findings in normal children, 103–104
  Holter recording, 103–104
implantable loop recorders, 105
indications for, 103
  interpretations of, 103
of mitral regurgitation, 379
of mitral stenosis, 376
of MVP, 385, 385f
of myocarditis, 350
of PAPVR, 182
of PDA, 169
  pediatric compared with adult, 44–45, 44f–45f
of pericarditis, 353
of persistent truncus arteriosus, 269
of polysplenia syndrome, 286, 286f
of PS, 185
of pulmonary atresia, 150–151, 150f
of pulmonary atresia with intact ventricular septum, 254
of single ventricle, 273
stress testing monitoring with, 96
  ST-segment changes on, 62–66
    nonpathologic ST-segment shift, 62, 62f–63f
    pathologic ST-segment shift, 62–63, 62f
for systemic hypertension, 471, 472t
of TAPVR, 239
of TOF, 225
of tricuspid atresia, 148–149, 244, 244f
T-wave changes on, 53t, 62–66, 63f–65f, 64t
12-lead scalar, information available on, 43–44, 43f
of vascular ring, 310
vectorial approach to, 41–44
  hexaxial reference system, 41–42, 42f
  horizontal reference system, 42f, 43
ventricle localization using, 315, 316f
ventricular conduction disturbances on, 57–62
  intraventricular block, 51t, 57–62, 58f
  LBBB, 60
  preexcitation, 51t, 57–62, 58f, 61f
  RBBB, 51t, 58–59, 58f–59f
  ventricular hypertrophy vs., 61–62, 61f
ventricular hypertrophy on, 52t, 54–57, 54f, 56f–57f
  ventricular conduction disturbances vs., 61–62, 61f
of VSD, 163, 163f
Electrolyte disturbances, ECG of, 65–66, 65f–66f
Electromagnetic interference (EMI), 445–446
Ellis-van Creveld syndrome, 11t–14t
Embolism, pulmonary, chest pain due to, 498
EMI, See Electromagnetic interference
Enalapril (Vasotec), 613t–634t
  for CHF, 463, 463t
  for DCM, 333
  for HCM, 328
  for Marfan’s syndrome, 396
  for systemic hypertension, 476t, 477
Encephalopathy, hypertensive, 481
Endocardial cushion defect (ECD)
  See also Complete ECD; Partial ECD
CHF due to, 451
differential diagnosis of, 32t, 33f
pathophysiology of, 129–130, 130f
Endocardial fibroelastosis, 334–335
   CHF due to, 452
Endocarditis, See Infective endocarditis
Endocrinopathy, CHF due to, 452
Endomyocardial biopsy, for cardiac transplantation, 578–579
Endothelin receptor antagonists, for pulmonary hypertension, 493
Endovascular stents, 114
End-to-end anastomosis, for COA, 199, 200f, 203
Endurance time, stress testing of, 97–98, 97–98, 98t
Energy balance, 543, 543f
Enoxaparin (Lovenox), 613t–634t
Enterococcus-caused native valve endocarditis, antibiotics for, 347
Epibrdial pacing, 444–445
Epilepsy, syncope vs., 514
Epinephrine (Adrenalin), 613t–634t
   for CHF, 459, 459t
   for ventricular fibrillation, 428
Epinephrine test, for long QT syndrome, 432
Epirubicin, cardiomyopathy caused by, 336
Epoprostenol, for pulmonary hypertension, 493
Ergocalciferol, for DiGeorge syndrome, 393
Erythema chronicum migrans, 363
Erythema marginatum, acute rheumatic fever causing, 369
Erythromycin
   for acute rheumatic fever, 371, 374
   for asplenia syndrome, 284
   ECG effects of, 51
Esidrix, See Hydrochlorothiazide
Esmolol (Brevibloc), 613t–634t
  
  for pharmacologic stress testing, 102

Esophagitis, chest pain with, 497

Essential hypertension, 466–467
  
  follow-up evaluation for, 477
  
  management of, 473–477, 475t–476t

Estrogen, history of maternal use of, 3

Ethacrynic acid (Edecrin), 613t–634t
  
  for CHF, 453f, 458
  
  for myocarditis, 351

Event recorders, 104–105

Exercise
  
  aerobic, 558
  
  anaerobic, 558
  
  dynamic, 557f, 558
  
  for obesity, 546
  
  sports classification for, 557–558, 557f
  
  static, 557f, 558

Exercise intolerance, history of, 5

Exercise stress testing, 96
  
  alternative protocols for, 101–102
  
  for athletes, 566
  
  cardiovascular response to, 96–97
  
  contraindications to, 101
  
  indications of, 101
  
  for long QT syndrome, 432
  
  monitoring during, 97–100, 98t–99t, 99f
  
  for premature ventricular contraction, 423
  
  for pulmonary hypertension, 490
  
  safety of, 100–101
termination of, 101
treadmill protocols for, 97–101, 98t–99t, 99f
for VT, 426–427
Exercise-induced asthma, 497, 503
Exercise-induced bronchospasm provocation, 102
Exercise-related syncope, 509
Extracardiac sounds, auscultation of, 28
Eyelids, puffy, history of, 5
Ezetimibe (Zetia, Ezetrol), 536–537, 537t
Fabry disease, HCM in, 330
Fallot type DORV, 276–277, 277f, 279–280, 281f
Familial combined hyperlipidemia (FCH), 530
Familial hypercholesterolemia (FH), 529, 529t
Familial hypertriglyceridemia, 530–531
Familial hypoalphalipoproteinemia, 531
Family history, 4b, 7–8
Fasting lipid profile (FLP), 532–533, 532b
FCH, See Familial combined hyperlipidemia
Feeding, for CHF, 457, 457t
Feeding pattern, history of, 4
Fetal alcohol syndrome, 11t–14t
Fetal circulation, 119–120, 120f
Fetal echocardiography, 91–92, 91b
Fetal trimethadione syndrome, 11t–14t
Fetal warfarin syndrome, 11t–14t
FH, See Familial hypercholesterolemia
Fibric acid derivatives, 536–546, 537t
   for low HDL syndrome, 542
   triglycerides and, 541
Fibroma, cardiac, 387–389, 390f, 391
Fick formula, 108
First heart sound (S1), auscultation of, 25
First-degree atrioventricular block, 436, 437f
Five-chamber apical view, 79f
Flecainide (Tambocor), 613t–634t
Florinef, See Fludrocortisone
Flow, cardiac catheterization measurement of, 108–109
FLP, See Fasting lipid profile
Fludrocortisone (Florinef, Fluohydrisone), 514, 613t–634t
Fluvastatin (Lescol), 539
Fontan operation, postoperative, athletic participation with, 561t
Fontan-type operation
  complications of
    early, 249–250
    late, 250
  for congenitally corrected TGA, 223
  for Ebstein’s anomaly, 266–267
  evolution of, 251–252, 252f
  for HLHS, 259–262
  postoperative medical follow-up for, 250–251
  for pulmonary atresia with intact ventricular septum, 256–257
  results of, 250
  for single ventricle, 275
  for tricuspid atresia, 245
    complications of, 249–250
    evolution of, 251–252, 252f
    medical follow-up with, 246, 246b, 248, 250–251
    results of, 250
    stage 1 operation for, 246, 246b
    stage 2 operation for, 246b, 247–248, 247f
    stage 3 operation for, 246b, 247f, 248–249, 249f
Food groups, serving size of various, 598t
Foramen ovale
  See also Patent foramen ovale
    closure of, 121
    in fetal circulation, 119, 120f
Forehead, inspection of, 16
Foreign bodies, chest pain with, 497
Four-chamber apical views, 79f, 83
Fourth heart sound (S4), auscultation of, 27, 27f
Fractional shortening, 87
Frank-Starling law, 453–454, 453f
Free fatty acids, 523–524
  metabolism of, 524, 525f
Friedreich’s ataxia, 11t–14t
  cardiovascular involvement in, 393–394
Functional classification, of New York Heart Association, 582t
Functional heart murmurs, See Innocent heart murmurs
Fungal IE, 348
Fungal infection, after cardiac transplantation, 578–579
Furosemide (Lasix, Furomide), 613t–634t
  for acute rheumatic fever, 372
  for cardiovascular involvement in acute glomerulonephritis, 392
  for CHF, 453f, 458
  for DCM, 333
  for hypertensive crisis, 482
  for myocarditis, 351
  for PDA, 173
Fusion beats, 421, 421f
Gallop rhythm, auscultation of, 27

Gamma globulin
  for Kawasaki’s disease, 359–360
  for myocarditis, 351

Gastroesophageal reflux disease (GERD), chest pain with, 497, 503

Gastrointestinal causes, of chest pain, 496b, 497, 503

Gastrointestinal system, malformations of, 15t

Gengraf, See Cyclosporine

Genitourinary system, malformations of, 15t

Gentamicin, for infective endocarditis, 346–348

GERD, See Gastroesophageal reflux disease

Gestational history, 3–4, 4b

Gianturco vascular occlusion coils, 115, 171

Glomerulonephritis, cardiovascular involvement in, 392

Glucose, fasting, in metabolic syndrome, 522–523, 522b

Glucose intolerance, 544

Glycogen storage disease II, 11t–14t

Goldenhar syndrome, 11t–14t

Goose-neck deformity, in ECD, 174, 177, 178f, 180

Gore-Tex interposition shunt, for TOF, 228–229, 228f

Gout, cyanosis causing, 141

Great arteries
  chest roentgenography evaluation of, 70–71, 71f
  localization of, 316, 316f

Group A streptococcal infection, evidence of, for rheumatic fever diagnosis, 370

Growth charts, 599f–600f

Growth pattern, physical examination of, 9
H
HACEK IE, antibiotics for, 348
Haloperidol, for acute rheumatic fever, 372
Harada score, 359
HCM, See Hypertrophic cardiomyopathy
HDL, See High-density lipoprotein
Head-up tilt table test, 507f, 512–513
Heart, block diagram of, 124, 125f
Heart block, See Atrioventricular block
Heart murmurs
  in AS, 189f, 190
  acute rheumatic fever causing, 368, 370
  in aortic regurgitation, 136, 381–382, 381f
  in ASD, 124–125, 156, 156f
auscultation of, 25, 28
  continuous murmurs, 35f, 36
  diastolic murmurs, 35, 35f
  innocent murmurs, 36–39, 36t, 37f
  intensity, 28
  systolic murmurs, 28–30, 29f, 31t–33t, 33f
classification of, 28
  in COA, 197, 200f, 201
  in complete TGA, 209, 209f
  in Ebstein’s anomaly, 264, 264f
  in ECD, 129, 176, 176f
history of, 5
  infective endocarditis causing, 343
  in mitral regurgitation, 135, 379, 379f
  in mitral stenosis, 134, 376, 376f
  in MVP, 384–385, 384f
myocarditis causing, 350
in obstructive lesions to ventricular output, 131–133, 132f
in PAPVR, 182
in PDA, 169–171, 169f
  in preterm neonates, 172
in persistent truncus arteriosus, 269
in PS, 185, 185f
in pulmonary atresia with intact ventricular septum, 254
in pulmonary regurgitation, 136
in single ventricle, 273
in TAPVR, 151–152, 238–239, 239f
in TGA, 220
in TOF, 145–146, 146f, 224–225, 224f
in TOF with absent pulmonary valve, 236
in tricuspid atresia, 150, 243
in tricuspid regurgitation, 135–136
in tricuspid stenosis, 135
of VSD, 127–128, 162–163, 162f
Heart rate
  auscultation of, 25
  ECG measurement of, 46–47, 46f–47f
    normal, 407, 408t
    stress testing response of, 96
Heart regularity, auscultation of, 25
Heart size, chest roentgenography of, 67, 68f
Heart sounds, auscultation of, 25–28, 25f, 26b, 27f
Heath-Edwards grading, 487, 487f
Helex septal occluder, 115, 158–159
Hemi-Fontan operation
  for HLHS, 261
for single ventricle, 275
for tricuspid atresia, 246b, 247–249, 247f, 249f
Hemitruncus arteriosus, 298–299, 298f
Hemodynamic calculations, routine, 108–109
Hemodynamic values, normal, 108, 109f
Hemoglobin dissociation curve, cyanosis and, 139–140, 140f
Hemoglobin levels, cyanosis occurrence and, 137, 138f
Heparin, 613t–634t
  for atrial fibrillation, 414
Hepatic steatosis, 544
Hereditary disease, family history of, 7
Hereditary hemorrhagic telangiectasia, 11t–14t
Hereditary syndromes, inspection of, 10, 11t–15t
Herpes zoster, chest pain due to, 498
Heterotaxia, 280–281, 282t
  See also Asplenia syndrome; Polysplenia syndrome
Hexaxial reference system, for vectorial approach to ECG, 41–42, 42f
Hib immunization, for asplenia syndrome, 284
High-density lipoprotein (HDL), 524
  lifestyle changes and, 540
  low HDL syndrome, 531, 541–542
    hypertriglyceridemia and, 542
    treatment of, 541–542
  measurement of, 526–527
  in metabolic syndrome, 521–531, 521b–522b
  metabolism of, 524–525, 525f
  nascent, 526
History taking
  family history, 4b, 7–8
  gestational and natal history, 3–4, 4b
postnatal history, 4–7, 4b
HIV infection, See Human immunodeficiency virus infection
HLHS, See Hypoplastic left heart syndrome
HMG-CoA reductase inhibitors, See Statins
HOCM, See Hypertrophic obstructive cardiomyopathy
Holosystolic heart murmurs, 29f, 30
Holter monitoring
  for long QT syndrome, 432
  for VT, 426–427
Holter recording, 103–104
Holt-Oram syndrome, 11t–14t
Homocystinuria, 11t–14t
Horizontal reference system, for vectorial approach to ECG, 42f, 43
Human immunodeficiency virus (HIV) infection
  clinical manifestations of, 365–366
  management of, 366
  prognosis of, 366
Human ventricular myocyte, action potential of, 585f
Hunter’s syndrome, 11t–14t
Hurler’s syndrome, 11t–14t
Hutchinson-Gilford syndrome, 11t–14t
Hybrid operation, for HLHS, 259–262, 262f
Hydralazine (Apresoline), 613t–634t
  for CHF, 463, 463t
  for hypertensive crisis, 482
  for systemic hypertension, 476t, 477
Hydraulic resistance, 109
Hydrochlorothiazide (HydroDIURIL, Esidrix, Hydro-Par, Oretic), 613t–634t
  for CHF, 453f, 458
  for systemic hypertension, 475, 476t
Hyperactive precordium, palpation of, 18
Hyperaldosteronism, 478, 478t
Hypercalcemia, ECG response to, 65, 65f
Hypercholesterolemia
  familial, 529, 529t
  management of, 534–539, 534f, 535t, 536b, 537t
  with obesity, 544
  primary, 529–531, 529t
Hypercyanotic spells, See Hypoxic spells
Hyperkalemia, ECG response to, 65–66, 66f
Hyperkinetic pulmonary hypertension, 484b, 485, 487, 487f
Hyperlipidemia, familial combined, 530
Hyperlipoproteinemia, type III, 531
Hyperoxitest, 138–139, 139f, 207–208, 207b
Hyperstat, See Diazoxide
Hypertension, 465, 465t
  accelerated malignant, 481
  curable forms of, 477–478, 478t
  family history of, 8
  in metabolic syndrome, 521b–522b
  pre-, 465, 465t
    athletes with, 570–571
  renoparenchymal, 471
  renovascular, See Renovascular hypertension
  systemic, See Systemic hypertension
  white-coat, 465–466, 478–479
    athletes with, 570–571
Hypertensive crisis, 481–482
Hypertensive emergencies, 481
Hypertensive encephalopathy, 481
Hypertensive urgencies, 481
Hyperthyroidism, cardiovascular involvement in, 394
Hypertriglyceridemia, 539–541
  carbohydrate-induced, 540
  familial, 530–531
  low HDL syndrome and, 542
  management of, 539–541, 540f
  with obesity, 544
Hypertrophic cardiomyopathy (HCM), 322f
  in athletes, 325, 554, 554t, 563, 564t
  chest pain due to, 499t, 500
  clinical characteristics of, 323t
  clinical manifestations of, 324–326, 325f–326f
  in Fabry disease, 330
  in infants of mothers with diabetes
    clinical manifestations of, 329–330
    management of, 330
    pathology of, 329, 329f
    prevalence of, 328
  management of, medical, 326–328
  natural history of, 326
  pathology and pathophysiology of, 321–324, 323f–324f
  in Pompe disease, 330
  syncope with, 510
Hypertrophic obstructive cardiomyopathy (HOCM), 321–322
  chest pain due to, 499t
  differential diagnosis of, 32t–33t, 33f
  syncope due to, 510
Hyperuricemia, cyanosis causing, 141
Hyperventilation
chest pain due to, 498
syncope vs., 515
Hypoalphalipoproteinemia, familial, 531
Hypocalcemia, ECG response to, 65, 65f
Hypochloremic alkalosis, 459
Hypoglycemia, syncope vs., 514–515
Hypokalemia, 459
ECG response to, 65–66, 66f
Hypoplasia of pulmonary artery, chest roentgenography of, 71, 71f
Hypoplastic left heart syndrome (HLHS)
clinical manifestations of, 258–259, 259f
management of, 259–262, 260f, 262f–263f
natural history of, 259
pathology of, 258
pathophysiology of, 258
prevalence of, 258
Hypotension, orthostatic, 507–508, 507f
Hypothyroidism, cardiovascular involvement in, 394–395, 395f
Hypoxemia, See Cyanosis
Hypoxic spells
cyanosis causing, 141
history of, 4–5
in TOF, 147–148, 148f, 227–228
Hysteria, syncope vs., 515
Ibuprofen (NeoProfen), 613t–634t
   for costochondritis, 503
   ductus arteriosus closure and, 123
   for PDA, 173–174
   for postpericardiotomy syndrome, 364
Ibutilide, for atrial flutter, 413
ICD, See Implantable cardioverter-defibrillator
Idarubicin, cardiomyopathy caused by, 336
Idiopathic dilatation of pulmonary artery, 299
Idiopathic hypertrophic subaortic stenosis (IHSS), 188f, 189
   differential diagnosis of, 32t–33t, 33f
IDL, See Intermediate-density lipoprotein
IE, See Infective endocarditis
IHSS, See Idiopathic hypertrophic subaortic stenosis
Imaging, See Noninvasive imaging
Imipramine, ECG effects of, 51
Immune globulin, for HIV infection, 366
Immunization
   for asplenia syndrome, 284
   for Lyme disease, 364
Immunosuppressive therapy, for cardiac transplantation, 576–578, 577t, 580
Implantable cardioverter-defibrillator (ICD), 440, 445–448
   electromagnetic interference with, 445–446
   follow-up for, 447–448
   for HCM, 328
   inappropriate shocks with, 445
   indications for, 445, 446b
   living with, 445–447
   for long QT syndrome, 434
Implantable loop recorders, 105
Imuran, See Azathioprine
Inamrinone (Inocor), 613t–634t
Incisional intraatrial reentrant tachycardia, 413
Incomplete right bundle branch block (IRBBB), 59–60
Incomplete vascular ring, 307
Inderal, See Propranolol
Indomethacin (Indocin), 613t–634t
  ductus arteriosus closure and, 123
  for PDA, 171, 173
  for postpericardiotomy syndrome, 364
Infants, See Neonates
Infections
  See also Cardiovascular infections
  after cardiac transplantation, 578–579, 578t
  maternal, history of, 3
  respiratory, history of, 5
Infective endocarditis (IE)
  clinical manifestations of, 343–345, 344f
  diagnosis of, 345–346, 346b–347b
  management of, 346–348
  microbiology of, 343
  pathogenesis of, 342
  pathology of, 342–343
  prevalence of, 342
  prevention of, 348–350, 349b, 349t
  prognosis of, 348
Inferior vena cava (IVC)
  anomalies of, 305–306, 306f
  in fetal circulation, 119, 120f
Inflammation, in metabolic syndrome, 521–522
Infliximab, for Kawasaki’s disease, 360
Informed consent, for cardiac transplantation, 574
Infracardiac TAPVR, 151, 238, 238f, 240–241, 241f
Infrapulmonary interruption of IVC, 305–306, 306f
Infundibular PS, 184, 185f
Infundibular septum defects, See Outlet septum defects
Inhalation nitric oxide (iNO), for persistent pulmonary hypertension of newborn, 289
Inlet septum defects, 160–162, 161f, 164f–165f, 165
Innocent heart murmurs, auscultation of, 36–37
  carotid bruit, 36t, 37f, 38–39
  classic vibratory murmur, 36t, 37, 37f
  pulmonary flow murmur of newborn, 36t, 37f, 38
  pulmonary flow murmur of older children, 36t, 37–38, 37f
  venous hum, 36t, 37f, 38
Innominate artery, anomalous, 308, 308f, 311–312
iNO, See Inhalation nitric oxide
Inocor, See Inamrinone
Inotropes
  for AS, 192
  for COA, 198
    for Ebstein’s anomaly, 266
    for myocarditis, 351
Inotropic agents, for CHF, 453f, 459, 459t
Inspection
  for acanthosis nigricans, 16
  of chest, 16
  for chromosomal syndromes, 9–10, 11t–14t
    of clubbing, 10, 15f
  of color, 10
of general appearance and nutritional state, 9
for hereditary and nonhereditary syndromes and system malformations, 10, 11t–15t
of respiratory rate, dyspnea, and retraction, 15
for sweat on forehead, 16
Insulin resistance, in metabolic syndrome, 521–523
Intermediate-density lipoprotein (IDL), 525, 525f
Interrupted aortic arch
  clinical manifestations of, 204
  management of, 204–205
  pathology of, 204, 204f
  prevalence of, 204
Interrupted IVC with azygos continuation, 305–306, 306f
Intervals, ECG measurement and normal/abnormal values of, 49–51, 50f, 50t–51t
Interventional cardiac catheterization, 113
  balloon and blade atrial septostomy, 113, 213
  balloon angioplasty, 114–115, 199, 201–202, 302
  balloon valvuloplasty, 110f, 113–114, 186–187, 192–193
  closure techniques, 115
  percutaneous valve replacement, 116
Intracardiac pressures
  Doppler echocardiography of, 88–89
  normal, 108, 109f
Intrapulmonary tunnel operation, for ALCAPA syndrome, 292, 292f
Intravascular echocardiography, 92
Intravascular pressures, Doppler echocardiography of, 88–89
Intraventricular block
  athletic participation with, 566–570, 569t
  ECG of, 51t, 57–62, 58f
Intraventricular septum (IVS), thickness of, 602t
Intropin, See Dopamine
Invasive procedures, 108
  cardiac catheterization and angiocardiography, 108–113, 109f–110f
  catheter intervention procedures, 110f, 113–116
IRBBB, See Incomplete right bundle branch block
Ischemia, See Myocardial ischemia
Isochronicity, 423
Isometric exercise, 96
Isoproterenol (Isuprel), 613t–634t
  for CHF, 459, 459t
  for sinus node dysfunction, 410
  stress testing with, 102
Isoptin, See Verapamil
Isosorbide dinitrate, for CHF, 463, 463t
Isotonic exercise, 557f, 558
Isradipine (DynaCirc), for systemic hypertension, 476t
Isuprel, See Isoproterenol
IVC, See Inferior vena cava
IVS, See Intraventricular septum
J-depression, 62, 62f–63f
Jervell and Lange-Nielsen syndrome, 11t–14t, 429, 429t
JET, *See* Junctional ectopic tachycardia
Joint symptoms, history of, 7
Jones criteria, 367, 368b, 370–371
JT interval, ECG measurement and normal/abnormal values of, 50f, 51
Junctional ectopic tachycardia (JET), 414, 418f, 419–420
Junctional escape beats, 418–419, 418f
  athletic participation with, 566, 567t–569t
Junctional premature beats, 418, 418f
Junctional rhythm, 418f, 419
  accelerated, 419
  athletic participation with, 566, 567t–569t
Junctional tachycardia, athletic participation with, 566, 567t–569t
Kabikinase, See Streptokinase
Kalcinat, See Calcium gluconate
Kartagener’s syndrome, 11t–14t, 299
Kawasaki’s disease
  athletic participation with, 559, 562t
  cause and epidemiology of, 354–355
  chest pain due to, 499t, 500
  clinical manifestations of, 355–358, 355b, 357f
  diagnosis of, 355b, 358–359
  differential diagnosis of, 359, 359b
  long-term follow-up of, 361, 362t
  management of, 359–360
  natural history of, 360–361
  pathology of, 355
Kayexalate, See Sodium polystyrene sulfonate
Kearns-Sayre syndrome, 337–338
Ketamine (Ketalar), 613t–634t
  for invasive procedure sedation, 112
  for TOF hypoxic spells, 148, 227
Ketorolac (Toradol), 613t–634t
Kionex, See Sodium polystyrene sulfonate
L

LA, See Left atrium

Labetalol (Normodyne, Trandate), 613t–634t
  for hypertensive crisis, 481

LAD, See Left axis deviation

LAH, See Left atrial hypertrophy

Lanoxin, See Digoxin

Laplace law, 454

Lasix, See Furosemide

Late diastolic murmurs, 35, 35f

Late systolic heart murmurs, 29f, 30

LBBB, See Left bundle branch block

LCAT, See Lecithin-cholesterol acyltransferase

LDL, See Low-density lipoprotein

Leads, for cardiac pacemakers, 444–445

Lecithin-cholesterol acyltransferase (LCAT), 525f, 526

Left atrial body surface area, 602t

Left atrial enlargement, chest roentgenography of, 69, 69f

Left atrial hypertrophy (LAH)
  ECG of, 53f, 54
  mitral regurgitation causing, 135
  mitral stenosis causing, 134, 134f

Left atrium (LA)
  IVC connecting to, 306, 306f
  persistent left SVC draining into, 305, 305f

Left axis deviation (LAD), 49, 49

Left bundle branch block (LBBB)
  athletic participation with, 566–570, 569t
  ECG of, 60

Left cardiac sympathetic denervation, for long QT syndrome, 434
Left coronary artery
  anomalous origin of, chest pain due to, 499t, 500
  measurement of, 607t
Left coronary artery implantation, for ALCAPA syndrome, 292
Left pulmonary artery, anomalous, 308f, 309, 310f, 311–312
Left subclavicular view, 82f, 85
Left ventricle (LV), in fetus, 120, 120f
Left ventricular diastolic dimension, 602t
Left ventricular enlargement, chest roentgenography of, 70, 70f
Left ventricular hypertrabeculation, See Noncompaction cardiomyopathy
Left ventricular hypertrophy (LVH)
  in aortic regurgitation, 136
  due to hypertension, 473–474
  ECG of, 49t, 52t, 56, 57f
  mitral regurgitation causing, 135
  in obstructive lesions to ventricular output, 132–133, 132f
  in pulmonary atresia, 150–151, 150f
  in tricuspid atresia, 148–149
Left ventricular mass
  by body surface area, 609t
  echocardiography of, 77, 85, 608t
Left ventricular noncompaction, See Noncompaction cardiomyopathy
Left ventricular posterior wall (LVPW), thickness of, 602t
Left ventricular systolic dimension, 602t
Left ventricular systolic function, echocardiography of, 87
Left-to-right shunts, 124, 125f
  ASD, See Atrial septal defect
  athletic participation with, 558
  ECD, See Endocardial cushion defect
  PAPVR, See Partial anomalous pulmonary venous return
PDA, See Patent ductus arteriosus
pulmonary hypertension due to, 484b, 485, 487, 487f
VSD, See Ventricular septal defect
LEOPARD syndrome, 11t–14t
Lescol, See Fluvastatin
Levarterenol, See Norepinephrine
Levophed, See Norepinephrine
Levotransposition of the great arteries (L-TGA), 316, 316f
clinical manifestations of, 219–221, 220f–221f
management of, 221–223, 222f
natural history of, 221
pathology of, 219, 219f
pathophysiology of, 142–144, 142f–143f
prevalence of, 218
Lidocaine (Xylocaine), 613t–634t
for ventricular fibrillation, 428
for VT, 426
Lipid triad, 521–522
Lipid-lowering drugs, 536–537, 537t
Lipids
biochemistry of, 523–524
measurement of, 526–527
metabolism of, 524–526, 525f
normal levels of, 527, 527t–528t
screening of, 531–534
application of, 533–534
current recommendations for, 531–534, 532b–533b
past recommendations for, 531
Lipitor, See Atorvastatin
Lipoprotein lipase (LPL), 524, 525f
Lipoproteins
  biochemistry of, 523–524
  disorders of, primary, 529–531, 529t
  measurement of, 526–527
  in metabolic syndrome, 521–523
  metabolism of, 524–526, 525f
  normal levels of, 527, 527t–528t
Lisinopril (Zestril, Prinivil), 613t–634t
  for muscular dystrophy, 397–398
  for systemic hypertension, 476t, 477
Lithium, history of maternal use of, 3
Liver, on chest roentgenography, 72, 72f
Long QT syndrome (LQTS), 11t–14t, 428–429
  acquired, 434
  athletic participation with, 566, 567t–569t
  causes of, 429–430, 429t
  clinical manifestations of, 430–431, 430f
  congenital, 433–434
  diagnosis of, 424b, 431–433, 432t
  management of, 424b, 433–434
  pathophysiology of, 430
  prognosis of, 434
  syncope with, 510
Long-axis apical views, 79f, 83
Long-axis parasternal views, 78f, 79
Long-axis subcostal views, 78f, 80f–81f, 84
Long-axis suprasternal views, 81f, 84–85
Long-term ECG recording, 103
  event recorders, 104–105
  findings in normal children, 103–104
Holter recording, 103–104
implantable loop recorders, 105
indications for, 103
interpretations of, 103
Loniten, See Minoxidil
Loop diuretics, for CHF, 453f, 458
Looping memory event monitors, 104
Lopressor, See Metoprolol
Losartan (Cozaar), 613t–634t
   for systemic hypertension, 476t
Lovastatin (Mevacor), 539, 613t–634t
Lovaza, See Omega-3-acid ethyl ester
Lovenox, See Enoxaparin
Low HDL syndrome, 531, 541–542
   with obesity, 544
   treatment of, 541–542
Low-birth-weight infants, Holter monitor findings in, 104
Low-density lipoprotein (LDL), 524
   in familial combined hyperlipidemia, 530
   lifestyle changes and, 540
   measurement of, 526–527
   in metabolic syndrome, 521–531, 521b–522b
   metabolism of, 525, 525f
   small, dense, 524
   target, 534f
Low-density lipoprotein (LDL) receptors, in familial hypercholesterolemia, 529–531
Lower left sternal border, systolic heart murmurs at, 35, 32t, 33f
Lown-Ganong-Levine syndrome, 61
LPL, See Lipoprotein lipase
LQTS, See Long QT syndrome
L-TGA, See Levotransposition of the great arteries

Lung transplantation, for pulmonary hypertension, 494

LV, See Left ventricle

LVH, See Left ventricular hypertrophy

LVPW, See Left ventricular posterior wall

Lyme carditis

  cause and pathology of, 361–363

  clinical manifestations of, 363

  diagnosis of, 363

  management of, 363–364

  prevalence of, 361

Lymphoproliferative disease, posttransplant, 580
Magnesium Biocorrodible Stent, 202
Magnesium sulfate
  for ventricular fibrillation, 428
  for VT, 426
Magnetic resonance imaging (MRI), 92–95, 93b
  of asplenia syndrome, 284
  of cardiac tumors, 391
  of COA, 198, 201
  of PAPVR, 183
  of polysplenia syndrome, 286
  of vascular ring, 311
  ventricle localization using, 315
Mahaim-type preexcitation syndrome, 61
Malignancy, after cardiac transplantation, 580
MAPCAs, See Multiple aortopulmonary collateral arteries
Marfan’s syndrome, 11t–14t
  athletic participation with, 564t, 565
  cardiovascular involvement in, 395–397
Mastalgia, chest pain due to, 498
Maternal conditions, history of, 4
Maternal diabetes, 11t–14t
  HCM caused by
    clinical manifestations of, 329–330
    management of, 330
    pathology of, 329, 329f
    prevalence of, 328
Maternal infections, history of, 3
Maternal medication or drug use, 3–4
McGoon ratio, 232
Mean BP value, 105
Mediastinum, chest roentgenography of, 74, 74f

Medications
  history of maternal use of, 3–4
  history of patient use of, 7
  in pediatric cardiology, 611t–613t
    dosages of, 613t–634t
Mee procedure, for TOF with pulmonary atresia, 233, 233f
Melody transcatheter pulmonary valve, 116, 235
Membranous septum defects, 160–162, 161f, 164f–166f, 165
Meningococcal conjugate vaccine, for asplenia syndrome, 284
Meperidine (Demerol), for invasive procedure sedation, 112
Mesocardia, 317–318, 317f
Metabolic syndrome, cardiovascular risk factors and, 521–523, 521b–522b
Methemoglobinemia, cyanosis caused by, 138
Methicillin, for infective endocarditis, 346–347
Methimazole (Tapazole), for cardiovascular involvement in hyperthyroidism, 394
Methyldopa (Aldomet), 613t–634t
Methylprednisolone, for cardiac transplantation, 577–578, 577t
Metolazone (Zaroxolyn, Diulo, Mykrox), 613t–634t
Metoprolol (Lopressor), 613t–634t
  for CHF, 464
  for DCM, 336
  for HCM, 327
  for muscular dystrophy, 397–398
  for syncope, 514
Mevacor, See Lovastatin
Mexiletine (Mexitil), 434, 613t–634t
MI, See Myocardial infarction
Micturition syncope, 509
Mid-diastolic murmurs, 35, 35f
  in ECD, 176, 176f
  in tricuspid stenosis, 135
Midsystolic click, 27f, 28
  in MVP, 384–385, 384f
Midsystolic heart murmurs
  in AS, 189f, 190
  auscultation of, 29–30, 29f
  in PS, 185, 185f
Midtrabecular septum defects, 160–162, 161f
Milrinone (Primacor), 613t–634t
Minipress, See Prazosin
Minoxidil (Loniten), 613t–634t
  for systemic hypertension, 476t, 477
Mitral mid-diastolic murmurs, 35
Mitral regurgitation (MR)
  athletic participation with, 562t–563t
  CHF due to, 452
  clinical manifestations of, 378–380, 379f
  differential diagnosis of, 33f, 33t
  management of, 380–381
  natural history of, 380
  pathology of, 378
  prevalence of, 378
  as valvular regurgitant lesion, 135, 135f
Mitral stenosis (MS)
  athletic participation with, 562t–563t
  clinical manifestations of, 376–377, 376f
  management of, 114, 377–378
  natural history of, 377
as obstructive lesion, 134–135, 134f
pathology and pathophysiology of, 375–376
prevalence of, 375
Mitral valve
cleft, 296
diameter of, 607t
on echocardiography, 77, 78f
parachute, 299
Mitral valve prolapse (MVP)
in ASD, 155
athletic participation with, 564t, 565
chest pain due to, 498–499, 499t
clinical manifestations of, 384–386, 384f–385f
differential diagnosis of, 33f, 33t
management of, 386
natural history of, 386
pathology of, 383–384
prevalence of, 383
Mitral valve repair, for mitral regurgitation, 380–381
Mitral valve replacement
for HCM, 328
for mitral regurgitation, 380–381
for mitral stenosis, 378
Mixed TAPVR, 238, 238f, 240
M-mode echocardiography, 86–87, 86f, 608t
measurements derived from, 602t
Mobitz type I AV block, 436–437, 437f
Mobitz type II AV block, 436–437, 437f
Modified BT shunt
for HLHS, 260, 260f
for TOF, 228–229, 228f
Monoclonal antibody to T3 lymphocytes (OKT3), for cardiac transplantation, 578
Monopartite pulmonary atresia, 253, 253f
Morphine, 613t–634t
   for invasive procedure sedation, 112
   for TOF hypoxic spells, 148, 227
Morquio’s syndrome, 11t–14t
Morrow’s myotomy–myectomy, for HCM, 327–328
MPS, See Mucopolysaccharidoses
MR, See Mitral regurgitation
MRI, See Magnetic resonance imaging
MS, See Mitral stenosis
Mucocutaneous lymph node syndrome, See Kawasaki's disease
Mucopolysaccharidoses (MPS), cardiovascular involvement in, 397
Mucopolysaccharidosis, 11t–14t
Multiple aortopulmonary collateral arteries (MAPCAs), in TOF with pulmonary atresia, 231
Multiple lentigines syndrome, 11t–14t
Murmurs, See Heart murmurs
Muscular dystrophy, 11t–14t
   cardiovascular involvement in, 397–398
Muscular septum defects, 160–162, 161f
Musculoskeletal causes, of chest pain, 496b, 497, 503
Mustard operation, for complete TGA, 213, 214f
MVP, See Mitral valve prolapse
Mycophenolate mofetil (CellCept), 613t–634t
   for cardiac transplantation, 577–578, 577t
Mykrox, See Metolazone
Myocardial bridging, athletic participation with, 564t, 565
Myocardial disease
   See also Cardiomyopathy
athletic participation with, 563–565, 564t

Myocardial infarction (MI)
- ECG changes in, 53t, 64–65, 64f–65f, 64t
- serum markers after, 585f
- syncope due to, 510

Myocardial ischemia
- chest pain due to, 498
- exercise-induced, 100
- syncope due to, 510

Myocarditis
- athletic participation with, 564t
- cause of, 350
- chest pain due to, 499t, 500
- CHF due to, 452
- clinical manifestations of, 350–351
- management of, 351–352
- natural history of, 351
- pathology of, 350
- prevalence of, 350

Myocyte, human ventricular, action potential of, 585f

Myotonic dystrophy, cardiovascular involvement in, 398

Myxoma, cardiac, 387–389, 390f, 391
Nafillin, for infective endocarditis, 346–348
Nakata index, 232
Naproxen, for cardiovascular involvement in rheumatoid arthritis, 399
NASPE, See North American Society of Pacing and Electrophysiology
Natal history, 3–4, 4b
National Cholesterol Education Program (NCEP), 521, 521
National High Blood Pressure Education Program (NHBPEP)
  blood pressure classification by, 465, 465t
  blood pressure levels of, by age and height percentiles, 586t–589t
  BP standards recommended by, 16, 18–19, 19f
Natriuretic peptides, in CHF, 455
NCEP, See National Cholesterol Education Program
Neo-Calglucon, See Calcium glubionate
Neonates
  See also Preterm neonates
  BP measurement in, 23, 23t
  Holter monitor findings in, 104
  physical examination of, 39–40
NeoProfen, See Ibuprofen
Neoral, See Cyclosporine
Neo-Synephrine, See Phenylephrine
Nephrectomy, 477
Nephritis, system hypertension with, 477, 478t
Neurally mediated syncope, 506–507, 507f–508f
Neurocardiogenic syndrome, 506–507, 507f–508f
Neurofibromatosis, 11t–14t
Neurologic symptoms, history of, 7
New York Heart Association, functional classification of, 582t
Newborns, premature, circulation of, 123
NHBPEP, See National High Blood Pressure Education Program
Niacin, See Nicotinic acid
Nicotine replacement, 550
Nicotinic acid (niacin, vitamin B₃), 536–546, 537t
    adverse effects of, 542
    for low HDL syndrome, 542
    triglycerides and, 541
Nifedipine (Procardia, Adalat), 613t–634t
    for hypertensive crisis, 482
    for pulmonary hypertension, 492
    side effects of, 492
    for systemic hypertension, 476t, 477
Nikaidoh procedure, 216–217, 217f, 280
Nipride, See Nitroprusside
Nitric oxide (NO)
    for persistent pulmonary hypertension of newborn, 289
    for pulmonary hypertension, 493
Nitroglycerine (Nitro-Bid, Tridil, Nitrostat), 613t–634t
    for CHF, 463, 463t
Nitroprusside (Nipride), 613t–634t
    for CHF, 463, 463t
    for hypertensive crisis, 481
Nitrostat, See Nitroglycerine
NO, See Nitric oxide
Noctec, See Chloral hydrate
Nocturnal dipping, 106
Nodal ectopic tachycardia, 416
Nodal escape beats, 418–419, 418f
Nodal premature beats, 418, 418f
Nodal reciprocating AV tachycardia, 415–416, 415f
Nodal rhythm, 418f, 419
Nodal tachycardia, 418f, 419–420
ectopic, 416
reciprocating AV, 415–416, 415f
Noncommitted VSD, 277–280, 281f
Noncompaction cardiomyopathy, 340–341, 341f
Nonfasting lipid profile (non-FLP), 532–533, 532b
Nonhereditary syndromes, inspection of, 10, 11t–15t
Noninvasive imaging, 77
ambulatory blood pressure monitoring, 105–107, 106t, 594t
CT, 92–95, 93b
echocardiography, 77–92
color-flow mapping, 91
contrast, 91
Doppler, 87–91, 88t, 89f–90f
fetal, 91–92, 91b
M-mode, 86–87, 86f, 608t
transesophageal, 92, 609f
two-dimensional, 77–85, 78f–82f
long-term ECG recording, 103
event recorders, 104–105
findings in normal children, 103–104
Holter recording, 103–104
implantable loop recorders, 105
indications for, 103
interpretations of, 103
MRI, 92–95, 93b
stress testing, 96
alternative protocols for, 101–102
cardiovascular response to, 96–97
contraindications to, 101
indications of, 101
monitoring during, 97–100, 98t–99t, 99f
safety of, 100–101
termination of, 101
treadmill protocols for, 97–101, 98t–99t, 99f
Nonlooping memory event monitors, 105
Nonpathologic ST-segment shift, 62, 62f–63f
Nonsteroidal antiinflammatory agents
  for cardiovascular involvement in rheumatoid arthritis, 399
  for postpericardiotomy syndrome, 364
Noonan syndrome, 11t–14t, 398–399
Norepinephrine (Levophed, Levarterenol), 613t–634t
Normodyne, See Labetalol
Norpace, See Disopyramide
North American Society of Pacing and Electrophysiology (NASPE), 443–444, 443t
Norvasc, See Amlodipine
Norwood operation, for HLHS, 259–262, 260f
N-terminal segment of tis prohormone (NT-ProBNT), in CHF, 455
Nutritional state, inspection of, 9
Obesity, 542–548
  cardiovascular disease and, 521–523
  evaluation of, 544–545
  health consequences of, 543–544
  hypertension due to, 466, 471
  management of, 545–548
    behavior modification, 547
    diet for, 545–546, 546b–547b
    early intervention and family involvement, 548
    physical activity, 546
  pathogenesis of, 543, 543f
  prevalence of, 543
Obligatory shunt, 130, 130f
Obstructive lesions
  athletic participation with, 558
  AV valve stenoses as, 134
    mitral stenosis, 134–135, 134f
    tricuspid stenosis, 135
  syncope due to, 510
  to ventricular output, 131, 132f
    aortic and pulmonary valve stenoses as, 131–132, 132f
    COA, 132–133, 133f
OKT3, See Monoclonal antibody to T3 lymphocytes
Omacor, See Omega-3-acid ethyl ester
Omega-3 fatty acids
  HDL levels and, 541
  triglycerides and, 540–541
Omega-3-acid ethyl ester (Lovaza, Omacor), 613t–634t
One and one-half ventricular repair, for pulmonary atresia with intact ventricular septum, 256–257
One-ventricular repair, See Fontan-type operation
Oretic, See Hydrochlorothiazide
Organ system malformations, inspection of, 10, 11t–15t
Organophosphates, ECG effects of, 51
Orthodromic reciprocating AV tachycardia, 415, 415f
Orthostatic hypotension, 507–508, 507f
Orthostatic intolerance, syncope due to, 505–506, 507f, 513–514
Os-Cal, See Calcium carbonate
Oscillometric BP measurement, 21–22, 466, 467t
Osler-Rendu-Weber syndrome, 11t–14t
Osteogenesis imperfecta, 11t–14t
Ostium primum defect, 155, 156f
  echocardiography of, 157–158, 157f
  surgical closure of, 160
Ostium secundum defect, 155, 156f
  echocardiography of, 157–158, 157f
  nonsurgical closure of, 158–159, 159f
  surgical closure of, 160
Outlet septum defects, 160–162, 161f, 164f–165f, 165
Overriding, in TGA, 209
Oxacillin, for infective endocarditis, 346–347
Oximetry, stress testing monitoring with, 100
Oxygen
  for complete TGA, 213
  ductus arteriosus closure and, 122
  for persistent pulmonary hypertension of newborn, 288–289
  for TOF hypoxic spells, 148, 227
Oxygen capacity, 109
Oxygen consumption, 109
  per body surface area, 583t
Oxygen saturation, 109
  in cyanosis, 137–140, 138b, 138f–140f
  in cyanotic congenital heart defects, 151f, 152
  of cyanotic neonate, 207b, 208
  normal values of, 108, 109f
Oystercal, See Calcium carbonate
P
P axis, on ECG, 45–46, 46f
P mitrale, See Left atrial hypertrophy
P pulmonale, See Right atrial hypertrophy
P wave–triggered ventricular pacemaker, 441, 441f
PA, See Pulmonary artery
PAC, See Premature atrial contraction
Pacemakers, See Cardiac pacemakers
Pain
  chest, See Chest pain
  history of, 5–6
Palliative shunt procedures, for TOF, 228–229, 228f
Palpation
  of chest, 17–18
  of peripheral pulses, 16–17, 17f
Palpitation, 516
  causes of, 516
  evaluation of, 516–519
  history of, 6–7, 516–518
  management of, 519
Papillary muscles, on echocardiography, 78f
PAPVR, See Partial anomalous pulmonary venous return
Parachute mitral valve, 299
Parasternal views, on two-dimensional echocardiography, 78f, 79
Paroxysmal atrial tachycardia (PAT), 415
Partial anomalous pulmonary venous return (PAPVR)
  clinical manifestations of, 182–183
  differential diagnosis of, 31t, 33f
  management of, 183
  natural history of, 183
pathology of, 182, 182f
pathophysiology of, 182
prevalence of, 181

Partial ECD
  clinical manifestations of, 129–130, 130f, 176f, 180–181
  management of, 181
  natural history of, 181
  pathology of, 174–175, 175f, 180
  prevalence of, 180

PAT, See Paroxysmal atrial tachycardia

Patau’s syndrome, 11t–14t

Patch aortoplasty, for COA, 199, 200f

Patent ductus arteriosus (PDA)
  athletic participation with, 560t
  CHF due to, 451
  clinical manifestations of, 128–129, 128f, 168–170, 169f
  closure techniques for, 115
  differential diagnosis of, 31t, 33f, 170–171
  management of, 171–172
  natural history of, 170
  pathology of, 168
  pathophysiology of, 128–129, 128f
  in preterm neonates
    clinical manifestations of, 169f, 172–173
    management of, 173–174
    pathophysiology of, 172
    prevalence of, 172
  prevalence of, 168
  in pulmonary atresia, 150
  in TGA, 211, 215, 218f
in TOF, 146
  with pulmonary atresia, 231
VSD with, 167
Patent foramen ovale (PFO), 299
  in pulmonary atresia, 150
  stroke vs., 300
  in TGA, 142–143
  in tricuspid atresia, 148–149
Pathologic ST-segment shift, 62–63, 62f
Pathological Determinants of Atherosclerosis in Youth Research Group, 521
PA-VSD, See Pulmonary atresia and ventricular septal defect
PBF, See Pulmonary blood flow
PDA, See Patent ductus arteriosus
Penicillin
  for acute rheumatic fever, 371–374
  for asplenia syndrome, 284
  for infective endocarditis, 346–347
Percutaneous alcohol septal ablation, for HCM, 328
Percutaneous valve replacement, 116
Pericardial defect, congenital, 300–301
Pericardial friction rub, 28, 352
Pericardial knock, 28
Pericarditis
  athletic participation with, 563–565, 564t
  cause of, 352
  chest pain due to, 499t, 500
  clinical manifestations of, 352–353, 353f
  constrictive, 354
  ECG changes in, 63, 63f
  management of, 353–354
pathology of, 352
pathophysiology of, 352
Perinatal circulation, 120–123, 121f–122f, 122b
Perindopril, for muscular dystrophy, 397–398
Peripheral amplification of systolic pressure, 23–24, 24f
Peripheral cyanosis, 137–138

See also Cyanosis
Peripheral pulses, palpation of, 16–17, 17f
Persantine, See Dipyridamole
Persistent left SVC, 304–305, 305f
Persistent pulmonary hypertension of newborn
clinical manifestations of, 288
management of, 288–289
pathology and pathophysiology of, 287–288, 287b
prevalence of, 287
prognosis of, 289
Persistent truncus arteriosus
clinical manifestations of, 269–270
management of, 270–272, 271f
natural history of, 270
pathology of, 268–269, 268f
pathophysiology of, 144–145, 144f
PDA compared with, 170
prevalence of, 268
PFO, See Patent foramen ovale
PGE₁, See Prostaglandin E₁
PGE₂, See Prostaglandin E₂
Pharmacologic stress protocols, 102
Phenergan, See Promethazine
Phenobarbital, for acute rheumatic fever, 372
Phentolamine (Regitine), 613t–634t
Phenylephrine (Neo-Synephrine), 613t–634t
  for TOF hypoxic spells, 148
Phenytoin (Dilantin), 613t–634t
  history of maternal use of, 3
Pheochromocytoma, 481
Phosphodiesterase inhibitor, for pulmonary hypertension, 493
Phospholipids, 523–524
Physical examination
  auscultation, 24–39, 25f, 26b, 27f, 29f, 31t–33t, 33f, 35f, 36t, 37f
  blood pressure measurement, 18–24, 19f, 21f–22f, 23t, 24f
  growth pattern, 9
  inspection, 9–16, 11t–15t, 15f
  of neonates, 39–40
  palpation, 16–18, 17f
Pierre Robin syndrome, 11t–14t
Pink TOF, See Acyanotic TOF
Piperacillin, for infective endocarditis, 348
Placenta, in fetal circulation, 119–120, 120f
Plavix, See Clopidogrel
Pleurodynia, chest pain due to, 498
PMI, See Point of maximal impulse
Pneumatothorax, spontaneous, chest pain due to, 498
Pneumococcal conjugate and polysaccharide vaccines, for asplenia syndrome, 284
Pneumocystis, after cardiac transplantation, 578–579
Pneumomediastinum, spontaneous, chest pain due to, 498
Point of maximal impulse (PMI), palpation of, 18
Polycystic ovary disease, 544
Polycythemia, cyanosis causing, 140–141
Polysplenia syndrome
cardiovascular malformations in, 282t, 285
clinical manifestations of, 285–286, 286f
management of, 286–287
natural history of, 286
pathology of, 283f, 285
pathophysiology of, 285
prevalence of, 285
Pompe disease, 330, 11t–14t
Posterior trabecular septum defects, 160–162, 161f
Postnatal history, 4–7, 4b
Postperfusion syndrome, 364–365
Postpericardiotomy syndrome
  chest pain due to, 499t, 500
  clinical manifestations of, 364
  management of, 364
Poststenotic dilatation, in obstructive lesions to ventricular output, 132–133, 132f
Postsurgical CHD patients, stress testing response in, 97
Posttransplant lymphoproliferative disease, 580
Postural hypotension, 507–508, 507f
Postural orthostatic tachycardia syndrome (POTS), 507f, 509
Potassium, ECG response to, 65–66, 66f
Potassium chloride, 613t–634t
Potassium gluconate, 613t–634t
POTS, See Postural orthostatic tachycardia syndrome
Potts operation, for TOF, 228f, 229
PR, See Pulmonary regurgitation
PR interval, ECG measurement and normal/abnormal values of, 49–50, 50f, 50t
Pravastatin (Pravachol), 539, 613t–634t
Prazosin (Minipress), 613t–634t
  for CHF, 463, 463t
Precordial catch, chest pain due to, 497
Prednisone
  for acute rheumatic fever, 372, 372t
  for cardiac transplantation, 577, 577t
  for cardiovascular involvement in rheumatoid arthritis, 399
Preexcitation, ECG of, 51t, 57–62, 58f, 61f
Pregnancy, with pulmonary hypertension, 492
Prehypertension, 465, 465t
  athletes with, 570–571
Preload, in CHF, 453–454
Premature atrial contraction (PAC), 410, 411f
  athletic participation with, 566, 567t–569t
Premature AV junctional complexes, athletic participation with, 566, 567t–569t
Premature infants, Holter monitor findings in, 104
Premature newborns, See Preterm neonates
Premature ventricular complexes (PVCs), athletic participation with, 566, 567t–569t
Premature ventricular contraction (PVC), 420–423, 420f–422f, 424b
  causes of, 422, 422f
  coupling interval of, 421–422
  management of, 423, 424b
  significance of, 422–423
  types of, 420–421, 421f
Preparticipation screening, for athletes, 554–557, 555b
Pressure gradients, Doppler echocardiography of, 88, 89f
Presystolic murmurs, 35, 35f
  in mitral stenosis, 134, 376, 376f
Preterm neonates
  circulation of, 123
  PDA in
    clinical manifestations of, 169f, 172–173
management of, 173–174
pathophysiology of, 172
prevalence of, 172
Prevalite, See Cholestyramine
Preventive cardiology, 550, 551t–552t
Primacor, See Milrinone
Primary hypertension, 466–467
  follow-up evaluation for, 477
  management of, 473–477, 475t–476t
Primary myocardial disease, See Cardiomyopathy
Prinivil, See Lisinopril
Priscoline, See Tolazoline
Procainamide (Procanbid, Pronestyl), 613t–634t
  for mitral stenosis, 377
  for MVP, 386
  toxicity effects of, 50, 60
Procardia, See Nifedipine
Progeria, 11t–14t
Progesterone, history of maternal use of, 3
Proglycem, See Diazoxide
Prograf, See Tacrolimus
Proinflammatory state, in metabolic syndrome, 521–522
Promethazine (Phenergan), for invasive procedure sedation, 112
Prominent main pulmonary artery segment, chest roentgenography of, 70, 71f
Pronestyl, See Procainamide
Propranolol (Inderal), 613t–634t
  for atrial fibrillation, 414
  for cardiovascular involvement in hyperthyroidism, 394
  for HCM, 327–328, 330
  for Marfan’s syndrome, 396
for MVP, 386
for sinus node dysfunction, 410
for systemic hypertension, 476, 476t
for TOF hypoxic spells, 148, 227–228
Propylthiouracil, for cardiovascular involvement in hyperthyroidism, 394
Prostacyclin, for pulmonary hypertension, 493
Prostaglandin E₁ (PGE₁, Prostin), 613t–634t
for cyanotic neonate, 207b, 208
for ductus arteriosus patency, 146, 150
  in AS, 192
  in asplenia syndrome, 284
  in COA, 198
  in complete TGA, 212
  in Ebstein’s anomaly, 266
  in HLHS, 259
  in interrupted aortic arch, 204–205
  in PS, 186–187
  in pulmonary atresia with intact ventricular septum, 255
  in single ventricle, 274
  in TOF with pulmonary atresia, 233
  in tricuspid atresia, 245
Prostaglandin E₂ (PGE₂), ductus arteriosus closure and, 122
Prosthetic conduits, stenosis of, balloon valvuloplasty for, 114
Prosthetic heart valves, athletic participation with, 562t–563t
Prostin, See Prostaglandin E₁
Protamine sulfate, 613t–634t
Prothrombotic state, in metabolic syndrome, 521–522
PS, See Pulmonary stenosis
Pseudocoarctation of aorta, 301
Pseudotumor cerebri, 544
Psychogenic causes, of chest pain, 496b, 497

Puffy eyelids, history of, 5

Pulmonary area, systolic heart murmurs at, 34, 31t, 33f, 34

Pulmonary arteriovenous fistula, 294–295
  after bidirectional Glenn operation, 248
  PDA compared with, 170

Pulmonary artery (PA)
  anomalous left, 308f, 309, 310f, 311–312
  chest roentgenography of
    hypoplasia, 71, 71f
    prominence, 70, 71f
  idiopathic dilatation of, 299
  measurement of, 605t
  responses to various stimuli by, 123

Pulmonary artery (PA) aneurysm, in TOF with absent pulmonary valve, 236–237, 236f

Pulmonary artery (PA) banding, 178
  for DORV, 279
  for persistent truncus arteriosus, 270
  for single ventricle, 274
  for tricuspid atresia, 246, 246b

Pulmonary artery (PA) pressure
  measurement of, 483
  normal, 483
  physiology of, 484–485

Pulmonary artery (PA) stenosis, 184, 185f
  balloon angioplasty for, 114–115
  clinical manifestations of, 301–302
  differential diagnosis of, 31t, 33f
  incidence of, 301
  management of, 302
pathology of, 301
PDA compared with, 170

Pulmonary atresia
with intact ventricular septum
  clinical manifestations of, 253f, 254, 255f
  management of, 255–258, 256f–257f
  natural history of, 255
  pathology of, 253–254, 253f
  prevalence of, 252
pathophysiology of, 150–151, 150f
TOF with, 146–147
  clinical manifestations of, 232–233
  management of, 233–236, 233f–235f
  natural history of, 233
  pathology of, 231–232, 232f
  prevalence of, 231

Pulmonary atresia and ventricular septal defect (PA-VSD)
  clinical manifestations of, 232–233
  management of, 233–236, 233f–235f
  natural history of, 233
  pathology of, 231–232, 232f
  prevalence of, 231

Pulmonary blood flow (PBF)
  cardiac catheterization measurement of, 108–109
  in cyanotic congenital heart defects, 151f, 152
Pulmonary edema, pulmonary hypertension and, 483
Pulmonary ejection murmur, 36t, 37–38, 37f
  differential diagnosis of, 31t, 33f
Pulmonary embolism, chest pain due to, 498
Pulmonary flow murmur of newborn
auscultation of, 36t, 37f, 38

differential diagnosis of, 31t, 33f

Pulmonary flow murmur of older children
auscultation of, 36t, 37–38, 37f
differential diagnosis of, 31t, 33f

Pulmonary hypertension, 483
alveolar hypoxia and, 484b, 485–486
causes of, 483, 484b
clinical manifestations of, 488–490, 489f–490f
diagnosis of, 490–491
hyperkinetic, 484b, 485, 487, 487f
management of, 491–494
natural history of, 491
normal physiology and, 484–485
pathogenesis of, 485–487
pathology of, 487–488, 487f
pathophysiology of, 488
pregnancy with, 492
primary, 484b, 486–487
syncope due to, 510
venous, 484b, 486–487

Pulmonary parenchyma, chest roentgenography of, 74

Pulmonary regurgitation (PR)
after TOF repair, 206, 230
as valvular regurgitant lesion, 136

Pulmonary regurgitation murmurs, 35

Pulmonary root autograft, See Ross procedure

Pulmonary stenosis (PS)
athletic participation with, 560t
chest pain due to, 498, 499t
clinical manifestations of, 184–186, 185f–186f
differential diagnosis of, 31t, 33f
management of, 110f, 113, 186–188
natural history of, 186
pathology of, 184, 185f
pathophysiology of, 131–132, 132f
prevalence of, 184
syncope due to, 510
in TOF, 145–148, 145f–149f
tricuspid atresia with, 242, 243f
Pulmonary valve, absent
  PDA compared with, 170
  TOF with, 236–237, 236f
Pulmonary valve annulus, measurement of, 605t
Pulmonary valve replacement
  percutaneous, 116
  for PR, 230
Pulmonary valvotomy, 187–188
Pulmonary vascular markings, chest roentgenography of, 71
  decreased pulmonary blood flow, 71
  increased pulmonary blood flow, 71
  normal pulmonary vasculature, 72
  pulmonary venous congestion, 72
Pulmonary vascular obstructive disease, See Eisenmenger’s syndrome
Pulmonary vascular resistance (PVR), 485
  after birth, 121–122, 121f–122f, 122b
  cardiac catheterization measurement of, 109
  in premature newborns, 123
Pulmonary vascular tone, 484
Pulmonary vasodilators, for pulmonary hypertension, 492–493

Pulmonary vein stenosis
  acquired, 303–304
  congenital, 302–303
  diagnosis of, 303
  treatment and prognosis of, 303

Pulmonary venous hypertension, 484b, 486–487

Pulmonary venous obstruction
  TAPVR with, 239–240
  TAPVR without, 238–239, 239f

Pulse, palpation of, 16–17, 17f

Pulse oximetry
  cyanotic congenital heart defect detection with, 206
  stress testing monitoring with, 96

Pulsus paradoxus, palpation of, 17, 17f

PVC, See Premature ventricular contraction

PVCs, See Premature ventricular complexes

PVR, See Pulmonary vascular resistance

P-wave duration and amplitude, ECG measurement and normal/abnormal values of, 51
Q waves, ECG measurement and normal/abnormal values of, 51–53, 53t
QRS amplitude
  ECG measurement and normal/abnormal values of, 51–53, 52t–53t
  ventricular hypertrophy effects on, 41, 52t, 54f
QRS axis, on ECG, 47
  abnormal values of, 49
  normal values of, 49, 49t
  successive approximation method for measurement of, 48, 48f
  ventricular hypertrophy effects on, 41
QRS duration, ECG measurement and normal/abnormal values of, 50, 50f, 51t
QRS-T angle, ECG measurement and normal/abnormal values of, 49
QT interval, ECG measurement and normal/abnormal values of, 50–51, 50f
QT prolongation, acquired causes of, 424b
QT syndrome
  long, See Long QT syndrome
  short, 434
Questran, See Cholestyramine
Quinidine (Cardioquin, Quinidex, Quinaglute), 613t–634t
  for mitral stenosis, 377
  for MVP, 386
  for sinus node dysfunction, 410
  toxicity effects of, 50, 60
R
RA, See Right atrial, Right atrium
RAAS, See Renin-angiotensin-aldosterone system
RAD, See Right axis deviation
Radiography, See Chest roentgenography
Radionuclide renal scan, for systemic hypertension, 472, 472t
RAH, See Right atrial hypertrophy
Rapamune, See Sirolimus
Rapid-acting diuretics, for CHF, 453f, 458
Rashkind procedure, 113, 213
  for tricuspid atresia, 245
Rastelli classification, of complete ECD, 175, 175f
Rastelli operation
  for complete TGA, 208, 214, 214f
  for congenitally corrected TGA, 223
  for DORV, 279
  for persistent truncus arteriosus, 270
Rate-adaptive pacemakers, 444
RAVT, See Reciprocating AV tachycardia
Reciprocating AV tachycardia (RAVT), 415–416, 415f
  antidromic, 415, 415f
  orthodromic, 415, 415f
Recoarctation of aorta, balloon angioplasty for, 114
Recombinant human growth hormone, for DCM, 334
Reentrant (reciprocating) supraventricular tachycardia, 411f, 414–416, 415f
Regitine, See Phentolamine
Regurgitant lesions, See Valvular regurgitant lesions
Regurgitant systolic murmurs, 28, 29f, 30
  in mitral regurgitation, 135, 379, 379f
  in persistent truncus arteriosus, 269
in TOF, 145–146
in tricuspid regurgitation, 135–136
in VSD, 162–163, 162f

Rejection, of cardiac transplantation, 578–579, 578t
Renal artery balloon angioplasty, 478, 478t
Renin–angiotensin–aldosterone system (RAAS), 479
Renoparenchymal hypertension, 471
Renovascular hypertension, 471, 479–481
  causes of, 479
  clinical manifestations of, 479–480
  diagnostic workup for, 472t, 480
  management of, 480–481
  pathogenesis of, 479, 480f
Réparation à l’étage ventriculare (REV)
  for complete TGA, 216, 216f
  for DORV, 280
Resistance, vascular, 109
Respiratory causes, of chest pain, 496b, 497, 503
Respiratory infections, history of, 5
Respiratory rate, inspection of, 15
Restrictive cardiomyopathy, 321, 322f
  clinical characteristics of, 323t
  clinical manifestations of, 338
  management of, 338–339
  pathology and pathophysiology of, 338
  prevalence and cause of, 338
Retinoic acid, history of maternal use of, 3
Retraction, inspection of, 15
REV, See Réparation à l’étage ventriculare
Revatio, See Sildenafil
Reverse cholesterol transport, 525f, 526
Rhabdomyoma, cardiac, 387–389, 390f, 391
Rheumatic carditis, CHF due to, 452
Rheumatic fever

  *See also Acute rheumatic fever*
family history of, 8
prophylaxis for, 348
Rheumatic valvular heart diseases, CHF due to, 452
Rheumatoid arthritis, cardiovascular involvement in, 399
Rhythm
  in Ebstein’s anomaly, 264, 264f
  ECG measurement of, 45–46, 46f
Rhythm strip, 43–44, 43f
Ribs, on chest roentgenography, 72, 73f
Right aortic arch with left ligamentum arteriosum, 307–308, 308f, 311–312
Right atrial cardiac transplantation, 574, 574f
Right atrial enlargement, chest roentgenography of, 70, 70f
Right atrial hypertrophy (RAH)
  ECG of, 53, 53f
  in pulmonary atresia, 150–151
  in TAPVR, 151–152
  in tricuspid atresia, 148–149
  tricuspid regurgitation causing, 135
  tricuspid stenosis causing, 135
Right atrium (RA)
  persistent left SVC draining into, 305, 305f
  TAPVR to, 241, 241f
Right axis deviation (RAD), 49
  on infant ECGs, 44–45, 44f–45f
Right bundle branch block (RBBB)
in ASD, 124–125, 156
athletic participation with, 566–570, 569t
ECG of, 51t, 58–59, 58f–59f
with ventricular tachycardia, 427
after VSD repair, 167–168

Right coronary artery, measurement of, 607t

Right subclavian artery, aberrant, 308–309, 308f–309f, 311–312
Right subclavicular view, 82f, 85

Right ventricle (RV)
See also Double-outlet right ventricle
double-chambered, 297–298
in fetus, 120, 120f

Right ventricular body surface area, 602t

Right ventricular cardiomyopathy
See also Arrhythmogenic cardiomyopathy
syncope due to, 510

Right ventricular dysplasia
See also Arrhythmogenic cardiomyopathy
syncope due to, 510

Right ventricular enlargement, chest roentgenography of, 70, 70f

Right ventricular hypertrophy (RVH)
in ASD, 156
ECG of, 49t, 52t, 54–56, 56f
mitral stenosis causing, 134, 134f
in obstructive lesions to ventricular output, 132–133, 132f
in pulmonary regurgitation, 136
in TAPVR, 151–152
in TGA, 209, 210f
in TOF, 145–148, 145f–149f
tricuspid regurgitation causing, 135
Right ventricular outflow tract (RVOT)
- obstruction of, in TOF, 145–148, 145f–149f
- with ventricular tachycardia, 427, 427f

Right-to-left shunts
- cyanosis and, 138–139, 139f
- in TOF, 146–147, 147f

Roentgenography, See Chest roentgenography

Romano-Ward syndrome, 11t–14t, 429, 429t

Ross procedure, 193–194, 194f, 383

Ross-Konno procedure, 194, 195f

Route, for cardiac pacemakers, 444–445

R/S ratio
- ECG measurement and normal/abnormal values of, 51–53, 52t
- ventricular hypertrophy effects on, 41, 52t

Rubella syndrome, 11t–14t

Rubinstein-Taybi syndrome, 11t–14t

Ruptured sinus of Valsalva aneurysm, PDA compared with, 170

RV, See Right ventricle, Right ventricular

RV inflow parasternal view, 78f, 82

RV outflow parasternal view, 78f, 82

RVH, See Right ventricular hypertrophy

RVOT, See Right ventricular outflow tract

RV-to-PA connection, for TOF with pulmonary atresia, 233–235, 234f–235f
S1, See First heart sound
S2, See Second heart sound
S3, See Third heart sound
S4, See Fourth heart sound
SA node, See Sinoatrial node
SACBPS, See San Antonio Children’s Blood Pressure Study
Safarin, See Warfarin
Salicylates
  for acute rheumatic fever, 371–372, 372t
  for pericarditis, 354
San Antonio Children’s Blood Pressure Study (SACBPS)
  auscultatory blood pressure values from, 589t–590t
  BP standards recommended by, 16, 20, 21f–22f
  Dinamap blood pressure values from, 592t–593t
Sandimmune, See Cyclosporine
Sano central shunt, for HLHS, 260, 260f
Scavenger receptor class BI (SR-BI), 526
Schwartz diagnostic criteria, for long QT syndrome, 431, 432t
Scimitar syndrome, 74, 182–183, 304
  sinus venosus defect in, 155
Scoliosis, cyanosis causing, 141
Screening
  for athletes, 554–557, 555b
  of cardiac donors, 573
Second heart sound (S2), auscultation of, 25, 26b
  intensity of P2, 25, 25f
  splitting of S2, 25f, 26
Secondary hypertension, 466–467, 468b, 479–481
  management of, 477–478, 478t
pheochromocytoma, 481
renovascular, 471, 479–481
  causes of, 479
  clinical manifestations of, 479–480
  diagnostic workup for, 472t, 480
  management of, 480–481
  pathogenesis of, 479, 480f
Second-degree atrioventricular block, 436–437, 437f
Sedation, for cardiac catheterization and angiocardiography, 112
Segmental expression, 316–317
Senning operation
  for complete TGA, 213, 214f
  for congenitally corrected TGA, 222–223
  for DORV, 280
Sertraline (Zoloft), for syncope, 514
Serum markers, after acute myocardial infarction, 585f
Serving size, of various food groups, 598t
Short QT syndrome, 434
  syncope with, 510
Short-axis parasternal views, 78, 78f
Short-axis subcostal views, 78, 80f–81f, 84
Short-axis suprasternal views, 81f, 85
Shunt procedures
  for Ebstein’s anomaly, 266
  for HLHS, 260–262, 260f
  for single ventricle, 275
  for TOF, 228–229, 228f
    with pulmonary atresia, 233, 233f
  for tricuspid atresia, 246–248, 246b, 247f
Shunts
See also Left-to-right shunts; Right-to-left shunts
cardiac catheterization measurement of, 108–109
in fetal circulation, 119, 120f
Sick sinus syndrome, 409–410
  athletic participation with, 566, 567t–569t
  syncope with, 510
Sickle cell anemia, cardiovascular involvement in, 399–400
Sildenafil (Revatio, Viagra), 613t–634t
  for pulmonary hypertension, 493
Simvastatin (Zocor), 539, 613t–634t
Single atrium, 296–297
Single ventricle
  clinical manifestations of, 273–274
  management of, 274–276, 275f–276f
  natural history of, 274
  pathology of, 272, 272f
  pathophysiology of, 144–145, 144f, 272–273
  prevalence of, 272
Sinoatrial exit block, 409
Sinoatrial (SA) node, rhythms originating in, 407–410, 408f
Sinotubular junction, measurement of, 604t
Sinus arrhythmia, 408, 408f
Sinus bradycardia, 407–408, 408f, 408t
Sinus node, rhythms originating in, 407–410, 408t
Sinus node dysfunction (sick sinus syndrome), 409–410
  athletic participation with, 566, 567t–569t
Sinus of Valsalva (SOV), measurement of, 604t
Sinus of Valsalva (SOV) aneurysm, See Aneurysm of sinus of Valsalva
Sinus pause, 408f, 409, 418–419, 418f
Sinus rhythm, 407, 408f
Sinus tachycardia, 407, 408f, 408t
Sinus venosus defect, 155, 156f
  echocardiography of, 157–158, 157f
  surgical closure of, 160
Sirolimus (Rapamune), 613t–634t
Sitaxsentan, for pulmonary hypertension, 493
Six-minute walk test, 102
Skeleton, on chest roentgenography, 72, 73f
Sleep apnea, 544
Slipping rib syndrome, chest pain due to, 498
Smith-Lemli-Opitz syndrome, 11t–14t
Smoking
  cardiovascular disease and, 548–550
  history of maternal use of, 3–4
  history of patient use of, 7
  management of, 549–550
  pathophysiological effects of, 549
  prevalence of, 548
  psychosociology of, 549
Snowman sign, 239, 239f
Sodium bicarbonate, See Bicarbonate
Sodium channel blockers, for systemic hypertension, 476, 476t
Sodium polystyrene sulfonate (Kayexalate, Kionex), 613t–634t
Sotalol (Betapace), 613t–634t
SOV, See Sinus of Valsalva
Spironolactone (Aldactone), 613t–634t
  for CHF, 453f, 458
    in VSD, 166
  for DCM, 333
  for long QT syndrome, 434
for systemic hypertension, 476, 476t
Splenic syndrome, See Heterotaxia
Splintzen syndrome, 11t–14t
Spongy myocardium, See Noncompaction cardiomyopathy
Sports
   See also Athletes
cardiac arrhythmias and, 565–570
diagnostic workup for, 565–570
eligibility recommendations for, 566, 567t–569t
classification of, 557–558, 557f
Squatting
cyanosis causing, 141
history of, 4–5
in TOF, 148, 149f
SR-BI, See Scavenger receptor class BI
ST segment
   ECG changes in, 62–66
      nonpathologic ST-segment shift, 62, 62f–63f
      pathologic ST-segment shift, 62–63, 62f
   ECG measurement and normal/abnormal values of, 53
St. Vitus’ dance, See Sydenham’s chorea
Staged conversion to ASO, for complete TGA, 216
Standard long-axis parasternal view, 78f, 81–82
Staphylococcal IE, antibiotics for, 347
Starnes operation, for Ebstein’s anomaly, 266
Static exercise, 557f, 558
Statins, 536–546, 537t
   adverse effects of, 538–539, 538b
dosages of, 539
   for hypercholesterolemia, 537–547
for low HDL syndrome, 542

Stent placement
  for COA, 202
  for pulmonary artery stenosis, 302

Steroids, for acute rheumatic fever, 371–372, 372t

Still’s murmur
  auscultation of, 36t, 37, 37f
  differential diagnosis of, 32t–33t, 33f

Stomach gas bubble, on chest roentgenography, 72, 72f

Straddling, in TGA, 209

Streptase, See Streptokinase

Streptococcal IE, antibiotics for, 347

Streptococcal infection, evidence of, for rheumatic fever diagnosis, 370

Streptokinase (Streptase, Kabikinase), 613t–634t

Stress testing, 96
  alternative protocols for, 101–102
  for athletes, 566
  cardiovascular response to, 96–97
  contraindications to, 101
  indications of, 101
  for long QT syndrome, 432
  monitoring during, 97–100, 98t–99t, 99f
  for premature ventricular contraction, 423
  for pulmonary hypertension, 490
  safety of, 100–101
  termination of, 101
  treadmill protocols for, 97–101, 98t–99t, 99f
  for VT, 426–427

Stroke
  cyanosis causing, 141
PFO vs., 300
Subaortic stenosis, differential diagnosis of, 32t
Subaortic VSD, 276–280, 277f–278f, 281f
Subclavian flap aortoplasty, for COA, 199, 200f
Subclavian-to–left coronary artery anastomosis, for ALCAPA syndrome, 292–293
Subclavicular views, on two-dimensional echocardiography, 82f, 85
Subcostal views, on two-dimensional echocardiography, 80f–81f, 84
Subcutaneous nodules, acute rheumatic fever causing, 369
Subdiaphragmatic TAPVR, See Infracardiac TAPVR
Subpulmonary VSD, 276, 277f–278f, 278–280, 281f
Subvalvular AS, 188–189, 188f
    echocardiography of, 191
    surgical management of, 193–194, 195f
Subvalvular PS, See Infundibular PS
Successive approximation method, QRS axis measurement using, 48, 48f
Sudden death
    in HCM, 326
    in Williams syndrome, 402
Sudden unexpected death, in athletes, 553–554, 554t
Sulfadiazine, for acute rheumatic fever, 374
Sulfisoxazole, for acute rheumatic fever, 374
Superior QRS axis, 49
Superior vena cava (SVC)
    anomalies of, 304–305, 305f
    in fetal circulation, 119, 120f
Supracardiac TAPVR, 151, 238, 238f, 240–241, 241f
Supraclavicular systolic murmur, 36t, 37f, 38–39
Suprasternal views, on two-dimensional echocardiography, 81f, 84–85
Supravalvular AS, 188–189, 188f
    differential diagnosis of, 32t, 33f
echocardiography of, 191
surgical management of, 193–194
Supravalvular PS, 184, 185f
Supraventricular tachycardia (SVT), 414–418
  athletic participation with, 566, 567t–569t
  automatic type of, 416
  CHF due to, 452
  reentrant (reciprocating), 411f, 414–416, 415f
  syncope with, 510
SVC, See Superior vena cava
SVR, See Systemic vascular resistance
SVT, See Supraventricular tachycardia
Sweat, inspection of, 16
Sydenham’s chorea, acute rheumatic fever causing, 369
Syncope, 505
  with cardiac arrhythmias, 510, 565
  causes of, 505, 506b
  cardiac, 506b, 509–510
  noncardiac, 505–509, 506b, 507f
cough, 509
differential diagnosis of, 514–515
evaluation of, 511–513
exercise-related, 509
history of, 6, 511–512
micturition, 509
prevalence of, 505–511
treatment of, 513–514
  vasovagal, 506–507, 507f–508f, 514
System malformations, inspection of, 10, 11t–15t
Systemic arteriovenous fistula, 170, 295–296
Systemic blood flow, cardiac catheterization measurement of, 108–109

Systemic disease, cardiovascular involvement in

- acute glomerulonephritis, 392
- DiGeorge syndrome, 392–393
- Friedreich’s ataxia, 393–394
- hyperthyroidism, 394
- hypothyroidism, 394–395, 395f
- Marfan’s syndrome, 395–397
- mucopolysaccharidoses, 397
- muscular dystrophy, 397–398
- myotonic dystrophy, 398
- Noonan syndrome, 398–399
- rheumatoid arthritis, 399
- sickle cell anemia, 399–400
- systemic lupus erythematosus, 400
- Turner syndrome, 400–401
- Williams syndrome, 401–403

Systemic hypertension, 465, 465t

- athletes with, 570–571
- causes of, 466–467, 468b, 469t
- CHF due to, 453
- diagnosis and workup for, 467–473
  - history, 470
  - initial investigation, 471–472, 472t
  - physical examination, 470–471
  - specialized studies for, 472–473, 472t
  - steps to confirm diagnosis, 467–470
- essential (primary), 466–467
- follow-up evaluation for, 477
- management of, 473–478, 478t
normative blood pressure standards and, 451–453, 467t
secondary, 466–467, 468b, 469t, 479–481
  pheochromocytoma, 481
  renovascular, 472t, 479–481, 480f
stage 1, 465, 465t
stage 2, 465, 465t
Systemic lupus erythematosus, cardiovascular involvement in, 400
Systemic vascular resistance (SVR), cardiac catheterization measurement of, 109
Systemic venous anomalies
  IVC anomalies, 305–306, 306f
  SVC anomalies, 304–305, 305f
Systemic venous stenosis, balloon angioplasty for, 115
Systolic BP
  peripheral amplification of, 23–24, 24f
  stress testing response of, 96, 98–100, 99f, 99t
Systolic click, in persistent truncus arteriosus, 269
Systolic heart murmurs
  in aortic regurgitation, 381–382, 381f
  in ASD, 156
  auscultation of, 28–30, 29f, 31t–33t, 33f
  in COA, 200f, 201
  in ECD, 176, 176f
  location of, 30
    apical area, 34, 33f, 33t
    lower left sternal border, 34, 32t, 33f
    upper left sternal border (pulmonary area), 34, 31t, 33f, 34
    upper right sternal border (aortic area), 34, 32t, 33f
  in mitral regurgitation, 135, 379, 379f
  in MVP, 384–385, 384f
  in obstructive lesions to ventricular output, 131–133, 132f
in persistent truncus arteriosus, 269
in PS, 185, 185f
quality of, 30
in single ventricle, 273
in TAPVR, 151–152, 238–239, 239f
in TGA, 220
in TOF, 145–146, 146f, 224–225, 224f
transmission of, 30
in tricuspid regurgitation, 135–136
types of, 29–30, 29f
in VSD, 162–163, 162f
Systolic sounds, auscultation of, 25, 27–28, 27f
Systolic thrill
  in AS, 189f, 190
  in COA, 200f, 201
  in ECD, 176, 176f
  in PDA, 169, 169f
  in PS, 184, 185f
  in tricuspid atresia, 243
  in VSD, 162, 162f
T
T axis
- ECG measurement and normal/abnormal values of, 49
  ventricular hypertrophy effects on, 41
T waves
- ECG changes in, 53t, 62–66, 63f–65f, 64t
- ECG measurement and normal/abnormal values of, 53
Tachycardia
  atrial
    - chaotic, 411f, 412
    - ectopic, 411–412, 411f, 414, 416
    - paroxysmal, 415
  atioventricular, reciprocating, 415–416, 415f
  incisional intraatrial reentrant, 413
  junctional ectopic, 414, 418f, 419–420
  nodal, 418f, 419–420
    - ectopic, 416
      - reciprocating AV, 415–416, 415f
  sinus, 407, 408f, 408t
  supraventricular, 411f, 414–418, 415f
  syncope with, 510
  ventricular, 420f, 424–427
    - right bundle branch block, 427
    - right ventricular outflow tract, 427, 427f
Tachypnea, history of, 5
Tacrolimus (Prograf), 613t–634t
  for cardiac transplantation, 577, 577t
Takeuchi repair, See Intrapulmonary tunnel operation
Tambocor, See Flecainide
Tangiers disease, 531
Tapazole, See Methimazole
TAPVR, See Total anomalous pulmonary venous return
TAR syndrome, See Thrombocytopenia-absent radius syndrome
Tashiro repair, for ALCAPA syndrome, 292
Taussig-Bing anomaly, See Subpulmonary VSD
TEE, See Transesophageal echocardiography
Tenormin, See Atenolol
Teratogens, history of, 3–4
Teratoma, cardiac, 389
Terfenadine, ECG effects of, 51
Tet spells, See Hypoxic spells
Tetralogy of Fallot (TOF)
  with absent pulmonary valve
    clinical manifestations of, 236–237, 236f
    management of, 237
    natural history of, 237
    pathology and pathophysiology of, 236, 236f
    prevalence of, 236
athletic participation with, 561t
CHF due to, 451
clinical manifestations of, 224–226, 224f–226f
differential diagnosis of, 31t–32t, 33f
hypoxic spells in, 147–148, 148f, 227–228
management of, 227–231, 228f–230f
natural history of, 227
pathology of, 223–224, 224f
pathophysiology of, 145–148, 145f–149f
prevalence of, 223
with pulmonary atresia, 146–147
  clinical manifestations of, 232–233
management of, 233–236, 233f–235f
natural history of, 233
pathology of, 231–232, 232f
prevalence of, 231
Texidor's twinge, chest pain due to, 497
TGA, See Transposition of the great arteries
TGs, See Triglycerides
THAM, See Tromethamine
Thiazide diuretics
  for CHF, 453f, 458
  for systemic hypertension, 475–476, 475t–476t
Thioridazine, ECG effects of, 51
Third heart sound (S3), auscultation of, 27, 27f
Third-degree atrioventricular block, 437f, 438–439
Thoracic cavity, malformations of, 15t
Thorazine, See Chlorpromazine
Thrills
  See also Systolic thrill
  palpation of, 18
Thrombocytopenia-absent radius (TAR) syndrome, 11t–14t
Thymus, chest roentgenography of, 74, 74f
Thyroid function test, for systemic hypertension, 471, 472t
Tiazac, See Diltiazem
Tietze’s syndrome, 497
Timothy syndrome, 429, 429t
Titralac, See Calcium carbonate
To-and-fro murmur, 36
Tobacco, See Smoking
TOF, See Tetralogy of Fallot
Tolazoline (Priscoline), 613t–634t
for persistent pulmonary hypertension of newborn, 289
Toradol, See Ketorolac
Torsades de pointes, 425
Total anomalous pulmonary venous return (TAPVR)
clinical manifestations of
  of all types, 240
  of cardiac type, 240
  of infracardiac type, 240
  of mixed type, 240
  with pulmonary venous obstruction, 239–240
  without pulmonary venous obstruction, 238–239, 239f
  of supracardiac type, 240
differential diagnosis of, 31t, 33f
management of, 241–242, 241f
natural history of, 240–241
pathology of, 237–238, 238f
pathophysiology of, 151–152, 151f, 237–238, 238f
PDA compared with, 170
prevalence of, 237
TR, See Tricuspid regurgitation
Trabecular septum defects, 160–162, 161f, 164f–165f, 166
Tracheography, of vascular ring, 311
Tracleer, See Bosentan
Trandate, See Labetalol
Transesophageal echocardiography (TEE), 92, 609f
Transposition of the great arteries (TGA)
  See also Dextroposition transposition of the great arteries; Levotransposition of the great arteries
  athletic participation with, 561t
  single ventricle with, 272
  tricuspid atresia with, 149–150, 149f, 242, 243f
Transvenous pacing, 444–445
Transverse aorta, measurement of, 604t
Treacher Collins syndrome, 11t–14t
Triamterene (Dyrenium), 476, 476t, 613t–634t
Tricuspid atresia
  clinical manifestations of, 242–245, 243f–244f
  management of, 245–251, 246b, 247f, 249f, 252f–253f
  natural history of, 245
  pathology of, 242, 243f
  pathophysiology of, 148–150, 149f
  prevalence of, 242
  with TGA, 149–150, 149f, 242, 243f
Tricuspid mid-diastolic murmurs, 35
Tricuspid regurgitation (TR)
  differential diagnosis of, 32t, 33f
  as valvular regurgitant lesion, 135–136
Tricuspid stenosis, as obstructive lesion, 135
Tricuspid valve
  diameter of, 607t
  Ebstein's anomaly of, See Ebstein's anomaly
Tricuspid valve replacement
  for congenitally corrected TGA, 223
  for Ebstein’s anomaly, 267
Tricyclic antidepressants, ECG effects of, 51
Tridil, See Nitroglycerine
Tridione, See Trimethadione
Trigeminy, 420
Triglycerides (TGs), 523–524
  biochemistry of, 524
  measurement of, 526–527
in metabolic syndrome, 521–523, 522b
metabolism of, 524–526, 525f
omega-3 fatty acids and, 540–541
Trimethadione (Tridione), history of maternal use of, 3
Trimethoprim-sulfa, ECG effects of, 51
Tripartite pulmonary atresia, 253, 253f
Triplets, 420
Trisomy 13, 11t–14t
Trisomy 18, 11t–14t
Trisomy 21, 11t–14t
Tromethamine (THAM), for persistent pulmonary hypertension of newborn, 289
Tuberous sclerosis, 11t–14t
Tumors, See Cardiac tumors
Turner syndrome, 11t–14t, 400–401
Turner-like syndrome, 11t–14t
12-Lead scalar ECG, information available on, 43–44, 43f
22q11 deletion syndrome, 392
Two-dimensional echocardiography, 77–79
   apical views on, 79f, 83
   measurements derived from, 604t–605t, 607t
   parasternal views on, 78f, 79
   quantitative values derived from, 85–86
   subclavicular views on, 82f, 85
   subcostal views on, 80f–81f, 84
   suprasternal views on, 81f, 84–85
Two-stage ASO, for complete TGA, 215
Two-to-one AV block, 436–437, 437f
Two-ventricular repair
   for Ebstein’s anomaly, 267, 267f
   for pulmonary atresia with intact ventricular septum, 256, 256f
Ultrasound, See Echocardiography
Unipolar leads, for cardiac pacemakers, 444
Upper left sternal border, systolic heart murmurs at, 34, 31t, 33f, 34
Upper mediastinum, chest roentgenography of, 74, 74f
Upper right sternal border, systolic heart murmurs at, 34, 32t, 33f
Urokinase (Abbokinase), 613t–634t
Vaccination
  for asplenia syndrome, 284
  after cardiac transplantation, 579
  for Lyme disease, 364
Valium, See Diazepam
Valproic acid
  for acute rheumatic fever, 372
  history of maternal use of, 3
Valvotomy
  aortic, 193–195, 194f–195f
  pulmonary, 187–188
Valvular AS, 188–189, 188f
  echocardiography of, 190–191, 191f
  surgical management of, 193–194, 194f
Valvular heart disease, 375
  AR, See Aortic regurgitation
  athletic participation with, 559, 562t–563t
  MR, See Mitral regurgitation
  MS, See Mitral stenosis
  MVP, See Mitral valve prolapse
Valvular PS, 184, 185f
Valvular regurgitant lesions, 135
  aortic regurgitation, 136, 136f
  mitral regurgitation, 135, 135f
  pulmonary regurgitation, 136
  tricuspid regurgitation, 135–136
Valvuloplasty, balloon, See Balloon valvuloplasty
Vancomycin, for infective endocarditis, 346–347
Vascular resistance, cardiac catheterization measurement of, 109
Vascular ring
  aortic arch branching variations and, 312–313, 313f
  clinical manifestations of, 309–310
  diagnosis of, 308f–309f, 310–311
  management of, 311–312
  pathology of, 307, 308f–310f
  prevalence of, 307–313
Vascular sling, 308f, 309, 310f, 311–312
Vascular stroke, cyanosis causing, 141
Vasodilators
  for cardiovascular involvement in acute glomerulonephritis, 392
  for CHF, 462–463, 463t
  peripheral amplification of systolic pressure and, 24
  for pulmonary hypertension, 493
  for systemic hypertension, 475t–476t, 477
Vasotec, See Enalapril
Vasovagal syncope, 506–507, 507f–508f, 514
VATER association, 11t–14t
Vectorial approach, to ECG, 41–44
  hexaxial reference system, 41–42, 42f
  horizontal reference system, 42f, 43
Velocardiofacial syndrome, 11t–14t
Venodilators, for CHF, 463, 463t
Venous hum
  auscultation of, 36t, 37f, 38
  PDA compared with, 170
Venous stenosis, balloon angioplasty for, 115
Ventral wall, malformations of, 15t
Ventricle, See Left ventricle
  See also Right ventricle
localization of, 315, 316f
rhythms originating in, 420–435, 420f
  single, as cyanotic heart defect, 144–145, 144f
Ventricular bigeminy, 420
Ventricular conduction, aberrant, 427–428
Ventricular conduction disturbances, ECG of, 51t, 57–62, 58f
  intraventricular block, 51t, 57–62, 58f
  LBBB, 60
  preexcitation, 51t, 57–62, 58f, 61f
  RBBB, 51t, 58–59, 58f–59f
  ventricular hypertrophy vs., 61–62, 61f
Ventricular contraction, premature, 420–423, 420f–422f, 424b
  causes of, 422, 422f
  coupling interval of, 421–422
  management of, 423, 424b
  significance of, 422–423
  types of, 420–421, 421f
Ventricular coupling, 420
Ventricular fibrillation, 420f, 428
Ventricular flutter, athletic participation with, 566, 567t–569t
Ventricular hypertrophy, ECG of, 52t, 54–57, 54f, 56f–57f
  ventricular conduction disturbances vs., 61–62, 61f
Ventricular inversion, 219, 219f
Ventricular output obstruction, 131, 132f
  aortic and pulmonary valve stenoses as, 131–132, 132f
  COA as, 132–133, 133f
Ventricular pacemakers, 440, 441f
  P wave–triggered, 441, 441f
Ventricular rhythm, accelerated, 423–424
Ventricular septal defect (VSD)
AR with, 168
athletic participation with, 560t
CHF due to, 451
clinical manifestations of, 126–128, 126f, 162–166, 162f–166f
closure techniques for, 115
COA with, 168, 199
differential diagnosis of, 32t, 33f
DORV with, 276–280, 277f–278f, 281f
in ECD, 129–130, 130f
management of, 166–168
natural history of, 166
pathology of, 160–162, 161f
pathophysiology of, 126–128, 126f–127f
PDA compared with, 170
PDA with, 167
in persistent truncus arteriosus, 144–145, 144f
prevalence of, 160
pulmonary atresia and
clinical manifestations of, 232–233
management of, 233–236, 233f–235f
natural history of, 233
pathology of, 231–232, 232f
prevalence of, 231
in TOF, 145–148, 145f–149f
tricuspid atresia with, 148–149, 242, 243f
Ventricular tachycardia (VT), 420f, 424–427
athletic participation with, 566, 567t–569t
right bundle branch block, 427
right ventricular outflow tract, 427, 427f
syncope with, 510
Ventricular trigeminy, 420
Ventriculography, ventricle localization using, 315
Verapamil (Isoptin, Calan), 613t–634t
  for HCM, 327
Vertical ductus, 232–233, 232f
Very low-density lipoprotein (VLDL), 524–526, 525f
  remnant, 525
Viagra, See Sildenafil
Vibratory innocent murmur
  auscultation of, 36t, 37, 37f
  differential diagnosis of, 32t–33t, 33f
Viral myocarditis, CHF due to, 452
Visceral adiposity, in metabolic syndrome, 522, 522b
Vitamin B₃, See Nicotinic acid
Vitamin D, for DiGeorge syndrome, 393
Vitamin K₁, 613t–634t
VLDL, See Very low-density lipoprotein
von Recklinghausen’s disease, 11t–14t
VOO device, 444
VSD, See Ventricular septal defect
VT, See Ventricular tachycardia
VVI device, 444
Waist circumference (WC)
  in metabolic syndrome, 522–523, 522b
  percentile regression of, 595t–596t
Wall stress, in CHF, 454
Wandering atrial pacemaker, 410–411, 411f
Warden procedure, 160
Warfarin (Coumadin, Safarin), 613t–634t
  See also Fetal warfarin syndrome
  after aortic valve replacement, 194–195, 383
  for atrial fibrillation, 414
  for atrial flutter, 413
  for DCM, 333
  after Fontan-type operation, 250–251
  for HCM, 328
  for Kawasaki’s disease, 360–361, 362t
  for mitral stenosis, 377–378
  after mitral valve replacement, 381
  for noncompaction cardiomyopathy, 341
  for PFO patients, 300
  for pulmonary hypertension, 492
  for restrictive cardiomyopathy, 339
Waterston shunt, 228–229
WC, See Waist circumference
Weight gain, history of, 4
WelChol, See Colesevelam
White balloon, 115
White-coat hypertension, 465–466, 478–479
  athletes with, 570–571
Williams syndrome, 11t–14t
cardiovascular involvement in, 401–403

Wolff-Parkinson-White syndrome

athletic participation with, 566, 567t–569t

ECG of, 58f, 60–61, 61f

syncope with, 510
XO syndrome, **11t–14t**

X-ray films, *See Chest roentgenography*

Xylocaine, *See Lidocaine*
Zaroxolyn, See Metolazone
Zellweger syndrome, 11t–14t
Zestril, See Lisinopril
Zetia, See Ezetimibe
Zidovudine, 366
Zocor, See Simvastatin
Zoloft, See Sertraline